PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	VANARSDEL, PP				VANARSDEL, PP			ASPIRIN IDIOSYNCRASY AND TOLERANCE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											VANARSDEL, PP (corresponding author), UNIV WASHINGTON HOSP,SCH MED,DEPT MED,SEATTLE,WA 98105, USA.							BALDOCCHI G, 1983, J ALLERGY CLIN IMMUN, V71, P148, DOI 10.1016/0091-6749(83)90362-7; BIANCO S, 1982, J ALLERGY CLIN IMMUN, V70, P222; CHAND N, 1983, J ALLERGY CLIN IMMUN, V71, P149, DOI 10.1016/0091-6749(83)90365-2; CHIU JT, 1983, J ALLERGY CLIN IMMUN, V71, P560, DOI 10.1016/0091-6749(83)90437-2; Cooke RA, 1919, J AMER MED ASSOC, V73, P759, DOI 10.1001/jama.1919.02610360029008; CUMMINGS N P, 1982, Journal of Allergy and Clinical Immunology, V69, P131; Ellis EF., 1983, ALLERGY PRINCIPLES P, P1389; FISH JE, 1981, AM REV RESPIR DIS, V123, P609; Gilbert GB., 1911, JAMA-J AM MED ASSOC, V56, P1262; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V71, P580, DOI 10.1016/0091-6749(83)90440-2; MCLEAN JA, 1983, J ALLERGY CLIN IMMUN, V72, P187, DOI 10.1016/0091-6749(83)90528-6; MUCCITELLI RM, 1983, PROSTAGLANDINS, V26, P197, DOI 10.1016/0090-6980(83)90088-6; PAAJANEN H, 1982, PROSTAGLANDINS, V23, P731, DOI 10.1016/S0090-6980(82)80011-7; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V72, P462, DOI 10.1016/0091-6749(83)90582-1; SPECTOR SL, 1981, CHEST, V80, P676, DOI 10.1378/chest.80.6.676; SPECTOR SL, 1983, ALLERGY PRINCIPLES P, P1249; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; SZCZEKLIK A, 1983, DRUGS, V25, P533, DOI 10.2165/00003495-198325060-00001; VANLEEUWEN WS, 1928, MUNCH MED WSCHR, V37, P1588; VANSELOW NA, 1967, ANN INTERN MED, V66, P568, DOI 10.7326/0003-4819-66-3-568; WASSERMAN SI, 1978, J ALLERGY CLIN IMMUN, V61, P139, DOI 10.1016/0091-6749(78)90276-2; 1981, LANCET, V2, P1266; 1909, JAMA, V52, P2106	23	20	20	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	4					431	434		10.1016/0091-6749(84)90351-8	http://dx.doi.org/10.1016/0091-6749(84)90351-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM089	6423718				2022-12-18	WOS:A1984SM08900002
J	BRUHN, JG				BRUHN, JG			THE APPLICATION OF THEORY IN CHILDHOOD ASTHMA SELF-HELP PROGRAMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BRUHN, JG (corresponding author), UNIV TEXAS, MED BRANCH, SCH ALLIED HLTH SCI, GALVESTON, TX 77550 USA.							Andersen R., 1968, RES SERIES U CHICAGO, V25; [Anonymous], 1974, Health Education Monograph, V2, P324; [Anonymous], GROWTH BUREAUCRATIC; BAEKELAND F, 1975, PSYCHOL BULL, V82, P738, DOI 10.1037/h0077132; BARANOWSKI T, 1982, J COMMUN, V32, P161, DOI 10.1111/j.1460-2466.1982.tb02508.x; BARANOWSKI TF, THEORY APPLIED HLTH; BARIC L, 1979, INT J HEALTH EDUC, V22, P2; Becker M H, 1977, Med Care, V15, P27, DOI 10.1097/00005650-197705001-00005; BECKER MH, 1975, MED CARE, V13, P10, DOI 10.1097/00005650-197501000-00002; BECKER MH, 1975, INT J HEALTH EDUC, V18, P173; BECKER MH, 1972, J PEDIATR-US, V81, P843, DOI 10.1016/S0022-3476(72)80118-5; BECKER MH, 1977, J HEALTH SOC BEHAV, V18, P348, DOI 10.2307/2955344; BECKER MH, 1978, PUBLIC HEALTH REP, V93, P268; Becker MH, 1979, COMPLIANCE HLTH CARE, P78; BROWN JS, 1982, J FAM ISSUES, V3, P91, DOI 10.1177/019251382003001007; BRUHN JG, 1977, J FAM PRACTICE, V4, P1057; BRUHN JG, 1982, HLTH ED Q, V9, P142; Caplan G., 1976, SUPPORT SYSTEM MUTUA, P19; DAVIS MS, 1968, AM J PUBLIC HEALTH N, V58, P274, DOI 10.2105/AJPH.58.2.274; DONABEDIAN A, 1964, J CHRON DIS, V17, P847, DOI 10.1016/0021-9681(64)90013-X; Eiser C, 1979, J Behav Med, V2, P141, DOI 10.1007/BF00846663; FRANCIS V, 1969, NEW ENGL J MED, V280, P535, DOI 10.1056/NEJM196903062801004; Friedson E., 1970, PROFESSION MED STUDY; Friedson K., 1961, PATIENTSVIEWS MEDICA, P146; GARRITY TF, 1980, PHS NIH812102 US DEP, P113; Glaser B, 1965, AWARENESS DYING; GODE RO, 1983, CHRONIC DISORDERS AD, P31; Gordis L, 1979, COMPLIANCE HLTH CARE, P23; GREEN LW, 1977, HEALTH EDUC QUART, V5, P161, DOI 10.1177/109019817700500206; GROLNICK L, 1972, FAM PROCESS, V11, P457, DOI 10.1111/j.1545-5300.1972.00457.x; HAGGERTY RJ, 1972, PEDIATR CLIN N AM, V19, P101; HAGGERTY RJ, 1965, AM J PUBLIC HEALTH N, V55, P1521, DOI 10.2105/AJPH.55.10.1521; Haynes RB, 1976, COMPLIANCE THERAPEUT, P26; Haynes RB., 1979, COMPLIANCE HLTH CARE; HOCHBAUM GM, 1958, PHS PUBLICATION, V572; HULKA BS, 1976, PATIENT COMPLIANCE, P123; HYMOVICH DP, 1976, PHS DHEW NIH76877 PU, P91; JACKSON DD, 1966, COMPR PSYCHIAT, V7, P338, DOI 10.1016/S0010-440X(66)80064-0; Janis I.L., 1977, DECISION MAKING PSYC; JANIS IL, 1979, HLTH PSYCHOL HDB, P487; Jenkins H. D. B., 1979, ADV INORG CHEM, V22, P1; KASL SV, 1974, HEALTH EDUC QUART, V2, P433, DOI 10.1177/109019817400200409; KASL SV, 1966, ARCH ENVIRON HEALTH, V12, P531, DOI 10.1080/00039896.1966.10664421; KASL SV, 1966, ARCH ENVIRON HEALTH, V12, P246, DOI 10.1080/00039896.1966.10664365; KASSEBAUM GG, 1965, J HEALTH HUM BEHAV, V6, P16, DOI 10.2307/2948615; KERN SP, 1974, DISS ABSTR INT     B, V35, P3022; KEY MK, 1975, THESIS G PEABODY COL; KIRITZ S, 1974, PSYCHOSOM MED, V36, P96, DOI 10.1097/00006842-197403000-00002; KIRSCHT JP, 1974, HEALTH EDUC QUART, V2, P455, DOI 10.1177/109019817400200410; LEVENTHAL H, 1980, PATIENT COMPLIANCE P, P1; Lewis J., 1976, NO SINGLE THREAD PSY; LITMAN TJ, 1974, SOC SCI MED, V8, P495, DOI 10.1016/0037-7856(74)90072-9; MAIMAN LA, 1974, HEALTH EDUC QUART, V2, P336, DOI 10.1177/109019817400200404; MARSTON MV, 1970, NURS RES, V19, P312; MITCHELL JH, 1974, HEALTH EDUC QUART, V2, P75, DOI 10.1177/109019817400200111; Moos R.H., 1979, HLTH PSYCHOL HDB, P523; MORISKY DE, 1983, AM J PUBLIC HEALTH, V73, P153, DOI 10.2105/AJPH.73.2.153; MULLEN PD, 1978, HEALTH EDUC QUART, V6, P280; NEELY E, 1968, NURS RES, V17, P52; PARCEL GS, 1979, PEDIATRICS, V64, P878; PETRONI FA, 1969, SOCIOL SOC RES, V53, P180; PLESS IB, 1972, INT J EPIDEMIOL, V1, P271, DOI 10.1093/ije/1.3.271; PLESS IB, 1981, RES PRIORITIES MATER, P185; PORTER AMW, 1969, BMJ-BRIT MED J, V1, P218, DOI 10.1136/bmj.1.5638.218; PRATT L, 1976, FAMILY STRUCTURE EFF; ROGHMANN KJ, 1975, CHILD HLTH COMMUNITY, P119; ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P328, DOI 10.1177/109019817400200403; ROSENSTOCK IM, 1966, MILBANK FUND Q, V44, P94, DOI 10.2307/3348967; ROSENSTOCK IM, 1959, PUBLIC HEALTH REP, V74, P98, DOI 10.2307/4590386; SACKETT DL, 1976, COMPLIANCE THERAPEUT, P11; SARGENT J, 1982, PSYCHOSOCIAL FAMILY, P125; SCHAFER LC, 1982, J BEHAV MED, V5, P353, DOI 10.1007/BF00846162; SIMONDS SK, 1976, INT J HEALTH EDUC, V19, P2; STECKEL SB, 1977, HOSPITALS, V51, P81; Strauss AL., 1975, CHRONIC ILLNESS QUAL; SUCHMAN EA, 1965, J HEALTH HUM BEHAV, V6, P2, DOI 10.2307/2948614; SUCHMAN EA, 1966, AM J PUBLIC HEALTH N, V56, P97, DOI 10.2105/AJPH.56.1.97; TRAVIS G, 1976, CHRONIC ILLNESS CHIL; WALLSTON BS, 1978, HEALTH EDUC QUART, V6, P107; WEAVER R, 1972, THESIS EMORY U ATLAN; WILSON SR, 1982, ANN M AM PUBLIC HLTH; Zborowski M., 1969, PEOPLE IN PAIN; ZOLA IK, 1972, ADV PSYCHOSOM MED, V8, P216; ZOLA IK, 1966, AM SOCIOL REV, V31, P615, DOI 10.2307/2091854; 1978, DHEW PHS781232 NAT C; 1978, DHEW HSA785744 PUBL; 1981, SELF MANAGEMENT ED P, V1	87	20	20	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	5					561	577		10.1016/0091-6749(83)90483-9	http://dx.doi.org/10.1016/0091-6749(83)90483-9			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RS163	6358327				2022-12-18	WOS:A1983RS16300009
J	FABBRI, LM; HENDRICK, DJ; DIEM, JE				FABBRI, LM; HENDRICK, DJ; DIEM, JE			EFFECT OF ATROPINE ON THE BRONCHIAL RESPONSE OF ASTHMATIC SUBJECTS TO THE INHALATION OF ULTRASONICALLY NEBULIZED DISTILLED WATER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,SCH MED,PULM DIS SECT,NEW ORLEANS,LA 70112	Tulane University			Fabbri, Leonardo M/I-4055-2012	Fabbri, Leonardo M/0000-0001-8894-1689	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL015092] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-15092] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEGRA L, 1980, EUR J RESPIR DIS, V61, P41; BRESLIN FJ, 1980, J APPL PHYSIOL, V48, P619, DOI 10.1152/jappl.1980.48.4.619; CAVANAUGH MJ, 1976, AM REV RESPIR DIS, V114, P517; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHENEY FW, 1968, ANESTHESIOLOGY, V29, P1099, DOI 10.1097/00000542-196811000-00004; DEAL EC, 1978, J APPL PHYSIOL, V45, P238, DOI 10.1152/jappl.1978.45.2.238; DIXON NJ, 1969, INTRO STATISTICAL AN, P164; FERRON GA, 1976, AM REV RESPIR DIS, V114, P899; HOLTZMAN MJ, 1983, J APPL PHYSIOL, V54, P134, DOI 10.1152/jappl.1983.54.1.134; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; MELVILLE GN, 1973, RESPIRATION, V30, P543; NETER J, 1974, APPLIED LINEAR STATI, P616; REBUCK AS, 1982, CHEST S, V82, P55; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285, DOI 10.1136/bmj.283.6302.1285; SHEPPARD D, 1982, J APPL PHYSIOL, V53, P169, DOI 10.1152/jappl.1982.53.1.169; WARD MJ, 1981, BRIT MED J, V282, P598, DOI 10.1136/bmj.282.6264.598	16	20	20	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	5					468	472		10.1016/0091-6749(83)90463-3	http://dx.doi.org/10.1016/0091-6749(83)90463-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QQ742	6841826				2022-12-18	WOS:A1983QQ74200006
J	PLESKOW, WW; CHENOWETH, DE; SIMON, RA; STEVENSON, DD; CURD, JG				PLESKOW, WW; CHENOWETH, DE; SIMON, RA; STEVENSON, DD; CURD, JG			THE ABSENCE OF DETECTABLE COMPLEMENT ACTIVATION IN ASPIRIN-SENSITIVE ASTHMATIC-PATIENTS DURING ASPIRIN CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN,DEPT BASIC & CLIN IMMUNOL,10666 N TORREY PINES RD,LA JOLLA,CA 92037; SCRIPPS CLIN & RES FDN,DEPT IMMUNOL,LA JOLLA,CA 92037	Scripps Research Institute; Scripps Research Institute					NCRR NIH HHS [RR 00833] Funding Source: Medline; NIADDK NIH HHS [AM 00543] Funding Source: Medline; NIAID NIH HHS [AI 10386] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARROYAVE CM, 1977, CLIN ALLERGY, V7, P173, DOI 10.1111/j.1365-2222.1977.tb01439.x; CHAFEE FH, 1974, J ALLERGY CLIN IMMUN, V53, P193, DOI 10.1016/0091-6749(74)90080-3; FRIEDLAENDER S, 1947, ANN INTERN MED, V26, P734, DOI 10.7326/0003-4819-26-5-734; GIRALDO B, 1969, ANN INTERN MED, V7, P479; HANSCH GM, 1980, INT ARCH ALLER A IMM, V61, P150, DOI 10.1159/000232428; MATHISON DA, 1979, J ALLERGY CLIN IMMUN, V64, P669, DOI 10.1016/0091-6749(79)90036-8; MAYER MM, 1971, EXPERIMENTAL IMMUNOC, pCH4; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; MILGROM H, 1980, J IMMUNOL, V124, P2780; NITSCHE JF, 1981, AM J CLIN PATHOL, V76, P679; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; Prickman LE, 1937, J AMER MED ASSOC, V108, P445, DOI 10.1001/jama.1937.02780060011004; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SAMTER M, 1973, HOSP PRACT, V8, P85; SCHLUMBERGER HD, 1974, ACTA MED SCAND, V196, P451; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; STENIUS BSM, 1976, CLIN ALLERGY, V6, P119, DOI 10.1111/j.1365-2222.1976.tb01889.x; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; VANOSS CJ, 1961, NATURE, V189, P147, DOI 10.1038/189147a0; VEDANTHAN PK, 1977, J ALLERGY CLIN IMMUN, V60, P8, DOI 10.1016/0091-6749(77)90077-X; VOIGTLANDER V, 1980, INT ARCH ALLER A IMM, V61, P145, DOI 10.1159/000232427; Widal M, 1922, PRESSE MED, V30, P189; YURCHAK AM, 1970, J ALLERGY, V46, P245, DOI 10.1016/0021-8707(70)90028-6	24	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	5					462	468		10.1016/0091-6749(83)90582-1	http://dx.doi.org/10.1016/0091-6749(83)90582-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RR916	6630797				2022-12-18	WOS:A1983RR91600006
J	BUTTERFIELD, JH; GLEICH, GJ; YUNGINGER, JW; ZIMMERMANN, EM; REED, CE				BUTTERFIELD, JH; GLEICH, GJ; YUNGINGER, JW; ZIMMERMANN, EM; REED, CE			IMMUNOTHERAPY WITH SHORT RAGWEED FRACTION A-D-GLUTAMIC ACID-D-LYSINE POLYMER IN RAGWEED HAY-FEVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & FDN,DEPT MED,ALLERG DIS RES LAB,ROCHESTER,MN 55905; MAYO MED SCH,DEPT MED,ROCHESTER,MN 55901; MAYO MED SCH,DEPT IMMUNOL,ROCHESTER,MN 55901; MAYO MED SCH,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO MED SCH,ALLERG DIS RES LAB,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic					NIAID NIH HHS [AI 11483] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CHIORAZZI N, 1976, P NATL ACAD SCI USA, V73, P2091, DOI 10.1073/pnas.73.6.2091; DAVIE JM, 1972, J EXP MED, V136, P426, DOI 10.1084/jem.136.3.426; DESAYMARD C, 1974, IMMUNOLOGICAL TOLERA, P225; DIXON WJ, 1957, INTRO STATISTICAL AN, P382; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GLEICH GJ, J IMMUNOL; KATZ DH, 1975, J ALLERGY CLIN IMMUN, V55, P403, DOI 10.1016/0091-6749(75)90079-2; KATZ DH, 1973, P NATL ACAD SCI USA, V70, P2776, DOI 10.1073/pnas.70.10.2776; KATZ DH, 1971, J EXP MED, V134, P201, DOI 10.1084/jem.134.1.201; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; LEVY DA, 1967, J IMMUNOL, V99, P1068; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LIU FT, 1979, P NATL ACAD SCI USA, V76, P1430, DOI 10.1073/pnas.76.3.1430; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; LIU FT, 1979, J IMMUNOL, V123, P2456; MARKOWITZ H, 1972, CLIN CHEM, V18, P1364; MAURER PH, 1962, J IMMUNOL, V88, P330; MAURER PH, 1965, J EXP MED, V121, P339, DOI 10.1084/jem.121.3.339; NOSSAL GJV, 1973, J EXP MED, V138, P312, DOI 10.1084/jem.138.1.312; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; Osler A G, 1968, Adv Immunol, V8, P183, DOI 10.1016/S0065-2776(08)60467-8; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; SELA MICHAEL, 1966, ADVANCE IMMUNOL, V5, P29, DOI 10.1016/S0065-2776(08)60272-2; TSE KS, 1978, J ALLERGY CLIN IMMUN, V61, P303, DOI 10.1016/0091-6749(78)90051-9; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	28	20	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	4					272	278		10.1016/0091-6749(81)90021-X	http://dx.doi.org/10.1016/0091-6749(81)90021-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LL697	6970763				2022-12-18	WOS:A1981LL69700004
J	PARKER, JL; YUNGINGER, JW; SWEDLUND, HA				PARKER, JL; YUNGINGER, JW; SWEDLUND, HA			ANAPHYLAXIS AFTER INGESTION OF MILLET SEEDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									MAYO CLIN & MAYO FDN,DEPT MED,ALLERG DIS RES LAB,ROCHESTER,MN 55901; UNIV MINNESOTA,MAYO GRAD SCH MED,DEPT PEDIAT,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; University of Minnesota System; University of Minnesota Rochester					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11483, AI 00107] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; BAILEY AV, 1980, J AGR FOOD CHEM, V28, P475, DOI 10.1021/jf60228a049; GILLESPIE DN, 1976, J ALLERGY CLIN IMMUN, V57, P302, DOI 10.1016/0091-6749(76)90086-5; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; GOLBERT TM, 1969, J ALLERGY, V44, P96, DOI 10.1016/0021-8707(69)90005-7; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; MARTIN JH, 1967, PRINCIPLES FIELD CRO, P519; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; NORMAN PS, 1978, ALLERGY PRINCIPLES P, P256	9	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	1					78	80		10.1016/0091-6749(81)90050-6	http://dx.doi.org/10.1016/0091-6749(81)90050-6			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KZ173	6161145				2022-12-18	WOS:A1981KZ17300015
J	WESCOTT, S; KALINER, M				WESCOTT, S; KALINER, M			THE EFFECTS OF HISTAMINE AND PROSTAGLANDIN-D2 ON RAT MAST-CELL CYCLIC-AMP AND MEDIATOR RELEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CTR CLIN,CLIN INVEST LAB,ALLERG DIS SECT,BLDG 10,ROOM 11N-250,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Institute of Allergy & Infectious Diseases (NIAID)								ASH ASF, 1966, BRIT J PHARM CHEMOTH, V27, P427, DOI 10.1111/j.1476-5381.1966.tb01674.x; BAUDRY M, 1975, NATURE LOND, V253, P361; BAXTER JH, 1972, P SOC EXP BIOL MED, V141, P576; BAZIN H, 1976, MOL BIOL ASPECTS ACU, P125; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BOURNE HR, 1971, SCIENCE, V173, P743, DOI 10.1126/science.173.3998.743; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; BURKA JF, 1976, INT ARCH ALLER A IMM, V50, P664, DOI 10.1159/000231545; CAELLA HL, 1973, ANAL BIOCH, V56, P394; CHASIN M, 1973, J NEUROCHEM, V21, P1415, DOI 10.1111/j.1471-4159.1973.tb06026.x; ENERBACK L, 1977, HISTOCHEMISTRY, V53, P193, DOI 10.1007/BF00511075; HOLGATE ST, 1980, J IMMUNOL, V125, P1367; HOLROYDE MC, 1978, J PHARMACOL EXP THER, V204, P183; ISERSKY C, 1974, J IMMUNOL, V112, P1909; KALINER M, 1978, AM REV RESPIR DIS, V118, P1015; KALINER M, 1974, J IMMUNOL, V112, P664; KALINER M, 1977, J ALLERGY CLIN IMMUN, V60, P204, DOI 10.1016/0091-6749(77)90125-7; KALINER MA, 1975, ANN REV PHARM, V15, P179; LICHTENSTEIN LM, 1973, NATURE, V244, P287, DOI 10.1038/244287a0; LICHTENSTEIN LM, 1975, J PHARM EXP THER, V192; LINDL T, 1974, BIOCHIM BIOPHYS ACTA, V343, P182, DOI 10.1016/0304-4165(74)90250-5; MAZINGUE C, 1978, J IMMUNOL METHODS, V21, P65, DOI 10.1016/0022-1759(78)90224-7; MORRISON DC, 1974, J IMMUNOL, V112, P573; PALMER GC, 1972, J NEUROCHEM, V19, P2251, DOI 10.1111/j.1471-4159.1972.tb01278.x; PARSONS ME, 1977, AGENTS ACTIONS, V7, P31, DOI 10.1007/BF01964878; PINI JJPB, 1978, AGENTS ACTIONS, V8, P491, DOI 10.1007/BF02111435; PLATSHON LF, 1978, J CLIN INVEST, V62, P1113, DOI 10.1172/JCI109230; RAPHAEL GD, 1978, EXP CELL RES, V115, P428, DOI 10.1016/0014-4827(78)90300-2; ROGUS M, 1975, J NEUROCHEM, V25, P531; SCHWARTZ JC, 1979, LIFE SCI, V25, P895, DOI 10.1016/0024-3205(79)90495-8; SHELHAMER JH, 1980, J ALLERGY CLIN IMMUN, V66, P52, DOI 10.1016/0091-6749(80)90138-4; SIRAGANIAN RP, 1976, MANUAL CLIN IMMUNOLO, P603; STEINER AL, 1972, ADV CYCL NUCL RES<D>, V2, P51; SULLIVAN TJ, 1975, J IMMUNOL, V114, P1473; SULLIVAN TJ, 1976, AM J PATHOL, V85, P437; SYDBOM A, 1976, ACTA PHYSIOL SCAND, V97, P222, DOI 10.1111/j.1748-1716.1976.tb10255.x; TAUBER AI, 1973, J IMMUNOL, V111, P27; VERMA SC, 1978, CAN J PHARM SCI, V13, P1	38	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	5					383	391		10.1016/0091-6749(81)90137-8	http://dx.doi.org/10.1016/0091-6749(81)90137-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MQ454	6271862				2022-12-18	WOS:A1981MQ45400007
J	BAER, H; ANDERSON, MC; HALE, R; GLEICH, GJ				BAER, H; ANDERSON, MC; HALE, R; GLEICH, GJ			THE HEAT-STABILITY OF SHORT RAGWEED POLLEN EXTRACT AND THE IMPORTANCE OF INDIVIDUAL ALLERGENS IN SKIN REACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ROCHESTER,MN 55901; US FDA,BUR BIOLOG,WICHITA,KS	Mayo Clinic; US Food & Drug Administration (FDA)	BAER, H (corresponding author), US FDA,BUR BIOLOG,BETHESDA,MD 20014, USA.				PHS HHS [A1-11483] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADOLPHSON C, 1978, J ALLERGY CLIN IMMUN, V62, P197, DOI 10.1016/0091-6749(78)90208-7; BLANCHARD GC, 1977, ANN ALLERGY, V39, P253; FRANKLIN RM, 1976, E J ALLERGY CLIN IMM, V58, P51; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, pCH77; GRATER WC, 1971, ANN ALLERGY, V29, P76; KING TP, 1967, BIOCHEMISTRY-US, V6, P1992, DOI 10.1021/bi00859a017; LOWENSTEIN H, 1978, ANNUAL M AM ACADEMY; MARSH DG, 1975, ANTIGENS, V2; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; 1979, FED REG 45642   0803, V44	11	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	4					281	285		10.1016/0091-6749(80)90022-6	http://dx.doi.org/10.1016/0091-6749(80)90022-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KM254	6775022	Bronze			2022-12-18	WOS:A1980KM25400004
J	MANSFIELD, LE; TRYGSTAD, CW; AJUGWO, RE; HEINER, DC				MANSFIELD, LE; TRYGSTAD, CW; AJUGWO, RE; HEINER, DC			SERUM CONCENTRATIONS OF IMMUNOGLOBULINS E AND G AND ALPHA-2-MACROGLOBULIN IN CHILDHOOD RENAL-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES, LOS ANGELES HARBOR MED CTR, SCH MED, DEPT PEDIAT, TORRANCE, CA 90509 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NICHD NIH HHS [HD 09674-01] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARNESS LA, 1950, PEDIATRICS, V5, P486; BARRATT TM, 1971, LANCET, V2, P402; BENNICH H, 1974, ACTA PATH MICRO IM B, VB 82, P245; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BLAKER F, 1972, UROLOGE, V11, P1; CAMUSSI G, 1978, Ricerca in Clinica e in Laboratorio, V8, P56; COLVIN RB, 1974, HUM PATHOL, V5, P315, DOI 10.1016/S0046-8177(74)80114-0; FONTANA VJ, 1956, NEW YORK STATE J MED, V56, P3907; FREED DLJ, 1976, CLIN ALLERGY, V6, P173, DOI 10.1111/j.1365-2222.1976.tb01895.x; GERBER MA, 1971, LANCET, V1, P1097; GIANGIACOMO J, 1975, NEW ENGL J MED, V293, P8, DOI 10.1056/NEJM197507032930103; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GROSHONG T, 1973, J PEDIATR-US, V83, P767, DOI 10.1016/S0022-3476(73)80367-1; HARDWICKE J, 1959, LANCET, V1, P500; ISHIZAKA K, 1974, JOHNS HOPKINS MED J, V135, P67; LEVINSKY RJ, 1978, NEW ENGL J MED, V298, P126, DOI 10.1056/NEJM197801192980303; LEWIS EJ, 1973, LANCET, V1, P1395; MANSFIELD LE, 1976, J ALLERGY CLIN IMMUN, V57, P230; MCLAREN R, 1965, ARCH DIS CHILD, V40, P659, DOI 10.1136/adc.40.214.659; MCPHAUL JJ, 1974, KIDNEY INT, V5, P292, DOI 10.1038/ki.1974.39; NAGAI T, 1973, JPN CIRC J, V37, P1227, DOI 10.1253/jcj.37.1227; ROBERTSON MR, 1976, NEPHRON, V16, P256, DOI 10.1159/000180610; SANDBERG DH, 1977, LANCET, V1, P388; SANDBERG DH, 1975, PEDIATR RES, V9, P378; SHAKIB F, 1977, CLIN EXP IMMUNOL, V28, P506; SHALHOUB RJ, 1974, LANCET, V2, P556; TADA T, 1973, ACTA HAEMATOL JAPON, V36, P500; TOMIZAWA S, 1977, INT ARCH ALLER A IMM, V54, P400, DOI 10.1159/000231854; Trygstad C W, 1972, Curr Probl Pediatr, V2, P3, DOI 10.1016/S0045-9380(72)80033-1; TRYGSTAD CW, 1973, THROMB DIATH HAEMOST, V30, P12; VENTERS HD, 1962, AM J DIS CHILD, V102, P688; WINTERS WD, 1976, J ALLERGY CLIN IMMUN, V57, P181, DOI 10.1016/0091-6749(76)90039-7; WITTIG HJ, 1970, LANCET, V1, P542; YEN T-S, 1977, Chinese Journal of Microbiology, V10, P21	34	20	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	3					227	232		10.1016/0091-6749(80)90044-5	http://dx.doi.org/10.1016/0091-6749(80)90044-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KH358	6157705				2022-12-18	WOS:A1980KH35800010
J	RUOHO, AE; DECLERQUE, JL; BUSSE, WW				RUOHO, AE; DECLERQUE, JL; BUSSE, WW			CHARACTERIZATION OF GRANULOCYTE BETA-ADRENERGIC RECEPTORS IN ATOPIC ECZEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,CTR HLTH SCI,DEPT PHARMACOL,MADISON,WI 53792; UNIV WISCONSIN,CTR HLTH SCI,DEPT MED,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								Boyum A., 1967, SCAND J CLIN LAB INV, V97, P77; BUSSE WW, 1976, J ALLERGY CLIN IMMUN, V58, P586, DOI 10.1016/0091-6749(76)90205-0; CARR RH, 1973, J ALLERGY CLIN IMMUN, V51, P255, DOI 10.1016/0091-6749(73)90127-9; GALANT SP, 1978, J LAB CLIN MED, V92, P613; GALANT SP, 1979, J INVEST DERMATOL, V72, P330, DOI 10.1111/1523-1747.ep12531768; HEMELS HGW, 1970, BRIT J DERMATOL, V83, P312, DOI 10.1111/j.1365-2133.1970.tb15706.x; JOHNSON LA, 1965, ARCH DERMATOL, V92, P621, DOI 10.1001/archderm.92.6.621; JUHLIN L, 1961, J INVEST DERMATOL, V37, P201, DOI 10.1038/jid.1961.107; KALINER M, 1976, J ALLERGY CLIN IMMUN, V58, P308, DOI 10.1016/0091-6749(76)90136-6; LEFKOWITZ RJ, 1976, NEW ENGL J MED, V295, P323, DOI 10.1056/NEJM197608052950607; LEFKOWITZ RJ, 1975, BIOCHEM PHARMACOL, V24, P583, DOI 10.1016/0006-2952(75)90178-1; LEFKOWITZ RJ, 1976, J BIOL CHEM, V251, P4686; LIMBIRD LE, 1976, J BIOL CHEM, V251, P5007; LOBITZ WC, 1953, AMA ARCH DERM SYPH, V67, P575, DOI 10.1001/archderm.1953.01540060037006; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGUIRE ME, 1976, J BIOL CHEM, V254, P1211; MUKHERJEE C, 1975, J BIOL CHEM, V250, P4869; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; WARNDORF.JA, 1970, BRIT J DERMATOL, V83, P306, DOI 10.1111/j.1365-2133.1970.tb15705.x; Whitfield A, 1938, BRIT J DERMATOL SYPH, V50, P71, DOI 10.1111/j.1365-2133.1938.tb10475.x; WILLIAMS LT, 1978, RECEPTOR BINDING STU, P111	21	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	1					46	51		10.1016/0091-6749(80)90137-2	http://dx.doi.org/10.1016/0091-6749(80)90137-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ541	6247379				2022-12-18	WOS:A1980JZ54100007
J	EGGLESTON, PA				EGGLESTON, PA			LABORATORY EVALUATION OF EXERCISE-INDUCED ASTHMA - METHODOLOGIC CONSIDERATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											EGGLESTON, PA (corresponding author), UNIV VIRGINIA,SCH MED,DEPT PEDIAT,CHARLOTTESVILLE,VA 22908, USA.							EGGLESTON PA, 1976, J ALLERGY CLIN IMMUN, V58, P414, DOI 10.1016/0091-6749(76)90122-6; HAYNES RL, 1976, AM REV RESPIR DIS, V114, P739; JONES RS, 1966, BRIT MED J, V2, P972, DOI 10.1136/bmj.2.5520.972; KATZ RM, 1971, J ALLERGY, V47, P148, DOI 10.1016/S0091-6749(71)80293-2; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; PIERSON WE, 1969, J ALLERGY, V43, P136, DOI 10.1016/S0021-8707(69)80004-3; PLUMMER AL, 1978, CHEST, V73, pS949; Polgar G, 1971, PULMONARY FUNCTION T; POPPIUS H, 1970, BRIT MED J, V4, P337, DOI 10.1136/bmj.4.5731.337; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; SNEDECOR GW, 1967, STATISTICAL METHODS, P147	11	20	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					604	608		10.1016/0091-6749(79)90022-8	http://dx.doi.org/10.1016/0091-6749(79)90022-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX843	512255				2022-12-18	WOS:A1979HX84300010
J	KOHLER, PF				KOHLER, PF			CIRCULATING IMMUNE-COMPLEXES AND THE PRACTICING ALLERGIST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											KOHLER, PF (corresponding author), UNIV COLORADO,DEPT MED,DIV CLIN IMMUNOL,DENVER,CO 80262, USA.							AMMANN AJ, 1971, MEDICINE, V50, P223, DOI 10.1097/00005792-197105000-00004; BRANDEIS WE, 1978, J CLIN INVEST, V62, P1201, DOI 10.1172/JCI109240; CANO PO, 1977, CLIN ALLERGY, V7, P167, DOI 10.1111/j.1365-2222.1977.tb01438.x; CONRADIE JD, 1975, IMMUNOCHEMISTRY, V12, P967, DOI 10.1016/0019-2791(75)90260-8; CUNNINGHAMRUNDLES C, 1978, P NATL ACAD SCI USA, V75, P3387, DOI 10.1073/pnas.75.7.3387; DREISIN RB, 1978, NEW ENGL J MED, V298, P353, DOI 10.1056/NEJM197802162980701; GUPTA RC, 1978, IMMUNOLOGY, V34, P751; KRONVALL G, 1970, IMMUNOCHEMISTRY, V7, P124, DOI 10.1016/0019-2791(70)90036-4; LAWRENCE DA, 1975, J CLIN INVEST, V55, P368, DOI 10.1172/JCI107940; LEVINSON AI, 1978, J ALLERGY CLIN IMMUN, V62, P109, DOI 10.1016/0091-6749(78)90087-8; MULLEREBERHARD HJ, 1968, HOSPITAL PRACTICE, V13, P65; PHANUPHAK P, UNPUBLISHED; PIRQUET CEV, 1911, ARCH INTERN MED, V7, P411; STEIN MR, 1978, J ALLERGY CLIN IMMUN, V62, P211, DOI 10.1016/0091-6749(78)90209-9; THEOFILOPOULOS AN, 1974, J EXP MED, V140, P1230, DOI 10.1084/jem.140.5.1230; YANG WH, 1979, J ALLERGY CLIN IMMUN, V63, P300, DOI 10.1016/0091-6749(79)90123-4	16	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	5					297	299		10.1016/0091-6749(79)90122-2	http://dx.doi.org/10.1016/0091-6749(79)90122-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GU943	429708				2022-12-18	WOS:A1979GU94300001
J	GECZY, AF; DEWECK, AL; GECZY, CL; TOFFLER, O				GECZY, AF; DEWECK, AL; GECZY, CL; TOFFLER, O			SUPPRESSION OF REAGINIC ANTIBODY-FORMATION IN GUINEA-PIGS BY ANTI-IDIOTYPIC ANTIBODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									INSELSPITAL,INST CLIN IMMUNOL,CH-3010 BERN,SWITZERLAND	University of Bern; University Hospital of Bern								ALTMAN R, 1977, J ALLERGY CLIN IMMUN, V59, P120, DOI 10.1016/0091-6749(77)90213-5; ANDERSSON LC, 1976, NATURE, V264, P778, DOI 10.1038/264778a0; AUGUSTIN A, 1976, EUR J IMMUNOL, V6, P497, DOI 10.1002/eji.1830060710; BINZ H, 1975, J EXP MED, V142, P197, DOI 10.1084/jem.142.1.197; Binz H, 1977, Prog Allergy, V23, P154, DOI 10.1159/000314240; EICHMANN K, 1974, EUR J IMMUNOL, V4, P296, DOI 10.1002/eji.1830040413; EICHMANN K, 1975, EUR J IMMUNOL, V5, P661, DOI 10.1002/eji.1830051002; EICHMANN K, 1977, CONT TOPICS IMMUNOBI, V7; GECZY AF, 1977, J EXP MED, V145, P1093, DOI 10.1084/jem.145.4.1093; GECZY AF, 1974, EUR J IMMUNOL, V4, P483, DOI 10.1002/eji.1830040708; GECZY AF, 1975, EUR J IMMUNOL, V5, P711, DOI 10.1002/eji.1830051012; GECZY AF, 1976, J EXP MED, V144, P226, DOI 10.1084/jem.144.1.226; HAIMOVIC.J, 1967, NATURE, V214, P1369, DOI 10.1038/2141369a0; HART DA, 1973, EUR J IMMUNOL, V3, P44, DOI 10.1002/eji.1830030110; HART DA, 1972, J EXP MED, V135, P1293, DOI 10.1084/jem.135.6.1293; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KLUSKENS L, 1974, P NATL ACAD SCI USA, V71, P5083, DOI 10.1073/pnas.71.12.5083; KOHLER H, 1975, TRANSPLANT REV, V27, P24; LEVINE BB, 1971, J IMMUNOL, V106, P29; MCDEVITT HO, 1967, J EXP MED, V126, P969, DOI 10.1084/jem.126.5.969; MCKEARN TJ, 1974, J IMMUNOL, V113, P1976; SCHNEIDER CH, 1966, HELV CHIM ACTA, V49, P1695, DOI 10.1002/hlca.19660490532; WISONOFF A, 1975, TRANSPLANT REV, V27, P100	23	20	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	5					261	270		10.1016/0091-6749(78)90156-2	http://dx.doi.org/10.1016/0091-6749(78)90156-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FW432	701661				2022-12-18	WOS:A1978FW43200002
J	IMBEAU, SA; HARRUFF, R; HIRSCHER, M; REED, CE				IMBEAU, SA; HARRUFF, R; HIRSCHER, M; REED, CE			TERBUTALINES EFFECTS ON ALLERGY SKIN-TEST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,CTR HLTH SCI,DEPT MED,MADISON,WI 53706; UNIV WISCONSIN,CTR HLTH SCI,DEPT PATHOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								ATKINS P, 1970, J ALLERGY CLIN IMMUN, V51, P263; KRAM JA, 1975, J ALLERGY CLIN IMMUN, V56, P387, DOI 10.1016/0091-6749(75)90132-3; ORANGE RP, 1971, J EXP MED          S, V134, P136; PERPER RJ, 1972, INT ARCH ALLER A IMM, V43, P837, DOI 10.1159/000230901; SHEREFF RH, 1973, J ALLERGY CLIN IMMUN, V52, P328, DOI 10.1016/0091-6749(73)90091-2; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; YAMAMOTO S, 1973, IMMUNOLOGY, V24, P77	7	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	4					193	196		10.1016/0091-6749(78)90207-5	http://dx.doi.org/10.1016/0091-6749(78)90207-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FS392	359625				2022-12-18	WOS:A1978FS39200001
J	KUDO, K; OKUDAIRA, H; MIYAMOTO, T; NAKAGAWA, T; HORIUCHI, Y				KUDO, K; OKUDAIRA, H; MIYAMOTO, T; NAKAGAWA, T; HORIUCHI, Y			IGE ANTIBODY-RESPONSE TO MITE ANTIGEN IN MOUSE - SUPPRESSION OF AN ESTABLISHED IGE ANTIBODY-RESPONSE BY CHEMICALLY MODIFIED ANTIGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TOKYO,SCH MED,DEPT INTERNAL MED & PHYS THERAPY,TOKYO 113,JAPAN	University of Tokyo	KUDO, K (corresponding author), UNIV TOKYO,SCH MED,DEPT INTERNAL MED,BUNKYO KU,TOKYO 113,JAPAN.							BACH MK, 1975, J IMMUNOL, V114, P1799; BIOZZI G, 1971, PROGR IMMUNOLOGY, V1, P528; EISEN H N, 1964, Methods Med Res, V10, P106; Fain A., 1966, Bulletin Acad R Med Belge (7), V6, P479; HERZENBERG LA, 1968, REGULATION ANTIBODY, P322; ISHIZAKA K, 1973, Journal of Immunology, V110, P1067; ISHIZAKA K, 1972, J IMMUNOL, V109, P84; ISHIZAKA K, 1976, J IMMUNOL, V117, P40; ISHIZAKA K, 1974, J IMMUNOL, V113, P70; ISHIZAKA K, 1975, J IMMUNOL, V114, P110; ITO K, 1976, Japanese Journal of Allergology, V25, P815; KING TP, 1974, IMMUNOCHEMISTRY, V11, P83, DOI 10.1016/0019-2791(74)90321-8; KLINMAN NR, 1969, CLIN EXP IMMUNOL, V4, P473; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; MAUNSELL K, 1968, LANCET, V1, P1267; MIYAMOTO T, 1969, J ALLERGY, V44, P228, DOI 10.1016/0021-8707(69)90089-6; MIYAMOTO T, 1969, J ALLERGY, V44, P282, DOI 10.1016/0021-8707(69)90033-1; MIYAMOTO T, 1968, J ALLERGY, V42, P146; MIYAMOTO T, 9TH INT C ALL; NAKAGAWA T, INT ARCH ALLERGY APP; OKUDAIRA H, 1973, J IMMUNOL, V111, P1420; PEPYS J, 1968, LANCET, V1, P1270; REVOLTELLA R, 1969, INT ARCH ALLER A IMM, V36, P282, DOI 10.1159/000230749; TAKATSU K, 1976, J IMMUNOL, V116, P1257; TAKATSU K, 1975, J IMMUNOL, V115, P1469; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; Voorhorst R., 1964, Allergie Asthma, V10, P329; WOFSY L, 1969, J IMMUNOL, V103, P380	28	20	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	1					1	9		10.1016/0091-6749(78)90466-9	http://dx.doi.org/10.1016/0091-6749(78)90466-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH112	618941	Bronze			2022-12-18	WOS:A1978EH11200001
J	SIMS, JA; DOPICO, GA; REED, CE				SIMS, JA; DOPICO, GA; REED, CE			BRONCHODILATING EFFECT OF ORAL THEOPHYLLINE-EPHEDRINE COMBINATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,DEPT MED,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								BOUHUYS A, 1970, AIRWAY DYNAMICS PHYS, P263; CANDER L, 1955, J ALLERGY, V26, P210, DOI 10.1016/0021-8707(55)90018-6; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P334; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; NELSON HS, 1973, J ALLERGY CLIN IMMUN, V51, P191, DOI 10.1016/0091-6749(73)90138-3; RACHELEFSKY GS, 1975, J ALLERGY CLIN IMMUN, V55, P117; RUBIN AHE, 1974, CHEST, V66, P133, DOI 10.1378/chest.66.2.133; SCHACK JA, 1949, J PHARMACOL EXP THER, V97, P283; STORMS WW, 1975, AM REV RESPIR DIS, V111, P419; TAYLOR WF, 1968, ANN ALLERGY, V26, P523; TURNERWARWICK M, 1957, BRIT MED J, V2, P67, DOI 10.1136/bmj.2.5036.67; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WELLING PG, 1976, J CLIN PHARMACOL, V16, P43, DOI 10.1002/j.1552-4604.1976.tb01490.x; WILSON AF, 1976, J ALLERGY CLIN IMMUN, V58, P204, DOI 10.1016/0091-6749(76)90156-1	15	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	1					15	21		10.1016/0091-6749(78)90066-0	http://dx.doi.org/10.1016/0091-6749(78)90066-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG870	350932	Bronze			2022-12-18	WOS:A1978FG87000004
J	HOFFMAN, DR				HOFFMAN, DR			ALLERGENS IN HYMENOPTERA VENOMS .4. COMPARISON OF VENOM AND VENOM SAC EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV,SCH MED,DEPT PATHOL,CRISS 2,OMAHA,NE 68178	Creighton University								BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; HOFFMAN DR, 1976, J ALLERGY CLIN IMMUN, V58, P551, DOI 10.1016/0091-6749(76)90201-3; HOFFMAN DR, 1974, PEDIATRICS, V54, P151; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P147, DOI 10.1016/0091-6749(77)90217-2; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; REISMAN RE, 1975, J ALLERGY CLIN IMMUN, V55, P79; SHEPHERD GW, 1974, PREP BIOCHEM, V4, P71, DOI 10.1080/00327487408068187; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0	12	20	20	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	5					367	370		10.1016/0091-6749(77)90020-3	http://dx.doi.org/10.1016/0091-6749(77)90020-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DF215	856902				2022-12-18	WOS:A1977DF21500006
J	SARACLAR, Y; MCGEADY, SJ; MANSMANN, HC				SARACLAR, Y; MCGEADY, SJ; MANSMANN, HC			LYMPHOCYTE SUBPOPULATIONS OF ATOPIC CHILDREN AND EFFECT OF THERAPY UPON THEM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,PHILADELPHIA,PA 19107	Jefferson University								BIANCO C, 1970, J EXP MED, V132, P702, DOI 10.1084/jem.132.4.702; BLAYLOCK WK, 1976, J ALLERGY CLIN IMMUN, V57, P62, DOI 10.1016/0091-6749(76)90080-4; BUCKLEY RH, 1975, J CLIN INVEST, V55, P157, DOI 10.1172/JCI107906; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; DAHL MV, 1976, ARCH DERMATOL, V112, P1387, DOI 10.1001/archderm.112.10.1387; DUPREE E, 1975, J ALLERGY CLIN IMMUN, V55, P102; FAUCI AS, 1974, J CLIN INVEST, V53, P240, DOI 10.1172/JCI107544; FLEISHER TA, 1975, PEDIATRICS, V55, P162; GOTTLIEB BR, 1974, CLIN RES, V22, pA159; GROVE DI, 1975, J ALLERGY CLIN IMMUN, V55, P152, DOI 10.1016/0091-6749(75)90011-1; GROVE DI, 1975, BRIT J DERMATOL, V92, P611, DOI 10.1111/j.1365-2133.1975.tb03139.x; GUPTA S, 1975, CLIN EXP IMMUNOL, V22, P438; HENDERSON LL, 1975, J ALLERGY CLIN IMMUN, V55, P10, DOI 10.1016/S0091-6749(75)80003-0; JONDAL M, 1972, J EXP MED, V136, P207, DOI 10.1084/jem.136.2.207; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LOBITZ WC, 1972, BRIT J DERMATOL, V86, P317, DOI 10.1111/j.1365-2133.1972.tb05045.x; LUKASEN JR, 1974, ARCH DERMAT, V110, P375; MCGEADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393, DOI 10.1016/0091-6749(75)90133-5; MENDES NF, 1973, J IMMUNOL, V111, P860; POLMAR SH, 1972, AM J PATHOL, V69, P499; RACHELEFSKY GS, 1976, J ALLERGY CLIN IMMUN, V57, P569, DOI 10.1016/0091-6749(76)90008-7; ROGGE JL, 1976, ARCH DERMATOL, V112, P1391, DOI 10.1001/archderm.112.10.1391; SHEVACH EM, 1973, TRANSPLANT REV, V16, P3; STRANNEGARD IL, 1976, INT ARCH ALLER A IMM, V50, P684, DOI 10.1159/000231547; TADA T, 1975, TRANSPLANT REV, V26, P107; WYBRAN J, 1972, J CLIN INVEST, V51, P2537, DOI 10.1172/JCI107069; YOCUM MW, 1976, J ALLERGY CLIN IMMUN, V57, P384, DOI 10.1016/0091-6749(76)90096-8; YU DTY, 1974, J CLIN INVEST, V53, P565, DOI 10.1172/JCI107591; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	29	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	5					301	305		10.1016/0091-6749(77)90109-9	http://dx.doi.org/10.1016/0091-6749(77)90109-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA243	21201				2022-12-18	WOS:A1977EA24300005
J	VOGT, F; CHERVINSKY, P; DWEK, J; GRIECO, M				VOGT, F; CHERVINSKY, P; DWEK, J; GRIECO, M			BECLOMETHASONE DIPROPIONATE AEROSOL IN TREATMENT OF CHRONIC BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCHERING CORP,BLOOMFIELD,NJ 07003; BOOTH MEM MED CTR,FLUSHING,NY; ROOSEVELT HOSP,RA COOKE INST ALLERGY,NEW YORK,NY 10019; ALLERGY ASSOC INC,NEW BEDFORD,MA	Merck & Company; Mount Sinai West								Chatterjee S S, 1972, Curr Med Res Opin, V1, P173, DOI 10.1185/03007997209111163; DICKSON W, 1973, ARCH DIS CHILD, V48, P671, DOI 10.1136/adc.48.9.671; GADDIE J, 1973, LANCET, V1, P691; GODFREY S, 1974, ANN ALLERGY, V33, P150; MABERLY DJ, 1973, BRIT MED J, V1, P778, DOI 10.1136/bmj.1.5856.778; MCALLEN MK, 1974, BMJ-BRIT MED J, V1, P171, DOI 10.1136/bmj.1.5900.171; SMITH A P, 1973, British Journal of Diseases of the Chest, V67, P208, DOI 10.1016/0007-0971(73)90055-7; SMITH J M, 1973, Clinical Allergy, V3, P249, DOI 10.1111/j.1365-2222.1973.tb01330.x; STREETEN DHP, 1975, JAMA-J AM MED ASSOC, V232, P1046, DOI 10.1001/jama.232.10.1046; VILSVIK JS, 1974, SCAND J RESPIR DIS, V55, P169	10	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	2					316	321		10.1016/0091-6749(76)90137-8	http://dx.doi.org/10.1016/0091-6749(76)90137-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA661	780407				2022-12-18	WOS:A1976CA66100009
J	SOIFER, MM; HIRSCH, SR				SOIFER, MM; HIRSCH, SR			DIRECT BASOPHIL DEGRANULATION TEST AND INTRACUTANEOUS TEST - COMPARISON USING FOOD EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN,DEPT PEDIAT,ALLERGY SECT,MILWAUKEE,WI; VET ADM CTR,RES SERV 151,WOOD,WI 53193	Medical College of Wisconsin								AAS K, 1971, J ALLERGY CLIN IMMUN, V48, P134, DOI 10.1016/0091-6749(71)90008-X; DOCKHORN R, 1969, ANN ALLERGY, V27, P411; FREEDMAN SS, 1969, PEDIATR CLIN N AM, V6, P853; HADDAD ZH, 1972, J ALLERGY CLIN IMMUN, V49, P210, DOI 10.1016/0091-6749(72)90084-X; HAYE KR, 1968, BRIT J DERMATOL, V80, P811, DOI 10.1111/j.1365-2133.1968.tb11951.x; HIRSCH SR, 1972, J ALLERGY CLIN IMMUN, V50, P338, DOI 10.1016/0091-6749(72)90037-1; ISHIZAKA T, 1971, J IMMUNOL, V106, P705; KATZ HI, 1964, JAMA, V188, P341; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MACLAREN WR, 1972, ANN ALLERGY, V30, P41; May C D, 1972, Clin Allergy, V2, P335, DOI 10.1111/j.1365-2222.1972.tb01298.x; PRUZANSKY JJ, 1970, INT ARCH ALLER A IMM, V38, P522, DOI 10.1159/000230305; RESNIK SS, 1965, J INVEST DERMATOL, V45, P269, DOI 10.1038/jid.1965.128; REYNOLDS RD, 1967, ANN ALLERGY, V25, P318; SHECTOR WE, 1974, JAMA, V227, P1448; SHELDON JM, 1967, MANUAL CLIN ALLERGY, P507; SHELLEY WB, 1962, NATURE, V195, P1181, DOI 10.1038/1951181a0; SHELLEY WB, 1964, COLL PHYS PHIL T STU, V32, P15	18	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	2					127	132		10.1016/0091-6749(75)90117-7	http://dx.doi.org/10.1016/0091-6749(75)90117-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AM325	1151008				2022-12-18	WOS:A1975AM32500006
J	BURNET, FM				BURNET, FM			TRANSFER-FACTOR - THEORETICAL DISCUSSION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MELBOURNE, SCH MICROBIOLOGY, PARKVILLE 3052, VICTORIA, AUSTRALIA	University of Melbourne								BARAM P, 1973, FED P, V32; BLOOM BR, CITED INDIRECTLY; BURNET FM, 1971, NATURE, V232, P230, DOI 10.1038/232230a0; CHILGREN RA, 1969, LANCET, V1, P1286; COOPER MD, 1968, AM J MED, V44, P499, DOI 10.1016/0002-9343(68)90051-X; KELLY WD, 1968, IMMUNOLOGIC DEFICIEN; KIRKPATRICK CH, 1972, J CLIN INVEST, V51, P2948, DOI 10.1172/JCI107119; Lawrence H S, 1968, Trans Assoc Am Physicians, V81, P240; LAWRENCE HS, 1955, J CLIN INVEST, V34, P219, DOI 10.1172/JCI103075; LAWRENCE HS, 1970, NEW ENGL J MED, V283, P411; LAWRENCE HS, 1960, J CLIN INVEST, V39, P185, DOI 10.1172/JCI104018; LAWRENCE HS, 1969, ADV IMMUNOLOGY, V11; LAWRENCE HS, 1973, PERSONAL COMMUNICATI; LEVIN AG, 1964, ANN NY ACAD SCI, V120, P400, DOI 10.1111/j.1749-6632.1964.tb34739.x; MACFARLANE RG, 1965, INFLAMMATORY PROCESS; MARCHALONIS JJ, 1972, J EXP MED, V135, P956, DOI 10.1084/jem.135.4.956; SCHULKIN.ML, 1972, CELL IMMUNOL, V3, P606, DOI 10.1016/0008-8749(72)90122-0; SCWARTZ RS, 1973, CLIN RES, V21, P588; SMYTHE PM, 1971, LANCET, V2, P939; SPITLER LE, 1972, J CLIN INVEST, V51, P3216, DOI 10.1172/JCI107148; VALDIMARSSON H, 1970, LANCET, V1, P1259; VALENTIN.FT, 1969, SCIENCE, V165, P1016, DOI 10.1126/science.165.3897.1014; 1973, JAMA, V224, P9	23	20	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	1					1	13		10.1016/S0091-6749(74)80002-3	http://dx.doi.org/10.1016/S0091-6749(74)80002-3			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T5232	4545806				2022-12-18	WOS:A1974T523200001
J	HAMBURGE.RN; LENOIR, M; GROSHONG, TE; MILLER, JR; WALLACE, W; ORGEL, HA				HAMBURGE.RN; LENOIR, M; GROSHONG, TE; MILLER, JR; WALLACE, W; ORGEL, HA			DEVELOPMENT OF IGE AND ALLERGY DURING FIRST YEAR OF LIFE - PRELIMINARY DATA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	2					94	94						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S0380					2022-12-18	WOS:A1974S038000073
J	LOPEZ, LR; JOHANSEN, KS; RADOVICH, J; TALMAGE, DW				LOPEZ, LR; JOHANSEN, KS; RADOVICH, J; TALMAGE, DW			THYMOCYTES, MACROPHAGES, AND ERYTHROCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,MED CTR,WEBB WARING LUNG INST,DENVER,CO 80220; UNIV COLORADO,MED CTR,DEPT MICROBIOL,4200 E NINTH AVE,DENVER,CO 80220	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								CHEN C, 1972, J EXP MED, V136, P604, DOI 10.1084/jem.136.3.604; CHEN C, 1972, SCIENCE, V176, P60, DOI 10.1126/science.176.4030.60; DEBRUYN PPH, 1950, ANAT REC, V108, P279, DOI 10.1002/ar.1091080208; DEBRUYN PPH, 1953, EXP CELL RES, V4, P174, DOI 10.1016/0014-4827(53)90200-6; FROLAND S S, 1972, Scandinavian Journal of Immunology, V1, P269, DOI 10.1111/j.1365-3083.1972.tb01818.x; HOFFMANN M, 1971, SCIENCE, V172, P1047, DOI 10.1126/science.172.3987.1047; JONDAL M, 1972, J EXP MED, V136, P207, DOI 10.1084/jem.136.2.207; LAWRENCE HS, 1959, PHYSIOL REV, V39, P811, DOI 10.1152/physrev.1959.39.4.811; LAWRENCE HS, 1969, PERSPECTIVE IMMUNOLO; MOSIER DE, 1967, SCIENCE, V158, P1573, DOI 10.1126/science.158.3808.1573; MOSIER DE, 1972, J EXP MED, V136, P1484, DOI 10.1084/jem.136.6.1484; MOSIER DE, 1969, J EXP MED, V129, P351, DOI 10.1084/jem.129.2.351; PLOTZ PH, 1967, J IMMUNOL, V99, P1236; ROSS GD, 1973, J CLIN INVEST, V52, P377, DOI 10.1172/JCI107194; SAUNDERS GC, 1970, J IMMUNOL, V105, P1299; SIEGEL I, 1970, J CELL BIOL, V47, pA191; SIEGEL I, 1970, J ALLERGY, V46, P190, DOI 10.1016/0021-8707(70)90097-3; SIEGEL I, 1972, J ALLERGY CLIN IMMUN, V50, P65, DOI 10.1016/0091-6749(72)90001-2; SIEGEL I, 1970, J IMMUNOL, V105, P879; SULITZEA.D, 1971, NATURE-NEW BIOL, V229, P254, DOI 10.1038/newbio229254a0; TALMAGE DW, 1973, NY ACAD SCI, V207, P29; WYBRAN J, 1972, J CLIN INVEST, V51, P2537, DOI 10.1172/JCI107069	22	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	6					336	344		10.1016/0091-6749(74)90117-1	http://dx.doi.org/10.1016/0091-6749(74)90117-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T2239	4133316				2022-12-18	WOS:A1974T223900003
J	SOBOTKA, A; FRANKLIN, R; VALENTIN.M; ADKINSON, NF; LICHTENS.L				SOBOTKA, A; FRANKLIN, R; VALENTIN.M; ADKINSON, NF; LICHTENS.L			HONEYBEE VENOM - PHOSPHOLIPASE A AS MAJOR ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	20	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	2					103	103						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S0380					2022-12-18	WOS:A1974S038000096
J	HENDERSON, LL; LARSON, JB; GLEICH, GJ				HENDERSON, LL; LARSON, JB; GLEICH, GJ			EFFECT OF CORTICOSTEROIDS ON SEASONAL INCREASES IN IGE ANTIBODY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN, ALLERGIC DIS RES LAB, ROCHESTER, MN 55901 USA	Mayo Clinic								BERG T, 1971, INT ARCH ALLER A IMM, V41, P452, DOI 10.1159/000230539; CARRYER HM, 1950, J ALLERGY, V21, P282, DOI 10.1016/0021-8707(50)90059-1; CLAMAN HN, 1972, NEW ENGL J MED, V287, P388, DOI 10.1056/NEJM197208242870806; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; HENCH PS, 1950, ARCH INTERN MED, V85, P545, DOI 10.1001/archinte.1950.00230100002001; JASANI M K, 1972, Clinical Allergy, V2, P1, DOI 10.1111/j.1365-2222.1972.tb01266.x; JOHANSSO.SG, 1967, LANCET, V2, P951; JOHANSSON S G O, 1970, British Journal of Dermatology, V82, P10, DOI 10.1111/j.1365-2133.1970.tb02185.x; KUMAR L, 1971, J ALLERGY CLIN IMMUN, V48, P305, DOI 10.1016/0091-6749(71)90032-7; KUMAR L, 1971, PEDIATRICS, V47, P848; LEVY DA, 1967, J IMMUNOL, V99, P1068; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LIEBERMAN PL, 1972, ALLERGIC DISEASES DI; MELBY JC, 1971, STEROID THERAPY; NORMAN PS, 1971, IMMUNOLOGICAL DIS, V2; NORMAN PS, 1966, INT ENCYCLOPEDIA PHA, V2; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	18	20	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	6					352	357		10.1016/0091-6749(73)90094-8	http://dx.doi.org/10.1016/0091-6749(73)90094-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R5074	4752933				2022-12-18	WOS:A1973R507400005
J	KAMMERMEYER, JK; MATHEWS, KP				KAMMERMEYER, JK; MATHEWS, KP			HYPERSENSITIVITY TO PHENYLGLYCINE ACID CHLORIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN, MED SCH,DEPT INTERN MED, MONTGOMERY ALLERGY RES LAB, R6609 KRESGEMED RES BLDG, ANN ARBOR, MI 48104 USA	University of Michigan System; University of Michigan								BIERMAN CW, 1972, J AMER MED ASSOC, V220, P1098, DOI 10.1001/jama.220.8.1098; BRUCKNER HC, 1968, ARCH ENVIRON HEALTH, V16, P619, DOI 10.1080/00039896.1968.10665117; FARAH FS, 1960, J EXP MED, V112, P1211, DOI 10.1084/jem.112.6.1211; FEINBERG SM, 1945, J ALLERGY, V16, P209, DOI 10.1016/0021-8707(45)90001-3; FREEDMAN SO, 1964, J ALLERGY, V35, P97, DOI 10.1016/0021-8707(64)90023-1; GELL PGH, 1968, CLINICAL ASPECTS IMM; HALPERN BN, 1958, SENSITIVITY REACTION; HIRSCHMA.R, 1967, J ORG CHEM, V32, P3415, DOI 10.1021/jo01286a030; HIRSCHMANN R, 1971, J AM CHEM SOC, V93, P2746, DOI 10.1021/ja00740a027; JOHNSTON TG, 1951, J ALLERGY, V22, P494, DOI 10.1016/0021-8707(51)90105-0; KERN RICHARD A., 1939, JOUR ALLERGY, V10, P164, DOI 10.1016/S0021-8707(39)90050-X; LEVINE BB, 1965, J IMMUNOL, V94, P121; LEVINE BB, 1965, J ALLERGY, V36, P342, DOI 10.1016/0021-8707(65)90041-9; MATHEWS KP, 1968, AM J MED, V44, P310, DOI 10.1016/0002-9343(68)90162-9; PARKER CW, 1962, J EXP MED, V115, P789, DOI 10.1084/jem.115.4.789; PUTNAM FW, 1960, PLASMA PROTEINS, V1; ROSENBERG LT, 1971, J IMMUNOL, V107, P1175; SHELDON JM, 1967, MANUAL CLINICAL ALLE; SHERMAN WB, 1947, AM J MED, V2, P588, DOI 10.1016/0002-9343(47)90049-1; VANDELLEN RG, 1971, J ALLERGY, V47, P230, DOI 10.1016/S0091-6749(71)80468-2	20	20	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	2					73	84		10.1016/0091-6749(73)90079-1	http://dx.doi.org/10.1016/0091-6749(73)90079-1			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q4190	4124984	Bronze			2022-12-18	WOS:A1973Q419000002
J	NORMAN, PS; LICHTENSTEIN, LM				NORMAN, PS; LICHTENSTEIN, LM			CAPACITY OF PURIFIED ANTIGENS AND WHOLE POLLEN EXTRACTS TO RELEASE HISTAMINE FROM LEUKOCYTES OF HAY-FEVER PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV, GOOD SAMARITAN HOSP,DEPT MED,CLIN IMMUNOL DIV, 5601 LOCH RAVEN BLVD, BALTIMORE, MD 21239 USA	Johns Hopkins University								BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; GOODFRIEND L, 1972, FED PROC, V31, P875; JOHNSON P, 1966, IMMUNOCHEMISTRY, V3, P101, DOI 10.1016/0019-2791(66)90291-6; JOHNSON P, 1966, IMMUNOCHEMISTRY, V3, P91, DOI 10.1016/0019-2791(66)90290-4; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; KING TP, 1967, BIOCHEMISTRY-US, V6, P1992, DOI 10.1021/bi00859a017; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1966, J ALLERGY, V38, P174, DOI 10.1016/0021-8707(66)90040-2; LICHTENSTEIN LM, 1969, J ALLERGY, V44, P307, DOI 10.1016/0021-8707(69)90035-5; MARSH DG, 1970, J ALLERGY, V46, P107, DOI 10.1016/0021-8707(70)90078-X; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MELAM H, 1970, J ALLERGY, V45, P43, DOI 10.1016/0021-8707(70)90015-8; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; REISMAN RE, 1969, J ALLERGY, V44, P82, DOI 10.1016/0021-8707(69)90004-5; UNDERDOWN BJ, 1969, BIOCHEMISTRY-US, V8, P980, DOI 10.1021/bi00831a031	19	20	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	2					94	104		10.1016/0091-6749(73)90081-X	http://dx.doi.org/10.1016/0091-6749(73)90081-X			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q4190	4124985				2022-12-18	WOS:A1973Q419000004
J	MAY, CD; WILLIAMS, CS; SCHUMACHER, MJ				MAY, CD; WILLIAMS, CS; SCHUMACHER, MJ			SIGNIFICANCE OF CONCORDANT FLUCTUATION AND LOSS OF LEUKOCYTE SENSITIVITY TO 2 ALLERGENS DURING INJECTION THERAPY WITH ONE NONSPECIFIC DESENSITIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		HULLIGER L, 1967, LANCET, V1, P1304; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1968, BIOCHEMISTRY ACUTE A, P158; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MAY CD, 1972, PEDIATRICS, V49, P536; MAY CD, 1971, J ALLERGY CLIN IMMUN, V48, P313, DOI 10.1016/0091-6749(71)90033-9; MAY CD, 1970, J ALLERGY, V46, P73, DOI 10.1016/0021-8707(70)90075-4; MELAM H, 1971, J ALLERGY, V47, P262, DOI 10.1016/S0091-6749(71)80004-0; SCHUMACHER MJ, IN PRESS	9	20	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	2					99	+		10.1016/0091-6749(72)90005-X	http://dx.doi.org/10.1016/0091-6749(72)90005-X			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N1795	4114296				2022-12-18	WOS:A1972N179500005
J	MORRIS, HG; EARLE, MR; DEROCHE, G				MORRIS, HG; EARLE, MR; DEROCHE, G			URINARY-EXCRETION OF EPINEPHRINE AND NOREPINEPHRINE IN ASTHMATIC CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ABRAMSON EA, 1968, DIABETES, V17, P141, DOI 10.2337/diab.17.3.141; ANTON AH, 1962, J PHARMACOL EXP THER, V138, P360; BLACKWELL EW, 1970, BRIT J PHARMACOL, V39, pP194; BROBERGER O, 1959, J PEDIATR-US, V55, P713, DOI 10.1016/S0022-3476(59)80262-6; CERASI E, 1969, Hormone and Metabolic Research, V1, P221; DEROCHE GM, IN PRESS; ELMADJIAN F, 1957, J CLIN ENDOCR METAB, V17, P608, DOI 10.1210/jcem-17-5-608; ELMADJIAN F, 1956, J CLIN ENDOCR METAB, V16, P876, DOI 10.1210/jcem-16-7-876; EULER ULF S. v, 1952, METABOLISM, V1, P528; FISHER RA, 1954, STATISTICAL METHODS; HATHAWAY PW, 1969, PSYCHOSOM MED, V31, P20, DOI 10.1097/00006842-196901000-00003; HOEHNE JH, 1970, J ALLERGY, V46, P336, DOI 10.1016/0021-8707(70)90084-5; HOELDTKE RD, 1970, J LAB CLIN MED, V75, P166; KNAUFF HG, 1962, KLIN WOCHENSCHR, V40, P411, DOI 10.1007/BF01732839; KUMAR L, 1971, J PEDIATR-US, V79, P955, DOI 10.1016/S0022-3476(71)80190-7; LEVI L, 1965, PSYCHOSOM MED, V27, P80, DOI 10.1097/00006842-196501000-00009; MAKINO S, 1970, J ALLERGY, V46, P178, DOI 10.1016/0021-8707(70)90096-1; MASUDA M, 1966, J PSYCOSOM RES, V10, P225; MATHE AA, 1969, NEW ENGL J MED, V281, P234, DOI 10.1056/NEJM196907312810503; MORRIS HE, IN PRESS; MORRIS HG, 1971, J ALLERGY, V47, P110; MORRIS HG, 1968, J CLIN INVEST, V47, P427, DOI 10.1172/JCI105739; MORRIS HG, 1971, J PEDIATR-US, V79, P480, DOI 10.1016/S0022-3476(71)80163-4; NAHAS GG, 1968, RESP PHYSIOL, V5, P108, DOI 10.1016/0034-5687(68)90080-7; OUELLETTE JJ, 1967, J ALLERGY, V39, P234, DOI 10.1016/0021-8707(67)90016-0; REED CE, 1968, YALE J BIOL MED, V40, P507; STEINSLAND OS, 1970, AM J PHYSIOL, V218, P995, DOI 10.1152/ajplegacy.1970.218.4.995; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; VOORHESS ML, 1962, J CLIN ENDOCR METAB, V22, P126, DOI 10.1210/jcem-22-2-126; WEGIERKO J, 1936, PRESSE MED, V44, P731	30	20	20	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	3					138	&		10.1016/0091-6749(72)90044-9	http://dx.doi.org/10.1016/0091-6749(72)90044-9			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	N4708	5065709				2022-12-18	WOS:A1972N470800002
J	PORTNER, MM; THAYER, KH; HARTER, JG; LIANG, TC; RAYYIS, S; KENT, JR				PORTNER, MM; THAYER, KH; HARTER, JG; LIANG, TC; RAYYIS, S; KENT, JR			SUCCESSFUL INITIATION OF ALTERNATE-DAY PREDNISONE IN CHRONIC STEROID-DEPENDENT ASTHMATIC PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ACKERMAN GL, 1968, NEW ENGL J MED, V278, P405, DOI 10.1056/NEJM196802222780801; BERSON SA, 1968, J CLIN INVEST, V47, P2725, DOI 10.1172/JCI105955; DALY JR, 1967, ANN RHEUM DIS, V26, P18, DOI 10.1136/ard.26.1.18; EASTON JG, PERSONAL COMMUNICATI; FALLIERS CJ, PERSONAL COMMUNICATI; FLEISHER DS, 1967, J PEDIATR-US, V70, P54, DOI 10.1016/S0022-3476(67)80165-3; Freedman S O, 1969, Appl Ther, V11, P81; GRABER AL, 1965, J CLIN ENDOCR METAB, V25, P11, DOI 10.1210/jcem-25-1-11; GREENWOO.FC, 1966, J CLIN INVEST, V45, P429, DOI 10.1172/JCI105357; HARTER JG, 1966, NEW YORK STATE J MED, V66, P827; HARTER JG, 1958, FEB AM AC ALL M; HEIMLICH EM, 1967, J ALLERGY, V39, P111; Hoffman WS, 1937, J BIOL CHEM, V120, P51; JASANI MK, 1968, ANN RHEUM DIS, V27, P352, DOI 10.1136/ard.27.4.352; KNOWLES JP, 1961, BRIT MED J, V2, P1396, DOI 10.1136/bmj.2.5264.1396; MACGREGOR RR, 1969, NEW ENGL J MED, V280, P427; MATTINGLY D, 1962, J CLIN PATHOL, V15, P374, DOI 10.1136/jcp.15.4.374; MAYNARD DE, 1966, ANN INTERN MED, V64, P552, DOI 10.7326/0003-4819-64-3-552; RAYYIS SS, 1969, J CLIN ENDOCR METAB, V29, P1231, DOI 10.1210/jcem-29-9-1231; SADEGHIN.A, 1969, PEDIATRICS, V43, P277; SHELDON J M, 1955, J Mich State Med Soc, V54, P1081; SIEGEL SC, 1965, J ALLERGY, V36, P209; SIEGEL SC, 1969, PEDIATR CLIN N AM, V16, P287; SOYKA LF, 1965, J AMER MED ASSOC, V192, P225, DOI 10.1001/jama.1965.03080160045012; TREADWELL BLJ, 1963, LANCET, V1, P355	25	20	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	1					16	&		10.1016/0091-6749(72)90119-4	http://dx.doi.org/10.1016/0091-6749(72)90119-4			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L3388	4331972				2022-12-18	WOS:A1972L338800003
J	Bork, K; Wulff, K; Mohl, BS; Steinmuller-Magin, L; Witzke, G; Hardt, J; Meinke, P				Bork, Konrad; Wulff, Karin; Moehl, Britta S.; Steinmueller-Magin, Lars; Witzke, Gunther; Hardt, Jochen; Meinke, Peter			Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hereditary angioedema; normal C1 INH; HAEnCI; HS3ST6; heparan sulfate-glucosamine 3-O-sulfotransferase 6; 3-OST-6	MISSENSE MUTATIONS; F12 GENE; PROTEOGLYCANS; KININOGEN; INHIBITOR; SERVER; ENTRY	Background: Hereditary angioedema (HAE) is a potentially fatal disorder resulting in recurrent attacks of severe swelling. It may be associated with a genetic deficiency of functional C1 inhibitor or with normal C1 inhibitor (HAEnCI). In families with HAEnCI, HAE-linked mutations in the F12, PLG, KNG1, ANGPT1, or MYOF genes have been identified. In many families with HAEnCI the genetic cause of the disease is currently unknown. Objective: The aim of this study was to identify a novel disease-linked mutation for HAEnCI. Methods: The study methods comprised whole exome sequencing, Sanger sequencing analysis, pedigree analysis, bioinformatic analysis of the mutation, and biochemical analysis of parameters of the kallikrein-kinin (contact) system. Results: By performing whole exome sequencing on a multigenerational family with HAEnCI we were able to identify the heparan sulfate (HS)-glucosamine 3-O-sulfotransferase 6 (HS3ST6) mutation c.430A>T (p.Thr144Ser) in all 3 affected family members who were sequenced. This gene encodes HS-glucosamine 3-O-sulfotransferase 6 (3-OST-6), which is involved in the last step of HS biosynthesis. The p.Thr144Ser mutation is likely to affect the interaction between 2 beta-sheets stabilizing the active center of the 3-OST-6 protein. Conclusions: We conclude that mutant 3-OST-6 fails to transfer sulfo groups to the 3-OH position of HS, resulting in incomplete HS biosynthesis. This likely affects cell surface interactions of key players in angioedema formation and is a novel mechanism for disease development.	[Bork, Konrad; Witzke, Gunther] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Dermatol, Langenbeckstr 1, D-55131 Mainz, Germany; [Wulff, Karin] Univ Greifswald, Univ Med, Greifswald, Germany; [Moehl, Britta S.] Tech Univ Munich, Sch Med, Inst Virol, Helmholtz Zentrum Munchen, Munich, Germany; [Steinmueller-Magin, Lars] Inst Lab Med & Human Genet, Singen, Germany; [Hardt, Jochen] Johannes Gutenberg Univ Mainz, Dept Med Psychol & Med Sociol, Mainz, Germany; [Meinke, Peter] Ludwig Maximilians Univ Munchen, Friedrich Baur Inst, Dept Neurol, Munich, Germany	Johannes Gutenberg University of Mainz; Ernst Moritz Arndt Universitat Greifswald; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Johannes Gutenberg University of Mainz; University of Munich	Bork, K (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Dermatol, Langenbeckstr 1, D-55131 Mainz, Germany.	konrad.bork@unimedizin-mainz.de	Bork, Konrad/AAE-4985-2022	Bork, Konrad/0000-0002-6084-4577; Meinke, Peter/0000-0003-3359-3837				Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Ariano A, 2020, ALLERGY, V75, P2989, DOI 10.1111/all.14454; Bafunno V, 2018, J ALLERGY CLIN IMMUN, V141, P1009, DOI 10.1016/j.jaci.2017.05.020; Bork K, 2006, AM J GASTROENTEROL, V101, P619, DOI 10.1111/j.1572-0241.2006.00492.x; Bork K, 2018, ALLERGY, V73, P442, DOI 10.1111/all.13270; Bork K, 2015, ALLERGY, V70, P1004, DOI 10.1111/all.12648; Bork K, 2014, HAEMOPHILIA, V20, pe372, DOI 10.1111/hae.12519; Bork K, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023-020-01570-x; Bork K, 2019, ALLERGY, V74, P2479, DOI 10.1111/all.13869; Bork K, 2011, CLIN IMMUNOL, V141, P31, DOI 10.1016/j.clim.2011.07.002; Bork K, 2009, J ALLERGY CLIN IMMUN, V124, P129, DOI 10.1016/j.jaci.2009.03.038; Busse PJ, 2020, NEW ENGL J MED, V382, P1136, DOI 10.1056/NEJMra1808012; CARLSON TH, 1995, BLOOD COAGUL FIBRIN, V6, P474, DOI 10.1097/00001721-199507000-00016; Choi Y, 2015, BIOINFORMATICS, V31, P2745, DOI 10.1093/bioinformatics/btv195; Damasceno IZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121721; de Agostini AI, 2008, J BIOL CHEM, V283, P28115, DOI 10.1074/jbc.M805338200; Dewald G, 2006, BIOCHEM BIOPH RES CO, V343, P1286, DOI 10.1016/j.bbrc.2006.03.092; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Fuster MM, 2010, PROG MOL BIOL TRANSL, V93, P179, DOI 10.1016/S1877-1173(10)93009-3; Gibbons KR, 2017, ANN ALLERG ASTHMA IM, V119, P558, DOI 10.1016/j.anai.2017.08.015; Gosswein T, 2008, CYTOGENET GENOME RES, V121, P181, DOI 10.1159/000138883; Gozzo AJ, 2011, BIOCHIMIE, V93, P1839, DOI 10.1016/j.biochi.2011.07.003; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; Kaplan AP, 2014, ADV IMMUNOL, V121, P41, DOI 10.1016/B978-0-12-800100-4.00002-7; Kaplan AP, 2010, ANN ALLERG ASTHMA IM, V104, P193, DOI 10.1016/j.anai.2010.01.007; Kiss N, 2013, CLIN IMMUNOL, V149, P142, DOI 10.1016/j.clim.2013.08.001; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Melo KRB, 2009, BIOL CHEM, V390, P145, DOI 10.1515/BC.2009.016; Moon AF, 2004, J BIOL CHEM, V279, P45185, DOI 10.1074/jbc.M405013200; Noguer O, 2009, EXP CELL RES, V315, P795, DOI 10.1016/j.yexcr.2008.11.016; O'Donnell Christopher D, 2008, Virol Sin, V23, P383, DOI 10.1007/s12250-008-2992-1; Pathak M, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00066; Renne T, 2000, J BIOL CHEM, V275, P33688, DOI 10.1074/jbc.M000313200; Renne T, 2005, J IMMUNOL, V175, P3377, DOI 10.4049/jimmunol.175.5.3377; Renne T, 2001, FEBS LETT, V500, P36, DOI 10.1016/S0014-5793(01)02570-4; Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890; Xiong AQ, 2014, FEBS J, V281, P4993, DOI 10.1111/febs.13097; Xu D, 2005, BIOCHEM J, V385, P451, DOI 10.1042/BJ20040908; Xu D, 2008, NAT CHEM BIOL, V4, P200, DOI 10.1038/nchembio.66; Zuraw BL, 2012, ALLERGY ASTHMA PROC, V33, pS145, DOI 10.2500/aap.2012.33.3627	40	19	19	3	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2021	148	4					1041	1048		10.1016/j.jaci.2021.01.011	http://dx.doi.org/10.1016/j.jaci.2021.01.011		OCT 2021	8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD6BK	33508266				2022-12-18	WOS:000705023300014
J	Zhang, YQ; Wei, J; Shi, YQ; Quan, C; Ho, HC; Song, YM; Zhang, L				Zhang, Yunquan; Wei, Jing; Shi, Yuqin; Quan, Chao; Ho, Hung Chak; Song, Yimeng; Zhang, Ling			Early-life exposure to submicron particulate air pollution in relation to asthma development in Chinese preschool children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fine particulate matter; PM1; early-life exposure; asthma; wheezing; preschool children	ENVIRONMENTAL TOBACCO-SMOKE; TRAFFIC-RELATED AIR; CHILDHOOD ASTHMA; RESPIRATORY ILLNESS; PM1; PM2.5; BIRTH; MORTALITY; ALLERGIES; RHINITIS	Background: Emerging research suggested an association of early-life particulate air pollution exposure with development of asthma in childhood. However, the potentially differential effects of submicron particulate matter (PM; PM with aerodynamic diameter <= 1 mm [PM1]) remain largely unknown. Objective: This study primarily aimed to investigate associations of childhood asthma and wheezing with in utero and first-year exposures to size-specific particles. Methods: We conducted a large cross-sectional survey among 5788 preschool children aged 3 to 5 years in central China. In utero and first-year exposures to ambient PM1, PM with aerodynamic diameter less than or equal to 2.5 mu m, and PM with aerodynamic diameter less than or equal to 10 mu m at 1 x 1-km resolution were assessed using machine learning- based spatiotemporal models. A time-to-event analysis was performed to examine associations between residential PM exposures and childhood onset of asthma and wheezing. Results: Early-life size-specific PM exposures, particularly during pregnancy, were significantly associated with increased risk of asthma, whereas no evident PM-wheezing associations were observed. Each 10-mu g/m(3) increase in in utero and first-year PM1 exposure was accordingly associated with an asthma's hazard ratio in childhood of 1.618 (95% CI, 1.159-2.258; P = .005) and 1.543 (0.822-2.896; P = .177). Subgroup analyses suggest that short breast-feeding duration may aggravate PM associated risk of childhood asthma. Each 10-mu g/m(3) increase in in utero exposure to PM1, for instance, was associated with a hazard ratio of 2.260 (1.393-3.666) among children with 0 to 5 months' breast-feeding and 1.156 (0.721-1.853) among those longer breast-fed. Conclusions: Our study added comparative evidence for increased risk of childhood asthma in relation to early-life PM exposures, highlighting stronger associations with ambient PM1 than with PM with aerodynamic diameter less than or equal to 2.5 mu m and PM with aerodynamic diameter less than or equal to 10 mu m.	[Zhang, Yunquan] Wuhan Univ Sci & Technol, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan 430065, Peoples R China; [Zhang, Yunquan; Shi, Yuqin; Quan, Chao; Zhang, Ling] Wuhan Univ Sci & Technol, Hubei Prov Key Lab Occupat Hazard Identificat & C, Wuhan, Peoples R China; [Wei, Jing] Univ Iowa, Iowa Technol Inst, Dept Chem & Biochem Engn, Iowa City, IA USA; [Shi, Yuqin; Quan, Chao; Zhang, Ling] Wuhan Univ Sci & Technol, Sch Publ Hlth, Dept Environm Hyg & Occupat Med, Wuhan 430065, Peoples R China; [Ho, Hung Chak] Univ Hong Kong, Dept Urban Planning & Design, Hong Kong, Peoples R China; [Song, Yimeng] Hong Kong Polytech Univ, Dept Land Surveying & GeoInformat, Hong Kong, Peoples R China; [Song, Yimeng] Hong Kong Polytech Univ, Smart Cities Res Inst, Hong Kong, Peoples R China	Wuhan University of Science & Technology; Wuhan University of Science & Technology; University of Iowa; Wuhan University of Science & Technology; University of Hong Kong; Hong Kong Polytechnic University; Hong Kong Polytechnic University	Zhang, YQ (corresponding author), Wuhan Univ Sci & Technol, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan 430065, Peoples R China.; Zhang, L (corresponding author), Wuhan Univ Sci & Technol, Sch Publ Hlth, Dept Environm Hyg & Occupat Med, Wuhan 430065, Peoples R China.	YunquanZhang@wust.edu.cn; zhangling@wust.edu.cn	Zhang, Yunquan/M-9828-2017; wei, jing/GXA-1455-2022; Song, Yimeng/I-9990-2019; Wei, Jing/L-5459-2017	Zhang, Yunquan/0000-0002-2618-5088; Song, Yimeng/0000-0001-9558-1220; Wei, Jing/0000-0002-8803-7056	Scientific Research Program - Hubei Provincial Department of Education [Q20201104]; Outstanding Young and Middle-Aged Technology Innovation Team Project of Hubei Provincial Department of Education [T2020003]; Open Fund Project of Hubei Province Key Laboratory of Occupational Hazard Identification and Control [OHIC2020Y01]; Key Research Center for Humanities and Social Sciences in Hubei Province (Hubei University of Medicine) [2020ZD001]	Scientific Research Program - Hubei Provincial Department of Education; Outstanding Young and Middle-Aged Technology Innovation Team Project of Hubei Provincial Department of Education; Open Fund Project of Hubei Province Key Laboratory of Occupational Hazard Identification and Control; Key Research Center for Humanities and Social Sciences in Hubei Province (Hubei University of Medicine)	This study was financially supported by the Scientific Research Program Funded by Hubei Provincial Department of Education (grant no. Q20201104), Outstanding Young and Middle-Aged Technology Innovation Team Project of Hubei Provincial Department of Education (grant no. T2020003), Open Fund Project of Hubei Province Key Laboratory of Occupational Hazard Identification and Control (grant no. OHIC2020Y01), and Key Research Center for Humanities and Social Sciences in Hubei Province (Hubei University of Medicine) (grant no. 2020ZD001).	Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Baker RJ, 2006, ENVIRON HEALTH PERSP, V114, P1126, DOI 10.1289/ehp.8501; Burbank AJ, 2017, J ALLERGY CLIN IMMUN, V140, P1, DOI 10.1016/j.jaci.2017.05.010; Cai J, 2019, ENVIRON INT, V126, P735, DOI 10.1016/j.envint.2019.03.013; Chen F, 2018, ENVIRON POLLUT, V232, P329, DOI 10.1016/j.envpol.2017.08.072; Chen GB, 2019, STROKE, V50, P563, DOI 10.1161/STROKEAHA.118.023264; Chen GB, 2017, LANCET PLANET HEALTH, V1, pE221, DOI [10.1016/S2542-5196(17)30100-6, 10.1016/s2542-5196(17)30100-6]; Chen K, 2020, ENVIRON HEALTH PERSP, V128, DOI 10.1289/EHP5478; Christensen S, 2017, ENVIRON MOL MUTAGEN, V58, P423, DOI 10.1002/em.22097; Chulada PC, 2003, J ALLERGY CLIN IMMUN, V111, P328, DOI 10.1067/mai.2003.127; Clark NA, 2010, ENVIRON HEALTH PERSP, V118, P284, DOI 10.1289/ehp.0900916; Clougherty JE, 2010, ENVIRON HEALTH PERSP, V118, P167, DOI 10.1289/ehp.0900994; Deal JA, 2019, JAMA OTOLARYNGOL, V145, P36, DOI 10.1001/jamaoto.2018.2876; Deng QH, 2016, ENVIRON RES, V150, P119, DOI 10.1016/j.envres.2016.05.050; Di Q, 2017, JAMA-J AM MED ASSOC, V318, P2446, DOI 10.1001/jama.2017.17923; Dick S, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006554; Dong GH, 2013, EPIDEMIOLOGY, V24, P387, DOI 10.1097/EDE.0b013e3182877eb8; GBD 2017 Gastrooesophageal, 2020, LANCET GASTROENTEROL, V5, P561, DOI 10.1016/S2468-1253(19)30408-X; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Gruzieva O, 2019, ENVIRON HEALTH PERSP, V127, DOI 10.1289/EHP4522; Gruzieva O, 2017, ENVIRON HEALTH PERSP, V125, P104, DOI 10.1289/EHP36; Herrera-Luis E, 2019, CURR OPIN PULM MED, V25, P101, DOI 10.1097/MCP.0000000000000533; Heydari H, 2020, ENVIRON POLLUT, V261, DOI 10.1016/j.envpol.2020.114195; Hsu HHL, 2015, AM J RESP CRIT CARE, V192, P1052, DOI 10.1164/rccm.201504-0658OC; Hu CY, 2020, CHEMOSPHERE, V253, DOI 10.1016/j.chemosphere.2020.126668; Hu KJ, 2018, ENVIRON INT, V121, P515, DOI 10.1016/j.envint.2018.09.033; Jedrychowski WA, 2010, PEDIAT ALLERG IMM-UK, V21, pE723, DOI 10.1111/j.1399-3038.2010.01034.x; Jung CR, 2019, J ALLERGY CLIN IMMUN, V143, P2254, DOI 10.1016/j.jaci.2019.03.024; Lavigne E, 2019, AM J RESP CRIT CARE, V199, P1487, DOI 10.1164/rccm.201810-1976OC; Lee A, 2018, J ALLERGY CLIN IMMUN, V141, P1880, DOI 10.1016/j.jaci.2017.07.017; Lee RY, 2020, JAMA-J AM MED ASSOC, V323, P950, DOI 10.1001/jama.2019.22523; Li X, 2020, J GLOB HEALTH, V10, DOI [10.7189/jogh.10.010801, 10.7189/jogh.10.01081]; Lin HL, 2016, INT J HYG ENVIR HEAL, V219, P204, DOI 10.1016/j.ijheh.2015.11.002; Liu H, 2018, EPIDEMIOLOGY, V29, P649, DOI [10.1097/EDE.0000000000000869, 10.1097/ede.0000000000000869]; Liu QB, 2019, INT J ENVIRON HEAL R, V29, P22, DOI 10.1080/09603123.2018.1506569; Liu W, 2020, ENVIRON INT, V142, DOI 10.1016/j.envint.2020.105853; Liu X, 2019, ENVIRON INT, V133, DOI 10.1016/j.envint.2019.105177; Liu YQ, 2016, INDOOR AIR, V26, P614, DOI 10.1111/ina.12240; Liu YW, 2019, AM J RESP CRIT CARE, V200, P24, DOI 10.1164/rccm.201810-1823OC; Miliku K, 2018, NUTRIENTS, V10, DOI 10.3390/nu10080995; Morales E, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00499; Moshammer H, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16030304; Norback D, 2019, ENVIRON INT, V123, P61, DOI 10.1016/j.envint.2018.11.033; Pejhan A, 2019, CHEMOSPHERE, V226, P447, DOI 10.1016/j.chemosphere.2019.03.185; Pennington AF, 2018, EPIDEMIOLOGY, V29, P22, DOI [10.1097/EDE.0000000000000754, 10.1097/ede.0000000000000754]; Qiao T, 2016, SCI TOTAL ENVIRON, V557, P386, DOI 10.1016/j.scitotenv.2016.03.095; Rabinovitch N, 2011, AM J RESP CRIT CARE, V184, P1350, DOI 10.1164/rccm.201010-1706OC; Rosa MJ, 2017, ANN ALLERG ASTHMA IM, V119, P232, DOI 10.1016/j.anai.2017.06.016; Samek L, 2018, ENVIRON POLLUT, V241, P406, DOI 10.1016/j.envpol.2018.05.082; Sbihi H, 2016, EUR RESPIR J, V47, P1062, DOI 10.1183/13993003.00746-2015; Sbihi H, 2015, ENVIRON HEALTH PERSP, V123, P902, DOI 10.1289/ehp.1408700; Sears CG, 2018, ENVIRON INT, V121, P574, DOI 10.1016/j.envint.2018.09.049; Sheridan P, 2019, AM J EPIDEMIOL, V188, P1608, DOI 10.1093/aje/kwz120; Smargiassi A, 2012, J EXPO SCI ENV EPID, V22, P331, DOI 10.1038/jes.2012.26; Sonnenschein-van der Voort AMM, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-91; Soriano JB, 2017, LANCET RESP MED, V5, P691, DOI 10.1016/S2213-2600(17)30293-X; Stieb DM, 2019, ENVIRON HEALTH-GLOB, V18, DOI 10.1186/s12940-018-0440-8; Vardoulakis S, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17238972; Wang Q, 2018, ENVIRON INT, V121, P317, DOI 10.1016/j.envint.2018.09.021; Wang YQ, 2015, ATMOS CHEM PHYS, V15, P13585, DOI 10.5194/acp-15-13585-2015; Wang YY, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2017.4872; Watanabe J, 2018, J ASTHMA, V55, P511, DOI 10.1080/02770903.2017.1349793; Wei J, 2021, ENVIRON INT, V146, DOI 10.1016/j.envint.2020.106290; Wei J, 2021, REMOTE SENS ENVIRON, V252, DOI 10.1016/j.rse.2020.112136; Wei J, 2020, ATMOS CHEM PHYS, V20, P3273, DOI 10.5194/acp-20-3273-2020; Wei J, 2019, ENVIRON SCI TECHNOL, V53, P13265, DOI 10.1021/acs.est.9b03258; Wei J, 2019, REMOTE SENS ENVIRON, V231, DOI 10.1016/j.rse.2019.111221; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; WOODWARD A, 1990, J EPIDEMIOL COMMUN H, V44, P224, DOI 10.1136/jech.44.3.224; Yan W, 2020, ENVIRON SCI POLLUT R, V27, P29280, DOI 10.1007/s11356-020-09014-6; Yang BY, 2019, ENVIRON INT, V123, P310, DOI 10.1016/j.envint.2018.12.012; Yang M, 2018, ENVIRON INT, V120, P516, DOI 10.1016/j.envint.2018.08.027; Yuan L, 2020, CHEMOSPHERE, V240, DOI 10.1016/j.chemosphere.2019.124904; Zhang C, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.4186; Zhang HH, 2017, ENVIRON RES, V159, P519, DOI 10.1016/j.envres.2017.08.038; Zhang YP, 2013, CHINESE SCI BULL, V58, P4182, DOI 10.1007/s11434-013-5914-z; Zhang YQ, 2020, ATMOS ENVIRON, V223, DOI 10.1016/j.atmosenv.2020.117271; Zhang YQ, 2020, CHEMOSPHERE, V246, DOI 10.1016/j.chemosphere.2019.125723; Zhang YQ, 2020, INT J HYG ENVIR HEAL, V224, DOI 10.1016/j.ijheh.2019.11.001; Zielinska MA, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16214181; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	82	19	19	8	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2021	148	3					771	+		10.1016/j.jaci.2021.02.030	http://dx.doi.org/10.1016/j.jaci.2021.02.030		SEP 2021	24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UP2VR	33684436				2022-12-18	WOS:000695242900026
J	Lehtimaki, J; Thorsen, J; Rasmussen, MA; Hjelmso, M; Shah, S; Mortensen, MS; Trivedi, U; Vestergaard, G; Bonnelykke, K; Chawes, BL; Brix, S; Sorensen, SJ; Bisgaard, H; Stokholm, J				Lehtimaki, Jenni; Thorsen, Jonathan; Rasmussen, Morten Arendt; Hjelmso, Mathis; Shah, Shiraz; Mortensen, Martin S.; Trivedi, Urvish; Vestergaard, Gisle; Bonnelykke, Klaus; Chawes, Bo Lund; Brix, Susanne; Sorensen, Soren J.; Bisgaard, Hans; Stokholm, Jakob			Urbanized microbiota in infants, immune constitution, and later risk of atopic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Microbiome; residential environment; urbanization; childhood; noncommunicable diseases	CHILDHOOD ASTHMA; ALLERGIC DISEASE; DIVERSITY; EXPOSURE; BACTERIA; WHEEZE; AIRWAY; BIODIVERSITY; PREVALENCE; PREVENTION	Background: Urbanization is linked with an increased burden of asthma and atopic traits. A putative mechanism is insufficient exposure to beneficial microbes early in life, leading to immune dysregulation, as was previously shown for indoor microbial exposures. Objective: Our aim was to investigate whether urbanization is associated with the microbiota composition in the infants' body and early immune function, and whether these contribute to the later risk of asthma and atopic traits. Methods: We studied the prospective Copenhagen Prospective Studies on Asthma in Childhood 20102010 mother-child cohort of 700 children growing up in areas with different degrees of urbanization. During their first year of life, airway and gut microbiotas, as well as immune marker concentrations, were defined. When the children were 6 years of age, asthma and atopic traits were diagnosed by pediatricians. Results: In adjusted analyses, the risk of asthma and aeroallergen sensitization were increased in urban infants. The composition of especially airway but also gut microbiotas differed between urban and rural infants. The living environment-related structure of the airway microbiota was already associated with immune mediator concentrations at 1 month of age. An urbanized structure of the airway and gut microbiotas was associated with an increased risk of asthma coherently during multiple time points and also with the risks of eczema and sensitization. Conclusion: Our findings suggest that urbanization-related changes in the infant microbiota may elevate the risk of asthma and atopic traits, probably via cross talk with the developing immune system. The airways may facilitate this effect, as they are open for colonization by environmental airborne microbes and serve as an immune interface. (J Allergy Clin Immunol 2021;148:234-43.)	[Lehtimaki, Jenni; Thorsen, Jonathan; Rasmussen, Morten Arendt; Hjelmso, Mathis; Shah, Shiraz; Bonnelykke, Klaus; Chawes, Bo Lund; Bisgaard, Hans; Stokholm, Jakob] Univ Copenhagen, Herlev & Gentofte Hosp, Copenhagen Prospect Studies Asthma Childhood, Gentofte, Denmark; [Thorsen, Jonathan] Univ Copenhagen, Novo Nordisk Fdn, Ctr Basic Metab Res, Fac Hlth & Med Sci, Copenhagen, Denmark; [Rasmussen, Morten Arendt] Univ Copenhagen, Dept Food Sci, Sect Chemometr & Analyt Technol, Frederiksberg, Denmark; [Mortensen, Martin S.; Trivedi, Urvish; Vestergaard, Gisle; Sorensen, Soren J.] Univ Copenhagen, Dept Biol, Sect Microbiol, Copenhagen, Denmark; [Mortensen, Martin S.] Wellcome Sanger Inst, Host Microbiota Interact Lab, Wellcome Genome Campus, Hinxton, England; [Vestergaard, Gisle] Tech Univ Denmark, Dept Hlth Technol, Sect Bioinformat, Lyngby, Denmark; [Brix, Susanne] Tech Univ Denmark, Dept Biotechnol & Biomed, Lyngby, Denmark	University of Copenhagen; Novo Nordisk Foundation; University of Copenhagen; University of Copenhagen; University of Copenhagen; Wellcome Trust Sanger Institute; Technical University of Denmark; Technical University of Denmark	Bisgaard, H (corresponding author), Ledreborg Alle 34, DK-2820 Gentofte, Denmark.	bisgaard@copsac.com	Mortensen, Martin Steen/M-5141-2014; Pedersen, Susanne Brix/B-3484-2009; Lehtimäki, Jenni/HDM-7952-2022; Thorsen, Jonathan/AAQ-9269-2021; Rasmussen, Morten Arendt/S-8843-2017; Bisgaard, Hans/N-4761-2016	Mortensen, Martin Steen/0000-0001-5483-7533; Pedersen, Susanne Brix/0000-0001-8951-6705; Lehtimäki, Jenni/0000-0001-7220-1985; Thorsen, Jonathan/0000-0003-0200-0461; Rasmussen, Morten Arendt/0000-0001-7431-5206; Stokholm, Jakob/0000-0003-4989-9769; Bisgaard, Hans/0000-0003-4131-7592; Bonnelykke, Klaus/0000-0003-2003-1018; Hjelmso, Mathis Hjort/0000-0001-9716-624X; Trivedi, Urvish/0000-0003-1541-6212; Vestergaard, Gisle/0000-0003-2541-4974	Lundbeck Foundation [R16A1694]; Ministry of Health, Denmark [903516]; Danish Council for Strategic Research [060300280B]; Capital Region Research Foundation; Danish Council for Independent Research's Sapere Aude programme [804500081B]; BRIDGE-Translational Excellence Programme at the Faculty of Health and Medical Sciences, University of Copenhagen - Novo Nordisk Foundation [NNF18SA0034956]	Lundbeck Foundation(Lundbeckfonden); Ministry of Health, Denmark; Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF)); Capital Region Research Foundation; Danish Council for Independent Research's Sapere Aude programme; BRIDGE-Translational Excellence Programme at the Faculty of Health and Medical Sciences, University of Copenhagen - Novo Nordisk Foundation	All funding received by the Copenhagen Prospective Studies on Asthma in Childhood (COPSAC) is listed at www.copsac.com . The Lundbeck Foundation (grant R16A1694) , the Ministry of Health, Denmark (grant 903516) , the Danish Council for Strategic Research (grant 060300280B) , and the Capital Region Research Foundation have provided core support to the COPSAC research center. J. Stokholm is supported by the Danish Council for Independent Research's Sapere Aude programme (Grant no. 804500081B) . J. Thorsen is supported by the BRIDGE-Translational Excellence Programme (bridge.ku.dk) at the Faculty of Health and Medical Sciences, University of Copenhagen, which is funded by the Novo Nordisk Foundation (grant agreement NNF18SA0034956) . The funding agencies did not have any role in design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the article. No pharmaceutical company was involved in the study. Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.	Abrahamsson TR, 2014, CLIN EXP ALLERGY, V44, P842, DOI 10.1111/cea.12253; Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Barberan A, 2015, P NATL ACAD SCI USA, V112, P5756, DOI 10.1073/pnas.1420815112; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Bisgaard H, 2013, CLIN EXP ALLERGY, V43, P1384, DOI 10.1111/cea.12213; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2016, NEW ENGL J MED, V375, P2530, DOI 10.1056/NEJMoa1503734; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V127, P1155, DOI 10.1016/j.jaci.2011.02.007; BRAY J. ROGER, 1957, ECOL MONOGR, V27, P325, DOI 10.2307/1942268; Brix S, 2017, JOVE-J VIS EXP, V126, P55800; Bronnum-Hansen H, 2018, ENVIRON INT, V121, P973, DOI 10.1016/j.envint.2018.09.050; Carlsten C, 2017, CURR OPIN ALLERGY CL, V17, P85, DOI 10.1097/ACI.0000000000000351; Cecchi L, 2018, J ALLERGY CLIN IMMUN, V141, P846, DOI 10.1016/j.jaci.2018.01.016; Chawes BL, 2016, JAMA-J AM MED ASSOC, V315, P353, DOI 10.1001/jama.2015.18318; Chawes BLK, 2015, J ALLERGY CLIN IMMUN, V135, P1450, DOI 10.1016/j.jaci.2014.11.020; Chawes BLK, 2010, J ALLERGY CLIN IMMUN, V125, P1387, DOI 10.1016/j.jaci.2010.01.039; Christensen SH, 2016, EUR CLIN RESPIR J, V3, DOI 10.3402/ecrj.v3.33463; Chung KF, 2017, J ALLERGY CLIN IMMUN, V139, P1071, DOI 10.1016/j.jaci.2017.02.004; Cooley D., 2018, GOOGLEWAY ACCESSES G; Debarry J, 2010, ALLERGY, V65, P690, DOI 10.1111/j.1398-9995.2009.02253.x; Depner M, 2020, NAT MED, V26, P1766, DOI 10.1038/s41591-020-1095-x; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Fauser P, 2017, ATMOS ENVIRON, V167, P283, DOI 10.1016/j.atmosenv.2017.08.033; Gras D, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02399-2016; Gupta S, 2020, MICROBIOME, V8, DOI 10.1186/s40168-020-00895-w; Hajar T, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.4205; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hanski I, 2012, P NATL ACAD SCI USA, V109, P8334, DOI 10.1073/pnas.1205624109; Hopkin JM, 2000, THORAX, V55, P443, DOI 10.1136/thorax.55.6.443; Karkman A, 2017, ANN NY ACAD SCI, V1399, P78, DOI 10.1111/nyas.13326; Kozyrskyj A. L., 2004, Journal of Allergy and Clinical Immunology, V113, pS306, DOI 10.1016/j.jaci.2004.01.596; Lahti L., MICROBIOME R PACKAGE; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Larsen JM, 2014, J ALLERGY CLIN IMMUN, V133, P1008, DOI 10.1016/j.jaci.2014.01.010; Lehtimaki J, 2017, SCI REP-UK, V7, DOI 10.1038/srep45651; Lozupone CA, 2007, APPL ENVIRON MICROB, V73, P1576, DOI 10.1128/AEM.01996-06; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Mortensen MS, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0215-9; Oksanen J, 2020, VEGAN COMMUNITY ECOL; Ottman N, 2019, J ALLERGY CLIN IMMUN, V143, P1198, DOI 10.1016/j.jaci.2018.06.024; R Core Team, R LANG ENV STAT COMP; Renz H, 2018, J ALLERGY CLIN IMMUN, V141, P1212, DOI 10.1016/j.jaci.2017.11.019; Rodriguez A, 2011, THORAX, V66, P1043, DOI 10.1136/thoraxjnl-2011-200225; Rohart F, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005752; Rook GA, 2013, P NATL ACAD SCI USA, V110, P18360, DOI 10.1073/pnas.1313731110; Rousseeuw P., 2018, CLUSTER CLUSTER ANAL; Ruokolainen L, 2017, CLIN EXP ALLERGY, V47, P665, DOI 10.1111/cea.12895; Ruokolainen L, 2015, ALLERGY, V70, P195, DOI 10.1111/all.12545; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Sharpe RA, 2015, J ALLERGY CLIN IMMUN, V135, P110, DOI 10.1016/j.jaci.2014.07.002; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Stokholm J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02573-2; Strachan DP, 2015, CLIN EXP ALLERGY, V45, P126, DOI 10.1111/cea.12349; Thornton J, 2019, NONPROFIT POLICY FOR, V10, DOI 10.1515/npf-2019-0037; Tuoresm_aki, 2019, NAT MED, V1; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027; von Hertzen L, 2011, EMBO REP, V12, P1089, DOI 10.1038/embor.2011.195; von Mutius E, 2020, LANCET, V396, P854, DOI 10.1016/S0140-6736(20)31861-4; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Zhang YX, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad4322	65	19	19	4	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2021	148	1					234	243		10.1016/j.jaci.2020.12.621	http://dx.doi.org/10.1016/j.jaci.2020.12.621		JUL 2021	10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE3IW	33338536	Green Published			2022-12-18	WOS:000669908500005
J	Holstein, J; Solimani, F; Baum, C; Meier, K; Pollmann, R; Didona, D; Tekath, T; Dugas, M; Casadei, N; Hudemann, C; Polakova, A; Matthes, J; Schafer, I; Yazdi, AS; Eming, R; Hertl, M; Pfutzner, W; Ghoreschi, K; Mobs, C				Holstein, Julia; Solimani, Farzan; Baum, Carolin; Meier, Katharina; Pollmann, Robert; Didona, Dario; Tekath, Tobias; Dugas, Martin; Casadei, Nicolas; Hudemann, Christoph; Polakova, Alexandra; Matthes, Jakob; Schaefer, Iris; Yazdi, Amir S.; Eming, Ruediger; Hertl, Michael; Pfuetzner, Wolfgang; Ghoreschi, Kamran; Moebs, Christian			Immunophenotyping in pemphigus reveals a T(H)17/T(FH)17 cell-dominated immune response promoting desmoglein 1/3-specific autoantibody production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pemphigus vulgaris; pemphigus foliaceus; helper T cells; follicular T cells; T-cell-B-cell interaction; IL-17; autoimmunity; bullous disease; desmoglein; autoantibodies	HELPER T-CELLS; T(H)17 CELLS; SKIN DISEASES; CYTOKINE; VULGARIS; IL-21; DIFFERENTIATION; INFLAMMATION; GENERATION; ESOPHAGEAL	Background: T(H)2 cells were thought to be a pivotal factor for initiation of the autoimmune blistering disease pemphigus. However, the role of other T-cell subsets in pemphigus pathogenesis remained unclear. Objective: We aimed to characterize the exact phenotype of T cells responsible for the development of pemphigus. Methods: Whole transcriptome shotgun sequencing was performed to determine differential gene expression in pemphigus lesions and skin of healthy individuals. The cutaneous cytokine signature was further evaluated by real-time quantitative PCR. In peripheral blood, the distribution of T H cell and folliclular helper (T-FH) cell subsets was analyzed by flow cytometry. Finally, the capacity of T-H and T-FH cell subsets to induce desmoglein (Dsg)-specific autoantibodies by memory B cells was evaluated in coculture experiments. Results: Transcriptome analysis of skin samples identified an IL-17A-dominated immune signature in patients with pemphigus, and Kyoto Encyclopedia of Genes and Genomes pathway analysis confirmed the dominance of the IL-17A signaling pathway. Increased expression of IL17A and associated cytokines was also detected by real-time quantitative PCR comparing lesional with perilesional or healthy skin. Interestingly, utilization of flow cytometry showed that patients with active pemphigus had elevated levels of circulating IL-17(+), T(H)17, T(FH)17, and T(FH)17.1 cells. Notably, levels of T(H)17 and T(FH)17 cells correlated with levels of Dsg-specific CD19(+) CD27(+) memory B cells, and patients with acute pemphigus showed higher levels of Dsg3-autoreactive T(FH)17 cells. Coculture experiments revealed T(FH)17 cells as primarily responsible for inducing Dsg-specific autoantibody production by B cells. Conclusion: Our findings show that T(FH)17 cells are critically involved in the pathogenesis of pemphigus and offer novel targets for therapeutic intervention.	[Holstein, Julia; Schaefer, Iris] Eberhard Karls Univ Tubingen, Univ Med Ctr, Dept Dermatol, Tubingen, Germany; [Solimani, Farzan; Meier, Katharina; Ghoreschi, Kamran] Charite Univ Med Berlin, Dept Dermatol Venereol & Allergol, Charitepl 1, D-10117 Berlin, Germany; [Solimani, Farzan; Meier, Katharina; Ghoreschi, Kamran] Free Univ Berlin, Berlin, Germany; [Solimani, Farzan; Meier, Katharina; Ghoreschi, Kamran] Humboldt Univ, Berlin, Germany; [Solimani, Farzan; Meier, Katharina; Ghoreschi, Kamran] Berlin Inst Hlth, Berlin, Germany; [Solimani, Farzan; Baum, Carolin; Pollmann, Robert; Didona, Dario; Hudemann, Christoph; Polakova, Alexandra; Eming, Ruediger; Hertl, Michael; Pfuetzner, Wolfgang; Moebs, Christian] Philipps Univ Marburg, Dept Dermatol & Allergol, Marburg, Germany; [Tekath, Tobias; Dugas, Martin] Univ Munster, Inst Med Informat, Munster, Germany; [Casadei, Nicolas; Matthes, Jakob] Eberhard Karls Univ Tubingen, Inst Med Genet & Appl Genom, Tubingen, Germany; [Yazdi, Amir S.] Uniklin RWTH Aachen, Dept Dermatol & Allergol, Aachen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Philipps University Marburg; University of Munster; Eberhard Karls University of Tubingen; RWTH Aachen University; RWTH Aachen University Hospital	Ghoreschi, K (corresponding author), Charite Univ Med Berlin, Dept Dermatol Venereol & Allergol, Charitepl 1, D-10117 Berlin, Germany.	kamran.ghoreschi@charite.de	Solimani, Farzan/AAI-2430-2019; Hudemann, Christoph/ABF-4275-2020	Solimani, Farzan/0000-0001-6507-5407; Hudemann, Christoph/0000-0001-5807-6882; Tekath, Tobias/0000-0002-9315-5452; Ghoreschi, Kamran/0000-0002-5526-7517; Admard, Jakob/0000-0003-0466-582X	Deutsche Forschungsgemeinschaft [FOR 2497/TP02, GH133/2-1, PF344/4-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	Supported by the Deutsche Forschungsgemeinschaft; FOR 2497/TP02 (GH133/2-1 [to K.G] and PF344/4-1 [to W.P.]).	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; AHMED AR, 1982, J AM ACAD DERMATOL, V7, P221; Amber KT, 2018, DRUGS, V78, P1527, DOI 10.1007/s40265-018-0976-5; Aoki-Ota M, 2004, BRIT J DERMATOL, V151, P346, DOI 10.1111/j.1365-2133.2004.06056.x; Ben Jmaa M, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/8206983; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Codarri L, 2011, NAT IMMUNOL, V12, P560, DOI 10.1038/ni.2027; Cosmi L, 2011, ARTHRITIS RHEUM-US, V63, P2504, DOI 10.1002/art.30332; Craft JE, 2012, NAT REV RHEUMATOL, V8, P337, DOI 10.1038/nrrheum.2012.58; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Didona D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01418; Duhen T, 2014, J IMMUNOL, V193, P120, DOI 10.4049/jimmunol.1302734; Egami S, 2020, J ALLERGY CLIN IMMUN, V145, P1031, DOI 10.1016/j.jaci.2020.02.013; Ettinger R, 2008, IMMUNOL REV, V223, P60, DOI 10.1111/j.1600-065X.2008.00631.x; Frankish A, 2019, NUCLEIC ACIDS RES, V47, pD766, DOI 10.1093/nar/gky955; Frentsch M, 2005, NAT MED, V11, P1118, DOI 10.1038/nm1292; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; Ghoreschi K, 2003, NAT MED, V9, P40, DOI 10.1038/nm804; Ghoreschi K, 2011, J IMMUNOL, V186, P4234, DOI 10.4049/jimmunol.1003668; Ghoreschi K, 2010, NATURE, V467, P967, DOI 10.1038/nature09447; Gudjonsson JE, 2020, J ALLERGY CLIN IMMUN, V146, P8, DOI 10.1016/j.jaci.2020.05.009; Hennerici T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148919; Hertl M, 1998, J INVEST DERMATOL, V110, P62, DOI 10.1046/j.1523-1747.1998.00086.x; Hirota K, 2013, NAT IMMUNOL, V14, P372, DOI 10.1038/ni.2552; Jin S, 2014, EXP DERMATOL, V23, P938, DOI 10.1111/exd.12563; Kanehisa M, 2019, NUCLEIC ACIDS RES, V47, pD590, DOI 10.1093/nar/gky962; Kasperkiewicz M, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.26; Kebir H, 2009, ANN NEUROL, V66, P390, DOI 10.1002/ana.21748; Kim AR, 2020, J ALLERGY CLIN IMMUN; Kohlmann J, 2019, HAUTARZT, V70, P641, DOI 10.1007/s00105-019-4414-8; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Kowalski EH, 2019, AUTOIMMUN REV, V18, P526, DOI 10.1016/j.autrev.2019.03.009; Kridin K, 2018, JAMA DERMATOL, V154, P435, DOI 10.1001/jamadermatol.2017.6334; Kumari S, 2013, IMMUNITY, V39, P899, DOI 10.1016/j.immuni.2013.10.009; Li XH, 2018, CHEM-BIOL INTERACT, V288, P76, DOI 10.1016/j.cbi.2018.04.021; Lin MS, 1997, J CLIN INVEST, V99, P31, DOI 10.1172/JCI119130; Linterman MA, 2009, J EXP MED, V206, P561, DOI 10.1084/jem.20081886; Lo PHY, 2010, CANCER RES, V70, P5567, DOI 10.1158/0008-5472.CAN-09-4510; Ma CS, 2012, J EXP MED, V209, P1241, DOI 10.1084/jem.20120994; Millar NL, 2016, SCI REP-UK, V6, DOI 10.1038/srep27149; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Nanke Yuki, 2016, Nihon Rinsho Meneki Gakkai Kaishi, V39, P473; Panzer M, 2012, J IMMUNOL, V188, P615, DOI 10.4049/jimmunol.1101164; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Pfeifle R, 2017, NAT IMMUNOL, V18, P104, DOI 10.1038/ni.3579; Pfutze M, 2007, EUR J DERMATOL, V17, P4; Pollmann R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01375; Rao DA, 2017, NATURE, V542, P110, DOI 10.1038/nature20810; Rico MJ, 1999, BRIT J DERMATOL, V140, P1079; Rutz S, 2014, NAT REV IMMUNOL, V14, P783, DOI 10.1038/nri3766; Rutz S, 2013, IMMUNOL REV, V252, P116, DOI 10.1111/imr.12027; Sabat R, 2019, SEMIN IMMUNOPATHOL, V41, P359, DOI 10.1007/s00281-019-00742-7; Song WZ, 2019, IMMUNOL REV, V288, P85, DOI 10.1111/imr.12740; Stockinger B, 2017, NAT REV IMMUNOL, V17, P535, DOI 10.1038/nri.2017.50; Takahashi H, 2008, J IMMUNOL, V181, P1526, DOI 10.4049/jimmunol.181.2.1526; Timoteo RP, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/7151285; Tsunoda K, 2003, J IMMUNOL, V170, P2170, DOI 10.4049/jimmunol.170.4.2170; van Langelaar J, 2018, BRAIN, V141, P1334, DOI 10.1093/brain/awy069; Veldman C, 2003, J IMMUNOL, V170, P635, DOI 10.4049/jimmunol.170.1.635; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wei L, 2007, J BIOL CHEM, V282, P34605, DOI 10.1074/jbc.M705100200; Welsch K, 2017, EUR J IMMUNOL, V47, P1096, DOI 10.1002/eji.201646680; Witte E, 2014, J INVEST DERMATOL, V134, P2757, DOI 10.1038/jid.2014.308; Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Yuan H, 2017, J INVEST DERMATOL, V137, pS7, DOI 10.1016/j.jid.2017.05.032; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505; Zhu CL, 2012, J CLIN ENDOCR METAB, V97, P943, DOI 10.1210/jc.2011-2003	68	19	20	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2021	147	6					2358	2369		10.1016/j.jaci.2020.11.008	http://dx.doi.org/10.1016/j.jaci.2020.11.008		JUN 2021	12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM7ID	33221382				2022-12-18	WOS:000657773400002
J	Cianferoni, A				Cianferoni, Antonella			Non-IgE-mediated anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Anaphylaxis; biologics; mast cells; food allergy	PLATELET-ACTIVATING-FACTOR; HUMAN MAST-CELLS; FC-GAMMA-RI; CHRONIC SPONTANEOUS URTICARIA; COMPLEMENT ACTIVATION; REVISED NOMENCLATURE; UP-REGULATION; CREMOPHOR-EL; OMALIZUMAB; MECHANISMS	Anaphylaxis is a rapidly evolving, acute, life-threatening reaction that occurs rapidly on contact with a trigger. Anaphylaxis is classically defined as an allergen-driven process that induces specific IgE and the activation of mast cells and basophils through the cross-linking of IgE receptors. However, it is clear that non-IgE-mediated pathways can induce symptoms indistinguishable from those of classic anaphylaxis, and their activation could explain the severity of IgE-mediated anaphylaxis. Indeed, mast cells and basophils can be activated by antibodies against IgE or their receptors, by molecules such as anaphylatoxins, or through G-coupled receptors. Some other allergens can induce antibodies of class IgG that can activate neutrophils to produce a molecule similar to histamine to induce anaphylaxis. Finally, some inflammatory mediators such as bradykinin or prostaglandin can also modulate mast cell and basophil activation as well as directly cause vasodilation and bronchoconstriction, resulting in anaphylaxis-like reactions.	[Cianferoni, Antonella] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Allergy & Immunol Div, ARC1206B,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Cianferoni, A (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Allergy & Immunol Div, ARC1206B,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	cianferonia@chop.edu			Children's Hospital of Philadelphia Frontier Program	Children's Hospital of Philadelphia Frontier Program	Supported by The Children's Hospital of Philadelphia Frontier Program.	Ankerst J, 2010, INT ARCH ALLERGY IMM, V152, P71, DOI 10.1159/000260086; Apostolovic D, 2015, ALLERGY, V70, P1497, DOI 10.1111/all.12695; Asero R, 2020, CLIN EXP IMMUNOL, V200, P242, DOI 10.1111/cei.13428; Asero R, 2018, EUR ANN ALLERGY CLIN, V50, P156, DOI 10.23822/EurAnnACI.1764-1489.57; Babina M, 2021, J INVEST DERMATOL, V141, P1286, DOI 10.1016/j.jid.2020.09.017; BEDARD PM, 1986, J ALLERGY CLIN IMMUN, V78, P1121, DOI 10.1016/0091-6749(86)90260-5; BERGAMASCHINI L, 1995, J LAB CLIN MED, V125, P348; Bergamaschini L, 1996, J IMMUNOL, V156, P1256; Blossom DB, 2008, NEW ENGL J MED, V359, P2674, DOI 10.1056/NEJMoa0806450; Blunk JA, 2004, ANESTH ANALG, V98, P364, DOI 10.1213/01.ANE.0000097168.32472.0D; Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121; Cao C, 2018, NAT STRUCT MOL BIOL, V25, P488, DOI 10.1038/s41594-018-0068-y; Carter MC, 2007, J ALLERGY CLIN IMMUN, V119, P1550, DOI 10.1016/j.jaci.2007.03.032; Castells M, 2017, J ALLERGY CLIN IMMUN, V140, P321, DOI 10.1016/j.jaci.2017.06.012; Cheifetz A, 2003, AM J GASTROENTEROL, V98, P1315, DOI 10.1016/S0002-9270(03)00231-4; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Cianferoni A, 2001, ANN ALLERG ASTHMA IM, V87, P27, DOI 10.1016/S1081-1206(10)62318-6; Cianferoni A, 2012, IMMUNOL ALLERGY CLIN, V32, P165, DOI 10.1016/j.iac.2011.10.002; Ertas R, 2018, ALLERGY, V73, P705, DOI 10.1111/all.13345; Farnam K, 2012, INT ARCH ALLERGY IMM, V159, P327, DOI 10.1159/000339690; Ferrer M, 2011, J ALLERGY CLIN IMMUN, V127, P1300, DOI 10.1016/j.jaci.2010.12.1085; Feuerstein JD, 2015, INFLAMM BOWEL DIS, V21, P1176, DOI 10.1097/MIB.0000000000000279; Finkelman FD, 2016, J ALLERGY CLIN IMMUN, V137, P1674, DOI 10.1016/j.jaci.2016.02.015; Fujisawa D, 2014, J ALLERGY CLIN IMMUN, V134, P622, DOI 10.1016/j.jaci.2014.05.004; Hammond C, 2018, IMMUNOL ALLERGY CLIN, V38, P153, DOI 10.1016/j.iac.2017.09.011; Hedin H, 1980, Dev Biol Stand, V48, P179; Jean T, 2019, ALLERGY ASTHMA PROC, V40, P316, DOI 10.2500/aap.2019.40.4241; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; Johansson SGO, 2006, ALLERGY, V61, P1216, DOI 10.1111/j.1398-9995.2006.01172.x; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Jonsson F, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat1479; Kaplan AP, 2017, ALLERGY, V72, P519, DOI 10.1111/all.13083; Kaplan AP, 2020, J ALLERGY CLIN IMMUN, V145, P1365, DOI 10.1016/j.jaci.2020.01.043; Khodoun M, 2009, J ALLERGY CLIN IMMUN, V123, P342, DOI 10.1016/j.jaci.2008.11.004; Kishimoto TK, 2008, NEW ENGL J MED, V358, P2457, DOI 10.1056/NEJMoa0803200; Kuitunen M, 2015, ALLERGY, V70, P955, DOI 10.1111/all.12647; Lawrence I D, 1989, Adv Exp Med Biol, V247A, P225; Mancardi DA, 2013, BLOOD, V121, P1563, DOI 10.1182/blood-2012-07-442541; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Metz M, 2019, ALLERGY, V74, P141, DOI 10.1111/all.13547; Metz M, 2017, THERANOSTICS, V7, P1266, DOI 10.7150/thno.18304; Metz M, 2014, J DERMATOL SCI, V73, P57, DOI 10.1016/j.jdermsci.2013.08.011; Molderings GJ, 2011, INTERNAL MED, V50, P611, DOI 10.2169/internalmedicine.50.4640; Munoz-Cano R, 2016, J INVEST ALLERG CLIN, V26, P73, DOI 10.18176/jiaci.0046; Novembre E, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.4.e8; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; Okayama Y, 2000, J IMMUNOL, V164, P4332, DOI 10.4049/jimmunol.164.8.4332; Oliver ET, 2015, ALLERGY, V70, P601, DOI 10.1111/all.12578; Oliver ET, 2016, J ALLERGY CLIN IMMUN, V137, P304, DOI 10.1016/j.jaci.2015.06.004; Pascal M, 2016, CLIN EXP ALLERGY, V46, P1111, DOI 10.1111/cea.12735; Rispens T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055566; Saini SS, 2017, J INVEST DERMATOL, V137, P958, DOI 10.1016/j.jid.2016.11.025; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Satoh T, 2011, ACTA DERM-VENEREOL, V91, P371, DOI 10.2340/00015555-1052; Schmetzer O, 2018, J ALLERGY CLIN IMMUN, V142, P876, DOI 10.1016/j.jaci.2017.10.035; Stafforini DM, 2003, CRIT REV CL LAB SCI, V40, P643, DOI 10.1080/714037693; Stapel SO, 2008, ALLERGY, V63, P793, DOI 10.1111/j.1398-9995.2008.01705.x; Steenholdt C, 2011, ALIMENT PHARM THER, V34, P51, DOI 10.1111/j.1365-2036.2011.04682.x; Steenholdt C, 2012, J CROHNS COLITIS, V6, P108, DOI 10.1016/j.crohns.2011.08.001; Straesser MD, 2018, J ALLER CL IMM-PRACT, V6, P1386, DOI 10.1016/j.jaip.2017.10.030; Strand V, 2017, BIODRUGS, V31, P299, DOI 10.1007/s40259-017-0231-8; Subramanian H, 2016, J ALLERGY CLIN IMMUN, V138, P700, DOI 10.1016/j.jaci.2016.04.051; Szebeni J, 1998, JNCI-J NATL CANCER I, V90, P300, DOI 10.1093/jnci/90.4.300; Taniguchi M, 2019, ALLERGOL INT, V68, P289, DOI 10.1016/j.alit.2019.05.001; Tkaczyk C, 2002, MOL IMMUNOL, V38, P1289, DOI 10.1016/S0161-5890(02)00077-9; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Vadas P, 2016, ANN ALLERG ASTHMA IM, V117, P455, DOI 10.1016/j.anai.2016.05.003; Vadas P, 2012, J ALLERGY CLIN IMMUN, V129, P1329, DOI 10.1016/j.jaci.2012.02.027; Veien M, 2000, ANESTHESIOLOGY, V92, P1074, DOI 10.1097/00000542-200004000-00026; Wedi B, 2020, ALLERGY, V75, P2229, DOI 10.1111/all.14213; WEISS ME, 1989, NEW ENGL J MED, V320, P886, DOI 10.1056/NEJM198904063201402; Weiszhar Z, 2012, EUR J PHARM SCI, V45, P492, DOI 10.1016/j.ejps.2011.09.016; Weller K, 2018, ALLERGY, V73, P2406, DOI 10.1111/all.13586; Wolbing F, 2013, ALLERGY, V68, P1085, DOI 10.1111/all.12193; Woolhiser MR, 2004, CLIN IMMUNOL, V110, P172, DOI 10.1016/j.clim.2003.11.007; Woolhiser MR, 2001, EUR J IMMUNOL, V31, P3298, DOI 10.1002/1521-4141(200111)31:11<3298::AID-IMMU3298>3.0.CO;2-U; Yoo DH, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-0981-6; Zwirner J, 1998, SCAND J IMMUNOL, V47, P19	80	19	20	5	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2021	147	4					1123	1131		10.1016/j.jaci.2021.02.012	http://dx.doi.org/10.1016/j.jaci.2021.02.012		APR 2021	9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RJ1NP	33832694				2022-12-18	WOS:000637368900001
J	Zhu, ZZ; Hasegawa, K; Camargo, CA; Liang, LM				Zhu, Zhaozhong; Hasegawa, Kohei; Camargo, Carlos A., Jr.; Liang, Liming			Investigating asthma heterogeneity through shared and distinct genetics: Insights from genome-wide cross-trait analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; heterogeneity; GWAS; shared genetics; cross-trait; allergic diseases; obesity		Asthma is a heterogeneous respiratory disease reflecting distinct pathobiologic mechanisms. These mechanisms are based, at least partly, on different genetic factors shared by many other conditions, such as allergic diseases and obesity. Investigating the shared genetic effects enables better understanding of the mechanisms of phenotypic correlations and is less subject to confounding by environmental factors. The increasing availability of large-scale genome-wide association study (GWAS) for asthma has enabled researchers to examine the genetic contributions to the epidemiologic associations between asthma subtypes and those between coexisting diseases and/or traits and asthma. Studies have found not only shared but also distinct genetic components between asthma subtypes, indicating that the heterogeneity is related to distinct genetics. This review summarizes a recently compiled analytic approach?genome-wide cross-trait analysis?to determine shared and distinct genetic architecture. The genome-wide cross-trait analysis features in several analytic aspects: genetic correlation, cross-trait meta-analysis, Mendelian randomization, polygenic risk score, and functional analysis. In this article, we discuss in detail the scientific goals that can be achieved by these analyses, their advantages, and their limitations. We also make recommendations for future directions: (1) ethnicity-specific asthma GWASs and (2) application of cross-trait methods to multiomics data to dissect the heritability found in GWASs. Finally, these analytic approaches are also applicable to complex and heterogeneous traits beyond asthma. (J Allergy Clin Immunol 2021;147:796-807.)	[Zhu, Zhaozhong; Camargo, Carlos A., Jr.; Liang, Liming] Harvard TH Chan Sch Publ Hlth, Program Genet Epidemiol & Stat Genet, Dept Epidemiol, Boston, MA USA; [Zhu, Zhaozhong] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Liang, Liming] Harvard TH Chan Sch Publ Hlth, Dept Biostat, 655 Huntington Ave, Boston, MA 02115 USA; [Zhu, Zhaozhong; Hasegawa, Kohei; Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Massachusetts General Hospital	Liang, LM (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Biostat, 655 Huntington Ave, Boston, MA 02115 USA.; Liang, LM (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, 655 Huntington Ave, Boston, MA 02115 USA.	lliang@hsph.harvard.edu	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654				Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; Belsky DW, 2013, LANCET RESP MED, V1, P453, DOI 10.1016/S2213-2600(13)70101-2; Bhattacharjee S, 2012, AM J HUM GENET, V90, P821, DOI 10.1016/j.ajhg.2012.03.015; Borish L, 2008, ANN ALLERG ASTHMA IM, V101, P1, DOI 10.1016/S1081-1206(10)60826-5; Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965; Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080; Bulik-Sullivan B, 2015, NAT GENET, V47, P1236, DOI 10.1038/ng.3406; Bulik-Sullivan BK, 2015, NAT GENET, V47, P291, DOI 10.1038/ng.3211; Burgess S, 2015, EUR J EPIDEMIOL, V30, P543, DOI 10.1007/s10654-015-0011-z; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Chen E, 2007, BRAIN BEHAV IMMUN, V21, P993, DOI 10.1016/j.bbi.2007.03.009; Chung W, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08535-0; Cortese S, 2018, LANCET PSYCHIAT, V5, P717, DOI 10.1016/S2215-0366(18)30224-4; Davies NM, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k601; Daya M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08469-7; de Groot EP, 2010, EUR RESPIR J, V36, P671, DOI 10.1183/09031936.00185709; Demenais F, 2018, NAT GENET, V50, P42, DOI 10.1038/s41588-017-0014-7; Denny JC, 2016, ANNU REV GENOM HUM G, V17, P353, DOI 10.1146/annurev-genom-090314-024956; DeVries A, 2016, ANN AM THORAC SOC, V13, pS48, DOI 10.1513/AnnalsATS.201507-420MG; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Ferreira MA, 2017, NAT GENET, V49, P1752, DOI 10.1038/ng.3985; Ferreira MAR, 2019, AM J HUM GENET, V104, P665, DOI 10.1016/j.ajhg.2019.02.022; Finucane HK, 2018, NAT GENET, V50, P621, DOI 10.1038/s41588-018-0081-4; Gobal Initiative for Asthma, 2018, GLOB STRAT ASTHM MAN; Granell R, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001669; Hartwig FP, 2017, INT J EPIDEMIOL, V46, P1985, DOI 10.1093/ije/dyx102; Heinze-Deml C, 2018, ANNU REV STAT APPL, V5, P371, DOI 10.1146/annurev-statistics-031017-100630; Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091; Huan TX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12228-z; Jiang X, 2020, CANCER CAUSE CONTROL, V31, P273, DOI 10.1007/s10552-020-01271-7; Khatri P, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002375; Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Larsen GL, 2000, J ALLERGY CLIN IMMUN, V106, pS153; Lavoie KL, 2005, RESP MED, V99, P1249, DOI 10.1016/j.rmed.2005.03.003; Lehto K, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02142-2018; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Macsali F, 2011, AM J RESP CRIT CARE, V183, P8, DOI 10.1164/rccm.200912-1886OC; Maier R, 2015, AM J HUM GENET, V96, P283, DOI 10.1016/j.ajhg.2014.12.006; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Martin AR, 2019, NAT GENET, V51, P584, DOI 10.1038/s41588-019-0379-x; Melen E, 2010, J ALLERGY CLIN IMMUN, V126, P631, DOI 10.1016/j.jaci.2010.06.030; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Morrison J, 2020, NAT GENET, V52, P740, DOI 10.1038/s41588-020-0631-4; O'Connor LJ, 2018, NAT GENET, V50, P1728, DOI 10.1038/s41588-018-0255-0; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Oraka E, 2013, J ASTHMA, V50, P488, DOI 10.3109/02770903.2013.790417; Peters U, 2018, J ALLERGY CLIN IMMUN, V141, P1169, DOI 10.1016/j.jaci.2018.02.004; Pickrell JK, 2016, NAT GENET, V48, P709, DOI 10.1038/ng.3570; Pividori M, 2019, LANCET RESP MED, V7, P509, DOI 10.1016/S2213-2600(19)30055-4; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; Price AL, 2010, NAT REV GENET, V11, P459, DOI 10.1038/nrg2813; Priftis KN, 2008, J ASTHMA, V45, P590, DOI 10.1080/02770900802032941; Relton CL, 2012, INT J EPIDEMIOL, V41, P161, DOI 10.1093/ije/dyr233; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Schoettler N, 2019, J ALLERGY CLIN IMMUN, V144, P1495, DOI 10.1016/j.jaci.2019.10.023; Scott KM, 2007, GEN HOSP PSYCHIAT, V29, P123, DOI 10.1016/j.genhosppsych.2006.12.006; Shrine N, 2019, LANCET RESP MED, V7, P20, DOI 10.1016/S2213-2600(18)30389-8; Simons F. E. R., 2003, Clinical and Experimental Allergy Reviews, V3, P9, DOI 10.1046/j.1472-9725.2003.00055.x; Sivakumaran S, 2011, AM J HUM GENET, V89, P607, DOI 10.1016/j.ajhg.2011.10.004; Solovieff N, 2013, NAT REV GENET, V14, P483, DOI 10.1038/nrg3461; Speed D, 2020, NAT GENET, V52, P458, DOI 10.1038/s41588-020-0600-y; Subbarao P, 2009, CAN MED ASSOC J, V181, pE181, DOI 10.1503/cmaj.080612; Sugrue LP, 2019, JAMA-J AM MED ASSOC, V321, P1820, DOI 10.1001/jama.2019.3893; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Tonolo G, 2000, EUR J CLIN INVEST, V30, P980, DOI 10.1046/j.1365-2362.2000.00735.x; Turley P, 2018, NAT GENET, V50, P229, DOI 10.1038/s41588-017-0009-4; VanderWeele TJ, 2016, ANNU REV PUBL HEALTH, V37, P17, DOI 10.1146/annurev-publhealth-032315-021402; Verbanck M, 2018, NAT GENET, V50, P693, DOI 10.1038/s41588-018-0099-7; Vilhjalmsson BJ, 2015, AM J HUM GENET, V97, P576, DOI 10.1016/j.ajhg.2015.09.001; Vink NM, 2010, J ALLERGY CLIN IMMUN, V126, P498, DOI 10.1016/j.jaci.2010.06.018; Wallace C, 2013, GENET EPIDEMIOL, V37, P802, DOI 10.1002/gepi.21765; Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011; Zhu XF, 2015, AM J HUM GENET, V96, P21, DOI 10.1016/j.ajhg.2014.11.011; Zhu ZZ, 2020, J ALLERGY CLIN IMMUN, V146, P327, DOI 10.1016/j.jaci.2020.06.001; Zhu ZZ, 2020, J ALLERGY CLIN IMMUN, V145, P537, DOI 10.1016/j.jaci.2019.09.035; Zhu ZZ, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.01507-2019; Zhu ZZ, 2018, NAT GENET, V50, P857, DOI 10.1038/s41588-018-0121-0; Zhu ZZ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193256; Zhu ZH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02317-2	80	19	19	3	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2021	147	3					796	807		10.1016/j.jaci.2020.07.004	http://dx.doi.org/10.1016/j.jaci.2020.07.004		MAR 2021	12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RA9TV	32693092	Green Published, Bronze			2022-12-18	WOS:000631762400002
J	Ruiz-Garcia, M; Bartra, J; Alvarez, O; Lakhani, A; Patel, S; Tang, A; Sim, M; Shamji, MH; Skypala, I; Mills, ENC; Lyon, AR; Hayward, C; Durham, SR; Turner, PJ; Boyle, RJ				Ruiz-Garcia, Monica; Bartra, Joan; Alvarez, Olaya; Lakhani, Ashna; Patel, Shalinee; Tang, Alistair; Sim, Marcus; Shamji, Mohamed H.; Skypala, Isabel; Mills, E. N. Clare; Lyon, Alexander R.; Hayward, Carl; Durham, Stephen R.; Turner, Paul J.; Boyle, Robert J.			Cardiovascular changes during peanut-induced allergic reactions in human subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; cardiac output; cardiovascular; food allergens; intravenous fluids; management; stroke volume; venous return	ANAPHYLACTIC SHOCK; PATHOPHYSIOLOGY; HEMODYNAMICS; GUIDELINES	Background: Food allergy is the most common cause of anaphylaxis. Changes in posture during acute reactions can trigger fatal outcomes, but the impact of allergic reactions on the cardiovascular system in nonfatal reactions remains poorly understood. Objective: Our aim was to systematically evaluate changes in cardiovascular function during acute allergic reactions to peanut. Methods: Participants underwent double-blind placebo-controlled food challenge to peanut as part of a clinical trial. Changes in hemodynamic parameters (heart rate, stroke volume, blood pressure, and peripheral blood flow) and electrocardiogram findings during food challenges were assessed using noninvasive continuous monitoring. Results: A total of 57 adults (median age 24 years [interquartile range 5 20-29]), 53% of whom were female, participated; 22 (39%) had anaphylaxis. Acute reactions were associated with significant changes in stroke volume (mean decrease of 4.2% [95% CI = 0.8-7.6; P = .03]), heart rate (mean increase 11.6% [95% CI = 8.4-14.8; P < .0001]), and peripheral blood flow (mean increase 19.7% [95% CI = 10.8-28.6; P < .0001]), irrespective of reaction severity. These changes were reproduced at a subsequent repeat peanut challenge in 26 participants, and could be reversed with administration of intravenous fluids which resulted in faster resolution of abdominal symptoms. Conclusions: In this first detailed human study of cardiovascular changes during food-induced allergic reactions, we found evidence for significant fluid redistribution, independent of reaction severity. This provides a sound rationale for optimizing venous return during significant allergic reactions to food. Finally, these data provide a new paradigm for understanding severity in anaphylaxis, in which poor outcomes may occur as a result of a failure in compensatory mechanisms.	[Ruiz-Garcia, Monica; Bartra, Joan; Alvarez, Olaya; Lakhani, Ashna; Patel, Shalinee; Tang, Alistair; Sim, Marcus; Shamji, Mohamed H.; Skypala, Isabel; Durham, Stephen R.; Turner, Paul J.; Boyle, Robert J.] Imperial Coll London, Natl Heart & Lung Inst, Sect Inflammat Repair & Dev, Norfolk Pl, London W2 1PG, England; [Lyon, Alexander R.; Hayward, Carl] Imperial Coll London, Natl Heart & Lung Inst, Myocardial Funct, London, England; [Bartra, Joan] Hosp Clin Barcelona, Barcelona, Spain; [Lyon, Alexander R.; Hayward, Carl] Cardiol Dept, London, England; [Skypala, Isabel; Durham, Stephen R.] Royal Brompton & Harefield Hosp NHS Fdn Trust, London, England; [Mills, E. N. Clare] Univ Manchester, Sch Biol Sci, Div Infect Immun & Resp Med, Manchester, Lancs, England; [Hayward, Carl] Barts Hlth NHS Trust, London, England	Imperial College London; Imperial College London; University of Barcelona; Hospital Clinic de Barcelona; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; University of Manchester; Barts Health NHS Trust	Turner, PJ (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, Sect Inflammat Repair & Dev, Norfolk Pl, London W2 1PG, England.	p.turner@imperial.ac.uk		Shamji, Mohamed/0000-0003-3425-3463; Turner, Paul/0000-0001-9862-5161	UK Medical Research Council Clinician Scientist award [MR/K010468/1]; UK Food Standards Agency; European Union [312147]; National Institute for Health Research Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London; MRC [MR/K010468/1] Funding Source: UKRI	UK Medical Research Council Clinician Scientist award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Food Standards Agency; European Union(European Commission); National Institute for Health Research Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This research was funded by a UK Medical Research Council Clinician Scientist award to P.J.T. (reference MR/K010468/1). Clinical challenges in the TRACE study were funded by the UK Food Standards Agency, with additional support for follow-up challenges through the European Union's Seventh Framework Program for Research, Technological Development, and Demonstration under grant agreement no. 312147 (Integrated Approaches to Food Allergen and Allergy Risk Management [chief investigator, Clare Mills) and the National Institute for Health Research Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.	BROWN SGA, 2004, ALLERGY, V21, P149; Camm AJ, 1996, CIRCULATION, V93, P1043; Dewachter P, 2005, ANESTHESIOLOGY, V103, P40, DOI 10.1097/00000542-200507000-00010; Dhami S, 2014, ALLERGY, V69, P168, DOI 10.1111/all.12318; Dua S, 2019, J ALLERGY CLIN IMMUN, V144, P1584, DOI 10.1016/j.jaci.2019.06.038; Faye N, 2012, ANESTHESIOLOGY, V117, P1072, DOI 10.1097/ALN.0b013e31826d3dc5; FISHER MM, 1986, ANAESTH INTENS CARE, V14, P17, DOI 10.1177/0310057X8601400105; FUDIM M, 2018, PREHOSP EMERG CARE, V39, P4255; Henricson J, 2011, MICROCIRCULATION, V18, P214, DOI 10.1111/j.1549-8719.2010.00079.x; JACOBSEN RC, 2011, CIRCULATION, V15, P61; Jonsson P, 2007, INT J PSYCHOPHYSIOL, V63, P48, DOI 10.1016/j.ijpsycho.2006.08.002; Marque S, 2009, CRIT CARE, V13, DOI 10.1186/cc7884; McCraty Rollin, 2015, Glob Adv Health Med, V4, P46, DOI 10.7453/gahmj.2014.073; Mullins RJ, 2016, CLIN EXP ALLERGY, V46, P1099, DOI 10.1111/cea.12748; Muraro A, 2014, ALLERGY, V69, P1026, DOI 10.1111/all.12437; Pumphrey RSH, 2003, J ALLERGY CLIN IMMUN, V112, P451, DOI 10.1067/mai.2003.1614; Reber LL, 2017, J ALLERGY CLIN IMMUN, V140, P335, DOI 10.1016/j.jaci.2017.06.003; Ruiz-Garcia M, 2016, J ALLERGY CLIN IMMUN, V137, pAB50, DOI 10.1016/j.jaci.2015.12.167; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; SIMONS FE, 2011, ALLERGY, V4, P13; SMEDEGARD G, 1981, ACTA PHYSIOL SCAND, V111, P239, DOI 10.1111/j.1748-1716.1981.tb06732.x; Soar J, 2008, RESUSCITATION, V77, P157, DOI 10.1016/j.resuscitation.2008.02.001; Squara P, 2007, INTENS CARE MED, V33, P1191, DOI 10.1007/s00134-007-0640-0; Turner PJ, 2016, ALLERGY, V71, P1241, DOI 10.1111/all.12924; Turner PJ, 2020, J ALLER CL IMM-PRACT, V8, P1169, DOI 10.1016/j.jaip.2019.11.027; Turner PJ, 2019, WORLD ALLERGY ORGAN, V12, DOI 10.1016/j.waojou.2019.100066; TURNER PJ, 2016, INT J PSYCHOPHYSIOL, V16, P441; TWOMEY N, 2014, EUR HEART J, V18, P1051; VIGORITO C, 1987, J AM COLL CARDIOL, V10, P1207, DOI 10.1016/S0735-1097(87)80120-1; Worm M, 2018, ALLERGY, V73, P1322, DOI 10.1111/all.13380	31	19	19	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					633	642		10.1016/j.jaci.2020.06.033	http://dx.doi.org/10.1016/j.jaci.2020.06.033		FEB 2021	10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	32707226	Green Published, hybrid			2022-12-18	WOS:000616665800025
J	Rastogi, S; Willmes, DM; Nassiri, M; Babina, M; Worm, M				Rastogi, Shruti; Willmes, Diana Maria; Nassiri, Maria; Babina, Magda; Worm, Margitta			PGE(2) deficiency predisposes to anaphylaxis by causing mast cell hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; prostaglandin E-2; EP receptors; 15-PGDH inhibitor; mast cells; degranulation; ERK; PLC gamma		Background: Reduced levels of prostaglandin E-2 (PGE(2)) contribute to aspirin-induced hypersensitivity. COX inhibitors are also frequent cofactors in anaphylaxis. Whether alterations in the PGE(2) system contribute to anaphylaxis independently of COX inhibitor intake is unclear. Objective: Our aim was to test the hypothesis that relative PGE(2) deficiency predisposes to anaphylaxis. Methods: Sera from 48 patients with anaphylaxis and 27 healthy subjects were analyzed for PGE(2) levels and correlated against severity; 9a,11b-PGF(2) and PGI(2) metabolites were measured for control purposes. PGE(2) stabilization by 15-hydroxyprostaglandin dehydrogenase inhibitor or EP2 or EP4 receptor agonists were used in a murine model of passive systemic anaphylaxis. Fc epsilon RI-triggered mediator release was determined in bone marrow-derived cultured mast cells (MCs) and human skin-derived MCs. Signaling was studied by Western blot analysis. Results: Patients with anaphylaxis were characterized by markedly reduced PGE(2) levels vis-a-vis healthy subjects, whereas prostacyclin metabolite levels were diminished only weakly, and 9a,11b-PGF(2) levels conversely increased. PGE(2) was negatively correlated with severity. Lower PGE(2) levels and higher susceptibility to anaphylaxis were also found in C57BL/6 mice vis-a-vis in Balb/c mice. Stabilization of PGE(2) level by 15-hydroxyprostaglandin dehydrogenase inhibitor protected mice against anaphylaxis. Exogenous PGE(2) attenuated bone marrow-derived cultured MC activation through EP2 and EP4 receptors. EP2 and EP4 agonism also curbed Fc epsilon RI-mediated degranulation of human MCs. Mechanistically, PGE(2) interfered with the phosphorylation of phospholipase C gamma-1 and extracellular signal-regulated kinase. Conclusions: Homeostatic levels of PGE(2) attenuate MC activation via EP2/EP4 and protect against anaphylaxis. Relative deficiency of PGE(2) predisposes to anaphylaxis in humans and mice, whereas PGE(2) stabilization protects against anaphylactic reactions.	Charite Univ Med Berlin, Dept Dermatol & Allergy, Berlin, Germany; Free Univ Berlin, Berlin, Germany; Humboldt Univ, Berlin, Germany; Berlin Inst Hlth, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health	Babina, M; Worm, M (corresponding author), Charite Univ Med Berlin, Klin Dermatol & Allergol, CCM, Allergie Ctr Charite, Charitepl 1, D-10117 Berlin, Germany.	magda.babina@charite.de; margitta.worm@charite.de		Worm, Margitta/0000-0002-3449-1245; Babina, Magda/0000-0002-4500-7615; Rastogi, Shruti/0000-0002-6014-3201	Deutsche Forschungsgemeinschaft [WO 541/16-1, 16-2]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by grants from the Deutsche Forschungsgemeinschaft to M.W. (WO 541/16-1 and 16-2).	Babina M, 2004, J LEUKOCYTE BIOL, V75, P244, DOI 10.1189/jlb.0403157; Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182; Hazzan T, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080829; Motakis E, 2014, BLOOD, V123, pE58, DOI 10.1182/blood-2013-02-483792; Nassiri M, 2015, J ALLERGY CLIN IMMUN, V135, P491, DOI 10.1016/j.jaci.2014.09.004; RING J, 1977, LANCET, V1, P466; Wang Z, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040341	7	19	19	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2020	146	6								10.1016/j.jaci.2020.03.046	http://dx.doi.org/10.1016/j.jaci.2020.03.046			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC3XH	32407837				2022-12-18	WOS:000596937900020
J	Bekhouche, B; Tourville, A; Ravichandran, Y; Tacine, R; Abrami, L; Dussiot, M; Khau-Dancasius, A; Boccara, O; Khirat, M; Mangeney, M; Dingli, F; Loew, D; Boeda, B; Jordan, P; Molina, TJ; Bellon, N; Fraitag, S; Hadj-Rabia, S; Blanche, S; Puel, A; Etienne-Manneville, S; van der Goot, FG; Cherfils, J; Hermine, O; Casanova, JL; Bodemer, C; Smahi, A; Delon, J				Bekhouche, Bahia; Tourville, Aurore; Ravichandran, Yamini; Tacine, Rachida; Abrami, Laurence; Dussiot, Michael; Khau-Dancasius, Andrea; Boccara, Olivia; Khirat, Meriem; Mangeney, Marianne; Dingli, Florent; Loew, Damarys; Boeda, Batiste; Jordan, Penelope; Molina, Thierry Jo; Bellon, Nathalia; Fraitag, Sylvie; Hadj-Rabia, Smail; Blanche, Stephane; Puel, Anne; Etienne-Manneville, Sandrine; van der Goot, F. Gisou; Cherfils, Jacqueline; Hermine, Olivier; Casanova, Jean-Laurent; Bodemer, Christine; Smahi, Asma; Delon, Jerome			A toxic palmitoylation of Cdc42 enhances NF-kappa B signaling and drives a severe autoinflammatory syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ACTIVATION; GTPASES		[Bekhouche, Bahia; Dussiot, Michael; Khau-Dancasius, Andrea; Molina, Thierry Jo; Hermine, Olivier; Smahi, Asma] Univ Paris 05, Sorbonne Paris Cite, Lab Excellence GR Ex, Inst Imagine,INSERM,U1163,CNRS,ERL 8254, Paris, France; [Tourville, Aurore; Tacine, Rachida; Khirat, Meriem; Mangeney, Marianne; Delon, Jerome] Univ Paris, Inst Cochin, INSERM, U1016,CNRS,UMR8104, Paris, France; [Ravichandran, Yamini; Boeda, Batiste; Etienne-Manneville, Sandrine] Inst Pasteur, CNRS, UMR3691, Cell Polar Migrat & Canc Unit,Equipe Labellisee L, Paris, France; [Ravichandran, Yamini] Sorbonne Univ, F-75005 Paris, France; [Abrami, Laurence; van der Goot, F. Gisou] Ecole Polytech Fed Lausanne, Sch Life Sci, Global Hlth Inst, Lausanne, Switzerland; [Boccara, Olivia; Bellon, Nathalia; Hadj-Rabia, Smail; Bodemer, Christine] Paris Descartes Sorbonne Paris Cite Univ, Necker Enfants Malades Hosp, AP HP,Imagine Inst, Dept Dermatol,Reference Ctr Genodermatoses MAGEC, Paris, France; [Dingli, Florent; Loew, Damarys] PSL Res Univ, Inst Curie, Ctr Rech, Lab Spectrometrie Masse Prote, Paris, France; [Jordan, Penelope] Hop Necker Enfants Malad, Serv Genet Mol, Federat Genet, Paris, France; [Molina, Thierry Jo] Univ Paris, Necker Enfants Malad, Dept Pathol, Paris, France; [Fraitag, Sylvie] Necker Enfants Malad Hosp, AP HP, Reference Ctr MAGEC, Dept Pathol, Paris, France; [Blanche, Stephane] Paris Descartes Sorbonne Paris Cite Univ, Necker Enfants Malad Hosp, AP HP5, Unite Immunol Hematol Rhumatol Pediat, Paris, France; [Puel, Anne; Casanova, Jean-Laurent] Descartes Univ, Imagine Inst, Lab Human Genet Infect Dis, Necker Branch,INSERM,U1163, Paris, France; [Cherfils, Jacqueline] CNRS, Lab Biol & Pharmacol Appl, Cachan, France; [Cherfils, Jacqueline] Ecole Normale Super Paris Saclay, Cachan, France; [Hermine, Olivier] Hop Necker Enfants Malad, AP HP, Dept Hematol, Paris, France; [Casanova, Jean-Laurent] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, 1230 York Ave, New York, NY 10021 USA; [Casanova, Jean-Laurent] Howard Hughes Med Inst, New York, NY USA; [Casanova, Jean-Laurent] Paris Descartes Sorbonne Paris Cite Univ, Necker Enfants Malad Hosp, AP HP, Dept Pediat Immunol & Hematol, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Rockefeller University; Howard Hughes Medical Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Bodemer, C (corresponding author), Paris Descartes Sorbonne Paris Cite Univ, Necker Enfants Malades Hosp, AP HP,Imagine Inst, Dept Dermatol,Reference Ctr Genodermatoses MAGEC, Paris, France.	christine.bodemer@aphp.fr; asma.smahi@inserm.fr; jerome.delon@inserm.fr	Puel, Anne/H-7305-2017; Etienne-Manneville, Sandrine/C-5879-2015; Hermine, Olivier/Q-7072-2018; van der Goot, Gisou/B-2279-2012	Puel, Anne/0000-0003-2603-0323; Etienne-Manneville, Sandrine/0000-0001-6651-3675; Delon, Jerome/0000-0003-0222-1192; Boeda, Batiste/0000-0002-0806-8582; Ravichandran, Yamini Yogalakshmi/0000-0003-3123-1242; van der Goot, Gisou/0000-0002-8522-274X	INSERM; CNRS; Universite de Paris; Association pour la Recherche contre le Cancer; Ligue Contre le Cancer; Societe Francaise de Dermatologie; Agence Nationale de la Recherche (RIDES); European Union [MSCA-ITN-2015-675407]; Institut Pasteur; Region Ile de France; Fondation pour la Recherche Medicale	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); CNRS(Centre National de la Recherche Scientifique (CNRS)); Universite de Paris; Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue Contre le Cancer(Ligue nationale contre le cancer); Societe Francaise de Dermatologie; Agence Nationale de la Recherche (RIDES)(French National Research Agency (ANR)); European Union(European Commission); Institut Pasteur(European Commission); Region Ile de France(Region Ile-de-France); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	Supported by INSERM, CNRS, Universite de Paris, Association pour la Recherche contre le Cancer (to J.D.), Ligue Contre le Cancer (to S.E.M.), Societe Francaise de Dermatologie (to A.S., C.B., and J.D.), Agence Nationale de la Recherche (RIDES to A.S., J.D., and J.C.), the European Union Horizon 2020 Marie Sklodowska-Curie research and innovation program (MSCA-ITN-2015-675407 to S.E.M.), Institut Pasteur, the Region Ile de France and the Fondation pour la Recherche Medicale (J.C. and D.L.).	Akula MK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11606-x; Akula MK, 2016, NAT IMMUNOL, V17, P922, DOI 10.1038/ni.3487; Bal E, 2017, NAT MED, V23, P1226, DOI 10.1038/nm.4368; Cherfils J, 2013, PHYSIOL REV, V93, P269, DOI 10.1152/physrev.00003.2012; Faure S, 2004, NAT IMMUNOL, V5, P272, DOI 10.1038/ni1039; Gernez Y, 2019, J ALLERGY CLIN IMMUN, V144, P1122, DOI 10.1016/j.jaci.2019.06.017; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Lam MT, 2019, J EXP MED, V216, P2778, DOI 10.1084/jem.20190147; Park YH, 2016, NAT IMMUNOL, V17, P914, DOI 10.1038/ni.3457; Pfajfer L, 2018, J ALLERGY CLIN IMMUN, V142, P1589, DOI 10.1016/j.jaci.2018.04.023; Poullet P, 2007, PROTEOMICS, V7, P2553, DOI 10.1002/pmic.200600784; Rougerie P, 2012, IMMUNOL LETT, V142, P1, DOI 10.1016/j.imlet.2011.12.003; Salazar-Fontana LI, 2003, J IMMUNOL, V171, P2225, DOI 10.4049/jimmunol.171.5.2225; Valot B, 2011, PROTEOMICS, V11, P3572, DOI 10.1002/pmic.201100120; Vizcaino JA, 2016, NUCLEIC ACIDS RES, V44, P11033, DOI 10.1093/nar/gkw880	15	19	19	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2020	146	5					1201	+		10.1016/j.jaci.2020.03.020	http://dx.doi.org/10.1016/j.jaci.2020.03.020			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OP5VH	32283203	Bronze			2022-12-18	WOS:000588153700022
J	Durack, J; Christian, LS; Nariya, S; Gonzalez, J; Bhakta, NR; Ansel, KM; Beigelman, A; Castro, M; Dyer, AM; Israel, E; Kraft, M; Martin, RJ; Mauger, DT; Peters, SP; Rosenberg, SR; Sorkness, CA; Wechsler, ME; Wenzel, SE; White, SR; Lynch, SV; Boushey, HA; Huang, YJ				Durack, Juliana; Christian, Laura S.; Nariya, Snehal; Gonzalez, Jeanmarie; Bhakta, Nirav R.; Ansel, K. Mark; Beigelman, Avraham; Castro, Mario; Dyer, Anne-Marie; Israel, Elliot; Kraft, Monica; Martin, Richard J.; Mauger, David T.; Peters, Stephen P.; Rosenberg, Sharon R.; Sorkness, Christine A.; Wechsler, Michael E.; Wenzel, Sally E.; White, Steven R.; Lynch, Susan, V; Boushey, Homer A.; Huang, Yvonne J.		Natl Heart Lung Blood Inst AsthmaN	Distinct associations of sputum and oral microbiota with atopic, immunologic, and clinical features in mild asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Microbiome; cytokines; sputum; oral; asthma; allergic; corticosteroids; type 2 inflammation	AIRWAY MICROBIOME; CELLS	Background: Whether microbiome characteristics of induced sputum or oral samples demonstrate unique relationships to features of atopy or mild asthma in adults is unknown. Objective: We sought to determine sputum and oral microbiota relationships to clinical or immunologic features in mild atopic asthma and the impact on the microbiota of inhaled corticosteroid (ICS) treatment administered to ICS-naive subjects with asthma. Methods: Bacterial microbiota profiles were analyzed in induced sputum and oral wash samples from 32 subjects with mild atopic asthma before and after inhaled fluticasone treatment, 18 atopic subjects without asthma, and 16 nonatopic healthy subjects in a multicenter study (NCT01537133). Associations with clinical and immunologic features were examined, including markers of atopy, type 2 inflammation, immune cell populations, and cytokines. Results: Sputum bacterial burden inversely associated with bronchial expression of type 2 (T2)-related genes. Differences in specific sputum microbiota also associated with T2-low asthma phenotype, a subgroup of whom displayed elevations in lung inflammatory mediators and reduced sputum bacterial diversity. Differences in specific oral microbiota were more reflective of atopic status. After ICS treatment of patients with asthma, the compositional structure of sputum microbiota showed greater deviation from baseline in ICS nonresponders than in ICS responders. Conclusions: Novel associations of sputum and oral microbiota to immunologic features were observed in this cohort of subjects with or without ICS-naive mild asthma. These findings confirm and extend our previous report of reduced bronchial bacterial burden and compositional complexity in subjects with T2-high asthma, with additional identification of a T2-low subgroup with a distinct microbiota-immunologic relationship.	[Durack, Juliana; Lynch, Susan, V] Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA 94143 USA; [Christian, Laura S.; Gonzalez, Jeanmarie; Ansel, K. Mark] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; [Christian, Laura S.; Gonzalez, Jeanmarie; Ansel, K. Mark] Univ Calif San Francisco, Sandler Asthma Basic Res Ctr, San Francisco, CA 94143 USA; [Nariya, Snehal; Bhakta, Nirav R.; Boushey, Homer A.] Univ Calif San Francisco, Dept Med, Div Pulm Crit Care Med, San Francisco, CA 94143 USA; [Beigelman, Avraham] Washington Univ, Sch Med, Div Pediat Allergy Immunol & Pulm Med, St Louis, MO USA; [Beigelman, Avraham] Tel Aviv Univ, Schneider Childrens Med Ctr Israel, Kipper Inst Allergy & Immunol, Tel Aviv, Israel; [Castro, Mario] Washington Univ, Sch Med, Div Pulm & Crit Care Med, St Louis, MO USA; [Dyer, Anne-Marie; Mauger, David T.] Penn State Univ, Dept Publ Hlth Sci, Hershey, PA USA; [Israel, Elliot] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Kraft, Monica] Univ Arizona, Hlth Sci, Tucson, AZ USA; [Martin, Richard J.; Wechsler, Michael E.] Natl Jewish Hosp, Dept Med, Denver, CO USA; [Peters, Stephen P.] Wake Forest Sch Med, Winston Salem, NC 27101 USA; [Rosenberg, Sharon R.] Northwestern Univ, Dept Med, Chicago, IL 60611 USA; [Sorkness, Christine A.] Univ Wisconsin, Dept Med, Madison, WI USA; [Wenzel, Sally E.] Univ Pittsburgh, Asthma Inst UPMC UPSOM, Pittsburgh, PA USA; [White, Steven R.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Huang, Yvonne J.] Univ Michigan, Dept Internal Med, Div Pulm Crit Care Med, Ann Arbor, MI 48109 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Washington University (WUSTL); Tel Aviv University; Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Harvard University; Brigham & Women's Hospital; University of Arizona; University of Arizona Health Sciences; National Jewish Health; Wake Forest University; Northwestern University; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Chicago; University of Michigan System; University of Michigan	Huang, YJ (corresponding author), Univ Michigan, Div Pulm Crit Care Med, 6301 MSRB3-SPC5642,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	yvjhuang@umich.edu		Huang, Yvonne/0000-0002-7497-6597; Wenzel, Sally/0000-0002-4242-0164; Gonzalez, Jeanmarie/0000-0001-8998-7726	National Heart, Lung, and Blood Institute AsthmaNet [U10HL098107]; National Institutes of Health [R01AI129958, R03HL13831]	National Heart, Lung, and Blood Institute AsthmaNet; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The analyses performed in this study were supported by National Heart, Lung, and Blood Institute AsthmaNet (grant no. U10HL098107), and by National Institutes of Health grant numbers R01AI129958 and R03HL13831 (both to Y.J.H.).	Anderson M. J., 2017, PERMUTATIONAL MULTIV; Anderson MJ, 2001, AUSTRAL ECOL, V26, P32, DOI 10.1046/j.1442-9993.2001.01070.x; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bhakta Nirav R, 2013, Clin Transl Allergy, V3, P24, DOI 10.1186/2045-7022-3-24; Caporaso JG, 2010, NAT METH, V7; Coquet JM, 2015, IMMUNITY, V43, P318, DOI 10.1016/j.immuni.2015.07.015; Demarche S, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0208-2; Denner DR, 2015, J ALLERGY CLIN IMMUN, V137; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Dickson RP, 2017, MBIO, V8, DOI 10.1128/mBio.02287-16; Diniz JAF, 2013, GENET MOL BIOL, V36, P475, DOI 10.1590/S1415-47572013000400002; Durack J, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0487-3; Durack J, 2018, J ALLERGY CLIN IMMUN, V141, P82, DOI 10.1016/j.jaci.2017.05.026; Durack J, 2017, J ALLERGY CLIN IMMUN, V140, P63, DOI 10.1016/j.jaci.2016.08.055; Durack J, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0631-8; Dzidic M, 2018, ALLERGY, V73, P2000, DOI 10.1111/all.13449; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Goleva E, 2013, AM J RESP CRIT CARE, V188, P1193, DOI 10.1164/rccm.201304-0775OC; Green BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100645; Halwani R, 2017, J ASTHMA, V54, P893, DOI 10.1080/02770903.2017.1283696; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Jevnikar Z, 2019, J ALLERGY CLIN IMMUN, V143, P577, DOI 10.1016/j.jaci.2018.05.026; Kelly EAB, 2009, J IMMUNOL, V182, P1404, DOI 10.4049/jimmunol.182.3.1404; Liu SC, 2018, J ALLERGY CLIN IMMUN, V141, P257, DOI 10.1016/j.jaci.2017.03.032; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; McCauley K, 2019, J ALLERGY CLIN IMMUN, V144, P1187, DOI 10.1016/j.jaci.2019.05.035; Ndum O, 2016, EMJ ALLERGY IMMUNOL, V1, P82; Pavord ID, 2018, LANCET, V391, P350, DOI 10.1016/S0140-6736(17)30879-6; Ramstein J, 2016, AM J RESP CRIT CARE, V193, P1281, DOI 10.1164/rccm.201507-1499OC; Sharma A, 2019, J ALLERGY CLIN IMMUN, V144, P1214, DOI 10.1016/j.jaci.2019.06.025; Simpson JL, 2016, EUR RESP J, V47; Singanayagam A, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav3879; Sverrild A, 2017, J ALLERGY CLIN IMMUN, V140, P407, DOI 10.1016/j.jaci.2016.10.046; Taylor SL, 2017, J ALLERGY CLIN IMMUN, P30743; Turturice BA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184566; Woodruff PG, 2009, AM J RESP CRIT CARE, V180; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Yeon SM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11492-7; Zhang QL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152724; Zhou YJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13698-x	42	19	20	3	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2020	146	5					1016	1026		10.1016/j.jaci.2020.03.028	http://dx.doi.org/10.1016/j.jaci.2020.03.028			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OP5VH	32298699	Green Accepted			2022-12-18	WOS:000588153700006
J	Fleischer, DM; Shreffler, WG; Campbell, DE; Green, TD; Anvari, S; Assa'ad, A; Begin, P; Beyer, K; Bird, JA; Brown-Whitehorn, T; Byrne, A; Chan, ES; Cheema, A; Chinthrajah, S; Chong, HJ; Davis, CM; Ford, LS; Gagnon, R; Greenhawt, M; Hourihane, JO; Jones, SM; Kim, EH; Lange, L; Lanser, BJ; Leonard, S; Mahler, V; Maronna, A; Nowak-Wegrzyn, A; Oriel, RC; O'Sullivan, M; Petroni, D; Pongracic, JA; Prescott, SL; Schneider, LC; Smith, P; Staab, D; Sussman, G; Wood, R; Yang, WH; Lambert, R; Peillon, A; Bois, T; Sampson, HA				Fleischer, David M.; Shreffler, Wayne G.; Campbell, Dianne E.; Green, Todd D.; Anvari, Sara; Assa'ad, Amal; Begin, Philippe; Beyer, Kirsten; Bird, J. Andrew; Brown-Whitehorn, Terri; Byrne, Aideen; Chan, Edmond S.; Cheema, Amarjit; Chinthrajah, Sharon; Chong, Hey Jin; Davis, Carla M.; Ford, Lara S.; Gagnon, Remi; Greenhawt, Matthew; Hourihane, Jonathan O'B; Jones, Stacie M.; Kim, Edwin H.; Lange, Lars; Lanser, Bruce J.; Leonard, Stephanie; Mahler, Vera; Maronna, Andreas; Nowak-Wegrzyn, Anna; Oriel, Roxanne C.; O'Sullivan, Michael; Petroni, Daniel; Pongracic, Jacqueline A.; Prescott, Susan L.; Schneider, Lynda C.; Smith, Peter; Staab, Doris; Sussman, Gordon; Wood, Robert; Yang, William H.; Lambert, Romain; Peillon, Aurelie; Bois, Timothee; Sampson, Hugh A.			Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; food allergy; immunotherapy; desensitization; eliciting dose; epicutaneous immunotherapy; EPIT; sustained unresponsiveness	REGULATORY T-CELLS; ANTIGEN TRAFFICKING; SKIN; QUALITY; PLACEBO; STEADY	Background: The PEPITES (Peanut EPIT Efficacy and Safety) trial, a 12-month randomized controlled study of children with peanut allergy and 4 to 11 years old, previously reported the safety and efficacy of epicutaneous immunotherapy (EPIT) for peanut allergy (250 mg, daily epicutaneous peanut protein; DBV712 250 mg). Objective: We sought to assess interim safety and efficacy of an additional 2 years of EPIT from the ongoing (5-year treatment) PEOPLE (PEPITES Open-Label Extension) study. Methods: Subjects who completed PEPITES were offered enrollment in PEOPLE. Following an additional 2 years of daily DBV712 250 mg, subjects who had received DBV712 250 mg in PEPITES underwent month-36 double-blind, placebocontrolled food challenge with an optional month-38 sustained unresponsiveness assessment. Results: Of 213 eligible subjects who had received DBV712 250 mg in PEPITES, 198 (93%) entered PEOPLE, of whom 141 (71%) had assessable double-blind, placebo-controlled food challenge at month 36. At month 36, 51.8% of subjects (73 of 141) reached an eliciting dose of >1000 mg, compared with 40.4% (57 of 141) at month 12; 75.9% (107 of 141) demonstrated increased eliciting dose compared with baseline;and 13.5% (19 of 141) tolerated the full double-blind, placebo-controlled food challenge of 5444 mg. Median cumulative reactive dose increased from 144 to 944 mg. Eighteen subjects underwent an optional sustained unresponsiveness assessment; 14 of those (77.8%) maintained an eliciting dose of >1000 mg at month 38. Local patch-site skin reactions were common but decreased over time. There was no treatment-related epinephrine use in years 2 or 3. Compliance was high (96.9%), and withdrawals due to treatment-related adverse events were low (1%). Conclusions: These results demonstrate that daily EPIT treatment for peanut allergy beyond 1 year leads to continued response from a well-tolerated, simple-to-use regimen.	[Fleischer, David M.; Greenhawt, Matthew] Univ Colorado Denver, Sch Med, Childrens Hosp Colorado, Sect Allergy & Immunol,Dept Pediat, Aurora, CO USA; [Shreffler, Wayne G.] Massachusetts Gen Hosp, Dept Pediat, Food Allergy Ctr, Boston, MA 02114 USA; [Shreffler, Wayne G.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Campbell, Dianne E.; Ford, Lara S.] Childrens Hosp Westmead, Dept Allergy & Immunol, Sydney, NSW, Australia; [Campbell, Dianne E.; Green, Todd D.; Lambert, Romain; Peillon, Aurelie; Bois, Timothee; Sampson, Hugh A.] DBV Technol, Montrouge, France; [Green, Todd D.; Chong, Hey Jin] Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Pediat, Div Allergy & Immunol,Med Ctr, Pittsburgh, PA 15213 USA; [Anvari, Sara] Texas Childrens Hosp, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA; [Anvari, Sara; Davis, Carla M.] Baylor Coll Med, Dept Pediatr, Allergy & Immunol Sect, Houston, TX 77030 USA; [Assa'ad, Amal] Univ Cincinnati, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Begin, Philippe] Univ Montreal, Dept Med, Div Clin Immunol & Allergy, Montreal, PQ, Canada; [Beyer, Kirsten] Charite Univ Med Berlin, Dept Pediat Pneumol Immunol & Intens Care Med, Berlin, Germany; [Bird, J. Andrew] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Brown-Whitehorn, Terri] Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Brown-Whitehorn, Terri] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Byrne, Aideen] Our Ladys Childrens Hosp, Paediat Allergy Dept, Dublin, Ireland; [Chan, Edmond S.] Univ British Columbia, British Columbia Childrens Hosp, Dept Pediat, Vancouver, BC, Canada; [Cheema, Amarjit] Cheema Res Inc, Mississauga, ON, Canada; [Chinthrajah, Sharon] Stanford Univ, Sean N Parker Ctr Allergy & Asthma Res, Palo Alto, CA 94304 USA; [Ford, Lara S.] Univ Sydney, Discipline Child & Adolescent Hlth, Sydney, NSW, Australia; [Gagnon, Remi] Ctr Hosp Univ Quebec, Serv Allergie & Immunol, Dept Med, Quebec City, PQ, Canada; [Hourihane, Jonathan O'B] Univ Coll Cork, Clin Res Facil, INFANT Ctr & Hlth Res Board, Paediat & Child Hlth, Cork, Ireland; [Hourihane, Jonathan O'B] Royal Coll Surg, Dept Paediat, Dublin, Ireland; [Jones, Stacie M.] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Pediat Allergy & Immunol, Little Rock, AR 72205 USA; [Kim, Edwin H.] Univ N Carolina, Sch Med, Div Rheumatol Allergy & Immunol, Chapel Hill, NC 27515 USA; [Lange, Lars] St Marien Hosp Bonn, Dept Pediat, Bonn, Germany; [Lanser, Bruce J.] Natl Jewish Hlth, Div Pediat Allergy & Clin Immunol, Denver, CO USA; [Leonard, Stephanie] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Leonard, Stephanie] Rady Childrens Hosp, San Diego, CA USA; [Mahler, Vera; Maronna, Andreas] Friedrich Alexander Univ, Univ Hosp Erlangen, Dept Dermatol, Erlangen, Germany; [Nowak-Wegrzyn, Anna] New York Univ Langone Hlth, Hassenfeld Childrens Hosp, New York, NY USA; [Nowak-Wegrzyn, Anna] Univ Warmia & Mazury, Dept Pediat Gastroenterol & Nutr, Olsztyn, Poland; [Oriel, Roxanne C.; Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Div Pediat Allergy & Immunol, New York, NY 10029 USA; [O'Sullivan, Michael; Prescott, Susan L.] Perth Childrens Hosp, Nedlands, WA, Australia; [Petroni, Daniel] Seattle Allergy & Asthma Res Inst, Seattle, WA USA; [Pongracic, Jacqueline A.] Ann & Robert H Lurie Childrens Hosp Chicago, Allergy & Immunol Div, Chicago, IL 60611 USA; [Prescott, Susan L.] Univ Western Australia, Dept Paediat, Sch Med, Perth, WA, Australia; [Schneider, Lynda C.] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Smith, Peter] Griffith Univ, Sch Med Sci, Southport, Qld, Australia; [Staab, Doris] Charite Univ Med Berlin, Dept Pediat, Div Pulmonol Immunol & Crit Care Med, Berlin, Germany; [Sussman, Gordon] Gordon Sussman Clin Res, Toronto, ON, Canada; [Wood, Robert] Johns Hopkins Univ Hosp, Div Allergy & Clin Immunol, Baltimore, MD 21287 USA; [Yang, William H.] Univ Ottawa, Dept Med, Med Sch, Ottawa, ON, Canada; [Mahler, Vera] Paul Ehrlich Inst, Langen, Germany	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Sydney; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Baylor College of Medicine; Baylor College of Medicine; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Universite de Montreal; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; BC Childrens Hospital; University of British Columbia; Stanford University; University of Sydney; Laval University; University College Cork; Royal College of Surgeons - Ireland; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; St. Marien Hospital; National Jewish Health; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of Erlangen Nuremberg; New York University; University of Warmia & Mazury; Icahn School of Medicine at Mount Sinai; Ann & Robert H. Lurie Children's Hospital of Chicago; University of Western Australia; Harvard University; Boston Children's Hospital; Griffith University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Johns Hopkins University; Johns Hopkins Medicine; University of Ottawa; Paul Ehrlich Institute	Fleischer, DM (corresponding author), Childrens Hosp Colorado, 13123 East 16th Ave,Box B518, Aurora, CO 80045 USA.	david.fleischer@childrenscolorado.org	Lanser, Bruce/GVU-1927-2022; Schneider, Lynda C/AAY-6545-2021; Bégin, Philippe/AAU-9126-2021; O'Sullivan, Michael/AAZ-5853-2021	Lanser, Bruce/0000-0002-3422-8658; Schneider, Lynda C/0000-0002-5633-0178; O'Sullivan, Michael/0000-0001-7896-2697; Kim, Edwin/0000-0001-6418-1785; Campbell, Dianne/0000-0002-0907-6963; Green, Todd/0000-0002-2586-3625; Nowak-Wegrzyn, Anna/0000-0002-0960-9854; Davis, Carla/0000-0003-0866-7822	DBV Technologies	DBV Technologies	We wish to thank the patients, family members, and staff from all trial sites who participated in the study. Clinical trial design and management were provided by Aline Schindele, Bruno Robin, and Remi Charretier, employees of DBV Technologies. Manuscript preparation assistance and support was provided by Sara Sherman and Katharine Bee, employees of DBV Technologies. Statistical support was provided by Cecile Hayem, a contractor of DBV Technologies. Editorial support was provided by International Meetings & Science and was funded by DBV Technologies.	Anagnostou K, 2014, LANCET, V383, P1297, DOI 10.1016/S0140-6736(13)62301-6; [Anonymous], 2019, ANN ALLERG ASTHMA S; Avery NJ, 2003, PEDIAT ALLERG IMM-UK, V14, P378, DOI 10.1034/j.1399-3038.2003.00072.x; Bird JA, 2018, WORLD ALLERGY ORGAN, V11, DOI 10.1186/s40413-018-0215-2; Blumchen K, 2019, J ALLER CL IMM-PRACT, V7, P479, DOI 10.1016/j.jaip.2018.10.048; Brown-Whitehorn TF, 2018, ALLERGY SS105, V73, P134; Chinthrajah RS, 2019, LANCET, V394, P1437, DOI 10.1016/S0140-6736(19)31793-3; Deschildre A, 2016, CLIN EXP ALLERGY, V46, P610, DOI 10.1111/cea.12681; Dioszeghy V, 2014, CLIN EXP ALLERGY, V44, P867, DOI 10.1111/cea.12312; Dioszeghy V, 2011, J IMMUNOL, V186, P5629, DOI 10.4049/jimmunol.1003134; Fleischer DM, 2020, ALLERGY ASTHMA PROC, V41, P326, DOI 10.2500/aap.2020.41.200047; Fleischer DM, 2019, JAMA-J AM MED ASSOC, V321, P946, DOI 10.1001/jama.2019.1113; Food and Drug Administration, 2020, FDA APPR 1 DRUG IND; Global Initiative for Asthma (GINA), ASTHM MAN PREV AD CH; Good Clinical Practice Network, ICH HARM GUID INT AD; Greenhawt M, 2020, J ALLER CL IMM-PRACT, V8, P3219, DOI 10.1016/j.jaip.2020.05.030; Greenhawt M, 2018, ANN ALLERG ASTHMA IM, V121, P575, DOI 10.1016/j.anai.2018.06.018; Gupta RS, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-1235; Jones SM, 2019, ALLERGY S106, V74, P376; Jones SM, 2017, J ALLERGY CLIN IMMUN, V139, P1242, DOI 10.1016/j.jaci.2016.08.017; Kansen HM, 2020, J ALLERGY CLIN IMMUN, V145, P705, DOI 10.1016/j.jaci.2019.09.011; Langlois A, 2019, EXPERT REV CLIN IMMU, V15, P449, DOI 10.1080/1744666X.2019.1593138; Leftwich J, 2011, CLIN EXP ALLERGY, V41, P243, DOI 10.1111/j.1365-2222.2010.03649.x; Mondoulet L, 2019, ALLERGY, V74, P152, DOI 10.1111/all.13479; Mondoulet Lucie, 2012, Clin Transl Allergy, V2, P22, DOI 10.1186/2045-7022-2-22; Motosue MS, 2018, PEDIAT ALLERG IMM-UK, V29, P538, DOI 10.1111/pai.12908; Parlaman Joshua P, 2016, Hosp Pediatr, V6, P269, DOI 10.1542/hpeds.2015-0153; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Purington N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02057; Remington B, 2020, J ALLERGY CLIN IMMUN, V145, pAB142, DOI 10.1016/j.jaci.2019.12.455; Remington BC, 2019, ANN ALLERG ASTHMA IM, V123, P488, DOI 10.1016/j.anai.2019.08.007; Roy KM, 2011, CLIN PEDIATR, V50, P1045, DOI 10.1177/0009922811412584; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sampson HA, 2017, JAMA-J AM MED ASSOC, V318, P1798, DOI 10.1001/jama.2017.16591; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Shaker M, 2020, ANN ALLERG ASTHMA IM, V124, P357, DOI 10.1016/j.anai.2020.01.004; Sicherer SH, 2018, J ALLERGY CLIN IMMUN, V141, P41, DOI 10.1016/j.jaci.2017.11.003; Taylor SL, 2014, FOOD CHEM TOXICOL, V63, P9, DOI 10.1016/j.fct.2013.10.032; Todd DG, 2007, PEDIATRICS, V120, P1304, DOI 10.1542/peds.2007-0350; Tordesillas L, 2017, J ALLERGY CLIN IMMUN, V139, P189, DOI 10.1016/j.jaci.2016.03.057; Turjanmaa K, 2006, ALLERGY, V61, P1377, DOI 10.1111/j.1398-9995.2006.01136.x; US Food and Drug Administration, 2016, ALL PROD ADV COMM CL; Vickery BP, 2018, NEW ENGL J MED, V379, P1991, DOI 10.1056/NEJMoa1812856; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Wang J, 2018, PEDIAT ALLERG IMM-UK, V29, P341, DOI 10.1111/pai.12869; Yoshino M, 2003, INT IMMUNOL, V15, P773, DOI 10.1093/intimm/dxg075; Yoshino M, 2006, INT IMMUNOL, V18, P1541, DOI 10.1093/intimm/dxl087	47	19	19	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2020	146	4					863	874						12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OH2JO	32659313	Green Published, hybrid			2022-12-18	WOS:000582395800017
J	Roberts, G; Fontanella, S; Selby, A; Howard, R; Filippi, S; Hedlin, G; Nordlund, B; Howarth, P; Hashimoto, S; Brinkman, P; Fleming, LJ; Murray, C; Bush, A; Frey, U; Singer, F; Schoos, AMM; van Aalderen, W; Djukanovic, R; Chung, KF; Sterk, PJ; Adnan, C				Roberts, Graham; Fontanella, Sara; Selby, Anna; Howard, Rebecca; Filippi, Sarah; Hedlin, Gunilla; Nordlund, Bjorn; Howarth, Peter; Hashimoto, Simone; Brinkman, Peter; Fleming, Louise J.; Murray, Clare; Bush, Andrew; Frey, Urs; Singer, Florian; Schoos, Ann-Marie Malby; van Aalderen, Wim; Djukanovic, Ratko; Chung, K. Fan; Sterk, Peter J.; Adnan, Custovic		U-BIOPRED Consortium	Connectivity patterns between multiple allergen specific IgE antibodies and their association with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergic sensitization; cluster; network analysis	PEDIATRIC SEVERE ASTHMA; CLINICAL SYMPTOMS; SENSITIZATION; CHILDHOOD; RESPONSES	Background: Allergic sensitization is associated with severe asthma, but assessment of sensitization is not recommended by most guidelines. Objective: We hypothesized that patterns of IgE responses to multiple allergenic proteins differ between sensitized participants with mild/moderate and severe asthma. Methods: IgE to 112 allergenic molecules (components, c-sIgE) was measured using multiplex array among 509 adults and 140 school-age and 131 preschool children with asthma/wheeze from the Unbiased BIOmarkers for the PREDiction of respiratory diseases outcomes cohort, of whom 595 had severe disease. We applied clustering methods to identify co-occurrence patterns of components (component clusters) and patterns of sensitization among participants (sensitization clusters). Network analysis techniques explored the connectivity structure of c-sIgE, and differential network analysis looked for differences in c-sIgE interactions between severe and mild/moderate asthma. Results: Four sensitization clusters were identified, but with no difference between disease severity groups. Similarly, component clusters were not associated with asthma severity. None of the c-sIgE were identified as associates of severe asthma. The key difference between school children and adults with mild/moderate compared with those with severe asthma was in the network of connections between c-sIgE. Participants with severe asthma had higher connectivity among components, but these connections were weaker. The mild/moderate network had fewer connections, but the connections were stronger. Connectivity between components with no structural homology tended to co-occur among participants with severe asthma. Results were independent from the different sample sizes of mild/moderate and severe groups. Conclusions: The patterns of interactions between IgE to multiple allergenic proteins are predictors of asthma severity among school children and adults with allergic asthma.	[Roberts, Graham; Selby, Anna; Howarth, Peter; Djukanovic, Ratko] Univ Southampton, Fac Med, Clin & Expt Sci & Human Dev Hlth Acad Unit, Southampton, Hants, England; [Roberts, Graham; Howarth, Peter; Djukanovic, Ratko] Univ Hosp Southampton NHS Fdn Trust, NIHR Southampton Biomed Res Ctr, Southampton, Hants, England; [Roberts, Graham] St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport, Wight, England; [Fontanella, Sara; Fleming, Louise J.; Adnan, Custovic] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Howard, Rebecca] Univ Manchester, Fac Biol Med & Hlth, Div Informat Imaging & Data Sci, Manchester, Lancs, England; [Filippi, Sarah] Imperial Coll London, Dept Math, London, England; [Hedlin, Gunilla; Nordlund, Bjorn] Karolinska Inst, Karolinska Univ Hosp, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Hedlin, Gunilla; Nordlund, Bjorn] Karolinska Inst, Karolinska Univ Hosp, Ctr Allergy Res, Stockholm, Sweden; [Hashimoto, Simone; Brinkman, Peter; Sterk, Peter J.] Univ Amsterdam, Dept Resp Med, Emma Childrens Hosp, Amsterdam UMC, Amsterdam, Netherlands; [Hashimoto, Simone; van Aalderen, Wim] Univ Amsterdam, Emma Childrens Hosp, Dept Paediat Resp Med & Allergy, Amsterdam UMC, Amsterdam, Netherlands; [Fleming, Louise J.; Bush, Andrew; Chung, K. Fan] Royal Brompton Hosp, Dept Resp Paediat, London, England; [Murray, Clare] Univ Manchester, Manchester Acad Hlth Sci Ctr, Univ Hosp South Manchester NHS Fdn Trust, Div Infect Immun & Resp Med, Manchester, Lancs, England; [Bush, Andrew; Schoos, Ann-Marie Malby] Univ Copenhagen, Herlev & Gentofte Hosp, COPSAC Copenhagen Prospect Studies Asthma Childho, Copenhagen, Denmark; [Frey, Urs] Univ Basel, Univ Childrens Hosp Basel UKBB, Spitalstr, Basel, Switzerland; [Singer, Florian] Univ Bern, Univ Childrens Hosp Bern, Dept Pediat, Div Resp Med, Bern, Switzerland	University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; Imperial College London; University of Manchester; Imperial College London; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Emma Children's Hospital; University of Amsterdam; Emma Children's Hospital; University of Amsterdam; Royal Brompton Hospital; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; University of Copenhagen; University of Basel; University of Bern; University Hospital of Bern	Roberts, G (corresponding author), Southampton Univ Hosp NHS Fdn Trust, Paediat Allergy & Resp Med, Mailpoint 805,Tremona Rd, Southampton SO16 6YD, Hants, England.	g.c.roberts@soton.ac.uk	Singer, Florian/AAO-1460-2021; Fontanella, Sara/ABA-7890-2021; Custovic, Adnan/A-2435-2012; Schoos, Ann-Marie Malby/AAO-7677-2020	Singer, Florian/0000-0003-3471-5664; Custovic, Adnan/0000-0001-5218-7071; Schoos, Ann-Marie Malby/0000-0002-5827-0885; Selby, Anna/0000-0003-4044-7125; Djukanovic, Ratko/0000-0001-6039-5612; Murray, Clare/0000-0002-8961-8055; Hashimoto, Simone/0000-0001-8995-3817; Filippi, Sarah/0000-0001-8652-358X; Howarth, Peter/0000-0003-0619-7927; Roberts, Graham/0000-0003-2252-1248; Frey, Urs/0000-0003-3773-2822	Innovative Medicines Initiative; University Hospital Southampton NHS Foundation Trust; NIHRWellcome Trust Clinical Research Facility, Southampton, UK; MRC [MR/S025340/1] Funding Source: UKRI	Innovative Medicines Initiative; University Hospital Southampton NHS Foundation Trust; NIHRWellcome Trust Clinical Research Facility, Southampton, UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This article is presented on behalf of the U-BIOPRED Study Group with input from the U-BIOPRED Patient Input Platform, Ethics Board, and Safety Management Board. We thank Tom Cull who undertook the ImmunoCAP Immuno-Solid phase Allergy Chip assays at University Hospital Southampton NHS Foundation Trust. We also acknowledge help in data and knowledge management from the eTRIKS project, which is funded by the Innovative Medicines Initiative. In addition, we acknowledge the support of the University Hospital Southampton NHS Foundation Trust and the NIHRWellcome Trust Clinical Research Facility, Southampton, UK.	Bahadori Katayoun, 2009, BMC Pulm Med, V9, P24, DOI 10.1186/1471-2466-9-24; Belgrave DCM, 2018, LANCET RESP MED, V6, P526, DOI 10.1016/S2213-2600(18)30099-7; Belgrave DCM, 2014, AM J RESP CRIT CARE, V189, P1101, DOI 10.1164/rccm.201309-1700OC; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Castanhinha S, 2015, J ALLERGY CLIN IMMUN, V136, P312, DOI 10.1016/j.jaci.2015.01.016; Chipps BE, 2007, J ALLERGY CLIN IMMUN, V119, P1156, DOI 10.1016/j.jaci.2006.12.668; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Csardi G., 2006, INTERJOURNAL COMPLEX, V1695, P5; Custovic A, 2019, J ALLERGY CLIN IMMUN, V144, P25, DOI 10.1016/j.jaci.2019.05.016; Custovic A, 2018, AM J RESP CRIT CARE, V197, P1265, DOI 10.1164/rccm.201708-1762OC; Custovic A, 2015, J ALLERGY CLIN IMMUN, V136, P1645, DOI 10.1016/j.jaci.2015.03.041; Custovic A, 2013, CURR OPIN ALLERGY CL, V13, P173, DOI 10.1097/ACI.0b013e32835e82b6; Del Giacco SR, 2017, ALLERGY, V72, P207, DOI 10.1111/all.13072; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Eiringhaus K, 2019, J APPL LAB MED, V3, P883, DOI 10.1373/jalm.2018.026526; Fang YX, 2012, COMPUT STAT DATA AN, V56, P468, DOI 10.1016/j.csda.2011.09.003; Fleming L, 2015, EUR RESPIR J, V46, P1322, DOI 10.1183/13993003.00780-2015; Fontanella S, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002691; Hennig C, 2010, R PACKAGE VERSION, V2, P0; Holguin F, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00588-2019; Holt PG, 2016, J ALLERGY CLIN IMMUN, V137, P379, DOI 10.1016/j.jaci.2015.08.044; Howard R, 2018, J ALLERGY CLIN IMMUN, V142, P1322, DOI 10.1016/j.jaci.2017.11.064; Ji JD, 2017, BIOINFORMATICS, V33, P3080, DOI 10.1093/bioinformatics/btx360; Konradsen JR, 2014, PEDIAT ALLERG IMM-UK, V25, P187, DOI 10.1111/pai.12198; Lawlor DA, 2016, INT J EPIDEMIOL, V45, P1866, DOI 10.1093/ije/dyw314; Lazic N, 2013, ALLERGY, V68, P764, DOI 10.1111/all.12134; McKenzie AT, 2016, BMC SYST BIOL, V10, DOI 10.1186/s12918-016-0349-1; Nwaru BI, 2019, J ALLER CL IMM-PRACT, V7, P1230, DOI 10.1016/j.jaip.2018.12.018; Oksel C, 2018, CURR OPIN ALLERGY CL, V18, P109, DOI 10.1097/ACI.0000000000000430; Papastamoulis P., 2016, J STAT SOFTWARE, V1; Papastamoulis P, 2017, R J, V9, P403; Prosperi MCF, 2014, PEDIAT ALLERG IMM-UK, V25, P71, DOI 10.1111/pai.12139; Roberts G, 2016, ALLERGY, V71, P1540, DOI 10.1111/all.12939; Saglani S, 2019, AM J RESP CRIT CARE, V199, P414, DOI 10.1164/rccm.201810-1956CI; Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015; Simpson A, 2015, J ALLERGY CLIN IMMUN, V136, P1224, DOI 10.1016/j.jaci.2015.03.027; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Sonntag HJ, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00251; Szefler SJ, 2012, J ALLERGY CLIN IMMUN, V129, pS9, DOI 10.1016/j.jaci.2011.12.979; Wickman M, 2017, EBIOMEDICINE, V26, P91, DOI 10.1016/j.ebiom.2017.11.009	40	19	20	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2020	146	4					821	830		10.1016/j.jaci.2020.02.031	http://dx.doi.org/10.1016/j.jaci.2020.02.031			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OH2JO	32188567	Green Accepted, Green Submitted			2022-12-18	WOS:000582395800013
J	Hoof, I; Schulten, V; Layhadi, JA; Stranzl, T; Christensen, LH; de la Mata, SH; Seumois, G; Vijayanand, P; Lundegaard, C; Niss, K; Lund, A; Ahrenfeldt, J; Holm, J; Steveling, E; Sharif, H; Durham, SR; Peters, B; Shamji, MH; Andersen, PS				Hoof, Ilka; Schulten, Veronique; Layhadi, Janice A.; Stranzl, Thomas; Christensen, Lars H.; de la Mata, Sara Herrera; Seumois, Gregory; Vijayanand, Pandurangan; Lundegaard, Claus; Niss, Kristoffer; Lund, Anders; Ahrenfeldt, Johanne; Holm, Jens; Steveling, Esther; Sharif, Hanisah; Durham, Stephen R.; Peters, Bjorn; Shamji, Mohamed H.; Andersen, Peter S.			Allergen-specific IgG(+) memory B cells are temporally linked to IgE memory responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IGe; sublingual immunotherapy; grass pollen allergy; B cells; plasmablasts; memory B cells	PLASMA-CELLS; NASAL-MUCOSA; REPERTOIRE; IMMUNOTHERAPY; PERSISTENCE; INTERLEUKIN-4; EXPRESSION; MATURATION; INDUCTION; LIMITS	Background: IgE is the least abundant immunoglobulin and tightly regulated, and IgE-producing B cells are rare. The cellular origin and evolution of IgE responses are poorly understood. Objective: The cellular and clonal origin of IgE memory responses following mucosal allergen exposure by sublingual immunotherapy (SLIT) were investigated. Methods: In a randomized double-blind, placebo-controlled, time course SLIT study, PBMCs and nasal biopsy samples were collected from 40 adults with seasonal allergic rhinitis at baseline and at 4, 8, 16, 28, and 52 weeks. RNA was extracted from PBMCs, sorted B cells, and nasal biopsy samples for heavy chain variable gene repertoire sequencing. Moreover, mAbs were derived from single B-cell transcriptomes. Results: Combining heavy chain variable gene repertoire sequencing and single-cell transcriptomics yielded direct evidence of a parallel boost of 2 clonally and functionally related B-cell subsets of short-lived IgE(+) plasmablasts and IgG(+) memory B cells. Mucosal grass pollen allergen exposure by SLIT resulted in highly diverse IgE and IgG(E) repertoires. These were extensively mutated and appeared relatively stable as per heavy chain isotype, somatic hypermutations, and clonal composition. Single IgG(E)(+) memory B-cell and IgE(+) preplasmablast transcriptomes encoded antibodies that were specific for major grass pollen allergens and able to elicit basophil activation at very low allergen concentrations. Conclusion: For the first time, we have shown that on mucosal allergen exposure, human IgE memory resides in allergen-specific IgG(+) memory B cells. These cells rapidly switch isotype, expand into short-lived IgE(+) plasmablasts, and serve as a potential target for therapeutic intervention.	[Hoof, Ilka; Stranzl, Thomas; Christensen, Lars H.; Lundegaard, Claus; Niss, Kristoffer; Lund, Anders; Ahrenfeldt, Johanne; Holm, Jens; Andersen, Peter S.] ALK Abello AS, Boge Alle 1, DK-2970 Horsholm, Denmark; [Schulten, Veronique; de la Mata, Sara Herrera; Seumois, Gregory; Vijayanand, Pandurangan; Peters, Bjorn] La Jolla Inst Immunol, La Jolla, CA USA; [Layhadi, Janice A.; Steveling, Esther; Sharif, Hanisah; Durham, Stephen R.; Shamji, Mohamed H.] Imperial Coll London, Natl Heart & Lung Inst, Immunomodulat & Tolerance Grp, Allergy & Clin Immunol,Inflammat,Repair & Dev,Ast, London, England	ALK-Abello AS; La Jolla Institute for Immunology; Imperial College London	Andersen, PS (corresponding author), ALK Abello AS, Boge Alle 1, DK-2970 Horsholm, Denmark.	PeterSejer.Andersen@alk.net	Ahrenfeldt, Johanne/GQZ-6257-2022; Sharif, Hanisah/AAZ-5132-2021	Sharif, Hanisah/0000-0002-2620-906X; Niss, Kristoffer/0000-0001-5910-1525; Ahrenfeldt, Johanne/0000-0001-9175-0373; Lund, Anders/0000-0003-0051-8400; Seumois, Gregory/0000-0002-8164-6852; Shamji, Mohamed/0000-0003-3425-3463; Herrera-De La Mata, Sara/0000-0002-9519-9520; Harder Christensen, Lars/0000-0003-4230-7820; Layhadi, Janice/0000-0002-5242-1806	Innovation Fund Denmark [5184-00010B]; National Institute of Health [S10OD016262]; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [U19AI135731]; Imperial College	Innovation Fund Denmark; National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Imperial College	Supported by the Innovation Fund Denmark (grant 5184-00010B [to P.S.A.]), the National Institute of Health (Sequencer grant S10OD016262 [to G.S.]), the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (grant U19AI135731 [to B.P.]), and the Imperial College (research funds to M.S). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Aasbjerg K, 2014, CLIN EXP ALLERGY, V44, P417, DOI 10.1111/cea.12241; Berkowska MA, 2014, J ALLERGY CLIN IMMUN, V134, P688, DOI 10.1016/j.jaci.2014.03.036; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Christensen LH, 2008, J ALLERGY CLIN IMMUN, V122, P298, DOI 10.1016/j.jaci.2008.05.026; Croote D, 2018, SCIENCE, V362, P1306, DOI 10.1126/science.aau2599; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; Engel I, 2016, NAT IMMUNOL, V17, P728, DOI 10.1038/ni.3437; Erazo A, 2007, IMMUNITY, V26, P191, DOI 10.1016/j.immuni.2006.12.006; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; Gould HJ, 2015, TRENDS IMMUNOL, V36, P40, DOI 10.1016/j.it.2014.11.002; Gupta NT, 2015, BIOINFORMATICS, V31, P3356, DOI 10.1093/bioinformatics/btv359; He JS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00723-0; He JS, 2013, J EXP MED, V210, P2755, DOI 10.1084/jem.20131539; He JS, 2017, NAT COMMUN, V8, P1; Hoh RA, 2016, J ALLERGY CLIN IMMUN, V137, P157, DOI 10.1016/j.jaci.2015.05.029; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Jimenez-Saiz R, 2019, ALLERGY, V74, P165, DOI 10.1111/all.13481; Jimenez-Saiz R, 2017, J ALLERGY CLIN IMMUN, V140, P1604, DOI 10.1016/j.jaci.2017.01.018; Levin M, 2016, J ALLERGY CLIN IMMUN, V137, P1535, DOI 10.1016/j.jaci.2015.09.027; Looney TJ, 2016, J ALLERGY CLIN IMMUN, V137, P579, DOI 10.1016/j.jaci.2015.07.014; Luger EO, 2009, J ALLERGY CLIN IMMUN, V124, P819, DOI 10.1016/j.jaci.2009.06.047; Lund G, 2012, J IMMUNOL METHODS, V383, P4, DOI 10.1016/j.jim.2012.05.021; Marth K, 2010, MOL IMMUNOL, V47, P2323, DOI 10.1016/j.molimm.2010.05.285; Otte M, 2016, J ALLERGY CLIN IMMUN, V137, P1884, DOI 10.1016/j.jaci.2015.12.1333; Patil SU, 2015, J ALLERGY CLIN IMMUN, V136, P125, DOI 10.1016/j.jaci.2015.03.026; Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006; Poulsen TR, 2011, J IMMUNOL, V187, P4229, DOI 10.4049/jimmunol.1000928; Ramadani F, 2017, ALLERGY, V72, P66, DOI 10.1111/all.12911; Rosales SL, 2018, METHODS MOL BIOL, V1799, P275, DOI 10.1007/978-1-4939-7896-0_21; Scadding GW, 2017, JAMA-J AM MED ASSOC, V317, P615, DOI 10.1001/jama.2016.21040; Shubinsky G, 1997, LEUKEMIA LYMPHOMA, V25, P521, DOI 10.3109/10428199709039040; Smurthwaite L, 2001, EUR J IMMUNOL, V31, P3422, DOI 10.1002/1521-4141(200112)31:12<3422::AID-IMMU3422>3.0.CO;2-T; Steveling EH, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0087-2; Suarez-Fueyo A, 2014, J ALLERGY CLIN IMMUN, V133, P130, DOI 10.1016/j.jaci.2013.09.043; Takhar P, 2005, J IMMUNOL, V174, P5024, DOI 10.4049/jimmunol.174.8.5024; Talay O, 2013, NAT IMMUNOL, V14, P1302, DOI 10.1038/ni.2770; Talay O, 2012, NAT IMMUNOL, V13, P396, DOI 10.1038/ni.2256; UMETSU DT, 1985, J EXP MED, V162, P202, DOI 10.1084/jem.162.1.202; Wong KJ, 2015, ALLERGY, V70, P420, DOI 10.1111/all.12563; Xiong HZ, 2012, J EXP MED, V209, P353, DOI 10.1084/jem.20111941; Yang ZY, 2012, IMMUNITY, V36, P857, DOI 10.1016/j.immuni.2012.02.009; Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382; Zhang JJ, 2014, BIOINFORMATICS, V30, P614, DOI 10.1093/bioinformatics/btt593	44	19	19	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					180	191		10.1016/j.jaci.2019.11.046	http://dx.doi.org/10.1016/j.jaci.2019.11.046			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	31883847	Bronze, Green Accepted, Green Submitted			2022-12-18	WOS:000579170500027
J	Honda, T; Kabashima, K				Honda, Tetsuya; Kabashima, Kenji			Reconciling innate and acquired immunity in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Atopic dermatitis; group 2 innate lymphoid cells; T(H)2 cells	LYMPHOID-CELLS; SKIN		[Honda, Tetsuya; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan; [Kabashima, Kenji] ASTAR, Singapore Immunol Network SIgN, Biopolis, Singapore; [Kabashima, Kenji] ASTAR, SRIS, Biopolis, Singapore	Kyoto University; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); Agency for Science Technology & Research (A*STAR)	Honda, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Dermatol, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	hontetsu@kuhp.kyoto-u.ac.jp						Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Czarnowicki T, 2019, J ALLERGY CLIN IMMUN, V143, P1, DOI 10.1016/j.jaci.2018.10.032; Endo Y, 2015, IMMUNITY, V42, P294, DOI 10.1016/j.immuni.2015.01.016; Guo LY, 2015, NAT IMMUNOL, V16, P1051, DOI 10.1038/ni.3244; Imai Y, 2013, P NATL ACAD SCI USA, V110, P13921, DOI 10.1073/pnas.1307321110; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Konishi H, 2002, P NATL ACAD SCI USA, V99, P11340, DOI 10.1073/pnas.152337799; Mashiko S, 2017, J DERMATOL SCI, V88, P167, DOI 10.1016/j.jdermsci.2017.07.003; Ricardo-Gonzalez RR, 2018, NAT IMMUNOL, V19, P1093, DOI 10.1038/s41590-018-0201-4; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351	10	19	21	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2020	145	4					1136	1137		10.1016/j.jaci.2020.02.008	http://dx.doi.org/10.1016/j.jaci.2020.02.008			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LA0FR	32109456				2022-12-18	WOS:000523633400006
J	Tomalin, LE; Russell, CB; Garcet, S; Ewald, DA; Klekotka, P; Nirula, A; Norsgaard, H; Suarez-Farinas, M; Krueger, JG				Tomalin, Lewis E.; Russell, Chris B.; Garcet, Sandra; Ewald, David Adrian; Klekotka, Paul; Nirula, Ajay; Norsgaard, Hanne; Suarez-Farinas, Mayte; Krueger, James G.			Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						brodalumab; IL-12; IL-17; IL-23; inflammatory cytokines; keratinocytes; psoriasis; transcriptomic profiling; ustekinumab	INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY; DOUBLE-BLIND; EXPRESSION; USTEKINUMAB; BRODALUMAB; SKIN; ETANERCEPT; EFFICACY; SAFETY	Background: IL-17 antagonists induce impressive clinical benefits in psoriasis, but it is unknown to what extent cellular and molecular psoriasis characteristics are suppressed by a clinically relevant dose/schedule of any IL-17-receptor antagonist. Objective: We sought to examine the effects of the IL-17 receptor-A antagonist brodalumab, on clinical and molecular psoriasis features over a 12-week period. Methods: A subset of patients (n = 116) enrolled in 3 phase-3 randomized clinical trials (AMAGINE-1 [Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects], -2 [P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis], and -3 [Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis in Subjects]) participated in a mechanistic substudy where punch biopsies were collected (lesional and nonlesional skin) between baseline and 12 weeks. This cohort included moderate-to-severe psoriasis patients treated with 140 mg (n = 46), 210 mg (n = 41) brodalumab, or placebo (n = 29). Key epidermal psoriatic features, including T-cell and dendritic cell subsets, were examined using immunohistochemistry. Treatment-induced changes in lesional skin gene expression profiles were evaluated using Affymetrix arrays. Results: IL-17 receptor-A antagonism caused extensive improvements in clinical, histologic, and transcriptomic features of psoriasis. Cellular infiltrates (CD3+, CD8+, CD11c+, CD163+), markers of keratinocyte proliferation (Ki67+, KRT16), and inflammatory cytokines (IL-17A/C/F, IL-23A, IL-12B) decreased progressively, reaching close to nonlesional levels, paralleled by decreases in epidermal thickness. Psoriasis transcriptome gene expression improved similar to 85% to 95% in responders whose psoriasis area severity index improved by 75% from baseline by week 12 (n = 63), compared with similar to 30% to 65% in nonresponders (n = 12), while the residual disease genomic profile was 10% of the psoriasis transcriptome, which is less than for earlier generation drugs. IL-17-dependent gene expression, including keratinocyte genes, improved earlier and more extensively following brodalumab treatment compared with ustekinumab treatment (anti-IL-23/IL-12). Conclusions: The clinically approved dose and schedule for brodalumab leads to nearly complete resolution of clinical, histologic, and transcriptomic features of psoriasis. Evidently, IL-17-induced release of keratinocyte-derived inflammatory mediators is a key driver of psoriasis pathogenesis.	[Tomalin, Lewis E.; Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Russell, Chris B.] BioMarin Pharmaceut Inc, Novato, CA USA; [Garcet, Sandra; Krueger, James G.] Rockefeller Univ, 1230 York Ave, New York, NY 10065 USA; [Ewald, David Adrian; Norsgaard, Hanne] Leo Pharma AS, Ballerup, Denmark; [Klekotka, Paul; Nirula, Ajay] Lilly Biotechnol Ctr, San Diego, CA USA	Icahn School of Medicine at Mount Sinai; BioMarin Pharmaceutical Inc.; Rockefeller University; LEO Pharma	Krueger, JG (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10065 USA.; Suarez-Farinas, M (corresponding author), Icahn Sch Med, 1 Gustave L Levy Pl, New York, NY 10029 USA.	Mayte.SuarezFarinas@mssm.edu; kruegej@mail.rockefeller.edu		Garcet, Sandra/0000-0002-4465-8547; Norsgaard, Hanne/0000-0002-5249-6701; Russell, Chris/0000-0002-0240-1815; Ewald, David Adrian/0000-0001-6620-2738	Irma T. Hirschl Trust Research Award (New York, NY); AMGEN (Thousand Oaks, Calif)	Irma T. Hirschl Trust Research Award (New York, NY); AMGEN (Thousand Oaks, Calif)(Amgen)	This work was supported by the Irma T. Hirschl Trust Research Award (New York, NY), and a grant from AMGEN (Thousand Oaks, Calif) to the Rockefeller University.	Brodmerkel C, 2019, J ALLERGY CLIN IMMUN, V143, P1965, DOI 10.1016/j.jaci.2019.01.017; Campa M, 2016, EXPERT OPIN INV DRUG, V25, P1337, DOI 10.1080/13543784.2016.1237502; Chiricozzi A, 2016, BRIT J DERMATOL, V174, P136, DOI 10.1111/bjd.14034; Chiricozzi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090284; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Chyou S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032828; da Rosa JC, 2017, J INVEST DERMATOL, V137, P305, DOI 10.1016/j.jid.2016.09.015; Gaffen SL, 2011, CURR OPIN IMMUNOL, V23, P613, DOI 10.1016/j.coi.2011.07.006; Goldminz AM, 2015, JAMA DERMATOL, V151, P837, DOI 10.1001/jamadermatol.2015.0452; Griffiths CEM, 2015, LANCET, V386, P541, DOI 10.1016/S0140-6736(15)60125-8; Griffiths CEM, 2010, NEW ENGL J MED, V362, P118, DOI 10.1056/NEJMoa0810652; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Johnson-Huang LM, 2012, J INVEST DERMATOL, V132, P1177, DOI 10.1038/jid.2011.458; Johnston A, 2013, J IMMUNOL, V190, P2252, DOI 10.4049/jimmunol.1201505; Kim J, 2017, ANNU REV MED, V68, P255, DOI 10.1146/annurev-med-042915-103905; Krueger J, 2016, J ALLERGY CLIN IMMUN, V137, P1079, DOI 10.1016/j.jaci.2015.12.1318; Krueger JG, 2019, J ALLERGY CLIN IMMUN, V144, P750, DOI 10.1016/j.jaci.2019.04.029; Krueger JG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142081; Krueger JG, 2012, J ALLERGY CLIN IMMUN, V130, P145, DOI 10.1016/j.jaci.2012.04.024; Kulig P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13466; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Lebwohl M, 2015, NEW ENGL J MED, V373, P1318, DOI 10.1056/NEJMoa1503824; Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Papp KA, 2016, BRIT J DERMATOL, V175, P273, DOI 10.1111/bjd.14493; Papp KA, 2008, LANCET, V371, P1675, DOI 10.1016/S0140-6736(08)60726-6; Ramirez-Carrozzi V, 2011, NAT IMMUNOL, V12, P1159, DOI 10.1038/ni.2156; Russell CB, 2014, J IMMUNOL, V192, P3828, DOI 10.4049/jimmunol.1301737; Shemer A, 2013, J ALLERGY CLIN IMMUN, V131, P577, DOI 10.1016/j.jaci.2012.11.010; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Suarez-Farinas M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-294; Suarez-Farinas M, 2011, J INVEST DERMATOL, V131, P391, DOI 10.1038/jid.2010.280; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Zaba LC, 2009, J ALLERGY CLIN IMMUN, V124, P1022, DOI 10.1016/j.jaci.2009.08.046	35	19	20	2	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					922	932		10.1016/j.jaci.2019.10.041	http://dx.doi.org/10.1016/j.jaci.2019.10.041			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	31883845	Bronze			2022-12-18	WOS:000518756700029
J	Ruiter, B; Smith, NP; Monian, B; Tu, AA; Fleming, E; Virkud, YV; Patil, SU; Whittaker, CA; Love, JC; Shreffler, WG				Ruiter, Bert; Smith, Neal P.; Monian, Brinda; Tu, Ang A.; Fleming, Elizabeth; Virkud, Yamini V.; Patil, Sarita U.; Whittaker, Charles A.; Love, J. Christopher; Shreffler, Wayne G.			Expansion of the CD4(+) effector T-cell repertoire characterizes peanut-allergic patients with heightened clinical sensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; food allergy; clinical sensitivity; CD4(+) T cell; effector T cell; regulatory T cell; T(H)2; CD154; TCR beta sequencing; RNA-Seq	ORAL FOOD CHALLENGES; RESPONSES; CHILDREN; IMMUNOTHERAPY; INDIVIDUALS; TOLERANCE; DIAGNOSIS; RECEPTOR; PLACEBO; ASSAY	Background: Individuals with peanut allergy range in clinical sensitivity: some can consume grams of peanut before experiencing any symptoms, whereas others suffer systemic reactions to 10 mg or less. Current diagnostic testing only partially predicts this clinical heterogeneity. Objective: We sought to identify characteristics of the peanut-specific CD4(+) T-cell response in peanut-allergic patients that correlate with high clinical sensitivity. Methods: We studied the T-cell receptor beta-chain (TCR beta) usage and phenotypes of peanut-activated, CD154(+) CD4(+) memory T cells using fluorescence-activated cell sorting, TCR beta sequencing, and RNA-Seq, in reactive and hyporeactive patients who were stratified by clinical sensitivity. Results: TCR beta analysis of the CD154(+) and CD154(-) fractions revealed more than 6000 complementarity determining region 3 sequences and motifs that were significantly enriched in the activated cells and 17% of the sequences were shared between peanut-allergic individuals, suggesting strong convergent selection of peanut-specific clones. These clones were more numerous among the reactive patients, and this expansion was identified within effector, but not regulatory T-cell populations. The transcriptional profile of CD154(+) T cells in the reactive group skewed toward a polarized T(H)2 effector phenotype, and expression of T(H)2 cytokines strongly correlated with peanut-specific IgE levels. There were, however, also non-T(H)2-related differences in phenotype. Furthermore, the ratio of peanut-specific clones in the effector versus regulatory T-cell compartment, which distinguished the clinical groups, was independent of specific IgE concentration. Conclusions: Expansion of the peanut-specific effector T-cell repertoire is correlated with clinical sensitivity, and this observation may be useful to inform our assessment of disease phenotype and to monitor disease longitudinally.	[Ruiter, Bert; Smith, Neal P.; Fleming, Elizabeth; Virkud, Yamini V.; Patil, Sarita U.; Shreffler, Wayne G.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Rio 8-409,149 13th St, Boston, MA 02129 USA; [Ruiter, Bert; Virkud, Yamini V.; Patil, Sarita U.; Shreffler, Wayne G.] Harvard Med Sch, Boston, MA 02115 USA; [Monian, Brinda; Tu, Ang A.; Whittaker, Charles A.; Love, J. Christopher] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Virkud, Yamini V.; Patil, Sarita U.; Shreffler, Wayne G.] Massachusetts Gen Hosp, Food Allergy Ctr, Boston, MA 02129 USA; [Whittaker, Charles A.] MIT, Barbara K Ostrom Bioinformat & Comp Facil 1978, Swanson Biotechnol Ctr, 77 Massachusetts Ave, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT)	Ruiter, B (corresponding author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Rio 8-409,149 13th St, Boston, MA 02129 USA.	bruiter@mgh.harvard.edu		Whittaker, Charles/0000-0002-2400-0094; Ruiter, Bert/0000-0003-3945-3202; Smith, Neal/0000-0003-1394-3158	National Institutes of Health/National Institute of Allergy and Infectious Diseases [U19AI095261, K23AI130408, K23AI121491]; Food Allergy Science Initiative; Massachusetts General Hospital; Sanofi US	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Food Allergy Science Initiative; Massachusetts General Hospital(General Electric); Sanofi US	This work was supported by the National Institutes of Health/National Institute of Allergy and Infectious Diseases (grant no. U19AI095261 to W.G.S. and Andrew D. Luster, grant no. K23AI130408 to Y.V.V., and grant no. K23AI121491 to S.U.P.), Sanofi US, the Food Allergy Science Initiative, and institutional funds from Massachusetts General Hospital.	Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Bacher P, 2016, CELL, V167, P1067, DOI 10.1016/j.cell.2016.09.050; Begin P, 2015, J ALLERGY CLIN IMMUN, V135, P1636, DOI 10.1016/j.jaci.2015.03.010; Birrueta G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204620; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P1329, DOI 10.1016/j.jaci.2014.06.032; Chattopadhyay PK, 2005, NAT MED, V11, P1113, DOI 10.1038/nm1293; Chattopadhyay PK, 2006, NAT PROTOC, V1, P1, DOI 10.1038/nprot.2006.1; Cherwinski HM, 2005, J IMMUNOL, V174, P1348, DOI 10.4049/jimmunol.174.3.1348; Chiang D, 2018, J ALLERGY CLIN IMMUN, V141, P2107, DOI 10.1016/j.jaci.2017.11.060; DeLong JH, 2011, J ALLERGY CLIN IMMUN, V127, P1211, DOI 10.1016/j.jaci.2011.02.028; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Fleischer DM, 2019, JAMA-J AM MED ASSOC, V321, P946, DOI 10.1001/jama.2019.1113; Glanville J, 2017, NATURE, V547, P94, DOI 10.1038/nature22976; Gupta RS, 2014, J ALLER CL IMM-PRACT, V2, P300, DOI 10.1016/j.jaip.2013.12.006; Guttman-Yassky E, 2017, CURR OPIN IMMUNOL, V48, P68, DOI 10.1016/j.coi.2017.08.008; Hourihane JO, 2017, J ALLERGY CLIN IMMUN, V139, P1583, DOI 10.1016/j.jaci.2017.01.030; Ito T, 2019, ALLERGOL INT, V68, P4, DOI 10.1016/j.alit.2018.10.002; Jimenez-Saiz R, 2017, J ALLERGY CLIN IMMUN, V140, P1604, DOI 10.1016/j.jaci.2017.01.018; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Litjens NHR, 2012, J IMMUNOL, V188, P1083, DOI 10.4049/jimmunol.1101974; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu D, 2017, ONCOTARGET, V8, P53552, DOI 10.18632/oncotarget.18614; McDonald D, 2014, INT J CRIME JUSTICE, V3, P68; Mercer F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008639; Mitson-Salazar A, 2016, J ALLERGY CLIN IMMUN, V137, P907, DOI 10.1016/j.jaci.2015.08.007; Renand A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01408; Ryan JF, 2016, P NATL ACAD SCI USA, V113, pE1286, DOI 10.1073/pnas.1520180113; Sampson HA, 2017, JAMA-J AM MED ASSOC, V318, P1798, DOI 10.1001/jama.2017.16591; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Schuster M, 2012, IMMUNITY, V37, P998, DOI 10.1016/j.immuni.2012.08.023; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Sicherer SH, 2018, J ALLERGY CLIN IMMUN, V141, P41, DOI 10.1016/j.jaci.2017.11.003; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Vaine CA, 2014, ADV IMMUNOL, V121, P191, DOI 10.1016/B978-0-12-800100-4.00005-2; van der Loo MPJ, 2014, R J, V6, P111; Vickery BP, 2018, NEW ENGL J MED, V379, P1991, DOI 10.1056/NEJMoa1812856; Wambre E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam9171; Weissler KA, 2018, J ALLERGY CLIN IMMUN, V141, P1699, DOI 10.1016/j.jaci.2018.01.035; Yu W, 2016, NAT REV IMMUNOL, V16, P751, DOI 10.1038/nri.2016.111; Zeitelhofer M, 2017, P NATL ACAD SCI USA, V114, pE1678, DOI 10.1073/pnas.1615783114	41	19	19	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					270	282		10.1016/j.jaci.2019.09.033	http://dx.doi.org/10.1016/j.jaci.2019.09.033			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31654649	Bronze, Green Submitted, Green Accepted			2022-12-18	WOS:000505590800032
J	Sakata, D; Uruno, T; Matsubara, K; Andoh, T; Yamamura, K; Magoshi, Y; Kunimura, K; Kamikaseda, Y; Furue, M; Fukui, Y				Sakata, Daiji; Uruno, Takehito; Matsubara, Keisuke; Andoh, Tsugunobu; Yamamura, Kazuhiko; Magoshi, Yuki; Kunimura, Kazufumi; Kamikaseda, Yasuhisa; Furue, Masutaka; Fukui, Yoshinori			Selective role of neurokinin B in IL-31-induced itch response in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RECEPTOR; CELLS		[Sakata, Daiji; Uruno, Takehito; Matsubara, Keisuke; Yamamura, Kazuhiko; Kunimura, Kazufumi; Kamikaseda, Yasuhisa; Fukui, Yoshinori] Kyushu Univ, Med Inst Bioregulat, Dept Immunobiol & Neurosci, Div Immunogenet, Fukuoka, Fukuoka, Japan; [Uruno, Takehito; Fukui, Yoshinori] Kyushu Univ, Res Ctr Adv Immunol, Fukuoka, Fukuoka, Japan; [Andoh, Tsugunobu; Magoshi, Yuki] Univ Toyama, Grad Sch Med & Pharmaceut Sci, Dept Appl Pharmacol, Toyama, Japan; [Yamamura, Kazuhiko; Furue, Masutaka] Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Fukuoka, Japan	Kyushu University; Kyushu University; University of Toyama; Kyushu University	Fukui, Y (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Immunobiol & Neurosci, Div Immunogenet, Fukuoka, Fukuoka, Japan.; Fukui, Y (corresponding author), Kyushu Univ, Res Ctr Adv Immunol, Fukuoka, Fukuoka, Japan.	fukui@bioreg.kyushu-u.ac.jp	Uruno, Takehito/AAF-7998-2019	Uruno, Takehito/0000-0002-2812-9645; Kunimura, Kazufumi/0000-0002-3445-804X; Matsubara, Keisuke/0000-0002-0478-9753; Fukui, Yoshinori/0000-0003-2335-8745	Leading Advanced Projects for Medical Innovation from Japan Agency for Medical Research and Development [JP19gm0010001]	Leading Advanced Projects for Medical Innovation from Japan Agency for Medical Research and Development	This work was supported by Leading Advanced Projects for Medical Innovation from Japan Agency for Medical Research and Development (grant no. JP19gm0010001 to Y.F.).	Bautista DM, 2014, NAT NEUROSCI, V17, P175, DOI 10.1038/nn.3619; Cevikbas F, 2014, J ALLERGY CLIN IMMUN, V133, P448, DOI 10.1016/j.jaci.2013.10.048; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Fraser GL, 2016, J CLIN ENDOCR METAB, V101, P417, DOI 10.1210/jc.2015-3621; Mar L, 2012, MOL BRAIN, V5, DOI 10.1186/1756-6606-5-3; Meng JH, 2018, J ALLERGY CLIN IMMUN, V141, P1677, DOI 10.1016/j.jaci.2017.12.1002; Ruzicka T, 2017, NEW ENGL J MED, V376, P826, DOI 10.1056/NEJMoa1606490; Spooren W, 2005, NAT REV DRUG DISCOV, V4, P967, DOI 10.1038/nrd1905; Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z; Yamamura K, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13946	10	19	19	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2019	144	4					1130	+		10.1016/j.jaci.2019.06.031	http://dx.doi.org/10.1016/j.jaci.2019.06.031			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB8FZ	31405606	hybrid			2022-12-18	WOS:000488803900031
J	Li, S; Morita, H; Sokolowska, M; Tan, G; Boonpiyathad, T; Opitz, L; Orimo, K; Archer, SK; Jansen, K; Tang, MLK; Purcell, D; Plebanski, M; Akdis, CA				Li, Shuo; Morita, Hideaki; Sokolowska, Milena; Tan, Ge; Boonpiyathad, Tadech; Opitz, Lennart; Orimo, Keisuke; Archer, Stuart K.; Jansen, Kirstin; Tang, Mimi L. K.; Purcell, Damian; Plebanski, Magdalena; Akdis, Cezmi A.			Gene expression signatures of circulating human type 1, 2, and 3 innate lymphoid cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HETEROGENEITY		[Li, Shuo; Purcell, Damian] Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia; [Li, Shuo; Morita, Hideaki; Sokolowska, Milena; Tan, Ge; Boonpiyathad, Tadech; Jansen, Kirstin; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Li, Shuo] Monash Univ, Dept Pathol, Clayton, Vic, Australia; [Morita, Hideaki; Boonpiyathad, Tadech] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Morita, Hideaki; Orimo, Keisuke] Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan; [Tan, Ge; Opitz, Lennart] Univ Zurich, ETH Zurich, Funct Genom Ctr Zurich, Zurich, Switzerland; [Boonpiyathad, Tadech] Phramongkutklao Hosp, Dept Med, Bangkok, Thailand; [Archer, Stuart K.] Monash Univ, Monash Bioinformat Platform, Clayton, Vic, Australia; [Tang, Mimi L. K.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Tang, Mimi L. K.] Univ Melbourne, Melbourne, Vic, Australia; [Plebanski, Magdalena] RMIT Univ, Sch Hlth & Biomed Sci, Melbourne, Vic, Australia	University of Melbourne; Swiss Institute of Allergy & Asthma Research; University of Zurich; Monash University; National Center for Child Health & Development - Japan; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; Phramongkutklao Hospital; Monash University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Royal Melbourne Institute of Technology (RMIT)	Li, S (corresponding author), Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia.; Li, S (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland.; Li, S (corresponding author), Monash Univ, Dept Pathol, Clayton, Vic, Australia.	shuo.li1@unimelb.edu.au; akdisac@siaf.uzh.ch	Jansen, Kirstin/AAS-3402-2020; Akdis, Cezmi/AAV-4844-2020; Morita, Hideaki/S-2214-2016; Morita, Hideaki/ADL-2008-2022; Plebanski, Magdalena/AAU-3144-2021; Tang, Mimi/ABD-8350-2020; Purcell, Damian F/G-5068-2011	Akdis, Cezmi/0000-0001-8020-019X; Morita, Hideaki/0000-0003-0928-8322; Tang, Mimi/0000-0002-3839-5293; Sokolowska, Milena/0000-0001-9710-6685; Tan, Ge/0000-0003-0026-8739; Archer, Stuart/0000-0003-0450-1243; Jansen, Kirstin/0000-0002-9176-8562; Boonpiyathad, Tadech/0000-0001-8690-7647; , Magdalena/0000-0001-6889-3667	Swiss National Science Foundation [310030_156823]; NHMRC [APP1052979]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	Supported by Swiss National Science Foundation grant no. 310030_156823; NHMRC program grant APP1052979. M.P. is the recipient of an NHMRC Senior Research Fellowship.	Bjorklund AK, 2016, NAT IMMUNOL, V17, P451, DOI 10.1038/ni.3368; Boyd A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108649; Brazee PL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00623; Cardoso V, 2017, NATURE, V549, P277, DOI 10.1038/nature23469; Govindaraj C, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00233; Klose CSN, 2017, NATURE, V549, P282, DOI 10.1038/nature23676; Morita H, 2016, J ALLERGY CLIN IMMUN, V138, P1253, DOI 10.1016/j.jaci.2016.09.011; Simoni Y, 2017, IMMUNITY, V46, P148, DOI 10.1016/j.immuni.2016.11.005; Vely F, 2016, NAT IMMUNOL, V17, P1291, DOI 10.1038/ni.3553	9	19	19	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2321	+		10.1016/j.jaci.2019.01.047	http://dx.doi.org/10.1016/j.jaci.2019.01.047			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30825467	Bronze			2022-12-18	WOS:000470113200045
J	Shamji, MH; Thomsen, I; Layhadi, JA; Kappen, J; Holtappels, G; Sahiner, U; Switzer, A; Durham, SR; Pabst, O; Bachert, C				Shamji, Mohamed H.; Thomsen, Irene; Layhadi, Janice A.; Kappen, Jasper; Holtappels, Gabriele; Sahiner, Umit; Switzer, Amy; Durham, Stephen R.; Pabst, Oliver; Bachert, Claus			Broad IgG repertoire in patients with chronic rhinosinusitis with nasal polyps regulates proinflammatory IgE responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgG; antibody repertoire; IgE; chronic rhinosinusitis; nasal polyps; allergic rhinitis	STAPHYLOCOCCUS-AUREUS ENTEROTOXINS; CLASS SWITCH RECOMBINATION; FLOW-CYTOMETRY; T-CELLS; ALLERGEN; SERUM; IMMUNOTHERAPY; ACTIVATION; EXPRESSION; ANTIBODIES	Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is often characterized by local production of polyclonal IgE idiotypes. Although tissue IgE concentrations can be in the range of several thousand kilounits per liter, the regulatory mechanisms by which IgE-mediated inflammation is controlled in patients with nasal polyps are not well understood. Objective: We sought to determine whether locally induced IgG antibodies in patients with nasal polyps can inhibit an IgE-mediated proallergic response. Methods: Nasal polyp homogenates were collected from patients with grass pollen allergy with CRSwNP and nonallergic control subjects. IgE levels were measured using the Immuno Solid-phase Allergen Chip assay. IgE-containing nasal polyp homogenates with or without IgG depletion were evaluated for their capacity to promote IgE-facilitated allergen presentation, basophil activation, and histamine release. Local IgE and IgG repertoires were evaluated using Immunoglobulin 454 sequencing. Results: We show that IgG plays a key role in controlling IgE-mediated inflammatory responses in patients with nasal polyps. Depletion of IgG from nasal homogenates resulted in an increase in CD23-mediated IgE-facilitated allergen binding to B cells but also enhanced FceRI-mediated allergen-driven basophil activation and histamine release. A similar response was observed in relation to specific IgE antibodies to Staphylococcus aureus enterotoxins. The capacity of IgG in nasal polyps to limit IgE-mediated inflammation is based on the fact that IgG repertoires widely share the antigen targets with the IgE repertoires in both allergic and nonallergic subjects. Conclusion: Polyclonal IgE idiotypes in patients with CRSwNP are functional, promote IgE-mediated proallergic inflammation, and are partially antagonized by corresponding IgG idiotypes. This is most likely due to the fact that IgE and IgG clonotypes are widely shared in patients with nasal polyps.	[Shamji, Mohamed H.; Layhadi, Janice A.; Kappen, Jasper; Switzer, Amy; Durham, Stephen R.] Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Inflammat Repair & Dev, London, England; [Shamji, Mohamed H.; Layhadi, Janice A.; Kappen, Jasper; Switzer, Amy; Durham, Stephen R.] Asthma UK Ctr Allerg Mech Asthma, London, England; [Holtappels, Gabriele; Bachert, Claus] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium; [Shamji, Mohamed H.; Holtappels, Gabriele; Bachert, Claus] Karolinska Inst, CLINTEC, Div ENT Dis, Stockholm, Sweden; [Thomsen, Irene; Pabst, Oliver] Hannover Med Sch, Inst Immunol, Hannover, Germany; [Pabst, Oliver] Rhein Westfal TH Aachen, Inst Mol Med, Aachen, Germany; [Kappen, Jasper] Sint Franciscus Vlietland Grp, STZ Ctr Excellence Asthma & COPD, Dept Pulmonol, Rotterdam, Netherlands; [Sahiner, Umit] Hacettepe Univ, Sch Med, Pediat Allergy Dept, Ankara, Turkey	Imperial College London; University of London; King's College London; Ghent University; Karolinska Institutet; Hannover Medical School; RWTH Aachen University; Hacettepe University	Shamji, MH (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Inflammat Repair & Dev, Fac Med,Immunomodulat & Tolerance Grp, London SW7 2AZ, England.	m.shamji@imperial.ac.uk	Layhadi, Janice/AAU-8807-2020; Sahiner, Umit M/AAT-4811-2020; Shamji, Mohamed/AAU-8811-2020; Bachert, Claus/J-8825-2012; Shamji, Mohamed/AAD-1788-2019; Switzer, Amy/AEP-0843-2022	Shamji, Mohamed/0000-0003-3425-3463; Layhadi, Janice/0000-0002-5242-1806	Imperial College research funds	Imperial College research funds	Supported by the Imperial College research funds.	Baba S, 2014, CLIN EXP ALLERGY, V44, P701, DOI 10.1111/cea.12287; Bachert C, 2003, J ALLERGY CLIN IMMUN, V111, P1131, DOI 10.1016/S0091-6749(03)70044-X; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126; Bachert C, 2015, J ALLERGY CLIN IMMUN, V136, P1431, DOI 10.1016/j.jaci.2015.10.010; Bachert C, 2012, J ALLERGY CLIN IMMUN, V130, P376, DOI 10.1016/j.jaci.2012.05.012; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Bahri R, 2018, J ALLERGY CLIN IMMUN, V142, P485, DOI 10.1016/j.jaci.2018.01.043; Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135, P1240, DOI 10.1016/j.jaci.2014.12.1917; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Ebo DG, 2012, J IMMUNOL METHODS, V375, P30, DOI 10.1016/j.jim.2011.09.003; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gevaert P, 2005, ALLERGY, V60, P71, DOI 10.1111/j.1398-9995.2004.00621.x; Gevaert P, 2013, ALLERGY, V68, P55, DOI 10.1111/all.12054; He JS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00723-0; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Lefranc MP, 2009, NUCLEIC ACIDS RES, V37, pD1006, DOI 10.1093/nar/gkn838; Lindner C, 2012, J EXP MED, V209, P365, DOI 10.1084/jem.20111980; Marth K, 2013, J IMMUNOL, V190, P3068, DOI 10.4049/jimmunol.1202441; Ocmant A, 2007, J IMMUNOL METHODS, V320, P40, DOI 10.1016/j.jim.2006.12.002; Orengo JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03636-8; Renand A, 2018, J ALLERGY CLIN IMMUN, V141, P1750, DOI 10.1016/j.jaci.2017.09.041; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Shamji MH, 2019, J ALLERGY CLIN IMMUN, V143, P1067, DOI 10.1016/j.jaci.2018.09.039; Shamji MH, 2015, J ALLERGY CLIN IMMUN, V135, P913, DOI 10.1016/j.jaci.2014.09.049; Sheahan P, 2010, J OTOLARYNGOL-HEAD N, V39, P45, DOI 10.2310/7070.2009.080280; Takhar P, 2007, J ALLERGY CLIN IMMUN, V119, P213, DOI 10.1016/j.jaci.2006.09.045; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Van Zele T, 2007, CLIN EXP ALLERGY, V37, P1840, DOI 10.1111/j.1365-2222.2007.02838.x; Van Zele T, 2014, AM J RHINOL ALLERGY, V28, P192, DOI 10.2500/ajra.2014.28.4033; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131; Zhang N, 2011, ALLERGY, V66, P141, DOI 10.1111/j.1398-9995.2010.02448.x	40	19	21	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2086	+		10.1016/j.jaci.2019.02.001	http://dx.doi.org/10.1016/j.jaci.2019.02.001			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30763592	Bronze			2022-12-18	WOS:000470113200014
J	Mahdavinia, M; Rasmussen, HE; Botha, M; Tran, TDB; Van den Berg, JP; Sodergren, E; Davis, E; Engen, K; Gray, C; Lunjani, N; Hlela, C; Preite, NZ; Basera, W; Hobane, L; Watkins, A; Engen, P; Mankahla, A; Gaunt, B; Thomas, F; Tobin, MC; Landay, A; Weinstock, GM; Keshavarzian, A; Levin, ME				Mahdavinia, Mahboobeh; Rasmussen, Heather E.; Botha, Maresa; Thi Dong Binh Tran; Van den Berg, Jolice P.; Sodergren, Erica; Davis, Erika; Engen, Krista; Gray, Claudia; Lunjani, Nonhlanhla; Hlela, Carol; Preite, Nailliw Z.; Basera, Wisdom; Hobane, Lelani; Watkins, Alexandra; Engen, Phillip; Mankahla, Avumile; Gaunt, Ben; Thomas, Facey; Tobin, Mary C.; Landay, Alan; Weinstock, George M.; Keshavarzian, Ali; Levin, Michael E.			Effects of diet on the childhood gut microbiome and its implications for atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CARE		[Mahdavinia, Mahboobeh; Tobin, Mary C.] Rush Univ, Med Ctr, Dept Internal Med, Allergy Immunol Div, Chicago, IL 60612 USA; [Rasmussen, Heather E.; Van den Berg, Jolice P.; Davis, Erika; Engen, Krista; Preite, Nailliw Z.; Engen, Phillip; Weinstock, George M.; Keshavarzian, Ali] Rush Univ, Med Ctr, Dept Internal Med, Div Gastroenterol, Chicago, IL 60612 USA; [Rasmussen, Heather E.] Univ Nebraska, Dept Nutr & Hlth Sci, Lincoln, NE USA; [Botha, Maresa; Gray, Claudia; Lunjani, Nonhlanhla; Basera, Wisdom; Hobane, Lelani; Watkins, Alexandra; Thomas, Facey; Levin, Michael E.] Univ Cape Town, Dept Paediat & Child Hlth, Div Allergy, Cape Town, South Africa; [Botha, Maresa; Sodergren, Erica; Levin, Michael E.] InVivo Planetary Hlth Network, Farmington, CT USA; [Thi Dong Binh Tran; Gray, Claudia] Jackson Lab Genom Med, Farmington, CT USA; [Hlela, Carol] Univ Cape Town, Dept Dermatol, Cape Town, South Africa; [Mankahla, Avumile] Eastern Cape Dept Hlth, Zithulele Hosp, Eastern Cape, South Africa; [Gaunt, Ben] Walter Sisulu Univ, Div Dermatol, Dept Med & Pharmacol, Cape Town, South Africa; [Landay, Alan] Rush Univ, Med Ctr, Dept Internal Med, Geriatr Div, Chicago, IL 60612 USA	Rush University; Rush University; University of Nebraska System; University of Nebraska Lincoln; University of Cape Town; Jackson Laboratory; University of Cape Town; Walter Sisulu University; Rush University	Mahdavinia, M (corresponding author), Rush Univ, Med Ctr, Dept Internal Med, Allergy Immunol Div, Chicago, IL 60612 USA.	Mahboobeh_mahdavinia@rush.edu	Hlela, Carol/AAC-2832-2020; Levin, Michael/AAT-2370-2020	Hlela, Carol/0000-0002-8028-3252; Levin, Michael/0000-0003-2439-7981; Mahdavinia, mahboobeh/0000-0003-4004-203X; Zanini Preite, Nailliw/0000-0002-0675-9080	Brinson Foundation; Medical Research Council of South Africa; Cohn research scholarship from Rush University; National Institutes of Health [R01 AT007143-05, R01 AA023417-02, R01 AA020216-05];  [R01 AI130348]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA023417] Funding Source: NIH RePORTER	Brinson Foundation; Medical Research Council of South Africa(South African Medical Research Council); Cohn research scholarship from Rush University; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This work is supported by a research grant from the Brinson Foundation and the Medical Research Council of South Africa. M.M. is also supported by grant number R01 AI130348 and by a Cohn research scholarship from Rush University. A.K. is supported by the National Institutes of Health (grant nos. R01 AT007143-05, R01 AA023417-02, and R01 AA020216-05).	Barros R, 2015, CLIN EXP ALLERGY, V45, P1673, DOI 10.1111/cea.12544; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; Dodd D, 2011, MOL MICROBIOL, V79, P292, DOI 10.1111/j.1365-2958.2010.07473.x; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Eichenfield LF, 2014, J AM ACAD DERMATOL, V70, P338, DOI 10.1016/j.jaad.2013.10.010; El-Osta A, 2008, J EXP MED, V205, P2409, DOI 10.1084/jem.20081188; Kim HK, 2015, BENEF MICROBES, V6, P783, DOI 10.3920/BM2015.0056; Laurence C, 2018, PEDIAT ALLERG IMM-UK, V29, P311, DOI 10.1111/pai.12859; Mahdavinia M, 2017, J ALLER CL IMM-PRACT, V5, P352, DOI 10.1016/j.jaip.2016.10.006; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; McMurdie PJ, 2017, PHYLOSEQ IMPORT SHAR; Paparo L, 2014, NUTRIENTS, V6, P4706, DOI 10.3390/nu6114706	14	19	19	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1636	+		10.1016/j.jaci.2018.11.034	http://dx.doi.org/10.1016/j.jaci.2018.11.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30578881	Bronze			2022-12-18	WOS:000463348900042
J	Fukuoka, A; Matsushita, K; Morikawa, T; Adachi, T; Yasuda, K; Kiyonari, H; Fujieda, S; Yoshimoto, T				Fukuoka, Ayumi; Matsushita, Kazufumi; Morikawa, Taiyo; Adachi, Takumi; Yasuda, Koubun; Kiyonari, Hiroshi; Fujieda, Shigeharu; Yoshimoto, Tomohiro			Human cystatin SN is an endogenous protease inhibitor that prevents allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; cystatin SN; nasal epithelial cells; protease; tight junctions	EPITHELIAL BARRIER FUNCTION; CELL CARCINOMA ANTIGEN-2; MITE ALLERGEN; EXPRESSION; SERPIN; GENE	Background: Protease allergens disrupt epithelial barriers to exert their allergenicity. Cystatin SN (encoded by CST1) is an endogenous cysteine protease inhibitor upregulated in nasal epithelia in patients with allergic rhinitis (AR). Objective: We sought to investigate the protective effect of human cystatin SN on AR symptoms using pollen-induced AR mouse models. Methods: We performed an in vitro protease activity assay to evaluate the effect of recombinant human cystatin SN (rhCystatin SN) on Japanese cedar (JC) or ragweed proteases. A human nasal epithelial cell line, RPMI 2650, was used to examine tight junction (TJ) disruption in vitro. Mice were sensitized and nasally challenged with JC or ragweed pollens with or without rhCystatin SN to examine the effect of rhCystatin SN on AR symptoms and the epithelial barrier in vivo. Because mice lack CST1, we generated transgenic (Tg) mice expressing human CST1 under control of its genomic control region (hCST1-Tg mice) to examine the role of cystatin SN in physiologically expressed conditions. Results: rhCystatin SN inhibited JC but not ragweed protease activities and prevented JC-induced but not ragweed-induced TJ disruption in vitro. Exogenous administration of rhCystatin SN ameliorated JC-induced but not ragweed-induced sneezing and nasal TJ disruption in vivo. Furthermore, hCST1-Tg mice showed decreased JC-induced but not ragweed-induced sneezing symptoms and nasal TJ disruption compared with wild-type mice. Conclusion: Human cystatin SN suppresses AR symptoms through inhibiting allergen protease activities and protecting the nasal TJ barrier in an allergen-specific manner. We propose that upregulation of nasal endogenous protease inhibitors, including cystatin SN, is a novel therapeutic strategy for protease allergen-induced AR.	[Fukuoka, Ayumi; Matsushita, Kazufumi; Adachi, Takumi; Yasuda, Koubun; Yoshimoto, Tomohiro] Hyogo Coll Med, Dept Immunol, Nishinomiya, Hyogo 6638501, Japan; [Matsushita, Kazufumi; Morikawa, Taiyo; Yoshimoto, Tomohiro] Hyogo Coll Med, Inst Adv Med Sci, Lab Allerg Dis, Nishinomiya, Hyogo, Japan; [Morikawa, Taiyo; Fujieda, Shigeharu] Univ Fukui, Fac Med Sci, Dept Otorhinolaryngol Head & Neck Surg, Fukui, Japan; [Kiyonari, Hiroshi] RIKEN Ctr Life Sci Technol, Anim Resource Dev Unit, Kobe, Hyogo, Japan; [Kiyonari, Hiroshi] RIKEN Ctr Life Sci Technol, Genet Engn Team, Kobe, Hyogo, Japan	Hyogo College of Medicine; Hyogo College of Medicine; University of Fukui; RIKEN; RIKEN	Fukuoka, A (corresponding author), Hyogo Coll Med, Dept Immunol, Nishinomiya, Hyogo 6638501, Japan.	afukuoka@hyo-med.ac.jp	Yasuda, Koubun/GQA-7622-2022	Fukuoka, Ayumi/0000-0002-6752-7814; Yasuda, Koubun/0000-0002-3533-1702	Ministry of Education, Culture, Sports, Science and Technology; Strategic Research Foundation at Private Universities [S1001055]; Japan Society for the Promotion of Science KAKENHI [17K15736, 24390253]; Naito Foundation	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Strategic Research Foundation at Private Universities; Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Naito Foundation(Naito Memorial Foundation)	Supported by a Ministry of Education, Culture, Sports, Science and Technology Grant-in-Aid for Scientific Research; the Strategic Research Foundation at Private Universities (no. S1001055); and a Japan Society for the Promotion of Science KAKENHI Grant-in-Aid for Scientific Research B (no. 24390253; all to T.Y.); a Japan Society for the Promotion of Science KAKENHI Grant-in-Aid for Young Scientist B (no. 17K15736; to A.F.); and the Naito Foundation (to K.M.).	Akasaki S, 2016, INT IMMUNOL, V28, P65, DOI 10.1093/intimm/dxv055; Bagarozzi DA, 1996, J BIOL CHEM, V271, P26227, DOI 10.1074/jbc.271.42.26227; Bai S, 2008, J PHARM SCI-US, V97, P1165, DOI 10.1002/jps.21031; Balenga NA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7763; Chhikara N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047672; Cornwall GA, 2003, ENDOCRINOLOGY, V144, P901, DOI 10.1210/en.2002-220997; CORNWALL GA, 1992, MOL ENDOCRINOL, V6, P1653, DOI 10.1210/me.6.10.1653; De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; de Sousa-Pereira P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109050; Fukuoka A, 2016, CLIN EXP ALLERGY, V46, P142, DOI 10.1111/cea.12597; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Giovannini-Chami L, 2012, EUR RESPIR J, V39, P1197, DOI 10.1183/09031936.00070511; Gunawan Hendra, 2008, Allergol Int, V57, P83, DOI 10.2332/allergolint.O-07-507; Haenuki Y, 2012, J ALLERGY CLIN IMMUN, V130, P184, DOI 10.1016/j.jaci.2012.02.013; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Henriquez OA, 2013, INT FORUM ALLERGY RH, V3, P630, DOI 10.1002/alr.21168; Imoto Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067057; ISEMURA S, 1986, FEBS LETT, V198, P145, DOI 10.1016/0014-5793(86)81201-7; Iwasaki N, 2017, J ALLERGY CLIN IMMUN, V139, P258, DOI 10.1016/j.jaci.2016.03.023; Jaruvongvanich V, 2016, ALLERGOL INT, V65, P199, DOI 10.1016/j.alit.2015.11.006; Kim BY, 2014, ALLERGY ASTHMA IMMUN, V6, P558, DOI 10.4168/aair.2014.6.6.558; Kojima T, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/947072; Koshizuka Y, 2003, J BIOL CHEM, V278, P48259, DOI 10.1074/jbc.M211639200; Kouzaki H, 2017, AM J RESP CRIT CARE, V195, P737, DOI 10.1164/rccm.201603-0529OC; KYHSEANDERSEN J, 1994, CLIN CHEM, V40, P1921; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Ndika J, 2017, J ALLERGY CLIN IMMUN, V140, P1288, DOI 10.1016/j.jaci.2017.05.040; Ochieng J, 2010, J HEALTH CARE POOR U, V21, P51, DOI 10.1353/hpu.0.0257; Sakata Y, 2004, J BIOL CHEM, V279, P5081, DOI 10.1074/jbc.M311585200; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; Schick C, 1997, J BIOL CHEM, V272, P1849, DOI 10.1074/jbc.272.3.1849; SILICIANO JD, 1988, J CELL BIOL, V107, P2389, DOI 10.1083/jcb.107.6.2389; Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, pS2, DOI 10.1067/mai.2001.115569; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Steelant B, 2018, J ALLERGY CLIN IMMUN, V141, P951, DOI 10.1016/j.jaci.2017.08.039; Steelant B, 2016, J ALLERGY CLIN IMMUN, V137, P1043, DOI 10.1016/j.jaci.2015.10.050; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Suzuki M, 2006, ACTA OTO-LARYNGOL, V126, P746, DOI 10.1080/00016480500475625; Takai T, 2009, J IMMUNOL, V183, P7958, DOI 10.4049/jimmunol.0713276; Tseng CC, 2000, ARCH BIOCHEM BIOPHYS, V380, P133, DOI 10.1006/abbi.2000.1909; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Turksen K, 2004, J CELL SCI, V117, P2435, DOI 10.1242/jcs.01235; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Yuki T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161759	45	19	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1153	+		10.1016/j.jaci.2018.06.035	http://dx.doi.org/10.1016/j.jaci.2018.06.035			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30012514	Bronze			2022-12-18	WOS:000460272900035
J	Orgel, K; Smeekens, JM; Ye, P; Fotsch, L; Guo, RS; Miller, DR; de Villena, FPM; Burks, AW; Ferris, MT; Kulis, MD				Orgel, Kelly; Smeekens, Johanna M.; Ye, Ping; Fotsch, Lauren; Guo, Rishu; Miller, Darla R.; de Villena, Fernando Pardo-Manuel; Burks, A. Wesley; Ferris, Martin T.; Kulis, Michael D.			Genetic diversity between mouse strains allows identification of the CC027/GeniUnc strain as an orally reactive model of peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Collaborative Cross; food allergy; peanut allergy; anaphylaxis; mouse model; Ara h 2	FOOD ALLERGY; COLLABORATIVE CROSS; SUBLINGUAL IMMUNOTHERAPY; CELL RESPONSES; MAST-CELLS; B-CELLS; ANAPHYLAXIS; PATHOGENESIS; CHILDREN; SENSITIZATION	Background: Improved animal models are needed to understand the genetic and environmental factors that contribute to food allergy. Objective: We sought to assess food allergy phenotypes in a genetically diverse collection of mice. Methods: We selected 16 Collaborative Cross (CC) mouse strains, as well as the classic inbred C57BL/6J, C3H/HeJ, and BALB/cJ strains, for screening. Female mice were sensitized to peanut intragastrically with or without cholera toxin and then challenged with peanut by means of oral gavage or intraperitoneal injection and assessed for anaphylaxis. Peanut-specific immunoglobulins, T-cell cytokines, regulatory T cells, mast cells, and basophils were quantified. Results: Eleven of the 16 CC strains had allergic reactions to intraperitoneal peanut challenge, whereas only CC027/GeniUnc mice reproducibly experienced severe symptoms after oral food challenge (OFC). CC027/GeniUnc, C3H/HeJ, and C57BL/6J mice all mounted a TH2 response against peanut, leading to production of IL-4 and IgE, but only the CC027/GeniUnc mice reacted to OFC. Orally induced anaphylaxis in CC027/GeniUnc mice was correlated with serum levels of Ara h 2 in circulation but not with allergen-specific IgE or mucosal mast cell protease 1 levels, indicating systemic allergen absorption is important for anaphylaxis through the gastrointestinal tract. Furthermore, CC027/GeniUnc, but not C3H/HeJ or BALB/cJ, mice can be sensitized in the absence of cholera toxin and react on OFC to peanut. Conclusions: We have identified and characterized CC027/GeniUnc mice as a strain that is genetically susceptible to peanut allergy and prone to severe reactions after OFC. More broadly, these findings demonstrate the untapped potential of the CC population in developing novel models for allergy research.	[Orgel, Kelly; Smeekens, Johanna M.; Ye, Ping; Fotsch, Lauren; Guo, Rishu; Burks, A. Wesley; Kulis, Michael D.] Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC 27515 USA; [Miller, Darla R.; de Villena, Fernando Pardo-Manuel; Ferris, Martin T.] Univ N Carolina, Sch Med, Dept Genet, Chapel Hill, NC 27515 USA; [Orgel, Kelly; Smeekens, Johanna M.; Ye, Ping; Fotsch, Lauren; Guo, Rishu; Burks, A. Wesley; Kulis, Michael D.] Univ North Carolina Food Allergy Initiat, Chapel Hill, NC USA; [de Villena, Fernando Pardo-Manuel] Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Kulis, MD (corresponding author), Univ N Carolina, 385 S Columbia St,Koury Bldg,Room 3604, Chapel Hill, NC 27599 USA.; Ferris, MT (corresponding author), Univ N Carolina, Dept Genet, CB 7292, Chapel Hill, NC 27599 USA.	mtferris@email.unc.edu	, UNC Flow Cytometry Core/AGU-9839-2022; Lynch, Rachel/GLS-1264-2022		UNC SOM Office of Research; TraCS Translational Team Science Award [TTSA017P1, TTSA017P2, U19AI100625]; Cancer Center Core Support Grant [P30 CA016086]; NATIONAL CANCER INSTITUTE [P30CA016086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI100625, T32AI007062] Funding Source: NIH RePORTER	UNC SOM Office of Research; TraCS Translational Team Science Award; Cancer Center Core Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by UNC SOM Office of Research and TraCS Translational Team Science Award (grant nos. TTSA017P1 and TTSA017P2; to A.W.B., F.P.-M.V., M.D.K., and M.T.F.) and U19AI100625 (to F.P.-M.V. and M.T.F.). The University of North Carolina (UNC) Flow Cytometry Core Facility and Systems Genetics Core Facility are supported in part by the P30 CA016086 Cancer Center Core Support Grant to the UNC Lineberger Comprehensive Cancer Center.	Andreux PA, 2012, CELL, V150, P1287, DOI 10.1016/j.cell.2012.08.012; Arumugam M, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-14; Asai Y, 2018, J ALLERGY CLIN IMMUN, V141, P991, DOI 10.1016/j.jaci.2017.09.015; Avery NJ, 2003, PEDIAT ALLERG IMM-UK, V14, P378, DOI 10.1034/j.1399-3038.2003.00072.x; Barclay AN, 2002, TRENDS IMMUNOL, V23, P285, DOI 10.1016/S1471-4906(02)02223-8; Berin MC, 2009, MUCOSAL IMMUNOL, V2, P24, DOI 10.1038/mi.2008.72; Blazquez AB, 2008, J IMMUNOL, V180, P4441, DOI 10.4049/jimmunol.180.7.4441; Bryce PJ, 2016, J ALLERGY CLIN IMMUN, V138, P769, DOI 10.1016/j.jaci.2016.01.049; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135, P1240, DOI 10.1016/j.jaci.2014.12.1917; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135, pe1; Burton OT, 2017, J ALLERGY CLIN IMMUN, V139, P314, DOI 10.1016/j.jaci.2016.04.034; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Churchill GA, 2012, MAMM GENOME, V23, P713, DOI 10.1007/s00335-012-9414-2; Cichocki JA, 2017, ENVIRON HEALTH PERSP, V125, DOI [10.1289/EHP788, 10.1289/ehp788]; Durrant C, 2011, GENOME RES, V21, P1239, DOI 10.1101/gr.118786.110; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; Gibbs BF, 2012, EXP DERMATOL, V21, P884, DOI 10.1111/exd.12018; Graham JB, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005996; Gralinski LE, 2017, G3-GENES GENOM GENET, V7, P1653, DOI 10.1534/g3.117.041434; Hong XM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7304; Iraqi FA, 2012, GENETICS, V190, P389, DOI 10.1534/genetics.111.132639; Iweala OI, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0616-7; JanssenDuijghuijsen LM, 2017, J IMMUNOL METHODS, V440, P52, DOI 10.1016/j.jim.2016.11.002; Jensen-Jarolim E, 2017, CURR OPIN ALLERGY CL, V17, P169, DOI 10.1097/ACI.0000000000000363; Jones SM, 2017, J ALLERGY CLIN IMMUN, V139, P1242, DOI 10.1016/j.jaci.2016.08.017; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kelada SNP, 2014, AM J RESP CELL MOL, V51, P436, DOI 10.1165/rcmb.2013-0501OC; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Kulis M, 2012, CLIN EXP ALLERGY, V42, P326, DOI 10.1111/j.1365-2222.2011.03934.x; Kulis M, 2013, MOL NUTR FOOD RES, V57, P906, DOI 10.1002/mnfr.201200410; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Liu H, 2009, GLIA, V57, P1, DOI 10.1002/glia.20729; Orgel KA, 2017, J ALLERGY CLIN IMMUN, V139, P366, DOI 10.1016/j.jaci.2016.06.053; Perrier C, 2011, CLIN EXP ALLERGY, V41, P20, DOI 10.1111/j.1365-2222.2010.03639.x; Rasmussen AL, 2014, SCIENCE, V346, P987, DOI 10.1126/science.1259595; Rogala AR, 2014, MAMM GENOME, V25, P95, DOI 10.1007/s00335-013-9499-2; Sampath V, 2017, ANN ALLERG ASTHMA IM, V118, P21, DOI 10.1016/j.anai.2016.10.017; Shreffler WG, 2006, ANN ALLERG ASTHMA IM, V96, P865, DOI 10.1016/S1081-1206(10)61351-8; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Srivastava A, 2017, GENETICS, V206, P537, DOI 10.1534/genetics.116.198838; Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017; Sun JF, 2007, J IMMUNOL, V179, P6696, DOI 10.4049/jimmunol.179.10.6696; Tordesillas L, 2014, J CLIN INVEST, V124, P4965, DOI 10.1172/JCI75660; Turcanu V, 2008, CLIN EXP ALLERGY, V38, P1132, DOI 10.1111/j.1365-2222.2008.03016.x; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Ventura MT, 2006, DIGEST LIVER DIS, V38, P732, DOI 10.1016/j.dld.2006.06.012; Vickery BP, 2017, J ALLERGY CLIN IMMUN, V139, P173, DOI 10.1016/j.jaci.2016.05.027; Warren HS, 2015, P NATL ACAD SCI USA, V112, pE345, DOI 10.1073/pnas.1414857111; Welsh CE, 2012, MAMM GENOME, V23, P706, DOI 10.1007/s00335-012-9410-6; Yu W, 2016, NAT REV IMMUNOL, V16, P751, DOI 10.1038/nri.2016.111	54	19	19	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1027	+		10.1016/j.jaci.2018.10.009	http://dx.doi.org/10.1016/j.jaci.2018.10.009			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30342892	Bronze, Green Published, Green Accepted			2022-12-18	WOS:000460272900023
J	Cohen, SB; Bainter, W; Johnson, JL; Lin, TY; Wong, JCY; Wallace, JG; Jones, J; Qureshi, S; Mir, F; Qamar, F; Cantley, LC; Geha, RS; Chou, J				Cohen, Sarah Beaussant; Bainter, Wayne; Johnson, Jared L.; Lin, Ting-Yu; Wong, Jenny C. Y.; Wallace, Jacqueline G.; Jones, Jennifer; Qureshi, Sonia; Mir, Fatima; Qamar, Farah; Cantley, Lewis C.; Geha, Raif S.; Chou, Janet			Human primary immunodeficiency caused by expression of a kinase-dead p110d mutant	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							B-CELL; P110-DELTA		[Cohen, Sarah Beaussant; Bainter, Wayne; Wallace, Jacqueline G.; Jones, Jennifer; Geha, Raif S.; Chou, Janet] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Johnson, Jared L.; Lin, Ting-Yu; Wong, Jenny C. Y.; Cantley, Lewis C.] Weill Cornell Med, Meyer Canc Ctr, New York, NY USA; [Qureshi, Sonia; Mir, Fatima; Qamar, Farah] Aga Khan Univ, Dept Paediat & Child Hlth, Karachi, Pakistan	Harvard University; Boston Children's Hospital; Harvard Medical School; Cornell University; Aga Khan University	Chou, J (corresponding author), Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA.	Janet.Chou@childrens.harvard.edu	Mir, Fatima/AAI-1080-2019	Wallace, Jacqueline/0000-0001-6565-2534; BEAUSSANT COHEN, Sarah/0000-0002-5591-9730; Johnson, Jared/0000-0003-1802-6527	Perkin Fund [5T32AI007512-33, NCI R35 CA197588, 5K08AI116979-04, 1R01AI139633-01]; NATIONAL CANCER INSTITUTE [R35CA197588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI139633, K08AI116979, T32AI007512] Funding Source: NIH RePORTER	Perkin Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by grant number 5T32AI007512-33 (S.B.C.), grant number NCI R35 CA197588 (L.C.C.), grant number 5K08AI116979-04 (J.C.), grant number 1R01AI139633-01 (R.S.G.), and the Perkin Fund (R.S.G.).	Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; Dura B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6940; Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029; Lucas CL, 2016, NAT REV IMMUNOL, V16, P702, DOI 10.1038/nri.2016.93; Okkenhaug K, 2002, SCIENCE, V297, P1031; Ramadani F, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001104; Sharfe N, 2018, J ALLERGY CLIN IMMUN, V142, P618, DOI 10.1016/j.jaci.2017.10.033; Sogkas G, 2018, J ALLERGY CLIN IMMUN, V142, P1650, DOI 10.1016/j.jaci.2018.06.039; Steinbach EC, 2014, J IMMUNOL, V192, P3958, DOI 10.4049/jimmunol.1301533	9	19	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					797	+		10.1016/j.jaci.2018.10.005	http://dx.doi.org/10.1016/j.jaci.2018.10.005			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	30336224	Green Accepted, Bronze			2022-12-18	WOS:000457718700045
J	Cheung, DS; Sigua, JA; Simpson, PM; Yan, K; Hussain, SRA; Santoro, JL; Buell, EJ; Hunter, DA; Rohlfing, M; Patadia, D; Grayson, MH				Cheung, Dorothy S.; Sigua, Jerome A.; Simpson, Pippa M.; Yan, Ke; Hussain, Syed-Rehan A.; Santoro, Jennifer L.; Buell, Erika J.; Hunter, Desire A.; Rohlfing, Michelle; Patadia, Deepa; Grayson, Mitchell H.			Cysteinyl leukotriene receptor 1 expression identifies a subset of neutrophils during the antiviral response that contributes to postviral atopic airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; viral infection; nasal lavage; neutrophils; cysteinyl leukotrienes	RESPIRATORY SYNCYTIAL VIRUS; LUNG DENDRITIC CELLS; VIRAL-INFECTION; ASTHMA; RESPONSIVENESS; BRONCHIOLITIS; MONTELUKAST; RECRUITMENT; INNATE; STRAIN	Background: Viral respiratory tract infections increase the risk of development and exacerbation of atopic disease. Previously, we demonstrated the requirement for a neutrophil (PMN) subset expressing CD49d to drive development of postviral atopic airway disease in mice. Objective: We sought to determine whether human CD49d(+) PMNs are present in the nasal mucosa during acute viral respiratory tract infections and further characterize this PMN subset in human subjects and mice. Methods: Sixty subjects (5-50 years old) were enrolled within 4 days of acute onset of upper respiratory symptoms. Nasal lavage for flow cytometry and nasal swabs for viral PCR were performed at enrollment and during convalescence. The Sendai virus mouse model was used to investigate the phenotype and functional relevance of CD49d(+) PMNs. Results: CD49d(+) PMN frequency was significantly higher in nasal lavage fluid during acute respiratory symptoms in all subjects (2.9% vs 1.0%, n = 42, P < .001). In mice CD49d(+) PMNs represented a "proatopic'' neutrophil subset that expressed cysteinyl leukotriene receptor 1 (CysLTR1) and produced TNF, CCL2, and CCL5. Inhibition of CysLTR1 signaling in the first days of a viral respiratory tract infection was sufficient to reduce accumulation of CD49d(+) PMNs in the lungs and development of postviral atopic airway disease. Similar to the mouse, human CD49d(+) PMNs isolated from nasal lavage fluid during a viral respiratory tract infection expressed CysLTR1. Conclusion: CD49d and CysLTR1-coexpressing PMNs are present during symptoms of an acute viral respiratory tract infection in human subjects. Further study is needed to examine selective targeting of proatopic neutrophils as a potential therapeutic strategy to prevent development of postviral atopic airway disease.	[Cheung, Dorothy S.; Sigua, Jerome A.; Santoro, Jennifer L.; Buell, Erika J.; Hunter, Desire A.; Rohlfing, Michelle; Patadia, Deepa; Grayson, Mitchell H.] Med Coll Wisconsin, Dept Pediat, Div Allergy & Immunol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Simpson, Pippa M.; Yan, Ke] Med Coll Wisconsin, Dept Pediat, Div Quantitat Hlth Sci, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Hussain, Syed-Rehan A.; Santoro, Jennifer L.; Rohlfing, Michelle; Patadia, Deepa; Grayson, Mitchell H.] Ohio State Univ, Sch Med, Nationwide Childrens Hosp, Div Allergy & Immunol,Dept Pediat, Columbus, OH 43210 USA; [Hussain, Syed-Rehan A.; Santoro, Jennifer L.; Rohlfing, Michelle; Grayson, Mitchell H.] Nationwide Childrens Hosp, Res Inst, Ctr Clin & Translat Res, Columbus, OH USA; [Cheung, Dorothy S.] Genentech Inc, San Francisco, CA 94080 USA; [Sigua, Jerome A.] VA San Diego Healthcare Syst, San Diego, CA USA; [Patadia, Deepa] Cleveland Clin, Dept Allergy & Immunol, Cleveland, OH 44106 USA	Medical College of Wisconsin; Medical College of Wisconsin; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; Roche Holding; Genentech; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; Cleveland Clinic Foundation	Grayson, MH (corresponding author), Nationwide Childrens Hosp, Div Allergy & Immunol, 700 Childrens Dr, Columbus, OH 43205 USA.	wheeze@allergist.com	Grayson, Mitchell/AAX-3674-2020	Grayson, Mitchell/0000-0002-4673-2122	National Institutes of Health [AI103037, HL087778]; American Thoracic Society/Merck Translational Research Grant in Asthma; Children's Research Institute of the Children's Hospital of Wisconsin; Research Institute at Nationwide Children's Hospital; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087778] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI103037] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Thoracic Society/Merck Translational Research Grant in Asthma; Children's Research Institute of the Children's Hospital of Wisconsin; Research Institute at Nationwide Children's Hospital(Ohio State University); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health (grants AI103037 to D.S.C. and HL087778 to M.H.G.), the American Thoracic Society/Merck Translational Research Grant in Asthma (to D.S.C.), the Children's Research Institute of the Children's Hospital of Wisconsin (to M.H.G. and D.S.C.), and the Research Institute at Nationwide Children's Hospital (to M.H.G.).	Akk AM, 2008, J IMMUNOL, V180, P3535, DOI 10.4049/jimmunol.180.5.3535; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bem RA, 2011, AM J PHYSIOL-LUNG C, V301, pL148, DOI 10.1152/ajplung.00065.2011; Bisgaard H, 2003, AM J RESP CRIT CARE, V167, P379, DOI 10.1164/rccm.200207-747OC; Bisgaard H, 2008, AM J RESP CRIT CARE, V178, P854, DOI 10.1164/rccm.200706-910OC; Buelow BJ, 2017, IMMUN INFLAMM DIS, V5, P98, DOI 10.1002/iid3.147; Carroll KN, 2008, IMMUNOL ALLERGY CLIN, V28, P539, DOI 10.1016/j.iac.2008.03.001; Cheung DS, 2012, CURR ALLERGY ASTHM R, V12, P613, DOI 10.1007/s11882-012-0295-y; Cheung DS, 2010, ANN ALLERG ASTHMA IM, V105, P437, DOI 10.1016/j.anai.2010.09.010; Cheung DS, 2010, J IMMUNOL, V185, P4983, DOI 10.4049/jimmunol.1002456; Chipps BE, 2012, J ALLERGY CLIN IMMUN, V130, P332, DOI 10.1016/j.jaci.2012.04.014; Choi JP, 2012, ALLERGY, V67, P1138, DOI 10.1111/j.1398-9995.2012.02871.x; Dyer KD, 2011, J IMMUNOL METHODS, V369, P91, DOI 10.1016/j.jim.2011.04.009; Escobar GJ, 2010, ARCH PEDIAT ADOL MED, V164, P915, DOI 10.1001/archpediatrics.2010.177; Figueroa DJ, 2003, CLIN EXP ALLERGY, V33, P1380, DOI 10.1046/j.1365-2222.2003.01786.x; Flandre TD, 2003, J APPL PHYSIOL, V94, P1129, DOI 10.1152/japplphysiol.00561.2002; Fullmer JJ, 2005, PEDIAT ALLERG IMM-UK, V16, P593, DOI 10.1111/j.1399-3038.2005.00248.x; Gotera J, 2012, ANN ALLERG ASTHMA IM, V108, P316, DOI 10.1016/j.anai.2012.03.006; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Holtzman MJ, 2012, J CLIN INVEST, V122, P2741, DOI 10.1172/JCI60325; Hunter D, 2014, J ALLERGY CLIN IMMUN, V133, P901, DOI 10.1016/j.jaci.2013.09.035; Khan SH, 2010, J ALLERGY CLIN IMMUN, V125, P265, DOI 10.1016/j.jaci.2009.09.038; Kloepfer KM, 2011, ANN ALLERG ASTHMA IM, V106, P252, DOI 10.1016/j.anai.2010.11.021; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Lammermann T, 2013, NATURE, V498, P371, DOI 10.1038/nature12175; Lewis SM, 2009, AM J RESP CELL MOL, V40, P724, DOI 10.1165/rcmb.2008-0252OC; Lofgren JLS, 2006, J APPL PHYSIOL, V101, P1495, DOI 10.1152/japplphysiol.00464.2006; McGovern T, 2016, J IMMUNOL, V197, P266, DOI 10.4049/jimmunol.1501084; Meliton AY, 2010, EUR RESPIR J, V35, P402, DOI 10.1183/09031936.00009309; Meltzer EO, 2011, ANN ALLERG ASTHMA IM, V106, pS12, DOI 10.1016/j.anai.2010.10.014; Parmentier CN, 2012, J ALLERGY CLIN IMMUN, V129, P1136, DOI 10.1016/j.jaci.2012.01.057; Pitrez PMC, 2005, RESPIROLOGY, V10, P365, DOI 10.1111/j.1440-1843.2005.00721.x; Sadik CD, 2011, TRENDS IMMUNOL, V32, P452, DOI 10.1016/j.it.2011.06.008; Sigurs Nele, 2002, Paediatr Respir Rev, V3, P177, DOI 10.1016/S1526-0542(02)00191-4; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Simoes EAF, 2010, J ALLERGY CLIN IMMUN, V126, P256, DOI 10.1016/j.jaci.2010.05.026; Subrata LS, 2009, J IMMUNOL, V183, P2793, DOI 10.4049/jimmunol.0900695; Tasker L, 2008, CLIN EXP IMMUNOL, V153, P277, DOI 10.1111/j.1365-2249.2008.03591.x; Trian T, 2015, AM J RESP CRIT CARE, V191, P538, DOI 10.1164/rccm.201409-1582OC; Zahran Hatice S., 2011, Morbidity and Mortality Weekly Report, V60, P547	40	19	19	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1206	+		10.1016/j.jaci.2017.11.026	http://dx.doi.org/10.1016/j.jaci.2017.11.026			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29269317	Bronze, Green Accepted			2022-12-18	WOS:000446327300020
J	Andre-Gregoire, G; Dilasser, F; Chesne, J; Braza, F; Magnan, A; Loirand, G; Sauzeau, V				Andre-Gregoire, Gwennan; Dilasser, Florian; Chesne, Julie; Braza, Faouzi; Magnan, Antoine; Loirand, Gervaise; Sauzeau, Vincent			Targeting of Rac1 prevents bronchoconstriction and airway hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rac1; airway smooth muscle; asthma; airway hyper responsiveness; calcium; PLC; pulmonary inflammation	SMOOTH-MUSCLE CONTRACTION; OBSTRUCTIVE PULMONARY-DISEASE; TIOTROPIUM BROMIDE; ASTHMA MODEL; IMMUNOLOGY; IL-17A; MOUSE; CELLS; MICE	Background: The molecular mechanisms responsible for airway smooth muscle cells' (aSMCs) contraction and proliferation in airway hyperresponsiveness (AHR) associated with asthma are still largely unknown. The small GTPases of the Rho family (RhoA, Rac1, and Cdc42) play a central role in SMC functions including migration, proliferation, and contraction. Objective: The objective of this study was to identify the role of Rac1 in aSMC contraction and to investigate its involvement in AHR associated with allergic asthma. Methods: To define the role of Rac1 in aSMC, ex and in vitro analyses of bronchial reactivity were performed on bronchi from smooth muscle (SM)-specific Rac1 knockout mice and human individuals. In addition, this murine model was exposed to allergens (ovalbumin or house dust mite extract) to decipher in vivo the implication of Rac1 in AHR. Results: The specific SMC deletion or pharmacological inhibition of Rac1 in mice prevented the bronchoconstrictor response to methacholine. In human bronchi, a similar role of Rac1 was observed during bronchoconstriction. We further demonstrated that Rac1 activation is responsible for bronchoconstrictor-induced increase in intracellular Ca2+ concentration and contraction both in murine and in human bronchial aSMCs, through its association with phospholipase C 132 and the stimulation of inositol 1,4,5-trisphosphate production. In vivo, Rac1 deletion in SMCs or pharmacological Rac1 inhibition by nebulization of NSC23766 prevented AHR in murine models of allergic asthma. Moreover, nebulization of NSC23766 decreased eosinophil and neutrophil populations in bronchoalveolar lavages from mice with asthma. Conclusions: Our data reveal an unexpected and essential role of Rac1 in the regulation of intracellular Ca2+ and contraction of aSMCs, and the development of AHR. Rac1 thus appears as an attractive therapeutic target in asthma, with a combined beneficial action on both bronchoconstriction and pulmonary inflammation.	[Andre-Gregoire, Gwennan; Dilasser, Florian; Chesne, Julie; Braza, Faouzi; Magnan, Antoine; Loirand, Gervaise; Sauzeau, Vincent] Univ Nantes, CNRS, NSERM, Inst Thorax, Nantes, France; [Magnan, Antoine; Loirand, Gervaise; Sauzeau, Vincent] CHU Nantes, Nantes, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	Sauzeau, V (corresponding author), Inserm 1087, Inst Thorax, 8 Quai Moncousu, F-44000 Nantes, France.	vincent.sauzeau@inserm.fr	Loirand, Gervaise/K-1834-2014; Sauzeau, Vincent/D-3548-2015; MAGNAN, ANTOINE/GVT-4308-2022; Andre-Gregoire, Gwennan/K-9284-2015	Loirand, Gervaise/0000-0002-2306-3931; Andre-Gregoire, Gwennan/0000-0002-9167-8727; Braza, Faouzi/0000-0003-1182-1413; Sauzeau, Vincent/0000-0002-6187-0312; Dilasser, Florian/0000-0002-3286-5549	Agence National de la Recherche [ANR-09-JCJC-0115-01]; Institut de Recherche en Sante Respiratoire des Pays de la Loire (G-Rar project); Societe d'Acceleration du Transfert de Technologie [STRAS-2117]; Fondation pour la Recherche Medicale [PMJ20151034369]; Institut National de la Sante et de la Recherche Medicale (INSERM); Ministere de la Recherche et de l'Enseignement Superieur	Agence National de la Recherche(French National Research Agency (ANR)); Institut de Recherche en Sante Respiratoire des Pays de la Loire (G-Rar project); Societe d'Acceleration du Transfert de Technologie; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Ministere de la Recherche et de l'Enseignement Superieur	This work was supported by grants from the Agence National de la Recherche (project no. ANR-09-JCJC-0115-01), the Institut de Recherche en Sante Respiratoire des Pays de la Loire (G-Rar project), the Societe d'Acceleration du Transfert de Technologie (project no. STRAS-2117), the Fondation pour la Recherche Medicale (project no. PMJ20151034369), and the Institut National de la Sante et de la Recherche Medicale (INSERM). G.A-G. was supported by a grant from Ministere de la Recherche et de l'Enseignement Superieur.	Andre G, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000852; Bahaie NS, 2012, J IMMUNOL, V188, P1479, DOI 10.4049/jimmunol.1102253; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Bento AM, 1998, ALLERGY ASTHMA PROC, V19, P353, DOI 10.2500/108854198778612672; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Bustelo Xose R, 2012, Small GTPases, V3, P60, DOI 10.4161/sgtp.19111; Chesne J, 2015, J ALLERGY CLIN IMMUN, V135, P1643, DOI 10.1016/j.jaci.2014.12.1872; Cockcroft DW, 2006, J ALLERGY CLIN IMMUN, V118, P551, DOI 10.1016/j.jaci.2006.07.012; Fabbiano S, 2014, MOL CELL BIOL, V34, P4404, DOI 10.1128/MCB.01066-14; Gayard M, 2011, ARTERIOSCL THROM VAS, V31, P2634, DOI 10.1161/ATVBAHA.111.228304; Gong DP, 2013, J IMMUNOL, V191, P4514, DOI 10.4049/jimmunol.1202603; Gosens R, 2005, AM J RESP CRIT CARE, V171, P1096, DOI 10.1164/rccm.200409-1249OC; Hoover WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042601; Illenberger D, 1997, EUR J BIOCHEM, V246, P71, DOI 10.1111/j.1432-1033.1997.t01-1-00071.x; Jezyk MR, 2006, NAT STRUCT MOL BIOL, V13, P1135, DOI 10.1038/nsmb1175; Juncadella IJ, 2013, NATURE, V493, P547, DOI 10.1038/nature11714; Kan W, 2014, J BIOL CHEM, V289, P11206, DOI 10.1074/jbc.M113.538546; Kang JY, 2012, ANN ALLERG ASTHMA IM, V109, P29, DOI 10.1016/j.anai.2012.05.005; Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684; Loirand G, 2013, PHYSIOL REV, V93, P1659, DOI 10.1152/physrev.00021.2012; McGraw DW, 2007, J CLIN INVEST, V117, P1391, DOI 10.1172/JCI30489; Moore WC, 2006, J ALLERGY CLIN IMMUN, V117, P487, DOI 10.1016/j.jaci.2006.01.033; Postma DS, 1998, AM J RESP CRIT CARE, V158, pS187, DOI 10.1164/ajrccm.158.supplement_2.13tac170; Prakash YS, 2013, AM J PHYSIOL-LUNG C, V305, pL912, DOI 10.1152/ajplung.00259.2013; Price D, 2014, NPJ PRIM CARE RESP M, V24, DOI 10.1038/npjpcrm.2014.23; Rahman A, 2014, J PHYSIOL-LONDON, V592, P915, DOI 10.1113/jphysiol.2013.262998; Roscioni SS, 2011, J CELL MOL MED, V15, P1551, DOI 10.1111/j.1582-4934.2010.01150.x; Rydell-Tormanen K, 2013, PULM PHARMACOL THER, V26, P13, DOI 10.1016/j.pupt.2012.04.003; Saez AMO, 2000, AM J RESP CRIT CARE, V161, P910; Snyder JT, 2003, J BIOL CHEM, V278, P21099, DOI 10.1074/jbc.M301418200; Suissa S, 2016, NEW ENGL J MED, V375, P897, DOI 10.1056/NEJMc1609305; To T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-204; Wasilewski NV, 2014, CURR OPIN PHARMACOL, V16, P148, DOI 10.1016/j.coph.2014.05.007; Yao HY, 2011, BBA-GEN SUBJECTS, V1810, P666, DOI 10.1016/j.bbagen.2011.03.020	34	19	19	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					824	+		10.1016/j.jaci.2017.09.049	http://dx.doi.org/10.1016/j.jaci.2017.09.049			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29155102	Green Submitted, Bronze			2022-12-18	WOS:000443726500015
J	Nguyen, DX; Cotton, A; Attipoe, L; Ciurtin, C; Dore, CJ; Ehrenstein, MR				Nguyen, Dao X.; Cotton, Alice; Attipoe, Laura; Ciurtin, Coziana; Dore, Caroline J.; Ehrenstein, Michael R.			Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR; METHOTREXATE; INHIBITION; VALIDATION; EXPRESSION; MONOCYTES; APOPTOSIS; CRITERIA; TARGET		[Nguyen, Dao X.; Cotton, Alice; Attipoe, Laura; Ciurtin, Coziana; Ehrenstein, Michael R.] UCL, Ctr Rheumatol, Div Med, London, England; [Dore, Caroline J.] UCL, Inst Clin Trials & Methodol, Comprehens Clin Trials Unit, London, England	University of London; University College London; University of London; University College London	Ehrenstein, MR (corresponding author), UCL, Ctr Rheumatol, Div Med, London, England.	m.ehrenstein@ucl.ac.uk	Coziana Ciurtin, C Ciurtin/ABA-3848-2021; Dore, Caroline J/J-4716-2012; Ciurtin, Coziana/GZM-3357-2022; Ciurtin, Coziana/P-1230-2018	Coziana Ciurtin, C Ciurtin/0000-0002-8911-4113; Dore, Caroline J/0000-0001-9796-4970; Ciurtin, Coziana/0000-0002-8911-4113; Cotton, Alice/0000-0003-4442-1467; Ehrenstein, Michael/0000-0003-1673-743X	Arthritis Research UK [20687]; UCLH Biomedical Research Centre; MRC [MC_UU_12023/14] Funding Source: UKRI	Arthritis Research UK(Versus Arthritis); UCLH Biomedical Research Centre; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by Arthritis Research UK (grant no. 20687) and the UCLH Biomedical Research Centre.	ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bluett J, 2017, RHEUM DIS CLIN N AM, V43, P377, DOI 10.1016/j.rdc.2017.04.008; Coulthard LR, 2011, ANN RHEUM DIS, V70, P98, DOI 10.1136/ard.2010.133249; Cribbs AP, 2015, ARTHRITIS RHEUMATOL, V67, P1182, DOI 10.1002/art.39031; Nguyen DX, 2016, J EXP MED, V213, P1241, DOI 10.1084/jem.20151255; Deng L, 2010, AM J PATHOL, V176, P952, DOI 10.2353/ajpath.2010.090622; Dobreva ZG, 2009, IMMUNOPHARM IMMUNOT, V31, P195, DOI 10.1080/08923970802626276; Ehrenstein MR, 2007, J EXP MED, V204, P2249, DOI 10.1084/jem.20071737; Fransen J, 2003, ANN RHEUM DIS, V62, P10; Ginhoux F, 2014, NAT REV IMMUNOL, V14, P392, DOI 10.1038/nri3671; Haas E, 1999, J BIOL CHEM, V274, P18107, DOI 10.1074/jbc.274.25.18107; Heiberg MS, 2006, ANN RHEUM DIS, V65, P1379, DOI 10.1136/ard.2006.051540; Hetland ML, 2010, ARTHRITIS RHEUM-US, V62, P22, DOI 10.1002/art.27227; Horiuchi T, 2010, RHEUMATOLOGY, V49, P1215, DOI 10.1093/rheumatology/keq031; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; Marra LE, 2004, J IMMUNOL, V172, P1028, DOI 10.4049/jimmunol.172.2.1028; McGovern JL, 2012, ARTHRITIS RHEUM-US, V64, P3129, DOI 10.1002/art.34565; Meusch U, 2009, ARTHRITIS RHEUM-US, V60, P2612, DOI 10.1002/art.24778; Mitoma H, 2005, GASTROENTEROLOGY, V128, P376, DOI 10.1053/j.gastro.2004.11.060; Murai M, 2009, NAT IMMUNOL, V10, P1178, DOI 10.1038/ni.1791; Schneider C, 2014, NAT IMMUNOL, V15, P1026, DOI 10.1038/ni.3005; Waetzig GH, 2002, J IMMUNOL, V168, P5342, DOI 10.4049/jimmunol.168.10.5342; Waetzig GH, 2003, GASTROENTEROLOGY, V125, P633, DOI 10.1016/S0016-5085(03)00979-X; Wang YM, 2012, NAT IMMUNOL, V13, P753, DOI 10.1038/ni.2360; Wells G, 2009, ANN RHEUM DIS, V68, P954, DOI 10.1136/ard.2007.084459; Yu XY, 2017, IMMUNITY, V47, P903, DOI 10.1016/j.immuni.2017.10.007; Zhang Xia, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1401s83; Zhou L, 2009, P NATL ACAD SCI USA, V106, P10266, DOI 10.1073/pnas.0811119106	28	19	20	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					978	+		10.1016/j.jaci.2018.04.026	http://dx.doi.org/10.1016/j.jaci.2018.04.026			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29935955	Green Published, hybrid			2022-12-18	WOS:000443726500031
J	Magnusson, J; Ekstrom, S; Kull, I; Hakansson, N; Nilsson, S; Wickman, M; Melen, E; Riserus, U; Bergstrom, A				Magnusson, Jessica; Ekstrom, Sandra; Kull, Inger; Hakansson, Niclas; Nilsson, Sara; Wickman, Magnus; Melen, Erik; Riserus, Ulf; Bergstrom, Anna			Polyunsaturated fatty acids in plasma at 8 years and subsequent allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adolescent; allergy; asthma; Children; Allergy; Milieu; Stockholm; Epidemiology study; children; fatty acid; rhinitis; plasma; prospective studies	ASTHMA SYMPTOMS; SCHOOL-CHILDREN; SEAFOOD INTAKE; ATOPY; DIET; BLOOD; INFLAMMATION; ASSOCIATION; RHINITIS; OBESITY	Background: Polyunsaturated fatty acids (PUFAs) are hypothesized to modulate the risk of allergic disease. However, evidence from previous studies is inconclusive, and limited longitudinal data exist using circulating biomarkers of PUFA intake and metabolism. Objective: We aimed to investigate associations between n-3 and n-6 PUFAs at age 8 years and asthma, rhinitis, and aeroallergen sensitization at age 16 years. Methods: Proportions of n-3 PUFAs (very long-chain n-3 [VLC n-3; sum of eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid] anda-linolenic acid) and n-6PUFAs (linoleic acid and arachidonic acid [AA]) in blood samples at age 8 years weremeasured for 940 children fromthe prospective Swedish birth cohort BAMSE (Children, Allergy, Milieu, Stockholm, Epidemiology). Allergic disease phenotypes were defined by using questionnaires and IgE measures at the ages of 8 and 16 years. Logistic regression was used to examine potential associations. Results: A higher proportion of total VLC n-3 PUFAs in plasma at age 8 years was associated with a reduced risk of prevalent asthma, rhinitis, and aeroallergen sensitization at age 16 years and with incidence of asthma between 8 and 16 years (adjusted odds ratio, 0.67; 95% CI, 0.47-0.94). AA was associated with a reduced risk of asthma, aeroallergen sensitization, and allergic rhinitis. The findings were most evident for allergic phenotypes of asthma and rhinitis. Additionally, AA was associated with an increased probability of asthma and rhinitis remission between 8 and 16 years of age. Conclusion: Higher proportions of certain VLC n-3 and very long-chain n-6 PUFAs in plasma phospholipids at age 8 years were associated with a reduced risk of allergic disease at age 16 years.	[Magnusson, Jessica; Ekstrom, Sandra; Kull, Inger; Hakansson, Niclas; Nilsson, Sara; Wickman, Magnus; Melen, Erik; Bergstrom, Anna] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Kull, Inger] Karolinska Inst, Dept Educ & Clin Sci, Stockholm, Sweden; [Kull, Inger; Wickman, Magnus; Melen, Erik] South Gen Hosp, Sachs Childrens Hosp, Dept Pediat, Stockholm, Sweden; [Nilsson, Sara; Melen, Erik; Bergstrom, Anna] Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden; [Riserus, Ulf] Uppsala Univ, Dept Publ Hlth & Caring Sci, Clin Nutr & Metab, Uppsala, Sweden	Karolinska Institutet; Karolinska Institutet; Stockholm County Council; Uppsala University	Bergstrom, A (corresponding author), Box 210, SE-17177 Stockholm, Sweden.	Anna.Bergstrom@ki.se	Ekström, Sandra/AAZ-7214-2021; Hakansson, Niclas/L-7913-2013	Hakansson, Niclas/0000-0001-7673-5554; Ekstrom, Sandra/0000-0002-2060-8190	Stockholm County Council; Swedish Research Council; Swedish Research Council Formas; Swedish Heart-Lung Foundation; Swedish Asthma and Allergy Association; Swedish Research Council for Health, Working Life and Welfare; European Commission's Seventh Framework 29 Program MeDALL [261357]	Stockholm County Council(Stockholm County Council); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Research Council Formas(Swedish Research CouncilSwedish Research Council Formas); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Asthma and Allergy Association; Swedish Research Council for Health, Working Life and Welfare(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte)); European Commission's Seventh Framework 29 Program MeDALL	Supported by the Stockholm County Council; the Swedish Research Council; the Swedish Research Council Formas; the Swedish Heart-Lung Foundation; the Swedish Asthma and Allergy Association; the Swedish Research Council for Health, Working Life and Welfare; and the European Commission's Seventh Framework 29 Program MeDALL (grant agreement no. 261357). Thermo Fisher Scientific kindly provided the reagents.	Almqvist C, 2007, J ALLERGY CLIN IMMUN, V119, P1438, DOI 10.1016/j.jaci.2007.01.046; Andreasyan K, 2005, ALLERGY, V60, P671, DOI 10.1111/j.1398-9995.2005.00757.x; Antova T, 2003, THORAX, V58, P231, DOI 10.1136/thorax.58.3.231; Arvaniti F, 2011, PEDIAT ALLERG IMM-UK, V22, P283, DOI 10.1111/j.1399-3038.2010.01113.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Barman M, 2014, ACTA PAEDIATR, V103, P968, DOI 10.1111/apa.12690; Beermann C, 2016, NUTRITION, V32, P1165, DOI 10.1016/j.nut.2016.04.004; Bjermo H, 2012, AM J CLIN NUTR, V95, P1003, DOI 10.3945/ajcn.111.030114; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; BOBERG M, 1985, CLIN SCI, V68, P581, DOI 10.1042/cs0680581; Burdge GC, 2006, NUTR RES REV, V19, P26, DOI 10.1079/NRR2005113; Burrows T, 2012, EUR J CLIN NUTR, V66, P825, DOI 10.1038/ejcn.2012.26; Calder PC, 2015, BBA-MOL CELL BIOL L, V1851, P469, DOI 10.1016/j.bbalip.2014.08.010; Calder PC, 2009, BIOCHIMIE, V91, P791, DOI 10.1016/j.biochi.2009.01.008; Chatzi L, 2007, PEDIAT ALLERG IMM-UK, V18, P480, DOI 10.1111/j.1399-3038.2007.00596.x; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Dunder T, 2001, ALLERGY, V56, P425, DOI 10.1034/j.1398-9995.2001.056005425.x; Ekstrom S, 2015, CLIN EXP ALLERGY, V45, P283, DOI 10.1111/cea.12340; Focke M, 2005, WIEN KLIN WOCHENSCHR, V117, P485, DOI 10.1007/s00508-005-0394-z; Hodge L, 1996, MED J AUSTRALIA, V164, P137, DOI 10.5694/j.1326-5377.1996.tb122010.x; Hodson L, 2008, PROG LIPID RES, V47, P348, DOI 10.1016/j.plipres.2008.03.003; Hwang I, 2007, LIPIDS, V42, P345, DOI 10.1007/s11745-007-3033-9; Kim JL, 2005, INDOOR AIR, V15, P170, DOI 10.1111/j.1600-0668.2005.00334.x; Kunitsugu I, 2012, PEDIATR INT, V54, P233, DOI 10.1111/j.1442-200X.2011.03542.x; Kurukulaaratchy RJ, 2011, CLIN EXP ALLERGY, V41, P851, DOI 10.1111/j.1365-2222.2011.03765.x; Lumia M, 2014, J ALLERGY CLIN IMMUN, V134, P488, DOI 10.1016/j.jaci.2014.04.012; Magnusson J, 2015, J ALLERGY CLIN IMMUN, V136, P1247, DOI 10.1016/j.jaci.2015.05.030; Miyake Y, 2008, CLIN EXP ALLERGY, V38, P1644, DOI 10.1111/j.1365-2222.2008.03074.x; Miyake Y, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-358; Murray CS, 2006, ALLERGY, V61, P438, DOI 10.1111/j.1398-9995.2005.00927.x; Nagel G, 2010, THORAX, V65, P516, DOI 10.1136/thx.2009.128256; Rett BS, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-36; Rodriguez-Rodriguez E, 2010, EUR J CLIN NUTR, V64, P1065, DOI 10.1038/ejcn.2010.127; Sastre B, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/645383; Standl M, 2014, PEDIAT ALLERG IMM-UK, V25, P344, DOI 10.1111/pai.12212; Tabak C, 2006, THORAX, V61, P1048, DOI 10.1136/thx.2005.043034; Tillander H, 2014, J ALLERGY CLIN IMMUN, V133, P580, DOI 10.1016/j.jaci.2013.09.009; Wallin A, 2014, EUR J NUTR, V53, P549, DOI 10.1007/s00394-013-0563-1; Wendell SG, 2014, J ALLERGY CLIN IMMUN, V133, P1255, DOI 10.1016/j.jaci.2013.12.1087; Westman M, 2013, ALLERGY, V68, P1571, DOI 10.1111/all.12267; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S	42	19	19	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					510	+		10.1016/j.jaci.2017.09.023	http://dx.doi.org/10.1016/j.jaci.2017.09.023			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29221817	hybrid, Green Published			2022-12-18	WOS:000440664400019
J	Sharfe, N; Karanxha, A; Dadi, H; Merico, D; Chitayat, D; Herbrick, JA; Freeman, S; Grinstein, S; Roifman, CM				Sharfe, Nigel; Karanxha, Ariana; Dadi, Harjit; Merico, Daniele; Chitayat, David; Herbrick, Jo-Anne; Freeman, Spencer; Grinstein, Sergio; Roifman, Chaim M.			Dual loss of p110 delta PI3-kinase and SKAP (KNSTRN) expression leads to combined immunodeficiency and multisystem syndromic features	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PIK3CD; PI3-kinase; SKAP; KNSTRN; syndromic; immunodeficiency; lymphocyte; MAP4; microtubule	B-CELL RECEPTOR; MICROTUBULE DYNAMICS; POSTTRANSLATIONAL MODIFICATIONS; PHOSPHOINOSITIDE 3-KINASES; ANTIBODY DEFICIENCY; MAP4; INTEGRIN; PROTEIN; ACTIVATION; ISOFORMS	Background: We previously reported a novel syndrome characterized by combined immunodeficiency associated with severe developmental defects-subsequently known as Roifman-Chitayat syndrome (RCS; OMIM 613328). Linkage analysis identified 2 disease-associated loci. Objectives: We sought to identify the genetic defect in these patients and characterize their immunologic cellular abnormalities. Methods: Genetic, immunologic, protein, and cellular functional analyses were used to identify and characterize patient genetic deficiencies and aberrant patient cell behavior. Results: Deleterious variants were found at both loci identified by linkage analysis: a homozygous stop codon in PI3-kinase p110 delta (PIK3CD) and a homozygous frame shift mutation in SKAP (KNSTRN), both ablating protein expression. Patients with RCS display aberrant B-cell development, similar to p110 delta-deficient mice, but also aberrant T-cell spreading, cell-cell interaction, and migration. Patients also display significant developmental abnormalities not seen in p110 delta knockouts (eg, optic nerve atrophy and skeletal anomalies) that we ascribe to loss of SKAP. Aberrant SKAP expression can prolong anaphase and this may contribute to developmental defects. However, we also identified microtubule-associated protein 4 microtubule-binding protein as a novel SKAP-binding partner and show that it undergoes relocalization in patient T cells, with associated areas of aberrant microtubule hyperstabilization, likely contributing not only to the altered properties of RCS lymphoid cells but also to developmental defects. Conclusions: The complex RCS presentation, with combined developmental and immunologic defects, is associated with a combined deficiency of 2 genes products, PI3-kinase p110 delta and SKAP, both of which appear to play a significant role in the disease.	[Sharfe, Nigel; Karanxha, Ariana; Dadi, Harjit; Roifman, Chaim M.] Hosp Sick Children, Div Immunol & Allergy, Canadian Ctr Primary Immunodeficiency, Immunogen Lab,Dept Pediat, Toronto, ON, Canada; [Merico, Daniele; Herbrick, Jo-Anne] Hosp Sick Children, Ctr Appl Genom, Toronto, ON, Canada; [Merico, Daniele] Deep Genom Inc, Toronto, ON, Canada; [Chitayat, David] Hosp Sick Children, Clin & Metab Genet, Toronto, ON, Canada; [Freeman, Spencer; Grinstein, Sergio] Hosp Sick Children, Cell Biol Program, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Roifman, CM (corresponding author), Hosp Sick Children, Div Immunol & Allergy, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	chaim.roifman@sickkids.ca		Merico, Daniele/0000-0002-3728-4401	Immunodeficiency Canada Distinguished Professorship in Immunology (CMR); Program for Immunogenomics; Canadian Centre for Primary Immunodeficiency; Jeffrey Modell Foundation; Immunodeficiency Canada; Genome Canada through the Ontario Genomics Institute; Canada Foundation for Innovation; Ontario Ministry of Research and Innovation	Immunodeficiency Canada Distinguished Professorship in Immunology (CMR); Program for Immunogenomics; Canadian Centre for Primary Immunodeficiency; Jeffrey Modell Foundation; Immunodeficiency Canada; Genome Canada through the Ontario Genomics Institute(Genome Canada); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Ontario Ministry of Research and Innovation(Ministry of Research and Innovation, Ontario)	This work was supported by the Immunodeficiency Canada Distinguished Professorship in Immunology (CMR), the Program for Immunogenomics, and the Canadian Centre for Primary Immunodeficiency, the Jeffrey Modell Foundation, and Immunodeficiency Canada. The Centre for Applied Genomics at SickKids was supported by Genome Canada through the Ontario Genomics Institute, Canada Foundation for Innovation, and the Ontario Ministry of Research and Innovation.	Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; Cao D, 2015, J BIOL CHEM, V290, P23766, DOI 10.1074/jbc.M115.673517; Carpenter EL, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-93; Chakraborti S, 2016, CYTOSKELETON, V73, P521, DOI 10.1002/cm.21290; Chang W, 2001, J CELL SCI, V114, P2879; Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; Conley ME, 2012, J EXP MED, V209, P463, DOI 10.1084/jem.20112533; Crank MC, 2014, J CLIN IMMUNOL, V34, P272, DOI 10.1007/s10875-014-0012-9; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; Dunsch AK, 2011, J CELL BIOL, V192, P959, DOI 10.1083/jcb.201008023; Elkaim E, 2016, J ALLERGY CLIN IMMUN, V138, P210, DOI 10.1016/j.jaci.2016.03.022; Fang L, 2009, CELL CYCLE, V8, P2819, DOI 10.4161/cc.8.17.9514; Filbert EL, 2012, J IMMUNOL, V188, P5421, DOI 10.4049/jimmunol.1200242; Holmfeldt P, 2002, CURR BIOL, V12, P1034, DOI 10.1016/S0960-9822(02)00897-7; Huang YJ, 2012, J BIOL CHEM, V287, P1500, DOI 10.1074/jbc.M111.277194; Huggins J, 2007, BLOOD, V109, P1611, DOI 10.1182/blood-2006-03-008441; Illenberger S, 1996, J BIOL CHEM, V271, P10834, DOI 10.1074/jbc.271.18.10834; Domaica CI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051677; Janke C, 2011, NAT REV MOL CELL BIO, V12, P773, DOI 10.1038/nrm3227; Jin R, 2008, INT J MOL MED, V21, P233; Jou ST, 2002, MOL CELL BIOL, V22, P8580, DOI 10.1128/MCB.22.24.8580-8591.2002; Jourdan M, 2009, BLOOD, V114, P5173, DOI 10.1182/blood-2009-07-235960; Khan WN, 2009, J IMMUNOL, V183, P3561, DOI 10.4049/jimmunol.0800933; Kreuzaler M, 2012, J IMMUNOL, V188, P497, DOI 10.4049/jimmunol.1102321; Lee CS, 2014, NAT GENET, V46, P1060, DOI 10.1038/ng.3091; Lopez MP, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5778; Lu S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092712; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; Matsushima K, 2012, J BIOCHEM, V151, P99, DOI 10.1093/jb/mvr119; McKenney RJ, 2016, EMBO J, V35, P1175, DOI 10.15252/embj.201593071; Okkenhaug K, 2002, SCIENCE, V297, P1031; Okkenhaug K, 2006, J IMMUNOL, V177, P5122, DOI 10.4049/jimmunol.177.8.5122; Okkenhaug K, 2013, ANN NY ACAD SCI, V1280, P24, DOI 10.1111/nyas.12027; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; Perdiz D, 2011, CELL SIGNAL, V23, P763, DOI 10.1016/j.cellsig.2010.10.014; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Poli A, 2009, IMMUNOLOGY, V126, P458, DOI 10.1111/j.1365-2567.2008.03027.x; Reed NA, 2006, CURR BIOL, V16, P2166, DOI 10.1016/j.cub.2006.09.014; Roifman CM, 2009, CLIN GENET, V76, P449, DOI 10.1111/j.1399-0004.2009.01239.x; Roifman CM, 2012, J ALLERGY CLIN IMMUN, V130, P177, DOI 10.1016/j.jaci.2012.04.029; Sasaki T, 2002, J BIOCHEM, V131, P495, DOI 10.1093/oxfordjournals.jbchem.a003126; Saudemont A, 2009, P NATL ACAD SCI USA, V106, P5795, DOI 10.1073/pnas.0808594106; Schmidt JC, 2010, J CELL BIOL, V191, P269, DOI 10.1083/jcb.201006129; Senis YA, 2005, PLATELETS, V16, P191, DOI 10.1080/09537100400016711; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P1092, DOI 10.1016/j.jaci.2013.09.044; Sirajuddin M, 2014, NAT CELL BIOL, V16, P335, DOI 10.1038/ncb2920; Song YY, 2015, TRENDS CELL BIOL, V25, P125, DOI 10.1016/j.tcb.2014.10.004; Vanhaesebroeck B, 2005, TRENDS BIOCHEM SCI, V30, P194, DOI 10.1016/j.tibs.2005.02.008; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang XW, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.406652; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Xiao H, 2012, ACS CHEM BIOL, V7, P744, DOI 10.1021/cb200403x; Zahnleiter D, 2015, HUM MUTAT, V36, P87, DOI 10.1002/humu.22711; Zhang KJ, 2013, J CLIN IMMUNOL, V33, P673	57	19	19	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					618	629		10.1016/j.jaci.2017.10.033	http://dx.doi.org/10.1016/j.jaci.2017.10.033			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29180244	Bronze			2022-12-18	WOS:000440664400028
J	Le Coz, C; Trofa, M; Syrett, CM; Martin, A; Jyonouchi, H; Jyonouchi, S; Anguera, MC; Romberg, N				Le Coz, Carole; Trofa, Melissa; Syrett, Camille M.; Martin, Anna; Jyonouchi, Harumi; Jyonouchi, Soma; Anguera, Montserrat C.; Romberg, Neil			CD40LG duplication-associated autoimmune disease is silenced by nonrandom X-chromosome inactivation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DIAGNOSED ASTHMA; IMMIGRATION; RESIDENCE; SELECTION; CHILDREN; SAMPLE		[Le Coz, Carole; Trofa, Melissa; Jyonouchi, Soma; Romberg, Neil] Childrens Hosp Philadelphia, Div Immunol & Allergy, Philadelphia, PA 19104 USA; [Syrett, Camille M.; Martin, Anna; Anguera, Montserrat C.] Univ Penn, Perelman Sch Med, Sch Vet Med, Dept Biomed Sci, Philadelphia, PA 19104 USA; [Jyonouchi, Harumi] St Peters Univ Hosp, Childrens Hosp, Dept Pediat, Pediat Allergy Immunol, New Brunswick, NJ USA; [Jyonouchi, Soma; Romberg, Neil] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Saint Peter's University Hospital; University of Pennsylvania; Pennsylvania Medicine	Romberg, N (corresponding author), Childrens Hosp Philadelphia, Div Immunol & Allergy, Philadelphia, PA 19104 USA.; Romberg, N (corresponding author), Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA.	rombergn@email.chop.edu		Romberg, Neil/0000-0002-1881-5318; Le Coz, Carole/0000-0002-9228-5896	National Institutes of Health-National Institute of Allergy and Infectious Diseases [K23 AI115001, AI124084, T32-HD083185]; National Institutes of Health-Eunice Kennedy Shriver National Institute of Child Health and Human Development [T32-HD083185, HD085848]; Jeffrey Modell Foundation; Howard Hughes Medical Institute/ Burroughs Wellcome Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD083185, K12HD085848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI124084, K23AI115001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM123604] Funding Source: NIH RePORTER	National Institutes of Health-National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health-Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Jeffrey Modell Foundation; Howard Hughes Medical Institute/ Burroughs Wellcome Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the National Institutes of Health-National Institute of Allergy and Infectious Diseases (grant no. K23 AI115001 to N.R., grant no. AI124084 to M.C.A, and grant no. T32-HD083185 to C.M.S.), the National Institutes of Health-Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant no. HD085848 to M.C.A and grant no. T32-HD083185 to C.M.S.), the Jeffrey Modell Foundation (to N.R.), and the Howard Hughes Medical Institute/ Burroughs Wellcome Fund (to A.M.).	[Anonymous], 2001, ILL HIGHW INF SYST R; [Anonymous], 2006, PRIMARY IMMUNODEFICI, P776; Balaton BP, 2015, BIOL SEX DIFFER, V6, DOI 10.1186/s13293-015-0053-7; Bird CE, 2010, J EPIDEMIOL COMMUN H, V64, P860, DOI 10.1136/jech.2008.084814; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; CDC National Center for Health Statistics, 2001, NAT HLTH NUTR EX SUR; Cesaroni G, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-41; Chang J, 2009, OCCUP ENVIRON MED, V66, P90, DOI 10.1136/oem.2008.039412; Clegg CH, 1997, INT IMMUNOL, V9, P1111, DOI 10.1093/intimm/9.8.1111; Cook AG, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-52; Dhir V, 2009, LUPUS, V18, P785, DOI 10.1177/0961203309103152; Eldeirawi K, 2009, J ASTHMA, V46, P796, DOI 10.3109/02770900903114572; Eldeirawi KM, 2007, ANN ALLERG ASTHMA IM, V99, P236, DOI 10.1016/S1081-1206(10)60659-X; FULEIHAN R, 1994, J CLIN INVEST, V93, P1315, DOI 10.1172/JCI117089; International Study of Asthma and Allergy in Children (ISAAC), 2000, PHAS 3 MAN; Lu Q, 2007, J IMMUNOL, V179, P6352, DOI 10.4049/jimmunol.179.9.6352; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Ryan PH, 2005, J ALLERGY CLIN IMMUN, V116, P279, DOI 10.1016/j.jaci.2005.05.014; Wang JL, 2016, P NATL ACAD SCI USA, V113, pE2029, DOI 10.1073/pnas.1520113113; Zhou Y, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-89	23	19	19	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2308	2311		10.1016/j.jaci.2018.02.010	http://dx.doi.org/10.1016/j.jaci.2018.02.010			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29499223	Green Accepted, Bronze			2022-12-18	WOS:000434701600045
J	O'Konek, JJ; Landers, JJ; Janczak, KW; Goel, RR; Mondrusov, AM; Wong, PT; Baker, JR				O'Konek, Jessica J.; Landers, Jeffrey J.; Janczak, Katarzyna W.; Goel, Rishi R.; Mondrusov, Anna M.; Wong, Pamela T.; Baker, James R., Jr.			Nanoemulsion adjuvant-driven redirection of T(H)2 immunity inhibits allergic reactions in murine models of peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; peanut allergy; nanoemulsion; adjuvant; intranasal immunization; allergen immunotherapy; allergic disease	REGULATORY T-CELLS; ORAL IMMUNOTHERAPY; INDUCED ANAPHYLAXIS; FOOD ALLERGY; SIGNAL TRANSDUCER; CELLULAR-IMMUNITY; STAT3 MUTATIONS; MAST-CELLS; IGE; RESPONSES	Background: Immunotherapy for food allergies involves progressive increased exposures to food that result in desensitization to food allergens in some subjects but not tolerance to the food. Therefore new approaches to suppress allergic immunity to food are necessary. Previously, we demonstrated that intranasal immunization with a nanoemulsion (NE) adjuvant induces robust mucosal antibody and T(H)17-polarized immunity, as well as systemic T(H)1-biased cellular immunity with suppression of pre-existing T(H)2-biased immunity. Objective: We hypothesized that immunization with food in conjunction with the nanoemulsion adjuvant could lead to modulation of allergic reactions in food allergy by altering preexisting allergic immunity and enhancing mucosal immunity. Methods: Mice were sensitized to peanut with aluminum hydroxide or cholera toxin. The animals were then administered 3 monthly intranasal immunizations with peanut in the nanoemulsion adjuvant or saline. Mice were then challenged with peanut to examine allergen reactivity. Results: The NE intranasal immunizations resulted in marked decreases in T(H)2 cytokine, IgG1, and IgE levels, whereas T(H)1 and mucosal T(H)17 immune responses were increased. After allergen challenge, these mice showed significant reductions in allergic hypersensitivity. Additionally, the NE immunizations significantly increased antigen-specific IL-10 production and regulatory T-cell counts, and the protection induced by NE was dependent in part on IL-10. Control animals immunized with intranasal peanut in saline had no modulation of their allergic response. Conclusions: NE adjuvant-mediated induction of mucosal T(H)17 and systemic T(H)1-biased immunity can suppress T(H)2-mediated allergy through multiple mechanisms and protect against anaphylaxis. These results suggest the potential therapeutic utility of this approach in the setting of food allergy.	[O'Konek, Jessica J.; Landers, Jeffrey J.; Janczak, Katarzyna W.; Goel, Rishi R.; Mondrusov, Anna M.; Wong, Pamela T.; Baker, James R., Jr.] Univ Michigan, Mary H Weiser Food Allergy Ctr, 9220 Med Sci Res Bldg 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Baker, JR (corresponding author), Univ Michigan, Mary H Weiser Food Allergy Ctr, 9220 Med Sci Res Bldg 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.; O'Konek, JJ (corresponding author), Univ Michigan, Mary H Weiser Food Allergy Ctr, 4341 Biomed Sci Res Bldg,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	jjoz@umich.edu; jbakerjr@umich.edu		Goel, Rishi/0000-0003-1715-5191	United States Department of Defense Award [W81XWH-14-PRMRP-DA]; Food Allergy Research&Education New Investigator Award	United States Department of Defense Award(United States Department of Defense); Food Allergy Research&Education New Investigator Award	This project has been funded by United States Department of Defense Award W81XWH-14-PRMRP-DA, a Food Allergy Research&Education New Investigator Award, and a generous gift from the Shaevsky family.	Ahrens R, 2012, AM J PATHOL, V180, P1535, DOI 10.1016/j.ajpath.2011.12.036; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Al Khatib S, 2009, J ALLERGY CLIN IMMUN, V124, P342, DOI 10.1016/j.jaci.2009.05.004; Baldwin SL, 2009, VACCINE, V27, P5956, DOI 10.1016/j.vaccine.2009.07.081; Bauer RN, 2015, J ALLERGY CLIN IMMUN, V135, P312, DOI 10.1016/j.jaci.2014.12.1908; Berin MC, 2013, MUCOSAL IMMUNOL, V6, P114, DOI 10.1038/mi.2012.55; Bielinska AU, 2016, VACCINE, V34, P4017, DOI 10.1016/j.vaccine.2016.06.043; Bielinska AU, 2014, J IMMUNOL, V192, P2722, DOI 10.4049/jimmunol.1301424; Bielinska AU, 2010, CRIT REV IMMUNOL, V30, P189, DOI 10.1615/CritRevImmunol.v30.i2.60; Brewer JM, 1999, J IMMUNOL, V163, P6448; Broide DH, 2009, ANNU REV MED, V60, P279, DOI 10.1146/annurev.med.60.041807.123524; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Casale TB, 2008, J ALLERGY CLIN IMMUN, V121, P288, DOI 10.1016/j.jaci.2007.11.040; Cauwelaert ND, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146372; Dioszeghy V, 2017, CELL MOL IMMUNOL, V14, P770, DOI 10.1038/cmi.2016.14; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gould HJ, 2015, TRENDS IMMUNOL, V36, P40, DOI 10.1016/j.it.2014.11.002; Gupta R, 2013, JAMA PEDIATR, V167, P1026, DOI 10.1001/jamapediatrics.2013.2376; Hikida M, 1996, J IMMUNOL, V156, P2730; Hinz D, 2016, CLIN EXP ALLERGY, V46, P705, DOI 10.1111/cea.12692; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Jin W, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.58; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Keles S, 2016, J ALLERGY CLIN IMMUN, V138, P1384, DOI 10.1016/j.jaci.2016.04.023; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Lajoie S, 2014, CLIN EXP ALLERGY, V44, P976, DOI 10.1111/cea.12341; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Lindell DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021823; Makidon PE, 2010, MED MICROBIOL IMMUN, V199, P81, DOI 10.1007/s00430-009-0137-2; Makidon PE, 2012, EUR J IMMUNOL, V42, P2073, DOI 10.1002/eji.201142346; Makidon PE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002954; Mantis NJ, 2011, MUCOSAL IMMUNOL, V4, P603, DOI 10.1038/mi.2011.41; Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510; McAleer JP, 2010, TRENDS IMMUNOL, V31, P429, DOI 10.1016/j.it.2010.08.005; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Mondoulet L, 2011, INT ARCH ALLERGY IMM, V154, P299, DOI 10.1159/000321822; Mukherjee S, 2011, AM J PATHOL, V179, P248, DOI 10.1016/j.ajpath.2011.03.003; Myc A, 2003, VACCINE, V21, P3801, DOI 10.1016/S0264-410X(03)00381-5; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, P1275, DOI 10.1016/j.jaci.2014.11.005; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135; Nasser R, 2013, BLOOD, V121, P1102, DOI 10.1182/blood-2012-06-432153; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Newcomb DC, 2013, CURR OPIN IMMUNOL, V25, P755, DOI 10.1016/j.coi.2013.08.002; Newcomb DC, 2012, J IMMUNOL, V188, P1027, DOI 10.4049/jimmunol.1102216; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Palomares O, 2014, GENES IMMUN, V15, P511, DOI 10.1038/gene.2014.45; Pichavant Muriel, 2007, Curr Protoc Immunol, VChapter 15, DOI 10.1002/0471142735.im1518s79; Platts-Mills TAE, 2015, J ALLERGY CLIN IMMUN, V136, P3, DOI 10.1016/j.jaci.2015.03.048; Polukort SH, 2016, J IMMUNOL, V196, P4865, DOI 10.4049/jimmunol.1600066; Qin LZ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00510; Reber LL, 2013, J ALLERGY CLIN IMMUN, V132, P881, DOI 10.1016/j.jaci.2013.06.008; Renner ED, 2008, J ALLERGY CLIN IMMUN, V122, P181, DOI 10.1016/j.jaci.2008.04.037; Rimaniol AC, 2004, VACCINE, V22, P3127, DOI 10.1016/j.vaccine.2004.01.061; Robinson MK, 1996, FUND APPL TOXICOL, V34, P15, DOI 10.1006/faat.1996.0171; Rodriguez B, 2012, FEMS MICROBIOL ECOL, V79, P192, DOI 10.1111/j.1574-6941.2011.01207.x; Ryan JF, 2016, P NATL ACAD SCI USA, V113, pE1286, DOI 10.1073/pnas.1520180113; Schimke LF, 2010, J ALLERGY CLIN IMMUN, V126, P611, DOI 10.1016/j.jaci.2010.06.029; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Schulten V, 2016, CLIN EXP ALLERGY, V46, P439, DOI 10.1111/cea.12653; Schulten V, 2014, J ALLERGY CLIN IMMUN, V134, P1076, DOI 10.1016/j.jaci.2014.05.033; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Smit JJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028917; Srivastava KD, 2016, J ALLERGY CLIN IMMUN, V138, P536, DOI 10.1016/j.jaci.2016.01.047; Stanberry LR, 2012, VACCINE, V30, P307, DOI 10.1016/j.vaccine.2011.10.094; Taube C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021799; Vickery BP, 2017, J ALLERGY CLIN IMMUN, V139, P173, DOI 10.1016/j.jaci.2016.05.027; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Walley ER, 1996, INFECT IMMUN, V64, P4733, DOI 10.1128/IAI.64.11.4733-4738.1996; Yang BH, 2016, MUCOSAL IMMUNOL, V9, P444, DOI 10.1038/mi.2015.74	72	19	23	3	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2121	2131		10.1016/j.jaci.2018.01.042	http://dx.doi.org/10.1016/j.jaci.2018.01.042			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29655584				2022-12-18	WOS:000434701600018
J	Hong, HY; Chen, FH; Sun, YQ; Yang, QT; Gao, WX; Cao, YJ; Fan, YP; Shi, JB; Li, HB				Hong, Haiyu; Chen, Fenghong; Sun, Yueqi; Yang, Qintai; Gao, Wenxiang; Cao, Yujie; Fan, Yunping; Shi, Jianbo; Li, Huabin			Nasal IL-25 predicts the response to oral corticosteroids in chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INTERLEUKIN-25		[Hong, Haiyu; Chen, Fenghong; Sun, Yueqi; Gao, Wenxiang; Cao, Yujie; Shi, Jianbo] Sun Yat Sen Univ, Allergy Ctr, Otorhinolaryngol Hosp, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Hong, Haiyu; Fan, Yunping] Sun Yat Sen Univ, Dept Otolaryngol, Affiliated Hosp 5, Zhuhai, Peoples R China; [Yang, Qintai] Sun Yat Sen Univ, Dept Otolaryngol, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China; [Li, Huabin] Fudan Univ, Dept Otolaryngol Head & Neck Surg, Affiliated Eye Ear Nose & Throat Hosp, Shanghai, Peoples R China; [Li, Huabin] Guangzhou Med Univ, Dept Otolaryngol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Fudan University; Guangzhou Medical University	Fan, YP (corresponding author), Sun Yat Sen Univ, Dept Otolaryngol, Affiliated Hosp 5, Zhuhai, Peoples R China.	zhfyp8835@163.com; tsjbent@163.com; allergyli@163.com	Yang, Qin-tai/AAC-4696-2019; Sun, Yueqi/N-4528-2018	Sun, Yueqi/0000-0002-2382-0429	National Natural Science Foundation of China [81470673, 81470675, 81500768, 81770975, 81725004]; Natural Science Foundation of Guangdong Province, China [2014A030313101, 2014A030310392]; Science and Technology Project of Guangdong Province [2016A020215030, 2016A020215049, 2017A020215180]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); Science and Technology Project of Guangdong Province	This study was supported by the National Natural Science Foundation of China (grant nos. 81470673, 81470675, 81500768, 81770975, and 81725004), the Natural Science Foundation of Guangdong Province, China (grant nos. 2014A030313101 and 2014A030310392), and the Science and Technology Project of Guangdong Province (grant nos. 2016A020215030, 2016A020215049, and 2017A020215180).	Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Cheng D, 2014, AM J RESP CRIT CARE, V190, P639, DOI 10.1164/rccm.201403-0505OC; Deng Jie, 2012, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V47, P1027; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Hissaria P, 2006, J ALLERGY CLIN IMMUN, V118, P128, DOI 10.1016/j.jaci.2006.03.012; Milara J, 2017, J ALLERGY CLIN IMMUN, V139, P855, DOI 10.1016/j.jaci.2016.06.064; Sullivan PW, 2018, J ALLERGY CLIN IMMUN, V141, P110, DOI 10.1016/j.jaci.2017.04.009; Tuncer U, 2003, AURIS NASUS LARYNX, V30, P263, DOI 10.1016/S0385-8146(03)00051-8; Wen WP, 2012, J ALLERGY CLIN IMMUN, V129, P1522, DOI 10.1016/j.jaci.2012.01.079	9	19	19	3	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1890	+		10.1016/j.jaci.2017.10.050	http://dx.doi.org/10.1016/j.jaci.2017.10.050			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29337030	Bronze			2022-12-18	WOS:000432148200034
J	Traidl, S; Kienlin, P; Begemann, G; Jing, LC; Koelle, DM; Werfel, T; Roesner, LM				Traidl, Stephan; Kienlin, Petra; Begemann, Gabriele; Jing, Lichen; Koelle, David M.; Werfel, Thomas; Roesner, Lennart M.			Patients with atopic dermatitis and history of eczema herpeticum elicit herpes simplex virus-specific type 2 immune responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CELLS; RISK; INFECTIONS		[Traidl, Stephan; Kienlin, Petra; Begemann, Gabriele; Werfel, Thomas; Roesner, Lennart M.] Hannover Med Sch, Div Immunodermatol & Allergy Res, Dept Dermatol & Allergy, Hannover, Germany; [Jing, Lichen] Univ Washington, Dept Med, Seattle, WA USA; [Koelle, David M.] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Med, Seattle, WA 98195 USA; [Koelle, David M.] Benaroya Res Inst, Seattle, WA USA	Hannover Medical School; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Benaroya Research Institute	Roesner, LM (corresponding author), Hannover Med Sch, Div Immunodermatol & Allergy Res, Dept Dermatol & Allergy, Hannover, Germany.	roesner.lennart@mh-hannover.de	Roesner, Lennart/K-1074-2019; Werfel, Thomas/B-6921-2012	Roesner, Lennart/0000-0001-6651-0458; Traidl, Stephan/0000-0003-4806-599X	NIAID NIH HHS [HHSH266200400006C, P01 AI030731, R01 AI094019] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI094019, P01AI030731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Bin LH, 2014, J ALLERGY CLIN IMMUN, V134, P848, DOI 10.1016/j.jaci.2014.07.018; Brunner PM, 2017, J INVEST DERMATOL, V137, P18, DOI 10.1016/j.jid.2016.08.022; Cosmi L, 2000, EUR J IMMUNOL, V30, P2972, DOI 10.1002/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V128, P242, DOI 10.1016/j.jaci.2011.02.014; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Ge XH, 2010, J VIROL, V84, P3312, DOI 10.1128/JVI.02226-09; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Kondo T, 2009, J IMMUNOL, V182, P1794, DOI 10.4049/jimmunol.0801347; Laing KJ, 2010, J CLIN IMMUNOL, V30, P703, DOI 10.1007/s10875-010-9441-2; Mahnke YD, 2013, CYTOM PART A, V83A, P439, DOI 10.1002/cyto.a.22269; Mathias RA, 2013, BRIT J DERMATOL, V169, P700, DOI 10.1111/bjd.12382; Morgan TK, 2015, J LOW GENIT TRACT DI, V19, P345, DOI 10.1097/LGT.0000000000000147; Olsen JR, 2016, BRIT J GEN PRACT, V66, pE53, DOI 10.3399/bjgp15X688093; Oran AE, 2004, J VIROL, V78, P4376, DOI 10.1128/JVI.78.8.4376-4380.2004; Roesner LM, 2015, J INVEST DERMATOL, V135, P2324, DOI 10.1038/jid.2015.162; Silverberg JI, 2014, J ALLERGY CLIN IMMUN, V133, P1041, DOI 10.1016/j.jaci.2013.08.012; van Velzen M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003547; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Wolfl M, 2008, CYTOM PART A, V73A, P1043, DOI 10.1002/cyto.a.20594; Wollenberg A, 2003, J ALLERGY CLIN IMMUN, V112, P667, DOI 10.1016/j.jaci.2003.07.001; Wollenberg A, 2012, CHEM IMMUNOL ALLERGY, V96, P89, DOI 10.1159/000331892; Zhang X, 2008, CLIN VACCINE IMMUNOL, V15, P1436, DOI 10.1128/CVI.00123-08	23	19	20	2	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					1144	+		10.1016/j.jaci.2017.09.048	http://dx.doi.org/10.1016/j.jaci.2017.09.048			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29155096	Bronze, Green Accepted			2022-12-18	WOS:000426974800042
J	Abuabara, K; Hoffstad, O; Troxel, AB; Gelfand, JM; McCulloch, CE; Margolis, DJ				Abuabara, Katrina; Hoffstad, Ole; Troxel, Andrea B.; Gelfand, Joel M.; McCulloch, Charles E.; Margolis, David J.			Patterns and predictors of atopic dermatitis disease control past childhood: An observational cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ASTHMA; BIRTH		[Abuabara, Katrina] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [McCulloch, Charles E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Hoffstad, Ole; Gelfand, Joel M.; Margolis, David J.] Univ Penn, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA; [Gelfand, Joel M.; Margolis, David J.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA; [Troxel, Andrea B.] NYU, Div Biostat, New York, NY USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Pennsylvania; University of Pennsylvania; New York University	Abuabara, K (corresponding author), Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.	Katrina.abuabara@ucsf.edu		Gelfand, Joel/0000-0003-3480-2661	National Institutes of Health National Center for Advancing Translational Sciences (UCSF-CTSI Grant) [KL2 TR000143]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [RO1 AR056755, K24 AR064310]; Valeant Pharmaceuticals International; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K24AR064310] Funding Source: NIH RePORTER	National Institutes of Health National Center for Advancing Translational Sciences (UCSF-CTSI Grant); National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Valeant Pharmaceuticals International; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the National Institutes of Health National Center for Advancing Translational Sciences (UCSF-CTSI Grant Number KL2 TR000143) and by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (RO1 AR056755 and K24 AR064310). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The PEER study was funded by Valeant Pharmaceuticals International through a grant to the Trustees of the University of Pennsylvania and D.J.M. Valeant had no role in the design and conduct of the study; collection, management, analysis and interpretation of data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.	Apfelbacher CJ, 2011, ALLERGY, V66, P206, DOI 10.1111/j.1398-9995.2010.02464.x; Ballardini N, 2013, BRIT J DERMATOL, V168, P588, DOI 10.1111/bjd.12196; Garmhausen D, 2013, ALLERGY, V68, P498, DOI 10.1111/all.12112; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Margolis JS, 2014, JAMA DERMATOL, V150, P593, DOI 10.1001/jamadermatol.2013.10271; Uphoff E, 2015, EUR RESPIR J, V46, P364, DOI 10.1183/09031936.00114514; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X	7	19	19	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					778	780		10.1016/j.jaci.2017.05.031	http://dx.doi.org/10.1016/j.jaci.2017.05.031			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28629748	Bronze, Green Accepted			2022-12-18	WOS:000424410800036
J	Ballmer-Weber, BK; Beyer, K				Ballmer-Weber, Barbara K.; Beyer, Kirsten			Food challenges	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; challenges; milk; egg; wheat; soy	DOUBLE-BLIND; ALLERGY; PLACEBO; THRESHOLDS		[Ballmer-Weber, Barbara K.] Univ Hosp, Dept Dermatol, Allergy Unit, Zurich, Switzerland; [Ballmer-Weber, Barbara K.] Luzerner Kantonsspital, Ctr Dermatol & Allergol, Luzern, Switzerland; [Beyer, Kirsten] Charite, Dept Paediat Pneumol & Immunol, Univ Med Ctr, Berlin, Germany	University of Zurich; University Zurich Hospital; Lucerne Cantonal Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Ballmer-Weber, BK (corresponding author), Luzerner Kantonsspital Luzern, Chefarztin Allergol, Zentrum Dermatol & Allergol, CH-6016 Luzern, Switzerland.	barbara.ballmer@luks.ch			Thermo Fisher Scientific; Novartis; Aimmune; DBV; Danone; Nestle; Med Update; Meda	Thermo Fisher Scientific; Novartis(Novartis); Aimmune; DBV; Danone(Danone Nutricia); Nestle(Nestle SA); Med Update; Meda	B. K. Ballmer-Weber serves as a consultant for Thermo Fisher Scientific and Novartis and receives payment for lectures from Thermo Fisher Scientific and Novartis. K. Beyer serves as a consultant for Hycor, Aimmune, Danone, Nestle, Meda, and Bausch & Lomb; receives grant support from Aimmune, DBV, and Danone; and receives payment for lectures from Aimmune, Nestle, Med Update, and Meda.	Ahrens B, 2014, CLIN EXP ALLERGY, V44, P572, DOI 10.1111/cea.12284; Ballmer-Weber BK, 2007, J ALLERGY CLIN IMMUN, V119, P1489, DOI 10.1016/j.jaci.2007.01.049; Ballmer-Weber BK, 2015, J ALLERGY CLIN IMMUN, V135, P964, DOI 10.1016/j.jaci.2014.10.047; Blumchen K, 2014, J ALLERGY CLIN IMMUN, V134, P390, DOI 10.1016/j.jaci.2014.03.035; Grabenhenrich LB, 2017, ALLERGY, V72, P453, DOI 10.1111/all.13049; Mackie A, 2012, MOL NUTR FOOD RES, V56, P1708, DOI 10.1002/mnfr.201200330; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017	8	19	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					69	+		10.1016/j.jaci.2017.06.038	http://dx.doi.org/10.1016/j.jaci.2017.06.038			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28757143	Bronze			2022-12-18	WOS:000419312200007
J	El-Gamal, YM; Hossny, EM; El-Sayed, ZA; Reda, SM				El-Gamal, Yehia M.; Hossny, Elham M.; El-Sayed, Zeinab A.; Reda, Shereen M.			Allergy and immunology in Africa: Challenges and unmet needs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Africa; allergy; asthma; aeroallergens; food allergy; immunology; primary immunodeficiency; HIV	PRIMARY IMMUNODEFICIENCIES; EGYPTIAN CHILDREN; NORTH-AFRICA; ASTHMA; SENSITIZATION; EXPERIENCE; DISEASES; ATOPY; ORGANIZATION; SENSITIVITY	The tremendous increase in allergy in the African continent cannot simply be explained by the change in public hygiene. There are many "prehygiene'' communities with sewagecontaminated water supplies, helminth infestations, bare footedness, and poor housing, and still there is a high prevalence of allergic disease. Africans can be exposed to many risk factors facilitating severe asthma and wheezing, including airborne viruses, smoke, indoor dampness, cockroaches, and poor access to health care. Although the reporting on food allergy is inadequate to perform systematic reviews or meta-analyses, the available data suggest that food allergy is underdiagnosed. The rate of new HIV infections in high-prevalence settings in Africa remains unacceptably high. Although the annual number of new HIV infections in SubSaharan Africa has decreased lately, new HIV infections in the Middle East and North Africa region have increased; however, the current prevalence of 0.1% is still among the lowest globally. Africa is densely populated, and consanguineous mating is high in some areas of North and Sub-Saharan Africa. This allows for emergence of many autosomal recessive primary immunodeficiency diseases. There is urgent need for the establishment of primary immunodeficiency disease registries, stem cell transplantation facilities, and neonatal screening programs. To address these expanding problems and perform local cutting-edge research, Africans need to be empowered by motivated governments, dedicated funds, and compassionate scientific partnership.	[El-Gamal, Yehia M.; Hossny, Elham M.; El-Sayed, Zeinab A.; Reda, Shereen M.] Ain Shams Univ, Childrens Hosp, Pediat Allergy & Immunol Unit, 40A Baghdad St, Cairo 11341, Egypt	Egyptian Knowledge Bank (EKB); Ain Shams University	Hossny, EM (corresponding author), Ain Shams Univ, Childrens Hosp, Pediat Allergy & Immunol Unit, 40A Baghdad St, Cairo 11341, Egypt.	elham.hossny@gmail.com		El-Gamal, Yehia/0000-0002-8177-4520; Hossny, Elham/0000-0001-6876-6318				Addo-Yobo EOD, 2007, PLOS MED, V4, P355, DOI 10.1371/journal.pmed.0040070; Altraide D D, 2008, Niger J Med, V17, P417; Benzarti M, 2002, Tunis Med, V80, P450; Bittles AH, 2010, P NATL ACAD SCI USA, V107, P1779, DOI 10.1073/pnas.0906079106; Bousfiha AA, 2015, J CLIN IMMUNOL, V35, P329, DOI 10.1007/s10875-015-0162-4; Bousfiha AA, 2014, J CLIN IMMUNOL, V34, P459, DOI 10.1007/s10875-014-0005-8; Caraballo L, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0110-7; Cose S, 2015, TROP MED INT HEALTH, V20, P1771, DOI 10.1111/tmi.12599; D'Amato G, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0073-0; El-Ghoneimy D, 2013, J ALLERGY CLIN IMMUN, V131, pAB163, DOI 10.1016/j.jaci.2012.12.1244; El-Sayed ZA, 2014, PULM MED, V2014, DOI 10.1155/2014/629187; ElGamal Y, 1995, PEDIATR ALLERGY IMMU, V6, P220, DOI 10.1111/j.1399-3038.1995.tb00290.x; Galal N, 2016, J CLIN IMMUNOL, V36, P649, DOI 10.1007/s10875-016-0314-1; Georgy V, 2006, EUR RESPIR J, V28, P756, DOI 10.1183/09031936.06.00089005; Gokengin D, 2016, INT J INFECT DIS, V44, P66, DOI 10.1016/j.ijid.2015.11.008; Hossny E, 2014, PEDIAT ALLER IMM PUL, V27, P133, DOI 10.1089/ped.2014.0333; Hossny E, 2011, ALLERGY ASTHMA CL IM, V7, DOI 10.1186/1710-1492-7-11; Jeevarathnum A C, 2015, SAMJ, S. Afr. med. j., V105, P567, DOI [10.7196/SAMJNEW.7786, 10.7196/SAMJnew.7786]; Kung SJ, 2014, CLIN REV ALLERG IMMU, V46, P241, DOI 10.1007/s12016-012-8341-z; Mellouli F, 2015, J CLIN IMMUNOL, V35, P745, DOI 10.1007/s10875-015-0206-9; Mpairwe H, 2008, T ROY SOC TROP MED H, V102, P367, DOI 10.1016/j.trstmh.2008.01.017; Naamane H, 2010, EUR J PEDIATR, V169, P1069, DOI 10.1007/s00431-010-1179-6; Nafti S, 2009, RESP MED, V103, pS2, DOI 10.1016/S0954-6111(09)70022-8; Naidoo R, 2011, J CLIN IMMUNOL, V31, P99, DOI 10.1007/s10875-010-9465-7; Nampijja M, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0702-5; Ngahane BHM, 2016, ALLERGY ASTHMA CL IM, V12, DOI 10.1186/s13223-015-0107-8; Oluwole O, 2013, AFR HEALTH SCI, V13, P144, DOI 10.4314/ahs.v13i1.20; Oninla OA, 2016, PAEDIATR INT CHILD H, V36, P106, DOI 10.1179/2046905515Y.0000000012; Pefura-Yone EW, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-22; Pefura-Yone EW, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004062; Platts-Mills TAE, 2015, J ALLERGY CLIN IMMUN, V136, P3, DOI 10.1016/j.jaci.2015.03.048; Potter PC, 2010, J INVEST ALLERG CLIN, V20, P179; Reda SM, 2009, J CLIN IMMUNOL, V29, P343, DOI 10.1007/s10875-008-9260-x; Rujeni N, 2012, INT ARCH ALLERGY IMM, V158, P288, DOI 10.1159/000332949; Sanchez JJ, 2007, ANN HUM GENET, V71, P336, DOI 10.1111/j.1469-1809.2006.00338.x; Seedat RY, 2010, SAMJ S AFR MED J, V100, P160, DOI 10.7196/SAMJ.3669; Sunyer J, 2000, ALLERGY, V55, P762, DOI 10.1034/j.1398-9995.2000.00657.x; UNAIDS, 2016, UNAIDS PREV GAP REP; WAO, WORLD ALL ORG WORLD; Wollmann E, 2015, ALLERGY, V70, P638, DOI 10.1111/all.12592	40	19	19	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1240	1243		10.1016/j.jaci.2017.09.004	http://dx.doi.org/10.1016/j.jaci.2017.09.004			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28962920	Bronze			2022-12-18	WOS:000414304300003
J	Munoz, MA; Jurczyluk, J; Mehr, S; Chai, RC; Arts, RJW; Sheu, A; McMahon, C; Center, JR; Singh-Grewal, D; Chaitow, J; Campbell, DE; Quinn, JMW; Alexandrov, K; Tnimov, Z; Tangye, SG; Simon, A; Phan, TG; Rogers, MJ				Munoz, Marcia A.; Jurczyluk, Julie; Mehr, Sam; Chai, Ryan C.; Arts, Rob J. W.; Sheu, Angela; McMahon, Chelsea; Center, Jacqueline R.; Singh-Grewal, Davinder; Chaitow, Jeffrey; Campbell, Dianne E.; Quinn, Julian M. W.; Alexandrov, Kirill; Tnimov, Zakir; Tangye, Stuart G.; Simon, Anna; Phan, Tri Giang; Rogers, Michael J.			Defective protein prenylation is a diagnostic biomarker of mevalonate kinase deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Munoz, Marcia A.; Jurczyluk, Julie; Chai, Ryan C.; Sheu, Angela; McMahon, Chelsea; Center, Jacqueline R.; Quinn, Julian M. W.; Rogers, Michael J.] UNSW Sydney, Bone Biol Div, Garvan Inst Med Res, Sydney, NSW, Australia; [Munoz, Marcia A.; Jurczyluk, Julie; Chai, Ryan C.; Sheu, Angela; McMahon, Chelsea; Center, Jacqueline R.; Quinn, Julian M. W.; Tangye, Stuart G.; Phan, Tri Giang; Rogers, Michael J.] UNSW Sydney, St Vincents Clin Sch, Sydney, NSW, Australia; [Mehr, Sam; Campbell, Dianne E.] Childrens Hosp Westmead, Dept Immunol & Allergy, Sydney, NSW, Australia; [Arts, Rob J. W.; Simon, Anna] Radboud Univ Nijmegen, Med Ctr, Lab Expt Internal Med, Nijmegen, Netherlands; [Sheu, Angela; Center, Jacqueline R.] St Vincents Hosp, Dept Endocrinol, Sydney, NSW, Australia; [Singh-Grewal, Davinder; Chaitow, Jeffrey] Sydney Childrens Hosp Network Randwick & Westmead, Dept Rheumatol, Sydney, NSW, Australia; [Alexandrov, Kirill; Tnimov, Zakir] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia; [Tangye, Stuart G.; Phan, Tri Giang] UNSW Australia, Garvan Inst Med Res, Immunol Div, Sydney, NSW, Australia	Garvan Institute of Medical Research; University of New South Wales Sydney; University of New South Wales Sydney; University of Sydney; Radboud University Nijmegen; St Vincents Hospital Sydney; University of Queensland; Garvan Institute of Medical Research; University of New South Wales Sydney	Rogers, MJ (corresponding author), UNSW Sydney, Bone Biol Div, Garvan Inst Med Res, Sydney, NSW, Australia.; Rogers, MJ (corresponding author), UNSW Sydney, St Vincents Clin Sch, Sydney, NSW, Australia.	m.rogers@garvan.org.au	Tnimov, Zakir/L-3052-2019; Singh-Grewal, Davinder/AAP-3585-2020; Center, Jacqueline/AAY-8712-2021; Tangye, Stuart G/H-4023-2014; Arts, Rob JW/P-8678-2015; Simon, Anna/D-3757-2009; Alexandrov, Kirill/A-5830-2013	Tnimov, Zakir/0000-0003-2466-2220; Center, Jacqueline/0000-0002-5278-4527; Tangye, Stuart G/0000-0002-5360-5180; Arts, Rob JW/0000-0002-6649-7190; Simon, Anna/0000-0002-6141-7921; Mehr, Sam/0000-0003-2483-917X; Alexandrov, Kirill/0000-0002-0957-6511; Rogers, Michael/0000-0002-1818-9249; Campbell, Dianne/0000-0002-0907-6963; Munoz, Marcia/0000-0001-7603-0351; Sheu, Angela/0000-0002-2599-8503	National Health and Medical Research Council (NHMRC) [APP1079522]; Mrs Janice Gibson and the Ernest Heine Family Foundation; NHMRC [APP1037320]	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Mrs Janice Gibson and the Ernest Heine Family Foundation; NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	We gratefully acknowledge the patients and families involved in the study. This work was supported in part by the National Health and Medical Research Council (NHMRC) project grant APP1079522 to M.J.R. and T.G.P., and by Mrs Janice Gibson and the Ernest Heine Family Foundation. K.A. acknowledges support of NHMRC program grant APP1037320. The contents of this article are solely the responsibility of the authors and do not reflect the views of the NHMRC.	Akula MK, 2016, NAT IMMUNOL, V17, P922, DOI 10.1038/ni.3487; Ali Naveid, 2015, Small GTPases, V6, P202, DOI 10.1080/21541248.2015.1085485; Houten SM, 2002, HUM MOL GENET, V11, P3115, DOI 10.1093/hmg/11.25.3115; Jurczyluk J, 2016, IMMUNOL CELL BIOL, V94, P994, DOI 10.1038/icb.2016.58; Messer L, 2016, RMD OPEN, V2, DOI 10.1136/rmdopen-2015-000196; Palsuledesai CC, 2015, ACS CHEM BIOL, V10, P51, DOI 10.1021/cb500791f; Park YH, 2016, NAT IMMUNOL, V17, P914, DOI 10.1038/ni.3457; Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008; Simon A, 2004, NEUROLOGY, V62, P994, DOI 10.1212/01.WNL.0000115390.33405.F7	9	19	20	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					873	+		10.1016/j.jaci.2017.02.033	http://dx.doi.org/10.1016/j.jaci.2017.02.033			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28501347	Green Published, hybrid			2022-12-18	WOS:000409241500031
J	Nakamura, T; Fujiwara, Y; Yamada, R; Fujii, W; Hamabata, T; Lee, MY; Maeda, S; Aritake, K; Roers, A; Sessa, WC; Nakamura, M; Urade, Y; Murata, T				Nakamura, Tatsuro; Fujiwara, Yuki; Yamada, Ryota; Fujii, Wataru; Hamabata, Taiki; Lee, Monica Yunkyung; Maeda, Shingo; Aritake, Kosuke; Roers, Axel; Sessa, William C.; Nakamura, Masataka; Urade, Yoshihiro; Murata, Takahisa			Mast cell-derived prostaglandin D-2 attenuates anaphylactic reactions in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SHOCK DEPENDS; GENERATION; VIVO		[Nakamura, Tatsuro; Fujiwara, Yuki; Yamada, Ryota; Hamabata, Taiki; Maeda, Shingo; Murata, Takahisa] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Anim Radiol, Tokyo, Japan; [Fujii, Wataru] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Genet, Tokyo, Japan; [Lee, Monica Yunkyung; Sessa, William C.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; [Aritake, Kosuke; Urade, Yoshihiro] Univ Tsukuba, Int Inst Integrat Sleep Med, Ibaraki, Japan; [Roers, Axel] Tech Univ Dresden, Inst Immunol, Dresden, Germany; [Nakamura, Masataka] Tokyo Med & Dent Univ, Human Gene Sci Ctr, Tokyo, Japan	University of Tokyo; University of Tokyo; Yale University; University of Tsukuba; Technische Universitat Dresden; Tokyo Medical & Dental University (TMDU)	Murata, T (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Anim Radiol, Tokyo, Japan.	amurata@mail.ecc.u-tokyo.ac.jp	Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938; Murata, Takahisa/0000-0002-3328-0796; Fujii, Wataru/0000-0002-6438-7350	Japan Society for the Promotion of Science; Foundation for Dietary Scientific Research; Cardiovascular Research Fund; Kurozumi Medical Foundation; Naito Foundation; Suzuken Memorial Foundation; Takeda Science Foundation; Nipponham Foundation; Sapporo Bioscience Foundation; Japan Foundation for Pediatric Research	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Foundation for Dietary Scientific Research; Cardiovascular Research Fund; Kurozumi Medical Foundation(Kurozumi Medical Foundation); Naito Foundation(Naito Memorial Foundation); Suzuken Memorial Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); Nipponham Foundation; Sapporo Bioscience Foundation; Japan Foundation for Pediatric Research	Supported by a Grant-in-Aid from the Japan Society for the Promotion of Science, the Foundation for Dietary Scientific Research, the Cardiovascular Research Fund, the Kurozumi Medical Foundation, the Naito Foundation, the Suzuken Memorial Foundation, the Takeda Science Foundation, the Nipponham Foundation, the Sapporo Bioscience Foundation, and the Japan Foundation for Pediatric Research.	[Anonymous], 2015, J INVESTIG ALLERGOL; Cauwels A, 2006, J CLIN INVEST, V116, P2244, DOI 10.1172/JCI25426; FISHER MM, 1986, ANAESTH INTENS CARE, V14, P17, DOI 10.1177/0310057X8601400105; Fujii W, 2014, BIOCHEM BIOPH RES CO, V445, P791, DOI 10.1016/j.bbrc.2014.01.141; Fujitani Y, 2010, FEBS J, V277, P1410, DOI 10.1111/j.1742-4658.2010.07565.x; Kobayashi K, 2013, ARTERIOSCL THROM VAS, V33, P565, DOI 10.1161/ATVBAHA.112.300993; Korhonen H, 2009, J EXP MED, V206, P411, DOI 10.1084/jem.20082150; Lundstrom SL, 2013, J LIPID RES, V54, P116, DOI 10.1194/jlr.M030171; Makabe-Kobayashi Y, 2002, J ALLERGY CLIN IMMUN, V110, P298, DOI 10.1067/mai.2002.125977; Mohri I, 2006, J NEUROSCI, V26, P4383, DOI 10.1523/JNEUROSCI.4531-05.2006; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; Satoh T, 2006, J IMMUNOL, V177, P2621, DOI 10.4049/jimmunol.177.4.2621; Scholten J., 2009, THESIS; Scholten J, 2008, TRANSGENIC RES, V17, P307, DOI 10.1007/s11248-007-9153-4; Walch L, 1999, BRIT J PHARMACOL, V126, P859, DOI 10.1038/sj.bjp.0702393	15	19	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					630	+		10.1016/j.jaci.2017.02.030	http://dx.doi.org/10.1016/j.jaci.2017.02.030			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28457595	Bronze			2022-12-18	WOS:000406855500050
J	Calderon, MA; Bousquet, J; Canonica, GW; Cardell, LO; de Rojas, DHF; Kleine-Tebbe, J; Demoly, P				Calderon, Moises A.; Bousquet, Jean; Canonica, G. Walter; Cardell, Lars-Olaf; Fernandez de Rojas, Dolores Hernandez; Kleine-Tebbe, Joerg; Demoly, Pascal			Guideline recommendations on the use of allergen immunotherapy in house dust mite allergy: Time for a change?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						House dust mite; allergy; allergic asthma; allergic rhinitis; treatment guidelines	SUBLINGUAL IMMUNOTHERAPY; INTERNATIONAL CONSENSUS; ASTHMA; RHINITIS; EFFICACY; MANAGEMENT; ADULTS; TABLET; DIAGNOSIS; ENDOTYPES	Guidelines on the treatment of asthma, allergic rhinitis (AR), and allergen immunotherapy (AIT) lack recommendations for house dust mite (HDM) allergy. An expert panel reviewed current guidelines in the light of new data to assess whether guidelines could be improved. Most guidelines and key position papers did not provide specific recommendations on treatment of allergic asthma (AA) caused by HDM allergy, although some included AIT as a treatment option for AA in general. Around half of the guidelines stated that AIT with HDM extract was an effective treatment for AR, with several indicating sublingual immunotherapy as an option. This heterogeneity is caused by quality issues affecting studies of AIT with perennial allergens in patients with AA and AR, including use of different diagnosis and severity criteria, lack of consistent scoring or grading systems for primary and safety outcomes, and lack of consensus on treatment parameters. There is a need for well-designed clinical trials to serve as a basis for guideline recommendations. Although results from recent studies strengthen the evidence base for the efficacy and safety of sublingual immunotherapy in patients with HDM-induced AA and AR, their effect on subsequent guideline updates will depend on the methodology and evidence model used by each guideline.	[Calderon, Moises A.] Imperial Coll London, Sect Allergy & Clin Immunol, Royal Brompton Hosp, NHLI, London, England; [Bousquet, Jean] Hop Arnaud de Villeneuve, Univ Hosp, Dept Resp Dis, Montpellier, France; [Bousquet, Jean] CESP Ctr Res Epidemiol & Populat Hlth, France Inserm, U1018, Resp & Environm Epidemiol Team, Villejuif, France; [Canonica, G. Walter] Humanitas Univ Rozzano, Dept Biomed Sci, Humanitas Clin & Res Ctr, Personalized Med Clin Asthma & Allergy, Milan, Italy; [Canonica, G. Walter] Univ Genoa, DIMI Med Sch, Genoa, Italy; [Cardell, Lars-Olaf] Karolinska Inst, Div Ear Nose & Throat Dis, Dept Clin Sci Intervent & Technol, Stockholm, Sweden; [Fernandez de Rojas, Dolores Hernandez] IIS Hosp La Fe, Dept Allergy, Valencia, Spain; [Kleine-Tebbe, Joerg] Outpatient Clin Hanf Ackermann & Kleine Tebbe, Allergy & Asthma Ctr Westend, Berlin, Germany; [Demoly, Pascal] Univ Hosp Montpellier, Hop Arnaud de Villeneuve, Dept Pneumol & Addictol, Montpellier, France; [Demoly, Pascal] UPMC, Sorbonne Univ, Paris, France	Imperial College London; Royal Brompton Hospital; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Humanitas University; University of Genoa; Karolinska Institutet; Universite de Montpellier; CHU de Montpellier; UDICE-French Research Universities; Sorbonne Universite	Demoly, P (corresponding author), Univ Hosp Montpellier, Pneumol & Addictol, 371 Av Doyen G Giraud, F-34295 Montpellier 5, France.	pascal.demoly@inserm.fr	Bousquet, Jean/O-4221-2019; Demoly, Pascal/Y-9938-2019; canonica, giorgio walter/ABF-2037-2020	Demoly, Pascal/0000-0001-7827-7964; canonica, giorgio walter/0000-0001-8467-2557; hernandez, Dolores/0000-0001-8427-6845; Bousquet, Jean/0000-0002-4061-4766	ALK-Abello	ALK-Abello	Supported by ALK-Abello.	Bacharier LB, 2008, ALLERGY, V63, P5, DOI 10.1111/j.1398-9995.2007.01586.x; Bachert C, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0078-8; Backer V, 2014, ANN C EUR RESP SOC S; Barnes ML, 2010, CLIN EXP ALLERGY, V40, P242, DOI 10.1111/j.1365-2222.2009.03381.x; Bergmann KC, 2014, J ALLERGY CLIN IMMUN, V133, P1608, DOI 10.1016/j.jaci.2013.11.012; Bousquet PJ, 2011, J ALLERGY CLIN IMMUN, V127, P49, DOI 10.1016/j.jaci.2010.09.017; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Calderon MA, 2013, J ALLERGY CLIN IMMUN, V132, P1322, DOI 10.1016/j.jaci.2013.09.004; Canonica GW, 2007, ALLERGY, V62, P17, DOI 10.1111/j.1398-9995.2007.01549.x; Canonica GW, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-6; Committee for Medicinal Products for Human Use (CHMP), 2016, CHMPEWP292201REV101; Committee for Medicinal Products for Human Use (CHMP) and Efficacy Working Party (EWP), EMEACHMPEWP185042006; Compalati E, 2009, ALLERGY, V64, P1570, DOI 10.1111/j.1398-9995.2009.02129.x; Corren J, 2013, DISCOV MED, V15, P243; Costa DJ, 2011, J ALLERGY CLIN IMMUN, V127, P920, DOI 10.1016/j.jaci.2010.10.058; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Demoly P, 2016, J ALLERGY CLIN IMMUN, V137, P444, DOI 10.1016/j.jaci.2015.06.036; Eifan AO, 2013, EXPERT OPIN BIOL TH, V13, P1543, DOI 10.1517/14712598.2013.844226; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Homer CJ, 2004, PEDIATRICS, V114, P874, DOI 10.1542/peds.2004-1260; Jadad AR, 2000, BRIT MED J, V320, P537, DOI 10.1136/bmj.320.7234.537; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Li JT, 2005, J ALLERGY CLIN IMMUN, V116, pS3, DOI 10.1016/j.jaci.2005.08.017; Lin SY, 2013, AHRQ PUBLICATION; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Motala C, 2009, SAMJ S AFR MED J, V99, P898; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Nelson HS, 2014, CURR OPIN ALLERGY CL, V14, P542, DOI 10.1097/ACI.0000000000000104; Nicholson PJ, 2005, OCCUP ENVIRON MED, V62, P290, DOI 10.1136/oem.2004.016287; Nieto A, 2009, J ALLERGY CLIN IMMUN, V124, P157, DOI 10.1016/j.jaci.2009.04.015; Nolte H, 2016, J ALLERGY CLIN IMMUN, V138, P1631, DOI 10.1016/j.jaci.2016.06.044; Okubo K, 2016, J ALLERGY CLIN IMMUN; Papadopoulos NG, 2012, ALLERGY, V67, P976, DOI 10.1111/j.1398-9995.2012.02865.x; Partridge Martyn R, 2006, BMC Pulm Med, V6, P13, DOI 10.1186/1471-2466-6-13; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Pfaar O, 2014, ALLERGY, V69, P854, DOI 10.1111/all.12383; Pfaar O, 2014, ALLERGO J, V23, P28, DOI 10.1007/s15007-014-0707-5; Scadding GK, 2008, CLIN EXP ALLERGY, V38, P19, DOI 10.1111/j.1365-2222.2007.02888.x; Seidman MD, 2015, OTOLARYNG HEAD NECK, V152, pS1, DOI 10.1177/0194599814561600; Shekelle PG, 1999, BRIT MED J, V318, P593, DOI 10.1136/bmj.318.7183.593; Sveum R, I CLIN SYSTEMS IMPRO; Virchow JC, 2016, JAMA-J AM MED ASSOC, V315, P1715, DOI 10.1001/jama.2016.3964; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003; Zuberbier T, 2010, ALLERGY, V65, P1525, DOI 10.1111/j.1398-9995.2010.02474.x	44	19	21	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					41	52		10.1016/j.jaci.2017.01.049	http://dx.doi.org/10.1016/j.jaci.2017.01.049			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	28526624	Bronze			2022-12-18	WOS:000404542000004
J	Kloepfer, KM; Sarsani, VK; Poroyko, V; Lee, WM; Pappas, TE; Kang, T; Grindle, KA; Bochkov, YA; Janga, SC; Lemanske, RF; Gern, JE				Kloepfer, Kirsten M.; Sarsani, Vishal K.; Poroyko, Valeriy; Lee, Wai Ming; Pappas, Tressa E.; Kang, Theresa; Grindle, Kristine A.; Bochkov, Yury A.; Janga, Sarath Chandra; Lemanske, Robert F., Jr.; Gern, James E.			Community-acquired rhinovirus infection is associated with changes in the airway microbiome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SEVERITY		[Kloepfer, Kirsten M.] Indiana Univ, Sch Med, Dept Pediat, Bloomington, IN 47405 USA; [Sarsani, Vishal K.; Janga, Sarath Chandra] Indiana Univ Purdue Univ, Dept Biohlth Informat, Sch Informat & Comp, Indianapolis, IN 46202 USA; [Poroyko, Valeriy] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; [Lee, Wai Ming; Pappas, Tressa E.; Kang, Theresa; Grindle, Kristine A.; Bochkov, Yury A.; Lemanske, Robert F., Jr.; Gern, James E.] Univ Wisconsin, Dept Pediat, Madison, WI USA; [Lemanske, Robert F., Jr.; Gern, James E.] Univ Wisconsin, Dept Med, Madison, WI USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; University of Chicago; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kloepfer, KM (corresponding author), Indiana Univ, Sch Med, Dept Pediat, Bloomington, IN 47405 USA.	kloepfer@iu.edu	Sarsani, Vishal/AAF-9312-2020	Sarsani, Vishal/0000-0002-9272-3438; Janga, Sarath Chandra/0000-0001-7351-6268	Clinical and Translational Science Award program of the National Center for Research Resources, National Institutes of Health [1UL1RR025011];  [U19 AI070503-01];  [P01 HL070831];  [T32AI007635];  [1K12HD068371-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD068371] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI104317, U19AI070503, T32AI007635] Funding Source: NIH RePORTER	Clinical and Translational Science Award program of the National Center for Research Resources, National Institutes of Health; ; ; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the following grants: grant no. U19 AI070503-01 (Rhino-Gen); grant no. P01 HL070831 (Childhood Origins of Asthma); grant no. 1UL1RR025011 from the Clinical and Translational Science Award program of the National Center for Research Resources, National Institutes of Health; grant no. T32AI007635 (University of Wisconsin Allergy Research Training program); and grant no. 1K12HD068371-01A1 (Indiana University School of Medicine Indiana Pediatric Scientist Award program through the Child Health Research Career Development Award).	Bogaert D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017035; Cox DW, 2013, AM J RESP CRIT CARE, V188, P1358, DOI 10.1164/rccm.201303-0498OC; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Laufer AS, 2011, MBIO, V2, DOI 10.1128/mBio.00245-10; Lee WM, 2012, AM J RESP CRIT CARE, V186, P886, DOI 10.1164/rccm.201202-0330OC; Nakagome K, 2014, J ALLERGY CLIN IMMUN, V134, P332, DOI 10.1016/j.jaci.2014.01.029; Olenec JP, 2010, J ALLERGY CLIN IMMUN, V125, P1001, DOI 10.1016/j.jaci.2010.01.059; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008	8	19	20	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					312	+		10.1016/j.jaci.2017.01.038	http://dx.doi.org/10.1016/j.jaci.2017.01.038			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	28327377	Green Accepted, Bronze, Green Submitted			2022-12-18	WOS:000404542000043
J	Madouri, F; Chenuet, P; Beuraud, C; Fauconnier, L; Marchiol, T; Rouxel, N; Ledru, A; Gallerand, M; Lombardi, V; Mascarell, L; Marquant, Q; Apetoh, L; Erard, F; Le Bert, M; Trovero, F; Quesniaux, VFJ; Ryffel, B; Togbe, D				Madouri, Fahima; Chenuet, Pauline; Beuraud, Chloe; Fauconnier, Louis; Marchiol, Tiffany; Rouxel, Nathalie; Ledru, Aurelie; Gallerand, Margaux; Lombardi, Vincent; Mascarell, Laurent; Marquant, Quentin; Apetoh, Lionel; Erard, Francois; Le Bert, Marc; Trovero, Fabrice; Quesniaux, Valerie F. J.; Ryffel, Bernhard; Togbe, Dieudonnee			Protein kinase C theta controls type 2 innate lymphoid cell and T(H)2 responses to house dust mite allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						House dust mite; allergic asthma; eosinophils; protein kinase C theta; innate lymphoid cells; nuclear factor of activated T cells; interferon regulatory factor 4	PKC-THETA; DENDRITIC CELLS; T-CELLS; AIRWAY INFLAMMATION; LUNG INFLAMMATION; IFN-GAMMA; ACTIVATION; ASTHMA; TH2; MICE	Background: Protein kinase C (PKC) theta, a serine/threonine kinase, is involved in T(H)2 cell activation and proliferation. Type 2 innate lymphoid cells (ILC2s) resemble T(H)2 cells and produce the T(H)2 cytokines IL-5 and IL-13 but lack antigen-specific receptors. The mechanism by which PKC-theta drives innate immune cells to instruct T(H)2 responses in patients with allergic lung inflammation remains unknown. Objectives: We hypothesized that PKC-theta contributes to ILC2 activation and might be necessary for ILC2s to instruct the T(H)2 response. Methods: PRKCQ gene expression was assessed in innate lymphoid cell subsets purified from human PBMCs and mouse lung ILC2s. ILC2 activation and eosinophil recruitment, T(H)2-related cytokine and chemokine production, lung histopathology, interferon regulatory factor 4 (IRF4) mRNA expression, and nuclear factor of activated T cells (NFAT1) protein expression were determined. Adoptive transfer of ILC2s from wild-type mice was performed in wild-type and PKC theta-deficient (PKC-theta(-/-)) mice. Results: Here we report that PKC-theta is expressed in both human and mouse ILC2s. Mice lacking PKC-theta had reduced ILC2 numbers, T(H)2 cell numbers and activation, airway hyperresponsiveness, and expression of the transcription factors IRF4 and NFAT1. Importantly, adoptive transfer of ILC2s restored eosinophil influx and IL-4, IL-5 and IL-13 production in lung tissue, as well as T(H)2 cell activation. The pharmacologic PKC-theta inhibitor (Compound 20) administered during allergen challenge reduced ILC2 numbers and activation, as well as airway inflammation and IRF4 and NFAT1 expression. Conclusions: Therefore our findings identify PKC-theta as a critical factor for ILC2 activation that contributes to T(H)2 cell differentiation, which is associated with IRF4 and NFAT1 expression in allergic lung inflammation.	[Madouri, Fahima; Chenuet, Pauline; Marquant, Quentin; Erard, Francois; Le Bert, Marc; Quesniaux, Valerie F. J.; Ryffel, Bernhard] Univ Orleans, Lab Expt & Mol Immunol & Neurogenet INEM, UMR CNRS 7355, Orleans, France; [Madouri, Fahima; Fauconnier, Louis; Marchiol, Tiffany; Rouxel, Nathalie; Ledru, Aurelie; Gallerand, Margaux; Marquant, Quentin; Trovero, Fabrice; Togbe, Dieudonnee] Artimmune SAS, 13 Ave Buffon, F-45100 Orleans, France; [Apetoh, Lionel] INSERM, U866, Dijon, France; [Ryffel, Bernhard] Univ Cape Town, Inst Infect Dis & Mol Med, Rondebosch, South Africa; [Beuraud, Chloe; Lombardi, Vincent; Mascarell, Laurent] Stallergenes Greer, Res Dept, Antony, France	Universite de Orleans; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; University of Cape Town; Stallergenes Greer	Togbe, D (corresponding author), Artimmune SAS, 13 Ave Buffon, F-45100 Orleans, France.	dieudo.togbe@artimmune.com	Apetoh, Lionel/AIC-2384-2022; Togbe, Dieudonnee/AAE-1135-2020; Le Bert, Marc/AAR-4577-2021; Apetoh, Lionel/G-3310-2014	Apetoh, Lionel/0000-0002-2774-438X; Togbe, Dieudonnee/0000-0001-6658-414X; Le Bert, Marc/0000-0002-5945-3800; Apetoh, Lionel/0000-0002-2774-438X; Marchiol, Tiffany/0000-0003-0714-1191	ArtImmune; University of Orleans; Region Centre (HabitAsthme) [2012-00073535]; Region Centre (Inflammation et Infection) [2013-00085470]; Conseil General 45; CIFRE PhD fellowship from ANRT (Association Nationale de la Recherche et de la Technologie)	ArtImmune; University of Orleans; Region Centre (HabitAsthme); Region Centre (Inflammation et Infection); Conseil General 45(Region Centre-Val de Loire); CIFRE PhD fellowship from ANRT (Association Nationale de la Recherche et de la Technologie)	Supported by ArtImmune, University of Orleans, la Region Centre (HabitAsthme no. 2012-00073535 and Inflammation et Infection no. 2013-00085470)m and Conseil General 45 to F. Madouri, PhD fellowship. C.B. was supported by a CIFRE PhD fellowship from ANRT (Association Nationale de la Recherche et de la Technologie).	Ahyi ANN, 2009, J IMMUNOL, V183, P1598, DOI 10.4049/jimmunol.0803302; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; Chambers L, 1998, BIOCHEM BIOPH RES CO, V253, P837, DOI 10.1006/bbrc.1998.9862; Chapman MD, 2007, CURR ALLERGY ASTHM R, V7, P363, DOI 10.1007/s11882-007-0055-6; Fang XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031174; Gao Y, 2013, IMMUNITY, V39, P722, DOI 10.1016/j.immuni.2013.08.028; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Gregory LG, 2011, TRENDS IMMUNOL, V32, P402, DOI 10.1016/j.it.2011.06.006; Gupta S, 2008, MOL IMMUNOL, V46, P213, DOI 10.1016/j.molimm.2008.08.275; Hachem P, 2005, EUR J IMMUNOL, V35, P2793, DOI 10.1002/eji.200535268; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Jacquet A, 2013, ISRN ALLERGY, V2013, DOI [10.1155/2013/735031, DOI 10.1155/2013/735031]; Kheradmand F, 2002, J IMMUNOL, V169, P5904, DOI 10.4049/jimmunol.169.10.5904; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lefrancais E, 2014, P NATL ACAD SCI USA, V111, P15502, DOI 10.1073/pnas.1410700111; Marsland BJ, 2005, P NATL ACAD SCI USA, V102, P14374, DOI 10.1073/pnas.0506250102; Marsland BJ, 2004, J EXP MED, V200, P181, DOI 10.1084/jem.20032229; Moro K, 2015, NAT PROTOC, V10, P792, DOI 10.1038/nprot.2015.047; Page KM, 2008, J LEUKOCYTE BIOL, V83, P1267, DOI 10.1189/jlb.1107745; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Rengarajan J, 2002, J EXP MED, V195, P1003, DOI 10.1084/jem.20011128; Salek-Ardakani S, 2004, J IMMUNOL, V173, P6440, DOI 10.4049/jimmunol.173.10.6440; Scanlon ST, 2012, CURR OPIN IMMUNOL, V24, P707, DOI 10.1016/j.coi.2012.08.009; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Sung HC, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00452; Takai Toshiro, 2011, Allergology International, V60, P25, DOI 10.2332/allergolint.10-RAI-0273; Tassi I, 2008, BLOOD, V112, P4109, DOI 10.1182/blood-2008-02-139527; Thomas WR, 2010, TRENDS MOL MED, V16, P321, DOI 10.1016/j.molmed.2010.04.008; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Williams JW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3990; Zanin-Zhorov A, 2011, TRENDS IMMUNOL, V32, P358, DOI 10.1016/j.it.2011.04.007; Zanin-Zhorov A, 2010, SCIENCE, V328, P372, DOI 10.1126/science.1186068	38	19	23	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1650	1666		10.1016/j.jaci.2016.08.044	http://dx.doi.org/10.1016/j.jaci.2016.08.044			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27746240	Bronze			2022-12-18	WOS:000400465300026
J	Veilleux, MS; Shear, NH				Veilleux, Mylene S.; Shear, Neil H.			Biologics in patients with skin diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Biologics; mAbs; pemphigus; psoriasis; eczema; hidradenitis suppurativa; melanoma	ANTI-CD20 RITUXIMAB TREATMENT; 2-PHASE 3 TRIALS; HIDRADENITIS SUPPURATIVA; ATOPIC-DERMATITIS; DOUBLE-BLIND; PLAQUE PSORIASIS; MONOCLONAL-ANTIBODY; ADJUVANT THERAPY; MODERATE; PEMPHIGUS	Biologic agents are important therapeutic options for treating multiple moderate-to-severe cutaneous diseases. Monoclonal antibodies already in use or under investigation are targeted for psoriasis, atopic dermatitis, melanoma, hidradenitis suppurativa, and pemphigus vulgaris.	[Veilleux, Mylene S.] Hotel Dieu de Levis Hosp, Quebec City, PQ, Canada; [Veilleux, Mylene S.] Univ Laval, Dept Med, Div Dermatol, Quebec City, PQ, Canada; [Shear, Neil H.] Sunnybrook Hlth Sci Ctr, Rm M1-700,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada; [Shear, Neil H.] Univ Toronto, Div Dermatol, Dept Med, Rm M1-700,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada	Laval University; Laval University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Shear, NH (corresponding author), Sunnybrook Hlth Sci Ctr, Rm M1-700,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.; Shear, NH (corresponding author), Univ Toronto, Div Dermatol, Dept Med, Rm M1-700,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	neil.shear@sunnybrook.ca			Janssen; Roche; Novartis; Valeant; Sanofi Genzyme; Eli Lilly; Celgene; Amgen	Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Roche(Roche Holding); Novartis(Novartis); Valeant; Sanofi Genzyme(Sanofi-AventisGenzyme Corporation); Eli Lilly(Eli Lilly); Celgene(Bristol-Myers SquibbCelgene Corporation); Amgen(Amgen)	N. H. Shear has consultant arrangements with and has received payment for lectures from Janssen, Roche, Novartis, Valeant, Sanofi Genzyme, Eli Lilly, Celgene, and Amgen. M. S. Veilleux declares no relevant conflicts of interest.	AbuHilal M, 2016, J CUTAN MED SURG, V20, P509, DOI 10.1177/1203475416651605; AbuHilal M, 2016, J CUTAN MED SURG, V20, P313, DOI 10.1177/1203475416631328; Ahmed AR, 2015, AUTOIMMUN REV, V14, P323, DOI 10.1016/j.autrev.2014.12.002; Alhusayen R, 2015, J AM ACAD DERMATOL, V73, pS42, DOI 10.1016/j.jaad.2015.07.049; Andrews AL, 2006, J IMMUNOL, V176, P7456, DOI 10.4049/jimmunol.176.12.7456; [Anonymous], 2009, NEW ERA APPROACHES A; [Anonymous], 2008, BLA SUPPLEMENT ETANE; [Anonymous], 2016, TALTZ APPROVAL HIST; [Anonymous], 2016, COSENTYX APPROVAL HI; Armstrong AW, 2016, JAMA DERMATOL, V152, P661, DOI 10.1001/jamadermatol.2016.0269; Atzmony L, 2015, J AM ACAD DERMATOL, V73, P264, DOI 10.1016/j.jaad.2015.04.038; Bakker CV, 2014, JAMA DERMATOL, V150, P459, DOI [10.1001/jamadermatol.2014.54, 10.1001/jamadermatol.2014.136]; Baum S, 2016, EUR J DERMATOL, V26, P382, DOI 10.1684/ejd.2016.2792; Baum S, 2014, AUTOIMMUN REV, V13, P482, DOI 10.1016/j.autrev.2014.01.047; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bhatia S, 2009, ONCOLOGY-NY, V23, P488; Blok JL, 2016, BRIT J DERMATOL, V174, P839, DOI 10.1111/bjd.14338; Braun-Falco M, 2012, J AM ACAD DERMATOL, V66, P409, DOI 10.1016/j.jaad.2010.12.025; Buka RL, 2005, J AM ACAD DERMATOL, V53, P358, DOI 10.1016/j.jaad.2005.03.013; Bystryn JC, 1996, ARCH DERMATOL, V132, P203, DOI 10.1001/archderm.132.2.203; Canadian Psoriasis Guidelines Addendum Committee, 2016, J CUTAN MED SURG, V20, P412; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Curti BD, 2014, NEW ENGL J MED, V371, P1929, DOI 10.1056/NEJMe1411158; D'Souza LS, 2015, J AM ACAD DERMATOL, V72, P589, DOI 10.1016/j.jaad.2014.11.028; Daneshpazhooh M, 2016, J AM ACAD DERMATOL, V74, P1160, DOI 10.1016/j.jaad.2015.10.051; Eyerich S, 2011, NEW ENGL J MED, V365, P231, DOI 10.1056/NEJMoa1104200; Futamura M, 2016, J AM ACAD DERMATOL, V74, P288, DOI 10.1016/j.jaad.2015.09.062; Grant A, 2010, J AM ACAD DERMATOL, V62, P205, DOI 10.1016/j.jaad.2009.06.050; Griffiths CL, 2016, S AFR J SCI, V112, P28; Gulliver WP, 2012, J EUR ACAD DERMATOL, V26, P911, DOI 10.1111/j.1468-3083.2011.04123.x; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; Heelan K, 2014, JAMA DERMATOL, V150, P703, DOI 10.1001/jamadermatol.2013.6739; Heil PM, 2010, J DTSCH DERMATOL GES, V8, P990, DOI 10.1111/j.1610-0387.2010.07497.x; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hsueh EC, 2016, EXP HEMATOL ONCOL, V5, DOI 10.1186/s40164-016-0054-1; Huang A, 2016, J AM ACAD DERMATOL, V74, P746, DOI 10.1016/j.jaad.2015.11.008; Khattri S, 2017, EXP DERMATOL, V26, P28, DOI 10.1111/exd.13112; Kimball AB, 2016, NEW ENGL J MED, V375, P422, DOI 10.1056/NEJMoa1504370; Kofoed K, 2015, ACTA DERM-VENEREOL, V95, P133, DOI 10.2340/00015555-1931; Kohorst JJ, 2015, J AM ACAD DERMATOL, V73, pS27, DOI 10.1016/j.jaad.2015.07.055; Kopp T, 2015, NATURE, V521, P222, DOI 10.1038/nature14175; Krueger JG, 2015, J ALLERGY CLIN IMMUN, V136, P116, DOI 10.1016/j.jaci.2015.01.018; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Lee RA, 2015, J AM ACAD DERMATOL, V73, pS82, DOI 10.1016/j.jaad.2015.07.053; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Long GV, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_supll.9506; Looney RJ, 2010, DRUGS, V70, P529, DOI 10.2165/11535420-000000000-00000; Mease PJ, 2017, ANN RHEUM DIS, V76, P79, DOI 10.1136/annrheumdis-2016-209709; Mease PJ, 2015, NEW ENGL J MED, V373, P1329, DOI 10.1056/NEJMoa1412679; Mehdizadeh A, 2015, J AM ACAD DERMATOL, V73, pS70, DOI 10.1016/j.jaad.2015.07.044; Navarini AA, 2011, J ALLERGY CLIN IMMUN, V128, P1128, DOI 10.1016/j.jaci.2011.09.009; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; Oldhoff JM, 2005, ALLERGY, V60, P693, DOI 10.1111/j.1398-9995.2005.00791.x; Papp KA, 2016, BRIT J DERMATOL, V175, P273, DOI 10.1111/bjd.14493; Prens E, 2015, J AM ACAD DERMATOL, V73, pS8, DOI 10.1016/j.jaad.2015.07.045; Puya R, 2012, INT J DERMATOL, V51, P115, DOI 10.1111/j.1365-4632.2011.05195.x; REFF ME, 1994, BLOOD, V83, P435; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Samorano LP, 2016, J EUR ACAD DERMATOL, V30, P522, DOI 10.1111/jdv.12918; Sediva A, 2008, J ALLERGY CLIN IMMUN, V121, P1515, DOI 10.1016/j.jaci.2008.03.007; Sharon VR, 2012, ACTA DERM-VENEREOL, V92, P320, DOI 10.2340/00015555-1229; Sheinkopf LE, 2008, ALLERGY ASTHMA PROC, V29, P530, DOI 10.2500/aap.2008.29.3160; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P122, DOI 10.1016/j.jaci.2007.11.016; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Singh BP, 2016, CANCERS, V8, DOI 10.3390/cancers8010017; Sofen H, 2014, J ALLERGY CLIN IMMUN, V133, P1032, DOI 10.1016/j.jaci.2014.01.025; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Thaci D, 2015, J AM ACAD DERMATOL, V73, P400, DOI 10.1016/j.jaad.2015.05.013; Torres T, 2016, EXPERT OPIN INV DRUG, V25, P751, DOI 10.1080/13543784.2016.1187130; Tsianakas A, 2016, LANCET, V387, P4, DOI 10.1016/S0140-6736(15)00389-X; Tzanetakou V, 2016, JAMA DERMATOL, V152, P52, DOI 10.1001/jamadermatol.2015.3903; van de Kerkhof PCM, 2016, J AM ACAD DERMATOL, V75, P83, DOI 10.1016/j.jaad.2016.03.024; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Yiu ZZN, 2016, AM J CLIN DERMATOL, V17, P191, DOI 10.1007/s40257-016-0179-3; Zamora-Atenza C, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4615	78	19	20	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1423	1430		10.1016/j.jaci.2017.03.012	http://dx.doi.org/10.1016/j.jaci.2017.03.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	28477721	Bronze			2022-12-18	WOS:000400465300002
J	Iwasaki, N; Matsushita, K; Fukuoka, A; Nakahira, M; Matsumoto, M; Akasaki, S; Yasuda, K; Shimizu, T; Yoshimoto, T				Iwasaki, Naruhito; Matsushita, Kazufumi; Fukuoka, Ayumi; Nakahira, Masakiyo; Matsumoto, Makoto; Akasaki, Shoko; Yasuda, Koubun; Shimizu, Takeshi; Yoshimoto, Tomohiro			Allergen endotoxins induce T-cell-dependent and non-IgE-mediated nasal hypersensitivity in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; CD4(+) T cell; endotoxin; histamine; hypersensitivity; IgE; monocyte/macrophage; nonallergic rhinitis; LPS	NONALLERGIC RHINITIS; MAST-CELLS; HISTIDINE-DECARBOXYLASE; HISTAMINE SYNTHESIS; INNATE IMMUNITY; INFLAMMATION; RESPONSES; MACROPHAGES; ACTIVATION; CHILDREN	Background: Allergen-mediated cross-linking of IgE on mast cells/basophils is a well-recognized trigger for type 1 allergic diseases such as allergic rhinitis (AR). However, allergens may not be the sole trigger for AR, and several allergic-like reactions are induced by non-IgE-mediated mechanisms. Objective: We sought to describe a novel non-IgE-mediated, endotoxin-triggered nasal type-1-hypersensitivity-like reaction in mice. Methods: To investigate whether endotoxin affects sneezing responses, mice were intraperitoneally immunized with ovalbumin (OVA), then nasally challenged with endotoxin-free or endotoxin-containing OVA. To investigate the role of T cells and mechanisms of the endotoxin-induced response, mice were adoptively transferred with in vitro-differentiated OVA-specific T(H)2 cells, then nasally challenged with endotoxin-free or endotoxin-containing OVA. Results: Endotoxin-containing, but not endotoxin-free, OVA elicited sneezing responses in mice independent from IgE-mediated signaling. OVA-specific T(H)2 cell adoptive transfer to mice demonstrated that local activation of antigen-specific T(H)2 cells was required for the response. The Toll-like receptor 4-myeloid differentiation factor 88 signaling pathway was indispensable for endotoxin-containing OVA-elicited rhinitis. In addition, LPS directly triggered sneezing responses in OVA-specific T(H)2-transferred and nasally endotoxin-free OVA-primed mice. Although antihistamines suppressed sneezing responses, mast-cell/basophil-depleted mice had normal sneezing responses to endotoxin-containing OVA. Clodronate treatment abrogated endotoxin-containing OVA-elicited rhinitis, suggesting the involvement of monocytes/ macrophages in this response. Conclusions: Antigen-specific nasal activation of CD4 1 T cells followed by endotoxin exposure induces mast cell/basophilindependent histamine release in the nose that elicits sneezing responses. Thus, environmental or nasal residential bacteria may exacerbate AR symptoms. In addition, this novel phenomenon might explain currently unknown mechanisms in allergic(-like) disorders.	[Iwasaki, Naruhito; Matsushita, Kazufumi; Fukuoka, Ayumi; Akasaki, Shoko; Yoshimoto, Tomohiro] Hyogo Coll Med, Inst Adv Med Sci, Lab Allerg Dis, Nishinomiya, Hyogo 6638501, Japan; [Iwasaki, Naruhito; Shimizu, Takeshi] Shiga Univ Med Sci, Dept Otorhinolaryngol, Otsu, Shiga, Japan; [Nakahira, Masakiyo; Matsumoto, Makoto; Yasuda, Koubun; Yoshimoto, Tomohiro] Hyogo Coll Med, Dept Immunol, Nishinomiya, Hyogo 6638501, Japan	Hyogo College of Medicine; Shiga University of Medical Science; Hyogo College of Medicine	Yoshimoto, T (corresponding author), Hyogo Coll Med, Inst Adv Med Sci, Lab Allerg Dis, Nishinomiya, Hyogo 6638501, Japan.; Yoshimoto, T (corresponding author), Hyogo Coll Med, Dept Immunol, Nishinomiya, Hyogo 6638501, Japan.	tomo@hyo-med.ac.jp	Yasuda, Koubun/GQA-7622-2022	Shimizu, Takeshi/0000-0002-1344-7210; Yasuda, Koubun/0000-0002-3533-1702; Fukuoka, Ayumi/0000-0002-6752-7814	MEXT [S1001055]; JSPS KAKENHI [24390253, 26860340]; Uehara Memorial Foundation; Takeda Science Foundation; Grants-in-Aid for Scientific Research [17K15736] Funding Source: KAKEN	MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Uehara Memorial Foundation(Uehara Memorial Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by MEXT Grant-in-Aid for Scientific Research, the Strategic Research Foundation at Private Universities (grant no. S1001055), and JSPS KAKENHI, a Grant-in-Aid for Scientific Research B (grant no. 24390253) to T.Y.; JSPS KAKENHI, a Grant-in-Aid for Young Scientists B (grant no. 26860340) to K.M.; and the Uehara Memorial Foundation and the Takeda Science Foundation to T.Y. and K.M.	Abraham JH, 2005, J ALLERGY CLIN IMMUN, V116, P431, DOI 10.1016/j.jaci.2005.05.015; Akasaki S, 2016, INT IMMUNOL, V28, P65, DOI 10.1093/intimm/dxv055; Becker Susanne, 2005, Toxicol Appl Pharmacol, V207, P269, DOI 10.1016/j.taap.2005.01.023; Becker S, 2016, EUR ARCH OTO-RHINO-L, V273, P1469, DOI 10.1007/s00405-015-3769-4; Bedoret D, 2009, J CLIN INVEST, V119, P3723, DOI 10.1172/JCI39717; Bernstein JA, 2013, CURR OPIN ALLERGY CL, V13, P410, DOI 10.1097/ACI.0b013e3283630cd8; Borish L, 2003, J ALLERGY CLIN IMMUN, V112, P1021, DOI 10.1016/j.jaci.2003.09.015; Braga CR, 2004, J INVEST ALLERG CLIN, V14, P142; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Campo P, 2015, CLIN EXP ALLERGY, V45, P872, DOI 10.1111/cea.12476; Danuser B, 2000, EUR ARCH OTO-RHINO-L, V257, P527, DOI 10.1007/s004050000285; De Corso E, 2014, RHINOLOGY, V52, P142, DOI [10.4193/Rhino13.102, 10.4193/Rhin13.102]; Fransson M, 2007, ACTA OTO-LARYNGOL, V127, P285, DOI 10.1080/00016480600801340; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gelardi M, 2008, INT J IMMUNOPATH PH, V21, P325, DOI 10.1177/039463200802100209; Gelardi M, 2008, J BIOL REG HOMEOS AG, V22, P73; Gutowska-Owsiak D, 2014, BRIT J DERMATOL, V171, P771, DOI 10.1111/bjd.13199; Halim TYF, 2016, INT IMMUNOL, V28, P13, DOI 10.1093/intimm/dxv050; Hegyi K, 2007, INFLAMM RES, V56, P339, DOI 10.1007/s00011-007-7049-7; Herre J, 2013, J IMMUNOL, V191, P1529, DOI 10.4049/jimmunol.1300284; Humbert M, 2009, ALLERGY, V64, P81, DOI 10.1111/j.1398-9995.2008.01846.x; Jenkins SJ, 2011, SCIENCE, V332, P1284, DOI 10.1126/science.1204351; Jeong KY, 2013, ALLERGY ASTHMA IMMUN, V5, P102, DOI 10.4168/aair.2013.5.2.102; Jutel M, 2009, CLIN EXP ALLERGY, V39, P1786, DOI 10.1111/j.1365-2222.2009.03374.x; Kamijo S, 2009, J IMMUNOL, V183, P6087, DOI 10.4049/jimmunol.0901039; Kato Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103540; Kim H, 2012, J ALLERGY CLIN IMMUN, V129, P1529, DOI 10.1016/j.jaci.2012.01.051; Kubo Y, 1999, INFLAMM RES, V48, P149, DOI 10.1007/s000110050438; Li DQ, 2011, J ALLERGY CLIN IMMUN, V128, P1318, DOI 10.1016/j.jaci.2011.06.041; Matsushita K, 2014, J IMMUNOL, V193, P5791, DOI 10.4049/jimmunol.1401768; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Natarajan S, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-12; Nomura I, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Nomura I, 2011, J ALLERGY CLIN IMMUN, V127, P685, DOI 10.1016/j.jaci.2011.01.019; Rajan TV, 2003, TRENDS IMMUNOL, V24, P376, DOI 10.1016/S1471-4906(03)00142-X; Sato N, 2007, CLIN EXP ALLERGY, V37, P743, DOI 10.1111/j.1365-2222.2007.02705.x; Satoh T, 2013, NATURE, V495, P524, DOI 10.1038/nature11930; Sawaguchi M, 2012, J IMMUNOL, V188, P1809, DOI 10.4049/jimmunol.1101746; SAXENA SP, 1989, SCIENCE, V243, P1596, DOI 10.1126/science.2928797; Smuda C, 2011, IMMUNOL LETT, V141, P102, DOI 10.1016/j.imlet.2011.08.002; Supajatura V, 2002, J CLIN INVEST, V109, P1351, DOI 10.1172/JCI200214704; Takamatsu S, 1996, J IMMUNOL, V156, P778; Thyssen JP, 2014, ALLERGY, V69, P28, DOI 10.1111/all.12358; Varol C, 2015, ANNU REV IMMUNOL, V33, P643, DOI 10.1146/annurev-immunol-032414-112220; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003; Yoshimoto T, 2007, J IMMUNOL, V179, P4415, DOI 10.4049/jimmunol.179.7.4415; Zhang YL, 2012, EUR J IMMUNOL, V42, P1735, DOI 10.1002/eji.201142123	48	19	21	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					258	+		10.1016/j.jaci.2016.03.023	http://dx.doi.org/10.1016/j.jaci.2016.03.023			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27287257	Bronze			2022-12-18	WOS:000393996800027
J	Anise, A; Hasnain-Wynia, R				Anise, Ayodola; Hasnain-Wynia, Romana			Patient-centered outcomes research to improve asthma outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; Patient-Centered Outcomes Research Institute; comparative effectiveness research; African American; Hispanic/Latino; National Asthma Education and Prevention Program guidelines	COMPARATIVE EFFECTIVENESS TRIAL; PRIMARY-CARE; NATIONAL GUIDELINES; DECISION-SUPPORT; AFRICAN-AMERICAN; INNER-CITY; MANAGEMENT; BARRIERS; CHILDREN; DESIGN	The Patient-Centered Outcomes Research Institute is funding 8 comparative effectiveness research projects to improve patientcentered outcomes for African American and Hispanic/Latino patients with uncontrolled asthma. These projects aimto compare multilevel interventions with known efficacy at the community, home, and health system levels to enhance patient and clinician uptake of the NationalHeart, Lung, and Blood Institute's National Asthma Education Prevention Program guidelines and improve outcomes. The National Asthma Education Prevention Program guidelines provide clinicianswith a range of acceptable approaches for the diagnosis and management of asthma and define general practices that meet the needs of most patients. Yet disparities in asthma care and outcomes remain pervasive for African Americans and Hispanics/Latinos. The NationalHeart, Lung, and Blood Institute AsthmaNet consortium has identified several top research priorities for pediatric and adult populations, including a recommendation to examine tailored approaches based on race/ethnicity. In addition, the guidelines emphasize the need for studies that focus onmulticomponent interventions recognizing that single interventions are generally ineffective. This article will describe the Patient-Centered Outcomes Research Institute-funded asthma projects and how they are individually and collectively addressing evidence gaps in asthma care by focusing on multicomponent and tailored approaches for improving outcomes and reducing disparities for African American and Hispanic/Latino patients.	[Anise, Ayodola; Hasnain-Wynia, Romana] Patient Ctr Outcomes Res Inst, Addressing Dispar Program, Washington, DC USA		Anise, A (corresponding author), Patient Ctr Outcomes Res Inst, 1828 L St,NW,Suite 900, Washington, DC 20036 USA.	aanise@pcori.org		Hasnain-Wynia, Romana/0000-0001-6009-3569				Agency for Healthcare Research and Quality, 2005, GUID SUMM ENV MAN PE; Akinbami Lara J, 2012, NCHS Data Brief, P1; Apter AJ, 2015, CONTEMP CLIN TRIALS, V44, P119, DOI 10.1016/j.cct.2015.08.001; Bell LM, 2010, PEDIATRICS, V125, pE770, DOI 10.1542/peds.2009-1385; Bender BG, 2002, J ALLERGY CLIN IMMUN, V109, pS554, DOI 10.1067/mai.2002.124570; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Bracha Y, 2011, EVAL HEALTH PROF, V34, P309, DOI 10.1177/0163278710392981; Brown RW, 2013, J NATL MED ASSOC, V105, P138, DOI 10.1016/S0027-9684(15)30111-5; Cabana MD, 2000, ARCH PEDIAT ADOL MED, V154, P685, DOI 10.1001/archpedi.154.7.685; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; California Department of Corrections and Rehabilitation, 2007, EXP PAN REP EXP PAN; Canino G, 2009, J ALLERGY CLIN IMMUN, V123, P1209, DOI 10.1016/j.jaci.2009.02.043; Centers for Disease Control and Prevention, 2019, MOST REC ASTHM DAT; Diette GB, 2001, J PEDIATR-US, V138, P59, DOI 10.1067/mpd.2001.109600; Dinakar C, 2014, ANN ALLERG ASTHMA IM, V113, P143, DOI 10.1016/j.anai.2014.05.017; Erwin K, 2016, J COMP EFFECT RES, V5, P17, DOI 10.2217/cer.15.52; Fathima M, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-189; Federman AD, 2015, CONTEMP CLIN TRIALS, V44, P103, DOI 10.1016/j.cct.2015.07.018; Finkelstein JA, 2000, PEDIATRICS, V106, P886; Fleurence R, 2013, HEALTH AFFAIR, V32, P393, DOI 10.1377/hlthaff.2012.1176; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Global Initiative For Asthma, 2016, GLOB STRAT ASTHM MAN; Hasnain-Wynia R, 2006, HEALTH SERV RES, V41, P1, DOI 10.1111/j.1475-6773.2006.00504.x; Herland K, 2005, RESP MED, V99, P11, DOI 10.1016/j.rmed.2004.03.026; James Tom, 2008, P T, V33, P454; Matiz LA, 2016, CLIN PEDIATR, V55, P165, DOI 10.1177/0009922815596070; National Heart Lung and Blood Advisory Council Asthma Expert Working Group, 2015, 32007 NAT HEART LUNG; [National Institutes of Health National Heart Lung and Blood Institute], 1995, NIH PUBL; Nelson KA, 2010, ADOLESC MED STATE AR, V21, pvii; Nelson Kyle A, 2010, Adolesc Med State Art Rev, V21, P21; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Okelo SO., 2013, INTERVENTIONS MODIFY; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Sutherland ER, 2014, J ALLERGY CLIN IMMUN, V133, P34, DOI 10.1016/j.jaci.2013.10.025; Sveum R, I CLIN SYSTEMS IMPRO; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V125, P521, DOI 10.1016/j.jaci.2010.01.025; Teach SJ, 2006, ARCH PEDIAT ADOL MED, V160, P535, DOI 10.1001/archpedi.160.5.535; Travers J, 2007, THORAX, V62, P219, DOI 10.1136/thx.2006.066837; [US Department of Health Human Services Office of Minority Health], 2016, ASTHM HISP AM; US Environmental Protection Agency, 2012, PRES TASK FORC ENV H; Wechsler ME, 2009, MAYO CLIN PROC, V84, P707, DOI 10.1016/S0025-6196(11)60521-1; Wisnivesky JP, 2008, ANN ALLERG ASTHMA IM, V101, P264, DOI 10.1016/S1081-1206(10)60491-7; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; Zahran Hatice S., 2011, Morbidity and Mortality Weekly Report, V60, P547	44	19	19	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1503	+		10.1016/j.jaci.2016.10.003	http://dx.doi.org/10.1016/j.jaci.2016.10.003			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	EF0MK	27931532	Bronze			2022-12-18	WOS:000390019300001
J	Szentpetery, SE; Forno, E; Canino, G; Celedon, JC				Szentpetery, Sylvia E.; Forno, Erick; Canino, Glorisa; Celedon, Juan C.			Asthma in Puerto Ricans: Lessons from a high-risk population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Asthma; multifactorial; high risk; Puerto Ricans	LUNG-FUNCTION; STRESS; ANCESTRY; CHILDREN		[Szentpetery, Sylvia E.; Forno, Erick; Celedon, Juan C.] Univ Pittsburgh, Childrens Hosp Pittsburgh, UPMC, Div Pediat Pulm Med Allergy & Immunol, Pittsburgh, PA 15224 USA; [Canino, Glorisa] Univ Puerto Rico, Behav Sci Res Inst, San Juan, PR 00936 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus	Celedon, JC (corresponding author), Childrens Hosp Pittsburgh, UPMC, Div Pediat Pulm Med Allergy & Immunol, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	juan.celedon@chp.edu	Forno, Erick/I-1476-2019	Forno, Erick/0000-0001-6497-9885	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL117191, K08HL125666, R01HL079966] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL125666, U01 HL119952, R01 HL117191, R01 HL079966] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akinbami Lara J, 2012, NCHS Data Brief, P1; Brehm JM, 2015, AM J RESP CRIT CARE, V192, P47, DOI 10.1164/rccm.201501-0037OC; Brehm JM, 2012, J ALLERGY CLIN IMMUN, V129, P1484, DOI 10.1016/j.jaci.2012.03.035; Castro-Rodriguez J.A., 2016, J ALLERGY CLIN IMMUN; Chen W, 2013, AM J RESP CRIT CARE, V187, P584, DOI 10.1164/rccm.201210-1789OC; Choudhry S, 2005, AM J RESP CRIT CARE, V171, P563, DOI 10.1164/rccm.200409-1286OC; Galanter JM, 2011, J ALLERGY CLIN IMMUN, V128, P37, DOI 10.1016/j.jaci.2011.03.050; Miller GE, 2006, P NATL ACAD SCI USA, V103, P5496, DOI 10.1073/pnas.0506312103; Pino-Yanes M, 2015, J ALLERGY CLIN IMMUN, V135, P228, DOI 10.1016/j.jaci.2014.07.053; Rosenberg SL, 2014, J ALLERGY CLIN IMMUN, V134, P1009, DOI 10.1016/j.jaci.2014.07.005; Rosser FJ, 2014, AM J RESP CRIT CARE, V189, P1316, DOI 10.1164/rccm.201401-0186PP; Vrijheid M, 2014, THORAX, V69, P876, DOI 10.1136/thoraxjnl-2013-204949	12	19	19	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1556	1558		10.1016/j.jaci.2016.08.047	http://dx.doi.org/10.1016/j.jaci.2016.08.047			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27751794	Bronze, Green Accepted			2022-12-18	WOS:000390019300008
J	Creidy, R; Moshous, D; Touzot, F; Elie, C; Neven, B; Gabrion, A; Leruez-Ville, M; Maury, S; Ternaux, B; Nisoy, J; Luby, JM; Heritier, S; Dalle, JH; Ouachee-Chardin, M; Xhaard, A; Thomas, X; Chevallier, P; Souchet, L; Treluyer, JM; Picard, C; Hacein-Bey-Abina, S; Dal Cortivo, L; Blanche, S; Cavazzana, M				Creidy, Rita; Moshous, Despina; Touzot, Fabien; Elie, Caroline; Neven, Benedicte; Gabrion, Aurelie; Leruez-Ville, Marianne; Maury, Sebastien; Ternaux, Brigitte; Nisoy, Jennifer; Luby, Jean-Marc; Heritier, Sebastien; Dalle, Jean-Hugues; Ouachee-Chardin, Marie; Xhaard, Alienor; Thomas, Xavier; Chevallier, Patrice; Souchet, Laetitia; Treluyer, Jean-Marc; Picard, Capucine; Hacein-Bey-Abina, Salima; Dal Cortivo, Liliane; Blanche, Stephane; Cavazzana, Marina			Specific T cells for the treatment of cytomegalovirus and/or adenovirus in the context of hematopoietic stem cell transplantation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INTERPARENTAL CONFLICT; ADOPTIVE TRANSFER; LUNG-FUNCTION; RECIPIENTS; EXPOSURE; RECONSTITUTION; IMMUNITY; VIOLENCE; MARROW; CHILD		[Creidy, Rita; Touzot, Fabien; Gabrion, Aurelie; Ternaux, Brigitte; Nisoy, Jennifer; Luby, Jean-Marc; Hacein-Bey-Abina, Salima; Dal Cortivo, Liliane; Cavazzana, Marina] Necker Childrens Hosp, AP HP, Biotherapy Dept, Paris, France; [Moshous, Despina; Touzot, Fabien; Neven, Benedicte; Heritier, Sebastien; Cavazzana, Marina] Necker Childrens Hosp, AP HP, Immunol & Pediat Hematol Dept, Paris, France; [Moshous, Despina; Neven, Benedicte] Paris Decartes Sorbonne Paris Cite Univ, Imagine Inst, INSERM UMR1163, Genome Dynam Immune System, Paris, France; [Touzot, Fabien; Cavazzana, Marina] Paris Decartes Sorbonne Paris Cite Univ, Imagine Inst, INSERM UMR1163, Human Lymphohematopoiesis, Paris, France; [Elie, Caroline; Treluyer, Jean-Marc] Necker Childrens Hosp, AP HP, Ctr Clin Investigat, Clin Reaserch Unit, Paris, France; [Leruez-Ville, Marianne] Necker Childrens Hosp, AP HP, Natl Reference Ctr Cytomegalovirus, Clin Microbiol Lab, Paris, France; [Leruez-Ville, Marianne; Blanche, Stephane] Paris Descartes Sorbonne Paris Cite Univ, Paris, France; [Maury, Sebastien] Henri Mondors Hosp, AP HP, Dept Hematol, Creteil, France; [Maury, Sebastien] Paris Est Creteil Univ UPEC, DHU Virus Immunity Canc, Creteil, France; [Dalle, Jean-Hugues] Robert Debres Hosp, AP HP, Dept Pediat Hematol, Paris, France; [Dalle, Jean-Hugues] Univ Paris Diderot, Robert Debres Hosp, INSERM UMR1149, Equipe Immunite Chez Enfant, Paris, France; [Xhaard, Alienor] St Louiss Hosp, AP HP, Dept Hematol, Hematopoiet Stem Cell Transplantat Unit, Paris, France; [Thomas, Xavier] Groupement Hosp Sud, Lyon Suds Hosp, Dept Hematol, Lyon, France; [Chevallier, Patrice] Univ Hotel Dieu, Ctr Hosp, Dept Hematol, Nantes, France; [Souchet, Laetitia] Hop La Pitie Salpetriere, AP HP, Dept Hematol, Paris, France; [Picard, Capucine] Necker Childrens Hosp, AP HP, CEDI, Paris, France; [Hacein-Bey-Abina, Salima] Paris Descartes Sorbonne Paris Cite Univ, Imagine Inst, Fac Sci Pharmaceut & Biol, Paris, France; [Hacein-Bey-Abina, Salima] Grp Hosp Univ Ouest, AP HP, INSERM, Biotherapy Clin Invest Ctr, Paris, France; [Leruez-Ville, Marianne; Blanche, Stephane] Univ Paris 11, Grp Hosp, AP HP, Immunol Lab, Le Kremlin Bicetre, France; [Blanche, Stephane] Necker Childrens Hosp, AP HP, Immunol Unit, Dept Pediat Hematol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; CHU Lyon; Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Cavazzana, M (corresponding author), Necker Childrens Hosp, AP HP, Biotherapy Dept, Paris, France.; Cavazzana, M (corresponding author), Necker Childrens Hosp, AP HP, Immunol & Pediat Hematol Dept, Paris, France.; Cavazzana, M (corresponding author), Paris Decartes Sorbonne Paris Cite Univ, Imagine Inst, INSERM UMR1163, Human Lymphohematopoiesis, Paris, France.	m.cavazzana@nck.aphp.fr	Touzot, Fabien/T-7797-2018; Dalle, jean-hugues/GRY-2936-2022; Héritier, Sébastien/D-8139-2017; maury, sebastien/Q-6573-2018; GABRION, AURELIE/K-1812-2017; Moshous, Despina/B-7507-2017	Touzot, Fabien/0000-0002-0889-4905; Héritier, Sébastien/0000-0003-0384-6370; maury, sebastien/0000-0002-1170-8683; GABRION, AURELIE/0000-0002-1885-2071; Moshous, Despina/0000-0001-6719-3693; Cavazzana, Marina/0000-0002-0264-0891				Booth J., 2012, J SOC SOC WELFARE, V39, P137; CRAPO RO, 1995, AM J RESP CRIT CARE, V152, P1107, DOI DOI 10.1164/AJRCCM.152.3.7663792; Davies PT, 2007, DEV PSYCHOL, V43, P918, DOI 10.1037/0012-1649.43.4.918; Davies PT, 2008, CHILD DEV, V79, P1693, DOI 10.1111/j.1467-8624.2008.01219.x; Einsele H, 2014, CURR OPIN HEMATOL, V21, P470, DOI 10.1097/MOH.0000000000000090; Feuchtinger T, 2006, BRIT J HAEMATOL, V134, P64, DOI 10.1111/j.1365-2141.2006.06108.x; Feuchtinger T, 2004, EXP HEMATOL, V32, P282, DOI 10.1016/j.exphem.2003.12.009; Flannery DJ, 2004, J COMMUNITY PSYCHOL, V32, P559, DOI 10.1002/jcop.20019; Flinn MV, 1996, HUM NATURE-INT BIOS, V7, P125, DOI 10.1007/BF02692108; Handgretinger R, 2008, BIOL BLOOD MARROW TR, V14, P59, DOI 10.1016/j.bbmt.2007.10.015; Hiwarkar P, 2013, BONE MARROW TRANSPL, V48, P803, DOI 10.1038/bmt.2012.221; Icheva V, 2013, J CLIN ONCOL, V31, P39, DOI 10.1200/JCO.2011.39.8495; Islam T, 2011, AM J RESP CRIT CARE, V184, P822, DOI 10.1164/rccm.201104-0720OC; Lindemans CA, 2010, BLOOD, V116, P5476, DOI 10.1182/blood-2010-04-259291; McLanahan S, 2013, ANNU REV SOCIOL, V39, P399, DOI 10.1146/annurev-soc-071312-145704; Ritz BR, 2009, TRAFFIC RELATED AIR, P1; Salzberger B, 1997, BLOOD, V90, P2502; Su JG, 2009, SCI TOTAL ENVIRON, V407, P3890, DOI 10.1016/j.scitotenv.2009.01.061; Su JG, 2009, ENVIRON RES, V109, P657, DOI 10.1016/j.envres.2009.06.001; Suglia SF, 2008, PSYCHOSOM MED, V70, P160, DOI 10.1097/PSY.0b013e318160687c; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; World Health Organization, ADOLESCENT HEALTH	22	19	19	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					920	+		10.1016/j.jaci.2016.03.032	http://dx.doi.org/10.1016/j.jaci.2016.03.032			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27246524	hybrid			2022-12-18	WOS:000385496000037
J	Shelfoon, C; Shariff, S; Traves, SL; Kooi, C; Leigh, R; Proud, D				Shelfoon, Christopher; Shariff, Sami; Traves, Suzanne L.; Kooi, Cora; Leigh, Richard; Proud, David			Chemokine release from human rhinovirus-infected airway epithelial cells promotes fibroblast migration	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway epithelium; chemoattractants; fibroblasts; human rhinovirus; migration; airway remodeling; inflammation	EOSINOPHILIC INFLAMMATION; PRESCHOOL WHEEZERS; CHILDHOOD ASTHMA; DISEASES; ILLNESSES; CHILDREN; CXCR3; ANTAGONIST; MODULATION; INDUCTION	Background: Thickening of the lamina reticularis, a feature of remodeling in the asthmatic airways, is now known to be present in young children who wheeze. Human rhinovirus (HRV) infection is a common trigger for childhood wheezing, which is a risk factor for subsequent asthma development. We hypothesized that HRV-infected epithelial cells release chemoattractants to recruit fibroblasts that could potentially contribute to thickening of the lamina reticularis. Objective: We sought to investigate whether conditioned medium from HRV-infected epithelial cells can trigger directed migration of fibroblasts. Methods: Human bronchial epithelial cells were exposed to medium alone or infected with HRV-16. Conditioned medium from both conditions were tested as chemoattractants for human bronchial fibroblasts in the xCELLigence cell migration apparatus. Results: HRV-conditioned medium was chemotactic for fibroblasts. Treatment of fibroblasts with pertussis toxin, an inhibitor of Gai-coupled receptors, prevented their migration. Production of epithelial chemoattractants required HRV replication. Multiplex analysis of epithelial supernatants identified CXCL10, CXCL8, and CCL5 as Gai-coupled receptor agonists of potential interest. Subsequent analysis confirmed that fibroblasts express CXCR3 and CXCR1 receptors and that CXCL10 and, to a lesser extent, CXCL8, but not CCL5, are major contributors to fibroblast migration caused by HRV-conditioned medium. Conclusion: CXCL10 and CXCL8 produced from HRV-infected epithelial cells are chemotactic for fibroblasts. This raises the possibility that repeated HRV infections in childhood could contribute to the initiation and progression of airway remodeling in asthmatic patients by recruiting fibroblasts that produce matrix proteins and thicken the lamina reticularis.	[Shelfoon, Christopher; Shariff, Sami; Traves, Suzanne L.; Kooi, Cora; Leigh, Richard; Proud, David] Univ Calgary, Cumming Sch, Snyder Inst Chron Dis, Dept Physiol & Pharmacol, Calgary, AB, Canada; [Leigh, Richard] Univ Calgary, Cumming Sch, Snyder Inst Chron Dis, Dept Med, Calgary, AB, Canada	University of Calgary; University of Calgary	Proud, D (corresponding author), Univ Calgary, Cumming Sch, Dept Physiol & Pharmacol, HRIC 4AC60,3280 Hosp Dr NW, Calgary, AB T2N 4Z6, Canada.	dproud@ucalgary.ca			Canadian Institutes of Health Research (CIHR) [43923, 82049]; Tier 1 Canada Research Chair in Inflammatory Airway Diseases; GlaxoSmithKline/CIHR Professorship in Inflammatory Lung Diseases	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Tier 1 Canada Research Chair in Inflammatory Airway Diseases; GlaxoSmithKline/CIHR Professorship in Inflammatory Lung Diseases	Supported by grants 43923 and 82049 from the Canadian Institutes of Health Research (CIHR). D.P. is the recipient of a Tier 1 Canada Research Chair in Inflammatory Airway Diseases. R.L. holds the GlaxoSmithKline/CIHR Professorship in Inflammatory Lung Diseases.	Al-Muhsen S, 2011, J ALLERGY CLIN IMMUN, V128, P451, DOI 10.1016/j.jaci.2011.04.047; Barnes JC, 2015, AM J RESP CELL MOL, V53, P217, DOI 10.1165/rcmb.2013-0433OC; Chapman RW, 2007, J PHARMACOL EXP THER, V322, P486, DOI 10.1124/jpet.106.119040; CHURCHILL L, 1989, AM REV RESPIR DIS, V140, P449, DOI 10.1164/ajrccm/140.2.449; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; James AL, 2007, EUR RESPIR J, V30, P134, DOI 10.1183/09031936.00146905; Jartti T, 2008, EUR RESPIR J, V32, P314, DOI 10.1183/09031936.00161907; Jeffery Peter K, 2004, Proc Am Thorac Soc, V1, P176, DOI 10.1513/pats.200402-009MS; Jenh CH, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-2; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Leigh R, 2008, J ALLERGY CLIN IMMUN, V121, P1238, DOI 10.1016/j.jaci.2008.01.067; Leigh R, 2015, PHARMACOL THERAPEUT, V148, P185, DOI 10.1016/j.pharmthera.2014.12.005; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; LIU Y, 2014, BIOMED RES INT, V2014; Nie L, 2010, ACTA PHARMACOL SIN, V31, P436, DOI 10.1038/aps.2009.192; O'Reilly R, 2013, J ALLERGY CLIN IMMUN, V131, P1024, DOI 10.1016/j.jaci.2012.08.044; Pare PD, 2007, CAN J PHYSIOL PHARM, V85, P653, DOI 10.1139/Y07-051; Pohunek P, 2005, PEDIAT ALLERG IMM-UK, V16, P43, DOI 10.1111/j.1399-3038.2005.00239.x; Proud D, 2011, IMMUNOL REV, V242, P186, DOI 10.1111/j.1600-065X.2011.01033.x; Psarras S, 2006, J ALLERGY CLIN IMMUN, V117, P291, DOI 10.1016/j.jaci.2005.11.005; Puxeddu I, 2006, J ALLERGY CLIN IMMUN, V117, P103, DOI 10.1016/j.jaci.2005.08.057; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-1404OC; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Sanders SP, 1998, J VIROL, V72, P934, DOI 10.1128/JVI.72.2.934-942.1998; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Spurrell JCL, 2005, AM J PHYSIOL-LUNG C, V289, pL85, DOI 10.1152/ajplung.00397.2004; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Tager AM, 2004, AM J RESP CELL MOL, V31, P395, DOI 10.1165/rcmb.2004-0175OC; Tomankova T, 2015, AM J PHYSIOL-LUNG C, V308, pL603, DOI 10.1152/ajplung.00203.2014; Wang XM, 2006, J IMMUNOL, V177, P6859, DOI 10.4049/jimmunol.177.10.6859; Winther B, 2006, J MED VIROL, V78, P644, DOI 10.1002/jmv.20588	31	19	19	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					114	+		10.1016/j.jaci.2015.12.1308	http://dx.doi.org/10.1016/j.jaci.2015.12.1308			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26883463	Bronze			2022-12-18	WOS:000379659100013
J	Reich, K; Deinzer, J; Fiege, AK; von Gruben, V; Sack, AL; Thraen, A; Weisenseel, P; Breuer, K; Jackle, S; Meier, M				Reich, Kristian; Deinzer, Julia; Fiege, Anne-Kathrin; von Gruben, Valerie; Sack, Anna-Lena; Thraen, Alice; Weisenseel, Peter; Breuer, Kristine; Jackle, Stefan; Meier, Markus			Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Reich, Kristian; Deinzer, Julia; Fiege, Anne-Kathrin; von Gruben, Valerie; Sack, Anna-Lena; Thraen, Alice; Weisenseel, Peter; Breuer, Kristine] Dermatologikum Hamburg, Hamburg, Germany; [Reich, Kristian; Meier, Markus] Interdisciplinary Apheresis Ctr, Reinbek, Germany; [Jackle, Stefan; Meier, Markus] Hosp St Adolf Stift, Reinbek, Germany; [Meier, Markus] Nephrol Ctr Reinbek & Geesthacht, Reinbek, Germany	Dermatologikum Hamburg	Reich, K (corresponding author), Dermatologikum Hamburg, Hamburg, Germany.	kreich@dermatologikum.de						Bieber T, 2015, ALLERGY, V70, P6, DOI 10.1111/all.12498; Daeschlein G, 2015, THER APHER DIAL, V19, P279, DOI 10.1111/1744-9987.12267; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Kasperkiewicz M, 2014, JAMA DERMATOL, V150, P1350, DOI 10.1001/jamadermatol.2014.2082; Kasperkiewicz M, 2011, J ALLERGY CLIN IMMUN, V127, P267, DOI 10.1016/j.jaci.2010.07.042; Liu FT, 2011, CLIN REV ALLERG IMMU, V41, P298, DOI 10.1007/s12016-011-8252-4; Quist SR, 2013, ACTA DERM-VENEREOL, V93, P206, DOI 10.2340/00015555-1442; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8	8	19	20	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1882	1884		10.1016/j.jaci.2016.01.016	http://dx.doi.org/10.1016/j.jaci.2016.01.016			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26993034	hybrid			2022-12-18	WOS:000377527200030
J	Wells, KE; Cajigal, S; Peterson, EL; Ahmedani, BK; Kumar, R; Lanfear, DE; Burchard, EG; Williams, LK				Wells, Karen E.; Cajigal, Sonia; Peterson, Edward L.; Ahmedani, Brian K.; Kumar, Rajesh; Lanfear, David E.; Burchard, Esteban G.; Williams, L. Keoki			Assessing differences in inhaled corticosteroid response by self-reported race-ethnicity and genetic ancestry among asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Inhaled corticosteroids; Adherence; medication; asthma; African Continental Ancestry Group; respiratory function tests	LUNG-FUNCTION; ADHERENCE; EXACERBATIONS; INTERVENTION; ASSOCIATION; WARFARIN; AFRICANS; OUTCOMES; CYP2C9; ADULTS	Background: Inhaled corticosteroids (ICSs) are the preferred treatment for achieving asthma control. However, little is known regarding the factors contributing to treatment response and whether treatment response differs by population group. Objective: We sought to assess behavioral, sociodemographic, and genetic factors related to ICS response among African American and European American subjects with asthma. Methods: Study participants were part of the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE). The analytic sample included asthmatic subjects aged 12 to 56 years with greater than 12% bronchodilator reversibility and percent predicted FEV1 of between 40% and 90%. Participants received 6 weeks of inhaled beclomethasone dipropionate. The primary measure of ICS response was a change in Asthma Control Test (ACT) score; the secondary measure was a change in prebronchodilator FEV1. Adherence was measured with electronic monitors. Genetic ancestry was estimated for African American participants by using genome-wide genotype data. Results: There were 339 study participants; 242 self-identified as African American and 97 as European American. Baseline ACT score, percent predicted FEV1, degree of bronchodilator response, and ICS adherence were significantly associated with ICS response. A baseline ACT score of 19 or less was useful in identifying those who would respond, as evidenced by the significant dose-response relationship with ICS adherence. Neither self-reported race-ethnicity among all participants nor proportion of African ancestry among African American participants was associated with ICS responsiveness. Conclusions: Our findings suggest that baseline lung function measures and self-reported asthma control predict ICS response, whereas self-reported race-ethnicity and genetic ancestry do not.	[Wells, Karen E.; Peterson, Edward L.] Henry Ford Hlth Syst, Dept Publ Hlth Sci, 1 Ford Pl,5C, Detroit, MI 48202 USA; [Cajigal, Sonia; Lanfear, David E.; Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI 48202 USA; [Ahmedani, Brian K.; Williams, L. Keoki] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI 48202 USA; [Kumar, Rajesh] Northwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; [Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Wells, KE (corresponding author), Henry Ford Hlth Syst, Dept Publ Hlth Sci, 1 Ford Pl,5C, Detroit, MI 48202 USA.	kewells1@aol.com		Kumar, Rajesh/0000-0002-1962-7108	American Asthma Foundation; Flight Attendant Medical Research Institute; Fund for Henry Ford Hospital; Robert Wood Johnson Foundation Amos Medical Faculty Development Program; Sandler Foundation; National Institutes of Health: the National Institute of Allergy and Infectious Diseases [AI077439, AI079139, AI061774]; National Heart, Lung, and Blood Institute [K23HL093023, HL078885, HL088133, HL118267, HL079055]; National Institute of Environmental Health Sciences [ES015794]; National Institute of Diabetes and Digestive and Kidney Diseases [DK064695]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL118267, R01HL088133, K23HL093023, R01HL079055, R01HL078885, R01HL103871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061774, U19AI077439, R01AI079139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015794] Funding Source: NIH RePORTER	American Asthma Foundation; Flight Attendant Medical Research Institute; Fund for Henry Ford Hospital; Robert Wood Johnson Foundation Amos Medical Faculty Development Program(Robert Wood Johnson Foundation (RWJF)); Sandler Foundation; National Institutes of Health: the National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by grants from the American Asthma Foundation (to E.G.B. and L.K.W.), the Flight Attendant Medical Research Institute (to E.G.B.), the Fund for Henry Ford Hospital (to D.E.L., B.K.A., and L.K.W.), the Robert Wood Johnson Foundation Amos Medical Faculty Development Program (to E.G.B.), the Sandler Foundation (to E.G.B.), and the following institutes of the National Institutes of Health: the National Institute of Allergy and Infectious Diseases (AI077439 to E.G.B. and AI079139 and AI061774 to L.K.W.); the National Heart, Lung, and Blood Institute (K23HL093023 to R.K., HL078885 and HL088133 to E.G.B. and HL118267 and HL079055 to L.K.W.); the National Institute of Environmental Health Sciences (ES015794 to E.G.B.); and the National Institute of Diabetes and Digestive and Kidney Diseases (DK064695 to L.K.W.).	Akinbami LJ, 2014, J ALLERGY CLIN IMMUN, V134, P547, DOI 10.1016/j.jaci.2014.05.037; Akinbami Lara J, 2012, NCHS Data Brief, P1; Apter AJ, 1999, J ALLERGY CLIN IMMUN, V103, P72, DOI 10.1016/S0091-6749(99)70528-2; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Bender B, 2003, J ALLERGY CLIN IMMUN, V112, P489, DOI 10.1067/mai.2003.1680; Bryc K, 2010, P NATL ACAD SCI USA, V107, P786, DOI 10.1073/pnas.0909559107; Carson P, 1999, J Card Fail, V5, P178, DOI 10.1016/S1071-9164(99)90001-5; Chen P, 2011, NEW ENGL J MED, V364, P1126, DOI 10.1056/NEJMoa1009717; Davis JS, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0544-y; Dickmann LJ, 2001, MOL PHARMACOL, V60, P382, DOI 10.1124/mol.60.2.382; Drozda K, 2015, PHARMACOGENET GENOM, V25, P73, DOI 10.1097/FPC.0000000000000108; Gould W, 2010, J ALLERGY CLIN IMMUN, V126, P1131, DOI 10.1016/j.jaci.2010.08.002; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Kumar R, 2010, NEW ENGL J MED, V363, P321, DOI 10.1056/NEJMoa0907897; Levin AM, 2014, AM J RESP CRIT CARE, V190, P266, DOI 10.1164/rccm.201402-0204OC; Mannino David M, 2002, MMWR Surveill Summ, V51, P1; Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Onyirimba F, 2003, ANN ALLERG ASTHMA IM, V90, P411, DOI 10.1016/S1081-1206(10)61825-X; Pasaniuc B, 2009, BIOINFORMATICS, V25, pI213, DOI 10.1093/bioinformatics/btp197; Pladevall M, 2010, CIRCULATION, V122, P1183, DOI 10.1161/CIRCULATIONAHA.109.892778; Reddel HK, 2002, BRIT MED J, V324, P146, DOI 10.1136/bmj.324.7330.146; Rhodes L., 2004, Morbidity and Mortality Weekly Report, V53, P145; Rumpel JA, 2012, J ALLERGY CLIN IMMUN, V130, P1302, DOI 10.1016/j.jaci.2012.09.001; Sankararaman S, 2008, AM J HUM GENET, V82, P290, DOI 10.1016/j.ajhg.2007.09.022; SAS Institute, 2008, SAS STAT US GUID VER; Sinha M, 2006, NEW ENGL J MED, V354, P421, DOI 10.1056/NEJMc052515; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Takahashi H, 2006, PHARMACOGENET GENOM, V16, P101, DOI 10.1097/01.fpc.0000184955.08453.a8; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; Tishkoff SA, 2009, SCIENCE, V324, P1035, DOI 10.1126/science.1172257; Wells KE, 2012, J ALLERGY CLIN IMMUN, V129, P1274, DOI 10.1016/j.jaci.2011.12.974; Williams LK, 2007, J ALLERGY CLIN IMMUN, V120, P1153, DOI 10.1016/j.jaci.2007.08.020; Williams LK, 2007, J ALLERGY CLIN IMMUN, V119, P168, DOI 10.1016/j.jaci.2006.09.029; Williams LK, 2011, J ALLERGY CLIN IMMUN, V128, P1185, DOI 10.1016/j.jaci.2011.09.011; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; Yang JJ, 2008, J ALLERGY CLIN IMMUN, V122, P820, DOI 10.1016/j.jaci.2008.07.044	39	19	19	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1364	U118		10.1016/j.jaci.2015.12.1334	http://dx.doi.org/10.1016/j.jaci.2015.12.1334			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	27016472	Bronze, Green Accepted			2022-12-18	WOS:000376180200008
J	Miller, EK; Linder, J; Kraft, D; Johnson, M; Lu, PC; Saville, BR; Williams, JV; Griffin, MR; Talbot, HK				Miller, E. Kathryn; Linder, Jodell; Kraft, David; Johnson, Monika; Lu, Pengcheng; Saville, Benjamin R.; Williams, John V.; Griffin, Marie R.; Talbot, H. Keipp			Hospitalizations and outpatient visits for rhinovirus-associated acute respiratory illness in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinovirus; acute respiratory illness; adults; hospitalized; emergency department; smoking	IDENTIFIED HUMAN RHINOVIRUS; POLYMERASE-CHAIN-REACTION; TRANSCRIPTION-PCR ASSAY; TRACT INFECTIONS; SYNCYTIAL VIRUS; MOLECULAR EPIDEMIOLOGY; BACTERIAL-INFECTION; ACUTE ASTHMA; CHILDREN; SEVERITY	Background: Rhinovirus is linked to asthma exacerbations and chronic obstructive pulmonary disease exacerbations in adults. The severity and rates of rhinovirus acute respiratory illnesses (ARIs) in adults are uncertain. Objectives: We sought to determine rhinovirus-associated ARI rates in adults presenting for care in multiple settings and identify factors associated with rhinovirus detection. Methods: This prospective, population-based cohort enrolled Tennessee residents 18 years or older in the emergency department (ED), outpatient clinics, or hospitalized for ARI from December 2008 to May 2010. Nasal/throat swabs were collected and tested for rhinovirus and other viruses by using RT-PCR. Rates of ED visits and hospitalizations were calculated and rhinovirus-positive and rhinovirus-negative patients were compared. Results: Among 2351 enrollees, rhinovirus was detected in 247 (11%). There were 7 rhinovirus-associated ED visits and 3 hospitalizations per 1000 adults annually. Patients with rhinovirus, compared with virus-negative ARI, were more likely to present with wheezing (odds ratio [OR], 1.7; 95% CI, 1.23-2.35; P < .001), to be a current smoker (OR, 2.31; 95% CI, 1.68-3.19) or live with a smoker (OR, 1.72; 95% CI, 1.10-2.67), have a history of chronic respiratory disease (OR, 1.61; 95% CI, 1.17-2.22), and were less likely to be hospitalized versus seen in the outpatient setting (OR, 0.58; 95% CI, 0.41-0.83). Conclusions: Rhinovirus is associated with a substantial number of ED visits and hospitalizations for ARIs in adults. There may be modifiable factors that can reduce the likelihood of presenting with rhinovirus-associated ARIs.	[Miller, E. Kathryn; Linder, Jodell; Kraft, David; Johnson, Monika] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; [Lu, Pengcheng; Saville, Benjamin R.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA; [Williams, John V.] Univ Pittsburgh, Sch Med, Dept Pediat, Childrens Hosp Pittsburgh,Med Ctr, Pittsburgh, PA 15261 USA; [Griffin, Marie R.; Talbot, H. Keipp] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; [Griffin, Marie R.] Vanderbilt Univ, Med Ctr, Dept Hlth Policy, Nashville, TN USA; [Griffin, Marie R.] VA TN Valley Hlth Care Syst, Midsouth Geriatr Res Educ & Clin Ctr, Nashville, TN USA; [Griffin, Marie R.] VA TN Valley Hlth Care Syst, Clin Res Ctr Excellence, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Vanderbilt University; Vanderbilt University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Miller, EK (corresponding author), Vanderbilt Univ, Dept Pediat, 2200 Childrens Way,11215 Doctors Off Tower, Nashville, TN 37232 USA.	eva.k.miller@Vanderbilt.edu	Williams, John/ABE-3227-2020	Williams, John/0000-0001-8377-5175	Clinical and Translational Science Award [5UL1 RR024975-03]; Vanderbilt-Ingram Cancer Center [P30 CA68485]; Vanderbilt Vision Center [P30 EY08126]; National Institutes of Health (NIH)/National Center for Research Resources [G20 RR030956]; National Center for Advancing Translational Sciences (NCATS)/NIH [UL1 TR000445]; NIH/National Institute of Allergy and Infectious Diseases [AI101629]; Centers for Disease Control and Prevention (CDC) [U18 1P000184]; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; NATIONAL CENTER FOR IMMUNICATION AND RESPIRATORY DISEASES [U18IP000184] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024975] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY008126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI101629] Funding Source: NIH RePORTER	Clinical and Translational Science Award; Vanderbilt-Ingram Cancer Center; Vanderbilt Vision Center; National Institutes of Health (NIH)/National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences (NCATS)/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIH/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR IMMUNICATION AND RESPIRATORY DISEASES(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The Vanderbilt VANTAGE Core provided technical assistance for this work. VANTAGE is supported in part by the Clinical and Translational Science Award (grant no. 5UL1 RR024975-03), the Vanderbilt-Ingram Cancer Center (grant no. P30 CA68485), the Vanderbilt Vision Center (grant no. P30 EY08126), and the National Institutes of Health (NIH)/National Center for Research Resources (grant no. G20 RR030956). The study was also supported by the National Center for Advancing Translational Sciences (NCATS)/NIH (grant no. UL1 TR000445), the NIH/National Institute of Allergy and Infectious Diseases (grant no. AI101629), and the Centers for Disease Control and Prevention (CDC) (grant no. U18 1P000184). Its contents are solely the responsibility of the authors and do not necessarily represent official views of the NCATS, the NIH, or the CDC.	Arakawa M, 2012, J MED MICROBIOL, V61, P410, DOI 10.1099/jmm.0.035006-0; Arden KE, 2006, J MED VIROL, V78, P1232, DOI 10.1002/jmv.20689; Bertino JS, 2002, AM J MED, V112, p42S; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Briese T, 2008, EMERG INFECT DIS, V14, P944, DOI 10.3201/eid1406.080271; Centers for Disease Control and Prevention, 2014, US CENS POP BRIDG RA; Davidson County, 2014, NUMB ARI HOSP ED VIS; Dominguez SR, 2008, J CLIN VIROL, V43, P219, DOI 10.1016/j.jcv.2008.06.007; Erdman DD, 2003, J CLIN MICROBIOL, V41, P4298, DOI 10.1128/JCM.41.9.4298-4303.2003; Ferreira A, 2002, RESPIRATION, V69, P136, DOI 10.1159/000056316; Fica A, 2015, BRAZ J INFECT DIS, V19, P118, DOI 10.1016/j.bjid.2014.10.003; Fry AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017780; Gern JE, 2002, AM J MED, V112, p19S; Griffin MR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023085; HAMPARIAN VV, 1987, VIROLOGY, V159, P191; Hayden FG, 2004, REV MED VIROL, V14, P17, DOI 10.1002/rmv.406; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Huang T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006355; Hudy MH, 2014, AM J RESP CELL MOL, V50, P571, DOI 10.1165/rcmb.2013-0129OC; Jartti T, 2004, EMERG INFECT DIS, V10, P1095, DOI 10.3201/eid1006.030629; Jartti T, 2004, J MED VIROL, V72, P695, DOI 10.1002/jmv.20027; Jin Y, 2009, J CLIN MICROBIOL, V47, P2895, DOI 10.1128/JCM.00745-09; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; Jules A, 2012, INFLUENZA OTHER RESP, V6, pe63, DOI 10.1111/j.1750-2659.2012.00343.x; Kaplan NM, 2008, J MED VIROL, V80, P168, DOI 10.1002/jmv.21067; Kaplan NM, 2006, SAUDI MED J, V27, P1081; Khetsuriani N, 2008, EMERG INFECT DIS, V14, P1793, DOI 10.3201/eid1411.080386; Kistler A, 2007, J INFECT DIS, V196, P817, DOI 10.1086/520816; Klemenc J, 2012, J CLIN VIROL, V54, P371, DOI 10.1016/j.jcv.2012.05.005; Kodani M, 2011, J CLIN MICROBIOL, V49, P2175, DOI 10.1128/JCM.02270-10; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Lamson D, 2006, J INFECT DIS, V194, P1398, DOI 10.1086/508551; Lau SKP, 2007, J CLIN MICROBIOL, V45, P3655, DOI 10.1128/JCM.01254-07; Lau SKP, 2009, J INFECT DIS, V200, P1096, DOI 10.1086/605697; Lee WM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000966; Lee WM, 2012, AM J RESP CRIT CARE, V186, P886, DOI 10.1164/rccm.201202-0330OC; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Linder JE, 2015, J VIROL METHODS, V211, P64, DOI 10.1016/j.jviromet.2014.09.020; Linder JE, 2013, J ALLERGY CLIN IMMUN, V131, P69, DOI 10.1016/j.jaci.2012.09.033; Linsuwanon P, 2009, J INFECTION, V59, P115, DOI 10.1016/j.jinf.2009.05.009; Linsuwanon P, 2009, EMERG INFECT DIS, V15, P978, DOI 10.3201/eid1506.081558; Louie JK, 2009, PEDIATR INFECT DIS J, V28, P337, DOI 10.1097/INF.0b013e31818ffc1b; Lu XY, 2008, J CLIN MICROBIOL, V46, P533, DOI 10.1128/JCM.01739-07; Mallia P, 2012, AM J RESP CRIT CARE, V186, P1117, DOI 10.1164/rccm.201205-0806OC; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McCulloch DJ, 2014, AM J CLIN PATHOL, V142, P165, DOI 10.1309/AJCPHIKRJC67AAZJ; McErlean P, 2007, J CLIN VIROL, V39, P67, DOI 10.1016/j.jcv.2007.03.012; McErlean P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001847; Midulla F, 2010, ARCH DIS CHILD, V95, P35, DOI 10.1136/adc.2008.153361; Miller EK, 2007, J INFECT DIS, V195, P773, DOI 10.1086/511821; Miller EK, 2009, J CLIN VIROL, V46, P85, DOI 10.1016/j.jcv.2009.06.007; Miller EK, 2009, J ALLERGY CLIN IMMUN, V123, P98, DOI 10.1016/j.jaci.2008.10.007; Nicholson KG, 1996, BMJ-BRIT MED J, V313, P1119, DOI 10.1136/bmj.313.7065.1119; Papadopoulos Nikolaos G, 2004, Paediatr Respir Rev, V5, P255, DOI 10.1016/j.prrv.2004.04.002; PELON W, 1957, P SOC EXP BIOL MED, V94, P262; Peltola V, 2013, CLIN MICROBIOL INFEC, V19, pE322, DOI 10.1111/1469-0691.12193; Peltola V, 2008, J CLIN VIROL, V43, P411, DOI 10.1016/j.jcv.2008.08.014; Piotrowska Z, 2009, PEDIATR INFECT DIS J, V28, P25, DOI 10.1097/INF.0b013e3181861da0; Piralla A, 2009, J CLIN VIROL, V45, P311, DOI 10.1016/j.jcv.2009.04.016; Proud D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040762; Renwick N, 2007, J INFECT DIS, V196, P1754, DOI 10.1086/524312; Savolainen C, 2002, VIRUS RES, V85, P41, DOI 10.1016/S0168-1702(02)00016-3; Sekiya K, 2013, ALLERGOL INT, V62, P331, DOI 10.2332/allergolint.12-OA-0525; Talbot HK, 2011, J INFECT DIS, V203, P500, DOI 10.1093/infdis/jiq076; Tan WC, 2005, CURR OPIN PULM MED, V11, P21; Thumerelle C, 2003, PEDIATR PULM, V35, P75, DOI 10.1002/ppul.10191; Treanor JJ, 2012, CLIN INFECT DIS, V55, P951, DOI 10.1093/cid/cis574; Venarske DL, 2006, J INFECT DIS, V193, P1536, DOI 10.1086/503809; Wark PAB, 2013, RESPIROLOGY, V18, P996, DOI 10.1111/resp.12099; Watanabe Aripuanã Sakurada Aranha, 2011, Rev. Soc. Bras. Med. Trop., V44, P18, DOI 10.1590/S0037-86822011000100005; Weinberg GA, 2004, J INFECT DIS, V189, P706, DOI 10.1086/381456; Widmer K, 2014, INFLUENZA OTHER RESP, V8, P347, DOI 10.1111/irv.12234; Xiang ZC, 2010, J INFECTION, V61, P289, DOI 10.1016/j.jinf.2010.07.001	73	19	20	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					734	+		10.1016/j.jaci.2015.06.017	http://dx.doi.org/10.1016/j.jaci.2015.06.017			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26255695	Green Accepted, Bronze			2022-12-18	WOS:000371897500015
J	Wiekmeijer, AS; Pike-Overzet, K; IJspeert, H; Brugman, MH; Wolvers-Tettero, ILM; Lankester, AC; Bredius, RGM; van Dongen, JJM; Fibbe, WE; Langerak, AW; van der Burg, M; Staal, FJT				Wiekmeijer, Anna-Sophia; Pike-Overzet, Karin; IJspeert, Hanna; Brugman, Martijn H.; Wolvers-Tettero, Ingrid L. M.; Lankester, Arjan C.; Bredius, Robbert G. M.; van Dongen, Jacques J. M.; Fibbe, Willem E.; Langerak, Anton W.; van der Burg, Mirjam; Staal, Frank J. T.			Identification of checkpoints in human T-cell development using severe combined immunodeficiency stem cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SCID; thymus; NSG; IL2RG; IL7RA; adenosine deaminase; Artemis; T-cell development; B-cell development	LYMPHOID DEVELOPMENT; BONE-MARROW; MICE; EXPRESSION; DIFFERENTIATION; IMMUNOGLOBULIN; REARRANGEMENTS; PROGENITORS; INSIGHTS; COMPLEX	Background: Severe combined immunodeficiency (SCID) represents congenital disorders characterized by a deficiency of T cells caused by arrested development in the thymus. Yet the nature of these developmental blocks has remained elusive because of the difficulty of taking thymic biopsy specimens from affected children. Objective: We sought to identify the stages of arrest in human T-cell development caused by various major types of SCID. Methods: We performed transplantation of SCID CD34(+) bone marrow stem/progenitor cells into an optimized NSG xenograft mouse model, followed by detailed phenotypic and molecular characterization using flow cytometry, immunoglobulin and T-cell receptor spectratyping, and deep sequencing of immunoglobulin heavy chain (IGH) and T-cell receptor delta (TRD) loci. Results: Arrests in T-cell development caused by mutations in IL-7 receptor alpha (IL7RA) and IL-2 receptor gamma (IL2RG) were observed at the most immature thymocytes much earlier than expected based on gene expression profiling of human thymocyte subsets and studies with corresponding mouse mutants. T-cell receptor rearrangements were functionally required at the CD4(-)CD8(-)CD7(+)CD5(+) stage given the developmental block and extent of rearrangements in mice transplanted with Artemis-SCID cells. The xenograft model used is not informative for adenosine deaminase-SCID, whereas hypomorphic mutations lead to less severe arrests in development. Conclusion: Transplanting CD34(+) stem cells from patients with SCID into a xenograft mouse model provides previously unattainable insight into human T-cell development and functionally identifies the arrest in thymic development caused by several SCID mutations.	[Wiekmeijer, Anna-Sophia; Pike-Overzet, Karin; Brugman, Martijn H.; Fibbe, Willem E.; Staal, Frank J. T.] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, L3-35,POB 9600, NL-2300 RC Leiden, Netherlands; [Lankester, Arjan C.; Bredius, Robbert G. M.] Leiden Univ, Med Ctr, Dept Pediat, NL-2300 RC Leiden, Netherlands; [IJspeert, Hanna; Wolvers-Tettero, Ingrid L. M.; van Dongen, Jacques J. M.; Langerak, Anton W.; van der Burg, Mirjam] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, Rotterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC	Staal, FJT (corresponding author), Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, L3-35,POB 9600, NL-2300 RC Leiden, Netherlands.	f.j.t.staal@lumc.nl	Bredius, Robbert/AAF-2592-2019; Pike-Overzet, Karin/AAT-3716-2021; IJspeert, Hanna/U-9479-2019	Pike-Overzet, Karin/0000-0002-8827-246X; van Dongen, Jacques J.M./0000-0002-3650-7087; Bredius, Robbert/0000-0001-8151-1539	KiKa (Children Cancer Free) [36]; ZonMW E-RARE [40-41900-98-020]; NWO [91712323]; Netherlands Institute for Regenerative Medicine (NIRM)	KiKa (Children Cancer Free); ZonMW E-RARE; NWO(Netherlands Organization for Scientific Research (NWO)); Netherlands Institute for Regenerative Medicine (NIRM)	Supported by KiKa (Children Cancer Free, grant no. 36), ZonMW E-RARE (grant no. 40-41900-98-020), NWO (Vidi grant no. 91712323) and the Netherlands Institute for Regenerative Medicine (NIRM).	ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BARCENA A, 1990, J EXP MED, V172, P439, DOI 10.1084/jem.172.2.439; BARCENA A, 1991, INT IMMUNOL, V3, P419, DOI 10.1093/intimm/3.5.419; Blom B, 1999, BLOOD, V93, P3033; Blom B, 2006, ANNU REV IMMUNOL, V24, P287, DOI 10.1146/annurev.immunol.24.021605.090612; Colpitts SL, 2013, J IMMUNOL, V191, P3017, DOI 10.4049/jimmunol.1301389; Dadi HK, 2003, NEW ENGL J MED, V349, P1821, DOI 10.1056/NEJMoa031178; de Saint Basile G, 2004, J CLIN INVEST, V114, P1512, DOI 10.1172/JCI200422588; Dik WA, 2005, J EXP MED, V201, P1715, DOI 10.1084/jem.20042524; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; Gaspar HB, 2013, BLOOD, V122, P3749, DOI 10.1182/blood-2013-02-380105; Halkias J, 2013, J CLIN INVEST, V123, P2131, DOI 10.1172/JCI67175; Hao QL, 2008, BLOOD, V111, P1318, DOI 10.1182/blood-2007-08-106294; Hollander GA, 2010, CURR OPIN PHARMACOL, V10, P443, DOI 10.1016/j.coph.2010.04.008; IJspeert H, 2014, J ALLERGY CLIN IMMUN, V133, P1124, DOI 10.1016/j.jaci.2013.11.028; Khoo MLM, 2014, AGING CELL, V13, P744, DOI 10.1111/acel.12229; Kohn LA, 2014, J IMMUNOL, V192, P5050, DOI 10.4049/jimmunol.1303496; Li S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3333; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Moorhouse MJ, 2014, BMC IMMUNOL, V15, DOI 10.1186/s12865-014-0059-7; Noordzij JG, 2002, BLOOD, V100, P2145; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; Parietti V, 2012, J IMMUNOL, V189, P1648, DOI 10.4049/jimmunol.1201251; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Pike-Overzet K, 2007, MOL THER, V15, P1910, DOI 10.1038/sj.mt.6300297; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Roifman CM, 2012, J ALLERGY CLIN IMMUN, V130, P177, DOI 10.1016/j.jaci.2012.04.029; Roifman CM, 2010, J ALLERGY CLIN IMMUN, V126, P1226, DOI 10.1016/j.jaci.2010.07.029; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Rothenberg EV, 2008, NAT REV IMMUNOL, V8, P9, DOI 10.1038/nri2232; SANCHEZ MJ, 1994, J EXP MED, V180, P569, DOI 10.1084/jem.180.2.569; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Six EM, 2007, J EXP MED, V204, P3085, DOI 10.1084/jem.20071003; Six EM, 2011, BLOOD CELL MOL DIS, V47, P72, DOI 10.1016/j.bcmd.2011.04.001; Soulier J, 2005, BLOOD, V106, P274, DOI 10.1182/blood-2004-10-3900; van der Burg M, 2006, J CLIN INVEST, V116, P137, DOI 10.1172/JCI26121; Van der Burg M, 2007, EUR J IMMUNOL, V37, P3522, DOI 10.1002/eji.200737624; van der Weerd K, 2014, THYROID, V24, P1051, DOI 10.1089/thy.2013.0396; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; Weerkamp F, 2006, TRENDS IMMUNOL, V27, P125, DOI 10.1016/j.it.2006.01.006; Weerkamp F, 2006, BLOOD, V107, P3131, DOI 10.1182/blood-2005-08-3412; Weerkamp F, 2005, J ALLERGY CLIN IMMUN, V115, P834, DOI 10.1016/j.jaci.2004.10.031; Wiekmeijer AS, 2014, BIORESEARCH OPEN ACC, V3, P110, DOI 10.1089/biores.2014.0008	47	19	19	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					517	+		10.1016/j.jaci.2015.08.022	http://dx.doi.org/10.1016/j.jaci.2015.08.022			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26441229				2022-12-18	WOS:000369235500021
J	Mousallem, T; Urban, TJ; McSweeney, KM; Kleinstein, SE; Zhu, MF; Adeli, M; Parrott, RE; Roberts, JL; Krueger, B; Buckley, RH; Goldstein, DB				Mousallem, Talal; Urban, Thomas J.; McSweeney, K. Melodi; Kleinstein, Sarah E.; Zhu, Mingfu; Adeli, Mehdi; Parrott, Roberta E.; Roberts, Joseph L.; Krueger, Brian; Buckley, Rebecca H.; Goldstein, David B.			Clinical application of whole-genome sequencing in patients with primary immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MUTATIONS; ARTEMIS; LYMPHOCYTE; DEFECTS		[Mousallem, Talal] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; [Mousallem, Talal] Wake Forest Sch Med, Dept Pediat, Winston Salem, NC USA; [Mousallem, Talal; Parrott, Roberta E.; Roberts, Joseph L.; Buckley, Rebecca H.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; [Urban, Thomas J.; McSweeney, K. Melodi; Kleinstein, Sarah E.; Zhu, Mingfu; Krueger, Brian; Goldstein, David B.] Duke Univ, Sch Med, Ctr Human Genome Variat, Durham, NC USA; [McSweeney, K. Melodi; Kleinstein, Sarah E.] Duke Univ, Sch Med, Dept Mol Genet & Microbiol, Durham, NC USA; [Adeli, Mehdi] Hamad Med Corp, Doha, Qatar; [Buckley, Rebecca H.] Duke Univ, Sch Med, Dept Immunol, Durham, NC USA; [Urban, Thomas J.] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA; [McSweeney, K. Melodi; Kleinstein, Sarah E.; Krueger, Brian; Goldstein, David B.] Columbia Univ, Med Ctr, Inst Genom Med, New York, NY USA	Wake Forest University; Wake Forest University; Duke University; Duke University; Duke University; Hamad Medical Corporation; Duke University; University of North Carolina; University of North Carolina Chapel Hill; Columbia University	Mousallem, T (corresponding author), Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA.	tmousall@wakehealth.edu; buckl003@mc.duke.edu	Kleinstein, Sarah E./ABB-2000-2020; Goldstein, David/AAY-8125-2020	Kleinstein, Sarah E./0000-0002-9714-5155; Adeli, Mehdi/0000-0002-3051-3080	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD043029] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [UC2HL102924, UC2HL102925, UC2HL102923, RC2HL102923, RC2HL102924, RC2HL102926, RC2HL102925, UC2HL103010, UC2HL102926, RC2HL103010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI067854, T32AI007062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007754, R25GM086262] Funding Source: NIH RePORTER; NHLBI NIH HHS [UC2 HL102924, RC2 HL103010, UC2 HL103010, UC2 HL102926, RC2 HL102923, RC2 HL102925, UC2 HL102923, RC2 HL102926, UC2 HL102925, RC2 HL102924] Funding Source: Medline; NIAID NIH HHS [T32 AI7062, T32 AI007062, U01 AI067854] Funding Source: Medline; NICHD NIH HHS [T32 HD43029, T32 HD043029] Funding Source: Medline; NIGMS NIH HHS [T32 GM007754, R25 GM086262] Funding Source: Medline; PHS HHS [UO1AIO67854] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; Buckley RH, 2011, IMMUNOL RES, V49, P25, DOI 10.1007/s12026-010-8191-9; Casanova JL, 2014, J EXP MED, V211, P2137, DOI 10.1084/jem.20140520; Choi M, 2009, P NATL ACAD SCI USA, V106, P19096, DOI 10.1073/pnas.0910672106; Durandy Anne, 2007, Adv Immunol, V94, P275, DOI 10.1016/S0065-2776(06)94009-7; Fromer M, 2012, AM J HUM GENET, V91, P597, DOI 10.1016/j.ajhg.2012.08.005; Ge DL, 2011, BIOINFORMATICS, V27, P1998, DOI 10.1093/bioinformatics/btr317; Hsu AP, 2013, BLOOD, V121, P3830, DOI 10.1182/blood-2012-08-452763; Kadalayil L, 2014, BRIEF BIOINFORM; Kracker S, 2010, ADV EXP MED BIOL, V685, P166; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lin Q, 1996, J CLIN INVEST, V97, P196, DOI 10.1172/JCI118389; Martin E, 2014, NATURE, V510, P288, DOI 10.1038/nature13386; Matute JD, 2009, BLOOD, V114, P3309, DOI 10.1182/blood-2009-07-231498; Mooster JL, 2010, J ALLERGY CLIN IMMUN, V126, P127, DOI 10.1016/j.jaci.2010.04.026; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2003, J CLIN INVEST, V111, P381, DOI 10.1172/JCI200316774; Mousallem T, 2014, BLOOD, V124, P2046, DOI 10.1182/blood-2014-04-571265; Need AC, 2012, J MED GENET, V49, P353, DOI 10.1136/jmedgenet-2012-100819; Nijman IJ, 2014, J ALLERGY CLIN IMMUN, V133, P529, DOI 10.1016/j.jaci.2013.08.032; Noack D, 2001, BLOOD, V97, P305, DOI 10.1182/blood.V97.1.305; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Orange JS, 2011, J ALLERGY CLIN IMMUN, V127, P1360, DOI 10.1016/j.jaci.2011.02.039; Pannicke U, 2010, HUM MUTAT, V31, P197, DOI 10.1002/humu.21168; Pannicke U, 2009, NAT GENET, V41, P101, DOI 10.1038/ng.265; Parvaneh N, 2013, J ALLERGY CLIN IMMUN, V131, P314, DOI 10.1016/j.jaci.2012.11.051; Rangel-Santos A, 2009, SCAND J IMMUNOL, V69, P169, DOI 10.1111/j.1365-3083.2008.02198.x; Roos D, 2006, HUM MUTAT, V27, P1218, DOI 10.1002/humu.20413; Saunders CJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004041; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Shashi V, 2014, GENET MED, V16, P176, DOI 10.1038/gim.2013.99; Triot A, 2014, BLOOD, V123, P3811, DOI 10.1182/blood-2013-11-535419; van Zelm MC, 2008, AM J HUM GENET, V82, P320, DOI 10.1016/j.ajhg.2007.10.011; Worthey EA, 2011, GENET MED, V13, P255, DOI 10.1097/GIM.0b013e3182088158; Zhu MF, 2012, AM J HUM GENET, V91, P408, DOI 10.1016/j.ajhg.2012.07.004	35	19	21	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					476	+		10.1016/j.jaci.2015.02.040	http://dx.doi.org/10.1016/j.jaci.2015.02.040			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25981738	Green Accepted			2022-12-18	WOS:000359004900030
J	Eschborn, M; Weigmann, B; Reissig, S; Waisman, A; Saloga, J; Bellinghausen, I				Eschborn, Melanie; Weigmann, Benno; Reissig, Sonja; Waisman, Ari; Saloga, Joachim; Bellinghausen, Iris			Activated glycoprotein A repetitions predominant (GARP)-expressing regulatory T cells inhibit allergen-induced intestinal inflammation in humanized mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Humanized mice; IgE; allergen; regulatory T cells; colon; inflammation	DENDRITIC CELLS; MOUSE MODEL; SCID MICE; DISEASE; ASTHMA; IMMUNOTHERAPY; TOLERANCE; RESPONSES; SUPPRESSION; EXPRESSION	Background: Recently, we developed a humanized mouse model of allergen-induced IgE-dependent gut inflammation in PBMC-engrafted immunodeficient mice. Objective: In the present study, we wanted to investigate the role of regulatory T (Treg) cells and their activation status in this model. Methods: Nonobese diabetic-severe combined immunodeficiency-gamma c(-/-) mice were injected intraperitoneally with human PBMCs from allergic donors together with the respective allergen or NaCl as control in the presence or absence of different concentrations of CD4(+) CD25(+) Treg cells of the same donor. After an additional allergen boost 1 week later, mice were challenged with the allergen rectally on day 21 and gut inflammation was monitored by a high-resolution video mini-endoscopic system evaluating translucency, granularity, fibrin production, vascularity, and stool. Results: Allergen-specific human IgE in mouse sera, which was detectable only in PBMC plus allergen-treated mice, was strongly inhibited by coinjection of Treg cells at a ratio of at least 1:10. Consequently, the presence of Treg cells significantly decreased IgE-dependent allergen-induced gut inflammation after rectal allergen challenge. In addition, Treg cells reduced allergen-specific proliferation and cytokine production of recovered human CD4(+) T cells in vitro. Activation of Treg cells before injection further increased all inhibitory effects. Prevention of gut inflammation also occurred by the administration of glycoprotein A repetitions predominant, a molecule expressed by activated Treg cells, whereas its blockade completely abrogated inhibition by Treg cells. Conclusions: These results demonstrate that allergen-specific gut inflammation in human PBMC-engrafted mice can be avoided by enhancing the numbers or activity of autologous Treg cells, which is of great interest for therapeutic intervention of allergic diseases of the intestine.	[Eschborn, Melanie; Saloga, Joachim; Bellinghausen, Iris] Univ Erlangen Nurnberg, Dept Dermatol, Univ Hosp Erlangen, Erlangen, Germany; [Weigmann, Benno] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Internal Med 1, Erlangen, Germany; [Reissig, Sonja; Waisman, Ari] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Mol Med, D-55131 Mainz, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; Johannes Gutenberg University of Mainz	Bellinghausen, I (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Dermatol, Langenbeckstr 1, D-55131 Mainz, Germany.	iris.bellinghausen@unimedizin-mainz.de	Waisman, Ari/C-7383-2015	Waisman, Ari/0000-0003-4304-8234; Eschborn, Melanie/0000-0003-4287-2678	Deutsche Forschungsgemeinschaft [BE 4504/2-2]; Clinical Research Unit 257 CEDER [WE 4656/2-2]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Clinical Research Unit 257 CEDER	This work was supported by Deutsche Forschungsgemeinschaft (grant no. BE 4504/2-2 to I.B.) and the Clinical Research Unit 257 CEDER (grant no. WE 4656/2-2 to B.W.).	Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; Becker C, 2006, NAT PROTOC, V1, P2900, DOI 10.1038/nprot.2006.446; Becker C, 2009, BLOOD, V114, P1263, DOI 10.1182/blood-2009-02-206730; Bellinghausen I, 2006, CLIN EXP ALLERGY, V36, P1546, DOI 10.1111/j.1365-2222.2006.02601.x; Bellinghausen I, 2005, IMMUNOLOGY, V116, P103, DOI 10.1111/j.1365-2567.2005.02205.x; Bellinghausen I, 2003, J ALLERGY CLIN IMMUN, V111, P862, DOI 10.1067/mai.2003.1412; Bellinghausen I, 2012, J ALLERGY CLIN IMMUN, V130, P1384, DOI 10.1016/j.jaci.2012.08.039; Brehm MA, 2013, CURR OPIN IMMUNOL, V25, P428, DOI 10.1016/j.coi.2013.05.012; Burks AW, 2013, J ALLERGY CLIN IMMUN, V131, P1288, DOI 10.1016/j.jaci.2013.01.049; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; GAGNON R, 1995, J ALLERGY CLIN IMMUN, V95, P1268, DOI 10.1016/S0091-6749(95)70085-4; Gri G, 2008, IMMUNITY, V29, P771, DOI 10.1016/j.immuni.2008.08.018; Grindebacke H, 2004, CLIN EXP ALLERGY, V34, P1364, DOI 10.1111/j.1365-2222.2004.02067.x; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Hahn SA, 2013, BLOOD, V122, P1182, DOI 10.1182/blood-2012-12-474478; Herz U, 2004, CLIN EXP ALLERGY, V34, P478, DOI 10.1111/j.1365-2222.2004.01887.x; Huter EN, 2009, INT IMMUNOPHARMACOL, V9, P540, DOI 10.1016/j.intimp.2009.01.022; Kalathil S, 2013, CANCER RES, V73, P2435, DOI 10.1158/0008-5472.CAN-12-3381; Kanjarawi R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069183; King M, 2008, CLIN IMMUNOL, V126, P303, DOI 10.1016/j.clim.2007.11.001; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Maazi H, 2012, CLIN EXP ALLERGY, V42, P1519, DOI 10.1111/j.1365-2222.2012.04064.x; Martin H, 2012, J ALLERGY CLIN IMMUN, V129, P521, DOI 10.1016/j.jaci.2011.09.038; Nguyen THT, 2011, IMMUNOL REV, V242, P258, DOI 10.1111/j.1600-065X.2011.01034.x; Nishikawa H, 2014, CURR OPIN IMMUNOL, V27, P1, DOI 10.1016/j.coi.2013.12.005; Pellerin L, 2014, IMMUNOL RES, V58, P358, DOI 10.1007/s12026-014-8512-5; Perros F, 2009, ALLERGY, V64, P995, DOI 10.1111/j.1398-9995.2009.02095.x; Pierkes M, 1999, J ALLERGY CLIN IMMUN, V103, P326, DOI 10.1016/S0091-6749(99)70509-9; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Shale M, 2013, IMMUNOL REV, V252, P164, DOI 10.1111/imr.12039; Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311; Sicherer SH, 2013, J ALLERGY CLIN IMMUN, V131, P55, DOI 10.1016/j.jaci.2012.11.007; Sonar SS, 2010, J CLIN INVEST, V120, P2767, DOI 10.1172/JCI39543; Soyer OU, 2013, ALLERGY, V68, P161, DOI 10.1111/all.12085; Stummvoll GH, 2008, J IMMUNOL, V181, P1908, DOI 10.4049/jimmunol.181.3.1908; Takeda K, 2009, CURR OPIN IMMUNOL, V21, P660, DOI 10.1016/j.coi.2009.09.005; Tran DQ, 2009, P NATL ACAD SCI USA, V106, P13445, DOI 10.1073/pnas.0901944106; Wang R, 2009, P NATL ACAD SCI USA, V106, P13439, DOI 10.1073/pnas.0901965106; Weigmann B, 2012, J ALLERGY CLIN IMMUN, V129, P1126, DOI 10.1016/j.jaci.2011.11.036; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wisniewski J, 2013, CLIN EXP ALLERGY, V43, P164, DOI 10.1111/cea.12016	41	19	20	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					159	168		10.1016/j.jaci.2015.04.020	http://dx.doi.org/10.1016/j.jaci.2015.04.020			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	26145987				2022-12-18	WOS:000357542200018
J	Begin, P; Nadeau, KC				Begin, Philippe; Nadeau, Kari C.			Changes in peanut-specific T-cell clonotype with oral immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGY		[Begin, Philippe] Hop St Justine, Dept Pediat, Montreal, PQ H3T 1C5, Canada; [Begin, Philippe] Univ Montreal, Dept Med, Ctr Hlth, Montreal, PQ H3C 3J7, Canada; [Nadeau, Kari C.] Stanford Univ, Sch Med, Div Allergy Immunol & Rheumatol, Sean N Parker Ctr Allergy Res, Stanford, CA 94305 USA	Universite de Montreal; Universite de Montreal; Stanford University	Begin, P (corresponding author), Hop St Justine, Dept Pediat, Montreal, PQ H3T 1C5, Canada.	philippe.begin@u.montreal.ca	Bégin, Philippe/AAU-9126-2021		NIAID NIH HHS [U19AI10420901] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Begin P, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-7; Burton OT, 2014, IMMUNITY, V41, P141, DOI 10.1016/j.immuni.2014.05.017; DeLong JH, 2011, J ALLERGY CLIN IMMUN, V127, P1211, DOI 10.1016/j.jaci.2011.02.028; Geiger R, 2009, J EXP MED, V206, P1525, DOI 10.1084/jem.20090504; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Qi Q, 2014, P NATL ACAD SCI USA, V111, P13139, DOI 10.1073/pnas.1409155111; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Van Hemelen D, 2015, ALLERGY, V70, P49, DOI 10.1111/all.12524	9	19	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1636	1638		10.1016/j.jaci.2015.03.010	http://dx.doi.org/10.1016/j.jaci.2015.03.010			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25930192				2022-12-18	WOS:000355933400027
J	Faber, MA; Sabato, V; Bridts, CH; Nayak, A; Beezhold, DH; Ebo, DG				Faber, Margaretha A.; Sabato, Vito; Bridts, Chris H.; Nayak, Ajay; Beezhold, Donald H.; Ebo, Didier G.			Clinical relevance of the Hevea brasiliensis lipid transfer protein Hev b 12	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LATEX; REACTIVITY; ALLERGY		[Faber, Margaretha A.; Sabato, Vito; Bridts, Chris H.; Ebo, Didier G.] Univ Antwerp, Fac Med & Hlth Sci, Immunol Allergol Rheumatol, B-2020 Antwerp, Belgium; [Faber, Margaretha A.; Sabato, Vito; Bridts, Chris H.; Ebo, Didier G.] Univ Antwerp Hosp, Antwerp, Belgium; [Nayak, Ajay; Beezhold, Donald H.] NIOSH, Hlth Effects Lab, Morgantown, WV USA	University of Antwerp; University of Antwerp; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Faber, MA (corresponding author), Univ Antwerp, Fac Med & Hlth Sci, Immunol Allergol Rheumatol, B-2020 Antwerp, Belgium.	immuno@uantwerpen.be	Faber, Margaretha/L-2903-2017; EBO, Didier/H-4894-2016; Sabato, Vito/B-6479-2017; BRIDTS, Chris HM/M-7933-2016	Faber, Margaretha/0000-0002-1277-5052; EBO, Didier/0000-0003-0672-7529; Sabato, Vito/0000-0002-1321-314X; BRIDTS, Chris HM/0000-0002-3324-7320; Beezhold, Donald/0000-0001-5543-5747				Batard T, 2006, INT ARCH ALLERGY IMM, V140, P295, DOI 10.1159/000093707; Beezhold DH, 2003, ANN ALLERG ASTHMA IM, V90, P439, DOI 10.1016/S1081-1206(10)61830-3; Ebo DG, 2013, INT ARCH ALLERGY IMM, V161, P220, DOI 10.1159/000346721; Ebo DG, 2010, CLIN EXP ALLERGY, V40, P348, DOI 10.1111/j.1365-2222.2009.03370.x; Faber MA, 2015, J INVESTIG IN PRESS; Palomares O, 2005, CLIN EXP ALLERGY, V35, P345, DOI 10.1111/j.1365-2222.2004.02186.x; Pamies R, 2005, ALLERGY, V60, P709, DOI 10.1111/j.1398-9995.2005.00739.x; Pomponi D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035697; Rihs HP, 2006, ANN ALLERG ASTHMA IM, V97, P643, DOI 10.1016/S1081-1206(10)61094-0; Rolland-Debord C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085976; Schuler Sarah, 2013, Clin Transl Allergy, V3, P11, DOI 10.1186/2045-7022-3-11	11	19	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1645	1648		10.1016/j.jaci.2014.12.1919	http://dx.doi.org/10.1016/j.jaci.2014.12.1919			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25649078				2022-12-18	WOS:000355933400031
J	Albano, GD; Zhao, JM; Etling, EB; Park, SY; Hu, HZ; Trudeau, JB; Profita, M; Wenzel, SE				Albano, Giusy D.; Zhao, Jinming; Etling, Emily B.; Park, Seo Young; Hu, Haizhen; Trudeau, John B.; Profita, Mirella; Wenzel, Sally E.			IL-13 desensitizes beta(2)-adrenergic receptors in human airway epithelial cells through a 15-lipoxygenase/G protein receptor kinase 2 mechanism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-13; cAMP; phosphatidylethanolamine binding protein 1; 15-lipoxygenase 1; beta(2)-adrenergic receptor; G protein receptor kinase 2; asthma	COUPLED RECEPTOR; BETA-ARRESTIN; SMOOTH-MUSCLE; SEVERE ASTHMA; AGONIST; BINDING; RAF-1; PHOSPHORYLATION; INFLAMMATION; SUPPRESSION	Background: beta 2-Adrenergic receptor (beta(2)AR) agonists are critical treatments for asthma. However, receptor desensitization can lead to loss of therapeutic effects. Although desensitization to repeated use of beta 2-agonists is well studied, type 2 inflammation could also affect beta 2AR function. Objective: We sought to evaluate the effect of the type 2 cytokine IL-13 on beta 2AR desensitization in human airway epithelial cells (HAECs) and determine whether 15-lipoxygenase-1 (15LO1) binding with phosphatidylethanolamine-binding protein 1 (PEBP1) contributes to desensitization through release of G protein receptor kinase 2 (GRK2). Methods: HAECs in air-liquid interface culture with or without IL-13 (48 hours) or isoproterenol hydrochloride (ISO; 30 minutes) pretreatment were stimulated with ISO (10 minutes). Cyclic adenosine 3, 5-monophosphate (cAMP) levels were measured using ELISA, and beta 2AR and GRK2 phosphorylation was measured using Western blotting. Short interfering RNAwas used for 15LO1 knockdown. Interactions of GRK2, PEBP1, and 15LO1 were detected by means of immunoprecipitation/Western blotting and immunofluorescence. HAECs and airway tissue from control subjects and asthmatic patients were evaluated for I5LO1, PEBP1, and GRK2. Results: Pretreatment with ISO or IL-13 decreased ISO-induced cAMP generation compared with ISO for 10 minutes alone paralleled by increases in beta 2AR and GRK2 phosphorylation. GRK2 associated with PEBP1 after 10 minutes of ISO in association with low phosphorylated GRK2 (pGRK2) levels. In contrast, in the presence of IL-13 plus ISO(10 minutes), binding of GRK2 to PEBP1 decreased, whereas 15LO1 binding and pGRK2 levels increased. 15LO1 knockdown restored ISO-induced cAMP generation. These findings were recapitulated in freshly brushed HAECs from cells and tissue of asthmatic patients. Conclusion: IL-13 treatment of HAECs leads to beta 2AR desensitization, which involves 15LO1/PEBP1 interactions to free GRK2, and allows it to phosphorylate (and desensitize) beta 2ARs, suggesting that the beneficial effects of beta 2-agonists could be blunted in patients with type 2 associated asthma.	[Albano, Giusy D.; Zhao, Jinming; Etling, Emily B.; Hu, Haizhen; Trudeau, John B.; Wenzel, Sally E.] Univ Pittsburgh, Asthma Inst UPMC, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA; [Park, Seo Young] Univ Pittsburgh, Ctr Res Hlth Care Data Ctr, Pittsburgh, PA 15260 USA; [Albano, Giusy D.; Profita, Mirella] Italian Natl Res Council, Inst Biomed & Mol Immunol, Palermo, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR)	Zhao, JM (corresponding author), NW 628 Montefiore,3459 Fifth Ave, Pittsburgh, PA 15213 USA.	zhaoj2@upmc.edu	Profita, Mirella/AAY-3165-2020; Profita, Mirella/AFU-7423-2022; Abano, Giusy Daniela/AAY-3896-2020; Profita, Mirella/D-8957-2018	Abano, Giusy Daniela/0000-0001-6944-4118; Profita, Mirella/0000-0002-7821-8283; Wenzel, Sally/0000-0002-4242-0164; Zhao, Jinming/0000-0003-4700-9734	National Institutes of Health [AI-40600-15]; CTSI [UL1-RR024153]; American Heart Association [0825556D]; American Lung Association [RG-231468-N]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL109152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040600] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CTSI; American Heart Association(American Heart Association); American Lung Association; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant AI-40600-15 (to S.E.W.); CTSI UL1-RR024153 (to S.E.W.), American Heart Association grant 0825556D (to J.Z.), and American Lung Association grant RG-231468-N (to J.Z.).	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; [Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; BHAGAT R, 1995, CHEST, V108, P1235, DOI 10.1378/chest.108.5.1235; Billington CK, 2003, RESP RES, V4; Bonini M, 2013, AM J RESP CRIT CARE, V188, P1407, DOI 10.1164/rccm.201307-1323OC; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; Chibana K, 2008, CLIN EXP ALLERGY, V38, P936, DOI 10.1111/j.1365-2222.2008.02969.x; Chu HW, 2004, AM J PATHOL, V165, P1097, DOI 10.1016/S0002-9440(10)63371-8; Cockcroft DW, 1995, J ALLERGY CLIN IMMUN, V96, P1013, DOI 10.1016/S0091-6749(95)70245-8; Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.M210015200; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Deshpande DA, 2006, CELL SIGNAL, V18, P2105, DOI 10.1016/j.cellsig.2006.04.008; Diviani D, 1996, J BIOL CHEM, V271, P5049; Dowell ML, 2014, CURR OPIN PULM MED, V20, P66, DOI 10.1097/MCP.0000000000000011; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; Heijink IH, 2004, CLIN EXP ALLERGY, V34, P1356, DOI 10.1111/j.1365-2222.2004.02037.x; Huang JA, 2007, AM J PHYSIOL-GASTR L, V292, pG867, DOI 10.1152/ajpgi.00326.2006; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Johnson M, 2006, J ALLERGY CLIN IMMUN, V117, P18, DOI 10.1016/j.jaci.2005.11.012; Krasel C, 2005, J BIOL CHEM, V280, P9528, DOI 10.1074/jbc.M413078200; LINDBERG S, 1995, EUR J PHARMACOL, V285, P275, DOI 10.1016/0014-2999(95)00416-I; Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158; Luttrell LM, 2002, J CELL SCI, V115, P455; McGraw Dennis W, 2005, Proc Am Thorac Soc, V2, P292, DOI 10.1513/pats.200504-027SR; McGraw DW, 2005, P AM THORAC SOC, V2, P311; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Nichols HL, 2012, P NATL ACAD SCI USA, V109, P16660, DOI 10.1073/pnas.1208881109; Penn RB, 2001, J BIOL CHEM, V276, P32648, DOI 10.1074/jbc.M104143200; Penn RB, 1996, AM J PHYSIOL-LUNG C, V271, pL601, DOI 10.1152/ajplung.1996.271.4.L601; Peters SP, 1999, AM J MED, V107, P283; Robinson JD, 2013, CELL SIGNAL, V25, P2831, DOI 10.1016/j.cellsig.2013.08.031; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Slupsky JR, 1999, CURR BIOL, V9, P971, DOI 10.1016/S0960-9822(99)80426-6; Tan KS, 1997, AM J RESP CRIT CARE, V156, P28, DOI 10.1164/ajrccm.156.1.9610113; Trudeau J, 2006, J ALLERGY CLIN IMMUN, V117, P1446, DOI 10.1016/j.jaci.2006.01.049; Villaran C, 1999, J ALLERGY CLIN IMMUN, V104, P547, DOI 10.1016/S0091-6749(99)70322-2; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Walker JKL, 2014, CURR OPIN PHARMACOL, V16, P142, DOI 10.1016/j.coph.2014.03.007; Wasilewski NV, 2014, CURR OPIN PHARMACOL, V16, P148, DOI 10.1016/j.coph.2014.05.007; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; Wenzel SE, 2013, NEW ENGL J MED, V369, P1276, DOI 10.1056/NEJMc1309809; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Zhao JM, 2011, P NATL ACAD SCI USA, V108, P14246, DOI 10.1073/pnas.1018075108; Zhao JM, 2009, AM J RESP CRIT CARE, V179, P782, DOI 10.1164/rccm.200811-1744OC	47	19	22	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1144	U510		10.1016/j.jaci.2015.02.006	http://dx.doi.org/10.1016/j.jaci.2015.02.006			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25819984	Green Accepted			2022-12-18	WOS:000353980700006
J	Urena-Tavera, A; Zamora-Verduga, M; Madrigal-Burgaleta, R; Angel-Pereira, D; Berges-Gimeno, MP; Alvarez-Cuesta, E				Urena-Tavera, Alicia; Zamora-Verduga, Miriam; Madrigal-Burgaleta, Ricardo; Angel-Pereira, Denisse; Berges-Gimeno, Maria Pilar; Alvarez-Cuesta, Emilio			Hypersensitivity reactions to racemic calcium folinate (leucovorin) during FOLFOX and FOLFIRI chemotherapy administrations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DESENSITIZATION; ALLERGY		[Urena-Tavera, Alicia; Zamora-Verduga, Miriam; Madrigal-Burgaleta, Ricardo; Angel-Pereira, Denisse; Berges-Gimeno, Maria Pilar; Alvarez-Cuesta, Emilio] Ramon & Cajal Univ Hosp, Div Allergy, Madrid, Spain	Hospital Universitario Ramon y Cajal	Urena-Tavera, A (corresponding author), Ramon & Cajal Univ Hosp, Div Allergy, Madrid, Spain.	rmadbur@hotmail.com	Berges-Gimeno, María Pilar/AAB-7399-2019; Madrigal-Burgaleta, Ricardo/AAF-3255-2019	Berges-Gimeno, María Pilar/0000-0002-0313-4122; Madrigal-Burgaleta, Ricardo/0000-0002-3358-3578; Angel, Denisse/0000-0002-2172-2622				Angel-Pereira D, 2014, J ALLER CL IMM-PRACT, V2, P346, DOI 10.1016/j.jaip.2013.12.011; Damaske Avni, 2012, J Oncol Pharm Pract, V18, P136, DOI 10.1177/1078155210396577; Dykewicz MS, 2000, J ALLERGY CLIN IMMUN, V106, P386, DOI 10.1067/mai.2000.108502; Kovoor PA, 2009, CLIN COLORECTAL CANC, V8, P200, DOI 10.3816/CCC.2009.n.034; Liu A, 2011, CLIN EXP ALLERGY, V41, P1679, DOI 10.1111/j.1365-2222.2011.03825.x; Madrigal-Burgaleta R, 2013, J INVEST ALLERG CLIN, V23, P435; Madrigal-Burgaleta R, 2013, ALLERGY, V68, P853, DOI 10.1111/all.12105; Vermeulen C, 2003, REV FR ALLERGOL, V43, P342, DOI 10.1016/S0335-7457(03)00115-1	8	19	19	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					1066	1067		10.1016/j.jaci.2014.09.045	http://dx.doi.org/10.1016/j.jaci.2014.09.045			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25457996				2022-12-18	WOS:000352238600031
J	Rosel, AL; Scheibenbogen, C; Schliesser, U; Sollwedel, A; Hoffmeister, B; Hanitsch, L; von Bernuth, H; Kruger, R; Warnatz, K; Volk, HD; Thomas, S				Roesel, Amelia L.; Scheibenbogen, Carmen; Schliesser, Ulrike; Sollwedel, Andre; Hoffmeister, Bodo; Hanitsch, Leif; von Bernuth, Horst; Krueger, Renate; Warnatz, Klaus; Volk, Hans-Dieter; Thomas, Sybill			Classification of common variable immunodeficiencies using flow cytometry and a memory B-cell functionality assay	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Memory B cell; enzyme-linked immunosorbent spot assay; common variable immunodeficiency subtyping; flow cytometry; antibody-secreting cells	ANTIBODY-DEFICIENCY SYNDROME; IMMUNE-DEFICIENCY; HETEROGENEOUS DISEASE; CVID PATIENTS; PLASMA-CELLS; SUBPOPULATIONS; RESPONSES; RECEPTOR; DEFECTS; DIFFERENTIATION	Background: The population of patients with common variable immunodeficiency (CVID) comprises a heterogeneous group of patients with different causes of hypogammaglobulinemia predisposing to recurrent infections, higher incidence of autoimmunity, and malignancy. Although memory B cells (memBcs) are key players in humoral defense and their numbers are commonly reduced in these patients, their functionality is not part of any current classification. Objective: We established and validated a memBc enzyme-linked immunosorbent spot (ELISpot) assay that reveals the capacity of memBcs to develop into antibody-secreting cells and present an idea for a new classification based on this functional capacity. Methods: The memBc ELISpot assay, combined with flow cytometry, was applied to patients with confirmed CVID in comparison with age-matched healthy control subjects. Results: Ex vivo frequency of IgG-, IgM-, and IgA-secreting plasmablasts was significantly diminished by 27.2-, 2.4-, and 23.3fold, respectively, compared with that seen in healthy control subjects. Moreover, invitro differentiation ofmemBcs into antibodysecreting cells was 6.1-, 2.6-, and 3.7-fold significantly reduced for IgG-, IgM-, and IgA-secreting cells, respectively. Proliferation of memBcs correlates inversely to immunoglobulin-secreting capacity, suggesting compensatory hyperproliferation. Furthermore, patients with no serum IgA can still have a detectable IgA ELISpot assay result in vitro. Most importantly, the large heterogeneity of memBc function in patients with CVID homogenously grouped bymeans of fluorescence-activated cell sorting allowed additional subclassification based on memBc/plasmablast function. Conclusion: These data suggest almost normal memBc/immunoglobulin-secreting plasmablast functionality in some patients if sufficient stimulatory signals are delivered, which might open up opportunities for new therapeutic approaches.	[Roesel, Amelia L.; Scheibenbogen, Carmen; Sollwedel, Andre; Volk, Hans-Dieter; Thomas, Sybill] Charite Univ Med Berlin, Inst Med Immunol, Berlin, Germany; [Scheibenbogen, Carmen; Schliesser, Ulrike; Volk, Hans-Dieter] Berlin Brandenburg Ctr Regenerat Therapies, Berlin, Germany; [Scheibenbogen, Carmen; Hoffmeister, Bodo; Hanitsch, Leif] Charite Univ Med Berlin, Out Patients Clin Immunodeficenc, Berlin, Germany; [von Bernuth, Horst; Krueger, Renate] Charite Univ Med Berlin, Dept Pneumol & Immunol, Pediat Clin, Berlin, Germany; [Warnatz, Klaus] Univ Freiburg, Freiburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Freiburg	Volk, HD (corresponding author), Charite, Inst Med Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.	hans-dieter.volk@charite.de	volk, hans-dieter/AAV-8053-2021; Warnatz, Klaus/AAD-3464-2022; von Bernuth, Horst/AAQ-9797-2021	volk, hans-dieter/0000-0002-7743-6668; von Bernuth, Horst/0000-0002-5812-7675; Hanitsch, Leif G./0000-0002-8181-0093; Scheibenbogen, Carmen/0000-0002-8554-9638	BMWi-ZIM (Federal Ministry of Economics and Technology) [KF2088107FR9]	BMWi-ZIM (Federal Ministry of Economics and Technology)	Supported by BMWi-ZIM (Federal Ministry of Economics and Technology), Cooperation Project KF2088107FR9, for the grant to partially finance this project.	Agarwal S, 2011, INFLAMM BOWEL DIS, V17, P251, DOI 10.1002/ibd.21376; Avery DT, 2010, J EXP MED, V207, P155, DOI 10.1084/jem.20091706; BAUMERT E, 1992, IMMUN INFEKT, V20, P73; Bekeredjian-Ding I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029806; Berglund LJ, 2008, PATHOLOGY, V40, P288, DOI 10.1080/00313020801911470; Borte S, 2010, KLIN PADIATR, V222, P362, DOI 10.1055/s-0030-1265207; BRYANT A, 1990, CLIN IMMUNOL IMMUNOP, V56, P239, DOI 10.1016/0090-1229(90)90145-G; Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545; Chovancova Z, 2011, VACCINE, V29, P4142, DOI 10.1016/j.vaccine.2011.03.087; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; Crotty S, 2004, J IMMUNOL METHODS, V286, P111, DOI 10.1016/j.jim.2003.12.015; Cunningham-Rundles C, 2012, HEMATOL-AM SOC HEMAT, P301, DOI 10.1182/asheducation-2012.1.301; Cunningham-Rundles C, 2010, BLOOD, V116, P7, DOI 10.1182/blood-2010-01-254417; Dauner JG, 2010, VACCINE, V28, P5407, DOI 10.1016/j.vaccine.2010.06.018; Driessen GJ, 2011, BLOOD, V118, P6814, DOI 10.1182/blood-2011-06-361881; Gaspar HB, 2000, CLIN EXP IMMUNOL, V119, P383, DOI 10.1046/j.1365-2249.2000.01192.x; Gathmann B, 2009, CLIN EXP IMMUNOL, V157, P3, DOI 10.1111/j.1365-2249.2009.03954.x; Golubev A, 2012, PROG BIOPHYS MOL BIO, V110, P87, DOI 10.1016/j.pbiomolbio.2012.05.002; Henn AD, 2012, SCI REP-UK, V2, DOI 10.1038/srep00345; Horn J, 2007, CLIN IMMUNOL, V122, P156, DOI 10.1016/j.clim.2006.10.002; JEONG G, 1985, J CLIN IMMUNOL, V5, P122, DOI 10.1007/BF00915010; Kuijpers TW, 2010, J CLIN INVEST, V120, P214, DOI 10.1172/JCI40231; Latner DR, 2011, CLIN VACCINE IMMUNOL, V18, P35, DOI 10.1128/CVI.00284-10; LeBien TW, 2008, BLOOD, V112, P1570, DOI 10.1182/blood-2008-02-078071; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Lucas M, 2010, J ALLERGY CLIN IMMUN, V125, P1354, DOI 10.1016/j.jaci.2010.02.040; Maarschalk-Ellerbroek LJ, 2011, INT J ANTIMICROB AG, V37, P396, DOI 10.1016/j.ijantimicag.2010.11.027; Maecker HT, 2012, NAT REV IMMUNOL, V12, P191, DOI 10.1038/nri3158; Mei Henrik E., 2007, V136, P3; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Moschese V, 2008, INT J IMMUNOPATH PH, V21, P343, DOI 10.1177/039463200802100211; Mouillot G, 2010, J CLIN IMMUNOL, V30, P746, DOI 10.1007/s10875-010-9424-3; Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X; Piqueras B, 2003, J CLIN IMMUNOL, V23, P385, DOI 10.1023/A:1025373601374; Salzer U, 2004, CLIN IMMUNOL, V113, P234, DOI 10.1016/j.clim.2004.07.002; Salzer U, 2012, ANN NY ACAD SCI, V1250, P41, DOI 10.1111/j.1749-6632.2011.06377.x; Schwartz-Albiez R, 2009, CLIN EXP IMMUNOL, V158, P43, DOI [10.1111/j.1365-2249.2009.04026.X, 10.1111/j.1365-2249.2009.04026.x]; Tangye SG, 2003, J IMMUNOL, V170, P261, DOI 10.4049/jimmunol.170.1.261; Tangye SG, 2009, EUR J IMMUNOL, V39, P2065, DOI 10.1002/eji.200939531; van de Ven AAJM, 2010, CLIN IMMUNOL, V135, P63, DOI 10.1016/j.clim.2009.11.010; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; van Zelm MC, 2010, J CLIN INVEST, V120, P1265, DOI 10.1172/JCI39748; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Warnatz K, 2008, CYTOM PART B-CLIN CY, V74B, P261, DOI 10.1002/cyto.b.20432; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Weiss GE, 2012, J IMMUNOL METHODS, V375, P68, DOI 10.1016/j.jim.2011.09.006; Yazdani Reza, 2014, Adv Biomed Res, V3, P2, DOI 10.4103/2277-9175.124627; Yong PFK, 2011, ADV IMMUNOL, V111, P47, DOI 10.1016/B978-0-12-385991-4.00002-7; Yoshida T, 2010, IMMUNOL REV, V237, P117, DOI 10.1111/j.1600-065X.2010.00938.x	50	19	21	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					198	U300		10.1016/j.jaci.2014.06.022	http://dx.doi.org/10.1016/j.jaci.2014.06.022			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25112698	Green Submitted			2022-12-18	WOS:000347298200024
J	Hochwallner, H; Alm, J; Lupinek, C; Johansson, C; Mie, A; Scheynius, A; Valenta, R				Hochwallner, Heidrun; Alm, Johan; Lupinek, Christian; Johansson, Catharina; Mie, Axel; Scheynius, Annika; Valenta, Rudolf			Transmission of allergen-specific IgG and IgE from maternal blood into breast milk visualized with microarray technology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SENSITIZATION; DIAGNOSIS; COLOSTRUM; RECEPTOR; SERUM; MICE		[Hochwallner, Heidrun; Lupinek, Christian; Valenta, Rudolf] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria; [Alm, Johan; Mie, Axel] Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, Stockholm, Sweden; [Alm, Johan] Soder Sjukhuset, Sachs Children & Youth Hosp, Stockholm, Sweden; [Johansson, Catharina; Scheynius, Annika] Karolinska Inst, Dept Med Solna, Translat Immunol Unit, Stockholm, Sweden; [Johansson, Catharina; Scheynius, Annika] Univ Hosp, Stockholm, Sweden	Medical University of Vienna; Karolinska Institutet; Sodersjukhuset Hospital; Sodersjukhuset Hospital; Karolinska Institutet	Hochwallner, H (corresponding author), Med Univ Vienna, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Lupinek, Christian/I-3311-2019	Lupinek, Christian/0000-0002-8612-8245; Valenta, Rudolf/0000-0001-5944-3365; Mie, Axel/0000-0001-8053-3541; Alm, Johan/0000-0002-9062-4479	Austrian Science Fund FWF [F 4605, P 25921] Funding Source: Medline; Austrian Science Fund (FWF) [P 25921] Funding Source: researchfish	Austrian Science Fund FWF(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))		Bednar-Tantscher E, 2001, INT ARCH ALLERGY IMM, V126, P300, DOI 10.1159/000049527; Bernard H, 2014, ALLERGY, V69, P888, DOI 10.1111/all.12411; Borgers H, 2010, CLIN IMMUNOL, V134, P198, DOI 10.1016/j.clim.2009.10.006; Chapgier A, 2006, PLOS GENET, V2, P1193, DOI 10.1371/journal.pgen.0020131; Cianga P, 2003, HUM IMMUNOL, V64, P1152, DOI 10.1016/j.humimm.2003.08.025; Danso-Abeam D, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-79; Denayer S, 2010, MOL ENDOCRINOL, V24, P898, DOI 10.1210/me.2009-0310; Duchen K, 1996, PEDIATR ALLERGY IMMU, V7, P44, DOI 10.1111/j.1399-3038.1996.tb00104.x; GASPARONI A, 1992, ARCH DIS CHILD-FETAL, V67, P41, DOI 10.1136/adc.67.1_Spec_No.41; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Macchiaverni P, 2014, CLIN TRANSL ALLERGY, V4, pP1; Matheson MC, 2012, CLIN EXP ALLERGY, V42, P827, DOI 10.1111/j.1365-2222.2011.03925.x; Oftedal BE, 2008, CLIN IMMUNOL, V129, P163, DOI 10.1016/j.clim.2008.07.002; Rasband WS., IMAGEJ; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; Rumbo M, 1998, CLIN EXP IMMUNOL, V112, P453; Stenius F, 2011, ALLERGY, V66, P1330, DOI 10.1111/j.1398-9995.2011.02662.x; Uthoff H, 2003, J IMMUNOL, V171, P3485, DOI 10.4049/jimmunol.171.7.3485	18	19	19	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1213	1215		10.1016/j.jaci.2014.08.041	http://dx.doi.org/10.1016/j.jaci.2014.08.041			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	25439230	Green Published, hybrid			2022-12-18	WOS:000344938900035
J	Chapuy, L; Bsat, M; Mehta, H; Rubio, M; Wakahara, K; Van, VQ; Baba, N; Cheong, C; Yun, TJ; Panzini, B; Wassef, R; Richard, C; Tamaz, R; Soucy, G; Delespesse, G; Sarfati, M				Chapuy, Laurence; Bsat, Marwa; Mehta, Heena; Rubio, Manuel; Wakahara, Keiko; Van, Vu Quang; Baba, Nobuyasu; Cheong, Cheolho; Yun, Tae Jin; Panzini, Benoit; Wassef, Ramses; Richard, Carole; Tamaz, Raja; Soucy, Genevieve; Delespesse, Guy; Sarfati, Marika			Basophils increase in Crohn disease and ulcerative colitis and favor mesenteric lymph node memory T(H)17/T(H)1 response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EPITHELIAL-CELLS; T-CELLS; INFLAMMATION; FIBROBLASTS; EXPRESSION; TH17		[Chapuy, Laurence; Bsat, Marwa; Mehta, Heena; Rubio, Manuel; Van, Vu Quang; Sarfati, Marika] Ctr Rech Ctr Hosp Univ Montreal CRCHUM, Immunoregulat Lab, Montreal, PQ, Canada; [Delespesse, Guy] Ctr Rech Ctr Hosp Univ Montreal CRCHUM, Allergy Lab, Montreal, PQ, Canada; [Wakahara, Keiko] Nagoya Univ, Grad Sch Med, Dept Resp Med, Nagoya, Aichi 4648601, Japan; [Baba, Nobuyasu] Kochi Univ, Sch Med, Ctr Innovat & Translat Med, Kochi 780, Japan; [Cheong, Cheolho; Yun, Tae Jin] Inst Rech Clin Montreal, Cellular Physiol & Immunol Res Unit, Montreal, PQ H2W 1R7, Canada; [Panzini, Benoit; Tamaz, Raja] Ctr Hosp Univ Montreal CHUM, Dept Gastroenterol, Montreal, PQ, Canada; [Wassef, Ramses; Richard, Carole] Ctr Hosp Univ Montreal CHUM, Dept Digest Tract Surg, Montreal, PQ, Canada; [Soucy, Genevieve] Ctr Hosp Univ Montreal CHUM, Dept Pathol, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Nagoya University; Kochi University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Chapuy, L (corresponding author), Ctr Rech Ctr Hosp Univ Montreal CRCHUM, Immunoregulat Lab, Montreal, PQ, Canada.	m.sarfati@umontreal.ca	Baba, Nobuyasu/AAF-8593-2019; WAKAHARA, Keiko/I-7324-2014	Baba, Nobuyasu/0000-0001-9945-080X; 	Canadian Institutes of Health Research [130533] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Banwell ME, 2002, CYTOKINE, V17, P317, DOI 10.1006/cyto.2002.1021; Gomez MR, 2014, MUCOSAL IMMUNOL, V7, P188, DOI 10.1038/mi.2013.38; Hoeck J, 2001, J IMMUNOL, V167, P3216, DOI 10.4049/jimmunol.167.6.3216; Kaser A, 2010, ANNU REV IMMUNOL, V28, P573, DOI 10.1146/annurev-immunol-030409-101225; Masopust D, 2013, NAT REV IMMUNOL, V13, P309, DOI 10.1038/nri3442; Mokhtari M, 2012, ACTA CYTOL, V56, P310, DOI 10.1159/000333832; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Rimoldi M, 2005, NAT IMMUNOL, V6, P507, DOI 10.1038/ni1192; Sathaliyawala T, 2013, IMMUNITY, V38, P187, DOI 10.1016/j.immuni.2012.09.020; Siracusa MC, 2013, J ALLERGY CLIN IMMUN, V132, P789, DOI 10.1016/j.jaci.2013.07.046; Sullivan BM, 2011, NAT IMMUNOL, V12, P527, DOI 10.1038/ni.2036; Suwara MI, 2014, MUCOSAL IMMUNOL, V7, P684, DOI 10.1038/mi.2013.87; Tanaka J, 2010, DIGEST DIS SCI, V55, P1896, DOI 10.1007/s10620-009-0979-x; Wakahara K, 2012, BLOOD, V120, P4761, DOI 10.1182/blood-2012-04-424226; Weigmann B, 2012, J ALLERGY CLIN IMMUN, V129, P1126, DOI 10.1016/j.jaci.2011.11.036; Xu RC, 2013, EUR J DERMATOL, V23, P795, DOI 10.1684/ejd.2013.2177	16	19	21	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					978	981		10.1016/j.jaci.2014.05.025	http://dx.doi.org/10.1016/j.jaci.2014.05.025			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	24996262				2022-12-18	WOS:000343155700034
J	Rozenblit, M; Suarez-Farinas, M; Shemer, A; Khattri, S; Gilleaudeau, P; Sullivan-Whalen, M; Zheng, XZ; Xu, H; Cardinale, I; Krueger, JG; Guttman-Yassky, E				Rozenblit, Mariya; Suarez-Farinas, Mayte; Shemer, Avner; Khattri, Saakshi; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Zheng, Xiuzhong; Xu, Hui; Cardinale, Irma; Krueger, James G.; Guttman-Yassky, Emma			Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Rozenblit, Mariya; Suarez-Farinas, Mayte; Khattri, Saakshi; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Zheng, Xiuzhong; Xu, Hui; Cardinale, Irma; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Investigat Dermatol, New York, NY 10021 USA; [Rozenblit, Mariya; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Rozenblit, Mariya; Suarez-Farinas, Mayte; Krueger, James G.] Rockefeller Univ, Ctr Clin & Translat Sci, New York, NY 10021 USA; [Shemer, Avner] Dept Dermatol, Tel Aviv, Israel	Rockefeller University; Icahn School of Medicine at Mount Sinai; Rockefeller University	Rozenblit, M (corresponding author), Rockefeller Univ, Lab Investigat Dermatol, 1230 York Ave, New York, NY 10021 USA.	eguttman@rockefeller.edu		Rozenblit, Mariya/0000-0002-8874-6688	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000043] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR000043] Funding Source: Medline; NCRR NIH HHS [5UL1RR024143-02, UL1 RR024143] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ali S, 2011, J IMMUNOL, V187, P1609, DOI 10.4049/jimmunol.1003080; Bandow GD, 2004, INT J DERMATOL, V43, P555, DOI 10.1111/j.1365-4632.2004.02032.x; Flohr C, 2014, ALLERGY, V69, P3, DOI 10.1111/all.12270; GRANLUND H, 1995, BRIT J DERMATOL, V132, P106, DOI 10.1111/j.1365-2133.1995.tb08633.x; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Leung DYM, 2013, ALLERGOL INT, V62, P151, DOI 10.2332/allergolint.13-RAI-0564; Stoitzner P, 2010, IMMUNOL CELL BIOL, V88, P348, DOI 10.1038/icb.2010.46; Su JL, 2013, INFLAMM BOWEL DIS, V19, P720, DOI 10.1097/MIB.0b013e3182802a76; Suarez-Farinas M, 2012, J ALLERGY CLIN IMMUN, V131, P577	9	19	21	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					955	957		10.1016/j.jaci.2014.05.024	http://dx.doi.org/10.1016/j.jaci.2014.05.024			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	24996261	Green Accepted			2022-12-18	WOS:000343155700025
J	Mandala, WL; Ananworanich, J; Apornpong, T; Kerr, SJ; MacLennan, JM; Hanson, C; Jaimulwong, T; Gondwe, EN; Rosenblatt, HM; Bunupuradah, T; Molyneux, ME; Spector, SA; Pancharoen, C; Gelman, RS; MacLennan, CA; Shearer, WT				Mandala, Wilson L.; Ananworanich, Jintanat; Apornpong, Tanakorn; Kerr, Stephen J.; MacLennan, Jenny M.; Hanson, Celine; Jaimulwong, Tanyathip; Gondwe, Esther N.; Rosenblatt, Howard M.; Bunupuradah, Torsak; Molyneux, Malcolm E.; Spector, Stephen A.; Pancharoen, Chitsanu; Gelman, Rebecca S.; MacLennan, Calman A.; Shearer, William T.			Control lymphocyte subsets: Can one country's values serve for another's?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HEALTHY; CHILDREN; MANAGEMENT; CYTOKINES; ADULTS; VIRUS; CELLS; CD4; AGE		[Mandala, Wilson L.; MacLennan, Jenny M.; Gondwe, Esther N.; Molyneux, Malcolm E.; MacLennan, Calman A.] Malawi Liverpool Wellcome Trust, Clin Res Programme, Blantyre, Malawi; [Mandala, Wilson L.] Coll Med, Dept Basic Med Sci, Blantyre, Malawi; [Mandala, Wilson L.; Gondwe, Esther N.; Molyneux, Malcolm E.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; [Ananworanich, Jintanat; Apornpong, Tanakorn; Kerr, Stephen J.; Jaimulwong, Tanyathip; Bunupuradah, Torsak] HIV Netherlands Australia Thailand Res Collaborat, Bangkok, Thailand; [Ananworanich, Jintanat] SEARCH, Thai Red Cross AIDS Res Ctr, Bangkok, Thailand; [Ananworanich, Jintanat] Chulalongkorn Univ, Fac Med, Bangkok 10330, Thailand; [Kerr, Stephen J.] UNSW Australia, Kirby Inst, Sydney, NSW, Australia; [MacLennan, Jenny M.] Univ Oxford, Dept Zool, Oxford OX1 2JD, England; [Hanson, Celine] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA; [Rosenblatt, Howard M.] Specialty Children, Austin, TX USA; [Spector, Stephen A.] Univ Calif San Diego, San Diego, CA 92103 USA; [Gelman, Rebecca S.] Rady Childrens Hosp, San Diego, CA USA; [Gelman, Rebecca S.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Gelman, Rebecca S.] Dana Farber Canc Inst, Boston, MA 02115 USA; [MacLennan, Calman A.] Univ Birmingham, Coll Med, MRC Ctr Immune Regulat & Clin Immunol Serv, Sch Immun & Infect, Birmingham, W Midlands, England; [MacLennan, Calman A.] Novartis Vaccines Inst Global Hlth, Siena, Italy; [Shearer, William T.] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA	University of Malawi; University of Malawi; Liverpool School of Tropical Medicine; University of Liverpool; Thai Red Cross Society; Chulalongkorn University; University of New South Wales Sydney; Kirby Institute; University of Oxford; Baylor College of Medicine; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of Birmingham; Novartis; Baylor College of Medicine	Mandala, WL (corresponding author), Malawi Liverpool Wellcome Trust, Clin Res Programme, Blantyre, Malawi.	wmandala2002@gmail.com	Ananworanich, Jintanat/AAC-6348-2021; Kerr, Stephen/J-6126-2012; MacLennan, Calman A/L-9343-2014	Ananworanich, Jintanat/0000-0003-1369-3224; Kerr, Stephen/0000-0002-1919-4525; MacLennan, Calman A/0000-0001-9694-0846; Mandala, Wilson/0000-0001-9386-9239; Shearer, William/0000-0002-2483-2130	NCRR NIH HHS [M01 RR-00188] Funding Source: Medline; NIAID NIH HHS [UM1 AI069536, UM1 AI068616, P30 AI036211, U01 AI068616, U01 AI068632, U01AI27551, R01AI075408-0, P30 AI36211, U01 AI027551, R01 AI94029, U01 AI41110] Funding Source: Medline; Wellcome Trust [101113] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI069536, U01AI027551, U01AI068616, R01AI075408, U01AI041110, U01AI068632, P30AI036211] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amatya R, 2004, CLIN IMMUNOL, V112, P290, DOI 10.1016/j.clim.2004.04.008; Ananworanich J, 2010, J ALLERGY CLIN IMMUN, V126, P1294, DOI 10.1016/j.jaci.2010.09.038; Ben-Smith A, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-139; Dejnirattisai W, 2008, J IMMUNOL, V181, P5865, DOI 10.4049/jimmunol.181.9.5865; Duramad P, 2007, TOXICOL LETT, V172, P48, DOI 10.1016/j.toxlet.2007.05.017; Embree J, 2001, PEDIATR INFECT DIS J, V20, P397, DOI 10.1097/00006454-200104000-00006; Jiang WM, 2004, CLIN DIAGN LAB IMMUN, V11, P811, DOI 10.1128/CDLI.11.4.811-813.2004; Likanonsakul Sirirat, 1998, Southeast Asian Journal of Tropical Medicine and Public Health, V29, P453; Lugada ES, 2004, CLIN DIAGN LAB IMMUN, V11, P29, DOI 10.1128/CDLI.11.1.29-34.2004; Mandala WL, 2010, J ALLERGY CLIN IMMUN, V125, P203, DOI 10.1016/j.jaci.2009.10.010; O'Gorman MRG, 2008, CYTOM PART B-CLIN CY, V74B, pS19, DOI 10.1002/cyto.b.20398; Oliveira JB, 2008, CURR OPIN ALLERGY CL, V8, P499, DOI 10.1097/ACI.0b013e328312c790; Pahwa S, 2008, PEDIATRICS, V122, P331, DOI 10.1542/peds.2007-2308; Sagnia B, 2011, CLIN VACCINE IMMUNOL, V18, P790, DOI 10.1128/CVI.00483-10; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Sutherland JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025230; Weiss GE, 2009, J IMMUNOL, V183, P2176, DOI 10.4049/jimmunol.0901297; World Health Organisation, 2006, ANT THER HIV INF INF; World Health Organization, STRENGTH HLTH SERV F; ZijenahL S, 2005, J TRANSL MED, V3, P6	20	19	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					759	+		10.1016/j.jaci.2014.06.030	http://dx.doi.org/10.1016/j.jaci.2014.06.030			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	25171870	Green Accepted			2022-12-18	WOS:000341372400041
J	Balenga, NA; Jester, W; Jiang, MQ; Panettieri, RA; Druey, KM				Balenga, Nariman A.; Jester, William; Jiang, Meiqi; Panettieri, Reynold A., Jr.; Druey, Kirk M.			Loss of regulator of G protein signaling 5 promotes airway hyperresponsiveness in the absence of allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway hyperresponsiveness; G proteins; regulator of G protein signaling proteins; Aspergillus fumigatus	SMOOTH-MUSCLE CONTRACTION; INNATE LYMPHOID-CELLS; LIGHT-CHAIN KINASE; MOLECULAR-BIOLOGY; RECEPTOR; ASTHMA; ACTIVATION; RESPONSES; RGS5; EXPRESSION	Background: Although eosinophilic inflammation typifies allergic asthma, it is not a prerequisite for airway hyperresponsiveness (AHR), suggesting that underlying abnormalities in structural cells, such as airway smooth muscle (ASM), contribute to the asthmatic diathesis. Dysregulation of procontractile G protein-coupled receptor (GPCR) signaling in ASM could mediate enhanced contractility. Objective: We explored the role of a regulator of procontractile GPCR signaling, regulator of G protein signaling 5 (RGS5), in unprovoked and allergen-induced AHR. Methods: We evaluated GPCR-evoked Ca2+ signaling, precision-cut lung slice (PCLS) contraction, and lung inflammation in naive and Aspergillus fumigatus-challenged wild-type and Rgs5(-/-) mice. We analyzed lung resistance and dynamic compliance in live anesthetized mice using invasive plethysmography. Results: Loss of RGS5 promoted constitutive AHR because of enhanced GPCR-induced Ca2+ mobilization in ASM. PCLSs from naive Rgs5(-/-) mice contracted maximally at baseline independently of allergen challenge. RGS5 deficiency had little effect on the parameters of allergic inflammation, including cell counts in bronchoalveolar lavage fluid, mucin production, ASM mass, and subepithelial collagen deposition. Unexpectedly, induced IL-13 and IL-33 levels were much lower in challenged lungs from Rgs5(-/-) mice relative to those seen in wild-type mice. Conclusion: Loss of RGS5 confers spontaneous AHR in mice in the absence of allergic inflammation. Because it is selectively expressed in ASM within the lung and does not promote inflammation, RGS5 might be a therapeutic target for asthma.	[Balenga, Nariman A.; Druey, Kirk M.] NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; [Jester, William; Jiang, Meiqi; Panettieri, Reynold A., Jr.] Univ Penn, Pulm Allergy & Crit Care Div, Airways Biol Initiat, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Pennsylvania	Druey, KM (corresponding author), 10 Ctr Dr,Rm 11N242, Bethesda, MD 20892 USA.	kdruey@niaid.nih.gov	panettieri, reynold/AAG-9485-2019; Balenga, Nariman/A-5895-2011	Balenga, Nariman/0000-0002-2741-9595; Jester Jr., William/0000-0002-2872-6095	National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH) [AI001746]; NIH [R01 HL097796, P30 ES013508]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL114471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000939] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH; project no. AI001746, to K. M. D.) and NIH grants R01 HL097796 and P30 ES013508 (to R. A. P.).	Albeck JG, 2013, MOL CELL, V49, P249, DOI 10.1016/j.molcel.2012.11.002; Altman MK, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/518437; Balenga NAB, 2011, CELL RES, V21, P1452, DOI 10.1038/cr.2011.60; Bansal G, 2008, NAT IMMUNOL, V9, P73, DOI 10.1038/ni1533; Bansal G, 2007, PHARMACOL THERAPEUT, V116, P473, DOI 10.1016/j.pharmthera.2007.09.005; Bartho L, 2013, EUR J PHARMACOL, V701, P181, DOI 10.1016/j.ejphar.2013.01.009; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bodenstein J, 2007, MOL PHARMACOL, V71, P1040, DOI 10.1124/mol.106.029397; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Chen CM, 2012, J ELECTRON MATER, V41, P1, DOI 10.1007/s11664-011-1777-8; Chiba Y, 2009, AM J RESP CELL MOL, V40, P159, DOI 10.1165/rcmb.2008-0162OC; Cho H, 2008, MOL CELL BIOL, V28, P2590, DOI 10.1128/MCB.01889-07; Chung F, 2000, METH MOLEC MED, V44, P1, DOI 10.1385/1-59259-072-1:1; Cooper PR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010235; Damera G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028504; Fan HK, 2011, BBA-MOL CELL RES, V1813, P466, DOI 10.1016/j.bbamcr.2011.01.012; Goto K, 2010, PHARMACOL RES, V61, P466, DOI 10.1016/j.phrs.2009.12.001; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Haczku A, 2005, ACAD RADIOL, V12, P1362, DOI 10.1016/j.acra.2005.08.027; Hannon J, 2008, BEHAV BRAIN RES, V195, P198, DOI 10.1016/j.bbr.2008.03.020; Holgate ST, 2011, IMMUNOL REV, V242, P205, DOI 10.1111/j.1600-065X.2011.01030.x; Kamijo S, 2013, J IMMUNOL, V190, P4489, DOI 10.4049/jimmunol.1201212; Kang SH, 2012, ALLERGY ASTHMA IMMUN, V4, P341, DOI 10.4168/aair.2012.4.6.341; Katsumoto TR, 2013, J CLIN INVEST, V123, P2037, DOI 10.1172/JCI66397; Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684; Labuda M, 2013, PEDIATR PULM, V48, P970, DOI 10.1002/ppul.22723; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Li PF, 2012, INFLAMMATION, V35, P1611, DOI 10.1007/s10753-012-9476-z; Li XW, 2003, INFECT IMMUN, V71, P4414, DOI 10.1128/IAI.71.8.4414-4420.2003; Liang GQ, 2009, J BIOL CHEM, V284, P21719, DOI 10.1074/jbc.M109.028407; Liu CY, 2013, RESP PHYSIOL NEUROBI, V185, P265, DOI 10.1016/j.resp.2012.10.003; Luyendyk JP, 2008, J IMMUNOL, V180, P4218, DOI 10.4049/jimmunol.180.6.4218; Mansfield PJ, 2000, BLOOD, V95, P2407, DOI 10.1182/blood.V95.7.2407.007k02_2407_2412; McGraw DW, 2007, J CLIN INVEST, V117, P1391, DOI 10.1172/JCI30489; Miller AM, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-22; Millien VO, 2013, SCIENCE, V341, P792, DOI 10.1126/science.1240342; Mukherjee S, 2013, J GEN PHYSIOL, V141, P165, DOI 10.1085/jgp.201210876; Penn Raymond B, 2008, Proc Am Thorac Soc, V5, P47, DOI 10.1513/pats.200705-054VS; Penn RB, 2008, N-S ARCH PHARMACOL, V378, P149, DOI 10.1007/s00210-008-0263-1; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Price RD, 2001, J BIOL CHEM, V276, P44663, DOI 10.1074/jbc.M106745200; Sakai H, 2005, MOL PHARMACOL, V68, P145, DOI 10.1124/mol.104.004325; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Song KS, 2009, AM J RESP CELL MOL, V41, P40, DOI 10.1165/rcmb.2008-0280OC; Wang Q, 2002, J BIOL CHEM, V277, P24949, DOI 10.1074/jbc.M203802200; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wills-Karp M, 2011, NAT IMMUNOL, V12, P1025, DOI 10.1038/ni.2142; Xie Y, 2012, J ALLERGY CLIN IMMUN, V130, P968, DOI 10.1016/j.jaci.2012.05.004; Xie Y, 2009, CANCER RES, V69, P5743, DOI 10.1158/0008-5472.CAN-08-3564; Yang Z, 2012, AM J RESP CELL MOL, V46, P823, DOI 10.1165/rcmb.2011-0110OC; Yang Z, 2011, J BIOL CHEM, V286, P11444, DOI [10.1074/jbc.M110.212480, 10.1074/jbc.M111.229344]; Zhu HQ, 2008, J PINEAL RES, V45, P328, DOI 10.1111/j.1600-079X.2008.00595.x	54	19	19	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					451	+		10.1016/j.jaci.2014.01.019	http://dx.doi.org/10.1016/j.jaci.2014.01.019			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24666695	Green Accepted			2022-12-18	WOS:000341370800026
J	Chou, J; Lutskiy, M; Tsitsikov, E; Notarangelo, LD; Geha, RS; Dioun, A				Chou, Janet; Lutskiy, Maxim; Tsitsikov, Erdyni; Notarangelo, Luigi D.; Geha, Raif S.; Dioun, Anahita			Presence of hypogammaglobulinemia and abnormal antibody responses in GATA2 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SPORADIC MONOCYTOPENIA; AUTOSOMAL-DOMINANT; MONOMAC SYNDROME; DENDRITIC CELL; MUTATIONS; MYELODYSPLASIA; LYMPHEDEMA		[Chou, Janet; Lutskiy, Maxim; Notarangelo, Luigi D.; Geha, Raif S.; Dioun, Anahita] Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Chou, Janet; Lutskiy, Maxim; Notarangelo, Luigi D.; Geha, Raif S.; Dioun, Anahita] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Tsitsikov, Erdyni] Boston Childrens Hosp, Dept Lab Med, Boston, MA USA; [Notarangelo, Luigi D.] Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Chou, J (corresponding author), Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Notarangelo, Luigi D/F-9718-2016	Notarangelo, Luigi D/0000-0002-8335-0262	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI094017, P01AI076210] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI076210, R03 AI094017, AI094017, AI-076210] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Calvo KR, 2011, HAEMATOL-HEMATOL J, V96, P1221, DOI 10.3324/haematol.2011.041152; Camargo JF, 2013, CLIN INFECT DIS, V57, P697, DOI 10.1093/cid/cit368; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Dickinson RE, 2011, BLOOD, V118, P2656, DOI 10.1182/blood-2011-06-360313; Hahn CN, 2011, NAT GENET, V43, P1012, DOI 10.1038/ng.913; Hsu AP, 2011, BLOOD, V118, P2653, DOI 10.1182/blood-2011-05-356352; Ishida H, 2012, EUR J PEDIATR, V171, P1273, DOI 10.1007/s00431-012-1715-7; JOLLIFF CR, 1982, CLIN CHEM, V28, P126; Kazenwadel J, 2012, BLOOD, V119, P1283, DOI 10.1182/blood-2011-08-374363; Mace EM, 2013, BLOOD, V121, P2669, DOI 10.1182/blood-2012-09-453969; Vinh DC, 2010, BLOOD, V115, P1519, DOI 10.1182/blood-2009-03-208629	11	19	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					223	226		10.1016/j.jaci.2014.01.041	http://dx.doi.org/10.1016/j.jaci.2014.01.041			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24726394	Green Accepted			2022-12-18	WOS:000338930300030
J	Forsberg, A; Bengtsson, M; Eringfalt, A; Ernerudh, J; Mjosberg, J; Jenmalm, MC				Forsberg, Anna; Bengtsson, Mathias; Eringfalt, Anna; Ernerudh, Jan; Mjosberg, Jenny; Jenmalm, Maria C.			GATA binding protein 3(+) group 2 innate lymphoid cells are present in cord blood and in higher proportions in male than in female neonates	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GENDER-DIFFERENCES; IMMUNITY; CHILDREN		[Forsberg, Anna; Bengtsson, Mathias; Eringfalt, Anna; Ernerudh, Jan; Jenmalm, Maria C.] Linkoping Univ, Dept Clin & Expt Med, Div Clin Immunol, Unit Autoimmun & Immune Regulat, Linkoping, Sweden; [Mjosberg, Jenny] Karolinska Inst, Dept Med, Ctr Infect Med, Karolinska Univ Hosp Huddinge, Stockholm, Sweden	Linkoping University; Karolinska Institutet; Karolinska University Hospital	Forsberg, A (corresponding author), Linkoping Univ, Dept Clin & Expt Med, Div Clin Immunol, Unit Autoimmun & Immune Regulat, Linkoping, Sweden.	anna.forsberg@liu.se	Forsberg, Anna/ABD-2423-2020	Forsberg, Anna/0000-0001-6896-4867; Mjosberg, Jenny/0000-0002-1119-0976				Abrahamsson TR, 2011, CLIN EXP ALLERGY, V41, P1729, DOI 10.1111/j.1365-2222.2011.03827.x; Borte S, 2012, BLOOD, V119, P2552, DOI 10.1182/blood-2011-08-371021; Casimir GJA, 2010, SHOCK, V33, P258, DOI 10.1097/SHK.0b013e3181b2b36b; Chen W, 2008, ALLERGY, V63, P1418, DOI 10.1111/j.1398-9995.2008.01880.x; Jenmalm MC, 2011, AM J REPROD IMMUNOL, V66, P75, DOI 10.1111/j.1600-0897.2011.01036.x; Meeths M, 2011, BLOOD, V118, P5783, DOI 10.1182/blood-2011-07-369090; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Pennell LM, 2012, J AUTOIMMUN, V38, pJ282, DOI 10.1016/j.jaut.2011.11.013; Postma DS, 2007, GENDER MED, V4, pS133, DOI 10.1016/S1550-8579(07)80054-4; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; van Zelm MC, 2007, J EXP MED, V204, P645, DOI 10.1084/jem.20060964	12	19	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					228	230		10.1016/j.jaci.2014.01.027	http://dx.doi.org/10.1016/j.jaci.2014.01.027			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24636083	Green Submitted			2022-12-18	WOS:000338930300032
J	Stevens, WW; Schleimer, RP; Chandra, RK; Peters, AT				Stevens, Whitney W.; Schleimer, Robert P.; Chandra, Rakesh K.; Peters, Anju T.			Biology of nasal polyposis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EXACERBATED RESPIRATORY-DISEASE; CHRONIC RHINOSINUSITIS; ALLERGIC INFLAMMATION; SINUS DISEASE; MAST-CELLS; ASPIRIN; EXPRESSION; TISSUE; PATHOGENESIS; IGE		[Stevens, Whitney W.; Schleimer, Robert P.; Peters, Anju T.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Dept Med, Chicago, IL 60611 USA; [Schleimer, Robert P.; Chandra, Rakesh K.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Schleimer, RP (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, 240 E Huron St,McGaw Rm M-318, Chicago, IL 60611 USA.	rpschleimer@northwestern.edu		Chandra, Rakesh/0000-0002-3612-0026	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI083216, P01AI106683, U19AI106683] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL068546] Funding Source: Medline; NIAID NIH HHS [U19 AI106683, T32 AI083216, P01 AI106683] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adamusiak AM, 2012, INT ARCH ALLERGY IMM, V157, P354, DOI 10.1159/000329744; Aukema AAC, 2005, J ALLERGY CLIN IMMUN, V115, P1017, DOI 10.1016/j.jaci.2004.12.1144; Awad OG, 2008, LARYNGOSCOPE, V118, P1282, DOI 10.1097/MLG.0b013e318170af1e; Bachert C, 1997, J ALLERGY CLIN IMMUN, V99, P837, DOI 10.1016/S0091-6749(97)80019-X; Bachert C, 2000, AM J RHINOL, V14, P279, DOI 10.2500/105065800781329573; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Boase S, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-210; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gevaert P, 2005, ALLERGY, V60, P71, DOI 10.1111/j.1398-9995.2004.00621.x; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Hulse KE, 2013, J ALLERGY CLIN IMMUN, V131, P1075, DOI 10.1016/j.jaci.2013.01.043; Kim BS, 2013, CURR OPIN IMMUNOL, V25, P738, DOI 10.1016/j.coi.2013.07.013; Kim SJ, 2013, OTOLARYNG HEAD NECK, V149, P431, DOI 10.1177/0194599813495363; Knight DA, 2003, RESPIROLOGY, V8, P432, DOI 10.1046/j.1440-1843.2003.00493.x; Laidlaw TM, 2013, IMMUNOL ALLERGY CLIN, V33, P195, DOI 10.1016/j.iac.2012.11.006; Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826; Lund VJ, 1998, ARCH OTOLARYNGOL, V124, P513, DOI 10.1001/archotol.124.5.513; Mahdavinia M, 2014, J ALLERGY CLIN IMMUN; Mainz JG, 2012, CURR ALLERGY ASTHM R, V12, P163, DOI 10.1007/s11882-012-0250-y; Mullol J, 2013, IMMUNOL ALLERGY CLIN, V33, P163, DOI 10.1016/j.iac.2012.11.002; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Picado C, 1999, AM J RESP CRIT CARE, V160, P291, DOI 10.1164/ajrccm.160.1.9808048; Richer SL, 2008, AM J RHINOL, V22, P228, DOI 10.2500/ajr.2008.22.3162; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Schleimer RP, 2013, EOSINOPHILS IN HEALTH AND DISEASE, P508; Schleimer Robert P, 2009, Proc Am Thorac Soc, V6, P288, DOI 10.1513/pats.200808-088RM; Schwartz Lawrence B, 2006, Methods Mol Biol, V315, P53; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Stevenson DD, 2003, CLIN REV ALLERG IMMU, V24, P169, DOI 10.1385/CRIAI:24:2:169; Takabayashi T, 2013, J ALLERGY CLIN IMMUN, V132, P584, DOI 10.1016/j.jaci.2013.02.003; Takabayashi T, 2013, AM J RESP CRIT CARE, V187, P49, DOI 10.1164/rccm.201207-1292OC; Takabayashi T, 2012, J ALLERGY CLIN IMMUN, V130, P410, DOI 10.1016/j.jaci.2012.02.046; Tan BK, 2011, J ALLERGY CLIN IMMUN, V128, P1198, DOI 10.1016/j.jaci.2011.08.037; Tieu DD, 2010, J ALLERGY CLIN IMMUN, V125, P667, DOI 10.1016/j.jaci.2009.11.045; Tripathi A, 2005, AM J RHINOL, V19, P327, DOI 10.1177/194589240501900401; Tripathi A, 2004, LARYNGOSCOPE, V114, P1822, DOI 10.1097/00005537-200410000-00027; Tritt S, 2008, AM J OTOLARYNG, V29, P230, DOI 10.1016/j.amjoto.2007.07.001; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018; White AA, 2013, IMMUNOL ALLERGY CLIN, V33, P211, DOI 10.1016/j.iac.2012.10.013; Yoshimura Tsuyoshi, 2008, Allergol Int, V57, P429, DOI 10.2332 allergolint.O-08-545; Zhang N, 2011, ALLERGY, V66, P141, DOI 10.1111/j.1398-9995.2010.02448.x; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008	45	19	20	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1503	U479		10.1016/j.jaci.2014.03.022	http://dx.doi.org/10.1016/j.jaci.2014.03.022			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24766878	Green Accepted			2022-12-18	WOS:000335450700052
J	Johns, CB; Savage, JH				Johns, Christina B.; Savage, Jessica H.			Access to health care and food in children with food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PREVALENCE; OUTCOMES		[Johns, Christina B.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; [Savage, Jessica H.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Johns, CB (corresponding author), Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA.	jrsavage@partners.org		Johns, Christina/0000-0002-0541-040X	NCATS NIH HHS [1KL2 TR001100-01, KL2 TR001100] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001100] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))		Cook JT, 2004, J NUTR, V134, P1432; Fox P, 2007, PEDIATRICS, V120, pE902, DOI 10.1542/peds.2006-1805; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Jones R, 2008, J ASTHMA, V45, P916, DOI 10.1080/02770900802395488; Keet CA, 2014, ANN ALLERGY IN PRESS; Kowaleski-Jones L, 2002, AM J PUBLIC HEALTH, V92, P799, DOI 10.2105/AJPH.92.5.799; McGowan EC, 2013, J ALLERGY CLIN IMMUN, V132, P1216, DOI 10.1016/j.jaci.2013.07.018; Price JH, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/787616; Taylor-Black S, 2012, ANN ALLERG ASTHMA IM, V109, P431, DOI 10.1016/j.anai.2012.09.012	9	19	20	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					582	585		10.1016/j.jaci.2013.12.006	http://dx.doi.org/10.1016/j.jaci.2013.12.006			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24636475	Bronze, Green Accepted			2022-12-18	WOS:000332397100038
J	Apter, AJ				Apter, Andrea J.			Advances in adult asthma diagnosis and treatment in 2013	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; adults; inhaled corticosteroids; asthma management	OBSTRUCTIVE PULMONARY-DISEASE; EXHALED NITRIC-OXIDE; SUBLINGUAL IMMUNOTHERAPY; LUNG-FUNCTION; AIRWAY INFLAMMATION; COMMUNITY VIOLENCE; ONSET ASTHMA; RECEPTOR; ALLERGEN; OUTCOMES	In 2013, several themes emerged: (1) a dedicated search for new therapies using new mechanisms; (2) the importance of the plasticity of the immune system (eg, that molecules that mediate inflammation in one setting can promote its resolution and return to homeostasis in other circumstances); (3) the complex role of viruses in asthma exacerbations; (4) the similarities and differences among asthma, asthma in smokers, and chronic obstructive pulmonary disease; and (5) the importance of understanding asthma phenotypes and their stability over time. Once new therapeutics pass the initial clinical trials, patient-oriented and real-world research will be needed.	[Apter, Andrea J.] Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Apter, AJ (corresponding author), Hosp Univ Penn, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.	apter@mail.med.upenn.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahluwalia SK, 2013, J ALLERGY CLIN IMMUN, V132, P830, DOI 10.1016/j.jaci.2013.05.005; Amelink M, 2013, J ALLERGY CLIN IMMUN, V132, P336, DOI 10.1016/j.jaci.2013.04.052; Apter AJ, 2013, J ALLERGY CLIN IMMUN, V132, P321, DOI 10.1016/j.jaci.2013.02.014; Apter AJ, 2013, J ALLERGY CLIN IMMUN, V131, P47, DOI 10.1016/j.jaci.2012.11.020; Apter AJ, 2010, J ALLERGY CLIN IMMUN, V126, P552, DOI 10.1016/j.jaci.2010.07.014; Barnes PJ, 2013, J ALLERGY CLIN IMMUN, V131, P636, DOI 10.1016/j.jaci.2012.12.1564; Beeh KM, 2013, J ALLERGY CLIN IMMUN, V131, P866, DOI 10.1016/j.jaci.2012.12.1561; Boudier A, 2013, AM J RESP CRIT CARE, V188, P550, DOI 10.1164/rccm.201301-0156OC; Brannan JD, 2013, J ALLERGY CLIN IMMUN, V131, P906, DOI 10.1016/j.jaci.2012.08.028; Buehring B, 2013, J ALLERGY CLIN IMMUN, V132, P1019, DOI 10.1016/j.jaci.2013.08.040; Burks AW, 2013, J ALLERGY CLIN IMMUN, V131, P1288, DOI 10.1016/j.jaci.2013.01.049; Busse WW, 2013, J ALLERGY CLIN IMMUN, V131, P339, DOI 10.1016/j.jaci.2012.10.013; Campbell-Harding G, 2013, J ALLERGY CLIN IMMUN, V131, P849, DOI 10.1016/j.jaci.2012.08.030; Carolan BJ, 2013, J ALLERGY CLIN IMMUN, V131, P627, DOI 10.1016/j.jaci.2013.01.010; Carson KV, 2013, COCHRANE DB SYST REV, V9; Castro M, 2010, AM J RESP CRIT CARE, V181, P116, DOI 10.1164/rccm.200903-0354OC; Colice G, 2013, J ALLERGY CLIN IMMUN, V132, P45, DOI 10.1016/j.jaci.2013.02.008; Coogan PF, 2013, J ALLERGY CLIN IMMUN, V131, P1058, DOI 10.1016/j.jaci.2012.10.023; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Diamant Z, 2013, J ALLERGY CLIN IMMUN, V132, P1045, DOI 10.1016/j.jaci.2013.08.023; Donohue KM, 2013, J ALLERGY CLIN IMMUN, V131, P361, DOI 10.1016/j.jaci.2012.11.036; Donohue KM, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Fajt ML, 2013, J ALLERGY CLIN IMMUN, V131, P1504, DOI 10.1016/j.jaci.2013.01.035; Felix R, 2013, J ALLERGY CLIN IMMUN, V131, P1423, DOI 10.1016/j.jaci.2012.10.007; Fernandez-Boyanapalli R, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Fernandez-Boyanapalli R, 2013, J ALLERGY CLIN IMMUN, V131, P1041, DOI 10.1016/j.jaci.2012.09.028; Frew E, 2013, J ALLERGY CLIN IMMUN; Gabriele L, 2013, J ALLERGY CLIN IMMUN, V132, P686, DOI 10.1016/j.jaci.2013.02.037; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Grotenboer NS, 2013, J ALLERGY CLIN IMMUN, V131, P856, DOI 10.1016/j.jaci.2012.11.028; Guan W, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Guan WJ, 2013, J ALLERGY CLIN IMMUN, V131, P332, DOI 10.1016/j.jaci.2012.08.020; Hastie AT, 2013, J ALLERGY CLIN IMMUN, V132, P72, DOI 10.1016/j.jaci.2013.03.044; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Jia CE, 2013, J ALLERGY CLIN IMMUN, V131, P695, DOI 10.1016/j.jaci.2012.08.023; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Kaiko GE, 2013, J ALLERGY CLIN IMMUN, V131, P1331, DOI 10.1016/j.jaci.2013.02.041; Kalliola S, 2013, J ALLERGY CLIN IMMUN, V131, P730, DOI 10.1016/j.jaci.2013.01.005; Kaminsky DA, 2013, J ALLERGY CLIN IMMUN, V131, P1329, DOI 10.1016/j.jaci.2013.02.015; Kanemitsu Y, 2013, J ALLERGY CLIN IMMUN, V132, P305, DOI 10.1016/j.jaci.2013.04.050; Kazani S, 2013, J ALLERGY CLIN IMMUN, V132, P547, DOI 10.1016/j.jaci.2013.01.058; Kern RC, 2013, J ALLERGY CLIN IMMUN, V131, P117, DOI 10.1016/j.jaci.2012.11.021; Kiel MA, 2013, J ALLERGY CLIN IMMUN, V132, P353, DOI 10.1016/j.jaci.2013.03.013; Kyoh S, 2013, J ALLERGY CLIN IMMUN, V132, P480, DOI 10.1016/j.jaci.2013.02.010; Lajunen TK, 2013, AM J RESP CRIT CARE, V188, P776, DOI 10.1164/rccm.201304-0773OC; Lajunen TK, 2013, J ALLERGY CLIN IMMUN, V131, P916, DOI 10.1016/j.jaci.2012.10.035; Laviolette M, 2013, J ALLERGY CLIN IMMUN, V132, P1086, DOI 10.1016/j.jaci.2013.05.020; Lemiere C, 2013, J ALLERGY CLIN IMMUN, V131, P704, DOI 10.1016/j.jaci.2012.08.024; Li XN, 2013, J ALLERGY CLIN IMMUN, V132, P313, DOI 10.1016/j.jaci.2013.01.051; Lin SY, 2013, JAMA-J AM MED ASSOC, V309, P1278, DOI 10.1001/jama.2013.2049; Lloyd CM, 2013, J ALLERGY CLIN IMMUN, V131, P1267, DOI 10.1016/j.jaci.2013.02.016; Malinovschi A, 2013, J ALLERGY CLIN IMMUN, V132, P821, DOI 10.1016/j.jaci.2013.06.007; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; Miyata J, 2013, J ALLERGY CLIN IMMUN, V131, P353, DOI 10.1016/j.jaci.2012.07.048; Moore WC, 2013, AM J RESP CRIT CARE, V188, P521, DOI 10.1164/rccm.201307-1203ED; Mueller GA, 2013, J ALLERGY CLIN IMMUN; Nair P, 2013, J ALLERGY CLIN IMMUN, V132, P81, DOI 10.1016/j.jaci.2013.05.007; Nanzer AM, 2013, J ALLERGY CLIN IMMUN, V132, P297, DOI 10.1016/j.jaci.2013.03.037; National Heart Lung and Blood Institute, NAT ASTHM ED PREV PR; Nelson HS, 2013, JAMA-J AM MED ASSOC, V309, P1297, DOI 10.1001/jama.2013.2739; Noonan M, 2013, J ALLERGY CLIN IMMUN, V132, P567, DOI 10.1016/j.jaci.2013.03.051; O'Byrne PM, 2013, J ALLERGY CLIN IMMUN, V132, P70, DOI 10.1016/j.jaci.2013.03.052; Oakley RH, 2013, J ALLERGY CLIN IMMUN, V132, P1033, DOI 10.1016/j.jaci.2013.09.007; Ownby DR, 2013, J ALLERGY CLIN IMMUN, V132, P836, DOI 10.1016/j.jaci.2013.06.046; Pavord ID, 2013, J ALLERGY CLIN IMMUN, V132, P828, DOI 10.1016/j.jaci.2013.07.045; Pennino D, 2013, J ALLERGY CLIN IMMUN, V131, P562, DOI 10.1016/j.jaci.2012.09.036; Perret JL, 2013, AM J RESP CRIT CARE, V187, P42, DOI 10.1164/rccm.201205-0788OC; Peters SP, 2013, J ALLERGY CLIN IMMUN, V132, P1068, DOI 10.1016/j.jaci.2013.08.003; Pinkerton M, 2013, J ALLERGY CLIN IMMUN, V132, P217, DOI 10.1016/j.jaci.2013.03.006; Potter P, 2013, J ALLERGY CLIN IMMUN, V132, P99, DOI 10.1016/j.jaci.2013.02.031; Price D, 2013, J ALLERGY CLIN IMMUN, V131, P763, DOI 10.1016/j.jaci.2012.12.673; Rank MA, 2013, J ALLERGY CLIN IMMUN, V131, P724, DOI 10.1016/j.jaci.2012.11.038; Sadatsafavi M, 2013, J ALLERGY CLIN IMMUN, V132, P63, DOI 10.1016/j.jaci.2013.02.007; Saito J, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Saito J, 2013, J ALLERGY CLIN IMMUN, V131, P232, DOI 10.1016/j.jaci.2012.10.005; Scichilone N, 2013, J ALLERGY CLIN IMMUN, V131, P1513, DOI 10.1016/j.jaci.2013.03.009; Short PM, 2013, AM J RESP CRIT CARE, V187, P1308, DOI 10.1164/rccm.201212-2206OC; Sigua JA, 2013, J ALLERGY CLIN IMMUN, V131, P1340, DOI 10.1016/j.jaci.2013.03.030; Szefler SJ, 2013, J ALLERGY CLIN IMMUN, V131, P36, DOI 10.1016/j.jaci.2012.11.009; Thompson BR, 2013, J ALLERGY CLIN IMMUN, V131, P1322, DOI 10.1016/j.jaci.2013.01.054; Thompson EE, 2013, J ALLERGY CLIN IMMUN, V132, P39, DOI 10.1016/j.jaci.2012.12.1575; Thomson NC, 2013, J ALLERGY CLIN IMMUN, V131, P1008, DOI 10.1016/j.jaci.2012.12.1574; van der Wiel E, 2013, J ALLERGY CLIN IMMUN, V131, P646, DOI 10.1016/j.jaci.2012.12.1567; Wechsler ME, 2013, J ALLERGY CLIN IMMUN; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Zetstra-van der Woude PA, 2013, J ALLERGY CLIN IMMUN, V131, P711, DOI 10.1016/j.jaci.2012.08.027	87	19	21	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					49	56		10.1016/j.jaci.2013.11.005	http://dx.doi.org/10.1016/j.jaci.2013.11.005			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24369799				2022-12-18	WOS:000329105700007
J	Lawrence, MG; Barber, JS; Sokolic, RA; Garabedian, EK; Desai, AN; O'Brien, M; Jones, N; Bali, P; Hershfield, MS; Stone, KD; Candotti, F; Milner, JD				Lawrence, Monica G.; Barber, John S.; Sokolic, Robert A.; Garabedian, Elizabeth K.; Desai, Avanti N.; O'Brien, Michelle; Jones, Nina; Bali, Pawan; Hershfield, Michael S.; Stone, Kelly D.; Candotti, Fabio; Milner, Joshua D.			Elevated IgE and atopy in patients treated for early-onset ADA-SCID	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGIC DISEASE; DEFICIENCY; CELLS		[Lawrence, Monica G.; Barber, John S.; Desai, Avanti N.; O'Brien, Michelle; Stone, Kelly D.; Milner, Joshua D.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; [Sokolic, Robert A.; Garabedian, Elizabeth K.; Candotti, Fabio] NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; [Jones, Nina] SAIC Frederick Inc, Clin Res Directorate CMRP, Frederick Natl Lab Canc Res, Frederick, MD USA; [Bali, Pawan; Hershfield, Michael S.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Bali, Pawan; Hershfield, Michael S.] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Duke University; Duke University	Lawrence, MG (corresponding author), NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	jdmilner@niaid.nih.gov	Sokolic, Robert/E-6224-2017	Sokolic, Robert/0000-0002-3399-7893; Candotti, Fabio/0000-0001-6399-6042	CCR NIH HHS [HHSN261200800001C] Funding Source: Medline; Intramural NIH HHS [ZIA AI001099-04] Funding Source: Medline; NCI NIH HHS [HHSN261200800001E] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001099, ZIAAI001183] Funding Source: NIH RePORTER	CCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Apasov SG, 2001, J CLIN INVEST, V108, P131, DOI 10.1172/JCI200110360; Avila EM, 2010, PEDIATRICS, V126, pE1248, DOI 10.1542/peds.2009-3171; Cassani B, 2008, BLOOD, V111, P4209, DOI 10.1182/blood-2007-05-092429; Datta S, 2011, J ALLERGY CLIN IMMUN, V127, P351, DOI 10.1016/j.jaci.2010.11.033; Felgentreff K, 2011, CLIN IMMUNOL, V141, P73, DOI 10.1016/j.clim.2011.05.007; Gaspar HB, 2009, BLOOD, V114, P3524, DOI 10.1182/blood-2009-06-189209; Kawamura N, 1998, IMMUNOL LETT, V64, P49, DOI 10.1016/S0165-2478(98)00083-2; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Yamane H, 2013, IMMUNOL REV, V252, P12, DOI 10.1111/imr.12032	9	19	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1444	1446		10.1016/j.jaci.2013.05.040	http://dx.doi.org/10.1016/j.jaci.2013.05.040			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	23895897	Green Accepted			2022-12-18	WOS:000327538200029
J	Nakamura, R; Nakamura, R; Sakai, S; Adachi, R; Hachisuka, A; Urisu, A; Fukutomi, Y; Teshima, R				Nakamura, Ryosuke; Nakamura, Rika; Sakai, Shinobu; Adachi, Reiko; Hachisuka, Akiko; Urisu, Atsuo; Fukutomi, Yuma; Teshima, Reiko			Tissue transglutaminase generates deamidated epitopes on gluten, increasing reactivity with hydrolyzed wheat protein-sensitized IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXERCISE-INDUCED ANAPHYLAXIS; VITRO ELICITATION TEST; CROSS-LINKING; EXPRESSION		[Nakamura, Ryosuke; Nakamura, Rika; Sakai, Shinobu; Adachi, Reiko; Hachisuka, Akiko; Teshima, Reiko] Natl Inst Hlth Sci, Setagaya Ku, Div Novel Foods & Immunochem, Tokyo 1588501, Japan; [Urisu, Atsuo] Fujita Hlth Univ, Dept Pediat, Teaching Hosp 2, Nagoya, Aichi, Japan; [Fukutomi, Yuma] Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan	National Institute of Health Sciences - Japan; Fujita Health University	Nakamura, R (corresponding author), Natl Inst Hlth Sci, Setagaya Ku, Div Novel Foods & Immunochem, Tokyo 1588501, Japan.	ryosnak@nihs.go.jp	Fukutomi, Yuma/AFQ-4306-2022	Fukutomi, Yuma/0000-0001-9913-4524				[Anonymous], 2012, JAP SOC ALL M SPEC C; Caja S, 2011, CELL MOL IMMUNOL, V8, P103, DOI 10.1038/cmi.2010.65; Chinuki Y, 2012, J ALLERGY CLIN IMMUN, V129, P1404, DOI 10.1016/j.jaci.2012.02.049; Fukutomi Y, 2011, J ALLERGY CLIN IMMUN, V127, P531, DOI 10.1016/j.jaci.2010.09.035; Nakamura R, 2010, ALLERGY, V65, P1266, DOI 10.1111/j.1398-9995.2010.02363.x; Nakamura R, 2013, INT ARCH ALLERGY IMM, V160, P259, DOI 10.1159/000341671; Nakamura R, 2012, ALLERGOL INT, V61, P431, DOI 10.2332/allergolint.11-OA-0407; Palosuo K, 2003, J ALLERGY CLIN IMMUN, V111, P1386, DOI 10.1067/mai.2003.1498; Yildiz F, 2010, ADVANCES IN FOOD BIOCHEMISTRY, P1	9	19	19	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1436	1438		10.1016/j.jaci.2013.07.017	http://dx.doi.org/10.1016/j.jaci.2013.07.017			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	23992746				2022-12-18	WOS:000327538200026
J	Abuabara, K; Margolis, DJ				Abuabara, Katrina; Margolis, David J.			Do children really outgrow their eczema, or is there more than one eczema?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Eczema; atopic dermatitis; epidemiology; adult; child	ATOPIC-DERMATITIS; LONGITUDINAL COHORT; MUTATIONS; ASTHMA		[Abuabara, Katrina; Margolis, David J.] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Margolis, David J.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Margolis, DJ (corresponding author), 901 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	margo@upenn.edu		Abuabara, Katrina/0000-0002-7736-6946	NIAMS NIH HHS [T32 AR007465, 5T32AR007465-30] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007465] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ballardini N, 2012, ALLERGY, V67, P537, DOI 10.1111/j.1398-9995.2012.02786.x; Bieber T, 2012, DERMATOLOGY, P203; Fierro MT, 2012, DERMATOLOGY, V224, P323, DOI 10.1159/000339180; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Katsarou A, 2011, J EUR ACAD DERMATOL, V25, P12, DOI 10.1111/j.1468-3083.2010.03737.x; Lan CCE, 2009, J AM ACAD DERMATOL, V61, P806, DOI 10.1016/j.jaad.2009.03.035; Langan SM, 2006, BRIT J DERMATOL, V154, P979, DOI 10.1111/j.1365-2133.2006.07153.x; Margolis DJ, 2012, J ALLERGY CLIN IMMUN, V130, P912, DOI 10.1016/j.jaci.2012.07.008; Rod NH, 2012, ALLERGY, V67, P1408, DOI 10.1111/j.1398-9995.2012.02882.x.; Shaw TE, 2011, J INVEST DERMATOL, V131, P67, DOI 10.1038/jid.2010.251; Simpson EL, 2012, J ALLERGY CLIN IMMUN, V130, P137, DOI 10.1016/j.jaci.2012.01.075; Siverberg J, 2013, J ALLERGY CLIN IMMUN, V132, P1132; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Wuthrich B, 1999, ANN ALLERG ASTHMA IM, V83, P464, DOI 10.1016/S1081-1206(10)62852-9	14	19	19	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1139	1140		10.1016/j.jaci.2013.08.028	http://dx.doi.org/10.1016/j.jaci.2013.08.028			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	24094545	Green Accepted, Bronze			2022-12-18	WOS:000326235600014
J	Gomez-Traseira, C; Lopez-Lera, A; Drouet, C; Lopez-Trascasa, M; Perez-Fernandez, E; Favier, B; Prior, N; Caballero, T				Gomez-Traseira, Carmen; Lopez-Lera, Alberto; Drouet, Christian; Lopez-Trascasa, Margarita; Perez-Fernandez, Elia; Favier, Bertrand; Prior, Nieves; Caballero, Teresa			Hereditary angioedema caused by the p.Thr309-Lys mutation in the F12 gene: A multifactorial disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CONSENSUS; PLASMA		[Gomez-Traseira, Carmen; Prior, Nieves; Caballero, Teresa] Hosp Univ La Paz, Dept Allergy, Madrid, Spain; [Gomez-Traseira, Carmen; Lopez-Lera, Alberto; Lopez-Trascasa, Margarita; Perez-Fernandez, Elia; Prior, Nieves; Caballero, Teresa] Hosp La Paz Hlth Res Inst IdiPAZ, Madrid, Spain; [Lopez-Lera, Alberto; Lopez-Trascasa, Margarita] Hosp Univ La Paz, Immunol Unit, Madrid, Spain; [Lopez-Lera, Alberto; Lopez-Trascasa, Margarita; Caballero, Teresa] CIBERER, Biomed Network Res Rare Dis U754, Madrid, Spain; [Drouet, Christian; Favier, Bertrand] Univ Grenoble 1, CHU Grenoble, GREPI AGIM CNRS FRE 3405, Ctr Explorat Angioedeme, Grenoble, France; [Perez-Fernandez, Elia] Hosp Univ La Paz, Res Unit, Biostat Sect, Madrid, Spain	Hospital Universitario La Paz; Hospital Universitario La Paz; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; CHU Grenoble Alpes; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Hospital Universitario La Paz	Gomez-Traseira, C (corresponding author), Hosp Univ La Paz, Dept Allergy, Madrid, Spain.	carmengomez.tras@gmail.com	López-Trascasa, Margarita/L-2699-2014; Caballero, Teresa/AAU-3982-2020; Lera, Alberto López/V-4181-2019; DROUET, Christian/J-8775-2019; Caballero, Teresa/H-6454-2014; DROUET, Christian/AAE-5682-2020; Favier, Bertrand/B-7258-2013	López-Trascasa, Margarita/0000-0001-8594-282X; Caballero, Teresa/0000-0003-3005-9858; DROUET, Christian/0000-0003-1318-4278; Caballero, Teresa/0000-0003-3005-9858; DROUET, Christian/0000-0003-1318-4278; Gomez-Traseira, Carmen/0000-0002-7486-6267; Perez-Fernandez, Elia/0000-0003-2726-8683				Bork K, 2011, CLIN IMMUNOL, V141, P31, DOI 10.1016/j.clim.2011.07.002; Caballero T, 2011, J INVEST ALLERG CLIN, V21, P333; Cichon S, 2006, AM J HUM GENET, V79, P1098, DOI 10.1086/509899; Defendi F, 2012, REV FR LAB, V42, P55; Drouet C, 2008, J ALLERGY CLIN IMMUN, V121, P429, DOI 10.1016/j.jaci.2007.10.048; Duan QL, 2009, J ALLERGY CLIN IMMUN, V123, P906, DOI 10.1016/j.jaci.2008.12.010; Kaplan AP, 2010, MOL IMMUNOL, V47, P2161, DOI 10.1016/j.molimm.2010.05.010; KLUFT C, 1978, J LAB CLIN MED, V91, P83; Marcos C, 2012, ANN ALLERG ASTHMA IM, V109, P195, DOI 10.1016/j.anai.2012.05.022; Martin L, 2007, J ALLERGY CLIN IMMUN, V120, P975, DOI 10.1016/j.jaci.2007.07.002; Zuraw BL, 2012, ALLERGY ASTHMA PROC, V33, pS145, DOI 10.2500/aap.2012.33.3627	11	19	19	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					986	989		10.1016/j.jaci.2013.04.032	http://dx.doi.org/10.1016/j.jaci.2013.04.032			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23849223	Bronze			2022-12-18	WOS:000325096500032
J	Gabriele, L; Schiavoni, G; Mattei, F; Sanchez, M; Sestili, P; Butteroni, C; Businaro, R; Mirchandani, A; Niedbala, W; Liew, FY; Afferni, C				Gabriele, Lucia; Schiavoni, Giovanna; Mattei, Fabrizio; Sanchez, Massimo; Sestili, Paola; Butteroni, Cinzia; Businaro, Rita; Mirchandani, Ananda; Niedbala, Wanda; Liew, Foo Y.; Afferni, Claudia			Novel allergic asthma model demonstrates ST2-dependent dendritic cell targeting by cypress pollen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-33; dendritic cells; cypress pollen; allergic asthma; ST2; mouse model; eosinophils; T cells	AIRWAY INFLAMMATION; IMMUNE-RESPONSES; GM-CSF; IL-33; INNATE; EXPRESSION; CYTOKINES; LICENSE; ANTIGEN; LEVEL	Background: Cypress pollen causes respiratory syndromes with different grades of severity, including asthma. IL-33, its receptor ST2, and dendritic cells (DCs) have been implicated in human respiratory allergy. Objective: We sought to define a new mouse model of allergy to cypress pollen that recapitulates clinical parameters in allergic patients and to evaluate the implications of DCs and the IL-33/ST2 pathway in this pathology. Methods: BALB/c mice, either wild-type or ST2 deficient (ST2(-/-)), were sensitized and challenged with the Cupressus arizonica major allergen nCup a 1. Local and systemic allergic responses were evaluated. Pulmonary cells were characterized by means of flow cytometry. DCs were stimulated with nCup a 1 and tested for their biological response to IL-33 in coculture assays. Results: nCup a 1 causes a respiratory syndrome closely resembling human pollinosis in BALB/c mice. nCup a 1-treated mice exhibit the hallmarks of allergic pathology associated with pulmonary infiltration of eosinophils, T cells, and DCs and a dominant T(H)2-type immune response. IL-33 levels were increased in lungs and sera of nCup a 1-treated mice and in subjects with cypress allergy. The allergen-specific reaction was markedly reduced in ST2(-/-) mice, which showed fewer infiltrating eosinophils, T cells, and DCs in the lungs. Finally, stimulation of DCs with nCup a 1 resulted in ST2 upregulation that endowed DCs with increased ability to respond to IL-33-mediated differentiation of IL-5- and IL-13-producing CD4 T cells. Conclusions: Our findings define a novel preclinical model of allergy to cypress pollen and provide the first evidence of a functionally relevant linkage between pollen allergens and T(H)2-polarizing activity by DCs through IL-33/ST2.	[Gabriele, Lucia; Schiavoni, Giovanna; Mattei, Fabrizio; Sestili, Paola] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Sanchez, Massimo] Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy; [Butteroni, Cinzia; Afferni, Claudia] Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, I-00161 Rome, Italy; [Businaro, Rita] Univ Roma La Sapienza, Dept Human Anat, I-00185 Rome, Italy; [Mirchandani, Ananda; Niedbala, Wanda; Liew, Foo Y.] Univ Glasgow, Inst Immun Infect & Inflammat, Glasgow, Lanark, Scotland; [Liew, Foo Y.] King Abdulaziz Univ, CEGMR, Jeddah 21413, Saudi Arabia	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); Istituto Superiore di Sanita (ISS); Sapienza University Rome; University of Glasgow; King Abdulaziz University	Afferni, C (corresponding author), Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, Viale Regina Elena 299, I-00161 Rome, Italy.	lucia.gabriele@iss.it; claudia.afferni@iss.it	Schiavoni, Giovanna/T-4418-2017; Sanchez, Massimo/AAD-1746-2021; Schiavoni, Giovanna/K-2448-2019; Businaro, Rita/AAG-1866-2021; Mattei, Fabrizio/J-6585-2016; AFFERNI, CLAUDIA/B-9978-2016; BUTTERONI, CINZIA/B-9981-2016; Gabriele, Lucia/J-8335-2016	Schiavoni, Giovanna/0000-0001-9135-0556; Sanchez, Massimo/0000-0003-3696-7582; Schiavoni, Giovanna/0000-0001-9135-0556; Businaro, Rita/0000-0002-7890-8524; Mattei, Fabrizio/0000-0002-5357-7773; AFFERNI, CLAUDIA/0000-0002-8567-7365; BUTTERONI, CINZIA/0000-0002-3919-5752; Gabriele, Lucia/0000-0002-1483-866X; reverberi, massimo/0000-0003-3671-6783; Sestili, Paola/0000-0002-9309-0767	Italian Ministry for the Environment and Territory and Sea [P8C]; Istituto Superiore di Sanita-Alliance Against Cancer (ACC) program 2; Wellcome Trust; Medical Research Council, UK; MRC [G0801198, G0601422, G9818261, G0902003] Funding Source: UKRI; Medical Research Council [G0801198, G0601422, G9818261, G0902003] Funding Source: researchfish	Italian Ministry for the Environment and Territory and Sea; Istituto Superiore di Sanita-Alliance Against Cancer (ACC) program 2; Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by grant no. P8C (2008-2010) from the Italian Ministry for the Environment and Territory and Sea (to C.A.), by the Istituto Superiore di Sanita-Alliance Against Cancer (ACC) program 2 (to L.G.), and by the Wellcome Trust and the Medical Research Council, UK.	Abramson MJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001186.pub2; Afferni C, 1999, CLIN EXP ALLERGY, V29, P1087, DOI 10.1046/j.1365-2222.1999.00590.x; Alisi C, 2001, ALLERGY, V56, P978, DOI 10.1034/j.1398-9995.2001.00125.x; Barrett NA, 2009, IMMUNITY, V31, P425, DOI 10.1016/j.immuni.2009.08.014; Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; Bhakta NR, 2011, IMMUNOL REV, V242, P220, DOI 10.1111/j.1600-065X.2011.01032.x; Charpin D, 2005, ALLERGY, V60, P293, DOI 10.1111/j.1398-9995.2005.00731.x; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Dullaers M, 2012, J ALLERGY CLIN IMMUN, V129, P635, DOI 10.1016/j.jaci.2011.10.029; Fuchs B, 2008, CURR DRUG TARGETS, V9, P495, DOI 10.2174/138945008784533589; Gluck J, 2012, INFLAMM RES, V61, P547, DOI 10.1007/s00011-012-0443-9; Gutermuth J, 2007, J ALLERGY CLIN IMMUN, V120, P293, DOI 10.1016/j.jaci.2007.03.017; Haenuki Y, 2012, J ALLERGY CLIN IMMUN, V130, P184, DOI 10.1016/j.jaci.2012.02.013; Hammad H, 2011, ALLERGY, V66, P579, DOI 10.1111/j.1398-9995.2010.02528.x; Iacovacci P., 2002, Clinical and Experimental Allergy, V32, P1620, DOI 10.1046/j.1365-2222.2002.01516.x; Ito T, 2012, ALLERGOL INT, V61, P35, DOI 10.2332/allergolint.11-RAI-0376; Jacobsen EA, 2008, J EXP MED, V205, P699, DOI 10.1084/jem.20071840; Kamijo S, 2009, J IMMUNOL, V183, P6087, DOI 10.4049/jimmunol.0901039; Komai-Koma M, 2007, EUR J IMMUNOL, V37, P2779, DOI 10.1002/eji.200737547; Komai-Koma M, 2011, J IMMUNOL, V186, P2584, DOI 10.4049/jimmunol.1002103; Kumar RK, 2008, CURR DRUG TARGETS, V9, P485, DOI 10.2174/138945008784533561; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780, DOI 10.4049/jimmunol.181.7.4780; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mariani V, 2007, J IMMUNOL, V178, P7623, DOI 10.4049/jimmunol.178.12.7623; Mayuzumi N, 2009, EUR J IMMUNOL, V39, P3331, DOI 10.1002/eji.200939472; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Nguyen THT, 2011, IMMUNOL REV, V242, P258, DOI 10.1111/j.1600-065X.2011.01034.x; Nilsson OB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024558; Oboki K, 2011, ALLERGY ASTHMA IMMUN, V3, P81, DOI 10.4168/aair.2011.3.2.81; Okamoto Yoshitaka, 2009, Allergology International, V58, P155, DOI 10.2332/allergolint.08-RAI-0074; Oseroff C, 2012, J IMMUNOL, V189, P1800, DOI 10.4049/jimmunol.1200850; Oseroff C, 2010, J IMMUNOL, V185, P943, DOI 10.4049/jimmunol.1000405; Platts-Mills TAE, 2011, IMMUNOL REV, V242, P51, DOI 10.1111/j.1600-065X.2011.01021.x; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; Sakashita M, 2008, CLIN EXP ALLERGY, V38, P1875, DOI 10.1111/j.1365-2222.2008.03114.x; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shin YS, 2009, ALLERGY ASTHMA IMMUN, V1, P10, DOI 10.4168/aair.2009.1.1.10; Smith DE, 2010, CLIN EXP ALLERGY, V40, P200, DOI 10.1111/j.1365-2222.2009.03384.x; Stolarski B, 2010, J IMMUNOL, V185, P3472, DOI 10.4049/jimmunol.1000730; Swoboda Ines, 2008, Clin Allergy Immunol, V21, P87; Thai P, 2005, AM J RESP CELL MOL, V33, P523, DOI 10.1165/rcmb.2004-0220RC; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Turnquist HR, 2009, EUR J IMMUNOL, V39, P3292, DOI 10.1002/eji.200940026; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; Willart Monique A. M., 2010, Allergology International, V59, P95, DOI 10.2332/allergolint.09-RAI-0162; Zimmer A, 2012, J ALLERGY CLIN IMMUN, V129, P1020, DOI 10.1016/j.jaci.2012.02.014	50	19	20	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					686	+		10.1016/j.jaci.2013.02.037	http://dx.doi.org/10.1016/j.jaci.2013.02.037			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23608732	Green Submitted			2022-12-18	WOS:000323612000021
J	Ma, SK; Yin, J; Jiang, NN				Ma, Shikun; Yin, Jia; Jiang, Nannan			Component-resolved diagnosis of peach allergy and its relationship with prevalent allergenic pollens in China	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LIPID-TRANSFER PROTEIN		[Ma, Shikun] Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Allergy, Beijing 100021, Peoples R China; Chinese Acad Med Sci, Beijing 100730, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College	Ma, SK (corresponding author), Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Allergy, Beijing 100021, Peoples R China.	doctoryinjia@163.com						Andersen MBS, 2011, CLIN REV ALLERG IMMU, V41, P4, DOI 10.1007/s12016-009-8177-3; Enrique E, 2002, ALLERGY, V57, P351, DOI 10.1034/j.1398-9995.2002.1s3509.x; Gao ZS, 2013, J ALLERGY CLIN IMMUN, V131, P224, DOI 10.1016/j.jaci.2012.07.015; Lauer I, 2007, CLIN EXP ALLERGY, V37, P261, DOI 10.1111/j.1365-2222.2007.02653.x; Lombardero M, 2004, CLIN EXP ALLERGY, V34, P1415, DOI 10.1111/j.1365-2222.2004.02053.x; Lopez JFF, 2002, ALLERGY, V57, P53, DOI 10.1034/j.1398-9995.2002.057s71053.x; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V110, P310, DOI 10.1067/mai.2002.125830; Vereda A, 2011, J ALLERGY CLIN IMMUN, V127, P603, DOI 10.1016/j.jaci.2010.09.010; Ye ST, 1991, INVESTIGATION AEROBO	9	19	20	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					764	767		10.1016/j.jaci.2013.04.017	http://dx.doi.org/10.1016/j.jaci.2013.04.017			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23791512	Bronze			2022-12-18	WOS:000323612000038
J	Sadatsafavi, M; Lynd, L; Marra, C; Bedouch, P; FitzGerald, M				Sadatsafavi, Mohsen; Lynd, Larry; Marra, Carlo; Bedouch, Pierrick; FitzGerald, Mark			Comparative outcomes of leukotriene receptor antagonists and long-acting beta-agonists as add-on therapy in asthmatic patients: A population-based study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RANDOMIZED CONTROLLED-TRIALS; HEALTH-CARE UTILIZATION; INHALED CORTICOSTEROIDS; CONTROLLER MEDICATIONS; RESOURCE UTILIZATION; EXTERNAL VALIDITY; PROPENSITY SCORES; CLAIMS ANALYSIS; MONTELUKAST; COSTS	Background: Recent evidence suggests that the use of leukotriene receptor antagonists (LTRAs) in addition to inhaled corticosteroids (ICSs) in asthmatic patients provides comparable benefits to the addition of long-acting beta-agonists (LABAs) to ICSs. Objective: We sought to compare, in a unified framework, adherence, outcomes, and costs associated with ICS+LTRA versus ICS+LABA as step-up therapies for asthma. Methods: Using the administrative databases of British Columbia, Canada (years 1997-2007), we created a propensity score-matched sample of asthmatic patients (12-45 years old) receiving ICS+LTRA therapy versus ICS+LABA therapy after a period of monotherapy with an ICS. We compared the outcomes using 2 analyses: an intention-to-treat (ITT) analysis that followed subjects for a fixed period of 2 years and an uninterrupted treatment analysis that followed subjects for as long as they continuously dispensed their index medications. Results: The matched cohort consisted of 1032 subjects in each group (mean age at entry, 27.4 years; 52.5% female). Adherence, which was defined as the proportion of days covered, was higher in the ICS1LABA group compared with the ICS+LTRA group. In both the ITT and uninterrupted treatment analyses, use of ICS+LTRA therapy was associated with more asthma-related outpatient visits, asthma-related medication dispensations, and dispensation of reliever medications. Dispensation of oral corticosteroids and rate of asthma exacerbations were higher in the ICS+LTRA group in the uninterrupted treatment analysis but not in the ITT analysis. Conclusions: In a real-world clinical setting subjects were more adherent to ICS+LABA therapy than ICS+LTRA therapy. ICS+LABA therapy seems to be more effective than ICS+LTRA therapy in the management of asthma, regardless of adherence.	[Sadatsafavi, Mohsen; FitzGerald, Mark] Univ British Columbia, Inst Heart & Lung Hlth, Fac Med, Vancouver, BC V5Z 1M9, Canada; [Sadatsafavi, Mohsen; FitzGerald, Mark] Univ British Columbia, Vancouver Coastal Hlth Inst, Ctr Clin Epidemiol & Evaluat, Vancouver, BC V5Z 1M9, Canada; [Sadatsafavi, Mohsen; Lynd, Larry; Marra, Carlo] Univ British Columbia, Collaborat Outcomes Res & Evaluat, Fac Pharmaceut Sci, Vancouver, BC V5Z 1M9, Canada; [Lynd, Larry; Marra, Carlo] Univ British Columbia, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V5Z 1M9, Canada; [Bedouch, Pierrick] Grenoble Univ Hosp, Dept Pharm, Grenoble, France	University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute; University of British Columbia; University of British Columbia; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Sadatsafavi, M (corresponding author), Ctr Clin Epidemiol & Evaluat, 7th Floor,828 W 10th Ave,Res Pavil, Vancouver, BC V5Z 1M9, Canada.	msafavi@mail.ubc.ca	Sadatsafayi, Mohsen/AAZ-1593-2020; Bedouch, Pierrick/M-6169-2014; Marra, Carlo/AAE-4904-2021	Sadatsafayi, Mohsen/0000-0002-0419-7862; Bedouch, Pierrick/0000-0003-2245-0160; Marra, Carlo/0000-0002-2625-2121; Lynd, Larry/0000-0002-7622-3919	AllerGen National Center of Excellence; AstraZeneca; GlaxoSmithKline; Boehringer-Ingelheim; Merck; Wyeth; Schering; Genentech; Topingen; Pfizer	AllerGen National Center of Excellence; AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Boehringer-Ingelheim(Boehringer Ingelheim); Merck(Merck & Company); Wyeth(Wyeth); Schering; Genentech(Roche HoldingGenentech); Topingen; Pfizer(Pfizer)	This study is part of the project "Platform for Outcomes Research and Translation in Asthma and aLlergy (PORTAL)'' funded by AllerGen National Center of Excellence, a peer-reviewed government funding agency. The agency did not have any input in the design, analysis, and preparing the reports of the present study.; Disclosure of potential conflict of interest: All of the authors have been supported by one or more grants from the AllerGen National Center of Excellence. M. FitzGerald is an Advisory Board member for GlaxoSmithKline, AstraZeneca, Novartis, Pfizer, Boehringer-Ingelheim, Altana, Merck, and Topingen; has received one or more grants from or has one or more grants pending with AstraZeneca, GlaxoSmithKline, Boehringer-Ingelheim, Merck, Wyeth, Schering, Genentech, and Topingen; has received one or more payments for lecturing from or is on the speakers' bureau for GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim, Pfizer, and Merck; and has received one or more payments for travel/accommodations/meeting expenses from GlaxoSmithKline, AstraZeneca, Novartis, Pfizer, Boehringer-Ingelheim, Altana, Merck, and Topingen.	Aaron SD, 2008, CAN MED ASSOC J, V179, P1121, DOI 10.1503/cmaj.081332; Accordini S, 2006, INT ARCH ALLERGY IMM, V141, P189, DOI 10.1159/000094898; Allen-Ramey FC, 2003, ALLERGY ASTHMA PROC, V24, P43; Allen-Ramey FC, 2006, J MANAGE CARE PHARM, V12, P310, DOI 10.18553/jmcp.2006.12.4.310; [Anonymous], 2007, J ALLERGY CLIN IMM S, V120, pS94; [Anonymous], 2009, NATL ASTHMA ED PREV; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Bedouch P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050949; Black N, 1996, BRIT MED J, V312, P1215; British Columbia Ministry of Health, POP DAT BC; Canadian Thoracic Society, 2010 CTS GUID ASTHM; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; Dorais M, 2005, J ASTHMA, V42, P385, DOI 10.1081/JAS-200063007; Ducharme FM, 2012, CURR MED RES OPIN, V28, P111, DOI 10.1185/03007995.2011.640668; Ducharme FM, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003137.pub4; Fish JE, 2001, CHEST, V120, P423, DOI 10.1378/chest.120.2.423; GARDNER W, 1995, PSYCHOL BULL, V118, P392, DOI 10.1037/0033-2909.118.3.392; Global Initiative for Asthma (GINA) NHLaBI National Institutes of Health, GINA REP GLOB STRAT; Glynn RJ, 2006, BASIC CLIN PHARMACOL, V98, P253, DOI 10.1111/j.1742-7843.2006.pto_293.x; Gu Xing S., 1993, J COMPUTATIONAL GRAP, V2, P405, DOI [DOI 10.1080/10618600.1993.10474623, DOI 10.7326/0003-4819-152-6-201003160-00008]; Hess LM, 2006, ANN PHARMACOTHER, V40, P1280, DOI 10.1345/aph.1H018; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; Latry P, 2008, CLIN THER, V30, P1058, DOI 10.1016/j.clinthera.2008.06.011; Lee TA, 2010, CURR MED RES OPIN, V26, P2851, DOI 10.1185/03007995.2010.531255; Mihaylova B, 2011, HEALTH ECON, V20, P897, DOI 10.1002/hec.1653; Persaud N, 2006, J EVAL CLIN PRACT, V12, P450, DOI 10.1111/j.1365-2753.2006.00730.x; PINK GH, 1994, CAN MED ASSOC J, V150, P1255; Price D, 2011, NEW ENGL J MED, V364, P1695, DOI 10.1056/NEJMoa1010846; Ringdal N, 2003, RESP MED, V97, P234, DOI 10.1053/rmed.2003.1436; Sadatsafavi M, 2010, CAN RESPIR J, V17, P74, DOI 10.1155/2010/361071; Sanson-Fisher RW, 2007, AM J PREV MED, V33, P155, DOI 10.1016/j.amepre.2007.04.007; Stempel DA, 2002, J ALLERGY CLIN IMMUN, V109, P433, DOI 10.1067/mai.2002.121953; Stempel DA, 2001, J ALLERGY CLIN IMMUN, V107, P94, DOI 10.1067/mai.2001.112029; Suissa S, 2002, THORAX, V57, P880, DOI 10.1136/thorax.57.10.880; Tan H, 2009, MAYO CLIN PROC, V84, P675, DOI 10.1016/S0025-6196(11)60517-X; Travers J, 2007, THORAX, V62, P219, DOI 10.1136/thx.2006.066837; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Weitzen S, 2004, PHARMACOEPIDEM DR S, V13, P841, DOI 10.1002/pds.969; Yong PL, 2009, J ALLERGY CLIN IMMUN, V124, P961, DOI 10.1016/j.jaci.2009.07.027; Zeiger RS, 2008, J ALLERGY CLIN IMMUN, V121, P885, DOI 10.1016/j.jaci.2007.12.1178	40	19	19	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					63	69		10.1016/j.jaci.2013.02.007	http://dx.doi.org/10.1016/j.jaci.2013.02.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23545274				2022-12-18	WOS:000321052300007
J	Pyle, DM; Yang, VS; Gruchalla, RS; Farrar, JD; Gill, MA				Pyle, David M.; Yang, Victoria S.; Gruchalla, Rebecca S.; Farrar, J. David; Gill, Michelle A.			IgE cross-linking critically impairs human monocyte function by blocking phagocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Monocyte; IgE; Fc epsilon RI; IgE cross-linking; allergy; proinflammatory; autoregulatory; phagocytosis; apoptotic debris	FC-EPSILON-RI; PLASMACYTOID DENDRITIC CELLS; ATOPIC-DERMATITIS; SERUM IGE; AIRWAY HYPERRESPONSIVENESS; ALVEOLAR MACROPHAGES; UNITED-STATES; SEVERE ASTHMA; MILD ASTHMA; TNF-ALPHA	Background: IgE cross-linking triggers many cellular processes that drive allergic disease. While the role of IgE in mediating allergic responses is best described on basophils and mast cells, expression of the high-affinity IgE receptor on other innate immune cells, including monocytes, suggests that it may affect the function of these cells in allergic environments. Objective: To determine the effect of IgE cross-linking on the function of human monocytes. Methods: Monocytes purified from healthy donor blood samples were cultured for 4 to 96 hours with media alone, a cross-linking anti-IgE antibody or control IgG. Surface CD14 and CD64 expression and secreted cytokine concentrations were determined. Monocyte function was determined by assessing (1) phagocytosis of Escherichia coli or apoptotic HEp2 cells and (2) killing of intracellular E coli. Select experiments were performed on monocytes obtained from participants with elevated versus normal serum IgE concentrations. Results: IgE cross-linking on monocytes increased CD14 expression and induced secretion of TNF-alpha, IL-6, and autoregulatory IL-10. These effects were greatest in individuals with elevated serum IgE concentrations. In contrast, IgE cross-linking reduced CD64 expression and significantly impaired phagocytic function without disrupting the capacity of monocytes to kill bacteria. Conclusions: IgE cross-linking drives monocyte proinflammatory processes and autoregulatory IL-10 in a serum IgE-dependent manner. In contrast, monocyte phagocytic function is critically impaired by IgE cross-linking. Our findings suggest that IgE cross-linking on monocytes may contribute to allergic disease by both enhancing detrimental inflammatory responses and concomitantly crippling phagocytosis, a primary mechanism used by these cells to resolve inflammation. (J Allergy Clin Immunol 2013;131:491-500.)	[Pyle, David M.; Gruchalla, Rebecca S.; Farrar, J. David; Gill, Michelle A.] Univ Texas SW Med Ctr Dallas, Dept Immunol, Dallas, TX 75390 USA; [Pyle, David M.; Yang, Victoria S.; Gruchalla, Rebecca S.; Gill, Michelle A.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Gruchalla, Rebecca S.; Gill, Michelle A.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Yang, Victoria S.] Childrens Med Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Gill, MA (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Immunol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Miehelle.Gill@UTSouthwestern.edu			William A. Sellars and Joyce M. Sellars Distinguished Chair in Allergy and Immunology; National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) [R01-AI098077]; NIH/NIAID [R01-AI056222]; NIH National Research Service Award [T32-AI005284]; NIH National Institute of General Medical Sciences [T32-GM008014]; National Institutes of Health National Research Service Award; National Institute of General Medical Sciences; National Institutes of Health Inner City Asthma Consortium; National Institutes of Health, National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI005284, R01AI056222, R01AI098077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008014] Funding Source: NIH RePORTER	William A. Sellars and Joyce M. Sellars Distinguished Chair in Allergy and Immunology; National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institutes of Health National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institutes of Health Inner City Asthma Consortium; National Institutes of Health, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by the William A. Sellars and Joyce M. Sellars Distinguished Chair in Allergy and Immunology; National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) grant no. R01-AI098077; NIH/NIAID grant no. R01-AI056222; NIH National Research Service Award no. T32-AI005284; and NIH National Institute of General Medical Sciences grant no. T32-GM008014.; D. M. Pyle has received research support from the National Institutes of Health National Research Service Award and the National Institute of General Medical Sciences. R. S. Gruchalla has received research support from the William A. Sellars and Joyce M. Sellars Distinguished Chair in Allergy and Immunology and the National Institutes of Health Inner City Asthma Consortium and is employed by the Food and Drug Association on an as-needed basis. J. D. Farrar and M. A. Gill have received research support from the National Institutes of Health, National Institute of Allergy and Infectious Diseases. V. S. Yang declares that she has no relevant conflicts of interest.	Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; Alexis NE, 2001, AM J PHYSIOL-LUNG C, V280, pL369; Brekke OL, 2008, MOL IMMUNOL, V45, P3804, DOI 10.1016/j.molimm.2008.05.017; Brooks DG, 2010, P NATL ACAD SCI USA, V107, P3018, DOI 10.1073/pnas.0914500107; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Cheng YX, 2006, CLIN EXP ALLERGY, V36, P1436, DOI 10.1111/j.1365-2222.2006.02578.x; Delavary BM, 2011, IMMUNOBIOLOGY, V216, P753, DOI 10.1016/j.imbio.2011.01.001; Fang HQ, 2004, J IMMUNOL, V173, P360, DOI 10.4049/jimmunol.173.1.360; Fitzpatrick AM, 2008, J ALLERGY CLIN IMMUN, V121, P1372, DOI 10.1016/j.jaci.2008.03.008; Foster B, 2003, J ALLERGY CLIN IMMUN, V112, P1132, DOI 10.1016/j.jaci.2003.09.011; Gibbs BF, 2006, J ALLERGY CLIN IMMUN, V118, P1060, DOI 10.1016/j.jaci.2006.07.022; Gill MA, 2008, J INFECT DIS, V198, P1667, DOI 10.1086/593018; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Ginhoux F, 2006, NAT IMMUNOL, V7, P265, DOI 10.1038/ni1307; Grace-Griebenow E, 2000, IMMUNOBIOLOGY, V202, P42, DOI 10.1016/S0171-2985(00)80051-0; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Hutchison S, 2008, CLIN EXP IMMUNOL, V151, P114, DOI 10.1111/j.1365-2249.2007.03509.x; Huynh MLN, 2005, AM J RESP CRIT CARE, V172, P972, DOI 10.1164/rccm.200501-035OC; Jackson DJ, 2010, J ALLERGY CLIN IMMUN, V125, P1178, DOI 10.1016/j.jaci.2010.04.021; Kamen LA, 2008, J IMMUNOL, V180, P7497, DOI 10.4049/jimmunol.180.11.7497; Kjaer HF, 2009, PEDIAT ALLERG IMM-UK, V20, P726, DOI 10.1111/j.1399-3038.2009.00862.x; Kovac K, 2007, ARCH MED RES, V38, P99, DOI 10.1016/j.arcmed.2006.07.007; Kraft S, 2002, J INVEST DERMATOL, V118, P830, DOI 10.1046/j.1523-1747.2002.01757.x; Kulkarni NS, 2010, J ALLERGY CLIN IMMUN, V126, P61, DOI 10.1016/j.jaci.2010.03.026; Landsman L, 2007, J IMMUNOL, V178, P2000, DOI 10.4049/jimmunol.178.4.2000; Laske N, 2004, PEDIAT ALLERG IMM-UK, V15, P86, DOI 10.1046/j.0905-6157.2003.00106.x; Le T, 2009, J ALLERGY CLIN IMMUN, V123, P217, DOI 10.1016/j.jaci.2008.09.013; Lee KS, 2011, J MICROBIOL, V49, P1050, DOI 10.1007/s12275-011-1043-z; Lee WI, 2012, IMMUNOBIOLO IN PRESS; Lensmar C, 2006, RESP MED, V100, P918, DOI 10.1016/j.rmed.2005.08.014; Lenzo JC, 2012, IMMUNOL CELL BIOL, V90, P429, DOI 10.1038/icb.2011.58; Leon B, 2008, BLOOD, V111, P3126, DOI 10.1182/blood-2007-07-100610; Liang Y, 2012, ALLERGY, V67, P424, DOI 10.1111/j.1398-9995.2011.02760.x; Makela SM, 2009, J LEUKOCYTE BIOL, V85, P664, DOI 10.1189/jlb.0808503; Mancini AJ, 2008, PEDIATR DERMATOL, V25, P1, DOI 10.1111/j.1525-1470.2007.00572.x; Matsui EC, 2010, ALLERGY, V65, P1414, DOI 10.1111/j.1398-9995.2010.02412.x; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059, DOI 10.1152/jappl.1989.66.3.1059; Monteseirin J, 2003, ALLERGY, V58, P1027, DOI 10.1034/j.1398-9995.2003.00249.x; Morjaria JB, 2011, THORAX, V66, P537, DOI 10.1136/thx.2010.136523; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Narasaraju T, 2010, AM J RESP CELL MOL, V42, P732, DOI 10.1165/rcmb.2008-0423OC; Nayyar A, 2012, J IMMUNOL, V189, P72, DOI 10.4049/jimmunol.1103286; Novak N, 2001, J IMMUNOL, V167, P797, DOI 10.4049/jimmunol.167.2.797; Reed JL, 2008, J INFECT DIS, V198, P1783, DOI 10.1086/593173; Sawaguchi M, 2012, J IMMUNOL, V188, P1809, DOI 10.4049/jimmunol.1101746; Schroeder JT, 2008, J ALLERGY CLIN IMMUN, V121, P486, DOI 10.1016/j.jaci.2007.09.049; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; Tamura N, 2009, BIOCHEM J, V423, P99, DOI 10.1042/BJ20090687; Thaiwat S, 2011, ASIAN PAC J ALLERGY, V29, P357; Tsuchiya K, 2012, AM J PHYSIOL-LUNG C, V303, pL54, DOI 10.1152/ajplung.00208.2011; Ugajin T, 2011, AM J PATHOL, V179, P775, DOI 10.1016/j.ajpath.2011.04.023; von Bubnoff D, 2002, J IMMUNOL, V169, P6170, DOI 10.4049/jimmunol.169.11.6170; Widegren H, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-15; Wu LC, 2011, J BIOL CHEM, V286, P32891, DOI 10.1074/jbc.R110.205104	55	19	21	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					491	+		10.1016/j.jaci.2012.11.037	http://dx.doi.org/10.1016/j.jaci.2012.11.037			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23374271	Green Accepted, Bronze			2022-12-18	WOS:000314661500029
J	Millon, L; Roussel, S; Rognon, B; Quadroni, M; Salamin, K; Reboux, G; Barrera, C; Fellrath, JM; Aubert, JD; Dalphin, JC; Monod, M				Millon, Laurence; Roussel, Sandrine; Rognon, Benedicte; Quadroni, Manfredo; Salamin, Karin; Reboux, Gabriel; Barrera, Coralie; Fellrath, Jean-Marc; Aubert, John D.; Dalphin, Jean-Charles; Monod, Michel			Aspergillus species recombinant antigens for serodiagnosis of farmer's lung disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HYPERSENSITIVITY PNEUMONITIS; IGG ANTIBODIES; FUMIGATUS; DIAGNOSIS		[Millon, Laurence; Roussel, Sandrine; Rognon, Benedicte; Quadroni, Manfredo; Salamin, Karin; Reboux, Gabriel; Barrera, Coralie; Dalphin, Jean-Charles] Univ Franche Comte, CNRS, UMR Chronoenvironm 6249, F-25030 Besancon, France; [Millon, Laurence; Roussel, Sandrine; Rognon, Benedicte; Reboux, Gabriel] Univ Hosp Besancon, Dept Parasitol Mycol, Besancon, France; [Reboux, Gabriel] Univ Hosp Besancon, Clin Invest Ctr, INSERM, CIT 808, Besancon, France; [Dalphin, Jean-Charles] Univ Hosp Besancon, Dept Pneumol, Besancon, France; [Quadroni, Manfredo] Univ Lausanne, Fac Biol & Med, Ctr Integrat Genom, Prot Anal Facil, Lausanne, Switzerland; [Salamin, Karin; Monod, Michel] CHU Vaudois, Dept Dermatol Mycol, Lausanne, Switzerland; [Salamin, Karin; Monod, Michel] CHU Vaudois, Dept Pulm Med, Lausanne, Switzerland; [Fellrath, Jean-Marc] Univ Hosp, Dept Pulm Med, Neuchatel, Switzerland	Centre National de la Recherche Scientifique (CNRS); Universite de Franche-Comte; Universite de Franche-Comte; CHU Besancon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte; CHU Besancon; Universite de Franche-Comte; CHU Besancon; University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Millon, L (corresponding author), Univ Franche Comte, CNRS, UMR Chronoenvironm 6249, F-25030 Besancon, France.	Laurence.millon@univ-fcomte.fr	Aubert, John-David/H-5561-2019; Millon, laurence/AAK-5980-2020	Aubert, John-David/0000-0001-8856-4000; Quadroni, Manfredo/0000-0002-2720-4084; Reboux, Gabriel/0000-0002-7923-0858				Erkinjuntti-Pekkanen R, 1999, ALLERGY, V54, P1181, DOI 10.1034/j.1398-9995.1999.00275.x; Fenoglio CM, 2007, EUR RESPIR J, V29, P706, DOI 10.1183/09031936.00001006; Fink JN, 2005, AM J RESP CRIT CARE, V171, P792, DOI 10.1164/rccm.200409-1205WS; Giddey K, 2007, J PROTEOME RES, V6, P3081, DOI 10.1021/pr070153m; Lacasse Y, 2003, AM J RESP CRIT CARE, V168, P952, DOI 10.1164/rccm.200301-137OC; Lappalainen S, 1998, ANN ALLERG ASTHMA IM, V81, P585, DOI 10.1016/S1081-1206(10)62710-X; MONOD M, 1993, FEMS MICROBIOL LETT, V106, P39, DOI 10.1111/j.1574-6968.1993.tb05932.x; Moran GP, 2011, EUKARYOT CELL, V10, P34, DOI 10.1128/EC.00242-10; Reboux G, 2001, AM J RESP CRIT CARE, V163, P1534, DOI 10.1164/ajrccm.163.7.2006077; Reboux G, 2007, J MED MICROBIOL, V56, P1317, DOI 10.1099/jmm.0.46953-0; Reichard U, 2006, APPL ENVIRON MICROB, V72, P1739, DOI 10.1128/AEM.72.3.1739-1748.2006; Roussel S, 2010, CLIN VACCINE IMMUNOL, V17, P160, DOI 10.1128/CVI.00129-09; Samson RA, 2010, FOOD INDOOR FUNGI, P68; Singh B, 2010, J PROTEOME RES, V9, P5530, DOI 10.1021/pr100605c; Sriranganadane D, 2010, J PROTEOME RES, V9, P3511, DOI 10.1021/pr901202z	15	19	19	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					803	+		10.1016/j.jaci.2012.03.039	http://dx.doi.org/10.1016/j.jaci.2012.03.039			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22608571				2022-12-18	WOS:000308463500032
J	Duong, M; Amin, R; Baatjes, AJ; Kritzinger, F; Qi, Y; Meghji, Z; Lou, W; Grasemann, H; O'Byrne, PM; Subbarao, P				Duong, MyLinh; Amin, Reshma; Baatjes, Adrian J.; Kritzinger, Fiona; Qi, Ying; Meghji, Zahida; Lou, Wendy; Grasemann, Hartmut; O'Byrne, Paul M.; Subbarao, Padmaja			The effect of montelukast, budesonide alone, and in combination on exercise-induced bronchoconstriction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LEUKOTRIENE RECEPTOR ANTAGONIST; INDUCED ASTHMA; PERSISTENT ASTHMA; KOREAN CHILDREN; RESPONSIVENESS; POLYMORPHISMS; FLUTICASONE; SALMETEROL; RESPONSES		[Duong, MyLinh; Baatjes, Adrian J.; Meghji, Zahida; O'Byrne, Paul M.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Amin, Reshma; Kritzinger, Fiona; Grasemann, Hartmut; Subbarao, Padmaja] Hosp Sick Children, Dept Pediat, Div Resp Med, Toronto, ON M5G 1X8, Canada; [Qi, Ying; Lou, Wendy] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada	McMaster University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Duong, M (corresponding author), McMaster Univ, Dept Med, Hamilton, ON, Canada.	duongmy@mcmaster.ca		O'Byrne, Paul/0000-0003-0979-281X; Subbarao, Padmaja/0000-0003-0394-1933				Duong M, 2008, CHEST, V133, P404, DOI 10.1378/chest.07-2048; Hallstrand TS, 2009, CURR ALLERGY ASTHM R, V9, P18, DOI 10.1007/s11882-009-0003-8; Kang MJ, 2008, PHARMACOGENET GENOM, V18, P551, DOI 10.1097/FPC.0b013e3282fe94c5; Kemp JP, 1998, J PEDIATR-US, V133, P424, DOI 10.1016/S0022-3476(98)70281-1; Kim JH, 2008, CLIN EXP ALLERGY, V38, P51, DOI 10.1111/j.1365-2222.2007.02874.x; Koh MS, 2007, COCHRANE DB SYST REV, V3; Lee SY, 2007, CLIN EXP ALLERGY, V37, P1487, DOI 10.1111/j.1365-2222.2007.02795.x; Melo RE, 2003, J ALLERGY CLIN IMMUN, V111, P301, DOI 10.1067/mai.2003.66; Pearlman D, 2009, PEDIATR PULM, V44, P429, DOI 10.1002/ppul.20962; Peters-Golden M, 2003, J ALLERGY CLIN IMM S, V111, pS3; Peters-Golden Marc, 2003, Journal of Allergy and Clinical Immunology, V111, pS37, DOI 10.1067/mai.2003.23; Simons FER, 1997, PEDIATRICS, V99, P655, DOI 10.1542/peds.99.5.655; Stelmach I, 2008, J ALLERGY CLIN IMMUN, V121, P383, DOI 10.1016/j.jaci.2007.09.007; Subbarao P, 2006, J ALLERGY CLIN IMMUN, V117, P1008, DOI 10.1016/j.jaci.2005.11.048; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Vidal C, 2001, ANN ALLERG ASTHMA IM, V86, P655, DOI 10.1016/S1081-1206(10)62294-6; Villaran C, 1999, J ALLERGY CLIN IMMUN, V104, P547, DOI 10.1016/S0091-6749(99)70322-2; Weiler JM, 2005, ANN ALLERG ASTHMA IM, V94, P65, DOI 10.1016/S1081-1206(10)61288-4; Weiler JM, 2007, J ALLERGY CLIN IMMUN, V119, P1349, DOI 10.1016/j.jaci.2007.02.041	19	19	19	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					535	539		10.1016/j.jaci.2012.02.051	http://dx.doi.org/10.1016/j.jaci.2012.02.051			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22534533				2022-12-18	WOS:000307002200040
J	Gelb, AF; Moridzadeh, R; Singh, DH; Fraser, C; George, SC				Gelb, Arthur F.; Moridzadeh, Roxanna; Singh, Deepak H.; Fraser, Christine; George, Steven C.			In moderate-to-severe asthma patients monitoring exhaled nitric oxide during exacerbation is not a good predictor of spirometric response to oral corticosteroid	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; exhaled nitric oxide; asthma mechanisms	ALVEOLAR; AIRWAY; INFLAMMATION; ADULTS; MANAGEMENT; DIFFUSION; SYMPTOMS; CHILDREN; THERAPY; SITES	Background: The importance of monitoring exhaled nitric oxide (NO) in asthma remains controversial. Objective: To measure exhaled NO, postnebulized albuterol/ipratropium spirometry, and Asthma Control Test (ACT) during asthma exacerbation requiring 8- to 10-day tapering oral corticosteroid in nonsmoking patients with moderate-to-severe asthma on moderate-dose inhaled corticosteroid and long-acting beta(2)-agonist but not maintenance oral corticosteroid. Methods: After measuring the fraction of exhaled NO (FENO [ppb]) at 50, 100, 150, and 200 mL/s, the total FENO at 50 mL/s (ppb), large central airway NO flux (J(awNO)' [nL/s]), and peripheral small airway/alveolar NO concentration (C-ANO [ppb]) were calculated and corrected for NO axial back-diffusion. Outpatient exacerbation required the patient with asthma to be afebrile with normal chest x-ray and white blood cell count. Results: Group 1 included 17 patients (6 men) with asthma, age 52 +/- 12 years, studied at baseline, during 18 exacerbations with abnormal FENO at 50 mL/s, J(awNO)', and/or C-ANO, and post 8- to 10-day tapering 40 mg prednisone (recovery). Baseline: IgE, 332 +/- 243 K mu; total blood eosinophils, 304 +/- 266 cells/mu L; body mass index, 28 +/- 6; ACT, 16 to 19; and FEV1, 2.5 +/- 0.7 L (86% +/- 20% predicted); exacerbation: FEV1, 1.7 +/- 0.4 L (60% +/- 17%) (P < .001); recovery: FEV1, 2.5 +/- 0.7 L (85% +/- 13%) (P < .001). Group 2 included 11 (7 men) similarly treated patients with asthma, age 49 +/- 14 years, studied at baseline, during 15 exacerbations with normal FENO at 50 mL/s, J(awNO)', and C-ANO. Baseline: IgE, 307 +/- 133 K mu; total blood eosinophils, 296 6 149 cells/mu L; body mass index, 28 +/- 6; ACT, 16 to 19; and FEV1, 2.7 +/- 0.9 L (71% +/- 12% predicted); exacerbation: FEV1, 1.7 +/- 0.6 L (54% +/- 19%) (P < .006); recovery: FEV1, 2.7 +/- 0.9 L (70% +/- 14%) (P = .002). On comparing group 1 versus group 2, there was no significant difference for baseline IgE, eosinophils, body mass index, and ACT and similar significant (<=.006) decrease from baseline in FEV1 (L) during exacerbation and similar increase (<=.006) at recovery. Conclusions: Increased versus normal exhaled NO during outpatient exacerbation in patients with moderate-to-severe asthma on inhaled corticosteroid and long-acting beta(2)-agonist but not maintenance oral corticosteroid does not preclude a robust clinical and spirometric response to tapering oral prednisone. (J Allergy Clin Immunol 2012;129:1491-8.)	[Gelb, Arthur F.; Moridzadeh, Roxanna; Singh, Deepak H.; Fraser, Christine] Lakewood Reg Med Ctr, Div Pulm, Dept Med, Lakewood, CO USA; [Gelb, Arthur F.] Univ Calif Los Angeles, Med Ctr, Geffen Sch Med, Los Angeles, CA 90024 USA; [George, Steven C.] Univ Calif Irvine, Dept Biomed Engn & Chem Engn & Mat Sci, Irvine, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Irvine	Gelb, AF (corresponding author), 3650 E South St,Suite 308, Lakewood, CA 90712 USA.	afgelb@msn.com	George, Steven/K-9359-2015	George, Steven/0000-0003-2263-1914				*AM THOR SOC, 2005, AM J RESP CRIT CARE, V160, P2104; Barnes PJ, 2010, CHEST, V138, P682, DOI 10.1378/chest.09-2090; Berry M, 2005, EUR RESPIR J, V25, P986, DOI 10.1183/09031936.05.00132404; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; Brindicci C, 2007, CHEST, V131, P1353, DOI 10.1378/chest.06-2531; Condorelli P, 2007, J APPL PHYSIOL, V102, P417, DOI 10.1152/japplphysiol.00533.2006; de Jongste JC, 2009, AM J RESP CRIT CARE, V179, P93, DOI 10.1164/rccm.200807-1010OC; Dweik RA, 2010, AM J RESP CRIT CARE, V181, P1033, DOI 10.1164/rccm.200905-0695OC; Gelb AF, 2004, CHEST, V126, P1138, DOI 10.1378/chest.126.4.1138; Gelb AF, 2004, AM J RESP CRIT CARE, V170, P737, DOI 10.1164/rccm.200403-408OC; Gelb AF, 1996, CHEST, V109, P353, DOI 10.1378/chest.109.2.353; GELB AF, 1983, CHEST, V84, P473, DOI 10.1378/chest.84.4.473; Gelb AE, 2011, CHEST, V139, P368, DOI 10.1378/chest.10-1157; Gelb AF, 2006, CHEST, V129, P1492, DOI 10.1378/chest.129.6.1492; Gelb AF, 2010, THORAX, V65, P619, DOI 10.1136/thx.2009.132696; George SC, 2004, J APPL PHYSIOL, V96, P831, DOI 10.1152/japplphysiol.00950.2003; Gibson PG, 2009, CLIN EXP ALLERGY, V39, P478, DOI 10.1111/j.1365-2222.2009.03226.x; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Haldar P, 2007, J ALLERGY CLIN IMMUN, V119, P1043, DOI 10.1016/j.jaci.2007.02.042; Hogman M, 2002, RESP MED, V96, P24, DOI 10.1053/rmed.2001.1204; Kerckx Y, 2008, J APPL PHYSIOL, V104, P918, DOI 10.1152/japplphysiol.01032.2007; Lehtimaki L, 2001, EUR RESPIR J, V18, P635, DOI 10.1183/09031936.01.00000201; Mahut B, 2004, CHEST, V125, P1012, DOI 10.1378/chest.125.3.1012; Mahut B, 2010, ALLERGY, V65, P636, DOI 10.1111/j.1398-9995.2009.02221.x; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Heart Lung and Blood Institute, NAT ASTHM ED PREV PR; Paraskakis E, 2006, AM J RESP CRIT CARE, V174, P260, DOI 10.1164/rccm.200506-962OC; Petsky HL, 2012, THORAX, V67, P199, DOI 10.1136/thx.2010.135574; Pietropaoli AP, 1999, J APPL PHYSIOL, V87, P1532, DOI 10.1152/jappl.1999.87.4.1532; Pijnenburg MW, 2005, AM J RESP CRIT CARE, V172, P831, DOI 10.1164/rccm.200503-458OC; Ricciardolo FLM, 2004, PHYSIOL REV, V84, P731, DOI 10.1152/physrev.00034.2003; Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-1427OC; Shin HW, 2004, J APPL PHYSIOL, V96, P65, DOI 10.1152/japplphysiol.00575.2003; Silkoff PE, 2005, J ALLERGY CLIN IMMUN, V116, P1249, DOI 10.1016/j.jaci.2005.09.029; Silkoff PE, 2000, AM J RESP CRIT CARE, V161, P1218, DOI 10.1164/ajrccm.161.4.9903111; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Taylor DR, 2011, J ALLERGY CLIN IMMUN, V128, P927, DOI 10.1016/j.jaci.2011.03.051; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653, DOI 10.1152/jappl.1998.85.2.653; van Veen IH, 2006, EUR RESPIR J, V27, P951, DOI 10.1183/09031936.06.00087905; Verbanck S, 2008, J APPL PHYSIOL, V104, P925, DOI 10.1152/japplphysiol.01019.2007; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110	43	19	20	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1491	1498		10.1016/j.jaci.2012.03.036	http://dx.doi.org/10.1016/j.jaci.2012.03.036			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22560478				2022-12-18	WOS:000304764600008
J	Beyer, K				Beyer, Kirsten			A European perspective on immunotherapy for food allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Allergy; food; immunotherapy; oral; sublingual; modified allergens; native allergens; European Medicine Agency	ORAL TOLERANCE INDUCTION; PEANUT ALLERGY; CHILDREN; SAFETY; EFFICACY; DESENSITIZATION	Food allergies are common, and frequently, the only treatment option is strict avoidance. Unfortunately, many patients accidentally ingest allergenic foods, which can result in severe anaphylactic reactions. Several immunotherapies are being developed for food allergies; these involve oral, sublingual, epicutaneous, or subcutaneous administration of small amounts of native or modified allergens to induce immune tolerance. Oral immunotherapy seems to be the most promising approach based on results from small uncontrolled and controlled studies. However, it is a challenge to compare results among immunotherapy trials because of differences in protocols. Studies conducted thus far have tested the most prevalent food allergens: it is not clear whether their results can be extended to other allergens. Sublingual administration of immunotherapy has shown some efficacy and fewer side effects than oral administration in some trials, yet neither approach can be recommended for routine practice. Controlled studies with larger numbers of subjects are needed to determine short- and long-term efficacy and side effects. In Europe immunotherapy trials for food allergies face many ethical and regulatory issues. Guidelines from the European Medicine Agency on the clinical development of products for specific immunotherapy of allergic diseases do not adequately address immunotherapy for food allergies, especially for therapies that orally administer native food or that include pediatric patients. (J Allergy Clin Immunol 2012;129:1179-84.)	Univ Hosp Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Beyer, K (corresponding author), Univ Hosp Charite, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.	kirsten.beyer@charite.de						Anagnostou K, 2011, CLIN EXP ALLERGY, V41, P1273, DOI 10.1111/j.1365-2222.2011.03699.x; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Beyer K, 2008, CURR OPIN ALLERGY CL, V8, P553, DOI 10.1097/ACI.0b013e32831952c8; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Brozek JL, 2012, CLIN EXP ALLERGY, V42, P363, DOI 10.1111/j.1365-2222.2011.03948.x; Burks AW, 2011, PEDIATRICS, V128, P955, DOI 10.1542/peds.2011-0539; Calderon MA, 2012, ALLERGY, V67, P302, DOI 10.1111/j.1398-9995.2011.02761.x; Calvani M, 2010, EUR ANN ALLERGY CLIN, V42, P11; Clark AT, 2009, ALLERGY, V64, P1218, DOI 10.1111/j.1398-9995.2009.01982.x; Dupont C, 2010, J ALLERGY CLIN IMMUN, V125, P1165, DOI 10.1016/j.jaci.2010.02.029; European Medicines Agency committee for medical products for human use (CHMP), 2009, CHMPEWP185042006; European Medicines Agency Pediatric Committee, 2010EMAPDCO737605200; Fisher HR, 2011, ARCH DIS CHILD, V96, P259, DOI 10.1136/adc.2009.172460; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Hompes S, 2011, PEDIAT ALLERG IMM-UK, V22, P568, DOI 10.1111/j.1399-3038.2011.01154.x; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Lieberman JA, 2011, CURR OPIN ALLERGY CL, V11, P236, DOI 10.1097/ACI.0b013e3283464cf0; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Nowak-Wegrzyn A, 2011, J ALLERGY CLIN IMMUN, V127, P558, DOI 10.1016/j.jaci.2010.12.1098; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Sheikh A, 2012, PRIM CARE RESP J, V21, P41, DOI 10.4104/pcrj.2011.00071; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Staden U, 2008, J ALLERGY CLIN IMMUN, V122, P418, DOI 10.1016/j.jaci.2008.06.002; Teuber SS, 2004, CURR OPIN ALLERGY CL, V4, P201, DOI 10.1097/01.all.0000129451.19469.e2; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111	33	19	19	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1179	1186		10.1016/j.jaci.2012.03.037	http://dx.doi.org/10.1016/j.jaci.2012.03.037			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22541359				2022-12-18	WOS:000303418000001
J	Bohm, M; Apel, M; Sugawara, K; Brehler, R; Jurk, K; Luger, TA; Haas, H; Paus, R; Eiz-Vesper, B; Walls, AF; Ponimaskin, E; Gehring, M; Kapp, A; Raap, U				Boehm, Markus; Apel, Mara; Sugawara, Koji; Brehler, Randolf; Jurk, Kerstin; Luger, Thomas A.; Haas, Helmut; Paus, Ralf; Eiz-Vesper, Britta; Walls, Andrew F.; Ponimaskin, Evgeni; Gehring, Manuela; Kapp, Alexander; Raap, Ulrike			Modulation of basophil activity: A novel function of the neuropeptide alpha-melanocyte-stimulating hormone	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Basophils; melanocyte-stimulating hormone; melanocortin receptors; neuropeptides	MAST-CELLS; MELANOCORTIN RECEPTORS; IN-VITRO; MECHANISMS; PURIFICATION; ACTIVATION; PEPTIDES; RELEASE; CALCIUM; ALLERGY	Background: Little is known about the effect of neuropeptides on basophils, which are important effector cells in immune and allergic responses. Objective: This study aimed at revealing the role of alpha-melanocyte-stimulating hormone (alpha-MSH) on basophil function. Methods: Expression of melanocortin receptors and proopiomelanocortin (POMC) was analyzed by means of RT-PCR, Western immunoblotting, fluorescence-activated cell sorting, and double-immunofluorescence analysis. Signal transduction studies included cyclic AMP and Ca2+ mobilization assays. Basophil activity was assessed based on CD63 surface expression and cytokine release. Results: MC-1R expression was detectable in basophils isolated from human peripheral blood, as well as in basophils within nasal tissue. In isolated basophils from human blood, truncated POMC transcripts were present, but there was no POMC protein. Treatment of basophils with alpha-MSH increased intracellular Ca2+ but not cyclic AMP levels. alpha-MSH at physiologic doses potently suppressed basophil activation induced by N-formyl-methionyl-leucyl-phenylalanine, phorbol 12-myristate 13-acetate, or grass pollen allergen in whole blood of healthy or allergic subjects, respectively. The effect of alpha-MSH on basophil activation was MC-1R mediated (as shown by blockade with a peptide analogue of agouti-signaling protein) and imitated by adrenocorticotropic hormone but not elicited by the tripeptides KPV and KdPT, both of which lack the central pharmacophore of alpha-MSH. Moreover, alpha-MSH at physiologic doses significantly suppressed secretion of 3 proallergic cytokines, IL-4, IL-6, and IL-13, in basophils stimulated with anti-IgE, N-formyl-methionyl-leucyl-phenylalanine, or phorbol 12-myristate 13-acetate. Conclusion: Our findings highlight a novel functional activity of alpha-MSH, which acts as a natural antiallergic basophil-response modifier. These findings might point to novel therapeutic strategies in treating allergic diseases. (J Allergy Clin Immunol 2012;129:1085-93.)	[Boehm, Markus; Apel, Mara; Brehler, Randolf; Luger, Thomas A.] Univ Munster, Dept Dermatol, D-48149 Munster, Germany; [Jurk, Kerstin] Univ Munster, Dept Anaesthesiol & Intens Care, D-48149 Munster, Germany; [Sugawara, Koji; Paus, Ralf] Univ Lubeck, Dept Dermatol, Lubeck, Germany; [Sugawara, Koji] Osaka City Univ, Grad Sch Med, Dept Dermatol, Osaka, Japan; [Haas, Helmut] Res Ctr Borstel, Div Cellular Allergol, Borstel, Germany; [Paus, Ralf] Univ Manchester, Sch Translat Med, Manchester M13 9PL, Lancs, England; [Eiz-Vesper, Britta] Hannover Med Sch, Dept Transfus Med, Hannover, Germany; [Ponimaskin, Evgeni] Hannover Med Sch, Dept Cellular Neurophysiol, Hannover, Germany; [Gehring, Manuela; Kapp, Alexander; Raap, Ulrike] Hannover Med Sch, Dept Dermatol & Allergy, Hannover, Germany; [Walls, Andrew F.] Univ Southampton, Southampton Gen Hosp, Immunopharmacol Grp, Southampton SO9 5NH, Hants, England	University of Munster; University of Munster; University of Lubeck; Osaka Metropolitan University; Forschungszentrum Borstel; University of Manchester; Hannover Medical School; Hannover Medical School; Hannover Medical School; University of Southampton	Bohm, M (corresponding author), Univ Munster, Dept Dermatol, Von Esmarch Str 58, D-48149 Munster, Germany.	bohmm@uni-muenster.de	Jurk, Kerstin/AAT-7768-2020; Paus, Ralf/F-6243-2011; Paus, Ralf/B-5279-2015	Walls, Andrew/0000-0003-4803-4595; Paus, Ralf/0000-0002-3492-9358; Kapp, Alexander/0000-0002-1748-6276; Ponimaskin, evgeni/0000-0002-4570-5130; Sugawara, Koji/0000-0003-1662-3272	Innovative Medizinische Forschung (IMF) [BO 110532]; Medical Research Council [G0500729] Funding Source: researchfish; MRC [G0500729] Funding Source: UKRI	Innovative Medizinische Forschung (IMF); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by a research grant from the Innovative Medizinische Forschung (IMF) to M.B. (BO 110532).	Andjelkov N, 2006, CELL BIOCHEM FUNCT, V24, P229, DOI 10.1002/cbf.1226; Aumuller E, 2003, INFLAMM RES, V52, P107, DOI 10.1007/s000110300022; Bohm M, 2004, J BIOL CHEM, V279, P6959, DOI 10.1074/jbc.M312549200; Bohm M, 1999, EXP DERMATOL, V8, P453, DOI 10.1111/j.1600-0625.1999.tb00303.x; Bohm M, 1999, ANN NY ACAD SCI, V885, P372; BRZOSKA T, 2008, ENDOCR REV, V29, P561; Catania A, 2007, J LEUKOCYTE BIOL, V81, P383, DOI 10.1189/jlb.0706426; CLARK AJL, 1990, MOL ENDOCRINOL, V4, P1737, DOI 10.1210/mend-4-11-1737; Cone RD, 1996, RECENT PROG HORM RES, V51, P287; Dijkstra D, 2007, J ALLERGY CLIN IMMUN, V120, P300, DOI 10.1016/j.jaci.2007.03.024; Dinulescu DM, 2000, J BIOL CHEM, V275, P6695, DOI 10.1074/jbc.275.10.6695; Ebo DG, 2004, CLIN EXP ALLERGY, V34, P332, DOI 10.1111/j.1365-2222.2004.01891.x; Elliott RJ, 2004, J INVEST DERMATOL, V122, P1010, DOI 10.1111/j.0022-202X.2004.22404.x; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; GHANEM G, 1989, ANTICANCER RES, V9, P1691; Gibbs BF, 2008, CLIN EXP ALLERGY, V38, P480, DOI 10.1111/j.1365-2222.2007.02919.x; Gibbs BF, 2005, CLIN EXP MED, V5, P43, DOI 10.1007/s10238-005-0064-5; Gibbs BF, 2005, INT IMMUNOPHARMACOL, V5, P735, DOI 10.1016/j.intimp.2004.12.004; Grutzkau A, 2000, BIOCHEM BIOPH RES CO, V278, P14, DOI 10.1006/bbrc.2000.3764; Haisch K, 1999, J IMMUNOL METHODS, V226, P129, DOI 10.1016/S0022-1759(99)00059-9; Harms J, 2009, NEW ENGL J MED, V360, P306, DOI 10.1056/NEJMc0805682; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354, DOI 10.1016/S0091-6749(98)70248-9; Lee SN, 2011, AM J RESP CELL MOL, V44, P716, DOI 10.1165/rcmb.2009-0420OC; Macfarlane AJ, 2000, J ALLERGY CLIN IMMUN, V105, P99, DOI 10.1016/S0091-6749(00)90184-2; MACGLASHAN D, 1991, J LEUKOCYTE BIOL, V49, P29, DOI 10.1002/jlb.49.1.29; MACGLASHAN D, 1991, J IMMUNOL, V147, P2259; Mandrika I, 2001, BIOCHEM PHARMACOL, V61, P613, DOI 10.1016/S0006-2952(00)00583-9; MARONE G, 1984, INT ARCH ALLER A IMM, V74, P356, DOI 10.1159/000233573; Marshall GD, 2004, ANN ALLERG ASTHMA IM, V93, pS11, DOI 10.1016/S1081-1206(10)61482-2; Mastrofrancesco A, 2010, J IMMUNOL, V185, P1903, DOI 10.4049/jimmunol.0902298; McEuen AR, 1999, LAB INVEST, V79, P27; Mountjoy KG, 2001, PHYSIOL GENOMICS, V5, P11, DOI 10.1152/physiolgenomics.2001.5.1.11; Obata K, 2007, BLOOD, V110, P913, DOI 10.1182/blood-2007-01-068718; Raap U, 2008, J ALLERGY CLIN IMMUN, V122, P1227, DOI 10.1016/j.jaci.2008.07.031; Sarkar A, 2003, FEBS LETT, V553, P286, DOI 10.1016/S0014-5793(03)01029-9; Schneider E, 2010, EUR CYTOKINE NETW, V21, P142, DOI 10.1684/ecn.2010.0197; SLOMINSKI A, 1995, FEBS LETT, V374, P113, DOI 10.1016/0014-5793(95)01090-2; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; WILLARD DH, 1995, BIOCHEMISTRY-US, V34, P12341, DOI 10.1021/bi00038a030; Wrona D, 2006, J NEUROIMMUNOL, V172, P38, DOI 10.1016/j.jneuroim.2005.10.017; Zhang L, 2003, ANN NY ACAD SCI, V994, P154, DOI 10.1111/j.1749-6632.2003.tb03175.x; Zhong Q, 2005, BONE, V36, P820, DOI 10.1016/j.bone.2005.01.020	43	19	21	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1085	1093		10.1016/j.jaci.2011.11.012	http://dx.doi.org/10.1016/j.jaci.2011.11.012			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22178636				2022-12-18	WOS:000302144600025
J	Tresch, S; Cozzio, A; Kamarashev, J; Harr, T; Schmid-Grendelmeier, P; French, LE; Feldmeyer, L				Tresch, Sandra; Cozzio, Antonio; Kamarashev, Jivko; Harr, Thomas; Schmid-Grendelmeier, Peter; French, Lars E.; Feldmeyer, Laurence			T cell-mediated acute localized exanthematous pustulosis caused by finasteride	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Acute generalized exanthematous pustulosis; acute localized exanthematous pustulosis; drug-related skin rash	AGEP; PUSTULODERMA; AMOXICILLIN; SPECTRUM	A 21-year-old man presented with multiple erythematous nonfollicular papules partially confluent to plaques on his breast and lower abdomen that had been present for 1 month. Grouped pustules were present under the right breast. The patient had been taking finasteride over the past 3 months for androgenetic alopecia. His medical history was negative for psoriasis. Our initial differential diagnosis included dyskeratosis follicularis Darier, allergic contact dermatitis, infectious folliculitis, varicella zoster virus infection, fixed drug eruption, and IgA pemphigus. The white blood cell count and differential were within the normal limits. Results of viral cultures and PCR, as well as bacterial and fungal cultures of skin lesions proved negative. A lesional biopsy specimen showed a slight psoriasiform acanthosis in association with spongiosis and infiltration of both the epidermis and dermis by neutrophils and eosinophils, resulting in formation of subcorneal, intraepidermal, and subepidermal pustules. The results of direct immunofluorescence were negative, excluding an IgA pemphigus. The result of a lymphocyte transformation test was positive for finasteride. On the basis of the time relationship between the administration of finasteride and the development of the skin disease in combination with symptoms resolution on cessation of the drug, the histologic findings, and the positive lymphocyte transformation test result, we consider this to be an unusual type of acute generalized exanthematous pustulosis defined as acute localized exanthematous pustulosis caused by finasteride. Within 4 weeks after withdrawal of finasteride, the rash resolved without any specific therapy. Transient discrete residual hyperpigmentation and scaling were present. The patient refused an oral provocation challenge. (J Allergy Clin Immunol 2012;129:589-94.)	[Tresch, Sandra; Cozzio, Antonio; Kamarashev, Jivko; Harr, Thomas; Schmid-Grendelmeier, Peter; French, Lars E.; Feldmeyer, Laurence] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Feldmeyer, L (corresponding author), Univ Zurich Hosp, Dept Dermatol, Gloriastr 31, CH-8091 Zurich, Switzerland.	laurence.feldmeyer@usz.ch	Feldmeyer, Laurence/Q-2662-2018; French, Lars/AAL-5977-2020	Feldmeyer, Laurence/0000-0002-4858-5525; French, Lars/0000-0002-4629-1486	Department of Dermatology, University Hospital Zurich.	Department of Dermatology, University Hospital Zurich.	Supported by the Department of Dermatology, University Hospital Zurich.	Al Hammadi Anwar, 2007, J Drugs Dermatol, V6, P460; Betto P, 2008, INT J DERMATOL, V47, P295, DOI 10.1111/j.1365-4632.2008.03477.x; Britschgi M, 2001, J CLIN INVEST, V107, P1433, DOI 10.1172/JCI12118; Britschgi M, 2002, CURR OPIN ALLERGY CL, V2, P325, DOI 10.1097/00130832-200208000-00006; Corbalan-Velez R, 2000, INT J DERMATOL, V39, P209, DOI 10.1046/j.1365-4362.2000.00909.x; de la Calle MC, 2005, BRIT J DERMATOL, V152, P1076, DOI 10.1111/j.1365-2133.2005.06568.x; DEARGILA D, 1996, ACTA DERMOSIFILIOGR, V87, P475; Gell PGH, 1968, CLIN ASPECTS IMMUNOL, VSecond, P580; Haber Robert S, 2004, Facial Plast Surg Clin North Am, V12, P181, DOI 10.1016/j.fsc.2003.12.008; Halevy S, 2010, BRIT J DERMATOL, V163, P1245, DOI 10.1111/j.1365-2133.2010.09967.x; Halevy S, 2009, CURR OPIN ALLERGY CL, V9, P322, DOI 10.1097/ACI.0b013e32832cf64e; Kabashima R, 2011, J EUR ACAD DERMATOL, V25, P485, DOI 10.1111/j.1468-3083.2010.03771.x; Kardaun SH, 2010, J CUTAN PATHOL, V37, P1220, DOI 10.1111/j.1600-0560.2010.01612.x; Kim Sung Woo, 2010, J Am Acad Dermatol, V63, pe44, DOI 10.1016/j.jaad.2009.05.007; Lateo S, 2002, BRIT J DERMATOL, V147, P624, DOI 10.1046/j.1365-2133.2002.488512.x; Lear JT, 1996, POSTGRAD MED J, V72, P127, DOI 10.1136/pgmj.72.844.127-a; Lee Ivy, 2010, J Am Acad Dermatol, V63, pe41, DOI 10.1016/j.jaad.2009.11.008; Moreno-Fernandez A, 2010, ALLERGY, V65, P405, DOI 10.1111/j.1398-9995.2009.02165.x; Oyama N, 2009, J AM ACAD DERMATOL, V60, P168, DOI 10.1016/j.jaad.2008.07.037; Pichler WJ, 2004, IMMUNOL ALLERGY CLIN, V24, P373, DOI 10.1016/j.iac.2004.03.012; Prange Birte, 2005, J Dtsch Dermatol Ges, V3, P210; Price VH, 2000, J AM ACAD DERMATOL, V43, P768, DOI 10.1067/mjd.2000.107953; Prieto A, 1997, ALLERGY, V52, P777, DOI 10.1111/j.1398-9995.1997.tb01240.x; Rastogi S, 2009, BRIT J ORAL MAX SURG, V47, P132, DOI 10.1016/j.bjoms.2008.07.185; SHUTTLEWORTH D, 1989, CLIN EXP DERMATOL, V14, P367, DOI 10.1111/j.1365-2230.1989.tb02587.x; Sidoroff A, 2007, BRIT J DERMATOL, V157, P989, DOI 10.1111/j.1365-2133.2007.08156.x; Sidoroff A, 2001, J CUTAN PATHOL, V28, P113, DOI 10.1034/j.1600-0560.2001.028003113.x; Speeckaert MM, 2010, EUR J DERMATOL, V20, P425, DOI 10.1684/ejd.2010.0932; Vickers JL, 2008, J AM DENT ASSOC, V139, P1200, DOI 10.14219/jada.archive.2008.0335	29	19	20	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					589	594		10.1016/j.jaci.2011.07.033	http://dx.doi.org/10.1016/j.jaci.2011.07.033			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	21868079	Bronze			2022-12-18	WOS:000299951700055
J	de Roock, S; Hoeks, SBEA; Meurs, L; Steur, A; Hoekstra, MO; Prakken, BJ; Boes, M; de Kleer, IM				de Roock, Sytze; Hoeks, Sanne B. E. A.; Meurs, Linda; Steur, Anouk; Hoekstra, Maarten O.; Prakken, Berent J.; Boes, Marianne; de Kleer, Isme M.			Critical role for programmed death 1 signaling and protein kinase B in augmented regulatory T-cell induction in cord blood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOXP3		[de Roock, Sytze; Hoeks, Sanne B. E. A.; Meurs, Linda; Steur, Anouk; Prakken, Berent J.; Boes, Marianne; de Kleer, Isme M.] Wilhelmina Childrens Hosp UMC Utrecht, Ctr Mol & Cellular Intervent CMCI, Utrecht, Netherlands; [Hoekstra, Maarten O.] Univ Med Ctr Nijmegen St Radboud, Nijmegen, Netherlands; [de Kleer, Isme M.] Univ Ghent, Lab Immunoregulat & Mucosal Immunol, B-9000 Ghent, Belgium	Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen; Ghent University	de Roock, S (corresponding author), Wilhelmina Childrens Hosp UMC Utrecht, Ctr Mol & Cellular Intervent CMCI, Utrecht, Netherlands.	ikleer@umcutrecht.nl		Steur, Anouk/0000-0001-5531-6027; Boes, Marianne/0000-0003-2590-1692				Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Gottschalk RA, 2010, J EXP MED, V207, P1701, DOI 10.1084/jem.20091999; Haxhinasto S, 2008, J EXP MED, V205, P565, DOI 10.1084/jem.20071477; Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075; Lu L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015150; Semple K, 2011, BLOOD, V117, P3096, DOI 10.1182/blood-2010-08-301275; Wang J, 2010, LEUKEMIA RES, V34, P1018, DOI 10.1016/j.leukres.2009.11.020	9	19	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1369	1371		10.1016/j.jaci.2011.08.006	http://dx.doi.org/10.1016/j.jaci.2011.08.006			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21868077				2022-12-18	WOS:000298342700037
J	Moshous, D; Meyts, I; Fraitag, S; Janssen, CEI; Debre, M; Suarez, F; Toelen, J; De Boeck, K; Roskams, T; Deschildre, A; Picard, C; Bodemer, C; Wouters, C; Fischer, A				Moshous, Despina; Meyts, Isabelle; Fraitag, Sylvie; Janssen, Carl E. I.; Debre, Marianne; Suarez, Felipe; Toelen, Jaan; De Boeck, Kris; Roskams, Tania; Deschildre, Antoine; Picard, Capucine; Bodemer, Christine; Wouters, Carine; Fischer, Alain			Granulomatous inflammation in cartilage-hair hypoplasia: Risks and benefits of anti-TNF-alpha mAbs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cartilage-hair hypoplasia; primary immunodeficiency; granulomatous inflammation; anti-TNF-alpha mAb therapy; infliximab; progressive multifocal leukoencephalopathy	COMMON VARIABLE IMMUNODEFICIENCY; TUMOR-NECROSIS-FACTOR; CASEATING CUTANEOUS GRANULOMAS; BONE-MARROW-TRANSPLANTATION; ATAXIA-TELANGIECTASIA; INFECTIOUS-DISEASES; IMMUNE-DEFICIENCY; CROHNS-DISEASE; RAG MUTATIONS; INFLIXIMAB	Background: Cartilage-hair hypoplasia (CHH) is a rare autosomal recessive disorder characterized by short-limbed skeletal dysplasia. Some patients also have defects in cell-mediated immunity and antibody production. Granulomatous inflammation has been described in patients with various forms of primary immunodeficiencies but has not been reported in patients with CHH. Objective: We sought to describe granulomatous inflammation as a novel feature in patients with CHH, assess associated immunodeficiency, and evaluate treatment options. Methods: In a retrospective observational study we collected clinical data on 21 patients with CHH to identify and further characterize patients with granulomatous inflammation. Results: Four unrelated patients with CHH (with variable degrees of combined immunodeficiency) had epithelioid cell granulomatous inflammation in the skin and visceral organs. Anti-TNF-alpha mAb therapy in 3 of these patients led to significant regression of granulomas. However, 1 treated patient had fatal progressive multifocal leukoencephalopathy caused by the JC polyomavirus. In 2 patients immune reconstitution after allogeneic hematopoietic stem cell transplantation led to the complete disappearance of granulomas. Conclusion: To the best of our knowledge, this is the first report of granulomatous inflammation in patients with CHH. Although TNF-alpha antagonists can effectively suppress granulomas, the risk of severe infectious complications limits their use in immunodeficient patients. (J Allergy Clin Immunol 2011;128:847-53.)	[Moshous, Despina; Debre, Marianne; Picard, Capucine; Fischer, Alain] Ctr Etude Deficits Immunitaires, Dept Pediat Immunol & Hematol, Paris, France; [Fraitag, Sylvie] Ctr Etude Deficits Immunitaires, Dept Pathol, Paris, France; [Suarez, Felipe] Ctr Etude Deficits Immunitaires, Dept Hematol, Paris, France; [Moshous, Despina] Hop Necker Enfants Malad, Unit Immunol & Hematol Pediatr, Dept Dermatol, Assistance Publ Hop Paris, F-75743 Paris 15, France; [Moshous, Despina; Fraitag, Sylvie; Debre, Marianne; Suarez, Felipe; Picard, Capucine; Bodemer, Christine; Fischer, Alain] Univ Paris 05, Univ Paris Descartes, Fac Med, Inst Federatif Rech Necker Enfants Malad IFR94, Paris, France; [Moshous, Despina; Fischer, Alain] Inst Natl Sante & Rech Med, Lab Developpement Normal & Pathol Syst Immunitair, Unite U768, Paris, France; [Meyts, Isabelle; Toelen, Jaan; De Boeck, Kris; Wouters, Carine] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; [Janssen, Carl E. I.; Roskams, Tania] Univ Hosp Gasthuisberg, Dept Pathol, B-3000 Louvain, Belgium; [Deschildre, Antoine] Ctr Hosp Reg & Univ Lille, Hop Jeanne Flandre, Unite Pneumol Pediat, F-59037 Lille, France; [Picard, Capucine] INSERM, Lab Human Genet Infect Dis, U980, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; Universite de Lille - ISITE; CHU Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Moshous, D (corresponding author), Hop Necker Enfants Malad, Unit Immunol & Hematol Pediatr, Dept Dermatol, Assistance Publ Hop Paris, 149 Rue Sevres, F-75743 Paris 15, France.	despina.moshous@nck.aphp.fr	Moshous, Despina/B-7507-2017; Meyts, Isabelle/Z-3295-2019; Picard, Capucine/H-3914-2017	Moshous, Despina/0000-0001-6719-3693; Picard, Capucine/0000-0001-8788-5056; Wouters, Carine/0000-0002-6426-8845; Roskams, Tania/0000-0002-2816-1530				[Anonymous], EBMT ESID GUID HAEM; ARBISER JL, 1995, J AM ACAD DERMATOL, V33, P82, DOI 10.1016/0190-9622(95)90016-0; Ardeniz O, 2009, CLIN IMMUNOL, V133, P198, DOI 10.1016/j.clim.2009.05.001; Aukrust P, 1996, BLOOD, V87, P674, DOI 10.1182/blood.V87.2.674.bloodjournal872674; Berthet F, 1996, EUR J PEDIATR, V155, P286; Bordon V, 2010, BLOOD, V116, P27, DOI 10.1182/blood-2010-01-259168; Clarridge JE, 2004, CLIN MICROBIOL REV, V17, P840, DOI 10.1128/CMR.17.4.840-862.2004; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Cunningham-Rundles C, 2010, BLOOD, V116, P7, DOI 10.1182/blood-2010-01-254417; de Jager M, 2008, J CUTAN PATHOL, V35, P467, DOI 10.1111/j.1600-0560.2007.00854.x; De Ravin SS, 2010, BLOOD, V116, P1263, DOI 10.1182/blood-2010-02-267583; de Villartay JP, 2005, J CLIN INVEST, V115, P3291, DOI 10.1172/JCI25178; Drolet BA, 1997, DERMATOLOGY, V194, P273, DOI 10.1159/000246117; Fernandez-Ruiz M, 2007, INTERNAL MED, V46, P1197, DOI 10.2169/internalmedicine.46.6414; FLEMING MG, 1991, J AM ACAD DERMATOL, V24, P629, DOI 10.1016/0190-9622(91)70097-L; Gallimore CI, 2004, J CLIN VIROL, V30, P196, DOI 10.1016/j.jcv.2003.10.007; Guggenheim R, 2006, BONE MARROW TRANSPL, V38, P751, DOI 10.1038/sj.bmt.1705520; Hatab AZ, 2005, J ALLERGY CLIN IMMUN, V116, P1161, DOI 10.1016/j.jaci.2005.08.041; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; Kruglov AA, 2008, CYTOKINE GROWTH F R, V19, P231, DOI 10.1016/j.cytogfr.2008.04.010; Kumar D, 2010, ARTHRITIS RHEUM-US, V62, P3191, DOI 10.1002/art.27687; Lavagna A, 2007, INFLAMM BOWEL DIS, V13, P896, DOI 10.1002/ibd.20131; Lin JH, 2006, J ALLERGY CLIN IMMUN, V117, P878, DOI 10.1016/j.jaci.2006.01.034; MAKITIE O, 1995, J MED GENET, V32, P39, DOI 10.1136/jmg.32.1.39; Makitie O, 1999, J PEDIATR-US, V134, P315, DOI 10.1016/S0022-3476(99)70456-7; MAKITIE O, 1993, EUR J PEDIATR, V152, P211, DOI 10.1007/BF01956147; Makitie O, 2001, ARCH DIS CHILD, V84, P65, DOI 10.1136/adc.84.1.65; Marodi L, 2010, J ALLERGY CLIN IMMUN, V126, P910, DOI 10.1016/j.jaci.2010.08.009; MCKUSICK VA, 1965, B JOHNS HOPKINS HOSP, V116, P285; Milman N, 2006, APMIS, V114, P912, DOI 10.1111/j.1600-0463.2006.apm_522.x; Mitra A, 2005, BRIT J DERMATOL, V153, P194, DOI 10.1111/j.1365-2133.2005.06619.x; Morelon E, 1996, BLOOD, V88, P1708; Morimoto Y, 2005, CURR ALLERGY ASTHM R, V5, P370, DOI 10.1007/s11882-005-0008-x; Mullighan CG, 1997, J IMMUNOL, V159, P6236; Notarangelo LD, 2008, CURR OPIN ALLERGY CL, V8, P534, DOI 10.1097/ACI.0b013e328310fe7d; PALLER AS, 1991, J PEDIATR-US, V119, P917, DOI 10.1016/S0022-3476(05)83043-4; Paramothayan S, 2008, RESP MED, V102, P1, DOI 10.1016/j.rmed.2007.08.010; Peyrin-Biroulet L, 2008, CLIN GASTROENTEROL H, V6, P644, DOI 10.1016/j.cgh.2008.03.014; Rider NL, 2009, CLIN IMMUNOL, V131, P119, DOI 10.1016/j.clim.2008.11.001; Rohr J, 2010, J CLIN IMMUNOL, V30, P314, DOI 10.1007/s10875-009-9349-x; RUDDLE NH, 1992, CURR OPIN IMMUNOL, V4, P327, DOI 10.1016/0952-7915(92)90084-R; Schuetz C, 2008, NEW ENGL J MED, V358, P2030, DOI 10.1056/NEJMoa073966; Sewell GW, 2009, CURR OPIN IMMUNOL, V21, P506, DOI 10.1016/j.coi.2009.06.003; Sweiss NJ, 2009, J INFUS MURS, V32, pS4, DOI 10.1097/NAN.0b013e318192e311; Taskinen M, 2008, AM J MED GENET A, V146A, P2370, DOI 10.1002/ajmg.a.32478; Thatayatikom A, 2005, ANN ALLERG ASTHMA IM, V95, P293, DOI 10.1016/S1081-1206(10)61228-8; Thiel CT, 2007, AM J HUM GENET, V81, P519, DOI 10.1086/521034; Thiel CT, 2005, AM J HUM GENET, V77, P795, DOI 10.1086/497708; Thielen AM, 2009, DERMATOLOGY, V219, P59, DOI 10.1159/000221005; TORRELO A, 1995, PEDIATR DERMATOL, V12, P170, DOI 10.1111/j.1525-1470.1995.tb00147.x; van den Berg JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005234; Vogel CA, 2010, PEDIATR DERMATOL, V27, P285, DOI 10.1111/j.1525-1470.2010.01140.x; Whitley R, 2008, NEW ENGL J MED, V358, P988, DOI 10.1056/NEJMp0708085	53	19	19	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					847	853		10.1016/j.jaci.2011.05.024	http://dx.doi.org/10.1016/j.jaci.2011.05.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21714993				2022-12-18	WOS:000296538100023
J	Collins, RA; Parsons, F; Deverell, M; Hollams, EM; Holt, PG; Sly, PD				Collins, Rachel A.; Parsons, Faith; Deverell, Marie; Hollams, Elysia M.; Holt, Patrick G.; Sly, Peter D.			Risk factors for bronchial hyperresponsiveness in teenagers differ with sex and atopic status	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; atopy; longitudinal birth cohort; lung function; sex differences	OBSTRUCTIVE PULMONARY-DISEASE; AIRWAY RESPONSIVENESS; CHILDHOOD ASTHMA; LUNG-FUNCTION; YOUNG-ADULTS; CHILDREN; METHACHOLINE; INFLAMMATION; WHEEZE; ADOLESCENCE	Background: Sex-related differences in bronchial hyperresponsiveness (BHR) have been reported in adolescents, but the mechanisms remain obscure. Objective: To investigate the risk factors for BHR in the Raine Study, a community-based longitudinal birth cohort. Methods: At 14 years of age, children underwent a respiratory assessment including a questionnaire, lung function testing, methacholine challenge, and determination of atopic status. Results: A total of 1779 children provided data for assessment, with 1510 completing lung function and methacholine challenge testing. Current asthma was present in 152 (10.4%), 762 (50.5%) were atopic, and 277 (18.6%) had BHR. BHR was more common in girls, whereas atopy was more common in boys, with no sex differences in asthma or current wheeze. Independent risk factors for BHR were being female (odds ratio [OR], 3.45; P < .001), atopy at 14 years (OR, 1.27; P = .004), and current asthma (OR, 2.15; P = .005). Better lung function was protective against BHR (forced expiratory flow between 25% and 75% of forced vital capacity/forced vital capacity, OR, 0.09; P < .001). Risk factors differed with sex and atopic status. Early-life factors were generally not independent risk factors for BHR at 14 years of age, with the exception of being smaller at birth in boys (birth length, OR, 6 x 10(-9); P = .017) and maternal asthma in girls (OR, 1.84; P = .041). Current asthma was not a risk for BHR in nonatopic children. Conclusion: Bronchial hyperresponsiveness was more common and more severe in girls. These differences could not be explained by differences in lung function or atopic status. (J Allergy Clin Immunol 2011;128:301-7.)	[Collins, Rachel A.; Parsons, Faith; Deverell, Marie; Sly, Peter D.] Univ Western Australia, Div Clin Sci, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6009, Australia; [Parsons, Faith; Hollams, Elysia M.; Holt, Patrick G.] Univ Western Australia, Div Cell Biol, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6009, Australia; [Sly, Peter D.] Univ Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia	Telethon Kids Institute; University of Western Australia; Telethon Kids Institute; University of Western Australia; University of Queensland	Sly, PD (corresponding author), Univ Queensland, Royal Brisbane Hosp, Queensland Childrens Med Res Inst, Level 4,Fdn Bldg,Herston Rd, Herston, Qld 4029, Australia.	p.sly@uq.edu.au	Study, Raine/K-4517-2013; Holt, Patrick G/H-1548-2011; Sly, Peter D/F-1486-2010	Holt, Patrick G/0000-0003-1193-0935; Sly, Peter D/0000-0001-6305-2201; Deverell, Marie/0000-0002-0048-8013; Hollams, Elysia/0000-0002-3481-6396	NHMRC, Australia [211912, 458513]; Stanley Trust UK; National Health and Medical Research Council; Stanley Trust; Phadia AB	NHMRC, Australia(National Health and Medical Research Council (NHMRC) of Australia); Stanley Trust UK; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Stanley Trust; Phadia AB(Phadia)	Supported by NHMRC, Australia #211912, #458513; and Stanley Trust UK.; P. G. Holt and P. D. Sly receive research support from the National Health and Medical Research Council, the Stanley Trust, and Phadia AB. The rest of the authors have declared that they have no conflict of interest.	American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Bush Andrew, 2008, Allergol Int, V57, P11, DOI 10.2332/allergolint.R-07-155; CHAPMAN ID, 1993, CLIN EXP ALLERGY, V23, P168, DOI 10.1111/j.1365-2222.1993.tb00877.x; Covar RA, 2010, J ALLERGY CLIN IMMUN, V125, P359, DOI 10.1016/j.jaci.2009.10.037; Dimitropoulou C, 2007, DRUG NEWS PERSPECT, V20, P241, DOI 10.1358/dnp.2007.20.4.1103523; Ernst P, 2002, EUR RESPIR J, V20, P635, DOI 10.1183/09031936.02.00962002; Forastiere F, 1996, AM J RESP CRIT CARE, V153, P1098, DOI 10.1164/ajrccm.153.3.8630551; Grol MH, 1999, AM J RESP CRIT CARE, V160, P150, DOI 10.1164/ajrccm.160.1.9707103; Hollams EM, 2009, J ALLERGY CLIN IMMUN, V124, P463, DOI 10.1016/j.jaci.2009.06.019; Joseph-Bowen J, 2004, J ALLERGY CLIN IMMUN, V114, P1040, DOI 10.1016/j.jaci.2004.07.051; Kurukulaaratchy RJ, 2004, THORAX, V59, P563, DOI 10.1136/thx.2003.010462; Lombardi E, 1997, AM J RESP CRIT CARE, V156, P1863, DOI 10.1164/ajrccm.156.6.9612066; Mandhane PJ, 2005, AM J RESP CRIT CARE, V172, P45, DOI 10.1164/rccm.200412-1738OC; Martinez FD, 2007, J ALLERGY CLIN IMMUN, V119, P30, DOI 10.1016/j.jaci.2006.10.020; Martinez Fernando D, 2009, Proc Am Thorac Soc, V6, P272, DOI 10.1513/pats.200808-092RM; Melgert BN, 2005, CLIN EXP ALLERGY, V35, P1496, DOI 10.1111/j.1365-2222.2005.02362.x; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; NEWNHAM JP, 1993, LANCET, V342, P887, DOI 10.1016/0140-6736(93)91944-H; Oryszczyn MP, 2007, J ALLERGY CLIN IMMUN, V119, P57, DOI 10.1016/j.jaci.2006.09.026; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836, DOI 10.1164/ajrccm.161.6.9805104; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; PEAT JK, 1992, EUR RESPIR J, V5, P921; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Postma DS, 2000, AM J RESP CRIT CARE, V162, pS118, DOI 10.1164/ajrccm.162.supplement_2.ras-13; Ramos JG, 2000, STEROIDS, V65, P409, DOI 10.1016/S0039-128X(00)00098-2; Rasmussen F, 2002, PEDIATR PULM, V34, P164, DOI 10.1002/ppul.10155; REDLINE S, 1989, AM REV RESPIR DIS, V140, P179, DOI 10.1164/ajrccm/140.1.179; Riffo-Vasquez Y, 2007, CLIN EXP ALLERGY, V37, P459, DOI 10.1111/j.1365-2222.2007.02670.x; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P957, DOI 10.1111/j.1365-2222.1993.tb00281.x; Stern DA, 2007, LANCET, V370, P758, DOI 10.1016/S0140-6736(07)61379-8; Strunk RC, 2006, J ALLERGY CLIN IMMUN, V118, P1040, DOI 10.1016/j.jaci.2006.07.053; Subrata LS, 2009, J IMMUNOL, V183, P2793, DOI 10.4049/jimmunol.0900695; Tager IB, 2005, EPIDEMIOLOGY, V16, P751, DOI 10.1097/01.ede.0000183166.68809.b0; Tantisira KG, 2008, AM J RESP CRIT CARE, V178, P325, DOI 10.1164/rccm.200708-1174OC; Ulrik CS, 1998, CHEST, V113, P973, DOI 10.1378/chest.113.4.973; Xuan W, 2002, THORAX, V57, P104, DOI 10.1136/thorax.57.2.104; 2000, AM J RESP CRIT CARE, V161, P309	42	19	19	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					301	U307		10.1016/j.jaci.2011.03.016	http://dx.doi.org/10.1016/j.jaci.2011.03.016			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21497891				2022-12-18	WOS:000293280800008
J	Slater, JE; Rabin, RL; Martin, D				Slater, Jay E.; Rabin, Ronald L.; Martin, David			Comments on cow's milk allergy and diphtheria, tetanus, and pertussis vaccines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ADOLESCENTS; ANAPHYLAXIS; CHILDREN		[Slater, Jay E.; Rabin, Ronald L.] US FDA, Off Vaccines Res & Review, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA; [Martin, David] US FDA, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Silver Spring, MD USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Slater, JE (corresponding author), US FDA, Off Vaccines Res & Review, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA.	Jay.slater@fda.hhs.gov		Rabin, Ronald/0000-0003-3496-0504				Bohlke K, 2003, PEDIATRICS, V112, P815, DOI 10.1542/peds.112.4.815; Gagnon R, 2010, J ALLERGY CLIN IMMUN, V126, P317, DOI 10.1016/j.jaci.2010.05.037; Howe LE, 2011, ANN ALLERG ASTHMA IM, V106, P446, DOI 10.1016/j.anai.2011.01.024; Kattan JD, 2011, J ALLERGY CLIN IMMUN, V128, P215, DOI 10.1016/j.jaci.2011.04.046; Powell KR, 2006, PEDIATRICS, V117, P965, DOI 10.1542/peds.2005-3038; Wood RA, 2003, PEDIATRICS, V111, P1631	6	19	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					434	434		10.1016/j.jaci.2011.06.028	http://dx.doi.org/10.1016/j.jaci.2011.06.028			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21807255				2022-12-18	WOS:000293280800039
J	von Jagwitz, M; Pessler, F; Akmatov, M; Li, JL; Range, U; Vogelberg, C				von Jagwitz, Marie; Pessler, Frank; Akmatov, Manas; Li, Jialiang; Range, Ursula; Vogelberg, Christian			Reduced breath condensate pH in asymptomatic children with prior wheezing as a risk factor for asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergic sensitization; Asthma Predictive Index; early childhood asthma; exhaled breath condensate pH; recurrent wheezy bronchitis	EXHALED NITRIC-OXIDE; 1ST 6 YEARS; PRESCHOOL-CHILDREN; ATOPIC SENSITIZATION; ALLERGIC RHINITIS; LIFE; CHILDHOOD; SYNOVITIS; PATHOLOGY; INFANTS	Background: Early noninvasive detection of increased risk of asthma with exhaled breath condensate (EBC) pH measurement has not been applied to preschool children. Objective: We sought to evaluate the ability of EBC pH measurement to identify young asymptomatic children at risk of asthma using the combination of recurrent wheezing and atopic sensitization as a proxy for a high risk of asthma. Methods: pH values were measured in deaerated EBC from 191 children (median age, 4.4 years [interquartile range, 2.2 years]). Children were divided into one of 5 groups: asymptomatic children with recurrent wheezy bronchitis with (group 1, n = 34) or without (group 2, n = 64) allergic sensitization, acute wheezy bronchitis (group 3, n = 18), allergic rhinoconjunctivitis without recurrent wheezy bronchitis (group 4, n = 15), and healthy control subjects (group 5, n = 60). The Asthma Predictive Index score was calculated for groups 1 and 2. Statistical significance was evaluated with the appropriate nonparametric tests, and the discriminatory accuracy was evaluated with receiver operating characteristic analysis. Results: Deaerated EBC pH values were significantly lower in groups 1 and 3 than in groups 2, 4, and 5 (median, 7.49 [interquartile range, 0.94] and 7.44 [interquartile range, 0.70] vs 7.93 [interquartile range, 0.23], 8.02 [interquartile range, 0.17], and 7.96 [interquartile range, 0.25], respectively; P < .001 and area under the receiver operating characteristic curve >= 0.80 in all comparisons). The area under the curve for the differentiation between groups 1 and 2 improved from 0.80 to 0.94 (sensitivity, 0.94; specificity, 0.84; positive predictive value, 0.76) when breath condensate pH values and Asthma Predictive Index scores were combined. Conclusion: A reduced deaerated EBC pH value might help identify young asymptomatic children at high risk of asthma. (J Allergy Clin Immunol 2011; 128: 50-5.)	[von Jagwitz, Marie; Vogelberg, Christian] Univ Childrens Hosp, Div Pediat Pulmonol & Allergol, D-01307 Dresden, Germany; [Pessler, Frank] Univ Childrens Hosp, Div Rheumatol & Immunol, D-01307 Dresden, Germany; [Pessler, Frank; Akmatov, Manas] Helmholtz Ctr Infect Res, Dept Infect Genet, Braunschweig, Germany; [Li, Jialiang] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore, Singapore; [Range, Ursula] Univ Hosp, Dept Med Comp Sci & Biometry, Dresden, Germany	Technische Universitat Dresden; University of Hamburg; University Medical Center Hamburg-Eppendorf; Technische Universitat Dresden; University of Hamburg; University Medical Center Hamburg-Eppendorf; Helmholtz Association; Helmholtz-Center for Infection Research; National University of Singapore; Technische Universitat Dresden; Carl Gustav Carus University Hospital	Vogelberg, C (corresponding author), Univ Childrens Hosp, Div Pediat Pulmonol & Allergol, Fetscherstr 74, D-01307 Dresden, Germany.	christian.vogelberg@uniklinikum-dresden.de	Li, Jialiang/N-8529-2019; Stangel, Martin/AAH-5345-2020; Li, Jialiang/B-9132-2014	Li, Jialiang/0000-0002-9704-4135; Li, Jialiang/0000-0002-9704-4135	Association for Pediatric Pneumology and Allergology (Arbeitsgemeinschaft Padiatrische Pneumologie und Allergologie); German Federal Ministry for Education and Science [SGP 09/1AP]	Association for Pediatric Pneumology and Allergology (Arbeitsgemeinschaft Padiatrische Pneumologie und Allergologie); German Federal Ministry for Education and Science	Supported by a Hans-Joachim-Dietzsch Research Award (to C.V.) from the Association for Pediatric Pneumology and Allergology (Arbeitsgemeinschaft Padiatrische Pneumologie und Allergologie) and German Federal Ministry for Education and Science grant no. SGP 09/1AP (to F.P.).	Bacharier LB, 2008, ALLERGY, V63, P5, DOI 10.1111/j.1398-9995.2007.01586.x; Bacharier LB, 2009, J ALLERGY CLIN IMMUN, V123, P1077, DOI 10.1016/j.jaci.2008.12.1120; Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Brunetti L, 2006, PEDIAT ALLERG IMM-UK, V17, P422, DOI 10.1111/j.1399-3038.2006.00426.x; Brussee JE, 2005, EUR RESPIR J, V25, P455, DOI 10.1183/09031936.05.00079604; Carraro S, 2005, ALLERGY, V60, P476, DOI 10.1111/j.1398-9995.2005.00718.x; Castro-Rodriguez JA, 2010, J ALLERGY CLIN IMMUN, V126, P212, DOI 10.1016/j.jaci.2010.06.032; Gaston B, 2006, J ALLERGY CLIN IMMUN, V118, P817, DOI 10.1016/j.jaci.2006.06.040; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; Hosmer W., 2000, APPL LOGISTIC REGRES, V2nd ed.; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694, DOI 10.1164/ajrccm.161.3.9911005; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kharitonov SA, 2006, CHEST, V130, P1541, DOI 10.1378/chest.130.5.1541; KJELLMAN NIM, 1977, ACTA PAEDIATR SCAND, V66, P465, DOI 10.1111/j.1651-2227.1977.tb07928.x; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Liu L, 2011, CHEST, V139, P328, DOI 10.1378/chest.10-0163; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Moeller A, 2008, J ALLERGY CLIN IMMUN, V121, P705, DOI 10.1016/j.jaci.2007.11.008; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Nicolaou NC, 2006, AM J RESP CRIT CARE, V174, P254, DOI 10.1164/rccm.200601-140OC; Ogdie A, 2010, BIOMARKERS, V15, P183, DOI 10.3109/13547500903411095; Orrell-Valente JK, 2008, PEDIATRICS, V122, pE1186, DOI 10.1542/peds.2008-0292; Paget-Brown AO, 2006, CHEST, V129, P426, DOI 10.1378/chest.129.2.426; Profita M, 2006, J ALLERGY CLIN IMMUN, V118, P1068, DOI 10.1016/j.jaci.2006.07.028; Ricciardolo FLM, 2004, J ALLERGY CLIN IMMUN, V113, P610, DOI 10.1016/j.jaci.2003.12.034; Rosias PPR, 2010, PEDIAT ALLERG IMM-UK, V21, pE235, DOI 10.1111/j.1399-3038.2009.00909.x; Schuepp KG, 2004, J AEROSOL MED, V17, P153, DOI 10.1089/0894268041457228; Simoes EAF, 2010, J ALLERGY CLIN IMMUN, V126, P256, DOI 10.1016/j.jaci.2010.05.026; Slansky E, 2010, HISTOPATHOLOGY, V57, P436, DOI 10.1111/j.1365-2559.2010.03641.x; Sonnappa S, 2010, J ALLERGY CLIN IMMUN, V126, P519, DOI 10.1016/j.jaci.2010.04.018; Soyer OU, 2006, ALLERGY, V61, P1016, DOI 10.1111/j.1398-9995.2006.01064.x; Turato G, 2008, AM J RESP CRIT CARE, V178, P476, DOI 10.1164/rccm.200712-1818OC; Vaughan J, 2003, EUR RESPIR J, V22, P889, DOI 10.1183/09031936.03.00038803; Vogelberg C, 2007, PEDIATR PULM, V42, P1166, DOI 10.1002/ppul.20712; Weinmayr G, 2007, AM J RESP CRIT CARE, V176, P565, DOI 10.1164/rccm.200607-994OC; Wells K, 2005, THORAX, V60, P27, DOI 10.1136/thx.2003.020602; ZWEIG MH, 1993, CLIN CHEM, V39, P561; ZWEIG MH, 1992, CLIN CHEM, V38, P1425	43	19	19	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					50	55		10.1016/j.jaci.2011.03.005	http://dx.doi.org/10.1016/j.jaci.2011.03.005			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21458041	Green Submitted, Bronze			2022-12-18	WOS:000292245600005
J	Dumitru, AF; Shamji, M; Wagenmann, M; Hindersin, S; Scheckenbach, K; Greve, J; Klenzner, T; Hess, L; Nebel, S; Zimmermann, C; Zahner, C; Schmidt-Weber, CB; Chaker, AM				Dumitru, Alina F.; Shamji, Mohamed; Wagenmann, Martin; Hindersin, Simone; Scheckenbach, Kathrin; Greve, Jens; Klenzner, Thomas; Hess, Lorenzo; Nebel, Sabine; Zimmermann, Christian; Zahner, Catherine; Schmidt-Weber, Carsten B.; Chaker, Adam M.			Petasol butenoate complex (Ze 339) relieves allergic rhinitis-induced nasal obstruction more effectively than desloratadine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Randomized controlled trial; allergic rhinitis; nasal obstruction; rhinomanometry; IL-8; leukotriene B-4; histamine; Ze 339; petasol butenoate complex; Petasites hybridus; desloratadine; nasal allergen challenge	INFLAMMATION; EXTRACT; IMPACT; PATHOPHYSIOLOGY; CONGESTION; MANAGEMENT; RELEASE; PLACEBO	Background: Allergic rhinitis symptoms of itching, sneezing, rhinorrhea, and nasal obstruction significantly decrease patients' quality of life. Compared with histamine and leukotriene receptor antagonists, the petasol butenoate complex Ze 339 displays pharmacologically distinct properties. In vitro it inhibits the biosynthesis of leukotrienes and mediator release from activated eosinophils. Objective: This study aimed to assess the efficacy and mode of action of Ze 339, desloratadine, and placebo on allergic rhinitis symptoms, nasal airflow, and local mediator levels after unilateral nasal allergen provocation. Methods: In this double-blind, randomized, crossover study 18 subjects with allergic rhinitis to grass pollen received Ze 339, desloratadine, and placebo for 5 days before nasal allergen challenge with grass pollen extract. Rhinomanometry, symptom assessment, and local inflammatory mediator measurement were performed during the 24 hours after allergen challenge. Results: With Ze 339, the patient's time to recovery (5.4 +/- 1.6 hours) from nasal obstruction after allergen challenge (time for return to 90% of baseline value +/- SEM) was significantly shorter than with placebo (9.1 +/- 2.3 hours, P = .035) and desloratadine (10.7 +/- 2.5 hours, P = .022). Likewise, Ze 339's standardized symptom assessment for nasal obstruction (3.2 +/- 1.3 hours) showed significantly faster relief (time for return to baseline value +/- SEM compared with placebo, 8.3 +/- 2.4 hours; P = .027) and desloratadine (4.5 +/- 1.2 hours, P = .030). One interesting finding was that Ze 339 significantly reduced IL-8 and leukotriene B-4 levels in nasal secretions before challenge. Conclusion: When compared with desloratadine and placebo, Ze 339 shows better efficacy in relieving nasal obstruction symptoms and inhibiting critical components of the chemokine network and as such represents a novel symptomatic and possible prophylactic treatment for allergic rhinitis. (J Allergy Clin Immunol 2011;127:1515-21.)	[Schmidt-Weber, Carsten B.] Tech Univ Munich, Ctr Allergy & Environm ZAUM, D-80802 Munich, Germany; [Schmidt-Weber, Carsten B.] Helmholtz Ctr Munich, D-80802 Munich, Germany; [Chaker, Adam M.] Tech Univ Munich, Dept Otorhinolaryngol, D-80802 Munich, Germany; [Dumitru, Alina F.; Shamji, Mohamed; Schmidt-Weber, Carsten B.; Chaker, Adam M.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sect Allergy & Clin Immunol, London SW7 2AZ, England; [Wagenmann, Martin; Hindersin, Simone; Scheckenbach, Kathrin; Klenzner, Thomas; Chaker, Adam M.] Heinrich Heine Univ Hosp Dusseldorf, Dept Otorhinolaryngol, Dusseldorf, Germany; [Greve, Jens] Univ Duisburg Essen, Dept Otorhinolaryngol, Essen, Germany; [Hess, Lorenzo] Brunner & Hess Software AG, Zurich, Switzerland; [Nebel, Sabine; Zimmermann, Christian; Zahner, Catherine] Max Zeller Sohne AG, Romanshorn, Switzerland	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Imperial College London; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; University of Duisburg Essen; Max Zeller Sohne AG	Schmidt-Weber, CB (corresponding author), Tech Univ Munich, Ctr Allergy & Environm ZAUM, Biedersteiner Str 29, D-80802 Munich, Germany.	csweber@tum.de	Shamji, Mohamed/AAU-8811-2020; Wagenman, Martin/B-2524-2012; Shamji, Mohamed/AAD-1788-2019; Schmidt-Weber, Carsten B./AAU-1621-2021; Greve, Jens/AAF-2688-2021	Shamji, Mohamed/0000-0003-3425-3463; Wagenman, Martin/0000-0002-9734-0241; Schmidt-Weber, Carsten B./0000-0002-3203-8084; Hess, Lorenzo/0000-0002-5815-2774; Chaker, Adam/0000-0002-5117-4073	Max Zeller Sohne AG, Romanshorn, Switzerland; GlaxoSmithKline; Zeller AG, Switzerland; Novartis Pharma AG, Switzerland	Max Zeller Sohne AG, Romanshorn, Switzerland; GlaxoSmithKline(GlaxoSmithKline); Zeller AG, Switzerland; Novartis Pharma AG, Switzerland	Supported by Max Zeller Sohne AG, Romanshorn, Switzerland.; T. Klenzner has received research support from Max Zeller Sohne AG, Romanshorn, Switzerland. L. Hess has provided legal consultation/expert witness testimony on the topics of Statistical Analysis and Statistical Report. A. M. Chaker has given lectures sponsored by GlaxoSmithKline and has received research support from Zeller AG, Switzerland, and Novartis Pharma AG, Switzerland. The rest of the authors have declared that they have no conflict of interest.	Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Brattstrom A, 2010, PHYTOTHER RES, V24, P680, DOI 10.1002/ptr.2972; Ciprandi G, 2005, INT IMMUNOPHARMACOL, V5, P1800, DOI 10.1016/j.intimp.2005.05.008; Ciprandi G, 2005, OTOLARYNG HEAD NECK, V133, P429, DOI 10.1016/j.otohns.2005.05.049; Ciprandi G, 2004, CLIN EXP ALLERGY, V34, P958, DOI 10.1111/j.1365-2222.2004.01960.x; Ciprandi G, 2004, INT ARCH ALLERGY IMM, V134, P34, DOI 10.1159/000077531; Corey J P, 2000, Ear Nose Throat J, V79, P690; Corey JP, 2000, ENT-EAR NOSE THROAT, V79, P696; Corey JP, 2000, ENT-EAR NOSE THROAT, V79, P698; DOUGLASS JA, 1994, AM J RESP CRIT CARE, V150, P1108, DOI 10.1164/ajrccm.150.4.7921444; Holmberg K, 2009, ALLERGY, V64, P1663, DOI 10.1111/j.1398-9995.2009.02096.x; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; MCCAIN RW, 1994, AM J RESP CELL MOL, V10, P651, DOI 10.1165/ajrcmb.10.6.8003341; Meltzer EO, 2009, ALLERGY ASTHMA PROC, V30, P244, DOI 10.2500/aap.2009.30.3230; Meltzer EO, 2009, ALLERGY ASTHMA PROC, V30, P75, DOI 10.2500/aap.2009.30.3198; Mukaida N, 1998, CYTOKINE GROWTH F R, V9, P9, DOI 10.1016/S1359-6101(97)00022-1; Nathan RA, 2005, J ALLERGY CLIN IMMUN, V116, P463, DOI 10.1016/j.jaci.2005.03.045; Nathan RA, 2008, CLIN THER, V30, P573, DOI 10.1016/j.clinthera.2008.04.011; Patou J, 2006, CLIN EXP ALLERGY, V36, P972, DOI 10.1111/j.1365-2222.2006.02544.x; Schapowal A, 2005, PHYTOTHER RES, V19, P530, DOI 10.1002/ptr.1705; Schapowal A, 2004, ARCH OTOLARYNGOL, V130, P1381, DOI 10.1001/archotol.130.12.1381; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Thomet OAR, 2001, CLIN EXP ALLERGY, V31, P1310, DOI 10.1046/j.1365-2222.2001.01158.x; Thomet OAR, 2001, BIOCHEM PHARMACOL, V61, P1041, DOI 10.1016/S0006-2952(01)00552-4; Wagenmann M, 2005, ALLERGY, V60, P1132, DOI 10.1111/j.1398-9995.2005.00867.x; Weller CL, 2005, J EXP MED, V201, P1961, DOI 10.1084/jem.20042407; Wilson AM, 2004, AM J MED, V116, P338, DOI 10.1016/j.amjmed.2003.10.030	28	19	21	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1515	U300		10.1016/j.jaci.2011.02.045	http://dx.doi.org/10.1016/j.jaci.2011.02.045			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21489609				2022-12-18	WOS:000291048500031
J	Ciprandi, G; Cirillo, I				Ciprandi, Giorgio; Cirillo, Ignazio			Forced expiratory flow between 25% and 75% of vital capacity may be a marker of bronchial impairment in allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Ciprandi, Giorgio] Univ Genoa, Dept Internal Med, I-16126 Genoa, Italy; [Cirillo, Ignazio] Navy Med Serv, La Spezia, Italy	University of Genoa	Ciprandi, G (corresponding author), Univ Genoa, Dept Internal Med, I-16126 Genoa, Italy.	gio.cip@libero.it	Ciprandi, Giorgio/G-7462-2012	Ciprandi, Giorgio/0000-0001-7016-8421				Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Ciprandi G, 2006, AM J RHINOL, V20, P641, DOI 10.2500/ajr.2006.20.2914; Ciprandi G, 2010, LARYNGOSCOPE, V120, P1288, DOI 10.1002/lary.20962; Cirillo I, 2006, ANN ALLERG ASTHMA IM, V96, P692, DOI 10.1016/S1081-1206(10)61067-8; McFadden ER, 2010, J ALLERGY CLIN IMMUN, V126, P535, DOI 10.1016/j.jaci.2010.06.035; Simon MR, 2010, J ALLERGY CLIN IMMUN, V126, P527, DOI 10.1016/j.jaci.2010.05.016; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003	7	19	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					549	549		10.1016/j.jaci.2010.10.053	http://dx.doi.org/10.1016/j.jaci.2010.10.053			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21281879				2022-12-18	WOS:000286808000044
J	Kerstan, A; Albert, C; Klein, D; Brocker, EB; Trautmann, A				Kerstan, Andreas; Albert, Christa; Klein, Detlef; Broecker, Eva-B.; Trautmann, Axel			Wasp venom immunotherapy induces activation and homing of CD4(+)CD25(+) forkhead box protein 3-positive regulatory T cells controlling T(H)1 responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunotherapy; lymph node; regulatory T cell; tolerance; wasp venom	HUMAN PERIPHERAL-BLOOD; BEE VENOM; IN-VIVO; ALLERGIC INDIVIDUALS; EXPRESSION; INTERLEUKIN-10; INCREASE; ANTIBODY; SUBSETS; DISEASE	Background: Despite a growing interest in CD4(+)CD25(+) forkhead box protein 3 (Foxp3)-positive regulatory T (Treg) cells, the fundamental parameters of the activation and homing of these cells during wasp venom immunotherapy (VIT) are largely unknown. Objective: We investigated longitudinally the phenotype and function of Treg cells in a well-characterized homogeneous group of patients with wasp venom allergy during VIT. Methods: In 30 patients peripheral Treg cells were ex vivo monitored for their activation status and homing capacities by means of flow cytometric analysis before and after 1 and 6 months of VIT. In addition, the in vitro suppressive activity of Treg cells, as well as cytokine secretion, in response to wasp venom was analyzed. Results: One month after initiating VIT, the proportion of both CD4(+)CD25(+)Foxp3(+) and CD4(+)Foxp3(+) Treg cells significantly decreased in peripheral blood. Coexpression of the lymph node homing receptors CCR7/CD62L were induced in CD4(+)Foxp3(+)CD45RO(+) Treg cells, indicating recirculation of VIT-activated Treg cells in secondary lymphoid organs. In vivo imaging by means of color duplex ultrasonography of the axillary draining lymph nodes demonstrated a VIT-induced 4-fold augmentation in afferent arterial blood flow. Furthermore, increased activation markers (CD45RO and HLA-DR) of Treg cells correlated with effective in vitro suppression of wasp venom-driven T-cell proliferation. After 1 month of VIT, Treg cell depletion in vitro greatly enhanced wasp venom-induced IFN-gamma secretion. Conclusions: Allergen exposure during VIT simultaneously induces the activation and selective homing of circulating Treg cells. Functionally, on the one hand, Treg cells balance the immune reaction toward tolerance, and on the other hand, they are involved in controlling overwhelming T(H)1 responses. (J Allergy Clin Immunol 2011;127:495-501.)	[Kerstan, Andreas; Albert, Christa; Broecker, Eva-B.; Trautmann, Axel] Univ Wurzburg, Dept Dermatol Venereol & Allergol, D-97080 Wurzburg, Germany; [Klein, Detlef] Univ Wurzburg, Inst Radiol, D-97080 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Kerstan, A (corresponding author), Univ Wurzburg, Dept Dermatol Venereol & Allergol, D-97080 Wurzburg, Germany.	kerstan_a@klinik.uni-wuerzburg.de		Kerstan, Andreas/0000-0001-6483-0191	Deutsche Forschungsgemeinschaft [TR460/3-1, TR460/3-2]; IZKF Wurzburg [Z-2/18]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); IZKF Wurzburg	Supported by the Deutsche Forschungsgemeinschaft (TR460/3-1 and -2 to A. K. and A. T.) and the IZKF Wurzburg (Z-2/18 to A.K.).	AALBERSE RC, 1983, CLIN REV ALLERG, V1, P289; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Alexander C, 2005, CLIN EXP ALLERGY, V35, P52, DOI 10.1111/j.1365-2222.2005.02143.x; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; Bonifazi F, 2005, ALLERGY, V60, P1459, DOI 10.1111/j.1398-9995.2005.00960.x; Bromley SK, 2008, NAT IMMUNOL, V9, P970, DOI 10.1038/ni.f.213; Colantonio L, 2002, EUR J IMMUNOL, V32, P3506, DOI 10.1002/1521-4141(200212)32:12<3506::AID-IMMU3506>3.0.CO;2-#; Fritzsching B, 2005, J IMMUNOL, V175, P32, DOI 10.4049/jimmunol.175.1.32; Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103; GERDES J, 1984, J IMMUNOL, V133, P1710; Godkin A, 2008, J ALLERGY CLIN IMMUN, V121, P1277, DOI 10.1016/j.jaci.2008.01.070; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Iellem A, 2003, EUR J IMMUNOL, V33, P1488, DOI 10.1002/eji.200323658; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; JUTEL M, 1995, J IMMUNOL, V154, P4187; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; Nasser SMS, 2001, EUR J IMMUNOL, V31, P3704, DOI 10.1002/1521-4141(200112)31:12<3704::AID-IMMU3704>3.0.CO;2-3; Ochando JC, 2005, J IMMUNOL, V174, P6993, DOI 10.4049/jimmunol.174.11.6993; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Schneider MA, 2007, J EXP MED, V204, P735, DOI 10.1084/jem.20061405; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Seddiki N, 2006, BLOOD, V107, P2830, DOI 10.1182/blood-2005-06-2403; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Senti G, 2009, CURR OPIN ALLERGY CL, V9, P537, DOI 10.1097/ACI.0b013e3283310ff7; Valmori D, 2005, J CLIN INVEST, V115, P1953, DOI 10.1172/JCI23963; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Vukmanovic-Stejic M, 2008, J CLIN INVEST, V118, P3639, DOI 10.1172/JCI35834; Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941; Zhang N, 2009, IMMUNITY, V30, P458, DOI 10.1016/j.immuni.2008.12.022	38	19	19	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					495	U1826		10.1016/j.jaci.2010.11.025	http://dx.doi.org/10.1016/j.jaci.2010.11.025			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21195472				2022-12-18	WOS:000286808000025
J	Brand, PLP				Brand, Paul L. P.			The Asthma Predictive Index: Not a useful tool in clinical practice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDREN; RISK; LIFE		[Brand, Paul L. P.] Isala Klin, Princess Amalia Childrens Clin, Zwolle, Netherlands; [Brand, Paul L. P.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands	Isala Clinics; University of Groningen	Brand, PLP (corresponding author), Isala Klin, Princess Amalia Childrens Clin, Zwolle, Netherlands.	p.l.p.brand@isala.nl	Brand, Paul/ABB-3693-2021					Bacharier LB, 2007, J ALLERGY CLIN IMMUN, V119, P604, DOI 10.1016/j.jaci.2006.12.607; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Castro-Rodriguez JA, 2010, J ALLERGY CLIN IMMUN, V126, P212, DOI 10.1016/j.jaci.2010.06.032; Goksor E, 2006, ACTA PAEDIATR, V95, P471, DOI 10.1080/08035250500499440; Haynes RB, 2006, CLIN EPIDEMIOLOGY CL; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Visser CAN, 2010, PEDIATR PULM, V45, P149, DOI 10.1002/ppul.21161	7	19	23	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					293	294		10.1016/j.jaci.2010.10.012	http://dx.doi.org/10.1016/j.jaci.2010.10.012			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21075441				2022-12-18	WOS:000285917300059
J	Egger, C; Horak, F; Vrtala, S; Valenta, R; Niederberger, V				Egger, Cornelia; Horak, Friedrich; Vrtala, Susanne; Valenta, Rudolf; Niederberger, Verena			Nasal application of rBet v 1 or non-IgE-reactive T-cell epitope-containingrBet v 1 fragments has different effects on systemic allergen-specific antibody responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNOTHERAPY; VACCINATION		[Egger, Cornelia; Vrtala, Susanne; Valenta, Rudolf] Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria; [Horak, Friedrich; Niederberger, Verena] Med Univ Vienna, Dept Otolaryngol, Vienna, Austria; [Vrtala, Susanne; Valenta, Rudolf] Med Univ Vienna, Christian Doppler Lab Allergy Res, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Egger, C (corresponding author), Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria.	verena.niederberger@meduniwien.ac.at		Valenta, Rudolf/0000-0001-5944-3365; Vrtala, Susanne/0000-0003-4250-8243	Austrian Science Fund FWF [F 4613] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Dente FL, 2000, RESP MED, V94, P1073, DOI 10.1053/rmed.2000.0907; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; Niederberger V, 2007, INT ARCH ALLERGY IMM, V142, P133, DOI 10.1159/000096439; Pree I, 2007, J IMMUNOL, V179, P5309, DOI 10.4049/jimmunol.179.8.5309; Saini SS, 2002, CURR OPIN IMMUNOL, V14, P694, DOI 10.1016/S0952-7915(02)00404-1; van Neerven RJ, 2006, INT ARCH ALLERGY IMM, V141, P119, DOI 10.1159/000094714; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330	10	19	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1312	1315		10.1016/j.jaci.2010.06.008	http://dx.doi.org/10.1016/j.jaci.2010.06.008			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	20673979	Bronze			2022-12-18	WOS:000284947800036
J	Yao, WG; Barbe-Tuana, FM; Llapur, CJ; Jones, MH; Tiller, C; Kimmel, R; Kisling, J; Nguyen, ET; Nguyen, J; Yu, ZS; Kaplan, MH; Tepper, RS				Yao, Weiguo; Barbe-Tuana, Florencia M.; Llapur, Conrado J.; Jones, Marcus H.; Tiller, Christina; Kimmel, Risa; Kisling, Jeffrey; Nguyen, Evelyn T.; Nguyen, James; Yu, Zhangsheng; Kaplan, Mark H.; Tepper, Robert S.			Evaluation of airway reactivity and immune characteristics as risk factors for wheezing early in life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Infants; wheezing; airway reactivity; atopy; dermatitis; cytokines; dendritic cells; food allergy	ATOPIC-DERMATITIS; CHILDHOOD ASTHMA; GAMMA PRODUCTION; INFANTS; CHILDREN; RESPONSIVENESS; SENSITIZATION	Background: Childhood asthma is most often characterized by recurrent wheezing, airway hyperreactivity, and atopy; however, our understanding of these relationships from early in life remains unclear. Respiratory tract illnesses and atopic sensitization early in life might produce an interaction between innate and acquired immune responses, leading to airway inflammation and heightened airway reactivity. Objective: We hypothesized that premorbid airway reactivity and immunologic characteristics of infants without prior episodes of wheezing would be associated with subsequent wheezing during a 1-year follow-up. Methods: One hundred sixteen infants with chronic dermatitis were enrolled before episodes of wheezing. Airway reactivity, allergen-specific IgE levels, cytokine production by stimulated PBMCs, and percentages of dendritic cells were measured on entry, and airway reactivity was reassessed at the 1-year follow-up. Linear regression models were used to evaluate a predictor's effect on continuous outcomes. Results: Milk sensitization, egg sensitization, or both were associated with heightened airway reactivity before wheezing and after the onset of wheezing; however, these factors were not associated with an increased risk of wheezing. There was an interaction between initial airway reactivity and wheezing as a determinant of airway reactivity at follow-up. In addition, cytokine production by stimulated PBMCs was a risk factor for wheezing, whereas increased percentages of conventional dendritic cells were protective against wheezing. Conclusion: Our data in a selected cohort of infants support a model with multiple risk factors for subsequent wheezing that are independent of initial airway reactivity; however, the causative factors that produce wheezing very early in life might contribute to heightened airway reactivity. (J Allergy Clin Immunol 2010;126:483-8.)	[Yao, Weiguo; Tiller, Christina; Kimmel, Risa; Kisling, Jeffrey; Nguyen, Evelyn T.; Kaplan, Mark H.; Tepper, Robert S.] Indiana Univ Sch Med, James Whitcomb Riley Hosp Children, Herman B Wells Ctr Pediat Res, Dept Pediat, Indianapolis, IN USA; [Nguyen, James; Yu, Zhangsheng] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN USA; [Kaplan, Mark H.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN USA; [Barbe-Tuana, Florencia M.] Pontificia Univ Catolica Rio Grande do Sul, Inst Pesquisas Biomed, Transplant Lab, Porto Alegre, RS, Brazil; [Llapur, Conrado J.] Univ Nacl Tucuman, Fac Med, Catedra Metodol Invest, Dept Pediat,Hosp Nino Jesus, RA-4000 San Miguel De Tucuman, Tucuman, Argentina; [Jones, Marcus H.] Pontificia Univ Catolica Rio Grande do Sul, Dept Pediat, Porto Alegre, RS, Brazil	Indiana University System; Indiana University Bloomington; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Pontificia Universidade Catolica Do Rio Grande Do Sul; Universidad Nacional de Tucuman; Pontificia Universidade Catolica Do Rio Grande Do Sul	Tepper, RS (corresponding author), Indiana Univ, James Whitcomb Riley Hosp Children, Med Ctr, Dept Pediat, 702 Barnhill Dr,ROC 4270, Indianapolis, IN 46202 USA.	RTEPPER@iupui.edu	Jones, Marcus Herbert/A-3580-2011; Barbe-Tuana, Florencia/L-4881-2015	Jones, Marcus Herbert/0000-0002-8263-1265; Barbe-Tuana, Florencia/0000-0002-5358-3524	National Institutes of Health [HL080071, AI070448]; National Heart, Lung, and Blood Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070448] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant nos. HL080071 and AI070448.; Disclosure of potential conflict of interest: Z. Yu has received research support from the National Institutes of Health. R. S. Tepper has received research support from the National Heart, Lung, and Blood Institute. The rest of the authors have declared that they have no conflict of interest.	Bohme M, 2003, CLIN EXP ALLERGY, V33, P1226, DOI 10.1046/j.1365-2222.2003.01749.x; CLARKE JR, 1995, AM J RESP CRIT CARE, V151, P1434, DOI 10.1164/ajrccm.151.5.7735597; Guerra S, 2004, AM J RESP CRIT CARE, V169, P70, DOI 10.1164/rccm.200304-499OC; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kusel MMH, 2005, J ALLERGY CLIN IMMUN, V116, P1067, DOI 10.1016/j.jaci.2005.06.038; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Pucci N, 2005, ALLERGY, V60, P113, DOI 10.1111/j.1398-9995.2004.00622.x; Saga R, 2001, CHEST, V119, P685, DOI 10.1378/chest.119.3.685; Sherrill D, 1999, CLIN EXP ALLERGY, V29, P905; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Tepper RS, 2008, J ALLERGY CLIN IMMUN, V122, P760, DOI 10.1016/j.jaci.2008.07.022; TEPPER RS, 1992, PEDIATR PULM, V13, P6, DOI 10.1002/ppul.1950130104; Tepper RS, 2005, AM J RESP CRIT CARE, V171, P78, DOI 10.1164/rccm.200406-711OC; Turner SW, 2009, AM J RESP CRIT CARE, V179, P98, DOI 10.1164/rccm.200805-804OC; Upham JW, 2009, J ALLERGY CLIN IMMUN, V124, P707, DOI 10.1016/j.jaci.2009.07.009; Wuthrich B, 2002, ALLERGY, V57, P267, DOI 10.1034/j.1398-9995.2002.1n3572.x; Zhang GC, 2009, AM J RESP CRIT CARE, V179, P205, DOI 10.1164/rccm.200803-438OC	20	19	20	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					483	U140		10.1016/j.jaci.2010.06.028	http://dx.doi.org/10.1016/j.jaci.2010.06.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20816184	Green Accepted			2022-12-18	WOS:000281512500011
J	La Shell, MS; Calabria, CW; Quinn, JM				La Shell, Mark S.; Calabria, Christopher W.; Quinn, James M.			Imported fire ant field reaction and immunotherapy safety characteristics: The IFACS study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ant; insect; sting; immunotherapy; safety; risk factors; systemic reactions; anaphylaxis; skin test	WHOLE-BODY EXTRACTS; CONVERTING ENZYME-INHIBITORS; SOLENOPSIS-INVICTA; VENOM IMMUNOTHERAPY; SYSTEMIC REACTIONS; HYMENOPTERA VENOM; FATAL ANAPHYLAXIS; RISK-FACTORS; STINGS; HYPERSENSITIVITY	Background: Imported fire ants (IFAs) are endemic in the southeastern United States, including Texas; can sting multiple times; and are a well-known cause of anaphylaxis. There are few data available on how many stings typically lead to systemic reactions (SRs). Likewise, there are no reports currently in the literature that characterize the safety of IFA subcutaneous immunotherapy (SCIT). Objective: We sought to analyze a case-cohort sample of patients for IFA SCIT risk factors and to characterize the index field reactions of these patients. Methods: A case-cohort study based on a 3-year retrospective chart review (2005-2008) at a single institution was performed for patients receiving IFA SCIT. Field reactions leading to initiation of IFA SCIT were also reviewed. Results: Seventy-seven patients (40 female patients; mean age, 34 years) received 1,887 injections, and 7 patients experienced 8 SRs, for a rate of 0.4% per injection and 9.1% per patient. SRs were mild. Having an SR to skin testing was associated with increased odds of having an SR to IFA SCIT (odds ratio, 4.75; 95% CI, 1.13-20.0), as were large local reactions (odds ratio, 34.5; 95% CI, 6.52-182). No other risk factors were identified. Of the index field reactions leading to IFA SCIT, 59% were the result of I sting, and 87% of subjects experienced only 1 SR before initiation of IFA SCIT. Two of 4 patients who experienced loss of consciousness during the index field reaction required an increased maintenance dose for optimal response. Conclusions: IFA SCIT is safe; however, having an SR to skin testing or the presence of large local reactions increases the odds of having an SR to IFA SCIT. The majority of SRs to IFA field stings resulted from 1 sting. (J Allergy Clin Immunol 2010;125:1294-9.)	[La Shell, Mark S.] David Grant USAF Med Ctr, Dept Allergy & Immunol, Travis AFB, CA 94535 USA; [Calabria, Christopher W.; Quinn, James M.] Wilford Hall USAF Med Ctr, Dept Allergy & Immunol, Lackland AFB, TX USA	United States Department of Defense; United States Air Force	La Shell, MS (corresponding author), David Grant USAF Med Ctr, Dept Allergy & Immunol, 101 Bodin Circle, Travis AFB, CA 94535 USA.	marklashell@gmail.com						Bagg A, 2009, ANN ALLERG ASTHMA IM, V102, P400, DOI 10.1016/S1081-1206(10)60511-X; Bhutani S, 2009, ANN ALLERG ASTHMA IM, V102, P145, DOI 10.1016/S1081-1206(10)60245-1; Brown SGA, 2005, J ALLERGY CLIN IMMUN, V116, P464, DOI 10.1016/j.jaci.2005.04.025; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; DESHAZO RD, 1984, J ALLERGY CLIN IMMUN, V74, P841, DOI 10.1016/0091-6749(84)90188-X; DIAZ JD, 1989, SOUTH MED J, V82, P775, DOI 10.1097/00007611-198906000-00026; Fernandez-Melendez S, 2007, J INVEST ALLERG CLIN, V17, P48; Forester JP, 2007, ALLERGY ASTHMA PROC, V28, P485, DOI 10.2500/aap.2007.28.3021; FREEMAN TM, 1992, J ALLERGY CLIN IMMUN, V90, P210, DOI 10.1016/0091-6749(92)90073-B; Freeman TM, 2004, NEW ENGL J MED, V351, P1978, DOI 10.1056/NEJMcp042013; Gastaminza G, 2003, CLIN EXP ALLERGY, V33, P470, DOI 10.1046/j.1365-2222.2003.01644.x; Hales S, 2002, LANCET, V360, P830, DOI 10.1016/S0140-6736(02)09964-6; HENSEL AE, 1983, ANN ALLERGY, V50, P359; HOFFMAN DR, 1990, J ALLERGY CLIN IMMUN, V85, P988, DOI 10.1016/0091-6749(90)90042-3; HOFFMAN DR, 1991, ANN ALLERGY, V66, P29; Kemp SF, 2000, J ALLERGY CLIN IMMUN, V105, P683, DOI 10.1067/mai.2000.105707; Korzukhin MD, 2001, ENVIRON ENTOMOL, V30, P645, DOI 10.1603/0046-225X-30.4.645; Letz AG, 2009, ANN ALLERG ASTHMA IM, V102, P303, DOI 10.1016/S1081-1206(10)60335-3; Li XM, 2007, J ALLERGY CLIN IMMUN, V120, P25, DOI 10.1016/j.jaci.2007.04.030; LIN MS, 1993, ANN ALLERGY, V71, P557; LOCKEY RF, 1989, J ALLERGY CLIN IMMUN, V84, P967, DOI 10.1016/0091-6749(89)90396-5; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; More DR, 2008, AM J FOREN MED PATH, V29, P62, DOI 10.1097/PAF.0b013e3181651b53; Mosbech H, 2000, ALLERGY, V55, P1005, DOI 10.1034/j.1398-9995.2000.00587.x; Prahlow JA, 1998, AM J FOREN MED PATH, V19, P137, DOI 10.1097/00000433-199806000-00007; Rank MA, 2008, ALLERGY ASTHMA PROC, V29, P400, DOI 10.2500/aap.2008.29.3141; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; RHOADES RB, 1989, J ALLERGY CLIN IMMUN, V84, P159, DOI 10.1016/0091-6749(89)90319-9; Solley GO, 2002, MED J AUSTRALIA, V176, P521, DOI 10.5694/j.1326-5377.2002.tb04548.x; Stumpf JL, 2006, ANN PHARMACOTHER, V40, P699, DOI 10.1345/aph.1G295; Summers CW, 2008, J ALLERGY CLIN IMMUN, V121, P632, DOI 10.1016/j.jaci.2007.12.003; Tankersley MS, 2008, CURR OPIN ALLERGY CL, V8, P354, DOI 10.1097/ACI.0b013e3283073b48; Tankersley MS, 2002, J ALLERGY CLIN IMMUN, V109, P556, DOI 10.1067/mai.2002.121956; TINKELMAN DG, 1995, J ALLERGY CLIN IMMUN, V95, P8, DOI 10.1016/S0091-6749(95)70146-X; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019; White KM, 2008, ANN ALLERG ASTHMA IM, V101, P426, DOI 10.1016/S1081-1206(10)60321-3; Wong S S Y, 2005, Hong Kong Med J, V11, P131	39	19	19	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1294	1299		10.1016/j.jaci.2010.02.041	http://dx.doi.org/10.1016/j.jaci.2010.02.041			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20451988				2022-12-18	WOS:000278831000017
J	Majak, P; Rychlik, B; Pulaski, L; Blauz, A; Agnieszka, B; Bobrowska-Korzeniowska, M; Kuna, P; Stelmach, I				Majak, Pawel; Rychlik, Blazej; Pulaski, Lukasz; Blauz, Andrzej; Agnieszka, Brzozowska; Bobrowska-Korzeniowska, Monika; Kuna, Piotr; Stelmach, Iwona			Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunotherapy; asthma; montelukast	T-REGULATORY CELLS; PHARMACOLOGICAL-TREATMENT; SERUM-LEVELS; ALLERGEN; IL-10; MECHANISMS; AVOIDANCE	Background: Allergen-specific immunotherapy (SIT) is the only available potentially curative approach in the management of allergic diseases. Therapies that boost regulatory T cell induction during SIT might further enhance its effectiveness. Objective: The purpose of this study was to assess the effect of montelukast treatment on early clinical and immunologic effects of allergen-specific immunotherapy in children with asthma. Methods: It was a randomized, double-blind, placebo-controlled trial conducted in 36 children with asthma and allergy to house dust mites who required from 400 to 800 mu g of inhaled budesonide per day during the 7-month run-in period. Patients were randomly allocated to receive 5 mg montelukast daily (n = 18) or placebo (n = 18) as an addition to inhaled corticosteroid (ICS) treatment during the 3-month build-up phase of SIT, when modification of ICS doses was not allowed. During the 7 months of the maintenance phase of SIT, ICS doses were adjusted to control the asthma symptoms. Results: After 12 months of SIT, a reduction of the median daily ICS dose, necessary to control asthma symptoms, was 16.7% grater in patients from the placebo group than in patients from the montelukast group. Intervention with montelukast significantly impaired the induction of regulatory T lymphocytes. During the build-up phase of SIT, patients in the placebo group frequently experienced an increase in asthma symptoms leading to exclusions from the per protocol population. Conclusion: Our study failed to show a beneficial effect of montelukast on SIT. In fact, quite the opposite occurred: compared with placebo, montelukast intervention led to less effectiveness of SIT. (J Allergy Clin Immunol 2010;125:1220-7.)	[Majak, Pawel; Agnieszka, Brzozowska; Bobrowska-Korzeniowska, Monika; Stelmach, Iwona] Med Univ Lodz, Dept Pediat & Allergy, Lodz, Poland; [Kuna, Piotr] Med Univ Lodz, Dept Internal Med Asthma & Allergy, Lodz, Poland; [Rychlik, Blazej; Pulaski, Lukasz; Blauz, Andrzej] Univ Lodz, Dept Mol Biophys, PL-90131 Lodz, Poland	Medical University Lodz; Medical University Lodz; University of Lodz	Stelmach, I (corresponding author), N Copernicus Hosp, Dept Pediat & Allergy, 62 Pabianicka Str, PL-93513 Lodz, Poland.	alergol@kopernik.lodz.pl	Rychlik, Blazej/D-2805-2012; Rychlik, Blazej/J-3197-2019; Stelmach, Iwona/S-9796-2016; Błauż, Andrzej/T-8347-2018	Rychlik, Blazej/0000-0001-8928-5900; Błauż, Andrzej/0000-0002-8037-0268; Brzozowska, Agnieszka/0000-0002-8988-189X; Kuna, Piotr/0000-0003-2401-0070; Stelmach, Iwona/0000-0002-1475-8221; Bobrowska-Korzeniowska, Monika/0000-0002-4516-5779; Pulaski, Lukasz/0000-0001-8063-801X; Majak, Pawel/0000-0002-2532-9983	Medical University of Lodz, Poland [502-12-760, 503-2056-1]; Merck Sharp Dohme	Medical University of Lodz, Poland; Merck Sharp Dohme(Merck & Company)	Supported by grants 502-12-760 and 503-2056-1 from the Medical University of Lodz, Poland. Montelukast and extracts for allergen-specific immunotherapy were provided by the manufacturers: MSD Polska and Stallergenes Pharmaceutical Co. respectively.; Disclosure of potential conflict of interest: P. Kuna has given sponsored lectures for Merck Sharp Dohme. The rest of the authors have declared that they have no conflict of interest.	Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Blumberga G, 2006, ALLERGY, V61, P843, DOI 10.1111/j.1398-9995.2006.01088.x; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Chen HY, 2009, PROSTAG LEUKOTR ESS, V80, P195, DOI 10.1016/j.plefa.2009.01.006; Johnston NW, 2007, PEDIATRICS, V120, pE702, DOI 10.1542/peds.2006-3317; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Maestrelli P, 2004, J ALLERGY CLIN IMMUN, V113, P643, DOI 10.1016/j.jaci.2003.12.586; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Nagato T, 2007, J IMMUNOL, V178, P1189, DOI 10.4049/jimmunol.178.2.1189; *NIH, NIH PUBL; Perng DW, 2006, AM J RESP CELL MOL, V34, P101, DOI 10.1165/rcmb.2005-0068OC; Perry TT, 2004, ANN ALLERG ASTHMA IM, V93, P431, DOI 10.1016/S1081-1206(10)61409-3; Pham-Thi N, 2007, PEDIAT ALLERG IMM-UK, V18, P47, DOI 10.1111/j.1399-3038.2006.00475.x; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; Riccioni G, 2001, ALLERGY ASTHMA PROC, V22, P5, DOI 10.2500/108854101778249221; Saeki S, 2004, J ALLERGY CLIN IMMUN, V114, P538, DOI 10.1016/j.jaci.2004.05.053; Stelmach I, 2005, PULM PHARMACOL THER, V18, P374, DOI 10.1016/j.pupt.2005.02.002; Stelmach I, 2005, CLIN EXP ALLERGY, V35, P213, DOI 10.1111/j.1365-2222.2005.02154.x; Stelmach I, 2002, CLIN EXP ALLERGY, V32, P264, DOI 10.1046/j.1365-2222.2002.01286.x; Stelmach I, 2008, J ALLERGY CLIN IMMUN, V121, P383, DOI 10.1016/j.jaci.2007.09.007; Wohrl S, 2007, INT ARCH ALLERGY IMM, V144, P137, DOI 10.1159/000103225; Woszczek G, 2008, J IMMUNOL, V180, P7597, DOI 10.4049/jimmunol.180.11.7597	26	19	20	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1220	1227		10.1016/j.jaci.2010.02.034	http://dx.doi.org/10.1016/j.jaci.2010.02.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20434204				2022-12-18	WOS:000278831000006
J	Rosenwasser, LJ; Rothenberg, ME				Rosenwasser, Lanny J.; Rothenberg, Marc E.			IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Churg-Strauss syndrome; IL-5 receptor alpha chain; hypereosinophilic syndrome	MEPOLIZUMAB		[Rosenwasser, Lanny J.] Univ Missouri Kansas City, Childrens Mercy Hosp & Clin, Div Clin Immunol & Allergy, Sch Med, Kansas City, MO 64110 USA; [Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Div Allergy & Immunol,Med Ctr,Dept Pediat, Cincinnati, OH 45221 USA	Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rosenwasser, LJ (corresponding author), Childrens Mercy Hosp, Div Allergy Immunol, 2401 Gillham Rd, Kansas City, MO 64108 USA.	lrosenwasser@cmh.edu						Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P1237, DOI 10.1016/j.jaci.2010.04.005; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Kahn JE, 2010, J ALLERGY CLIN IMMUN, V125, P267, DOI 10.1016/j.jaci.2009.10.014; Kim S, 2010, J ALLERGY CLIN IMMUN, V125, P1336, DOI 10.1016/j.jaci.2010.03.028; Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Walsh GM, 2009, CURR OPIN MOL THER, V11, P329	9	19	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1245	1246		10.1016/j.jaci.2010.04.022	http://dx.doi.org/10.1016/j.jaci.2010.04.022			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20513522				2022-12-18	WOS:000278831000010
J	Park, JH; Ahn, SS; Sicherer, SH				Park, J. H.; Ahn, S. S.; Sicherer, S. H.			Prevalence of Allergy to Multiple Versus Single Foods in a Pediatric Food Allergy Referral Practice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	66th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	FEB 26-MAR 02, 2010	New Orleans, LA	Amer Acad Allergy, Asthma & Immunol					[Park, J. H.; Ahn, S. S.; Sicherer, S. H.] Mt Sinai Sch Med, New York, NY USA	Icahn School of Medicine at Mount Sinai									0	19	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		1			AB216	AB216		10.1016/j.jaci.2009.12.843	http://dx.doi.org/10.1016/j.jaci.2009.12.843			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	629MS		Bronze			2022-12-18	WOS:000280204100843
J	Zhang, N; Liu, SX; Lin, P; Li, XY; van Bruaene, N; Zhang, J; van Zele, T; Bachert, C				Zhang, Nan; Liu, Shixi; Lin, Ping; Li, Xiaoyuan; van Bruaene, Nicholas; Zhang, Jie; van Zele, Thibaut; Bachert, Claus			Remodeling and inflammation in Chinese versus white patients with chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SINUS DISEASE		[Zhang, Nan; van Bruaene, Nicholas; van Zele, Thibaut; Bachert, Claus] Univ Ghent, Dept ORL, Upper Airway Res Lab, Ghent, Belgium; [Liu, Shixi; Li, Xiaoyuan] Sichuan Univ, W China Hosp, Dept ORL, Chengdu 610064, Peoples R China; [Lin, Ping; Zhang, Jie] Sichuan Univ, W China Hosp, Upper Airway Res Lab, Chengdu 610064, Peoples R China; [Zhang, Nan] Zhongshan City Peoples Hosp, Dept ORL, Zhongshan, Peoples R China	Ghent University; Sichuan University; Sichuan University; Sun Yat Sen University	Zhang, N (corresponding author), Univ Ghent, Dept ORL, Upper Airway Res Lab, Ghent, Belgium.	linping9@yahoo.com.cn	Bachert, Claus/J-8825-2012; Zhang, Nan/AAQ-3944-2020	Van Zele, Thibaut/0000-0002-6031-4293				Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018; Van Bruaene N, 2009, J ALLERGY CLIN IMMUN, V124, P253, DOI 10.1016/j.jaci.2009.04.013; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008	4	19	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					507	507		10.1016/j.jaci.2009.10.015	http://dx.doi.org/10.1016/j.jaci.2009.10.015			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20061013				2022-12-18	WOS:000274764000038
J	Gaier, S; Oberhuber, C; Hemmer, W; Radauer, C; Rigby, NM; Marsh, JT; Mills, CEN; Shewry, PR; Hoffmann-Sommergruber, K				Gaier, Sonja; Oberhuber, Christina; Hemmer, Wolfgang; Radauer, Christian; Rigby, Neil M.; Marsh, Justin T.; Mills, Clare E. N.; Shewry, Peter R.; Hoffmann-Sommergruber, Karin			Pru p 3 as a marker for symptom severity for patients with peach allergy in a birch pollen environment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LIPID TRANSFER PROTEIN; PROFILIN; REACTIVITY; EUROPE; APPLE		[Gaier, Sonja; Radauer, Christian; Hoffmann-Sommergruber, Karin] Med Univ Vienna, Dept Pathophysiol, Vienna, Austria; [Oberhuber, Christina] Biomay AG, Vienna, Austria; [Hemmer, Wolfgang] Allergy Clin Floridsdorf, Vienna, Austria; [Rigby, Neil M.; Mills, Clare E. N.] Inst Food Res, Norwich NR4 7UA, Norfolk, England; [Marsh, Justin T.; Shewry, Peter R.] Rothamsted Res, Harpenden, Herts, England	Medical University of Vienna; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Hoffmann-Sommergruber, K (corresponding author), Med Univ Vienna, Dept Pathophysiol, Vienna, Austria.	karin.hoffmann@meduniwien.ac.at	Radauer, Christian/AAN-6260-2021	Radauer, Christian/0000-0001-9920-4449; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X	Biotechnology and Biological Sciences Research Council [BBS/E/F/00041800] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Asero R, 2008, CLIN EXP ALLERGY, V38, P1033, DOI 10.1111/j.1365-2222.2008.02980.x; Fernandez-Rivas M, 2003, J ALLERGY CLIN IMMUN, V112, P789, DOI 10.1016/S0091-6749(03)02016-5; Fernandez-Rivas M, 2006, J ALLERGY CLIN IMMUN, V118, P481, DOI 10.1016/j.jaci.2006.05.012; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P423, DOI 10.1016/j.jaci.2007.10.009; Gaier S, 2008, MOL NUTR FOOD RES, V52, pS220, DOI 10.1002/mnfr.200700274; Lopez-Torrejon G, 2005, ALLERGY, V60, P1424, DOI 10.1111/j.1398-9995.2005.00903.x; Lopez-Torrejon G, 2005, CLIN EXP ALLERGY, V35, P1065, DOI 10.1111/j.1365-2222.2005.02303.x; Marion D., 2003, PLANT FOOD ALLERGENS, P57; Reuter A, 2006, CLIN EXP ALLERGY, V36, P815, DOI 10.1111/j.1365-2222.2006.2492.x; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8	10	19	19	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					166	167		10.1016/j.jaci.2009.02.023	http://dx.doi.org/10.1016/j.jaci.2009.02.023			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19368964	Green Submitted			2022-12-18	WOS:000267909700023
J	Yamada, A; Ohshima, Y; Yasutomi, M; Ogura, K; Tokuriki, S; Naiki, H; Mayumi, M				Yamada, Akiko; Ohshima, Yusei; Yasutomi, Motoko; Ogura, Kazumasa; Tokuriki, Shuko; Naiki, Hironobu; Mayumi, Mitsufumi			Antigen-primed splenic CD8(+) T cells impede the development of oral antigen-induced allergic diarrhea	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; allergic diarrhea; CD8(+) T cells; regulatory T cells; IL-10; transgenic mice; tolerance; IgE	DENDRITIC CELLS; INDUCED SENSITIZATION; AIRWAY SENSITIZATION; REGULATORY CELLS; FOOD ALLERGY; MURINE MODEL; IFN-GAMMA; TOLERANCE; IGE; LYMPHOCYTES	Background: Although CD4(+) T-cell populations are thought to be involved in the pathophysioiogy of food allergy and oral tolerance, the role of CD8(+) T cells remains uncertain. Objective: We analyzed regulatory effects of adoptively transferred CD8(+) T cells on the development of allergic diarrhea in antigen-sensitized mice that had a significantly reduced number of conventional TCR alpha beta(+) CD8(+) T cells. Methods: Ovalbumin-specific T-cell receptor transgenic mice were systemically sensitized to ovalbumin. Splenic CD8(+) T cells purified from ovalbumin-sensitized or nonsensitized wild-type mice or IL-10 knockout mice were adoptively transferred to ovalbumin-sensitized ovalbumin-specific T-cell receptor transgenic mice. Allergic diarrhea induced by oral administration of ovalbumin, ovalbumin-specific immunoglobulin production, and cytokine production in intestines and mesenteric lymph nodes were assessed. Results: Adoptive transfer of splenic CD8(+) T cells from ovalbumin-primed mice, but not from nonprimed mice, suppressed the development of allergic diarrhea, which was associated with in vivo increased IL-10 mRNA expression and in vitro antigen-specific IL-10 production by mesenteric lymph node cells. Upregulation of serum ovalbumin-specific IgE was not suppressed by ovalbumin-primed CD8(+) T-cell transfer. Although administration of IL-10 before ovalbumin challenge failed to alleviate allergic diarrhea, transfer of splenic CD8(+) T cells from IL-10 knockout mice showed diminished preventive effects. Conclusion: Systemic immunization with allergen simultaneously induces regulatory CD8(+) T cells that can inhibit the development of allergic diarrhea. IL-10 production by regulatory CD8(+) T cells appears to be partially involved in these inhibitory mechanisms. (J Allergy Clin Immunol 2009;123:889-94.)	[Yamada, Akiko; Ohshima, Yusei; Yasutomi, Motoko; Ogura, Kazumasa; Tokuriki, Shuko; Mayumi, Mitsufumi] Univ Fukui, Fac Med Sci, Dept Pediat, Eiheiji, Fukui 9101193, Japan; [Naiki, Hironobu] Univ Fukui, Fac Med Sci, Dept Pathol, Eiheiji, Fukui 9101193, Japan	University of Fukui; University of Fukui	Ohshima, Y (corresponding author), Univ Fukui, Fac Med Sci, Dept Pediat, 23-3 Shimoaizuki, Eiheiji, Fukui 9101193, Japan.	yohshima@u-fukui.ac.jp	Naiki, Hironobu/G-5599-2014	Yasutomi, Motoko/0000-0003-1165-3632; Ohshima, Yusei/0000-0002-4488-0308	Morinaga Hoshi-kai; Ministry of Health, Labor and Welfare, Japan	Morinaga Hoshi-kai; Ministry of Health, Labor and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan)	Supported by research grants from the Morinaga Hoshi-kai and the Ministry of Health, Labor and Welfare, Japan.	Allez M, 2002, GASTROENTEROLOGY, V123, P1516, DOI 10.1053/gast.2002.36588; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P707, DOI 10.1067/mai.2002.122503; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Brimnes J, 2005, J IMMUNOL, V174, P5814, DOI 10.4049/jimmunol.174.9.5814; de Lafaille MAC, 2008, IMMUNITY, V29, P114, DOI 10.1016/j.immuni.2008.05.010; Endharti AT, 2005, J IMMUNOL, V175, P7093, DOI 10.4049/jimmunol.175.11.7093; Frossard CP, 2007, J ALLERGY CLIN IMMUN, V119, P952, DOI 10.1016/j.jaci.2006.12.615; Gonzalez-Rey E, 2006, BLOOD, V107, P3632, DOI 10.1182/blood-2005-11-4497; Hamelmann E, 1996, J EXP MED, V183, P1719, DOI 10.1084/jem.183.4.1719; Ho J, 2008, J IMMUNOL, V180, P2573, DOI 10.4049/jimmunol.180.4.2573; Joetham A, 2007, P NATL ACAD SCI USA, V104, P15057, DOI 10.1073/pnas.0706765104; Knight AK, 2007, AM J PHYSIOL-GASTR L, V293, pG1234, DOI 10.1152/ajpgi.00323.2007; Kosiewicz MM, 2004, INT IMMUNOL, V16, P697, DOI 10.1093/intimm/dxh067; Laffont S, 2006, BLOOD, V108, P2257, DOI 10.1182/blood-2005-10-4059; Lin XP, 2002, J ALLERGY CLIN IMMUN, V109, P879, DOI 10.1067/mai.2002.123238; Maciorkowska E, 2000, Med Sci Monit, V6, P567; Myers L, 2005, J IMMUNOL, V174, P7625, DOI 10.4049/jimmunol.174.12.7625; Nakajima H, 1999, J IMMUNOL, V162, P782; Niederkorn JY, 2008, CURR OPIN IMMUNOL, V20, P327, DOI 10.1016/j.coi.2008.02.003; Ohshima Y, 2007, PEDIATR RES, V62, P60, DOI 10.1203/PDR.0b013e3180674dae; PERZHOU J, 2001, J IMMUNOL, V167, P107; Pomie C, 2008, HUM IMMUNOL, V69, P708, DOI 10.1016/j.humimm.2008.08.288; Qu C, 2007, CLIN EXP ALLERGY, V37, P846, DOI 10.1111/j.1365-2222.2007.02718.x; RENZ H, 1994, J IMMUNOL, V152, P351; Schwarze J, 1999, J IMMUNOL, V163, P5729; Smith TRF, 2008, TRENDS IMMUNOL, V29, P337, DOI 10.1016/j.it.2008.04.002; Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352; Stock P, 2004, EUR J IMMUNOL, V34, P1817, DOI 10.1002/eji.200324623; Takayama N, 2007, CLIN IMMUNOL, V123, P199, DOI 10.1016/j.clim.2007.01.007; Thomas MJ, 2001, INT ARCH ALLERGY IMM, V124, P187, DOI 10.1159/000053706; Uss E, 2006, J IMMUNOL, V177, P2775, DOI 10.4049/jimmunol.177.5.2775; Worbs T, 2006, J EXP MED, V203, P519, DOI 10.1084/jem.20052016	32	19	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					889	894		10.1016/j.jaci.2008.12.1115	http://dx.doi.org/10.1016/j.jaci.2008.12.1115			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19201014				2022-12-18	WOS:000265058600016
J	Andina, N; Didichenko, S; Schmidt-Mende, J; Dahinden, CA; Simon, HU				Andina, Nicola; Didichenko, Svetlana; Schmidt-Mende, Jan; Dahinden, Clemens A.; Simon, Hans-Uwe			Proviral integration site for Moloney murine leukemia virus 1, but not phosphatidylinositol-3 kinase, is essential in the antiapoptotic signaling cascade initiated by IL-5 in eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Apoptosis; eosinophils; inflammation; IL-5; phosphatidylinositol-3 kinase; proviral integration site for Moloney murine leukemia virus	COLONY-STIMULATING FACTOR; ANTI-APOPTOTIC SIGNALS; NEUTROPHIL APOPTOSIS; ANTI-INTERLEUKIN-5 ANTIBODY; HYPEREOSINOPHILIC SYNDROME; SURVIVAL; EXPRESSION; PROTEIN; TRANSDUCTION; PIM-1	Background: Eosinophil differentiation, activation, and survival are largely regulated by IL-5. IL-5-mediated transmembrane signal transduction involves both Lyn-mitogen-activated protein kinases and Janus kinase 2-signal transducer and activator of transcription pathways. Objective: We sought to determine whether additional signaling molecules/pathways are critically involved in IL-5-mediated eosinophil survival. Methods: Eosinophil survival and apoptosis were measured in the presence and absence of IL-5 and defined pharmacologic inhibitors in vitro. The specific role of the serine/threonine kinase proviral integration site for Moloney murine leukemia virus (Pim) 1 was tested by using HIV-transactivator of transcription fusion proteins containing wild-type Pim-1 ora dominant-negative form of Pim-1. The expression of Pim-1 in eosinophils was analyzed by means of immunoblotting and immunofluorescence. Results: Although pharmacologic inhibition of phosphatidylinositol-3 kinase (PI3K) by LY294002, wortmannin, or the selective PI3K p110 delta isoform inhibitor IC87114 was successful in each case, only LY294002 blocked increased IL-5-mediated eosinophil survival. This suggested that LY294002 inhibited another kinase that is critically involved in this process in addition to PI3K. Indeed, Pim-1 was rapidly and strongly expressed in eosinophils after IL-5 stimulation in vitro and readily detected in eosinophils under inflammatory conditions in vivo. Moreover, by using specific protein transfer, we identified Pim-1 as a critical element in IL-5-mediated antiapoptotic signaling in eosinophils. Conclusions: Pim-1, but not PI3K, plays a major role in IL-5-mediated antiapoptotic signaling in eosinophils. (J Allergy Clin Immunol 2009;123:603-.11.)	[Simon, Hans-Uwe] Univ Bern, Dept Pharmacol, Inst Pharmacol, CH-3010 Bern, Switzerland; [Didichenko, Svetlana; Dahinden, Clemens A.] Univ Bern, Inst Immunol, CH-3010 Bern, Switzerland	University of Bern; University of Bern	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Inst Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736	Swiss National Science Foundation [310000-107526, 320000-116304]; OPO Foundation, Zurich, Switzerland	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); OPO Foundation, Zurich, Switzerland	Supported by grants from the Swiss National Science Foundation (310000-107526 and 320000-116304) and the OPO Foundation, Zurich, Switzerland.	Adachi T, 2007, J IMMUNOL, V179, P8105, DOI 10.4049/jimmunol.179.12.8105; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Bates ME, 2004, AM J RESP CELL MOL, V30, P736, DOI 10.1165/rcmb.2003-0234OC; Burgel PR, 2000, J ALLERGY CLIN IMMUN, V106, P705, DOI 10.1067/mai.2000.109823; Chaussade C, 2007, BIOCHEM J, V404, P449, DOI 10.1042/BJ20070003; Conus S, 2005, J ALLERGY CLIN IMMUN, V116, P1228, DOI 10.1016/j.jaci.2005.09.003; Conus S, 2008, J EXP MED, V205, P685, DOI 10.1084/jem.20072152; Cowburn AS, 2002, BLOOD, V100, P2607, DOI 10.1182/blood-2001-11-0122; DANNER RL, 1989, ANTIMICROB AGENTS CH, V33, P1428, DOI 10.1128/AAC.33.9.1428; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; Druilhe A, 1998, AM J RESP CELL MOL, V18, P315, DOI 10.1165/ajrcmb.18.3.3019; Duan ZF, 2006, CLIN CANCER RES, V12, P6844, DOI 10.1158/1078-0432.CCR-06-1330; Dzhagalov I, 2007, BLOOD, V109, P1620, DOI 10.1182/blood-2006-03-013771; Edwards SW, 2004, BIOCHEM SOC T, V32, P489, DOI 10.1042/BST0320489; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Fox CJ, 2005, J EXP MED, V201, P259, DOI 10.1084/jem.20042020; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; GAZIT A, 1991, J MED CHEM, V34, P1896, DOI 10.1021/jm00110a022; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Hall DJ, 2001, BLOOD, V98, P2014, DOI 10.1182/blood.V98.7.2014; Jacobs MD, 2005, J BIOL CHEM, V280, P13728, DOI 10.1074/jbc.M413155200; Kirken RA, 1999, J LEUKOCYTE BIOL, V65, P891, DOI 10.1002/jlb.65.6.891; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Martinelli S, 2006, ONCOGENE, V25, P6915, DOI 10.1038/sj.onc.1209692; Miike S, 1999, J LEUKOCYTE BIOL, V65, P700, DOI 10.1002/jlb.65.5.700; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Pazdrak K, 1998, J EXP MED, V188, P421, DOI 10.1084/jem.188.3.421; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; Pope SM, 2005, J IMMUNOL, V175, P5341, DOI 10.4049/jimmunol.175.8.5341; Rosas M, 2006, J LEUKOCYTE BIOL, V80, P186, DOI 10.1189/jlb.1105636; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Simon D, 2005, PATHOBIOLOGY, V72, P287, DOI 10.1159/000091326; Simon D, 2007, J ALLERGY CLIN IMMUN, V119, P1291, DOI 10.1016/j.jaci.2007.02.010; Simon HU, 2000, J IMMUNOL, V165, P4069, DOI 10.4049/jimmunol.165.7.4069; Simon HU, 2006, CHEM IMMUNOL ALLERGY, V91, P49; Simon HU, 1997, EUR J IMMUNOL, V27, P3536, DOI 10.1002/eji.1830271256; Simon HU, 2003, EUR J IMMUNOL, V33, P834, DOI 10.1002/eji.200323727; Simon HU, 2001, IMMUNOL REV, V179, P156, DOI 10.1034/j.1600-065X.2001.790115.x; Simon HU, 1997, J IMMUNOL, V158, P3902; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Stout BA, 2004, J IMMUNOL, V173, P6409, DOI 10.4049/jimmunol.173.10.6409; Temple R, 2001, AM J RESP CELL MOL, V25, P425, DOI 10.1165/ajrcmb.25.4.4456; Vassina EM, 2006, EUR J IMMUNOL, V36, P1975, DOI 10.1002/eji.200635943; Verploegen S, 2005, BLOOD, V106, P1076, DOI 10.1182/blood-2004-09-3755; von Gunten S, 2007, J ALLERGY CLIN IMMUN, V119, P1005, DOI 10.1016/j.jaci.2007.01.023; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; Yousefi S, 2008, NAT MED, V14, P949, DOI 10.1038/nm.1855	51	19	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					603	611		10.1016/j.jaci.2008.12.004	http://dx.doi.org/10.1016/j.jaci.2008.12.004			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19152965	Bronze			2022-12-18	WOS:000264731200018
J	Engler, RJM; With, CM; Gregory, PJ; Jellin, JM				Engler, Renata J. M.; With, Catherine M.; Gregory, Philip J.; Jellin, Jeff M.			Complementary and alternative medicine for the allergist-immunologist: Where do I start?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Complementary and alternative medicine; integrative medicine; herbals; herbs; adverse reactions; risk communication; quality of care	ADVISING PATIENTS; PELARGONIUM-SIDOIDES; CURRICULUM; ANAPHYLAXIS; THERAPIES; EDUCATION; REFLECTIONS	Complementary and alternative medicine (CAM) therapies present a growing information management challenge for physicians because nearly 40% of their patients may be using and another 50% may he considering use of CAM as part of their healthcare regimen. The National Health Statistics Reports for 2007 described the most commonly used nonvitamin, nonmineral therapy as natural products (eg, herbals at 17.7%). More than 5% of children under the age of 18 years used CAM for allergic conditions including asthma. The amount and quality of information available and concerns about liability risk represent a challenge for most physicians. This review focuses on considerations for approaching a CAM-related consultation, incorporating legal and logistic factors affecting how such an encounter should be approached. A 10-step process is presented that addresses different components of (CAM consultations and what should be documented. Access to timely, high-quality information regarding product specific efficacy and safety data, as found in the Natural Medicines Comprehensive Database, is needed to support CAM consultation efficiently. Understanding of serious adverse events associated with CAM is limited; an international need exists for improved safety surveillance and information sharing. Allergy-immunology, as a specialty with expertise in adverse drug reaction evaluation and management, has a unique opportunity to support enhanced CAM-related adverse events evaluations, reporting, and research. (J Allergy Clin Immunol 2009;123:309-16.	[Engler, Renata J. M.] Walter Reed Army Med Ctr, Allergy Immunol Dept, Vaccine Healthcare Ctr Network, Washington, DC 20307 USA; [Engler, Renata J. M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [With, Catherine M.] Armed Forces Inst Pathol, Washington, DC 20306 USA; [Gregory, Philip J.; Jellin, Jeff M.] Nat Med Comprehensiv Databse, Stockton, CA USA; [Jellin, Jeff M.] Pharmacists Letter & Prescribers Letter, Stockton, CA USA; [Gregory, Philip J.] Creighton Univ, Ctr Drug Informat & Evidence Based Practice, Omaha, NE 68178 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA; United States Department of Defense; Creighton University	Engler, RJM (corresponding author), Walter Reed Army Med Ctr, Allergy Immunol Dept, Vaccine Healthcare Ctr Network, Washington, DC 20307 USA.	renata.engler@gmail.com			NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [K07AT005463] Funding Source: NIH RePORTER; NCCIH NIH HHS [K07 AT005463] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Adams KE, 2003, ANN INTERN MED, V138, P940, DOI 10.7326/0003-4819-138-11-200306030-00018; Adams KE, 2002, ANN INTERN MED, V137, P660, DOI 10.7326/0003-4819-137-8-200210150-00010; Agbabiaka TB, 2008, PHYTOMEDICINE, V15, P378, DOI 10.1016/j.phymed.2007.11.023; BARNES PM, 2002, ADV DATA, V343, P1; Barnes PM, 2008, NATL HLTH STAT REPOR, V12, P1, DOI DOI 10.1037/E623942009-001; BARRETT S, 2005, I MED COMM ISS IRR C; BARRETTE JA, 2007, LEGAL MED, P67; Benson H, 1996, ANNU REV MED, V47, P193; *BOARD HLTH CAR SE, 2007, PREV MED ERR QUAL CH; Brokaw JJ, 2002, ACAD MED, V77, P876, DOI 10.1097/00001888-200209000-00013; Buettner C, 2006, BREAST CANCER RES TR, V100, P219, DOI 10.1007/s10549-006-9239-3; CHERRY DK, 2007, ADV DATA, V387, P1; Cohen MH, 2002, MED CLIN N AM, V86, P185, DOI 10.1016/S0025-7125(03)00080-4; Cohen MH, 2002, ANN INTERN MED, V136, P596, DOI 10.7326/0003-4819-136-8-200204160-00009; COHEN MH, 2003, LEGAL ISSUES ALTERNA; Cohen Michael, 1998, COMPLEMENTARY ALTERN; *COMM US COMPL ALT, 2005, COMPL ALT MED US; de Boer HJ, 2007, DRUG SAFETY, V30, P677, DOI 10.2165/00002018-200730080-00004; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Ebell MH, 2004, AM FAM PHYSICIAN, V69, P548; Eisenberg D, 1998, ANN INTERN MED, V128, P329, DOI 10.7326/0003-4819-128-4-199802150-00049; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; Eisenberg DM, 2005, ALTERN THER HEALTH M, V11, P10; Federation of State Medical Boards, 2002, MOD GUID US COMPL AL; Fendrick AM, 2003, ARCH INTERN MED, V163, P487, DOI 10.1001/archinte.163.4.487; Harris D. M., 2007, CONT ISSUES HEALTHCA; Higgins JPT., 2008, COCHRANE HDB SYSTEMA, V1 edn; HIKIKINEN T, 2003, LANCET, V361, P51; JELLIN JM, 2008, NATURAL MED COMPREHE; Kemper KJ, 1999, J ALTERN COMPLEM MED, V5, P261, DOI 10.1089/acm.1999.5.261; Kligler B, 2000, FAM MED, V32, P30; Li XM, 2007, J ALLERGY CLIN IMMUN, V120, P25, DOI 10.1016/j.jaci.2007.04.030; LIN RY, 2006, ANN ALLERG ASTHMA IM, V101, P387; Lizogub VG, 2007, EXPLORE-NY, V3, P573, DOI 10.1016/j.explore.2007.09.004; Lu CY, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-75; Maizes V, 2002, ACAD MED, V77, P851, DOI 10.1097/00001888-200209000-00003; Marcus DM, 2006, SCIENCE, V313, P301, DOI 10.1126/science.1126978; *MED EC, 1998, PHYS DESK REF HERB M; NCCAM, 2005, EXP HOR HLTH CAR STR, P2005; Patrick G, 2008, J FAM PRACTICE, V57, P157; Perlman AI, 1999, RHEUM DIS CLIN N AM, V25, P815, DOI 10.1016/S0889-857X(05)70102-2; Prajapati SH, 2007, FAM MED, V39, P190; Rakel DP, 2008, J ALTERN COMPLEM MED, V14, P87, DOI 10.1089/acm.2007.0562; Sheikh A, 2008, J ROY SOC MED, V101, P139, DOI 10.1258/jrsm.2008.070306; Simons FER, 2008, J ALLERGY CLIN IMMUN, V122, P1166, DOI 10.1016/j.jaci.2008.10.019; Stewart M, 2005, BRIT J GEN PRACT, V55, P793; Steyer T E, 2001, Fam Pract Manag, V8, P37; Studdert DM, 1998, JAMA-J AM MED ASSOC, V280, P1610, DOI 10.1001/jama.280.18.1610; Weiger WA, 2002, ANN INTERN MED, V137, P889, DOI 10.7326/0003-4819-137-11-200212030-00010	49	19	19	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					309	316		10.1016/j.jaci.2009.01.001	http://dx.doi.org/10.1016/j.jaci.2009.01.001			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19203654	Green Accepted, Green Published			2022-12-18	WOS:000263495000003
J	Park, JW; Min, HJ; Sohn, JH; Kim, JY; Hong, JH; Sigrist, KS; Glimcher, LH; Hwang, ES				Park, Jung Won; Min, Hyun Jung; Sohn, Jung Ho; Kim, Joo Young; Hong, Jeong Ho; Sigrist, Kirsten S.; Glimcher, Laurie H.; Hwang, Eun Sook			Restoration of T-box-containing protein expressed in T cells protects against allergen-induced asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-bet; T cell; transgenic mice; OVA; asthma; airway hyperresponsiveness	IFN-GAMMA; LINEAGE COMMITMENT; AIRWAY INFLAMMATION; TH1 CELLS; TRANSCRIPTION FACTOR; BET EXPRESSION; GENE; CD4; HYPERRESPONSIVENESS; LYMPHOCYTES	Background: A Till-specific transcription factor, T-box-containing protein expressed in T cells (T-bet), controls the production of both T(H)1 and T(H)2 cytokines in T-H cell differentiation by means of distinct mechanisms. T-bet-deficient mice overproduce T(H)2 cytokines and have spontaneous airway inflammation. Objectives: We tested whether T-bet overexpression could protect against the development or progression of asthma. Methods: We generated a T cell-specific and inducible line of T-bet-transgenic mice on a T-bet-deficient genetic background and used it to study the function of T-bet in an ovalbumin (OVA)-induced asthma model. Results: Induction of T-bet in a T cell-specific manner in an OVA model of asthma concomitant with OVA injection prevented airway hyperresponsiveness, eosinophilic and lymphocytic inflammation, and IL-5 and IL-13 production in bronchoalveolar lavage fluid and also reduced serum IgE and T(H)2 cytokine production by peripheral T cells. Even when T-bet expression was induced (luring later stages of asthma progression, T-bet overexpression still attenuated airway hyperresponsiveness and goblet cell hyperplasia, as well as T(H)2 cytokine production. Conclusions: Our results suggest that T-bet expression in T cells can prevent the initiation of airway inflammation and progression of chronic inflammation and might be extrapolated to human asthma. (J Allergy Clin Immunol 2009;123:479-85.)	[Min, Hyun Jung; Hwang, Eun Sook] Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea; [Park, Jung Won; Sohn, Jung Ho; Kim, Joo Young] Yonsei Univ, Coll Med, Dept Internal Med, Inst Allergy, Seoul, South Korea; [Min, Hyun Jung; Hwang, Eun Sook] Ewha Womans Univ, Div Life & Pharmaceut Sci, Seoul 120750, South Korea; [Min, Hyun Jung; Hwang, Eun Sook] Ewha Womans Univ, Ctr Cell Signaling & Drug Discovery Res, Seoul 120750, South Korea; [Hong, Jeong Ho] Korea Univ, Sch Life Sci & Biotechnol, Seoul, South Korea; [Sigrist, Kirsten S.; Glimcher, Laurie H.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; [Glimcher, Laurie H.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Ewha Womans University; Yonsei University; Yonsei University Health System; Ewha Womans University; Ewha Womans University; Korea University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Hwang, ES (corresponding author), Ewha Womans Univ, Coll Pharm, 11-1 Dachyun Dong, Seoul 120750, South Korea.	eshwang@ewha.ac.kr	Hong, Jeong-Ho/T-8099-2018; Min, Hyunjung/ABA-8709-2020; Kim, Jooyoung/R-5839-2018	Hong, Jeong-Ho/0000-0002-8235-9855; Kim, Jooyoung/0000-0003-4846-6259; Park, Jung-Won/0000-0003-0249-8749	Korea Research Foundation [2006-E00100]; National Research & Development Program for Cancer Control, Ministry for Health, Welfare, and Family Affairs [0620380]; National Core Research Center program of the Ministry of Education, Science Technology; Korean Science and Engineering Foundation [R15-2000-020]; National Institutes of Health [U19 AI031541]; Yonsei University College of Medicine; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031541] Funding Source: NIH RePORTER	Korea Research Foundation(National Research Foundation of Korea); National Research & Development Program for Cancer Control, Ministry for Health, Welfare, and Family Affairs; National Core Research Center program of the Ministry of Education, Science Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korean Science and Engineering Foundation(Korea Science and Engineering Foundation); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Yonsei University College of Medicine(General Electric); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Korea Research Foundation (2006-E00100); the National Research & Development Program for Cancer Control, Ministry for Health, Welfare, and Family Affairs (0620380); the National Core Research Center program of the Ministry of Education, Science & Technology and the Korean Science and Engineering Foundation (R15-2000-020 to E.S.H.): and National Institutes of Health grant U19 AI031541 (to L.H.G.). This work was also supported by a grant from Yonsei University College of Medicine (to J.W.P.).	Akahoshi M, 2005, HUM GENET, V117, P16, DOI 10.1007/s00439-005-1285-0; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Butz NV, 2006, GENE, V377, P130, DOI 10.1016/j.gene.2006.03.016; Cao BW, 2007, CLIN CHEM LAB MED, V45, P333, DOI 10.1515/CCLM.2007.062; Chung Hun Taek, 2003, Hum Mutat, V22, P257, DOI 10.1002/humu.9169; Djuretic IM, 2007, NAT IMMUNOL, V8, P145, DOI 10.1038/ni1424; Finotto S, 2005, INT IMMUNOL, V17, P993, DOI 10.1093/intimm/dxh281; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Frohlich A, 2007, BLOOD, V109, P2023, DOI 10.1182/blood-2006-05-021600; Fujiwara M, 2007, J ALLERGY CLIN IMMUN, V119, P662, DOI 10.1016/j.jaci.2006.12.643; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gocke AR, 2007, J IMMUNOL, V178, P1341, DOI 10.4049/jimmunol.178.3.1341; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Harrington LE, 2006, CURR OPIN IMMUNOL, V18, P349, DOI 10.1016/j.coi.2006.03.017; Huang TJ, 2001, J IMMUNOL, V166, P207, DOI 10.4049/jimmunol.166.1.207; Hwang ES, 2005, SCIENCE, V307, P430, DOI 10.1126/science.1103336; Hwang ES, 2005, J EXP MED, V202, P1289, DOI 10.1084/jem.20051044; Kawashima M, 2005, J CLIN IMMUNOL, V25, P209, DOI 10.1007/s10875-005-4092-4; Kiwamoto T, 2006, AM J RESP CRIT CARE, V174, P142, DOI 10.1164/rccm.200601-079OC; Ko FWS, 2007, CLIN EXP IMMUNOL, V147, P526, DOI 10.1111/j.1365-2249.2006.03315.x; Koch A, 2007, RESP MED, V101, P1321, DOI 10.1016/j.rmed.2006.10.010; Koch M, 2006, AM J RESP CELL MOL, V35, P211, DOI 10.1165/rcmb.2005-0293OC; Legname G, 2000, IMMUNITY, V12, P537, DOI 10.1016/S1074-7613(00)80205-8; Li L, 1996, CELL IMMUNOL, V168, P133, DOI 10.1006/cimm.1996.0059; Maldonado RA, 2004, NATURE, V431, P527, DOI 10.1038/nature02916; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Meyts I, 2006, J IMMUNOL, V177, P6460, DOI 10.4049/jimmunol.177.9.6460; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Mullen AC, 2001, SCIENCE, V292, P1907, DOI 10.1126/science.1059835; Munthe-Kaas MC, 2008, J ALLERGY CLIN IMMUN, V121, P51, DOI 10.1016/j.jaci.2007.07.068; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Nakamura T, 1997, J IMMUNOL, V158, P1085; Peng SL, 2002, P NATL ACAD SCI USA, V99, P5545, DOI 10.1073/pnas.082114899; Raby BA, 2006, AM J RESP CRIT CARE, V173, P64, DOI 10.1164/rccm.200503-505OC; Randolph AG, 2004, AM J HUM GENET, V75, P709, DOI 10.1086/424886; Randolph DA, 1999, J IMMUNOL, V162, P2375; Sasaki Y, 2004, HUM GENET, V115, P177, DOI 10.1007/s00439-004-1146-2; Shanker A, 2004, J IMMUNOL, V172, P5069, DOI 10.4049/jimmunol.172.8.5069; Stockinger B, 2007, CURR OPIN IMMUNOL, V19, P281, DOI 10.1016/j.coi.2007.04.005; Sur S, 1996, J IMMUNOL, V157, P4173; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Tantisira KG, 2004, P NATL ACAD SCI USA, V101, P18099, DOI 10.1073/pnas.0408532102; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Wendland J, 2006, J BASIC MICROB, V46, P513, DOI 10.1002/jobm.200610167; Werneck MBF, 2008, J IMMUNOL, V180, P8004, DOI 10.4049/jimmunol.180.12.8004; Yu HR, 2003, J LEUKOCYTE BIOL, V74, P952, DOI 10.1189/jlb.0902474; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139	50	19	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					479	485		10.1016/j.jaci.2008.10.035	http://dx.doi.org/10.1016/j.jaci.2008.10.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19081613				2022-12-18	WOS:000263495000029
J	Suttner, K; Ruoss, I; Rosenstiel, P; Depner, M; Pinto, LA; Schedel, M; Adamski, J; Illig, T; Schreiber, S; von Murtius, E; Kabesch, M				Suttner, Kathrin; Ruoss, Isabell; Rosenstiel, Philip; Depner, Martin; Pinto, Leonardo A.; Schedel, Michaela; Adamski, Jerzy; Illig, Thomas; Schreiber, Stefan; von Murtius, Erika; Kabesch, Michael			HLX1 gene variants influence the development of childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HLX1; asthma; association study; genetic analysis; functional promoter analysis	CD4 T-CELLS; TRANSCRIPTION FACTOR; ALLERGIC-ASTHMA; BET; POLYMORPHISMS; ASSOCIATION; HAPLOTYPE; DIFFERENTIATION; INDUCTION; CHILDREN	Background: Major transcription factors controlling T(H)1 and T(H)2 development, such as T-box transcription factor and GATA3, might be centrally involved in asthma and atopic diseases. Only recently, the homeobox transcription factor H.20-like homeobox 1 (HLX1), interacting closely with T-box transcription factor, has been identified as an important regulator of T(H)1 differentiation and suppressor of T(H)2 commitment. Objective: We investigated whether genetic variations in the HLX1 gene exist and whether these could affect the development of childhood asthma. Methods: The HLX1 gene was resequenced in 80 chromosomes. Associations between identified polymorphisms, asthma, and atopic diseases were investigated in German children (total n = 3099) from the cross-sectional International Study of Asthma and Allergy in Childhood phase II. Functional properties of polymorphisms were studied by using luciferase reporter gene assays and electrophoretic mobility shift assays in T cells. All statistical analyses were performed with SAS/Genetics software (SAS Institute, Inc, Cary, NC). Results: Nineteen polymorphisms were identified in the HLX1 gene, and 2 tagging single nucleotide polymorphisms representing 7 polymorphisms were associated with childhood asthma in our study population. Two promoter polymorphisms, C-1407T and C-742G, contained in I tagging block were associated with asthma (odds ratio, 1.44; 95% CI, 1.11-1.86; P = .0061), significantly decrease promoter transactivation, and disrupt specificity protein-transcription factor binding in in vitro experiments. Conclusions: Our data suggest that polymorphisms in the HLX1 gene increase the risk for childhood asthma. On the cellular level, altered binding of specificity protein-transcription factors to the HLX1 promoter and subsequent changes in HLX1 gene expression might contribute to these effects. (J Allergy Clin Immunol 2009;123:82-8.)	[Suttner, Kathrin; Ruoss, Isabell; Depner, Martin; Pinto, Leonardo A.; Schedel, Michaela; von Murtius, Erika; Kabesch, Michael] Univ Munich, Univ Childrens Hosp, D-80337 Munich, Germany; [Illig, Thomas] Helmholtz Zentrum Munich, Inst Epidemiol, Neuherberg, Germany; [Adamski, Jerzy] Helmholtz Zentrum Munich, Inst Expt Genet, Neuherberg, Germany; [Rosenstiel, Philip; Schreiber, Stefan] Univ Hosp Schleswig Holstein, Inst Clin Mol Biol, Kiel, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Kiel; Schleswig Holstein University Hospital	Kabesch, M (corresponding author), Univ Munich, Univ Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.	Michael.Kabesch@med.uni-muenchen.de	Kabesch, Michael/GZM-1583-2022; Kabesch, Michael/AAB-5701-2020; Pinto, Leonardo A./C-6866-2008; Rosenstiel, Philip/A-5137-2009; Schedel, Michaela/B-3065-2019; Pinto, Leonardo A./AAG-2800-2020	Pinto, Leonardo A./0000-0002-3906-5456; Rosenstiel, Philip/0000-0002-9692-8828; Schedel, Michaela/0000-0001-8465-2986; Pinto, Leonardo A./0000-0002-3906-5456; von Mutius, Erika/0000-0002-8893-4515; Adamski, Jerzy/0000-0001-9259-0199	National Genome Research Network (NGFN) [NGFN 01GS 0429]; NUW-S23T16 project; German Research Foundation	National Genome Research Network (NGFN); NUW-S23T16 project; German Research Foundation(German Research Foundation (DFG))	Supported by National Genome Research Network (NGFN) research grant NGFN 01GS 0429, the NUW-S23T16 project (to P.R.), and the German Research Foundation as part of the Transregional Collaborative Research Program TR22 "Allergic Immune Responses of the Lung," grant A15. Genotyping was performed in the Genome Analysis Center (GAC) of the Helmholtz Zentrum Munich.	Akahoshi M, 2005, HUM GENET, V117, P16, DOI 10.1007/s00439-005-1285-0; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Cameron L, 2006, J IMMUNOL, V177, P8633, DOI 10.4049/jimmunol.177.12.8633; Chung Hun Taek, 2003, Hum Mutat, V22, P257, DOI 10.1002/humu.9169; Grabe Niels, 2002, In Silico Biology, V2, pS1; Huebner M, 2008, J ALLERGY CLIN IMMUN, V121, P408, DOI 10.1016/j.jaci.2007.09.020; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; Mikhalkevich N, 2006, J IMMUNOL, V176, P1553, DOI 10.4049/jimmunol.176.3.1553; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mullen AC, 2002, NAT IMMUNOL, V3, P652, DOI 10.1038/ni807; Munthe-Kaas MC, 2008, J ALLERGY CLIN IMMUN, V121, P51, DOI 10.1016/j.jaci.2007.07.068; Neurath MF, 2002, NAT MED, V8, P567, DOI 10.1038/nm0602-567; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Pykalainen M, 2005, J ALLERGY CLIN IMMUN, V115, P80, DOI 10.1016/j.jaci.2004.10.006; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Raby BA, 2006, AM J RESP CRIT CARE, V173, P64, DOI 10.1164/rccm.200503-505OC; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Schedel M, 2004, J ALLERGY CLIN IMMUN, V114, P1100, DOI 10.1016/j.jaci.2004.07.048; Schedel M, 2008, AM J RESP CRIT CARE, V177, P613, DOI 10.1164/rccm.200703-373OC; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Ylikoski E, 2004, CLIN EXP ALLERGY, V34, P1049, DOI 10.1111/j.1365-2222.2004.01995.x; Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	28	19	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					82	88		10.1016/j.jaci.2008.09.047	http://dx.doi.org/10.1016/j.jaci.2008.09.047			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19038437	Bronze			2022-12-18	WOS:000262793900012
J	Zanoni, G; Puccetti, A; Dolcino, M; Simone, R; Peretti, A; Ferro, A; Tridente, G				Zanoni, Giovanna; Puccetti, Antonio; Dolcino, Marzia; Simone, Rita; Peretti, Andrea; Ferro, Antonio; Tridente, Giuseppe			Dextran-specific IgG response in hypersensitivity reactions to measles-mumps-rubella vaccine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANAPHYLACTOID REACTIONS		[Zanoni, Giovanna; Peretti, Andrea; Tridente, Giuseppe] Univ Verona, Dept Pathol, Immunol Sect, I-37100 Verona, Italy; [Zanoni, Giovanna; Tridente, Giuseppe] Univ Hosp, Green Channel Reference Ctr Prevaccinat Consultan, Verona, Italy; [Puccetti, Antonio; Dolcino, Marzia] Univ Genoa, Dept Expt Med, Sect Histol, Genoa, Italy; [Puccetti, Antonio; Dolcino, Marzia] Inst G Gaslini, Immunol Unit, Genoa, Italy; [Simone, Rita] Univ Verona, Dept Clin & Expt Med, Sect Internal Med, I-37100 Verona, Italy; [Ferro, Antonio] ALSS N 17, Dept Prevent, Padua, Italy	University of Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Verona	Zanoni, G (corresponding author), Univ Verona, Dept Pathol, Immunol Sect, I-37100 Verona, Italy.	giovanna.zanoni@univr.it						HEDIN H, 1982, INT ARCH ALLER A IMM, V68, P122, DOI 10.1159/000233080; KELSO JM, 2003, MIDDLETONS ALLERGY P, P1665; KRAFT D, 1982, ALLERGY, V37, P481, DOI 10.1111/j.1398-9995.1982.tb02331.x; NOVEY HS, 1994, ANN ALLERGY, V72, P224; Patja A, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.2.e27; RING J, 1977, LANCET, V1, P466; RUDIN C, 1995, EUR J PEDIATR, V154, P941, DOI 10.1007/BF01957516; Ruggeberg JU, 2007, VACCINE, V25, P5675, DOI 10.1016/j.vaccine.2007.02.064; Zinderman CE, 2006, J VASC SURG, V43, P1004, DOI 10.1016/j.jvs.2006.01.006	9	19	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1233	1235		10.1016/j.jaci.2008.09.015	http://dx.doi.org/10.1016/j.jaci.2008.09.015			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	18926562				2022-12-18	WOS:000261711800030
J	Park, SS; Grayson, MH				Park, Stephanie S.; Grayson, Mitchell H.			Clinical research: Protection of the "vulnerable"?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ethics; informed consent; children; clinical research	RETHINKING RESEARCH ETHICS; CHILDREN	In this age of evidence-based medicine, clinical research is critical for developing new therapeutics and determining the best way to use these therapies. To perform appropriate clinical research, researchers must adhere to ethical standards. These standards have developed in large part as a response to egregious violations of ethically appropriate behavior. In this respect certain populations have been identified as at risk of being treated inappropriately in medical research. Current ethical guidelines prohibit or severely limit what types of research can be performed involving these "vulnerable" populations. Although this might protect these populations, the lack of research on them might actually do harm in limiting their access to life-saving therapies. We explore the historical underpinnings of protecting the vulnerable populations and whether a newer ethical paradigm that would allow for protected research on these populations should be adopted by society.	[Park, Stephanie S.; Grayson, Mitchell H.] Washington Univ, Sch Med, Div Allergy & Immunol, Dept Internal Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Grayson, MH (corresponding author), Washington Univ, Sch Med, Div Allergy & Immunol, Dept Internal Med, Campus Box 8122,660 S Euclid Ave, St Louis, MO 63110 USA.	wheeze@allergist.com	Grayson, Mitchell/AAX-3674-2020	Grayson, Mitchell/0000-0002-4673-2122				Brody H, 2005, AM J BIOETHICS, V5, P14, DOI 10.1080/15265160500244983; Burns JP, 2003, CRIT CARE MED, V31, pS131, DOI 10.1097/01.CCM.0000054905.39382.58; Chen DT, 2006, SEMIN NEUROL, V26, P140, DOI 10.1055/s-2006-933318; Cheng MH, 2007, LANCET INFECT DIS, V7, P13, DOI 10.1016/S1473-3099(06)70675-2; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; Emanuel EJ, 2005, AM J BIOETHICS, V5, P9, DOI 10.1080/15265160500244959; Fost N, 1998, SEMIN PERINATOL, V22, P223, DOI 10.1016/S0146-0005(98)80038-4; hhs, 1979, BELM REP ETH PRINC G; KOLATA G, 2005, NY TIMES        0221; Kral JG, 2005, SURGERY, V137, P279, DOI 10.1016/j.surg.2004.11.004; Leavitt FJ, 2006, CAMB Q HEALTHC ETHIC, V15, P81; Lemaire Francois, 2004, Curr Opin Crit Care, V10, P565; Levine C, 2004, AM J BIOETHICS, V4, P44, DOI 10.1080/15265160490497083; O'Lonergan TA, 2005, CURR ALLERGY ASTHM R, V5, P451, DOI 10.1007/s11882-005-0025-9; O'Lonergan TA, 2006, CURR OPIN ALLERGY CL, V6, P139, DOI 10.1097/01.all.0000225148.06909.61; Onder RF, 2005, J ALLERGY CLIN IMMUN, V115, P1228, DOI 10.1016/j.jaci.2005.01.059; Prentice ED, 1999, ACAD EMERG MED, V6, P774, DOI 10.1111/j.1553-2712.1999.tb01204.x; Rhodes R, 2005, AM J BIOETHICS, V5, pW15, DOI 10.1080/15265160590944094; Rhodes R, 2005, AM J BIOETHICS, V5, P7, DOI 10.1080/15265160590900678; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; *US DEP HHS NIH NA, 2007, NIH PUBL; White RM, 2000, ARCH INTERN MED, V160, P585, DOI 10.1001/archinte.160.5.585	22	19	19	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1103	1107		10.1016/j.jaci.2008.01.014	http://dx.doi.org/10.1016/j.jaci.2008.01.014			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18313131				2022-12-18	WOS:000255961700004
J	Ma, ZC; Jhun, B; Jung, SY; Oh, CK				Ma, Zhongcai; Jhun, BongSook; Jung, Sandy Y.; Oh, Chad K.			Binding of upstream stimulatory factor 1 to the E-Box regulates the 4G/5G polymorphism-dependent plasminogen activator inhibitor 1 expression in mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						plasminogen activator inhibitor 1; 4G/5G polymorphism; transcription; human mast cells; upstream stimulatory factor 1; E-box	ALLERGIC-ASTHMA PATIENTS; PLASMA PAI-1 LEVELS; MYOCARDIAL-INFARCTION; PROMOTER POLYMORPHISM; BASAL TRANSCRIPTION; GENE; REGION; KERATINOCYTES; ASSOCIATION; POPULATION	Background: Plasminogen activator inhibitor (PAI)-1 is a key regulator of the fibrinolytic system. PAI-1 levels are markedly elevated in the asthmatic airways. The 4G/5G polymorphism of the PAI-1 gene is associated with allergic asthma. Objective: To characterize the mechanisms of the 4G/5G-dependent PAI-1 expression in mast cells (MCs), a major source of PAI-1 and key effector cells in asthma. Methods: Transcription of PAI-1 was assessed by transiently transfecting human MC line (HMC-1) cells with the luciferasetagged PAI-1 promoters containing the 4G or 5G allele (4G-PAI-1 or 5G-PAI-1 promoter). Upstream stimulatory factor (USF)-1 and the E-box interactions were studied by electrophoretic mobility shift assays and supershift assays. Expression of USF-1 was determined by Western blot analysis. Results: The 4G-PAI-1 promoter has higher promoter activity than the 5G-PAI-1 promoter in stimulated HMC-1 cells, and the E-box adjacent to the 4G/5G site (E-4G/5G) regulates the genotype-specific PAI-1 transcription. USF-1 binds to the E-4G with greater affinity than to the E-5G. USF-1 level is increased in HMC-1 cells after stimulation, and elevated USF-1 enhances PAI-1 transcription. Overexpression of wild-type USF-1 or dominant-negative USF remedies the 4G/5G-dependent PAI-1 transcription. Conclusion: Binding of USF-1 to the E-4G/5G regulates the 4G/5G polymorphism-dependent PAI-1 expression in MCs.	[Ma, Zhongcai; Jhun, BongSook; Jung, Sandy Y.; Oh, Chad K.] Harbor UCLA Med Ctr, Div Allergy & Immunol, Sch Med, Dept Pediat, Torrance, CA 90502 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Oh, CK (corresponding author), Harbor UCLA Med Ctr, Div Allergy & Immunol, Sch Med, Dept Pediat, Bldg N-25,1000 W Carson St, Torrance, CA 90502 USA.	coh@labiomed.org		Jhun, Bong Sook/0000-0001-9916-9962				Allen RR, 2005, J CELL PHYSIOL, V203, P156, DOI 10.1002/jcp.20211; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Buckova D, 2002, ALLERGY, V57, P446; Cho SH, 2001, J ALLERGY CLIN IMMUN, V108, P212, DOI 10.1067/mai.2001.117260; Cho SH, 2000, J IMMUNOL, V165, P3154, DOI 10.4049/jimmunol.165.6.3154; Chong NW, 2006, FEBS LETT, V580, P4469, DOI 10.1016/j.febslet.2006.07.014; Corre S, 2005, PIGM CELL RES, V18, P337, DOI 10.1111/j.1600-0749.2005.00262.x; DAWSON SJ, 1993, J BIOL CHEM, V268, P10739; Diamanti-Kandarakis E, 2004, EUR J ENDOCRINOL, V150, P793, DOI 10.1530/eje.0.1500793; Dimova EY, 2006, J BIOL CHEM, V281, P2999, DOI 10.1074/jbc.M512078200; Ding JZ, 2006, AM HEART J, V152, P1109, DOI 10.1016/j.ahj.2006.06.021; Ding ZR, 2005, ANN HEMATOL, V84, P183, DOI 10.1007/s00277-004-0926-z; ERIKSSON P, 1995, P NATL ACAD SCI USA, V92, P1851, DOI 10.1073/pnas.92.6.1851; Eriksson P, 1998, ARTERIOSCL THROM VAS, V18, P20, DOI 10.1161/01.ATV.18.1.20; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; Huber K, 2001, J THROMB THROMBOLYS, V11, P183, DOI 10.1023/A:1011955018052; Jennings BH, 1999, MOL CELL BIOL, V19, P4600; Kowal K, 2007, INT ARCH ALLERGY IMM, V144, P240, DOI 10.1159/000103998; Lyons LC, 2000, J BIOL RHYTHM, V15, P472, DOI 10.1177/074873000129001585; Martinez-Calatrava MJ, 2007, DIABETES OBES METAB, V9, P134, DOI 10.1111/j.1463-1326.2006.00584.x; Nakajima T, 2002, BLOOD, V100, P3861, DOI 10.1182/blood-2002-02-0602; Oh CK, 2002, BIOCHEM BIOPH RES CO, V294, P1155, DOI 10.1016/S0006-291X(02)00577-6; Pampuch A, 2006, ALLERGY, V61, P234, DOI 10.1111/j.1398-9995.2005.00948.x; Qi L, 2006, J CELL BIOCHEM, V99, P495, DOI 10.1002/jcb.20885; Roncal C, 2004, CARDIOVASC RES, V63, P176, DOI 10.1016/j.cardiores.2004.03.023; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Sejima T, 2005, J IMMUNOL, V174, P8135, DOI 10.4049/jimmunol.174.12.8135; Sejima T, 2004, HISTOCHEM CELL BIOL, V122, P61, DOI 10.1007/s00418-004-0664-2; Shimizu T, 1997, EMBO J, V16, P4689, DOI 10.1093/emboj/16.15.4689; Zhan M, 2004, INT J HEMATOL, V79, P400; Zietz B, 2004, J MOL ENDOCRINOL, V32, P155, DOI 10.1677/jme.0.0320155	31	19	19	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					1006	1012		10.1016/j.jaci.2007.11.015	http://dx.doi.org/10.1016/j.jaci.2007.11.015			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18234320				2022-12-18	WOS:000254884000029
J	Kanazawa, H; Tochino, Y; Asai, K				Kanazawa, Hiroshi; Tochino, Yoshihiro; Asai, Kazuhisa			Angiopoietin-2 as a contributing factor of exercise-induced bronchoconstriction in asthmatic patients receiving inhaled corticosteroid therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exercise; bronchial asthma; airway microcirculation; induced sputum	AIRWAY MICROVASCULAR PERMEABILITY; ENDOTHELIAL GROWTH-FACTOR; BRONCHIAL-ASTHMA; NITRIC-OXIDE; ADULT VASCULATURE; ANGIOGENESIS; LEAKAGE; TIE2; INFLAMMATION; MONTELUKAST	Background: Airway microcirculation has the potential to contribute to the pathogenesis of exercise-induced bronchoconstriction (EIB) in asthma. Recently, angiopoietin-1 has been found to stabilize microvessels and make them leak resistant, whereas angiopoietin-2 is an antagonist of angiopoietin-1 and enhances microvascular permeability. Objective: We sought to examine the roles of angiopoietin-2 in EIB in asthmatic patients with inhaled corticosteroid therapy. Methods: Levels of angiopoietin-1 and angiopoietin-2 in induced sputum were examined in 32 asthmatic patients who were receiving inhaled corticosteroid therapy for more than 6 months at the entry of this study and 14 healthy control subjects. All asthmatic patients performed an exercise test. Results: The degree of eosinophilic airway inflammation did not differ significantly between asthmatic patients and healthy control subjects. Angiopoietin-1 levels were also similar in the 2 groups (asthmatic patients: median, 6.0 ng/mL [range, 2.0-10.7 ng/mL]; healthy control subjects: median, 4.2 ng/mL [range, 1.5-10.7 ng/mL]). In contrast, angiopoietin-2 levels were significantly higher in asthmatic patients than in healthy control subjects (asthmatic patients: median, 0.74 ng/mL [range, 0.3-1.2 ng/mL]; healthy control subjects: median, 0.26 ng/mL [range, 0.05-0.47 ng/mL]; P < .001). There was no significant correlation between angiopoietin-1 levels and the severity of EIB in asthmatic patients. However, angiopoietin-2 levels were significantly correlated with the severity of EIB and airway microvascular permeability index. Conclusion: Angiopoietin-2 levels were increased in the airways of asthmatic patients with inhaled corticosteroid therapy, and its levels were associated with the severity of EIB.	[Kanazawa, Hiroshi; Tochino, Yoshihiro; Asai, Kazuhisa] Osaka City Univ, Grad Sch Med, Dept Resp Med, Abeno Ku, Osaka 5458585, Japan	Osaka Metropolitan University	Kanazawa, H (corresponding author), Osaka City Univ, Grad Sch Med, Dept Resp Med, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.	kanazawa-h@med.osaka-cu.ac.jp						ANDERSON SD, 2004, PEDIAT DRUGS, V6, P1; BALUK P, 1994, AM J PHYSIOL, V266, pL461, DOI 10.1152/ajplung.1994.266.4.L461; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Cabral ALB, 1999, AM J RESP CRIT CARE, V159, P1819, DOI 10.1164/ajrccm.159.6.9805093; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Feltis BN, 2006, AM J RESP CRIT CARE, V173, P1201, DOI 10.1164/rccm.200507-1105OC; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P586, DOI 10.1016/j.jaci.2005.04.035; Hallstrand TS, 2005, AM J RESP CRIT CARE, V172, P679, DOI 10.1164/rccm.200412-1667OC; Hashimoto T, 2006, PLOS MED, V3, P294, DOI 10.1371/journal.pmed.0030113; Kanazawa H, 2005, CLIN EXP ALLERGY, V35, P1432, DOI 10.1111/j.1365-2222.2005.02358.x; Kanazawa H, 2004, AM J RESP CRIT CARE, V169, P1125, DOI 10.1164/rccm.200401-123OC; Kanazawa H, 2003, CHEST, V124, P1755, DOI 10.1378/chest.124.5.1755; Kanazawa H, 2002, CHEST, V122, P166, DOI 10.1378/chest.122.1.166; Kanazawa H, 1997, J ALLERGY CLIN IMMUN, V99, P624, DOI 10.1016/S0091-6749(97)70024-1; Kanazawa H, 2000, J ALLERGY CLIN IMMUN, V106, P1081, DOI 10.1067/mai.2000.110803; Kanazawa H, 2007, CHEST, V131, P1035, DOI 10.1378/chest.06-2758; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MCFADDEN ER, 1990, LANCET, V335, P880, DOI 10.1016/0140-6736(90)90478-N; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; Nomura S, 2005, J ASTHMA, V42, P141, DOI 10.1081/JAS-51346; Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046; Peters KG, 2004, RECENT PROG HORM RES, V59, P51, DOI 10.1210/rp.59.1.51; Rudolfsson SH, 2003, BIOL REPROD, V69, P1231, DOI 10.1095/biolreprod.102.013375; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Subbarao P, 2006, J ALLERGY CLIN IMMUN, V117, P1008, DOI 10.1016/j.jaci.2005.11.048; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Van Rensen ELJ, 2002, AM J RESP CRIT CARE, V165, P1275, DOI 10.1164/rccm.2110092; Villaran C, 1999, J ALLERGY CLIN IMMUN, V104, P547, DOI 10.1016/S0091-6749(99)70322-2; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; Yoshikawa T, 1998, EUR RESPIR J, V12, P879, DOI 10.1183/09031936.98.12040879; Zagzag D, 2000, LAB INVEST, V80, P837, DOI 10.1038/labinvest.3780088	35	19	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					390	395		10.1016/j.jaci.2007.09.026	http://dx.doi.org/10.1016/j.jaci.2007.09.026			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18037159				2022-12-18	WOS:000253337800017
J	Jabara, HH; Chaudhuri, J; Dutt, S; Dedeoglu, F; Weng, Y; Murphy, MM; Franco, S; Alt, FW; Manis, J; Gehal, RS				Jabara, Haifa H.; Chaudhuri, Jayanta; Dutt, Shilpee; Dedeoglu, Fatma; Weng, Yu; Murphy, Michael M.; Franco, Sonia; Alt, Fredrick W.; Manis, John; Gehal, Raif S.			B-cell receptor cross-linking delays activation-induced cytidine deaminase induction and inhibits class-switch recombination to IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B-cell receptor; isotype switching; IgE; activation-induced cytidine deaminase	ANTIBODY DIVERSIFICATION ENZYME; CD40 LIGAND; DNA BREAKS; AID; LIPOPOLYSACCHARIDE; DIFFERENTIATION; MU; TRANSLOCATIONS; TRANSCRIPTION; SUPPRESSION	Background: During differentiation, B cells receive signals by antigen through the B-cell receptor (BCR) and signals that induce isotype switching. Objective: We sought to investigate the effects of BCR ligation on isotype switching. Methods: Naive B cells from BALB/c mice were stimulated with LPS plus IL-4 alone or plus anti-IgM (0.1-10 mu g/mL). IgE and IgG1 levels in supernatants were measured by means of ELISA on day 6. C mu or C epsilon germline transcripts, activation-induced cytidine deaminase (AID), and I mu-C epsilon postswitch transcripts were measured by means of RT-PCR. Deletional switch recombination was assessed by means of digestion circularization PCR of S mu-S epsilon products. Results: BCR cross-linking inhibited IgE and IgG1 switching in a dose-dependent fashion. This was not due to inhibition of proliferation, increased apoptosis, or cell death. BCR cross-linking had no effect on C mu or C epsilon germline transcripts but suppressed the generation of S mu-S epsilon switch products and I mu-C epsilon postswitch transcripts and caused a delay in the expression of AID mRNA, with decreased expression on days 2 and 3 after stimulation. Concomitantly, the number of DNA repair foci at the IgH locus on day 3 was significantly decreased. AID expression and activity became normal on day 4, but isotype switching remained profoundly diminished 8 days after stimulation. Conclusion: BCR cross-linking delays AID expression. This might interfere with class-switch recombination by disrupting the temporal coordination of signals that lead to class-switch recombination.	[Jabara, Haifa H.; Dedeoglu, Fatma; Weng, Yu; Gehal, Raif S.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Chaudhuri, Jayanta; Murphy, Michael M.; Franco, Sonia; Alt, Fredrick W.] Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; [Jabara, Haifa H.; Dedeoglu, Fatma; Gehal, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Chaudhuri, Jayanta; Franco, Sonia; Alt, Fredrick W.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [Chaudhuri, Jayanta] Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY USA; [Dutt, Shilpee; Manis, John] Harvard Univ, Sch Med, Joint Program Transfus Med, Boston, MA 02115 USA; [Dutt, Shilpee; Manis, John] Harvard Univ, Sch Med, Dept Lab Med, Childrens Hosp,Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Memorial Sloan Kettering Cancer Center; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Gehal, RS (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	raif.gelia@childrens.harvard.edu			NCI NIH HHS [P01CA09265] Funding Source: Medline; NIAID NIH HHS [R01-AI-031136, AI31541] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031136, U19AI031541, U01AI031541] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Basu U, 2005, NATURE, V438, P508, DOI 10.1038/nature04255; Chaudhuri J, 2004, NATURE, V430, P992, DOI 10.1038/nature02821; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; CHEN U, 1991, NUCLEIC ACIDS RES, V19, P5981, DOI 10.1093/nar/19.21.5981; FLAHART RE, 1987, J EXP MED, V166, P864, DOI 10.1084/jem.166.4.864; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Franco S, 2006, DNA REPAIR, V5, P1030, DOI 10.1016/j.dnarep.2006.05.024; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Hasbold J, 1998, EUR J IMMUNOL, V28, P1040, DOI 10.1002/(SICI)1521-4141(199803)28:03<1040::AID-IMMU1040>3.3.CO;2-0; Jabara HH, 2005, J ALLERGY CLIN IMMUN, V115, P856, DOI 10.1016/j.jaci.2005.01.020; Jabara HH, 2002, IMMUNITY, V17, P265, DOI 10.1016/S1074-7613(02)00394-1; KEARNEY JF, 1978, J IMMUNOL, V120, P158; Manis JP, 2004, NAT IMMUNOL, V5, P481, DOI 10.1038/ni1067; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; MOORE BB, 1993, J IMMUNOL, V150, P3366; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; PECANHA LMT, 1993, J IMMUNOL, V150, P2160; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; Rush JS, 2002, J IMMUNOL, V168, P2676, DOI 10.4049/jimmunol.168.6.2676; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021	20	19	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					191	196		10.1016/j.jaci.2007.08.008	http://dx.doi.org/10.1016/j.jaci.2007.08.008			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17900678				2022-12-18	WOS:000252372000029
J	Chan-Yeung, M; Dimich-Ward, H; Becker, A				Chan-Yeung, Moira; Dimich-Ward, Helen; Becker, Allan			Atopy in early life and effect of a primary prevention program for asthma in a high-risk cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDHOOD; OUTCOMES; AGE		Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Univ Manitoba, Winnipeg, MB, Canada	University of British Columbia; University of Manitoba	Chan-Yeung, M (corresponding author), Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.	myeung@interchange.ubc.ca						Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657, DOI 10.1001/archpedi.154.7.657; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Schiessl B, 2003, INT ARCH ALLERGY IMM, V130, P125, DOI 10.1159/000069011	7	19	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1221	1223		10.1016/j.jaci.2007.08.025	http://dx.doi.org/10.1016/j.jaci.2007.08.025			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17919706				2022-12-18	WOS:000250973400038
J	Kelly, HW				Kelly, H. William			Rationale for the major changes in the pharmacotherapy section of the National Asthma Education and Prevention Program guidelines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; treatment guidelines; pediatrics; childhood asthma; omalizumab; long-acting inhaled beta(2)-agonists; inhaled corticosteroids; adverse effects	ACTING BETA-AGONISTS; ANTIIMMUNOGLOBULIN-E THERAPY; E ANTIBODY OMALIZUMAB; PERSISTENT ASTHMA; INHALED CORTICOSTEROIDS; BETA(2)-ADRENERGIC RECEPTOR; DOUBLE-BLIND; SALMETEROL; EXACERBATIONS; ALBUTEROL	Numerous changes have been incorporated into the new National Asthma Education and Prevention Program's Expert Panel Report 3. In the pharmacotherapy section of the report, many of these changes are minor in that they do not alter the basic philosophy of treatment recommendations from the previous Expert Panel Report but only add new formulations, change dosing or dosage forms, or add discussion of risks. However, 4 major changes have been identified, and the rationales for 3 are discussed in detail here. The treatment of childhood asthma is divided into 2 distinct age groups, infants less than 5 years of age and children 5 to 12 years of age, because of the availability of more data suggesting differences in response in these patients, as well as a relative paucity of quality data in the younger patients. Omalizumab, a humanized mAb to IgE, is the only new entity approved for the treatment of asthma since the previous guidelines, and its recommendations were reviewed. The indication for combination therapy with inhaled corticosteroids and long-acting inhaled beta(2)-agonists (LABAs) has been modified in lieu of the recent black box warning concerning the increased risk of severe asthma exacerbations and death associated with LABA use. However, the inhaled corticosteroids/LABAs are still recommended for patients with moderate-to-severe persistent asthma. The rationale for the continued recommendation is provided.	Univ New Mexico, Dept Pediat, Albuquerque, NM 87131 USA	University of New Mexico	Kelly, HW (corresponding author), Univ New Mexico, Dept Pediat, MSC10-5590, Albuquerque, NM 87131 USA.	hwkelly@salud.unm.edu						Amirav I, 2005, PEDIATR PULM, V39, P447, DOI 10.1002/ppul.20180; Anderson HR, 2005, BRIT MED J, V330, P117, DOI 10.1136/bmj.38316.729907.8F; Ayres JG, 2004, ALLERGY, V59, P701, DOI 10.1111/j.1398-9995.2004.00533.x; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bisgaard H, 1997, J ASTHMA, V34, P443, DOI 10.3109/02770909709055389; Bisgaard H, 2003, PEDIATR PULM, V36, P391, DOI 10.1002/ppul.10381; Bleecker ER, 2006, J ALLERGY CLIN IMMUN, V118, P809, DOI 10.1016/j.jaci.2006.06.036; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Dolovich MB, 2005, CHEST, V127, P335, DOI 10.1378/chest.127.1.335; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Haney S, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-107; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Inman MD, 1996, AM J RESP CRIT CARE, V153, P65, DOI 10.1164/ajrccm.153.1.8542164; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Jones SL, 2001, EUR RESPIR J, V17, P368, DOI 10.1183/09031936.01.17303680; Kelly HW, 2006, PHARMACOTHERAPY, V26, p164S, DOI 10.1592/phco.26.9part2.164S; Kelly HW, 2005, ANN PHARMACOTHER, V39, P931, DOI 10.1345/aph.1E611; Knorr B, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.3.e48; Korosec M, 1999, AM J MED, V107, P209, DOI 10.1016/S0002-9343(99)00222-3; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lee DKC, 2004, BRIT J CLIN PHARMACO, V57, P68, DOI 10.1046/j.1365-2125.2003.01955.x; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Mann M, 2003, CHEST, V124, P70, DOI 10.1378/chest.124.1.70; Mann RD, 1996, J CLIN EPIDEMIOL, V49, P247, DOI 10.1016/0895-4356(95)00555-2; Martinez FD, 2005, NEW ENGL J MED, V353, P2637, DOI 10.1056/NEJMp058299; Masoli M, 2005, THORAX, V60, P730, DOI 10.1136/thx.2004.039180; Matz J, 2001, J ALLERGY CLIN IMMUN, V107, P783, DOI 10.1067/mai.2001.114709; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; MININO AM, 2006, NAT VITAL STAT REPOR, V54; Murphy S, 2006, J ALLERGY CLIN IMMUN, V117, P34, DOI 10.1016/j.jaci.2005.10.031; Nelson HS, 2006, J ALLERGY CLIN IMMUN, V117, P3, DOI 10.1016/j.jaci.2005.10.013; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; NICHROININ M, COCHRANE DATABASE SY; *NIH, 2002, J ALLERGY CLIN IMMUN, V110, pS142; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Palmer CNA, 2006, THORAX, V61, P940, DOI 10.1136/thx.2006.059386; Qaqundah PY, 2006, J PEDIATR-US, V149, P663, DOI 10.1016/j.jpeds.2006.07.045; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; Robinson DS, 2001, LANCET, V357, P2007, DOI 10.1016/S0140-6736(00)05113-8; Salpeter SR, 2006, ANN INTERN MED, V144, P904, DOI 10.7326/0003-4819-144-12-200606200-00126; Salpeter SR, 2004, ANN INTERN MED, V140, P802, DOI 10.7326/0003-4819-140-10-200405180-00010; Sin DD, 2004, JAMA-J AM MED ASSOC, V292, P367, DOI 10.1001/jama.292.3.367; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Strunk RC, 2006, NEW ENGL J MED, V354, P2689, DOI 10.1056/NEJMct055184; Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594, DOI 10.1164/ajrccm.160.2.9811100; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; *US DEP HHS, 2006, NIH PUBL; US Department of Health and Human Services, 1997, NIH PUBL, V01-3680; *US FDA, 2005, M PULM ALL DRUGS ADV; *US FDA, GUID IND E11 CLIN IN; *US FDA, CTR DRUG EV RES PED; van der Woude HJ, 2001, THORAX, V56, P529, DOI 10.1136/thorax.56.7.529; Vignola AM, 2004, ALLERGY, V59, P709, DOI 10.1111/j.1398-9995.2004.00550.x; Walters JAE, 2005, RESP MED, V99, P384, DOI 10.1016/j.rmed.2005.01.003; Wechsler ME, 2006, AM J RESP CRIT CARE, V173, P519, DOI 10.1164/rccm.200509-1519OC; Wildhaber JH, 1999, J PEDIATR-US, V135, P28, DOI 10.1016/S0022-3476(99)70323-9	61	19	19	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					989	994		10.1016/j.jaci.2007.01.035	http://dx.doi.org/10.1016/j.jaci.2007.01.035			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17983867	Bronze			2022-12-18	WOS:000250973400001
J	Kaplan, AP; Joseph, K				Kaplan, Allen P.; Joseph, Kustanam			Basophil secretion in chronic urticaria: Autoantibody-dependent or not?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC IDIOPATHIC URTICARIA		Med Univ S Carolina, Dept Med, Div Pulm Crit Care Allerg & Immunol, Charleston, SC 29425 USA; Med Univ S Carolina, Div Clin Immunol & Rheumatol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Kaplan, AP (corresponding author), Med Univ S Carolina, Dept Med, Div Pulm Crit Care Allerg & Immunol, Charleston, SC 29425 USA.	kaplana@musc.edu						Asero R, 2006, J ALLERGY CLIN IMMUN, V117, P1113, DOI 10.1016/j.jaci.2005.12.1343; Confino-Cohen R, 2002, J ALLERGY CLIN IMMUN, V109, P349, DOI 10.1067/mai.2002.121314; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; Luquin E, 2005, CLIN EXP ALLERGY, V35, P456, DOI 10.1111/j.1365-2222.2005.02212.x; Soundararajan S, 2005, J ALLERGY CLIN IMMUN, V115, P815, DOI 10.1016/j.jaci.2004.12.1120; Vonakis BM, 2007, J ALLERGY CLIN IMMUN, V119, P441, DOI 10.1016/j.jaci.2006.09.035	7	19	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					729	730		10.1016/j.jaci.2007.05.008	http://dx.doi.org/10.1016/j.jaci.2007.05.008			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17604092	Bronze			2022-12-18	WOS:000249505400047
J	Simons, KJ; Benedetti, MS; Simons, FER; Gillard, M; Baltes, E				Simons, Keith J.; Benedetti, Margherita Strolin; Simons, F. Estelle R.; Gillard, Michel; Baltes, Eugene			Relevance of H-1-receptor occupancy to H-1-antihistamine dosing in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HISTAMINE-RECEPTORS; LEVOCETIRIZINE; PHARMACODYNAMICS; CETIRIZINE		Univ Manitoba, Fac Pharm, Dept Pediat & Child Hlth, Fac Med, Winnipeg, MB R3T 2N2, Canada; UCB Bioprod SA, Drug Metab & Pharmacokinet, Nanterre, France; Univ Manitoba, Dept Pediat & Child Hlth, Dept Immunol, Fac Med, Winnipeg, MB R3T 2N2, Canada; UCB Bioprod SA, Cellular & Mol Biol, Braine Ialleud, Belgium; UCB Bioprod SA, Drug Metab & Pharmacokinet, Braine Ialleud, Belgium	University of Manitoba; UCB Pharma SA; University of Manitoba; UCB Pharma SA; UCB Pharma SA	Simons, KJ (corresponding author), Univ Manitoba, Fac Pharm, Dept Pediat & Child Hlth, Fac Med, Winnipeg, MB R3T 2N2, Canada.	lmcniven@hsc.mb.ca	Beldar, Sagar V/C-8542-2011					Akdis CA, 2006, EUR J PHARMACOL, V533, P69, DOI 10.1016/j.ejphar.2005.12.044; Baltes E, 2001, FUNDAM CLIN PHARM, V15, P269, DOI 10.1046/j.1472-8206.2001.00035.x; Bree F, 2002, FUND CLIN PHARMACOL, V16, P471, DOI 10.1046/j.1472-8206.2002.00111.x; Gillard M, 2005, INFLAMM RES, V54, P367, DOI 10.1007/s00011-005-1368-3; Gillard M, 2002, MOL PHARMACOL, V61, P391, DOI 10.1124/mol.61.2.391; Leurs R, 2002, CLIN EXP ALLERGY, V32, P489, DOI 10.1046/j.0954-7894.2002.01314.x; Simons FER, 2005, J ALLERGY CLIN IMMUN, V116, P355, DOI 10.1016/j.jaci.2005.04.010; Simons FER, 2004, NEW ENGL J MED, V351, P2203, DOI 10.1056/NEJMra033121	8	19	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1551	1554		10.1016/j.jaci.2007.02.048	http://dx.doi.org/10.1016/j.jaci.2007.02.048			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17556060	Bronze			2022-12-18	WOS:000247232800040
J	Buckland, KF; O'Connor, EC; Coleman, EM; Lira, SA; Lukacs, NW; Hogaboam, CM				Buckland, Karen F.; O'Connor, Erica C.; Coleman, Eilish M.; Lira, Sergio A.; Lukacs, Nicholas W.; Hogaboam, Cory M.			Remission of chronic fungal asthma in the absence of CCR8	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asperaillus; CCR8; CCL1; chemokine receptor; chemokines; fungal asthma; fungal allergy; and ABPA	ALLERGIC AIRWAY DISEASE; CHEMOKINE RECEPTOR EXPRESSION; INVASIVE ASPERGILLOSIS; INFLAMMATORY PROTEIN; DENDRITIC CELLS; CUTTING EDGE; T-CELLS; IDENTIFICATION; RECRUITMENT; FUMIGATUS	Background: Experimental studies have generated conflicting data regarding the role of CCR8 in antigen-driven allergic airway disease models, thereby dampening enthusiasm for further exploration of the targeting of CCR8 in asthma. Objective: Recent data show that the absence of CCR8 leads to a marked amplification of the innate immune response, and these data provided impetus for the current study, which addressed the role of this chemokine receptor in a model of fungal asthma. Methods: Wild-type (CCR8(+/+)) and CCR8-deficient (CCR8(-/-)) mice were sensitized to Aspergillus fumigatus antigens and challenged via intra-tracheal injection with live fungal conidia, and parameters of airway hyperresponsiveness, inflammation, and remodeling were examined. Results: At day 7 after conidia challenge in wild-type (CCR8(+/+)) and CCR8-deficient (CCR8(-/-)) mice sensitized to A fumigatus antigens, markedly less fungal material was present in the lungs of the CCR8(-/-) group compared with the CCR8(+/+) group. At day 14 after conidia challenge, all characteristic airway physiology inflammatory, and remodeling parameters of fungal asthma were significantly decreased or abolished in the CCR8(-/-) group relative to the CCR8(+/+) group. Conclusion: Together these data show that an enhanced innate immune response in the absence of CCR8 promotes the rapid clearance of fungal material from the lung, thereby facilitating the remission of fungal asthma. Clinical implications: This study shows that the clearance of fungal material from the lung was enhanced in the absence of CCR8, which suggests that this receptor may be an attractive target in fungal-allergic asthma and other fungal-associated pulmonary diseases.	Univ Michigan, Sch Med, Dept Pathol, Program Immunol, Ann Arbor, MI 48109 USA; Mt Sinai Sch Med, Ctr Immunobiol, New York, NY USA	University of Michigan System; University of Michigan; Icahn School of Medicine at Mount Sinai	Hogaboam, CM (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Program Immunol, Pathol Room 4057,BSRB,109 Zina Pitcher, Ann Arbor, MI 48109 USA.	hogaboam@med.umich.edu	Hogaboam, Cory M./AAI-1433-2021; hogaboam, cory/M-3578-2014; Lukacs, Nicholas W/ABH-5583-2020	Hogaboam, Cory M./0000-0003-3366-4850; Buckland, Karen/0000-0001-6989-2228	NHLBI NIH HHS [HL069865] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069865] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benjamim CF, 2005, BLOOD, V105, P3588, DOI 10.1182/blood-2004-08-3251; Bishop B, 2003, J IMMUNOL, V170, P4810, DOI 10.4049/jimmunol.170.9.4810; Blease K, 2001, J IMMUNOL, V167, P6583, DOI 10.4049/jimmunol.167.11.6583; Blease K, 2001, J IMMUNOL, V166, P1832, DOI 10.4049/jimmunol.166.3.1832; Blease K, 2000, J IMMUNOL, V165, P2603, DOI 10.4049/jimmunol.165.5.2603; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Bozza S, 2003, BLOOD, V102, P3807, DOI 10.1182/blood-2003-03-0748; Bozza S, 2002, MICROBES INFECT, V4, P1281, DOI 10.1016/S1286-4579(02)00007-2; Bozza S, 2002, J IMMUNOL, V168, P1362, DOI 10.4049/jimmunol.168.3.1362; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Chensue SW, 2001, J EXP MED, V193, P573, DOI 10.1084/jem.193.5.573; Chung CD, 2003, J IMMUNOL, V170, P581, DOI 10.4049/jimmunol.170.1.581; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; ELSHOURA S, 1993, VIRCHOWS ARCH B, V64, P395, DOI 10.1007/BF02915140; Gehring U, 2001, EUR RESPIR J, V18, P555, DOI 10.1183/09031936.01.00096801; Goya I, 1998, J IMMUNOL, V160, P1975; Goya I, 2003, J IMMUNOL, V170, P2138, DOI 10.4049/jimmunol.170.4.2138; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; Hogaboam CM, 2000, AM J PATHOL, V156, P723, DOI 10.1016/S0002-9440(10)64775-X; Howard OMZ, 2000, BLOOD, V96, P840, DOI 10.1182/blood.V96.3.840.015k32_840_845; Lloyd CM, 2003, CURR OPIN PHARMACOL, V3, P443, DOI 10.1016/S1471-4892(03)00069-9; Matsukawa A, 2006, FASEB J, V20, P302, DOI 10.1096/fj.04-1728fje; Morrison BE, 2003, J CLIN INVEST, V112, P1862, DOI [10.1172/JCI200318125, 10.1172/JCI18125]; Nomiyama H, 2001, INT IMMUNOL, V13, P1021, DOI 10.1093/intimm/13.8.1021; Oliveira SHP, 2002, J LEUKOCYTE BIOL, V71, P1019; Onuffer JJ, 2002, TRENDS PHARMACOL SCI, V23, P459, DOI 10.1016/S0165-6147(02)02064-3; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; Sallusto F, 1999, EUR J IMMUNOL, V29, P2037, DOI 10.1002/(SICI)1521-4141(199906)29:06<2037::AID-IMMU2037>3.0.CO;2-V; Schuh JM, 2003, EUR J IMMUNOL, V33, P3080, DOI 10.1002/eji.200323917; Schuh JM, 2002, FASEB J, V16, P1313, DOI 10.1096/fj.02-0193fje; Sebastiani S, 2001, J IMMUNOL, V166, P996, DOI 10.4049/jimmunol.166.2.996; Sozzani S, 1998, BLOOD, V92, P4036, DOI 10.1182/blood.V92.11.4036.423k17_4036_4039; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; WILSON SD, 1990, J IMMUNOL, V145, P2745; Zingoni A, 1998, J IMMUNOL, V161, P547	38	19	19	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					997	1004		10.1016/j.jaci.2006.12.660	http://dx.doi.org/10.1016/j.jaci.2006.12.660			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17321573				2022-12-18	WOS:000245729500032
J	Chen, WG; Hershey, GKK				Chen, Weiguo; Hershey, Gurjit K. Khurana			Signal transducer and activator of transcription signals in allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; STAT; cytokine; JAK-STAT; review	REGULATORY T-CELLS; INFLAMMATORY-BOWEL-DISEASE; IMMUNOLOGICAL SELF-TOLERANCE; GENE G2964A POLYMORPHISM; NUCLEAR EXPORT SIGNAL; COILED-COIL DOMAIN; SERINE PHOSPHORYLATION; AIRWAY INFLAMMATION; STAT6 GENE; DNA-BINDING	Signal transducer and activator of transcription (STAT) proteins are a group of transcription factors that transmit signals from the extracellular milieu of cells to the nucleus. They are crucial for the signaling of many cytokines that are mediators of allergic inflammation and impact various cell types critical to allergy including epithelial cells, mast cells, lymphocytes, dendritic cells, and eosinophils. Dysregulation of STAT signaling has been implicated in allergic disease, highlighting the importance of these ubiquitous molecules in allergic inflammation and the potential of these pathways as a target for therapeutic intervention. This review will summarize the current understanding of the roles of STAT signaling in allergic disease and the potential of targeting STATs for the treatment of allergic disorders, emphasizing recent observations.	Childrens Hosp, Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Pediat, Cincinnati, OH 45221 USA	Cincinnati Children's Hospital Medical Center; University of Cincinnati; University of Cincinnati	Hershey, GKK (corresponding author), Childrens Hosp, Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave,MLC 7028, Cincinnati, OH 45229 USA.	Gurjit.Hershey@cchmc.org		Khurana Hershey, Gurjit/0000-0001-6663-977X				Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Amoli MM, 2002, GENES IMMUN, V3, P220, DOI 10.1038/sj.gene.6363872; Andrews RP, 2002, J BIOL CHEM, V277, P36563, DOI 10.1074/jbc.M200986200; [Anonymous], 2004, AM J TRANSPLANT, V4, P51, DOI 10.1046/j.1600-6143.2003.00281.x; Antov A, 2003, J IMMUNOL, V171, P3435, DOI 10.4049/jimmunol.171.7.3435; Arnaud C, 2005, ARTERIOSCL THROM VAS, V25, P1231, DOI 10.1161/01.ATV.0000163840.63685.0c; Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; Bailey DP, 2004, EXP HEMATOL, V32, P52, DOI 10.1016/j.exphem.2003.10.011; Balasubramanian A, 2006, J INFECT DIS, V194, P670, DOI 10.1086/505708; Banninger G, 2004, J BIOL CHEM, V279, P39199, DOI 10.1074/jbc.M400815200; Barnstein BO, 2006, J IMMUNOL, V177, P3421, DOI 10.4049/jimmunol.177.5.3421; Barthlott T, 2005, INT IMMUNOL, V17, P279, DOI 10.1093/intimm/dxh207; Barton BE, 2004, MOL CANCER THER, V3, P1183; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Begitt A, 2000, P NATL ACAD SCI USA, V97, P10418, DOI 10.1073/pnas.190318397; Behera AK, 2002, HUM GENE THER, V13, P1697, DOI 10.1089/104303402760293547; Bhattacharya S, 2003, J CLIN INVEST, V111, P553, DOI 10.1172/JCI200315372; Blease K, 2002, AM J PATHOL, V160, P481, DOI 10.1016/S0002-9440(10)64867-5; Burchill MA, 2003, J IMMUNOL, V171, P5853, DOI 10.4049/jimmunol.171.11.5853; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Candotti F, 1997, BLOOD, V90, P3996, DOI 10.1182/blood.V90.10.3996; Chang YT, 2006, CLIN EXP DERMATOL, V31, P419, DOI 10.1111/j.1365-2230.2006.02124.x; Changelian PS, 2003, SCIENCE, V302, P875, DOI 10.1126/science.1087061; Chen WG, 2004, J ALLERGY CLIN IMMUN, V114, P476, DOI 10.1016/j.jaci.2004.06.042; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chen YH, 2006, BLOOD, V108, P566, DOI 10.1182/blood-2005-12-4777; Cohen AC, 2006, J IMMUNOL, V177, P2770, DOI 10.4049/jimmunol.177.5.2770; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; de Jong DJ, 2003, EUR J HUM GENET, V11, P884, DOI 10.1038/sj.ejhg.5201058; de la Rosa M, 2004, EUR J IMMUNOL, V34, P2480, DOI 10.1002/eji.200425274; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Di Stefano A, 2004, EUR RESPIR J, V24, P78, DOI 10.1183/09031936.04.00080303; Duetsch G, 2002, HUM MOL GENET, V11, P613, DOI 10.1093/hmg/11.6.613; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EILERS A, 1995, MOL CELL BIOL, V15, P3579; Eriksen KW, 2005, J INVEST DERMATOL, V125, P936, DOI 10.1111/j.0022-202X.2005.23864.x; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; Feng X, 2002, J NEUROIMMUNOL, V129, P205, DOI 10.1016/S0165-5728(02)00182-0; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Frisullo G, 2006, J NEUROSCI RES, V84, P1027, DOI 10.1002/jnr.20995; Fulkerson PC, 2004, J IMMUNOL, V173, P7565, DOI 10.4049/jimmunol.173.12.7565; Gao PS, 2004, J MED GENET, V41, P535, DOI 10.1136/jmg.2003.015842; Ghaffar O, 2000, CLIN EXP ALLERGY, V30, P86; Gleason EL, 2004, BIOCHEM BIOPH RES CO, V325, P716, DOI 10.1016/j.bbrc.2004.10.081; Goenka S, 2006, P NATL ACAD SCI USA, V103, P4210, DOI 10.1073/pnas.0506981103; Gu XL, 2006, J INVEST DERMATOL, V126, P137, DOI 10.1038/sj.jid.5700010; Han C, 2006, J BIOL CHEM, V281, P24831, DOI 10.1074/jbc.M602201200; Han XN, 2005, GASTROENTEROLOGY, V129, P185, DOI 10.1053/j.gastro.2005.05.018; Heller NM, 2004, AM J RESP CELL MOL, V31, P573, DOI 10.1165/rcmb.2004-0195OC; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Hevehan DL, 2002, BLOOD, V99, P1627, DOI 10.1182/blood.V99.5.1627; Ho HH, 2006, J BIOL CHEM, V281, P14111, DOI 10.1074/jbc.M511797200; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Hoeck J, 2001, J IMMUNOL, V167, P3216, DOI 10.4049/jimmunol.167.6.3216; Hoeck J, 2001, J IMMUNOL, V166, P4507, DOI 10.4049/jimmunol.166.7.4507; Hoey T, 2003, EMBO J, V22, P4237, DOI 10.1093/emboj/cdg393; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Jacoby JJ, 2003, P NATL ACAD SCI USA, V100, P12929, DOI 10.1073/pnas.2134694100; Kagami S, 2001, BLOOD, V97, P2358, DOI 10.1182/blood.V97.8.2358; Kano A, 2003, J EXP MED, V198, P1517, DOI 10.1084/jem.20030077; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kato T, 2004, J BIOL CHEM, V279, P31076, DOI 10.1074/jbc.M400637200; Kitamura Y, 1997, NEUROSCI LETT, V237, P17, DOI 10.1016/S0304-3940(97)00797-0; Klampfer L, 2006, CURR CANCER DRUG TAR, V6, P107, DOI 10.2174/156800906776056491; Klein W, 2005, DIGEST LIVER DIS, V37, P159, DOI 10.1016/j.dld.2004.10.011; Kofoed EM, 2003, NEW ENGL J MED, V349, P1139, DOI 10.1056/NEJMoa022926; Koster M, 1999, EUR J BIOCHEM, V260, P137, DOI 10.1046/j.1432-1327.1999.00149.x; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Land KJ, 2004, ENDOCRINOLOGY, V145, P3724, DOI 10.1210/en.2004-0352; Lanvin O, 2004, ONCOGENE, V23, P3040, DOI 10.1038/sj.onc.1207450; Li HZ, 2004, CANCER RES, V64, P4774, DOI 10.1158/0008-5472.CAN-03-3499; Lin W, 2005, J ALLERGY CLIN IMMUN, V116, P1106, DOI 10.1016/j.jaci.2005.08.046; Litonjua AA, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-52; Liu AMF, 2006, J BIOL CHEM, V281, P35812, DOI 10.1074/jbc.M605288200; Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396; Liu L, 2005, P NATL ACAD SCI USA, V102, P8150, DOI 10.1073/pnas.0501643102; Liu Q, 2004, INFECT IMMUN, V72, P3706, DOI 10.1128/IAI.72.7.3706-3715.2004; Lodige I, 2005, J BIOL CHEM, V280, P43087, DOI 10.1074/jbc.M509180200; Lokuta MA, 1998, J IMMUNOL, V161, P1594; Lovato P, 2003, J BIOL CHEM, V278, P16777, DOI 10.1074/jbc.M207999200; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Ma J, 2006, CELL SIGNAL, V18, P1117, DOI 10.1016/j.cellsig.2005.06.016; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Mao X, 2005, MOL CELL, V17, P761, DOI 10.1016/j.molcel.2005.02.021; Marg A, 2004, J CELL BIOL, V165, P823, DOI 10.1083/jcb.200403057; Maritano D, 2004, NAT IMMUNOL, V5, P401, DOI 10.1038/ni1052; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Martin P, 2005, P NATL ACAD SCI USA, V102, P9866, DOI 10.1073/pnas.0501202102; Mathew A, 2001, J EXP MED, V193, P1087, DOI 10.1084/jem.193.9.1087; Matsubara S, 2007, AM J RESP CELL MOL, V36, P324, DOI 10.1165/rcmb.2006-0231OC; Mazzarella G, 2003, AM J PATHOL, V162, P1845, DOI 10.1016/S0002-9440(10)64319-2; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; McBride KM, 2002, EMBO J, V21, P1754, DOI 10.1093/emboj/21.7.1754; McMillan S, 2002, J EXP MED, V195, P51, DOI 10.1084/jem.20011732; McNamara PS, 2005, DRUG NEWS PERSPECT, V18, P615, DOI 10.1358/dnp.2005.18.10.959575; McWhinney CD, 1998, J MOL CELL CARDIOL, V30, P751, DOI 10.1006/jmcc.1998.0639; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Miyazaki Y, 2006, AM J PATHOL, V169, P697, DOI 10.2353/ajpath.2006.051211; Miyoshi K, 2001, GENOMICS, V71, P150, DOI 10.1006/geno.2000.6433; Mowen K, 2000, MOL CELL BIOL, V20, P7273, DOI 10.1128/MCB.20.19.7273-7281.2000; Mudter J, 2005, AM J GASTROENTEROL, V100, P64, DOI 10.1111/j.1572-0241.2005.40615.x; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Mullings RE, 2001, J ALLERGY CLIN IMMUN, V108, P832, DOI 10.1067/mai.2001.119554; Musso A, 2005, INFLAMM BOWEL DIS, V11, P91, DOI 10.1097/00054725-200502000-00001; Muthian G, 2006, J CLIN IMMUNOL, V26, P73, DOI 10.1007/s10875-006-8787-y; Nagarkatti R, 2004, AM J RESP CELL MOL, V31, P317, DOI 10.1165/rcmb.2003-0128OC; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; Neculai D, 2005, J BIOL CHEM, V280, P40782, DOI 10.1074/jbc.M507682200; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Ng DCH, 2003, CARDIOVASC RES, V57, P333, DOI 10.1016/S0008-6363(02)00664-8; Notorangelo LD, 2001, HUM MUTAT, V18, P255; O'Shea JJ, 2004, NAT REV DRUG DISCOV, V3, P555, DOI 10.1038/nrd1441; Park BL, 2005, J HUM GENET, V50, P133, DOI 10.1007/s10038-005-0232-1; Park C, 2000, IMMUNITY, V13, P795, DOI 10.1016/S1074-7613(00)00077-7; Pranada AL, 2004, J BIOL CHEM, V279, P15114, DOI 10.1074/jbc.M312530200; Pykalainen M, 2005, J ALLERGY CLIN IMMUN, V115, P80, DOI 10.1016/j.jaci.2004.10.006; Quarcoo D, 2004, J ALLERGY CLIN IMMUN, V114, P288, DOI 10.1016/j.jaci.2004.03.055; Raman K, 2003, J IMMUNOL, V170, P3859, DOI 10.4049/jimmunol.170.7.3859; Ray S, 2005, GASTROENTEROLOGY, V129, P1616, DOI 10.1053/j.gastro.2005.07.055; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Reich NC, 2006, NAT REV IMMUNOL, V6, P602, DOI 10.1038/nri1885; Roberts JL, 2004, BLOOD, V103, P2009, DOI 10.1182/blood-2003-06-2104; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; Sato N, 2005, BIOCHEM BIOPH RES CO, V336, P617, DOI 10.1016/j.bbrc.2005.08.145; Satterthwaite G, 2005, AM HEART J, V150, P488, DOI 10.1016/j.ahj.2004.10.025; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Schindler CW, 2002, J CLIN INVEST, V109, P1133, DOI 10.1172/JCI200215644; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; Seto Y, 2003, J IMMUNOL, V170, P1077, DOI 10.4049/jimmunol.170.2.1077; Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982; Shelburne CP, 2003, BLOOD, V102, P1290, DOI 10.1182/blood-2002-11-3490; Shelburne CP, 2002, CYTOKINE, V19, P218, DOI 10.1006/cyto.2002.1957; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Showe LC, 1999, J IMMUNOL, V163, P4073; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Shum BOV, 2006, J CLIN INVEST, V116, P2183, DOI 10.1172/JCI24767; Skinnider BF, 2002, BLOOD, V99, P618, DOI 10.1182/blood.V99.2.618; Snow JW, 2003, J IMMUNOL, V171, P5042, DOI 10.4049/jimmunol.171.10.5042; Snyder M, 2005, P NATL ACAD SCI USA, V102, P14539, DOI 10.1073/pnas.0507479102; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stancato LF, 1996, J BIOL CHEM, V271, P4134; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Suzuki K, 2002, J EXP MED, V196, P27, DOI 10.1084/jem.20011682; Swameye I, 2003, P NATL ACAD SCI USA, V100, P1028, DOI 10.1073/pnas.0237333100; Takatori H, 2005, J IMMUNOL, V174, P3734, DOI 10.4049/jimmunol.174.6.3734; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tamai M, 2006, J LAB CLIN MED, V147, P182, DOI 10.1016/j.lab.2005.12.001; Tamura K, 2003, INT ARCH ALLERGY IMM, V131, P33, DOI 10.1159/000070432; Tanaka T, 2005, IMMUNITY, V22, P729, DOI 10.1016/j.immuni.2005.04.008; Tang XR, 2005, P NATL ACAD SCI USA, V102, P5132, DOI 10.1073/pnas.0501159102; Temann UA, 2002, J CLIN INVEST, V109, P29, DOI 10.1172/JCI13696; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Tomkinson A, 1999, AM J RESP CRIT CARE, V160, P1283, DOI 10.1164/ajrccm.160.4.9809065; Townsend MJ, 2000, IMMUNITY, V13, P573, DOI 10.1016/S1074-7613(00)00056-X; Toyoda H, 2004, J IMMUNOL, V172, P3905, DOI 10.4049/jimmunol.172.6.3905; Trifilieff A, 2000, BRIT J PHARMACOL, V130, P1581, DOI 10.1038/sj.bjp.0703501; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Ushijima R, 2005, BIOCHEM BIOPH RES CO, V330, P880, DOI 10.1016/j.bbrc.2005.03.063; van Boxel-Dezaire AHH, 2006, IMMUNITY, V25, P361, DOI 10.1016/j.immuni.2006.08.014; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Walker JG, 2006, ANN RHEUM DIS, V65, P149, DOI 10.1136/ard.2005.037929; Wan YSY, 2006, IMMUNOL REV, V212, P114, DOI 10.1111/j.0105-2896.2006.00407.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Wang R, 2005, J BIOL CHEM, V280, P11528, DOI 10.1074/jbc.M413930200; Weidinger S, 2004, J MED GENET, V41, P658, DOI 10.1136/jmg.2004.020263; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Wong M, 1998, J BIOL CHEM, V273, P309, DOI 10.1074/jbc.273.1.309; Xia B, 2003, CLIN EXP IMMUNOL, V131, P446, DOI 10.1046/j.1365-2249.2003.02079.x; Xia Z, 2001, LEUKEMIA RES, V25, P473, DOI 10.1016/S0145-2126(00)00158-2; Yang M, 2006, J IMMUNOL, V177, P5595, DOI 10.4049/jimmunol.177.8.5595; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhong MH, 2005, P NATL ACAD SCI USA, V102, P3966, DOI 10.1073/pnas.0501063102; Zhou YH, 2001, ONCOLOGY-BASEL, V60, P330, DOI 10.1159/000058529; Zhu JB, 2006, J GASTROEN HEPATOL, V21, P1854, DOI 10.1111/j.1440-1746.2006.04427.x; Zimmermann N, 2004, J IMMUNOL, V172, P1815, DOI 10.4049/jimmunol.172.3.1815; Zorn E, 2006, BLOOD, V108, P1571, DOI 10.1182/blood-2006-02-004747	202	19	24	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					529	541		10.1016/j.jaci.2007.01.004	http://dx.doi.org/10.1016/j.jaci.2007.01.004			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17336608				2022-12-18	WOS:000244925000001
J	Acevedo, N; Vergara, C; Mercado, D; Jimenez, S; Caraballo, L				Acevedo, Nathalie; Vergara, Candelaria; Mercado, Dilia; Jimenez, Silvia; Caraballo, Luis			The A-444C polymorphism of leukotriene C-4 synthase gene is associated with IgE antibodies to Dermatophagoides pteronyssinus in a Colombian population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASPIRIN-INTOLERANT ASTHMA; MODERATE		Univ Cartagena, Immunol Res Inst, Cartagena, Colombia	Universidad de Cartagena	Acevedo, N (corresponding author), Univ Cartagena, Immunol Res Inst, Cartagena, Colombia.	luiscaraballo@costa.net.co	Caraballo, Luis/G-1585-2010	Caraballo, Luis/0000-0002-5204-1109; Acevedo, Nathalie/0000-0002-5154-2964				Asano K, 2002, PHARMACOGENETICS, V12, P565, DOI 10.1097/00008571-200210000-00009; CARABALLO LR, 1992, TISSUE ANTIGENS, V39, P128, DOI 10.1111/j.1399-0039.1992.tb01922.x; Choi JH, 2004, HUM GENET, V114, P337, DOI 10.1007/s00439-004-1082-1; Kedda MA, 2004, J ALLERGY CLIN IMMUN, V113, P889, DOI 10.1016/j.jaci.2004.02.008; Kim DC, 2006, J IMMUNOL, V176, P4440, DOI 10.4049/jimmunol.176.7.4440; Lamoureux J, 2006, J ALLERGY CLIN IMMUN, V117, P924, DOI 10.1016/j.jaci.2005.12.1329; Sanak M, 2000, AM J RESP CELL MOL, V23, P290, DOI 10.1165/ajrcmb.23.3.4051; Sayers I, 2003, THORAX, V58, P417, DOI 10.1136/thorax.58.5.417; Van Sambeek R, 2000, J ALLERGY CLIN IMMUN, V106, P72, DOI 10.1067/mai.2000.107603	9	19	19	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					505	507		10.1016/j.jaci.2006.10.002	http://dx.doi.org/10.1016/j.jaci.2006.10.002			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17291864				2022-12-18	WOS:000244327900035
J	Strunk, RC				Strunk, Robert C.		Childhood Asthma Management Progra	Childhood Asthma Management Program: Lessons learned	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; childhood; clinical trial	LUNG-FUNCTION; INHALED CORTICOSTEROIDS; CHILDREN; POLYMORPHISMS; BUDESONIDE; DESIGN; GENE	The National Heart, Lung, and Blood Institute Childhood Asthma Management Program was initiated in 1991 and is now the largest and most comprehensive study of long-term intervention with anti-inflammatory therapy in children with mild to moderate asthma. The purpose of this perspective is to review key findings of the study and lessons learned in conducting research in more than 1000 children with persistent asthma for more than 10 years. A key lesson was absence of a continued effect of inhaled corticosteroid on lung growth during long-term follow-up even as symptoms and airway responsiveness remained improved.	Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63178 USA	Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Strunk, RC (corresponding author), Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, 1 Childrens Pl, St Louis, MO 63110 USA.	strunk@kids.wustl.edu			DIVISION OF LUNG DISEASES [N01HR016047, N01HR016050, N01HR016045, N01HR016051, N01HR016049, N01HR016048, N01HR016046, N01HR016044] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719, M01RR000051] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00051, M01RR0099718-24, M01RR02719-14, RR00036] Funding Source: Medline; NHLBI NIH HHS [N01-HR-16044, N01-HR-16049, N01-HR-16051, N01-HR-16045, N01-HR-16046, N01-HR-16047, N01-HR-16048, N01-HR-16050] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bacharier LB, 2004, PEDIATRICS, V113, P1693, DOI 10.1542/peds.113.6.1693; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Covar RA, 2006, J ALLERGY CLIN IMMUN, V117, P709, DOI 10.1016/j.jaci.2006.01.010; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Lyon H, 2004, GENET EPIDEMIOL, V26, P155, DOI 10.1002/gepi.10298; Raby BA, 2006, AM J RESP CRIT CARE, V173, P64, DOI 10.1164/rccm.200503-505OC; Randolph AG, 2004, AM J HUM GENET, V75, P709, DOI 10.1086/424886; Strunk RC, 2006, J ALLERGY CLIN IMMUN, V118, P1040, DOI 10.1016/j.jaci.2006.07.053; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Szefler SJ, 1998, ANN ALLERG ASTHMA IM, V81, P571; Tantisira KG, 2006, J ALLERGY CLIN IMMUN, V117, P1264, DOI 10.1016/j.jaci.2006.01.050; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; Tantisira KG, 2004, P NATL ACAD SCI USA, V101, P18099, DOI 10.1073/pnas.0408532102	13	19	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					36	42		10.1016/j.jaci.2006.09.038	http://dx.doi.org/10.1016/j.jaci.2006.09.038			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17125822				2022-12-18	WOS:000243622200007
J	Tenda, Y; Yamashita, M; Kimura, MY; Hasegawa, A; Shimizu, C; Kitajima, M; Onodera, A; Suzuki, A; Seki, N; Nakayama, T				Tenda, Yoshiyuki; Yamashita, Masakatsu; Kimura, Motoko Y.; Hasegawa, Akihiro; Shimizu, Chiori; Kitajima, Masayuki; Onodera, Atsushi; Suzuki, Akane; Seki, Nobuo; Nakayama, Toshinori			Hyperresponsive T(H)2 cells with enhanced nuclear factor-kappa B activation induce atopic dermatitis-like skin lesions in Nishiki-Nezumi Cinnamon Nagoya mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; NC/Nga mouse; NF-kappa B; AP1; ERK1 MAPK cascade; T(H)2	LYMPHOCYTE-ASSOCIATED ANTIGEN; IGE HYPERPRODUCTION; IFN-GAMMA; T-CELLS; AIRWAY HYPERRESPONSIVENESS; HISTONE HYPERACETYLATION; TRANSCRIPTION FACTOR; ALLERGIC DISEASES; NC/NGA MICE; GENE LOCUS	Background: Nishiki-nezumi Cinnamon/Nagoya (NC/Nga) mice raised in nonair-controlled conventional circumstances spontaneously develop atopic dermatitis-like skin lesions; however, the underlying mechanisms remain unclear. Objective: We wanted to identify the critical intracellular signaling molecules in T cells that induce atopic dermatitis-like skin legions in NC/Nga mice. Methods: We examined the levels of signal transduction and cytokine production in T cells, particularly those in atopic dermatitis-like lesions induced by the topical injection of mite antigens in NC/Nga mice under specific pathogen-free conditions. Results: In NC/Nga mice maintained under specific pathogen-free conditions, the capability of T(H)1/T(H)2 and T cytotoxic 1/T cytotoxic 2 (Tc1/Tc2) cell differentiation increased significantly. T-cell antigen receptor-mediated activation of the extracellular signal-regulated kinase/mitogen-activated protein kinase cascade and nuclear factor-kappa B (NF-kappa B) signaling were enhanced in NC/Nga T cells. The expression of T(H)2 cytokines (IL-4, IL-13, and IL-5) and that of GATA-binding protein 3 (GATA3), avian musculoaponeurotic fibrosarcoma (c-Maf), NF-kappa B, and activator protein 1 (AP1) selectively increased in draining lymph node T cells of NC/Nga mice. Moreover, the cell transfer of inhibitory NF-kappa B mutant-infected T(H)2 cells reduced ear thickness in the mite antigen-induced skin lesion of NC/Nga mice. Conclusion: Hyperresponsive T(H)2 cells with an enhanced activity of NF-kappa B and AP1 play a crucial role in the pathogenesis of atopic dermatitis-like skin lesions in NC/Nga mice. Clinical implications: These results indicate potential therapeutic usefulness of developing selective inhibitors for NF-kappa B in the treatment of human atopic dermatitis.	Chiba Univ, Dept Immunol, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan; Astellas Pharma Inc, Dept Transplantat, Med Biol Res Labs, Osaka, Japan	Chiba University; Astellas Pharmaceuticals	Nakayama, T (corresponding author), Chiba Univ, Dept Immunol, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	tnakayama@faculty.chiba-u.jp	Onodera, Atsushi/E-3136-2017; Nakayama, Toshinori/E-1067-2017	Nakayama, Toshinori/0000-0002-1434-2007				Akdis CA, 2000, CURR OPIN IMMUNOL, V12, P641, DOI 10.1016/S0952-7915(00)00156-4; Akdis M, 1999, J IMMUNOL, V163, P466; Akdis M, 2000, EUR J IMMUNOL, V30, P3533, DOI 10.1002/1521-4141(2000012)30:12<3533::AID-IMMU3533>3.0.CO;2-5; Aronica MA, 1999, J IMMUNOL, V163, P5116; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Barton D, 2000, EUR J IMMUNOL, V30, P2323, DOI 10.1002/1521-4141(2000)30:8<2323::AID-IMMU2323>3.0.CO;2-H; Boonstra A, 2001, J IMMUNOL, V167, P4974, DOI 10.4049/jimmunol.167.9.4974; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Corn RA, 2003, J IMMUNOL, V171, P1816, DOI 10.4049/jimmunol.171.4.1816; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Donovan CE, 1999, J IMMUNOL, V163, P6827; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Habu Y, 2001, J IMMUNOL, V166, P5439, DOI 10.4049/jimmunol.166.9.5439; Hasegawa A, 2006, J IMMUNOL, V176, P2546, DOI 10.4049/jimmunol.176.4.2546; Inami M, 2004, J BIOL CHEM, V279, P23123, DOI 10.1074/jbc.M401248200; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kay AB, 2001, NEW ENGL J MED, V344, P109, DOI 10.1056/NEJM200101113440206; Kimura MY, 2005, J EXP MED, V201, P397, DOI 10.1084/jem.20040733; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Makarov SS, 2000, MOL MED TODAY, V6, P441, DOI 10.1016/S1357-4310(00)01814-1; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; Matsumoto M, 1999, J IMMUNOL, V162, P1056; Matsumoto M, 2001, J IMMUNOL, V167, P5955, DOI 10.4049/jimmunol.167.10.5955; Nakamura H, 2002, GENE THER, V9, P1221, DOI 10.1038/sj.gt.3301724; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Omori M, 2003, IMMUNITY, V19, P281, DOI 10.1016/S1074-7613(03)00210-3; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Rudikoff D, 1998, LANCET, V351, P1715, DOI 10.1016/S0140-6736(97)12082-7; Sasakawa T, 2004, INT ARCH ALLERGY IMM, V133, P55, DOI 10.1159/000076128; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Sha WC, 1998, J EXP MED, V187, P143, DOI 10.1084/jem.187.2.143; Shibata Y, 2002, J IMMUNOL, V169, P2134, DOI 10.4049/jimmunol.169.4.2134; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tsudzuki M, 1997, IMMUNOGENETICS, V47, P88, DOI 10.1007/s002510050330; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Yagi R, 2002, J IMMUNOL, V168, P2020, DOI 10.4049/jimmunol.168.4.2020; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yamashita M, 1999, P NATL ACAD SCI USA, V96, P1024, DOI 10.1073/pnas.96.3.1024; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739	47	19	19	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					725	733		10.1016/j.jaci.2006.05.024	http://dx.doi.org/10.1016/j.jaci.2006.05.024			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950294				2022-12-18	WOS:000240649000030
J	de Jong, AB; Brouwer, AFJ; Roorda, RJ; Brand, PLP				de Jong, Adriana Baatenburg; Brouwer, Alwin F. J.; Roorda, Ruurd Jan; Brand, Paul L. P.			Normal lung function in children with mild to moderate persistent asthma well controlled by inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDHOOD ASTHMA; FLUTICASONE; MONTELUKAST; SEVERITY		Isala Klinieken, Princess Amalia Childrens Clin, Zwolle, Netherlands	Isala Clinics	de Jong, AB (corresponding author), Isala Klinieken, Princess Amalia Childrens Clin, Zwolle, Netherlands.		Brand, Paul/ABB-3693-2021					Adams N P, 2005, COCHRANE DB SYST REV, V1; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Garcia MLG, 2005, PEDIATRICS, V116, P360, DOI 10.1542/peds.2004-1172; Kamps AWA, 2003, THORAX, V58, P968, DOI 10.1136/thorax.58.11.968; Limb SL, 2005, J ALLERGY CLIN IMMUN, V116, P1213, DOI 10.1016/j.jaci.2005.09.024; *NAEPP EXP PAN, 2002, NIH PUBL; Paull K, 2005, PEDIATR PULM, V39, P311, DOI 10.1002/ppul.20161; Spahn JD, 2004, AM J RESP CRIT CARE, V169, P784, DOI 10.1164/rccm.200309-1234OE; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; ZAPLETAL A, 1987, PROGR RESP RES, P114	10	19	19	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					280	282		10.1016/j.jaci.2006.03.013	http://dx.doi.org/10.1016/j.jaci.2006.03.013			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815168				2022-12-18	WOS:000239184800036
J	Hendeles, L; Hatton, RC				Hendeles, Leslie; Hatton, Randy C.			Oral phenylephrine: An ineffective replacement for pseudoephedrine?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PHARMACOKINETICS		Univ Florida, Coll Pharm, Dept Pharm Practice, Gainesville, FL 32611 USA; Univ Florida, Shands Hosp, Drug Informat Ctr, Gainesville, FL USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Hendeles, L (corresponding author), Univ Florida, Coll Pharm, Dept Pharm Practice, Gainesville, FL 32611 USA.							BICKERMAN HA, 1971, PHYSL PHARM STUDIES; BLACK MJ, 1980, CAN MED ASSOC J, V122, P881; COHEN BM, 1972, EUR J CLIN PHARMACOL, V5, P81, DOI 10.1007/BF00561750; DRESSLER WE, 1977, ANN OTO RHINOL LARYN, V86, P310, DOI 10.1177/000348947708600306; *FDA, 1976, FED REGISTER, V41, P38399; HENDELES L, 1993, PHARMACOTHERAPY, V13, pS129; HENGSTMANN JH, 1982, EUR J CLIN PHARMACOL, V21, P335, DOI 10.1007/BF00637623; KANFER I, 1993, PHARMACOTHERAPY, V13, pS116; Kernan WN, 2000, NEW ENGL J MED, V343, P1826, DOI 10.1056/NEJM200012213432501; McLAURIN J. W., 1961, LARYNGOSCOPE, V71, P54, DOI 10.1288/00005537-196101000-00007; Pullerits T, 2002, J ALLERGY CLIN IMMUN, V109, P949, DOI 10.1067/mai.2002.124467	11	19	20	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					279	280		10.1016/j.jaci.2006.03.002	http://dx.doi.org/10.1016/j.jaci.2006.03.002			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815167	Bronze			2022-12-18	WOS:000239184800035
J	Johansson, MW; Barthel, SR; Swenson, CA; Evans, MD; Jajour, NN; Mosher, DF; Busse, WW				Johansson, MW; Barthel, SR; Swenson, CA; Evans, MD; Jajour, NN; Mosher, DF; Busse, WW			Eosinophil beta(1) integrin activation state correlates with asthma activity in a blind study of inhaled corticosteroid withdrawal	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXACERBATION; INTEGRIN		Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Johansson, MW (corresponding author), Univ Wisconsin, Dept Med, Madison, WI 53706 USA.			Johansson, Mats/0000-0001-5699-978X; Evans, Michael/0000-0001-7449-3993	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056396] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR03186] Funding Source: Medline; NHLBI NIH HHS [HL56396, P50 HL056396] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bochner BS, 2005, J ALLERGY CLIN IMMUN, V115, P953, DOI 10.1016/j.jaci.2005.02.032; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; Grayson MH, 1998, J EXP MED, V188, P2187, DOI 10.1084/jem.188.11.2187; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; HANLEY JA, 1983, RADIOLOGY, V160, P93; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406, DOI 10.1164/ajrccm.163.2.9912091; LOUIS TA, 1988, STAT MED, V7, P29, DOI 10.1002/sim.4780070108; Seminario MC, 1997, MEM I OSWALDO CRUZ, V92, P157, DOI 10.1590/S0074-02761997000800021; Wilkins JA, 1996, J BIOL CHEM, V271, P3046, DOI 10.1074/jbc.271.6.3046	9	19	19	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1502	1504		10.1016/j.jaci.2006.02.032	http://dx.doi.org/10.1016/j.jaci.2006.02.032			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751021				2022-12-18	WOS:000238332300048
J	Viola, M; Quaratino, D; Volpetti, S; Gaeta, F; Romano, A				Viola, M; Quaratino, D; Volpetti, S; Gaeta, F; Romano, A			Parecoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASPIRIN-INDUCED ASTHMA; URTICARIA; INHIBITOR; SAFETY		Univ Cattolica Sacro Cuore, Allergy Unit, Dept Internal Med & Geriatr, Rome, Italy; Ist Dermopat Immacolata, Capranica, Italy; Univ Cattolica Sacro Cuore, Inst Anesthesia & Intens Care, Rome, Italy; Ist Ricovero & Cura, Troina, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Viola, M (corresponding author), Univ Cattolica Sacro Cuore, Allergy Unit, Dept Internal Med & Geriatr, Complesso Integrato Columbus, Rome, Italy.		Romano, Antonino/D-3102-2017; Gaeta, Francesco/AAC-7107-2020	Romano, Antonino/0000-0001-9742-9898; Gaeta, Francesco/0000-0003-2942-7633				CZERNIAWSKAMYSIK G, 1981, ALLERGY, V36, P381, DOI 10.1111/j.1398-9995.1981.tb01842.x; Himly M, 2003, J ALLERGY CLIN IMMUN, V111, P882, DOI 10.1067/mai.2003.163; Looney Y, 2005, ANESTHESIOLOGY, V102, P473, DOI 10.1097/00000542-200502000-00031; Mastalerz L, 2004, J ALLERGY CLIN IMMUN, V113, P771, DOI 10.1016/j.jaci.2003.12.323; Sanchez-Borges M, 2005, ANN ALLERG ASTHMA IM, V95, P154, DOI 10.1016/S1081-1206(10)61205-7; Scala E, 2001, J ALLERGY CLIN IMMUN, V107, P557, DOI 10.1067/mai.2001.113241; Stevenson DD, 2001, J ALLERGY CLIN IMMUN, V108, P47, DOI 10.1067/mai.2001.116290; Stevenson DD, 2001, ANN ALLERG ASTHMA IM, V87, P177, DOI 10.1016/S1081-1206(10)62221-1; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Szczeklik A, 2001, CLIN EXP ALLERGY, V31, P219, DOI 10.1046/j.1365-2222.2001.01075.x; Viola M, 2005, INT ARCH ALLERGY IMM, V137, P145, DOI 10.1159/000085794	11	19	20	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1189	1191		10.1016/j.jaci.2006.02.011	http://dx.doi.org/10.1016/j.jaci.2006.02.011			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675352				2022-12-18	WOS:000237436300036
J	van der Zalm, MM; Uiterwaal, CSPM; de Jong, BM; Wilbrink, B; van der Ent, CK				van der Zalm, MM; Uiterwaal, CSPM; de Jong, BM; Wilbrink, B; van der Ent, CK			Viral specimen collection by parents increases response rate in population-based virus studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ILLNESSES		Univ Med Ctr Utrecht, Dept Pediat Resp Dis, NL-3508 AB Utrecht, Netherlands; Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 AB Utrecht, Netherlands; Natl Inst Publ Hlth & Environm, Diagnost Lab Infect Dis & Perinatal Screening, NL-3720 BA Bilthoven, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Netherlands National Institute for Public Health & the Environment	van der Zalm, MM (corresponding author), Univ Med Ctr Utrecht, Dept Pediat Resp Dis, KH 01-419-0,POB 85090, NL-3508 AB Utrecht, Netherlands.			van der Zalm, Marieke M/0000-0002-8787-9139				Benediktsdottir Bryndis, 1993, Scandinavian Journal of Primary Health Care, V11, P197, DOI 10.3109/02813439308994830; Katier N, 2004, EUR J EPIDEMIOL, V19, P895, DOI 10.1023/B:EJEP.0000040530.98310.0c; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024	3	19	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					955	956		10.1016/j.jaci.2006.01.006	http://dx.doi.org/10.1016/j.jaci.2006.01.006			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630966				2022-12-18	WOS:000236862800044
J	Apter, AJ; Szefler, SJ				Apter, AJ; Szefler, SJ			Advances in adult and pediatric asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway remodeling; airway smooth muscle; obesity; adults; children; health disparities; therapeutics	EXHALED NITRIC-OXIDE; QUALITY-OF-LIFE; LUNG-FUNCTION; RESPIRATORY-INFECTIONS; SEPTEMBER EPIDEMIC; COST-EFFECTIVENESS; PRIMARY PREVENTION; ALLERGEN EXPOSURE; LONG-TERM; BODY-MASS	This year we present updates on the management and therapeutics of asthma and research on the relationship of airway remodeling to clinically irreversible disease and continue a discussion about the origins of asthma. Significant advances are occurring in our understanding of the natural history of asthma, including the application of biomarkers and genetics. These tools should assist the clinician in defining patients at risk for significant morbidity related to asthma. Incorporating this knowledge will help prompt the development of more effective management techniques and new medications. Meanwhile, more effective health care strategies must be developed to reduce the reported disparities in asthma care noted in our patient populations.	Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA; Natl Jewish Med & Res Ctr, Div Pediat Clin Pharmacol & Allergy, Denver, CO USA; Natl Jewish Med & Res Ctr, Div Immunol, Dept Pediat, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA	University of Pennsylvania; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Apter, AJ (corresponding author), Hosp Univ Penn, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.	apter@mail.med.upenn.edu						Adler A, 2005, J ALLERGY CLIN IMMUN, V115, P67, DOI 10.1016/j.jaci.2004.10.008; Agertoft L, 2005, J ALLERGY CLIN IMMUN, V115, P940, DOI 10.1016/j.jaci.2005.01.066; [Anonymous], 2005, J ALLERGY CLIN IMMUN, V115, P34, DOI 10.1016/j.jaci.2004.10.023; Appleton SL, 2005, J ALLERGY CLIN IMMUN, V116, P976, DOI 10.1016/j.jaci.2005.08.034; Apter AJ, 2004, J ALLERGY CLIN IMMUN, V113, P407, DOI 10.1016/j.jaci.2003.12.002; APTER AJ, IN PRESS FISHMANS PU; Arshad SH, 2005, J ALLERGY CLIN IMMUN, V116, P3, DOI 10.1016/j.jaci.2005.03.043; Asche CV, 2005, J ALLERGY CLIN IMMUN, V115, P1095, DOI 10.1016/j.jaci.2004.12.1136; Bakhireva LN, 2005, J ALLERGY CLIN IMMUN, V116, P503, DOI 10.1016/j.jaci.2005.05.027; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V116, P983, DOI 10.1016/j.jaci.2005.07.029; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V115, P1102, DOI 10.1016/j.jaci.2005.03.018; Bisgaard H, 2005, J ALLERGY CLIN IMMUN, V115, P708, DOI 10.1016/j.jaci.2004.11.018; Brussee JE, 2005, J ALLERGY CLIN IMMUN, V115, P946, DOI 10.1016/j.jaci.2005.02.035; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Busse PJ, 2005, J ALLERGY CLIN IMMUN, V116, P146, DOI 10.1016/j.jaci.2005.03.031; Cabana MD, 2005, J ALLERGY CLIN IMMUN, V115, P1225, DOI 10.1016/j.jaci.2005.03.004; Calvert J, 2005, J ALLERGY CLIN IMMUN, V116, P773, DOI 10.1016/j.jaci.2005.05.025; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Colice GL, 2005, J ALLERGY CLIN IMMUN, V115, P200, DOI 10.1016/j.jaci.2004.07.065; Covar RA, 2005, J ALLERGY CLIN IMMUN, V115, P700, DOI 10.1016/j.jaci.2005.01.034; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; de Blic J, 2005, J ALLERGY CLIN IMMUN, V116, P750, DOI 10.1016/j.jaci.2005.07.009; de Winter-de Groot KM, 2005, J ALLERGY CLIN IMMUN, V115, P419, DOI 10.1016/j.jaci.2004.11.025; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.1139; Eldeirawi K, 2005, J ALLERGY CLIN IMMUN, V116, P42, DOI 10.1016/j.jaci.2005.03.041; Enriquez R, 2005, J ALLERGY CLIN IMMUN, V115, P737, DOI 10.1016/j.jaci.2004.12.1128; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; *FDA ADV COMM, 2005, SER ADV FOR WITHDR C; *FDA PUBL HLTH ADV, 2005, SER DISK SALM XIN IN; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Friedlander SL, 2005, J ALLERGY CLIN IMMUN, V116, P267, DOI 10.1016/j.jaci.2005.06.003; Gauvreau GM, 2005, J ALLERGY CLIN IMMUN, V116, P285, DOI 10.1016/j.jaci.2005.05.021; Gern JE, 2005, J ALLERGY CLIN IMMUN, V115, P668, DOI 10.1016/j.jaci.2005.01.057; Gold DR, 2005, J ALLERGY CLIN IMMUN, V116, P38, DOI 10.1016/j.jaci.2005.04.033; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P586, DOI 10.1016/j.jaci.2005.04.035; Hartl D, 2005, J ALLERGY CLIN IMMUN, V115, P728, DOI 10.1016/j.jaci.2004.11.049; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; *I MED, 2003, UN TREATM CONFR RAC; Instanes C, 2005, INDOOR AIR, V15, P356, DOI 10.1111/j.1600-0668.2005.00381.x; Johnson CC, 2005, J ALLERGY CLIN IMMUN, V115, P1218, DOI 10.1016/j.jaci.2005.04.020; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; Juhn YJ, 2005, J ALLERGY CLIN IMMUN, V116, P510, DOI 10.1016/j.jaci.2005.05.043; Kattan M, 2005, J ALLERGY CLIN IMMUN, V116, P1058, DOI 10.1016/j.jaci.2005.07.032; Kim C, 2005, J ALLERGY CLIN IMMUN, V115, P810, DOI 10.1016/j.jaci.2004.11.032; Larsen GL, 2005, J ALLERGY CLIN IMMUN, V115, P657, DOI 10.1016/j.jaci.2004.12.1112; Lazaar AL, 2005, J ALLERGY CLIN IMMUN, V116, P488, DOI 10.1016/j.jaci.2005.06.030; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lemiere C, 2005, J ALLERGY CLIN IMMUN, V116, P501, DOI 10.1016/j.jaci.2005.06.009; Li JT, 2005, J ALLERGY CLIN IMMUN, V116, pS3, DOI 10.1016/j.jaci.2005.08.017; Limb SL, 2005, J ALLERGY CLIN IMMUN, V116, P1213, DOI 10.1016/j.jaci.2005.09.024; Limb SL, 2005, J ALLERGY CLIN IMMUN, V115, P61, DOI 10.1016/j.jaci.2004.09.032; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; Lucas SR, 2005, J ALLERGY CLIN IMMUN, V115, P928, DOI 10.1016/j.jaci.2005.01.033; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; McSharry CP, 2005, J ALLERGY CLIN IMMUN, V116, P88, DOI 10.1016/j.jaci.2005.03.025; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Nafstad P, 2005, PEDIATRICS, V116, pE255, DOI 10.1542/peds.2004-2785; Oba Y, 2005, J ALLERGY CLIN IMMUN, V115, P1095, DOI 10.1016/j.jaci.2004.12.1137; Onder RF, 2005, J ALLERGY CLIN IMMUN, V115, P1228, DOI 10.1016/j.jaci.2005.01.059; Pascual RM, 2005, J ALLERGY CLIN IMMUN, V116, P477, DOI 10.1016/j.jaci.2005.07.011; Pearlman DS, 2005, J ALLERGY CLIN IMMUN, V116, P1206, DOI 10.1016/j.jaci.2005.08.037; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Rasmussen LM, 2005, J ALLERGY CLIN IMMUN, V115, P1137, DOI 10.1016/j.jaci.2005.03.030; Santamaria F, 2005, J ALLERGY CLIN IMMUN, V116, P1163, DOI 10.1016/j.jaci.2005.07.018; Schatz M, 2005, J ALLERGY CLIN IMMUN, V115, P1049, DOI 10.1016/j.jaci.2005.02.008; Simpson A, 2005, J ALLERGY CLIN IMMUN, V116, P744, DOI 10.1016/j.jaci.2005.06.032; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Stempel DA, 2005, J ALLERGY CLIN IMMUN, V115, P466, DOI 10.1016/j.jaci.2004.12.1113; Stempel DA, 2005, J ALLERGY CLIN IMMUN, V115, P230, DOI 10.1016/j.jaci.2004.10.035; Suissa S, 2005, J ALLERGY CLIN IMMUN, V115, P714, DOI 10.1016/j.jaci.2004.12.1118; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P470, DOI 10.1016/j.jaci.2004.12.1123; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; SZELLER SJ, 2005, J ALLERGY CLIN IMMUN, V115, P685; Weiss ST, 2005, NAT IMMUNOL, V6, P537, DOI 10.1038/ni0605-537; Wen MC, 2005, J ALLERGY CLIN IMMUN, V116, P517, DOI 10.1016/j.jaci.2005.05.029; Whelan GJ, 2005, J ALLERGY CLIN IMMUN, V116, P525, DOI 10.1016/j.jaci.2005.05.044; Williams JV, 2005, J ALLERGY CLIN IMMUN, V115, P1311, DOI 10.1016/j.jaci.2005.02.001; Wisnivesky JP, 2005, J ALLERGY CLIN IMMUN, V116, P636, DOI 10.1016/j.jaci.2005.05.031; Xepapadaki P, 2005, J ALLERGY CLIN IMMUN, V116, P299, DOI 10.1016/j.jaci.2005.04.007	81	19	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					512	518		10.1016/j.jaci.2005.12.1353	http://dx.doi.org/10.1016/j.jaci.2005.12.1353			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522448				2022-12-18	WOS:000236263100004
J	Lee, SJ; Kavanaugh, A				Lee, SJ; Kavanaugh, A			Autoimmunity, vasculitis, and autoantibodies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rheumatoid arthritis; systemic lupus erythematosus; vasculitis; autoantibodies	RHEUMATOID-ARTHRITIS; ANTIBODIES; PROGRESSION	Autoimmune diseases are distinct clinical syndromes characterized by various alterations in normal immune responsiveness, such that there is a loss of tolerance to particular host constituents. In most cases, despite years of intense investigation, the etiopathogenic antigens initiating these systemic inflammatory conditions remain undefined. However, a great deal has been learned about the changes in components of the immune response relevant to the propagation and sustenance of these often chronic disorders. In addition, various hormonal, environmental, physiologic, and other influences that affect their expression have been identified. The expression and ultimate clinical outcome of autoimmune diseases usually relate to inflammation-related damage to the target organ with subsequent dysfunction. Certain immune conditions, such as autoimmune thyroid disease, largely, affect a single organ, whereas others, such as systemic lupus erythematosus, heterogeneously affect sundry organ systems. Autoantibodies directed against normal host antigens are a common feature of many autoimmune diseases. In some cases they are pathogenic, whereas in others they serve as markers for organ involvement or outcomes. Clinical descriptions of autoimmune diseases date back many decades in some cases. Recent efforts at formulating classification criteria have allowed clearer distinctions and more accurate stratification. Greater understanding of the immunopathogenesis of autoimmune conditions has led to the development and introduction into the clinic of novel immunomodulatory therapies and treatment paradigms that have substantially improved the outcomes for patients affected by these serious conditions.	Univ Calif San Diego, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Innovat Therapy, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Kavanaugh, A (corresponding author), Univ Calif San Diego, Div Rheumatol Allergy & Immunol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	akavanaugh@ucsd.edu						Ballinger S, 2003, CURR OPIN RHEUMATOL, V15, P591, DOI 10.1097/00002281-200309000-00012; Burns JC, 2004, LANCET, V364, P533, DOI 10.1016/S0140-6736(04)16814-1; Davis MDP, 2004, IMMUNOL ALLERGY CLIN, V24, P183, DOI 10.1016/j.iac.2004.01.007; De Rycke L, 2004, ANN RHEUM DIS, V63, P1587, DOI 10.1136/ard.2003.017574; Forslind K, 2004, ANN RHEUM DIS, V63, P1090, DOI 10.1136/ard.2003.014233; Galie N, 2004, J AM COLL CARDIOL, V43, p81S, DOI 10.1016/j.jacc.2004.02.038; Lopez-Hoyos M, 2004, RHEUMATOLOGY, V43, P655, DOI 10.1093/rheumatology/keh143; Ng B, 2004, J ALLERGY CLIN IMMUN, V114, P1463, DOI 10.1016/j.jaci.2004.09.006; Ramos-Casals M, 2005, ANN RHEUM DIS, V64, P347, DOI 10.1136/ard.2004.025676; Sheldon J, 2004, BEST PRACT RES CL RH, V18, P249, DOI 10.1016/j.berh.2004.03.007; Stone JH, 2005, NEW ENGL J MED, V352, P351; van Gaalen FA, 2004, ARTHRITIS RHEUM, V50, P709, DOI 10.1002/art.20044; Wener MH, 2004, ARTHRITIS RHEUM-US, V50, P2305, DOI 10.1002/art.20355; WEYLAND CM, 2003, NEW ENGL J MED, V349, P160	14	19	19	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2		1			S445	S450		10.1016/j.jaci.2005.06.023	http://dx.doi.org/10.1016/j.jaci.2005.06.023			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	019VS	16455344				2022-12-18	WOS:000235865400005
J	Blumenthal, MN; Langefeld, CD; Barnes, KC; Ober, C; Meyers, DA; King, RA; Beaty, TH; Beck, SR; Bleecker, ER; Rich, SS				Blumenthal, MN; Langefeld, CD; Barnes, KC; Ober, C; Meyers, DA; King, RA; Beaty, TH; Beck, SR; Bleecker, ER; Rich, SS		Collaborative Study Genetics Asthm	A genome-wide search for quantitative trait loci contributing to variation in seasonal pollen reactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						genome scan; seasonal pollen sensitivity; asthma; atopy; linkage	ASTHMA-SUSCEPTIBILITY LOCI; FOUNDER POPULATION; LINKAGE ANALYSIS; GENETICS; FAMILIES; SCREEN; IDENTIFICATION; HYPERRESPONSIVENESS; SENSITIZATION; ASSOCIATION	Background: Asthma and atopy represent complex traits for which genetic predisposition has been demonstrated. Pollen sensitivity, whether seasonal or chronic, appears to be a major contributor to the asthmatic phenotype. Objective: Regions of the genome contributing to skin test reactivity to 5 seasonal allergens are to be identified in a genome-wide scan. These regions may be distinct from those contributing to risk for asthma and/or atopy. Methods: In the Collaborative Study on the Genetics of Asthma, 4 sites collected 287 families with 2 or more members with asthma. Reactivity to individual pollens were determined on all family members. A genome scan was performed at 9-centiMorgan intervals, and skin test reactivity to 5 seasonal allergens was the focus of nonparametric genetic linkage analysis. Results: Chromosomal regions that exhibited suggestive linkage (logarithm of the odds > 1.18; P < .01) to seasonal pollen reactivity were identified on chromosomes 13q34, 20p12, and 21q21. Evidence of ethnic differences in linkage to seasonal allergens was demonstrated, with support for linkage in African American subjects on chromosomes 8, 10, and 12, in European American subjects on chromosomes 14, 19, 20, and 22, and in Hispanics on chromosome 21. In all families, evidence for linkage of skin test reactivity for Betula, Lolium, and Artemisia was strongest in a region on chromosome 21 that contained the candidate gene, A Disintegrin And Metalloprotease domain 33 (ADAM33). Conclusion: These results suggest both substantial genetic overlap and extensive heterogeneity in the genetic basis for the allergic response to seasonal allergens.	Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, MRI Ctr 310, Winston Salem, NC 27157 USA; Wake Forest Univ, Ctr Human Genom, Winston Salem, NC 27157 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	Wake Forest University; Wake Forest University; University of Minnesota System; University of Minnesota Twin Cities; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Chicago	Rich, SS (corresponding author), Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, MRI Ctr 310, Med Ctr Blvd, Winston Salem, NC 27157 USA.	srich@wfubmc.edu	Beck-Roth, Stephanie/B-8167-2009	Rich, Stephen/0000-0003-3872-7793; Ober, Carole/0000-0003-4626-9809	NCRR NIH HHS [M01 RR00055, M01 RR00600, M01 RR00400] Funding Source: Medline; NHLBI NIH HHS [U01 HL49602, U01 HL58977, U01 HL59609, U01 HL49596, U01 HL49612, U01 HL49609] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000400, M01RR000055] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL049602, U01HL049612, U01HL049609, U01HL049596, R01HL059609, U01HL058977] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLUMENTHAL M, 1992, J IMMUNOL, V148, P411; Blumenthal MN, 2004, GENES IMMUN, V5, P226, DOI 10.1038/sj.gene.6364063; Blumenthal MN, 2004, HUM GENET, V114, P157, DOI 10.1007/s00439-003-1030-5; Blumenthal MN, 1996, CLIN EXP ALLERGY, V26, P892, DOI 10.1046/j.1365-2222.1996.d01-399.x; Cheng L, 2004, CLIN EXP ALLERGY, V34, P1192, DOI 10.1111/j.1365-2222.2004.02008.x; Cooke RA, 1916, J IMMUNOL, V1, P201; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; Holgate ST, 2004, CLIN REV ALLERG IMMU, V27, P23, DOI 10.1385/CRIAI:27:1:023; Holloway John W., 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404007963; Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Kurz T, 2000, J ALLERGY CLIN IMMUN, V106, P925, DOI 10.1067/mai.2000.110557; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; Marsh DG, 1997, NAT GENET, V15, P389; Mathias RA, 2001, GENET EPIDEMIOL, V20, P340, DOI 10.1002/gepi.5; McPeek MS, 2000, AM J HUM GENET, V66, P1076, DOI 10.1086/302800; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Oguma T, 2004, NEW ENGL J MED, V351, P1752, DOI 10.1056/NEJMoa031785; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; VANEERDEWEGH P, 2002, NATURE, V878, P1; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Xu X, 2001, AM J HUM GENET, V69, P1271, DOI 10.1086/324650; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201; Yoshinaka T, 2002, GENE, V282, P227, DOI 10.1016/S0378-1119(01)00818-6; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166	31	19	19	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					79	85		10.1016/j.jaci.2005.09.038	http://dx.doi.org/10.1016/j.jaci.2005.09.038			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387588				2022-12-18	WOS:000235687100013
J	Williams, HC; Johansson, SGO				Williams, HC; Johansson, SGO			Two types of eczema - or are there?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							ATOPIC-DERMATITIS		Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham NG7 2RD, England; Karolinska Inst, Dept Med, Allergy & Clin Immunol Unit, Stockholm, Sweden	University of Nottingham; Karolinska Institutet	Williams, HC (corresponding author), Univ Nottingham Hosp, Queens Med Ctr, Ctr Evidence Based Dermatol, Nottingham NG7 2UH, England.	hywel.williams@nottingham.ac.uk		williams, hywel/0000-0002-5646-3093				Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; IMAYAMA S, 1992, J AM ACAD DERMATOL, V27, P531, DOI 10.1016/0190-9622(92)70218-5; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kusel MMH, 2005, J ALLERGY CLIN IMMUN, V116, P1067, DOI 10.1016/j.jaci.2005.06.038; Sterne JAC, 2001, BMJ-BRIT MED J, V322, P226, DOI 10.1136/bmj.322.7280.226; von Elm E, 2004, BMJ-BRIT MED J, V329, P868, DOI 10.1136/bmj.329.7471.868; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x	8	19	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1064	1066		10.1016/j.jaci.2005.08.026	http://dx.doi.org/10.1016/j.jaci.2005.08.026			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275377				2022-12-18	WOS:000235686700018
J	Allmers, H				Allmers, H			Frequent acetaminophen use and allergic diseases: Is the association clear?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							GLUTATHIONE LEVELS; PARACETAMOL USE; ASTHMA; CHILDHOOD; ADULTS; LUNG; RISK		Univ Osnabruck, Dept Dermatol Environm Med & Hlth Sci, D-49090 Osnabruck, Germany	University Osnabruck	Allmers, H (corresponding author), Univ Osnabruck, Dept Dermatol Environm Med & Hlth Sci, Sedanstr 115, D-49090 Osnabruck, Germany.	hallmers@uos.de						Barr RG, 2004, AM J RESP CRIT CARE, V169, P836, DOI 10.1164/rccm.200304-596OC; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152, DOI 10.1152/jappl.1987.63.1.152; CHEN TS, 1990, DRUG METAB DISPOS, V18, P882; Davey G, 2005, J ALLERGY CLIN IMMUN, V116, P863, DOI 10.1016/j.jaci.2005.05.045; de Paramo BJ, 2000, ANN ALLERG ASTHMA IM, V85, P508; DELENKHEYDENREI.K, 1988, ARZNEIMITTELVERZEICH, P197; Droge W, 2000, P NUTR SOC, V59, P595, DOI 10.1017/S0029665100000847; Eneli I, 2005, CHEST, V127, P604, DOI 10.1378/chest.127.2.604; Galindo P A, 1998, Allergol Immunopathol (Madr), V26, P199; Matricardi PM, 2001, ANN ALLERG ASTHMA IM, V87, P24, DOI 10.1016/S1081-1206(10)62336-8; McKeever TM, 2005, AM J RESP CRIT CARE, V171, P966, DOI 10.1164/rccm.200409-1269OC; MICHELI L, 1994, ENVIRON HEALTH PERSP, V102, P63, DOI 10.1289/ehp.94102s963; *NAT CTR HLTH STAT, 1994, DHHS PUBL; Newson RB, 2000, EUR RESPIR J, V16, P817, DOI 10.1183/09031936.00.16581700; Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071; Shaheen SO, 2005, CLIN EXP ALLERGY, V35, P18, DOI 10.1111/j.1365-2222.2005.02151.x; Shaheen SO, 2000, THORAX, V55, P266, DOI 10.1136/thorax.55.4.266; Shaheen SO, 2002, THORAX, V57, P958, DOI 10.1136/thorax.57.11.958; Varner A, 2000, THORAX, V55, P882	19	19	20	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					859	862		10.1016/j.jaci.2005.07.019	http://dx.doi.org/10.1016/j.jaci.2005.07.019			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210061				2022-12-18	WOS:000235686600021
J	Nathan, RA				Nathan, RA			Leukotriene receptor antagonists are not as effective as intranasal corticosteroids for managing nighttime symptoms of allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DOUBLE-BLIND; MONTELUKAST; COMBINATION		Univ Colorado, Hlth Sci Ctr, Colorado Springs, CO 80907 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado at Colorado Springs	Nathan, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, 2709 N Tejon, Colorado Springs, CO 80907 USA.							Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Nayak AS, 2002, ANN ALLERG ASTHMA IM, V88, P592, DOI 10.1016/S1081-1206(10)61891-1; Philip G, 2002, CLIN EXP ALLERGY, V32, P1020, DOI 10.1046/j.1365-2222.2002.01422.x; Pullerits T, 2002, J ALLERGY CLIN IMMUN, V109, P949, DOI 10.1067/mai.2002.124467; Ratner PH, 2003, ANN ALLERG ASTHMA IM, V90, P536, DOI 10.1016/S1081-1206(10)61847-9; van Adelsberg J, 2003, ANN ALLERG ASTHMA IM, V90, P214, DOI 10.1016/S1081-1206(10)62144-8	6	19	19	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					463	464		10.1016/j.jaci.2005.03.045	http://dx.doi.org/10.1016/j.jaci.2005.03.045			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083809				2022-12-18	WOS:000235686400037
J	Frew, AJ				Frew, AJ			Advances in environmental and occupational diseases 2004	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						environment; allergens; pets; mice; endotoxin; latex; risk factors; air pollution	LPS-BINDING-PROTEIN; MOUSE ALLERGEN; LOW-INCOME; ASTHMA; EXPOSURE; CHILDREN; EXACERBATIONS; AEROALLERGENS; COMMUNITY; HOMES	2004 was another good year for publications on environmental and occupational disorders in our journal. The major focus is clearly on the environment and particularly on environmental risk factors for sensitization and asthma. There is a growing consensus that exposure to pets is good, provided there is enough of it. Low levels enhance sensitization, and higher levels protect against the consequences of that sensitization. Following on from previous work on cockroaches, we now see allergy to feral mice as an emergent problem-at least we now have the tools to study this properly. Emphasis seems to be swinging away from the outdoor environment as a cause of allergic disease and toward the indoor environment, which is, after all, where most of us spend most of our lives. New techniques for studying isocyanate allergy might kindle a revival of interest in the mechanisms of occupational asthma caused by low-molecular-weight compounds. But for all types of occupational allergy, prevention remains key, and it is good to see that comprehensive programs of allergen reduction can pay off in reduced rates of latex allergy in health care workers. Further work in the area of recombinant allergens is welcome but needs soon to be translated into new diagnostic and therapeutic strategies. This sector of allergy research remains vibrant, and the editors will continue to welcome outstanding contributions in this area.	Univ Southampton, Allergy & Inflammat Res Grp, Infect Inflammat & Repair Div, Sch Med, Southampton, Hants, England	University of Southampton	Frew, AJ (corresponding author), Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.	A.J.Frew@soton.ac.uk	Kelly, Frank J/C-6125-2009	Kelly, Frank J/0000-0003-2558-8392				Al-Mousawi MSH, 2004, J ALLERGY CLIN IMMUN, V114, P1389, DOI 10.1016/j.jaci.2004.09.005; Allmers H, 2004, J ALLERGY CLIN IMMUN, V114, P347, DOI 10.1016/j.jaci.2004.05.054; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V113, P109, DOI 10.1016/j.jaci.2003.10.042; Barderas R, 2004, J ALLERGY CLIN IMMUN, V113, P1192, DOI 10.1016/j.jaci.2003.12.587; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Brass DM, 2004, J ALLERGY CLIN IMMUN, V114, P586, DOI 10.1016/j.jaci.2004.04.043; Brown RH, 2004, J ALLERGY CLIN IMMUN, V114, P358, DOI 10.1016/j.jaci.2004.04.003; Bufe A, 2004, J ALLERGY CLIN IMMUN, V114, P583, DOI 10.1016/j.jaci.2004.06.034; Cabana MD, 2004, J ALLERGY CLIN IMMUN, V114, P352, DOI 10.1016/j.jaci.2004.04.047; Cohn RD, 2004, J ALLERGY CLIN IMMUN, V113, P1167, DOI 10.1016/j.jaci.2003.12.592; Dales RE, 2004, J ALLERGY CLIN IMMUN, V113, P303, DOI 10.1016/j.jaci.2003.11.016; de Meer G, 2004, J ALLERGY CLIN IMMUN, V113, P433, DOI 10.1016/j.jaci.2003.10.008; Enrique E, 2002, ALLERGY, V57, P351, DOI 10.1034/j.1398-9995.2002.1s3509.x; Ferrari E, 2004, J ALLERGY CLIN IMMUN, V114, P341, DOI 10.1016/j.jaci.2004.04.028; GEM JE, 2004, J ALLERGY CLIN IMMUN, V113, P307; Howell MD, 2004, J ALLERGY CLIN IMMUN, V113, P916, DOI 10.1016/j.jaci.2004.02.017; Ibarrola I, 2004, J ALLERGY CLIN IMMUN, V113, P1185, DOI 10.1016/j.jaci.2004.02.031; Johnson CC, 2004, J ALLERGY CLIN IMMUN, V114, P105, DOI 10.1016/j.jaci.2004.04.007; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Karlsson AS, 2004, J ALLERGY CLIN IMMUN, V113, P1172, DOI 10.1016/j.jaci.2003.12.590; Korpi A, 2004, J ALLERGY CLIN IMMUN, V113, P677, DOI 10.1016/j.jaci.2003.11.039; Matsui EC, 2004, J ALLERGY CLIN IMMUN, V113, P910, DOI 10.1016/j.jaci.2004.02.034; O'Connor GT, 2004, J ALLERGY CLIN IMMUN, V114, P599, DOI 10.1016/j.jaci.2004.05.064; Portnoy JM, 2004, J ALLERGY CLIN IMMUN, V113, P189, DOI 10.1016/j.jaci.2003.11.021; Rabinovitch N, 2004, J ALLERGY CLIN IMMUN, V114, P1131, DOI 10.1016/j.jaci.2004.08.026; van den Bemt L, 2004, J ALLERGY CLIN IMMUN, V114, P858, DOI 10.1016/j.jaci.2004.05.069; van Ort E, 2004, J ALLERGY CLIN IMMUN, V114, P1124, DOI 10.1016/j.jaci.2004.06.050; von Mutius E, 2004, J ALLERGY CLIN IMMUN, V113, P373, DOI 10.1016/j.jaci.2003.12.040; Wisnewski AV, 2004, J ALLERGY CLIN IMMUN, V113, P1178, DOI 10.1016/j.jaci.2004.03.009; Yeang HY, 2004, J ALLERGY CLIN IMMUN, V114, P593, DOI 10.1016/j.jaci.2004.05.039	31	19	19	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1197	1202		10.1016/j.jaci.2005.03.006	http://dx.doi.org/10.1016/j.jaci.2005.03.006			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940134				2022-12-18	WOS:000229815400014
J	Konno, S; Golden, DBK; Schroeder, J; Hamilton, RG; Lichtenstein, LM; Huang, SK				Konno, S; Golden, DBK; Schroeder, J; Hamilton, RG; Lichtenstein, LM; Huang, SK			Level of osteopontin is increased after bee venom immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Konno, S (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.		Huang, Shau-Ku/F-5509-2010; Konno, Satoshi/G-1669-2012		NIAID NIH HHS [AI 52468] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Chehimi J, 2001, CLIN IMMUNOL, V100, P49, DOI 10.1006/clim.2001.5039; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298, DOI 10.1016/S0091-6749(98)70239-8; Hamilton RG, 2001, ANN ALLERG ASTHMA IM, V87, P134, DOI 10.1016/S1081-1206(10)62207-7; Konno S, 2005, J ALLERGY CLIN IMMUN, V115, P1063, DOI 10.1016/j.jaci.2005.01.055; Mazzali M, 2002, QJM-INT J MED, V95, P3, DOI 10.1093/qjmed/95.1.3; Portnoy J M, 1999, J Allergy Clin Immunol, V103, P963, DOI 10.1016/S0091-6749(99)70450-1; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024	9	19	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1317	1318		10.1016/j.jaci.2005.02.019	http://dx.doi.org/10.1016/j.jaci.2005.02.019			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940156				2022-12-18	WOS:000229815400035
J	Wang, J; Rodrigue-Davalos, M; Levi, G; Sauter, B; Gondolesi, GE; Cunningham-Rundles, C				Wang, J; Rodrigue-Davalos, M; Levi, G; Sauter, B; Gondolesi, GE; Cunningham-Rundles, C			Common variable immunodeficiency presenting with a large abdominal mass	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Mt Sinai Med Ctr, Div Clin Immunol, New York, NY 10029 USA; Mt Sinai Med Ctr, Recanti Miller Transplantat Inst, New York, NY 10029 USA; Mt Sinai Med Ctr, Dept Pathol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Wang, J (corresponding author), Mt Sinai Med Ctr, Div Clin Immunol, 1 Gustave L Levy Pl,Box 1089, New York, NY 10029 USA.		Huang, Shau-Ku/F-5509-2010; Konno, Satoshi/G-1669-2012		NIAID NIH HHS [AI 52468] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		*AM AC PED, 2000, 2000 RED BOOK REP CO, P325; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; JAMES DG, 1995, Q J MED, V24, P49; Kanathur N, 2000, SOUTHERN MED J, V93, P631; Kataria YP, 1997, CLIN CHEST MED, V18, P719, DOI 10.1016/S0272-5231(05)70415-9; Mechanic LJ, 1997, ANN INTERN MED, V127, P613, DOI 10.7326/0003-4819-127-8_Part_1-199710150-00005; Mullighan CG, 1997, J IMMUNOL, V159, P6236; Thomas KW, 2003, JAMA-J AM MED ASSOC, V289, P3300, DOI 10.1001/jama.289.24.3300	8	19	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1318	1320		10.1016/j.jaci.2005.02.021	http://dx.doi.org/10.1016/j.jaci.2005.02.021			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940156				2022-12-18	WOS:000229815400036
J	Yeang, HY; Arif, SAM; Raulf-Heimsoth, M; Loke, YH; Sander, I; Sulong, SH; Lau, CH; Hamilton, RG				Yeang, HY; Arif, SAM; Raulf-Heimsoth, M; Loke, YH; Sander, I; Sulong, SH; Lau, CH; Hamilton, RG			Hev b 5 and Hev b 13 as allergen markers to estimate the allergenic potency of latex gloves	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; latex glove; allergen; Hev b 5; Hev b 13; step-wise multiple regression; immunoassay; protein; IEMA	NATURAL-RUBBER LATEX; ELONGATION-FACTOR; ELISA INHIBITION; MEDICAL GLOVES; PROTEINS; BRASILIENSIS; ASSAY; PRECIPITATION; QUANTITATION; PRODUCTS	Background: Sensitization to natural rubber latex has been linked to proteins from medical latex gloves. Various assays to estimate the amount of residual allergenic proteins extractable from latex gloves to assess their potential exposure hazard have inherent weaknesses. Objective: This investigation was aimed at developing 2-site immunoenzymetric assays and identifying appropriate protein markers to assess the allergenic potential of latex gloves. Methods: The presence of 6 latex allergens-Hev b 1, 2, 3, 5, 6, and 13-was measured in a cross-section of commercial latex medical gloves by using monoclonal and polyclonal antibody-based 2-site immunoenzymetric assays. The overall allergenic potential of these gloves was assessed by IgE-inhibition assay. Stepwise multiple regression analyses were performed to identify marker allergens that best explained the variation in latex glove allergenicity. Results: All 6 latex allergens were detected in at least some of the glove samples. Hev 6 5 and Hev b 13 were identified as the marker allergens that combined best to explain the variation in the glove allergenicity. The significant multiple correlation (R = 0.855) between these 2 markers and glove allergenic potency forms the basis of an assay to gauge latex glove allergenicity. Conclusion: The overall allergenic potential of latex gloves can be estimated by using Hev b 5 and Hev b 13 as indicator allergens. The correlation between glove allergenicity and the level of these allergens was maintained for low-protein gloves (< 200 mug/g). This estimation of glove allergenicity was superior to that obtained by using total protein readings.	Malaysian Rubber Board, Rubber Res Inst Malaysia, Biotechnol & Strateg Res Unit, Kuala Lumpur 50908, Malaysia; Ruhr Univ Bochum, Res Inst Occupat Med, Berufsgenossenschaftliches Forschungsinst Arbeits, D-4630 Bochum, Germany; Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA	Institute Penyelidikan Getah Malaysia; Malaysian Rubber Board; Ruhr University Bochum; Johns Hopkins University; Johns Hopkins Medicine	Yeang, HY (corresponding author), Malaysian Rubber Board, Rubber Res Inst Malaysia, Biotechnol & Strateg Res Unit, POB 10150, Kuala Lumpur 50908, Malaysia.	hyyeang@lgm.gov.my	Sander, Ingrid/R-8940-2017	Sander, Ingrid/0000-0002-5014-4112	NIAID NIH HHS [AI-43654] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043654] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alenius H, 1996, INT ARCH ALLERGY IMM, V109, P362, DOI 10.1159/000237264; *ASTM, 1999, 571299 ASTM D; *ASTM, 2000, 649900 ASTM D; Baur X, 1997, ALLERGY, V52, P661, DOI 10.1111/j.1398-9995.1997.tb01046.x; Beezhold D, 1996, ANN ALLERG ASTHMA IM, V76, P520, DOI 10.1016/S1081-1206(10)63271-1; BEEZHOLD D, 1992, GUTHRIE J, V61, P77; Beezhold DH, 2002, METHODS, V27, P46, DOI 10.1016/S1046-2023(02)00050-6; Bernstein DI, 2003, J ALLERGY CLIN IMMUN, V111, P610, DOI 10.1067/mai.2003.164; BROEKAERT W, 1990, P NATL ACAD SCI USA, V87, P7633, DOI 10.1073/pnas.87.19.7633; KING TP, 1995, ALLERGY, V50, P765, DOI 10.1111/j.1398-9995.1995.tb01222.x; Kurup VP, 2000, CLIN EXP ALLERGY, V30, P359; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Palosuo T, 2002, METHODS, V27, P52, DOI 10.1016/S1046-2023(02)00051-8; Palosuo T, 1998, ALLERGY, V53, P59, DOI 10.1111/j.1398-9995.1998.tb03774.x; Tomazic-Jezic VJ, 2002, J ALLERGY CLIN IMMUN, V110, pS40, DOI 10.1067/mai.2002.125335; Tomazic-Jezic VJ, 2002, J IMMUNOASS IMMUNOCH, V23, P261, DOI 10.1081/IAS-120013026; Turjanmaa K, 1996, ALLERGY, V51, P593, DOI 10.1111/j.1398-9995.1996.tb04678.x; Yeang H.Y., 2002, J RUBBER RES, V5, P167; YEANG HY, 1995, ANAL BIOCHEM, V226, P35, DOI 10.1006/abio.1995.1188; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0; Yeang HY, 1998, ANAL BIOCHEM, V265, P381; Yip E., 1994, J RUBBER RES, V9, P79; YUNGINGER JW, 1994, J ALLERGY CLIN IMMUN, V93, P836, DOI 10.1016/0091-6749(94)90374-3; YUSOF F, 1992, J NATL RUBBER RES, V7, P206	24	19	21	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					593	598		10.1016/j.jaci.2004.05.039	http://dx.doi.org/10.1016/j.jaci.2004.05.039			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356563				2022-12-18	WOS:000223799600019
J	Chinen, J; Shearer, WT				Chinen, J; Shearer, WT			Advances in asthma, allergy and immunology series 2004: Basic and clinical immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunology; regulatory T cells; immunodeficiency; HIV; gene therapy; lymphocyte subsets	SEVERE COMBINED IMMUNODEFICIENCY; REGULATORY T-CELLS; GENE-THERAPY; HIV-1 REPLICATION; DEFICIENCY; RESPONSES; INFECTION; DISEASE; EXPRESSION; CHILDREN	This review highlights some of the most significant advances in basic and clinical immunology that were published from August 2002 to December 2003, focusing on manuscripts that appeared in the Journal. Articles selected were those considered most relevant to Journal readers. With regard to basic immunology, this report includes articles describing FcepsilonRI expression in mucosal Langerhans cells and type II dendritic cells, mechanisms of T(H)1 and T(H)2 regulation, the role of Foxp3 in the development of CD4(+)CD25(+) regulatory T cells, and the increasing importance of Toll receptors in immunity. Articles related to clinical immunology that were selected include the first report of lymphocyte subsets values from a large cohort of normal children; the description of new genetic defects in primary immunodeficiencies; a description of the complications of gene therapy for X-linked severe combined immunodeficiency; a report of 79 patients with hyper-IgM syndrome; a report of the mechanism of action and complications of intravenous immunoglobulin; a report of new approaches for immunotherapy; and an article on advances in HIV infection and management, including a report of defensins, small molecules with anti-HIV properties. Also summarized is an article that studied the immune system during a prolonged stay in the Antarctic, a model for human studies on the effect of environmental conditions similar to space expeditions.	NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; Baylor Coll Med, Dept Pediat Allergy & Immunol Sect, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Baylor College of Medicine	Chinen, J (corresponding author), NHGRI, Genet & Mol Biol Branch, NIH, 49 Covent Dr,Bldg 49,Room 4A18, Bethesda, MD 20892 USA.	jchinen@nhgri.nih.gov		Shearer, William/0000-0002-2483-2130				Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Allam JP, 2003, J ALLERGY CLIN IMMUN, V112, P141, DOI 10.1067/mai.2003.1607; Altznauer F, 2003, J ALLERGY CLIN IMMUN, V112, P1185, DOI 10.1016/j.jaci.2003.09.045; Bailes E, 2003, SCIENCE, V300, P1713, DOI 10.1126/science.1080657; Bellinghausen I, 2003, J ALLERGY CLIN IMMUN, V111, P862, DOI 10.1067/mai.2003.1412; Brightling CE, 2002, J ALLERGY CLIN IMMUN, V110, P899, DOI 10.1067/mai.2002.129698; Brown HC, 2003, J ALLERGY CLIN IMMUN, V112, P797, DOI 10.1016/S0091-6749(03)01780-9; Casartelli N, 2003, AIDS, V17, P1291, DOI 10.1097/00002030-200306130-00003; Cates EC, 2003, J ALLERGY CLIN IMMUN, V111, P1076, DOI 10.1067/mai.2003.1460; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chinen J, 2003, J ALLERGY CLIN IMMUN, V111, P573, DOI 10.1067/mai.2003.165; Dadi HK, 2003, NEW ENGL J MED, V349, P1821, DOI 10.1056/NEJMoa031178; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Feeney ME, 2003, J IMMUNOL, V171, P6968, DOI 10.4049/jimmunol.171.12.6968; Fellrath JM, 2003, J ALLERGY CLIN IMMUN, V111, P854, DOI 10.1067/mai.2003.1337; Fieschi C, 2003, J EXP MED, V197, P527, DOI 10.1084/jem.20021769; Fiset PO, 2003, J ALLERGY CLIN IMMUN, V111, P580, DOI 10.1067/mai.2003.179; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Foster B, 2003, J ALLERGY CLIN IMMUN, V112, P1132, DOI 10.1016/j.jaci.2003.09.011; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Habib T, 2003, J ALLERGY CLIN IMMUN, V112, P1033, DOI 10.1016/j.jaci.2003.08.039; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; Hernandez PA, 2003, NAT GENET, V34, P70, DOI 10.1038/ng1149; Herrick CA, 2003, J ALLERGY CLIN IMMUN, V111, P1087, DOI 10.1067/mai.2003.1413; Hess C, 2004, LANCET, V363, P863, DOI 10.1016/S0140-6736(04)15735-8; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kawai K, 2003, J ALLERGY CLIN IMMUN, V112, P951, DOI 10.1016/S0091-6749(03)02007-4; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kilby JM, 2003, NEW ENGL J MED, V348, P2228, DOI 10.1056/NEJMra022812; Kusunoki T, 2003, J ALLERGY CLIN IMMUN, V111, P136, DOI 10.1067/mai.2003.29; Laaksonen K, 2003, J ALLERGY CLIN IMMUN, V112, P1171, DOI 10.1016/j.jaci.2003.08.043; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211; Marks GB, 2003, J ALLERGY CLIN IMMUN, V111, P541, DOI 10.1067/mai.2003.171; McHugh RS, 2002, J ALLERGY CLIN IMMUN, V110, P693, DOI 10.1067/mai.2002.129339; Nance CL, 2003, J ALLERGY CLIN IMMUN, V112, P851, DOI 10.1016/j.jaci.2003.08.048; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Poirier MC, 2003, JAIDS-J ACQ IMM DEF, V33, P175, DOI 10.1097/00126334-200306010-00010; Quinones-Mateu ME, 2003, AIDS, V17, pF39, DOI [10.1097/01.aids.0000096878.73209.4f, 10.1097/00002030-200311070-00001]; Scott ZA, 2003, J IMMUNOL, V170, P5786, DOI 10.4049/jimmunol.170.11.5786; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Shirai T, 2003, J ALLERGY CLIN IMMUN, V111, P1353, DOI 10.1067/mai.2003.1504; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Wang W, 2003, J IMMUNOL, V170, P4708, DOI 10.4049/jimmunol.170.9.4708; Winkelstein JA, 2003, MEDICINE, V82, P373, DOI 10.1097/01.md.0000100046.06009.b0; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812	54	19	21	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					398	405		10.1016/j.jaci.2004.05.036	http://dx.doi.org/10.1016/j.jaci.2004.05.036			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316523				2022-12-18	WOS:000223405600030
J	Piacentini, GL; Bodini, A; Peroni, D; Ress, M; Costella, S; Boner, AL				Piacentini, GL; Bodini, A; Peroni, D; Ress, M; Costella, S; Boner, AL			Exhaled air temperature and eosinophil airway inflammation in allergic asthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BREATH CONDENSATE; NITRIC-OXIDE; 8-ISOPROSTANE; MARKER; SPUTUM		Policlin GB Rossi, Pediat Clin, Dipartimento Pediat, I-37134 Verona, Italy; Ist Pio XII, Misurina, Belluno, Italy	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	Piacentini, GL (corresponding author), Policlin GB Rossi, Pediat Clin, Dipartimento Pediat, I-37134 Verona, Italy.	giorgio.piacentini@univr.it	Peroni, Diego G/K-4002-2018; Peroni, Diego/K-8795-2016	Peroni, Diego/0000-0002-0234-1373				Bodini A, 2004, PEDIAT ALLERG IMM-UK, V15, P26, DOI 10.1046/j.0905-6157.2003.00097.x; Gibson PG, 2000, EUR RESPIR J, V16, P1008; Holgate ST, 1998, LANCET, V351, P1300, DOI 10.1016/S0140-6736(05)79051-6; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693, DOI 10.1164/ajrccm.163.7.2009041; Kharitonov SA, 1996, CURR OPIN ANAESTH, V9, P542; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216, DOI 10.1164/ajrccm.160.1.9809140; Netea MG, 2000, CLIN INFECT DIS, V31, pS178, DOI 10.1086/317513; Paredi P, 2002, AM J RESP CRIT CARE, V165, P181, DOI 10.1164/ajrccm.165.2.2103053; Piacentini GL, 2002, EUR RESPIR J, V20, P108, DOI 10.1183/09031936.02.00237702; Zanconato S, 2004, J ALLERGY CLIN IMMUN, V113, P257, DOI 10.1016/j.jaci.2003.10.046	10	19	20	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					202	204		10.1016/j.jaci.2004.04.010	http://dx.doi.org/10.1016/j.jaci.2004.04.010			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15282940				2022-12-18	WOS:000222534300033
J	Nelson, HS; Kolehmainen, C; Lahr, J; Murphy, J; Buchmeier, A				Nelson, HS; Kolehmainen, C; Lahr, J; Murphy, J; Buchmeier, A			A comparison of multiheaded devices for allergy skin testing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PERFORMANCE		Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	National Jewish Health	Nelson, HS (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.							ADINOFF AD, 1989, J ALLERGY CLIN IMMUN, V84, P168, DOI 10.1016/0091-6749(89)90321-7; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V101, P153, DOI 10.1016/S0091-6749(98)70409-9; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P750, DOI 10.1016/0091-6749(93)90019-C	3	19	19	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1218	1219		10.1016/j.jaci.2004.01.566	http://dx.doi.org/10.1016/j.jaci.2004.01.566			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15214360				2022-12-18	WOS:000222091000032
J	Man, AL; Bertelli, E; Regoli, M; Chambers, SJ; Nicoletti, C				Man, AL; Bertelli, E; Regoli, M; Chambers, SJ; Nicoletti, C			Antigen-specific T cell-mediated apoptosis of dendritic cells is impaired in a mouse model of food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cell; food allergy; IgE; T cell	RESPONSES; ENGAGEMENT; RECEPTOR; SPLEEN; NAIVE; IL-12; IGE	Background: Dendritic cells (DCs) play a pivotal role in antigen presentation and regulation of immune responses, and strong evidence suggests their involvement in the pathogenesis of allergy. However, hitherto, DC-T-cell cross-talk in relation to IgE-mediated allergic reactions to food has not been investigated. Objective: Our aim was to investigate T cell-mediated apoptosis of myeloid DCs from spleen and Peyer's patches of mice with cow's milk (CM) allergy after cognate interaction with antigen (CM)-specific T cells. Methods: Freshly isolated myeloid CD11c(+/hi)/B220(-) DCs from spleen and Peyer's patches of mice with CM allergy and control mice were cultured with CM-specific T cells in the presence or absence of CM or unrelated antigen as a control. Levels of apoptosis in DCs were evaluated by assessing propidium iodide uptake and annexin V expression by means of flow cytometry. Results: We observed that both systemic and gastrointestinal-derived DCs showed an increased resistance to T cell-mediated cell death compared with DCs from control but not allergic donors. Further experiments demonstrated that in both allergic and control mice, T cell-mediated DC apoptosis takes place exclusively in the presence of the specific antigen, is MHC II dependent, and is only partially CD95-CD95 ligand dependent. Conclusion: Here we demonstrate, for the first time, that the reciprocal, finely balanced regulation between these 2 cell types, which plays a central role in controlling immune responses, is altered in allergy. We hypothesize that these events are likely to have a profound influence on the genesis and maintenance of adverse reaction to food.	Inst Food Res, Lab Gut Immunol, Programme Gastrointestinal Hlth & Funct, Norwich NR4 7UA, Norfolk, England; Univ Siena, Dept Pharmacol G Segre, I-53100 Siena, Italy	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; University of Siena	Nicoletti, C (corresponding author), Inst Food Res, Lab Gut Immunol, Programme Gastrointestinal Hlth & Funct, Norwich NR4 7UA, Norfolk, England.		Bertelli, Eugenio/J-2948-2012	Bertelli, Eugenio/0000-0002-9681-4556; Man, Angela/0000-0002-9596-0068; Regoli, Mari/0000-0002-8835-8386				Ashany D, 1999, J IMMUNOL, V163, P5303; ASHANY D, 1995, P NATL ACAD SCI USA, V92, P11225, DOI 10.1073/pnas.92.24.11225; Bellinghausen I, 2000, J ALLERGY CLIN IMMUN, V105, P988, DOI 10.1067/mai.2000.105526; Hammad H, 2000, LAB INVEST, V80, P605, DOI 10.1038/labinvest.3780065; Holloway JA, 2001, J ALLERGY CLIN IMMUN, V107, P1009, DOI 10.1067/mai.2001.115039; Ingulli E, 1997, J EXP MED, V185, P2133, DOI 10.1084/jem.185.12.2133; Iwasaki A, 1999, J EXP MED, V190, P229, DOI 10.1084/jem.190.2.229; JULIA V, 2002, IMMUNITY, V271, P93; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; Li XM, 2003, J ALLERGY CLIN IMMUN, V111, P1140, DOI 10.1067/mai.2003.1494; Maldonado-Lopez R, 2001, SEMIN IMMUNOL, V13, P275, DOI 10.1006/smim.2001.0323; Matsue H, 1999, J IMMUNOL, V162, P5287; METLAY JP, 1990, J EXP MED, V171, P1753, DOI 10.1084/jem.171.5.1753; Miller E, 2004, METH MOLEC MED, V88, P191; Morafo V, 2003, J ALLERGY CLIN IMMUN, V111, P1122, DOI 10.1067/mai.2003.1463; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; Muller G, 2002, J INVEST DERMATOL, V119, P836, DOI 10.1046/j.1523-1747.2002.00496.x; Nat R, 2002, J CELL MOL MED, V6, P223, DOI 10.1111/j.1582-4934.2002.tb00189.x; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Reider N, 2002, J ALLERGY CLIN IMMUN, V109, P89, DOI 10.1067/mai.2002.120556; Rescigno M, 2000, J EXP MED, V192, P1661, DOI 10.1084/jem.192.11.1661; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; SALOGA J, 2001, ACI INT, V13, P107; Sicherer SH, 2002, LANCET, V360, P701, DOI 10.1016/S0140-6736(02)09831-8; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Uchida Y, 2001, J ALLERGY CLIN IMMUN, V108, P1005, DOI 10.1067/mai.2001.119741; van den Heuvel MM, 1998, J ALLERGY CLIN IMMUN, V101, P90, DOI 10.1016/S0091-6749(98)70198-8; YAMASUGA S, 2003, J VET MED SCI, V65, P295; Yokota A, 2003, MICROBIOL IMMUNOL, V47, P285, DOI 10.1111/j.1348-0421.2003.tb03397.x	32	19	20	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					965	972		10.1016/j.jaci.2004.02.038	http://dx.doi.org/10.1016/j.jaci.2004.02.038			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131581	Bronze			2022-12-18	WOS:000221269000021
J	Marth, K; Focke, M; Flicker, S; Valenta, R				Marth, K; Focke, M; Flicker, S; Valenta, R			Human monoclonal antibody-based quantification of group 2 grass pollen allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						grass pollen allergy; group 2 allergens; competitive ELISA; allergen measurement; recombinant human antibody; recombinant allergen	PHLEUM-PRATENSE POLLEN; LOL-P-I; MAJOR ALLERGEN; CDNA CLONING; IGE-BINDING; ISOFORMS; EXPRESSION; REACTIVITY; DIAGNOSIS; PROTEIN	Background: Grasses belong to the most potent allergen sources worldwide. Group 2 grass pollen allergens are recognized by more than 100 million allergic patients. Objective: The aim was to develop an assay for the specific detection and quantification of group 2 grass pollen allergens. Methods: We have isolated a monoclonal human IgE Fab specific for group 2 grass pollen allergens by combinatorial cloning from lymphocytes of a grass pollen-allergic patient. This Fab was converted into a complete human IgG(1) antibody and used together with rPhl p 2 to develop a competitive ELISA for the specific measurement of group 2 allergens. ELISA plate-bound purified recombinant human Phl p 2-specific IgG(1) is incubated with a constant amount of biotinylated rPhl p 2 competing with increasing concentrations of group 2 allergens to be determined. Defined concentrations of purified rPhl p 2 are used to establish a standard curve. The concentration of unlabeled group 2 allergens can thus be deduced from the displacement of biotinylated rPhl p 2, which can be detected with peroxidase-labeled streptavidin. Results: The competition-ELISA measured rPhl p 2 concentrations ranging from 10 ng/mL to 500 ng/mL and allowed to quantify group 2 allergens from 9 different grass families. The results were in good agreement with immunoblot data. Conclusions: The described assay can be used for standardization of diagnostic and therapeutic vaccines as well as for the quantification of group 2 allergens in environmental samples.	Med Univ Vienna, Vienna Gen Hosp, Dept Pathophysiol, Mol Immunopathol Grp, A-1090 Vienna, Austria	Medical University of Vienna	Valenta, R (corresponding author), Med Univ Vienna, Vienna Gen Hosp, Dept Pathophysiol, Mol Immunopathol Grp, Waehringer Guertel 18-20, A-1090 Vienna, Austria.			Flicker, Sabine/0000-0003-4768-8693; Valenta, Rudolf/0000-0001-5944-3365				Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; ANSARI AA, 1989, BIOCHEMISTRY-US, V28, P8665, DOI 10.1021/bi00447a058; Arilla MC, 2001, CLIN EXP ALLERGY, V31, P1271, DOI 10.1046/j.1365-2222.2001.01166.x; BAYER EA, 1986, ANAL BIOCHEM, V154, P367, DOI 10.1016/0003-2697(86)90538-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; CHAPMAN M, 1994, ARB P EHRLICH I BUND, V120, P136; De Marino S, 1999, STRUCT FOLD DES, V7, P943; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; FAHLBUSCH B, 1994, CLIN EXP ALLERGY, V24, P752, DOI 10.1111/j.1365-2222.1994.tb00986.x; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Flicker S, 2002, EUR J IMMUNOL, V32, P2156, DOI 10.1002/1521-4141(200208)32:8<2156::AID-IMMU2156>3.0.CO;2-A; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; HAYEK B, 1999, ALLERGY, V54, pOP1; Heiss S, 1999, J INVEST DERMATOL, V113, P830, DOI 10.1046/j.1523-1747.1999.00796.x; Helsper JPFG, 2002, J ALLERGY CLIN IMMUN, V110, P131, DOI 10.1067/mai.2002.125599; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Laffer S, 1996, J ALLERGY CLIN IMMUN, V98, P652, DOI 10.1016/S0091-6749(96)70099-4; Laffer S, 1996, MOL IMMUNOL, V33, P417, DOI 10.1016/0161-5890(95)00152-2; Maglio O, 2002, PROTEIN ENG, V15, P635, DOI 10.1093/protein/15.8.635; MITTERMANN I, 1995, PLANT MOL BIOL, V27, P137, DOI 10.1007/BF00019185; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258, DOI 10.1016/S0091-6749(98)70391-4; PEREZ M, 1990, J BIOL CHEM, V265, P16210; Schappi GF, 1999, CLIN EXP ALLERGY, V29, P633, DOI 10.1046/j.1365-2222.1999.00567.x; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; Steinberger P, 1996, J BIOL CHEM, V271, P10967, DOI 10.1074/jbc.271.18.10967; Suphioglu C, 2000, CLIN EXP ALLERGY, V30, P1335, DOI 10.1046/j.1365-2222.2000.00955.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANREE R, 1994, ARB PEI GSH, V87, P127; VRTALA S, 1993, J IMMUNOL, V151, P4773; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567	34	19	21	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					470	474		10.1016/j.jaci.2003.11.042	http://dx.doi.org/10.1016/j.jaci.2003.11.042			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007349	Bronze			2022-12-18	WOS:000220144200019
J	Hellermann, G; Kong, XY; Gunnarsdottir, J; San Juan, H; Singam, R; Behera, S; Zhang, WD; Lockey, RF; Mohapatra, SS				Hellermann, G; Kong, XY; Gunnarsdottir, J; San Juan, H; Singam, R; Behera, S; Zhang, WD; Lockey, RF; Mohapatra, SS			Mechanism of bronchoprotective effects of a novel natriuretic hormone peptide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ANP; asthma; NF kappa B; ERK; anti-inflammatory; bronchodilation; natriuretic; signaling	NF-KAPPA-B; NITRIC-OXIDE; INDUCED BRONCHOCONSTRICTION; PULMONARY-ARTERIES; EPITHELIAL-CELLS; ATRIAL; EXPRESSION; ACTIVATION; INDUCTION; BRONCHODILATOR	Background: The natriuretic hormone peptide (NHP) (99-126), a C-terminal peptide of pro-atrial natrituretic factor (proANF), induces bronchodilatory effects in people with asthma. Recently, another plasmid-encoded C-terminal peptide, pNHP(73-102), was shown to induce a long-lasting bronchoprotective effect in a mouse model of allergic asthma. Objective: This study was carried out to determine the role of lung epithelial cells in the bronchoprotective and anti-inflammatory activity of these peptides. Methods: Human type 11 alveolar epithelial cells (A549) and normal human bronchial epithelial (NHBE) cells were transfected with pNHP(73-102) to test the effect of this peptide on activation of these cells. After transfection, cells were analyzed for changes in Ca++ and nitric oxide (NO) levels. Also, activation of NFkappaB and the extracellularly regulated kinase (ERK) 1, 2 signaling pathway was examined by luciferase reporter assay and phosphorylation studies respectively. Results: Analysis of intracellular Ca++ levels in pNHP(73-102) -transfected A549 or NHBE showed that the peptide increases release. This Ca++ release was accompanied by an increase in the production of NO. Also, overexpression of pNHP(73-102), but not pVAX control, in phorbol myristate acetate-activated A549 cells resulted in a significant decrease in expression of a cotransfected nuclear factorkappabeta (NFkappaB)-luciferase reporter. Similarly, pNHP(73-102) decreased TNF-alpha-induced NFkappaB activation in NHBE cells. Furthermore, NHP73-102 but not atrial natriuretic peptide decreased phosphorylation of Erk- 1, 2 in A549 cells. Conclusions: Overexpression of pNHP(73-102) in epithelial cells causes increased production of intracellular Ca++ and NO, with a concomitant decrease in activation of NFkappaB and ERK1, 2. These results suggest a bronchodilatory and anti-inflammatory activity of this peptide.	Univ S Florida, Coll Med, Dept Internal Med,Div Allergy & Immunol, Joy McCann Culverhouse Airway Dis Ctr, Tampa, FL 33612 USA; James A Haley Vet Hosp, Tampa, FL 33612 USA; Univ Iceland, Dept Med, Reykjavik, Iceland	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; University of Iceland	Mohapatra, SS (corresponding author), Univ S Florida, Coll Med, Dept Internal Med,Div Allergy & Immunol, Joy McCann Culverhouse Airway Dis Ctr, POB MDC 019, Tampa, FL 33612 USA.		Hellermann, Gary/A-8855-2013; Mohapatra, Shyam/C-2500-2012	Gunnarsdottir, Johanna/0000-0002-2989-7160; San Juan Vergara, Homero/0000-0002-3808-4647				Abbey SE, 2003, ENDOCRINOLOGY, V144, P240, DOI 10.1210/en.2002-220702; ANGUS RM, 1995, AM J RESP CRIT CARE, V151, P2003, DOI 10.1164/ajrccm.151.6.7767551; ANGUS RM, 1994, CLIN EXP ALLERGY, V24, P784, DOI 10.1111/j.1365-2222.1994.tb00991.x; ANGUS RM, 1993, AM REV RESPIR DIS, V147, P1122, DOI 10.1164/ajrccm/147.5.1122; BIOLLAZ J, 1987, CLIN PHARMACOL THER, V41, P671, DOI 10.1038/clpt.1987.94; Calderone A, 2003, HEART FAIL REV, V8, P55, DOI 10.1023/A:1022147005110; Carini R, 2003, HEPATOLOGY, V37, P277, DOI 10.1053/jhep.2003.50033; Christman JW, 2000, CHEST, V117, P1482, DOI 10.1378/chest.117.5.1482; Cvek K, 1998, ENDOCRINOLOGY, V139, P2615, DOI 10.1210/en.139.5.2615; de Boer J, 2001, BRIT J PHARMACOL, V133, P1235, DOI 10.1038/sj.bjp.0704191; Demaurex N, 2002, METHOD CELL BIOL, V70, P453; Devillier P, 2001, EUR J PHARMACOL, V430, P325, DOI 10.1016/S0014-2999(01)01298-5; DINARDO P, 1992, CAN J CARDIOL, V8, P503; FLUGE T, 1995, EUR J CLIN INVEST, V25, P728, DOI 10.1111/j.1365-2362.1995.tb01951.x; Folkerts G, 1998, TRENDS PHARMACOL SCI, V19, P334, DOI 10.1016/S0165-6147(98)01232-2; GUTKOWSKA J, 1987, FEBS LETT, V214, P17, DOI 10.1016/0014-5793(87)80005-4; Hamad AM, 1999, AM J PHYSIOL-LUNG C, V277, pL910, DOI 10.1152/ajplung.1999.277.5.L910; Holschermann H, 1997, AM J PHYSIOL-HEART C, V272, pH91, DOI 10.1152/ajpheart.1997.272.1.H91; HOWARTH PH, 1995, INT ARCH ALLERGY IMM, V107, P228, DOI 10.1159/000236986; HULKS G, 1991, AM REV RESPIR DIS, V143, P778, DOI 10.1164/ajrccm/143.4_Pt_1.778; ISHII Y, 1989, J ANAT, V166, P85; Kiemer AK, 1998, J BIOL CHEM, V273, P13444, DOI 10.1074/jbc.273.22.13444; Kiemer AK, 2003, ENDOCRINOLOGY, V144, P802, DOI 10.1210/en.2002-220610; Kiemer AK, 2002, BIOCHEM BIOPH RES CO, V295, P1068, DOI 10.1016/S0006-291X(02)00807-0; Kiemer AK, 2002, CIRC RES, V90, P874, DOI 10.1161/01.RES.0000017068.58856.F3; Kiemer AK, 2001, IMMUNOL CELL BIOL, V79, P11, DOI 10.1046/j.1440-1711.2001.00969.x; Kiemer AK, 2001, ANN RHEUM DIS, V60, pIII68; Kiemer AK, 2000, J HEPATOL, V33, P236, DOI 10.1016/S0168-8278(00)80364-5; Kook H, 2003, AM J PHYSIOL-HEART C, V284, pH1388, DOI 10.1152/ajpheart.00414.2002; Kumar M, 2002, J ALLERGY CLIN IMMUN, V110, P879, DOI 10.1067/mai.2002.129699; LINDBERG F, 1988, ACTA PHYSIOL SCAND, V134, P391, DOI 10.1111/j.1748-1716.1988.tb08506.x; Liu LX, 2003, AM J RESP CELL MOL, V28, P713, DOI 10.1165/rcmb.4771; MCALPINE LG, 1992, AM REV RESPIR DIS, V146, P912, DOI 10.1164/ajrccm/146.4.912; Mikawa K, 1998, ARZNEIMITTELFORSCH, V48, P914; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Misono KS, 2002, MOL CELL BIOCHEM, V230, P49, DOI 10.1023/A:1014257621362; Mizuguchi M, 2000, CLIN EXP ALLERGY, V30, P439; Ohbayashi H, 1998, EUR J PHARMACOL, V346, P55, DOI 10.1016/S0014-2999(98)00014-4; Pawliczak R, 2001, J BIOL CHEM, V276, P44613, DOI 10.1074/jbc.M104993200; ROBICHAUD A, 1993, PEPTIDES, V14, P1325, DOI 10.1016/0196-9781(93)90193-K; Silberbach M, 2001, CELL SIGNAL, V13, P221, DOI 10.1016/S0898-6568(01)00139-5; Silkoff PE, 2000, J ALLERGY CLIN IMMUN, V105, P438, DOI 10.1067/mai.2000.104938; Sweeney M, 2002, J APPL PHYSIOL, V92, P1594, DOI 10.1152/japplphysiol.00722.2001; Toda M, 2002, J ALLERGY CLIN IMMUN, V109, P246, DOI 10.1067/mai.2002.121555; Tolsa JF, 2002, AM J PHYSIOL-HEART C, V282, pH273, DOI 10.1152/ajpheart.2002.282.1.H273; Vesely DL, 2002, IUBMB LIFE, V53, P153, DOI 10.1080/15216540212336	46	19	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2004	113	1					79	85		10.1016/j.jaci.2003.10.009	http://dx.doi.org/10.1016/j.jaci.2003.10.009			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	760MP	14713911	Bronze			2022-12-18	WOS:000187837900010
J	Lee, WI; Zhu, QL; Gambineri, E; Jin, YZ; Welcher, AA; Ochs, HD				Lee, WI; Zhu, QL; Gambineri, E; Jin, YZ; Welcher, AA; Ochs, HD			Inducible CO-stimulator molecule, a candidate gene for defective isotype switching, is normal in patients with hyper-IgM syndrome of unknown molecular diagnosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hyper-IgM phenotypic immunodeficiency disorders; hyper IgM syndrome; inducible costimulatory molecule; common variable immunodeficiency	X-LINKED IMMUNODEFICIENCY; AUTOSOMAL RECESSIVE FORM; CD40 LIGAND; T-CELLS; ECTODERMAL DYSPLASIA; CD40-DEFICIENT MICE; GERMINAL CENTER; ICOS; MUTATIONS; DEFICIENCY	Background: Inducible CO-stimulatory molecule (ICOS), the third member of the CD28/CTLA4 family, is expressed by activated T cells and interacts with its ligand (ICOSL, B7-related protein-1 [B7RP-1]) that is constitutively expressed by B cells. The interaction of ICOS with its ligand leads to terminal differentiation of B cells to plasma cells. ICOS-deficient mice fail to undergo immunoglobulin-class switch recombination (CSR) and germinal center formation, suggesting that ICOS could be a candidate gene for phenotypic hyper-IgM (HIGM) syndromes characterized by recurrent infections, low serum IgG and IgA, and normal or elevated IgM. Genetically, at least 4 distinct molecular defects have been identified that result in defective CSR and present as HIGM syndromes: defects of the CD40 ligand gene (CD40L; HIGM1, X-linked), the activation-induced cytidine deaminase gene (AID; HIGM2, autosomal recessive), the CD40 gene (HIGM3, autosomal recessive), and the nuclear factor-KB (NF-KB) essential modulator gene (NEMO, or IKK-gamma, X-linked). In a substantial subgroup of HIGM patients, these 4 genes are normal, and the genetic defect is unknown. Objective: We sought to investigate the possibility that mutations of ICOS could account for some patients' belonging to this HIGM subgroup. Methods: The expression of ICOS protein by activated peripheral blood mononuclear cells and/or interieukin-2-dependent T cell lines derived from these patients was estimated by flow cytometery after incubation of the cells with the ICOS ligand fusion protein B7RP-1 Fe. The coding region and exon-intron boundaries. of ICOS were assessed by sequence analysis. Results: We studied 33 HIGM patients from 30 families, selected from an original cohort of 136 patients from 113 families, by excluding mutations of CD40L, AID, CD40, and NEMO. Activated T cells from all 33 patients expressed ICOS normally, and sequence analysis of the coding region and exon-intron boundaries revealed only wild-type ICOS, predicting that the protein structure is normal in this patient population. Conclusion: These findings strongly suggest that ICOS does not belong to the group of genes that, if mutated, present clinically as the HIGM syndrome.	Univ Washington, Dept Pediat, Sch Med, Seattle, WA 98195 USA; Chang Gung Mem Hosp, Taoyuan, Taiwan; Childrens Hosp, Taoyuan, Taiwan; Amgen Inc, Thousand Oaks, CA 91320 USA	University of Washington; University of Washington Seattle; Chang Gung Memorial Hospital; Amgen	Ochs, HD (corresponding author), Univ Washington, Dept Pediat, Sch Med, 1959 NE Pacific St,Box 356320, Seattle, WA 98195 USA.		Gambineri, Eleonora/J-8747-2016	Gambineri, Eleonora/0000-0002-4676-6541	NICHD NIH HHS [HD 17427-33] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017427, R37HD017427] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Beier KC, 2000, EUR J IMMUNOL, V30, P3707, DOI 10.1002/1521-4141(200012)30:12<3707::AID-IMMU3707>3.0.CO;2-Q; Buonfiglio D, 2000, EUR J IMMUNOL, V30, P3463, DOI 10.1002/1521-4141(2000012)30:12<3463::AID-IMMU3463>3.0.CO;2-5; CASTIGLI E, 1994, P NATL ACAD SCI USA, V91, P12135, DOI 10.1073/pnas.91.25.12135; Choe J, 1998, EUR J IMMUNOL, V28, P508, DOI 10.1002/(SICI)1521-4141(199802)28:02<508::AID-IMMU508>3.0.CO;2-I; CONLEY ME, 1994, J CLIN INVEST, V94, P1404, DOI 10.1172/JCI117476; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Ferrari S, 2001, P NATL ACAD SCI USA, V98, P12614, DOI 10.1073/pnas.221456898; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Haimila KE, 2002, IMMUNOGENETICS, V53, P1028, DOI 10.1007/s00251-002-0431-2; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Kindler V, 1997, J IMMUNOL, V159, P2085; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Ling V, 2001, J IMMUNOL, V166, P7300, DOI 10.4049/jimmunol.166.12.7300; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; OCHS HD, 1971, J CLIN INVEST, V50, P2559, DOI 10.1172/JCI106756; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Seyama K, 1998, BLOOD, V92, P2421, DOI 10.1182/blood.V92.7.2421.2421_2421_2434; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; Wang SD, 2000, BLOOD, V96, P2808; Witsch EJ, 2002, EUR J IMMUNOL, V32, P2680, DOI 10.1002/1521-4141(200209)32:9<2680::AID-IMMU2680>3.0.CO;2-6; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	32	19	19	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					958	964		10.1016/S0091-6749(03)02021-9	http://dx.doi.org/10.1016/S0091-6749(03)02021-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610488				2022-12-18	WOS:000186553300020
J	Perackis, K; Celik-Bilgili, S; Staden, U; Mehl, A; Niggemann, B				Perackis, K; Celik-Bilgili, S; Staden, U; Mehl, A; Niggemann, B			Influence of age on the outcome of the atopy patch test with food in children with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DOUBLE-BLIND; ALLERGY; CHALLENGES; INFANTS; ECZEMA; SKIN		Humboldt Univ, Childrens Hosp Charite, Dept Pediat Pneumol & Immunol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Perackis, K (corresponding author), Humboldt Univ, Childrens Hosp Charite, Dept Pediat Pneumol & Immunol, Berlin, Germany.							BOCK SA, 1994, PEDIATR CLIN N AM, V41, P1047; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Kekki OM, 1997, ALLERGY, V52, P755, DOI 10.1111/j.1398-9995.1997.tb01234.x; Niggemann B, 2002, J ALLERGY CLIN IMMUN, V110, P515, DOI 10.1067/mai.2002.126659; Niggemann B, 1999, CLIN EXP ALLERGY, V29, P91, DOI 10.1046/j.1365-2222.1999.00454.x; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; Niggemann B, 2000, ALLERGY, V55, P281, DOI 10.1034/j.1398-9995.2000.00464.x; Niggemann B, 2002, CURR OPIN ALLERGY CL, V2, P253, DOI 10.1097/00130832-200206000-00016; Roehr CC, 2001, J ALLERGY CLIN IMMUN, V107, P548, DOI 10.1067/mai.2001.112849; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; SEIDENARI S, 1992, ANN ALLERGY, V69, P201; SEYMOUR JL, 1987, J AM ACAD DERMATOL, V17, P988, DOI 10.1016/S0190-9622(87)70288-6; Sicherer SH, 1999, PEDIAT ALLERG IMM-UK, V10, P226, DOI 10.1034/j.1399-3038.1999.00040.x	14	19	21	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					625	627		10.1067/mai.2003.1656	http://dx.doi.org/10.1067/mai.2003.1656			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679826				2022-12-18	WOS:000185231200026
J	Tarlo, SM				Tarlo, SM			Laboratory challenge testing for occupational asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						occupational asthma; specific inhalation challenge testing; natural rubber latex allergy	NATURAL-RUBBER LATEX; ALLERGEN; AGENTS; RESPONSIVENESS; DIAGNOSIS; WORKERS		Toronto Western Hosp, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Tarlo, SM (corresponding author), Toronto Western Hosp, EC4-009,399 Bathurst St, Toronto, ON M5T 2S8, Canada.			Tarlo, Susan/0000-0002-4746-5310				Allmers H, 2002, J ALLERGY CLIN IMMUN, V110, P318, DOI 10.1067/mai.2002.126461; Banks DE, 1996, CHEST, V109, P1370, DOI 10.1378/chest.109.5.1370; Baur X, 1998, J ALLERGY CLIN IMMUN, V101, P24, DOI 10.1016/S0091-6749(98)70188-5; Charous BL, 2002, J ALLERGY CLIN IMMUN, V109, P31, DOI 10.1067/mai.2002.120953; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; Hunt LW, 2002, J ALLERGY CLIN IMMUN, V110, pS96, DOI 10.1067/mai.2002.125442; Lemiere C, 2001, J ALLERGY CLIN IMMUN, V107, P1063, DOI 10.1067/mai.2001.115486; Liss GM, 2001, AM J IND MED, V40, P347, DOI 10.1002/ajim.1108; MALO JL, 1990, J ALLERGY CLIN IMMUN, V85, P834, DOI 10.1016/0091-6749(90)90065-C; Ortega HG, 2002, CHEST, V121, P1323, DOI 10.1378/chest.121.4.1323; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; Poulos LM, 2002, J ALLERGY CLIN IMMUN, V109, P701, DOI 10.1067/mai.2002.122463; Quirce S, 2003, J ALLERGY CLIN IMMUN, V111, P788, DOI 10.1067/mai.2003.166; Tarlo S M, 1998, Can Respir J, V5, P289; Tarlo SM, 2002, J ALLERGY CLIN IMMUN, V109, P603, DOI 10.1067/mai.2002.123618; Vandenplas O, 1996, THORAX, V51, P472, DOI 10.1136/thx.51.5.472; Vandenplas O, 2002, J ALLERGY CLIN IMMUN, V109, P125, DOI 10.1067/mai.2002.120760; VANDENPLAS O, 1992, J ALLERGY CLIN IMMUN, V89, P1183, DOI 10.1016/0091-6749(92)90303-J; Vandenplas O, 2001, J ALLERGY CLIN IMMUN, V107, P542, DOI 10.1067/mai.2001.113519	19	19	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					692	694		10.1067/mai.2003.1374	http://dx.doi.org/10.1067/mai.2003.1374			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704344				2022-12-18	WOS:000182258500003
J	Asero, R				Asero, R			Fixed drug eruptions caused by tonic water	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							QUININE; INPATIENTS; SERIES; PERIOD		Osped Caduti Bollatesi, Ambulatorio Allergol, Bollate, MI, Italy		Asero, R (corresponding author), Osped Caduti Bollatesi, Ambulatorio Allergol, Bollate, MI, Italy.							ADKINSON NF, 1998, ALLERGY PRINCIPLES P, P1212; Batanero E, 2002, ALLERGY, V57, P65, DOI 10.1034/j.1398-9995.2002.13368.x; Ellis EF., 1983, ALLERGY PRINCIPLES P, P1389; Glynne P, 1999, AM J KIDNEY DIS, V33, P133, DOI 10.1016/S0272-6386(99)70269-6; Hunziker T, 1997, ALLERGY, V52, P388, DOI 10.1111/j.1398-9995.1997.tb01017.x; KAUPPINEN K, 1984, ACTA DERM-VENEREOL, V64, P320; KUOKKANEN K, 1972, ACTA ALLERGOL, V27, P407, DOI 10.1111/j.1398-9995.1972.tb01440.x; LJUNGGREN B, 1992, CONTACT DERMATITIS, V26, P1, DOI 10.1111/j.1600-0536.1992.tb00859.x; Mahboob A, 1998, INT J DERMATOL, V37, P833, DOI 10.1046/j.1365-4362.1998.00451.x; PIN I, 1985, PRESSE MED, V14, P967; PRICE EJ, 1992, BRIT J CLIN PRACT, V46, P138; RosaRe D, 1996, ANN RHEUM DIS, V55, P559, DOI 10.1136/ard.55.8.559-b; STUBB S, 1994, ACTA DERM-VENEREOL, V74, P289; YATES AB, 2001, CLIN IMMUNOLOGY PRIN	14	19	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					198	199		10.1067/mai.2003.44	http://dx.doi.org/10.1067/mai.2003.44			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532122				2022-12-18	WOS:000180465500034
J	Hall, G; Lund, L; Lamb, JR; Jarman, ER				Hall, G; Lund, L; Lamb, JR; Jarman, ER			Kinetics and mode of peptide delivery via the respiratory mucosa determine the outcome of activation versus T(H)2 immunity in allergic inflammation of the airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; tolerance; immunotherapy; in vivo animal models	REGULATORY T-CELLS; TOLERANCE; ANTIGEN; RESPONSES; INTERLEUKIN-10; IMMUNOTHERAPY; EXPOSURE; NAIVE; INDUCTION; DURATION	Background: Specific immunotherapy involving systemic injection of allergen, though highly effective, can cause severe side effects due to IgE-mediated activation of effector cells. Allergen-derived peptides might provide a safer alternative. We have investigated the use of mucosally delivered peptide to induce CD4(+) T(H)2 cell tolerance and thus protect against allergen-induced airway inflammation. Objective: The purpose of this study was to investigate whether intranasal administration of an allergen-derived peptide, either alone or adsorbed to chitosan, can prevent the induction of T(H)2-mediated pulmonary inflammation after sensitization and challenge of the airways with allergen. Methods: Mice were given (intranasally) a peptide containing an inummodominant epitope of the Dermataphagoides pteronyssinus (Der p) 1 allergen, either as soluble antigen or adsorbed to chitosan, before sensitization and allergen challenge. Pulmonary inflammation, antigen-specific CD4+ T-cell responses, and antibody levels in sera were then determined. Results: Mice given peptide adsorbed to chitosan had significant reductions in airway eosinophilia, which correlated with reduced levels of IL-4 and IL-5 in the bronchoalveolar lavage fluid. There was decreased recruitment of activated CD4+ T cells into the airways after allergen challenge, which correlated with a loss of Der p 1-specific T-cell cytokine responses in the periphery and the localized production of IL-10 by antigen-specific T cells in bronchial lymph nodes. Induction of peripheral T-cell tolerance was preceded by transient T-cell activation and IFN-gamma production. Conclusion: Our data demonstrate that suppression of airway inflammation by intranasal administration of peptide antigen adsorbed to chitosan is initiated by transient T-cell activation and maintained by the production of IL-10 by antigen-specific T cells in the draining lymph nodes.	ALK Abello AS, DK-2970 Horsholm, Denmark; Univ Edinburgh, Sch Med, Immunobiol Grp, MRC Ctr Inflammat Res,Resp Med Unit, Edinburgh EH8 9YL, Midlothian, Scotland	ALK-Abello AS; University of Edinburgh	Jarman, ER (corresponding author), ALK Abello AS, Boege Alle 6-8, DK-2970 Horsholm, Denmark.							Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Astori M, 2000, J IMMUNOL, V165, P3497, DOI 10.4049/jimmunol.165.6.3497; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Benson JM, 2000, J CLIN INVEST, V106, P1031, DOI 10.1172/JCI10738; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Burkhart C, 1999, INT IMMUNOL, V11, P1625, DOI 10.1093/intimm/11.10.1625; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Fernandez-Urrusuno R, 1999, PHARMACEUT RES, V16, P1576, DOI 10.1023/A:1018908705446; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659; Hamid QA, 2000, J ALLERGY CLIN IMMUN, V105, P20, DOI 10.1016/S0091-6749(00)90172-6; HIGGINS JA, 1994, J ALLERGY CLIN IMMUN, V93, P891, DOI 10.1016/0091-6749(94)90383-2; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; Howland KC, 2000, J IMMUNOL, V164, P4465, DOI 10.4049/jimmunol.164.9.4465; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; Iezzi G, 1999, EUR J IMMUNOL, V29, P4092, DOI 10.1002/(SICI)1521-4141(199912)29:12<4092::AID-IMMU4092>3.3.CO;2-1; ILLUM L, 1994, PHARMACEUT RES, V11, P1186, DOI 10.1023/A:1018901302450; Jahn-Schmid B, 1999, J ALLERGY CLIN IMMUN, V104, P1015, DOI 10.1016/S0091-6749(99)70083-7; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Lezzi G, 1998, IMMUNITY, V8, P89, DOI 10.1016/S1074-7613(00)80461-6; Metzler B, 1996, ANN NY ACAD SCI, V778, P228, DOI 10.1111/j.1749-6632.1996.tb21131.x; Oldfield WLG, 2001, J IMMUNOL, V167, P1734, DOI 10.4049/jimmunol.167.3.1734; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SEDGWICK JD, 1984, EUR J IMMUNOL, V14, P893, DOI 10.1002/eji.1830141006; Steinbrink K, 1997, J IMMUNOL, V159, P4772; Takeuchi H, 2001, ADV DRUG DELIVER REV, V47, P39, DOI 10.1016/S0169-409X(00)00120-4; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Wardlaw AJ, 1999, J ALLERGY CLIN IMMUN, V104, P917, DOI 10.1016/S0091-6749(99)70069-2; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	36	19	20	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2002	110	6					883	890		10.1067/mai.2002.129800	http://dx.doi.org/10.1067/mai.2002.129800			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	624TL	12464955				2022-12-18	WOS:000179777400011
J	Pignatti, P; Delmastro, M; Perfetti, L; Bossi, A; Balestrino, A; Di Stefano, A; Pisati, P; Balbi, B; Moscato, G				Pignatti, P; Delmastro, M; Perfetti, L; Bossi, A; Balestrino, A; Di Stefano, A; Pisati, P; Balbi, B; Moscato, G			Is dithiothreitol affecting cells and soluble mediators during sputum processing? A modified methodology to process sputum	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFLAMMATION						Pignatti, Patrizia/K-9595-2016; Di Stefano, Antonino/AAB-8041-2020; perfetti, luca/AAE-1094-2020; Balbi, Bruno/E-8380-2019; balestrino, antonella/AAC-6967-2020	Pignatti, Patrizia/0000-0001-5283-3897; Di Stefano, Antonino/0000-0003-3479-0875; Balbi, Bruno/0000-0002-4439-1424; balestrino, antonella/0000-0002-7982-1578; perfetti, luca/0000-0001-7646-8214				Di Stefano A, 2001, CLIN EXP ALLERGY, V31, P893, DOI 10.1046/j.1365-2222.2001.01098.x; Efthimiadis A, 1997, EUR RESPIR J, V10, P1336, DOI 10.1183/09031936.97.10061336; Holz O, 2000, EUR RESPIR J, V16, P355, DOI 10.1034/j.1399-3003.2000.16b26.x; Kelly MM, 2000, J ALLERGY CLIN IMMUN, V105, P1162, DOI 10.1067/mai.2000.106375; Kelly MM, 2001, EUR RESPIR J, V18, P685, DOI 10.1183/09031936.01.00098501; Spanevello A, 1997, CLIN EXP ALLERGY, V27, P1138; Stockley RA, 2000, EUR RESPIR J, V15, P778, DOI 10.1034/j.1399-3003.2000.15d24.x	7	19	19	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2002	110	4					667	669		10.1067/mai.2002.128279	http://dx.doi.org/10.1067/mai.2002.128279			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	602JJ	12373281				2022-12-18	WOS:000178501900023
J	Buckner, JH; Holzer, U; Novak, EJ; Reijonen, H; Kwok, WW; Nepom, GT				Buckner, JH; Holzer, U; Novak, EJ; Reijonen, H; Kwok, WW; Nepom, GT			Defining antigen-specific responses with human MHC class II tetramers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						human immunology; HLA molecules; immunotherapy; CD4(+) T cells; immunogenetics	CD8(+) T-CELLS; PEPTIDE COMPLEXES; MELANOMA PATIENTS; ESCHERICHIA-COLI; CUTTING EDGE; EX-VIVO; LYMPHOCYTES; CD4(+); INDUCTION; BINDING	Antigen-specific CD4(+) T lymphocytes play key roles in the orchestration of immune responses, including the initiation and amplification of allergic and immune-mediated disorders. Direct detection and quantitation of these cells is made possible by the use of HLA class II tetramers, soluble recombinant forms of a complex of HLA molecule and antigenic peptide that bind the antigen-specific T-cell receptor used for T-cell recognition. By using flow cytometry with fluorescent tetramers, specific T cells can be identified, recovered, and analyzed for functional markers and transcripts, helping to characterize the lineage and commitment program for individual lymphocytes. Several newly emerging uses for tetramers in clinical immunology are under development for patient management or prognosis when the number or nature of antigen-specific T cells can be clinically important. Tetramers might be useful as patient-monitoring tools for evaluating response to immunotherapy, providing a surrogate marker for the immunologic response foreshadowing a clinical response to either immune stimulation, suppression, or deviation therapeutic modalities.	Virginia Mason Res Ctr, Benaroya Res Inst, Seattle, WA 98101 USA; Univ Washington, Sch Med, Seattle, WA USA	Benaroya Research Institute; Virginia Mason Medical Center; University of Washington; University of Washington Seattle	Nepom, GT (corresponding author), Virginia Mason Res Ctr, Benaroya Res Inst, 1201 9th St, Seattle, WA 98101 USA.			Nepom, Gerald/0000-0002-8063-1464; Reijonen, Helena/0000-0002-9386-3918				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Appay V, 2002, J IMMUNOL, V168, P3660, DOI 10.4049/jimmunol.168.7.3660; Appel H, 2000, J BIOL CHEM, V275, P312, DOI 10.1074/jbc.275.1.312; Blake N, 2000, J IMMUNOL, V165, P7078, DOI 10.4049/jimmunol.165.12.7078; Bonini C, 2001, J IMMUNOL, V166, P5250, DOI 10.4049/jimmunol.166.8.5250; Brusic V, 1998, BIOINFORMATICS, V14, P121, DOI 10.1093/bioinformatics/14.2.121; Buckner JH, 2002, ARTHRITIS RHEUM, V46, P238, DOI 10.1002/1529-0131(200201)46:1<238::AID-ART10030>3.0.CO;2-M; Burrows SR, 2000, J IMMUNOL, V165, P6229, DOI 10.4049/jimmunol.165.11.6229; Cameron TO, 2001, J IMMUNOL, V166, P741, DOI 10.4049/jimmunol.166.2.741; CASARES, 2001, PROTEIN ENG, V14, P195; Casares S, 2002, NAT IMMUNOL, V3, P383, DOI 10.1038/ni770; Cochran JR, 2000, IMMUNITY, V12, P241, DOI 10.1016/S1074-7613(00)80177-6; Cochran JR, 2000, CHEM BIOL, V7, P683, DOI 10.1016/S1074-5521(00)00019-3; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Denkberg G, 2000, EUR J IMMUNOL, V30, P3522, DOI 10.1002/1521-4141(2000012)30:12<3522::AID-IMMU3522>3.0.CO;2-D; Dunbar PR, 2000, J IMMUNOL, V165, P6644, DOI 10.4049/jimmunol.165.11.6644; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Gea-Banacloche JC, 2000, J IMMUNOL, V165, P1082, DOI 10.4049/jimmunol.165.2.1082; Geluk A, 2000, J IMMUNOL, V165, P6463, DOI 10.4049/jimmunol.165.11.6463; Greten TF, 2002, CLIN DIAGN LAB IMMUN, V9, P216, DOI 10.1128/CDLI.9.2.216-220.2002; HAMMER J, 1994, J EXP MED, V180, P2353, DOI 10.1084/jem.180.6.2353; Jensen PE, 1999, IMMUNOL REV, V172, P229, DOI 10.1111/j.1600-065X.1999.tb01368.x; Kim SK, 2000, J IMMUNOL, V165, P7285, DOI 10.4049/jimmunol.165.12.7285; Kotzin BL, 2000, P NATL ACAD SCI USA, V97, P291, DOI 10.1073/pnas.97.1.291; Kwok WW, 2000, J IMMUNOL, V164, P4244, DOI 10.4049/jimmunol.164.8.4244; Kwok WW, 2001, TRENDS IMMUNOL, V22, P583, DOI 10.1016/S1471-4906(01)02038-5; Lechner F, 2001, REV MED VIROL, V11, P11, DOI 10.1002/rmv.295; Meyer AL, 2000, P NATL ACAD SCI USA, V97, P11433, DOI 10.1073/pnas.190335897; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Nepom GT, 2002, ARTHRITIS RHEUM, V46, P5, DOI 10.1002/1529-0131(200201)46:1<5::AID-ART10063>3.0.CO;2-S; Novak EJ, 1999, J CLIN INVEST, V104, pR63, DOI 10.1172/JCI8476; Novak EJ, 2001, J IMMUNOL, V166, P6665, DOI 10.4049/jimmunol.166.11.6665; Novak EJ, 2001, INT IMMUNOL, V13, P799, DOI 10.1093/intimm/13.6.799; Oelke M, 2000, SCAND J IMMUNOL, V52, P544, DOI 10.1046/j.1365-3083.2000.00810.x; Ogg GS, 1999, IMMUNOL LETT, V66, P77, DOI 10.1016/S0165-2478(98)00161-8; Palermo B, 2001, EUR J IMMUNOL, V31, P412, DOI 10.1002/1521-4141(200102)31:2<412::AID-IMMU412>3.0.CO;2-4; Pelfrey CM, 2000, J IMMUNOL, V165, P1641, DOI 10.4049/jimmunol.165.3.1641; PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569; Prezzi C, 2001, EUR J IMMUNOL, V31, P894, DOI 10.1002/1521-4141(200103)31:3<894::AID-IMMU894>3.0.CO;2-I; Quarsten H, 2001, J IMMUNOL, V167, P4861, DOI 10.4049/jimmunol.167.9.4861; Reichstetter S, 2000, J IMMUNOL, V165, P6994, DOI 10.4049/jimmunol.165.12.6994; Reijonen H, 2002, DIABETES, V51, P1375, DOI 10.2337/diabetes.51.5.1375; Romero P, 1998, J EXP MED, V188, P1641, DOI 10.1084/jem.188.9.1641; Roy MJ, 2000, VACCINE, V19, P764, DOI 10.1016/S0264-410X(00)00302-9; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; Schneck Jonathan P., 2000, Immunological Investigations, V29, P163, DOI 10.3109/08820130009062300; SHARMA SD, 1991, P NATL ACAD SCI USA, V88, P11465, DOI 10.1073/pnas.88.24.11465; Skinner PJ, 2000, J IMMUNOL, V165, P613, DOI 10.4049/jimmunol.165.2.613; Spack EG, 1995, J AUTOIMMUN, V8, P787, DOI 10.1016/S0896-8411(95)80018-2; Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555, DOI 10.1038/9858; Tao X, 1997, J IMMUNOL, V158, P4237; Valmori D, 2001, CANCER RES, V61, P509; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618; Yee C, 1999, J IMMUNOL, V162, P2227	55	19	22	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					199	208	UNSP 1/10/125976	10.1067/mai.2002.125976	http://dx.doi.org/10.1067/mai.2002.125976			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170258				2022-12-18	WOS:000177509800002
J	Condemi, JJ				Condemi, JJ			Allergic reactions to natural rubber latex at home, to rubber products, and to cross-reacting foods	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on Natural Rubber Latex Sensitivity	FEB 09-10, 2001	SAN FRANCISCO, CALIFORNIA	Malaysian Rubber Res Inst		allergic reactions; natural rubber latex; home; foods	FRUIT SYNDROME; SENSITIZATION; SENSITIVITY; PREVALENCE; ANTIBODIES; CHILDREN; PATIENT	The prevalence of clinical sensitivity to natural rubber latex (NRL) has increased dramatically in the last 15 years. In the health care setting this has been associated with the increased use of latex gloves. It does not, however, explain the observation that IgE antibodies to NRL are detected in equal rates in both health care workers and the general population, with the numerous reactions occurring in homes and in health care settings in non-health care workers. This increase in NRL sensitivity has occurred at the same time as our observation of an increase in atopy. In addition, atopy is a definite risk factor that has been associated with NRL sensitivity in all studies. Exposure to NRL products outside the health care environment is significant and ubiquitous. Exposure to NRL epitopes also occurs by ingestion of foods, food additives, and pollen. This exposure is sufficient to induce IgE antibodies to both the food and NRL proteins. It is therefore difficult in an individual patient to implicate any single product as the cause of NRL sensitization leading to the development of symptoms. Outside of the health care environment there does not appear to be an increase in exposure to NRL products or to cross-reacting materials. This would suggest that there is an increase in the susceptible population, which clearly appears to be the atopic individual. A great deal of attention is devoted to reducing exposure to latex gloves in the health care setting, which may be only the visible portion of the iceberg. More attention should be devoted to reducing the antigens present in all NRL products and consideration given to developing vaccines for the food-sensitive individuals.	Allergy Asthma Immunol Rochester, PC, Rochester, NY 14618 USA		Condemi, JJ (corresponding author), Allergy Asthma Immunol Rochester, PC, 919 Westfall Rd,Suite B120, Rochester, NY 14618 USA.							APPLEYARD J, 1994, J ALLERGY CLIN IMMUN, V93, pS55; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; Bernardini R, 1998, J ALLERGY CLIN IMMUN, V101, P621, DOI 10.1016/S0091-6749(98)70169-1; BLANCO C, 1994, ANN ALLERGY, V73, P309; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; Diaz-Perales A, 1999, J ALLERGY CLIN IMMUN, V104, P681, DOI 10.1016/S0091-6749(99)70342-8; Fiocchi A, 2001, J ALLERGY CLIN IMMUN, V108, P298, DOI 10.1067/mai.2001.116985; FORSTROM L, 1980, CONTACT DERMATITIS, V6, P633; Fuchs T, 1997, J ALLERGY CLIN IMMUN, V100, P356, DOI 10.1016/S0091-6749(97)70249-5; KELLY KJ, 1995, IMMUNOL ALLERGY CLIN, V15, P139; LAVAUD F, 1992, LANCET, V339, P492, DOI 10.1016/0140-6736(92)91100-M; Lavaud F, 1997, CLIN REV ALLERG IMMU, V15, P429, DOI 10.1007/BF02737738; Levy DA, 1997, REV FR ALLERGOL, V37, P1188, DOI 10.1016/S0335-7457(97)80150-5; Liebke C, 1996, PEDIATR ALLERGY IMMU, V7, P103, DOI 10.1111/j.1399-3038.1996.tb00115.x; MAKINENKILJUNEN S, 1994, J ALLERGY CLIN IMMUN, V93, P990, DOI 10.1016/S0091-6749(94)70046-X; Miguel AG, 1996, ENVIRON HEALTH PERSP, V104, P1180, DOI 10.2307/3432911; Novembre E, 1997, ALLERGY, V52, P101, DOI 10.1111/j.1398-9995.1997.tb02553.x; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; Palosuo T, 1997, REV FR ALLERGOL, V37, P1184, DOI 10.1016/S0335-7457(97)80149-9; Posch A, 1998, CLIN EXP ALLERGY, V28, P134; RAULFHEIMSOTH M, 1997, ENVIRON TOXICOL PHAR, V4, P61; Sanchez-Lopez G, 2000, J INVEST ALLERG CLIN, V10, P280; Stern G, 1927, KLIN WOCHENSCHR, V6, P1096; TURJANMAA K, 1995, IMMUNOL ALLERGY CLIN, V15, P71; Vandenplas O, 1996, J ALLERGY CLIN IMMUN, V97, P1421, DOI 10.1016/S0091-6749(96)70216-6; Yeang HY, 2000, J INVEST ALLERG CLIN, V10, P215	27	19	20	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2		S			S107	S110		10.1067/mai.2002.124968	http://dx.doi.org/10.1067/mai.2002.124968			4	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	586ET	12170250				2022-12-18	WOS:000177572200015
J	Hoff, M; Krail, M; Kastner, M; Haustein, D; Vieths, S				Hoff, M; Krail, M; Kastner, M; Haustein, D; Vieths, S			Fusarium culmorum causes strong degradation of pollen allergens in extract mixtures	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen extract mixtures; stability; protease; immunoblot; rat basophilic leukemia assay	APPLE ALLERGEN; STABILITY; STORAGE; IMMUNOTHERAPY; BIRCH	Background. Therapeutic allergen extracts are frequently stored as mixtures to provide preparations used for specific immunotherapy. Substantial protease activity, found in certain mold extracts, has been suspected to cause a loss of allergenic activity as a result of self-degradation, as well as by means of degradation of allergens from pollen and other allergenic sources. Objective: This study was performed to address possible deterioration of individual pollen allergens during storage of extract mixtures, with a mold extract as the source of proteolytic activity. Methods: Aqueous birch and timothy pollen extracts were stored for 60 days at VC with and without addition of an extract derived from the mold Fusarium culmorum. The stability of the pollen allergens Bet v 1, Bet v 6, PhI p 1, and PhI p 5, as well as, 2 to-date-undefined F culmorum allergens was examined by using immunoblotting analysis with sera from allergic patients and allergen-specific mAbs. Furthermore, the residual allergenic activity of the pollen extracts was monitored by using the rat basophilic leukemia cell-mediator release assay. Proteolytic activity of extracts was determined by using a commercial protease assay and gelatinase zymography. Results: Pollen extracts were very stable, corresponding to the low proteolytic activity of these extracts. In contrast, high proteolytic activity was found for the F culmorum extract, resulting in self-degradation of mold proteins and deactivation of allergens. Similarly, the mixtures showed a strong decrease of allergenic potency in the mediator release assay. Bet v 1 and PhI p 1 were relatively stable, whereas Bet v 6 and PhI p 5 were almost entirely degraded within 1 day. Conclusions: Proteases of the mold F culmorum clearly affected the overall allergenic activity of pollen extracts within a short time period. Apart from general objections against the use of mixtures of non-cross-reacting allergens, mixing of pollen extracts with extracts derived from molds for immunotherapy is not recommended unless they are applied directly after preparation of the mixture.	Paul Ehrlich Inst, Dept Allergol, D-63225 Langen, Germany	Paul Ehrlich Institute	Vieths, S (corresponding author), Paul Ehrlich Inst, Dept Allergol, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.							ANDERSON MC, 1982, J ALLERGY CLIN IMMUN, V69, P3, DOI 10.1016/0091-6749(82)90080-X; AYUSO R, 1984, ANN ALLERGY, V53, P426; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; BOUSQUET J, 1985, CLIN ALLERGY, V15, P426; BUCHMEIER A, 1992, J ALLERGY CLIN IMMUN, V89, P149; ESCH RE, 1992, ROLE PROTEASES STABI, V85; ESCH RE, 2000, FORMULATION THERAPEU, V93, P57; FROSTAD AB, 1983, CLIN ALLERGY, V13, P337, DOI 10.1111/j.1365-2222.1983.tb02609.x; HANSEN MY, 1994, ALLERGY, V49, P235, DOI 10.1111/j.1398-9995.1994.tb02655.x; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P192; Hoffmann A, 1997, FOOD AGR IMMUNOL, V9, P309, DOI 10.1080/09540109709354961; HOFFMANN A, 1997, J ALLERGY CLIN IMMUN, V99, P1; INO Y, 1989, INT ARCH ALLER A IMM, V89, P321, DOI 10.1159/000234970; Karamloo F, 1999, J ALLERGY CLIN IMMUN, V104, P991, DOI 10.1016/S0091-6749(99)70080-1; KERSTEN W, 1980, WIEN MED WOCHENSCHR, V8, P275; KNOLL R, 1991, Journal of Allergy and Clinical Immunology, V87, P188, DOI 10.1016/0091-6749(91)91483-A; KORDASH TH, 2000, REQUIREMENTS DEMONST, V93, P145; KORDASH TR, 1993, ANN ALLERGY, V71, P240; MALLING HJ, 1993, ALLERGY, V48, P9; MALLING HJ, 2000, NAMED PATIENT PRODUC, V93, P67; MOLLER C, 1986, CLIN ALLERGY, V16, P135, DOI 10.1111/j.1365-2222.1986.tb00757.x; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V98, P382, DOI 10.1016/S0091-6749(96)70162-8; NELSON HS, 1981, J ALLERGY CLIN IMMUN, V67, P64, DOI 10.1016/0091-6749(81)90047-6; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V62, P314, DOI 10.1016/0091-6749(78)90164-1; OLIVER JD, 1992, J ALLERGY CLIN IMMUN, V89, P147; PETERSEN A, 1995, J ALLERGY CLIN IMMUN, V95, P987, DOI 10.1016/S0091-6749(95)70099-4; PETERSEN A, 1994, CLIN EXP ALLERGY, V24, P250, DOI 10.1111/j.1365-2222.1994.tb00227.x; SAPORTA A, 2000, NAMED PATIENT PREPAR, V93, P63; SAVOLAINEN J, 1992, CLIN EXP ALLERGY, V22, P991, DOI 10.1111/j.1365-2222.1992.tb03026.x; SRIDHARA S, 1992, ASIAN PAC J ALLERGY, V10, P33; VANHOEYVELD EM, 1985, J ALLERGY CLIN IMMUN, V76, P543, DOI 10.1016/0091-6749(85)90773-0; VIETHS S, 1994, INT ARCH ALLERGY IMM, V104, P399, DOI 10.1159/000236698; VIETHS S, 1995, ALLERGY, V50, P421, DOI 10.1111/j.1398-9995.1995.tb01172.x; White D., 1993, PROMEGA NOTES, V44, P2; WIHL JA, 1988, ALLERGY, V43, P363, DOI 10.1111/j.1398-9995.1988.tb00430.x; WONGTIM S, 1993, ALLERGY PROC, V14, P163; Zamir LO, 2000, CAN J MICROBIOL, V46, P143	37	19	20	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					96	101		10.1067/mai.2002.120560	http://dx.doi.org/10.1067/mai.2002.120560			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799372				2022-12-18	WOS:000173739300015
J	Sakaguchi, M; Inouye, S				Sakaguchi, M; Inouye, S			Anaphylaxis to gelatin-containing rectal suppositories	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						anaphylaxis; gelatin; IgE; suppository	IMMEDIATE-TYPE REACTIONS; VACCINES; CHILDREN; MEASLES; ALLERGY; MUMPS; IGE	Background: Some children-though the number is few-have been sensitized with gelatin. Objective: To investigate the relationship between the presence of antigelatin IgE and anaphylaxis to gelatin-containing rectal suppository, we measured antigelatin IgE in the sera of the children with anaphylaxis. Methods: Ten children showed systemic allergic reactions, including anaphylaxis, to a chloral hydrate rectal suppository containing gelatin (231 mg/dose) that had been used as a sedative. These children's clinical histories and serum samples were submitted from physicians to the National Institute of Infectious Diseases during a 2-year period from 1996 to 1997. Results: Of the 10 children, 5 showed apparent anaphylaxis, including hypotension and/or cyanosis, along with urticaria or wheezing; 2 showed both urticaria and wheezing without hypotension or cyanosis; the other 3 showed only urticaria. All of the children had antigelatin IgE (mean value +/- SD, 7.9 +/- 8.4 Ua/mL). As a control, samples from 250 randomly selected children had no antigelatin IgE. These findings suggest that the 10 children's systemic allergic reactions to this suppository were caused by the gelatin component. Conclusion: Gelatin-containing suppositories must be used with the same caution as gelatin-containing vaccines and other medications.	Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Tokyo 1628640, Japan; Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Shinjuku Ku, Tokyo 1628640, Japan	National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID)	Sakaguchi, M (corresponding author), Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Toyama 1-23-1, Tokyo 1628640, Japan.		Inouye, Sharon/R-7216-2019					HASEGAWA M, 1997, J JPN PEDIAT SOC, V101, P1199; HOSHINO M, 1977, JPN J PEDIAT, V30, P35; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; Malviya S, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.3.e42; PICHLER WJ, 1992, ANN ALLERGY, V69, P521; Sakaguchi M, 2000, VACCINE, V19, P431, DOI 10.1016/S0264-410X(00)00206-1; Sakaguchi M, 1999, J ALLERGY CLIN IMMUN, V103, P349, DOI 10.1016/S0091-6749(99)70512-9; SAKAGUCHI M, 1995, J ALLERGY CLIN IMMUN, V96, P563, DOI 10.1016/S0091-6749(95)70304-7; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V98, P1058, DOI 10.1016/S0091-6749(96)80191-6	9	19	20	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					1033	1034		10.1067/mai.2001.119412	http://dx.doi.org/10.1067/mai.2001.119412			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742284				2022-12-18	WOS:000172938400022
J	Casale, TB				Casale, TB			Experience with monoclonal antibodies in allergic mediated disease: Seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; anti-IgE; omalizumab; allergy; immunoglobulin; pollen	ANTI-IGE ANTIBODY; QUALITY-OF-LIFE; THERAPY; IMMUNOTHERAPY; INHIBITION	Current therapies for the treatment of seasonal allergic rhinitis include allergen avoidance; pharmacologic interventions such as sympathomimetics, topical and systemic corticosteroids, and chromones; and immunotherapy. In an attempt to create a novel therapy, therapeutic agents have been designed to inhibit IgE responses that are intimately involved in the induction of the allergic response. Omalizumab, a humanized monoclonal antibody against IgE, represents a novel therapeutic intervention for seasonal allergic rhinitis. Complex formation of omalizumab with serum-free IgE reduces the amount of IgE available for binding to effector cells and thus has the potential to reduce IgE-mediated allergic symptoms. Clinical trial results confirmed that omalizumab reduces free IgE to a level that is associated with suppressed allergic symptoms. reduces concomitant rescue medication use, and improves rhinitis-specific quality of lire. Patients treated with omalizumab during one pollen season can be re-treated during the subsequent season with minimal risk of adverse events. Omalizumab is non-allergen-specific and does not induce acute anaphylaxis because of the lack or IgE crosslinking with basophil- or mast-celt-bound IgE. Furthermore, subcutaneous or intravenous administration of omalizumab does not invoke the generation of anti-omalizumab antibodies. Thus, omalizumab represents a novel agent that should assist in the treatment of allergic rhinitis.	Creighton Univ, Omaha, NE 68131 USA	Creighton University	Casale, TB (corresponding author), Creighton Univ, 601 N 30th St,Suite 5850, Omaha, NE 68131 USA.		Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377				Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Adkinson NF, 1999, NEW ENGL J MED, V341, P522, DOI 10.1056/NEJM199908123410710; Barnes PJ, 1999, NATURE, V402, pB31, DOI 10.1038/35037026; Barnes PJ, 1999, NEW ENGL J MED, V341, P2006, DOI 10.1056/NEJM199912233412610; Blaiss MS, 1999, ANN ALLERG ASTHMA IM, V83, P449, DOI 10.1016/S1081-1206(10)62850-5; Casale T, 1999, ANN ALLERG ASTHMA IM, V82, P75; Casale TB, 2000, J ALLERGY CLIN IMMUN, V105, pS357, DOI 10.1016/S0091-6749(00)91478-7; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; CASALE TB, 2000, ANN ALLERG ASTHMA IM, V84, P125; Demoly P, 1997, AM J RESP CRIT CARE, V155, P1825, DOI 10.1164/ajrccm.155.6.9196081; DuBuske LM, 1999, ALLERGY ASTHMA PROC, V20, P341, DOI 10.2500/108854199778251744; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P478, DOI 10.1016/S1081-1206(10)63155-9; Fox JA, 1996, J PHARMACOL EXP THER, V279, P1000; Heusser C, 1997, CURR OPIN IMMUNOL, V9, P805, DOI 10.1016/S0952-7915(97)80182-3; Jardieu PM, 1999, INT ARCH ALLERGY IMM, V118, P112, DOI 10.1159/000024043; Nayak A, 1999, J ALLERGY CLIN IMMUN, V103, pS49; Patalano F, 1999, ALLERGY, V54, P103; PRESTA LG, 1993, J IMMUNOL, V151, P2623; Ragusa FV, 1997, J INVEST ALLERG CLIN, V7, P151; Schoenhoff M., 1995, PHARMACOL RES S, V12, P411; SHIELDS RL, 1995, INT ARCH ALLERGY IMM, V107, P308, DOI 10.1159/000237010; SHIELDS RL, 1995, INT ARCH ALLERGY IMM, V107, P412, DOI 10.1159/000237058	22	19	19	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2		S			S84	S88		10.1067/mai.2001.116433	http://dx.doi.org/10.1067/mai.2001.116433			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	466VB	11498678				2022-12-18	WOS:000170665900004
J	Santanello, NC				Santanello, NC			Pediatric asthma assessment: Validation of 2 symptom diaries	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pediatric clinical trials; questionnaires; diaries	EXPIRATORY FLOW-RATES; CHILDREN; DIARY; MONTELUKAST; MANAGEMENT	Accurate assessment of the value of asthma interventions in pediatric clinical trials is an essential step toward the improvement of the treatment of this disorder in children. Conventional pulmonary function measures can be infeasible and unreliable In younger children, particularly for use in multisite studies. As an alternative or supplemental approach, diary questionnaires completed by the patients or their caregivers may provide valuable data regarding the efficacy of asthma interventions in pediatric clinical trials. These questionnaires, however, have routinely not been validated for use in pediatric populations. Two pediatric diary questionnaires (the child-completed Pediatric Asthma Diary [PAD] and the parent/caregiver-completed Pediatric Asthma Caregiver Diary [PACD]) were designed to evaluate asthma symptoms in children aged 6 to 14 years and 2 to 5 years, respectively. The validity of these diary questionnaires was evaluated in 2 separate prospective studies that included children who were divided into 2 asthma groups: stable (requiring no additional asthma medication) and unstable (requiring either an increase in or the addition of asthma medication). Both scales displayed significant discriminant validity, construct validity, and responsiveness to change in asthma therapy. Only the PACD detected differences between groups in nighttime symptoms, such as awakenings caused by asthma, These validity studies suggest that diary questionnaires such as the PAD and PACD can be valuable as an alternative for the evaluation of interventions in pediatric asthma when pulmonary function testing is inappropriate or as an adjunct to such objective measures.	Merck Res Labs, West Point, PA 19486 USA	Merck & Company	Santanello, NC (corresponding author), Merck Res Labs, POB 4,BL 1-7, West Point, PA 19486 USA.							*AM AC ALL ASHTM I, 1999, PED ASTHM PROM BEST; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BRUNEKREEF B, 1992, EUR RESPIR J, V5, P930; CHRISTIE MJ, 1993, PSYCHOSOM MED, V55, P541, DOI 10.1097/00006842-199311000-00010; Condemi JJ, 1997, J ALLERGY CLIN IMMUN, V100, P467, DOI 10.1016/S0091-6749(97)70137-4; FLOREY CV, 1982, WHO REGIONAL PUBLICA, V2; FRITZ GK, 1989, PSYCHOSOM MED, V51, P347, DOI 10.1097/00006842-198905000-00009; *GLOB IN ASTHM, 1998, NIH PUBLICATION; HENRY R, 1991, J PAEDIATR CHILD H, V27, P218, DOI 10.1111/j.1440-1754.1991.tb00395.x; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; Lara M, 2000, MED CARE, V38, P342, DOI 10.1097/00005650-200003000-00011; MALO JL, 1993, J ALLERGY CLIN IMMUN, V91, P702, DOI 10.1016/0091-6749(93)90189-M; MALO JL, 1989, AM REV RESPIR DIS, V140, P624, DOI 10.1164/ajrccm/140.3.624; MCFADDEN ER, 1986, J ALLERGY CLIN IMMUN, V77, P1, DOI 10.1016/0091-6749(86)90313-1; Parkin PC, 1996, J CLIN EPIDEMIOL, V49, P821, DOI 10.1016/0895-4356(96)00027-3; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Santanello NC, 1997, EUR RESPIR J, V10, P646; Santanello NC, 2000, J ALLERGY CLIN IMMUN, V106, P861, DOI 10.1067/mai.2000.110478; Santanello NC, 1999, ARCH DIS CHILD, V80, P414, DOI 10.1136/adc.80.5.414; SCHLOSSER M, 1992, J ASTHMA, V29, P99, DOI 10.3109/02770909209059878; Shingo S, 2001, EUR RESPIR J, V17, P220, DOI 10.1183/09031936.01.17202200; SLY PD, 1985, AM J DIS CHILD, V139, P479, DOI 10.1001/archpedi.1985.02140070053032; Sly PD, 1997, EUR RESPIR J, V10, pS80; TAYLOR GH, 1991, J PSYCHOSOM RES, V35, P483, DOI 10.1016/0022-3999(91)90043-N; TOWNSEND M, 1991, ANN ALLERGY, V67, P403; USHERWOOD TP, 1990, ARCH DIS CHILD, V65, P779, DOI 10.1136/adc.65.7.779; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; Wu AW, 1999, AM J RESP CRIT CARE, V159, pA911	29	19	19	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5		S			S465	S472		10.1067/mai.2001.114948	http://dx.doi.org/10.1067/mai.2001.114948			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	435RD	11344376				2022-12-18	WOS:000168894200005
J	Pumphrey, RSH; Duddridge, M; Norton, J				Pumphrey, RSH; Duddridge, M; Norton, J			Fatal latex allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANAPHYLAXIS; FOOD		St Marys Hosp, Cent Manchester Healthcare NHS Trust Hosp, Immunol Unit, Manchester M13 0JH, Lancs, England; Leicester Royal Infirm, Dept Immunol, Leicester LE1 5WW, Leics, England; Univ Hosp, London SE13 6LH, England	University of Manchester; University of Leicester	Pumphrey, RSH (corresponding author), St Marys Hosp, Cent Manchester Healthcare NHS Trust Hosp, Immunol Unit, Hathersage Rd, Manchester M13 0JH, Lancs, England.							JABALOYAS JMM, 1995, ACTA UROL ESP, V19, P143; Liss GM, 1999, AM J IND MED, V35, P196, DOI 10.1002/(SICI)1097-0274(199902)35:2<196::AID-AJIM12>3.0.CO;2-Y; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; Pumphrey RSH, 2000, LANCET, V355, P1099, DOI 10.1016/S0140-6736(05)72220-0; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Salkie ML, 1998, ALLERGY ASTHMA PROC, V19, P131, DOI 10.2500/108854198778604121; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603	7	19	19	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					558	558		10.1067/mai.2001.113518	http://dx.doi.org/10.1067/mai.2001.113518			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240964				2022-12-18	WOS:000167793300025
J	Sanak, M; Szczeklik, A				Sanak, M; Szczeklik, A			Leukotriene C-4 synthase polymorphism and aspirin-induced asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INTOLERANT ASTHMA		Jagiellonian Univ, Sch Med, Dept Med, PL-31066 Krakow, Poland	Jagiellonian University	Sanak, M (corresponding author), Jagiellonian Univ, Sch Med, Dept Med, 8 Skawifiska St, PL-31066 Krakow, Poland.		Sanak, Marek/AAV-1628-2021; Sanak, Marek/A-2115-2008	Sanak, Marek/0000-0001-7635-8103; 				Sanak M, 2000, AM J RESP CELL MOL, V23, P290, DOI 10.1165/ajrcmb.23.3.4051; Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9; Silverman EK, 2000, AM J RESP CELL MOL, V22, P645, DOI 10.1165/ajrcmb.22.6.f191; Van Sambeek R, 2000, J ALLERGY CLIN IMMUN, V106, P72, DOI 10.1067/mai.2000.107603	4	19	20	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					561	561		10.1067/mai.2001.112853	http://dx.doi.org/10.1067/mai.2001.112853			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240968	Green Submitted, Bronze			2022-12-18	WOS:000167793300029
J	Quirce, S; Hinojosa, M; Maranon, F; Ferrer, A; Fernandez-Caldas, E; Sastre, J				Quirce, S; Hinojosa, M; Maranon, F; Ferrer, A; Fernandez-Caldas, E; Sastre, J			Identification of obeche wood (Triplochiton scleroxylon) allergens associated with occupational asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							DUST		Fdn Jimenez Diaz, Serv Alergia, E-28040 Madrid, Spain; Hosp Ramon y Cajal, Dept Allergy, E-28034 Madrid, Spain; Clin San Carlos, Dept Allergy, Alicante, Spain	Hospital Universitario Ramon y Cajal	Quirce, S (corresponding author), Fdn Jimenez Diaz, Serv Alergia, Avda Reyes Catolicos 2, E-28040 Madrid, Spain.		s, q/AAD-7171-2020	Ferrer, Angel/0000-0001-6567-053X				Fernandez-Caldas E, 1998, J ALLERGY CLIN IMMUN, V101, P554, DOI 10.1016/S0091-6749(98)70364-1; HINOJOSA M, 1990, ANN ALLERGY, V64, P476; HINOJOSA M, 1984, J ALLERGY CLIN IMMUN, V74, P782, DOI 10.1016/0091-6749(84)90179-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; REIJULA K, 1994, THORAX, V49, P622, DOI 10.1136/thx.49.6.622	5	19	20	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					400	401						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932087				2022-12-18	WOS:000088708100026
J	Mahmudi-Azer, S; Velazquez, JR; Lacy, P; Denburg, JA; Moqbel, R				Mahmudi-Azer, S; Velazquez, JR; Lacy, P; Denburg, JA; Moqbel, R			Immunofluorescence analysis of cytokine and granule protein expression during eosinophil maturation from cord blood-derived CD34(+) progenitors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; CD34(+) progenitor; cytokine; chemokine; cord blood; IL-3; IL-5; IL-6; RANTES; confocal microscopy; crystalloid granule	MAJOR BASIC-PROTEIN; CATIONIC PROTEIN; INTERFERON-GAMMA; DIFFERENTIATION; LOCALIZATION; CELLS; IDENTIFICATION; INTERLEUKIN-5; INFLAMMATION; ASSOCIATION	Background: In allergic inflammation and asthma, eosinophils are major effector cells. They have been shown to synthesize at least 23 cytokines, some of which are stored intracellularly in their unique crystalloid granules together with cationic granule protein. Little is known about the synthesis and storage of cytokines relative to cationic granule proteins in maturing eosinophils during eosinophilopoiesis. Objective: Our purpose was to analyze the expression of eosinophil-derived mediators, major basic protein (MBP), eosinophil cationic protein (ECP), IL-6, and RANTES, during early stages of eosinophil maturation in CD34(+) cell-derived colonies. Methods: Purified human cord blood CD34(+) cells mere grown in methylcellulose cultures in the presence of recombinant human IL-3 and IL-5. By confocal laser scanning microscopy the coexpression of eosinophil granular proteins MBP and ECP was determined concurrently with IL-6 and RANTES during eosinophil maturation on days 16, 19, 23, and 28 of culture. Results: Immunoreactivity against MBP, ECP, IL-6, and RANTES mas not detectable in freshly purified CD34(+) cells. Maturing eosinophils (>95%) exhibited positive immunostaining for all these proteins between days 16 and 28 of culture. At early stages of culture, discrete immunostaining mas observed around the periphery but not in the center of granular structures. By day 28 cultured eosinophil-like cells showed evidence of the acquisition of crystalloid granule-like structures, analogous to those observed in mature peripheral blood eosinophils. Conclusions: Eosinophils express and store cytokines simultaneously with cationic granule proteins during the process of maturation. We propose that the storage of cytokines during the development of eosinophils Is an early event and it may be integral to inflammatory responses involving these cells. The results of this study suggest a potential immunoregulatory function for maturing eosinophils.	Univ Alberta, Dept Med, Pulm Res Grp, Heritage Med Res Ctr 574, Edmonton, AB T6G 2S2, Canada; McMaster Univ, Dept Med, Asthma Res Grp, Hamilton, ON, Canada	University of Alberta; McMaster University	Moqbel, R (corresponding author), Univ Alberta, Dept Med, Pulm Res Grp, Heritage Med Res Ctr 574, Edmonton, AB T6G 2S2, Canada.		Lacy, Paige/A-6021-2010	Lacy, Paige/0000-0001-8885-6011; Velazquez, Juan/0000-0001-6910-0358				ACKERMAN SJ, 1983, J IMMUNOL, V131, P2977; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BEIL WJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1611, DOI 10.1177/41.11.8409368; Deetz DC, 1997, AM J RESP CRIT CARE, V155, P254, DOI 10.1164/ajrccm.155.1.9001321; DUBUCQUOI S, 1994, J EXP MED, V179, P703, DOI 10.1084/jem.179.2.703; DVORAK AM, 1989, LAB INVEST, V61, P116; Dvorak Ann M., 1993, P13; FLAVAHAN N, 1998, AM REV RESPIR DIS, V138, P685; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.me.44.020193.000505; Lacy P, 2000, CHEM IMMUNOL, V76, P134; Lacy P, 1999, BLOOD, V94, P23, DOI 10.1182/blood.V94.1.23.413k13_23_32; Lacy P, 1998, BLOOD, V91, P2508, DOI 10.1182/blood.V91.7.2508.2508_2508_2516; LeviSchaffer F, 1996, IMMUNOLOGY, V87, P155; LEVISCHAFFER F, 1995, BLOOD, V85, P2579, DOI 10.1182/blood.V85.9.2579.bloodjournal8592579; LEWIS DM, 1978, J CELL BIOL, V77, P702, DOI 10.1083/jcb.77.3.702; MOQBEL R, 1994, J ALLERGY CLIN IMMUN, V94, P1183, DOI 10.1016/0091-6749(94)90330-1; NAKAHATA T, 1982, J CELL PHYSIOL, V113, P455, DOI 10.1002/jcp.1041130314; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; Nakajima H, 1999, J LEUKOCYTE BIOL, V66, P447, DOI 10.1002/jlb.66.3.447; Popken-Harris P, 1998, BLOOD, V92, P623, DOI 10.1182/blood.V92.2.623.414k32_623_631; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; Scepek S, 1997, BLOOD, V89, P510, DOI 10.1182/blood.V89.2.510; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCOTT RE, 1970, J ULTRA MOL STRUCT R, V33, P16, DOI 10.1016/S0022-5320(70)90116-4; Shalit M, 1997, Allerg Immunol (Paris), V29, P7; SHALIT M, 1995, CELL IMMUNOL, V160, P50, DOI 10.1016/0008-8749(95)80008-7; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; Wardlaw AJ, 1995, ADV IMMUNOL, V60, P151, DOI 10.1016/S0065-2776(08)60586-6; WELLER P, 1994, MECHANISMS ASTHMA RH, P255; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; YOKOYAMA A, 1995, AM J RESP CRIT CARE, V151, P1354, DOI 10.1164/ajrccm.151.5.7735584	31	19	20	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1178	1184		10.1067/mai.2000.106930	http://dx.doi.org/10.1067/mai.2000.106930			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856153	Bronze			2022-12-18	WOS:000087781800020
J	Bocchino, V; Bertorelli, G; D'Ippolito, R; Castagnaro, A; Zhuo, XS; Grima, P; Di Comite, V; Damia, R; Olivieri, D				Bocchino, V; Bertorelli, G; D'Ippolito, R; Castagnaro, A; Zhuo, XS; Grima, P; Di Comite, V; Damia, R; Olivieri, D			The increased number of very late activation antigen-4-positive cells correlates with eosinophils and severity of disease in the induced sputum of asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; eosinophils; integrins; very late activation antigen-4; macrophage antigen-1; lymphocyte function-associated antigen-1; induced sputum	AIRWAY HYPERRESPONSIVENESS; BRONCHOALVEOLAR LAVAGE; BRONCHIAL BIOPSIES; INFILTRATION; EXPRESSION; INFLAMMATION; RESPONSES; ANTIBODY; COUNTS; SHEEP	Background: Lymphocyte function associate-1 (LFA-1), macrophage antigen-1 (Mac-l), and very late activation antigen-4 (VLA-4) are involved in the infiltration of leukocytes into the tissues. Experimental models of allergic inflammation suggest that VLA-4 could determine the selective recruitment of eosinophils into the inflamed airways. Objective: Our purpose was to evaluate the involvement of integrins in eosinophil recruitment in asthma. Methods: We evaluated by immunocytochemistry the expression of VLA-4 LFA-1, and Mac-1 and their relationship with inflammatory cells and severity of disease in the induced sputum of 20 mild to moderate atopic asthmatic subjects and in 8 healthy subjects. Results: The number of VLA-4+ cells is increased in asthmatic patients and VLA-4 is mainly localized on eosinophils. Furthermore, VLA-4+ cells are significantly related to eosinophils. In contrast, LFA-1 and Mac-1 cellular expressions do not differ between asthmatic and control subjects and are not related to any specific cell type. Eosinophils and VLA-4+ cells are significantly higher in moderately compared with mildly asthmatic patients (P < .01, P < .05) and with healthy control subjects (P < .0005, P < .001), Eosinophils and VLA-4+ cells are also higher in mildly asthmatic patients compared with control subjects (P < .001, P < .005). Conclusion: This is the first report demonstrating, by a noninvasive method in humans, that VLA-4+ cells are increased and correlate with the eosinophils in the induced sputum of atopic patients with mild to moderate asthma and that VLA-4 expression is related to the severity of disease.	Univ Parma, Dept Resp Dis, Parma, Italy	University of Parma	Bocchino, V (corresponding author), Univ Parma, Rasori Hosp, Dept Resp Dis, Via Rasori 10, I-43100 Parma, Italy.							Abraham WM, 1997, AM J RESP CRIT CARE, V156, P696, DOI 10.1164/ajrccm.156.3.9609039; ABRAHAM WM, 1994, J CLIN INVEST, V93, P776, DOI 10.1172/JCI117032; Bertorelli G, 1998, CLIN EXP ALLERGY, V28, P551; BOCCHINO V, 1995, EUR RESP J S19, V19, pS18; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910, DOI 10.1164/ajrccm.153.3.8630572; D'Ippolito R, 1999, CHEST, V115, P1611, DOI 10.1378/chest.115.6.1611; Foresi A, 1997, J ALLERGY CLIN IMMUN, V100, P58, DOI 10.1016/S0091-6749(97)70195-7; FORESI A, 1990, CHEST, V98, P528, DOI 10.1378/chest.98.3.528; FUKUDA T, 1996, AM J RESPIR CELL MOL, V14, P8494; Grootendorst DC, 1997, CLIN EXP ALLERGY, V27, P769, DOI 10.1111/j.1365-2222.1997.tb01211.x; HOLGATE ST, 1997, J JPN BRONCHOESOPHAG, V48, P51; Kraneveld AD, 1997, J ALLERGY CLIN IMMUN, V100, P242, DOI 10.1016/S0091-6749(97)70231-8; LABERGE S, 1995, AM J RESP CRIT CARE, V151, P822; Lantero S, 1998, EUR RESPIR J, V12, P1094, DOI 10.1183/09031936.98.12051094; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V152, P1926, DOI 10.1164/ajrccm.152.6.8520757; NAKAJIMA H, 1994, J EXP MED, V179, P1145, DOI 10.1084/jem.179.4.1145; *NIH NATL HEART LU, 1995, NIH PUBLICATION; OHKAWARA Y, 1995, AM J RESP CELL MOL, V12, P4, DOI 10.1165/ajrcmb.12.1.7529029; PILEWSKI JM, 1997, ASTHMA, P523; PRETOLANI M, 1994, J EXP MED, V180, P795, DOI 10.1084/jem.180.3.795; Richards IM, 1996, AM J RESP CELL MOL, V15, P172, DOI 10.1165/ajrcmb.15.2.8703473; ten Hacken NHT, 1998, CLIN EXP ALLERGY, V28, P1518; WALSH GM, 1991, J IMMUNOL, V146, P3419; ZANGRILLI JG, 1995, AM J RESP CRIT CARE, V151, P1346, DOI 10.1164/ajrccm.151.5.7537586	24	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				65	70		10.1016/S0091-6749(00)90179-9	http://dx.doi.org/10.1016/S0091-6749(00)90179-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629454				2022-12-18	WOS:000084992100009
J	Ten, RM; McKinstry, MJ; Bren, GD; Paya, CV				Ten, RM; McKinstry, MJ; Bren, GD; Paya, CV			Signal transduction pathways triggered by the Fc epsilon RIIb receptor (CD23) in human monocytes lead to nuclear factor-kappa B activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD23; Fc epsilon RI; IgE; signal transduction; nuclear-factor-kappa B; I kappa B	TYROSINE PHOSPHORYLATION; MONONUCLEAR PHAGOCYTES; TRANSCRIPTION FACTOR; ALPHA; MACROPHAGES; EXPRESSION; DEGRADATION; ANTIGEN; ASTHMA	Background: Alveolar macrophages play a key role in the initiation of the inflammatory reaction of allergic asthma, Alveolar macrophages and peripheral blood monocytes are activated when IgE/allergen immune complexes bind to the CD23 receptor, which leads to the production of inflammatory cytokines. Objective: We sought to investigate the molecular mechanisms regulating this early inflammatory response, We have focused on the study of the signal transduction pathways triggered by CD23 in human monocytes and the promonocytic cell line U937. Methods: CD23 was cross-linked in human monocytes and U937 cells with IgE immune complexes. Surface expression of CD23 was determined by FACS analysis. Transcription factor activation and gene transcription were studied by gel-shift assays and Northern blot analysis, respectively. I kappa B alpha phosphorylation and degradation was analyzed by Western blot. Results: Nuclear factor (NF)-kappa B is the main transcription factor involved in the gene activation that follows CD23 crosslinking in monocytes, CD23-induced NF-kappa B is a heterodimer composed of p65/p50 subunits, NF-kappa B nuclear translocation is secondary to the phosphorylation and subsequent degradation of the NF-kappa B inhibitory molecule I kappa B alpha. Tyrosine kinase-dependent, and not protein kinase C-dependent, pathways mediate CD23-triggered NF-kappa B activation but do not participate in the direct phosphorylation of I kappa B alpha. I kappa B alpha degradation and NF-kappa B nuclear translocation correlate with transcriptional activation of the inflammatory cytokines TNF-alpha and IL-1 beta. Conclusions: NF-kappa B is the main transcription factor involved in the signal transduction pathway of CD23 in monocytes.	Mayo Clin & Mayo Fdn, Div Allergy, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Immunol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Ten, RM (corresponding author), 200 2nd St SW, Rochester, MN 55905 USA.							Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bayon Y, 1998, BIOCHEM BIOPH RES CO, V242, P570, DOI 10.1006/bbrc.1997.8011; Campbell AM, 1997, ALLERGY, V52, P483, DOI 10.1111/j.1398-9995.1997.tb02591.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dugas N, 1996, EUR J IMMUNOL, V26, P1394, DOI 10.1002/eji.1830260632; GOSSET P, 1992, AM REV RESPIR DIS, V146, P768, DOI 10.1164/ajrccm/146.3.768; Gosset P, 1999, J ALLERGY CLIN IMMUN, V103, P289, DOI 10.1016/S0091-6749(99)70504-X; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; MARX J, 1995, SCIENCE, V270, P232, DOI 10.1126/science.270.5234.232; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; MCELHINNY JA, 1995, J VIROL, V69, P1500, DOI 10.1128/JVI.69.3.1500-1509.1995; MUDDE GC, 1995, IMMUNOL TODAY, V16, P380, DOI 10.1016/0167-5699(95)80005-0; PAULEUGENE N, 1992, J IMMUNOL, V149, P3066; QUAAZ F, 1994, BLOOD, V84, P3095; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; TAKENAKA M, 1995, INT ARCH ALLERGY IMM, V108, P247, DOI 10.1159/000237160; VERCELLI D, 1988, J EXP MED, V167, P1406, DOI 10.1084/jem.167.4.1406; WILLIAMS J, 1992, J IMMUNOL, V149, P2823; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X	22	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				376	387		10.1016/S0091-6749(99)70382-9	http://dx.doi.org/10.1016/S0091-6749(99)70382-9			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452760				2022-12-18	WOS:000082364800031
J	Nakada, M; Nishizaki, K; Yoshino, T; Okano, M; Yamamoto, T; Masuda, Y; Ohta, N; Akagi, T				Nakada, M; Nishizaki, K; Yoshino, T; Okano, M; Yamamoto, T; Masuda, Y; Ohta, N; Akagi, T			CD80 (B7-1) and CD86 (B7-2) antigens on house dust mite-specific T cells in atopic disease function through T-T cell interactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen-specific T cell; atopic disease; CD80; CD86; T-T cell interactions	DERMATOPHAGOIDES-PTERONYSSINUS; MAJOR ALLERGEN; B-CELLS; CD28; EXPRESSION; CTLA-4; RECEPTOR; STIMULATION; INDUCTION; RESPONSES	Background: CD80 (B7-1) and CD86 (B7-2) play an important role in antigen presentation to effector cells. Recent studies have demonstrated that these costimulatory molecules are also expressed on activated T cells. However, the functional role of CD80 and CD86 expressed on allergen-specific T cells in atopic diseases has not yet been clarified. Objective: We sought to determine the functional role of CD80 and CD86 expressed on allergen-specific T cells in atopic diseases. Methods: We assayed the expression of CD80 and CD86 on allergen-specific T-cell lines from patients with perennial allergic rhinitis stimulated by Dermatophagoides farinae-crude (Der f-c) antigen, 1 of the major allergens causing house dust mite allergy T-cell proliferation induced by Der f-c-specific T-T cell interactions was measured, and the role of CD80 and CD86 in this proliferation was examined. In addition, we compared the proportion of CD45RO(+)CD86(+) T cells in primary culture of PBMCs stimulated by Der f-c antigen between patients with perennial allergic rhinitis and control subjects. Results: On T-cell activation, CD86 antigen was upregulated earlier than CD80. Both CD80 and CD86 expressed on Der fc-specific T cells could provide costimulatory signals to induce allergen-specific T-cell proliferation that was partially inhibitable by both anti-CD80 and anti-CD86 mAbs, The proportion of CD45RO(+)CD86(+) T cells in primary culture from atopic patients was significantly higher than that from control subjects. Conclusion: These results suggest that costimulatory molecules, such as CD80 and CD86, expressed on allergen-specific T cells may be involved in the amplification of allergen-specific immune responses through T-T cell interactions in atopic diseases.	Okayama Univ, Sch Med, Dept Otorhinolaryngol, Okayama 7008558, Japan; Okayama Univ, Sch Med, Dept Pathol, Okayama 7008558, Japan; Nagoya City Univ, Sch Med, Dept Med Zool, Nagoya, Aichi 467, Japan	Okayama University; Okayama University; Nagoya City University	Nishizaki, K (corresponding author), Okayama Univ, Sch Med, Dept Otorhinolaryngol, 2-5-1 Shikata Cho, Okayama 7008558, Japan.							AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; AZUMA M, 1993, J EXP MED, V177, P845, DOI 10.1084/jem.177.3.845; BARNABA V, 1994, EUR J IMMUNOL, V24, P71, DOI 10.1002/eji.1830240112; BOISE LH, 1995, CURR OPIN IMMUNOL, V7, P520; Boussiotis VA, 1996, IMMUNOL REV, V153, P5, DOI 10.1111/j.1600-065X.1996.tb00918.x; DANDEU JP, 1982, IMMUNOLOGY, V46, P679; DAS MRP, 1995, EUR J IMMUNOL, V25, P207, DOI 10.1002/eji.1830250134; FREEMAN GJ, 1989, J IMMUNOL, V143, P2714; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; Greenfield EA, 1997, J IMMUNOL, V158, P2025; Hollsberg P, 1997, J IMMUNOL, V159, P4799; Ishiguro A, 1992, Arerugi, V41, P1658; ISHIZAKA K, 1984, ANNU REV IMMUNOL, V2, P159, DOI 10.1146/annurev.immunol.2.1.159; JENKINS MK, 1988, J IMMUNOL, V140, P3324; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KIMURA JY, 1990, IMMUNOLOGY, V70, P385; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; Nakada M, 1998, ALLERGY, V53, P527, DOI 10.1111/j.1398-9995.1998.tb04091.x; OKANO M, 1993, INT ARCH ALLERGY IMM, V101, P82, DOI 10.1159/000236502; Okano M, 1996, ALLERGY, V51, P29, DOI 10.1111/j.1398-9995.1996.tb04546.x; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SANSOM DM, 1993, EUR J IMMUNOL, V23, P295, DOI 10.1002/eji.1830230148; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; Sperling AI, 1996, IMMUNOL REV, V153, P155, DOI 10.1111/j.1600-065X.1996.tb00924.x; THOMPSON CB, 1995, CELL, V81, P979, DOI 10.1016/S0092-8674(05)80001-7; Tsicopoulos A, 1996, CLIN EXP ALLERGY, V26, P1119, DOI 10.1111/j.1365-2222.1996.tb00497.x; VERWILGHEN J, 1994, J IMMUNOL, V153, P1378; Voorhorst R., 1964, Allergie Asthma, V10, P329; WIERENGA EA, 1990, EUR J IMMUNOL, V20, P1519, DOI 10.1002/eji.1830200717; WYSSCORAY T, 1993, EUR J IMMUNOL, V23, P2175, DOI 10.1002/eji.1830230919	33	19	19	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					222	227		10.1016/S0091-6749(99)70139-9	http://dx.doi.org/10.1016/S0091-6749(99)70139-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400865				2022-12-18	WOS:000081738900035
J	Sanchez-Guerrero, IM; Escudero, AI; Bartolome, B; Palacios, R				Sanchez-Guerrero, IM; Escudero, AI; Bartolome, B; Palacios, R			Occupational allergy caused by carnation (Dianthus caryophyllus)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						occupational asthma; dianthus caryophyllus	GYPSOPHILA-PANICULATA; ASTHMA	Background: Occupational respiratory symptoms caused by decorative flowers are seldom reported in the literature. In our area a large portion of the population works in carnation (Dianthus caryophyllus) winter quarters, and many workers have symptoms of rhinitis and asthma related to exposition. Objective: The purposes of this study were to investigate whether the symptoms induced by carnation were IgE-mediated and to study the possible allergens involved. Methods: A total of 16 subjects employed in indoor carnation cultivation with symptoms during exposition time were studied along with 15 patients with allergic asthma who were not exposed to carnations and 15 healthy carnation workers used as control subjects, Skin prick tests with carnation extract and RASTs were performed. Protein bands were isolated by SDS-PAGE, and afterwards immunoblotting was performed to characterize the extract. Specific nasal provocation and nonspecific bronchial provocation tests were performed for all the asthmatic patients. Diurnal variation in peak expiratory flow was also measured. Results: Skin prick test responses with carnation extract were positive in 15 of the 16 patients and negative in all control subjects. Nasal provocation test responses with carnation extract were positive in 13 of 16 patients. A significant correlation was seen between RAST and nasal provocation results (P < .01). Immunoblotting of sera from 13 patients showed 2 major IgE-binding fractions of 34 and 35 kd in most of the patients, which could constitute the major allergen. Methacholine PD20 showed a variable degree of nonspecific bronchial hyperresponsiveness in all asthmatic subjects. Conclusion: Data demonstrate the involvement of carnation in occupational allergy, mediated by an IgE-dependent mechanism.	Hosp Rafael Mendez Lorca, Allergy Unit, Murcia, Spain; Bial Aristegui, Dept Res & Dev, Bilbao, Spain		Sanchez-Guerrero, IM (corresponding author), Inmaculada Sanchez Guerrero Villajos, Ricardo Gil 26,2 B, Murcia 30002, Spain.							ANTEPARA I, 1994, ALLERGY, V49, P478, DOI 10.1111/j.1398-9995.1994.tb00843.x; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; Bangha E, 1996, Am J Contact Dermat, V7, P188, DOI 10.1016/S1046-199X(96)90011-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CHANGYEUNG M, 1986, AM REV RESPIR DIS, V65, P169; COCKCROFT DW, 1990, ANN ALLERGY, V65, P169; GARCIAORTEGA P, 1992, J ALLERGY CLIN IMMUN, V89, P987, DOI 10.1016/0091-6749(92)90221-M; HAUSEN BM, 1984, ARCH DERMATOL, V120, P1206, DOI 10.1001/archderm.120.9.1206; KANERVA L, 1995, ALLERGY, V50, P174, DOI 10.1111/j.1398-9995.1995.tb05076.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGIER F, 1990, REV MAL RESPIR, V7, P337; LOSADA E, 1986, J ALLERGY CLIN IMMUN, V77, P635, DOI 10.1016/0091-6749(86)90358-1; MAESTRELLI P, 1992, CLIN EXP ALLERGY, V22, P103; MOIRA CY, 1990, CLIN EXP ALLERGY, V20, P1; Moneo I, 1993, Allergol Immunopathol (Madr), V21, P145; NEWMANTAYLOR AJ, 1980, THORAX, V35, P241, DOI 10.1136/thx.35.4.241; ORDOQUI E, 1994, SESIONES INTERHOSPIT, P169; PERRIN B, 1991, J ALLERGY CLIN IMMUN, V87, P630, DOI 10.1016/0091-6749(91)90381-W; PIIRILA P, 1994, INT ARCH OCC ENV HEA, V66, P131, DOI 10.1007/BF00383369; SCHROECKENSTEIN DC, 1990, J ALLERGY CLIN IMMUN, V86, P189, DOI 10.1016/S0091-6749(05)80065-X; TWIGGS JT, 1982, J ALLERGY CLIN IMMUN, V69, P474, DOI 10.1016/0091-6749(82)90124-5; WIDE L, 1967, LANCET, V2, P1105	23	19	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					181	185		10.1016/S0091-6749(99)70132-6	http://dx.doi.org/10.1016/S0091-6749(99)70132-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400858				2022-12-18	WOS:000081738900028
J	Kato, M; Hattori, T; Ito, H; Kageyama, M; Yamashita, T; Nitta, Y; Nakashima, I				Kato, M; Hattori, T; Ito, H; Kageyama, M; Yamashita, T; Nitta, Y; Nakashima, I			Serum-soluble Fas levels as a marker to distinguish allergic and nonallergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS		Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Otorhinolaryngol, Showa Ku, Aichi 4668550, Japan; Nagoya City Univ, Sch Med, Dept Otorhinolaryngol, Nagoya, Aichi 467, Japan; Mitsubishi Kagaku Bioclin Labs Inc, Tokyo, Japan; Aichi Med Univ, Dept Dermatol, Nagakute, Aichi 48011, Japan	Nagoya University; Nagoya University; Nagoya City University; Mitsubishi Kagaku Bio-Clinical Laboratories; Aichi Medical University	Kato, M (corresponding author), Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, 65 Tsurumai Cho, Aichi 4668550, Japan.		KATO, Masashi/I-7250-2014					CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Kato M, 1998, BRIT J DERMATOL, V138, P1091; KIMMELMAN CP, 1986, OTOLARYNG CLIN N AM, V19, P65; Knipping E, 1995, ARTHRITIS RHEUM, V38, P1735, DOI 10.1002/art.1780381205; Midis GP, 1996, CANCER RES, V56, P3870; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101	6	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1213	1214		10.1016/S0091-6749(99)70202-2	http://dx.doi.org/10.1016/S0091-6749(99)70202-2			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359909				2022-12-18	WOS:000080929500036
J	Corren, J; Rachelefsky, G; Spector, S; Schanker, H; Siegel, S; Holton, D; Karcher, K; Travers, S				Corren, J; Rachelefsky, G; Spector, S; Schanker, H; Siegel, S; Holton, D; Karcher, K; Travers, S			Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						levocabastine; topical antihistamine; nasal allergen challenge; H-1-receptor antagonist	SEASONAL ALLERGIC RHINITIS; TOPICAL TREATMENT; EFFICACY; SYMPTOMS; PLACEBO; CONJUNCTIVITIS; ANTIHISTAMINE; TOLERABILITY; CROMOGLYCATE; ANTAGONISTS	Background: Although prior studies have documented the rapid onset of action of topical intranasal levocabastine (LEV), little is known about its duration of action under nasal challenge conditions. Objectives: We sought to assess the onset and duration of action of escalating doses of LEV nasal spray by using a nasal allergen challenge (NAC) model. Methods: Eighteen asymptomatic subjects with histories of seasonal allergic rhinitis were enrolled into a randomized, single-blind, placebo-controlled, dose-ranging crossover study. Each patient was randomly assigned to receive single doses of placebo and intranasal LEV 0.1, 0.2, and 0.4 mg during 2 parts of the study. In part 1 (onset of action), NAC consisted of a single dose of allergen administered 5 minutes after study drug treatment. In part 2 (duration of action), NAC consisted of increasing doses of allergen administered 0.5, 6, 12, and 24 hours on separate days after study drug treatment. Nasal symptom scores (NSSs) and nasal peak expiratory pow rates were measured after NAC in both phases of the study, Blood samples for plasma LEV concentrations were drawn after each NAC. Results: In part 1, NSSs were significantly lower after the administration of LEV 0.1, 0.2, and 0.4 mg compared with placebo (P < .05). In part 2, NSSs were significantly tower after LEV doses of 0.2 and 0.4 mg compared with placebo at 0.5, 6, 12, and 24 hours after treatment (P < .05), The mean provocative dose of allergen required to elicit a positive nasal reaction was increased after LEV doses of 0.2 and 0.4 mg at 0.5, 6, and 12 hours after treatment. Nasal peak expiratory flow rates demonstrated no significant differences between LEV and placebo for any doses at any time points. Mean plasma LEV concentrations were low (range, 0 to 3.7 ng/mL) after all doses and did not correlate with drug efficacy. Conclusions: Single intranasal LEV doses of 0.1, 0.2, and 0.4 mg significantly reduced the severity of the immediate nasal response to allergen when administered 5 minutes before NAC. This protective effect against NAC continued to be present 24 hours after administration of LEV doses of 0.2 and 0.4 mg. Efficacy in blocking the reaction to NAC did not correlate with plasma LEV levels, suggesting that the inhibitory effect was due largely to topical rather than systemic effects.	Allergy Res Fdn Inc, Los Angeles, CA 90025 USA; Janssen Res Fdn, Titusville, NJ USA	Johnson & Johnson; Johnson & Johnson USA	Corren, J (corresponding author), Allergy Res Fdn Inc, 11620 Wilshire Blvd,Suite 200, Los Angeles, CA 90025 USA.							AWOUTERS F, 1992, AGENTS ACTIONS, V35, P12, DOI 10.1007/BF01990945; Bachert Claus, 1996, Rhinology (Utrecht), V34, P140; Baraniuk JN, 1997, J ALLERGY CLIN IMMUN, V99, pS763, DOI 10.1016/S0091-6749(97)70125-8; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P881, DOI 10.1016/0091-6749(88)90094-2; Busse W, 1996, AM J RHINOL, V10, P105, DOI 10.2500/105065896781795076; Dahl R., 1995, Rhinology (Utrecht), V33, P121; Day JH, 1997, ANN ALLERG ASTHMA IM, V79, P163, DOI 10.1016/S1081-1206(10)63104-3; Day JH, 1997, ANN ALLERG ASTHMA IM, V79, P533, DOI 10.1016/S1081-1206(10)63062-1; DECHANT KL, 1991, DRUGS, V41, P202, DOI 10.2165/00003495-199141020-00006; HEYKANTS J, 1995, CLIN PHARMACOKINET, V29, P221, DOI 10.2165/00003088-199529040-00002; HOLMBERG K, 1989, ALLERGY, V44, P281, DOI 10.1111/j.1398-9995.1989.tb01070.x; KIRKEGAARD J, 1983, BRIT J DIS CHEST, V77, P113, DOI 10.1016/0007-0971(83)90017-7; KOLLY M, 1986, BRIT J CLIN PHARMACO, V22, P389, DOI 10.1111/j.1365-2125.1986.tb02907.x; Meltzer EO, 1996, J ALLERGY CLIN IMMUN, V97, P617, DOI 10.1016/S0091-6749(96)70307-X; MICHIELS M, 1983, N34319 JANSS PHARM; NOBLE S, 1995, DRUGS, V50, P1032, DOI 10.2165/00003495-199550060-00009; PALMACARLOS AG, 1988, INT J CLIN PHARM RES, V8, P25; SCHATA M, 1991, J ALLERGY CLIN IMMUN, V87, P873, DOI 10.1016/0091-6749(91)90136-C; VANDENBUSSCHE G, 1986, DRUGS FUTURE, V11, P841; VANWAUWE JP, 1989, RHINOCONJUNCTIVITIS, P27	20	19	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					574	580		10.1016/S0091-6749(99)70226-5	http://dx.doi.org/10.1016/S0091-6749(99)70226-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200003				2022-12-18	WOS:000079723900006
J	Finkel, TH; Hunter, DJ; Paisley, JE; Finkel, RS; Larsen, GL				Finkel, TH; Hunter, DJ; Paisley, JE; Finkel, RS; Larsen, GL			Drug-induced lupus in a child after treatment with zafirlukast (Accolate)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Natl Jewish Med & Res Ctr, Eleanor & Michael Stobin Lab Pediat Res, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Div Pediat Rheumatol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Div Pediat Pulm Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Ft Collins Youth Clin, Ft Collins, CO USA; Colorado Neurol Serv PC, Denver, CO USA	National Jewish Health; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Finkel, TH (corresponding author), Natl Jewish Med & Res Ctr, Eleanor & Michael Stobin Lab Pediat Res, 1400 Jackson St, Denver, CO 80206 USA.							Cassidy JT, 1995, PEDIAT RHEUMATOLOGY; MONESTIER M, 1992, RHEUM DIS CLIN N AM, V18, P415; RUBIN RL, 1997, DUBOIS LUPUS ERYTHEM, P871; Wechsler ME, 1998, JAMA-J AM MED ASSOC, V279, P455, DOI 10.1001/jama.279.6.455	4	19	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				533	534		10.1016/S0091-6749(99)70482-3	http://dx.doi.org/10.1016/S0091-6749(99)70482-3			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069891				2022-12-18	WOS:000079175700026
J	Denburg, JA				Denburg, JA			The origins of basophils and eosinophils in allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Festschrift Meeting in Honor of Jerry Dolovich	MAY 24, 1997	HAMILTON, CANADA	McMaster Univ, Fac Hlth Sci, Astra Canada			PERIPHERAL-BLOOD BASOPHILS; NASAL METACHROMATIC CELLS; BONE-MARROW PROGENITORS; MAST-CELL; CIRCULATING EOSINOPHILS; DIFFERENTIATION FACTORS; AIRWAY RESPONSIVENESS; INDUCED INCREASES; GROWTH; HETEROGENEITY	The bone marrow actively participates in the production of IgE-positive inflammatory cells (eosinophils, basophil, and mast cells), which are typically recruited to tissues in atopic individuals. Understanding the signaling between the tissue and the bone marrow at the molecular level may well open up new avenues of therapy for allergic inflammation.	McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada	McMaster University	Denburg, JA (corresponding author), McMaster Univ, Dept Med, HSC-3V46, Hamilton, ON L8N 3Z5, Canada.							BEFUS AD, 1985, IMMUNOL TODAY, V6, P281, DOI 10.1016/0167-5699(85)90169-0; DENBURG JA, 1980, IMMUNOLOGY, V41, P195; DENBURG JA, 1985, BLOOD, V66, P312; DENBURG JA, 1989, CLIN EXP ALLERGY, V19, P249, DOI 10.1111/j.1365-2222.1989.tb02379.x; DENBURG JA, 1985, EXP HEMATOL, V13, P185; DENBURG JA, 1985, J ALLERGY CLIN IMMUN, V76, P466, DOI 10.1016/0091-6749(85)90728-6; Denburg JA, 1986, MAST CELL DIFFERENTI, P71; GIBSON PG, 1989, THORAX, V44, P693, DOI 10.1136/thx.44.9.693; GIBSON PG, 1991, AM REV RESPIR DIS, V143, P331, DOI 10.1164/ajrccm/143.2.331; GIBSON PG, 1990, CLIN EXP ALLERGY, V20, P661, DOI 10.1111/j.1365-2222.1990.tb02705.x; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; IHLE JN, 1983, J IMMUNOL, V131, P282; Inman MD, 1996, AM J RESP CELL MOL, V15, P305, DOI 10.1165/ajrcmb.15.3.8924277; Inman MD, 1997, AM J RESP CELL MOL, V17, P634, DOI 10.1165/ajrcmb.17.5.2746; KASUGAI T, 1995, BLOOD, V85, P1334, DOI 10.1182/blood.V85.5.1334.bloodjournal8551334; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; OTSUKA H, 1986, AM REV RESPIR DIS, V133, P757; OTSUKA H, 1986, J ALLERGY CLIN IMMUN, V78, P365, DOI 10.1016/S0091-6749(86)80091-4; OTSUKA H, 1987, AM REV RESPIR DIS, V136, P710, DOI 10.1164/ajrccm/136.3.710; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645, DOI 10.1165/ajrcmb.15.5.8918371; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Wood JJ, 1998, AM J RESP CRIT CARE, V157, P99, DOI 10.1164/ajrccm.157.1.9704125; WOOLLEY MJ, 1994, AM J RESP CELL MOL, V11, P600, DOI 10.1165/ajrcmb.11.5.7946389	23	19	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					S74	S76		10.1016/S0091-6749(98)70034-X	http://dx.doi.org/10.1016/S0091-6749(98)70034-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	139MR	9819312	Bronze			2022-12-18	WOS:000077033400030
J	O'Byrne, P				O'Byrne, P			Asthma pathogenesis and allergen-induced late responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Festschrift Meeting in Honor of Jerry Dolovich	MAY 24, 1997	HAMILTON, CANADA	McMaster Univ, Fac Hlth Sci, Astra Canada			BRONCHOALVEOLAR LAVAGE; INDUCED BRONCHOCONSTRICTION; BRONCHIAL RESPONSIVENESS; INDUCED INCREASE; LUNG-DISEASE; LEUKOTRIENES; HISTAMINE; IMMEDIATE; IGE; EOSINOPHILIA	Increases in airway eosinophils occur during the late asthmatic response, 7 hours after allergen inhalation, and these can persist for 3 days. Also, increases in airway metachromatic cells occur which are most marked after 7 hours. These increases in airway cells are associated with increases in bone marrow progenitors, which are caused by an increased responsiveness of the bone marrow to IL-5 after allergen because of an increased expression of the IL-5 receptor on the progenitors. These studies suggest that after allergen inhalation, signals are sent from the airways to the hone marrow, which increase production of progenitors and make more tells available to he recruited into the airways.	McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada	McMaster University	O'Byrne, P (corresponding author), McMaster Univ, Dept Med, HSC-3U1,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.			O'Byrne, Paul/0000-0003-0979-281X				AALBERS R, 1993, AM REV RESPIR DIS, V147, P76, DOI 10.1164/ajrccm/147.1.76; ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; Boschetto P, 1989, Eur Respir J Suppl, V6, p456s; BOULET LP, 1984, CLIN ALLERGY, V14, P379, DOI 10.1111/j.1365-2222.1984.tb02219.x; BROCKLEHURST WE, 1960, J PHYSIOL-LONDON, V151, P416, DOI 10.1113/jphysiol.1960.sp006449; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; Calhoun WJ, 1998, AM J RESP CRIT CARE, V157, P1381, DOI 10.1164/ajrccm.157.5.9609014; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHOUDHURY SR, 1993, COMMUN NUMER METH EN, V9, P1, DOI 10.1002/cnm.1640090103; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; CRIMI E, 1986, J ALLERGY CLIN IMMUN, V78, P908, DOI 10.1016/0091-6749(86)90239-3; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAMANT Z, 1995, J ALLERGY CLIN IMMUN, V95, P42, DOI 10.1016/S0091-6749(95)70151-6; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; GIBSON PG, 1991, AM REV RESPIR DIS, V143, P331, DOI 10.1164/ajrccm/143.2.331; Hamilton AL, 1997, THORAX, V52, P348, DOI 10.1136/thx.52.4.348; HAMILTON AL, 1998, IN PRESS J ALLERGY C; HARGREAVE FE, 1974, CAN MED ASSOC J, V110, P415; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323, DOI 10.1159/000227979; HILL DJ, 1981, ALLERGY, V36, P549, DOI 10.1111/j.1398-9995.1981.tb01872.x; KEYZER JJ, 1984, J ALLERGY CLIN IMMUN, V74, P240, DOI 10.1016/0091-6749(84)90252-5; KIRBY JG, 1986, CLIN ALLERGY, V16, P191, DOI 10.1111/j.1365-2222.1986.tb00765.x; KNOL K, 1969, SCAND J RESPIR DIS, V50, P76; LAM S, 1987, AM REV RESPIR DIS, V131, pA42; MANNING PJ, 1990, J ALLERGY CLIN IMMUN, V86, P211, DOI 10.1016/S0091-6749(05)80068-5; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; PEPYS J, 1968, ALLERGOLOGIE, P221; PEPYS J, 1990, CLIN ALLERGY, V142, P73; PIPER PJ, 1991, ANN NY ACAD SCI, V629, P112; PRICE JF, 1982, CLIN EXP IMMUNOL, V47, P587; RASMUSSEN JB, 1992, J ALLERGY CLIN IMMUN, V90, P193, DOI 10.1016/0091-6749(92)90071-9; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Taylor G, 1973, Clin Allergy, V3, P103, DOI 10.1111/j.1365-2222.1973.tb01314.x; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; TURNER MO, 1995, THORAX, V50, P1057, DOI 10.1136/thx.50.10.1057; WARDLAW AJ, 1989, J ALLERGY CLIN IMMUN, V84, P19, DOI 10.1016/0091-6749(89)90173-5; Wood JJ, 1998, AM J RESP CRIT CARE, V157, P99, DOI 10.1164/ajrccm.157.1.9704125	41	19	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					S85	S89		10.1016/S0091-6749(98)70036-3	http://dx.doi.org/10.1016/S0091-6749(98)70036-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	139MR	9819314				2022-12-18	WOS:000077033400032
J	Phillips, E; Knowles, S; Weber, E; Shear, NH				Phillips, E; Knowles, S; Weber, E; Shear, NH			Skin reactions associated with bisphosphonates: A report of 3 cases and an approach to management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Sunnybrook Hlth Sci Ctr, Div Clin Pharmacol, Dept Med Clin Pharmacol, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, Div Clin Pharmacol, Dept Med Allergy Immunol, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, Div Clin Pharmacol, Dept Pharm, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, Div Clin Pharmacol, Dept Pharmacol, Toronto, ON M4N 3M5, Canada; Glaxo Wellcome Inc, Sunnybrook Drug Safety Clin, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; GlaxoSmithKline	Phillips, E (corresponding author), Sunnybrook Hlth Sci Ctr, Div Clin Pharmacol, Dept Med Clin Pharmacol, Room E-242,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							Adami S, 1996, DRUG SAFETY, V14, P158, DOI 10.2165/00002018-199614030-00003; COAKLEY G, 1995, BRIT J RHEUMATOL, V34, P798; MAUTALEN CA, 1984, BRIT MED J, V288, P828, DOI 10.1136/bmj.288.6420.828-a; Nakamura M, 1996, BRIT J PHARMACOL, V119, P205, DOI 10.1111/j.1476-5381.1996.tb15972.x; PAJUS I, 1993, BRIT MED J, V307, P484, DOI 10.1136/bmj.307.6902.484; ROUX C, 1992, CALCIFIED TISSUE INT, V50, P78	6	19	19	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				697	698		10.1016/S0091-6749(98)70291-X	http://dx.doi.org/10.1016/S0091-6749(98)70291-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802383				2022-12-18	WOS:000076600400025
J	Pisati, G; Baruffini, A; Bernabeo, F; Falagiani, P				Pisati, G; Baruffini, A; Bernabeo, F; Falagiani, P			Environmental and clinical study of latex allergy in a textile factory	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							OCCUPATIONAL ASTHMA; MANUFACTURING PLANT		Osped Lecco, Serv Med Lavoro, I-22053 Lecco, Italy; Lab Farmaceut Lofarma, Milan, Italy		Pisati, G (corresponding author), Osped Lecco, Serv Med Lavoro, Cso PSPOSO 1, I-22053 Lecco, Italy.							ANDERSON HC, 1983, RAST INHIBITION PROC; CARRILLO T, 1995, J ALLERGY CLIN IMMUN, V96, P699, DOI 10.1016/S0091-6749(95)70273-3; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; ORFAN NA, 1994, J ALLERGY CLIN IMMUN, V94, P826, DOI 10.1016/0091-6749(94)90149-X; PISATI G, 1994, EUR RESPIR J, V7, P332, DOI 10.1183/09031936.94.07020332; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; 1993, EUR RESP J S16, V6, P1	8	19	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					327	329		10.1016/S0091-6749(98)70243-X	http://dx.doi.org/10.1016/S0091-6749(98)70243-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525447	Bronze			2022-12-18	WOS:000072593900008
J	Xu, W; Peng, Z; Simons, FER				Xu, W; Peng, Z; Simons, FER			Isolation of a cDNA encoding Aed a 3, a 30 kDa IgE-binding protein of mosquito Aedes aegypti saliva.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Univ Manitoba, Winnipeg, MB, Canada	University of Manitoba									0	19	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	2			840	S203	S203						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YW339					2022-12-18	WOS:000071924800839
J	Pullerits, T; Praks, L; Sjostrand, M; Rak, S; Skoogh, BE; Lotvall, J				Pullerits, T; Praks, L; Sjostrand, M; Rak, S; Skoogh, BE; Lotvall, J			An intranasal glucocorticoid inhibits the increase of specific IgE initiated during birch pollen season	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; intranasal glucocorticoids; anti-birch IgE	AQUEOUS NASAL SPRAY; ALLERGIC RHINITIS; HUMAN-LYMPHOCYTES; LANGERHANS CELLS; B-CELLS; INFLAMMATORY CELLS; ANTIGEN CHALLENGE; INTERFERON-GAMMA; IMMUNOGLOBULIN-E; INTERLEUKIN-4	Background: Recent in vitro findings show that glucocorticoids in combination with IL-4 can induce the synthesis of IgE, indicating that glucocorticoids may promote allergy. Objective: A double-blind, placebo-controlled study was performed to evaluate the effect of an intranasal glucocorticoid on the levels of birch pollen-specific IgE antibodies in serum from patients with allergic rhinitis. Methods: Eighteen patients with allergic rhinitis received treatment with an intranasal glucocorticoid (beclomethasone dipropionate, 400 mu g/day) or placebo for 5 weeks, starting from the beginning of the birch pollen season. Blood samples for anti-birch IgE evaluation sere taken before treatment was initiated and at 2 and 5 weeks after the beginning of the study. Results: The beclomethasone group (n = 9) had significantly lower symptom scores when compared with the placebo group (n = 9) (0.86 +/- 0.26 vs 2.79 +/- 0.76, p value = 0.01). Both the treatment group and the placebo group showed a trend of an increase in anti-birch IgE levels 2 weeks after the beginning of the treatment (from 33.1 +/- 13.1 kU/L to 44.9 +/- 20.9 kU/L in the beclomethasone group and from 53.2 +/- 18.9 kU/L to 64.1 +/- 22.1 kU/L in the placebo group). Treatment with beclomethasone returned anti-birch IgE levels to baseline by the end of the study, whereas in the placebo group the anti-birch IgE levels continued to increase (final values, 33.1 +/- 11.9 kU/L vs 72.6 +/- 23.2 kU/L, respectively). The change in IgE antibody levels in the placebo group was significantly higher than that in the beclomethasone group. No statistically significant changes in total IgE or soluble CD23 levels were detected. Conclusion: We conclude that treatment with an intranasal glucocorticoid initiated at the beginning of the pollen season inhibits the induced increase in specific IgE.	GOTHENBURG UNIV, DEPT RESP MED & ALLERGOL, S-41346 GOTHENBURG, SWEDEN; TARTU STATE UNIV, LUNG HOSP, EE-202400 TARTU, ESTONIA	University of Gothenburg; University of Tartu	Pullerits, T (corresponding author), GOTHENBURG UNIV, DEPT CLIN PHARMACOL, LUNG PHARMACOL GRP, S-41346 GOTHENBURG, SWEDEN.			Lotvall, Jan/0000-0001-9195-9249				AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BERG T, 1971, INT ARCH ALLER A IMM, V41, P452, DOI 10.1159/000230539; BISGAARD H, 1990, J ALLERGY CLIN IMMUN, V85, P891, DOI 10.1016/0091-6749(90)90074-E; BONNEFOY JY, 1993, CURR OPIN IMMUNOL, V5, P944, DOI 10.1016/0952-7915(93)90110-E; BONNEFOY JY, 1988, EUR J IMMUNOL, V18, P117, DOI 10.1002/eji.1830180118; BRADDING P, 1995, AM J RESP CRIT CARE, V151, P1900, DOI 10.1164/ajrccm.151.6.7767538; BYRON KA, 1992, IMMUNOLOGY, V77, P624; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; CRIMI E, 1990, J ALLERGY CLIN IMMUN, V85, P1014, DOI 10.1016/0091-6749(90)90045-6; Davidsson Ake, 1994, Rhinology (Utrecht), V32, P184; DELESPESSE G, 1991, ADV IMMUNOL, V49, P149; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DEUSCHL H, 1976, INT ARCH ALLER A IMM, V52, P376, DOI 10.1159/000231704; DOLECEK C, 1995, CLIN EXP ALLERGY, V25, P879, DOI 10.1111/j.1365-2222.1995.tb00031.x; FOKKENS WJ, 1991, IMMUNOBIOLOGY, V182, P135, DOI 10.1016/S0171-2985(11)80197-X; FOKKENS WJ, 1989, J ALLERGY CLIN IMMUN, V84, P39, DOI 10.1016/0091-6749(89)90176-0; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; HOLM AF, 1995, ALLERGY, V50, P204, DOI 10.1111/j.1398-9995.1995.tb01134.x; IGARASHI Y, 1995, J ALLERGY CLIN IMMUN, V95, P716, DOI 10.1016/S0091-6749(95)70177-X; JABARA HH, 1991, J IMMUNOL, V147, P1557; JUNIPER EF, 1989, J ALLERGY CLIN IMMUN, V83, P627, DOI 10.1016/0091-6749(89)90075-4; KLEMENTSSON H, 1991, CLIN EXP ALLERGY, V21, P705, DOI 10.1111/j.1365-2222.1991.tb03199.x; Lagier B, 1995, J ALLERGY CLIN IMMUN, V96, P932, DOI 10.1016/S0091-6749(95)70231-8; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P221, DOI 10.1016/S0091-6749(05)80069-7; MYGIND N, 1973, BRIT MED J, V4, P464, DOI 10.1136/bmj.4.5890.464; NACLERIO RM, 1993, J ALLERGY CLIN IMMUN, V92, P717, DOI 10.1016/0091-6749(93)90015-8; NUSSLEIN HG, 1994, ALLERGY, V49, P365, DOI 10.1111/j.1398-9995.1994.tb02283.x; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PIPKORN U, 1982, ALLERGY, V37, P129, DOI 10.1111/j.1398-9995.1982.tb01886.x; POSEY WC, 1978, J ALLERGY CLIN IMMUN, V62, P340, DOI 10.1016/0091-6749(78)90134-3; Pullerits T, 1997, INT ARCH ALLERGY IMM, V112, P279, DOI 10.1159/000237466; SARFATI M, 1989, J EXP MED, V170, P1775, DOI 10.1084/jem.170.5.1775; SMALL P, 1982, ANN ALLERGY, V49, P20; VERCELLI D, 1988, J EXP MED, V167, P1406, DOI 10.1084/jem.167.4.1406; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; WU CY, 1991, J CLIN INVEST, V87, P870, DOI 10.1172/JCI115092; WU CY, 1991, EUR J IMMUNOL, V21, P2645, DOI 10.1002/eji.1830211053; ZIEG G, 1994, J ALLERGY CLIN IMMUN, V94, P222, DOI 10.1016/0091-6749(94)90044-2	40	19	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					601	605		10.1016/S0091-6749(97)70162-3	http://dx.doi.org/10.1016/S0091-6749(97)70162-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389288				2022-12-18	WOS:A1997YG20200005
J	Hiller, KM; Esch, RE; Klapper, DG				Hiller, KM; Esch, RE; Klapper, DG			Mapping of an allergenically important determinant of grass group I allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						grass allergen; monoclonal antibody; epitope map; peptide	POLLEN; AFFINITY; PEPTIDE	This report documents the mapping of the second major epitope, previously described as site D, of grass group I allergens to residues 23-35 of meadow fescue group I (STFYGKPTGAGPK). Mapping was accomplished by screening fractions from a meadow fescue group I tryptic digest for peptide(s) that inhibit the ability of monoclonal antibody 24.64 (specific for site D) to bind to immobilized group I allergen. One such peptide, representing residues 23-35 of meadow fescue group I, was identified. Additional studies with the use of synthetic analogs of this peptide demonstrate that it binds mAb 24.64 directly. Examination of extracts containing group I glycoproteins from seven other species of grass confirms antigenic cross-reactivity due to this peptide. We also report based on protein sequence analysis that the amino terminal segment (which includes the site D epitope) of GpI allergens from seven different grass species is highly conserved and contains two hydroxyproline residues and an N-linked carbohydrate moiety.	UNIV N CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599; GREER LABS,LENOIR,NC	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine								DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; ESCH RE, 1989, J IMMUNOL, V142, P179; ESCH RE, 1989, MOL IMMUNOL, V26, P557, DOI 10.1016/0161-5890(89)90007-2; ESCH RE, 1987, J ALLERGY CLIN IMMUN, V78, P489; GRIFFITH IJ, 1991, FEBS LETT, V279, P210, DOI 10.1016/0014-5793(91)80151-R; KUMAR V, 1995, P NATL ACAD SCI USA, V92, P9510, DOI 10.1073/pnas.92.21.9510; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSH DG, 1970, J ALLERGY, V46, P107, DOI 10.1016/0021-8707(70)90078-X; MARSH DG, 1975, ANTIGENS, V3, P271; MATTIESEN F, 1992, J ALLERGY, V12, P47; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; PEREZ M, 1990, J BIOL CHEM, V265, P16210; PETERSEN A, 1993, J ALLERGY CLIN IMMUN, V92, P789, DOI 10.1016/0091-6749(93)90055-K; PETERSEN A, 1995, J ALLERGY CLIN IMMUN, V95, P967; VANREE R, 1995, INT ARCH ALLERGY IMM, V106, P250, DOI 10.1159/000236850; Voller A., 1980, MANUAL CLIN IMMUNOLO, P359; WINDHAGEN A, 1995, IMMUNITY, V2, P373, DOI 10.1016/1074-7613(95)90145-0	17	19	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					335	340		10.1016/S0091-6749(97)70246-X	http://dx.doi.org/10.1016/S0091-6749(97)70246-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314345				2022-12-18	WOS:A1997XX47900010
J	Ebo, DG; Stevens, WJ; Bosmans, JL				Ebo, DG; Stevens, WJ; Bosmans, JL			An adverse reaction to angiotensin-converting enzyme inhibitors in a patient with neglected C1 esterase inhibitor deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HEREDITARY ANGIOEDEMA; KININ SYSTEM; INVOLVEMENT		UNIV ANTWERP, DEPT IMMUNOL ALLERGOL & RHEUMATOL, B-2610 ANTWERP, BELGIUM; UNIV ANTWERP, DEPT NEPHROL, B-2020 ANTWERP, BELGIUM	University of Antwerp; University of Antwerp			EBO, Didier/H-4894-2016; Bosmans, Jean-Louis/C-7139-2017	EBO, Didier/0000-0003-0672-7529; Bosmans, Jean-Louis/0000-0001-7928-5675				AGOSTONI A, 1991, AM J MED, V90, P278; BORK K, 1984, ARCH DERMATOL RES, V276, P375, DOI 10.1007/BF00413358; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; Fitzgibbon W R, 1993, Curr Opin Nephrol Hypertens, V2, P283, DOI 10.1097/00041552-199303000-00016; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; LUSCHER TF, 1993, BASIC RES CARDIOL, V88, P15; MARCEAU F, 1983, GEN PHARMACOL, V14, P209, DOI 10.1016/0306-3623(83)90001-0; SHEPHERD GM, 1990, AM J MED, V88, P446, DOI 10.1016/0002-9343(90)90514-E; SIM TC, 1990, AM J MED, V88, P656, DOI 10.1016/0002-9343(90)90535-L; SLATER EE, 1988, JAMA-J AM MED ASSOC, V260, P967, DOI 10.1001/jama.260.7.967; WAEBER B, 1989, BRIT J CLIN PHARMACO, V27, pS175, DOI 10.1111/j.1365-2125.1989.tb03479.x; ZUSMAN RM, 1984, KIDNEY INT, V25, P969, DOI 10.1038/ki.1984.119	12	19	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					425	426		10.1016/S0091-6749(97)70063-0	http://dx.doi.org/10.1016/S0091-6749(97)70063-0			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058701				2022-12-18	WOS:A1997WM42200022
J	Hinojosa, M; Fraj, J; DeLaHoz, B; Alcazar, R; Sueiro, A				Hinojosa, M; Fraj, J; DeLaHoz, B; Alcazar, R; Sueiro, A			Hypersensitivity pneumonitis in workers exposed to esparto grass (Stipa tenacissima) fibers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hypersensitivity pneumonitis; extrinsic allergic alveolitis; esparto grass; stipatosis	PROTEIN	Esparto grass (Stipa tenacissima), which is commonly found in the Mediterranean countries, has a wide variety of uses. Five stucco makers who had cough, dyspnea, malaise, and fever after exposure to esparto fiber used in their jobs showed a significant decrease in symptoms when they were away from work. Precipitating antibodies against art esparto extract were found in the sera of all patients. Specific IgG antibodies against the esparto extract were also demonstrated in all patient sera, as were IgG antibodies to Aspergillus fumigatus and thermophilic microorganisms (Micropolyspora faeni and Thermoactinomyces vulgaris) by means of an ELISA method. Esparto activity was inhibited in different ranges by the above antigens by inhibition ELISA. Only A. fumigatus could be identified after microbiologic evaluation of the esparto fiber samples. After inhalation challenge tests were performed with esparto extracts, all patients showed significant decreases in forced vital capacity, transfer lung CO, and PaO2 blood gas from baseline values. Fever, chills, malaise dry cough, tachycardia, tachypnea, and rales an chest auscultation were also observed in all patients. Findings from bronchoalveolar lavage were suggestive of allergic alveolitis. Transbronchial biopsy specimens showed interstitial alveolitis with lymphocyte-macrophage infiltrate and granuloma. Unexposed control subjects did not exhibit reactivity to any of the tests listed above. The dust derived from esparto fibers can cause hypersensitivity pneumonitis in exposed subjects. Organisms such as A. fumigatus and thermophilic actinomyces could be the causative antigens. ''Stipatosis'' might be an appropriate name for this disorder.	GEN HOSP,DEPT RESP MED,JAEN,SPAIN; HOSP RAMON Y CAJAL,DEPT RESP MED,E-28034 MADRID,SPAIN	Hospital Universitario Ramon y Cajal	Hinojosa, M (corresponding author), HOSP RAMON Y CAJAL,DEPT ALLERGY & CLIN IMMUNOL,CTRA COMENAR,KM 9 1,E-28034 MADRID,SPAIN.		de la Hoz, Belen/AAA-8067-2019	de la Hoz, Belen/0000-0002-5127-8702				ADRADOS JR, 1961, REV CLIN ESP, V82, P184; CAMPBELL JM, 1932, BRIT MED J, V2, P1143; COSTABEL U, 1985, CHEST, V87, P134, DOI 10.1378/chest.87.1.134-a; DIAZ CJ, 1966, REV CLIN ESP, V3, P182; FINK JN, 1988, ALLERGY PRINCIPLES P, P1237; FINK JN, 1978, ALLERGY PRINCIPLES P, P855; GALLEGO JD, 1975, MED SEG TRAB, V91, P13; GALLEGO JD, 1969, MED EMPR, V2, P94; GREGORY PH, 1963, J GEN MICROBIOL, V33, P147, DOI 10.1099/00221287-33-1-147; GREGORY PH, 1963, J GEN MICROBIOL, V30, P75, DOI 10.1099/00221287-30-1-75; HENDRICK DJ, 1980, THORAX, V35, P415, DOI 10.1136/thx.35.6.415; HINOJOSA M, 1986, TRATADO ALERGOLOGFA, V2, P15; Hinojosa Macias M, 1984, Med Clin (Barc), V82, P214; OUCHTERLONY D, 1953, ACTA PATHOL MIC SC, V32, P1; PARKES WR, 1982, OCCUPATIONAL LUNG DI, P359; PEPYS J, 1969, MONOGR ALLERGY, V4, P69; REYES CN, 1982, CHEST, V81, P142, DOI 10.1378/chest.81.2.142; REYNOLDS HY, 1977, J CLIN INVEST, V59, P165, DOI 10.1172/JCI108615; SALVAGGIO JE, 1979, CHEST, V75, P270, DOI 10.1378/chest.75.2.270; SALVAGGIO JE, 1980, HOSP PRACT, V15, P93, DOI 10.1080/21548331.1980.11946685; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; TURNERWARWICK M, 1978, IMMUNOLOGY LUNG, P116; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55	23	19	20	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	1				985	991		10.1016/S0091-6749(96)80016-9	http://dx.doi.org/10.1016/S0091-6749(96)80016-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VU764	8939163				2022-12-18	WOS:A1996VU76400016
J	Weber, EA				Weber, EA			Cefazolin specific side chain hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							GOOD TOLERANCE; BETA-LACTAMS; PENICILLIN; ALLERGY; ANAPHYLAXIS		UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,TORONTO,ON,CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center								BLANCA M, 1990, CLIN EXP ALLERGY, V20, P475, DOI 10.1111/j.1365-2222.1990.tb03139.x; BLANCA M, 1988, ALLERGY, V43, P508, DOI 10.1111/j.1398-9995.1988.tb01628.x; MENDELSON LM, 1984, J ALLERGY CLIN IMMUN, V73, P76, DOI 10.1016/0091-6749(84)90487-1; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; WARRINGTON RJ, 1995, J ALLERGY CLIN IMMUN, V95, P284	5	19	21	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1996	98	4					849	850		10.1016/S0091-6749(96)70138-0	http://dx.doi.org/10.1016/S0091-6749(96)70138-0			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VM665	8876565				2022-12-18	WOS:A1996VM66500022
J	Apter, AJ; Reisine, ST; Willard, A; Clive, J; Wells, M; Metersky, M; McNally, D; ZuWallack, RL				Apter, AJ; Reisine, ST; Willard, A; Clive, J; Wells, M; Metersky, M; McNally, D; ZuWallack, RL			The effect of inhaled albuterol in moderate to severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; peak expiratory flow rate; albuterol; compliance; quality of life	QUALITY-OF-LIFE; BETA-AGONIST; QUESTIONNAIRE	Background: Some recent clinical investigations suggest that regular use of inhaled bronchodilators may lead to deterioration in asthma control. Objective: The purpose of this study was to evaluate the effect of albuterol dosing schedule on clinical outcome in subjects with moderate to severe stable asthma. Methods: Seventeen adults were randomized to two 15-week treatment periods in a double-blind crossover design. Throughout the study, subjects were instructed to take two inhalations four times daily from an unlabeled ''test'' canister. In the four times daily and as-needed (QID+PRN) period, this canister contained albuterol; in the as-needed (PRN) period, it contained placebo. A ''rescue'' albuterol canister was available for as-needed use at all times. Inhaler actuations from both the test and rescue canisters were electronically recorded. Outcome measures included prednisone requirements, morning and evening symptoms and peak expiratory flow rates, total and nighttime rescue albuterol use, and asthma-specific quality of life. Results: The two treatment periods did not differ in symptoms, nighttime albuterol use, or asthma quality of life. During the QID+PRN period both morning and evening peak expiratory flow rates were significantly higher (p<0.01 and 0.001, respectively) and total rescue use of albuterol was significantly less (p<0.05) than the PRN period. Days on prednisone tended to be lower in the regular dosing period (p=0.08). Conclusion: In our sample of patients with moderate to severe asthma, four times daily dosing of albuterol did not lead to deterioration of asthma control.	UNIV CONNECTICUT,CTR HLTH,GEN CLIN RES CTR,FARMINGTON,CT 06030; UNIV CONNECTICUT,CTR HLTH,DEPT BEHAV SCI & COMMUNITY MED,FARMINGTON,CT 06030; ST FRANCIS HOSP & MED CTR,DEPT MED,HARTFORD,CT 06105	University of Connecticut; University of Connecticut; Saint Francis Hospital & Medical Center	Apter, AJ (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT MED,FARMINGTON,CT 06030, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006192] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR06192] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		CHAPMAN KR, 1994, LANCET, V343, P1379, DOI 10.1016/S0140-6736(94)92520-8; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; JUNIPER EWF, 1994, AM J RESP CRIT CARE, V151, P66; *NAT ASTHM ED PAN, 1991, 913042 NIH NAT ASTHM; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134	9	19	19	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					295	301		10.1016/S0091-6749(96)70153-7	http://dx.doi.org/10.1016/S0091-6749(96)70153-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757206				2022-12-18	WOS:A1996VC99500008
J	Naito, K; Hirama, M; Okumura, K; Ra, CS				Naito, K; Hirama, M; Okumura, K; Ra, CS			Recombinant soluble form of the human high-affinity receptor for IgE prevents anaphylactic shock in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						high affinity IgE receptor (Fc epsilon RI); IgE; allergy; anaphylactic shock	IMMUNOGLOBULIN-E; ALPHA-SUBUNIT; TRANSFECTED CELLS; MAST-CELLS; RAT; BINDING; EXPRESSION; GENE; PRODUCTS; THERAPY	The ectodomain of the alpha subunit of the human high-affinity receptor for IgE (Fc epsilon RI) has been engineered as a recombinant soluble protein (sFc epsilon RI alpha) and purified in large quantity from the supernatant of transfected mammalian cells. The sFc epsilon RI alpha was apparently heterogenous in terms of molecular weight (40 to 60 kd), and this heterogeneity was largely due to N-linked carbohydrates on the molecule. The amino terminal sequence was homogenous and identical to the sequence predicted from the complementary DNA sequence. The amino acid composition of the sFc epsilon RI alpha was in agreement with the values expected from the cDNA sequence. The sFc epsilon RI alpha formed a complex with IgE, and gel filtration analyses of the complex of the sFc epsilon RI alpha and human IgE supported the ideal that the stoichiometry of the IgE binding was 1:1. Passive anaphylactic shock in mice was suppressed when the sFc epsilon RI alpha was intravenously injected after sensitization with anti-trinitrophenyl IgE and challenged with the appropriate antigen. In this model the sFc epsilon RI alpha was effective when administered 48 hours before the antigen challenge, but not 24 hours before the challenge. These results suggest that the sFc epsilon RI alpha facilitated the dissociation of IgE from Fc epsilon RI on mast cells in vivo and suppressed type I allergic reactions.	JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN; GREEN CROSS CO,DIV RES,OSAKA,JAPAN	Juntendo University; Green Cross Corporation								ALT FW, 1978, J BIOL CHEM, V253, P1357; BLANK U, 1991, J BIOL CHEM, V266, P2639; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; COHEN SA, 1988, ANAL BIOCHEM, V174, P1, DOI 10.1016/0003-2697(88)90512-X; HAAKFRENDSCHO M, 1993, J IMMUNOL, V151, P351; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; ISHIZAKA T, 1985, J IMMUNOL, V134, P532; KINET JP, 1991, INT ARCH ALLER A IMM, V94, P51, DOI 10.1159/000235323; KINET JP, 1990, CURR OPIN IMMUNOL, V2, P499, DOI 10.1016/0952-7915(90)90002-X; KOCHAN J, 1988, NUCLEIC ACIDS RES, V16, P3584, DOI 10.1093/nar/16.8.3584; KULCZYCK.A, 1974, J EXP MED, V140, P1676, DOI 10.1084/jem.140.6.1676; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTLE JR, 1967, METHODS IMMUNOLOGY I, V1, P128; MENDOZA G, 1976, NATURE, V264, P548, DOI 10.1038/264548a0; MILLER L, 1989, SCIENCE, V244, P334, DOI 10.1126/science.2523561; MORSE SI, 1976, J EXP MED, V143, P1483, DOI 10.1084/jem.143.6.1483; MUNOZ J, 1958, J IMMUNOL, V80, P77; NEWMAN SA, 1977, P NATL ACAD SCI USA, V74, P869, DOI 10.1073/pnas.74.3.869; RA C, 1993, INT IMMUNOL, V5, P47, DOI 10.1093/intimm/5.1.47; RA C, 1989, J BIOL CHEM, V264, P15323; RICCIO A, 1985, NUCLEIC ACIDS RES, V13, P2759, DOI 10.1093/nar/13.8.2759; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; ROSSI G, 1977, J BIOL CHEM, V252, P704; RUDOLPH AK, 1981, EUR J IMMUNOL, V11, P527, DOI 10.1002/eji.1830110617; SABAN R, 1994, J ALLERGY CLIN IMMUN, V94, P836, DOI 10.1016/0091-6749(94)90151-1; SCHLESSINGER J, 1976, NATURE, V264, P550, DOI 10.1038/264550a0; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; TUNG AS, 1983, METHOD ENZYMOL, V92, P47; WANK SA, 1983, BIOCHEMISTRY-US, V22, P954, DOI 10.1021/bi00273a038	30	19	20	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1996	97	3					773	780		10.1016/S0091-6749(96)80155-2	http://dx.doi.org/10.1016/S0091-6749(96)80155-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UA975	8613634				2022-12-18	WOS:A1996UA97500008
J	Sicherer, SH; Sampson, HA				Sicherer, SH; Sampson, HA			Auriculotemporal syndrome: A masquerader of food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,DIV IMMUNOL & ALLERGY,BALTIMORE,MD 21205	Johns Hopkins University								BECK SA, 1989, PEDIATRICS, V83, P901; BEDNAREK J, 1976, AM J SURG, V131, P592, DOI 10.1016/0002-9610(76)90019-2; DAVIS RS, 1981, AM J DIS CHILD, V135, P832, DOI 10.1001/archpedi.1981.02130330042013; Dolovich J, 1989, Ann Allergy, V62, P479; KOZMA C, 1993, CLIN PEDIATR, V32, P629, DOI 10.1177/000992289303201013; SLY RM, 1981, CUTIS, V28, P423	6	19	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1996	97	3					851	852		10.1016/S0091-6749(96)80163-1	http://dx.doi.org/10.1016/S0091-6749(96)80163-1			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UA975	8613642	Bronze			2022-12-18	WOS:A1996UA97500016
J	MAGNARIN, M; KNOWLES, A; VENTURA, A; VITA, F; FANTI, L; ZABUCCHI, G				MAGNARIN, M; KNOWLES, A; VENTURA, A; VITA, F; FANTI, L; ZABUCCHI, G			A ROLE FOR EOSINOPHILS IN THE PATHOGENESIS OF SKIN-LESIONS IN PATIENTS WITH FOOD-SENSITIVE ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EOSINOPHIL; ATOPIC DERMATITIS; ADHESION	PLATELET-ACTIVATING-FACTOR; COLONY-STIMULATING FACTOR; CATIONIC PROTEIN; ASTHMA; BLOOD; NEUTROPHILS; GENERATION; HYPODENSE; CELLS; INTERLEUKIN-3	Background: Atopic dermatitis is associated with skin and blood eosinophilia, but the role of eosinophils in the pathogenesis of the skin lesions is poorly understood. Methods: To determine whether eosinophils play a role in the pathogenesis of the skin lesions in atopic dermatitis, we studied the relationship between the severity of the disease and both the number and the extent of activation of eosinophils in 15 patients with food-sensitive atopic dermatitis. Furthermore, this relationship was re-evaluated in eight of these patients who after a period of elemental diet or total pal enteral nutrition, showed significant clinical improvement. Results: A clear relationship was found between the number of light-density eosinophils and the severity of the disease both during the active disease and after clinical improvement. Furthermore, we describe an adhesion-stimulating activity for eosinophils in patients' plasma, which does not change after recovery, Conclusions: Taken together, these observations strongly indicate that eosinophils play a pivotal role in the pathogenesis of the skin lesions in atopic dermatitis. In particular, the light-density phenotype seems to be an essential feature of eosinophils involved in this process The adhesion-promoting activity that we observed in the patients' plasma could be important in the recruitment of eosinophils from the blood into the skin.	UNIV TRIESTE, INST GEN PATHOL, TRIESTE, ITALY; UNIV TRIESTE, DEPT PEDIAT, TRIESTE, ITALY; UNIV PISA, DEPT PEDIAT, PISA, ITALY	University of Trieste; University of Trieste; University of Pisa				Knowles, Alessandra/0000-0003-4504-6371; Ventura, Alessandro/0000-0002-4657-1760				AGATA H, 1992, ARCH DIS CHILD, V67, P280, DOI 10.1136/adc.67.3.280; BOCHNER BS, 1991, J ALLERGY CLIN IMMUN, V88, P629, DOI 10.1016/0091-6749(91)90157-J; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BROWN MA, 1990, CURR OPIN IMMUNOL, V2, P531, DOI 10.1016/0952-7915(90)90006-3; BRUIJNZEELKOOMEN C, 1992, J ALLERGY CLIN IMMUN, V89, P52, DOI 10.1016/S0091-6749(05)80040-5; BURKE LA, 1991, J ALLERGY CLIN IMMUN, V88, P226, DOI 10.1016/0091-6749(91)90333-J; CAPRON M, 1984, J IMMUNOL, V132, P462; COEFFIER E, 1991, J IMMUNOL, V147, P2595; CRAMER R, 1992, J LEUKOCYTE BIOL, V52, P331, DOI 10.1002/jlb.52.3.331; CROMWELL O, 1990, J IMMUNOL, V145, P3862; DEVLIN J, 1991, ARCH DIS CHILD, V66, P93, DOI 10.1136/adc.66.1.93; FERGUSON AC, 1992, J ALLERGY CLIN IMMUN, V90, P609, DOI 10.1016/0091-6749(92)90133-M; GRIFFIN E, 1991, J ALLERGY CLIN IMMUN, V87, P548, DOI 10.1016/0091-6749(91)90014-F; HAKANSSON L, 1990, J ALLERGY CLIN IMMUN, V85, P743, DOI 10.1016/0091-6749(90)90193-8; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; HAY I, 1989, INT ARCH ALLER A IMM, V90, P345; HILL DJ, 1982, CLIN ALLERGY, V12, P313, DOI 10.1111/j.1365-2222.1982.tb02533.x; KIMANI G, 1988, J IMMUNOL, V140, P3161; LAMAS AM, 1989, J IMMUNOL, V142, P3978; LEIFERMAN KM, 1989, ALLERGY, V44, P20, DOI 10.1111/j.1398-9995.1989.tb02450.x; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; MAHAUTHAMAN R, 1988, J ALLERGY CLIN IMMUN, V81, P696, DOI 10.1016/0091-6749(88)91041-X; MENEGAZZI R, 1992, J LEUKOCYTE BIOL, V52, P619, DOI 10.1002/jlb.52.6.619; MOSER R, 1992, J IMMUNOL, V149, P1432; NEUBER K, 1991, IMMUNOLOGY, V73, P83; NEUBER K, 1991, IMMUNOLOGY, V73, P197; OWEN WF, 1990, P NATL ACAD SCI USA, V87, P8647, DOI 10.1073/pnas.87.21.8647; PAGANELLI R, 1991, INT ARCH ALLER A IMM, V96, P175, DOI 10.1159/000235490; PISANI CV, 1991, BLOOD, V78, P1538, DOI 10.1182/blood.V78.6.1538.1538; PLATTSMILLS TAE, 1991, CURR OPIN IMMUNOL, V3, P874, DOI 10.1016/S0952-7915(05)80006-8; POLLA BS, 1992, J ALLERGY CLIN IMMUN, V89, P545, DOI 10.1016/0091-6749(92)90321-R; RAK S, 1990, J ALLERGY CLIN IMMUN, V86, P706, DOI 10.1016/S0091-6749(05)80174-5; REIMERT CM, 1993, J IMMUNOL METHODS, V166, P183, DOI 10.1016/0022-1759(93)90359-F; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SAMPSON HA, 1990, CURR OPIN IMMUNOL, V2, P542, DOI 10.1016/0952-7915(90)90008-5; SUMIMOTO S, 1992, ARCH DIS CHILD, V67, P277, DOI 10.1136/adc.67.3.277; SUZUKI K, 1983, ANAL BIOCHEM, V132, P345, DOI 10.1016/0003-2697(83)90019-2; THORNE KJI, 1990, J IMMUNOL METHODS, V133, P47, DOI 10.1016/0022-1759(90)90317-O; VENGE P, 1991, J ALLERGY CLIN IMMUN, V88, P699, DOI 10.1016/0091-6749(91)90175-N; VENGE P, 1993, CLIN EXP ALLERGY, V23, P3, DOI 10.1111/j.1365-2222.1993.tb00372.x; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; VENTURA A, 1989, ALLERGY, V44, P159; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WALSH GM, 1991, INT ARCH ALLER A IMM, V94, P174, DOI 10.1159/000235355; WINQVIST I, 1992, IMMUNOLOGY, V77, P531	46	19	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					200	208		10.1016/S0091-6749(95)70009-9	http://dx.doi.org/10.1016/S0091-6749(95)70009-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636058				2022-12-18	WOS:A1995RQ00100009
J	SLUNT, JB; ROGERS, BL; CHAPMAN, MD				SLUNT, JB; ROGERS, BL; CHAPMAN, MD			IGE ANTIBODIES TO RECOMBINANT FORMS OF FEL-D-I - DICHOTOMY BETWEEN FLUID-PHASE AND SOLID-PHASE BINDING-STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RECOMBINANT ALLERGEN; CAT ALLERGEN; IGE ANTIBODIES; MONOCLONAL ANTIBODIES	CAT ALLERGEN; MONOCLONAL-ANTIBODIES; DERMATOPHAGOIDES-PTERONYSSINUS; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; POLLEN ALLERGEN; MAJOR ALLERGEN; DOMESTIC CAT; P-II; EXPRESSION	Background: The major cat allergen Fel d I consists of two polypeptide chains linked by disulfide bonds, each of which has been expressed in bacteria. To investigate the antigenic structure of Fel d 1; antibody binding to the native molecule and to each recombinant chain were compared. Methods: Polyclonal human IgE and IgG antibodies and monoclonal antibodies (mAbs) to Fel d I were compared for binding to Fel d I, chain 1, or chain 2 by fluid-phase inhibition radioimmunoassay, RAST, and immunoabsorption. Results: In the fluid-phase assay, neither recombinant chain significantly inhibited the binding of antibody to native Fel d I at concentrations of up to 10 mu g/ml. partial inhibition was observed when chain 1 was used, which inhibited the binding of two mAbs by 40% and 75%. In contrast, when the solid-phase RAST assay was used, IgE antibodies bound both chains with high specificity, and there was a good quantitative correlation between IgE antibody binding to Fel d I and both chain 1 (r = 0.58, p < 0.01) and chain 2 (r = 0.47, p < 0.01). Up to 70% of IgG or IgE anti-Fel d I antibodies could be absorbed by either chain 1 or chain 5 and both chains in combination produced similar absorption values in response to native Fel d I. Four mAbs were fully absorbed by chain I, but not chain 2, and three mAbs were nor absorbed by either chain. Conclusions: The results demonstrate a dichotomy between antibody binding to recombinant Fel d I chains, which may be explained by confirmational differences between the chains in the fluid phase or on solid supports. The results also suggest that chain I is art important site for mAb-defined B-cell epitopes on Fel d I.	UNIV VIRGINIA,DEPT MED,CTR ASTHMA & ALLERG DIS,CHARLOTTESVILLE,VA 22908; IMMULOG PHARMACEUT CORP,WALTHAM,MA	University of Virginia				Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034607, R01AI020565, R37AI020565, R01AI032557, U19AI034607] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32557, AI 34607, AI 20565] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON MC, 1981, J IMMUNOL, V127, P972; ANDERSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P563, DOI 10.1016/0091-6749(85)90776-6; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; BARTHOLOME K, 1985, J ALLERGY CLIN IMMUN, V76, P503, DOI 10.1016/0091-6749(85)90734-1; BOND JF, 1993, MOL IMMUNOL, V30, P1529, DOI 10.1016/0161-5890(93)90461-J; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHAPMAN MD, 1989, CURR OPIN IMMUNOL, V1, P647, DOI 10.1016/0952-7915(89)90035-6; CHAPMAN MD, 1991, CLIN EXP ALLERGY, V21, P155, DOI 10.1111/j.1365-2222.1991.tb00823.x; CHUA KY, 1991, CLIN EXP ALLERGY, V21, P161, DOI 10.1111/j.1365-2222.1991.tb00825.x; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P124, DOI 10.1159/000235102; CHUA KY, 1992, J ALLERGY CLIN IMMUN, V89, P95, DOI 10.1016/S0091-6749(05)80045-4; DABROWSKI AJ, 1990, J ALLERGY CLIN IMMUN, V86, P462, DOI 10.1016/S0091-6749(05)80200-3; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DEGROOT H, 1988, J ALLERGY CLIN IMMUN, V82, P778, DOI 10.1016/0091-6749(88)90079-6; DEGROOT H, 1990, J ALLERGY CLIN IMMUN, V86, P107, DOI 10.1016/S0091-6749(05)80130-7; DUFFORT O, 1988, IMMUNOL LETT, V17, P71, DOI 10.1016/0165-2478(88)90104-6; DUFFORT OA, 1991, MOL IMMUNOL, V28, P301, DOI 10.1016/0161-5890(91)90141-6; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; FINDLAY SR, 1983, AM REV RESPIR DIS, V128, P1008; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GHOSH B, 1993, J IMMUNOL, V150, P5391; GREENE WK, 1991, J IMMUNOL, V147, P3768; GRIFFITH IJ, 1992, GENE, V113, P263, DOI 10.1016/0378-1119(92)90405-E; HEYMANN PW, 1986, J IMMUNOL, V137, P2841; KUO MC, 1993, MOL IMMUNOL, V30, P1077, DOI 10.1016/0161-5890(93)90154-4; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LOWENSTEIN H, 1985, ALLERGY, V40, P430, DOI 10.1111/j.1398-9995.1985.tb02682.x; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; OHMAN JL, 1974, J IMMUNOL, V113, P1668; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; RAFNAR T, 1992, J BIOL CHEM, V267, P21119; ROGERS BL, 1993, MOL IMMUNOL, V30, P559, DOI 10.1016/0161-5890(93)90030-F; SKERRA A, 1993, CURR OPIN IMMUNOL, V5, P256, DOI 10.1016/0952-7915(93)90014-J; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; VAILES LD, 1994, J ALLERGY CLIN IMMUN, V93, P22, DOI 10.1016/0091-6749(94)90229-1; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; VANMILLIGEN FJ, 1994, J ALLERGY CLIN IMMUN, V93, P34, DOI 10.1016/0091-6749(94)90230-5; VANMILLIGEN FJ, 1992, INT ARCH ALLERGY IMM, V99, P63, DOI 10.1159/000236337	41	19	22	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1995	95	6					1221	1228		10.1016/S0091-6749(95)70079-X	http://dx.doi.org/10.1016/S0091-6749(95)70079-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD309	7797791				2022-12-18	WOS:A1995RD30900010
J	CRETICOS, P; BURK, J; SMITH, L; COMP, R; NORMAN, P; FINDLAY, S				CRETICOS, P; BURK, J; SMITH, L; COMP, R; NORMAN, P; FINDLAY, S			THE USE OF TWICE-DAILY NEDOCROMIL SODIUM IN THE TREATMENT OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; ANTIINFLAMMATORY; PYRANOQUINOLINE; NEDOCROMIL SODIUM; TWICE DAILY DOSING	MANAGEMENT; EFFICACY; THERAPY	The efficacy and safety of nedocromil sodium inhalation aerosol (4 mg* of Tilade administered by metered-dose inhaler) given twice daily was compared with placebo in 112 patients with mild-to-moderate asthma who had been receiving maintenance therapy with oral or inhaled bronchodilators or both. After a 2-week run-in period and a subsequent 2-week baseline period, patients were randomized to active treatment (n = 56) or placebo (n = 56) for 8 weeks. All maintenance bronchodilators were withdrawn before the baseline period, and patients entered the treatment period only after demonstrating a specified level of asthma symptoms. Twice daily administration of nedocromil sodium improved all asthma symptoms in these patients who had symptoms as a result of the withdrawal of their maintenance theophylline and/or and inhaled beta(2)-agonist bronchodilators. During the primary time period (treatment weeks 5 to 8), statistically significant between-group differences favored nedocromil sodium for the asthma summary score (primary variable, p = 0.001), daytime asthma (p = 0.001), and sleep difficulty caused by asthma (p = 0.006). Furthermore, significant reductions in the use of as-needed rescue medications were reported in the nedocromil sodium group (p = 0.003) compared with the placebo group. Final overall opinions of treatment effectiveness expressed by physicians (p = 0.016) and patients (p = 0.002) strongly favored nedocromil sodium.	PULM CONSULTANTS TEXAS PA,FT WORTH,TX; NORTHWESTERN UNIV,SCH MED,DEPT MED,DIV PULM,CHICAGO,IL 60611; PULM ASSOCIATES PA,PHOENIX,AZ; HLTH QUEST THERAPY & RES INST INC,AUSTIN,TX	Northwestern University	CRETICOS, P (corresponding author), JOHNS HOPKINS ASTHMA & ALLERGY CTR,5501 HOPKINS BAYVIEW CIRCLE,SUITE 2B57B,BALTIMORE,MD 21224, USA.			Smith, Lewis J/0000-0002-4728-1562				AALBERS R, 1991, J ALLERGY CLIN IMMUN, V87, P993, DOI 10.1016/0091-6749(91)90422-K; BEL EH, 1990, AM REV RESPIR DIS, V141, P21, DOI 10.1164/ajrccm/141.1.21; BROGDEN RN, 1993, DRUGS, V45, P693, DOI 10.2165/00003495-199345050-00007; CALLAGHAN B, 1992, CHEST, V101, P787, DOI 10.1378/chest.101.3.787; CHERNIACK R M, 1990, Chest, V97, P1299; COCHRANE GM, 1992, EUR RESPIR J, V5, P122; DEJONG JW, 1994, AM J RESP CRIT CARE, V149, P91, DOI 10.1164/ajrccm.149.1.8111606; GIBSON P, 1993, BRIT MED J, V306, P1514, DOI 10.1136/bmj.306.6891.1514; KOCH GG, 1990, STATISTICAL METHODOL, P201; MARCOUX JP, 1992, EUR RESPIR J S15, V5, pS83; RAINEY DK, 1992, CLIN EXP ALLERGY, V22, P976, DOI 10.1111/j.1365-2222.1992.tb03023.x; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; VANAS A, 1986, EUR J RESPIR DIS, V69, P143; WASSERMAN SI, 1993, J ALLERGY CLIN IMMUN, V92, P210, DOI 10.1016/0091-6749(93)90111-R; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WILLIAMS AJ, 1986, EUR J RESPIR DIS, V69, P340; 1992, NIH PUBLICATION, V3091; 1991, NIH PUBLICATION, V3042	18	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1995	95	4					829	836		10.1016/S0091-6749(95)70126-5	http://dx.doi.org/10.1016/S0091-6749(95)70126-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QT468	7722163	Bronze			2022-12-18	WOS:A1995QT46800008
J	LEVY, J; ZALKINDER, I; KUPERMAN, O; SKIBIN, A; APTE, R; BEARMAN, JE; MIELKE, PW; TAL, A				LEVY, J; ZALKINDER, I; KUPERMAN, O; SKIBIN, A; APTE, R; BEARMAN, JE; MIELKE, PW; TAL, A			EFFECT OF PROLONGED USE OF INHALED STEROIDS ON THE CELLULAR-IMMUNITY OF CHILDREN WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CORTICOSTEROIDS; BECLOMETHASONE DIPROPIONATE; ASTHMA; CELLULAR IMMUNITY	BECLOMETHASONE DIPROPIONATE AEROSOL; CHILDHOOD ASTHMA; PLASMA-CORTISOL; THERAPY; CORTICOSTEROIDS; BUDESONIDE; GROWTH	Background: Systemic corticosteroids may affect the cellular immunity, but there is no available controlled data on such effects associated with a prolonged use of inhaled corticosteroids. Objective: The investigation was designed to study the effect of long-term inhaled beclomethasone dipropionate in daily doses of np to 600 mu g on cellular immune functions. Methods: Twenty-four children with asthma treated with inhaled beclomethasone dipropionate for a mean of 22.6 months were compared with 16 children with asthma not treated with an inhaled steroid and with 20 healthy adults. Cellular immune parameters included differential white blood count, T- and B-cell numbers, T helper and suppressor counts, T-cell mitogenic transformation and interleukin-1 and interleukin-2 secretion. Results: There was no difference in any of the studied cellular immune functions among the three study groups. Conclusion: Long-term use of inhaled beclomethasone dipropionate by children with asthma, at daily doses of up to 600 mu g, has no effect on certain parameters of cellular immunity.	SOROKA MED CTR KUPAT HOLIM,DEPT CLIN IMMUNOL LAB,BEER SHEVA,ISRAEL; SOROKA MED CTR KUPAT HOLIM,DEPT IMMUNOL & MICROBIOL,BEER SHEVA,ISRAEL; SOROKA MED CTR KUPAT HOLIM,DEPT EPIDEMIOL,BEER SHEVA,ISRAEL; BEN GURION UNIV NEGEV,FAC HLTH SCI,BEER SHEVA,ISRAEL; COLORADO STATE UNIV,DEPT STAT,DENVER,CO	Ben Gurion University; Soroka Medical Center; Ben Gurion University; Soroka Medical Center; Ben Gurion University; Soroka Medical Center; Ben Gurion University; Colorado State University	LEVY, J (corresponding author), SOROKA MED CTR KUPAT HOLIM,DEPT PEDIAT,POB 151,BEER SHEVA,ISRAEL.		Tal, Asher/B-4286-2012	Tal, Asher/0000-0002-5670-8804				ABZUG MJ, 1993, J PEDIATR-US, V123, P577, DOI 10.1016/S0022-3476(05)80954-0; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BLAISS MS, 1982, ANN ALLERGY, V48, P210; CLAMAN HN, 1983, HOSP PRACT, V7, P143; CUPPS TR, 1982, IMMUNOL REV, V65, P133, DOI 10.1111/j.1600-065X.1982.tb00431.x; EVANS PM, 1993, J ALLERGY CLIN IMMUN, V91, P643, DOI 10.1016/0091-6749(93)90270-P; Fisher RA., 1925, STAT METHOD RES WORK, V11th; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; GOLDSTEIN DE, 1983, PEDIATRICS, V72, P60; GRAFFLONNEVIG V, 1979, ALLERGY, V34, P57, DOI 10.1111/j.1398-9995.1979.tb02001.x; GURMAN G, 1990, INTENS CARE MED, V16, P44, DOI 10.1007/BF01706324; HERISHANU YO, 1989, ACTA NEUROL SCAND, V80, P569, DOI 10.1111/j.1600-0404.1989.tb03928.x; JENNINGS BH, 1990, EUR J CLIN PHARMACOL, V39, P127, DOI 10.1007/BF00280045; KERREBIJN KF, 1990, AM REV RESPIR DIS, V141, pS77; MIELKE HW, 1983, AM J PUBLIC HEALTH, V73, P1366, DOI 10.2105/AJPH.73.12.1366; MIELKE PW, 1986, J STAT PLAN INFER, V13, P377, DOI 10.1016/0378-3758(86)90147-3; MOLEMA J, 1988, EUR J CLIN PHARMACOL, V34, P577, DOI 10.1007/BF00615220; Mukivaya G., 1988, PEDIATR INFECT DIS J, V7, P499; PARRILLO JE, 1979, ANNU REV PHARMACOL, V19, P179, DOI 10.1146/annurev.pa.19.040179.001143; PHILLIP M, 1992, PEDIATR PULM, V12, P84, DOI 10.1002/ppul.1950120205; POUW EM, 1991, BRIT MED J, V302, P627, DOI 10.1136/bmj.302.6777.627; RACHELEFSKY GS, 1983, PEDIATRICS, V72, P130; RINEHART JJ, 1975, NEW ENGL J MED, V292, P236, DOI 10.1056/NEJM197501302920504; ROSE NR, 1986, MANUAL CLIN LABORATO, P453; SHAIKH WA, 1992, ALLERGY, V47, P327, DOI 10.1111/j.1398-9995.1992.tb02063.x; SZEFLER SJ, 1991, J ALLERGY CLIN IMMUN, V88, P147, DOI 10.1016/0091-6749(91)90323-G; TABACHNIK E, 1991, J PEDIATR-US, V118, P294, DOI 10.1016/S0022-3476(05)80506-2; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; TOOGOOD JH, 1990, AM REV RESPIR DIS, V141, pS89; TOOGOOD JH, 1984, AM REV RESPIR DIS, V129, P723, DOI 10.1164/arrd.1984.129.5.723; TOOGOOD JH, 1991, J ALLERGY CLIN IMMUN, V88, P572, DOI 10.1016/0091-6749(91)90150-M; WEIR DM, 1978, HDB EXPT IMMUNOLOGY, V3, P471; WEMPE JB, 1992, J ALLERGY CLIN IMMUN, V90, P757, DOI 10.1016/0091-6749(92)90099-N; WOLTHERS OD, 1991, BMJ-BRIT MED J, V303, P163, DOI 10.1136/bmj.303.6795.163; 1993, J ALLERGY CLIN IMMUN, V92, P223; 1991, FDA MED B, V21, P3	36	19	21	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1995	95	4					806	812		10.1016/S0091-6749(95)70122-2	http://dx.doi.org/10.1016/S0091-6749(95)70122-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QT468	7722159				2022-12-18	WOS:A1995QT46800004
J	[Anonymous]				[Anonymous]			MEASUREMENT OF SPECIFIC AND NONSPECIFIC IGG(4) LEVELS AS DIAGNOSTIC AND PROGNOSTIC TESTS FOR CLINICAL ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MITE-SPECIFIC IGE; IGG4 ANTIBODIES; PERENNIAL RHINITIS; DIETARY PROTEINS; SUB-CLASS; SUBCLASS; IMMUNOTHERAPY; ANTIGENS; CHILDREN; ASTHMA											AALBERSE RC, 1983, CLIN REV ALLERG, V1, P289; BARNES RMR, 1986, INT ARCH ALLER A IMM, V81, P141, DOI 10.1159/000234123; BROUWER R, 1986, AM J IND MED, V10, P283, DOI 10.1002/ajim.4700100314; DJURUP R, 1985, ALLERGY, V40, P469, DOI 10.1111/j.1398-9995.1985.tb00253.x; GARCIA BE, 1993, J INVEST ALLERG CLIN, V3, P19; GENTLESK MJ, 1988, NEW ENGL REG ALLERGY, V9, P17; GOODWIN BFJ, 1983, CLIN REV ALLERG, V1, P249; GWYNN CM, 1982, LANCET, V1, P254; HOMBURGER HA, 1986, J ALLERGY CLIN IMMUN, V77, P427, DOI 10.1016/0091-6749(86)90176-4; HOST A, 1992, ALLERGY, V47, P218, DOI 10.1111/j.1398-9995.1992.tb00654.x; KEMENY DM, 1991, J ALLERGY CLIN IMMUN, V87, P920, DOI 10.1016/0091-6749(91)90413-I; LEE TH, 1982, LANCET, V2, P1048; NAKAGAWA T, 1987, INT ARCH ALLER A IMM, V82, P95, DOI 10.1159/000234297; NORDVALL SL, 1986, ALLERGY, V41, P575, DOI 10.1111/j.1398-9995.1986.tb00349.x; OHASHI Y, 1987, ANN OTO RHINOL LARYN, V96, P434, DOI 10.1177/000348948709600417; PARISH WE, 1970, LANCET, V2, P591; PERELMUTTER L, 1983, CLIN REV ALLERG, V1, P267; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; SHAKIB F, 1986, CLIN ALLERGY, V16, P451, DOI 10.1111/j.1365-2222.1986.tb01980.x; STANWORTH DR, 1983, CLIN REV ALLERG, V1, P183; STANWORTH DR, 1987, NEW ENGL REG ALLERGY, V8, P379; STANWORTH DR, 1973, CLIN ALLERGY, V1, P37; URBANEK R, 1986, CLIN ALLERGY, V16, P317, DOI 10.1111/j.1365-2222.1986.tb01963.x; VANDERZEE JS, 1991, EUR RESPIR J, V4, pS91; YAMASHITA N, 1987, CLIN EXP IMMUNOL, V68, P93	25	19	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					652	654						3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017					2022-12-18	WOS:A1995QM01700002
J	BUSSE, WW; SEDGWICK, JB; JARJOUR, NN; CALHOUN, WJ				BUSSE, WW; SEDGWICK, JB; JARJOUR, NN; CALHOUN, WJ			EOSINOPHILS AND BASOPHILS IN ALLERGIC AIRWAY INFLAMMATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HISTAMINE-RELEASE; ANTIGEN CHALLENGE; BRONCHOALVEOLAR LAVAGE; ASTHMATICS; RHINITIS; RELEASABILITY; MEDIATORS; IMMEDIATE; INVITRO; IGE				BUSSE, WW (corresponding author), UNIV WISCONSIN, DEPT MED, ALLERGY & CLIN IMMUNOL SECT, MADISON, WI USA.			Calhoun, William/0000-0001-7075-712X				BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BUSSE WW, 1986, J ALLERGY CLIN IMMUN, V78, P90, DOI 10.1016/0091-6749(86)90119-3; BUTLER JM, 1983, J ALLERGY CLIN IMMUN, V71, P490, DOI 10.1016/0091-6749(83)90467-0; BUTLER JM, 1985, ACTA DERM-VENEREOL, P55; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; CONROY MC, 1977, J IMMUNOL, V118, P1317; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; GADDY JN, 1986, AM REV RESPIR DIS, V134, P969, DOI 10.1164/arrd.1986.134.5.969; JARJOUR NN, 1990, AM REV RESPIR DIS, V142, P100, DOI 10.1164/ajrccm/142.1.100; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; KUNA P, 1993, J IMMUNOL, V150, P1932; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; MARONE G, 1986, J ALLERGY CLIN IMMUN, V78, P974, DOI 10.1016/0091-6749(86)90288-5; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P432, DOI 10.1016/0091-6749(76)90124-X; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; PETERS SP, 1985, INT ARCH ALLER A IMM, V76, P344, DOI 10.1159/000233719; RICKETTI AJ, 1983, J ALLERGY CLIN IMMUN, V72, P386, DOI 10.1016/0091-6749(83)90504-3; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; STAHLSKOV P, 1977, CLIN EXP IMMUNOL, V27, P432; TUNG R, 1982, J IMMUNOL, V128, P2067	20	19	19	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1250	1254		10.1016/0091-6749(94)90339-5	http://dx.doi.org/10.1016/0091-6749(94)90339-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7528233				2022-12-18	WOS:A1994QA02000019
J	DEBENEDICTIS, FM; TUTERI, G; BERTOTTO, A; BRUNI, L; VACCARO, R				DEBENEDICTIS, FM; TUTERI, G; BERTOTTO, A; BRUNI, L; VACCARO, R			COMPARISON OF THE PROTECTIVE EFFECTS OF CROMOLYN SODIUM AND NEDOCROMIL SODIUM IN THE TREATMENT OF EXERCISE-INDUCED ASTHMA IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EXERCISE-INDUCED ASTHMA; CROMOLYN SODIUM; NEDOCROMIL SODIUM; CHILDREN	DOSE-RESPONSE; INDUCED BRONCHOCONSTRICTION; CROMOGLYCATE; STANDARDIZATION; DURATION; AEROSOL; EIA	Seventeen children with asthma were studied in a double-blind crossover; placebo-controlled study designed to compare the efficacy of cromolyn sodium with that of nedocromil sodium in preventing exercise-induced asthma. All drugs were delivered through a metered-dose inhaler (cromolyn sodium, 10 mg; nedocromil sodium, 4 mg; placebo two puffs). Nedocromil sodium and cromolyn sodium provided significant, comparable protection from exercise-induced asthma, and both drugs were better than placebo. We conclude that nedocromil sodium and cromolyn sodium administered by a pressurized aerosol provide equal protection against exercise-induced asthma in children.			DEBENEDICTIS, FM (corresponding author), UNIV PERUGIA, MONTELUCE POLICLIN, PEDIAT CLIN, I-06123 PERUGIA, ITALY.							ALBAZZAZ MK, 1989, THORAX, V44, P816, DOI 10.1136/thx.44.10.816; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; [Anonymous], 1979, AM REV RESPIR DIS, V119, P831; BARYISHAY E, 1983, ARCH DIS CHILD, V58, P624, DOI 10.1136/adc.58.8.624; BONER AL, 1989, ANN ALLERGY, V62, P38; CHUDRY N, 1987, ARCH DIS CHILD, V62, P412, DOI 10.1136/adc.62.4.412; COMIS A, 1993, EUR RESPIR J, V6, P523; DEBELIC M, 1986, EUR J RESPIR DIS, V69, P266; EADY RP, 1985, BRIT J PHARMACOL, V85, P323, DOI 10.1111/j.1476-5381.1985.tb08864.x; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; HENRIKSEN JM, 1988, ALLERGY, V43, P449, DOI 10.1111/j.1398-9995.1988.tb00917.x; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; KONIG P, 1987, J ALLERGY CLIN IMMUN, V79, P64, DOI 10.1016/S0091-6749(87)80018-0; LEUNG KBP, 1986, EUR J RESPIR DIS, V69, P223; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MORTON AR, 1992, ANN ALLERGY, V68, P143; NOVEMBRE E, 1993, J ALLERGY CLIN IMMUN, V91, P168; PATEL KR, 1982, THORAX, V37, P663, DOI 10.1136/thx.37.9.663; SILVERMAN M, 1973, THORAX, V28, P574, DOI 10.1136/thx.28.5.574; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; TAUSSIG LM, 1980, J PEDIATR-US, V97, P668, DOI 10.1016/S0022-3476(80)80039-4; TULLETT WM, 1985, THORAX, V40, P41, DOI 10.1136/thx.40.1.41	22	19	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1994	94	4					684	688		10.1016/0091-6749(94)90175-9	http://dx.doi.org/10.1016/0091-6749(94)90175-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PM273	7930301				2022-12-18	WOS:A1994PM27300006
J	NAGATA, M; SHIBASAKI, M; SAKAMOTO, Y; FUKUDA, T; MAKINO, S; YAMAMOTO, K; DOHI, Y				NAGATA, M; SHIBASAKI, M; SAKAMOTO, Y; FUKUDA, T; MAKINO, S; YAMAMOTO, K; DOHI, Y			SPECIFIC IMMUNOTHERAPY REDUCES THE ANTIGEN-DEPENDENT PRODUCTION OF EOSINOPHIL CHEMOTACTIC ACTIVITY FROM MONONUCLEAR-CELLS IN PATIENTS WITH ATOPIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EOSINOPHIL CHEMOTACTIC ACTIVITY; DERMATOPHAGOIDES FARINAE; IMMUNOTHERAPY; RUSH IMMUNOTHERAPY	RECOMBINANT HUMAN INTERLEUKIN-5; COLONY-STIMULATING FACTOR; LYMPHOCYTES-T; BRONCHIAL BIOPSIES; HOUSE DUST; CHEMOATTRACTANT; HYPOSENSITIZATION; EXPRESSION; HYPODENSE; MIGRATION	Background:The efficacy of specific immunotherapy has been verified. There is accumulating evidence focusing on the T lymphocyte-eosinophil interaction in the pathogenesis of asthma. The aim of this study was to clarify whether immunotherapy affects the production of eosinophil chemotactic activity (ECA) from peripheral blood mononuclear cells (PBMC). Methods: PBMC obtained from persons with bronchial asthma who were sensitive to Dermatophagoides farinae (Df) or from healthy volunteers were cultured for 96 hours in the presence or absence of Df. ECA in culture supernatants was assayed by means of the modified Boyden's chamber method. Results: There was no significant difference in the baseline levels of ECA between asthmatic persons treated with immunotherapy and those without immunotherapy. The addition of Df (10 to 10(4) ng/ml) enhanced the ECA production in a dose-dependent fashion in asthmatic persons without immunotherapy, and there was a statistically significant correlation between the concentrations of Df and the levels of ECA (r(k) = 0.34; p < 0.05). In contrast, Df-dependent ECA production was suppressed in asthmatic persons with immunotherapy, and the suppressive effect was observed from 4 week after rush immunotherapy. Conclusions: These results indicate that immunotherapy induces the suppression of antigen-dependent production of ECA from PBMC. This may contribute to the attenuation of eosinophil infiltration into the airways in asthma patients.	SAITAMA MED SCH,DEPT INTERNAL MED 2,SAITAMA 35004,JAPAN; DOKKYO UNIV,SCH MED,DEPT MED & CLIN IMMUNOL,TOCHIGI,JAPAN	Saitama Medical University; Dokkyo Medical University								AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V86, P292, DOI 10.1016/S0091-6749(05)80091-0; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; CENTER DM, 1983, J IMMUNOL, V131, P1854; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; FOWLER JW, 1966, J ALLERGY, V37, P19, DOI 10.1016/0021-8707(66)90106-7; FREW AJ, 1990, AM REV RESPIR DIS, V141, P407, DOI 10.1164/ajrccm/141.2.407; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; HAKANSSON L, 1989, J ALLERGY CLIN IMMUN, V83, P933, DOI 10.1016/0091-6749(89)90108-5; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HSIEH KH, 1987, ANN ALLERGY, V59, P57; HSIEH KH, 1985, J ALLERGY CLIN IMMUN, V76, P188, DOI 10.1016/0091-6749(85)90700-6; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MILLER DL, 1971, ANN ALLERGY, V29, P178; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PARISH WE, 1982, CLIN ALLERGY, V12, P475, DOI 10.1111/j.1365-2222.1982.tb01646.x; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; RAND TH, 1991, J EXP MED, V173, P1521, DOI 10.1084/jem.173.6.1521; RAND TH, 1991, J CLIN INVEST, V88, P825, DOI 10.1172/JCI115383; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SANSONE LA, 1986, IRCS MED SCI-BIOCHEM, V14, P148; SEHMI R, 1992, BLOOD, V79, P2952; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; WARRINGA RAJ, 1991, BLOOD, V77, P2694	31	19	20	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2					160	166		10.1016/0091-6749(94)90035-3	http://dx.doi.org/10.1016/0091-6749(94)90035-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC926	8064068				2022-12-18	WOS:A1994PC92600004
J	TSIMIKAS, S; HOLLINGSWORTH, HM; NASH, G				TSIMIKAS, S; HOLLINGSWORTH, HM; NASH, G			ASPERGILLUS BRAIN-ABSCESS COMPLICATING ALLERGIC ASPERGILLUS-SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							BRONCHOPULMONARY ASPERGILLOSIS		UNIV MASSACHUSETTS,MED CTR,DEPT MED,WORCESTER,MA; UNIV MASSACHUSETTS,MED CTR,DEPT PATHOL,WORCESTER,MA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester				Hollingsworth, Helen/0000-0001-9007-9012				FINK JN, 1988, HOSP PRACT      0530, P105; Handley GH, 1990, AM J RHINOL, V4, P149; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; RILEY DJ, 1975, AM REV RESPIR DIS, V111, P232; SARTI EJ, 1988, LARYNGOSCOPE, V98, P632; SHAH A, 1990, ANN ALLERGY, V64, P507; SHER TH, 1988, J ALLERGY CLIN IMMUN, V81, P844, DOI 10.1016/0091-6749(88)90940-2; WAXMAN JE, 1987, LARYNGOSCOPE, V97, P261	8	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2					264	267		10.1016/0091-6749(94)90051-5	http://dx.doi.org/10.1016/0091-6749(94)90051-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC926	8064081				2022-12-18	WOS:A1994PC92600020
J	GALOPPIN, L; DEBLIC, J; AZEVEDO, I; SCHEINMANN, P; VARGAFTIG, BB; BACHELET, M				GALOPPIN, L; DEBLIC, J; AZEVEDO, I; SCHEINMANN, P; VARGAFTIG, BB; BACHELET, M			NONSPECIFIC REFRACTORINESS TO ADENYLYL-CYCLASE STIMULATION IN ALVEOLAR MACROPHAGES FROM INFANTS WITH RECURRENT BRONCHIOLITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						WHEEZING; RECURRENT BRONCHIOLITIS; ASTHMA; INFANTS; BRONCHOALVEOLAR LAVAGE; ADENYLYL CYCLASE; MACROPHAGE; BETA-ADRENERGIC AGONISTS	SYNCYTIAL VIRUS-INFECTION; BETA-ADRENERGIC RECEPTORS; BRONCHOALVEOLAR LAVAGE; RESPIRATORY-TRACT; RANDOMIZED TRIAL; FOLLOW-UP; ASTHMA; DESENSITIZATION; LYMPHOCYTES; CHILDHOOD	Epidemiologic studies suggest an association between recurrent bronchiolitis in children younger than 3 years of age and diagnosis of asthma later in life. Bronchoalveolar lavages from 20 infants with recurrent wheezing and 18 nonwheezy control subjects were analyzed to determine whether alveolar macrophages of wheezy infants present abnormalities similar to those described in adults with asthma. Alveolar macrophages from both groups responded in vitro, in a concentration-dependent manner, to prostaglandin E(2), salbutamol, and forskolin, drugs that increase cyclic adenosine monophosphate levels. However, alveolar macrophages from infants with recurrent wheezing accumulated less cyclic adenosine monophosphate than those from control subjects in response to all three stimulations. These results are in agreement with the reduced cyclic adenosine monophosphate response to different agonists demonstrated in leukocytes from patients with asthma, and suggest that this refractoriness could be one of the precipitating events in the development of asthma observed in a large proportion of infants who have had bronchiolitis.	INST PASTEUR,INSERM,UA 285,UNITE PHARMACOL CELLULAIRE,F-75724 PARIS 15,FRANCE; HOP NECKER ENFANTS MALAD,SERV PNEUMOL & ALLERGOL INFANTILES,PARIS,FRANCE; CHU COCHIN PORT ROYAL,SERIMM,PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite			Azevedo, Ines/AAX-7347-2021; Azevedo, Ines/G-5129-2015; Vargaftig, Bernardo Boris B.B.J./C-3323-2013	Azevedo, Ines/0000-0002-0090-8612; Azevedo, Ines/0000-0002-0090-8612; 				BACHELET M, 1991, J ALLERGY CLIN IMMUN, V88, P322, DOI 10.1016/0091-6749(91)90093-4; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BROOKS SM, 1979, J ALLERGY CLIN IMMUN, V63, P401, DOI 10.1016/0091-6749(79)90213-6; DARFLER FJ, 1982, J BIOL CHEM, V257, P1901; DEBLIC J, 1992, ARCH DIS CHILD, V67, P159, DOI 10.1136/adc.67.2.159; DEBLIC J, 1989, ARCH DIS CHILD, V64, P1246, DOI 10.1136/adc.64.9.1246; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; GAROFALO R, 1992, J PEDIATR-US, V120, P28, DOI 10.1016/S0022-3476(05)80592-X; GARRITY M, 1983, J BIOL CHEM, V258, P8692; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; KARIMAN K, 1977, CLIN RES, V25, pA593; KASSIS S, 1982, J BIOL CHEM, V257, P5312; KLASSEN TP, 1991, J PEDIATR-US, V118, P807, DOI 10.1016/S0022-3476(05)80051-4; LOGSDON PJ, 1980, J ALLERGY CLIN IMMUN, V66, P52; LOUGHLIN GM, 1990, DISORDERS RESPIRATOR, P349; MAKINO S, 1977, J ALLERGY CLIN IMMUN, V59, P348, DOI 10.1016/0091-6749(77)90016-1; MCCONNOCHIE KM, 1984, PEDIATRICS, V74, P1; MEURS H, 1987, J ALLERGY CLIN IMMUN, V80, P326, DOI 10.1016/0091-6749(87)90039-X; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; REYNOLDS HY, 1987, AM REV RESPIR DIS, V135, P250; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SPORIK R, 1991, ARCH DIS CHILD, V66, P1059; SPRINGER C, 1990, PEDIATR PULM, V9, P181, DOI 10.1002/ppul.1950090311; Stark JM, 1991, PEDIATR ALLERGY IMMU, V2, P95; TABACHNIK E, 1981, J ALLERGY CLIN IMMUN, V67, P339, DOI 10.1016/0091-6749(81)90077-4; TEPPER RS, 1992, PEDIATR PULM, V13, P6, DOI 10.1002/ppul.1950130104; VOLOVITZ B, 1988, J PEDIATR-US, V112, P218, DOI 10.1016/S0022-3476(88)80058-1; WANG EEL, 1992, ARCH DIS CHILD, V67, P289, DOI 10.1136/adc.67.3.289; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WARNER JO, 1992, ARCH DIS CHILD, V67, P240; WELLIVER RC, 1984, J IMMUNOL, V133, P1925; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WELLIVER RC, 1986, J PEDIATR-US, V109, P776, DOI 10.1016/S0022-3476(86)80692-8; WILSON NM, 1989, ARCH DIS CHILD, V64, P1194, DOI 10.1136/adc.64.8.1194; WOOD RE, 1988, J PEDIATR-US, V112, P1, DOI 10.1016/S0022-3476(88)80109-4; 1992, AM REV RESPIR DIS, V145, P233	39	19	19	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					885	890		10.1016/0091-6749(94)90382-4	http://dx.doi.org/10.1016/0091-6749(94)90382-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	8182232				2022-12-18	WOS:A1994NL91900013
J	ALMOHANNA, F; PARHAR, R; KAWAASI, A; ERNST, P; SHETH, K; HARFI, H; ALSEDAIRY, S				ALMOHANNA, F; PARHAR, R; KAWAASI, A; ERNST, P; SHETH, K; HARFI, H; ALSEDAIRY, S			INHIBITION OF NEUTROPHIL FUNCTIONS BY HUMAN IMMUNOGLOBULIN-E	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NEUTROPHIL; IMMUNOGLOBULIN-E; PHAGOCYTOSIS; SECRETION; ADHESION; OXIDASE ACTIVATION; HYPERIMMUNOGLOBULINEMIA-E	RECEPTOR-MEDIATED PHAGOCYTOSIS; HYPERIMMUNOGLOBULINEMIA-E; ACTIN POLYMERIZATION; FC-RECEPTORS; RECURRENT INFECTIONS; SURFACE GLYCOPROTEIN; CHEMOTAXIS; ACTIVATION; OXIDASE; IGG	Incubation of human neutrophils with human immunoglobulin (Ig) E caused dose-dependent inhibition of adhesion, phagocytosis, secretion of myeloperoxidase, and oxygen radical production. The concentrations of IgE that caused 50% inhibition of adhesion, phagocytosis, and secretion were 2 +/- 0.3, 2.16 +/- 0.21, and 1.95 +/- 0.28 ng/ml, respectively. Oxidase activation as measured by luminol-dependent chemiluminescence by the receptor-mediated N-formyl-methionyl-leucyl-phenylalanine, phorbol 12-myristate 13-acetate, or the particulate stimulus Staphylococcus aureus was inhibited by IgE with concentrations causing 50% effect of 1.2 +/- 0.13, 1.09 +/- 0.16, and 0.6 +/- 0.09 ng/ml, respectively. IgE also inhibited oxygen consumption rate and cytochrome c reduction with similar K0.5 values. The effect of IgE was unlikely to be due to nonspecific cytotoxicity because trypan blue exclusion test and the cytoplasmic marker lactate dehydrogenase revealed that the cells retained their viability after IgE treatment. Similar or higher concentrations of IgG invoked either no inhibition or a slight enhancement of neutrophil functions. Pretreatment of neutrophils with IgG failed to affect the IgE-induced inhibition. Because the effect of IgE occurs at concentrations less than those reported in hyperimmunoglobulinemia E, we propose that direct inhibition of neutrophil functions may underlie the pathogenesis of recurrent infection associated with hyperimmunoglobulinemia E.	KING FAISAL SPECIALIST HOSP & RES CTR,DEPT BIOL & MED RES,RIYADH 11211,SAUDI ARABIA	King Faisal Specialist Hospital & Research Center	ALMOHANNA, F (corresponding author), UNIV LONDON UNIV COLL,DEPT PHYSIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.							Absolom D R, 1986, Methods Enzymol, V132, P95; ALLEN RC, 1986, METHOD ENZYMOL, V133, P449; Allison A C, 1973, Ciba Found Symp, V14, P109; ALMOHANNA FA, 1987, FEBS LETT, V219, P40, DOI 10.1016/0014-5793(87)81187-0; ALMOHANNA FA, 1990, BIOCHEM BIOPH RES CO, V169, P1222, DOI 10.1016/0006-291X(90)92027-W; ALMOHANNA FA, 1987, BIOCHIM BIOPHYS ACTA, V927, P366, DOI 10.1016/0167-4889(87)90101-7; ALMOHANNA FA, 1991, BLOOD CELL BIOCH, V3, P289; Altman DG, 1991, PRACTICAL STAT MED R, P179; ANDERSON CL, 1986, IMMUNOL TODAY, V7, P264, DOI 10.1016/0167-5699(86)90007-1; ARNAOUT MA, 1985, NEW ENGL J MED, V312, P457, DOI 10.1056/NEJM198502213120801; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BEATTY PG, 1984, LANCET, V1, P535; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; CLARK RA, 1973, ANN INTERN MED, V78, P515, DOI 10.7326/0003-4819-78-4-515; DANA N, 1986, J IMMUNOL, V137, P3259; DAVIS SD, 1966, LANCET, V1, P1013; FANGER MW, 1989, IMMUNOL TODAY, V10, P92, DOI 10.1016/0167-5699(89)90234-X; GALLIN JI, 1980, ANN INTERN MED, V92, P520, DOI 10.7326/0003-4819-92-4-520; GRESHAM HD, 1986, J IMMUNOL, V137, P868; Hallet M. B., 1989, NEUTROPHIL CELLULAR, P1; HALLETT MB, 1983, BIOCHEM J, V216, P459, DOI 10.1042/bj2160459; HARTWIG JH, 1983, J CLIN CHEM CLIN BIO, V21, P535; HILL HR, 1974, LANCET, V1, P183; HILL HR, 1976, ANN INTERN MED, V85, P39, DOI 10.7326/0003-4819-85-1-39; JEPPSON JD, 1991, J PEDIATR-US, V118, P383, DOI 10.1016/S0022-3476(05)82151-1; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTIONS; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LEW DP, 1985, NATURE, V315, P509, DOI 10.1038/315509a0; MELLMAN IS, 1983, J CELL BIOL, V96, P887, DOI 10.1083/jcb.96.3.887; NATHAN C, 1980, J EXP MED, V1952, P183; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; NOELLE RJ, 1989, J IMMUNOL, V143, P1807; NYBROE O, 1988, NEUROCHEM INT, V12, P251, DOI 10.1016/0197-0186(88)90162-3; PARHAR RS, 1991, J ALLERGY CLIN IMMUN, V87, P245; PASSWELL JH, 1980, J IMMUNOL, V125, P910; PATARROYO M, 1985, SCAND J IMMUNOL, V22, P619, DOI 10.1111/j.1365-3083.1985.tb01924.x; QUIE PG, 1983, LEUCOCYTE LOCOMOTION, P398; ROSALES C, 1991, J IMMUNOL, V146, P3937; SCHOPFER K, 1979, NEW ENGL J MED, V300, P835, DOI 10.1056/NEJM197904123001506; SEGAL AW, 1988, EUR J CLIN INVEST, V18, P433, DOI 10.1111/j.1365-2362.1988.tb01037.x; UNKLESS JC, 1988, ANNU REV IMMUNOL, V6, P251; VANFURTH R, 1987, ADV BIOSCI, V66, P391; WEENING RS, 1983, CELL BIOL IMMUNOLOGY, P901; WILLIAMS JG, 1989, BIOCHEM PHARMACOL, V38, P149, DOI 10.1016/0006-2952(89)90161-5	44	19	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					757	766		10.1016/0091-6749(93)90020-G	http://dx.doi.org/10.1016/0091-6749(93)90020-G			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	8227868				2022-12-18	WOS:A1993MG98200018
J	SALE, ME; WOOSLEY, RL; BARBY, JT; YEH, J; CHUNG, M				SALE, ME; WOOSLEY, RL; BARBY, JT; YEH, J; CHUNG, M			LACK OF ELECTROCARDIOGRAPHIC EFFECTS OF CETIRIZINE IN HEALTHY HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract													Woosley, Raymond/AAE-4874-2020	Woosley, Raymond/0000-0002-2588-328X					0	19	19	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1993	91	1	2				258	258						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK431					2022-12-18	WOS:A1993KK43100471
J	ULRIK, CS				ULRIK, CS			BRONCHIAL RESPONSIVENESS TO INHALED HISTAMINE IN BOTH ADULTS WITH INTRINSIC AND EXTRINSIC-ASTHMA - THE IMPORTANCE OF PRECHALLENGE FORCED EXPIRATORY VOLUME IN 1 SECOND	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; BRONCHIAL RESPONSIVENESS; ADULTS; HISTAMINE; PRECHALLENGE PULMONARY FUNCTION; INTRINSIC ASTHMA; EXTRINSIC ASTHMA	OBSTRUCTIVE PULMONARY-DISEASE; AIRWAY HYPERRESPONSIVENESS; METHACHOLINE; REACTIVITY; CHALLENGE	Background: Recent evidence suggests that both nonspecific bronchial hyperresponsiveness and degree of airflow obstruction may be involved in the deterioration of lung function observed in patients with bronchial asthma. To investigate to which degree the level of bronchial hyperresponsiveness reflects the size of the airways at the time of testing, we examined the relationship of nonspecific bronchial responsiveness to prechallenge pulmonary function in adult asthmatic patients. Methods: Bronchial responsiveness to inhaled histamine was measured in 100 patients (age range, 28 to 79 years), of whom 62 had intrinsic and 38 had extrinsic asthma. Histamine responsiveness was analyzed by means of the dose-response slope (DRS). Results: No significant difference in prechallenge forced expiratory volume expressed as a percentage of predicted value (FEV1%pred), duration of asthma, smoking habits (pack years), or bronchial responsiveness (DRS) was found between the patients with intrinsic and those with extrinsic asthma. The patients had, in general, reduced pulmonary function, because 80% had a prechallenge FEV1 less than 80%pred. The DRS displayed a significant inverse relationship to the prechallenge level of FEV1%pred in both patients with intrinsic asthma and those with extrinsic asthma (p < 0.000001); the initial FEV1%pred accounted for approximately 35% of the variance in measurements of histamine responsiveness. Excluding patients with abnormal prechallenge FEV1 (< 70%pred), or current and exsmokers (never smoked: n = 67) from the analysis did not change these findings. Conclusion: Nonspecific bronchial responsiveness is to some extent determined by the prechallenge level of pulmonary function in both adults with intrinsic and extrinsic asthma.			ULRIK, CS (corresponding author), UNIV HOSP COPENHAGEN, RIGHOSP,DEPT MED B,RESP PHYSIOL LAB,KF-4011, BLEGDAMSVEJ 9, DK-2100 COPENHAGEN 0, DENMARK.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BUIST AS, 1987, CHEST, V91, pS119, DOI 10.1378/chest.91.6.119S; Clausen JL, 1982, PULMONARY FUNCTION T, P215; COCKCROFT DW, 1988, ANN ALLERGY, V60, P465; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Dirksen A, 1982, Dan Med Bull, V29, P5; GERRITSEN J, 1987, CLIN ALLERGY, V17, P119, DOI 10.1111/j.1365-2222.1987.tb02329.x; GROSS NJ, 1980, AM REV RESPIR DIS, V121, P203; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; KIRKWOOD BR, 1988, ESSENTIALS MED STATI, P138; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P1520, DOI 10.1164/ajrccm/140.6.1520; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225, DOI 10.1164/ajrccm/140.1.225; OSWALD NC, 1955, LANCET, V2, P843; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; RAMSDALE EH, 1984, THORAX, V39, P912, DOI 10.1136/thx.39.12.912; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; STAHLSKOV P, 1977, SCAND J IMMUNOL, V6, P1021; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9; VILJANEN AA, 1982, SCAND J CLIN LAB INV, V42, P5; WEEKE B, 1977, ALLERGOL IMMUNOPATH, V4, P333; YAN K, 1985, AM REV RESPIR DIS, V132, P25	24	19	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1993	91	1	1				120	126		10.1016/0091-6749(93)90304-X	http://dx.doi.org/10.1016/0091-6749(93)90304-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK044	7678613				2022-12-18	WOS:A1993KK04400011
J	SUBIZA, J; SUBIZA, JL; VALDIVIESO, R; ESCRIBANO, PM; GARCIA, R; JEREZ, M; SUBIZA, E				SUBIZA, J; SUBIZA, JL; VALDIVIESO, R; ESCRIBANO, PM; GARCIA, R; JEREZ, M; SUBIZA, E			TOOTHPASTE FLAVOR-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									UNIV MADRID,HOSP SAN CARLOS,SERV IMMUNOL,MADRID 3,SPAIN	Hospital Clinico San Carlos	SUBIZA, J (corresponding author), GEN PARDINAS,CTR ALERGIA & INMUNOL CLIN,GEN PARDINAS 116,E-28006 MADRID,SPAIN.							LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; SPURLOCK BW, 1990, NEW ENGL J MED, V323, P1845; SUBIZA J, 1991, J ALLERGY CLIN IMMUN, V88, P731, DOI 10.1016/0091-6749(91)90179-R; TOOGOOD JH, 1981, J ALLERGY CLIN IMMUN, V67, P317, DOI 10.1016/0091-6749(81)90028-2; 1989, EXTRA PHARMACOPOEIA, P1586	5	19	20	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1992	90	6	1				1004	1006		10.1016/0091-6749(92)90478-K	http://dx.doi.org/10.1016/0091-6749(92)90478-K			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD190	1460190				2022-12-18	WOS:A1992KD19000022
J	LAVINS, BJ; DOLEN, WK; NELSON, HS; WEBER, RW				LAVINS, BJ; DOLEN, WK; NELSON, HS; WEBER, RW			USE OF STANDARDIZED AND CONVENTIONAL ALLERGEN EXTRACTS IN PRICK SKIN TESTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGEN EXTRACTS; SKIN TESTING; ATOPY; STANDARDIZATION	RADIOALLERGOSORBENT TEST; INHIBITORY CAPACITIES; POTENCY	This study examined whether commercially available conventional and standardized allergen extracts differ enough in potency to affect routine prick skin test results. Extracts of white oak, timothy, Bermuda, Russian thistle, short ragweed, sagebrush, Alternaria, and cat dander were examined in allergic patients and in nonatopic subjects with no personal or family history of asthma, rhinitis, or eczema. Conventional nonstandardized extracts (1:10 or 1:20 wt/vol) from two sources were compared with three concentrations (100,000, 10,000, and 1000 AU/ml) of a single standardized extract. Preparations were compared in the allergic patients with computerized planimetry, and in all patients and subjects with a conventional skin test grading system. Skin test area for the conventional extracts generally fell between the 10,000 and 100,000 AU/ml concentrations of the standardized extract. Skin test reactivity to at least one allergen extract occurred in 31% of the nonatopic subjects; there was no difference between the number of 3+ and 4+ reactions for conventional and standardized extracts. Results indicate that standardized and conventional extracts are frequently similar, but are not directly interchangeable.	FITZSIMONS ARMY MED CTR,ALLERGY IMMUNOL SERV,AURORA,CO 80045									ADINOFF AD, 1990, J ALLERGY CLIN IMMUN, V86, P766, DOI 10.1016/S0091-6749(05)80181-2; [Anonymous], 1989, ALLERGY S10, V44, P1; CURRAN WS, 1961, ANN INTERN MED, V55, P777, DOI 10.7326/0003-4819-55-5-777; GLEICH GJ, 1976, J ALLERGY CLIN IMMUN, V58, P31, DOI 10.1016/0091-6749(76)90104-4; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GROW MH, 1936, J ALLERGY, V7, P108; LINDBLAD JH, 1961, J ALLERGY, V32, P392, DOI 10.1016/0021-8707(61)90016-8; PEARSON RSB, 1937, Q J MED, V30, P165; VANSELOW NA, 1967, MANUAL CLIN ALLERGY, P55	9	19	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1992	89	3					658	666		10.1016/0091-6749(92)90371-8	http://dx.doi.org/10.1016/0091-6749(92)90371-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HJ340	1545087				2022-12-18	WOS:A1992HJ34000003
J	BRUIJNZEELKOOMEN, C; STORZ, E; MENZ, G; BRUIJNZEEL, P				BRUIJNZEELKOOMEN, C; STORZ, E; MENZ, G; BRUIJNZEEL, P			SKIN EOSINOPHILIA IN PATIENTS WITH ALLERGIC AND NONALLERGIC ASTHMA AND ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EOSINOPHILS; PLATELET-ACTIVATING FACTOR; ALLERGENS; SKIN; ASTHMA; ATOPIC DERMATITIS	PLATELET-ACTIVATING FACTOR; PAF-ACETHER; ACCUMULATION; CHEMOTAXIS; INHIBITION	Skin eosinophilia induced by grass pollen or platelet-activating factor (PAF) was investigated in patients with allergic and nonallergic asthma and atopic dermatitis (AD) and in normal control subjects. Intracutaneous injection of PAF resulted in positive immediate skin reactions in all tested individuals. Since most of the patients with allergic and nonallergic asthma and eczema under investigation were characterized by a peripheral blood eosinophilia, we investigated whether PAF should be capable of mobilizing blood eosinophils to the skin of patients with nonallergic asthma and AD using the Rebuck skin window technique. Our results demonstrated that, in allergic individuals, allergen induced a much stronger skin eosinophilia than PAF and in a larger percentage of the patients (77% versus 45%). There was no correlation between skin eosinophilia induced by PAF and the occurrence of late skin reactions to allergen. Furthermore, the PAF-induced and the allergen-induced skin eosinophilia differed histologically. In nonallergic individuals, neither allergen nor PAF was capable of mobilizing eosinophils in the skin window, in spite of the presence of peripheral blood eosinophilia. Our results indicate that the allergen- and PAF-induced skin eosinophilia are different and that in patients with nonallergic asthma and AD, another chemoattractant than PAF must be responsible for eosinophil mobilization in the target organ.	HOCHGEBIRGSKLIN DAVOS WOLFGANG,DAVOS,SWITZERLAND		BRUIJNZEELKOOMEN, C (corresponding author), SWISS INST ALLERGY & ASTHMA RES,OBERE STR 22,CH-7270 DAVOS,SWITZERLAND.							ARCHER CB, 1985, BRIT J DERMATOL, V112, P285, DOI 10.1111/j.1365-2133.1985.tb04855.x; ARNOUX B, 1988, AM REV RESPIR DIS, V137, P855, DOI 10.1164/ajrccm/137.4.855; ATKINS PC, 1983, CLIN REV ALLERG, V1, P385; BOOYNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344; BOOYNOORD H, 1972, CLIN ALLERGY, V2, P43; BRUIJNZEEL PLB, 1990, BRIT J PHARMACOL, V99, P798, DOI 10.1111/j.1476-5381.1990.tb13009.x; BRUIJNZEEL PLB, 1989, CLIN EXP ALLERGY S1, V19, P25; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HENOCQ E, 1988, J ALLERGY CLIN IMMUN, V81, P691, DOI 10.1016/0091-6749(88)91040-8; HENOCQ E, 1986, LANCET, V1, P1379; LELLOUCHTUBIANA A, 1988, AM REV RESPIR DIS, V137, P948, DOI 10.1164/ajrccm/137.4.948; MARKEY AC, 1990, J AM ACAD DERMATOL, V23, P263, DOI 10.1016/0190-9622(90)70210-9; OFLAHERTY JT, 1983, CLIN REV ALLERG, V1, P353; RACKEMANN FM, 1947, AM J MED, V3, P601, DOI 10.1016/0002-9343(47)90204-0; SPRY CJF, 1985, IMMUNOL TODAY, V6, P332, DOI 10.1016/0167-5699(85)90130-6; TAMURA N, 1987, BIOCHEM BIOPH RES CO, V142, P638, DOI 10.1016/0006-291X(87)91462-8; Virchow C, 1989, Agents Actions Suppl, V28, P9; WALKER C, 1991, J IMMUNOL, V146, P1829; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WARRINGA RAJ, 1991, BLOOD, V77, P2694; 1987, AM REV RESPIR DIS, V136, P225	23	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	1				52	59		10.1016/S0091-6749(05)80040-5	http://dx.doi.org/10.1016/S0091-6749(05)80040-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ908	1730840	Bronze			2022-12-18	WOS:A1992GZ90800006
J	LITTLE, MM; CASALE, TB				LITTLE, MM; CASALE, TB			COMPARISON OF PLATELET-ACTIVATING-FACTOR INDUCED CHEMOTAXIS OF NORMODENSE AND HYPODENSE EOSINOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PLATELET-ACTIVATING FACTOR; EOSINOPHILS; CHEMOTAXIS	BLOOD EOSINOPHILS; CELL-DENSITY; ASTHMA; INVITRO; HETEROGENEITY; VARIABILITY; INDIVIDUALS; APPEARANCE	Platelet-activating factor (PAF)-induced eosinophil (EOS) migration is an important event in the development of tissue eosinophilia and allergic inflammation. EOSs are heterogeneous cells in that different states of activation have been ascribed to EOSs of varying densities. We therefore studied the ability of PAF to induce hypodense and normodense EOS chemotaxis. Both hypodense and normodense EOSs were isolated in pure form from seven subjects and studied concurrently. Dose-response and time-course experiments indicated no significant differences in PAF-induced hypodense versus normodense EOS chemotactic responses. Hypodense and normodense cells achieved maximal chemotaxis in response to 1-mu-mol/L of PAF, and maximal chemotaxis was achieved at 2 hours. However, marked differences in PAF-induced EOS chemotactic responses existed between patients. We conclude that PAF is a potent EOS chemoattractant, and despite reported differences in metabolic activity, normodense and hypodense EOSs exhibit similar chemotactic responsiveness to PAF.	UNIV IOWA,COLL MED,IOWA CITY,IA 52242; VET ADM MED CTR,DEPT INTERNAL MED,IOWA CITY,IA 52240	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI019093] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 19093] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASS DA, 1980, J CLIN INVEST, V66, P1265, DOI 10.1172/JCI109978; CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974; CAULFIELD JP, 1990, AM J PATHOL, V137, P27; CHIHARA J, 1989, ALLERGY PROC, V10, P27, DOI 10.2500/108854189778968515; CONNELL JT, 1968, J ALLERGY, V41, P1, DOI 10.1016/0021-8707(68)90002-6; DESIMONE C, 1982, CLIN EXP IMMUNOL, V48, P249; FRICK WE, 1989, AM REV RESPIR DIS, V139, P1401, DOI 10.1164/ajrccm/139.6.1401; FRICK WE, 1988, J ALLERGY CLIN IMMUN, V82, P119, DOI 10.1016/0091-6749(88)90061-9; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; KAJITA T, 1985, INT ARCH ALLER A IMM, V78, P406, DOI 10.1159/000233922; KAUFFMAN HF, 1987, J ALLERGY CLIN IMMUN, V79, P611, DOI 10.1016/S0091-6749(87)80157-4; KLOPROGGE E, 1989, J ALLERGY CLIN IMMUN, V83, P393, DOI 10.1016/0091-6749(89)90124-3; PRIN L, 1983, INT ARCH ALLER A IMM, V72, P336, DOI 10.1159/000234893; PRIN L, 1984, CLIN EXP IMMUNOL, V57, P735; SARAN R, 1973, AM REV RESPIR DIS, V108, P1283; SEDGWICK JB, 1990, J ALLERGY CLIN IMMUN, V85, P557, DOI 10.1016/0091-6749(90)90093-J; SHULT PA, 1988, J ALLERGY CLIN IMMUN, V81, P429, DOI 10.1016/0091-6749(88)90912-8; SPRY CJF, 1976, CLIN EXP IMMUNOL, V24, P423; TAI PC, 1976, CLIN EXP IMMUNOL, V24, P415; Vadas M, 1979, Adv Exp Med Biol, V114, P677; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WINQVIST I, 1982, IMMUNOLOGY, V47, P531	22	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1991	88	2					187	192		10.1016/0091-6749(91)90327-K	http://dx.doi.org/10.1016/0091-6749(91)90327-K			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB225	1880319				2022-12-18	WOS:A1991GB22500006
J	SCHIFF, RI; SEDLAK, D; BUCKLEY, RH				SCHIFF, RI; SEDLAK, D; BUCKLEY, RH			RAPID INFUSION OF SANDOGLOBULIN IN PATIENTS WITH PRIMARY HUMORAL IMMUNODEFICIENCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INTRAVENOUS GAMMA-GLOBULIN; IMMUNE SERUM GLOBULIN; PRIMARY HUMORAL IMMUNODEFICIENCY	GAMMA-GLOBULIN	We studied 16 patients with primary disorders of humoral immunity to determine the practicality of infusing intravenous gamma globulin at rates of infusion and concentrations higher than the 4 mg/kg/min and 6% currently recommended. In the first portion of the study, the concentration of Sandoglobulin was increased from 6% to 12%. In the second portion, the flow rate was increased to 5 mg/kg/min, and if no reactions occurred, the time of each successive infusion was decreased by 10 minutes until infusions were completed in 15 to 20 minutes or vasomotor reactions occurred. Thirteen of the 16 patients completed the study; six patients achieved reaction-free rates > 15 mg/kg/min, and the other patients achieved rates ranging from 7.1 to 12 mg/kg/min. Seven patients had infusion times < 30 minutes, with four patients completing infusions in 15 minutes. In the 13 patients who completed the study, there were 14 reactions in 159 infusions, mostly fever and chills, and often at the end or after the infusion. Only one infusion could not be completed because of an adverse reaction. Three patients were not able to complete the study because of adverse reactions; there were seven reactions in 11 infusions in these three patients, although none of the reactions were considered serious. Overall, in this study, most immunodeficient patients (13/16) were able to tolerate infusion rates of Sandoglobulin two to 10 times higher than the standard rates now recommended. The maximal rate of infusion must be individualized, but for carefully selected patients, infusions of 400 mg/kg can be completed in 1 hour or less. Such short infusion times could greatly decrease the amount of time lost from work or school and thus improve compliance.	DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710	Duke University; Duke University	SCHIFF, RI (corresponding author), DUKE UNIV,MED CTR,DEPT PEDIAT,BOX 2981,DURHAM,NC 27710, USA.		Buckley, Rebecca/AAB-1578-2019		NCRR NIH HHS [M01-RR-30] Funding Source: Medline; PHS HHS [A107062-13] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMMANN AJ, 1982, CLIN IMMUNOL IMMUNOP, V22, P60, DOI 10.1016/0090-1229(82)90022-8; BARANDUN S, 1986, VOX SANG, V51, P157, DOI 10.1111/j.1423-0410.1986.tb00235.x; BARANDUN S, 1962, VOX SANG, V7, P157, DOI 10.1111/j.1423-0410.1962.tb03240.x; BERNATOWSKA E, 1987, CLIN IMMUNOL IMMUNOP, V43, P157; BURKS AW, 1986, NEW ENGL J MED, V314, P560, DOI 10.1056/NEJM198602273140907; BUSSEL JB, 1985, J PEDIATR-US, V106, P886, DOI 10.1016/S0022-3476(85)80231-6; CUNNINGHAMRUNDL.C, 1981, IMMUNOCHEMOTHERAPY G, P283; JANEWAY CA, 1966, NEW ENGL J MED, V275, P826, DOI 10.1056/NEJM196610132751508; MONTANARO A, 1984, AM J MED, V76, pS67; NAGASHIMA M, 1987, J PEDIATR-US, V110, P710, DOI 10.1016/S0022-3476(87)80007-0; OCHS HD, 1984, AM J MED, V76, pS78	11	19	21	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1991	88	1					61	67		10.1016/0091-6749(91)90301-4	http://dx.doi.org/10.1016/0091-6749(91)90301-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY204	1906490				2022-12-18	WOS:A1991FY20400007
J	MICHOUD, MC; LEDUC, T; PROULX, F; PERREAULT, S; DUSOUICH, P; DURANCEAU, A; AMYOT, R				MICHOUD, MC; LEDUC, T; PROULX, F; PERREAULT, S; DUSOUICH, P; DURANCEAU, A; AMYOT, R			EFFECT OF SALBUTAMOL ON GASTROESOPHAGEAL REFLUX IN HEALTHY-VOLUNTEERS AND PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ESOPHAGEAL SPHINCTER PRESSURE; ALBUTEROL; RADIOIMMUNOASSAY; PHARMACOKINETICS	The aim of this work was to establish whether beta-adrenergic agonists promote or increase gastroesophageal reflux in patients with asthma. Ten healthy individuals and eight patients with asthma were studied on 2 different days. One day they received a placebo, and the other day they received 4 mg of salbutamol by mouth. Complete measurements of esophageal manometry were performed before and every 30 minutes for 210 minutes after the administration of the drugs. Esophageal pH was measured continuously for the duration of the experiment. The results demonstrate that (1) salbutamol had no effect on the lower esophageal sphincter pressure gradient, the peak esophageal contraction pressure, or the number and duration of reflux episodes in patients with asthma and normal individuals, and (2) patients with asthma have a resting lower esophageal sphincter pressure higher than healthy subjects. We conclude that the administration of salbutamol does not affect esophageal function.	HOP HOTEL DIEU,DEPT SURG,MONTREAL H2W 1T8,QUEBEC,CANADA; UNIV MONTREAL,FAC MED,DEPT PHARMACOL,MONTREAL H3C 3J7,QUEBEC,CANADA	Universite de Montreal; Universite de Montreal	MICHOUD, MC (corresponding author), HOP HOTEL DIEU,DEPT MED,SERV PNEUMOL,3840 ST URBAIN,MONTREAL H2W 1T8,QUEBEC,CANADA.		Perreault, Sylvie/AAM-8009-2020	Perreault, Sylvie/0000-0002-0066-0127				BEAULIEU N, 1985, J PHARMACEUT BIOMED, V3, P575, DOI 10.1016/0731-7085(85)80075-3; BOYLE JT, 1985, AM REV RESPIR DIS, V131, pS16; DENT J, 1980, J CLIN INVEST, V65, P256, DOI 10.1172/JCI109667; DIMARINO AJ, 1982, DIGEST DIS SCI, V27, P1063, DOI 10.1007/BF01391441; GOLDMAN J, 1988, LANCET, V2, P493, DOI 10.1016/S0140-6736(88)90132-8; GRIFFITH M, 1989, CHEST, V96, pS178; LOO JCK, 1987, RES COMMUN CHEM PATH, V55, P283; MOOTE DW, 1986, J ALLERGY CLIN IMMUN, V78, P619, DOI 10.1016/0091-6749(86)90079-5; MORGAN DJ, 1986, BRIT J CLIN PHARMACO, V22, P587, DOI 10.1111/j.1365-2125.1986.tb02939.x; NELSON HS, 1984, J ALLERGY CLIN IMMUN, V73, P547, DOI 10.1016/0091-6749(84)90509-8; POWELL ML, 1985, J PHARM SCI, V74, P217, DOI 10.1002/jps.2600740225; SCHINDLBECK NE, 1988, JAMA-J AM MED ASSOC, V260, P3156, DOI 10.1001/jama.260.21.3156; VANTHIEL DH, 1979, AM J OBSTET GYNECOL, V134, P64, DOI 10.1016/0002-9378(79)90797-X; ZFASS AM, 1970, AM J DIG DIS, V15, P303, DOI 10.1007/BF02239282; 1987, AM REV RESPIR DIS, V136, P225	15	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1991	87	4					762	767		10.1016/0091-6749(91)90119-9	http://dx.doi.org/10.1016/0091-6749(91)90119-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG059	2013669				2022-12-18	WOS:A1991FG05900002
J	REIJULA, KE; KURUP, VP; FINK, JN				REIJULA, KE; KURUP, VP; FINK, JN			ULTRASTRUCTURAL DEMONSTRATION OF SPECIFIC IGG AND IGE ANTIBODIES BINDING TO ASPERGILLUS-FUMIGATUS FROM PATIENTS WITH ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTIGENS	Aspergillus-induced diseases usually demonstrate elevated circulating antibodies belonging to different isotypes. The antigens currently used to detect antibodies are crude culture filtrate and mycelial extracts of A. fumigatus (Af). Most Af-associated diseases result from the inhalation of the spores of the organisms present in the environment. However, it is not known whether specific circulating antibodies directed only against spore or mycelia of Af exist in the sera of patients with Af-induced diseases. With colloidal gold we have investigated thin sections of spores and hyphae of Af for their reactivity with Af-specific IgG and IgE antibodies. The results indicate that both spores and hyphae reacted identically with IgG and IgE antibodies from patients. None of the sera from normal control subjects reacted in this system, although low levels of antibodies were detected in the sera by ELISA. Sera from both patients with allergic bronchopulmonary aspergillosis or aspergilloma reacted with cell envelope antigens, whereas sera from patients with invasive aspergillosis also bound to cell sap. This method therefore demonstrates localization of antigens binding to different isotypes in the sera from different clinical forms of aspergillosis and may be useful in purifying specific antigens for immunodiagnosis.	ZABLOCKI VET AFFAIRS MED CTR,RES SERV 151,5000 W NATL AVE,MILWAUKEE,WI 53295; MED COLL WISCONSIN,DEPT MED,DIV ALLERGY IMMUNOL,MILWAUKEE,WI 53226	Medical College of Wisconsin					NIAID NIH HHS [AI23071] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023071] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARDANA E. J, 1980, CRC CRIT REV CLIN LA, V13, P21; BRUMMUND W, 1987, J CLIN MICROBIOL, V25, P5, DOI 10.1128/JCM.25.1.5-9.1987; FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0; GEOGHEGAN WD, 1977, J HISTOCHEM CYTOCHEM, V25, P1187, DOI 10.1177/25.11.21217; GORDON MA, 1977, J CLIN MICROBIOL, V6, P161; GREENBERGER PA, 1987, CHEST, V91, pS165, DOI 10.1378/chest.91.6.165S; GUGNANI HC, 1990, MYCOPATHOLOGIA, V109, P33, DOI 10.1007/BF00437004; KURUP VP, 1988, INT ARCH ALLER A IMM, V86, P176, DOI 10.1159/000234568; KURUP VP, 1990, J LAB CLIN MED, V115, P298; KURUP VP, 1986, J ALLERGY CLIN IMMUN, V78, P1166, DOI 10.1016/0091-6749(86)90267-8; KURUP VP, 1978, J CLIN PATHOL, V69, P414; KURUP VP, 1978, MICROBIOS, V19, P191; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x	14	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1991	87	3					683	688		10.1016/0091-6749(91)90389-6	http://dx.doi.org/10.1016/0091-6749(91)90389-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FB801	1706370				2022-12-18	WOS:A1991FB80100013
J	PERISTORTAJADA, A; GINER, A; PEREZ, C; HERNANDEZ, D; BASOMBA, A				PERISTORTAJADA, A; GINER, A; PEREZ, C; HERNANDEZ, D; BASOMBA, A			CONTACT ALLERGY TO TOPICAL BUDESONIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note											PERISTORTAJADA, A (corresponding author), HOSP LA FE,DIV ALLERGY,AVDA CAMPANAR 21,E-46009 VALENCIA,SPAIN.							BOUJNAHKHOUADJA A, 1984, CONTACT DERMATITIS, V11, P83, DOI 10.1111/j.1600-0536.1984.tb00932.x; CAMARASA JG, 1988, CONTACT DERMATITIS, V19, P147, DOI 10.1111/j.1600-0536.1988.tb05519.x; COOPMAN S, 1988, CONTACT DERMATITIS, V19, P145, DOI 10.1111/j.1600-0536.1988.tb05517.x; DOOMSGOOSSENS A, 1988, CONTACT DERMATITIS, V18, P124, DOI 10.1111/j.1600-0536.1988.tb02767.x; MEDING B, 1986, CONTACT DERMATITIS, V14, P253, DOI 10.1111/j.1600-0536.1986.tb01241.x; VANHECKE E, 1980, CONTACT DERMATITIS, V6, P509, DOI 10.1111/j.1600-0536.1980.tb05589.x	6	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1991	87	2					597	598		10.1016/0091-6749(91)90021-F	http://dx.doi.org/10.1016/0091-6749(91)90021-F			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX987	1993819				2022-12-18	WOS:A1991EX98700020
J	LIAO, TN; HSIEH, KH				LIAO, TN; HSIEH, KH			ALTERED PRODUCTION OF HISTAMINE-RELEASING FACTOR (HRF) ACTIVITY AND RESPONSIVENESS TO HRF AFTER IMMUNOTHERAPY IN CHILDREN WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HUMAN MONONUCLEAR-CELLS; HOUSE-DUST; MAST-CELLS; HYPOSENSITIZATION; BASOPHIL; MITOGEN; HYPERSENSITIVITY; INTERLEUKIN-2; LYMPHOKINE; ALLERGEN	To delineate the working mechanisms of immunotherapy (IT) (hyposensitization), the production of, and responsiveness to, histamine-releasing factor (HRF) was studied in four groups. These groups consisted of 32 newly diagnosed children with asthma, 40 good responders and 18 poor responders to IT (older than 2 years), and 15 healthy subjects. The results demonstrated (1) peripheral blood mononuclear cells of new patients produced a much greater HRF activity, either spontaneously or after stimulation, than did those of normal subjects, (2) the spontaneous HRF activity decreased significantly in good responders, whereas that of poor responders increased, (3) both the allergen (mite)- and mitogen (phytohemagglutinin [PHA])-stimulated HRF activity was decreased, although decrease was not significant, in good responders, but the activity was not changed in poor responders, (4) the granulocytes of new patients responded to HRF much more vigorously than did granulocytes of normal subjects. The responsiveness diminished significantly in both good and poor responders, although the magnitude of decrease was slightly greater in the former, (5) there was a positive-correlation between PHA- and mite-stimulated HRF activity, mite-stimulated HRF Activity and responsiveness to to HRF, and plasma histamine level and responsiveness to HRF in the new patients, and (6) there was an inverse correlation between PHA-stimulated HRF production and responsiveness to HRF in good responders, but the correlation was positive in poor responders. Thus, IT is able to suppress the HRF activity, particularly the type of spontaneous synthesis, and responsiveness to HRF in clinically benefitted children with asthma, and this effect may be used to explain, partly, the efficacy of IT in a proportion of allergic patients.	NATL TAIWAN UNIV HOSP, DEPT PEDIAT, 1 CHANG TE ST, TAIPEI 10016, TAIWAN; NATL TAIWAN UNIV, COLL MED, GRAD INST MICROBIOL & IMMUNOL, TAIPEI, TAIWAN	National Taiwan University; National Taiwan University Hospital; National Taiwan University								ALAM R, 1988, CELL IMMUNOL, V115, P447, DOI 10.1016/0008-8749(88)90197-9; ALAM R, 1984, ANN ALLERGY, V53, P66; ALAM R, 1988, J CLIN INVEST, V82, P2056, DOI 10.1172/JCI113826; BAEZA ML, 1988, J IMMUNOL, V141, P2688; BAEZA ML, 1989, J CLIN INVEST, V83, P1204, DOI 10.1172/JCI114002; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; COCKCROFT DW, 1987, ANN ALLERGY, V59, P405; CROMWELL O, 1980, CLIN ALLERGY, V10, P365, DOI 10.1111/j.1365-2222.1980.tb02120.x; DVORAK HF, 1974, LAB INVEST, V31, P111; GOETZL EJ, 1984, IMMUNOLOGY, V53, P227; HSIEH KH, 1985, J ALLERGY CLIN IMMUN, V76, P188, DOI 10.1016/0091-6749(85)90700-6; HSIEH KH, 1987, J ASTHMA, V24, P19, DOI 10.3109/02770908709073189; HSIEH KH, 1984, J ALLERGY CLIN IMMUN, V74, P34, DOI 10.1016/0091-6749(84)90084-8; IHLE JN, 1983, J IMMUNOL, V131, P282; ISHIZAKA K, 1969, J IMMUNOL, V103, P588; KAPLAN AP, 1985, J IMMUNOL, V135, P2027; KAY AB, 1986, ASTHMA CLIN PHARM TH, P1; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LOCKEY RF, 1976, BRONCHIAL ASTHMA MEC, P613; LUE KH, 1989, ASIAN PAC J ALLERGY, V7, P9; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NAKADA S, 1985, ANN ALLERGY, V54, P437; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P281, DOI 10.1016/0091-6749(78)90047-7; ORCHARD MA, 1986, J IMMUNOL, V136, P2240; PATTERSON R, 1978, ALLERGY PRINCIPLES P, P877; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SEDGWICK JD, 1981, CLIN EXP IMMUNOL, V45, P409; SMITH CA, 1986, P NATL ACAD SCI USA, V83, P1857, DOI 10.1073/pnas.83.6.1857; STADLER BM, 1985, INT ARCH ALLER A IMM, V77, P151, DOI 10.1159/000233770; THUESON DO, 1979, J IMMUNOL, V123, P626; WANG JY, 1989, ASIAN PAC J ALLERGY, V7, P119; WHITE MV, 1987, J IMMUNOL, V139, P1624	39	19	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	1				894	901		10.1016/S0091-6749(05)80152-6	http://dx.doi.org/10.1016/S0091-6749(05)80152-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EQ045	1702128				2022-12-18	WOS:A1990EQ04500010
J	ICHINOSE, M; BARNES, PJ				ICHINOSE, M; BARNES, PJ			HISTAMINE-H3 RECEPTORS MODULATE ANTIGEN-INDUCED BRONCHOCONSTRICTION IN GUINEA-PIGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP,NATL HEART & LUNG INST,DEPT THORAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND	Imperial College London; Royal Brompton Hospital				Barnes, Peter/0000-0002-5122-4018				Adams G K 3rd, 1979, Monogr Allergy, V14, P95; ANDERSSON P, 1980, ALLERGY, V35, P65, DOI 10.1111/j.1398-9995.1980.tb01718.x; ANTONISSEN LA, 1980, J PHARMACOL EXP THER, V213, P150; ARRANG JM, 1983, NATURE, V302, P832, DOI 10.1038/302832a0; ARRANG JM, 1987, NATURE, V327, P117, DOI 10.1038/327117a0; BARNES PJ, 1988, PHARMACOL REV, V40, P49; BOURNE HR, 1971, SCIENCE, V173, P743, DOI 10.1126/science.173.3998.743; EVANS TW, 1988, AM REV RESPIR DIS, V138, P395, DOI 10.1164/ajrccm/138.2.395; ICHINOSE M, 1990, J APPL PHYSIOL, V68, P21, DOI 10.1152/jappl.1990.68.1.21; ICHINOSE M, 1989, BRIT J PHARMACOL, V97, P13, DOI 10.1111/j.1476-5381.1989.tb11917.x; ICHINOSE M, 1989, EUR J PHARMACOL, V174, P49, DOI 10.1016/0014-2999(89)90872-8; ICHINOSE M, 1989, EUR J PHARMACOL, V163, P383, DOI 10.1016/0014-2999(89)90212-4; INGENITO EP, 1982, AM REV RESPIR DIS S4, V138, pA229; KALINER M, 1978, AM REV RESPIR DIS, V118, P1015; KAY AB, 1984, ASTHMA PHYSL IMMUNOP, P211; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; LICHTENSTEIN LM, 1973, NATURE, V244, P287, DOI 10.1038/244287a0; MILLS JE, 1970, BRIT J PHARMACOL, V39, P729; PEARCE FL, 1988, ASTHMA BASIC MECHANI, P81; SNAPPER JR, 1980, J ALLERGY CLIN IMMUN, V66, P70, DOI 10.1016/0091-6749(80)90140-2; WHITE J, 1983, BRIT J DIS CHEST, V77, P215; WHITE MV, 1988, ASTHMA BASIC MECHANI, P231	22	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	1				491	495		10.1016/S0091-6749(05)80204-0	http://dx.doi.org/10.1016/S0091-6749(05)80204-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EG454	2172348				2022-12-18	WOS:A1990EG45400008
J	NAHM, MH; MACKE, K; KWON, OH; MADASSERY, JV; SHERMAN, LA; SCOTT, MG				NAHM, MH; MACKE, K; KWON, OH; MADASSERY, JV; SHERMAN, LA; SCOTT, MG			IMMUNOLOGICAL AND CLINICAL STATUS OF BLOOD-DONORS WITH SUBNORMAL LEVELS OF IGG2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; AMER RED CROSS,BISTATE CHAPTER,ST LOUIS,MO	Washington University (WUSTL); American Red Cross	NAHM, MH (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,660 S EUCLID AVE,BOX 8118,ST LOUIS,MO 63110, USA.			Nahm, Moon/0000-0002-6922-1042	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI015353] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15353] Funding Source: Medline; PHS HHS [A1-19676] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMBROSINO DM, 1985, J CLIN INVEST, V75, P1935, DOI 10.1172/JCI111909; BARRETT DJ, 1986, CLIN EXP IMMUNOL, V63, P127; BUCKLEY RH, 1986, CLIN IMMUNOL IMMUNOP, V40, P13, DOI 10.1016/0090-1229(86)90065-6; BUTCH AW, 1989, HUM IMMUNOL, V24, P207, DOI 10.1016/0198-8859(89)90061-X; CLARK JA, 1983, AM J CLIN PATHOL, V80, P210, DOI 10.1093/ajcp/80.2.210; COLTON T, 1974, STAT MED, P129; COLTON T, 1974, STAT MED, P174; FYFE G, 1987, J IMMUNOL, V139, P2187; GRANOFF DM, 1986, NEW ENGL J MED, V315, P1584, DOI 10.1056/NEJM198612183152505; GRANOFF DM, 1988, J INFECT DIS, V157, P1142, DOI 10.1093/infdis/157.6.1142; HAMMARSTROM L, 1983, CLIN EXP IMMUNOL, V51, P600; LEFRANC MP, 1982, NATURE, V300, P760, DOI 10.1038/300760a0; MADASSERY JV, 1988, CLIN CHEM, V34, P1407; MCLEAN RH, 1984, J PEDIATR-US, V105, P179, DOI 10.1016/S0022-3476(84)80110-9; MIGONE N, 1984, P NATL ACAD SCI-BIOL, V81, P5811, DOI 10.1073/pnas.81.18.5811; MORRELL A, 1972, J IMMUNOL, V108, P195; NAHM MH, 1986, J IMMUNOL, V137, P3484; OXELIUS VA, 1981, NEW ENGL J MED, V304, P1476, DOI 10.1056/NEJM198106113042408; OXELIUS VA, 1982, NEW ENGL J MED, V306, P515, DOI 10.1056/NEJM198203043060905; PAGE R, 1988, J PEDIATR-US, V112, P127, DOI 10.1016/S0022-3476(88)80137-9; SCHUR PH, 1979, PEDIATR RES, V13, P181, DOI 10.1203/00006450-197903000-00010; SCHUR PH, 1970, NEW ENGL J MED, V283, P631, DOI 10.1056/NEJM197009172831205; SCOTT MG, 1988, DIAGN CLIN IMMUNOL, V5, P241; SEPPALA IJT, 1984, EUR J IMMUNOL, V14, P868, DOI 10.1002/eji.1830140918; SHACKELFORD PG, 1990, PEDIATR RES, V27, P16, DOI 10.1203/00006450-199001000-00004; SHACKELFORD PG, 1987, J IMMUNOL, V138, P587; SHACKELFORD PG, 1986, J PEDIATR-US, V108, P647, DOI 10.1016/S0022-3476(86)81035-6; SHAKIB F, 1980, RES CLIN LAB, V10, P463, DOI 10.1007/BF02938793; SIBER G, 1980, NEW ENGL J MED, V283, P178; SILK H, 1987, J ALLERGY CLIN IMMUN, V79, P188; SKVARIL F, 1984, CLIN EXP IMMUNOL, V55, P671; SLACK JH, 1987, J IMMUNOL, V139, P3734; SMITH TF, 1984, J PEDIATR-US, V105, P896, DOI 10.1016/S0022-3476(84)80073-6; Spiegelberg H L, 1974, Adv Immunol, V19, P259, DOI 10.1016/S0065-2776(08)60254-0; STANLEY PJ, 1984, CLIN EXP IMMUNOL, V58, P703; STEVENS R, 1983, J CLIN IMMUNOL, V3, P65, DOI 10.1007/BF00919140; TARRAND JJ, 1989, J IMMUNOL, V142, P2519; Ugazio A G, 1983, Birth Defects Orig Artic Ser, V19, P169; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002; VANDERGIESSEN M, 1975, CLIN EXP IMMUNOL, V21, P501; YOUNT WJ, 1968, J EXP MED, V127, P633, DOI 10.1084/jem.127.3.633	41	19	19	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1990	85	4					769	777		10.1016/0091-6749(90)90197-C	http://dx.doi.org/10.1016/0091-6749(90)90197-C			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA437	2324414				2022-12-18	WOS:A1990DA43700014
J	KIVITY, S; YARCHOVSKY, J				KIVITY, S; YARCHOVSKY, J			RELAPSING ANAPHYLAXIS TO BEE STING IN A PATIENT TREATED WITH BETA-BLOCKER AND CA BLOCKER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter											KIVITY, S (corresponding author), ICHILOV HOSP,INST PULM & ALLERG DIS,ALLERGY UNIT,6 WEIZMAN ST,IL-64239 TEL AVIV,ISRAEL.							AWAI LE, 1984, ANN ALLERGY, V53, P48; HANNAWAY PJ, 1983, NEW ENGL J MED, V308, P1536; INGALL M, 1984, JAMA-J AM MED ASSOC, V251, P1432, DOI 10.1001/jama.1984.03340350026019; MORRIS DL, 1985, J AM COLL CARDIOL, V6, P785, DOI 10.1016/S0735-1097(85)80483-6; NICKLAS RA, 1988, J ALLERGY CLIN IMMUN, V81, P237, DOI 10.1016/0091-6749(88)90512-X; OPIE LH, 1980, BRIT MED J, V281, P1462, DOI 10.1136/bmj.281.6253.1462; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X	8	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1990	85	3					669	670		10.1016/0091-6749(90)90111-G	http://dx.doi.org/10.1016/0091-6749(90)90111-G			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CU668	2312997	Bronze			2022-12-18	WOS:A1990CU66800022
J	KIVITY, S; SCHWARTZ, Y; WOLF, R; TOPILSKY, M				KIVITY, S; SCHWARTZ, Y; WOLF, R; TOPILSKY, M			SYSTEMIC COLD-INDUCED URTICARIA - CLINICAL AND LABORATORY CHARACTERIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ICHILOV HOSP,DEPT DERMATOL,IL-64239 TEL AVIV,ISRAEL; TEL AVIV UNIV,TEL AVIV MED CTR,IL-69978 TEL AVIV,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,TEL AVIV,ISRAEL	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	KIVITY, S (corresponding author), ICHILOV HOSP,INST PULM & ALLERG DIS,6 WEIZMAN ST,IL-64239 TEL AVIV,ISRAEL.							COSTANZI JJ, 1969, J LAB CLIN MED, V74, P902; DAVIS KC, 1984, J ALLERGY CLIN IMMUN, V73, P810, DOI 10.1016/0091-6749(84)90451-2; GOMERIC PD, 1980, INT J DERMATOL, V19, P417; KAPLAN AP, 1984, J ALLERGY CLIN IMMUN, V73, P453, DOI 10.1016/0091-6749(84)90354-3; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P438; KAPLAN AP, 1978, NEW ENGL J MED, V305, P1074; ORMEROD AD, 1988, BRIT J DERMATOL, V118, P621, DOI 10.1111/j.1365-2133.1988.tb02562.x; SARKANY I, 1971, BRIT J DERMATOL, V85, P46; SUSSMAN GL, 1982, J ALLERGY CLIN IMMUN, V70, P337, DOI 10.1016/0091-6749(82)90022-7	9	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				52	54		10.1016/0091-6749(90)90220-X	http://dx.doi.org/10.1016/0091-6749(90)90220-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2299105	Bronze			2022-12-18	WOS:A1990CM37800008
J	GARTY, BZ; LEVINSON, AI; DANON, YL; WILMOTT, R; DOUGLAS, SD				GARTY, BZ; LEVINSON, AI; DANON, YL; WILMOTT, R; DOUGLAS, SD			LYMPHOCYTE SUBPOPULATIONS IN CHILDREN WITH ABNORMAL LYMPHATIC CIRCULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104; A BEILINSON MED CTR,DEPT PEDIAT,PETAL TIQVA,ISRAEL; UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania								ARNOLD WC, 1980, PEDIATRICS, V66, P792; CARNEY WP, 1981, J IMMUNOL, V126, P2114; DEWAELE M, 1981, NEW ENGL J MED, V304, P460; Evans J T, 1975, Rev Surg, V32, P77; EVANS RL, 1978, J IMMUNOL, V120, P1423; HUNNINGHAKE GW, 1981, NEW ENGL J MED, P305; KEYSTONE EC, 1982, CLIN EXP IMMUNOL, V48, P443; LESTER LA, 1986, J ALLERGY CLIN IMMUN, V78, P891, DOI 10.1016/0091-6749(86)90236-8; LEVINSON AI, 1981, CLIN RES, V29, pA302; MACHLEDER HI, 1978, SURGERY, V84, P157; MCWILLIAMS BC, 1981, J PEDIATR-US, V99, P595, DOI 10.1016/S0022-3476(81)80267-3; MILLS KHG, 1983, BRIT J HAEMATOL, V53, P271, DOI 10.1111/j.1365-2141.1983.tb02021.x; REINHERZ EL, 1979, J IMMUNOL, V123, P2894; REINHERZ EL, 1981, J CLIN INVEST, V68, P699, DOI 10.1172/JCI110305; REINHERZ EL, 1981, NEW ENGL J MED, P304; REINHERZ EL, 1980, NEW ENGL J MED, V303, P373; RUBINSTEIN A, 1983, JAMA-J AM MED ASSOC, V249, P2350, DOI 10.1001/jama.249.17.2350; SAKANE T, 1983, J IMMUNOL, V131, P753; SARLES HE, 1970, ARCH INTERN MED, V125, P443, DOI 10.1001/archinte.125.3.443; SHOHAT B, 1981, THYMUS, V2, P93; THIVOLET J, 1982, ACTA DERM-VENEREOL, V62, P337; YOUNG M, 1986, ANNU REV MED, V37, P165	22	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	1				515	520		10.1016/0091-6749(89)90365-5	http://dx.doi.org/10.1016/0091-6749(89)90365-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW760	2529303	Bronze			2022-12-18	WOS:A1989AW76000013
J	SANCHEZLEGRAND, F; SMITH, TF				SANCHEZLEGRAND, F; SMITH, TF			INTERACTION OF PARAMYXOVIRUSES WITH HUMAN BASOPHILS AND THEIR EFFECT ON HISTAMINE-RELEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									EMORY UNIV,SCH MED,DEPT PEDIAT,DIV ALLERGY IMMUNOL,69 BUTLER ST SE,ATLANTA,GA 30303	Emory University					NCRR NIH HHS [SO7RRO5364] Funding Source: Medline; NIAID NIH HHS [AI21072] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005364] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R23AI021072] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUSSE WW, 1983, J ALLERGY CLIN IMMUN, V71, P382, DOI 10.1016/0091-6749(83)90066-0; CHONMAITREE T, 1988, J INFECT DIS, V157, P127, DOI 10.1093/infdis/157.1.127; DENNY FW, 1986, AM J TROP MED HYG, V35, P1; EGGLESTON PA, 1978, INT ARCH ALLER A IMM, V57, P193, DOI 10.1159/000232103; GRANT JA, 1977, J ALLERGY CLIN IMMUN, V60, P306, DOI 10.1016/0091-6749(77)90110-5; HENDERSON FW, 1979, J PEDIATR-US, V95, P183; IDA S, 1977, J EXP MED, V145, P892, DOI 10.1084/jem.145.4.892; KAUL TN, 1982, J MED VIROL, V9, P149, DOI 10.1002/jmv.1890090210; LANDRY FJ, 1983, J IMMUNOL METHODS, V63, P329, DOI 10.1016/S0022-1759(83)80006-4; LEEDER SR, 1975, J INFECT DIS, V131, P731, DOI 10.1093/infdis/131.6.731; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; ROONEY JC, 1971, J PEDIATR-US, V79, P744, DOI 10.1016/S0022-3476(71)80385-2; SMITH TF, 1985, CLIN IMMUNOL IMMUNOP, V34, P355, DOI 10.1016/0090-1229(85)90184-9; SMITH TF, 1982, INT ARCH ALLER A IMM, V67, P380, DOI 10.1159/000233051; SMITH TF, 1981, INFECT IMMUN, V33, P43, DOI 10.1128/IAI.33.1.43-48.1981; SUGIYAMA K, 1977, NATURE, V270, P614, DOI 10.1038/270614a0; WELLIVER RC, 1981, NEW ENGL J MED, V305, P842; WYKE AM, 1980, BIOCHEM J, V190, P625, DOI 10.1042/bj1900625; 1979, US DHEW NIH789387 PU, P387; 1985, LANCET, V2, P699	20	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	1				538	546		10.1016/0091-6749(89)90368-0	http://dx.doi.org/10.1016/0091-6749(89)90368-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW760	2477431	Green Published, Bronze			2022-12-18	WOS:A1989AW76000016
J	KEMP, JP; FURUKAWA, CT; BRONSKY, EA; GROSSMAN, J; LEMANSKE, RF; MANSFIELD, LE; MURPHY, S; RATNER, PH; REESE, ME; ROGENES, PR; SPECTOR, SL; TINKELMAN, DG				KEMP, JP; FURUKAWA, CT; BRONSKY, EA; GROSSMAN, J; LEMANSKE, RF; MANSFIELD, LE; MURPHY, S; RATNER, PH; REESE, ME; ROGENES, PR; SPECTOR, SL; TINKELMAN, DG			ALBUTEROL TREATMENT FOR CHILDREN WITH ASTHMA - A COMPARISON OF INHALED POWDER AND AEROSOL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KEMP, JP (corresponding author), ALLERGY & ASTHMA MED GRP & RES CTR,3444 KEARNY VILLA RD,SUITE 100,SAN DIEGO,CA 92123, USA.							BERG IM, 1982, EUR J RESPIR DIS, V63, P305; BRONSKY E, 1987, J ALLERGY CLIN IMMUN, V79, P741, DOI 10.1016/0091-6749(87)90205-3; CROMPTON GK, 1982, EUR J RESPIR DIS, V63, P101; CRONER S, 1980, ALLERGY, V35, P589; FRANCIS PWJ, 1980, PEDIATRICS, V66, P103; HARM DL, 1984, J ASTHMA, V21, P295, DOI 10.3109/02770908409077439; HARTLEY JPR, 1977, BRIT J CLIN PHARMACO, V4, P673, DOI 10.1111/j.1365-2125.1977.tb00429.x; LEE HS, 1982, J PEDIATR-US, V101, P632, DOI 10.1016/S0022-3476(82)80728-2; LENNEY W, 1978, ARCH DIS CHILD, V53, P958, DOI 10.1136/adc.53.12.958; NELSON HS, 1983, J ALLERGY CLIN IMMUN, V72, P371, DOI 10.1016/0091-6749(83)90502-X; ORGEL HA, 1985, J ALLERGY CLIN IMMUN, V75, P468; PATERSON IC, 1976, BRIT MED J, V1, P76, DOI 10.1136/bmj.1.6001.76-a; SAUNDERS KB, 1965, BRIT MED J, V1, P1037, DOI 10.1136/bmj.1.5441.1037	13	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1989	83	3					697	702		10.1016/0091-6749(89)90085-7	http://dx.doi.org/10.1016/0091-6749(89)90085-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T8596	2647819				2022-12-18	WOS:A1989T859600019
J	MILLER, JD; MILLER, A; LUCZYNSKA, C; ROSE, G; PLATTSMILLS, TAE				MILLER, JD; MILLER, A; LUCZYNSKA, C; ROSE, G; PLATTSMILLS, TAE			EFFECT OF TANNIC-ACID SPRAY ON DUST-MITE ANTIGEN LEVELS IN CARPETS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	19	20	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					262	262						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419					2022-12-18	WOS:A1989T041900385
J	CROMWELL, O; MOQBEL, R; FITZHARRIS, P; KURLAK, L; HARVEY, C; WALSH, GM; SHAW, RJ; KAY, AB				CROMWELL, O; MOQBEL, R; FITZHARRIS, P; KURLAK, L; HARVEY, C; WALSH, GM; SHAW, RJ; KAY, AB			LEUKOTRIENE C-4 GENERATION FROM HUMAN EOSINOPHILS STIMULATED WITH IGG-ASPERGILLUS-FUMIGATUS ANTIGEN IMMUNE-COMPLEXES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KAY, AB (corresponding author), CARDIOTHORAC INST, DEPT ALLERGY & CLIN IMMUNOL, DOVEHOUSE ST, LONDON SW3 6LY, ENGLAND.		Kurlak, Lesia/D-5798-2013	Kurlak, Lesia/0000-0001-7938-6994				ANWAR ARE, 1977, J IMMUNOL, V119, P976; BORGEAT P, 1984, J ALLERGY CLIN IMMUN, V74, P310, DOI 10.1016/0091-6749(84)90122-2; BUTTERWORTH AE, 1984, ADV PARASIT, V23, P143, DOI 10.1016/S0065-308X(08)60287-0; CAPRON M, 1986, J EXP MED, V164, P72, DOI 10.1084/jem.164.1.72; CARLSON MGC, 1985, J IMMUNOL, V134, P1875; CROMWELL O, 1985, INT J IMMUNOPHARMACO, V7, P775, DOI 10.1016/0192-0561(85)90165-1; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; FERRERI NR, 1986, J IMMUNOL, V136, P4188; FITZHARRIS P, 1986, CLIN EXP IMMUNOL, V66, P673; FRIGAS E, 1980, LAB INVEST, V42, P35; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; GREENBERGER PA, 1987, J ALLERGY CLIN IMMUN, V79, P141; HARVEY C, 1987, J ALLERGY CLIN IMMUN, V79, P324, DOI 10.1016/0091-6749(87)90149-7; HENDERSON WR, 1984, IMMUNOLOGY, V51, P679; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; KALINER M, 1984, J ALLERGY CLIN IMMUN, V73, P318, DOI 10.1016/0091-6749(84)90403-2; KHALIFE J, 1986, J IMMUNOL, V137, P1659; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; LOWRY OH, 1951, J BIOL CHEM, V193, P265; METCALFE DD, 1977, J IMMUNOL, V119, P1744; OLSSON I, 1974, BLOOD, V44, P235, DOI 10.1182/blood.V44.2.235.235; PARRILLO JE, 1978, BLOOD, V51, P457; RANKIN JA, 1984, J IMMUNOL, V132, P1993; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; SHAW RJ, 1984, CLIN EXP IMMUNOL, V56, P716; SHAW RJ, 1985, NATURE, V316, P150, DOI 10.1038/316150a0; TURK J, 1982, J BIOL CHEM, V257, P7068; VADAS MA, 1979, J IMMUNOL, V122, P1228; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WINQVIST I, 1984, IMMUNOLOGY, V51, P1	34	19	19	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					535	543		10.1016/0091-6749(88)90962-1	http://dx.doi.org/10.1016/0091-6749(88)90962-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	3139729				2022-12-18	WOS:A1988Q639900002
J	JUNIPER, EF; WHITE, J; DOLOVICH, J				JUNIPER, EF; WHITE, J; DOLOVICH, J			EFFICACY OF CONTINUOUS TREATMENT WITH ASTEMIZOLE (HISMANAL) AND TERFENADINE (SELDANE) IN RAGWEED POLLEN-INDUCED RHINOCONJUNCTIVITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST JOSEPHS HOSP,DEPT MED,HAMILTON L8N 4A6,ONTARIO,CANADA; MCMASTER UNIV,DEPT MED,HAMILTON L8S 4L8,ONTARIO,CANADA	McGill University; McMaster University; McMaster University								BLACKHOUSE CI, 1982, PRACTIONER, V226, P347; CHATTERJEE J, 1974, CAN MED ASSOC J, V110, P659; DANNENBERG TB, 1951, J ALLERGY, V22, P330, DOI 10.1016/0021-8707(51)90033-0; GARTEIZ DA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1185; HOWARTH PH, 1984, BRIT J CLIN PHARMACO, V18, P1; HOWARTH PH, 1984, THORAX, V39, P668, DOI 10.1136/thx.39.9.668; JUNIPER EF, 1981, CLIN ALLERGY, V11, P61, DOI 10.1111/j.1365-2222.1981.tb01567.x; NICHOLSON AN, 1982, BRIT J CLIN PHARMACO, V14, P683, DOI 10.1111/j.1365-2125.1982.tb04957.x; NICHOLSON AN, 1982, BRIT J CLIN PHARMACO, V13, P199, DOI 10.1111/j.1365-2125.1982.tb01356.x; RICHARDS DM, 1984, DRUGS, V28, P38, DOI 10.2165/00003495-198428010-00003; WILSON JD, 1982, CLIN ALLERGY, V12, P131; WOOD SF, 1986, PRACTITIONER, V230, P41	12	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					670	675		10.1016/0091-6749(88)90981-5	http://dx.doi.org/10.1016/0091-6749(88)90981-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	3139730	Bronze			2022-12-18	WOS:A1988Q639900021
J	ROHATGI, N; DUNN, K; CHAI, H				ROHATGI, N; DUNN, K; CHAI, H			CAT-INDUCED OR DOG-INDUCED IMMEDIATE AND LATE ASTHMATIC RESPONSES BEFORE AND AFTER IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH CTR IMMUNOL & RESP MED,DEPT ALLERGY,DENVER,CO	National Jewish Health								AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, J ALLERGY CLIN IMMUN, V60, P56, DOI 10.1016/0091-6749(77)90083-5; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; FRANKLAND AW, 1954, LANCET, V1, P1055; HARGREAVE FE, 1974, CAN MED ASSOC J, V110, P415; METZGER WJ, 1983, J ALLERGY CLIN IMMUN, V71, P119, DOI 10.1016/0091-6749(83)90245-2; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V72, P145, DOI 10.1016/0091-6749(83)90522-5; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TUCHINDA M, 1973, J ALLERGY CLIN IMMUN, V51, P131, DOI 10.1016/0091-6749(73)90018-3; WARNER JO, 1978, LANCET, V2, P912	16	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1988	82	3	1				389	397		10.1016/0091-6749(88)90010-3	http://dx.doi.org/10.1016/0091-6749(88)90010-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q3229	3049744				2022-12-18	WOS:A1988Q322900010
J	SHAPIRO, GG				SHAPIRO, GG			SINUSITIS IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		FRIEDMAN R, 1984, J ALLERGY CLIN IMMUN, V74, P185, DOI 10.1016/0091-6749(84)90284-7; KOVATCH AL, 1984, PEDIATRICS, V73, P306; RACHELEFSKY GS, 1982, J ALLERGY CLIN IMMUN, V69, P382, DOI 10.1016/0091-6749(82)90150-6; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; RACHELEFSKY GS, 1980, ALLERGIC DISORDERS I, P526; ROHR AS, 1986, J ALLERGY CLIN IMMUN, V78, P58, DOI 10.1016/0091-6749(86)90115-6; SHAPIRO GG, 1986, J ALLERGY CLIN IMMUN, V77, P59, DOI 10.1016/0091-6749(86)90324-6; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002; WALD ER, 1984, J PEDIATR-US, V104, P297, DOI 10.1016/S0022-3476(84)81018-5; WALD ER, 1986, PEDIATRICS, V77, P795; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302	13	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	2	S			1025	1027		10.1016/0091-6749(88)90173-X	http://dx.doi.org/10.1016/0091-6749(88)90173-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7037	3286728	Bronze			2022-12-18	WOS:A1988N703700018
J	SHAPIRO, GG; FURUKAWA, CT; PIERSON, WE; SHARPE, MJ; MENENDEZ, R; BIERMAN, CW				SHAPIRO, GG; FURUKAWA, CT; PIERSON, WE; SHARPE, MJ; MENENDEZ, R; BIERMAN, CW			DOUBLE-BLIND EVALUATION OF NEBULIZED CROMOLYN, TERBUTALINE, AND THE COMBINATION FOR CHILDHOOD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; CHILDRENS HOSP & MED CTR,DIV ALLERGY,SEATTLE,WA	University of Washington; University of Washington Seattle; Seattle Children's Hospital								BERNSTEIN IL, 1985, CHEST, V87, pS68, DOI 10.1378/chest.87.1_Supplement.68S; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LABRALCO J M, 1984, Journal of Allergy and Clinical Immunology, V73, P124; LATIMER KM, 1983, AM REV RESPIR DIS, V128, P440, DOI 10.1164/arrd.1983.128.3.440; RITCHIE D, 1979, NEW ZEAL MED J, V90, P332; SHAPIRO GG, 1985, PHARMACOTHERAPY, V5, P156; SHAPIRO GG, 1982, J ALLERGY CLIN IMMUN, V69, P365, DOI 10.1016/0091-6749(82)90147-6; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V63, P116, DOI 10.1016/0091-6749(79)90201-X; 1984, LANCET, V2, P789	9	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1988	81	2					449	454		10.1016/0091-6749(88)90915-3	http://dx.doi.org/10.1016/0091-6749(88)90915-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0993	3123540				2022-12-18	WOS:A1988M099300013
J	ELLIS, EF				ELLIS, EF			ADVERSE-EFFECTS OF CORTICOSTEROID-THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											ELLIS, EF (corresponding author), CHILDRENS HOSP,SCH MED,DEPT PEDIAT,DIV ALLERGY IMMUNOL,BUFFALO,NY 14222, USA.							ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; BAYLINK DJ, 1983, NEW ENGL J MED, V309, P306, DOI 10.1056/NEJM198308043090509; BIHARI M, 1968, AM J DIS CHILD, V116, P604, DOI 10.1001/archpedi.1968.02100020608006; BLODGETT FM, 1956, NEW ENGL J MED, V254, P636, DOI 10.1056/NEJM195604052541402; BUCHANAN WW, 1970, ANN RHEUM DIS, V29, P560, DOI 10.1136/ard.29.5.560-b; CHANG KC, 1982, CLIN ALLERGY, V12, P369, DOI 10.1111/j.1365-2222.1982.tb02541.x; COHEN MB, 1948, J ALLERGY, V19, P165, DOI 10.1016/0021-8707(48)90049-5; COLE WG, 1976, AUST PAEDIATR J, V12, P37; DAVID DS, 1970, J CHRON DIS, V22, P637, DOI 10.1016/0021-9681(70)90078-0; DAVID DS, 1969, LANCET, V2, P149; DAWSON B, 1969, LANCET, V1, P827; DUJOVNE CA, 1973, MED CLIN N AM, V57, P1331, DOI 10.1016/S0025-7125(16)32233-7; FALLIERS CJ, 1961, J ALLERGY, V32, P420, DOI 10.1016/0021-8707(61)90020-X; FALLIERS CJ, 1963, AM J DIS CHILD, V105, P127, DOI 10.1001/archpedi.1963.02080040129002; FERGUSON AC, 1982, J ALLERGY CLIN IMMUN, V69, P461, DOI 10.1016/0091-6749(82)90122-1; FRIEDMAN M, 1969, Scandinavian Journal of Respiratory Diseases Supplementum, V68, P58; Giles C L, 1967, Mich Med, V66, P298; GILES CL, 1962, JAMA-J AM MED ASSOC, V182, P719, DOI 10.1001/jama.1962.03050460011003; GILLAM GL, 1970, ARCH DIS CHILD, V45, P789, DOI 10.1136/adc.45.244.789; GLUCK OS, 1981, ARTHRITIS RHEUM-US, V24, P892, DOI 10.1002/art.1780240705; GODFREY S, 1974, ARCH DIS CHILD, V49, P591, DOI 10.1136/adc.49.8.591; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; HAUSPIE R, 1977, J ALLERGY CLIN IMMUN, V59, P200, DOI 10.1016/0091-6749(77)90150-6; HAUSPIE R, 1976, HUM BIOL, V48, P271; KLEIN G, 1978, J ALLERGY CLIN IMMUN, V61, P158, DOI 10.1016/0091-6749(78)90340-8; MAHONY JF, 1982, MED J AUSTRALIA, V2, P426, DOI 10.5694/j.1326-5377.1982.tb132505.x; MARTIN AJ, 1981, ACTA PAEDIATR SCAND, V70, P683, DOI 10.1111/j.1651-2227.1981.tb05768.x; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; MCNICOL KN, 1970, ARCH DIS CHILD, V45, P783, DOI 10.1136/adc.45.244.783; MURRAY AB, 1976, LANCET, V2, P197; NASSIF E, 1987, J ALLERGY CLIN IMMUN, V80, P518, DOI 10.1016/0091-6749(87)90002-9; REIMER LG, 1975, J ALLERGY CLIN IMMUN, V55, P224, DOI 10.1016/0091-6749(75)90141-4; RICHARDS JM, 1980, ARCH INTERN MED, V140, P1473, DOI 10.1001/archinte.140.11.1473; SAVILLE PD, 1967, ARTHRITIS RHEUM, V10, P423, DOI 10.1002/art.1780100504; SEALE JP, 1986, MED J AUSTRALIA, V144, P139, DOI 10.5694/j.1326-5377.1986.tb112242.x; SHOHAT M, 1987, ARCH DIS CHILD, V62, P63, DOI 10.1136/adc.62.1.63; SNYDER RD, 1967, CLIN PEDIATR, V6, P389, DOI 10.1177/000992286700600705; Solomon L, 1973, J Bone Joint Surg Br, V55, P246; SPOCK A, 1965, ANN ALLERGY, V23, P608; SWEETNAM DR, 1960, BRIT MED J, V1, P1392, DOI 10.1136/bmj.1.5183.1392; VANMETRE TE, 1959, J ALLERGY, V30, P103, DOI 10.1016/0021-8707(59)90079-6; WITTIG HJ, 1978, ALLERGOL IMMUNOPATH, V6, P203	44	19	19	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1987	80	4					515	518		10.1016/0091-6749(87)90001-7	http://dx.doi.org/10.1016/0091-6749(87)90001-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K5224	3668115				2022-12-18	WOS:A1987K522400001
J	DRAZEN, JM; BOUSHEY, HA; HOLGATE, ST; KALINER, M; OBYRNE, P; VALENTINE, M; WIDDICOMBE, JH; WOOLCOCK, A				DRAZEN, JM; BOUSHEY, HA; HOLGATE, ST; KALINER, M; OBYRNE, P; VALENTINE, M; WIDDICOMBE, JH; WOOLCOCK, A			THE PATHOGENESIS OF SEVERE ASTHMA - A CONSENSUS REPORT FROM THE WORKSHOP ON PATHOGENESIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											DRAZEN, JM (corresponding author), BETH ISRAEL HOSP,PULM UNIT,330 BROOKLINE AVE,BOSTON,MA 02215, USA.		Drazen, Jeffrey M/E-5841-2012	O'Byrne, Paul/0000-0003-0979-281X				ALBAZZAZ F, 1981, AM J PHYSIOL, V240, pF101, DOI 10.1152/ajprenal.1981.240.2.F101; ALBAZZAZ FJ, 1985, AM REV RESPIR DIS, V131, P86; ALBAZZAZ FJ, 1979, J APPL PHYSIOL, V47, P397, DOI 10.1152/jappl.1979.47.2.397; BARTER CE, 1976, AM REV RESPIR DIS, V113, P305; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; BHASKAR KR, 1985, EXP LUNG RES, V9, P289, DOI 10.3109/01902148509057529; BISGAARD H, 1985, BRIT MED J, V290, P1468, DOI 10.1136/bmj.290.6480.1468; BOUCHER RC, 1981, J APPL PHYSIOL, V51, P706, DOI 10.1152/jappl.1981.51.3.706; BOUCHER RC, 1982, FLUID ELECTROLYTE AB, P271; BROWN R, 1978, AM REV RESPIR DIS, V118, P685, DOI 10.1164/arrd.1978.118.4.685; CADE JF, 1971, CLIN SCI, V40, P381, DOI 10.1042/cs0400381; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1983, LANCET, V2, P253; COCKCROFT DW, 1984, IMMUNOL ALLERGY PRAC, V6, P92; COLES SJ, 1981, AM REV RESPIR DIS, V124, P531; CORRALES RJ, 1986, J APPL PHYSIOL, V61, P1065, DOI 10.1152/jappl.1986.61.3.1065; CUSHLEY MJ, 1984, AM REV RESPIR DIS, V129, P380; CUSS FM, 1986, LANCET, V2, P189; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DEMONCHY JGR, 1985, AGENTS ACTIONS, V16, P252; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAMOND JM, 1979, J MEMBRANE BIOL, V51, P195, DOI 10.1007/BF01869084; DRAZEN JM, 1986, CHEST, V89, P414, DOI 10.1378/chest.89.3.414; DULFANO MJ, 1982, THORAX, V37, P646, DOI 10.1136/thx.37.9.646; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; ELING TE, 1986, J BIOL CHEM, V261, P2841; ENGSTROM I, 1964, ACTA PAEDIATR      S, V155, P1; FABBRI LM, 1985, B EUR PHYSIOPATH RES, V21, P421; FICK RB, 1985, AM REV RESPIR DIS, V131, P178; FILLEY WV, 1982, LANCET, V2, P11; FINUCANE KE, 1969, J APPL PHYSIOL, V26, P330, DOI 10.1152/jappl.1969.26.3.330; FREEDMAN S, 1975, J APPL PHYSIOL, V38, P974, DOI 10.1152/jappl.1975.38.6.974; FRIGAS E, 1980, LAB INVEST, V42, P35; GELB AF, 1979, J ALLERGY CLIN IMMUN, V64, P18, DOI 10.1016/0091-6749(79)90077-0; GERBER F, 1985, REV MAL RESPIR, V2, P313; GOLD WM, 1967, J APPL PHYSL, V23, P43; HABIB MP, 1979, J APPL PHYSIOL, V47, P51, DOI 10.1152/jappl.1979.47.1.51; HANNA CJ, 1981, NATURE, V290, P343, DOI 10.1038/290343a0; HENDERSON WR, 1978, J CLIN INVEST, V61, P187, DOI 10.1172/JCI108917; HOLGATE ST, 1984, ASTHMA PHYSL IMMUNOP, P391; JACOBI D, UNPUB; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; KALINER M, 1984, FED PROC, V43, P2846; KALINER M, 1976, TXB IMMUNOPATHOLOGY, P387; KIRBY JG, 1986, J APPL PHYSIOL, V61, P2144, DOI 10.1152/jappl.1986.61.6.2144; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LEIKAUF GD, 1986, AM J PHYSIOL, V250, pF47, DOI 10.1152/ajprenal.1986.250.1.F47; LEIKAUF GD, 1985, AM J PHYSIOL, V248, pF48, DOI 10.1152/ajprenal.1985.248.1.F48; LOPEZVIDRIERO MT, 1978, AM REV RESPIR DIS, V117, P465; Lucas AM, 1934, ARCHIV OTOLARYNGOL, V20, P518; MARIN MG, 1977, J APPL PHYSIOL, V42, P735, DOI 10.1152/jappl.1977.42.5.735; MARIN MG, 1976, AM J PHYSIOL, V231, P1546, DOI 10.1152/ajplegacy.1976.231.5.1546; MARSH WR, 1985, AM REV RESPIR DIS, V131, P875; MARTIN J, 1980, AM REV RESPIR DIS, V121, P441, DOI 10.1164/arrd.1980.121.3.441; MCFADDEN ER, 1968, NEW ENGL J MED, V278, P1027, DOI 10.1056/NEJM196805092781901; MCFADDEN ER, 1969, J APPL PHYSIOL, V27, P452, DOI 10.1152/jappl.1969.27.4.452; MEIER HL, 1983, J CLIN INVEST, V72, P574, DOI 10.1172/JCI111005; MESSER JW, 1960, DIS CHEST, V38, P616, DOI 10.1378/chest.38.6.616; METCALFE DD, 1981, CRC CR REV IMMUNOL, V3, P23; MOSSBERG B, 1976, SCAND J RESPIR DIS, V57, P119; Nadel JA, 1985, HDB PHYSL RESP SYSTE, V1, P419; NATHANSON I, 1983, J APPL PHYSIOL, V55, P1257, DOI 10.1152/jappl.1983.55.4.1257; NATHANSON I, 1983, J APPL PHYSIOL, V55, P1844, DOI 10.1152/jappl.1983.55.6.1844; OBYRNE PM, IN PRESS AM REV RESP; OLIVE JT, 1972, AM REV RESPIR DIS, V106, P366, DOI 10.1164/arrd.1972.106.3.366; OLVER RE, 1975, AM REV RESPIR DIS, V112, P811; PALMER KNV, 1969, BRIT MED J, V1, P31, DOI 10.1136/bmj.1.5635.31; PALMER KNV, 1968, LANCET, V1, P318; PALMER KNV, 1969, LANCET, V1, P591; PERESS L, 1976, AM J MED, V61, P165, DOI 10.1016/0002-9343(76)90165-0; PERMUTT S, 1973, P15; Phipps R J, 1981, Int Rev Physiol, V23, P213; PHIPPS RJ, 1982, CLIN SCI, V63, P23, DOI 10.1042/cs0630023; PLATSHON LF, 1978, J CLIN INVEST, V62, P1113, DOI 10.1172/JCI109230; RANGACHARI PK, 1985, REGUL PEPTIDES, V12, P9, DOI 10.1016/0167-0115(85)90182-X; REES HA, 1968, Q J MED, V37, P541; REID LYNNE, 1960, THORAX, V15, P132, DOI 10.1136/thx.15.2.132; REISSIG M, 1978, AM REV RESPIR DIS, V117, P327; RHODIN JAG, 1966, AM REV RESPIR DIS, V93, P1; RODENSTEIN D, 1983, J APPL PHYSIOL, V54, P152, DOI 10.1152/jappl.1983.54.1.152; RODENSTEIN DO, 1983, J APPL PHYSIOL, V54, P159, DOI 10.1152/jappl.1983.54.1.159; SANTACRUZ R, 1974, AM REV RESPIR DIS, V109, P458; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321, DOI 10.1152/jappl.1986.60.4.1321; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; SHORE S, 1982, AM REV RESPIR DIS, V126, P515; SPANNHAKE EW, 1981, PROSTAGLANDINS, V22, P1013, DOI 10.1016/0090-6980(81)90028-9; STANESCU DC, 1973, B PHYSIO-PATHOL RESP, V9, P523; STURGESS JM, 1979, PEDIATR CLIN N AM, V26, P481; TAI E, 1967, LANCET, V1, P644; TAYLOR RG, 1985, THORAX, V40, P9, DOI 10.1136/thx.40.1.9; Tegner H, 1979, Rhinology, V17, P199; VERDUGO P, 1984, CIBA F SYMP, V109, P212, DOI 10.1002/9780470720905.ch15; WELSH MJ, 1980, J APPL PHYSIOL, V49, P905, DOI 10.1152/jappl.1980.49.5.905; WESTERMAN DE, 1979, AM J MED, V66, P565, DOI 10.1016/0002-9343(79)91165-3; WIDDICOMBE JH, 1984, CIBA F SYMP, V109, P109, DOI 10.1002/9780470720905.ch8; WOOLCOCK AJ, 1986, EUR J RESPIR DIS, V69, P166; WOOLCOCK AJ, 1966, AM J MED, V41, P259, DOI 10.1016/0002-9343(66)90021-0; YONEDA K, 1976, AM REV RESPIR DIS, V114, P837	98	19	19	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			428	437		10.1016/0091-6749(87)90069-8	http://dx.doi.org/10.1016/0091-6749(87)90069-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037	3624698				2022-12-18	WOS:A1987K103700019
J	SCHOEN, FJ				SCHOEN, FJ			CARDIAC PATHOLOGY IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	SCHOEN, FJ (corresponding author), BRIGHAM & WOMENS HOSP,DEPT PATHOL,75 FRANCIS ST,BOSTON,MA 02115, USA.							ALHILLAWI AH, 1984, BRIT MED J, V288, P367, DOI 10.1136/bmj.288.6414.367; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; CALVERLEY PMA, 1983, BRIT J DIS CHEST, V77, P303; CLARK TJH, 1977, ASTHMA; COCHRANE GM, 1975, THORAX, V30, P300, DOI 10.1136/thx.30.3.300; CONRADSON TB, 1985, CHEST, V88, P537, DOI 10.1378/chest.88.4.537; DEJONG JW, 1986, ANN THORAC SURG, V42, P593, DOI 10.1016/S0003-4975(10)60595-4; DRISLANE FW, 1987, AM REV RESPIR DIS, V135, P498; EDMUNDS AT, 1981, THORAX, V36, P534, DOI 10.1136/thx.36.7.534; HAALBOOM JRE, 1985, LANCET, V1, P1125; HALL KW, 1984, ANN INTERN MED, V101, P457, DOI 10.7326/0003-4819-101-4-457; HETZEL MR, 1977, BMJ-BRIT MED J, V1, P808, DOI 10.1136/bmj.1.6064.808; JACK D, 1971, BRIT MED J, V2, P708, DOI 10.1136/bmj.2.5763.708-b; JENNINGS RB, 1986, J MOL CELL CARDIOL, V18, P769, DOI 10.1016/S0022-2828(86)80952-X; KARCH SB, 1986, HUM PATHOL, V17, P9, DOI 10.1016/S0046-8177(86)80150-2; KELLY HW, 1985, ANN ALLERGY, V54, P405; KURLAND G, 1979, J ALLERGY CLIN IMMUN, V63, P407, DOI 10.1016/0091-6749(79)90214-8; LEHR D, 1972, NEW ENGL J MED, V287, P987; LUCHTRATH H, 1979, VIRCHOWS ARCH A, V381, P343, DOI 10.1007/BF00432476; MACDONALD JB, 1976, BRIT MED J, V1, P1493, DOI 10.1136/bmj.1.6024.1493; MAGUIRE JF, 1987, J ALLERGY CLIN IMMUN, V78, P631; MARTELLI NA, 1986, CHEST, V89, P192, DOI 10.1378/chest.89.2.192; MATSON JR, 1978, J PEDIATR-US, V92, P776, DOI 10.1016/S0022-3476(78)80150-4; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; NEWHOUSE MT, 1986, NEW ENGL J MED, V315, P870, DOI 10.1056/NEJM198610023151406; NICKLAS RA, 1986, J ALLERGY CLIN IMMUN, V78, P806, DOI 10.1016/0091-6749(86)90065-5; RENZETTI AD, 1966, AM J MED, V41, P115, DOI 10.1016/0002-9343(66)90009-X; RONA G, 1985, J MOL CELL CARDIOL, V17, P291, DOI 10.1016/S0022-2828(85)80130-9; SAMUELS MA, 1984, SEMIN NEUROL, V4, P453, DOI 10.1055/s-2008-1041578; SCHARF SM, 1985, CLIN REV ALLERG, V3, P487; TAYLOR GJ, 1970, J AMER MED ASSOC, V214, P81, DOI 10.1001/jama.214.1.81; WILSON JD, 1981, LANCET, V1, P1235; WINSOR T, 1975, MICROVASC RES, V9, P261, DOI 10.1016/0026-2862(75)90063-1; [No title captured]; 1985, J ALLERGY CLIN IMMUN, V75, P443	35	19	19	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			419	423		10.1016/0091-6749(87)90066-2	http://dx.doi.org/10.1016/0091-6749(87)90066-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037	3624697	Bronze			2022-12-18	WOS:A1987K103700017
J	BOXER, MB; GRAMMER, LC; HARRIS, KE; ROACH, DE; PATTERSON, R				BOXER, MB; GRAMMER, LC; HARRIS, KE; ROACH, DE; PATTERSON, R			6-YEAR CLINICAL AND IMMUNOLOGICAL FOLLOW-UP OF WORKERS EXPOSED TO TRIMELLITIC ANHYDRIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT MED,OCCUPAT MED SECT,CHICAGO,IL 60611; THREE M CO,DEPT MED,ST PAUL,MN 55144	Northwestern University; Northwestern University; 3M				Grammer, Leslie/0000-0001-6860-2014	NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNSTEIN DI, 1982, J ALLERGY CLIN IMMUN, V69, P311, DOI 10.1016/S0091-6749(82)80009-2; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; MCGRATH KG, 1984, J OCCUP ENVIRON MED, V26, P671; PATTERSON R, 1979, AM REV RESPIR DIS, V120, P1259; PATTERSON R, 1978, J CLIN INVEST, V62, P971, DOI 10.1172/JCI109226; SALE SR, 1981, J ALLERGY CLIN IMMUN, V68, P188, DOI 10.1016/0091-6749(81)90182-2; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; SNEDECOR GW, 1967, STATISTICAL METHODS, P26; TURNER ES, 1980, CLIN EXP IMMUNOL, V39, P470; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250	13	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1987	80	2					147	152		10.1016/0091-6749(87)90123-0	http://dx.doi.org/10.1016/0091-6749(87)90123-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J6575	3611536				2022-12-18	WOS:A1987J657500005
J	MINOR, MW; FOX, RW; BUKANTZ, SC; LOCKEY, RF				MINOR, MW; FOX, RW; BUKANTZ, SC; LOCKEY, RF			MELKERSSON-ROSENTHAL SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JAMES A HALEY VET ADM HOSP, TAMPA, FL USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital	MINOR, MW (corresponding author), UNIV S FLORIDA, COLL MED, DEPT INTERNAL MED, DIV ALLERGY & IMMUNOL, 13000 BRUCE B DOWNS BLVD, TAMPA, FL 33612 USA.							ALEXANDER RW, 1972, J ORAL SURG, V30, P599; BENINSON J, 1971, ANGIOLOGY, V22, P448, DOI 10.1177/000331977102200802; CAIRNS RJ, 1961, P ROY SOC MED, V54, P217, DOI 10.1177/003591576105400308; CARR RD, 1966, ARCH DERMATOL, V93, P426, DOI 10.1001/archderm.93.4.426; CASTELLANI A., 1934, Journal of Tropical Medicine and Hygiene, V37, P257; CERIMELE D, 1965, ARCH DERMATOL, V92, P695, DOI 10.1001/archderm.92.6.695; COCKAYNE EA, 1933, INHERITED ABNORMALIT, P95; CONNELLY TJ, 1986, J AM ACAD DERMATOL, V14, P353, DOI 10.1016/S0190-9622(86)70042-X; HALLETT JW, 1968, AM J OPHTHALMOL, V65, P542, DOI 10.1016/0002-9394(68)93870-1; HINES H, 1985, ARCH DERMATOL, V121, P127; HOLLANDER DI, 1985, J ALLERGY CLIN IMMUN, V75, P450, DOI 10.1016/S0091-6749(85)80016-6; HUBSCHMAN H, 1884, NEUROLOGY, V13, P185; Humphrey JH, 1944, BMJ-BRIT MED J, V1944, P315, DOI 10.1136/bmj.1.4339.315; KRUTCHKOFF D, 1978, ARCH DERMATOL, V114, P1203, DOI 10.1001/archderm.114.8.1203; LUSCHER E, 1949, SCHWEIZ MED WSCHR, V79, P1; MADANES AE, 1982, ANN INTERN MED, V96, P625, DOI 10.7326/0003-4819-96-5-625; MELBY JC, 1985, HOSP PRACT, V20, pE68; Melkersson E, 1928, HYGEA, V90, P737; NALLY FF, 1970, ORAL SURG ORAL MED O, V29, P694, DOI 10.1016/0030-4220(70)90266-5; RICHTER F, 1950, ARCH DERMATOL SYPHIL, V190, P486; Rosenthal C, 1931, Z GESAMTE NEUROL PSY, V131, P475, DOI 10.1007/BF02865984; SCHIFF BL, 1980, CUTIS, V25, P88; SCOTT GA, 1968, POSTGRAD MED J, V44, P447, DOI 10.1136/pgmj.44.512.447; SONGSIRIDEJ V, 1985, ANN INTERN MED, V103, P503, DOI 10.7326/0003-4819-103-4-503; SOTER NA, 1982, CECIL TXB MED, P1799; STREETO JM, 1964, NEW ENGL J MED, V271, P308, DOI 10.1056/NEJM196408062710609; VISTNES LM, 1971, PLAST RECONSTR SURG, V48, P126, DOI 10.1097/00006534-197108000-00004; WORSAAE N, 1982, ORAL SURG ORAL MED O, V54, P404, DOI 10.1016/0030-4220(82)90387-5	28	19	19	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1987	80	1					64	67		10.1016/S0091-6749(87)80192-6	http://dx.doi.org/10.1016/S0091-6749(87)80192-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J2194	3598030	Bronze			2022-12-18	WOS:A1987J219400010
J	YANAGIHARA, Y; KAJIWARA, K; KINIWA, M; YUI, Y; SHIDA, T; DELESPESSE, G				YANAGIHARA, Y; KAJIWARA, K; KINIWA, M; YUI, Y; SHIDA, T; DELESPESSE, G			ENHANCEMENT OF IGE SYNTHESIS AND HISTAMINE-RELEASE BY T-CELL FACTORS DERIVED FROM ATOPIC PATIENTS WITH BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC MED,DEPT IMMUNOL,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba	YANAGIHARA, Y (corresponding author), NATL SAGAMIHARA HOSP,CLIN RES CTR ALLERGY & RHEUMATOL,SAKURADAI 18-1,SAGAMIHARA,KANAGAWA 228,JAPAN.							ADACHI M, 1983, J IMMUNOL, V131, P1246; BAMZAI AK, 1978, J ALLERGY CLIN IMMUN, V62, P137, DOI 10.1016/0091-6749(78)90097-0; BAZARAL M, 1972, J ALLERGY CLIN IMMUN, V49, P189, DOI 10.1016/0091-6749(72)90113-3; BICHTHUY LT, 1982, J IMMUNOL, V129, P150; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P31; DEGUCHI H, 1983, J IMMUNOL, V131, P2751; DELESPESSE G, 1983, IMMUNOL LETT, V7, P11, DOI 10.1016/0165-2478(83)90048-2; HIRASHIMA M, 1981, J IMMUNOL, V127, P1804; HOOVER RG, 1983, J IMMUNOL, V130, P521; ISHIZAKA T, 1985, J IMMUNOL, V134, P1880; KAPLAN AP, 1985, J IMMUNOL, V135, P2027; KIYONO H, 1982, J EXP MED, V156, P1115, DOI 10.1084/jem.156.4.1115; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LUM LG, 1979, J IMMUNOL, V122, P65; MITSUYA H, 1983, CLIN IMMUNOL IMMUNOP, V26, P171, DOI 10.1016/0090-1229(83)90135-6; ROMAGNANI S, 1983, CLIN EXP IMMUNOL, V52, P85; SARFATI M, 1984, IMMUNOLOGY, V53, P207; SARFATI M, 1984, IMMUNOLOGY, V53, P783; SARFATI M, 1984, IMMUNOLOGY, V53, P197; SARYAN JA, 1983, J IMMUNOL, V130, P242; THOMPSON LF, 1983, J IMMUNOL, V131, P2772; THUESON DO, 1979, J IMMUNOL, V123, P633; THUESON DO, 1979, J IMMUNOL, V123, P626; UEDA T, 1983, J IMMUNOL, V130, P649; UEDA T, 1982, J IMMUNOL, V129, P1384; UEDA T, 1984, J IMMUNOL, V133, P359; YODOI J, 1980, J IMMUNOL, V125, P1436; YODOI J, 1980, J IMMUNOL, V124, P1322; YOUNG MC, 1984, EUR J IMMUNOL, V14, P871, DOI 10.1002/eji.1830141003; ZURAW BL, 1981, J IMMUNOL, V127, P1169	30	19	19	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1987	79	3					448	456		10.1016/0091-6749(87)90362-9	http://dx.doi.org/10.1016/0091-6749(87)90362-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G4795	2434549				2022-12-18	WOS:A1987G479500007
J	WEISSMAN, DN; DESHAZO, RD; BANKS, DE				WEISSMAN, DN; DESHAZO, RD; BANKS, DE			MODULATION OF NATURAL-KILLER CELL-FUNCTION BY HUMAN ALVEOLAR MACROPHAGES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TUFTS UNIV,SCH MED,DEPT MED,CLIN IMMUNOL SECT,HERBERT HARVEY LAB,1700 PERDIDO ST,BOSTON,MA 02111; TUFTS UNIV,SCH MED,PULM DIS SECT,HERBERT HARVEY LAB,BOSTON,MA 02111; VET ADM MED CTR,NEW ORLEANS,LA 70146	Tufts University; Tufts University; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007376, P50HL015092] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07376, HL-15092] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BORDIGNON C, 1982, J IMMUNOL, V129, P587; BORDIGNON C, 1982, CLIN EXP IMMUNOL, V47, P437; BRUNDA MJ, 1980, J IMMUNOL, V124, P2682; DESHAZO RD, 1983, AM REV RESPIR DIS, V127, P545, DOI 10.1164/arrd.1983.127.5.545; DJEU JY, 1979, J IMMUNOL, V122, P175; DROLLER MJ, 1978, CELL IMMUNOL, V39, P165, DOI 10.1016/0008-8749(78)90091-6; ETTENSOHN DB, 1983, AM REV RESPIR DIS, V128, P516, DOI 10.1164/arrd.1983.128.3.516; FOLCH H, 1973, J IMMUNOL, V110, P835; GIDLUND M, 1978, NATURE, V273, P759, DOI 10.1038/273759a0; HENNEY CS, 1981, NATURE, V291, P335, DOI 10.1038/291335a0; HOCKING WG, 1979, NEW ENGL J MED, V301, P639, DOI 10.1056/NEJM197909203011205; HOFFMAN T, 1983, CLIN IMMUNOL IMMUNOP, V29, P323, DOI 10.1016/0090-1229(83)90035-1; HUNNINGHAKE GW, 1979, AM J PATHOL, V97, P149; JAMES K, 1984, IMMUNOL TODAY, V5, P193, DOI 10.1016/0167-5699(84)90219-6; KALTREIDER HB, 1982, CHEST, V82, P261, DOI 10.1378/chest.82.3.261; KLEINBAUM DG, 1978, APPLIED REGRESSION A, P37; LAWRENCE C, 1980, STAIN TECHNOL, V54, P321; LAWRENCE EC, 1982, AM REV RESPIR DIS, V126, P248; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MIYASAKA N, 1983, ARTHRITIS RHEUM, V26, P954, DOI 10.1002/art.1780260803; MORRISON D, 1976, MULTIVARIATE STATIST, P134; PENNLINE KJ, 1981, J RETICULOENDOTH SOC, V30, P205; ROBINSON BWS, 1984, J CLIN INVEST, V74, P942, DOI 10.1172/JCI111513; RODER JC, 1982, J CLIN IMMUNOL, V2, P249, DOI 10.1007/BF00915064; ROSENBER.EB, 1974, JNCI-J NATL CANCER I, V52, P345, DOI 10.1093/jnci/52.2.345; SEAMAN WE, 1982, J CLIN INVEST, V69, P876, DOI 10.1172/JCI110527; STEVENSON HC, 1984, AM J MED, V77, P355, DOI 10.1016/0002-9343(84)90720-4; TOEWS GB, 1984, J IMMUNOL, V132, P181; VICENZI E, 1984, CLIN EXP IMMUNOL, V57, P385; YANG J, 1984, CELL IMMUNOL, V86, P171, DOI 10.1016/0008-8749(84)90370-8; YOUNG KR, 1984, IMMUNOLOGY LUNG UPPE, P157	31	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	1				571	577		10.1016/0091-6749(86)90073-4	http://dx.doi.org/10.1016/0091-6749(86)90073-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5682	3490501	Bronze			2022-12-18	WOS:A1986E568200004
J	NEWCOMB, RW; AKHTER, J				NEWCOMB, RW; AKHTER, J			OUTCOMES OF EMERGENCY ROOM VISITS FOR ASTHMA .1. PATIENT DETERMINANTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CHICAGO,PRITZKER SCH MED,DEPT PEDIAT,65TH ST & LAKE MICHIGAN,CHICAGO,IL 60649; UNIV CHICAGO,LA RABIDA CHILDRENS HOSP & RES CTR,CHICAGO,IL 60649	University of Chicago; University of Chicago								ANDERSON HR, 1983, ARCH DIS CHILD, V58, P777, DOI 10.1136/adc.58.10.777; CENTOR RM, 1984, NEW ENGL J MED, V310, P577, DOI 10.1056/NEJM198403013100907; CROMPTON GK, 1979, BRIT MED J, V2, P1199, DOI 10.1136/bmj.2.6199.1199; DIRKS JF, 1977, PSYCHOSOM MED, V39, P120, DOI 10.1097/00006842-197703000-00006; ELLIS EF, 1983, CURRENT THERAPY ALLE, P22; FANTA CH, 1982, AM J MED, V72, P416, DOI 10.1016/0002-9343(82)90498-3; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P705, DOI 10.7326/0003-4819-99-5-705; FISCHL MA, 1981, NEW ENGL J MED, V305, P783, DOI 10.1056/NEJM198110013051402; GANDHI M D, 1984, Journal of Allergy and Clinical Immunology, V73, P122; KARETZKY MS, 1977, J ALLERGY CLIN IMMUN, V60, P383, DOI 10.1016/0091-6749(77)90070-7; LULLA S, 1980, J PEDIATR-US, V97, P346, DOI 10.1016/S0022-3476(80)80179-X; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; MANSMANN HC, 1980, CLIN CHEST MED, V1, P339; MARTIN AJ, 1980, BRIT MED J, V1, P1397; PARCEL GS, 1979, PEDIATRICS, V64, P878; RICHARDS W, 1979, CLIN PEDIATR, V18, P345, DOI 10.1177/000992287901800606; ROSE CC, 1984, NEW ENGL J MED, V310, P573, DOI 10.1056/NEJM198403013100906; SILVER RB, 1984, CLIN PEDIATR, V23, P81, DOI 10.1177/000992288402300203; SIMPSON H, 1978, ARCH DIS CHILD, V53, P714, DOI 10.1136/adc.53.9.714; SKONER D, 1984, Journal of Allergy and Clinical Immunology, V73, P121; STEIN REK, 1984, PEDIATR CLIN N AM, V31, P189; STEVENSON DD, 1975, ARCH INTERN MED, V135, P777, DOI 10.1001/archinte.135.6.777; WESTERMAN DE, 1979, AM J MED, V66, P565, DOI 10.1016/0002-9343(79)91165-3	23	19	19	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1986	77	2					309	315		10.1016/S0091-6749(86)80109-9	http://dx.doi.org/10.1016/S0091-6749(86)80109-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A0899	3944381				2022-12-18	WOS:A1986A089900007
J	SHER, MR; SUCHAR, C; LOCKEY, RF				SHER, MR; SUCHAR, C; LOCKEY, RF			ANAPHYLACTIC SHOCK-INDUCED BY ORAL DESENSITIZATION TO TRIMETHOPRIM SULFMETHOXAZOLE (TMP-SMZ)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	2	S			133	133						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD38					2022-12-18	WOS:A1986AZD3800052
J	SIMON, RA; WASSERMAN, SI				SIMON, RA; WASSERMAN, SI			IGE MEDIATED SULFITE SENSITIVE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	2	S			157	157						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD38					2022-12-18	WOS:A1986AZD3800144
J	BLUMENTHAL, M; AWDEH, Z; ALPER, C; YUNIS, E				BLUMENTHAL, M; AWDEH, Z; ALPER, C; YUNIS, E			RA5 IMMUNE-RESPONSES, HLA ANTIGENS AND COMPLOTYPES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					155	155		10.1016/0091-6749(85)90338-0	http://dx.doi.org/10.1016/0091-6749(85)90338-0			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ACF22		Bronze			2022-12-18	WOS:A1985ACF2200203
J	LEONARD, EJ; SKEEL, A				LEONARD, EJ; SKEEL, A			SEPARATION OF HUMAN BASOPHILS INTO 2 FRACTIONS WITH DIFFERENT DENSITY AND HISTAMINE CONTENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LEONARD, EJ (corresponding author), NCI,FREDERICK CANC RES FACIL,IMMUNOBIOL LAB,IMMUNOPATHOL SECT,FREDERICK,MD 21701, USA.							Askenase P W, 1977, Prog Allergy, V23, P199, DOI 10.1159/000314242; BEFUS AD, 1982, J IMMUNOL, V128, P2475; CODE CF, 1957, J PHYSIOL-LONDON, V136, P449, DOI 10.1113/jphysiol.1957.sp005773; DVORAK AM, 1980, LAB INVEST, V43, P126; DVORAK HF, 1970, J EXP MED, V132, P558, DOI 10.1084/jem.132.3.558; HIRSCH SR, 1976, J ALLERGY CLIN IMMUN, V58, P676, DOI 10.1016/0091-6749(76)90179-2; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; LEONARD EJ, 1979, INT ARCH ALLER A IMM, V58, P460, DOI 10.1159/000232227; LEONARD EJ, 1984, J LEUKOCYTE BIOL, V35, P405; LETTBROWN MA, 1976, J IMMUNOL, V117, P246; LETTBROWN MA, 1977, J IMMUNOL, V118, P815; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; SAAVEDRADELGADO AMP, 1980, J ALLERGY CLIN IMMUN, V66, P464, DOI 10.1016/0091-6749(80)90007-X; SCHRADER JW, 1981, P NATL ACAD SCI-BIOL, V78, P323, DOI 10.1073/pnas.78.1.323; SCHULMAN ES, 1983, J IMMUNOL, V131, P1936; SIRAGANIAN RP, 1976, MANUAL CLIN IMMUNOLO, P603; WENNESLAND R, 1959, J CLIN INVEST, V38, P1065, DOI 10.1172/JCI103883	17	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	4					556	562		10.1016/0091-6749(85)90775-4	http://dx.doi.org/10.1016/0091-6749(85)90775-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ATH66	2414351				2022-12-18	WOS:A1985ATH6600006
J	MESSINA, MS; SMALDONE, GC				MESSINA, MS; SMALDONE, GC			EVALUATION OF QUANTITATIVE AEROSOL TECHNIQUES FOR USE IN BRONCHOPROVOCATION STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY STONY BROOK,DEPT MED,DIV PULM DIS,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NHLBI NIH HHS [HL00461] Funding Source: Medline; NIAID NIH HHS [AI16337] Funding Source: Medline; NIEHS NIH HHS [ES07088-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI016337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007088] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ACEVEDO JC, 1982, HLTH IMPACTS DIFFERE, P361; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHAI H, 1979, J ALLERGY CLIN IMMUN, V64, P565; DAVIES CN, 1972, J APPL PHYSIOL, V32, P591, DOI 10.1152/jappl.1972.32.5.591; DOLOVICH M, 1981, CHEST, V80, P834; GEBHART J, 1981, J APPL PHYSIOL, V51, P465, DOI 10.1152/jappl.1981.51.2.465; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HENDEE WR, 1981, RAD THERAPY PHYSICS, P56; HENDEE WR, 1979, MED RAD PHYSICS ROEN, P96; Heyder J., 1975, J AEROSOL SCI, V6, P311, DOI DOI 10.1016/0021-8502(75)90020-8; ITOH H, 1981, CHEST, V80, P387; ITOH H, 1980, J NUCL MED, V21, P11; MACEY DJ, 1982, J NUCL MED, V23, P731; MUIR D. C. F., 1967, ANN OCCUP HYG, V10, P161; PALMES ED, 1973, J APPL PHYSIOL, V34, P356, DOI 10.1152/jappl.1973.34.3.356; ROSENTHAL RR, 1979, J ALLERGY CLIN IMMUN, V64, P564, DOI 10.1016/0091-6749(79)90013-7; RUFFIN RE, 1978, CLIN PHARMACOL THER, V23, P338; RUFFIN RE, 1978, AM REV RESPIR DIS, V117, P485; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; SMALDONE GC, 1982, AM REV RESPIR DIS, V125, P258; SMALDONE GC, 1979, AM REV RESPIR DIS, V120, P747; SMALDONE GC, 1982, AM REV RESPIR DIS, V125, P158; SMALDONE GC, 1983, J APPL PHYSIOL, V54, P393, DOI 10.1152/jappl.1983.54.2.393; SPECTOR S, 1979, J ALLERGY CLIN IMMUN, V64, P580, DOI 10.1016/0091-6749(79)90016-2; THOMAS SR, 1976, MED PHYS, V3, P252; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9	26	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	2					252	257		10.1016/0091-6749(85)90054-5	http://dx.doi.org/10.1016/0091-6749(85)90054-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABZ05	3968336				2022-12-18	WOS:A1985ABZ0500004
J	SPECTOR, SL				SPECTOR, SL			ADVANTAGES AND DISADVANTAGES OF 24-HOUR THEOPHYLLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,CIRID,LOS ANGELES,CA 90024; ALLERGY RES FDN,LOS ANGELES,CA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								AYD FJ, 1974, JAMA-J AM MED ASSOC, V230, P263, DOI 10.1001/jama.230.2.263; BIERMAN CW, 1977, PEDIATRICS, V60, P845; DEDERICH RA, 1981, J ALLERGY CLIN IMMUN, V67, P465, DOI 10.1016/0091-6749(81)90100-7; ENEY RD, 1976, PEDIATRICS, V57, P513; Gatley M S, 1968, J R Coll Gen Pract, V16, P39; HENDELES L, 1984, CLIN PHARMACOKINET, V9, P95, DOI 10.2165/00003088-198409020-00001; HOFFMAN M, 1985, J ALLERGY CLIN IMMUN, V75, P128, DOI 10.1016/0091-6749(85)90228-3; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P349; KARIM A, 1984, PHARMACOTHERAPY, V4, P192; KATZ RM, 1978, J PEDIATR-US, V92, P663, DOI 10.1016/S0022-3476(78)80318-7; KATZ RM, 1983, ANN ALLERGY, V50, P23; KEMP JP, 1984, J ALLERGY CLIN IMMUN, V73, P32, DOI 10.1016/0091-6749(84)90481-0; KLEIN JJ, 1983, AM REV RESPIR DIS, V127, P413, DOI 10.1164/arrd.1983.127.4.413; LEVY G, 1975, J PEDIATR-US, V86, P789, DOI 10.1016/S0022-3476(75)80374-X; LONNERHOLM G, 1981, BRIT MED J, V282, P1029, DOI 10.1136/bmj.282.6269.1029; MASELLI R, 1970, J PEDIATR, V76, P777, DOI 10.1016/S0022-3476(70)80305-5; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; NICHOLSON DP, 1973, AM REV RESPIR DIS, V108, P241; NICKLAS RA, 1984, J ALLERGY CLIN IMMUN, V73, P20, DOI 10.1016/0091-6749(84)90479-2; PEDERSEN S, 1984, PEDIATRICS, V74, P534; PETTY T, 1984, JUN CLIN ABSTR P FRE; PHILLIPS MJ, 1981, BRIT J DIS CHEST, V75, P181, DOI 10.1016/0007-0971(81)90051-6; POLLOCK J, 1977, PEDIATRICS, V60, P840; PRIMROSE WR, 1983, LANCET, V1, P927; RACHELEFSKY GS, 1978, ANN ALLERGY, V40, P252; ROGERS RJ, 1985, J PEDIATR-US, V106, P496, DOI 10.1016/S0022-3476(85)80690-9; SCOTT PH, 1981, J PEDIATR-US, V99, P476, DOI 10.1016/S0022-3476(81)80354-X; SHAPIRO GG, 1981, PEDIATRICS, V67, P508; SPECTOR SL, 1985, J ALLERGY CLIN IMMUN, V75, P105, DOI 10.1016/0091-6749(85)90139-3; SUBLETT JL, 1979, ANN ALLERGY, V43, P95; SVEDMYR N, 1979, CURR MED RES OPIN, V6, P83; TABACHNIK E, 1982, J PEDIATR-US, V100, P489, DOI 10.1016/S0022-3476(82)80467-8; TINKELMAN DG, 1980, ANN ALLERGY, V44, P283; WEINBERGER M, 1984, J ALLERGY CLIN IMMUN, V73, P525, DOI 10.1016/0091-6749(84)90505-0; WEINBERGER M, 1984, PHARMACOTHERAPY, V4, P187; WILSON JD, 1981, LANCET, V1, P1235; WOLFE JD, 1978, NEW ENGL J MED, V298, P363, DOI 10.1056/NEJM197802162980703; YUNGINGER JW, 1966, ANN ALLERGY, V24, P469	38	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					302	311		10.1016/0091-6749(85)90646-3	http://dx.doi.org/10.1016/0091-6749(85)90646-3			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	2862173				2022-12-18	WOS:A1985APE8900010
J	UMETSU, DT; HAHN, JS; PEREZATAYDE, AR; GEHA, RS				UMETSU, DT; HAHN, JS; PEREZATAYDE, AR; GEHA, RS			SERUM SICKNESS TRIGGERED BY ANAPHYLAXIS - A COMPLICATION OF IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP MED CTR,DEPT MED,DIV ALLERGY,300 LONGWOOD AVE,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School								CANO PO, 1977, CLIN ALLERGY, V7, P167, DOI 10.1111/j.1365-2222.1977.tb01438.x; CLAUSEN RW, 1983, J ALLERGY CLIN IMMUN, V72, P199, DOI 10.1016/0091-6749(83)90530-4; Cochrane C G, 1973, Adv Immunol, V16, P185, DOI 10.1016/S0065-2776(08)60298-9; FAUCI AS, 1980, CLIN IMMUNOLOGY, P486; GEHA RS, 1983, J IMMUNOL, V130, P1634; KNIKER WT, 1971, PEDIATR RES, V5, P381, DOI 10.1203/00006450-197108000-00045; KOHLER PF, 1983, ALLERGY PRINCIPLES P, P167; LAWLEY TJ, 1984, NEW ENGL J MED, V311, P1407, DOI 10.1056/NEJM198411293112204; LEVINSON AI, 1978, J ALLERGY CLIN IMMUN, V62, P109, DOI 10.1016/0091-6749(78)90087-8; LIGHT WC, 1977, J ALLERGY CLIN IMMUN, V59, P391, DOI 10.1016/0091-6749(77)90024-0; PATTERSON R, 1983, ALLERGY PRINCIPLES P, P1119; PHANUPHAK P, 1980, AM J MED, V68, P479, DOI 10.1016/0002-9343(80)90285-5; ROCKLIN RE, 1983, J ALLERGY CLIN IMMUN, V72, P323, DOI 10.1016/0091-6749(83)90492-X; SHEEHAN RK, 1965, JAMA, V193, P149; STEIN MR, 1978, J ALLERGY CLIN IMMUN, V62, P211, DOI 10.1016/0091-6749(78)90209-9; WANG VA, 1984, CLIN RES, V32, pA471; YANG WH, 1979, J ALLERGY CLIN IMMUN, V63, P300, DOI 10.1016/0091-6749(79)90123-4	17	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	5					713	718		10.1016/0091-6749(85)90676-1	http://dx.doi.org/10.1016/0091-6749(85)90676-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AUU34	4056255	Bronze			2022-12-18	WOS:A1985AUU3400010
J	ATKINS, PC; BEDARD, PM; ZWEIMAN, B; DYER, J; KALINER, MA				ATKINS, PC; BEDARD, PM; ZWEIMAN, B; DYER, J; KALINER, MA			INCREASED ANTIGEN-INDUCED LOCAL AND SYSTEMIC MEDIATOR RELEASE IN RHINITIS SUBJECTS WITH PULMONARY SYMPTOMS IN THE POLLEN SEASON	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN, SCH MED, DEPT MED, ALLERGY & IMMUNOL SECT, PHILADELPHIA, PA 19104 USA; NIAID, CLIN INVEST LAB, ALLERGY & IMMUNOL SECT, BETHESDA, MD 20205 USA	University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)					NIAID NIH HHS [5 R0 AI 14332-05] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS PC, 1979, J ALLERGY CLIN IMMUN, V64, P251, DOI 10.1016/0091-6749(79)90140-4; ATKINS PC, 1982, J ALLERGY CLIN IMMUN, V69, P39, DOI 10.1016/0091-6749(82)90085-9; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; ATKINS PC, 1980, J ALLERGY CLIN IMMUN, V66, P478, DOI 10.1016/0091-6749(80)90009-3; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BEDARD PM, 1983, J ALLERGY CLIN IMMUN, V71, P394, DOI 10.1016/0091-6749(83)90068-4; BOUCHER RC, 1979, J ALLERGY CLIN IMMUN, V64, P197, DOI 10.1016/0091-6749(79)90095-2; BRUCE CA, 1975, J ALLERGY CLIN IMMUN, V56, P331, DOI 10.1016/0091-6749(75)90126-8; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; FISH JE, 1980, J ALLERGY CLIN IMMUN, V65, P154, DOI 10.1016/0091-6749(80)90201-8; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V66, P295, DOI 10.1016/0091-6749(80)90024-X; LEVY DA, 1973, J LAB CLIN MED, V81, P291; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; MCFADDEN ER, 1980, J ALLERGY CLIN IMMUN, V66, P472, DOI 10.1016/0091-6749(80)90008-1; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; ROSENTHAL RR, 1975, J ALLERGY CLIN IMMUN, V56, P338, DOI 10.1016/0091-6749(75)90127-X; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P417, DOI 10.1016/0091-6749(80)90122-0; TING S, 1981, J ALLERGY CLIN IMMUN, V68, P65, DOI 10.1016/0091-6749(81)90125-1; WEINER H, 1979, ANN ALLERGY, V43, P146	22	19	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	3					341	347		10.1016/0091-6749(84)90406-8	http://dx.doi.org/10.1016/0091-6749(84)90406-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SK155	6199397				2022-12-18	WOS:A1984SK15500007
J	FARNAM, J; GRANT, JA; GUERNSEY, BG; JORIZZO, JL; PETRUSA, ER				FARNAM, J; GRANT, JA; GUERNSEY, BG; JORIZZO, JL; PETRUSA, ER			SUCCESSFUL TREATMENT OF CHRONIC IDIOPATHIC URTICARIA AND ANGIOEDEMA WITH CIMETIDINE ALONE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,MED BRANCH,DEPT DERMATOL,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston	FARNAM, J (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV ADULT ALLERGY,SCI CLIN 409,GALVESTON,TX 77550, USA.				NIAID NIH HHS [AI-12621] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASH ASF, 1966, BRIT J PHARM CHEMOTH, V27, P427, DOI 10.1111/j.1476-5381.1966.tb01674.x; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BRIMBLECOMBE RW, 1975, J INT MED RES, V3, P86, DOI 10.1177/030006057500300205; CHAKRIN LW, 1974, AGENTS ACTIONS, V4, P297, DOI 10.1007/BF01964930; COMMENS CA, 1978, BRIT J DERMATOL, V99, P675, DOI 10.1111/j.1365-2133.1978.tb07062.x; COOK J, 1979, BRIT J DERMATOL, V101, P21; COUTTS AA, 1981, EUR J PHARMACOL, V76, P391, DOI 10.1016/0014-2999(81)90110-2; Douglas W. W., 1980, PHARMACOL BASIS THER, P609; DRAZEN JM, 1978, AM REV RESPIR DIS, V117, P479; GREAVES M, 1977, BRIT J DERMATOL, V97, P225, DOI 10.1111/j.1365-2133.1977.tb15071.x; HARVEY RP, 1980, J ALLERGY CLIN IMMUN, V65, P136, DOI 10.1016/0091-6749(80)90198-0; HARVEY RP, 1981, J ALLERGY CLIN IMMUN, V68, P262, DOI 10.1016/0091-6749(81)90149-4; HUTCHCROFT BJ, 1979, J ALLERGY CLIN IMMUN, V63, P376, DOI 10.1016/0091-6749(79)90209-4; JORIZZO JL, 1983, EUR J PHARMACOL, V87, P67, DOI 10.1016/0014-2999(83)90051-1; KAISER HB, 1980, LANCET, V2, P206; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; LEMANSKE RF, 1983, J ALLERGY CLIN IMMUN, V72, P94, DOI 10.1016/0091-6749(83)90058-1; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; LICHTENSTEIN LM, 1973, NATURE, V244, P287, DOI 10.1038/244287a0; MANSFIELD LE, 1983, ANN ALLERGY, V50, P264; MARKS R, 1977, BRIT J CLIN PHARMACO, V4, P367, DOI 10.1111/j.1365-2125.1977.tb00725.x; MATHEWS KP, 1983, J ALLERGY CLIN IMMUN, V72, P1, DOI 10.1016/0091-6749(83)90042-8; MONROE EW, 1981, ARCH DERMATOL, V117, P404, DOI 10.1001/archderm.117.7.404; NATHAN RA, 1981, J ALLERGY CLIN IMMUN, V67, P171, DOI 10.1016/0091-6749(81)90057-9; PHANUPHAK P, 1978, CLIN ALLERGY, V8, P429, DOI 10.1111/j.1365-2222.1978.tb01493.x; ROBERTS LJ, 1979, NEW ENGL J MED, V300, P236, DOI 10.1056/NEJM197902013000506; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; TUNG R, 1982, J IMMUNOL, V129, P2113	29	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	6					842	845		10.1016/0091-6749(84)90457-3	http://dx.doi.org/10.1016/0091-6749(84)90457-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SV829	6725793				2022-12-18	WOS:A1984SV82900013
J	GEORGITIS, JW; CLAYTON, WF; WYPYCH, JI; BARDE, SH; REISMAN, RE				GEORGITIS, JW; CLAYTON, WF; WYPYCH, JI; BARDE, SH; REISMAN, RE			FURTHER EVALUATION OF LOCAL INTRANASAL IMMUNOTHERAPY WITH AQUEOUS AND ALLERGOID GRASS EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO, BUFFALO GEN HOSP,DEPT MED,DIV ALLERGY & IMMUNOL, ALLERGY RES LAB, BUFFALO, NY 14260 USA	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIAID NIH HHS [5-R01-AI01303] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COOK N, 1974, Journal of Laryngology and Otology, V88, P1169, DOI 10.1017/S0022215100079901; DEUSCHL H, 1977, ACTA ALLERGOL, V32, P248, DOI 10.1111/j.1398-9995.1977.tb01357.x; GEORGITIS JW, 1983, J ALLERGY CLIN IMMUN, V71, P71, DOI 10.1016/0091-6749(83)90549-3; HADDAD ZH, 1972, J ALLERGY CLIN IMMUN, V49, P197, DOI 10.1016/0091-6749(72)90083-8; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; MATHEWS KP, 1981, INT ARCH ALLER A IMM, V66, P218, DOI 10.1159/000232821; MEHTA S B, 1975, Clinical Allergy, V5, P279; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P41, DOI 10.1016/0091-6749(81)90121-4; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P33, DOI 10.1016/0091-6749(81)90120-2; NICKELSEN JA, 1983, CLIN ALLERGY, V13, P509, DOI 10.1111/j.1365-2222.1983.tb02632.x; NORMAN PS, 1965, J ALLERGY, V36, P284, DOI 10.1016/0021-8707(65)90087-0; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P241, DOI 10.1007/BF00458318; SCHUMACHER MJ, 1982, ALLERGY, V37, P241, DOI 10.1111/j.1398-9995.1982.tb01906.x; Siegel S., 1956, NONPARAMETRIC STAT, P116; TAYLOR G, 1972, Clinical Allergy, V2, P125, DOI 10.1111/j.1365-2222.1972.tb01277.x; WELSH PW, 1981, J ALLERGY CLIN IMMUN, V67, P237, DOI 10.1016/0091-6749(81)90067-1; WELSH PW, 1983, J ALLERGY CLIN IMMUN, V71, P454, DOI 10.1016/0091-6749(83)90461-X	17	19	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	5					694	699		10.1016/0091-6749(84)90232-X	http://dx.doi.org/10.1016/0091-6749(84)90232-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TT169	6389648				2022-12-18	WOS:A1984TT16900007
J	LEARY, HL; HALSEY, JF				LEARY, HL; HALSEY, JF			AN ASSAY TO MEASURE ANTIGEN-SPECIFIC IMMUNE-COMPLEXES IN FOOD-ALLERGY PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV KANSAS,MED CTR,COLL HLTH SCI & HOSP,DEPT BIOCHEM,KANSAS CITY,KS 66103	University of Kansas; University of Kansas Medical Center					NICHD NIH HHS [HD 12416] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BROSTOFF J, 1979, MAST CELL, P380; BUCKLEY RH, 1982, JAMA-J AM MED ASSOC, V248, P2611, DOI 10.1001/jama.248.20.2611; CAMBIASO CL, 1975, IMMUNOCHEMISTRY, V12, P273, DOI 10.1016/0019-2791(75)90175-5; CHAPMAN MD, 1983, J ALLERGY CLIN IMMUN, V72, P27, DOI 10.1016/0091-6749(83)90048-9; CUNNINGHAMRUNDLES C, 1978, P NATL ACAD SCI USA, V75, P3387, DOI 10.1073/pnas.75.7.3387; DELIRE M, 1978, NATURE, V272, P632, DOI 10.1038/272632a0; DVORAK HF, 1976, J INVEST DERMATOL, V67, P391, DOI 10.1111/1523-1747.ep12514713; INGANAS M, 1980, CLIN ALLERGY, V10, P293, DOI 10.1111/j.1365-2222.1980.tb02110.x; JENSENIUS JC, 1983, J IMMUNOL METHODS, V56, P19, DOI 10.1016/0022-1759(83)90045-5; LEVINSKY RJ, 1981, IMMUNOLOGY INFANT FE, P23; MITCHELL EB, 1982, LANCET, V1, P127; PAGANELLI R, 1979, LANCET, V1, P1270; PAGANELLI R, 1981, CLIN EXP IMMUNOL, V46, P44; SONODA S, 1970, IMMUNOCHEMISTRY, V7, P885, DOI 10.1016/0019-2791(70)90051-0; TRON F, 1982, CLIN EXP IMMUNOL, V49, P481; Virella G, 1981, Methods Enzymol, V74 Pt C, P644; WALKER WA, 1974, GASTROENTEROLOGY, V67, P531	17	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	2					190	195		10.1016/0091-6749(84)90285-9	http://dx.doi.org/10.1016/0091-6749(84)90285-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE226	6205036				2022-12-18	WOS:A1984TE22600013
J	ZALOGA, GP; HIERLWIMMER, UR; ENGLER, RJ				ZALOGA, GP; HIERLWIMMER, UR; ENGLER, RJ			ANAPHYLAXIS FOLLOWING PSYLLIUM INGESTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA	ZALOGA, GP (corresponding author), USN HOSP,DEPT MED,ALLERGY BRANCH,BETHESDA,MD 20814, USA.							Bernton H S, 1970, Med Ann Dist Columbia, V39, ppassim; BUSSE WW, 1975, ANN INTERN MED, V83, P361, DOI 10.7326/0003-4819-83-3-361; MACHADO L, 1979, ALLERGY, V34, P51, DOI 10.1111/j.1398-9995.1979.tb02000.x; NORMAN PS, 1978, ALLERGY PRINCIPLES P, P256; ROSENBERG S, 1982, ANN ALLERGY, V48, P294	5	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	1					79	80		10.1016/0091-6749(84)90091-5	http://dx.doi.org/10.1016/0091-6749(84)90091-5			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SZ648	6736485				2022-12-18	WOS:A1984SZ64800012
J	AHMED, T; KRAINSON, JP; YERGER, LD				AHMED, T; KRAINSON, JP; YERGER, LD			FUNCTIONAL DEPRESSION OF H-2 HISTAMINE-RECEPTORS IN SHEEP WITH EXPERIMENTAL ALLERGIC-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											AHMED, T (corresponding author), MT SINAI MED CTR, DEPT MED, DIV PULM DIS, MIAMI BEACH, FL 33140 USA.				NHLBI NIH HHS [HL 27798] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM WM, 1981, AM REV RESPIR DIS, V124, P554; ABRAHAM WM, 1981, AM J IND MED, V1, P383; ADVENIER C, 1979, AGENTS ACTIONS, V9, P467, DOI 10.1007/BF01968112; AHMED T, 1980, J APPL PHYSIOL, V49, P826, DOI 10.1152/jappl.1980.49.5.826; ARUNLAKSHANA O, 1954, J PHYSIOL-LONDON, V123, P32, DOI 10.1113/jphysiol.1954.sp005032; ASH ASF, 1966, BRIT J PHARM CHEMOTH, V27, P427, DOI 10.1111/j.1476-5381.1966.tb01674.x; AUSTEN KF, 1975, AM REV RESPIR DIS, V112, P423; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BUSSE WW, 1977, J CLIN INVEST, V59, P1080, DOI 10.1172/JCI108731; CHENG HC, 1979, ARCH INT PHARMACOD T, V240, P214; COOK CD, 1957, J CLIN INVEST, V36, P440, DOI 10.1172/JCI103441; CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; DAUTREBANDE L, 1962, MICROAEROSOLS, P1; DELEHUNT J C, 1981, Physiologist, V24, P29; DRAZEN JM, 1978, AM REV RESPIR DIS, V117, P479; DULABH R, 1978, AGENTS ACTIONS, V8, P559, DOI 10.1007/BF01998882; EISER NM, 1979, THORAX, V34, P703; EYRE P, 1973, BRIT J PHARMACOL, V48, P321, DOI 10.1111/j.1476-5381.1973.tb06920.x; EYRE P, 1969, BRIT J PHARMACOL, V36, P409, DOI 10.1111/j.1476-5381.1969.tb07997.x; EYRE P, 1977, ASTHMA PHYSL IMMUNOP, P169; HARTMANN V, 1983, AGENTS ACTIONS, V13, P16, DOI 10.1007/BF01994276; HARVEY RP, 1980, J ALLERGY CLIN IMMUN, V65, P136, DOI 10.1016/0091-6749(80)90198-0; HAWKINS DF, 1955, BRIT J PHARM CHEMOTH, V10, P230, DOI 10.1111/j.1476-5381.1955.tb00088.x; HUTCHCROFT BJ, 1979, J ALLERGY CLIN IMMUN, V63, P376, DOI 10.1016/0091-6749(79)90209-4; KIRKPATRICK CH, 1967, AM REV RESPIR DIS, V96, P692; KLEINSTIVER PW, 1979, J PHARMACOL METHOD, V2, P175, DOI 10.1016/0160-5402(79)90041-X; KRELL RD, 1976, J ALLERGY CLIN IMMUN, V58, P664, DOI 10.1016/0091-6749(76)90178-0; KRELL RD, 1977, EUR J PHARMACOL, V44, P35, DOI 10.1016/0014-2999(77)90113-3; KUNG M, 1980, J APPL PHYSIOL, V49, P22, DOI 10.1152/jappl.1980.49.1.22; MACONOCHIE JG, 1979, BRIT J CLIN PHARMACO, V7, P231, DOI 10.1111/j.1365-2125.1979.tb00927.x; MARKS R, 1977, BRIT J CLIN PHARMACO, V4, P367, DOI 10.1111/j.1365-2125.1977.tb00725.x; MATHE AA, 1972, ADV BIOSCI, V9, P241; MENDENHALL W, 1977, STATISTICS PSYCHOL, P246; MERCER TT, 1968, AM IND HYG ASSOC J, V29, P66, DOI 10.1080/00028896809342983; MICHOUD MC, 1978, J APPL PHYSIOL, V45, P846, DOI 10.1152/jappl.1978.45.6.846; MILICEMILI J, 1964, J APPL PHYSIOL, V19, P207, DOI 10.1152/jappl.1964.19.2.207; NATHAN RA, 1981, J ALLERGY CLIN IMMUN, V67, P171, DOI 10.1016/0091-6749(81)90057-9; PARE P, 1980, AM REV RESPIR DIS, V121, P749; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PATTERSON R, 1976, J CLIN INVEST, V57, P586, DOI 10.1172/JCI108314; POPA V, 1973, J ALLERGY CLIN IMMUN, V51, P344, DOI 10.1016/0091-6749(73)90073-0; POPA VT, 1977, J ALLERGY CLIN IMMUN, V59, P54, DOI 10.1016/0091-6749(77)90177-4; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; WANNER A, 1978, J APPL PHYSIOL, V44, P479, DOI 10.1152/jappl.1978.44.3.479; WANNER A, 1979, J APPL PHYSIOL, V47, P917, DOI 10.1152/jappl.1979.47.5.917; YAMATAKE Y, 1972, JPN J PHARMACOL, V27, P791	49	19	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	3					310	320		10.1016/0091-6749(83)90037-4	http://dx.doi.org/10.1016/0091-6749(83)90037-4			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RH938	6136540				2022-12-18	WOS:A1983RH93800013
J	SOGN, DD; CASALE, TB; CONDEMI, JJ; EVANS, R; GREENBERGER, PA; KOHLER, PF; SAXON, A; SHEPHERD, GM; SUMMERS, RJ; VANARSDEL, PP; LEVINE, BB				SOGN, DD; CASALE, TB; CONDEMI, JJ; EVANS, R; GREENBERGER, PA; KOHLER, PF; SAXON, A; SHEPHERD, GM; SUMMERS, RJ; VANARSDEL, PP; LEVINE, BB			INTERIM RESULTS OF THE NIAID COLLABORATIVE CLINICAL-TRIAL OF SKIN TESTING WITH MAJOR AND MINOR PENICILLIN DERIVATIVES IN HOSPITALIZED ADULTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract													Casale, Thomas B/K-4334-2013; Greenberger, Paul/L-2770-2019	Casale, Thomas B/0000-0002-3149-7377; Greenberger, Paul/0000-0003-3882-8498					0	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	1					147	147		10.1016/0091-6749(83)90358-5	http://dx.doi.org/10.1016/0091-6749(83)90358-5			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PZ462					2022-12-18	WOS:A1983PZ46200235
J	OWNBY, DR; ANDERSON, JA				OWNBY, DR; ANDERSON, JA			AN IMPROVED PRICK SKIN-TEST PROCEDURE FOR YOUNG-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											OWNBY, DR (corresponding author), HENRY FORD HOSP,DIV ALLERGY & CLIN IMMUNOL,DETROIT,MI 48202, USA.							BOCK SA, 1978, CLIN ALLERGY, V8, P559, DOI 10.1111/j.1365-2222.1978.tb01509.x; CAVANAUGH MJ, 1977, J ALLERGY CLIN IMMUN, V59, P41, DOI 10.1016/0091-6749(77)90175-0; ERIKSSON NE, 1977, INT ARCH ALLER A IMM, V53, P341, DOI 10.1159/000231770; FOX DJ, 1976, DOCUMENTATION MIDAS; NORMAN PS, 1978, ALLERGY PRINCIPLES P, P259; SQUIRE JR, 1950, CLIN SCI, V9, P127; VANSLOW NA, 1967, MANUAL CLIN ALLERGY, P58	7	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	6					533	535		10.1016/0091-6749(82)90179-8	http://dx.doi.org/10.1016/0091-6749(82)90179-8			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT025	7076995				2022-12-18	WOS:A1982NT02500010
J	REID, MJ; KWASNICKI, JM; CHEUNG, NKV				REID, MJ; KWASNICKI, JM; CHEUNG, NKV			A QUANTITATIVE ENZYME-LINKED IMMUNOSORBENT-ASSAY FOR HONEYBEE VENOM SPECIFIC IMMUNOGLOBULIN-G	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP,STANFORD,CA	Children's Hospital Los Angeles	REID, MJ (corresponding author), USAF,DAVID GRANT MED CTR,SGHMI,ALLERGY CLIN,TRAVIS AFB,CA 94535, USA.							BRUNDA MJ, 1978, FED P, V37, P1853; CHEUNG NKV, 1981, ANN ALLERGY, V46, P132; CHEUNG NV, UNPUB REDUCTION INTE; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; FORSTER J, 1979, KLIN WOCHENSCHR, V57, P421, DOI 10.1007/BF01480482; GLEICH GJ, 1981, J IMMUNOL, V126, P575; GODING JW, 1978, J IMMUNOL METHODS, V20, P241, DOI 10.1016/0022-1759(78)90259-4; GRANT JA, 1981, J ALLERGY CLIN IMMUN, V68, P112, DOI 10.1016/0091-6749(81)90168-8; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; JOHANSSON SGO, 1978, IMMUNOL REV, V41, P248, DOI 10.1111/j.1600-065X.1978.tb01467.x; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LOVELESS MH, 1940, J IMMUNOL, V38, P1925; MCDOWELL G, 1971, ACTA PATH MICRO IM A, VB 79, P801; REID MJ, 1981, J ALLERGY CLIN IMMUN, V67, P263, DOI 10.1016/0091-6749(81)90020-8; SAXTON EH, 1978, FED P, V37, P1853; SHIMIZU M, 1978, J IMMUNOL METHODS, V19, P317, DOI 10.1016/0022-1759(78)90016-9; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; TYSON CJ, 1981, ANN ALLERGY, V47, P43	21	19	19	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	3					191	198		10.1016/0091-6749(82)90041-0	http://dx.doi.org/10.1016/0091-6749(82)90041-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG384	6179974				2022-12-18	WOS:A1982PG38400006
J	BROWN, LA; KAPLAN, RA; BENJAMIN, PA; HOFFMAN, LS; SHEARER, WT				BROWN, LA; KAPLAN, RA; BENJAMIN, PA; HOFFMAN, LS; SHEARER, WT			IMMUNOGLOBULIN E-MEDIATED ANAPHYLAXIS WITH INHALED CROMOLYN SODIUM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BAYLOR COLL MED,DEPT PEDIAT,ALLERGY & IMMUNOL SECT,HOUSTON,TX 77030; TEXAS CHILDRENS HOSP,ALLERGY & IMMUNOL SERV,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MICROBIOL & MOLEC GENET,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine				Shearer, William/0000-0002-2483-2130				BERNSTEIN IL, 1978, ANN INTERN MED, V89, P228, DOI 10.7326/0003-4819-89-2-228; BURGHER LW, 1974, CHEST, V66, P83; Cox J S, 1970, Adv Drug Res, V5, P115; DOUGLAS WW, 1980, PHARMACOL BASIS THER, P590; FARR RS, 1958, J INFECT DIS, V103, P239, DOI 10.1093/infdis/103.3.239; FOGLEHANSSON M, 1979, ACTA OTOLARYNGOL S, V360, P33; HANDELMAN NI, 1977, J ALLERGY CLIN IMMUN, V59, P237, DOI 10.1016/0091-6749(77)90156-7; HELMER RE, 1980, AM J MED, V69, P953, DOI 10.1016/S0002-9343(80)80026-X; KINGSLEY PJ, 1978, ALLERGY PRINCIPLES P, P481; KOCOSHIS S, 1979, JAMA-J AM MED ASSOC, V242, P1169; Kus J, 1978, Pneumonol Pol, V46, P745; LOBEL H, 1972, LANCET, V2, P1032; MCLEAN WL, 1973, AM J DIS CHILD, V125, P332, DOI 10.1001/archpedi.1973.04160030014003; MENON MPS, 1977, SCAND J RESPIR DIS, V58, P145; RIBON A, 1980, ANN ALLERGY, V44, P220; ROSENBERG JL, 1978, ARCH INTERN MED, V138, P989, DOI 10.1001/archinte.138.6.989; SETTIPANE GA, 1979, JAMA-J AM MED ASSOC, V241, P811, DOI 10.1001/jama.241.8.811; SHEFFER AL, 1975, NEW ENGL J MED, V293, P1220, DOI 10.1056/NEJM197512112932402; SLATER EE, 1978, CHEST, V73, P878, DOI 10.1378/chest.73.6.878	19	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	6					416	420		10.1016/0091-6749(81)90194-9	http://dx.doi.org/10.1016/0091-6749(81)90194-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MU790	6796617				2022-12-18	WOS:A1981MU79000002
J	CASE, RL; ALTMAN, LC; VANARSDEL, PP				CASE, RL; ALTMAN, LC; VANARSDEL, PP			ROLE OF CELL-MEDIATED-IMMUNITY IN HYMENOPTERA ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,DEPT MED,DIV ALLERGY & INFECT DIS,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIAID NIH HHS [AI 07763] Funding Source: Medline; NIDCR NIH HHS [DE 02600] Funding Source: Medline; NIGMS NIH HHS [GM 24990] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI007763, R37AI007763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE002600] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; GREEN AW, 1980, J ALLERGY CLIN IMMUN, V66, P186, DOI 10.1016/0091-6749(80)90037-8; HOFFMAN DR, 1978, ANN ALLERGY, V41, P278; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Lichtenstein L. M., 1975, Hospital Practice, V10, P67; OPPENHEIM JJ, 1980, MANUAL CLIN IMMUNOLO, P233; REISMAN RF, 1975, J ALLERGY CLIN IMMUN, V56, P433; ROCKLIN RE, 1976, J CLIN INVEST, V57, P1051, DOI 10.1172/JCI108347; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X	11	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	5					399	405		10.1016/0091-6749(81)90139-1	http://dx.doi.org/10.1016/0091-6749(81)90139-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MQ454	7028843				2022-12-18	WOS:A1981MQ45400009
J	CLAYTON, DE; KOOISTRA, JB; GELLER, M; OUELLETTE, J; COHEN, M; REED, CE; BUSSE, W				CLAYTON, DE; KOOISTRA, JB; GELLER, M; OUELLETTE, J; COHEN, M; REED, CE; BUSSE, W			SHORT-TERM EFFICACY TRIAL AND 24-MONTH FOLLOW-UP OF FLUNISOLIDE NASAL SPRAY IN THE TREATMENT OF PERENNIAL RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,CTR CLIN SCI,DEPT INTERNAL MED,ALLERGY IMMUNOL SECT,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison					NIAID NIH HHS [AI 00343-01] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AARON TH, 1965, ANN ALLERGY, V23, P100; CZARNY D, 1968, LANCET, V2, P188; GODFREY MP, 1957, LANCET, V1, P757; HORAN JD, 1978, CAN MED ASSOC J, V119, P334; INCAUDO G, 1980, J ALLERGY CLIN IMMUN, V65, P41, DOI 10.1016/0091-6749(80)90175-X; JONES LM, 1979, ANN ALLERGY, V42, P139; KAMMERMEYER JK, 1977, J ALLERGY CLIN IMMUN, V59, P287, DOI 10.1016/0091-6749(77)90049-5; MURPHY BP, 1963, J CLIN ENDOCR METAB, V23, P293, DOI 10.1210/jcem-23-3-293; MYGIND N, 1973, BRIT MED J, V4, P464, DOI 10.1136/bmj.4.5890.464; NORMAN PS, 1967, J ALLERGY, V40, P57, DOI 10.1016/0021-8707(67)90060-3; NORMAN PS, 1966, J ALLERGY, V38, P93, DOI 10.1016/0021-8707(66)90048-7; SCARSFIELD JK, 1979, BRIT MED J, V2, P95; SCHULZ JI, 1978, CLIN ALLERGY, V8, P313, DOI 10.1111/j.1365-2222.1978.tb00466.x; TURKELTAUB PC, 1976, J ALLERGY CLIN IMMUN, V58, P597, DOI 10.1016/0091-6749(76)90206-2	14	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	1					2	7		10.1016/0091-6749(81)90037-3	http://dx.doi.org/10.1016/0091-6749(81)90037-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KZ173	7005293				2022-12-18	WOS:A1981KZ17300002
J	SCHWARTZ, RH; HOLLICK, GE				SCHWARTZ, RH; HOLLICK, GE			ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS WITH LOW SERUM IMMUNOGLOBULIN-E	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT,DIV ALLERGY & CLIN IMMUNOL,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT,DIV MICROBIOL,ROCHESTER,NY 14642	University of Rochester; University of Rochester	SCHWARTZ, RH (corresponding author), STRONG MEM HOSP,ROCHESTER,NY 14642, USA.							ASSEM ESK, 1976, CLIN EXP IMMUNOL, V26, P67; BATTEN JC, 1975, MOD PROBL PEDIATR, V10, P227; BRUETON MJ, 1980, ARCH DIS CHILD, V55, P348, DOI 10.1136/adc.55.5.348; CHUSID MJ, 1975, ANN INTERN MED, V82, P682, DOI 10.7326/0003-4819-82-5-682; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; KAGEN SL, 1981, 37TH P ANN M AM AC A, P63; LAHAM MN, 1981, ANN ALLERGY, V46, P74; LEWISTON NJ, 1973, ALLERGIC BRONCHOPULM, P47; LLAMAS R, 1978, CHEST, V73, P871, DOI 10.1378/chest.73.6.871; MEARNS M, 1965, THORAX, V20, P385, DOI 10.1136/thx.20.5.385; MEARNS M, 1967, LANCET, V1, P538; MITCHELLHEGGS P, 1976, Q J MED, V45, P479; NELSON LA, 1979, AM REV RESPIR DIS, V120, P863; ORES CN, 1975, ALLERGIC BRONCHOPULM, P20; PARISH WE, 1970, LANCET, V2, P591; PATTERSON R, 1973, AM J MED, V54, P16, DOI 10.1016/0002-9343(73)90078-8; Pepys J, 1973, Clin Allergy, V3, P1, DOI 10.1111/j.1365-2222.1973.tb01304.x; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; ROSENBERG M, 1977, J PEDIATR-US, V91, P914, DOI 10.1016/S0022-3476(77)80889-5; ROSENBERG M, 1978, AM J MED, V64, P599, DOI 10.1016/0002-9343(78)90579-X; SCHWARTZ RH, 1970, AM J DIS CHILD, V120, P432, DOI 10.1001/archpedi.1970.02100100096009; SLAVIN RG, 1978, ALLERGY PRINCIPLES P, P843; STAIB F, 1980, DEUT MED WOCHENSCHR, V105, P442, DOI 10.1055/s-2008-1070684; VERVLOET D, 1974, Clinical Allergy, V4, P359, DOI 10.1111/j.1365-2222.1974.tb01397.x; WANG JLF, 1979, AM REV RESPIR DIS, V120, P87; ZIMMERMANN EM, 1980, J ALLERGY CLIN IMMUN, V66, P386, DOI 10.1016/0091-6749(80)90118-9	26	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	4					290	294		10.1016/0091-6749(81)90154-8	http://dx.doi.org/10.1016/0091-6749(81)90154-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML525	7026647				2022-12-18	WOS:A1981ML52500008
J	ABRAMOWITZ, PW; PEREZ, MM; JOHNSON, CE; MCLEAN, JA				ABRAMOWITZ, PW; PEREZ, MM; JOHNSON, CE; MCLEAN, JA			EFFECT OF THEOPHYLLINE, TERBUTALINE, AND THEIR COMBINATION ON THE IMMEDIATE HYPERSENSITIVITY SKIN-TEST REACTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN HOSP,COLL PHARM,DEPT PHARM & INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan								BECKER EL, 1948, J ALLERGY, V19, P317, DOI 10.1016/0021-8707(48)90112-9; BOURNE HR, 1972, J IMMUNOL, V108, P695; CHIPPS BE, 1978, J ALLERGY CLIN IMMUN, V61, P171, DOI 10.1016/0091-6749(78)90382-2; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; FOX DJ, 1976, DOCUMENTATION MIDAS; GALANT S, 1972, ANN ALLERGY, V30, P53; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P193, DOI 10.1016/0091-6749(78)90207-5; IMBER WE, 1977, J ALLERGY CLIN IMMUN, V60, P47, DOI 10.1016/0091-6749(77)90082-3; JOHNSON CE, 1978, AM J HOSP PHARM, V35, P1045, DOI 10.1093/ajhp/35.9.1045; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; MARKS R, 1977, BRIT J CLIN PHARMACO, V4, P367, DOI 10.1111/j.1365-2125.1977.tb00725.x; MURAD F, 1962, J BIOL CHEM, V237, P1233; MUSKO MM, 1950, J ALLERGY, V21, P242; ORANGE RP, 1971, J EXP MED, V134, pS136; PATON WDM, 1957, PHARMACOL REV, V9, P269; PHILLIPS GL, 1967, MANUAL CLIN ALLERGY, P507; REINBERG A, 1965, J ALLERGY, V36, P273, DOI 10.1016/0021-8707(65)90086-9; SLOTT RI, 1974, J ALLERGY CLIN IMMUN, V54, P229, DOI 10.1016/0091-6749(74)90065-7; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P23, DOI 10.1016/0091-6749(79)90078-2; TRIPP SL, 1978, ANAL LETT, V11, P727; TUFT L, 1936, J ALLERGY, V7, P238; VOORHORST R, 1973, ANN ALLERGY, V31, P137; VOORHORST R, 1973, ANN ALLERGY, V31, P195; WEINBERGER M, 1975, CLIN CHEM, V21, P834; WOLFE JD, 1978, NEW ENGL J MED, V298, P363, DOI 10.1056/NEJM197802162980703	26	19	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	2					123	128		10.1016/0091-6749(80)90059-7	http://dx.doi.org/10.1016/0091-6749(80)90059-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD119	7400476				2022-12-18	WOS:A1980KD11900006
J	FARR, RS; SPECTOR, SL; WANGAARD, CH				FARR, RS; SPECTOR, SL; WANGAARD, CH			EVALUATION OF ASPIRIN AND TARTRAZINE IDIOSYNCRASY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,MED CTR,DENVER,CO 80202	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	FARR, RS (corresponding author), NATL JEWISH HOSP & RES CTR,DENVER,CO 80206, USA.								0	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					667	668		10.1016/0091-6749(79)90035-6	http://dx.doi.org/10.1016/0091-6749(79)90035-6			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX843	512262				2022-12-18	WOS:A1979HX84300023
J	HOFFMAN, DR; KOZAK, PP				HOFFMAN, DR; KOZAK, PP			SHARED AND SPECIFIC ALLERGENS IN MOLD EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	19	20	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	3					213	213						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GN274					2022-12-18	WOS:A1979GN27400270
J	OWNBY, DR; BUCKLEY, RH				OWNBY, DR; BUCKLEY, RH			LYMPHOCYTE-RESPONSES TO RAGWEED ANTIGENS FROM DIFFERENT SOURCES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									DUKE UNIV,SCH MED,DEPT PEDIAT,DURHAM,NC 27710; DUKE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Duke University; Duke University			Buckley, Rebecca/AAB-1578-2019					BUCKLEY RH, 1977, J ALLERGY CLIN IMMUN, V59, P70, DOI 10.1016/0091-6749(77)90180-4; GATIEN JG, 1975, CLIN IMMUNOL IMMUNOP, V4, P32, DOI 10.1016/0090-1229(75)90036-7; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; MATHEWS KP, 1977, CELL IMMUNOL, V32, P120, DOI 10.1016/0008-8749(77)90187-3; ROCKLIN RE, 1974, J CLIN INVEST, V53, P735, DOI 10.1172/JCI107612	5	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	1					65	66		10.1016/0091-6749(79)90164-7	http://dx.doi.org/10.1016/0091-6749(79)90164-7			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GE110	758341				2022-12-18	WOS:A1979GE11000010
J	PATTERSON, R				PATTERSON, R			CLINICAL EFFICACY OF ALLERGEN IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PATTERSON, R (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,CHICAGO,IL 60611, USA.							AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; JOHNSTONE D, 1961, PEDIATRICS, V27, P39; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; Lieberman P, 1974, Adv Intern Med, V19, P391; LOCKEY RF, 1976, BRONCHIAL ASTHMA MEC, P613; PATTERSON R, 1978, J CLIN INVEST, V62, P519, DOI 10.1172/JCI109155; PATTERSON R, 1978, ALLERGY PRINCIPLES P, P877; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; SHERMAN WILLIAM B., 1940, JOUR ALLERGY, V11, P225, DOI 10.1016/S0021-8707(40)90568-8; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; VANSELOW N A, 1968, University of Michigan Medical Center Journal, V34, P137	12	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	3					155	158		10.1016/0091-6749(79)90089-7	http://dx.doi.org/10.1016/0091-6749(79)90089-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HL221	469116				2022-12-18	WOS:A1979HL22100001
J	HUNT, KJ; SOBOTKA, AK; VALENTINE, MD; YUNGINGER, JW; LICHTENSTEIN, LM				HUNT, KJ; SOBOTKA, AK; VALENTINE, MD; YUNGINGER, JW; LICHTENSTEIN, LM			SENSITIZATION FOLLOWING HYMENOPTERA WHOLE-BODY EXTRACT THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239; MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901	Johns Hopkins University; Mayo Clinic								ADKINSON NF, 1976, MANUAL CLINICAL IMMU; BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; HUNT K, UNPUBLISHED; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; LEVINE BB, 1966, NEW ENGL J MED, V275, P1115, DOI 10.1056/NEJM196611172752009; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P159; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; PARRISH HM, 1963, AM J MED SCI, V245, P129; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; SCHWARTZ HJ, 1965, J AMER MED ASSOC, V194, P703, DOI 10.1001/jama.194.7.703; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; 1962, NY STATE J MED, V62, P3560	18	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	1					48	53		10.1016/0091-6749(78)90473-6	http://dx.doi.org/10.1016/0091-6749(78)90473-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH112	637904				2022-12-18	WOS:A1978EH11200008
J	PATRONO, C; CIABATTONI, G; VENUTI, A; PUGLIESE, F; SCHIAVINO, D; PATRIARCA, G				PATRONO, C; CIABATTONI, G; VENUTI, A; PUGLIESE, F; SCHIAVINO, D; PATRIARCA, G			ASPIRIN INTOLERANCE - UNALTERED SUSCEPTIBILITY OF PLATELET CYCLO-OXYGENASE TO INHIBITION BY ASPIRIN INVITRO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CATHOLIC UNIV,DEPT MED,I-00168 ROME,ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	PATRONO, C (corresponding author), CATHOLIC UNIV,DEPT PHARMACOL,I-00168 ROME,ITALY.			Patrono, Carlo/0000-0002-6447-2424				BIZZI B, 1976, FOLIA ALLERGOL IMMUN, V23, P444; FISHERMAN EW, 1974, ANN ALLERGY, V33, P86; FLOWER RJ, 1974, PHARMACOL RES COMMUN, V26, P33; GRYGLEWSKI RJ, 1977, PROSTAGLANDINS THROM, P191; HORODNIAK JW, 1974, BIOCHEM BIOPH RES CO, V57, P539, DOI 10.1016/0006-291X(74)90966-8; MARCUS AJ, 1969, J LIPID RES, V10, P108; PATRIARCA G, 1976, Z IMMUNITATSFORSCH, V151, P295, DOI 10.1016/S0300-872X(76)80024-8; PATRONO C, 1975, PROSTAGLANDINS, V9, P557, DOI 10.1016/0090-6980(75)90061-1; PATRONO C, 1973, J NUCL BIOL MED, V17, P25; PATRONO C, 1976, ADV PROSTAG THROMB R, V1, P125; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SAMUELSSON B, 1976, ADV PROSTAG THROMB R, V2, P737; SCHLUMBERGER HD, 1974, ACTA MED SCAND, V196, P451; SCHWARTZ HJ, 1973, INT ARCH ALLER A IMM, V45, P899, DOI 10.1159/000231088; SETTIPANE GA, 1974, J ALLERGY CLIN IMMUN, V53, P200, DOI 10.1016/0091-6749(74)90081-5; SNIDER DE, 1976, CLIN RES, V24, pA450; STONE KJ, 1975, PROSTAGLANDINS, V10, P241, DOI 10.1016/0090-6980(75)90043-X; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; SZCZEKLIK A, 1975, 11 C POL SOC HEM, P64; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; YURCHAK AM, 1970, J ALLERGY, V46, P245, DOI 10.1016/0021-8707(70)90028-6	21	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	5					271	275		10.1016/0091-6749(78)90157-4	http://dx.doi.org/10.1016/0091-6749(78)90157-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FW432	100540				2022-12-18	WOS:A1978FW43200003
J	ZEISS, CR; LEVITZ, D; SUSZKO, IM				ZEISS, CR; LEVITZ, D; SUSZKO, IM			QUANTITATION OF IGE ANTIBODY SPECIFIC FOR RAGWEED AND GRASS ALLERGENS - BINDING OF RADIOLABELED ALLERGENS BY SOLID-PHASE BOUND IGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University								BOOTH BH, 1972, ALLERGIC DISEASES DI, P63; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; IRONS JS, 1977, J ALLERGY CLIN IMMUN, V59, P190, DOI 10.1016/0091-6749(77)90149-X; KING TP, 1976, ADV IMMUNOL, V23, P77, DOI 10.1016/S0065-2776(08)60319-3; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; METZGER WJ, 1976, NEW ENGL J MED, V295, P1160, DOI 10.1056/NEJM197611182952103; PATTERSON R, 1977, J ALLERGY CLIN IMMUN, V59, P314, DOI 10.1016/0091-6749(77)90053-7; PATTERSON R, 1973, J IMMUNOL, V110, P1402; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; ZEISS CR, 1973, J IMMUNOL, V110, P414	11	19	19	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	2					83	90		10.1016/0091-6749(78)90083-0	http://dx.doi.org/10.1016/0091-6749(78)90083-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL835	670609				2022-12-18	WOS:A1978FL83500003
J	DUNSKY, EH; ATKINS, PC; ZWEIMAN, B				DUNSKY, EH; ATKINS, PC; ZWEIMAN, B			HISTOLOGIC RESPONSES IN HUMAN-SKIN TEST REACTIONS TO RAGWEED .4. EFFECTS OF A SINGLE INTRAVENOUS-INJECTION OF STEROIDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,PHILADELPHIA,PA 19174; VET ADM HOSP,PHILADELPHIA,PA 19104	University of Pennsylvania								ANDERSEN V, 1969, CELL TISSUE KINET, V2, P139, DOI 10.1111/j.1365-2184.1969.tb01000.x; ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BRORASMUSSEN F, 1973, ACTA PATH MICRO IM A, VA 81, P593; BROSEILA AWA, 1963, ANN NY ACAD SCI, V103, P394; CARVER HA, 1968, BLOOD, V27, P739; CODE CF, 1954, P STAFF M MAYO CLIN, V29, P200; DALE DC, 1976, J LAB CLIN MED, V87, P487; EDINGER D, 1964, J ALLERGY, V35, P77; ESELLIER AF, 1954, BLOOD, V9, P531; FELARCA AB, 1971, J ALLERGY CLIN IMMUN, V48, P125, DOI 10.1016/0091-6749(71)90007-8; FELARCA AB, 1969, J ALLERGY, V43, P114, DOI 10.1016/0021-8707(69)90131-2; FOWLER JW, 1966, J ALLERGY, V37, P19, DOI 10.1016/0021-8707(66)90106-7; GREAVES MW, 1974, IMMUNOLOGY, V27, P359; HUDSON G, 1968, Seminars in Hematology, V5, P166; KAY AB, 1970, CLIN EXP IMMUNOL, V6, P75; LEVY DA, 1967, J IMMUNOL, V99, P1068; LEVY DA, 1973, J LAB CLIN MED, V81, P291; LEWIS RA, 1975, J IMMUNOL, V114, P87; LITT M, 1963, AM J PATHOL, V42, P529; OTTOLENGHI A, 1974, J PHARMACOL EXP THER, V189, P303; SCHMUTZLER W, 1975, INT ARCH ALLER A IMM, V49, P209, DOI 10.1159/000231396; SLOTT RI, 1975, J ALLERGY CLIN IMMUN, V55, P232, DOI 10.1016/0091-6749(75)90142-6; SLOTT RI, 1974, J ALLERGY CLIN IMMUN, V54, P229, DOI 10.1016/0091-6749(74)90065-7; SPRY CJF, 1971, CELL TISSUE KINET, V4, P365, DOI 10.1111/j.1365-2184.1971.tb01546.x; WASSERMAN SI, 1974, J IMMUNOL, V112, P351; WASSERMAN SI, 1974, IMMUNOLOGY, V26, P677; ZWEIMAN B, 1975, CLIN RES, V23, pA232; ZWEIMAN B, IN PRESS	29	19	19	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	2					142	146		10.1016/0091-6749(77)90216-0	http://dx.doi.org/10.1016/0091-6749(77)90216-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CV622	319141				2022-12-18	WOS:A1977CV62200008
J	KANG, KY; BICE, D; HOFFMANN, E; DAMATO, R; SALVAGGIO, J				KANG, KY; BICE, D; HOFFMANN, E; DAMATO, R; SALVAGGIO, J			EXPERIMENTAL STUDIES OF SENSITIZATION TO BERYLLIUM, ZIRCONIUM, AND ALUMINUM COMPOUNDS IN RABBIT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,MED CTR,DEPT MED,CLIN IMMUNOL SECT,NEW ORLEANS,LA 70112	Tulane University								Alekseeva O G, 1966, Fed Proc Transl Suppl, V25, P843; BOROS D L, 1973, Journal of Immunology, V110, P1118; BOROS DL, 1973, NATURE, V246, P224, DOI 10.1038/246224a0; BROWN J R, 1963, Am Ind Hyg Assoc J, V24, P131, DOI 10.1080/00028896309342940; CHIAPPINO G, 1969, ARCH PATHOL, V87, P131; CURTIS GH, 1951, AMA ARCH DERM SYPH, V64, P470, DOI 10.1001/archderm.1951.01570100087014; DAVID JR, 1964, J IMMUNOL, V93, P274; DAVID JR, 1971, IN VITRO METHODS CEL, P249; DREW RT, 1974, ARCH ENVIRON HEALTH, V28, P321, DOI 10.1080/00039896.1974.10666500; EPSTEIN WL, 1962, J INVEST DERMATOL, V38, P223, DOI 10.1038/jid.1962.40; EPSTEIN WL, 1967, PROG ALLERGY, V11, P36, DOI 10.1159/000287243; GALINDO B, 1970, J IMMUNOL, V105, P227; HANIFIN JM, 1970, J INVEST DERMATOL, V55, P284, DOI 10.1111/1523-1747.ep12260036; HENDERSON WR, 1972, J INVEST DERMATOL, V58, P5, DOI 10.1111/1523-1747.ep13077177; JONES JM, 1975, INT ARCH ALLER A IMM, V48, P22, DOI 10.1159/000231290; MARX JJ, 1973, J IMMUNOL, V111, P590; MEALEY J, 1957, NATURE, V179, P673, DOI 10.1038/179673a0; MYRVIK QN, 1961, J IMMUNOL, V86, P128; PRIOR JT, 1960, ARCH ENVIRON HEALTH, V1, P297, DOI 10.1080/00039896.1960.10662700; REED C E, 1956, AMA Arch Ind Health, V13, P578; REEVES AL, 1972, INT ARCH ARBEITSMED, V29, P209, DOI 10.1007/BF00539249; REINER E, 1971, MECHANISMS TOXICITY, P111; RUBIN L, 1956, JAMA-J AM MED ASSOC, V162, P953, DOI 10.1001/jama.1956.02970270013005; SALVAGGIO JE, 1965, J IMMUNOL, V95, P840; SHELLEY WB, 1958, BRIT J DERMATOL, V70, P75, DOI 10.1111/j.1365-2133.1958.tb13297.x; SHELLEY WB, 1971, J INVEST DERMATOL, V57, P411, DOI 10.1111/1523-1747.ep12293277; SPECTOR WG, 1969, J PATHOL, V98, P31, DOI 10.1002/path.1710980105; UNANUE ER, 1973, AM J PATHOL, V71, P349; VONDERDECKEN A, 1967, TECHNIQUES PROTEIN B, P65; WARREN KS, 1974, MONONUCLEAR PHAGOCYT; WHEATER RH, 1975, J AM MED ASS, V231, P1289	31	19	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	6					425	436		10.1016/0091-6749(77)90005-7	http://dx.doi.org/10.1016/0091-6749(77)90005-7			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DJ990	864101				2022-12-18	WOS:A1977DJ99000004
J	TINKELMAN, DG; AVNER, SE; COOPER, DM				TINKELMAN, DG; AVNER, SE; COOPER, DM			ASSESSING BRONCHODILATOR RESPONSIVENESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR,DENVER,CO 80206	National Jewish Health								ANDERSON SD, 1975, BRIT J DIS CHEST, V69, P1; CHAI H, 1968, J ALLERGY, V4, P1; COTTON T, 1974, STATISTICS MEDICINE; FEATHERBY EA, 1969, ARCH DIS CHILD, V44, P382, DOI 10.1136/adc.44.235.382; HUME K. M., 1957, THORAX, V12, P276, DOI 10.1136/thx.12.3.276; KEMM J R, 1970, Clinical Science (London), V39, P747; KIVILOOG J, 1975, SCAND J RESPIR DIS, V56, P129; Polgar G, 1971, PULMONARY FUNCTION T; REBUCK AS, 1971, AM J MED, V51, P778; SHENFIELD GM, 1975, BRIT J DIS CHEST, V69, P273; 1962, AM REV RESPIR DIS, V85, P762; 1959, THORAX, V44, P286	12	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	2					109	114		10.1016/0091-6749(77)90211-1	http://dx.doi.org/10.1016/0091-6749(77)90211-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CV622	319139				2022-12-18	WOS:A1977CV62200003
J	SCHACHTER, J; HIGGINS, MW				SCHACHTER, J; HIGGINS, MW			MEDIAN AGE AT ONSET OF ASTHMA AND ALLERGIC RHINITIS IN TECUMSEH, MICHIGAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI; NIAID,BETHESDA,MD 20014	University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; BRODER I, 1962, J ALLERGY, V33, P524, DOI 10.1016/0021-8707(62)90020-5; BRODER I, 1974, J ALLERGY CLIN IMMUN, V53, P127, DOI 10.1016/0091-6749(74)90001-3; BRODER I, 1962, J ALLERGY, V33, P513, DOI 10.1016/0021-8707(62)90019-9; Siegel S., 1956, NONPARAMETRIC STAT B; SPIEGELMAN M, 1957, AM J PUBLIC HEALTH N, V47, P297, DOI 10.2105/AJPH.47.3.297; 1964, MORTALITY, V2	7	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	4					342	351		10.1016/0091-6749(76)90091-9	http://dx.doi.org/10.1016/0091-6749(76)90091-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	BM689	1262609				2022-12-18	WOS:A1976BM68900008
J	WEINER, E; DICAMELLI, R; SHOWEL, J; OSMAND, AP; SASSETTI, RJ; GEWURZ, H				WEINER, E; DICAMELLI, R; SHOWEL, J; OSMAND, AP; SASSETTI, RJ; GEWURZ, H			IGE MYELOMA PRESENTING WITH CLASSICAL MYELOMA FEATURES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									RUSH MED COLL, DEPT IMMUNOL, CHICAGO, IL 60612 USA; RUSH MED COLL, DEPT MED, HEMATOL SECT, CHICAGO, IL 60612 USA	Rush University; Rush University			Gewurz, Henry/P-8678-2019					Bennich H, 1971, Adv Immunol, V13, P1; COSTA G, 1973, AM J MED, V54, P589, DOI 10.1016/0002-9343(73)90116-2; FISHKIN BG, 1972, BLOOD-J HEMATOL, V39, P361, DOI 10.1182/blood.V39.3.361.361; ISHIZAKA K, COMMUNICATION; JOHANSSON SG, 1967, IMMUNOLOGY, V13, P381; KYLE RA, 1975, MAYO CLIN PROC, V50, P29; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; NILSSON K, 1970, CLIN EXP IMMUNOL, V7, P477; OGAWA M, 1969, NEW ENGL J MED, V281, P1217, DOI 10.1056/NEJM196911272812204; OUCHTERLONY O, 1962, PROG ALLERGY, V6, P30, DOI 10.1159/000313795; PRUZANSKI W, 1969, AM J MED, V47, P60, DOI 10.1016/0002-9343(69)90241-1; SALMON SE, 1971, BLOOD-J HEMATOL, V37, P696, DOI 10.1182/blood.V37.6.696.696; SCHEIDEGGER JJ, 1955, INT ARCH ALLER A IMM, V7, P103, DOI 10.1159/000228215; STEFANI DV, 1972, PROBL HAEMATOL USSR, V12, P44; TAKATSU K, 1975, J IMMUNOL, V114, P1838	15	19	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	3					373	380		10.1016/0091-6749(76)90117-2	http://dx.doi.org/10.1016/0091-6749(76)90117-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD454	823190				2022-12-18	WOS:A1976CD45400003
J	ELLIS, EF; EDDY, ED				ELLIS, EF; EDDY, ED			ANHYDROUS THEOPHYLLINE EQUIVALENCE OF COMMERCIAL THEOPHYLLINE FORMULATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									NATL JEWISH HOSP,PEDIAT ALLERGY DEPT,DENVER,CO 80206; CHILDRENS HOSP,DEPT PHARM SERV,BUFFALO,NY 14222	National Jewish Health; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								BOSSO JA, IN PRESS; RITCHIE JM, 1970, PHARMACOLOGICAL BASI	2	19	19	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	2					116	118		10.1016/0091-6749(74)90073-6	http://dx.doi.org/10.1016/0091-6749(74)90073-6			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S0380	4810107				2022-12-18	WOS:A1974S038000126
J	GRIECO, MH; CHUANG, CY				GRIECO, MH; CHUANG, CY			HYPERMACROGLOBULINEMIA ASSOCIATED WITH HEROIN USE IN ADOLESCENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST LUKES HOSP CTR,DEPT MED,IMMUNOL STUDY UNIT,NEW YORK,NY 10025; ST LUKES HOSP CTR,DEPT MED,ALLERGY & INFECT DIS,NEW YORK,NY 10025; ST LUKES HOSP CTR,DEPT PATHOL,IMMUNOL STUDY UNIT,NEW YORK,NY 10025	Mount Sinai St. Luke's; Mount Sinai St. Luke's; Mount Sinai St. Luke's								ALLANSMITH M, 1968, AM J MED, V44, P124, DOI 10.1016/0002-9343(68)90243-X; BARDEN J, 1967, ARTHRITIS RHEUM, V10, P228, DOI 10.1002/art.1780100308; BEVAN G, 1969, GASTROENTEROLOGY, V56, P1040; BLAESE RM, 1971, J CLIN INVEST, V50, P2331, DOI 10.1172/JCI106731; BUCKLEY CE, 1970, ANN INTERN MED, V72, P37, DOI 10.7326/0003-4819-72-1-37; CAPRA JD, 1969, VOX SANG, V16, P10, DOI 10.1111/j.1423-0410.1969.tb04711.x; CAPRA JD, 1969, ARTHRITIS RHEUM, V12, P67, DOI 10.1002/art.1780120202; CHENG CT, 1971, ANN INTERN MED, V75, P683, DOI 10.7326/0003-4819-75-5-683; CHERUBIN CE, 1970, AM J EPIDEMIOL, V91, P510, DOI 10.1093/oxfordjournals.aje.a121161; CLAMAN HN, 1965, J ALLERGY, V36, P463, DOI 10.1016/0021-8707(65)90140-1; FAHEY JL, 1965, JAMA-J AM MED ASSOC, V194, P141; GILES JP, 1969, NEW ENGL J MED, V281, P119, DOI 10.1056/NEJM196907172810302; GILES JP, 1969, J AMER MED ASSOC, V208, P497, DOI 10.1001/jama.208.3.497; GITNICK GL, 1969, LANCET, V2, P285; GLEICHMANN E, 1968, KLIN WOCHENSCHR, V46, P171, DOI 10.1007/BF01746229; GOCKE DJ, 1970, J IMMUNOL, V104, P1031; GOCKE DJ, 1969, LANCET, V1, P1055; JOHNSON GD, 1965, LANCET, V2, P878; KANTOR GL, 1970, ANN INTERN MED, V73, P553, DOI 10.7326/0003-4819-73-4-553; KAPLAN ME, 1968, J LAB CLIN MED, V71, P754; KLEMOLA E, 1969, ANN INTERN MED, V71, P11, DOI 10.7326/0003-4819-71-1-11; LEVY J, 1970, J CLIN INVEST, V49, P708, DOI 10.1172/JCI106283; LOGRIPPO GA, 1966, J AMER MED ASSOC, V195, P939, DOI 10.1001/jama.195.11.939; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MCKELVEY EM, 1965, J CLIN INVEST, V44, P1778, DOI 10.1172/JCI105285; MOORE DF, 1970, ANN INTERN MED, V72, P43, DOI 10.7326/0003-4819-72-1-43; NICKERSON DS, 1970, ANN INTERN MED, V72, P671, DOI 10.7326/0003-4819-72-5-671; PARONETTO F, 1964, NEW ENGL J MED, V271, P1123, DOI 10.1056/NEJM196411262712201; ROSEN FS, 1961, PEDIATRICS, V28, P182; RYAN J, 1971, MAY AM FED CLIN RES, P450; SELIGMANN M, 1967, AM J MED, V43, P66, DOI 10.1016/0002-9343(67)90149-0; SEVER JL, 1962, J IMMUNOL, V88, P320; STIEHM ER, 1966, AM J MED, V40, P805, DOI 10.1016/0002-9343(66)90163-X; SUTNICK AI, 1971, ARCH INTERN MED, V127, P939, DOI 10.1001/archinte.127.5.939; VEYS EM, 1968, ANN RHEUM DIS, V27, P431, DOI 10.1136/ard.27.5.431; VISCHER TL, 1970, BRIT MED J, V2, P695, DOI 10.1136/bmj.2.5711.695; WALKER G, 1968, GUT, V9, P266, DOI 10.1136/gut.9.3.266; WALKER JG, 1965, LANCET, V1, P827; WOLLHEIM FA, 1966, NEW ENG J MED, V274, P64; WRIGHT R, 1969, LANCET, V2, P117	40	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	3					152	160		10.1016/0091-6749(73)90020-1	http://dx.doi.org/10.1016/0091-6749(73)90020-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0896	4631663				2022-12-18	WOS:A1973P089600003
J	LICHTENSTEIN, L; ROEBBER, M; GOODFRIEND, L				LICHTENSTEIN, L; ROEBBER, M; GOODFRIEND, L			STUDIES ON IMMUNOLOGICAL RELATIONSHIP OF RAGWEED POLLEN ANTIGENS E AND RA.3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROY VICTORIA HOSP, DIV IMMUNOCHEM & ALLERGY, MONTREAL, QUEBEC, CANADA; JOHNS HOPKINS UNIV, GOOD SAMARITAN HOSP, SCH MED, BALTIMORE, MD 21239 USA	McGill University; Royal Victoria Hospital; Johns Hopkins University								BELIN L, 1972, INT ARCH ALLER A IMM, V42, P329, DOI 10.1159/000230616; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; KING TP, 1967, BIOCHEMISTRY-US, V6, P1992, DOI 10.1021/bi00859a017; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1971, J ALLERGY, V47, P103; LICHTENSTEIN LM, 1969, J ALLERGY, V44, P307, DOI 10.1016/0021-8707(69)90035-5; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P169; MARSH DG, 1966, ARCH ALLERGY, V29, P521; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; ROEBBER M, IN PRESS; UNDERDOWN BJ, 1969, BIOCHEMISTRY-US, V8, P980, DOI 10.1021/bi00831a031	12	19	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	5					285	295		10.1016/0091-6749(73)90130-9	http://dx.doi.org/10.1016/0091-6749(73)90130-9			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P5931	4121388	Bronze			2022-12-18	WOS:A1973P593100004
J	STEINBERG, AD				STEINBERG, AD			APPROACH TO USE OF IMMUNOSUPPRESSIVE DRUGS IN NONMALIGNANT DISEASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAMDD, ARTHRITIS & RHEUMATISM BRANCH, BETHESDA, MD 20014 USA									ABRAMOWI.M, 1970, LANCET, V1, P959; ALEPA FP, 1970, ARTHRITIS RHEUM-US, V13, P754; ARINOVICHE R, 1970, ANN RHEUM DIS, V29, P32, DOI 10.1136/ard.29.1.32; ARKINS JA, 1966, J ALLERGY, V37, P90, DOI 10.1016/0021-8707(66)90125-0; BACK N, 1964, LIFE SCI, V3, P803, DOI 10.1016/0024-3205(64)90141-9; BARRATT TM, 1970, LANCET, V2, P479; BERENBAU.MC, 1965, IMMUNOLOGY, V8, P251; BERENBAUM MC, 1964, IMMUNOLOGY, V7, P65; BLACK RL, 1964, JAMA-J AM MED ASSOC, V189, P743; BOOTH LJ, 1970, LANCET, V2, P1010; BUSHKIRK HH, 1965, JNCI-J NATL CANCER I, V34, P747; DAHL MGC, 1971, BRIT MED J, V1, P625; DIAMOND HS, 1972, ARTHRITIS RHEUM, V15, P434; DODSON WH, 1969, J CLIN PHARMACOL N D, V9, P251, DOI 10.1177/009127006900900408; DONADIO JV, 1972, ANN INTERN MED, V76, P873, DOI 10.7326/0003-4819-76-5-873_4; FAUCI AS, 1971, NEW ENGL J MED, V285, P1493, DOI 10.1056/NEJM197112302852701; FRIES JF, 1970, ARTHRITIS RHEUM, V13, P316; GELFAND MC, 1972, ARTHRITIS RHEUM-US, V15, P239, DOI 10.1002/art.1780150304; GELFAND MC, 1972, ARTHRITIS RHEUM-US, V15, P247, DOI 10.1002/art.1780150305; HAHN BH, 1973, ARTHRITIS RHEUM-US, V16, P120; HERSH EM, 1966, BLOOD-J HEMATOL, V27, P38, DOI 10.1182/blood.V27.1.38.38; HUNTER GA, 1973, AUSTRALAS J DERMATOL, V7, P91; HURD ER, 1968, J EXP MED, V128, P785, DOI 10.1084/jem.128.4.785; KAISER HB, 1966, ANN ALLERGY, V24, P369; LEVIN RH, 1964, NEW ENGL J MED, V271, P16, DOI 10.1056/NEJM196407022710103; LEVY J, 1972, ARTHRITIS RHEUM, V15, P444; LEVY J, 1972, ARTHRITIS RHEUM, V15, P116; LIDSKY MD, 1972, ARTHRITIS RHEUM, V15, P117; MAGUIRE HC, 1961, J INVEST DERMATOL, V37, P427, DOI 10.1038/jid.1961.138; MAIBACH HI, 1966, INT ARCH ALLER A IMM, V29, P209, DOI 10.1159/000229702; MASON M, 1969, BMJ-BRIT MED J, V1, P420, DOI 10.1136/bmj.1.5641.420; MATHEWS JD, 1969, BRIT J OPHTHALMOL, V53, P327, DOI 10.1136/bjo.53.5.327; MILLAC P, 1969, LANCET, V1, P783; MUKHERJEE AP, 1971, LANCET, V2, P1350; NOVACK SN, 1971, NEW ENGL J MED, V284, P938, DOI 10.1056/NEJM197104292841703; PAGE AR, 1964, AM J MED, V36, P200, DOI 10.1016/0002-9343(64)90083-X; PAGE AR, 1964, AM J PATHOL, V45, P1029; PAGE AR, 1962, AM J PATHOL, V40, P519; PENN I, 1971, TRANSPLANT P, V3, P773; RHODES J, 1970, LANCET, V2, P1142; ROSS A, 1970, GUT, V11, P1058; SANTOS GW, 1967, FED PROC, V26, P907; SANTOS GW, 1966, NATURE, V209, P622, DOI 10.1038/209622a0; SCHWARTZ RS, 1971, ARTHRITIS RHEUM, V14, P134, DOI 10.1002/art.1780140118; SHARPSTONE P, 1969, BMJ-BRIT MED J, V2, P535, DOI 10.1136/bmj.2.5656.535; SOLOWAY RD, 1971, GASTROENTEROLOGY, V60, P167; STEINBER.AD, 1971, ANN INTERN MED, V75, P165, DOI 10.7326/0003-4819-75-2-165; STEINBERG AD, 1972, ARTHRITIS RHEUM-US, V15, P456; STEINBERG AD, 1972, ANN INTERN MED, V76, P619, DOI 10.7326/0003-4819-76-4-619; STEINBERG AD, 1970, CLIN EXP IMMUNOL, V687, P687; STERZL J., 1963, J HYG EPIDEMIOL MICROBIOL IMMUNOL, V7, P301; STEVENS JE, 1969, J PATHOL, V97, P367, DOI 10.1002/path.1710970223; SZTEJNBOK M, 1971, ARTHRITIS RHEUM-US, V14, P639, DOI 10.1002/art.1780140511; TOWNES AS, 1972, ARTHRITIS RHEUM, V15, P129; TURK JL, 1963, CELL BOUND ANTIBODIE; UROWITZ MB, 1971, ARTHRITIS RHEUM-US, V14, P419; ZWEIMAN B, 1970, SCIENCE, V169, P284, DOI 10.1126/science.169.3942.284; 1971, BRIT MED J, V2, P239; 1970, N ENGL J MED, V283, P883	59	19	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	4					242	250		10.1016/0091-6749(73)90062-6	http://dx.doi.org/10.1016/0091-6749(73)90062-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q9817	4602869	Bronze			2022-12-18	WOS:A1973Q981700006
J	STEMBER, RH; LEVINE, BB				STEMBER, RH; LEVINE, BB			PREVALENCE OF ALLERGIC DISEASES, PENICILLIN HYPERSENSITIVITY, AND AEROALLERGEN HYPERSENSITIVITY IN VARIOUS POPULATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	2					100	100		10.1016/S0091-6749(73)80048-X	http://dx.doi.org/10.1016/S0091-6749(73)80048-X			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	O7913					2022-12-18	WOS:A1973O791300048
J	TOWNLEY, RG; HONRATH, T; GUIRGIS, HM				TOWNLEY, RG; HONRATH, T; GUIRGIS, HM			INHIBITORY EFFECT OF HYDROCORTISONE ON ALPHA ADRENERGIC RESPONSES OF HUMAN AND GUINEA-PIG ISOLATED RESPIRATORY SMOOTH MUSCLE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																		1969, J ALLERG CL, V45, P188	1	19	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	2					88	&						0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L5997					2022-12-18	WOS:A1972L599700007
J	Li, XN; Christenson, SA; Modena, B; Li, HS; Busse, WW; Castro, M; Denlinger, LC; Erzurum, SC; Fahy, JV; Gaston, B; Hastie, AT; Israel, E; Jarjour, NN; Levy, BD; Moore, WC; Woodruff, PG; Kaminski, N; Wenzel, SE; Bleecker, ER; Meyers, DA				Li, Xingnan; Christenson, Stephanie A.; Modena, Brian; Li, Huashi; Busse, William W.; Castro, Mario; Denlinger, Loren C.; Erzurum, Serpil C.; Fahy, John V.; Gaston, Benjamin; Hastie, Annette T.; Israel, Elliot; Jarjour, Nizar N.; Levy, Bruce D.; Moore, Wendy C.; Woodruff, Prescott G.; Kaminski, Naftali; Wenzel, Sally E.; Bleecker, Eugene R.; Meyers, Deborah A.		NHLBI Severe Asthma Res Program	Genetic analyses identify GSDMB associated with asthma severity, exacerbations, and antiviral pathways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antiviral pathways; asthma exacerbations; asthma severity; eQTL; genetics; GSDMA; GSDMB; PGAP3; whole-genome sequence; RNAseq		Background: The Chr17q12-21.2 region is the strongest and most consistently associated region with asthma susceptibility. The functional genes or single nucleotide polymorphisms (SNPs) are not obvious due to linkage disequilibrium. Objectives: We sought to comprehensively investigate whole-genome sequence and RNA sequence from human bronchial epithelial cells to dissect functional genes/SNPs for asthma severity in the Severe Asthma Research Program. Methods: Expression quantitative trait loci analysis (n = 114), correlation analysis (n = 156) of gene expression and asthma phenotypes, and pathway analysis were performed in bronchial epithelial cells and replicated. Genetic association for asthma severity (426 severe vs 531 nonsevere asthma) and longitudinal asthma exacerbations (n = 273) was performed. Results: Multiple SNPs in gasdermin B (GSDMB) associated with asthma severity (odds ratio, >1.25) and longitudinal asthma exacerbations (P < .05). Expression quantitative trait loci analyses identified multiple SNPs associated with expression levels of post-GPI attachment to proteins 3, GSDMB, or gasdermin A (3.1 x 10(-9) < P < 1.8 x 10(-4)). Higher expression levels of GSDMB correlated with asthma and greater number of exacerbations (P < .05). Expression levels of GSDMB correlated with genes involved in IFN signaling, MHC class I antigen presentation, and immune system pathways (false-discovery rate-adjusted P < .05). rs1031458 and rs3902920 in GSDMB colocalized with IFN regulatory factor binding sites and associated with GSDMB expression, asthma severity, and asthma exacerbations (P < .05). Conclusions: By using a unique set of gene expression data from lung cells obtained using bronchoscopy from comprehensively characterized subjects with asthma, we show that SNPs in GSDMB associated with asthma severity, exacerbations, and GSDMB expression levels. Furthermore, its expression levels correlated with asthma exacerbations and antiviral pathways. Thus, GSDMB is a functional gene for both asthma susceptibility and severity.	[Li, Xingnan; Li, Huashi; Bleecker, Eugene R.; Meyers, Deborah A.] Univ Arizona, Dept Med, Div Genet Genom & Precis Med, 1230 N Cherry Ave,POB 210242, Tucson, AZ 85719 USA; [Christenson, Stephanie A.; Fahy, John V.; Woodruff, Prescott G.] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA; [Modena, Brian] Natl Jewish Hlth, Dept Med, Div Allergy & Clin Immunol, Denver, CO USA; [Busse, William W.; Denlinger, Loren C.; Jarjour, Nizar N.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA; [Castro, Mario] Univ Kansas, Sch Med, Div Pulm Crit Care & Sleep Med, Kansas City, KS USA; [Erzurum, Serpil C.] Cleveland Clin, Lerner Res Inst, Cleveland, OH 44106 USA; [Erzurum, Serpil C.] Cleveland Clin, Resp Inst, Cleveland, OH 44106 USA; [Gaston, Benjamin] Indiana Univ, Wells Ctr Pediat Res, Indianapolis, IN 46204 USA; [Gaston, Benjamin] Indiana Univ, Riley Hosp Children, Indianapolis, IN 46204 USA; [Hastie, Annette T.; Moore, Wendy C.] Wake Forest Sch Med, Dept Med, Winston Salem, NC 27101 USA; [Israel, Elliot; Levy, Bruce D.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Israel, Elliot; Levy, Bruce D.] Harvard Med Sch, Boston, MA 02115 USA; [Kaminski, Naftali] Yale Sch Med, Div Pulm Crit Care & Sleep Med, Dept Internal Med, New Haven, CT USA; [Wenzel, Sally E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA	University of Arizona; University of California System; University of California San Francisco; National Jewish Health; University of Wisconsin System; University of Wisconsin Madison; University of Kansas; University of Kansas Medical Center; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Wake Forest University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Li, XN (corresponding author), Univ Arizona, Dept Med, Div Genet Genom & Precis Med, 1230 N Cherry Ave,POB 210242, Tucson, AZ 85719 USA.	lixingnan1@deptofmed.arizona.edu		Kaminski, Naftali/0000-0001-5917-4601; Li, Xingnan/0000-0002-1208-8658	National Heart, Lung, and Blood Institute (NHLBI); New York Genome Center [HHSN268201500016C, phs001446]; TOPMed Informatics Research Center [3R01HL-117626-02S1, HHSN268201800002I]; TOPMed Data Coordinating Center [R01HL-120393, U01HL-120393, HHSN268201800001I]	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); New York Genome Center; TOPMed Informatics Research Center; TOPMed Data Coordinating Center	TOPMed Acknowledgments: Molecular data for the TOPMed program were supported by the National Heart, Lung, and Blood Institute (NHLBI). Genome sequencing for "NHLBI TOPMed: Severe Asthma Research Program'' (phs001446) was performed at the New York Genome Center (HHSN268201500016C). Core support including centralized genomic read mapping and genotype calling, along with variant quality metrics and filtering, were provided by the TOPMed Informatics Research Center (grant no. 3R01HL-117626-02S1; contract no. HHSN268201800002I). Core support including phenotype harmonization, data management, sample-identity QC, and general program coordination were provided by the TOPMed Data Coordinating Center (grant nos. R01HL-120393 and U01HL-120393; contract no. HHSN268201800001I). We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed.	Acevedo N, 2015, HUM MOL GENET, V24, P875, DOI 10.1093/hmg/ddu479; Almoguera B, 2017, AM J RESP CRIT CARE, V195, P456, DOI 10.1164/rccm.201604-0861OC; Anantharaman R, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-170; Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764; Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Barrett JC, 2009, NAT GENET, V41, P703, DOI 10.1038/ng.381; Beecham AH, 2013, NAT GENET, V45, P1353, DOI 10.1038/ng.2770; Bentham J, 2015, NAT GENET, V47, P1457, DOI 10.1038/ng.3434; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Cordell HJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9019; Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656; Das S, 2017, ADV IMMUNOL, V135, P1, DOI 10.1016/bs.ai.2017.06.001; Das S, 2016, P NATL ACAD SCI USA, V113, P13132, DOI 10.1073/pnas.1610433113; Daya M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08469-7; de Lange KM, 2017, NAT GENET, V49, P256, DOI 10.1038/ng.3760; Demenais F, 2018, NAT GENET, V50, P42, DOI 10.1038/s41588-017-0014-7; Denlinger LC, 2017, AM J RESP CRIT CARE, V195, P302, DOI 10.1164/rccm.201602-0419OC; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Ellinghaus D, 2016, NAT GENET, V48, P510, DOI 10.1038/ng.3528; Eyre S, 2012, NAT GENET, V44, P1336, DOI 10.1038/ng.2462; Fabregat A, 2018, NUCLEIC ACIDS RES, V46, pD649, DOI [10.1093/nar/gkx1132, 10.1093/nar/gkz1031]; Ferreira MA, 2017, NAT GENET, V49, P1752, DOI 10.1038/ng.3985; Ferreira MAR, 2019, AM J HUM GENET, V104, P665, DOI 10.1016/j.ajhg.2019.02.022; Ferreira MAR, 2014, J ALLERGY CLIN IMMUN, V133, P1564, DOI 10.1016/j.jaci.2013.10.030; Ferreira MAR, 2011, EUR J HUM GENET, V19, P458, DOI 10.1038/ejhg.2010.191; Fishilevich S, 2017, DATABASE-OXFORD, DOI 10.1093/database/bax028; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383; Giovannini-Chami L, 2012, EUR RESPIR J, V39, P1197, DOI 10.1183/09031936.00070511; Halapi E, 2010, EUR J HUM GENET, V18, P902, DOI 10.1038/ejhg.2010.38; Hao K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003029; Hinds DA, 2013, NAT GENET, V45, P907, DOI 10.1038/ng.2686; Hirschfield GM, 2009, NEW ENGL J MED, V360, P2544, DOI 10.1056/NEJMoa0810440; Hodge SJ, 2004, CYTOM PART B-CLIN CY, V61B, P27, DOI 10.1002/cyto.b.20020; Jarjour NN, 2012, AM J RESP CRIT CARE, V185, P356, DOI 10.1164/rccm.201107-1317PP; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Kawashima M, 2017, HUM MOL GENET, V26, P650, DOI 10.1093/hmg/ddw406; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kim K, 2015, ANN RHEUM DIS, V74, DOI 10.1136/annrheumdis-2013-204749; Langefeld CD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16021; Li MX, 2012, HUM GENET, V131, P747, DOI 10.1007/s00439-011-1118-2; Li X, 2015, ALLERGY, V70, P1309, DOI 10.1111/all.12683; Li XN, 2018, BMC MED GENET, V19, DOI 10.1186/s12881-018-0656-z; Li XN, 2016, J ASTHMA, V53, P775, DOI 10.3109/02770903.2016.1158268; Li XN, 2012, J ALLERGY CLIN IMMUN, V130, P861, DOI 10.1016/j.jaci.2012.04.041; Li YR, 2015, NAT MED, V21, P1018, DOI 10.1038/nm.3933; Liu JZ, 2015, NAT GENET, V47, P979, DOI 10.1038/ng.3359; Liu JZ, 2012, NAT GENET, V44, P1137, DOI 10.1038/ng.2395; Liu XD, 2010, NAT GENET, V42, P658, DOI 10.1038/ng.627; Loss GJ, 2016, AM J RESP CRIT CARE, V193, P889, DOI 10.1164/rccm.201507-1493OC; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Marenholz I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9804; Martin JE, 2013, HUM MOL GENET, V22, P4021, DOI 10.1093/hmg/ddt248; Mayes MD, 2014, AM J HUM GENET, V94, P47, DOI 10.1016/j.ajhg.2013.12.002; McGovern DPB, 2010, NAT GENET, V42, P332, DOI 10.1038/ng.549; Modena BD, 2017, AM J RESP CRIT CARE, V195, P1449, DOI 10.1164/rccm.201607-1407OC; Modena BD, 2014, AM J RESP CRIT CARE, V190, P1363, DOI 10.1164/rccm.201406-1099OC; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Morris DL, 2016, NAT GENET, V48, P940, DOI 10.1038/ng.3603; Morrison FS, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-627; Nakamura M, 2012, AM J HUM GENET, V91, P721, DOI 10.1016/j.ajhg.2012.08.010; Nicodemus-Johnson J, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.90151; Nieuwenhuis MA, 2016, ALLERGY, V71, P1712, DOI 10.1111/all.12990; Ober C, 2020, LANCET RESP MED, V8, P482, DOI 10.1016/S2213-2600(20)30011-4; Onengut-Gumuscu S, 2015, NAT GENET, V47, P381, DOI 10.1038/ng.3245; Pickrell JK, 2016, NAT GENET, V48, P709, DOI 10.1038/ng.3570; Pividori M, 2019, LANCET RESP MED, V7, P509, DOI 10.1016/S2213-2600(19)30055-4; Plagnol V, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002216; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Qiu F, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14828; Schmiedel BJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13426; Shrine N, 2019, LANCET RESP MED, V7, P20, DOI 10.1016/S2213-2600(18)30389-8; Stahl EA, 2010, NAT GENET, V42, P508, DOI 10.1038/ng.582; Stein MM, 2018, J ALLERGY CLIN IMMUN, V142, P749, DOI 10.1016/j.jaci.2017.12.974; Teague WG, 2018, J ALLER CL IMM-PRACT, V6, P545, DOI 10.1016/j.jaip.2017.05.032; Terao C, 2017, ANN RHEUM DIS, V76, P1150, DOI 10.1136/annrheumdis-2016-210645; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Waage J, 2018, NAT GENET, V50, P1072, DOI 10.1038/s41588-018-0157-1; Wan YI, 2012, THORAX, V67, P762, DOI 10.1136/thoraxjnl-2011-201262; Wang YT, 2013, J BIOL CHEM, V288, P25490, DOI 10.1074/jbc.M113.492611; Wu W, 2019, AM J RESP CRIT CARE, V199, P1358, DOI 10.1164/rccm.201808-1543OC; Yan Q, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01505-2016; Zhu ZZ, 2018, NAT GENET, V50, P857, DOI 10.1038/s41588-018-0121-0	92	18	18	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2021	147	3					894	909		10.1016/j.jaci.2020.07.030	http://dx.doi.org/10.1016/j.jaci.2020.07.030		MAR 2021	16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RA9TV	32795586	Green Accepted, Green Submitted			2022-12-18	WOS:000631762400012
J	Marrs, T; Jo, JH; Perkin, MR; Rivett, DW; Witney, AA; Bruce, KD; Logan, K; Craven, J; Radulovic, S; Versteeg, SA; van Ree, R; McLean, WHI; Strachan, DP; Lack, G; Kong, HH; Flohr, C				Marrs, Tom; Jo, Jay-Hyun; Perkin, Michael R.; Rivett, Damian W.; Witney, Adam A.; Bruce, Kenneth D.; Logan, Kirsty; Craven, Joanna; Radulovic, Suzana; Versteeg, Serge A.; van Ree, Ronald; McLean, W. H. Irwin; Strachan, David P.; Lack, Gideon; Kong, Heidi H.; Flohr, Carsten			Gut microbiota development during infancy: Impact of introducing allergenic foods	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; bacteria; diet; environment; food; microbiome; colonization; tolerance		Background: The gut microbiota potentially plays an important role in the immunologic education of the host during early infancy. Objective: We sought to determine how the infant gut microbiota evolve during infancy, particularly in relation to hygiene-related environmental factors, atopic disorders, and a randomized introduction of allergenic solids. Methods: A total of 1303 exclusively breast-fed infants were enrolled in a dietary randomized controlled trial (Enquiring About Tolerance study) from 3 months of age. In this nested longitudinal study, fecal samples were collected at baseline, with additional sampling of selected cases and controls at 6 and 12 months to study the evolution of their gut microbiota, using 16S ribosomal RNA gene-targeted amplicon sequencing. Results: In the 288 baseline samples from exclusively breast-fed infant at 3 months, the gut microbiota was highly heterogeneous, forming 3 distinct clusters: Bifidobacterium-rich, Bacteroides-rich, and Escherichia/Shigella-rich. Mode of delivery was the major discriminating factor. Increased Clostridium sensu stricto relative abundance at 3 months was associated with presence of atopic dermatitis on examination at age 3 and 12 months. From the selected cases and controls with longitudinal samples (n = 70), transition to Bacteroides-rich communities and influx of adult-specific microbes were observed during the first year of life. The introduction of allergenic solids promoted a significant increase in Shannon diversity and representation of specific microbes, such as genera belonging to Prevotellaceae and Proteobacteria (eg, Escherichia/Shigella), as compared with infants recommended to exclusively breast-feed. Conclusions: Specific gut microbiota characteristics of samples from 3-month-old breast-fed infants were associated with cesarean birth, and greater Clostridium sensu stricto abundance was associated with atopic dermatitis. The randomized introduction of allergenic solids from age 3 months alongside breast-feeding was associated with differential dynamics of maturation of the gut microbial communities.	[Marrs, Tom; Logan, Kirsty; Craven, Joanna; Radulovic, Suzana; Lack, Gideon] Kings Coll London, Paediat Allergy Res Grp, Dept Women & Childrens Hlth, Sch Life Course Sci,Fac Life Sci & Med, London, England; [Marrs, Tom; Radulovic, Suzana] Guys & St Thomas NHS Fdn Trust, St Thomas Hosp, Childrens Allergies Dept, Lambeth, England; [Jo, Jay-Hyun; Kong, Heidi H.] NIAMSD, Dermatol Branch, NIH, Bethesda, MD 20892 USA; [Perkin, Michael R.; Strachan, David P.] St Georges Univ London, Populat Hlth Res Inst, London, England; [Rivett, Damian W.] Manchester Metropolitan Univ, Dept Nat Sci, Manchester, Lancs, England; [Witney, Adam A.] St Georges Univ London, Inst Infect & Immun, London, England; [Bruce, Kenneth D.] Kings Coll London, Pharmaceut Sci Div, Mol Microbiol Res Lab, London, England; [Versteeg, Serge A.; van Ree, Ronald] Univ Amsterdam, Med Ctr, Expt Immunol, Amsterdam, Netherlands; [van Ree, Ronald] Univ Amsterdam, Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands; [McLean, W. H. Irwin] Univ Dundee, Sch Life Sci, Div Biol Chem & Drug Discovery, Dundee, Scotland; [Flohr, Carsten] Kings Coll London, Unit Populat Based Dermatol Res, St Johns Inst Dermatol, Sch Basic & Med Biosci, London, England	University of London; King's College London; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); St Georges University London; Manchester Metropolitan University; St Georges University London; University of London; King's College London; University of Amsterdam; University of Amsterdam; University of Dundee; University of London; King's College London	Flohr, C (corresponding author), Kings Coll London, Unit Populat Based Dermatol Res, St Johns Inst Dermatol, Sch Basic & Med Biosci, London, England.; Flohr, C (corresponding author), St Thomas NHS Fdn Trust, London, England.	carsten.flohr@kcl.ac.uk	Perkin, Michael/AID-7491-2022; Rivett, Damian/H-6491-2019	Rivett, Damian/0000-0002-1852-6137; Witney, Adam/0000-0003-4561-7170; Perkin, Michael/0000-0001-9272-2585	UK Food Standards Agency [T07051]; Medical Research Council (MRC) [MC_G1001205]; UK National Institute for Health Research (NIHR) [NIHRCS/01/2008/009]; British Skin Foundation (BSF) [5047i]; NIHR Biomedical Research Centre at Guy's & St Thomas' NHS Foundation Trust and King's College London; EU; Innovative Medicines Initiative 2 Joint Undertaking (JU) [821511]; European Union; EFPIA; Wellcome Trust [092530/Z/10/Z, 090066/B/09/Z, 098439/Z/12/Z]; US National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases; Korean Health Technology R&D Project, Ministry of Health andWelfare, Republic of Korea [HI15C1095]	UK Food Standards Agency; Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); British Skin Foundation (BSF)(US-Israel Binational Science Foundation); NIHR Biomedical Research Centre at Guy's & St Thomas' NHS Foundation Trust and King's College London; EU(European Commission); Innovative Medicines Initiative 2 Joint Undertaking (JU); European Union(European Commission); EFPIA; Wellcome Trust(Wellcome Trust); US National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Korean Health Technology R&D Project, Ministry of Health andWelfare, Republic of Korea	The main components of the Enquiring About Tolerance study were jointly funded by the UK Food Standards Agency (grant code T07051) and the Medical Research Council (MRC, grant no. MC_G1001205). The skin-related aspects of the study were supported by a Clinician Scientist Award from the UK National Institute for Health Research (NIHR) held by C.F. (NIHRCS/01/2008/009). The British Skin Foundation (BSF) funded the fecal sample sequencing work (BSF large grant 5047i, principle investigator C.F.). T.M., C.F., and G.L. are supported by the NIHR Biomedical Research Centre at Guy's & St Thomas' NHS Foundation Trust and King's College London. C.F. is also a Principle Investigator of the EU-funded IMI Consortium BIOMAP, and the work described in this project was performed within the frame of the BIOMAP project which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821511 (BIOMAP). The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. The McLean lab is funded by Wellcome Trust Programme (092530/Z/10/Z toW.H.I.M.) and Bioresources grants (090066/B/09/Z toW.H.I.M.). The Centre for Dermatology and Genetic Medicine, University of Dundee, is supported by a Wellcome Trust Strategic Award (098439/Z/12/Z to W.H.I.M.). This work was supported by the Intramural Research Program of the US National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases (J.-H.J., H.H.K.). J.-H.J. was also supported by a grant of the Korean Health Technology R&D Project, Ministry of Health andWelfare, Republic of Korea (grant no. HI15C1095). The views expressed in this publication are those of the authors and not necessarily those of the Food Standards Agency, the MRC, the NHS, the UK NIHR, the UK Department of Health, the US National Institutes of Health, or the Wellcome Trust.	Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Backhed F, 2015, CELL HOST MICROBE, V17, P690, DOI [10.1016/j.chom.2015.05.012, 10.1016/j.chom.2015.04.004]; Baumann-Dudenhoeffer AM, 2018, NAT MED, V24, P1822, DOI 10.1038/s41591-018-0216-2; Bezirtzoglou E, 2011, ANAEROBE, V17, P478, DOI 10.1016/j.anaerobe.2011.03.009; Bokulich NA, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7121; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/nmeth.3869, 10.1038/NMETH.3869]; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; Clemente JC, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500183; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; EXCOFFIER L, 1992, GENETICS, V131, P479; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Goodrich JK, 2014, CELL, V159, P789, DOI 10.1016/j.cell.2014.09.053; Green GL, 2006, J APPL MICROBIOL, V100, P460, DOI 10.1111/j.1365-2672.2005.02783.x; Jackson MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05184-7; Jakobsson HE, 2014, GUT, V63, P559, DOI 10.1136/gutjnl-2012-303249; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Marungruang N, 2018, EUR J NUTR, V57, P2927, DOI 10.1007/s00394-017-1563-3; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; Perkin MR, 2016, J ALLERGY CLIN IMMUN, V137, P1477, DOI 10.1016/j.jaci.2015.12.1322; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Rogers GB, 2013, ISME J, V7, P697, DOI 10.1038/ismej.2012.145; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; Rutayisire E, 2016, BMC GASTROENTEROL, V16, DOI 10.1186/s12876-016-0498-0; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Schnorr SL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4654; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Shao Y, 2019, NATURE, V574, P117, DOI 10.1038/s41586-019-1560-1; Stewart CJ, 2018, NATURE, V562, P583, DOI 10.1038/s41586-018-0617-x; Stokholm J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02573-2; Stokholm J, 2016, J ALLERGY CLIN IMMUN, V138, P881, DOI 10.1016/j.jaci.2016.01.028; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; Westcott SL, 2017, MSPHERE, V2, DOI 10.1128/mSphereDirect.00073-17; Yassour M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad0917; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Yue JC, 2005, COMMUN STAT-THEOR M, V34, P2123, DOI 10.1080/STA-200066418; Zeissig S, 2014, NAT IMMUNOL, V15, P307, DOI 10.1038/ni.2847	43	18	19	3	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					613	+		10.1016/j.jaci.2020.09.042	http://dx.doi.org/10.1016/j.jaci.2020.09.042		FEB 2021	18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	33551026	Green Accepted, Green Submitted, hybrid, Green Published			2022-12-18	WOS:000616665800023
J	Sharif, H; Acharya, S; Dhondalay, GKR; Varricchi, G; Krasner-Macleod, S; Laisuan, W; Switzer, A; Lenormand, M; Kashe, E; Parkin, RV; Yi, Y; Koc, M; Fedina, O; Vila-Nadal, G; Marone, G; Eifan, A; Scadding, GW; Fear, DJ; Nadeau, KC; Durham, SR; Shamji, MH				Sharif, Hanisah; Acharya, Swati; Dhondalay, Gopal Krishna R.; Varricchi, Gilda; Krasner-Macleod, Shoshanna; Laisuan, Wannada; Switzer, Amy; Lenormand, Madison; Kashe, Elena; Parkin, Rebecca, V; Yi, Yi; Koc, Merve; Fedina, Oleksandra; Vila-Nadal, Gemma; Marone, Gianni; Eifan, Aarif; Scadding, Guy W.; Fear, David J.; Nadeau, Kari C.; Durham, Stephen R.; Shamji, Mohamed H.			Altered chromatin landscape in circulating T follicular helper and regulatory cells following grass pollen subcutaneous and sublingual immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; seasonal allergic rhinitis; allergen-specific immunotherapy; T follicular helper cells; T follicular regulatory cells; chromatin accessibility; ATAC-seq		Background: Allergen-specific immunotherapy is a disease-modifying treatment that induces long-term T-cell tolerance. Objective: We sought to evaluate the role of circulating CXCR5(+)PD-1(+) T follicular helper (cT(FH)) and T follicular regulatory (T-FR) cells following grass pollen subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) and the accompanying changes in their chromatin landscape. Methods: Phenotype and function of cT(FH) cells were initially evaluated in the grass pollen-allergic (GPA) group (n = 28) and nonatopic healthy controls (NAC, n = 13) by mathematical algorithms developed to manage high-dimensional data and cell culture, respectively. cT(FH) and T-FR cells were further enumerated in NAC (n = 12), GPA (n = 14), SCIT- (n = 10), and SLIT- (n = 8) treated groups. Chromatin accessibility in cT(FH) and T-FR cells was assessed by assay for trans-posaseaccessible chromatin sequencing (ATAC-seq) to investigate epigenetic mechanisms underlying the differences between NAC, GPA, SCIT, and SLIT groups. Results: cT(FH) cells were shown to be distinct from T(H)2- and T(H)2A-cell subsets, capable of secreting IL-4 and IL-21. Both cytokines synergistically promoted B-cell class switching to IgE and plasma cell differentiation. Grass pollen allergen induced cT(FH)-cell proliferation in the GPA group but not in the NAC group (P<.05). cT(FH) cells were higher in the GPA group compared with the NAC group and were lower in the SCIT and SLIT groups (P<.01). Time-dependent induction of IL-4, IL-21, and IL-6 was observed in nasal mucosa following intranasal allergen challenge in the GPA group but not in SCIT and SLIT groups. TFR and IL-101 cT(FH) cells were induced in SCIT and SLIT groups (all, P<.01). ATAC-seq analyses revealed differentially accessible chromatin regions in all groups. Conclusions: For the first time, we showed dysregulation of cT(FH) cells in the GPA group compared to NAC, SCIT, and SLIT groups and induction of T-FR and IL-101 cT(FH) cells following SCIT and SLIT. Changes in the chromatin landscape were observed following allergen-specific immunotherapy in cT(FH) and T-FR cells.	[Sharif, Hanisah; Varricchi, Gilda; Krasner-Macleod, Shoshanna; Laisuan, Wannada; Switzer, Amy; Lenormand, Madison; Kashe, Elena; Parkin, Rebecca, V; Yi, Yi; Koc, Merve; Fedina, Oleksandra; Vila-Nadal, Gemma; Eifan, Aarif; Scadding, Guy W.; Durham, Stephen R.; Shamji, Mohamed H.] Dept Natl Heart & Lung Inst, Allergy & Clin Immunol, Immunomodulat & Tolerance Grp, London, England; [Sharif, Hanisah; Laisuan, Wannada; Lenormand, Madison; Parkin, Rebecca, V; Yi, Yi; Koc, Merve; Shamji, Mohamed H.] Imperial Coll London, Asthma UK Ctr Allerg Mech Asthma, London, England; [Sharif, Hanisah] Univ Brunei Darussalam, PAPRSB Inst Hlth Sci, Gadong, Brunei; [Acharya, Swati; Dhondalay, Gopal Krishna R.; Nadeau, Kari C.] Stanford Univ, Dept Med, Sean N Parker Ctr Asthma & Allergy Res, Stanford, CA 94305 USA; [Varricchi, Gilda] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy; [Marone, Gianni] Univ Naples Federico II, Ctr Basic & Clin Immunol Res CISI, Div Clin Immunol & Allergy, Naples, Italy; [Fear, David J.] Kings Coll London, Asthma UK Ctr Allerg Mech Asthma, Sch Immunol & Microbial Sci, Peter Gorer Dept Immunobiol, London, England	Imperial College London; University of London; King's College London; University Brunei Darussalam; Stanford University; University of Naples Federico II; University of Naples Federico II; University of London; King's College London	Shamji, MH (corresponding author), Imperial Coll London, Immunomodulat & Tolerance Grp, Allergy & Clin Immunol Inflammat Repair & Dev, Natl Heart & Lung Inst,Fac Med, London SW7 2AZ, England.	m.shamji@imperial.ac.uk	Sharif, Hanisah/AAZ-5132-2021; Switzer, Amy/AEP-0843-2022; VARRICCHI, GILDA/AAB-9563-2022; Varricchi, Gilda/A-4620-2014	Sharif, Hanisah/0000-0002-2620-906X; VARRICCHI, GILDA/0000-0002-9285-4657; laisuan, wannada/0000-0001-6037-8812; Shamji, Mohamed/0000-0003-3425-3463	Royal Brompton Hospital charity research funds, United Kingdom; National Institute for Health Research (NIHR) Biomedical Research Centre, United Kingdom	Royal Brompton Hospital charity research funds, United Kingdom; National Institute for Health Research (NIHR) Biomedical Research Centre, United Kingdom	This research was funded by Royal Brompton Hospital charity research funds, United Kingdom and National Institute for Health Research (NIHR) Biomedical Research Centre, United Kingdom.	Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Asmal M, 2003, IMMUNITY, V19, P535, DOI 10.1016/S1074-7613(03)00268-1; Avery DT, 2008, BLOOD, V112, P1784, DOI 10.1182/blood-2008-02-142745; Belanger S, 2016, NAT IMMUNOL, V17, P1135, DOI 10.1038/ni.3561; Bensinger SJ, 2008, CELL, V134, P97, DOI 10.1016/j.cell.2008.04.052; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Caprioli F, 2008, J IMMUNOL, V180, P1800, DOI 10.4049/jimmunol.180.3.1800; CHEN HW, 1975, P NATL ACAD SCI USA, V72, P1950, DOI 10.1073/pnas.72.5.1950; Chen Y, 2018, ARTHRITIS RHEUMATOL, V70, P1853, DOI 10.1002/art.40556; Choi YS, 2013, J IMMUNOL, V190, P3049, DOI 10.4049/jimmunol.1203032; Chung Y, 2011, NAT MED, V17, P983, DOI 10.1038/nm.2426; Corces MR, 2017, NAT METHODS, V14, P959, DOI [10.1038/NMETH.4396, 10.1038/nmeth.4396]; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Dhaeze T, 2015, J IMMUNOL, V195, P832, DOI 10.4049/jimmunol.1500759; Didier A, 2011, J ALLERGY CLIN IMMUN, V128, P559, DOI 10.1016/j.jaci.2011.06.022; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Dykewicz MS, 2010, J ALLERGY CLIN IMMUN, V125, pS103, DOI 10.1016/j.jaci.2009.12.989; Eto D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017739; Ettinger R, 2005, J IMMUNOL, V175, P7867, DOI 10.4049/jimmunol.175.12.7867; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Gensous N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01637; Gonzalez DG, 2018, J IMMUNOL, V201, P3569, DOI 10.4049/jimmunol.1500497; Han YW, 2007, J MICROBIOL BIOTECHN, V17, P1955; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hsu C.-L, 2019, IMMUNOMETABOLISM, V1; Jeannin P, 1998, J IMMUNOL, V160, P3555; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kobayashi N, 2002, CLIN EXP IMMUNOL, V129, P446, DOI 10.1046/j.1365-2249.2002.01932.x; Kobayashi T, 2017, J ALLERGY CLIN IMMUN, V139, P300, DOI 10.1016/j.jaci.2016.04.021; Kotecha Nikesh, 2010, Curr Protoc Cytom, VChapter 10, DOI 10.1002/0471142956.cy1017s53; Lin Adora A, 2018, Immunohorizons, V2, P398, DOI 10.4049/immunohorizons.1800076; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031; Matsuoka T, 2013, ALLERGOL INT, V62, P403, DOI 10.2332/allergolint.13-RAI-0650; Naclerio R, 1999, J ALLERGY CLIN IMMUN, V103, pS382, DOI 10.1016/S0091-6749(99)70216-2; Noble A, 2016, CLIN EXP ALLERGY, V46, P1075, DOI 10.1111/cea.12750; Nurieva RI, 2008, IMMUNITY, V29, P138, DOI 10.1016/j.immuni.2008.05.009; Nurieva RI, 2009, SCIENCE, V325, P1001, DOI 10.1126/science.1176676; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Palmer CS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00001; Pene J, 2006, J IMMUNOL, V177, P5006, DOI 10.4049/jimmunol.177.8.5006; Rahman AH, 2009, IMMUNOL RES, V45, P25, DOI 10.1007/s12026-009-8113-x; Renand A, 2018, J ALLERGY CLIN IMMUN, V141, P1750, DOI 10.1016/j.jaci.2017.09.041; Sage PT, 2014, IMMUNITY, V41, P1026, DOI 10.1016/j.immuni.2014.12.005; Sage PT, 2014, J CLIN INVEST, V124, P5191, DOI 10.1172/JCI76861; Scadding GW, 2015, ALLERGY, V70, P689, DOI 10.1111/all.12608; Scadding GW, 2010, CLIN EXP ALLERGY, V40, P598, DOI 10.1111/j.1365-2222.2010.03462.x; Schaerli P, 2000, J EXP MED, V192, P1553, DOI 10.1084/jem.192.11.1553; Schmitt N, 2014, TRENDS IMMUNOL, V35, P436, DOI 10.1016/j.it.2014.06.002; Shamji MH, 2019, J ALLERGY CLIN IMMUN, V143, P1131, DOI 10.1016/j.jaci.2018.06.041; Sharif H, 2019, J ALLERGY CLIN IMMUN, V144, P738, DOI 10.1016/j.jaci.2019.02.023; Suto A, 2002, BLOOD, V100, P4565, DOI 10.1182/blood-2002-04-1115; Ueno H, 2015, NAT IMMUNOL, V16, P142, DOI 10.1038/ni.3054; Uwadiae FI, 2019, ALLERGY, V74, P650, DOI 10.1111/all.13602; van der Windt GJW, 2012, IMMUNOL REV, V249, P27, DOI 10.1111/j.1600-065X.2012.01150.x; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Varricchi G, 2016, ALLERGY, V71, P1086, DOI 10.1111/all.12878; Varricchi G, 2020, AGEING RES REV, V61, DOI 10.1016/j.arr.2020.101071; Wambre E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam9171; Weinstein JS, 2016, NAT IMMUNOL, V17, P1197, DOI 10.1038/ni.3554; Wood N, 2004, CELL IMMUNOL, V231, P133, DOI 10.1016/j.cellimm.2005.01.001; Yao Y, 2019, J ALLERGY CLIN IMMUN, V144, P118, DOI 10.1016/j.jaci.2019.02.008	65	18	18	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					663	676		10.1016/j.jaci.2020.10.035	http://dx.doi.org/10.1016/j.jaci.2020.10.035		FEB 2021	14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	33160969	hybrid, Green Published			2022-12-18	WOS:000616665800028
J	Verbsky, JW; Hintermeyer, MK; Simpson, PM; Feng, MG; Barbeau, J; Rao, N; Cool, CD; Sosa-Lozano, LA; Baruah, D; Hammelev, E; Busalacchi, A; Rymaszewski, A; Woodliff, J; Chen, SY; Bausch-Jurken, M; Routes, JM				Verbsky, James W.; Hintermeyer, Mary K.; Simpson, Pippa M.; Feng, Mingen; Barbeau, Jody; Rao, Nagarjun; Cool, Carlyne D.; Sosa-Lozano, Luis A.; Baruah, Dhiraj; Hammelev, Erin; Busalacchi, Alyssa; Rymaszewski, Amy; Woodliff, Jeff; Chen, Shaoying; Bausch-Jurken, Mary; Routes, John M.			Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Common variable immunodeficiency; granulomatous and lymphocytic interstitial lung disease; primary immunodeficiency	PULMONARY-FUNCTION; COMPUTED-TOMOGRAPHY; MUTATIONS; GLILD; AUTOIMMUNITY; PHENOTYPES; DIAGNOSIS; CHILDREN; EFFICACY; SPECTRUM	Background: Granulomatous and lymphocytic interstitial lung disease (GLILD) is a life-threatening complication in patients with common variable immunodeficiency (CVID), but the optimal treatment is unknown. Objective: Our aim was to determine whether rituximab with azathioprine or mycophenolate mofetil improves the high-resolution computed tomography (HRCT) chest scans and/or pulmonary function test results in patients with CVID and GLILD. Methods: A retrospective chart review of clinical and laboratory data on 39 patients with CVID and GLILD who completed immunosuppressive therapy was performed. Chest HRCT scans, performed before therapy and after the conclusion of therapy, were blinded, randomized, and scored independently by 2 radiologists. Differences between pretreatment and posttreatment HRCT scan scores, pulmonary function test results, and lymphocyte subsets were analyzed. Whole exome sequencing was performed on all patients. Results: Immunosuppressive therapy improved patients' HRCT scan scores (P < .0001), forced vital capacity (P = .0017), FEV1 (P = .037), and total lung capacity (P = .013) but not their lung carbon monoxide diffusion capacity (P = .12). Nine patients relapsed and 6 completed retreatment, with 5 of 6 of these patients (83%) having improved HRCT scan scores (P = .063). Relapse was associated with an increased number of B cells (P = .016) and activated CD4 T cells (P = .016). Four patients (10%) had pneumonia while undergoing active treatment, and 2 patients (5%) died after completion of therapy. Eight patients (21%) had a damaging mutation in a gene known to predispose (TNFRSF13B [n = 3]) or cause a CVID-like primary immunodeficiency (CTLA4 [n = 2], KMT2D [n = 2], or BIRC4 [n = 1]). Immunosuppression improved the HRCT scan scores in patients with (P = .0078) and without (P < .0001) a damaging mutation. Conclusions: Immunosuppressive therapy improved the radiographic abnormalities and pulmonary function of patients with GLILD. A majority of patients had sustained remissions.	[Verbsky, James W.; Chen, Shaoying] Med Coll Wisconsin, Div Pediat Rheumatol, Milwaukee, WI 53226 USA; [Verbsky, James W.; Simpson, Pippa M.; Feng, Mingen; Barbeau, Jody; Hammelev, Erin; Busalacchi, Alyssa; Rymaszewski, Amy; Woodliff, Jeff; Bausch-Jurken, Mary; Routes, John M.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; [Hintermeyer, Mary K.] Childrens Wisconsin, Asthma Allergy & Clin Immunol, Milwaukee, WI USA; [Simpson, Pippa M.; Feng, Mingen; Barbeau, Jody] Med Coll Wisconsin, Dept Quantitat Hlth Sci, Milwaukee, WI 53226 USA; [Rao, Nagarjun] Aurora West Allis Med Ctr, Dept Pathol, Aurora Clin Labs, Great Lakes Pathologists, W Allis, WI USA; [Cool, Carlyne D.] Univ Colorado, Dept Pathol, Anschutz Med Campus, Aurora, CO USA; [Cool, Carlyne D.] Univ Colorado, Div Pulm & Crit Care Med, Anschutz Med Campus, Aurora, CO USA; [Cool, Carlyne D.] Natl Jewish Hlth, Denver, CO USA; [Sosa-Lozano, Luis A.] Med Coll Wisconsin, Div Diagnost Radiol, Milwaukee, WI 53226 USA; [Baruah, Dhiraj] Med Univ South Carolina, Div Thorac Radiol, Charleston, SC USA; [Hammelev, Erin; Busalacchi, Alyssa; Rymaszewski, Amy; Woodliff, Jeff; Chen, Shaoying; Bausch-Jurken, Mary; Routes, John M.] Med Coll Wisconsin, Div Asthma Allergy & Clin Immunol, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; Children's Hospital of Wisconsin; Medical College of Wisconsin; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; National Jewish Health; Medical College of Wisconsin; Medical University of South Carolina; Medical College of Wisconsin	Routes, JM (corresponding author), Med Coll Wisconsin, 9000 W Wisconsin Ave, Milwaukee, WI 53226 USA.	jroutes@mcw.edu			Jeffrey Modell Foundation; Children's Research Institute; Department of Pediatrics, Medical College of Wisconsin	Jeffrey Modell Foundation; Children's Research Institute; Department of Pediatrics, Medical College of Wisconsin	Supported by the Jeffrey Modell Foundation, Children's Research Institute, and the Department of Pediatrics, Medical College of Wisconsin.	Adeleye A, 2014, CAN RESPIR J, V21, P20, DOI 10.1155/2014/904675; Akira M, 2008, AM J RESP CRIT CARE, V178, P372, DOI 10.1164/rccm.200709-1365OC; Alkhairy OK, 2016, J CLIN IMMUNOL, V36, P33, DOI 10.1007/s10875-015-0224-7; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Andrau JC, 2019, GENET MED; Bates CA, 2004, J ALLERGY CLIN IMMUN, V114, P415, DOI 10.1016/j.jaci.2004.05.057; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Boursiquot JN, 2013, J CLIN IMMUNOL, V33, P84, DOI 10.1007/s10875-012-9778-9; Bucciol G, 2017, PEDIATR PULM, V52, pE73, DOI 10.1002/ppul.23757; Buchbinder D, 2015, J CLIN IMMUNOL, V35, P119, DOI 10.1007/s10875-014-0121-5; Cereser L, 2019, J ALLER CL IMM-PRACT, V7, P1055, DOI 10.1016/j.jaip.2018.10.041; Chase NM, 2013, J CLIN IMMUNOL, V33, P30, DOI 10.1007/s10875-012-9755-3; Culver BH, 2017, AM J RESP CRIT CARE, V196, P1463, DOI 10.1164/rccm.201710-1981ST; De Dios Jose Angelo A, 2012, Conn Med, V76, P15; Deya-Martinez A, 2018, PEDIAT ALLERG IMM-UK, V29, P425, DOI 10.1111/pai.12890; Franxman TJ, 2014, J CLIN IMMUNOL, V34, P820, DOI 10.1007/s10875-014-0079-3; Gathmann B, 2014, J ALLERGY CLIN IMMUN, V134, P116, DOI 10.1016/j.jaci.2013.12.1077; Gregersen S, 2009, RESP MED, V103, P873, DOI 10.1016/j.rmed.2008.12.015; Hasegawa M, 2017, INTERNAL MED, V56, P2899, DOI 10.2169/internalmedicine.7757-16; Hoffman JD, 2005, AM J MED GENET A, V135A, P278, DOI 10.1002/ajmg.a.30722; Hurst JR, 2017, J ALLER CL IMM-PRACT, V5, P938, DOI 10.1016/j.jaip.2017.01.021; Jolles S, 2017, CLIN EXP IMMUNOL, V187, P138, DOI 10.1111/cei.12856; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Lawless D, 2018, J ALLERGY CLIN IMMUN, V141, P2303, DOI 10.1016/j.jaci.2018.02.007; Li R, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3724630; Lin JH, 2006, J ALLERGY CLIN IMMUN, V117, P878, DOI 10.1016/j.jaci.2006.01.034; Lindsley AW, 2016, J ALLERGY CLIN IMMUN, V137, P179, DOI 10.1016/j.jaci.2015.06.002; Maarschalk-Ellerbroek LJ, 2014, J CLIN IMMUNOL, V34, P642, DOI 10.1007/s10875-014-0068-6; Maglione PJ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122728; Mannina A, 2016, ANN AM THORAC SOC, V13, P1042, DOI 10.1513/AnnalsATS.201511-728OC; Miller MR, 2005, EUR RESPIR J, V26, P153, DOI 10.1183/09031936.05.00034505; Moraes-Fontes MF, 2017, CLIN CASE REP, V5, P2066, DOI 10.1002/ccr3.1257; Mouillot G, 2010, J CLIN IMMUNOL, V30, P746, DOI 10.1007/s10875-010-9424-3; Ohshimo S, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0012-2017; Park JH, 2010, CLIN IMMUNOL, V134, P97, DOI 10.1016/j.clim.2009.10.002; Pecoraro Antonio, 2019, Clin Mol Allergy, V17, P9, DOI 10.1186/s12948-019-0113-3; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Rao N, 2015, HUM PATHOL, V46, P1306, DOI 10.1016/j.humpath.2015.05.011; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; Schkade PA, 1996, J ALLERGY CLIN IMMUN, V98, P710, DOI 10.1016/S0091-6749(96)70108-2; Schwab C, 2018, J ALLERGY CLIN IMMUN, V142, P1932, DOI 10.1016/j.jaci.2018.02.055; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Showalter K, 2018, J RHEUMATOL, V45, P1572, DOI 10.3899/jrheum.171362; Steele CL, 2016, J CLIN IMMUNOL, V36, P733, DOI 10.1007/s10875-016-0320-3; Suliman YA, 2015, ARTHRITIS RHEUMATOL, V67, P3256, DOI 10.1002/art.39405; Tillman R, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00105; Urbine D, 2016, BMJ CASE REP, V2016; Vitale J, 2015, J ALLER CL IMM-PRACT, V3, P273, DOI 10.1016/j.jaip.2014.09.019; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Worthey EA, 2011, GENET MED, V13, P255, DOI 10.1097/GIM.0b013e3182088158	51	18	18	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					704	+		10.1016/j.jaci.2020.07.021	http://dx.doi.org/10.1016/j.jaci.2020.07.021		FEB 2021	26	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	32745555	Bronze			2022-12-18	WOS:000616665800032
J	Yeh, TW; Okano, T; Naruto, T; Yamashita, M; Okamura, M; Tanita, K; Du, L; Pan-Hammarstrom, Q; Mitsuiki, N; Okada, S; Kanegane, H; Imai, K; Morio, T				Yeh, Tzu-Wen; Okano, Tsubasa; Naruto, Takuya; Yamashita, Motoi; Okamura, Miko; Tanita, Kay; Du, Likun; Pan-Hammarstrom, Qiang; Mitsuiki, Noriko; Okada, Satoshi; Kanegane, Hirokazu; Imai, Kohsuke; Morio, Tomohiro			APRIL-dependent lifelong plasmacyte maintenance and immunoglobulin production in humans	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						APRIL; BAFF; TACI; BCMA; B cell; plasmacyte; somatic hypermutation; class switch recombination; common variable immunodeficiency	COMMON VARIABLE IMMUNODEFICIENCY; ZONE B-CELLS; NECROSIS-FACTOR FAMILY; BONE-MARROW; TNF FAMILY; LIGAND; BAFF; TACI; DIFFERENTIATION; CLASSIFICATION	Background: Interactions between the tumor necrosis factor (TNF) ligand superfamily and TNF receptor superfamily play critical roles in B-cell development and maturation. A proliferation-inducing ligand (APRIL), a member of the TNF ligand superfamily, is secreted from myeloid cells and known to induce the differentiation of memory B cells to plasmacytes. Objective: We sought to elucidate the role of APRIL in B-cell differentiation and immunoglobulin production through the analysis of complete APRIL deficiency in human. Methods: We performed whole exome sequencing in a patient with adult common variable immunodeficiency. His parents were in a consanguineous marriage. TNFSF13 mRNA and protein expression were analyzed in the primary cells and plasma from the patient and in cDNA-transfected cells and supernatants of the cultures in vitro. Immunologic analysis was performed by using flow cytometry and next-generation sequencing. Monocyte-derived dendritic cells differentiated from induced pluripotent stem cells (iPSC-moDCs) were cocultured with memory B cells from healthy controls to examine in vitro plasmacyte differentiation. Results: We identified a homozygous frameshift mutation in TNFSF13, the gene encoding APRIL, in the patient. APRIL mRNA and protein were completely absent in the monocytes and iPSC-moDCs of the patient. In contrast to the results of previous animal model studies, the patient showed hypogammaglobulinemia with a markedly reduced level of plasmacytes in peripheral blood and a clearly increased level of circulating marginal zone B cells. Although iPSC-moDC-induced in vitro plasmacyte differentiation was reduced in the patient, recombinant APRIL supplementation corrected this abnormality. Conclusion: The first APRIL deficiency in an adult patient with common variable immunodeficiency revealed the role of APRIL in lifelong maintenance of plasmacytes and immunoglobulin production in humans.	[Yeh, Tzu-Wen; Okano, Tsubasa; Okamura, Miko; Tanita, Kay; Mitsuiki, Noriko; Morio, Tomohiro] Tokyo Med & Dent Univ TMDU, Dept Pediat & Dev Biol, Tokyo, Japan; [Naruto, Takuya] Tokyo Med & Dent Univ TMDU, Dept Lifetime Clin Immunol, Tokyo, Japan; [Yamashita, Motoi; Kanegane, Hirokazu] Tokyo Med & Dent Univ TMDU, Dept Child Hlth & Dev, Tokyo, Japan; [Imai, Kohsuke] Tokyo Med & Dent Univ TMDU, Dept Community Pediat Perinatal & Maternal Med, Tokyo, Japan; [Du, Likun; Pan-Hammarstrom, Qiang] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden; [Okada, Satoshi] Hiroshima Univ, Dept Pediat, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Karolinska Institutet; Hiroshima University	Imai, K (corresponding author), Tokyo Med & Dent Univ TMDU, Dept Community Pediat Perinatal & Maternal Med, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	kimai.ped@tmd.ac.jp	Okada, Satoshi/B-8901-2011; 岡野, 翼/AAU-8246-2021; Yamashita, Motoi/ABB-5789-2021; Imai, Kohsuke/Q-2602-2015; hammarstrom, qiang pan/ABA-4589-2021	Okada, Satoshi/0000-0002-4622-5657; Imai, Kohsuke/0000-0003-2132-8403; Du, Likun/0000-0002-8448-2187; pan-hammarstrom, qiang/0000-0003-1990-8804	Japanese Society for the Promotion of Science [15K09640, 18K07814]; Japan Ministry of Health, Labor, and Welfare; Japan Agency for Medical Research and Development, Japanese Agency for Medical Research and Development [JP16kk0205012, JP16ek0109179]; Center for Innovative Medicine (CIMED), the Swedish Cancer Society; Swedish Research Council; Jeffrey Modell Foundation	Japanese Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Ministry of Health, Labor, and Welfare(Ministry of Health, Labour and Welfare, Japan); Japan Agency for Medical Research and Development, Japanese Agency for Medical Research and Development; Center for Innovative Medicine (CIMED), the Swedish Cancer Society; Swedish Research Council(Swedish Research CouncilEuropean Commission); Jeffrey Modell Foundation	Supported by grants from the Japanese Society for the Promotion of Science Grants-in-Aid for Scientific Research program (grants 15K09640 and 18K07814); the Japan Ministry of Health, Labor, and Welfare; the Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development (grants JP16kk0205012 and JP16ek0109179), Japanese Agency for Medical Research and Development; Center for Innovative Medicine (CIMED), the Swedish Cancer Society; the Swedish Research Council; and the Jeffrey Modell Foundation.	Balazs M, 2002, IMMUNITY, V17, P341, DOI 10.1016/S1074-7613(02)00389-8; Belnoue E, 2008, BLOOD, V111, P2755, DOI 10.1182/blood-2007-09-110858; Blanco E, 2018, J ALLERGY CLIN IMMUN, V141, P2208, DOI 10.1016/j.jaci.2018.02.017; Bogaert DJA, 2016, J MED GENET, V53, P575, DOI 10.1136/jmedgenet-2015-103690; Bossen C, 2006, SEMIN IMMUNOL, V18, P263, DOI 10.1016/j.smim.2006.04.006; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Castigli E, 2004, P NATL ACAD SCI USA, V101, P3903, DOI 10.1073/pnas.0307348101; Cerutti A, 2013, NAT REV IMMUNOL, V13, P118, DOI 10.1038/nri3383; Craxton A, 2003, BLOOD, V101, P4464, DOI 10.1182/blood-2002-10-3123; Dong WJ, 2009, RHEUMATOL INT, V29, P801, DOI 10.1007/s00296-008-0773-7; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; Hu JZ, 2016, NAT PROTOC, V11, P853, DOI 10.1038/nprot.2016.043; Ishimura M, 2011, J CLIN IMMUNOL, V31, P968, DOI 10.1007/s10875-011-9594-7; Jin R, 2008, INT J MOL MED, V21, P233; Joo H, 2012, J EXP MED, V209, P1335, DOI 10.1084/jem.20111644; Jung S, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00174; Kamae C, 2013, J ALLERGY CLIN IMMUN, V131, P1437, DOI 10.1016/j.jaci.2012.10.059; Khodadadi L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00721; Klein U, 1997, BLOOD, V89, P1288, DOI 10.1182/blood.V89.4.1288; Lightman SM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00965; Lin HT, 2015, MOL THER-METH CLIN D, V2, DOI 10.1038/mtm.2015.46; Lopez-Fraga M, 2001, EMBO REP, V2, P945, DOI 10.1093/embo-reports/kve198; Naruto T, 2015, SCI REP-UK, V5, DOI 10.1038/srep11334; O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330; Okumura T, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1273-2; Pan-Hammarstrom Q, 2007, NAT GENET, V39, P429, DOI 10.1038/ng0407-429; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Pieper K, 2013, J ALLERGY CLIN IMMUN, V131, P959, DOI 10.1016/j.jaci.2013.01.046; Piqueras B, 2003, J CLIN IMMUNOL, V23, P385, DOI 10.1023/A:1025373601374; Puga I, 2012, NAT IMMUNOL, V13, P170, DOI 10.1038/ni.2194; Roschke V, 2002, J IMMUNOL, V169, P4314, DOI 10.4049/jimmunol.169.8.4314; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Shu HB, 1999, J LEUKOCYTE BIOL, V65, P680, DOI 10.1002/jlb.65.5.680; Takashima T, 2017, J CLIN IMMUNOL, V37, P486, DOI 10.1007/s10875-017-0405-7; Tangye SG, 2011, TRENDS IMMUNOL, V32, P595, DOI 10.1016/j.it.2011.09.001; Taubenheim N, 2005, J IMMUNOL, V175, P5498, DOI 10.4049/jimmunol.175.8.5498; Tezuka H, 2011, IMMUNITY, V34, P247, DOI 10.1016/j.immuni.2011.02.002; Treamtrakanpon W, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4095; Van TC, 2011, NAT IMMUNOL, V12, P151, DOI 10.1038/ni.1981; Varfolomeev E, 2004, MOL CELL BIOL, V24, P997, DOI 10.1128/MCB.24.3.997-1006.2004; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Weller S, 2004, BLOOD, V104, P3647, DOI 10.1182/blood-2004-01-0346; Yanagimachi MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059243; Yong PFK, 2011, ADV IMMUNOL, V111, P47, DOI 10.1016/B978-0-12-385991-4.00002-7	45	18	18	2	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2020	146	5					1109	+		10.1016/j.jaci.2020.03.025	http://dx.doi.org/10.1016/j.jaci.2020.03.025			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OP5VH	32298700				2022-12-18	WOS:000588153700015
J	Valent, P; Akin, C; Bonadonna, P; Brockow, K; Niedoszytko, M; Nedoszytko, B; Butterfield, JH; Alvarez-Twose, I; Sotlar, K; Schwaab, J; Jawhar, M; Reiter, A; Castells, M; Sperr, WR; Kluin-Nelemans, HC; Hermine, O; Gotlib, J; Zanotti, R; Broesby-Olsen, S; Horny, HP; Triggiani, M; Siebenhaar, F; Orfao, A; Metcalfe, DD; Arock, M; Hartmann, K				Valent, Peter; Akin, Cem; Bonadonna, Patrizia; Brockow, Knut; Niedoszytko, Marek; Nedoszytko, Boguslaw; Butterfield, Joseph H.; Alvarez-Twose, Ivan; Sotlar, Karl; Schwaab, Juliana; Jawhar, Mohamad; Reiter, Andreas; Castells, Mariana; Sperr, Wolfgang R.; Kluin-Nelemans, Hanneke C.; Hermine, Olivier; Gotlib, Jason; Zanotti, Roberta; Broesby-Olsen, Sigurd; Horny, Hans-Peter; Triggiani, Massimo; Siebenhaar, Frank; Orfao, Alberto; Metcalfe, Dean D.; Arock, Michel; Hartmann, Karin			Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; mastocytosis; tryptase; KIT D816V; coronavirus; COVID-19; SARS-CoV-2; mast cell activation syndrome	CELL ACTIVATION SYNDROMES; MAST-CELLS; CLASSIFICATION; INFECTION; MIDOSTAURIN; DISORDERS; DIAGNOSIS; EFFICACY; CRITERIA; SAFETY	The coronavirus disease 2019 (COVID-19) (caused by severe acute respiratory syndrome coronavirus 2) pandemic has massively distorted our health care systems and caused catastrophic consequences in our affected communities. The number of victims continues to increase, and patients at risk can only be protected to a degree, because the virulent state may be asymptomatic. Risk factors concerning COVID-19 induced morbidity and mortality include advanced age, an impaired immune system, cardiovascular or pulmonary diseases, obesity, diabetes mellitus, and cancer treated with chemotherapy. Here, we discuss the risk and impact of COVID-19 in patients with mastocytosis and mast cell activation syndromes. Because no published data are yet available, expert opinions are, by necessity, based on case experience and reports from patients. Although the overall risk to acquire the severe acute respiratory syndrome coronavirus 2 may not be elevated in mast cell disease, certain conditions may increase the risk of infected patients to develop severe COVID-19. These factors include certain comorbidities, mast cell activation related events affecting the cardiovascular or bronchopulmonary system, and chemotherapy or immunosuppressive drugs. Therefore, such treatments should be carefully evaluated on a case-by-case basis during a COVID-19 infection. In contrast, other therapies, such as anti-mediator-type drugs, venom immunotherapy, or vitamin D, should be continued. Overall, patients with mast cell disorders should follow the general and local guidelines in the COVID-19 pandemic and advice from their medical provider.	[Valent, Peter; Sperr, Wolfgang R.] Med Univ Vienna, Dept Internal Med 1, Div Haematol, Vienna, Austria; [Valent, Peter; Sperr, Wolfgang R.] Med Univ Vienna, Ludwig Boltzmann Inst Hematol & Oncol, Waehringer Guertel 18-20, A-1090 Vienna, Austria; [Akin, Cem] Univ Michigan, Div Allergy & Clin Immunol, Ann Arbor, MI 48109 USA; [Bonadonna, Patrizia] Verona Univ Hosp, Allergy Unit, Verona, Italy; [Brockow, Knut] Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Munich, Germany; [Niedoszytko, Marek] Med Univ Gdansk, Dept Allergol, Gdansk, Poland; [Nedoszytko, Boguslaw] Med Univ Gdansk, Dept Dermatol, Gdansk, Poland; [Butterfield, Joseph H.] Mayo Clinic, Div Allerg Dis, Rochester, MN USA; [Alvarez-Twose, Ivan] Hosp Virgen del Valle, Inst Estudios Mastocitosis Castilla La Mancha CLM, Toledo, Spain; [Alvarez-Twose, Ivan] Hosp Virgen del Valle, CIBERONC, Toledo, Spain; [Sotlar, Karl] Paracelsus Med Univ Salzburg, Inst Pathol, Salzburg, Austria; [Schwaab, Juliana; Jawhar, Mohamad; Reiter, Andreas] Univ Hosp Mannheim, Dept Hematol & Oncol, Mannheim, Germany; [Castells, Mariana] Harvard Med Sch, Mastocytosis Ctr, Brigham & Womens Hosp, Boston, MA 02115 USA; [Kluin-Nelemans, Hanneke C.] Univ Groningen, Univ Med Ctr Groningen, Dept Haematol, Groningen, Netherlands; [Hermine, Olivier] Univ Paris 05, Imagine Inst, Sorbonne Paris Cite, Ctr Natl Reference Mastocytoses, Paris, France; [Gotlib, Jason] Stanford Univ, Stanford Canc Inst, Sch Med, Stanford, CA 94305 USA; [Zanotti, Roberta] Univ Verona, Dept Med, Sect Hematol, Verona, Italy; [Broesby-Olsen, Sigurd] Odense Univ Hosp, Dept Dermatol, Odense, Denmark; [Broesby-Olsen, Sigurd] Odense Univ Hosp, Allergy Ctr, Odense, Denmark; [Horny, Hans-Peter] Ludwig Maximilians Univ Munchen, Inst Pathol, Munich, Germany; [Triggiani, Massimo] Univ Salerno, Div Allergy & Clin Immunol, Salerno, Italy; [Siebenhaar, Frank] Charite Univ Med Berlin, Dermatol Allergol, Dept Dermatol & Allergy, Berlin, Germany; [Siebenhaar, Frank] Free Univ Berlin, Berlin, Germany; [Siebenhaar, Frank] Humboldt Univ, Berlin, Germany; [Siebenhaar, Frank] Berlin Inst Hlth, Berlin, Germany; [Orfao, Alberto] Univ Salamanca, Serv Cent Citometria, Ctr Invest Canc, IBMCC,CSICUSAL,IBSAL,CIBERONC, Salamanca, Spain; [Orfao, Alberto] Univ Salamanca, Dept Med, Salamanca, Spain; [Metcalfe, Dean D.] Charite Univ Med Berlin, Dept Dermatol & Allergy, Berlin, Germany; [Arock, Michel] Pierre & Marie Curie Univ UPMC, Dept Hematol Biol, Pitie Salpetriere Hosp, Paris, France; [Hartmann, Karin] Univ Basel, Div Allergy, Dept Dermatol, Basel, Switzerland; [Hartmann, Karin] Univ Basel, Dept Biomed, Basel, Switzerland	Medical University of Vienna; Ludwig Boltzmann Institute; Medical University of Vienna; University of Michigan System; University of Michigan; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; Technical University of Munich; Fahrenheit Universities; Medical University Gdansk; Fahrenheit Universities; Medical University Gdansk; Mayo Clinic; Complejo Hospitalario de Toledo; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Complejo Hospitalario de Toledo; Paracelsus Private Medical University; Ruprecht Karls University Heidelberg; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Groningen; UDICE-French Research Universities; Universite Paris Cite; Stanford Cancer Institute; Stanford University; University of Verona; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Munich; University of Salerno; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Basel; University of Basel	Valent, P (corresponding author), Med Univ Vienna, Ludwig Boltzmann Inst Hematol & Oncol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.; Valent, P (corresponding author), Univ Vienna, Dept Med 1, Div Hematol & Hemostaseol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	peter.valent@meduniwien.ac.at	Hartmann, Karin/N-4865-2015; Valent, Peter/B-8533-2016; Hermine, Olivier/Q-7072-2018; Nedoszytko, Boguslaw/AAY-5079-2020; Niedoszytko, Marek/U-1250-2018	Hartmann, Karin/0000-0002-4595-8226; Valent, Peter/0000-0003-0456-5095; Siebenhaar, Frank/0000-0003-4532-1644; Sperr, Wolfgang/0000-0003-3288-8027; Nedoszytko, Boguslaw/0000-0002-6286-0693; Niedoszytko, Marek/0000-0003-1089-1911	Austrian Science Fund (FWF) [P32470-B, F4704B20]; Charles and Ann Johnson Foundation; Division of Intramural Research, National Institute of Allergy and Infectious Diseases	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Charles and Ann Johnson Foundation; Division of Intramural Research, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	P.V. was supported by the Austrian Science Fund (FWF; projects P32470-B and F4704B20). J.G. is supported by the Charles and Ann Johnson Foundation. D.D.M. is supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases.	Akin C, 2010, J ALLERGY CLIN IMMUN, V126, P1099, DOI 10.1016/j.jaci.2010.08.035; Akoto C, 2017, CLIN EXP ALLERGY, V47, P351, DOI 10.1111/cea.12879; Arock M, 2015, LEUKEMIA, V29, P1223, DOI 10.1038/leu.2015.24; Arock M, 2015, EUR J HAEMATOL, V94, P474, DOI 10.1111/ejh.12544; Broesby-Olsen S, 2018, ALLERGY, V73, P230, DOI 10.1111/all.13237; Caccialanza R, 2020, NUTRITION, V74, DOI 10.1016/j.nut.2020.110835; Carter SJ, 2020, OBESITY, V28, P1176, DOI 10.1002/oby.22838; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Cruse G, 2010, J IMMUNOL, V184, P7108, DOI 10.4049/jimmunol.0900802; D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756; Dawicki W, 2007, CURR OPIN IMMUNOL, V19, P31, DOI 10.1016/j.coi.2006.11.006; Galli SJ, 2010, EUR J IMMUNOL, V40, P1843, DOI 10.1002/eji.201040559; Gavillet M, 2020, LEUKEMIA RES, V92, DOI 10.1016/j.leukres.2020.106353; Gotlib J, 2016, NEW ENGL J MED, V374, P2530, DOI 10.1056/NEJMoa1513098; GRANT WB, 2020, NUTRIENTS, V12, DOI [10.3390/nu12040988, DOI 10.3390/NU12040988]; Hartmann K, 2016, J ALLERGY CLIN IMMUN, V137, P35, DOI 10.1016/j.jaci.2015.08.034; Horny H-P., 2017, WHO CLASSIFICATION T, P61; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jakovac H, 2020, AM J PHYSIOL-ENDOC M, V318, pE589, DOI 10.1152/ajpendo.00138.2020; Jendoubi F, 2020, CLIN EXP ALLERGY, V50, P654, DOI 10.1111/cea.13592; Kluin-Nelemans HC, 2003, BLOOD, V102, P4270, DOI 10.1182/blood-2003-05-1699; Kritas SK, 2020, J BIOL REG HOMEOS AG, V34, P9, DOI 10.23812/20-Editorial-Kritas; Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0; Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6; Lyons JJ, 2016, NAT GENET, V48, P1564, DOI 10.1038/ng.3696; Lyons JJ, 2014, J ALLERGY CLIN IMMUN, V133, P1471, DOI 10.1016/j.jaci.2013.11.039; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Mayerhofer M, 2007, INT J IMMUNOPATH PH, V20, P421, DOI 10.1177/039463200702000301; McCartney D M, 2020, Ir Med J, V113, P58; Metcalfe DD, 2008, BLOOD, V112, P946, DOI 10.1182/blood-2007-11-078097; Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097; Reiter A, 2020, BLOOD, V135, P1365, DOI 10.1182/blood.2019000932; Sabato V, 2018, J CLIN IMMUNOL, V38, P457, DOI 10.1007/s10875-018-0506-y; St John AL, 2011, P NATL ACAD SCI USA, V108, P9190, DOI 10.1073/pnas.1105079108; Sundstrom JB, 2007, BLOOD, V109, P5293, DOI 10.1182/blood-2006-11-058438; Theoharides TC, 2015, NEW ENGL J MED, V373, P163, DOI 10.1056/NEJMra1409760; Ustun C, 2014, J CLIN ONCOL, V32, P3264, DOI 10.1200/JCO.2014.55.2018; VALENT F, 2019, J ALLERGY CLIN IMMUN, V7, DOI DOI 10.1136/FMCH-2019-000198; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Valent P, 2017, ANN ONCOL, V28, P2367, DOI 10.1093/annonc/mdx290; Valent P, 2004, J ALLERGY CLIN IMMUN, V114, P3, DOI 10.1016/j.jaci.2004.02.045; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Valent P, 2013, ALLERGY, V68, P417, DOI 10.1111/all.12126; Valent P, 2017, BLOOD, V129, P1420, DOI 10.1182/blood-2016-09-731893; Valent P, 2012, INT ARCH ALLERGY IMM, V157, P215, DOI 10.1159/000328760; Valent P, 2010, BLOOD, V116, P5812, DOI 10.1182/blood-2010-08-292144; Vatent P, 2019, INT J MOL SCI, V20; Wang DW, 2020, J COASTAL RES, P1, DOI [10.1001/jama.2020.1585, 10.2112/JCR-SI109-001.1]; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou YL, 2020, ANN PALLIAT MED, V9, P428, DOI 10.21037/apm.2020.03.26	52	18	19	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2020	146	2					300	306		10.1016/j.jaci.2020.06.009	http://dx.doi.org/10.1016/j.jaci.2020.06.009			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ0TA	32561389	Green Published, hybrid			2022-12-18	WOS:000558835000014
J	Jian, L; Yi, W; Zhang, N; Wen, WP; Krysko, O; Song, WJ; Bachert, C				Jian, Li; Yi, Wei; Zhang, Nan; Wen, Weiping; Krysko, Olga; Song, Woo-Jung; Bachert, Claus			Perspective: COVID-19, implications of nasal diseases and consequences for their management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						SARS-CoV-2; COVID-19; chronic rhinosinusitis; allergy; corticosteroids; biologics	ACE2		[Jian, Li; Yi, Wei; Wen, Weiping; Bachert, Claus] Sun Yat Sen Univ, Int Airway Res Ctr, Affiliated Hosp 1, 58 Zhong Shan Er Lu, Guangzhou 510080, Peoples R China; [Zhang, Nan; Krysko, Olga; Bachert, Claus] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium; [Zhang, Nan; Krysko, Olga; Bachert, Claus] Univ Ghent, Dept Otorhinolaryngol, Ghent, Belgium; [Song, Woo-Jung] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Allergy & Clin Immunol, Seoul, South Korea; [Bachert, Claus] Univ Stockholm, Karolinska Inst, CLINTEC, Div ENT Dis, Stockholm, Sweden	Sun Yat Sen University; Ghent University; Ghent University; University of Ulsan; Asan Medical Center; Karolinska Institutet; Stockholm University	Bachert, C (corresponding author), Sun Yat Sen Univ, Int Airway Res Ctr, Affiliated Hosp 1, 58 Zhong Shan Er Lu, Guangzhou 510080, Peoples R China.	claus.bachert@ugent.be	Krysko, Olga/C-2481-2009; Bachert, Claus/J-8825-2012; 温, 家琦/GYV-3177-2022	Krysko, Olga/0000-0001-5019-0752; 				Bousquet J, 2020, ALLERGY, V75, P2440, DOI 10.1111/all.14302; Brann DH, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc5801; Dhawale VS, 2016, TOXICOL APPL PHARM, V306, P17, DOI 10.1016/j.taap.2016.06.026; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Kam YW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007870; Patel ZM, 2020, NEUROSURGERY, V87, pE66, DOI 10.1093/neuros/nyaa125; Sungnak W, 2020, ARXIV200306122; Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238; Ziegler C, CELL; Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737	10	18	19	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					67	69		10.1016/j.jaci.2020.04.030	http://dx.doi.org/10.1016/j.jaci.2020.04.030			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32360869	Green Published, Bronze			2022-12-18	WOS:000579170500012
J	Malipiero, G; Paoletti, G; Puggioni, F; Racca, F; Ferri, S; Marsala, A; Leoncini, O; Porli, M; Pieri, G; Canonica, GW; Heffler, E				Malipiero, Giacomo; Paoletti, Giovanni; Puggioni, Francesca; Racca, Francesca; Ferri, Sebastian; Marsala, Antonino; Leoncini, Ornella; Porli, Monica; Pieri, Gabriella; Canonica, Giorgio Walter; Heffler, Enrico			An academic allergy unit during COVID-19 pandemic in Italy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Malipiero, Giacomo; Paoletti, Giovanni; Puggioni, Francesca; Racca, Francesca; Ferri, Sebastian; Canonica, Giorgio Walter; Heffler, Enrico] IRCCS, Humanitas Clin & Res Ctr, Personalized Med, Asthma & Allergy, Rozzano, Italy; [Paoletti, Giovanni; Puggioni, Francesca; Ferri, Sebastian; Canonica, Giorgio Walter; Heffler, Enrico] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy; [Marsala, Antonino] Humanitas Univ, IT Serv, Pieve Emanuele, Italy; [Leoncini, Ornella] IRCCS, Humanitas Clin & Res Ctr, Hosp Hlth Direct Off, Hlth Informat Flow Management, Rozzano, Italy; [Porli, Monica] IRCCS, Humanitas Clin & Res Ctr, Qual Monitoring Off, Rozzano, Italy; [Pieri, Gabriella] IRCCS, Humanitas Clin & Res Ctr, Pharm, Milan, Italy	IRCCS Humanitas Research Hospital; Humanitas University; Humanitas University; IRCCS Humanitas Research Hospital; IRCCS Humanitas Research Hospital	Heffler, E (corresponding author), IRCCS, Humanitas Clin & Res Ctr, Personalized Med, Asthma & Allergy, Rozzano, Italy.; Heffler, E (corresponding author), Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy.	enrico.heffler@hunimed.eu	canonica, giorgio walter/ABF-2037-2020; Paoletti, Giovanni/ABC-1135-2020; Heffler, Enrico/F-9455-2010	canonica, giorgio walter/0000-0001-8467-2557; Paoletti, Giovanni/0000-0003-3953-9225; Heffler, Enrico/0000-0002-0492-5663; Malipiero, Giacomo/0000-0002-2914-8258; Ferri, Sebastian/0000-0002-1831-9672; Puggioni, Francesca/0000-0001-6638-5626				Codispoti CD, 2020, J ALLERGY CLIN IMMUN, V145, P1357, DOI 10.1016/j.jaci.2020.03.018; Heffler E, 2019, J ALLER CL IMM-PRACT, V7, P1462, DOI 10.1016/j.jaip.2018.10.016; Pitsios C, 2019, CLIN TRANSL ALLERGY, V9, DOI 10.1186/s13601-019-0285-4	3	18	19	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					227	227		10.1016/j.jaci.2020.04.003	http://dx.doi.org/10.1016/j.jaci.2020.04.003			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32317114	Green Published, Bronze			2022-12-18	WOS:000579170500038
J	Kicic, A; de Jong, E; Ling, KM; Nichol, K; Anderson, D; Wark, PAB; Knight, DA; Bosco, A; Stick, SM				Kicic, Anthony; de Jong, Emma; Ling, Kak-Ming; Nichol, Kristy; Anderson, Denise; Wark, Peter A. B.; Knight, Darryl A.; Bosco, Anthony; Stick, Stephen M.		WAERP; AusREC	Assessing the unified airway hypothesis in children via transcriptional profiling of the airway epithelium	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway epithelium; unified airway hypothesis; transcriptomics; gene expression; biological processes	ALLERGIC RHINITIS; GENE-EXPRESSION; ASTHMA; NASAL; DISEASE; CELL; BIOLOGY; HYPERRESPONSIVENESS; INFLAMMATION; PERIOSTIN	Background: Emerging evidence suggests that disease vulnerability is expressed throughout the airways, the so-called unified airway hypothesis, but the evidence to support this is predominantly indirect. Objectives: We sought to establish the transcriptomic profiles of the upper and lower airways and determine their level of similarity irrespective of airway symptoms (wheeze) and allergy. Methods: We performed RNA sequencing on upper and lower airway epithelial cells from 63 children with or without wheeze and accompanying atopy, using differential gene expression and gene coexpression analyses to determine transcriptional similarity. Results: We observed approximately 91% homology in the expressed genes between the 2 sites. When coexpressed genes were grouped into modules relating to biological functions, all were found to be conserved between the 2 regions, resulting in a consensus network containing 16 modules associated with ribosomal function, metabolism, gene expression, mitochondrial activity, and antiviral responses through IFN activity. Although symptom-associated gene expression changes were more prominent in the lower airway, they were reflected in nasal epithelium and included IL-1 receptor like 1, prostaglandin-endoperoxide synthase 1, CCL26, and periostin. Through network analysis we identified a cluster of coexpressed genes associated with atopic wheeze in the lower airway, which could equally distinguish atopic and nonatopic phenotypes in upper airway samples. Conclusions: We show that the upper and lower airways are significantly conserved in their transcriptional composition, and that variations associated with disease are present in both nasal and tracheal epithelium. Findings from this study supporting a unified airway imply that clinical insight regarding the lower airway in health and disease can be gained from studying the nasal epithelium.	[Kicic, Anthony; de Jong, Emma; Anderson, Denise; Bosco, Anthony; Stick, Stephen M.; WAERP] Univ Western Australia, Ctr Hlth Res, Telethon Kids Inst, Nedlands, WA, Australia; [Kicic, Anthony] Curtin Univ, Sch Publ Hlth, Occupat & Environm, Perth, WA, Australia; [Kicic, Anthony; Ling, Kak-Ming; Stick, Stephen M.] Univ Western Australia, Sch Biomed Sci, Nedlands, WA, Australia; [Kicic, Anthony; Stick, Stephen M.] Princess Margaret Hosp Children, Dept Resp Med, Perth, WA, Australia; [Kicic, Anthony; Stick, Stephen M.] Univ Western Australia, Ctr Cell Therapy & Regenerat Med, Sch Med & Pharmacol, Nedlands, WA, Australia; [Kicic, Anthony; Stick, Stephen M.] Harry Perkins Inst Med Res, Nedlands, WA, Australia; [Nichol, Kristy; Wark, Peter A. B.; Knight, Darryl A.] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW, Australia; [Nichol, Kristy; Wark, Peter A. B.; Knight, Darryl A.] Hunter Med Res Inst, Prior Res Ctr Hlth Lungs, Newcastle, NSW, Australia; [Knight, Darryl A.] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC, Canada; Univ Adelaide, Robinson Res Inst, Adelaide, SA, Australia; [AusREC] Prior Res Ctr Asthma & Resp Dis, Hunter Med Res Inst, New Lambton Hts, Australia	Telethon Kids Institute; University of Western Australia; Curtin University; University of Western Australia; University of Western Australia; University of Western Australia; Harry Perkins Institute of Medical Research; University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of British Columbia; Robinson Research Institute; University of Adelaide; Hunter Medical Research Institute; University of Newcastle	Kicic, A (corresponding author), Telethon Kids Inst, 15 Hosp Ave, Perth, WA 6009, Australia.	Anthony.Kicic@telethonkids.org.au	Kicic, Anthony/ABA-1252-2021; Bosco, Anthony/AAC-6900-2022; Stick, Stephen/GZG-7584-2022; de Jong, Emma/AHC-9300-2022; Ling, Kak Ming/AAD-1167-2020; Montgomery, Samuel/AAD-4406-2022; Garratt, Luke/N-2371-2013	Kicic, Anthony/0000-0002-0008-9733; de Jong, Emma/0000-0002-2501-6119; Ling, Kak Ming/0000-0001-7743-3179; Martinovich, Kelly/0000-0002-9283-2204; Grainge, Christopher/0000-0002-6565-9928; Roscioli, Eugene/0000-0002-3201-3899; Montgomery, Samuel/0000-0001-7132-852X; Garratt, Luke/0000-0001-9381-326X; Larcombe, Alexander/0000-0003-4196-4482; Sutanto, Erika/0000-0002-4224-2839; Bosco, Anthony/0000-0002-4335-615X; Anderson, Denise/0000-0003-0643-4136; Landwehr, Katherine/0000-0002-1543-6304	Asthma Australia; Simon Lee Foundation	Asthma Australia; Simon Lee Foundation	This work was supported by a grant from Asthma Australia. S.M.S. is an National Health and Medical Research Council (NHMRC) Practitioner Fellow. A.K. is a Rothwell Family Fellow. A.B. is supported by a Fellowship from the Simon Lee Foundation.	Agondi RC, 2008, J ASTHMA, V45, P754, DOI 10.1080/02770900802249149; Alevy YG, 2012, J CLIN INVEST, V122, P4555, DOI 10.1172/JCI64896; Andrews S, FASTQC QUALITY CONTR; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bachert C, 2004, IMMUNOL ALLERGY CLIN, V24, P19, DOI 10.1016/S0889-8561(03)00104-8; Baslan T, 2017, NAT REV CANCER, V17, P557, DOI 10.1038/nrc.2017.58; Bentley JK, 2014, J ALLERGY CLIN IMMUN, V134, P1433, DOI 10.1016/j.jaci.2014.05.029; Bhakta Nirav R, 2013, Clin Transl Allergy, V3, P24, DOI 10.1186/2045-7022-3-24; Boudewijn IM, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0696-5; Bourdin A, 2009, THORAX, V64, P999, DOI 10.1136/thx.2008.112862; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Braunstahl GJ, 2001, AM J RESP CRIT CARE, V164, P858, DOI 10.1164/ajrccm.164.5.2006082; Brett TJ, 2015, EXPERT REV RESP MED, V9, P503, DOI 10.1586/17476348.2015.1081064; Breuer K, 2013, NUCLEIC ACIDS RES, V41, pD1228, DOI 10.1093/nar/gks1147; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588, DOI 10.1164/ajrccm.159.2.9801022; Chen Yunshun, 2016, F1000Res, V5, P1438, DOI 10.12688/f1000research.8987.2; Clarke LA, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-38; Court MH, 2010, DRUG METAB REV, V42, P209, DOI 10.3109/03602530903209288; Crystal-Peters J, 2002, J ALLERGY CLIN IMMUN, V109, P57, DOI 10.1067/mai.2002.120554; Dickinson DP, 2002, CRIT REV ORAL BIOL M, V13, P485, DOI 10.1177/154411130201300606; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fabian TK, 2012, INT J MOL SCI, V13, P4295, DOI 10.3390/ijms13044295; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Fontanari P, 1997, EUR RESPIR J, V10, P2250, DOI 10.1183/09031936.97.10102250; Gaga M, 2000, CLIN EXP ALLERGY, V30, P663; Giavina-Bianchi P, 2016, J ASTHMA ALLERGY, V9, P93, DOI 10.2147/JAA.S81541; Guajardo JR, 2005, J ALLERGY CLIN IMMUN, V115, P243, DOI 10.1016/j.jaci.2004.10.032; Heydel JM, 2010, DRUG METAB REV, V42, P74, DOI 10.3109/03602530903208363; Huang F, 2012, P NATL ACAD SCI USA, V109, P16354, DOI 10.1073/pnas.1214596109; Imoto Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067057; Jain R, 2010, AM J RESP CELL MOL, V43, P731, DOI 10.1165/rcmb.2009-0328OC; Jones AC, 2017, AM J RESP CRIT CARE, V195, P1409, DOI 10.1164/rccm.201612-2572ED; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56, DOI 10.1164/ajrccm.153.1.8542163; Kicic A, 2006, AM J RESP CRIT CARE, V174, P1110, DOI 10.1164/rccm.200603-392OC; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kolodziejczyk AA, 2015, MOL CELL, V58, P610, DOI 10.1016/j.molcel.2015.04.005; Krouse JH, 2008, OTOLARYNG CLIN N AM, V41, P257, DOI 10.1016/j.otc.2007.11.002; Lane C, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-53; Lane C, 2004, THORAX, V59, P757, DOI 10.1136/thx.2003.014894; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lassmann T, 2011, BIOINFORMATICS, V27, P130, DOI 10.1093/bioinformatics/btq614; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; Li BS, 2014, J INVEST DERMATOL, V134, P1828, DOI 10.1038/jid.2014.28; Lindahl M, 1999, ELECTROPHORESIS, V20, P3670, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3670::AID-ELPS3670>3.0.CO;2-Z; Lohia S, 2013, ALLERGY, V68, P569, DOI 10.1111/all.12124; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Meena RS, 2013, INDIAN J OTOLARYNGOL, V65, pS338, DOI 10.1007/s12070-012-0495-8; MICHEL FB, 1977, AM REV RESPIR DIS, V115, P609; Mirsafian H, 2017, GENOMICS, V109, P463, DOI 10.1016/j.ygeno.2017.07.003; Mygind N, 1990, RHINITIS ASTHMA SIMI; Nunomura S, 2018, WOUND REPAIR REGEN, V26, P6, DOI 10.1111/wrr.12616; Ogilvie V, 2011, GENOMICS, V98, P327, DOI 10.1016/j.ygeno.2011.06.008; Ohno S, 2009, DRUG METAB DISPOS, V37, P32, DOI 10.1124/dmd.108.023598; Ouzzine M, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00349; Platts-Mills TAE, 1998, J ALLERGY CLIN IMMUN, V101, pS364, DOI 10.1016/S0091-6749(98)70221-0; Poole A, 2014, J ALLERGY CLIN IMMUN, V133, P670, DOI 10.1016/j.jaci.2013.11.025; Reynolds LM, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1522-4; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Ross AJ, 2007, AM J RESP CELL MOL, V37, P169, DOI 10.1165/rcmb.2006-0466OC; Singhania A, 2018, AM J RESP CELL MOL, V58, P261, DOI 10.1165/rcmb.2017-0162OC; Sridhar S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-259; Szczepankiewicz A, 2013, RESP MED, V107, P30, DOI 10.1016/j.rmed.2012.09.024; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Traister RS, 2015, J ALLERGY CLIN IMMUN, V135, P92, DOI 10.1016/j.jaci.2014.06.023; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; Walker JT, 2016, CELL TISSUE RES, V365, P453, DOI 10.1007/s00441-016-2426-6; Winpenny John P., 2009, Inflammation & Allergy Drug Targets, V8, P146; Yuyama N, 2002, CYTOKINE, V19, P287, DOI 10.1006/cyto.2002.1972; Zhang XL, 2010, PHYSIOL GENOMICS, V41, P1, DOI 10.1152/physiolgenomics.00167.2009; Zissler UM, 2016, ALLERGY, V71, P475, DOI 10.1111/all.12828	70	18	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1562	1573		10.1016/j.jaci.2020.02.018	http://dx.doi.org/10.1016/j.jaci.2020.02.018			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	32113981	Bronze			2022-12-18	WOS:000539157800012
J	Mucha, S; Baurecht, H; Novak, N; Rodriguez, E; Bej, S; Mayr, G; Emmert, H; Stolzl, D; Gerdes, S; Jung, ES; Degenhardt, F; Hubenthal, M; Ellinghaus, E; Kassens, JC; Wienbrandt, L; Lieb, W; Muller-Nurasyid, M; Hotze, M; Dand, N; Grosche, S; Marenholz, I; Arnold, A; Homuth, G; Schmidt, CO; Wehkamp, U; Nothen, MM; Hoffmann, P; Paternoster, L; Standl, M; Bonnelykke, K; Ahluwalia, TS; Bisgaard, H; Peters, A; Gieger, C; Waldenberger, M; Schulz, H; Strauch, K; Werfel, T; Lee, YA; Wolfien, M; Rosenstiel, P; Wolkenhauer, O; Schreiber, S; Franke, A; Weidinger, S; Ellinghaus, D				Mucha, Soren; Baurecht, Hansjorg; Novak, Natalija; Rodriguez, Elke; Bej, Saptarshi; Mayr, Gabriele; Emmert, Hila; Stoelzl, Dora; Gerdes, Sascha; Jung, Eun Suk; Degenhardt, Frauke; Huebenthal, Matthias; Ellinghaus, Eva; Kaessens, Jan Christian; Wienbrandt, Lars; Lieb, Wolfgang; Mueller-Nurasyid, Martina; Hotze, Melanie; Dand, Nick; Grosche, Sarah; Marenholz, Ingo; Arnold, Andreas; Homuth, Georg; Schmidt, Carsten O.; Wehkamp, Ulrike; Nothen, Markus M.; Hoffmann, Per; Paternoster, Lavinia; Standl, Marie; Bonnelykke, Klaus; Ahluwalia, Tarunveer S.; Bisgaard, Hans; Peters, Annette; Gieger, Christian; Waldenberger, Melanie; Schulz, Holger; Strauch, Konstantin; Werfel, Thomas; Lee, Young-Ae; Wolfien, Markus; Rosenstiel, Philip; Wolkenhauer, Olaf; Schreiber, Stefan; Franke, Andre; Weidinger, Stephan; Ellinghaus, David		Early Genetics Lifecourse	Protein-coding variants contribute to the risk of atopic dermatitis and skin-specific gene expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; exome chip association analysis; network analysis; protein sequence and structural domain analysis; RNA sequencing	GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; NEGATIVE REGULATORS; ALLERGIC DISEASE; CELL DEVELOPMENT; ROLES; DOK-2; RASGAP; ASTHMA; FAMILY	Background: Fifteen percent of atopic dermatitis (AD) liability-scale heritability could be attributed to 31 susceptibility loci identified by using genome-wide association studies, with only 3 of them (IL13, IL-6 receptor [IL6R], and filaggrin [FLG]) resolved to protein-coding variants. Objective: We examined whether a significant portion of unexplained AD heritability is further explained by low-frequency and rare variants in the gene-coding sequence. Methods: We evaluated common, low-frequency, and rare protein-coding variants using exome chip and replication genotype data of 15,574 patients and 377,839 control subjects combined with whole-transcriptome data on lesional, nonlesional, and healthy skin samples of 27 patients and 38 control subjects. Results: An additional 12.56% (SE, 0.74%) of AD heritability is explained by rare protein-coding variation. We identified docking protein 2 (DOK2) and CD200 receptor 1 (CD200R1) as novel genome-wide significant susceptibility genes. Rare coding variants associated with AD are further enriched in 5 genes (IL-4 receptor [IL4R], IL13, Janus kinase 1 [JAK1], JAK2, and tyrosine kinase 2 [TYK2]) of the IL13 pathway, all of which are targets for novel systemic AD therapeutics. Multiomics-based network and RNA sequencing analysis revealed DOK2 as a central hub interacting with, among others, CD200R1, IL6R, and signal transducer and activator of transcription 3 (STAT3). Multitissue gene expression profile analysis for 53 tissue types from the Genotype-Tissue Expression project showed that disease-associated protein-coding variants exert their greatest effect in skin tissues. Conclusion: Our discoveries highlight a major role of rare coding variants in AD acting independently of common variants. Further extensive functional studies are required to detect all potential causal variants and to specify the contribution of the novel susceptibility genes DOK2 and CD200R1 to overall disease susceptibility.	[Mucha, Soren; Mayr, Gabriele; Jung, Eun Suk; Degenhardt, Frauke; Huebenthal, Matthias; Ellinghaus, Eva; Kaessens, Jan Christian; Wienbrandt, Lars; Rosenstiel, Philip; Schreiber, Stefan; Franke, Andre; Ellinghaus, David] Christian Albrechts Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Lieb, Wolfgang] Christian Albrechts Univ Kiel, Inst Epidemiol & Biobank PopGen, Kiel, Germany; [Baurecht, Hansjorg; Rodriguez, Elke; Emmert, Hila; Stoelzl, Dora; Gerdes, Sascha; Huebenthal, Matthias; Hotze, Melanie; Wehkamp, Ulrike; Weidinger, Stephan] Univ Hosp Schleswig Holstein, Dept Dermatol Venereol & Allergy, Campus Kiel, Kiel, Germany; [Baurecht, Hansjorg] Univ Regensburg, Dept Epidemiol & Prevent Med, Regensburg, Germany; [Novak, Natalija] Univ Hosp Bonn, Dept Dermatol & Allergy, Bonn, Germany; [Bej, Saptarshi; Wolfien, Markus; Wolkenhauer, Olaf] Univ Rostock, Dept Syst Biol & Bioinformat, Rostock, Germany; [Jung, Eun Suk] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Jung, Eun Suk] Yonsei Univ, Coll Med, Inst Gastroenterol, Seoul, South Korea; [Mueller-Nurasyid, Martina; Strauch, Konstantin] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Genet Epidemiol, Neuherberg, Germany; [Mueller-Nurasyid, Martina; Standl, Marie; Peters, Annette; Schulz, Holger; Strauch, Konstantin] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol, Neuherberg, Germany; [Gieger, Christian; Waldenberger, Melanie] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Mol Epidemiol, Neuherberg, Germany; [Gieger, Christian; Waldenberger, Melanie] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 2, Neuherberg, Germany; [Mueller-Nurasyid, Martina; Strauch, Konstantin] Ludwig Maximilians Univ Munchen, Fac Med, IBE, Chair Genet Epidemiol, Munich, Germany; [Mueller-Nurasyid, Martina; Lee, Young-Ae] Hosp Ludwig Maximilians Univ, Dept Internal Med Cardiol 1, Munich, Germany; [Dand, Nick; Lee, Young-Ae] Kings Coll London, Fac Life Sci & Med, Sch Basic & Med Biosci, London, England; [Grosche, Sarah; Marenholz, Ingo] Charite Univ Med Berlin, Pediat Allergol Expt & Clin Res Ctr, Berlin, Germany; [Grosche, Sarah; Marenholz, Ingo] Max Delbruck Ctr Mol Med, Berlin, Germany; [Arnold, Andreas] Univ Med Greifswald, Clin & Polyclin Dermatol, Greifswald, Germany; [Schmidt, Carsten O.] Univ Med Greifswald, Study Hlth Pomerania KEF, Inst Community Med, Greifswald, Germany; [Homuth, Georg] Univ Med & Ernst Moritz Arndt Univ Greifswald, Dept Funct Genom, Interfac Inst Genet & Funct Genom, Greifswald, Germany; [Nothen, Markus M.; Hoffmann, Per] Univ Bonn, Inst Human Genet, Bonn, Germany; [Paternoster, Lavinia] Univ Bristol, MRC, Integrat Epidemiol Unit, Bristol Med Sch, Bristol, Avon, England; [Paternoster, Lavinia] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England; [Bonnelykke, Klaus; Ahluwalia, Tarunveer S.; Bisgaard, Hans] Herlev & Gentofte Hosp, Copenhagen Prospect Studies Asthma Childhood COPS, Gentofte, Denmark; [Ahluwalia, Tarunveer S.; Werfel, Thomas] Steno Diabet Ctr, Gentofte, Denmark; [Werfel, Thomas] Hannover Med Sch, Div Immunodermatol & Allergy Res, Dept Dermatol & Allergy, Hannover, Germany; [Schreiber, Stefan] Univ Hosp Schleswig Holstein, Dept Med 1, Kiel, Germany	University of Kiel; University of Kiel; University of Kiel; Schleswig Holstein University Hospital; University of Regensburg; University of Bonn; University of Rostock; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich; University of London; King's College London; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Greifswald Medical School; Greifswald Medical School; Ernst Moritz Arndt Universitat Greifswald; Greifswald Medical School; University of Bonn; University of Bristol; University of Bristol; Steno Diabetes Center; Hannover Medical School; University of Kiel; Schleswig Holstein University Hospital	Weidinger, S (corresponding author), Arnold Heller Str 3,Haus 19, D-24105 Kiel, Germany.; Ellinghaus, D (corresponding author), Rosalind Franklin Str 12, D-24105 Kiel, Germany.	sweidinger@dermatology.uni-kiel.de; d.ellinghaus@ikmb.uni-kiel.de	Werfel, Thomas/B-6921-2012; Lieb, Wolfgang/AAC-7650-2022; Franke, Andre/B-2151-2010; Grosche, Sarah/ABA-8480-2021; Müller-Nurasyid, Martina/I-8735-2018; Schmidt, Carsten Oliver/AAH-2778-2019; Ellinghaus, David/ABC-3610-2020; Wienbrandt, Lars/O-8383-2016; Emmert, Hila/AAT-1086-2020; Wolfien, Markus/AAD-2809-2020; Hoffmann, Per/A-5149-2010; Gerdes, Sascha/J-4308-2017; Waldenberger, Melanie/B-5355-2014; Peters, Annette/A-6117-2011; Hubenthal, Matthias/M-8149-2015; Rosenstiel, Philip/A-5137-2009	Franke, Andre/0000-0003-1530-5811; Müller-Nurasyid, Martina/0000-0003-3793-5910; Schmidt, Carsten Oliver/0000-0001-5266-9396; Ellinghaus, David/0000-0002-4332-6110; Wienbrandt, Lars/0000-0001-5685-2032; Emmert, Hila/0000-0002-7051-7350; Wolfien, Markus/0000-0002-1887-4772; Hoffmann, Per/0000-0002-6573-983X; Gerdes, Sascha/0000-0002-6667-7757; Waldenberger, Melanie/0000-0003-0583-5093; Peters, Annette/0000-0001-6645-0985; Rodriguez, Elke/0000-0003-3692-3950; Kassens, Jan Christian/0000-0001-7840-1160; Mucha, Soren/0000-0002-1647-2526; Degenhardt, Frauke/0000-0001-7516-3179; Bonnelykke, Klaus/0000-0003-2003-1018; Dand, Nick/0000-0002-1805-6278; Hubenthal, Matthias/0000-0002-5956-3006; Rosenstiel, Philip/0000-0002-9692-8828	German Federal Ministry of Education and Research (BMBF) [01ZX1606A, 01ZX1709]; German ELIXIR node de.NBI [031L0106C]; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy [EXC 2167-390884018]; DFG Excellence Cluster [306]; Helmholtz Zentrum M_unchen-German Research Center for Environmental Health - BMBF; State of Bavaria; Munich Center of Health Sciences (MC Health); Ludwig-Maximilians-Universitat, as part of LMUinnovativ; SHIP (Study of Health in Pomerania) - BMBF [01ZZ9603, 01ZZ0103, 01ZZ0403]; Ministry of Cultural Affairs; Social Ministry of the Federal State of MecklenburgWest Pomerania - BMBF [03IS2061A]; BMBF [03Z1CN22]; Federal State of Mecklenburg-West Pomerania; UK Medical Research Council fellowship [MR/J012165/1]; BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis) - Innovative Medicines Initiative 2 Joint Undertaking [821511]; European Union; EFPIA; MRC [MR/J012165/1] Funding Source: UKRI	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); German ELIXIR node de.NBI; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy(German Research Foundation (DFG)); DFG Excellence Cluster(German Research Foundation (DFG)); Helmholtz Zentrum M_unchen-German Research Center for Environmental Health - BMBF; State of Bavaria; Munich Center of Health Sciences (MC Health); Ludwig-Maximilians-Universitat, as part of LMUinnovativ; SHIP (Study of Health in Pomerania) - BMBF(Federal Ministry of Education & Research (BMBF)); Ministry of Cultural Affairs; Social Ministry of the Federal State of MecklenburgWest Pomerania - BMBF(Federal Ministry of Education & Research (BMBF)); BMBF(Federal Ministry of Education & Research (BMBF)); Federal State of Mecklenburg-West Pomerania; UK Medical Research Council fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis) - Innovative Medicines Initiative 2 Joint Undertaking; European Union(European Commission); EFPIA; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (SysInflame grant 01ZX1606A and GB-XMAP grant 01ZX1709), as well as the German ELIXIR node de.NBI (de.STAIR grant 031L0106C). The project was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy (EXC 2167-390884018). The project received infrastructure support from the DFG Excellence Cluster no. 306 ``Inflammation at Interfaces'' and the PopGen Biobank (Kiel, Germany). The Kooperative Gesundheitsforschung in der Region Augsburg (KORA) research platform (Cooperative Research in the Region of Augsburg) was initiated and financed by the Helmholtz Zentrum M_unchen-German Research Center for Environmental Health, which is funded by BMBF and the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC Health), Ludwig-Maximilians-Universitat, as part of LMUinnovativ. SHIP (Study of Health in Pomerania) is part of the Community Medicine Research net (CMR) of the University of Greifswald, Greifswald, Germany, which is funded by BMBF (grants 01ZZ9603, 01ZZ0103, and 01ZZ0403) and the Ministry of Cultural Affairs, as well as the Social Ministry of the Federal State of MecklenburgWest Pomerania, and the network ``Greifswald Approach to Individualized Medicine (GANI_MED)'' funded by BMBF (grant 03IS2061A). Exome chip data have been supported by BMBF (grant no. 03Z1CN22) and the Federal State of Mecklenburg-West Pomerania. L.P. was supported by a UK Medical Research Council fellowship (MR/J012165/1). This work was supported by BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis), a project funded by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 821511 and in-kind contributions of the participating pharma companies. The Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and EFPIA.	Abramson J, 2003, EUR J IMMUNOL, V33, P85, DOI 10.1002/immu.200390011; Bernstein BE, 2010, NAT BIOTECHNOL, V28, P1045, DOI 10.1038/nbt1010-1045; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Boulay I, 2005, J IMMUNOL, V175, P4483, DOI 10.4049/jimmunol.175.7.4483; Celis-Gutierrez J, 2014, EMBO J, V33, P1928, DOI 10.15252/embj.201387404; Cotsapas C, 2018, CELL, V175, P1679, DOI 10.1016/j.cell.2018.09.049; de Leeuw CA, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004219; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Ellinghaus D, 2013, NAT GENET, V45, P808, DOI 10.1038/ng.2642; Esparza-Gordillo J, 2013, J ALLERGY CLIN IMMUN, V132, P371, DOI 10.1016/j.jaci.2013.01.057; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Fehrmann RSN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002197; Ferreira MA, 2017, NAT GENET, V49, P1752, DOI 10.1038/ng.3985; Gerard A, 2004, ONCOGENE, V23, P1594, DOI 10.1038/sj.onc.1207283; Gugasyan R, 2002, J CELL BIOL, V158, P115, DOI 10.1083/jcb.200112066; Hafler DA, 2018, CELL, V175, pe7; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Holmannova Drahomira, 2012, Acta Medica (Hradec Kralove), V55, P12; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Mashima R, 2013, GENES CELLS, V18, P56, DOI 10.1111/gtc.12016; Mashima R, 2009, IMMUNOL REV, V232, P273, DOI 10.1111/j.1600-065X.2009.00844.x; Mihrshahi R, 2010, J IMMUNOL, V185, P7216, DOI 10.4049/jimmunol.1002858; Mihrshahi R, 2009, J IMMUNOL, V183, P4879, DOI 10.4049/jimmunol.0901531; Nothlings U, 2012, BUNDESGESUNDHEITSBLA, V55, P831, DOI 10.1007/s00103-012-1487-2; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Schaarschmidt H, 2015, J ALLERGY CLIN IMMUN, V136, P802, DOI 10.1016/j.jaci.2015.01.047; Schmermund A, 2002, AM HEART J, V144, P212, DOI 10.1067/mhj.2002.123579; Schrambach S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000518; Shinohara H, 2005, J EXP MED, V201, P333, DOI 10.1084/jem.20041817; Sun LD, 2011, NAT GENET, V43, P690, DOI 10.1038/ng.851; Tsoi LC, 2019, J INVEST DERMATOL, V139, P1480, DOI 10.1016/j.jid.2018.12.018; Tsunemi Y, 2002, J DERMATOL SCI, V30, P100, DOI 10.1016/S0923-1811(02)00065-8; Volzke H, 2011, INT J EPIDEMIOL, V40, P294, DOI 10.1093/ije/dyp394; Watanabe K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01261-5; Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Westra HJ, 2013, NAT GENET, V45, P1238, DOI 10.1038/ng.2756; Wichmann HE, 2005, GESUNDHEITSWESEN, V67, pS26, DOI 10.1055/s-2005-858226; Yasuda T, 2007, INT IMMUNOL, V19, P487, DOI 10.1093/intimm/dxm015; Zhang SL, 2004, J IMMUNOL, V173, P6786, DOI 10.4049/jimmunol.173.11.6786	43	18	19	4	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2020	145	4					1208	1218		10.1016/j.jaci.2019.10.030	http://dx.doi.org/10.1016/j.jaci.2019.10.030			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LA0FR	31707051	Green Published, Bronze, Green Submitted			2022-12-18	WOS:000523633400017
J	Peng, YQ; Qin, ZL; Fang, SB; Xu, ZB; Zhang, HY; Chen, D; Liu, Z; Bellanti, JA; Zheng, SG; Fu, QL				Peng, Ya-Qi; Qin, Zi-Li; Fang, Shu-Bin; Xu, Zhi-Bin; Zhang, Hong-Yu; Chen, Dong; Liu, Zheng; Bellanti, Joseph A.; Zheng, Song Guo; Fu, Qing-Ling			Effects of myeloid and plasmacytoid dendritic cells on ILC2s in patients with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Group 2 innate lymphoid cells; myeloid dendritic cells; plasmacytoid dendritic cells; allergic rhinitis; IL-33; ST2; IL-6	INNATE LYMPHOID-CELLS; TYPE-2 IMMUNE-RESPONSE; REGULATORY T-CELLS; PERIPHERAL-BLOOD; IN-VIVO; DIFFERENTIATION; MAINTENANCE; ACTIVATION; EXPRESSION; MATURATION	Background: Group 2 innate lymphoid cells (ILC2s) were reported to serve a critical role in allergic diseases. Myeloid dendritic cells (mDCs) and plasmacytoid DCs (pDCs) play significant roles in allergic immune response. However, effects of DCs on ILC2s in allergic diseases, especially for patients with allergic rhinitis (AR), remain unclear. Objective: We sought to address the roles of mDCs and pDCs in regulating ILC2 function in AR. Methods: mDCs and pDCs were cocultured with human PBMCs isolated from patients with AR or ILC2s to measure soluble or intracellular T(H)2 cytokines, transcription factors, signaling pathways in ILC2s, and the following mechanisms were further investigated. The levels of peripheral IL-33(+) mDCs, pDCs, and ILC2s were studied in patients under an inhaled allergen challenge. Results: We confirmed the presence of ILC2s, mDCs, and pDCs in the nasal mucosa of patients with AR. Both allogenic and autologous mDCs were found to activate ILC2s from patients with AR to produce T(H)2 cytokines, and increase the levels of GATA-3 and signal transducer and activator of transcription signaling pathways, in which IL-33-producing mDCs exerted the major role by binding on ST2 on ILC2s. We further identified high levels of IL-33(+) mDCs and ILC2s in patients with AR under antigen challenge. Activated pDCs inhibited the cytokine production of ILC2s isolated from patients with AR by secretion of IL-6. Conclusions: mDCs promote ILC2 function by the IL-33/ST2 pathway, and activation of pDCs suppresses ILC2 function through IL-6 in patients with AR. Our findings provide new understanding of the interplay between DCs and ILC2s in allergic diseases.	[Peng, Ya-Qi; Qin, Zi-Li; Fang, Shu-Bin; Xu, Zhi-Bin; Zhang, Hong-Yu; Chen, Dong; Fu, Qing-Ling] Sun Yat sen Univ, Otorhinolaryngol Hosp, Affiliated Hosp 1, 58 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China; [Liu, Zheng] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, Tongji Med Coll, Wuhan, Peoples R China; [Bellanti, Joseph A.] Georgetown Univ, Med Ctr, Dept Pediat & Microbiol Immunol, Washington, DC 20007 USA; [Zheng, Song Guo] Ohio State Univ, Coll Med, Dept Internal Med, Columbus, OH 43210 USA; [Zheng, Song Guo] Wexner Med Ctr, Columbus, OH USA	Sun Yat Sen University; Huazhong University of Science & Technology; Georgetown University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Fu, QL (corresponding author), Sun Yat sen Univ, Otorhinolaryngol Hosp, Affiliated Hosp 1, 58 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.	fuqingl@mail.sysu.edu.cn	Peng, Yaqi/ABD-1927-2020	Fang, Shubin/0000-0002-4792-3713; QIN, ZILI/0000-0003-0609-2527	National Natural Science Foundation, China [81671882, 81770984, 81970863]; Science and Technology Foundation of Guangdong Province, China [2015B020225001]; Guangdong grant 'key technologies for treatment of brain disorders' [2018B030332001]; Natural Science Foundation of Guangdong Province [2014A030313051, 2016A030308017]	National Natural Science Foundation, China(National Natural Science Foundation of China (NSFC)); Science and Technology Foundation of Guangdong Province, China; Guangdong grant 'key technologies for treatment of brain disorders'; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	This study was supported by grants from the National Natural Science Foundation, China (grant nos. 81671882, 81770984, and 81970863), the key grant from the Science and Technology Foundation of Guangdong Province, China (grant no. 2015B020225001), Guangdong grant 'key technologies for treatment of brain disorders' (grant no. 2018B030332001), and the Natural Science Foundation of Guangdong Province (grant nos. 2014A030313051 and 2016A030308017).	Barlow JL, 2013, J ALLERGY CLIN IMMUN, V132, P933, DOI 10.1016/j.jaci.2013.05.012; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bernink JH, 2015, IMMUNITY, V43, P146, DOI 10.1016/j.immuni.2015.06.019; Brozek JL, 2017, J ALLERGY CLIN IMMUN, V140, P950, DOI 10.1016/j.jaci.2017.03.050; Bruggen MC, 2016, J INVEST DERMATOL, V136, P2396, DOI 10.1016/j.jid.2016.07.017; Buttari B, 2011, BLOOD, V117, P6152, DOI 10.1182/blood-2010-12-325514; Cai T, 2019, J ALLERGY CLIN IMMUN, V143, P229, DOI 10.1016/j.jaci.2018.03.007; Camelo A, 2017, BLOOD ADV, V1, P577, DOI 10.1182/bloodadvances.2016002352; Cherrier DE, 2018, IMMUNITY, V48, P1091, DOI 10.1016/j.immuni.2018.05.010; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Doherty TA, 2014, J ALLERGY CLIN IMMUN, V133, P1203, DOI 10.1016/j.jaci.2013.12.1086; Fan DC, 2016, CHINESE MED J-PEKING, V129, P2824, DOI 10.4103/0366-6999.194642; Froidure A, 2015, M S-MED SCI, V31, P151, DOI 10.1051/medsci/20153102011; Gao WX, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0499-0; Greiner AN, 2011, LANCET, V378, P2112, DOI 10.1016/S0140-6736(11)60130-X; Gueguen C, 2016, J ALLERGY CLIN IMMUN, V137, P545, DOI 10.1016/j.jaci.2015.09.015; Halim TYF, 2018, IMMUNITY, V48, P1195, DOI 10.1016/j.immuni.2018.05.003; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Kamide Y, 2011, ALLERGY, V66, P1183, DOI 10.1111/j.1398-9995.2011.02611.x; Katelaris CH, 2012, CLIN EXP ALLERGY, V42, P186, DOI 10.1111/j.1365-2222.2011.03891.x; Kinnebrew MA, 2012, IMMUNITY, V36, P276, DOI 10.1016/j.immuni.2011.12.011; Klechevsky E, 2015, ADV EXP MED BIOL, V850, P43, DOI 10.1007/978-3-319-15774-0_4; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Lambrecht BN, 2010, LANCET, V376, P835, DOI 10.1016/S0140-6736(10)61226-3; Lao-Araya M, 2014, J ALLERGY CLIN IMMUN, V134, P1193, DOI 10.1016/j.jaci.2014.07.029; Liu XX, 2019, CYTOKINE GROWTH F R, V50, P60, DOI 10.1016/j.cytogfr.2019.04.004; Liu Y, 2013, J ALLERGY CLIN IMMUN, V131, P387, DOI 10.1016/j.jaci.2012.11.027; Lopez-Bravo M, 2008, IMMUNITY, V29, P343, DOI 10.1016/j.immuni.2008.08.008; Lynch JP, 2014, EUR RESPIR J, V43, P264, DOI 10.1183/09031936.00203412; Maazi H, 2018, J ALLERGY CLIN IMMUN, V141, P893, DOI 10.1016/j.jaci.2017.04.043; Madouri F, 2015, J MOL CELL BIOL, V7, P351, DOI 10.1093/jmcb/mjv012; Mjosberg J, 2016, J ALLERGY CLIN IMMUN, V138, P1265, DOI 10.1016/j.jaci.2016.09.009; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Mouries J, 2008, BLOOD, V112, P3713, DOI 10.1182/blood-2008-03-146290; Mudter J, 2008, J CLIN INVEST, V118, P2415, DOI 10.1172/JCI33227; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129, P510, DOI 10.1016/j.jaci.2011.09.031; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Ryffel B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00702; Sirvent S, 2016, J ALLERGY CLIN IMMUN, V138, P558, DOI 10.1016/j.jaci.2016.02.029; Su Z, 2013, MUCOSAL IMMUNOL, V6, P921, DOI 10.1038/mi.2012.130; Vely F, 2016, NAT IMMUNOL, V17, P1291, DOI 10.1038/ni.3553; Wohlfahrt T, 2016, ANN RHEUM DIS, V75, P623, DOI 10.1136/annrheumdis-2015-207388; Yu QN, 2018, ALLERGY, V73, P1860, DOI 10.1111/all.13438; Yu QN, 2018, INT ARCH ALLERGY IMM, V176, P124, DOI 10.1159/000488050; Zhong H, 2017, CLIN IMMUNOL, V183, P293, DOI 10.1016/j.clim.2017.09.008	47	18	18	3	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					855	+		10.1016/j.jaci.2019.11.029	http://dx.doi.org/10.1016/j.jaci.2019.11.029			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	31812574	hybrid			2022-12-18	WOS:000518756700023
J	Ding, XL; Willenborg, S; Bloch, W; Wickstrom, SA; Wagle, P; Brodesser, S; Roers, A; Jais, A; Bruning, JC; Hall, MN; Ruegg, MA; Eming, SA				Ding, Xiaolei; Willenborg, Sebastian; Bloch, Wilhelm; Wickstroem, Sara A.; Wagle, Prerana; Brodesser, Susanne; Roers, Axel; Jais, Alexander; Bruening, Jens C.; Hall, Michael N.; Rueegg, Markus A.; Eming, Sabine A.			Epidermal mammalian target of rapamycin complex 2 controls lipid synthesis and filaggrin processing in epidermal barrier formation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epidermal barrier; mammalian target of rapamycin complex 2; Rictor; ichthyosis; filaggrin; epidermal lipid synthesis	STRATUM-CORNEUM BARRIER; OF-FUNCTION MUTATIONS; CAUSE ICHTHYOSIS; STEM-CELLS; T-CELLS; IN-VIVO; DIFFERENTIATION; AKT; EXPRESSION; ABNORMALITIES	Background: Perturbation of epidermal barrier formation will profoundly compromise overall skin function, leading to a dry and scaly, ichthyosis-like skin phenotype that is the hallmark of a broad range of skin diseases, including ichthyosis, atopic dermatitis, and a multitude of clinical eczema variants. An overarching molecular mechanism that orchestrates the multitude of factors controlling epidermal barrier formation and homeostasis remains to be elucidated. Objective: Here we highlight a specific role of mammalian target of rapamycin complex 2 (mTORC2) signaling in epidermal barrier formation. Methods: Epidermal mTORC2 signaling was specifically disrupted by deleting rapamycin-insensitive companion of target of rapamycin (Rictor), encoding an essential subunit of mTORC2 in mouse epidermis (epidermis-specific homozygous Rictor deletion [Ric(EKO)] mice). Epidermal structure and barrier function were investigated through a combination of gene expression, biochemical, morphological and functional analysis in Ric(EKO) and control mice. Results: Ric(EKO) newborns displayed an ichthyosis-like phenotype characterized by dysregulated epidermal de novo lipid synthesis, altered lipid lamellae structure, and aberrant filaggrin (FLG) processing. Despite a compensatory transcriptional epidermal repair response, the protective epidermal function was impaired in Ric(EKO) mice, as revealed by increased transepidermal water loss, enhanced corneocyte fragility, decreased dendritic epidermal T cells, and an exaggerated percutaneous immune response. Restoration of Akt-Ser473 phosphorylation in mTORC2-deficient keratinocytes through expression of constitutive Akt rescued FLG processing. Conclusion: Our findings reveal a critical metabolic signaling relay of barrier formation in which epidermal mTORC2 activity controls FLG processing and de novo epidermal lipid synthesis during cornification. Our findings provide novel mechanistic insights into epidermal barrier formation and could open up new therapeutic opportunities to restore defective epidermal barrier conditions.	[Ding, Xiaolei; Willenborg, Sebastian; Eming, Sabine A.] Univ Cologne, Dept Dermatol, Kerpenerstr 62, D-50937 Cologne, Germany; [Ding, Xiaolei; Bruening, Jens C.; Eming, Sabine A.] Univ Cologne, CMMC, Cologne, Germany; [Wickstroem, Sara A.; Wagle, Prerana; Brodesser, Susanne; Bruening, Jens C.; Eming, Sabine A.] Univ Cologne, Cluster Excellence Cellular Stress Responses Agin, Cologne, Germany; [Bloch, Wilhelm] German Sport Univ Cologne, Dept Mol & Cellular Sport Med, Cologne, Germany; [Wickstroem, Sara A.] Max Planck Inst Biol Ageing, Paul Gerson Unna Grp Skin Homeostasis & Ageing, Cologne, Germany; [Wickstroem, Sara A.] Univ Helsinki, Helsinki Inst Life Sci, Biomed Helsinki, Helsinki, Finland; [Wickstroem, Sara A.] Univ Helsinki, Wihuri Res Inst, Biomed Helsinki, Helsinki, Finland; [Roers, Axel] Tech Univ Dresden, Inst Immunol, Med Fac Carl Gustav Carus, Dresden, Germany; [Jais, Alexander; Bruening, Jens C.] Max Planck Inst Metab Res, Cologne, Germany; [Hall, Michael N.; Rueegg, Markus A.] Univ Basel, Biozentrum, Basel, Switzerland	University of Cologne; University of Cologne; University of Cologne; German Sport University Cologne; Max Planck Society; University of Helsinki; University of Helsinki; Wihuri Research Institute; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Basel	Eming, SA (corresponding author), Univ Cologne, Dept Dermatol, Kerpenerstr 62, D-50937 Cologne, Germany.	sabine.eming@uni-koeln.de	Jais, Alexander/AAQ-9102-2021	Jais, Alexander/0000-0002-9897-4983; Ruegg, Markus/0000-0002-4974-9384; Hall, Michael N/0000-0002-2998-0757	Deutsche Forschungsgemeinschaft [73111208-SFB829, FOR2599]; Center for Molecular Medicine Cologne; Deutsche Forschungsgemeinschaft (CECAD)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Center for Molecular Medicine Cologne; Deutsche Forschungsgemeinschaft (CECAD)(German Research Foundation (DFG))	The funding source for this article was the Deutsche Forschungsgemeinschaft (Projektnummer 73111208-SFB829 and CECAD to S.A.E., S.A.W., and J.C.B. and FOR2599 to S.A.E. and A.R.) and the Center for Molecular Medicine Cologne (to S.A.E.).	Aldahmesh MA, 2011, AM J HUM GENET, V89, P745, DOI 10.1016/j.ajhg.2011.10.011; Barbee SD, 2011, P NATL ACAD SCI USA, V108, P3330, DOI 10.1073/pnas.1010890108; Belgardt BF, 2010, P NATL ACAD SCI USA, V107, P6028, DOI 10.1073/pnas.1001796107; Bentzinger CF, 2008, CELL METAB, V8, P411, DOI 10.1016/j.cmet.2008.10.002; Bhattacharya N, 2019, TRENDS MOL MED, V25, P551, DOI 10.1016/j.molmed.2019.04.001; Blanpain C, 2009, NAT REV MOL CELL BIO, V10, P207, DOI 10.1038/nrm2636; Boireau-Adamezyk E, 2014, SKIN RES TECHNOL, V20, P409, DOI 10.1111/srt.12132; Breiden B, 2014, BBA-MOL CELL BIOL L, V1841, P441, DOI 10.1016/j.bbalip.2013.08.010; Brunner PM, 2018, J ALLERGY CLIN IMMUN, V141, P2094, DOI 10.1016/j.jaci.2018.02.040; Calautti E, 2005, J BIOL CHEM, V280, P32856, DOI 10.1074/jbc.M506119200; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Caron A, 2015, ANNU REV NUTR, V35, P321, DOI 10.1146/annurev-nutr-071714-034355; Cheng T, 2006, J BIOL CHEM, V281, P15893, DOI 10.1074/jbc.M600694200; Craiglow BG, 2013, SEMIN PERINATOL, V37, P26, DOI 10.1053/j.semperi.2012.11.001; Dainichi T, 2016, CELL REP, V15, P1615, DOI 10.1016/j.celrep.2016.04.051; De Benedetto A, 2012, J INVEST DERMATOL, V132, P949, DOI 10.1038/jid.2011.435; Ding X, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13226; Ding X, 2015, CANCER RES, V75, P330, DOI 10.1158/0008-5472.CAN-13-3007; Ding XL, 2014, STEM CELLS DEV, V23, P931, DOI 10.1089/scd.2013.0267; Duff Michelle, 2015, Clin Diabetes, V33, P40, DOI 10.2337/diaclin.33.1.40; Egberts F, 2004, J CELL SCI, V117, P2295, DOI 10.1242/jcs.01075; Elias PM, 2008, CURR ALLERGY ASTHM R, V8, P299, DOI 10.1007/s11882-008-0048-0; Elias PM, 2008, J LIPID RES, V49, P697, DOI 10.1194/jlr.R800002-JLR200; Elias PM, 2010, ANN DERMATOL, V22, P245, DOI 10.5021/ad.2010.22.3.245; Enk CD, 2006, ONCOGENE, V25, P2601, DOI 10.1038/sj.onc.1209292; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Gruber R, 2011, AM J PATHOL, V178, P2252, DOI 10.1016/j.ajpath.2011.01.053; Guri Y, 2017, CANCER CELL, V32, P807, DOI 10.1016/j.ccell.2017.11.011; Hafner M, 2004, GENESIS, V38, P176, DOI 10.1002/gene.20016; Hagiwara A, 2012, CELL METAB, V15, P725, DOI 10.1016/j.cmet.2012.03.015; Huebner AJ, 2012, DEV CELL, V23, P1238, DOI 10.1016/j.devcel.2012.11.002; Ilic D, 2014, BBA-MOL CELL BIOL L, V1841, P416, DOI 10.1016/j.bbalip.2013.11.002; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kakanj P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12972; Katsuta M, 2006, J IMMUNOL, V176, P7736, DOI 10.4049/jimmunol.176.12.7736; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Kharas MG, 2010, BLOOD, V115, P1406, DOI 10.1182/blood-2009-06-229443; Knipper JA, 2015, IMMUNITY, V43, P803, DOI 10.1016/j.immuni.2015.09.005; Komori H, 2006, CURR OPIN IMMUNOL, V18, P534, DOI 10.1016/j.coi.2006.06.001; Kubo A, 2012, J CLIN INVEST, V122, P440, DOI 10.1172/JCI57416; Lessard JC, 2013, P NATL ACAD SCI USA, V110, P19537, DOI 10.1073/pnas.1309576110; Lopez-Pajares V, 2013, TRENDS GENET, V29, P31, DOI 10.1016/j.tig.2012.10.005; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Naeem AS, 2017, J ALLERGY CLIN IMMUN, V139, P1228, DOI 10.1016/j.jaci.2016.09.052; Natsuga K, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a018218; Nielsen MM, 2017, NAT REV IMMUNOL, V17, P733, DOI 10.1038/nri.2017.101; O'Shaughnessy RFL, 2007, J BIOL CHEM, V282, P17297, DOI 10.1074/jbc.M610386200; Oji V, 2006, BRIT J DERMATOL, V154, P860, DOI 10.1111/j.1365-2133.2005.07109.x; Ovaere P, 2009, TRENDS BIOCHEM SCI, V34, P453, DOI 10.1016/j.tibs.2009.08.001; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Reichelt J, 2004, EUR J CELL BIOL, V83, P747, DOI 10.1078/0171-9335-00429; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Schafer M, 2012, EMBO MOL MED, V4, P364, DOI 10.1002/emmm.201200219; Sevilla LM, 2007, J CELL BIOL, V179, P1599, DOI 10.1083/jcb.200706187; Signorelli P, 2002, METHOD ENZYMOL, V345, P275; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Toomes C, 1999, NAT GENET, V23, P421, DOI 10.1038/70525; Tu CL, 2012, J INVEST DERMATOL, V132, P2350, DOI 10.1038/jid.2012.159; van Smeden J, 2014, BBA-MOL CELL BIOL L, V1841, P295, DOI 10.1016/j.bbalip.2013.11.006; Vasireddy V, 2007, HUM MOL GENET, V16, P471, DOI 10.1093/hmg/ddl480; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Westerberg R, 2004, J BIOL CHEM, V279, P5621, DOI 10.1074/jbc.M310529200; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	69	18	18	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					283	+		10.1016/j.jaci.2019.07.033	http://dx.doi.org/10.1016/j.jaci.2019.07.033			26	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31401286	Bronze, Green Accepted			2022-12-18	WOS:000505590800033
J	Liu, JX; Liao, B; Yu, QH; Wang, H; Liu, YB; Guo, CL; Wang, ZC; Li, ZY; Wang, ZZ; Ruan, JW; Pan, L; Yao, Y; Chen, CL; Wang, H; Liang, YX; Zhen, GH; Liu, Z				Liu, Jin-Xin; Liao, Bo; Yu, Qi-Hong; Wang, Hai; Liu, Yi-Bo; Guo, Cui-Lian; Wang, Zhi-Chao; Li, Zhi-Yong; Wang, Zhe-Zheng; Ruan, Jian-Wen; Pan, Li; Yao, Yin; Chen, Cai-Ling; Wang, Heng; Liang, Yuxia; Zhen, Guohua; Liu, Zheng			The IL-37-Mex3B-Toll-like receptor 3 axis in epithelial cells in patients with eosinophilic chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophil; epithelial cell; chronic rhinosinusitis; IL-37; Mex3 RNA binding family member B; nasal polyp; Toll-like receptor 3	THYMIC STROMAL LYMPHOPOIETIN; IL-37 REQUIRES; EXPRESSION; INFLAMMATION; CYTOKINE; IMMUNITY; IL-18R-ALPHA; SUPPRESSION; IL-1-BETA; PROFILES	Background: The role of IL-37, an immunosuppressive cytokine, in patients with inflammatory diseases is unclear. Objective: We sought to explore the expression and pathogenic function of IL-37 in patients with chronic rhinosinusitis (CRS). Methods: Expression levels of IL-37, IL-18 receptor alpha, IL-1 receptor 8, Mex3 RNA binding family member B (Mex3B), and thymic stromal lymphopoietin (TSLP) in nasal samples were studied by using quantitative RT-PCR, immunohistochemistry, Western blotting, and ELISA. Human nasal epithelial cells (HNECs) and the BEAS-2B cell line were stimulated with various cytokines and Toll-like receptor (TLR) agonists. In some experiments BEAS-2B cells were transfected with Mex3B small interfering RNA or overexpressing lentiviruses. Genes regulated by IL-37b in HNECs were studied by using RNA sequencing analysis. IL-37b function was confirmed in mice in vivo. Results: Compared with control subjects, although mRNA and protein expression of IL-37 were upregulated in diseased tissues, especially in nasal epithelial cells, in patients with CRS without nasal polyps or in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), IL-37 levels in nasal secretions were reduced in patients with eosinophilic CRSwNP. Type 2 cytokines inhibited IL-37 secretion from HNECs. HNECs expressed IL-37 receptors, IL-18 receptor alpha, and IL-1 receptor 8. IL-37b downregulated the expression of Mex3B, a TLR3 coreceptor, in HNECs. IL-37b suppressed polyinosinic-polycytidylic acid- induced TSLP production in HNECs in vitro and in murine nasal epithelial cells in vivo. Knocking down or overexpressing Mex3B in BEAS-2B cells abolished the inhibitory effect of IL-37b. Secreted IL-37 levels negatively correlated with Mex3B and TSLP levels and eosinophil numbers in patients with eosinophilic CRSwNP. Conclusions: The suppressed IL-37 secretion caused by a type 2 milieu can enhance Mex3B-mediated TLR3 activation and subsequent TSLP production in nasal epithelial cells and therefore promotes eosinophilic inflammation in patients with CRSwNP.	[Liu, Jin-Xin; Liao, Bo; Wang, Hai; Liu, Yi-Bo; Guo, Cui-Lian; Wang, Zhi-Chao; Li, Zhi-Yong; Wang, Zhe-Zheng; Ruan, Jian-Wen; Pan, Li; Yao, Yin; Chen, Cai-Ling; Wang, Heng; Liu, Zheng] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China; [Liang, Yuxia; Zhen, Guohua] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Div Pulm & Crit Care Med,Dept Internal Med, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China; [Yu, Qi-Hong] Huazhong Univ Sci & Technol, Dept Hepatobiliary Surg, Union Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [Liang, Yuxia; Zhen, Guohua] Minist Hlth, Key Lab Resp Dis, Wuhan, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Liu, Z (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.	zhengliuent@hotmail.com	Zhen, Guohua/HHC-2805-2022	Yin, Yao/0000-0002-5833-5263	National Natural Science Foundation of China (NSFC) [81630024, 81570899, 81325006, 81873694, 81670019, 91742108, 81700893]; Hubei Province Natural Science Foundation [2017CFA016, 2017CFB477]; "Ten thousand plan''-National high-level talents special support plan; National Key Research and Development Program of China [2016YFC1304400]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Hubei Province Natural Science Foundation(Natural Science Foundation of Hubei Province); "Ten thousand plan''-National high-level talents special support plan; National Key Research and Development Program of China	Supported by the National Natural Science Foundation of China (NSFC) grants 81630024, 81570899, 81325006 (to Z.L.), 81873694 (to H.W.), 81670019, 91742108 (to G.H.Z.) and 81700893 (to B.L.); Hubei Province Natural Science Foundation grants 2017CFA016 (to Z.L.) and 2017CFB477 (to H.W.); the "Ten thousand plan''-National high-level talents special support plan (to Z.L.); and National Key Research and Development Program of China 2016YFC1304400 (to G.H.Z.).	Airoldi I, 2004, CLIN CANCER RES, V10, P144, DOI 10.1158/1078-0432.CCR-1026-3; Bachert C, 2016, J ALLERGY CLIN IMMUN, V138, P1277, DOI 10.1016/j.jaci.2016.09.008; Bachert C, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-25; Berings M, 2017, J ALLERGY CLIN IMMUN, V140, P301, DOI 10.1016/j.jaci.2016.11.047; Bufler P, 2002, P NATL ACAD SCI USA, V99, P13723, DOI 10.1073/pnas.212519099; Bulau AM, 2014, P NATL ACAD SCI USA, V111, P2650, DOI 10.1073/pnas.1324140111; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Cavalli G, 2018, IMMUNOL REV, V281, P179, DOI 10.1111/imr.12605; Cho GS, 2013, J CLIN MICROBIOL, V51, P979, DOI 10.1128/JCM.02806-12; Chustz RT, 2011, AM J RESP CELL MOL, V45, P145, DOI 10.1165/rcmb.2010-0075OC; Coll-Miro M, 2016, P NATL ACAD SCI USA, V113, P1411, DOI 10.1073/pnas.1523212113; Callejas FD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100537; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Imaeda H, 2013, CLIN EXP IMMUNOL, V172, P410, DOI 10.1111/cei.12061; Jang YJ, 2006, AM J RHINOL, V20, P634, DOI 10.2500/ajr.2006.20.2899; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kolinska J, 2008, J INTERF CYTOK RES, V28, P287, DOI 10.1089/jir.2006.0130; Li J, 2012, AM J TRANSPLANT, V12, P2029, DOI 10.1111/j.1600-6143.2012.04082.x; Li SZ, 2015, P NATL ACAD SCI USA, V112, P2497, DOI 10.1073/pnas.1424626112; Liao B, 2018, ALLERGY, V73, P1459, DOI 10.1111/all.13411; Liao B, 2015, ALLERGY, V70, P1169, DOI 10.1111/all.12667; Liao B, 2014, LARYNGOSCOPE, V124, P832, DOI 10.1002/lary.24348; Liu ZQ, 2014, N AM J MED SCI, V6, P160, DOI 10.4103/1947-2714.128482; Lou HF, 2015, AM J RHINOL ALLERGY, V29, P350, DOI 10.2500/ajra.2015.29.4231; Lunding L, 2015, ALLERGY, V70, P366, DOI 10.1111/all.12566; Luo YC, 2014, P NATL ACAD SCI USA, V111, P15178, DOI 10.1073/pnas.1416714111; Lv J, 2018, ALLERGY, V73, P1642, DOI 10.1111/all.13395; McNamee EN, 2011, P NATL ACAD SCI USA, V108, P16711, DOI 10.1073/pnas.1111982108; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Nold MF, 2010, NAT IMMUNOL, V11, P1014, DOI 10.1038/ni.1944; Nold-Petry CA, 2015, NAT IMMUNOL, V16, P354, DOI 10.1038/ni.3103; Ogasawara N, 2018, ALLERGY, V73, P2251, DOI 10.1111/all.13552; Onderdijk AJ, 2015, J IMMUNOL, V195, P1744, DOI 10.4049/jimmunol.1401740; Ota K, 2015, EXP LUNG RES, V41, P335, DOI 10.3109/01902148.2015.1033569; Quirk S, 2014, EXPERT REV CLIN IMMU, V10, P1703, DOI 10.1586/1744666X.2014.971014; Shi JB, 2015, ALLERGY, V70, P533, DOI 10.1111/all.12577; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Stevens WW, 2015, J ALLERGY CLIN IMMUN, V136, P1442, DOI 10.1016/j.jaci.2015.10.009; TEVELDE AA, 1990, BLOOD, V76, P1392; Wang BF, 2017, ALLERGY, V72, P1384, DOI 10.1111/all.13153; Wang BF, 2016, INT FORUM ALLERGY RH, V6, P1013, DOI 10.1002/alr.21799; Wang C, 2014, NAT BIOTECHNOL, V32, P926, DOI 10.1038/nbt.3001; Wang H, 2018, J ALLERGY CLIN IMMUN, V141, P1646, DOI 10.1016/j.jaci.2017.12.972; Wang LQ, 2018, CYTOKINE, V110, P291, DOI 10.1016/j.cyto.2018.02.015; Wang X-Q., 2012, INT J CLIN MED, V3, P319, DOI DOI 10.4236/IJCM.2012.35063; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; Watelet JB, 2004, EUR ARCH OTO-RHINO-L, V261, P242, DOI 10.1007/s00405-003-0691-y; Wood AJ, 2011, INT FORUM ALLERGY RH, V1, P95, DOI 10.1002/alr.20030; Xu HQ, 2018, SCI TOTAL ENVIRON, V639, P550, DOI 10.1016/j.scitotenv.2018.05.159; Yang Y, 2016, CELL RES, V26, P288, DOI 10.1038/cr.2016.16; Zhang XH, 2012, AM J RESP CRIT CARE, V185, P140, DOI 10.1164/rccm.201103-0456OC; Zhang YN, 2016, J ALLERGY CLIN IMMUN, V137, P462, DOI 10.1016/j.jaci.2015.07.025	52	18	18	2	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					160	172		10.1016/j.jaci.2019.07.009	http://dx.doi.org/10.1016/j.jaci.2019.07.009			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31330219	Bronze			2022-12-18	WOS:000505590800023
J	Reiger, M; Traidl-Hoffmann, C; Neumann, AU				Reiger, Matthias; Traidl-Hoffmann, Claudia; Neumann, Avidan U.			The skin microbiome as a clinical biomarker in atopic eczema: Promises, navigation, and pitfalls	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Atopic dermatitis; atopic eczema; skin microbiome; Staphylococcus aureus; clinical biomarker; personalized medicine; standardized methods; next-generation sequencing; deep sequencing; quantitative PCR			[Reiger, Matthias; Traidl-Hoffmann, Claudia; Neumann, Avidan U.] Tech Univ Munich, UNIKA T, Chair & Inst Environm Med, Augsburg, Germany; [Reiger, Matthias; Traidl-Hoffmann, Claudia; Neumann, Avidan U.] Helmholtz Zentrum Munchen, Augsburg, Germany; [Reiger, Matthias; Traidl-Hoffmann, Claudia; Neumann, Avidan U.] Christine Kuhne Ctr Allergy Res & Educ, CK CARE, Davos, Switzerland; [Traidl-Hoffmann, Claudia] Tech Univ Munich, ZIEL Inst Food & Hlth, Freising Weihenstephan, Germany	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich	Neumann, AU (corresponding author), UNIKA T, Chair & Inst Environm Med, Neusasser Str 47, D-86156 Augsburg, Germany.	avidan.neumann@tum.de						Bieber T, 2016, ALLERGY, V71, P588, DOI 10.1111/all.12857; Callewaert C., 2019, J INVEST DERMATOL; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P104, DOI 10.1016/j.jaci.2015.01.020; Fishbein AB, 2019, J ALLERGY CLIN IMMUN; Fricker AM, 2019, J ADV RES, V19, P105, DOI 10.1016/j.jare.2019.03.006; Kong HH, 2017, J INVEST DERMATOL, V137, P561, DOI 10.1016/j.jid.2016.10.033; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Nakatsuji T, 2019, ANN ALLERG ASTHMA IM, V122, P263, DOI 10.1016/j.anai.2018.12.003; Neumann AU, 2019, ALLERGY, V74, P112	10	18	20	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					93	96		10.1016/j.jaci.2019.11.004	http://dx.doi.org/10.1016/j.jaci.2019.11.004			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31910987	Bronze			2022-12-18	WOS:000505590800010
J	Tscheppe, A; Palmberger, D; van Rijt, L; Kalic, T; Mayr, V; Palladino, C; Kitzmuller, C; Hemmer, W; Hafner, C; Bublin, M; van Ree, R; Grabherr, R; Radauer, C; Breiteneder, H				Tscheppe, Angelika; Palmberger, Dieter; van Rijt, Leonie; Kalic, Tanja; Mayr, Vanessa; Palladino, Chiara; Kitzmueller, Claudia; Hemmer, Wolfgang; Hafner, Christine; Bublin, Merima; van Ree, Ronald; Grabherr, Reingard; Radauer, Christian; Breiteneder, Heimo			Development of a novel Ara h 2 hypoallergen with no IgE binding or anaphylactogenic activity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; Ara h 2; epitopes; hypoallergen; mouse model; immunotherapy	MAJOR PEANUT ALLERGEN; T-CELL EPITOPES; BASOPHIL ACTIVATION; IMMUNOTHERAPY; SEVERITY; PROTEINS	Background: To date, no safe allergen-specific immunotherapy for patients with peanut allergy is available. Previous trials were associated with severe side effects. Objective: We sought to determine the relative importance of conformational and linear IgE-binding epitopes of the major peanut allergen Ara h 2 and to produce a hypoallergenic variant with abolished anaphylactogenic activity. Methods: Wild-type Ara h 2 and a mutant lacking the loops containing linear IgE epitopes were produced in insect cells. Conformational IgE epitopes were removed by unfolding these proteins through reduction and alkylation. IgE binding was tested by means of ELISA with sera from 48 Ara h 2-sensitized patients with peanut allergy. Basophil activation and T-cell proliferation were tested with blood samples from selected patients. Anaphylactogenic potency was tested by using intraperitoneal challenge of mice sensitized intragastrically to peanut extract. Results: Patients' IgE recognized conformational and linear epitopes in a patient-specific manner. The unfolded mutant lacking both types of epitopes displayed significantly lower IgE binding (median ELISA OD, 0.03; interquartile range, 0.010.06) than natural Ara h 2 (median ELISA OD, 0.99; interquartile range, 0.90-1.03; P < .01). Basophil activation by unfolded mutant Ara h 2 was low (median area under the curve, 72 vs 138 for native wild-type Ara h 2; P < .05), but its ability to induce T-cell proliferation was retained. Unfolded mutants without conformational epitopes did not induce anaphylaxis in peanut-sensitized mice. Conclusions: By removing conformational and linear IgE epitopes, a hypoallergenic Ara h 2 mutant with abolished IgE binding and anaphylactogenic potency but retained T-cell activation was generated.	[Tscheppe, Angelika; Kalic, Tanja; Mayr, Vanessa; Palladino, Chiara; Kitzmueller, Claudia; Bublin, Merima; Radauer, Christian; Breiteneder, Heimo] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Inst Pathophysiol & Allergy Res, Wahringer Gurtel 18-20, A-1090 Vienna, Austria; [Palmberger, Dieter; Grabherr, Reingard] Univ Nat Resources & Life Sci, Dept Biotechnol, Vienna, Austria; [van Rijt, Leonie; van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Amsterdam UMC, Amsterdam, Netherlands; [van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam UMC, Amsterdam, Netherlands; [Hemmer, Wolfgang] FAZ Floridsdorf Allergy Ctr, Vienna, Austria; [Hafner, Christine] Karl Landsteiner Univ Hlth Sci, Univ Hosp St Polten, Dept Dermatol, St Polten, Austria; [Hafner, Christine] Karl Landsteiner Inst Dermatol Res, St Polten, Austria	Medical University of Vienna; University of Natural Resources & Life Sciences, Vienna; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Radauer, C (corresponding author), Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Inst Pathophysiol & Allergy Res, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	christian.radauer@muv.ac.at	Kalic, Tanja/M-3217-2018; Radauer, Christian/AAN-6260-2021	Kalic, Tanja/0000-0002-9641-0244; Radauer, Christian/0000-0001-9920-4449; Kitzmuller, Claudia/0000-0002-3829-8020; Tscheppe, Angelika/0000-0002-6620-5645	Austrian Science Fund (FWF) [W1248-B30, P 30936-B30]; Medical University of Vienna; European Union (Horizon 2020 COST Action [ImpARAS]) [FA1402]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Medical University of Vienna; European Union (Horizon 2020 COST Action [ImpARAS])	Supported by the Austrian Science Fund (FWF; Doctoral Program W1248-B30 [MCCA] and grant P 30936-B30), the Medical University of Vienna, and the European Union (Horizon 2020 COST Action FA1402 [ImpARAS]).	Albrecht M, 2009, J ALLERGY CLIN IMMUN, V124, P328, DOI 10.1016/j.jaci.2009.05.031; Apostolovic D, 2013, BBA-PROTEINS PROTEOM, V1834, P2832, DOI 10.1016/j.bbapap.2013.10.004; Bannon GA, 2001, INT ARCH ALLERGY IMM, V124, P70, DOI 10.1159/000053672; Bernard H, 2015, J ALLERGY CLIN IMMUN, V135, P1267, DOI 10.1016/j.jaci.2014.10.025; Birrueta G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204620; Chu DK, 2019, LANCET, V393, P2222, DOI 10.1016/S0140-6736(19)30420-9; Fleischer DM, 2019, JAMA-J AM MED ASSOC, V321, P946, DOI 10.1001/jama.2019.1113; Glaspole IN, 2005, ALLERGY, V60, P35, DOI 10.1111/j.1398-9995.2004.00608.x; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; King N, 2005, MOL NUTR FOOD RES, V49, P963, DOI 10.1002/mnfr.200500073; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; Koppelman SJ, 2001, ALLERGY, V56, P132, DOI 10.1034/j.1398-9995.2001.056002132.x; Lehmann K, 2006, BIOCHEM J, V395, P463, DOI 10.1042/BJ20051728; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; Li XM, 2003, J IMMUNOL, V170, P3289, DOI 10.4049/jimmunol.170.6.3289; Lin J, 2012, J ALLERGY CLIN IMMUN, V129, P1321, DOI 10.1016/j.jaci.2012.02.012; Mahajan A, 2017, J IMMUNOL, V198, P1034, DOI 10.4049/jimmunol.1601334; Mueller GA, 2011, ALLERGY, V66, P878, DOI 10.1111/j.1398-9995.2010.02532.x; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Otsu K, 2015, CLIN EXP ALLERGY, V45, P471, DOI 10.1111/cea.12407; Pajno GB, 2018, ALLERGY, V73, P799, DOI 10.1111/all.13319; Palladino C, 2018, ALLERGY, V73, P1746, DOI 10.1111/all.13475; Palladino C, 2018, MOL IMMUNOL, V100, P58, DOI 10.1016/j.molimm.2018.04.005; Pascal M, 2013, CLIN EXP ALLERGY, V43, P116, DOI 10.1111/cea.12014; Patil SU, 2012, CLIN EXP IMMUNOL, V167, P59, DOI 10.1111/j.1365-2249.2011.04503.x; Prickett SR, 2011, J ALLERGY CLIN IMMUN, V127, P608, DOI 10.1016/j.jaci.2010.09.027; Renand A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01408; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P179, DOI 10.1016/j.jaci.2014.09.001; Savage J, 2015, IMMUNOL ALLERGY CLIN, V35, P45, DOI 10.1016/j.iac.2014.09.004; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Starkl P, 2012, CLIN EXP ALLERGY, V42, P1801, DOI 10.1111/cea.12031; Tscheppe A, 2017, INT ARCH ALLERGY IMM, V172, P187, DOI 10.1159/000464104; van der Kleij HPM, 2019, ALLERGY, V74, P986, DOI 10.1111/all.13687; van Hoffen E, 2014, CLIN EXP ALLERGY, V44, P1558, DOI 10.1111/cea.12319; Walker S, 2018, HOSP PHARM, V53, P369, DOI 10.1177/0018578718797266; Wood RA, 2013, ALLERGY, V68, P803, DOI 10.1111/all.12158; Zhuang YH, 2013, IMMUNOL RES, V55, P125, DOI 10.1007/s12026-012-8355-x	38	18	19	3	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					229	238		10.1016/j.jaci.2019.08.036	http://dx.doi.org/10.1016/j.jaci.2019.08.036			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31525384	hybrid, Green Accepted			2022-12-18	WOS:000505590800029
J	Grossman, NL; Ortega, VE; King, TS; Bleecker, ER; Ampleford, EA; Bacharier, LB; Cabana, MD; Cardet, JC; Carr, TF; Castro, M; Denlinger, LC; Denson, JL; Fandino, N; Fitzpatrick, AM; Hawkins, GA; Holguin, F; Krishnan, JA; Lazarus, SC; Nyenhuis, SM; Phipatanakul, W; Ramratnam, SK; Wenzel, S; Peters, SP; Meyers, DA; Wechsler, ME; Israel, E				Grossman, Nicole L.; Ortega, Victor E.; King, Tonya S.; Bleecker, Eugene R.; Ampleford, Elizabeth A.; Bacharier, Leonard B.; Cabana, Michael D.; Cardet, Juan C.; Carr, Tara F.; Castro, Mario; Denlinger, Loren C.; Denson, Joshua L.; Fandino, Nicolas; Fitzpatrick, Anne M.; Hawkins, Gregory A.; Holguin, Fernando; Krishnan, Jerry A.; Lazarus, Stephen C.; Nyenhuis, Sharmilee M.; Phipatanakul, Wanda; Ramratnam, Sima K.; Wenzel, Sally; Peters, Stephen P.; Meyers, Deborah A.; Wechsler, Michael E.; Israel, Elliot			Exacerbation-prone asthma in the context of race and ancestry in Asthma Clinical Research Network trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Exacerbations; race; ancestry; admixture; lung function; genetics; asthma; black; African American; ethnic group	ACTING BETA-AGONIST; INHALED CORTICOSTEROIDS; GENETIC ANCESTRY; LUNG-FUNCTION; RISK-FACTORS; TREATMENT FAILURES; PERSISTENT ASTHMA; AFRICAN ANCESTRY; PUERTO-RICAN; ADULTS	Background: Minority groups of African descent experience disproportionately greater asthma morbidity compared with other racial groups, suggesting that genetic variation from a common ancestry could influence exacerbation risk. Objective: We evaluated clinical trial measures in the context of self-reported race and genetic ancestry to identify risk factors for asthma exacerbations. Methods: One thousand eight hundred forty multiethnic subjects from 12 Asthma Clinical Research Network and AsthmaNet trials were analyzed for incident asthma exacerbations with Poisson regression models that included clinical measures, self-reported race (black, non-Hispanic white, and other), and estimates of global genetic African ancestry in a subgroup (n = 760). Results: Twenty-four percent of 1840 subjects self-identified as black. Black and white subjects had common risk factors for exacerbations, including a history of 2 or more exacerbations in the previous year and FEV1 percent predicted values, whereas chronic sinusitis, allergic rhinitis, and gastroesophageal reflux disease were only associated with increased exacerbation risk in black subjects. In the combined multiethnic cohort, neither race (P = .30) nor percentage of genetic African ancestry as a continuous variable associated with exacerbation risk (adjusted rate ratio [RR], 1.26 [95% CI, 0.94-1.70; P = .13]; RR per 1-SD change [32% ancestry], 0.97 [95% CI, 0.78-1.19; P = .74]). However, in 161 black subjects with genetic data, those with African ancestry greater than the median (>82%) had a significantly greater risk of exacerbation (RR, 3.06 [95% CI, 1.09-8.6; P = .03]). Conclusion: Black subjects have unique risk factors for asthma exacerbations, of which global African genetic ancestry had the strongest effect.	[Grossman, Nicole L.] Lahey Hosp & Med Ctr, Div Pulm & Crit Care, Dept Internal Med, Burlington, ON, Canada; [Ortega, Victor E.; Ampleford, Elizabeth A.; Peters, Stephen P.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC 27101 USA; [King, Tonya S.] Penn State Univ, Sch Med, Dept Publ Hlth Sci, Hershey, PA USA; [Bleecker, Eugene R.; Meyers, Deborah A.] Univ Arizona, Coll Med, Div Genet Genom & Precis Med, Dept Med, Tucson, AZ USA; [Bacharier, Leonard B.] Washington Univ, Sch Med, Div Allergy Immunol & Pulm, Dept Pediat, St Louis, MO USA; [Cabana, Michael D.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Cardet, Juan C.] Univ S Florida, Morsani Coll Med, Div Allergy & Immunol, Deparment Internal Med, Tampa, FL USA; [Carr, Tara F.] Univ Arizona, Div Pulm Allergy Crit Care & Sleep Med, Dept Med, Tucson, AZ USA; [Castro, Mario] Univ Kansas, Div Pulm Dis & Crit Care Med, Dept Internal Med, Kansas City, KS USA; [Denlinger, Loren C.] Univ Wisconsin, Sch Med, Dept Med, Madison, WI USA; [Denson, Joshua L.; Wechsler, Michael E.] Natl Jewish Hlth, Div Pulm Crit Care & Sleep Med, Dept Med, Denver, CO USA; [Fandino, Nicolas] Brigham & Womens Hosp, Div Pulm & Crit Care Med, 1, 75 Francis St, Boston, MA 02115 USA; [Fandino, Nicolas] Harvard Med Sch, Boston, MA 02115 USA; [Fitzpatrick, Anne M.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; [Hawkins, Gregory A.] Wake Forest Sch Med, Dept Biochem, Winston Salem, NC 27101 USA; [Holguin, Fernando] Univ Colorado, Anschutz Med Campus, Dept Med, Denver, CO USA; [Krishnan, Jerry A.] Univ Illinois Hosp & Hlth Sci Syst, Dept Med, Chicago, IL USA; [Lazarus, Stephen C.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Nyenhuis, Sharmilee M.] Harvard Med Sch, Boston Childrens Hosp, Div Pediat Allergy & Immunol, Boston, MA USA; [Phipatanakul, Wanda; Ramratnam, Sima K.] Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53706 USA; [Wenzel, Sally] Univ Pittsburgh, Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA	Wake Forest University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Arizona; Washington University (WUSTL); University of California System; University of California San Francisco; State University System of Florida; University of South Florida; University of Arizona; University of Kansas; University of Wisconsin System; University of Wisconsin Madison; National Jewish Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Emory University; Wake Forest University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California San Francisco; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ortega, VE (corresponding author), Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC 27101 USA.	vortega@wakehealth.edu		Wenzel, Sally/0000-0002-4242-0164; Bacharier, Leonard/0000-0003-0432-2704; Denson, Joshua/0000-0002-8654-7765	National Institutes of Health/National Heart, Lung, and Blood Institute [K08 HL118128, R01 HL142992]; AsthmaNet [HL098102, HL098096, HL098075, HL098090, HL098177, HL098098, HL098107, HL098112, HL098103, HL098115]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL142992, U10HL109250, K08HL118128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI125785] Funding Source: NIH RePORTER	National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AsthmaNet; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the National Institutes of Health/National Heart, Lung, and Blood Institute (K08 HL118128 and R01 HL142992) and AsthmaNet (grants HL098102, HL098096, HL098075, HL098090, HL098177, HL098098, HL098107, HL098112, HL098103, and HL098115).	Alexander DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/gr.094052.109; Bonham VL, 2018, JAMA-J AM MED ASSOC, V320, P1533, DOI 10.1001/jama.2018.13609; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Brehm JM, 2012, J ALLERGY CLIN IMMUN, V129, P1484, DOI 10.1016/j.jaci.2012.03.035; Bryc K, 2015, AM J HUM GENET, V96, P37, DOI 10.1016/j.ajhg.2014.11.010; Calhoun WJ, 2012, JAMA-J AM MED ASSOC, V308, P987, DOI 10.1001/2012.jama.10893; Cardet JC, 2018, J ALLERGY CLIN IMMUN, V141, P754, DOI 10.1016/j.jaci.2017.04.036; Castro M, 2014, JAMA-J AM MED ASSOC, V311, P2083, DOI 10.1001/jama.2014.5052; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; Cooper RS, 2018, JAMA-J AM MED ASSOC, V320, P1531, DOI 10.1001/jama.2018.10960; de Groot JC, 2015, AM J RESP CRIT CARE, V192, P899, DOI 10.1164/rccm.201505-1003LE; Denlinger LC, 2017, AM J RESP CRIT CARE, V195, P302, DOI 10.1164/rccm.201602-0419OC; Deykin A, 2007, AM J RESP CRIT CARE, V175, P228, DOI 10.1164/rccm.200601-112OC; Duong M, 2013, LANCET RESP MED, V1, P599, DOI 10.1016/S2213-2600(13)70164-4; Eisner MD, 2001, RESP RES, V2, P53, DOI 10.1186/rr37; Federico MJ, 2005, CHEST, V127, P571, DOI 10.1378/chest.127.2.571; Flores C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0026807; Griswold SK, 2005, CHEST, V127, P1579, DOI 10.1378/chest.127.5.1579; Grossman NL, 2019, J ASTHMA, V56, P704, DOI 10.1080/02770903.2018.1486855; Haselkorn T, 2008, ANN ALLERG ASTHMA IM, V101, P256, DOI 10.1016/S1081-1206(10)60490-5; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Kang HR, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020825; Keet CA, 2015, J ALLERGY CLIN IMMUN, V135, P655, DOI 10.1016/j.jaci.2014.11.022; Koga T, 2006, RESP MED, V100, P273, DOI 10.1016/j.rmed.2005.05.017; Kumar R, 2010, NEW ENGL J MED, V363, P321, DOI 10.1056/NEJMoa0907897; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Levin AM, 2014, AM J RESP CRIT CARE, V190, P266, DOI 10.1164/rccm.201402-0204OC; Li XN, 2011, J ALLERGY CLIN IMMUN, V127, P1457, DOI 10.1016/j.jaci.2011.01.056; Mao XY, 2007, AM J HUM GENET, V80, P1171, DOI 10.1086/518564; Moorman Jeanne E, 2012, Vital Health Stat 3, P1; Nyenhuis SM, 2017, J ALLERGY CLIN IMMUN, V140, P257, DOI 10.1016/j.jaci.2016.10.024; Ortega VE, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0516-2; Ortega VE, 2014, LANCET RESP MED, V2, P204, DOI 10.1016/S2213-2600(13)70289-3; Ortega VE, 2014, J ALLERGY CLIN IMMUN, V133, P16, DOI 10.1016/j.jaci.2013.10.040; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Pino-Yanes M, 2015, J ALLERGY CLIN IMMUN, V135, P228, DOI 10.1016/j.jaci.2014.07.053; Rumpel JA, 2012, J ALLERGY CLIN IMMUN, V130, P1302, DOI 10.1016/j.jaci.2012.09.001; Sutherland ER, 2010, J ALLERGY CLIN IMMUN, V126, P747, DOI 10.1016/j.jaci.2010.07.024; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Szefler SJ, 2012, THORAX, V67, P450, DOI 10.1136/thoraxjnl-2012-201876; ten Brinke A, 2005, EUR RESPIR J, V26, P812, DOI 10.1183/09031936.05.00037905; Vergara C, 2013, GENET EPIDEMIOL, V37, P393, DOI 10.1002/gepi.21702; Vergara C, 2009, HUM GENET, V125, P565, DOI 10.1007/s00439-009-0649-2; Wechsler ME, 2015, JAMA-J AM MED ASSOC, V314, P1720, DOI 10.1001/jama.2015.13277; Wechsler ME, 2011, AM J RESP CRIT CARE, V184, P1247, DOI 10.1164/rccm.201103-0514OC; Wechsler ME, 2009, LANCET, V374, P1754, DOI 10.1016/S0140-6736(09)61492-6; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025	50	18	18	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2019	144	6					1524	1533		10.1016/j.jaci.2019.08.033	http://dx.doi.org/10.1016/j.jaci.2019.08.033			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT0NR	31520679	Green Accepted, Bronze			2022-12-18	WOS:000500694900011
J	Noah, TK; Knoop, KA; McDonald, KG; Gustafsson, JK; Waggoner, L; Vanoni, S; Batie, M; Arora, K; Naren, AP; Wang, YH; Lukacs, NW; Munitz, A; Helmrath, MA; Mahe, MM; Newberry, RD; Hogan, SP				Noah, Taeko K.; Knoop, Kathryn A.; McDonald, Keely G.; Gustafsson, Jenny K.; Waggoner, Lisa; Vanoni, Simone; Batie, Matthew; Arora, Kavisha; Naren, Anjaparavanda P.; Wang, Yui-Hsi; Lukacs, Nicholas W.; Munitz, Ariel; Helmrath, Michael A.; Mahe, Maxime M.; Newberry, Rodney D.; Hogan, Simon P.			IL-13-induced intestinal secretory epithelial cell antigen passages are required for IgE-mediated food-induced anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; antigen passages; intestinal epithelium; mast cells; anaphylaxis; secretory cells	AIRWAY SMOOTH-MUSCLE; MAST-CELLS; IN-VIVO; BARRIER FUNCTION; DENDRITIC CELLS; IL-4 RECEPTOR; ALLERGY; INTERLEUKIN-13; DIAGNOSIS; TRANSPORT	Background: Food-induced anaphylaxis (FIA) is an IgE-dependent immune response that can affect multiple organs and lead to life-threatening complications. The processes by which food allergens cross the mucosal surface and are delivered to the subepithelial immune compartment to promote the clinical manifestations associated with food-triggered anaphylaxis are largely unexplored. Objective: We sought to define the processes involved in the translocation of food allergens across the mucosal epithelial surface to the subepithelial immune compartment in FIA. Methods: Two-photon confocal and immunofluorescence microscopy was used to visualize and trace food allergen passage in a murine model of FIA. A human colon cancer cell line, RNA silencing, and pharmacologic approaches were used to identify the molecular regulation of intestinal epithelial allergen uptake and translocation. Human intestinal organoid transplants were used to demonstrate the conservation of these molecular processes in human tissues. Results: Food allergens are sampled by using small intestine (SI) epithelial secretory cells (termed secretory antigen passages [SAPs]) that are localized to the SI villous and crypt region. SAPs channel food allergens to lamina propria mucosal mast cells through an IL-13-CD38-cyclic adenosine diphosphate ribose (cADPR)-dependent process. Blockade of IL-13-induced CD38/cADPR-dependent SAP antigen passaging in mice inhibited induction of clinical manifestations of FIA. IL-13-CD38-cADPR-dependent SAP sampling of food allergens was conserved in human intestinal organoids. Conclusion: We identify that SAPs are a mechanism by which food allergens are channeled across the SI epithelium mediated by the IL-13/CD38/cADPR pathway, regulate the onset of FIA reactions, and are conserved in human intestine.	[Noah, Taeko K.; Lukacs, Nicholas W.; Hogan, Simon P.] Univ Michigan, Dept Pathol, Mary H Weiser Food Allergy Ctr, 4051 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA; [Noah, Taeko K.; Waggoner, Lisa; Vanoni, Simone; Wang, Yui-Hsi; Hogan, Simon P.] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Dept Pediat, Cincinnati, OH 45229 USA; [Helmrath, Michael A.; Mahe, Maxime M.] Cincinnati Childrens Hosp Med Ctr, Div Pediat Surg, Dept Pediat, Cincinnati, OH 45229 USA; [Batie, Matthew] Cincinnati Childrens Hosp Med Ctr, Div Clin Engn, Dept Pediat, Cincinnati, OH 45229 USA; [Arora, Kavisha; Naren, Anjaparavanda P.] Cincinnati Childrens Hosp Med Ctr, Div Pulm Med, Dept Pediat, Cincinnati, OH 45229 USA; [Knoop, Kathryn A.; McDonald, Keely G.; Gustafsson, Jenny K.; Newberry, Rodney D.] Washington Univ, Sch Med, Div Gastroenterol, St Louis, MO 63110 USA; [Munitz, Ariel] Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, Tel Aviv, Israel	University of Michigan System; University of Michigan; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Washington University (WUSTL); Tel Aviv University; Sackler Faculty of Medicine	Hogan, SP (corresponding author), Univ Michigan, Dept Pathol, Mary H Weiser Food Allergy Ctr, 4051 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	sihogan@med.umich.edu	Lukacs, Nicholas W/ABH-5583-2020; Knoop, Kathryn/AAM-3570-2020; Vanoni, Simone/AAJ-8108-2020; Mahe, Maxime/G-5552-2017	Vanoni, Simone/0000-0002-4464-2959; Knoop, Kathryn/0000-0003-2007-3066; Mahe, Maxime/0000-0003-2560-193X	National Institutes of Health [DK073553, DK090119, AI138177, AI112626]; Food Allergy Research & Education (FARE); Department of Defense [W81XWH-15-1-051730]; M-FARA; Mary H. Weiser Food Allergy Center; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI112626, R21AI138177, R01AI140133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food Allergy Research & Education (FARE); Department of Defense(United States Department of Defense); M-FARA; Mary H. Weiser Food Allergy Center; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institutes of Health grants DK073553, DK090119, AI138177, and AI112626; Food Allergy Research & Education (FARE); Department of Defense grant W81XWH-15-1-051730; M-FARA; and the Mary H. Weiser Food Allergy Center supported (to S.P.H.).	Abonia JP, 2005, BLOOD, V105, P4308, DOI 10.1182/blood-2004-09-3578; Ahrens R, 2012, AM J PATHOL, V180, P1535, DOI 10.1016/j.ajpath.2011.12.036; Berin MC, 1997, GASTROENTEROLOGY, V113, P856, DOI 10.1016/S0016-5085(97)70180-X; Birchenough GMH, 2015, MUCOSAL IMMUNOL, V8, P712, DOI 10.1038/mi.2015.32; Chen CY, 2015, IMMUNITY, V43, P788, DOI 10.1016/j.immuni.2015.08.020; Deshpande DA, 2004, AM J RESP CELL MOL, V31, P36, DOI 10.1165/rcmb.2003-0313OC; Deshpande DA, 2003, FASEB J, V17, P452, DOI 10.1096/fj.02-0450fje; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Hase K, 2009, NATURE, V462, P226, DOI 10.1038/nature08529; Herbert DR, 2004, IMMUNITY, V20, P623, DOI 10.1016/S1074-7613(04)00107-4; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KELEFIOTIS D, 1993, AGENTS ACTIONS, V40, P150, DOI 10.1007/BF01984054; Knoop KA, 2015, MUCOSAL IMMUNOL, V8, P198, DOI 10.1038/mi.2014.58; Knoop KA, 2018, MUCOSAL IMMUNOL, V11, P1551, DOI 10.1038/s41385-018-0039-y; Knoop KA, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aao1314; Kondo M, 2002, AM J RESP CELL MOL, V27, P536, DOI 10.1165/rcmb.4682; Kulkarni DH, 2018, MUCOSAL IMMUNOL, V11, P1103, DOI 10.1038/s41385-018-0007-6; Lee JB, 2016, J ALLERGY CLIN IMMUN, V137, P1216, DOI 10.1016/j.jaci.2015.09.019; Lo YH, 2017, CELL MOL GASTROENTER, V3, P51, DOI 10.1016/j.jcmgh.2016.10.001; Lorentz A, 1999, EUR J IMMUNOL, V29, P1496, DOI 10.1002/(SICI)1521-4141(199905)29:05<1496::AID-IMMU1496>3.0.CO;2-5; McDermott JR, 2006, GUT, V55, P492, DOI 10.1136/gut.2005.081752; McDole JR, 2012, NATURE, V483, P345, DOI 10.1038/nature10863; Motosue MS, 2017, J ALLER CL IMM-PRACT, V5, P171, DOI 10.1016/j.jaip.2016.08.013; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Neutra MR, 1996, CELL, V86, P345, DOI 10.1016/S0092-8674(00)80106-3; Neutra MR, 1999, CURR TOP MICROBIOL, V236, P17; Noah TK, 2010, EXP CELL RES, V316, P452, DOI 10.1016/j.yexcr.2009.09.020; Osterfeld H, 2010, J ALLERGY CLIN IMMUN, V125, P469, DOI 10.1016/j.jaci.2009.09.054; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Rose MF, 2009, P NATL ACAD SCI USA, V106, P22462, DOI 10.1073/pnas.0911579106; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Santos J, 2000, AM J PHYSIOL-GASTR L, V278, pG847, DOI 10.1152/ajpgi.2000.278.6.G847; Shroyer NF, 2007, GASTROENTEROLOGY, V132, P2478, DOI 10.1053/j.gastro.2007.03.047; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Stockinger S, 2014, J INNATE IMMUN, V6, P530, DOI 10.1159/000357644; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653; Wang J, 2011, J CLIN INVEST, V121, P827, DOI [10.1172/JCI45434, 10.1186/1710-1492-7-S1-S7]; Watson CL, 2014, NAT MED, V20, P1310, DOI 10.1038/nm.3737; Wills-Karp M, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1.51.pe55; Wu D, 2011, J BIOL CHEM, V286, P13357, DOI 10.1074/jbc.M110.214965; Yamani A, 2018, J ALLERGY CLIN IMMUN, V142, P1159, DOI 10.1016/j.jaci.2017.08.046; Yang PC, 2000, J CLIN INVEST, V106, P879, DOI 10.1172/JCI9258	49	18	18	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2019	144	4					1058	+		10.1016/j.jaci.2019.04.030	http://dx.doi.org/10.1016/j.jaci.2019.04.030			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB8FZ	31175877	Green Accepted, Bronze			2022-12-18	WOS:000488803900021
J	Sly, PD; Galbraith, S; Islam, Z; Holt, B; Troy, N; Holt, PG				Sly, Peter D.; Galbraith, Sally; Islam, Zahir; Holt, Barbara; Troy, Niamh; Holt, Patrick G.			Primary prevention of severe lower respiratory illnesses in at-risk infants using the immunomodulator OM-85	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							VIRAL-INFECTIONS; SENSITIZATION		[Sly, Peter D.; Galbraith, Sally; Islam, Zahir] Univ Queensland, Child Hlth Res Ctr, Childrens Hlth & Environm Program, South Brisbane, Australia; [Holt, Barbara; Troy, Niamh; Holt, Patrick G.] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia	University of Queensland; Telethon Kids Institute; University of Western Australia	Sly, PD (corresponding author), Univ Queensland, Child Hlth Res Ctr, Childrens Hlth & Environm Program, South Brisbane, Australia.	p.sly@uq.edu.cn	Sly, Peter D/F-1486-2010; Holt, Patrick/H-1548-2011	Sly, Peter D/0000-0001-6305-2201; Troy, Niamh Mary/0000-0002-1608-8292; Holt, Patrick/0000-0003-1193-0935	National Health and Medical Research Council, Australia [1041983]	National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia)	Supported by the National Health and Medical Research Council, Australia (#1041983).	Holt PG, 2012, NAT MED, V18, P726, DOI 10.1038/nm.2768; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2016, J ALLERGY CLIN IMMUN, V137, P659, DOI 10.1016/j.jaci.2016.01.002; Kusel MMH, 2012, EUR RESPIR J, V39, P876, DOI 10.1183/09031936.00193310; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Razi CH, 2010, J ALLERGY CLIN IMMUN, V126, P763, DOI 10.1016/j.jaci.2010.07.038; Schaad UB, 2002, CHEST, V122, P2042, DOI 10.1378/chest.122.6.2042; Scott NM, 2017, MUCOSAL IMMUNOL, V10, P789, DOI 10.1038/mi.2016.85; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008	9	18	18	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2019	144	3					870	+		10.1016/j.jaci.2019.05.032	http://dx.doi.org/10.1016/j.jaci.2019.05.032			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IW8CV	31185221	Bronze			2022-12-18	WOS:000485222300034
J	Bell, AJ; Foy, BH; Richardson, M; Singapuri, A; Mirkes, E; van den Berge, M; Kay, D; Brightling, C; Gorban, AN; Galban, CJ; Siddiqui, S				Bell, Alex J.; Foy, Brody H.; Richardson, Matthew; Singapuri, Amisha; Mirkes, Evgeny; van den Berge, Maarten; Kay, David; Brightling, Chris; Gorban, Alexander N.; Galban, Craig J.; Siddiqui, Salman			Functional CT imaging for identification of the spatial determinants of small-airways disease in adults with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; computed tomography; parametric response mapping; imaging; visualization; small-airways physiology; biomarker	VENTILATION HETEROGENEITY; LUNG-FUNCTION; STANDARDIZATION; RESISTANCE; STATEMENT; PERFUSION; SCANS; COPD	Background: Asthma is a disease characterized by ventilation heterogeneity (VH). A number of studies have demonstrated that VH markers derived by using impulse oscillometry (IOS) or multiple-breath washout (MBW) are associated with key asthmatic patient related outcome measures and airways hyperresponsiveness. However, the topographical mechanisms of VH in the lung remain poorly understood. Objectives: We hypothesized that specific regionalization of topographical small-airway disease would best account for IOS- and MBW-measured indices in patients. Methods: We evaluated the results of paired expiratory/inspiratory computed tomography in a cohort of asthmatic (n = 41) and healthy (n = 11) volunteers to understand the determinants of clinical VH indices commonly reported by using IOS and MBW. Parametric response mapping (PRM) was used to calculate the functional small-airways disease marker PRMfSAD and Hounsfield unit (HU)-based density changes from total lung capacity to functional residual capacity (Delta HU); gradients of Delta HU in gravitationally perpendicular (parallel) inferior-superior (anterior-posterior) axes were quantified. Results: The Delta HU gradient in the inferior-superior axis provided the highest level of discrimination of both acinar VH (measured by using phase 3 slope analysis of multiple-breath washout data) and resistance at 5 Hz minus resistance at 20 Hz measured by using impulse oscillometry (R5-R20) values. Patients with a high inferior-superior Delta HU gradient demonstrated evidence of reduced specific ventilation in the lower lobes of the lungs and high levels of PRMfSAD. A computational small-airway tree model confirmed that constriction of gravitationally dependent, lower-zone, small airway branches would promote the largest increases in R5-R20 values. Ventilation gradients correlated with asthma control and quality of life but not with exacerbation frequency. Conclusions: Lower lobe predominant small-airways disease is a major driver of clinically measured VH in adults with asthma.	[Bell, Alex J.; Richardson, Matthew; Singapuri, Amisha; Brightling, Chris; Siddiqui, Salman] Univ Leicester, NIHR Resp Biomed Res Ctr BRC, Dept Resp Sci, Leicester, Leics, England; [Mirkes, Evgeny; Gorban, Alexander N.] Univ Leicester, Dept Math, Leicester, Leics, England; [Foy, Brody H.; Kay, David] Univ Oxford, Dept Comp Sci, Computat Biol, Oxford, England; [van den Berge, Maarten] Univ Med Ctr Groningen, Dept Pulmonol, Groningen, Netherlands; [Galban, Craig J.] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA	University of Leicester; University of Leicester; University of Oxford; University of Groningen; University of Michigan System; University of Michigan	Siddiqui, S (corresponding author), Glenfield Hosp, NIHR Biomed Res Ctr Resp Theme, Resp BRU Bldg,Groby Rd, Leicester LE3 9QP, Leics, England.	ss338@leicester.ac.uk	Gorban, Alexander N/D-7310-2011; Mirkes, Evgeny/Y-9614-2018	Gorban, Alexander N/0000-0001-6224-1430; Mirkes, Evgeny/0000-0003-1474-1734; van den Berge, Maarten/0000-0002-9336-7340; brightling, chris/0000-0002-9345-4903	Sir Jules Thorn trust; Roche Pharmaceuticals; European Union Airways Disease Predicting Outcomes in Patient Specific Computational Models (AirPROM-FP7) consortium; National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Centre (BRC)	Sir Jules Thorn trust; Roche Pharmaceuticals(Roche Holding); European Union Airways Disease Predicting Outcomes in Patient Specific Computational Models (AirPROM-FP7) consortium; National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Centre (BRC)	Supported by the Sir Jules Thorn trust, "Systems medicine: novel mathematical approaches to personalized care in asthma patients,'' through a clinical senior lecturer award (Professor Siddiqui). Additional funding was received for the original computed tomographic scan and physiologic analyses from Roche Pharmaceuticals (C.B. and S.S.) and the European Union Airways Disease Predicting Outcomes in Patient Specific Computational Models (AirPROM-FP7) consortium. This article was also supported by the National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR, or the Department of Health.	BENADE AH, 1968, J ACOUST SOC AM, V44, P616, DOI 10.1121/1.1911130; Bhatawadekar SA, 2015, CAN J PHYSIOL PHARM, V93, P207, DOI 10.1139/cjpp-2014-0436; Bhatt SP, 2016, AM J RESP CRIT CARE, V194, P178, DOI 10.1164/rccm.201511-2219OC; Boes JL, 2015, TOMOGRAPHY, V1, P69, DOI 10.18383/j.tom.2015.00148; Boes JL, 2015, ACAD RADIOL, V22, P186, DOI 10.1016/j.acra.2014.08.015; Bordas R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144105; Boudewijn IM, 2015, EUR RESPIR J, V46, P1193, DOI 10.1183/09031936.00009415; Campana L, 2009, J APPL PHYSIOL, V106, P1293, DOI 10.1152/japplphysiol.91428.2008; CAUBERGHS M, 1983, J APPL PHYSIOL, V55, P335, DOI 10.1152/jappl.1983.55.2.335; Choi S, 2013, J APPL PHYSIOL, V115, P730, DOI 10.1152/japplphysiol.00113.2013; Dutrieue B, 2000, J APPL PHYSIOL, V89, P1859, DOI 10.1152/jappl.2000.89.5.1859; Farah CS, 2012, J ALLERGY CLIN IMMUN, V129, P381, DOI 10.1016/j.jaci.2011.11.017; Farrow CE, 2017, J APPL PHYSIOL, V123, P1188, DOI 10.1152/japplphysiol.00640.2016; Farrow CE, 2012, J APPL PHYSIOL, V113, P958, DOI 10.1152/japplphysiol.01618.2011; Galant SP, 2017, ANN ALLERG ASTHMA IM, V118, P664, DOI 10.1016/j.anai.2017.04.009; Galban CJ, 2012, NAT MED, V18, P1711, DOI 10.1038/nm.2971; Galvin I, 2007, BRIT J ANAESTH, V98, P420, DOI 10.1093/bja/aem036; Gonem S, 2014, CLIN EXP ALLERGY, V44, P499, DOI 10.1111/cea.12257; Gonem S, 2016, J ALLERGY CLIN IMMUN, V137, P417, DOI 10.1016/j.jaci.2015.06.027; Gupta S, 2014, J ALLERGY CLIN IMMUN, V133, P729, DOI 10.1016/j.jaci.2013.09.039; Heaney LG, 2010, THORAX, V65, P787, DOI 10.1136/thx.2010.137414; Henderson AC, 2013, J APPL PHYSIOL, V115, P313, DOI 10.1152/japplphysiol.01531.2012; Hopkins SR, 2007, J APPL PHYSIOL, V103, P240, DOI 10.1152/japplphysiol.01289.2006; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Kaczka DW, 2007, ANN BIOMED ENG, V35, P1722, DOI 10.1007/s10439-007-9339-1; Lui JK, 2017, CLIN TRANSL MED, V6, DOI 10.1186/s40169-017-0159-0; Lutchen KR, 1997, J APPL PHYSIOL, V83, P1192, DOI 10.1152/jappl.1997.83.4.1192; MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Oostveen E, 2003, EUR RESPIR J, V22, P1026, DOI 10.1183/09031936.03.00089403; Partridge Martyn R, 2006, BMC Pulm Med, V6, P13, DOI 10.1186/1471-2466-6-13; Postma DS, 2015, EUR RESPIR J, V45, P1534, DOI 10.1183/09031936.00214314; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Robinson PD, 2013, EUR RESPIR J, V41, P507, DOI 10.1183/09031936.00069712; Shim SS, 2018, J ALLERGY CLIN IMMUN, V142, P1773, DOI 10.1016/j.jaci.2017.12.1004; Soares M, 2016, EUR RESPIR J, V48, DOI 10.1183/13993003.congress-2016.OA4968; Tahir BA, 2016, RADIOLOGY, V278, P585, DOI 10.1148/radiol.2015142278; Teague WG, 2014, J ASTHMA, V51, P677, DOI 10.3109/02770903.2014.914535; Thompson BR, 2013, J ALLERGY CLIN IMMUN, V131, P1322, DOI 10.1016/j.jaci.2013.01.054; Tzeng YS, 2009, J APPL PHYSIOL, V106, P813, DOI 10.1152/japplphysiol.01133.2007; Venegas J, 2013, J AEROSOL MED PULM D, V26, P1, DOI 10.1089/jamp.2011.0944; Verbanck S, 2018, THORAX, V73, P82, DOI 10.1136/thoraxjnl-2017-210496; Verbanck S, 2011, COMPR PHYSIOL, V1, P809, DOI 10.1002/cphy.c100018; Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005; Zha W, 2018, J MAGN RESON IMAGING, V47, P1287, DOI 10.1002/jmri.25877	46	18	18	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					83	93		10.1016/j.jaci.2019.01.014	http://dx.doi.org/10.1016/j.jaci.2019.01.014			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30682455	Green Submitted			2022-12-18	WOS:000473432800012
J	Matsui, EC; Adamson, AS; Peng, RD				Matsui, Elizabeth C.; Adamson, Adewole S.; Peng, Roger D.			Time's up to adopt a biopsychosocial model to address racial and ethnic disparities in asthma outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Childhood asthma; disparities; biopsychosocial model; inner-city asthma	HEALTH		[Matsui, Elizabeth C.] Univ Texas Austin, Dept Populat Hlth & Pediat, Dell Med Sch, 1701 Trinity St,Stop Z0500, Austin, TX 78712 USA; [Adamson, Adewole S.] Univ Texas Austin, Dept Med, Dell Med Sch, 1701 Trinity St,Stop Z0500, Austin, TX 78712 USA; [Peng, Roger D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Matsui, EC (corresponding author), Univ Texas Austin, Dept Populat Hlth & Pediat, Dell Med Sch, 1701 Trinity St,Stop Z0500, Austin, TX 78712 USA.	ematsui@utexas.edu		Matsui, Elizabeth/0000-0001-8134-5593				Alvidrez J, 2019, AM J PUBLIC HEALTH, V109, pS16, DOI [10.2105/AJPH.2018.304883, 10.2105/ajph.2018.304883]; Beck AF, 2016, JAMA PEDIATR, V170, P695, DOI 10.1001/jamapediatrics.2016.0269; Fitzpatrick AM, 2019, J ALLERGY CLIN IMMUN, V143, P1734, DOI 10.1016/j.jaci.2019.01.005; King DW, 2009, J CANCER EDUC, V24, pS26, DOI [10.1007/BF03182308, 10.1080/08858190903412091]; Matsui EC, 2014, ALLERGY, V69, P553, DOI 10.1111/all.12361; Milligan KL, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0609-6; Oraka E, 2013, J ASTHMA, V50, P488, DOI 10.3109/02770903.2013.790417; VanderWeele TJ, 2015, EXPLANATION CAUSAL I; Wood BL, 2018, ANN ALLERG ASTHMA IM, V121, P421, DOI 10.1016/j.anai.2018.06.031; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006	10	18	18	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2024	2025		10.1016/j.jaci.2019.03.015	http://dx.doi.org/10.1016/j.jaci.2019.03.015			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30940518	Bronze			2022-12-18	WOS:000470113200008
J	Tortola, L; Pawelski, H; Sonar, SS; Ampenberger, F; Kurrer, M; Kopf, M				Tortola, Luigi; Pawelski, Helga; Sonar, Sanchaita Sriwal; Ampenberger, Franziska; Kurrer, Michael; Kopf, Manfred			IL-21 promotes allergic airway inflammation by driving apoptosis of FoxP3(+) regulatory T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-21; asthma; colitis; regulatory T cells; mucosal immunity	CUTTING EDGE; TYPE-2 IMMUNITY; INTERLEUKIN-21; SUPPRESSION; EXPRESSION; RESPONSES; INDUCE; PROLIFERATION; COUNTERACTS; GENERATION	Background: IL-21 is a key player of adaptive immunity, with well-established roles in B-cell and cytotoxic T-cell responses. IL-21 has been implicated in promotion of effector CD4(+) T cells and inhibition of forkhead box P3-positive regulatory T (Treg) cells, but the mechanism and functional relevance of these findings remain controversial. Objective: We sought to understand the mechanisms by which IL21 controls effector CD4(+) cell responses and Treg cell homeostasis. Methods: We used IL-21 receptor-deficient mice to study the effect of IL-21 on T-cell responses in models of asthma and colitis. We used mixed bone marrow chimeras and adoptive transfer of naive CD4(+) T cells and Treg cells into lymphopenic mice to assess the cell-intrinsic effects of IL-21. Using various in vitro T-cell assays, we characterized the mechanism of IL-21-mediated inhibition of Treg cells. Results: We show that IL-21 production by TH2 and follicular helper T/ex-follicular helper T cells promotes asthma by inhibiting Treg cells. Il21r(-/-) mice displayed reduced generation of T(H)2 cells and increased generation of Treg cells. In mixed chimeras we demonstrate that IL-21 promotes T(H)2 responses indirectly through inhibition of Treg cells. Depleting Treg cells in Il21r(-/-) mice restored T(H)2 generation and eosinophilia. Furthermore, IL-21 inhibited Treg cell generation in mice with colitis. Using competitive transfer of Il21r(+/+) and Il21r(-/-) CD4(+) cells, we show that IL-21 directly inhibited expansion of differentiated Treg cells but was dispensable for T(H)1/T(H)17 effectors. We show that IL-21 sensitizes Treg cells to apoptosis by interfering with the expression of Bcl-2 family genes. Conclusion: IL-21 directly promotes apoptosis of Treg cells and therefore indirectly sustains generation of inflammatory TH cells and related effector responses.	[Tortola, Luigi; Pawelski, Helga; Sonar, Sanchaita Sriwal; Ampenberger, Franziska; Kopf, Manfred] Swiss Fed Inst Technol, Dept Biol, Inst Mol Hlth Sci, Zurich, Switzerland; [Kurrer, Michael] Pathol Inst, Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Tortola, L; Kopf, M (corresponding author), Swiss Fed Inst Technol, Inst Mol Hlth Sci, Otto Stern Weg 7, CH-8093 Zurich, Switzerland.	luigi.tortola@biol.ethz.ch; manfred.kopf@ethz.ch	Kopf, Manfred/B-6907-2009	Kopf, Manfred/0000-0002-0628-7140; Tortola, Luigi/0000-0002-8480-2080	SNF [SNF 310030B_141175, SNF 310030_163443/1]	SNF	Research was funded by grants from SNF (SNF 310030B_141175 and SNF 310030_163443/1).	Attridge K, 2012, BLOOD, V119, P4656, DOI 10.1182/blood-2011-10-388546; Bacher P, 2016, CELL, V167, P1067, DOI 10.1016/j.cell.2016.09.050; Ballesteros-Tato A, 2016, IMMUNITY, V44, P259, DOI 10.1016/j.immuni.2015.11.017; Battaglia A, 2013, IMMUNOLOGY, V139, P109, DOI 10.1111/imm.12061; Bessa J, 2010, J IMMUNOL, V184, P4615, DOI 10.4049/jimmunol.0903949; Bucher C, 2009, BLOOD, V114, P5375, DOI 10.1182/blood-2009-05-221135; Comes A, 2006, J IMMUNOL, V176, P1750, DOI 10.4049/jimmunol.176.3.1750; Coquet JM, 2008, J IMMUNOL, V180, P7097, DOI 10.4049/jimmunol.180.11.7097; Coquet JM, 2015, IMMUNITY, V43, P318, DOI 10.1016/j.immuni.2015.07.015; Elsaesser H, 2009, SCIENCE, V324, P1569, DOI 10.1126/science.1174182; Fabrizi M, 2014, DIABETES, V63, P2086, DOI 10.2337/db13-0939; Fantini MC, 2007, EUR J IMMUNOL, V37, P3155, DOI 10.1002/eji.200737766; Feng YQ, 2014, CELL, V158, P749, DOI 10.1016/j.cell.2014.07.031; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Frohlich A, 2009, SCIENCE, V324, P1576, DOI 10.1126/science.1172815; Frohlich A, 2007, BLOOD, V109, P2023, DOI 10.1182/blood-2006-05-021600; Hoffmann P, 2009, EUR J IMMUNOL, V39, P1088, DOI 10.1002/eji.200838904; Hue S, 2006, J EXP MED, V203, P2473, DOI 10.1084/jem.20061099; Jin HL, 2004, J IMMUNOL, V173, P657, DOI 10.4049/jimmunol.173.1.657; Kannappan V, 2017, CANCER IMMUNOL IMMUN, V66, P637, DOI 10.1007/s00262-017-1970-6; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Lal G, 2009, J IMMUNOL, V182, P259, DOI 10.4049/jimmunol.182.1.259; Leonard WJ, 2005, NAT REV IMMUNOL, V5, P688, DOI 10.1038/nri1688; Li YQ, 2008, BLOOD, V111, P229, DOI 10.1182/blood-2007-05-089375; Mehta DS, 2003, J IMMUNOL, V170, P4111, DOI 10.4049/jimmunol.170.8.4111; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Ohnmacht C, 2015, SCIENCE, V349, P989, DOI 10.1126/science.aac4263; Ozaki K, 2004, J IMMUNOL, V173, P5361, DOI 10.4049/jimmunol.173.9.5361; Peluso I, 2007, J IMMUNOL, V178, P732, DOI 10.4049/jimmunol.178.2.732; Pene J, 2004, J IMMUNOL, V172, P5154, DOI 10.4049/jimmunol.172.9.5154; Pesce J, 2006, J CLIN INVEST, V116, P2044, DOI 10.1172/JCI27727; Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; POWRIE F, 1993, INT IMMUNOL, V5, P1461, DOI 10.1093/intimm/5.11.1461; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Schmitz I, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003362; Sefik E, 2015, SCIENCE, V349, P993, DOI 10.1126/science.aaa9420; Skak K, 2008, NAT REV DRUG DISCOV, V7, P231, DOI 10.1038/nrd2482; Sonderegger I, 2008, EUR J IMMUNOL, V38, P1833, DOI 10.1002/eji.200838511; Spolski R, 2014, NAT REV DRUG DISCOV, V13, P381, DOI 10.1038/nrd4296; Suto A, 2006, J IMMUNOL, V177, P3721, DOI 10.4049/jimmunol.177.6.3721; Tortola L, 2010, BLOOD, V116, P5200, DOI 10.1182/blood-2010-05-284547; Vegran F, 2014, NAT IMMUNOL, V15, P758, DOI 10.1038/ni.2925; Wan CK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8988; Wan CK, 2013, IMMUNITY, V38, P514, DOI 10.1016/j.immuni.2013.02.011; Wang L, 2011, P NATL ACAD SCI USA, V108, P9542, DOI 10.1073/pnas.1018182108; Weiss EM, 2011, J IMMUNOL, V187, P1684, DOI 10.4049/jimmunol.1002321; Yang BH, 2016, MUCOSAL IMMUNOL, V9, P444, DOI 10.1038/mi.2015.74; Yi JS, 2009, SCIENCE, V324, P1572, DOI 10.1126/science.1175194	50	18	20	3	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2178	+		10.1016/j.jaci.2018.11.047	http://dx.doi.org/10.1016/j.jaci.2018.11.047			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30654048	Bronze			2022-12-18	WOS:000470113200022
J	Brodmerkel, C; Li, K; Garcet, S; Hayden, K; Chiricozzi, A; Novitskaya, I; Fuentes-Duculan, J; Suarez-Farinas, M; Campbell, K; Krueger, JG				Brodmerkel, Carrie; Li, Katherine; Garcet, Sandra; Hayden, Karen; Chiricozzi, Andrea; Novitskaya, Inna; Fuentes-Duculan, Judilyn; Suarez-Farinas, Mayte; Campbell, Kim; Krueger, James G.			Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Brodmerkel, Carrie; Li, Katherine; Hayden, Karen; Campbell, Kim] Janssen Res & Dev, Immunol Biomarkers, Spring House, PA USA; [Garcet, Sandra; Novitskaya, Inna; Fuentes-Duculan, Judilyn; Krueger, James G.] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA; [Chiricozzi, Andrea] Catholic Univ, Inst Dermatol, Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA	Johnson & Johnson; Janssen Pharmaceuticals; Rockefeller University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Krueger, JG (corresponding author), Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA.	jgk@rockefeller.edu		Garcet, Sandra/0000-0002-4465-8547	Janssen Research AMP; Development, LLC	Janssen Research AMP; Development, LLC	Janssen Research & Development, LLC, funded this study.	Costanzo A, 2018, DERMATOLOGY, V234, P1, DOI 10.1159/000488586; Griffiths CEM, 2010, NEW ENGL J MED, V362, P118, DOI 10.1056/NEJMoa0810652; Matos TR, 2017, J CLIN INVEST, V127, P4031, DOI 10.1172/JCI93396; No DJ, 2018, J DERMATOL TREAT, V29, P460, DOI 10.1080/09546634.2017.1398393; Sbidian E, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011535.pub2; 2011, J INVEST DERMATOL, V131, P391, DOI DOI 10.1038/JID.2010.280	6	18	18	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1965	1969		10.1016/j.jaci.2019.01.017	http://dx.doi.org/10.1016/j.jaci.2019.01.017			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30703387	hybrid			2022-12-18	WOS:000466784600041
J	Toivonen, L; Camargo, CA; Gern, JE; Bochkov, YA; Mansbach, JM; Piedra, PA; Hasegawa, K				Toivonen, Laura; Camargo, Carlos A., Jr.; Gern, James E.; Bochkov, Yury A.; Mansbach, Jonathan M.; Piedra, Pedro A.; Hasegawa, Kohei			Association between rhinovirus species and nasopharyngeal microbiota in infants with severe bronchiolitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INFECTION; CHILDREN; UNIFRAC		[Toivonen, Laura; Camargo, Carlos A., Jr.; Hasegawa, Kohei] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA; [Toivonen, Laura] Turku Univ Hosp, Dept Paediat & Adolescent Med, Turku, Finland; [Toivonen, Laura] Univ Turku, Turku, Finland; [Gern, James E.; Bochkov, Yury A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI USA; [Gern, James E.; Bochkov, Yury A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI USA; [Mansbach, Jonathan M.] Boston Childrens Hosp, Dept Pediat, Boston, MA USA; [Piedra, Pedro A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Piedra, Pedro A.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Turku; University of Turku; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Boston Children's Hospital; Baylor College of Medicine; Baylor College of Medicine	Toivonen, L (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA.	ltoivonen@mgh.harvard.edu	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	National Institutes of Health (Bethesda, Md) [UG3 OD-023253, U01 AI-087881, R01 AI-134940, R01 AI-137091]; Finnish Medical Foundation; Paivikki and Sakari Sohlberg Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI104317, R01AI137091, U01AI087881, R01AI134940, R01AI127507] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [UG3OD023253] Funding Source: NIH RePORTER	National Institutes of Health (Bethesda, Md)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Finnish Medical Foundation; Paivikki and Sakari Sohlberg Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The current analysis was supported by the National Institutes of Health (Bethesda, Md; grant nos. UG3 OD-023253, U01 AI-087881, R01 AI-134940, and R01 AI-137091). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. L.T. was supported by the Finnish Medical Foundation and Paivikki and Sakari Sohlberg Foundation.	BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bochkov YA, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0608-7; Bochkov YA, 2014, J CLIN MICROBIOL, V52, P2461, DOI 10.1128/JCM.00075-14; Bosch AATM, 2017, AM J RESP CRIT CARE, V196, P1582, DOI 10.1164/rccm.201703-0554OC; Caporaso JG, 2012, ISME J, V6, P1621, DOI 10.1038/ismej.2012.8; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Cox DW, 2013, AM J RESP CRIT CARE, V188, P1358, DOI 10.1164/rccm.201303-0498OC; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Hasegawa K, 2017, PEDIATR INT, V59, P473, DOI 10.1111/ped.13168; Hasegawa K, 2016, EUR RESPIR J, V48, P1329, DOI 10.1183/13993003.00152-2016; Hasegawa K, 2014, EXPERT REV ANTI-INFE, V12, P817, DOI 10.1586/14787210.2014.906901; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Iwane MK, 2011, J INFECT DIS, V204, P1702, DOI 10.1093/infdis/jir634; Karppinen S, 2017, AM J RESP CRIT CARE, V196, P1172, DOI 10.1164/rccm.201702-0357OC; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Lozupone C, 2011, ISME J, V5, P169, DOI 10.1038/ismej.2010.133; Mansbach JM, 2012, PEDIATRICS, V130, pE492, DOI 10.1542/peds.2012-0444; Methe BA, 2012, NATURE, V486, P215, DOI 10.1038/nature11209; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742; ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Vrtis R, 2018, J ALLERGY CLIN IMMUN, V141, P822, DOI 10.1016/j.jaci.2017.09.027; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344	26	18	18	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1925	+		10.1016/j.jaci.2018.12.1004	http://dx.doi.org/10.1016/j.jaci.2018.12.1004			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30654045	Bronze, Green Accepted, Green Published			2022-12-18	WOS:000466784600028
J	Persson, C				Persson, Carl			Airways exudation of plasma macromolecules: Innate defense, epithelial regeneration, and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Plasma proteins; innate immunity; airway epithelium; airway microcirculation; epithelial permeability; epithelial regeneration; asthma pathogenesis	SUBEPITHELIAL HYDROSTATIC-PRESSURE; SEASONAL ALLERGIC RHINITIS; PLATELET-ACTIVATING-FACTOR; CELL SECRETORY PROTEIN; RISK WORSENING RATHER; HUMAN NASAL; MUCOSAL EXUDATION; BRONCHOALVEOLAR LAVAGE; BRONCHIAL EPITHELIUM; BARRIER DYSFUNCTION	This review discusses in vivo airway aspects of plasma exudation in relation to current views on epithelial permeability and epithelial regeneration in health and disease. Microvascular-epithelial exudation of bulk plasma proteins characteristically occurs in asthmatic patients, being especially pronounced in those with severe and exacerbating asthma. Healthy human and guinea pig airways challenged by noninjurious histamine-leukotriene-type autacoids also respond through prompt mucosal exudation of nonsieved plasma macromolecules. Contrary to current beliefs, epithelial permeability in the opposite direction (ie, absorption of inhaled molecules) has not been increased in patients with asthma and allergic rhinitis or in acutely exuding healthy airways. A slightly increased subepithelial hydrostatic pressure produces such unidirectional outward perviousness to macromolecules. Lack of increased absorption permeability in asthmatic patients can further be reconciled with occurrence of epithelial shedding, leaving small patches of denuded basement membrane. Counteracting escalating barrier breaks, plasma exudation promptly covers the denuded patches. Here it creates and sustains a biologically active barrier involving a neutrophil-rich, fibrin-fibronectin net. Furthermore, in the plasma-derived milieu, all epithelial cell types bordering the denuded patch dedifferentiate and migrate from all sides to cover the denuded basement membrane. However, this speedy epithelial regeneration can come at a cost. Guinea pig in vivo studies demonstrate that patches of epithelial denudation regeneration are exudation hot spots evoking asthma-like features, including recruitment/activation of granulocytes, proliferation of fibrocytes/smooth muscle cells, and basement membrane thickening. In conclusion, nonsieved plasma macromolecules can operate on the intact airway mucosa as potent components of first-line innate immunity responses. Exuded plasma also takes center stage in epithelial regeneration. When exaggerated, epithelial regeneration can contribute to the inception and development of asthma.	[Persson, Carl] Univ Hosp Lund, Dept Lab Med, S-22185 Lund, Sweden	Lund University; Skane University Hospital	Persson, C (corresponding author), Univ Hosp Lund, Dept Lab Med, S-22185 Lund, Sweden.	carl.persson@med.lu.se						Adcock Ian M., 2004, Current Drug Targets - Inflammation and Allergy, V3, P257, DOI 10.2174/1568010043343660; Aitken M L, 1989, Symp Soc Exp Biol, V43, P73; AKERLUND A, 1993, ACTA OTO-LARYNGOL, V113, P642, DOI 10.3109/00016489309135878; Anderson SD, 2008, J ALLERGY CLIN IMMUN, V122, P225, DOI 10.1016/j.jaci.2008.05.001; ANDERSSON M, 1994, ALLERGY, V49, P242, DOI 10.1111/j.1398-9995.1994.tb02656.x; Baluk P, 1998, AM J PATHOL, V152, P1463; Berger G, 2007, ARCH OTOLARYNGOL, V133, P78, DOI 10.1001/archotol.133.1.78; Blom AM, 2009, MOL IMMUNOL, V46, P2808, DOI 10.1016/j.molimm.2009.04.025; Bochner BS, 2015, J ALLERGY CLIN IMMUN, V135, P1662, DOI 10.1016/j.jaci.2015.02.028; Brims FJH, 2009, THORAX, V64, P1037, DOI 10.1136/thx.2009.114439; Chan T B, 1985, Ann Acad Med Singap, V14, P462; CHUNG KF, 1990, EUR RESPIR J, V3, P329; CROMWELL O, 1992, IMMUNOLOGY, V77, P330; Cruz AA, 2006, J ALLERGY CLIN IMMUN, V117, P1351, DOI 10.1016/j.jaci.2006.01.054; Curtis Jeffrey L, 2007, Proc Am Thorac Soc, V4, P512, DOI 10.1513/pats.200701-002FM; Cyranoski D, 2015, NATURE, V521, P406, DOI 10.1038/nature.2015.17605; Davis MS, 2003, MED SCI SPORT EXER, V35, P608, DOI 10.1249/01.MSS.0000058660.88987.A0; Davis MS, 2001, AM J RESP CRIT CARE, V164, P785, DOI 10.1164/ajrccm.164.5.2003081; de Boer JD, 2012, BLOOD, V119, P3236, DOI 10.1182/blood-2011-11-391532; DelDonno M, 1997, CHEST, V111, P1255, DOI 10.1378/chest.111.5.1255; Delvaeye M, 2009, BLOOD, V114, P2367, DOI 10.1182/blood-2009-05-199208; Desai D, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-17; DU T, 1992, AM REV RESPIR DIS, V146, P1037, DOI 10.1164/ajrccm/146.4.1037; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Egesten A, 2011, J BIOL CHEM, V286, P2469, DOI 10.1074/jbc.M110.148171; Elovsson S, 2005, VASC PHARMACOL, V43, P267, DOI 10.1016/j.vph.2005.08.016; ELWOOD RK, 1983, AM REV RESPIR DIS, V128, P523, DOI 10.1164/arrd.1983.128.3.523; Emmanouil P, 2015, ALLERGY, V70, P711, DOI 10.1111/all.12603; ERJEFALT I, 1991, CLIN EXP ALLERGY, V21, P217, DOI 10.1111/j.1365-2222.1991.tb00833.x; Erjefalt I, 1989, Pulm Pharmacol, V2, P93, DOI 10.1016/0952-0600(89)90030-6; ERJEFALT I, 1993, AM REV RESPIR DIS, V148, P695, DOI 10.1164/ajrccm/148.3.695; ERJEFALT I, 1991, AM REV RESPIR DIS, V143, P1008, DOI 10.1164/ajrccm/143.5_Pt_1.1008; ERJEFALT I, 1992, CLIN EXP ALLERGY, V22, P854, DOI 10.1111/j.1365-2222.1992.tb02831.x; ERJEFALT I, 1993, J APPL PHYSIOL, V74, P817, DOI 10.1152/jappl.1993.74.2.817; ERJEFALT IAL, 1985, J PHARMACOL METHOD, V14, P275, DOI 10.1016/0160-5402(85)90003-8; ERJEFALT JS, 1994, AM J RESP CRIT CARE, V150, P227, DOI 10.1164/ajrccm.150.1.8025753; Erjefalt JS, 1997, THORAX, V52, P213, DOI 10.1136/thx.52.3.213; ERJEFALT JS, 1995, CLIN EXP ALLERGY, V25, P187, DOI 10.1111/j.1365-2222.1995.tb01025.x; ERJEFALT JS, 1995, THORAX, V50, P785, DOI 10.1136/thx.50.7.785; ERJEFALT JS, 1995, CELL TISSUE RES, V281, P305, DOI 10.1007/BF00583399; Erjefalt JS, 1997, CLIN EXP ALLERGY, V27, P1344; Erjefalt JS, 1997, CLIN EXP ALLERGY, V27, P1458, DOI 10.1046/j.1365-2222.1997.1200932.x; Erjefalt JS, 1997, THORAX, V52, P1010, DOI 10.1136/thx.52.11.1010; Erjefalt JS, 1996, AM J RESP CRIT CARE, V153, P1666, DOI 10.1164/ajrccm.153.5.8630618; ERJEFALT JS, 1994, MICROVASC RES, V48, P161, DOI 10.1006/mvre.1994.1047; Esnault S, 2016, J ALLERGY CLIN IMMUN, V137, P767, DOI 10.1016/j.jaci.2015.05.053; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; GERMONPRE PR, 1995, ARCH INT PHARMACOD T, V329, P185; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; GREGA GJ, 1988, MICROCIRC ENDOTH LYM, V4, P143; GREIFF L, 1995, THORAX, V50, P225, DOI 10.1136/thx.50.3.225; Greiff L, 1997, EUR RESPIR J, V10, P841; Greiff L, 1997, AM J RESP CRIT CARE, V156, P783, DOI 10.1164/ajrccm.156.3.9607013; GREIFF L, 1995, ALLERGY, V50, P593, DOI 10.1111/j.1398-9995.1995.tb01205.x; Greiff L, 2002, CLIN PHYSIOL FUNCT I, V22, P55, DOI 10.1046/j.1365-2281.2002.00401.x; Greiff L, 2002, CLIN PHYSIOL FUNCT I, V22, P28; GREIFF L, 1991, THORAX, V46, P630, DOI 10.1136/thx.46.9.630; Greiff L, 1997, CLIN EXP ALLERGY, V27, P438; GREIFF L, 1993, THORAX, V48, P648, DOI 10.1136/thx.48.6.648; GREIFF L, 1994, EUR RESPIR J, V7, P1120; Greiff L, 1998, THORAX, V53, P1010, DOI 10.1136/thx.53.12.1010; GREIFF L, 1990, CLIN EXP ALLERGY, V20, P253, DOI 10.1111/j.1365-2222.1990.tb02680.x; GREIFF L, 1994, THORAX, V49, P121, DOI 10.1136/thx.49.2.121; Greiff L, 1999, THORAX, V54, P33, DOI 10.1136/thx.54.1.33; GUSTAFSSON B, 1992, SCAND J GASTROENTERO, V27, P587; GUSTAFSSON BG, 1991, CLIN EXP ALLERGY, V21, P121, DOI 10.1111/j.1365-2222.1991.tb00813.x; Halldorsdottir H, 1997, THORAX, V52, P964, DOI 10.1136/thx.52.11.964; HUTT G, 1954, PFLUG ARCH GES PHYS, V258, P311, DOI 10.1007/BF00363639; Imamura T, 2005, J EXP MED, V201, P1669, DOI 10.1084/jem.20042041; Innes AL, 2009, AM J RESP CRIT CARE, V180, P203, DOI 10.1164/rccm.200807-1056OC; INTAGLIETTA M, 1971, MICROVASC RES, V3, P396, DOI 10.1016/0026-2862(71)90041-0; Jakiela B, 2008, AM J RESP CELL MOL, V38, P517, DOI 10.1165/rcmb.2007-0050OC; Johansson MW, 2013, AM J RESP CELL MOL, V48, P503, DOI 10.1165/rcmb.2012-0150OC; KAULBACH HC, 1993, J ALLERGY CLIN IMMUN, V92, P457, DOI 10.1016/0091-6749(93)90125-Y; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; Khakpour S, 2015, INNATE IMMUN-LONDON, V21, P827, DOI 10.1177/1753425915606525; Khor YH, 2009, CLIN EXP ALLERGY, V39, P1659, DOI 10.1111/j.1365-2222.2009.03349.x; Kicic A, 2016, CLIN EXP ALLERGY, V46, P1441, DOI 10.1111/cea.12767; KONTOUKARAKITSOS K, 1975, J ALLERGY CLIN IMMUN, V55, P241, DOI 10.1016/0091-6749(75)90143-8; Krug N, 2001, AM J RESP CRIT CARE, V164, P1841, DOI 10.1164/ajrccm.164.10.2010096; Lackie PM, 1997, AM J RESP CELL MOL, V16, P14, DOI 10.1165/ajrcmb.16.1.8998074; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; Lakind JS, 2007, BIOMARKERS, V12, P445, DOI 10.1080/13547500701359327; Lecaille F, 2016, BIOCHIMIE, V122, P151, DOI 10.1016/j.biochi.2015.08.014; LEMARCHAND P, 1992, AM REV RESPIR DIS, V145, P147, DOI 10.1164/ajrccm/145.1.147; Liu LX, 1996, ANN NY ACAD SCI, V796, P21, DOI 10.1111/j.1749-6632.1996.tb32563.x; Lopuhaa CE, 2003, INT ARCH ALLERGY IMM, V130, P266, DOI 10.1159/000070213; Loser S, 2017, J ALLERGY CLIN IMMUN, V140, P1211, DOI 10.1016/j.jaci.2017.01.048; Louis R, 2012, CLIN CHEST MED, V33, P531, DOI 10.1016/j.ccm.2012.05.004; LUTS A, 1990, INT ARCH ALLER A IMM, V91, P385, DOI 10.1159/000235146; Mackay RMA, 2016, CHEST, V149, P1165, DOI 10.1016/j.chest.2015.11.012; Malmstrom K, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0575-0; MCDONALD DM, 1994, AM J PHYSIOL, V266, pL61, DOI 10.1152/ajplung.1994.266.1.L61; McHugh KJ, 1996, SCAND J GASTROENTERO, V31, P900, DOI 10.3109/00365529609051999; Meerschaert J, 1999, AM J RESP CRIT CARE, V159, P619, DOI 10.1164/ajrccm.159.2.9806053; Meyer P, 2003, PEDIAT ALLERG IMM-UK, V14, P60, DOI 10.1034/j.1399-3038.2003.02102.x; MIDGREN B, 1992, AM REV RESPIR DIS, V146, P347, DOI 10.1164/ajrccm/146.2.347; MINNICOZZI M, 1994, J IMMUNOL, V153, P2664; MONTEFORT S, 1992, THORAX, V47, P499, DOI 10.1136/thx.47.7.499; MONTEFORT S, 1993, CLIN EXP ALLERGY, V23, P185, DOI 10.1111/j.1365-2222.1993.tb00880.x; Mosesson MW, 2005, J THROMB HAEMOST, V3, P1894, DOI 10.1111/j.1538-7836.2005.01365.x; Mosser AG, 2002, J INFECT DIS, V185, P734, DOI 10.1086/339339; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; NAYLOR B, 1964, J CLIN PATHOL, V17, P84, DOI 10.1136/jcp.17.1.84; NAYLOR BERNARD, 1962, THORAX, V17, P69, DOI 10.1136/thx.17.1.69; Nihlberg K, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-50; Nocker RET, 2000, J LAB CLIN MED, V136, P39, DOI 10.1067/mlc.2000.107305; Nourshargh S, 2010, NAT REV MOL CELL BIO, V11, P366, DOI 10.1038/nrm2889; OBYRNE PM, 1984, J APPL PHYSIOL, V57, P77, DOI 10.1152/jappl.1984.57.1.77; ODONNELL SR, 1990, J PHARMACOL EXP THER, V254, P65; Oehmcke-Hecht S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00312; Ogata H, 1990, Arerugi, V39, P1567; Olivenstein R, 1997, PULM PHARMACOL THER, V10, P223, DOI 10.1006/pupt.1997.0095; Ordonez C, 2000, AM J RESP CRIT CARE, V162, P2324, DOI 10.1164/ajrccm.162.6.2001041; OUT TA, 1991, EUR RESPIR J, V4, pS148; Pain M, 2014, EUR RESPIR REV, V23, P118, DOI 10.1183/09059180.00004413; Persson C, 2014, CLIN EXP ALLERGY, V44, P173, DOI 10.1111/cea.12255; Persson C, 2009, CLIN EXP ALLERGY, V39, P1626, DOI 10.1111/j.1365-2222.2009.03373.x; Persson C, 2017, J ALLERGY CLIN IMMUN, V141, P1164; Persson C, 2017, J ALLERGY CLIN IMMUN, V140, P1211, DOI 10.1016/j.jaci.2017.01.047; Persson C, 2015, J ALLERGY CLIN IMMUN, V135, P1662, DOI 10.1016/j.jaci.2015.02.029; Persson C, 2014, AM J RESP CRIT CARE, V189, P628, DOI 10.1164/rccm.201311-2069OE; Persson C, 2012, BRIT J PHARMACOL, V165, P2100, DOI 10.1111/j.1476-5381.2011.01772.x; Persson C, 2010, THORAX, V65, P1111, DOI 10.1136/thx.2009.133363; Persson CGA, 1997, LANCET, V350, P1021, DOI 10.1016/S0140-6736(96)02335-5; PERSSON CGA, 1988, LUNG, V166, P1, DOI 10.1007/BF02714025; PERSSON CGA, 1992, THORAX, V47, P993, DOI 10.1136/thx.47.12.993; Persson CGA, 1996, CLIN EXP ALLERGY, V26, P746, DOI 10.1046/j.1365-2222.1996.d01-374.x; PERSSON CGA, 1990, INT ARCH ALLER A IMM, V92, P148, DOI 10.1159/000235206; PERSSON CGA, 1986, ACTA PHYSIOL SCAND, V127, P95, DOI 10.1111/j.1748-1716.1986.tb07880.x; PERSSON CGA, 1993, ALLERGY, V48, P581, DOI 10.1111/j.1398-9995.1993.tb00752.x; Persson CGA, 1998, EUR RESPIR J, V11, P958, DOI 10.1183/09031936.98.11040958; PERSSON CGA, 1986, LANCET, V2, P1126; Pizzichini MMM, 1998, AM J RESP CRIT CARE, V158, P1178, DOI 10.1164/ajrccm.158.4.9712082; Pizzichini MMM, 1997, AM J RESP CRIT CARE, V155, P1501, DOI 10.1164/ajrccm.155.5.9154849; PLOTKOWSKI MC, 1992, MEM I OSWALDO CRUZ, V87, P61, DOI 10.1590/S0074-02761992000900008; Proud D, 1998, CLIN REV ALLERG IMMU, V16, P351, DOI 10.1007/BF02737656; ROGERS DF, 1990, J PHYSIOL-LONDON, V431, P643, DOI 10.1113/jphysiol.1990.sp018352; Rogers DF, 2004, CURR OPIN PHARMACOL, V4, P241, DOI 10.1016/j.coph.2004.01.011; SALOMONSSON P, 1992, AM REV RESPIR DIS, V146, P1535, DOI 10.1164/ajrccm/146.6.1535; Schleimer Robert P, 2004, Proc Am Thorac Soc, V1, P222, DOI 10.1513/pats.200402-018MS; Schleimer RP, 2017, J ALLERGY CLIN IMMUN, V139, P1752, DOI 10.1016/j.jaci.2017.04.010; SCHOONBROOD DFM, 1994, AM J RESP CRIT CARE, V150, P1519, DOI 10.1164/ajrccm.150.6.7952610; Serikov VB, 2002, J APPL PHYSIOL, V92, P1702, DOI 10.1152/japplphysiol.00645.2001; SPINA D, 1989, AM REV RESPIR DIS, V140, P1410, DOI 10.1164/ajrccm/140.5.1410; Steelant B, 2016, J ALLERGY CLIN IMMUN, V137, P1043, DOI 10.1016/j.jaci.2015.10.050; Stenberg H, 2018, BIOMARKERS, V23, P51, DOI 10.1080/1354750X.2017.1375559; Sturton G, 2008, TRENDS PHARMACOL SCI, V29, P340, DOI 10.1016/j.tips.2008.04.003; SVENSJO E, 1979, AM J PHYSIOL, V236, pH600, DOI 10.1152/ajpheart.1979.236.4.H600; SVENSSON C, 1995, CLIN EXP ALLERGY, V25, P942, DOI 10.1111/j.1365-2222.1995.tb00396.x; SVENSSON C, 1995, J ALLERGY CLIN IMMUN, V96, P239, DOI 10.1016/S0091-6749(95)70013-7; SVENSSON C, 1989, THORAX, V44, P13, DOI 10.1136/thx.44.1.13; SVENSSON C, 1994, EUR J CLIN PHARMACOL, V46, P59; Sweerus K, 2017, J ALLERGY CLIN IMMUN, V139, P72, DOI 10.1016/j.jaci.2016.02.035; Terada M, 2004, AM J RESP CRIT CARE, V169, P373, DOI 10.1164/rccm.200308-1156OC; Thwaites RS, 2018, J ALLERGY CLIN IMMUN, V141, P1892, DOI 10.1016/j.jaci.2018.01.022; Tokuda S, 2009, BIOCHEM BIOPH RES CO, V390, P1315, DOI 10.1016/j.bbrc.2009.10.144; Tomazic PV, 2014, J ALLERGY CLIN IMMUN, V133, P741, DOI 10.1016/j.jaci.2013.09.040; Uller L, 2018, J ALLERGY CLIN IMMUN, V142, P712, DOI 10.1016/j.jaci.2018.01.051; Van Rensen ELJ, 2002, AM J RESP CRIT CARE, V165, P1275, DOI 10.1164/rccm.2110092; van Wetering S, 1999, J ALLERGY CLIN IMMUN, V104, P1131, DOI 10.1016/S0091-6749(99)70004-7; VANDEGRAAF EA, 1991, AM REV RESPIR DIS, V143, P362, DOI 10.1164/ajrccm/143.2.362; Wagner EM, 2015, ANGIOGENESIS, V18, P1, DOI 10.1007/s10456-014-9441-6; Wang Y, 2015, J IMMUNOL, V195, P1171, DOI 10.4049/jimmunol.1401819; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; Widegren H, 2007, RESP MED, V101, P1982, DOI 10.1016/j.rmed.2007.04.005; Wills-Karp Marsha, 2007, Proc Am Thorac Soc, V4, P247, DOI 10.1513/pats.200704-046AW; Yamada Y, 2004, PEDIAT ALLERG IMM-UK, V15, P159, DOI 10.1111/j.1399-3038.2004.00155.x	168	18	18	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1271	1286		10.1016/j.jaci.2018.07.037	http://dx.doi.org/10.1016/j.jaci.2018.07.037			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30170125	Bronze, Green Published			2022-12-18	WOS:000463348900001
J	Campana, R; Marth, K; Zieglmayer, P; Weber, M; Lupinek, C; Zhernov, Y; Elisyutina, O; Khaitov, M; Rigler, E; Westritschnig, K; Berger, U; Wolkersdorfer, M; Horak, F; Horak, F; Valenta, R				Campana, Raffaela; Marth, Katharina; Zieglmayer, Petra; Weber, Milena; Lupinek, Christian; Zhernov, Yury; Elisyutina, Olga; Khaitov, Musa; Rigler, Eva; Westritschnig, Kerstin; Berger, Uwe; Wolkersdorfer, Martin; Horak, Fritz, Jr.; Horak, Friedrich; Valenta, Rudolf			Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							IMMUNOTHERAPY		[Campana, Raffaela; Marth, Katharina; Weber, Milena; Lupinek, Christian; Rigler, Eva; Westritschnig, Kerstin; Valenta, Rudolf] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Vienna, Austria; [Zieglmayer, Petra; Horak, Friedrich] Vienna Challenge Chamber, Huetteldorfer Str, Vienna, Austria; [Zhernov, Yury; Elisyutina, Olga; Khaitov, Musa; Valenta, Rudolf] NRC Inst Immunol FMBA Russia, Moscow, Russia; [Berger, Uwe] Med Univ Vienna, Dept Otorhinolaryngol, Vienna, Austria; [Wolkersdorfer, Martin] Landesapotheke Salzburg, Dept Prod, Muellner Hauptstr, Salzburg, Austria; [Horak, Fritz, Jr.; Horak, Friedrich] Allergy Ctr Vienna West, Huetteldorfer Str, Vienna, Austria; [Valenta, Rudolf] Sechenov First Moscow State Med Univ, Dept Clin Immunol & Allergy, Lab Immunopathol, Moscow, Russia	Medical University of Vienna; NRC Institute of Immunology FMBA of Russia; Medical University of Vienna; Sechenov First Moscow State Medical University	Valenta, R (corresponding author), Med Univ Vienna, Dept Pathophysiol & Allergy Res, Vienna, Austria.; Valenta, R (corresponding author), NRC Inst Immunol FMBA Russia, Moscow, Russia.; Valenta, R (corresponding author), Sechenov First Moscow State Med Univ, Dept Clin Immunol & Allergy, Lab Immunopathol, Moscow, Russia.	Rudolf.valenta@meduniwien.ac.at	Elisyutina, Olga/S-2549-2016; Khaitov, Musa R/L-3369-2017; Zieglmayer, Petra/AAG-1006-2020; Lupinek, Christian/I-3311-2019; Zhernov, Yury/K-8219-2014; Khaitov, Musa/AAC-1516-2021	Elisyutina, Olga/0000-0002-4609-2591; Khaitov, Musa R/0000-0003-4961-9640; Lupinek, Christian/0000-0002-8612-8245; Zhernov, Yury/0000-0001-8734-5527; Khaitov, Musa/0000-0003-4961-9640; Campana, Raffaela/0000-0001-9309-9908; Valenta, Rudolf/0000-0001-5944-3365	Austrian Science Fund (FWF) [F4605]; Government of the Russian Federation [14.W03.31.0024]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Government of the Russian Federation	This study was supported by project F4605 of the Austrian Science Fund (FWF) and by a Megagrant of the Government of the Russian Federation (grant no. 14.W03.31.0024 to R.V.).	Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Kundig TM, 2006, J ALLERGY CLIN IMMUN, V117, P1470, DOI 10.1016/j.jaci.2006.01.040; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niederberger V, 2007, INT ARCH ALLERGY IMM, V142, P133, DOI 10.1159/000096439; Szepfalusi Z, 2014, PEDIAT ALLERG IMM-UK, V25, P788, DOI 10.1111/pai.12310; Valenta R, 2012, J INTERN MED, V272, P144, DOI 10.1111/j.1365-2796.2012.02556.x; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Wickman M, 2017, EBIOMEDICINE, V26, P91, DOI 10.1016/j.ebiom.2017.11.009	8	18	18	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1258	1261		10.1016/j.jaci.2018.11.011	http://dx.doi.org/10.1016/j.jaci.2018.11.011			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30471304	Green Accepted, hybrid			2022-12-18	WOS:000460272900056
J	Mertz, P; Lebrun-Vignes, B; Salem, JE; Arnaud, L				Mertz, Philippe; Lebrun-Vignes, Benedicte; Salem, Joe-Elie; Arnaud, Laurent			Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DISEASE		[Mertz, Philippe; Arnaud, Laurent] Univ Strasbourg, Serv Rhumatol, Hop Univ Strasbourg, Lab ImmunoRhumatol Mol,INSERM,UMR S1109, Strasbourg, France; [Lebrun-Vignes, Benedicte; Salem, Joe-Elie] Hop La Pitie Salpetriere, AP HP, Dept Pharmacol, Reg Pharmacovigilance Ctr, Paris, France; [Lebrun-Vignes, Benedicte; Salem, Joe-Elie] INSERM, Paris, France; [Lebrun-Vignes, Benedicte; Salem, Joe-Elie] UPMC Univ Paris 06, Sorbonne Univ, Fac Med, Paris, France; [Lebrun-Vignes, Benedicte; Salem, Joe-Elie] Inst Cardiometab & Nutr ICAN, Paris, France	CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite	Arnaud, L (corresponding author), Univ Strasbourg, Serv Rhumatol, Hop Univ Strasbourg, Lab ImmunoRhumatol Mol,INSERM,UMR S1109, Strasbourg, France.	Laurent.arnaud@chru-strasbourg.fr	Mertz, Philippe/AAF-4123-2019	Mertz, Philippe/0000-0002-9781-7388; ARNAUD, Laurent/0000-0002-8077-8394; Salem, Joe-Elie/0000-0002-0331-3307				Bate A, 1998, EUR J CLIN PHARMACOL, V54, P315, DOI 10.1007/s002280050466; Druey KM, 2017, J ALLERGY CLIN IMMUN, V140, P663, DOI 10.1016/j.jaci.2016.10.042; Druey KM, 2010, ANN INTERN MED, V153, P90, DOI 10.7326/0003-4819-153-2-201007200-00005; Duron L, 2015, REV MED INTERNE, V36, P386, DOI 10.1016/j.revmed.2014.11.005; Gousseff M, 2011, ANN INTERN MED, V154, DOI 10.7326/0003-4819-154-7-201104050-00004; Guffroy A, 2017, SEMIN ARTHRITIS RHEU, V46, P509, DOI 10.1016/j.semarthrit.2016.08.001; Kapoor P, 2010, MAYO CLIN PROC, V85, P905, DOI 10.4065/mcp.2010.0159; Xie ZH, 2012, BLOOD, V119, P4321, DOI 10.1182/blood-2011-08-375816	8	18	18	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					433	+		10.1016/j.jaci.2018.09.001	http://dx.doi.org/10.1016/j.jaci.2018.09.001			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30244023	Bronze			2022-12-18	WOS:000454918300055
J	Nassenstein, C; Krasteva-Christ, G; Renz, H				Nassenstein, Christina; Krasteva-Christ, Gabriela; Renz, Harald			New aspects of neuroinflammation and neuroimmune crosstalk in the airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic asthma; airway innervation; C-fibers; parasympathetic neurons; neurogenic inflammation; vagal ganglia; nucleus of the solitary tract	A-INDUCED BRONCHOCONSTRICTION; NK-2 RECEPTOR ANTAGONIST; SUBSTANCE-P; SENSORY NEURONS; DENDRITIC CELL; MOUSE MODEL; MAST-CELL; INFLAMMATION; EXPRESSION; PEPTIDE	Neuroimmune interaction has long been discussed in the pathogenesis of allergic airway diseases, such as allergic asthma. Mediators released during inflammation can alter the function of both sensory and parasympathetic neurons innervating the airways. Evidence has been provided that the inflammatory response can be altered by various mediators that are released by sensory and parasympathetic neurons and vice versa. Our aim is to demonstrate recent developments in the reciprocal neuroimmune interaction and to include, if available, data from in vivo and clinical studies.	[Nassenstein, Christina] Justus Liebig Univ, Inst Anat & Cell Biol, Giessen, Germany; [Krasteva-Christ, Gabriela] Saarland Univ, Inst Anat & Cell Biol, Homburg, Germany; [Renz, Harald] Philipps Univ Marburg, Inst Lab Med & Pathobiochem, Mol Diagnost, Marburg, Germany; [Nassenstein, Christina; Renz, Harald] Univ Giessen, German Ctr Lung Res DZL, Giessen, Germany; [Nassenstein, Christina; Renz, Harald] Univ Marburg, German Ctr Lung Res DZL, Lung Ctr, Giessen, Germany; [Nassenstein, Christina; Renz, Harald] Univ Giessen, German Ctr Lung Res DZL, Marburg, Germany; [Nassenstein, Christina; Renz, Harald] Univ Marburg, German Ctr Lung Res DZL, Lung Ctr, Marburg, Germany; [Nassenstein, Christina] Philipps Univ Marburg, CMBB, Marburg, Germany; [Nassenstein, Christina] Justus Liebig Univ Giessen, Res Campus Cent Hessen FCMH, Giessen, Germany	Justus Liebig University Giessen; Universitatsklinikum des Saarlandes; Philipps University Marburg; Justus Liebig University Giessen; Philipps University Marburg; Justus Liebig University Giessen; Philipps University Marburg; Philipps University Marburg; Justus Liebig University Giessen	Nassenstein, C (corresponding author), Inst Anat & Cell Biol, Aulweg 123, D-35385 Giessen, Germany.	christina.nassenstein@anatomie.med.uni-giessen.de	Krasteva-Christ, Gabriela/CAI-9036-2022	Krasteva-Christ, Gabriela/0000-0002-0113-521X	German Center for Lung Research (DZL); German Research Foundation (DFG) [TRR 152 / P22]	German Center for Lung Research (DZL); German Research Foundation (DFG)(German Research Foundation (DFG))	Supported by the German Center for Lung Research (DZL; C.N. and H.R.) and the German Research Foundation (DFG), TRR 152 / P22 (G.K.-C.).	ALIAKBARI J, 1987, BIOCHEM BIOPH RES CO, V148, P1440, DOI 10.1016/S0006-291X(87)80293-0; Audrit KJ, 2017, CELL TISSUE RES, V367, P571, DOI 10.1007/s00441-016-2559-7; Balentova S, 2013, RESP PHYSIOL NEUROBI, V189, P195, DOI 10.1016/j.resp.2013.07.006; Boot JD, 2007, AM J RESP CRIT CARE, V175, P450, DOI 10.1164/rccm.200608-1186OC; Cevikbas F, 2014, J ALLERGY CLIN IMMUN, V133, P448, DOI 10.1016/j.jaci.2013.10.048; Chen CY, 2001, J ALLERGY CLIN IMMUN, V108, P557; Chen SD, 2008, NEUROSCI LETT, V440, P87, DOI 10.1016/j.neulet.2008.03.092; Costello RW, 1997, AM J PHYSIOL-LUNG C, V273, pL93, DOI 10.1152/ajplung.1997.273.1.L93; DEY RD, 1981, CELL TISSUE RES, V220, P231; Drake MG, 2018, J LEUKOCYTE BIOL, V104, P61, DOI 10.1002/JLB.3MR1117-426R; Dunzendorfer S, 1998, J LEUKOCYTE BIOL, V64, P828, DOI 10.1002/jlb.64.6.828; Ferry X, 2002, PEPTIDES, V23, P1507, DOI 10.1016/S0196-9781(02)00090-6; Fischer A, 1996, J CLIN INVEST, V98, P2284, DOI 10.1172/JCI119039; Fryer AD, 2006, J CLIN INVEST, V116, P228, DOI 10.1172/JCI25423; Groneberg DA, 2001, PULM PHARMACOL THER, V14, P391, DOI 10.1006/pupt.2001.0306; Hale MW, 2012, CHEM IMMUNOL ALLERGY, V98, P118, DOI 10.1159/000336505; Han L, 2018, NAT NEUROSCI, V21, P324, DOI 10.1038/s41593-018-0074-8; Hoyle GW, 1998, AM J RESP CELL MOL, V18, P149, DOI 10.1165/ajrcmb.18.2.2803m; Imamachi N, 2009, P NATL ACAD SCI USA, V106, P11330, DOI 10.1073/pnas.0905605106; Jacoby DB, 2001, J ALLERGY CLIN IMMUN, V107, P211, DOI 10.1067/mai.2001.112940; Johnston LK, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00051; Joos GF, 1996, AM J RESP CRIT CARE, V153, P1781, DOI 10.1164/ajrccm.153.6.8665034; Joos GF, 2004, EUR RESPIR J, V23, P76, DOI 10.1183/09031936.03.00101902; Kabashima K, 2018, J ALLERGY CLIN IMMUN, V142, P1121, DOI 10.1016/j.jaci.2018.03.018; Kaur D, 2015, ALLERGY, V70, P556, DOI 10.1111/all.12593; Kistemaker LEM, 2015, TRENDS PHARMACOL SCI, V36, P164, DOI 10.1016/j.tips.2014.11.005; Kistemaker LEM, 2015, AM J PHYSIOL-LUNG C, V308, pL96, DOI 10.1152/ajplung.00259.2014; Kistemaker LEM, 2012, LIFE SCI, V91, P1126, DOI 10.1016/j.lfs.2012.02.021; Kraan J, 2001, CLIN EXP ALLERGY, V31, P274, DOI 10.1046/j.1365-2222.2001.00975.x; Le DD, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-73; Levite M, 1998, J IMMUNOL, V160, P993; Linden A, 1999, EUR RESPIR J, V14, P443, DOI 10.1034/j.1399-3003.1999.14b34.x; Liu BY, 2016, P NATL ACAD SCI USA, V113, pE7572, DOI 10.1073/pnas.1606608113; LUCK JC, 1970, J PHYSIOL-LONDON, V211, P63, DOI 10.1113/jphysiol.1970.sp009266; Maggi CA, 1997, REGUL PEPTIDES, V70, P75, DOI 10.1016/S0167-0115(97)00029-3; METWALI A, 1994, J NEUROIMMUNOL, V52, P69, DOI 10.1016/0165-5728(94)90164-3; Mikami N, 2011, J IMMUNOL, V186, P6886, DOI 10.4049/jimmunol.1100028; MYERS AC, 1991, J APPL PHYSIOL, V71, P970, DOI 10.1152/jappl.1991.71.3.970; Nassenstein C, 2007, J ALLERGY CLIN IMMUN, V120, P1089, DOI 10.1016/j.jaci.2007.07.007; Nassenstein C, 2010, J PHYSIOL-LONDON, V588, P4769, DOI 10.1113/jphysiol.2010.195339; Nie ZY, 2007, J ALLERGY CLIN IMMUN, V119, P1415, DOI 10.1016/j.jaci.2007.03.005; NIEBER K, 1992, J ALLERGY CLIN IMMUN, V90, P646, DOI 10.1016/0091-6749(92)90138-R; Noga O, 2005, REGUL PEPTIDES, V132, P74, DOI 10.1016/j.regpep.2005.09.023; Oetjen LK, 2017, CELL, V171, P217, DOI 10.1016/j.cell.2017.08.006; PACK AI, 1983, J APPL PHYSIOL, V55, P955, DOI 10.1152/jappl.1983.55.3.955; PALMER JBD, 1986, J APPL PHYSIOL, V61, P1322, DOI 10.1152/jappl.1986.61.4.1322; Pan J, 2010, AM J RESP CELL MOL, V43, P452, DOI 10.1165/rcmb.2009-0130OC; PIEDIMONTE G, 1993, J APPL PHYSIOL, V74, P2462, DOI 10.1152/jappl.1993.74.5.2462; Pohunek P, 2005, PEDIAT ALLERG IMM-UK, V16, P43, DOI 10.1111/j.1399-3038.2005.00239.x; Pretolani M, 2017, J ALLERGY CLIN IMMUN, V139, P1176, DOI 10.1016/j.jaci.2016.08.009; Ramalho R, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-41; Schelfhout V, 2006, PULM PHARMACOL THER, V19, P413, DOI 10.1016/j.pupt.2005.10.007; Schelfhout Venessa, 2009, Ther Adv Respir Dis, V3, P219, DOI 10.1177/1753465809349741; Shen ZJ, 2015, IMMUNOL LETT, V167, P1, DOI 10.1016/j.imlet.2015.06.012; Silberstein SD, 2017, NEW ENGL J MED, V377, P2113, DOI 10.1056/NEJMoa1709038; Spaziano G, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/980983; Suzuki H, 2018, J PEPT SCI, V24, DOI 10.1002/psc.3069; Talbot S, 2015, NEURON, V87, P341, DOI 10.1016/j.neuron.2015.06.007; Trankner D, 2014, P NATL ACAD SCI USA, V111, P11515, DOI 10.1073/pnas.1411032111; Vacca G, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-24; Van Schoor J, 1998, EUR RESPIR J, V12, P17, DOI 10.1183/09031936.98.12010017; Veres TZ, 2007, AM J RESP CELL MOL, V37, P553, DOI 10.1165/rcmb.2007-0087OC; Veres TZ, 2009, AM J PATHOL, V174, P808, DOI 10.2353/ajpath.2009.080800; Vocca L, 2015, IMMUNOBIOLOGY, V220, P954, DOI 10.1016/j.imbio.2015.02.005; Voedisch S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045951; Wallrapp A, 2017, NATURE, V549, P351, DOI 10.1038/nature24029; Weigand LA, 2015, AM J RESP CELL MOL, V53, P443, DOI 10.1165/rcmb.2014-0280OC; Weigand LA, 2012, J PHYSIOL-LONDON, V590, P4109, DOI 10.1113/jphysiol.2012.233460; Widdicombe JG, 2003, PULM PHARMACOL THER, V16, P23, DOI 10.1016/S1094-5539(02)00178-5; Wilkerson EM, 2016, J PROTEOME RES, V15, P1524, DOI 10.1021/acs.jproteome.6b00006; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Zhang XM, 2005, EMBO J, V24, P4211, DOI 10.1038/sj.emboj.7600893; Zhu WM, 2001, AM J RESP CELL MOL, V24, P38, DOI 10.1165/ajrcmb.24.1.4255; Zoltowska AM, 2016, CLIN EXP ALLERGY, V46, P479, DOI 10.1111/cea.12683	74	18	18	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1415	1422		10.1016/j.jaci.2018.09.011	http://dx.doi.org/10.1016/j.jaci.2018.09.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	30409249	Bronze			2022-12-18	WOS:000449429800004
J	Cao, HL; Biondo, M; Lioe, H; Busfield, S; Rayzman, V; Nieswandt, B; Bork, K; Harrison, LC; Auyeung, P; Farkas, H; Csuka, D; Pelzing, M; Dower, S; Wilson, MJ; Nash, A; Nolte, MW; Panousis, C				Cao, Helen; Biondo, Mark; Lioe, Hadi; Busfield, Samantha; Rayzman, Veronika; Nieswandt, Bernhard; Bork, Konrad; Harrison, Leonard C.; Auyeung, Priscilla; Farkas, Henriette; Csuka, Dorottya; Pelzing, Matthias; Dower, Steve; Wilson, Michael J.; Nash, Andrew; Nolte, Marc W.; Panousis, Con			Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HEREDITARY ANGIOEDEMA; ACTIVATION; ATTACKS		[Cao, Helen; Biondo, Mark; Lioe, Hadi; Busfield, Samantha; Rayzman, Veronika; Pelzing, Matthias; Dower, Steve; Wilson, Michael J.; Nash, Andrew; Panousis, Con] CSL Ltd, Inst BIO21, Parkville, Vic, Australia; [Nieswandt, Bernhard] Univ Wurzburg, Univ Hosp Wurzburg, Dept Expt Biomed, Wurzburg, Germany; [Nieswandt, Bernhard] Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, Wurzburg, Germany; [Bork, Konrad] Johannes Gutenberg Univ Mainz, Dept Dermatol, Mainz, Germany; [Harrison, Leonard C.; Auyeung, Priscilla] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia; [Harrison, Leonard C.; Auyeung, Priscilla] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia; [Farkas, Henriette; Csuka, Dorottya] Semmelweis Univ, Hungarian Angioedema Ctr, Dept Internal Med 3, Budapest, Hungary; [Nolte, Marc W.] CSL Behring GmbH, Emil Von Behring Str 76, Marburg, Germany	CSL; University of Wurzburg; University of Wurzburg; Johannes Gutenberg University of Mainz; Walter & Eliza Hall Institute; University of Melbourne; Semmelweis University; CSL	Panousis, C (corresponding author), CSL Ltd, Inst BIO21, Parkville, Vic, Australia.	con.panousis@csl.com.au	Bork, Konrad/AAE-4985-2022; Csuka, Dorottya/F-2224-2010; Pelzing, Matthias/AAB-2663-2021	Bork, Konrad/0000-0002-6084-4577; Csuka, Dorottya/0000-0003-3610-9852; dower, steve/0000-0002-4675-4225; Farkas, Henriette/0000-0003-2929-1721	CSL Limited	CSL Limited	This work was supported by CSL Limited.	Bjorkqvist J, 2013, THROMB HAEMOSTASIS, V110, P399, DOI 10.1160/TH13-03-0258; Bork K, 2008, EXPERT REV CLIN IMMU, V4, P13, DOI 10.1586/1744666X.4.1.13; Csuka D, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0351-5; Cugno M, 1996, IMMUNOPHARMACOLOGY, V33, P361, DOI 10.1016/0162-3109(96)00086-0; Gompels MM, 2005, CLIN EXP IMMUNOL, V139, P379, DOI 10.1111/j.1365-2249.2005.02726.x; Larsson M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3006804; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Nussberger J, 1999, J ALLERGY CLIN IMMUN, V104, P1321, DOI 10.1016/S0091-6749(99)70030-8; Oschatz C, 2011, IMMUNITY, V34, P258, DOI 10.1016/j.immuni.2011.02.008	9	18	18	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1355	1358		10.1016/j.jaci.2018.06.014	http://dx.doi.org/10.1016/j.jaci.2018.06.014			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29936101	Bronze			2022-12-18	WOS:000446327300038
J	Kothari, PH; Qiu, WL; Croteau-Chonka, DC; Martinez, FD; Liu, AH; Lemanske, RF; Ober, C; Krishnan, JA; Nicolae, DL; Barnes, KC; London, SJ; Barraza-Villarreal, A; White, SR; Naureckas, ET; Millstein, J; Gauderman, WJ; Gilliland, FD; Carey, VJ; Weiss, ST; Raby, BA				Kothari, Parul H.; Qiu, Weiliang; Croteau-Chonka, Damien C.; Martinez, Fernando D.; Liu, Andrew H.; Lemanske, Robert F., Jr.; Ober, Carole; Krishnan, Jerry A.; Nicolae, Dan L.; Barnes, Kathleen C.; London, Stephanie J.; Barraza-Villarreal, Albino; White, Steven R.; Naureckas, Edward T.; Millstein, Joshua; Gauderman, W. James; Gilliland, Frank D.; Carey, Vincent J.; Weiss, Scott T.; Raby, Benjamin A.		Asthma BioRepository Integrative	Role of local CpG DNA methylation in mediating the 17q21 asthma susceptibility gasdermin B (GSDMB)/ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3) expression quantitative trait locus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							POLYMORPHISMS; RISK		[Kothari, Parul H.; Qiu, Weiliang; Croteau-Chonka, Damien C.; Carey, Vincent J.; Weiss, Scott T.; Raby, Benjamin A.] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Kothari, Parul H.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA; [Raby, Benjamin A.] Brigham & Womens Hosp, Pulm Genet Ctr, 75 Francis St, Boston, MA 02115 USA; [Raby, Benjamin A.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Raby, Benjamin A.] Harvard Med Sch, Boston, MA USA; [Martinez, Fernando D.] Univ Arizona Hlth Sci, Asthma & Airway Dis Res Ctr, Tucson, AZ USA; [Liu, Andrew H.] Childrens Hosp Colorado, Natl Jewish Hlth, Dept Pediat, Sect Pulm Med, Denver, CO USA; [Liu, Andrew H.] Univ Colorado, Sch Med, Denver, CO USA; [Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Ober, Carole; Nicolae, Dan L.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Nicolae, Dan L.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Nicolae, Dan L.] Univ Chicago, Dept Stat, Chicago, IL 60637 USA; [White, Steven R.; Naureckas, Edward T.] Univ Chicago, Dept Med, Sect Pulm & Crit Care Med, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Krishnan, Jerry A.] Univ Illinois, Dept Med, Div Pulm Crit Care Sleep & Allergy, Chicago, IL USA; [Barnes, Kathleen C.] Univ Colorado, Dept Med, Div Biomed Informat & Personalized Med, Anschutz Med Campus, Aurora, CO USA; [London, Stephanie J.] NIEHS, Div Intramural Res, US Dept HHS, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Barraza-Villarreal, Albino] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico; [Millstein, Joshua; Gauderman, W. James] Univ Southern Calif, Keck Sch Med, Div Biostat, Dept Prevent Med, Los Angeles, CA USA; [Gilliland, Frank D.] Univ Southern Calif, Keck Sch Med, Div Environm Hlth, Dept Prevent Med, Los Angeles, CA USA; [Weiss, Scott T.] Partners Hlth Care, Partners HealthCare Personalized Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Arizona; University of Arizona Health Sciences; Children's Hospital Colorado; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Wisconsin System; University of Wisconsin Madison; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Instituto Nacional de Salud Publica; University of Southern California; University of Southern California; Partners Healthcare System	Kothari, PH (corresponding author), Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.; Kothari, PH (corresponding author), Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA.	repko@channing.harvard.edu	London, Stephanie/C-3734-2019; Raby, Benjamin/AAK-3866-2021	London, Stephanie/0000-0003-4911-5290; Ober, Carole/0000-0003-4626-9809; Nicolae, Dan/0000-0002-0918-4630	National Institutes of Health (NIH) through the National Heart, Lung, and Blood Institute [RC2 HL101543, R01 HL086601]; National Institute of Allergy and Infectious Diseases [T32 AI007306]; NIH [K01 HL127265, P30 ES007048, R01 ES023262, R01 HL061768, R01 ES021801, P01 ES011627, ZO1 ES49019]; NATIONAL CANCER INSTITUTE [P01CA196569] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831, K01HL127265, R01HL086601, R01HL061768, R01HL123546, RC2HL101543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES023262, P30ES006694, P30ES007048, Z01ES049019, P01ES011627, R01ES021801] Funding Source: NIH RePORTER	National Institutes of Health (NIH) through the National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by extramural grants from the National Institutes of Health (NIH) through the National Heart, Lung, and Blood Institute (RC2 HL101543 [America Recovery and Reinvestment Act "Grand Opportunity"] and R01 HL086601) and the National Institute of Allergy and Infectious Diseases (T32 AI007306 to P.H.K.). Additional support was provided by the NIH (K01 HL127265 to D.C.C.-C.; P30 ES007048, R01 ES023262, R01 HL061768, R01 ES021801, and P01 ES011627 to F.D.G.; and the Intramural Research Program ZO1 ES49019 to S.J.L.).	Acevedo N, 2015, HUM MOL GENET, V24, P875, DOI 10.1093/hmg/ddu479; Bonder MJ, 2017, NAT GENET, V49, P131, DOI 10.1038/ng.3721; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Croteau-Chonka DC, 2017, AM J RESP CRIT CARE, V195, P179, DOI 10.1164/rccm.201601-0107OC; Flory JH, 2009, J ALLERGY CLIN IMMUN, V124, P605, DOI 10.1016/j.jaci.2009.05.047; Millstein J, 2016, BIOINFORMATICS, V32, P2364, DOI 10.1093/bioinformatics/btw135; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Schedel M, 2015, J ALLERGY CLIN IMMUN, V136, P893, DOI 10.1016/j.jaci.2015.03.014; Verlaan DJ, 2009, AM J HUM GENET, V85, P377, DOI 10.1016/j.ajhg.2009.08.007	9	18	19	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2282	2286		10.1016/j.jaci.2017.11.057	http://dx.doi.org/10.1016/j.jaci.2017.11.057			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29374573	Green Accepted, Bronze			2022-12-18	WOS:000434701600036
J	Sood, AK; Kesic, MJ; Hernandez, ML				Sood, Amika K.; Kesic, Matthew J.; Hernandez, Michelle L.			Electronic cigarettes: One size does not fit all	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Electronic cigarette; e-cigarette; electronic nicotine delivery system; e-liquid; aerosol; cytotoxicity; inflammation; barrier dysfunction; microbial defense; smoking cessation; respiratory effects	SMOKING-CESSATION TRIAL; TOBACCO USE; ASTHMATIC SMOKERS; AEROSOL EXPOSURE; EPITHELIAL-CELLS; HARM REDUCTION; LUNG-FUNCTION; PATHOGENESIS; NICOTINE; INFLAMMATION	Electronic cigarettes (ECs) have been growing rapidly in popularity among youth and adults in the United States over the last decade. This increasing prevalence is driven partially by the ability to customize devices, flavors, and nicotine content and the general notion that ECs are harmless, particularly in comparison with conventional cigarettes. In vitro and in vivo murine models have demonstrated a number of harmful biological effects of e-liquids and their aerosols. However, limited clinical data exist on whether these effects translate into detrimental long-term outcomes in human subjects. The short-term harmful respiratory effects of EC use demonstrated in nonsmokers argue against their use. However, slightly more favorable data exist for the respiratory benefits of substituting conventional cigarettes with ECs and the short-term efficacy of ECs as smoking cessation tools. Nonetheless, available research is severely limited in regard to long-term outcomes and by study designs fraught with bias, pointing to the need for additional research efforts with well-designed longitudinal studies to guide US Food and Drug Administration regulatory efforts. The hurdle presented by diverse device designs and e-liquid permutations, which contribute to the inconsistency of available data, also highlights the need for legislative standardization of ECs.	[Sood, Amika K.; Kesic, Matthew J.; Hernandez, Michelle L.] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, 104 Mason Farm Rd,CB 7310, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill	Sood, AK (corresponding author), Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, 104 Mason Farm Rd,CB 7310, Chapel Hill, NC 27515 USA.	amika_sood@med.unc.edu			American Academy of Allergy, Asthma & Immunology Foundation; National Heart, Lung, and Blood Institute [NHLBI135235];  [5T32AI007062-39]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL135235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007062] Funding Source: NIH RePORTER	American Academy of Allergy, Asthma & Immunology Foundation; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	A.K.S. is supported by 5T32AI007062-39. MLH is supported by the American Academy of Allergy, Asthma & Immunology Foundation and National Heart, Lung, and Blood Institute grant NHLBI135235.	Adriaens K, 2014, INT J ENV RES PUB HE, V11, P11220, DOI 10.3390/ijerph111111220; Anderson C, 2016, TOXICOL SCI, V154, P332, DOI 10.1093/toxsci/kfw166; Antherieu S, 2017, TOXICOL IN VITRO, V45, P417, DOI 10.1016/j.tiv.2016.12.015; Aufderheide M, 2017, EXP TOXICOL PATHOL, V69, P393, DOI 10.1016/j.etp.2017.03.004; Azzopardi David, 2016, Toxicol Mech Methods, V26, P477; Ballbe M, 2014, ENVIRON RES, V135, P76, DOI 10.1016/j.envres.2014.09.005; Behar RZ, 2017, TOB CONTROL; Berg K, 2016, ARCH PATHOL LAB MED, V140, P1423, DOI 10.5858/arpa.2015-0455-RS; Bowler RP, 2017, J GEN INTERN MED, V32, P1315, DOI 10.1007/s11606-017-4150-7; Bullen C, 2013, LANCET, V382, P1629, DOI 10.1016/S0140-6736(13)61842-5; Campagna D, 2016, EUR J CLIN INVEST, V46, P698, DOI 10.1111/eci.12651; Caponnetto P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066317; Cervellati F, 2014, TOXICOL IN VITRO, V28, P999, DOI 10.1016/j.tiv.2014.04.012; Cheng TR, 2014, TOB CONTROL, V23, P11, DOI 10.1136/tobaccocontrol-2013-051482; Cho JH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151022; Cibella F, 2016, CLIN SCI, V130, P1929, DOI 10.1042/CS20160268; Clapp PW, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0747-5; Clapp PW, 2017, AM J PHYSIOL-LUNG C, V313, pL278, DOI 10.1152/ajplung.00452.2016; Dai HY, 2017, PREV CHRONIC DIS, V14, DOI 10.5888/pcd14.170073; Desai M, 2016, ANN ALLERG ASTHMA IM, V116, P394, DOI 10.1016/j.anai.2015.12.024; Dobbs PD, 2016, PREV MED, V88, P90, DOI 10.1016/j.ypmed.2016.03.010; El Dib R, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012680; EL-Hellani A, 2018, NICOTINE TOB RES, V20, P215, DOI 10.1093/ntr/ntw280; Etter JF, 2017, ADDICTION; Evans CM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7281; Farsalinos KE, 2015, INT J ENV RES PUB HE, V12, P9046, DOI 10.3390/ijerph120809046; Farsalinos KE, 2014, INT J ENV RES PUB HE, V11, P4356, DOI 10.3390/ijerph110404356; Ferrari M, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0106-z; Flora JW, 2017, J CHROMATOGR SCI, V55, P142, DOI 10.1093/chromsci/bmw157; Flouris AD, 2013, INHAL TOXICOL, V25, P91, DOI 10.3109/08958378.2012.758197; Gao W, 2015, RESPIROLOGY, V20, P722, DOI 10.1111/resp.12542; Garcia-Arcos I, 2016, THORAX, V71, P1119, DOI 10.1136/thoraxjnl-2015-208039; Gerloff Janice, 2017, Appl In Vitro Toxicol, V3, P28, DOI 10.1089/aivt.2016.0030; Gillman IG, 2016, REGUL TOXICOL PHARM, V75, P58, DOI 10.1016/j.yrtph.2015.12.019; Gon Y, 2018, ALLERGOL INT, V67, P12, DOI 10.1016/j.alit.2017.08.011; Goniewicz ML, 2014, TOB CONTROL, V23, P133, DOI 10.1136/tobaccocontrol-2012-050859; Gummin DD, 2017, CLIN TOXICOL, V55, P1072, DOI 10.1080/15563650.2017.1388087; Harrell Melissa B, 2017, Tob Regul Sci, V3, P168, DOI 10.18001/TRS.3.2.4; Herrington JS, 2015, J CHROMATOGR A, V1418, P192, DOI 10.1016/j.chroma.2015.09.034; Higham A, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0368-x; Holliday Richard, 2016, Evid Based Dent, V17, P2, DOI 10.1038/sj.ebd.6401143; Husari A, 2016, NICOTINE TOB RES, V18, P613, DOI 10.1093/ntr/ntv169; Hwang JH, 2016, J MOL MED, V94, P667, DOI 10.1007/s00109-016-1378-3; Jamal A, 2017, MMWR-MORBID MORTAL W, V66, P597, DOI 10.15585/mmwr.mm6623a1; Jha P, 2013, NEW ENGL J MED, V368, P341, DOI 10.1056/NEJMsa1211128; Kenne DR, 2017, SUBST ABUS-RES TREAT, V11, DOI 10.1177/1178221817733736; Khlystov A, 2016, ENVIRON SCI TECHNOL, V50, P13080, DOI 10.1021/acs.est.6b05145; Kleniewska P, 2017, BIOMED PHARMACOTHER, V94, P100, DOI 10.1016/j.biopha.2017.07.066; Lappas AS, 2018, RESPIROLOGY, V23, P291, DOI 10.1111/resp.13180; Larcombe AN, 2017, AM J PHYSIOL-LUNG C, V313, pL67, DOI 10.1152/ajplung.00203.2016; Larsen K, 2016, RESP MED, V120, P10, DOI 10.1016/j.rmed.2016.09.013; Lee MS, 2017, ENVIRON HEALTH-GLOB, V16, DOI 10.1186/s12940-017-0249-x; Leigh NJ, 2016, TOB CONTROL, V25, pii81, DOI 10.1136/tobaccocontrol-2016-053205; Lerner CA, 2016, BIOCHEM BIOPH RES CO, V477, P620, DOI 10.1016/j.bbrc.2016.06.109; Lerner CA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116732; Leslie LJ, 2017, INHAL TOXICOL, V29, P126, DOI 10.1080/08958378.2017.1318193; Leung JM, 2017, RESPIROLOGY, V22, P634, DOI 10.1111/resp.13032; Lim HB, 2014, TOX RESEARCH, V30, P13, DOI 10.5487/TR.2014.30.1.013; Malas M, 2016, NICOTINE TOB RES, V18, P1926, DOI 10.1093/ntr/ntw119; Martin EM, 2016, AM J PHYSIOL-LUNG C, V311, pL135, DOI 10.1152/ajplung.00170.2016; McConnell R, 2017, AM J RESP CRIT CARE, V195, P1043, DOI 10.1164/rccm.201604-0804OC; McMillen RC, 2015, NICOTINE TOB RES, V17, P1195, DOI 10.1093/ntr/ntu213; Misra M, 2014, INT J ENV RES PUB HE, V11, P11325, DOI 10.3390/ijerph111111325; Neilson L, 2015, TOXICOL IN VITRO, V29, P1952, DOI 10.1016/j.tiv.2015.05.018; Nickels AS, 2017, NICOTINE TOB RES, V19, P197, DOI 10.1093/ntr/ntw194; O'Connell G, 2016, TOXICOL MECH METHOD, V26, P443, DOI 10.1080/15376516.2016.1196282; Ofei-Dodoo S, 2017, J AM BOARD FAM MED, V30, P448, DOI 10.3122/jabfm.2017.04.170084; Ogunwale MA, 2017, ACS OMEGA, V2, P1207, DOI 10.1021/acsomega.6b00489; Patel D, 2016, PREV MED, V93, P14, DOI 10.1016/j.ypmed.2016.09.011; Patterson SB, 2017, J BURN CARE RES, V38, pE95, DOI 10.1097/BCR.0000000000000471; Pericot-Valverde I, 2017, PREV MED, V104, P92, DOI 10.1016/j.ypmed.2017.07.014; Polosa R, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0187-5; Polosa R, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0481-x; Polosa R, 2016, DISCOV MED, V21, P99; Polosa R, 2014, INT J ENV RES PUB HE, V11, P4965, DOI 10.3390/ijerph110504965; Putzhammer R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157337; Rawlinson C, 2017, J CHROMATOGR A, V1497, P144, DOI 10.1016/j.chroma.2017.02.050; Reidel B, 2018, AM J RESP CRIT CARE, V197, P492, DOI 10.1164/rccm.201708-1590OC; Rubenstein DA, 2015, MOL IMMUNOL, V67, P652, DOI 10.1016/j.molimm.2015.05.020; Saddleson ML, 2016, ADDICT BEHAV, V54, P33, DOI 10.1016/j.addbeh.2015.11.012; Schoenborn Charlotte A, 2015, NCHS Data Brief, P1; Schweitzer KS, 2015, AM J PHYSIOL-LUNG C, V309, pL175, DOI 10.1152/ajplung.00411.2014; Sherwood CL, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0369-9; Singh T, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-4155; Siqueira LM, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-3436; Soneji S, 2017, JAMA PEDIATR, V171, P788, DOI 10.1001/jamapediatrics.2017.1488; Stratton K, 2018, PUBLIC HLTH CONSEQUE, P680; Sun Y, 2014, TOXICOL LETT, V229, P384, DOI 10.1016/j.toxlet.2014.06.021; Sussan TE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116861; Teasdale JE, 2016, DRUG ALCOHOL DEPEN, V163, P256, DOI 10.1016/j.drugalcdep.2016.04.020; Tseng TY, 2016, NICOTINE TOB RES, V18, P1937, DOI 10.1093/ntr/ntw017; Uchiyama S, 2016, ANAL SCI, V32, P549, DOI 10.2116/analsci.32.549; US Public Health Services US Department of Health and Human Services, 2016, E CIG US YOUTH YOUNG; Vanderkam P, 2016, PRESSE MED, V45, P971, DOI 10.1016/j.lpm.2016.05.026; Vardavas CI, 2012, CHEST, V141, P1400, DOI 10.1378/chest.11-2443; Villanti AC, 2016, NICOTINE TOB RES, V18, P1331, DOI 10.1093/ntr/ntv235; Webley WC, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0584-z; Ween MP, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13370; Welz C, 2016, J ENVIRON PATHOL TOX, V35, P343, DOI 10.1615/JEnvironPatholToxicolOncol.2016016652; Williams M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175430; Wills TA, 2015, PEDIATRICS, V135, pE43, DOI 10.1542/peds.2014-0760; Wu Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108342; Yu V, 2016, ORAL ONCOL, V52, P58, DOI 10.1016/j.oraloncology.2015.10.018; Zhou-Suckow Z, 2017, CELL TISSUE RES, V367, P537, DOI 10.1007/s00441-016-2562-z; Zhu SH, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3262; Zhu SH, 2014, TOB CONTROL, V23, P3, DOI 10.1136/tobaccocontrol-2014-051670; 2016, JAMA PEDIATR, V170, P89	107	18	18	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					1973	1982		10.1016/j.jaci.2018.02.029	http://dx.doi.org/10.1016/j.jaci.2018.02.029			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	GI7SD	29522848	Bronze, Green Accepted			2022-12-18	WOS:000434701600002
J	Schulke, S; Fiedler, AH; Junker, AC; Flaczyk, A; Wolfheimer, S; Wangorsch, A; Heinz, A; Beckert, H; Nagl, B; Bohle, B; Vieths, S; Toda, M; Scheurer, S				Schuelke, Stefan; Fiedler, Anna-Helena; Junker, Ann-Christine; Flaczyk, Adam; Wolfheimer, Sonja; Wangorsch, Andrea; Heinz, Anke; Beckert, Hendrik; Nagl, Birgit; Bohle, Barbara; Vieths, Stefan; Toda, Masako; Scheurer, Stephan			Critical role of mammalian target of rapamycin for IL-10 dendritic cell induction by a flagellin A conjugate in preventing allergic sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vaccine; Bet v 1; flagellin; rFlaA; fusion protein; birch pollen allergy; IL-10 dendritic cell; mammalian target of rapamycin; metabolism	FUSION PROTEIN VACCINE; PSEUDOMONAS-AERUGINOSA; RESPIRATORY CHALLENGE; TYPHIMURIUM FLAGELLIN; BACTERIAL FLAGELLIN; IMMUNE-RESPONSES; T-CELLS; MTOR; INNATE; IMMUNOGENICITY	Background: Fusion proteins incorporating the Toll-like receptor 5 ligand flagellin are currently undergoing clinical trials as vaccine candidates for many diseases. Objective: We studied the mechanisms of immune modulation by a flagellin: allergen fusion protein containing the Toll-like receptor 5 ligand flagellin A from Listeria monocytogenes and the birch pollen allergen Bet v 1 (recombinant flagellin A [rFlaA]:Betv1). Methods: BALB/c mice were vaccinated with rFlaA: Betv1 in an experimental Bet v 1 sensitization model. Myeloid dendritic cells (mDCs) were differentiated from mouse bone marrow, and PBMCs were isolated from subjects with birch pollen allergy. Cells were stimulated with equimolar amounts of rFlaA, rBet v 1, rFlaA plus rBet v 1, or the rFlaA: Betv1 conjugate and analyzed for cell activation, cytokine secretion, and metabolic state. Results: rFlaA: Betv1 displayed strong immune-modulating properties both in vivo and in vitro, as characterized by secretion of both proinflammatory and anti-inflammatory cytokines from murine mDCs and PBMCs from patients with birch allergy. rFlaA: Betv1 suppressed T(H)2 responses from Bet v 1-specific CD4(+) T cells and prevented allergic sensitization in a mouse allergy model. Aggregation of rFlaA: Betv1 resulted in stronger protein uptake accompanied by an increased resistance to microsomal digestion. Remarkably, rFlaA:Betv1 induced activation of mammalian target of rapamycin, which increased the metabolic activity of the stimulated mDCs. rFlaA: Betv1-mediated IL-10 secretion, but not proinflammatory cytokine secretion, was inhibited by rapamycin in mDCs. Conclusion: These results provide evidence that mammalian target of rapamycin is a key player involved in prevention of T(H)2 responses by flagellin A conjugate vaccines.	[Schuelke, Stefan; Fiedler, Anna-Helena; Junker, Ann-Christine; Flaczyk, Adam; Wolfheimer, Sonja; Wangorsch, Andrea; Vieths, Stefan; Toda, Masako; Scheurer, Stephan] Paul Ehrlich Inst, Mol Allergol, Langen, Germany; [Heinz, Anke] Univ Med Ctr, Med Clin, Pulm Dept 3, Mainz, Germany; [Beckert, Hendrik] Univ Duisburg Essen, Univ Hosp, West German Lung Ctr, Dept Pneumol,Ruhrlandklin, Essen, Germany; [Nagl, Birgit; Bohle, Barbara] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Vienna, Austria; [Flaczyk, Adam] Univ Coll Dublin, Sch Med & Med Sci, Dublin, Ireland	Paul Ehrlich Institute; Johannes Gutenberg University of Mainz; University of Duisburg Essen; Medical University of Vienna; University College Dublin	Schulke, S (corresponding author), Paul Ehrlich Inst, Vice Presidents Res Grp Mol Allergol, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.	Stefan.Schuelke@pei.de	Beckert, Hendrik/AAY-4286-2021; Scheurer, Stephan/A-6509-2019; Toda, Masako/S-9810-2019	Beckert, Hendrik/0000-0003-0098-3548; Scheurer, Stephan/0000-0002-2859-562X; Bohle, Barbara/0000-0002-5105-7985	German Research Foundation (DFG) [SCHE 637/3]	German Research Foundation (DFG)(German Research Foundation (DFG))	Part of this work was supported by the German Research Foundation (DFG SCHE 637/3).	Leal MTA, 2013, CLIN VACCINE IMMUNOL, V20, P1418, DOI 10.1128/CVI.00312-13; Baker AK, 2009, MOL IMMUNOL, V46, P2249, DOI 10.1016/j.molimm.2009.04.011; Bao WL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125910; Bates JT, 2009, J IMMUNOL, V182, P7539, DOI 10.4049/jimmunol.0804225; Cao WP, 2008, NAT IMMUNOL, V9, P1157, DOI 10.1038/ni.1645; Chang J, 2013, P NATL ACAD SCI USA, V110, P2270, DOI 10.1073/pnas.1206048110; Cuadros C, 2004, INFECT IMMUN, V72, P2810, DOI 10.1128/IAI.72.5.2810-2816.2004; Delaney KN, 2010, VIRAL IMMUNOL, V23, P201, DOI 10.1089/vim.2009.0107; Finlay D, 2011, NAT REV IMMUNOL, V11, P109, DOI 10.1038/nri2888; Foldenauer MEB, 2013, J IMMUNOL, V190, P5649, DOI 10.4049/jimmunol.1203094; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Honko AN, 2006, INFECT IMMUN, V74, P1113, DOI 10.1128/IAI.74.2.1113-1120.2006; Huleatt JW, 2007, VACCINE, V25, P763, DOI 10.1016/j.vaccine.2006.08.013; Kitzmuller C, 2018, J ALLERGY CLIN IMMUN, V141, P293, DOI 10.1016/j.jaci.2017.02.044; Kitzmuller C, 2015, J ALLERGY CLIN IMMUN, V136, P151, DOI 10.1016/j.jaci.2014.12.1928; Kuznik A, 2011, J IMMUNOL, V186, P4794, DOI 10.4049/jimmunol.1000702; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SE, 2006, INFECT IMMUN, V74, P694, DOI 10.1128/IAI.74.1.694-702.2006; Lee SE, 2015, CLIN EXP VACCINE RES, V4, P59, DOI 10.7774/cevr.2015.4.1.59; Legge KL, 2000, J EXP MED, V191, P2039, DOI 10.1084/jem.191.12.2039; McDonald WF, 2007, J INFECT DIS, V195, P1607, DOI 10.1086/517613; Narayanan K, 2016, ADV HEALTHC MATER, V5, P696, DOI 10.1002/adhm.201500613; Ohtani M, 2008, BLOOD, V112, P635, DOI 10.1182/blood-2008-02-137430; Ohtani M, 2012, J IMMUNOL, V188, P4736, DOI 10.4049/jimmunol.1200069; Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.0818-9641.2004.01272.x; Powell JD, 2012, ANNU REV IMMUNOL, V30, P39, DOI 10.1146/annurev-immunol-020711-075024; Ren WK, 2016, EUR J IMMUNOL, V46, P291, DOI 10.1002/eji.201545886; Saemann MD, 2009, AM J TRANSPLANT, V9, P2655, DOI 10.1111/j.1600-6143.2009.02832.x; Schmitz F, 2008, EUR J IMMUNOL, V38, P2981, DOI 10.1002/eji.200838761; Schulke S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087822; Schulke S, 2011, J ALLERGY CLIN IMMUN, V128, P1340, DOI 10.1016/j.jaci.2011.07.036; Schulke S, 2010, MOL IMMUNOL, V48, P341, DOI 10.1016/j.molimm.2010.07.006; Siebeneicher S, 2014, ALLERGY, V69, P328, DOI 10.1111/all.12326; Song L, 2015, BMC BIOTECHNOL, V15, DOI 10.1186/s12896-015-0195-z; Stepanova LA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119520; Treanor JJ, 2010, VACCINE, V28, P8268, DOI 10.1016/j.vaccine.2010.10.009; Turley CB, 2011, VACCINE, V29, P5145, DOI 10.1016/j.vaccine.2011.05.041; Wang BZ, 2014, J CONTROL RELEASE, V178, P1, DOI 10.1016/j.jconrel.2014.01.002; Weichhart T, 2008, IMMUNITY, V29, P565, DOI 10.1016/j.immuni.2008.08.012; Weichhart T, 2015, NAT REV IMMUNOL, V15, P599, DOI 10.1038/nri3901; Weichhart T, 2009, TRENDS IMMUNOL, V30, P218, DOI 10.1016/j.it.2009.02.002; Weimer ET, 2009, VACCINE, V27, P6762, DOI 10.1016/j.vaccine.2009.08.080; Weimer ET, 2009, INFECT IMMUN, V77, P2356, DOI 10.1128/IAI.00054-09; Zhao JW, 2010, MOL IMMUNOL, V48, P294, DOI 10.1016/j.molimm.2010.07.014; Zhu SS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147432	45	18	18	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1786	+		10.1016/j.jaci.2017.07.002	http://dx.doi.org/10.1016/j.jaci.2017.07.002			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	28886863	Bronze			2022-12-18	WOS:000432148200025
J	Guerra, S; Melen, E; Sunyer, J; Xu, CJ; Lavi, I; Benet, M; Bustamante, M; Carsin, AE; Dobano, C; Guxens, M; Tischer, C; Vrijheid, M; Kull, I; Bergstrom, A; Kumar, A; Soderhall, C; Gehring, U; Dijkstra, DJ; van der Vlies, P; Wickman, M; Bousquet, J; Postma, DS; Anto, JM; Koppelman, GH				Guerra, Stefano; Melen, Erik; Sunyer, Jordi; Xu, Cheng-Jian; Lavi, Iris; Benet, Marta; Bustamante, Mariona; Carsin, Anne-Elie; Dobano, Carlota; Guxens, Monica; Tischer, Christina; Vrijheid, Martine; Kull, Inger; Bergstrom, Anna; Kumar, Ashish; Soderhall, Cilla; Gehring, Ulrike; Dijkstra, Dorieke J.; van der Vlies, Pieter; Wickman, Magnus; Bousquet, Jean; Postma, Dirkje S.; Anto, Josep M.; Koppelman, Gerard H.			Genetic and epigenetic regulation of YKL-40 in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						YKL-40; CHI3L1; asthma; epigenetics; DNA methylation; genetics	CHITINASE-LIKE PROTEIN; EPIGENOME-WIDE ASSOCIATION; ASTHMATIC-PATIENTS; DNA METHYLATION; 3-LIKE 1; CHI3L1; LUNG; POLYMORPHISMS; CHILDREN; ALLERGY	Background: Circulating levels of the chitinase-like protein YKL-40 are influenced by genetic variation in its encoding gene (chitinase 3-like 1 [CHI3L1]) and are increased in patients with several diseases, including asthma. Epigenetic regulation of circulating YKL-40 early in life is unknown. Objective: We sought to determine (1) whether methylation levels at CHI3L1 CpG sites mediate the association of CHI3L1 single nucleotide polymorphisms (SNPs) with YKL-40 levels in the blood and (2) whether these biomarkers (CHI3L1 SNPs, methylation profiles, and YKL-40 levels) are associated with asthma in early childhood. Methods: We used data from up to 2405 participants from the Spanish Infancia y Medio Ambiente; the Swedish Barn/Children, Allergy, Milieu, Stockholm, Epidemiological survey; and the Dutch Prevention and Incidence of Asthma and Mite Allergy birth cohorts. Associations between 68 CHI3L1 SNPs, methylation levels at 14 CHI3L1 CpG sites in whole-blood DNA, and circulating YKL-40 levels at 4 years of age were tested by using correlation analysis, multivariable regression, and mediation analysis. Each of these biomarkers was also tested for association with asthma at 4 years of age by using multivariable logistic regression. Results: YKL-40 levels were significantly associated with 7 SNPs and with methylation at 5 CpG sites. Consistent associations between these 7 SNPs (particularly rs10399931 and rs4950928) and 5 CpG sites were observed. Alleles linked to lower YKL-40 levels were associated with higher methylation levels. Participants with high YKL-40 levels (defined as the highest YKL-40 tertile) had increased odds for asthma compared with subjects with low YKL-40 levels (meta-analyzed adjusted odds ratio, 1.90 [95% CI, 1.08-3.36]). In contrast, neither SNPs nor methylation levels at CpG sites in CHI3L1 were associated with asthma. Conclusions: The effects of CHI3L1 genetic variation on circulating YKL-40 levels are partly mediated by methylation profiles. In our study YKL-40 levels, but not CHI3L1 SNPs or methylation levels, were associated with childhood asthma.	[Guerra, Stefano; Sunyer, Jordi; Lavi, Iris; Benet, Marta; Bustamante, Mariona; Carsin, Anne-Elie; Guxens, Monica; Tischer, Christina; Vrijheid, Martine; Anto, Josep M.] Ctr Res Environm Epidemiol CREAL, ISGlobal, Barcelona, Spain; [Guerra, Stefano; Sunyer, Jordi; Lavi, Iris; Benet, Marta; Bustamante, Mariona; Carsin, Anne-Elie; Guxens, Monica; Tischer, Christina; Vrijheid, Martine; Anto, Josep M.] Univ Pompeu Fabra, Barcelona, Spain; [Guerra, Stefano; Sunyer, Jordi; Lavi, Iris; Benet, Marta; Bustamante, Mariona; Carsin, Anne-Elie; Guxens, Monica; Tischer, Christina; Vrijheid, Martine; Anto, Josep M.] CIBER Epidemiol & Salud Publ CIBERES, Troy, NY USA; [Guerra, Stefano] Univ Arizona, Asthma & Airway Dis Res Ctr, Tucson, AZ USA; [Melen, Erik; Bergstrom, Anna; Kumar, Ashish; Wickman, Magnus] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Sunyer, Jordi; Carsin, Anne-Elie; Anto, Josep M.] Hosp Mar, Med Res Inst, IMIM, Barcelona, Spain; [Xu, Cheng-Jian; Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, Groningen, Netherlands; [Xu, Cheng-Jian; Postma, Dirkje S.; Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD, Groningen, Netherlands; [Xu, Cheng-Jian; van der Vlies, Pieter] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands; [Bustamante, Mariona] Barcelona Inst Sci & Technol, Ctr Genom Regulat CRG, Barcelona, Spain; [Dobano, Carlota] Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, ISGlobal, Barcelona, Spain; [Guxens, Monica] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Child & Adolescent Psychiat Psychol, Rotterdam, Netherlands; [Kull, Inger] Sachs Childrens Hosp, Sodersjukhuset, Stockholm, Sweden; [Kull, Inger] Soder Sjukhuset, Karolinska Inst, Dept Clin Sci & Educ, Stockholm, Sweden; [Kumar, Ashish] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland; [Kumar, Ashish] Univ Basel, Basel, Switzerland; [Soderhall, Cilla] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden; [Soderhall, Cilla] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Gehring, Ulrike] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [Dijkstra, Dorieke J.] Univ Groningen, Univ Med Ctr Groningen, Dept Obstet & Gynecol, Groningen, Netherlands; [Bousquet, Jean] Univ Hosp Montpellier, Montpellier, France; [Bousquet, Jean] INSERM 1018, CESP Ctr, Resp & Environm Epidemiol Team, Villejuif, France; [Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, Groningen, Netherlands	ISGlobal; Pompeu Fabra University; Pompeu Fabra University; University of Arizona; Karolinska Institutet; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; University of Groningen; University of Groningen; University of Groningen; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); ISGlobal; CRESIB; University of Barcelona; Hospital Clinic de Barcelona; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Sodersjukhuset Hospital; Karolinska Institutet; Sodersjukhuset Hospital; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Karolinska Institutet; Karolinska Institutet; Utrecht University; University of Groningen; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of Groningen	Guerra, S (corresponding author), Asthma & Airway Dis Res Ctr, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	stefano.guerra@isglobal.org	Anto, J M/H-2676-2014; Bustamante, Mariona/ABB-9142-2021; Vrijheid, Martine/H-2702-2014; Bousquet, Jean/O-4221-2019; Xu, Cheng-Jian/G-9144-2018; Guxens, Monica/T-2285-2018; Dobaño, Carlota/N-4119-2014; Sunyer, Jordi/G-6909-2014; Carsin, Anne-Elie/AAF-6815-2021; Koppelman, Gerard/AAG-9187-2020; Xu, Cheng/GXH-4815-2022; Söderhäll, Cilla/E-3940-2012	Anto, J M/0000-0002-4736-8529; Bustamante, Mariona/0000-0003-0127-2860; Vrijheid, Martine/0000-0002-7090-1758; Xu, Cheng-Jian/0000-0003-1586-4672; Guxens, Monica/0000-0002-8624-0333; Dobaño, Carlota/0000-0002-6751-4060; Sunyer, Jordi/0000-0002-2602-4110; Carsin, Anne-Elie/0000-0003-3981-977X; Xu, Cheng/0000-0003-1000-733X; Söderhäll, Cilla/0000-0002-8397-3080; Gehring, Ulrike/0000-0003-3612-5780; Koppelman, Gerard/0000-0001-8567-3252; Benet Mora, Marta/0000-0001-9600-3510; Bousquet, Jean/0000-0002-4061-4766	EU Seventh Framework Programme [261357]; INMA (Instituto de Salud Carlos III) [Red INMA G03/176, CB06/02/0041, PI041436; PI081151]; INMA (FEDER funds) [MS13/00054]; Generalitat de Catalunya [CIRIT 1999SGR 00241]; Fundacio La marato de TV3 [090430]; BAMSE (the Swedish Heart-Lung Foundation); BAMSE (Swedish Research Council); BAMSE (Freemason Child House Foundation in Stockholm); BAMSE (Stockholm County Council [ALF]); BAMSE (Swedish Foundation for Strategic Research [SSF]) [RBc08-0027]; BAMSE (Strategic Research Programme [SFO] in Epidemiology at Karolinska Institute); PIAMA (The Netherlands Organization for Health Research and Development); PIAMA (Netherlands Organization for Scientific Research); PIAMA (Netherlands Lung Foundation) [AF 4.1.14.001]; PIAMA (The Netherlands Ministry of Spatial Planning, Housing, and the Environment); PIAMA (The Netherlands Ministry of Health, Welfare, and Sport)	EU Seventh Framework Programme; INMA (Instituto de Salud Carlos III); INMA (FEDER funds); Generalitat de Catalunya(Generalitat de Catalunya); Fundacio La marato de TV3; BAMSE (the Swedish Heart-Lung Foundation)(Swedish Heart-Lung Foundation); BAMSE (Swedish Research Council)(Swedish Research Council); BAMSE (Freemason Child House Foundation in Stockholm); BAMSE (Stockholm County Council [ALF]); BAMSE (Swedish Foundation for Strategic Research [SSF]); BAMSE (Strategic Research Programme [SFO] in Epidemiology at Karolinska Institute); PIAMA (The Netherlands Organization for Health Research and Development); PIAMA (Netherlands Organization for Scientific Research)(Netherlands Organization for Scientific Research (NWO)); PIAMA (Netherlands Lung Foundation); PIAMA (The Netherlands Ministry of Spatial Planning, Housing, and the Environment); PIAMA (The Netherlands Ministry of Health, Welfare, and Sport)	Supported by grant agreement no. 261357 (Mechanisms of the Development of Allergy [MeDALL]) from the EU Seventh Framework Programme. Additional funding for individual cohorts was provided as follows: INMA (Instituto de Salud Carlos III [Red INMA G03/176; CB06/02/0041; PI041436; PI081151 incl. FEDER funds; MS13/00054], Generalitat de Catalunya-CIRIT 1999SGR 00241, Fundacio La marato de TV3 [090430]); BAMSE (the Swedish Heart-Lung Foundation, Swedish Research Council, Freemason Child House Foundation in Stockholm, Stockholm County Council [ALF], Swedish Foundation for Strategic Research [SSF, RBc08-0027, EpiGene project] and the Strategic Research Programme [SFO] in Epidemiology at Karolinska Institute); and PIAMA (The Netherlands Organization for Health Research and Development; The Netherlands Organization for Scientific Research; The Netherlands Lung Foundation (AF 4.1.14.001); The Netherlands Ministry of Spatial Planning, Housing, and the Environment; and The Netherlands Ministry of Health, Welfare, and Sport).	Ahangari F, 2015, AM J RESP CRIT CARE, V191, P746, DOI 10.1164/rccm.201405-0796OC; Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10; Bousquet J, 2011, ALLERGY, V66, P596, DOI 10.1111/j.1398-9995.2010.02534.x; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; Cunningham J, 2011, ANN ALLERG ASTHMA IM, V106, P381, DOI 10.1016/j.anai.2011.01.030; Duru S, 2013, IRAN J ALLERGY ASTHM, V12, P247; Garcia-Aymerich J, 2015, ALLERGY, V70, P973, DOI 10.1111/all.12640; Gavala ML, 2013, CLIN EXP ALLERGY, V43, P187, DOI 10.1111/cea.12032; Gomez JL, 2015, J ALLERGY CLIN IMMUN, V136, P51, DOI 10.1016/j.jaci.2014.11.027; Gruzieva O, 2014, PAEDIATR RESPIR REV, V15, P348, DOI 10.1016/j.prrv.2014.07.003; Guerra S, 2015, LANCET RESP MED, V3, P613, DOI 10.1016/S2213-2600(15)00196-4; Guerra S, 2013, RESP MED, V107, P1923, DOI 10.1016/j.rmed.2013.07.013; Hellman A, 2010, EPIGENET CHROMATIN, V3, DOI 10.1186/1756-8935-3-11; Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86; James AJ, 2016, AM J RESP CRIT CARE, V193, P131, DOI 10.1164/rccm.201504-0760OC; Kerkel K, 2008, NAT GENET, V40, P904, DOI 10.1038/ng.174; Kjaergaard AD, 2013, J MED GENET, V50, P831, DOI 10.1136/jmedgenet-2013-101908; Konradsen JR, 2013, J ALLERGY CLIN IMMUN, V132, P328, DOI 10.1016/j.jaci.2013.03.003; Kruit A, 2007, RESP MED, V101, P1563, DOI 10.1016/j.rmed.2006.12.006; Kuepper M, 2008, NEW ENGL J MED, V358, P1073, DOI 10.1056/NEJMc073406; Kull I, 2010, J ALLERGY CLIN IMMUN, V125, P1013, DOI 10.1016/j.jaci.2010.01.051; Lai TW, 2015, BMC PULM MED, V15, DOI 10.1186/1471-2466-15-1; Lee CG, 2011, ANNU REV PHYSIOL, V73, P479, DOI 10.1146/annurev-physiol-012110-142250; Lee CG, 2009, J EXP MED, V206, P1149, DOI 10.1084/jem.20081271; Lemire M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7326; Lienert F, 2011, NAT GENET, V43, P1091, DOI 10.1038/ng.946; Liu Y, 2013, NAT BIOTECHNOL, V31, P142, DOI 10.1038/nbt.2487; Martin TC, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0568-2; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Otsuka K, 2012, RESPIRATION, V83, P507, DOI 10.1159/000330840; Park JA, 2010, J BIOL CHEM, V285, P29817, DOI 10.1074/jbc.M110.103416; Pidsley R, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-293; Pinart M, 2014, LANCET RESP MED, V2, P131, DOI 10.1016/S2213-2600(13)70277-7; Rakyan VK, 2011, NAT REV GENET, V12, P529, DOI 10.1038/nrg3000; Rathcke CN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006106; Ribas-Fito N, 2006, PAEDIATR PERINAT EP, V20, P403, DOI 10.1111/j.1365-3016.2006.00745.x; Saba M, 2014, IRAN J ALLERGY ASTHM, V13, P271; Santos CB, 2014, ANN ALLERG ASTHMA IM, V113, P263, DOI 10.1016/j.anai.2014.05.024; Shi JX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4365; Sohn MH, 2009, AM J RESP CRIT CARE, V179, P449, DOI 10.1164/rccm.200809-1422OC; Tang H, 2010, EUR RESPIR J, V35, P757, DOI 10.1183/09031936.00034409; Tingley D, 2014, J STAT SOFTW, V59; Tsai Y, 2014, BMC MED GENET, V15, DOI 10.1186/1471-2350-15-86; Usemann J, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0239-8; Verlaan DJ, 2012, J ALLERGY CLIN IMMUN, V130, P533, DOI 10.1016/j.jaci.2012.03.015; Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864; Wijga AH, 2014, INT J EPIDEMIOL, V43, P527, DOI 10.1093/ije/dys231; Wu AC, 2010, J ALLERGY CLIN IMMUN, V125, P754, DOI 10.1016/j.jaci.2009.12.995; Yousefi P, 2015, ENVIRON MOL MUTAGEN, V56, P751, DOI 10.1002/em.21966; Zhang DD, 2010, AM J HUM GENET, V86, P411, DOI 10.1016/j.ajhg.2010.02.005	52	18	19	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					1105	1114		10.1016/j.jaci.2017.06.030	http://dx.doi.org/10.1016/j.jaci.2017.06.030			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	28739286	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000426974800030
J	Jiao, J; Wang, M; Duan, S; Meng, YF; Meng, N; Li, Y; Fan, E; Akdis, CA; Zhang, L				Jiao, Jian; Wang, Ming; Duan, Su; Meng, Yifan; Meng, Na; Li, Ying; Fan, Erzhong; Akdis, Cezmi A.; Zhang, Luo			Transforming growth factor-beta 1 decreases epithelial tight junction integrity in chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EXPRESSION		[Jiao, Jian; Wang, Ming; Meng, Yifan; Meng, Na; Li, Ying; Fan, Erzhong; Zhang, Luo] Capital Med Univ, Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China; [Jiao, Jian; Wang, Ming; Meng, Na; Li, Ying; Fan, Erzhong; Zhang, Luo] Capital Med Univ, Beijing TongRen Hosp, Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, Beijing, Peoples R China; [Duan, Su; Zhang, Luo] Capital Med Univ, Beijing TongRen Hosp, Dept Allergy, Beijing, Peoples R China; [Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland	Capital Medical University; Capital Medical University; Capital Medical University; Swiss Institute of Allergy & Asthma Research; University of Zurich	Zhang, L (corresponding author), Capital Med Univ, Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China.; Zhang, L (corresponding author), Capital Med Univ, Beijing TongRen Hosp, Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, Beijing, Peoples R China.; Zhang, L (corresponding author), Capital Med Univ, Beijing TongRen Hosp, Dept Allergy, Beijing, Peoples R China.	dr.luozhang@139.com	Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X; Zhang, Luo/0000-0002-0910-9884				Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; ELOVIC A, 1994, J ALLERGY CLIN IMMUN, V93, P864, DOI 10.1016/0091-6749(94)90379-4; Fokkens W, 2007, RHINOLOGY, P1; Jiao J, 2016, CLIN EXP ALLERGY, V46, P449, DOI 10.1111/cea.12644; Li Y, 2014, ORL J OTO-RHINO-LARY, V76, P110, DOI 10.1159/000362246; Overgaard CE, 2015, AM J PHYSIOL-LUNG C, V308, pL1212, DOI 10.1152/ajplung.00042.2014; Ramezanpour M, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9798206; Schamberger AC, 2014, AM J RESP CELL MOL, V50, P1040, DOI 10.1165/rcmb.2013-0090OC; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Van Bruaene N, 2009, J ALLERGY CLIN IMMUN, V124, P253, DOI 10.1016/j.jaci.2009.04.013; Wawrzyniak P, 2017, J ALLERGY CLIN IMMUN, V139, P93, DOI 10.1016/j.jaci.2016.03.050	11	18	21	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					1160	+		10.1016/j.jaci.2017.08.045	http://dx.doi.org/10.1016/j.jaci.2017.08.045			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29132958	Bronze			2022-12-18	WOS:000426974800047
J	Kusuba, N; Kitoh, A; Dainichi, T; Honda, T; Otsuka, A; Egawa, G; Nakajima, S; Miyachi, Y; Kabashima, K				Kusuba, Nobuhiro; Kitoh, Akihiko; Dainichi, Teruki; Honda, Tetsuya; Otsuka, Atsushi; Egawa, Gyohei; Nakajima, Saeko; Miyachi, Yoshiki; Kabashima, Kenji			Inhibition of IL-17-committed T cells in a murine psoriasis model by a vitamin D analogue	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Psoriasis; calcipotriol; vitamin D analogue; IL-17A; IL-23; imiquimod	THYMIC STROMAL LYMPHOPOIETIN; DERMAL DENDRITIC CELLS; D-RECEPTOR LIGANDS; SKIN INFLAMMATION; DOUBLE-BLIND; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; LANGERHANS CELLS; 1,25-DIHYDROXYVITAMIN D-3; TRANSCRIPTION FACTOR; CALCIPOTRIOL MC-903	Background: A better understanding of the means by which topical vitamin D analogues exert their therapeutic effect on psoriasis is of theoretical and practical importance. Objective: We sought to clarify whether and how the topical vitamin D analogue calcipotriol (CAL) controls the IL-17A-mediated pathogenesis of murine psoriasis-like dermatitis in vivo. Methods: Psoriasis-like dermatitis was induced by the topical application of an imiquimod (IMQ)-containing cream on the murine ear for 4 to 6 consecutive days. For topical CAL treatment, mice were treated daily with CAL solution on the ear before IMQ application. Results: Mice treated topically with CAL exhibited much milder IMQ-induced psoriasis-like dermatitis compared with vehicle-treated mice, with impaired accumulation of IL-17A-committed T (T17) cells in the lesional skin. The IMQ-induced upregulation of Il12b and Il23a was marked in the epidermis and was abrogated by CAL application, suggesting CAL-mediated suppression of IL-23 expression. CAL inhibited Il12b and Il23a expression by Langerhans cells ex vivo stimulated with IMQ and CD40 cross-linking. Topical CAL also inhibited T17 cell expansion in the draining lymph nodes of IMQ-treated skin, implying a possible effect on T17 cell-mediated dermatitis at distant sites. In fact, topical CAL application on the IMQ-treated left ear resulted in amelioration of T17 cell accumulation and psoriasis-like dermatitis in the right ear subsequently treated with IMQ. Conclusion: Topical CAL can exert its antipsoriatic effect on CAL-treated lesions and, concomitantly, distant lesions by attenuating the T17 cell accumulation in both CAL-treated lesions and draining lymph nodes.	[Kusuba, Nobuhiro; Kitoh, Akihiko; Dainichi, Teruki; Honda, Tetsuya; Otsuka, Atsushi; Egawa, Gyohei; Nakajima, Saeko; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan; [Miyachi, Yoshiki] ASTAR, Shiga Med Ctr Adults, Singapore, Singapore; [Kabashima, Kenji] ASTAR, Singapore Immunol Network & Inst Med Biol, Singapore, Singapore; [Kabashima, Kenji] Japan Sci & Technol Agcy, PRESTO, Saitama, Japan	Kyoto University; Agency for Science Technology & Research (A*STAR); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); A*STAR - Singapore Immunology Network (SIgN); Japan Science & Technology Agency (JST)	Kitoh, A; Kabashima, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Dermatol, Sakyo Ku, 54 Shogoin Kawara, Kyoto 6068507, Japan.	kichu@kuhp.kyoto-u.ac.jp; kaba@kuhp.kyoto-u.ac.jp	Dainichi, Teruki/AAL-5400-2020; Nakajima, Saeko/AAB-1577-2021; Kabashima, Kenji/G-2521-2014	Dainichi, Teruki/0000-0002-9497-0029; Otsuka, Atsushi/0000-0001-7365-947X; Nakajima, Saeko/0000-0003-0831-1447; Egawa, Gyohei/0000-0002-6101-4719; Kabashima, Kenji/0000-0002-0773-0554	Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Precursory Research for Embryonic Science and Technology of Japan; Ministry of Health, Labour and Welfare of Japan; Torii Pharmaceutical	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Precursory Research for Embryonic Science and Technology of Japan; Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Torii Pharmaceutical	Supported in part by Grants-in-Aid for Scientific Research from the Ministries of Education, Culture, Sports, Science and Technology, Precursory Research for Embryonic Science and Technology, and Health, Labour and Welfare of Japan and Torii Pharmaceutical.	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Adorini L, 2004, J STEROID BIOCHEM, V89-90, P437, DOI 10.1016/j.jsbmb.2004.03.013; Adorini L, 2003, J CELL BIOCHEM, V88, P227, DOI 10.1002/jcb.10340; Anderson AE, 2008, J LEUKOCYTE BIOL, V84, P124, DOI 10.1189/jlb.1107744; Barker JNWN, 1999, BRIT J DERMATOL, V141, P274; Berer A, 2000, EXP HEMATOL, V28, P575, DOI 10.1016/S0301-472X(00)00143-0; BRENNAN A, 1987, IMMUNOLOGY, V61, P457; Cai YH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4986; Cai YH, 2012, CELL MOL IMMUNOL, V9, P302, DOI 10.1038/cmi.2012.15; Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001; Canning MO, 2001, EUR J ENDOCRINOL, V145, P351, DOI 10.1530/eje.0.1450351; Carlberg C, 2013, STEROIDS, V78, P127, DOI 10.1016/j.steroids.2012.10.019; CUNLIFFE WJ, 1992, J AM ACAD DERMATOL, V26, P736, DOI 10.1016/0190-9622(92)70103-M; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; Fujiyama T, 2016, J ALLERGY CLIN IMMUN, V138, P517, DOI 10.1016/j.jaci.2016.03.048; Gauzzi MC, 2005, J IMMUNOL, V174, P270, DOI 10.4049/jimmunol.174.1.270; Girolomoni G, 2012, BRIT J DERMATOL, V167, P717, DOI 10.1111/j.1365-2133.2012.11099.x; Gray EE, 2013, NAT IMMUNOL, V14, P584, DOI 10.1038/ni.2585; Gregori S, 2002, DIABETES, V51, P1367, DOI 10.2337/diabetes.51.5.1367; Gregori S, 2001, J IMMUNOL, V167, P1945, DOI 10.4049/jimmunol.167.4.1945; Griffin MD, 2001, P NATL ACAD SCI USA, V98, P6800, DOI 10.1073/pnas.121172198; Griffin MD, 2000, BIOCHEM BIOPH RES CO, V270, P701, DOI 10.1006/bbrc.2000.2490; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; Hansel A, 2011, J ALLERGY CLIN IMMUN, V127, P787, DOI 10.1016/j.jaci.2010.12.009; Harden JL, 2015, J AUTOIMMUN, V64, P66, DOI 10.1016/j.jaut.2015.07.008; Hartwig T, 2015, EUR J IMMUNOL, V45, P3022, DOI 10.1002/eji.201545883; Hegyi Z, 2012, J INVEST DERMATOL, V132, P1416, DOI 10.1038/jid.2011.486; HIGHTON A, 1995, J AM ACAD DERMATOL, V32, P67, DOI 10.1016/0190-9622(95)90186-8; Homey B, 2000, J IMMUNOL, V164, P6621, DOI 10.4049/jimmunol.164.12.6621; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; KRAGBALLE K, 1991, LANCET, V337, P193, DOI 10.1016/0140-6736(91)92157-W; KRAGBALLE K, 1988, BRIT J DERMATOL, V119, P223, DOI 10.1111/j.1365-2133.1988.tb03204.x; KRAGBALLE K, 1990, ARCH DERMATOL RES, V282, P164, DOI 10.1007/BF00372616; Kubin ME, 2017, ACTA DERM-VENEREOL, V97, P449, DOI 10.2340/00015555-2579; Laggner U, 2011, J IMMUNOL, V187, P2783, DOI 10.4049/jimmunol.1100804; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; Levine D, 2010, J AM ACAD DERMATOL, V63, P775, DOI 10.1016/j.jaad.2009.10.016; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Lovato P, 2016, J DERMATOL SCI, V81, P153, DOI 10.1016/j.jdermsci.2015.12.009; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Lowes MA, 2013, TRENDS IMMUNOL, V34, P174, DOI 10.1016/j.it.2012.11.005; Ma HL, 2008, J CLIN INVEST, V118, P597, DOI 10.1172/JCI33263; Mason J, 2000, BRIT J DERMATOL, V142, P351, DOI DOI 10.1046/J.0007-0963.2002.04713.X; Menter A, 2011, J AM ACAD DERMATOL, V65, P137, DOI 10.1016/j.jaad.2010.11.055; MILDE P, 1991, J INVEST DERMATOL, V97, P230, DOI 10.1111/1523-1747.ep12480255; Nakashima C, 2014, J ALLERGY CLIN IMMUN, V134, P100, DOI 10.1016/j.jaci.2014.02.026; Nast A, 2015, J EUR ACAD DERMATOL, V29, pE1, DOI 10.1111/jdv.13353; Ouyang WJ, 2010, CYTOKINE GROWTH F R, V21, P435, DOI 10.1016/j.cytogfr.2010.10.007; Pantelyushin S, 2012, J CLIN INVEST, V122, P2252, DOI 10.1172/JCI61862; Papp K, 2011, J CUTAN MED SURG, V15, P210, DOI 10.2310/7750.2011.10066; Pedersen AW, 2009, CLIN EXP IMMUNOL, V157, P48, DOI 10.1111/j.1365-2249.2009.03961.x; Penna G, 2000, J IMMUNOL, V164, P2405, DOI 10.4049/jimmunol.164.5.2405; Peric M, 2008, J IMMUNOL, V181, P8504, DOI 10.4049/jimmunol.181.12.8504; Piemonti L, 2000, J IMMUNOL, V164, P4443, DOI 10.4049/jimmunol.164.9.4443; PROVVEDINI DM, 1983, SCIENCE, V221, P1181, DOI 10.1126/science.6310748; Rabeony H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101937; Ramirez-Valle F, 2015, P NATL ACAD SCI USA, V112, P8046, DOI 10.1073/pnas.1508990112; Riol-Blanco L, 2014, NATURE, V510, P157, DOI 10.1038/nature13199; Roller A, 2012, J IMMUNOL, V189, P4612, DOI 10.4049/jimmunol.1103173; Romani N, 2003, APMIS, V111, P725, DOI 10.1034/j.1600-0463.2003.11107805.x; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Sato-Deguchi E, 2012, BRIT J DERMATOL, V167, P77, DOI 10.1111/j.1365-2133.2012.10917.x; Soleymani T, 2015, INT J DERMATOL, V54, P383, DOI 10.1111/ijd.12790; Sun J, 2014, IMMUNOPHARM IMMUNOT, V36, P17, DOI 10.3109/08923973.2013.862542; Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001; Tonel G, 2009, INT J BIOCHEM CELL B, V41, P963, DOI 10.1016/j.biocel.2008.10.022; Tortola L, 2012, J CLIN INVEST, V122, P3965, DOI 10.1172/JCI63451; Urry Z, 2012, EUR J IMMUNOL, V42, P2697, DOI 10.1002/eji.201242370; Van Belle AB, 2012, J IMMUNOL, V188, P462, DOI 10.4049/jimmunol.1102224; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; van Halteren AGS, 2004, J AUTOIMMUN, V23, P233, DOI 10.1016/j.jaut.2004.06.004; VandeKerkhof PCM, 1996, BRIT J DERMATOL, V135, P758, DOI 10.1046/j.1365-2133.1996.d01-1075.x; Visekruna A, 2015, MUCOSAL IMMUNOL, V8, P307, DOI 10.1038/mi.2014.68; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Wohn C, 2013, P NATL ACAD SCI USA, V110, P10723, DOI 10.1073/pnas.1307569110; Wu P, 2014, IMMUNITY, V40, P785, DOI 10.1016/j.immuni.2014.03.013; Yoshiki R, 2014, J INVEST DERMATOL, V134, P1912, DOI 10.1038/jid.2014.98	81	18	18	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					972	+		10.1016/j.jaci.2017.07.033	http://dx.doi.org/10.1016/j.jaci.2017.07.033			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	28870465	Green Submitted, Bronze			2022-12-18	WOS:000426974800017
J	Ihuoma, H; Belgrave, DC; Murray, CS; Foden, P; Simpson, A; Custovic, A				Ihuoma, Healton; Belgrave, Danielle C.; Murray, Clare S.; Foden, Philip; Simpson, Angela; Custovic, Adnan			Cat ownership, cat allergen exposure, and trajectories of sensitization and asthma throughout childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RISK		[Ihuoma, Healton; Murray, Clare S.; Foden, Philip; Simpson, Angela] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Div Infect Immun & Resp Med, Manchester, Lancs, England; [Ihuoma, Healton; Murray, Clare S.; Foden, Philip; Simpson, Angela] Univ Hosp South Manchester NHS Fdn Trust, Manchester, Lancs, England; [Belgrave, Danielle C.; Custovic, Adnan] Imperial Coll, Paediat Sect, Dept Med, London, England	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Imperial College London	Custovic, A (corresponding author), Imperial Coll, Paediat Sect, Dept Med, London, England.	a.custovic@imperial.ac.uk	Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Simpson, Angela/0000-0003-2733-6666; Murray, Clare/0000-0002-8961-8055; Ihuoma, Healson/0000-0002-3069-0490	Asthma UK [301, 362, 01/012, 04/014]; BMA James Trust; JP Moulton Charitable Foundation; North West Lung Centre Charity; Medical Research Council (MRC) [G0601361, MR/K002449/1, MR/L012693/1]; MRC Career development grant [MR/M015181/1]; MRC [MR/M015181/1, MR/L012693/1, MR/K002449/1, G0601361, MR/K002449/2] Funding Source: UKRI; Medical Research Council [MR/K002449/1, MR/K002449/2, G0601361, MR/M015181/1] Funding Source: researchfish	Asthma UK; BMA James Trust; JP Moulton Charitable Foundation; North West Lung Centre Charity; Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC Career development grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The Manchester Asthma and Allergy Study (MAAS) was supported by Asthma UK (grant nos. 301 [1995-1998], 362 [1998-2001], 01/012 [2001-2004], and 04/014 [2004-2007]), BMA James Trust (2005), the JP Moulton Charitable Foundation (2004-current), The North West Lung Centre Charity (1997-current), and the Medical Research Council (MRC) (grant nos. G0601361 [2007-2012], MR/K002449/1 [20132014], and MR/L012693/1 [2014-2018]). D.C.B. is supported by the MRC Career development grant (grant no. MR/M015181/1).	Almqvist C, 2003, CLIN EXP ALLERGY, V33, P1190, DOI 10.1046/j.1365-2222.2003.01764.x; Brussee JE, 2005, J ALLERGY CLIN IMMUN, V115, P946, DOI 10.1016/j.jaci.2005.02.035; Carlsen KCL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043214; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lin S, 2012, INT J HYG ENVIR HEAL, V215, P297, DOI 10.1016/j.ijheh.2011.08.017; MOSER M, 1994, J ALLERGY CLIN IMMUN, V93, P1, DOI 10.1016/0091-6749(94)90227-5; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Schawaller M, 2003, A cuvette for a reader device for assaying substances using the evanescence field method, Patent No. [EP 1'371'967 B1, 1371967]; SOUTHWICK PL, 1990, CYTOMETRY, V11, P418, DOI 10.1002/cyto.990110313; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7	12	18	18	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					820	+		10.1016/j.jaci.2017.09.030	http://dx.doi.org/10.1016/j.jaci.2017.09.030			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	29111216	Green Published, hybrid			2022-12-18	WOS:000424410800051
J	Kitzmuller, C; Kalser, J; Mutschlechner, S; Hauser, M; Zlabinger, GJ; Ferreira, F; Bohle, B				Kitzmueller, Claudia; Kalser, Julia; Mutschlechner, Sonja; Hauser, Michael; Zlabinger, Gerhard J.; Ferreira, Fatima; Bohle, Barbara			Fusion proteins of flagellin and the major birch pollen allergen Bet v 1 show enhanced immunogenicity, reduced allergenicity, and intrinsic adjuvanticity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen-specific immunotherapy; adjuvant; Toll-like receptor 5; flagellin; Bet v 1	CD4(+) T-CELLS; MONOPHOSPHORYL-LIPID-A; DENDRITIC CELLS; TYPHIMURIUM FLAGELLIN; RECEPTOR LIGANDS; GRASS-POLLEN; VACCINE; IMMUNOTHERAPY; ACTIVATION; RESPONSES	Background: Recombinant fusion proteins of flagellin and antigens have been demonstrated to induce strong innate and adaptive immune responses. Such fusion proteins can enhance the efficacy of allergen-specific immunotherapy. Objective: We sought to characterize different fusion proteins of flagellin and the major birch pollen allergen Bet v 1 for suitability as allergy vaccines. Methods: A truncated version of flagellin (NtCF1g) was genetically fused to the N- or C-terminus of Bet v 1. Toll-like receptor (TLR) 5 binding was assessed with HEK293 cells expressing TLR5. Upregulation of CD40, CD80, CD83, and CD86 on monocyte-derived dendritic cells from allergic patients was analyzed by using flow cytometry. The T cell stimulatory capacity of the fusion proteins was assessed with naive and Bet v 1 specific T cells. IgE binding was tested in inhibition ELISAs and basophil activation tests. Mice were immunized with the fusion proteins in the absence and presence of aluminum hydroxide. Cellular and antibody responses were monitored. Murine antibodies were tested for blocking capacity in basophil activation tests. Results: Both fusion proteins matured monocyte-derived dendritic cells through TLR5. Compared with Bet v 1, the fusion proteins showed stronger T cell stimulatory and reduced IgE-binding capacity and induced murine Bet v 1 specific antibodies in the absence of aluminum hydroxide. However, only antibodies induced by means of immunization with NtCF1g fused to the C-terminus of Bet v 1 inhibited binding of patients' IgE antibodies to Bet v 1. Conclusion: Bet v 1 flagellin fusion proteins show enhanced immunogenicity, reduced allergenicity, and intrinsic adjuvanticity and thus represent promising vaccines for birch pollen allergen-specific immunotherapy. However, the sequential order of allergen and adjuvant within a fusion protein determines its immunologic characteristics.	[Kitzmueller, Claudia; Kalser, Julia; Mutschlechner, Sonja; Bohle, Barbara] Christian Doppler Lab Immunomodulat, Dept Pathophysiol & Allergy Res, Vienna, Austria; [Zlabinger, Gerhard J.] Med Univ Vienna, Inst Immunol, Vienna, Austria; [Hauser, Michael; Ferreira, Fatima] Univ Salzburg, Dept Mol Biol, Salzburg, Austria	Medical University of Vienna; Salzburg University	Bohle, B (corresponding author), Med Univ Vienna, Dept Pathophysiol & Allergy Res, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	barbara.bohle@meduniwien.ac.at	Ferreira, Fatima/AAB-4321-2019; Ferreira, Fatima/E-4889-2011	Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Kalser, Julia/0000-0002-9872-3367; Kitzmuller, Claudia/0000-0002-3829-8020; Zlabinger, Gerhard/0000-0002-7478-4173; Bohle, Barbara/0000-0002-5105-7985	Christian Doppler Research Association; Biomay AG, Austria; Austrian Science Fund [SFB F4610]	Christian Doppler Research Association; Biomay AG, Austria; Austrian Science Fund(Austrian Science Fund (FWF))	Supported by the Christian Doppler Research Association; Biomay AG, Austria; and the Austrian Science Fund, project SFB F4610.	Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Aryan Z, 2014, INT ARCH ALLERGY IMM, V164, P46, DOI 10.1159/000362553; Caron G, 2005, J IMMUNOL, V175, P1551, DOI 10.4049/jimmunol.175.3.1551; Crellin NK, 2005, J IMMUNOL, V175, P8051, DOI 10.4049/jimmunol.175.12.8051; Cuadros C, 2004, INFECT IMMUN, V72, P2810, DOI 10.1128/IAI.72.5.2810-2816.2004; Deifl S, 2014, ALLERGY, V69, P1602, DOI 10.1111/all.12501; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; DuBuske LH, 2011, ALLERGY ASTHMA PROC, V32, P239, DOI 10.2500/aap.2011.32.3453; Duthie MS, 2011, IMMUNOL REV, V239, P178, DOI 10.1111/j.1600-065X.2010.00978.x; Ghose C, 2013, INFECT IMMUN, V81, P2190, DOI 10.1128/IAI.01074-12; Hoffmann HJ, 2015, ALLERGY, V70, P1393, DOI 10.1111/all.12698; Horner AA, 2002, J ALLERGY CLIN IMMUN, V110, P413, DOI 10.1067/mai.2002.126660; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Huleatt JW, 2007, VACCINE, V25, P763, DOI 10.1016/j.vaccine.2006.08.013; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Johansen P, 2005, CLIN EXP ALLERGY, V35, P1591, DOI 10.1111/j.1365-2222.2005.02384.x; Jutz S, 2016, J IMMUNOL METHODS, V430, P10, DOI 10.1016/j.jim.2016.01.007; Kiel MA, 2013, J ALLERGY CLIN IMMUN, V132, P353, DOI 10.1016/j.jaci.2013.03.013; Kitzmuller C, 2012, ALLERGY, V67, P1375, DOI 10.1111/all.12016; Kitzmuller C, 2015, J ALLERGY CLIN IMMUN, V136, P151, DOI 10.1016/j.jaci.2014.12.1928; Lu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep18379; McCormack PL, 2006, DRUGS, V66, P931, DOI 10.2165/00003495-200666070-00004; Mizel SB, 2010, J IMMUNOL, V185, P5677, DOI 10.4049/jimmunol.1002156; Moingeon P, 2015, INT ARCH ALLERGY IMM, V168, P107, DOI 10.1159/000442524; Nempont C, 2008, J IMMUNOL, V181, P2036, DOI 10.4049/jimmunol.181.3.2036; Nony E, 2015, ALLERGY, V70, P795, DOI 10.1111/all.12622; Patel P, 2014, J ALLERGY CLIN IMMUN, V133, P121, DOI 10.1016/j.jaci.2013.05.032; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Pfaar O, 2012, CURR OPIN ALLERGY CL, V12, P648, DOI 10.1097/ACI.0b013e32835a11d6; Puggioni F, 2005, ALLERGY, V60, P678, DOI 10.1111/j.1398-9995.2005.00762.x; Schulke S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087822; Schulke S, 2011, J ALLERGY CLIN IMMUN, V128, P1340, DOI 10.1016/j.jaci.2011.07.036; Schulke S, 2010, MOL IMMUNOL, V48, P341, DOI 10.1016/j.molimm.2010.07.006; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Song L, 2015, BMC BIOTECHNOL, V15, DOI 10.1186/s12896-015-0195-z; Taylor DN, 2011, VACCINE, V29, P4897, DOI 10.1016/j.vaccine.2011.05.001; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Treanor JJ, 2010, VACCINE, V28, P8268, DOI 10.1016/j.vaccine.2010.10.009; Turley CB, 2011, VACCINE, V29, P5145, DOI 10.1016/j.vaccine.2011.05.041; Vicente-Suarez I, 2009, IMMUNOL LETT, V125, P114, DOI 10.1016/j.imlet.2009.06.007	40	18	19	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					293	+		10.1016/j.jaci.2017.02.044	http://dx.doi.org/10.1016/j.jaci.2017.02.044			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28456624	Bronze			2022-12-18	WOS:000419312200034
J	Larsson, O; Tengroth, L; Xu, Y; Uddman, R; Georen, SK; Cardell, LO				Larsson, Olivia; Tengroth, Lotta; Xu, Yuan; Uddman, Rolf; Georen, Susanna Kumlien; Cardell, Lars-Olaf			Substance P represents a novel first-line defense mechanism in the nose	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Toll-like receptor; substance P; Toll-like receptor 7; viral infection; epithelial cells; nasal mucosa; innate immunity	GENE-RELATED PEPTIDE; TOLL-LIKE RECEPTORS; HUMAN NASAL-MUCOSA; EPITHELIAL-CELLS; LIPOPOLYSACCHARIDE; INFLAMMATION; ACTIVATION; EXPRESSION; RESPONSES; INCREASE	Background: Neuropeptides, such as substance P (SP), have long been seen as mediators of widespread continuous airway inflammation, a process known as neurogenic inflammation. However, this has been difficult to demonstrate clinically, suggesting an alternative role for these signaling molecules. Objectives: We sought to examine the role of SP in nasal infection by assessing the release of SP in response to viral stimulation and characterizing the effects of SP on innate immunity, with the latter reflected in changes in local Toll-like receptor (TLR) expression. Methods: The distribution of SP and TLRs in the nasal mucosa and local airway neurons was assessed with immunohistochemistry. The TLR7 agonists R-837 and R-848 were used to mimic a viral insult in the upper airways represented by primary human nasal epithelial cells (HNECs) and murine nasal epithelial cells (MNECs) and isolated murine trigeminal ganglial neurons. SP release from HNECs, MNECs, and trigeminal ganglial neurons was quantified with EIA. The effects of SP on TLR expression on HNECs were determined by using flow cytometry and confocal microscopy. Results: SP was released from the sensory neurons, MNECs, and HNECs within 15 minutes of local TLR7 stimulation. Subsequently, stimulation with SP induced upregulation of TLR expression in HNECs within 30 minutes through induction of TLR movement within HNECs. Upregulation of TLR expression was not evident when cells were treated with the neurokinin 1 receptor antagonist aprepitant before SP stimulation. Conclusions: This highlights a novel role for sensory neuropeptides as acute and local mediators of pathogen-driven inflammation, rapidly priming innate immune defenses in the airway.	[Larsson, Olivia; Tengroth, Lotta; Xu, Yuan; Georen, Susanna Kumlien; Cardell, Lars-Olaf] Karolinska Inst, Div ENT Dis, CLINTEC, Stockholm, Sweden; [Uddman, Rolf] Lund Univ, Skane Univ Hosp, Dept Otorhinolaryngol, Malmo, Sweden; [Cardell, Lars-Olaf] Karolinska Univ Hosp, Dept ENT Dis, Stockholm, Sweden	Karolinska Institutet; Lund University; Skane University Hospital; Karolinska Institutet; Karolinska University Hospital	Cardell, LO (corresponding author), Karolinska Inst, Karolinska Univ Hosp, Div ENT Dis, Dept CLINTEC, S-14186 Stockholm, Sweden.	lars-olaf.cardell@ki.se		Kumlien Georen, Susanna/0000-0001-7292-9255	Vetenskapsradet; Hjart-Lungfonden; Karolinska Institutet; Karolinska Sjukhuset Research Foundations	Vetenskapsradet(Swedish Research Council); Hjart-Lungfonden; Karolinska Institutet(Karolinska Institutet); Karolinska Sjukhuset Research Foundations	Supported by Vetenskapsradet, Hjart-Lungfonden, and the Karolinska Institutet and Karolinska Sjukhuset Research Foundations.	Arebro J, 2016, J ALLERGY CLIN IMMUN, V137, P957, DOI 10.1016/j.jaci.2015.08.053; Baraniuk JN, 1999, AM J RESP CRIT CARE, V160, P655, DOI 10.1164/ajrccm.160.2.9805081; BARANIUK JN, 1990, AM J PHYSIOL, V258, pL81, DOI 10.1152/ajplung.1990.258.2.L81; BARANIUK JN, 1991, AM J RESP CELL MOL, V4, P228, DOI 10.1165/ajrcmb/4.3.228; Barnes PJ, 2001, RESP PHYSIOL, V125, P145, DOI 10.1016/S0034-5687(00)00210-3; Bost KL, 2004, FRONT BIOSCI-LANDMRK, V9, P1994, DOI 10.2741/1376; CARDELL LO, 1994, EUR RESPIR J, V7, P2169, DOI 10.1183/09031936.94.07122169; Chanput W, 2010, FOOD FUNCT, V1, P254, DOI 10.1039/c0fo00113a; Diogenes A, 2011, J DENT RES, V90, P759, DOI 10.1177/0022034511400225; Fransson M, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-17; Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200; Harrison S, 2001, INT J BIOCHEM CELL B, V33, P555, DOI 10.1016/S1357-2725(01)00031-0; Harzenetter MD, 2007, J IMMUNOL, V179, P607, DOI 10.4049/jimmunol.179.1.607; Haynes LM, 2002, J VIROL, V76, P6873, DOI 10.1128/JVI.76.14.6873-6881.2002; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Jiang XY, 2012, J IMMUNOL, V189, P269, DOI 10.4049/jimmunol.1200365; JOOS G, 1986, EUR J RESPIR DIS, V68, P107; Lee BL, 2014, TRENDS CELL BIOL, V24, P360, DOI 10.1016/j.tcb.2013.12.002; Lu ZK, 2012, MOL BIOL REP, V39, P3557, DOI 10.1007/s11033-011-1129-z; LUNDBERG JM, 1983, P NATL ACAD SCI-BIOL, V80, P1120, DOI 10.1073/pnas.80.4.1120; Malin SA, 2007, NAT PROTOC, V2, P152, DOI 10.1038/nprot.2006.461; MCGREGOR GP, 1983, LIFE SCI, V32, P655, DOI 10.1016/0024-3205(83)90211-4; MOSIMANN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95, DOI 10.1016/0091-6749(93)90043-F; Mukhopadhyay I, 2011, J RECEPT SIG TRANSD, V31, P350, DOI 10.3109/10799893.2011.602413; Nakamura Y, 2012, J NEUROCHEM, V120, P1036, DOI 10.1111/j.1471-4159.2011.07628.x; O'Connor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061; Park CK, 2014, NEURON, V82, P47, DOI 10.1016/j.neuron.2014.02.011; SKIDGEL RA, 1984, PEPTIDES, V5, P769, DOI 10.1016/0196-9781(84)90020-2; Starkhammar M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104114; Tancowny BP, 2010, IMMUNOLOGY, V131, P220, DOI 10.1111/j.1365-2567.2010.03296.x; Tengroth L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098239; van Tongeren J, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0086-3; Whitsett JA, 2015, NAT IMMUNOL, V16, P27, DOI 10.1038/ni.3045; Xagorari Angeliki, 2008, Open Microbiol J, V2, P49, DOI 10.2174/1874285800802010049	34	18	19	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					128	+		10.1016/j.jaci.2017.01.021	http://dx.doi.org/10.1016/j.jaci.2017.01.021			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28219705	Bronze			2022-12-18	WOS:000419312200019
J	Rothenberg, ME; Saito, H; Peebles, RS				Rothenberg, Marc E.; Saito, Hirohisa; Peebles, R. Stokes, Jr.			Advances in mechanisms of allergic disease in 2016	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; immunology; innate; inflammation; food allergy; asthma; mast cell; eosinophil; ozone; IL-33; extracellular vesicles	INNATE LYMPHOID-CELLS; THYMIC STROMAL LYMPHOPOIETIN; RESPIRATORY SYNCYTIAL VIRUS; FC-EPSILON-RI; FOOD ALLERGY; DOUBLE-BLIND; INHALED CORTICOSTEROIDS; EOSINOPHILIC ASTHMA; ATOPIC-DERMATITIS; CESAREAN-SECTION	This review highlights advances in mechanisms of allergic disease, particularly type 2 innate lymphoid cells; T(H)2 lymphocytes; eicosanoid regulation of inflammation; extracellular vesicles in allergic responses; IL-33; microbiome properties, especially as they relate to mucosal barrier function; and a series of findings concerning the allergic inflammatory cells eosinophils, basophils, and mast cells. During the last year, mechanistic advances occurred in understanding type 2 innate lymphoid cells, particularly related to their response to ozone, involvement with experimental food allergy responses, and regulation by IL-33. Novel ways of regulating T(H)2 cells through epigenetic regulation of GATA-3 through sirtuin-1, a class III histone deacetylase, were published. The understanding of eicosanoid regulation of inflammation increased and focused on additional properties of phospholipase A(2) and the role of prostaglandin D-2 and its receptors and inhibitory prostaglandin E-2 pathways. Mechanisms through which extracellular vesicles are released and contribute to allergic responses were reported. There was a deeper appreciation of mucosal barrier function, the epithelial alarmin IL-33, and the microbiome. Finally, there were advances concerning allergic inflammatory cells (mast cells, basophils, and eosinophils) that will undoubtedly have an effect on disease understanding and new therapeutic strategies.	[Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Saito, Hirohisa] Natl Res Inst Child Hlth & Dev, Tokyo, Japan; [Peebles, R. Stokes, Jr.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; National Center for Child Health & Development - Japan; Vanderbilt University	Rothenberg, ME (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave,MLC7028, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org		Saito, Hirohisa/0000-0002-6630-8337	National Institutes of Health; US-Israel Binational Grant; Patient-Centered Outcomes Research Institute; Merck; Shiseido; Merck Sharp; Dohme KK; AstraZeneca	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US-Israel Binational Grant(US-Israel Binational Science Foundation); Patient-Centered Outcomes Research Institute(Patient-Centered Outcomes Research Institute - PCORI); Merck(Merck & Company); Shiseido; Merck Sharp; Dohme KK; AstraZeneca(AstraZeneca)	M. E. Rothenberg has received grants from the National Institutes of Health, a US-Israel Binational Grant, and the Patient-Centered Outcomes Research Institute; has consultant arrangements with Celgene, Genetech, Immune Pharmaceuticals, NKT Therapeutics, and PulmOne Therapeutics; has received payment for lectures from Merck; is the inventor on a patent owned by Cincinnati Children's Hospital Medical Center; and has stock/stock options with PulmOne Therapeutics, NKT Therapeutics, and Immune Pharmaceuticals. H. Saito has received payment for lectures from Shiseido, Merck Sharp and Dohme KK, and AstraZeneca. R.S. Peebles declares that he has no relevant conflicts of interest.	Akimoto M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13589; Antwi-Baffour S, 2015, IMMUN INFLAMM DIS, V3, P133, DOI 10.1002/iid3.66; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bisgaard H, 2016, NEW ENGL J MED, V375, P2530, DOI 10.1056/NEJMoa1503734; Bleecker ER, 2016, LANCET, V388, P2115, DOI 10.1016/S0140-6736(16)31324-1; Bos LD, 2016, J ALLERGY CLIN IMMUN, V138, P970, DOI 10.1016/j.jaci.2016.08.004; Buchheit KM, 2016, J ALLERGY CLIN IMMUN, V137, P1566, DOI 10.1016/j.jaci.2015.10.020; Buchheit KM, 2016, J ALLERGY CLIN IMMUN, V137, pe5; Bunyavanich S, 2016, J ALLERGY CLIN IMMUN, V138, P1122, DOI 10.1016/j.jaci.2016.03.041; Caucheteux SM, 2016, J ALLERGY CLIN IMMUN, V138, P898, DOI 10.1016/j.jaci.2016.02.033; Chinthrajah RS, 2016, J ALLERGY CLIN IMMUN, V137, P984, DOI 10.1016/j.jaci.2016.02.004; Colley T, 2016, J ALLERGY CLIN IMMUN, V137, P1595, DOI 10.1016/j.jaci.2015.10.013; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, P1091, DOI 10.1016/j.jaci.2015.08.013; Desai A, 2016, J ALLERGY CLIN IMMUN, V137, P1863, DOI 10.1016/j.jaci.2015.09.059; du Toit G, 2016, J ALLERGY CLIN IMMUN, V137, P998, DOI 10.1016/j.jaci.2016.02.005; Erwin EA, 2016, J ALLERGY CLIN IMMUN, V138, P625, DOI 10.1016/j.jaci.2016.01.048; Everaere L, 2016, J ALLERGY CLIN IMMUN, V138, P1309, DOI 10.1016/j.jaci.2016.03.019; Ferreira MAR, 2017, J ALLERGY CLIN IMMUN, V139, P1148, DOI 10.1016/j.jaci.2016.07.017; FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]; Frossi B, 2017, J ALLERGY CLIN IMMUN, V139, P1266, DOI 10.1016/j.jaci.2016.08.011; Gagliardo R, 2016, J ALLERGY CLIN IMMUN, V137, P1796, DOI 10.1016/j.jaci.2015.11.045; Gernez Y, 2016, J ALLERGY CLIN IMMUN, V138, P1195, DOI 10.1016/j.jaci.2016.04.002; Gonem S, 2016, LANCET RESP MED, V4, P699, DOI 10.1016/S2213-2600(16)30179-5; Hallstrand TS, 2016, J ALLERGY CLIN IMMUN, V137, P268, DOI 10.1016/j.jaci.2015.05.026; Hayashi H, 2016, J ALLERGY CLIN IMMUN, V137, pe1; Hayashi H, 2016, J ALLERGY CLIN IMMUN, V137, P1585, DOI 10.1016/j.jaci.2015.09.034; Hristova M, 2016, J ALLERGY CLIN IMMUN, V137, P1545, DOI 10.1016/j.jaci.2015.10.003; Huang BH, 2017, NAT MED, V23, P128, DOI 10.1038/nm.4244; Huang WS, 2016, J ALLERGY CLIN IMMUN, V137, P1197, DOI 10.1016/j.jaci.2015.08.056; Jandl K, 2016, J ALLERGY CLIN IMMUN, V137, P833, DOI 10.1016/j.jaci.2015.11.012; Jang HY, 2016, J ALLERGY CLIN IMMUN, V138, P1452, DOI 10.1016/j.jaci.2016.05.019; Kakkar R, 2012, J BIOL CHEM, V287, P6941, DOI 10.1074/jbc.M111.298703; Kamijo S, 2016, J ALLERGY CLIN IMMUN, V137, P1613, DOI 10.1016/j.jaci.2015.10.037; Katial RK, 2016, J ALLERGY CLIN IMMUN, V138, P579, DOI 10.1016/j.jaci.2015.11.038; Kelleher MM, 2016, J ALLERGY CLIN IMMUN, V137, P1111, DOI 10.1016/j.jaci.2015.12.1312; Kennedy EA, 2017, J ALLERGY CLIN IMMUN, V139, P166, DOI 10.1016/j.jaci.2016.07.029; Kirstein F, 2016, J ALLERGY CLIN IMMUN, V137, P1852, DOI 10.1016/j.jaci.2015.10.036; Kliewer KL, 2016, J ALLERGY CLIN IMMUN, V137, P1011, DOI 10.1016/j.jaci.2015.10.040; Kondeti V, 2016, J ALLERGY CLIN IMMUN, V137, P289, DOI 10.1016/j.jaci.2015.06.030; Kristensen K, 2016, J ALLERGY CLIN IMMUN, V137, P587, DOI 10.1016/j.jaci.2015.07.040; Laidlaw TM, 2014, J ALLERGY CLIN IMMUN, V133, P1692, DOI 10.1016/j.jaci.2013.12.1034; Lam EPS, 2016, J ALLERGY CLIN IMMUN, V137, P1514, DOI 10.1016/j.jaci.2015.10.019; Lech Z, 2016, J ALLERGY CLIN IMMUN, V138, P1199, DOI 10.1016/j.jaci.2016.03.024; Lee JB, 2016, J ALLERGY CLIN IMMUN, V137, P1216, DOI 10.1016/j.jaci.2015.09.019; Li JG, 2016, J ALLERGY CLIN IMMUN, V138, P150, DOI 10.1016/j.jaci.2016.01.013; Ling ZX, 2016, J ALLERGY CLIN IMMUN, V137, P648, DOI 10.1016/j.jaci.2015.09.043; Lombardi V, 2016, J ALLERGY CLIN IMMUN, V138, P305, DOI 10.1016/j.jaci.2015.12.1325; Lucendo AJ, 2016, J ALLERGY CLIN IMMUN, V137, P931, DOI 10.1016/j.jaci.2015.07.033; Luo X, 2015, SCI REP-UK, V5, DOI 10.1038/srep15937; Lynch JP, 2016, J ALLERGY CLIN IMMUN, V138, P1326, DOI 10.1016/j.jaci.2016.02.039; MacGlashan D, 2016, J ALLERGY CLIN IMMUN, V137, P1256, DOI 10.1016/j.jaci.2015.10.043; Machado-Carvalho L, 2016, J ALLERGY CLIN IMMUN, V137, P99, DOI 10.1016/j.jaci.2015.09.028; Majewska-Szczepanik M, 2016, J ALLERGY CLIN IMMUN, V138, pe6; Majewska-Szczepanik M, 2016, J ALLERGY CLIN IMMUN, V138, P262, DOI 10.1016/j.jaci.2015.11.018; Maniscalco M, 2017, J ALLERGY CLIN IMMUN, V139, P1536, DOI 10.1016/j.jaci.2016.08.038; Mansbach JM, 2016, J ALLERGY CLIN IMMUN, V137, P1909, DOI 10.1016/j.jaci.2016.01.036; Martinez-Bravo MJ, 2017, J ALLERGY CLIN IMMUN, V139, P1186, DOI 10.1016/j.jaci.2016.05.051; Martorana D, 2016, J ALLERGY CLIN IMMUN, V137, P1597, DOI 10.1016/j.jaci.2015.09.053; Mazzeo C, 2015, J ALLERGY CLIN IMMUN, V135, P1603, DOI 10.1016/j.jaci.2014.11.026; Min JY, 2017, J ALLERGY CLIN IMMUN, V139, P130, DOI 10.1016/j.jaci.2016.07.020; Mitson-Salazar A, 2016, J ALLERGY CLIN IMMUN, V137, P907, DOI 10.1016/j.jaci.2015.08.007; Morita H, 2017, J ALLERGY CLIN IMMUN, V140, P381, DOI 10.1016/j.jaci.2017.03.042; Morita H, 2015, IMMUNITY, V43, P175, DOI 10.1016/j.immuni.2015.06.021; Morris DW, 2016, J ALLERGY CLIN IMMUN, V138, P915, DOI 10.1016/j.jaci.2016.03.027; Nakamura Y, 2016, J ALLERGY CLIN IMMUN, V137, P1226, DOI 10.1016/j.jaci.2015.08.052; Noguchi T, 2016, J ALLERGY CLIN IMMUN, V138, P1449, DOI 10.1016/j.jaci.2016.05.020; Odegaard JI, 2016, CELL, V166, P841, DOI 10.1016/j.cell.2016.06.040; Oliver ET, 2016, J ALLERGY CLIN IMMUN, V137, P304, DOI 10.1016/j.jaci.2015.06.004; Perkin MR, 2016, J ALLERGY CLIN IMMUN, V138, P509, DOI 10.1016/j.jaci.2016.03.031; Rivas M Noval, 2016, J ALLERGY CLIN IMMUN, V138, pe9; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P801, DOI 10.1016/j.jaci.2016.02.030; Rothenberg Marc E, 2016, Cell, V165, P509, DOI 10.1016/j.cell.2016.04.020; Ryan D, 2016, J ALLERGY CLIN IMMUN, V138, P308, DOI 10.1016/j.jaci.2015.11.044; Salter BM, 2016, J ALLERGY CLIN IMMUN, V137, P936, DOI 10.1016/j.jaci.2015.08.024; Schwartz C, 2016, J ALLERGY CLIN IMMUN, V138, P1443, DOI 10.1016/j.jaci.2016.04.031; Shoda T, 2016, J ALLERGY CLIN IMMUN, V138, P299, DOI 10.1016/j.jaci.2015.11.042; Shubin NJ, 2017, J ALLERGY CLIN IMMUN, V139, P323, DOI 10.1016/j.jaci.2016.03.051; Simpson EL, 2017, NEW ENGL J MED, V376, P1090, DOI 10.1056/NEJMc1700366; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Smits HH, 2016, J ALLERGY CLIN IMMUN, V137, P690, DOI 10.1016/j.jaci.2016.01.004; Sodikoff J, 2016, J ALLERGY CLIN IMMUN, V137, P631, DOI 10.1016/j.jaci.2015.07.008; Steelant B, 2016, J ALLERGY CLIN IMMUN, V137, P1043, DOI 10.1016/j.jaci.2015.10.050; Stier MT, 2016, J ALLERGY CLIN IMMUN, V138, P814, DOI 10.1016/j.jaci.2016.01.050; Stokholm J, 2016, J ALLERGY CLIN IMMUN, V138, P881, DOI 10.1016/j.jaci.2016.01.028; Subramanian H, 2016, J ALLERGY CLIN IMMUN, V138, P700, DOI 10.1016/j.jaci.2016.04.051; Suurmond J, 2016, J ALLERGY CLIN IMMUN, V138, P869, DOI 10.1016/j.jaci.2016.01.017; Takeda T, 2016, J ALLERGY CLIN IMMUN, V138, P1395, DOI 10.1016/j.jaci.2016.01.032; Tkachenko E, 2016, J ALLERGY CLIN IMMUN, V137, P1270, DOI 10.1016/j.jaci.2015.09.020; Tordesillas L, 2016, J ALLERGY CLIN IMMUN, V138, P1741, DOI 10.1016/j.jaci.2016.06.048; Ueki S, 2016, J ALLERGY CLIN IMMUN, V137, P258, DOI 10.1016/j.jaci.2015.04.041; Vasanthakumar A, 2015, NAT IMMUNOL, V16, P276, DOI 10.1038/ni.3085; Verhoef PA, 2016, J ALLERGY CLIN IMMUN, V137, P591, DOI 10.1016/j.jaci.2015.07.050; Wang ZP, 2017, J ALLERGY CLIN IMMUN, V139, P1205, DOI 10.1016/j.jaci.2016.09.019; Wen T, 2015, J ALLERGY CLIN IMMUN, V135, P187, DOI 10.1016/j.jaci.2014.08.043; Wenzel S, 2016, LANCET, V388, P31, DOI 10.1016/S0140-6736(16)30307-5; Wesemann DR, 2016, IMMUNITY, V44, P728, DOI 10.1016/j.immuni.2016.02.002; Wright BL, 2016, J ALLERGY CLIN IMMUN, V138, P1190, DOI 10.1016/j.jaci.2016.02.024; Yang JQ, 2016, J ALLERGY CLIN IMMUN, V137, P231, DOI 10.1016/j.jaci.2015.05.004; Yang Q, 2016, J ALLERGY CLIN IMMUN, V137, P571, DOI 10.1016/j.jaci.2015.06.037; Zhou YJ, 2016, J ALLERGY CLIN IMMUN, V138, P1215, DOI 10.1016/j.jaci.2016.03.054	100	18	21	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1622	1631		10.1016/j.jaci.2017.08.029	http://dx.doi.org/10.1016/j.jaci.2017.08.029			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	29038009	Bronze			2022-12-18	WOS:000417206000017
J	Sanchez-Vidaurre, S; Eldh, M; Larssen, P; Daham, K; Martinez-Bravo, MJ; Dahlen, SE; Dahlen, B; van Hage, M; Gabrielsson, S				Sanchez-Vidaurre, Sara; Eldh, Maria; Larssen, Pia; Daham, Kameran; Martinez-Bravo, Maria-Jose; Dahlen, Sven-Erik; Dahlen, Barbro; van Hage, Marianne; Gabrielsson, Susanne			RNA-containing exosomes in induced sputum of asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AIRWAY INFLAMMATION; CELL; MECHANISM; VESICLES		[Sanchez-Vidaurre, Sara; Eldh, Maria; Larssen, Pia; Martinez-Bravo, Maria-Jose; van Hage, Marianne; Gabrielsson, Susanne] Karolinska Univ Hosp, Immunol & Allergy Unit, Dept Med Solna, Karolinska Inst, Solna, Sweden; [Daham, Kameran; Dahlen, Sven-Erik; Dahlen, Barbro] Karolinska Univ Hosp, Karolinska Inst, Ctr Allergy Res, Solna, Sweden; [Dahlen, Sven-Erik] Karolinska Univ Hosp, Karolinska Inst, Inst Environm Med, Solna, Sweden; [Daham, Kameran; Dahlen, Barbro] Karolinska Inst, Dept Med Huddinge, Huddinge, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Gabrielsson, S (corresponding author), Karolinska Univ Hosp, Immunol & Allergy Unit, Dept Med Solna, Karolinska Inst, Solna, Sweden.	Susanne.Gabrielsson@ki.se	van Hage, Marianne/A-9678-2017; Eldh, Maria/AFO-1744-2022; Gabrielsson, S./E-4145-2014	van Hage, Marianne/0000-0003-3091-1596; Gabrielsson, S./0000-0003-1771-1346; Eldh, Maria/0000-0003-2173-1796; Martinez-Bravo, Maria-Jose/0000-0003-1566-8727	Swedish Research Council; Swedish Heart-Lung Foundation; Hesselman's Foundation; Swedish Asthma and Allergy Association's Research Foundation; King Gustaf V 80th Birthday Foundation; Cancer and Allergy Research Foundation; Center for Allergy Research; Stockholm County Council (ALF); ChAMP Consortium; Swedish Strategical Research Foundation (SSF); Vardal Foundation; Karolinska Institutet	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Hesselman's Foundation; Swedish Asthma and Allergy Association's Research Foundation; King Gustaf V 80th Birthday Foundation; Cancer and Allergy Research Foundation; Center for Allergy Research; Stockholm County Council (ALF)(Stockholm County Council); ChAMP Consortium; Swedish Strategical Research Foundation (SSF); Vardal Foundation; Karolinska Institutet(Karolinska Institutet)	This work was supported by the Swedish Research Council, the Swedish Heart-Lung Foundation, the Hesselman's Foundation, the Swedish Asthma and Allergy Association's Research Foundation, the King Gustaf V 80th Birthday Foundation, the Cancer and Allergy Research Foundation, the Center for Allergy Research, the Stockholm County Council (ALF), the ChAMP Consortium, the Swedish Strategical Research Foundation (SSF), the Vardal Foundation, and Karolinska Institutet.	Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267; Crescitelli R, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20677; Daham K, 2014, J ALLERGY CLIN IMMUN, V134, P306, DOI 10.1016/j.jaci.2013.12.002; Hargreave FE, 2007, CURR OPIN ALLERGY CL, V7, P102, DOI 10.1097/ACI.0b013e328013e3c2; Levanen B, 2013, J ALLERGY CLIN IMMUN, V131, P894, DOI 10.1016/j.jaci.2012.11.039; Palanisamy V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008577; Paredes PT, 2012, ALLERGY, V67, P911, DOI 10.1111/j.1398-9995.2012.02835.x; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Qazi KR, 2009, BLOOD, V113, P2673, DOI 10.1182/blood-2008-04-153536; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Szul T, 2016, AM J RESP CELL MOL, V54, P359, DOI 10.1165/rcmb.2015-0108OC; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596	12	18	23	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1459	+		10.1016/j.jaci.2017.05.035	http://dx.doi.org/10.1016/j.jaci.2017.05.035			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28629752	Bronze			2022-12-18	WOS:000414304300033
J	Sharkia, I; Erlich, TH; Landolina, N; Assayag, M; Motzik, A; Rachmin, I; Kay, G; Porat, Z; Tshori, S; Berkman, N; Levi-Schaffer, F; Razin, E				Sharkia, Israa; Erlich, Tal Hadad; Landolina, Nadine; Assayag, Miri; Motzik, Alex; Rachmin, Inbal; Kay, Gillian; Porat, Ziv; Tshori, Sagi; Berkman, Neville; Levi-Schaffer, Francesca; Razin, Ehud			Pyruvate dehydrogenase has a major role in mast cell function, and its activity is regulated by mitochondrial microphthalmia transcription factor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; mast cells; degranulation; cytokines; pyruvate dehydrogenase; microphthalmia transcription factor; asthma; mitochondria	CALCIUM INFLUX; B-LYMPHOCYTES; ACTIVATION; METABOLISM; GENE; MITF; DEGRANULATION; PHOSPHATASE; EXOCYTOSIS; EXPRESSION	Background: We have recently observed that oxidative phosphorylation-mediated ATP production is essential for mast cell function. Pyruvate dehydrogenase (PDH) is the main regulator of the Krebs cycle and is located upstream of the electron transport chain. However, the role of PDH in mast cell function has not been described. Microphthalmia transcription factor (MITF) regulates the development, number, and function of mast cells. Localization of MITF to the mitochondria and its interaction with mitochondrial proteins has not been explored. Objective: We sought to explore the role played by PDH in mast cell exocytosis and to determine whether MITF is localized in the mitochondria and involved in regulation of PDH activity. Methods: Experiments were performed in vitro by using human and mouse mast cells, as well as rat basophil leukemia cells, and in vivo in mice. The effect of PDH inhibition on mast cell function was examined. PDH interaction with MITF was measured before and after immunologic activation. Furthermore, mitochondrial localization of MITF and its effect on PDH activity were determined. Results: PDH is essential for immunologically mediated degranulation of mast cells. After activation, PDH is serine dephosphorylated. In addition, for the first time, we show that MITF is partially located in the mitochondria and interacts with PDH. This interaction is dependent on the phosphorylation state of PDH. Furthermore, mitochondrial MITF regulates PDH activity. Conclusion: The association of mitochondrial MITF with PDH emerges as an important regulator of mast cell function. Our findings indicate that PDH could arise as a new target for the manipulation of allergic diseases.	[Sharkia, Israa; Erlich, Tal Hadad; Motzik, Alex; Rachmin, Inbal; Kay, Gillian; Razin, Ehud] Inst Med Res Israel Canada, Dept Biochem & Mol Biol, Jerusalem, Israel; [Landolina, Nadine; Levi-Schaffer, Francesca] Hebrew Univ Jerusalem, Pharmacol & Expt Therapeut Unit, Sch Pharm, Inst Drug Res,Fac Med, Jerusalem, Israel; [Assayag, Miri; Berkman, Neville] Hadassah Hebrew Univ, Inst Pulm Med, Med Ctr, Jerusalem, Israel; [Porat, Ziv] Hadassah Hebrew Univ, Dept Nucl Med, Med Ctr, Jerusalem, Israel; [Tshori, Sagi] Weizmann Inst Sci, Biol Serv Dept, Flow Cytometry Unit, Rehovot, Israel; [Rachmin, Inbal] Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA; [Rachmin, Inbal] Brigham & Womens Hosp, Dept Med, Brigham Regenerat Med Ctr, 75 Francis St, Boston, MA 02115 USA; [Rachmin, Inbal] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA; [Rachmin, Inbal] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Weizmann Institute of Science; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University	Razin, E (corresponding author), Hebrew Univ Med Sch, Inst Med Res Israel Canada, Dept Biochem & Mol Biol, POB 12272, IL-91120 Jerusalem, Israel.	ehudr@ekmd.huji.ac.il	Landolina, Nadine/AAA-2440-2020; Porat, Ziv/K-1672-2012; Kay, Gillian/F-3474-2014	Porat, Ziv/0000-0003-3059-181X; Kay, Gillian/0000-0003-0966-2388; Erlich, Tal/0000-0003-0601-2574; Levi-Schaffer, Francesca/0000-0003-0620-2810	Israel Science Foundation [1925/12, 115/2013, 472/15]; National Research Foundation of Singapore (HUJ-CREATE); Rosetrees Trust; Rosetrees Trust [M416] Funding Source: researchfish	Israel Science Foundation(Israel Science Foundation); National Research Foundation of Singapore (HUJ-CREATE); Rosetrees Trust(Rosetrees Trust); Rosetrees Trust(Rosetrees Trust)	Supported by the Israel Science Foundation (1925/12 to S.T. and 115/2013 to E.R.), the National Research Foundation of Singapore (HUJ-CREATE to E.R.), and a grant from the Rosetrees Trust and Israel Science Foundation 472/15 (to F.L.-S.).	Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016; Doughty CA, 2006, BLOOD, V107, P4458, DOI 10.1182/blood-2005-12-4788; Dufort FJ, 2007, J IMMUNOL, V179, P4953, DOI 10.4049/jimmunol.179.8.4953; Erlich TH, 2014, J ALLERGY CLIN IMMUN, V134, P460, DOI 10.1016/j.jaci.2013.12.1075; FORSTER O, 1968, ARCH INT PHARMACOD T, V174, P144; Gill T, 2013, J BIOL CHEM, V288, P26246, DOI 10.1074/jbc.M113.476895; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; HIDE M, 1991, J BIOL CHEM, V266, P15221; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Holness MJ, 2003, BIOCHEM SOC T, V31, P1143; Huang BL, 1998, J BIOL CHEM, V273, P17680, DOI 10.1074/jbc.273.28.17680; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; Jin ZX, 2014, CELL METAB, V20, P483, DOI 10.1016/j.cmet.2014.07.011; Kaminski MM, 2010, J IMMUNOL, V184, P4827, DOI 10.4049/jimmunol.0901662; Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154; King C, 2015, OPEN LAB PHAS 2 TRIA; Kitamura Y, 2002, MOL IMMUNOL, V38, P1173, DOI 10.1016/S0161-5890(02)00058-5; Korotchkina LG, 2006, J BIOL CHEM, V281, P9688, DOI 10.1074/jbc.M511481200; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; Patel MS, 2014, J BIOL CHEM, V289, P16615, DOI 10.1074/jbc.R114.563148; Quintana A, 2007, P NATL ACAD SCI USA, V104, P14418, DOI 10.1073/pnas.0703126104; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; Ryu SD, 2009, CELL CALCIUM, V45, P99, DOI 10.1016/j.ceca.2008.07.002; Sanchez-Miranda E, 2010, BIOCHEM BIOPH RES CO, V391, P1714, DOI 10.1016/j.bbrc.2009.12.139; Sena LA, 2013, IMMUNITY, V38, P225, DOI 10.1016/j.immuni.2012.10.020; Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Tshori S, 2010, J LEUKOCYTE BIOL, V88, P837, DOI 10.1189/jlb.0610365; Turkan A, 2002, J BIOL CHEM, V277, P14976, DOI 10.1074/jbc.M108434200; West AP, 2011, NATURE, V472, P476, DOI 10.1038/nature09973; Zachar Z, 2011, J MOL MED, V89, P1137, DOI 10.1007/s00109-011-0785-8; Zhang BD, 2011, J ALLERGY CLIN IMMUN, V127, P1522, DOI 10.1016/j.jaci.2011.02.005; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831	35	18	18	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					204	+		10.1016/j.jaci.2016.09.047	http://dx.doi.org/10.1016/j.jaci.2016.09.047			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	27871875	Bronze			2022-12-18	WOS:000404542000020
J	Li, J; Guo, AY; Chen, WQ; Bin, LH; He, YJ; Zhu, W; Peng, C; Yan, SY; Chen, ML; Zhang, JL; Su, J; Yi, M; Liu, ZQ; Zhang, W; Zeng, WQ; Leung, DYM; Chen, X				Li, Jie; Guo, Aiyuan; Chen, Wangqing; Bin, Lianghua; He, Yijing; Zhu, Wu; Peng, Cong; Yan, Siyu; Chen, Mingliang; Zhang, Jianglin; Su, Juan; Yi, Mei; Liu, Zhaoqian; Zhang, Wei; Zeng, Weiqi; Leung, Donald Y. M.; Chen, Xiang			Association of ORAI1 gene polymorphisms with chronic spontaneous urticaria and the efficacy of the nonsedating H1 antihistamine desloratadine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RESPIRATORY SYNCYTIAL VIRUS; NASOPHARYNGEAL MICROBIOTA; PROSPECTIVE MULTICENTER; SEVERE BRONCHIOLITIS; GENOMIC LOAD; CHILDREN; DISEASE; SEVERITY; OUTCOMES; UNIFRAC		[Li, Jie; Guo, Aiyuan; Chen, Wangqing; He, Yijing; Zhu, Wu; Peng, Cong; Yan, Siyu; Chen, Mingliang; Zhang, Jianglin; Su, Juan; Yi, Mei; Zeng, Weiqi; Chen, Xiang] Cent S Univ, Dept Dermatol, Xiangya Hosp, Changsha, Hunan, Peoples R China; [Guo, Aiyuan] Cent S Univ, Dept Dermatol, Changsha, Hunan, Peoples R China; [Guo, Aiyuan] Cent S Univ, Xiangya Hosp 3, Changsha, Hunan, Peoples R China; [Bin, Lianghua; Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA; [Liu, Zhaoqian; Zhang, Wei] Cent S Univ, Xiangya Hosp, Inst Clin Pharmacol, Changsha, Hunan, Peoples R China	Central South University; Central South University; Central South University; National Jewish Health; Central South University	Leung, DYM (corresponding author), Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA.	leungd@njhealth.org; chenxiangck@126.com	Li, jie/GXG-4583-2022	Liu, Zhaoqian/0000-0003-0428-3928; Jianglin, Zhang/0000-0003-0434-1729; Bin, Lianghua/0000-0002-3786-0106	National Natural Science Foundations of China [81430075, 81225013, 81673065]; National Key Research [2016YFC095000, 2016JJ3170]; Edelstein Family Chair of Pediatric Allergy-Immunology	National Natural Science Foundations of China(National Natural Science Foundation of China (NSFC)); National Key Research; Edelstein Family Chair of Pediatric Allergy-Immunology	This study was supported by grants from the National Natural Science Foundations of China (grant nos. 81430075 and 81225013 to X.C.; grant no. 81673065 to J.L.) and National Key Research (grant no. 2016YFC095000 to W.Z. and grant no. 2016JJ3170 to J.L.). D.Y.M.L. is partially supported by The Edelstein Family Chair of Pediatric Allergy-Immunology.	Anthes JC, 2002, EUR J PHARMACOL, V449, P229, DOI 10.1016/S0014-2999(02)02049-6; Ashmole I, 2012, J ALLERGY CLIN IMMUN, V129, P1628, DOI 10.1016/j.jaci.2012.01.070; Bae JS, 2007, J ALLERGY CLIN IMMUN, V119, P449, DOI 10.1016/j.jaci.2006.10.006; Beckham JD, 2005, J INFECTION, V50, P322, DOI 10.1016/j.jinf.2004.07.011; Caporaso JG, 2012, ISME J, V6, P1621, DOI 10.1038/ismej.2012.8; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Chang WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029387; Edgar RC, 2015, BIOINFORMATICS, V31, P3476, DOI 10.1093/bioinformatics/btv401; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Feske S, 2007, NAT REV IMMUNOL, V7, P690, DOI 10.1038/nri2152; Harvima IT, 2014, J ALLERGY CLIN IMMUN, V134, P530, DOI 10.1016/j.jaci.2014.03.007; Hasegawa K, 2016, EUR RESPIR J, V48, P1329, DOI 10.1183/13993003.00152-2016; Hasegawa K, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0218; Hasegawa K, 2015, J INFECT DIS, V211, P1550, DOI 10.1093/infdis/jiu658; Hasegawa K, 2014, EXPERT REV ANTI-INFE, V12, P817, DOI 10.1586/14787210.2014.906901; Hilchie AL, 2013, NAT CHEM BIOL, V9, P761, DOI [10.1038/NCHEMBIO.1393, 10.1038/nchembio.1393]; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Jartti T, 2015, J ALLERGY CLIN IMMUN, V136, P509, DOI 10.1016/j.jaci.2015.02.021; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Lozupone C, 2011, ISME J, V5, P169, DOI 10.1038/ismej.2010.133; Mansbach JM, 2016, J ALLERGY CLIN IMMUN, V137, P1909, DOI 10.1016/j.jaci.2016.01.036; Mansbach JM, 2012, PEDIATRICS, V130, pE492, DOI 10.1542/peds.2012-0444; Mansbach JM, 2012, ARCH PEDIAT ADOL MED, V166, P700, DOI 10.1001/archpediatrics.2011.1669; Methe BA, 2012, NATURE, V486, P215, DOI 10.1038/nature11209; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742; ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7; Sanchez-Borges M, 2013, J INVEST ALLERG CLIN, V23, P141; Vandamme D, 2012, CELL IMMUNOL, V280, P22, DOI 10.1016/j.cellimm.2012.11.009; Vig M, 2008, NAT IMMUNOL, V9, P89, DOI 10.1038/ni1550; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344; Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313	33	18	22	4	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1386	1388		10.1016/j.jaci.2016.10.017	http://dx.doi.org/10.1016/j.jaci.2016.10.017			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27864023	Bronze			2022-12-18	WOS:000398771800037
J	Zuberbier, T; Abelson, MB; Akdis, CA; Bachert, C; Berger, U; Bindslev-Jensen, C; Boelke, G; Bousquet, J; Canonica, GW; Casale, TB; Jutel, M; Kowalski, ML; Madonini, E; Papadopoulos, NG; Pfaar, O; Sehlinger, T; Bergmann, KC				Zuberbier, Torsten; Abelson, Mark B.; Akdis, Cezmi A.; Bachert, Claus; Berger, Uwe; Bindslev-Jensen, Carsten; Boelke, Georg; Bousquet, Jean; Canonica, Giorgio Walter; Casale, Thomas B.; Jutel, Marek; Kowalski, Marek L.; Madonini, Enzo; Papadopoulos, Nikolaos G.; Pfaar, Oliver; Sehlinger, Torsten; Bergmann, Karl-Christian		Global Allergy Asthma European	Validation of the Global Allergy and Asthma European Network (GA(2)LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy trial; environmental exposure chamber; validation; grasses; placebo; Global Allergy and Asthma European Network (GA(2)LEN)	POLLEN CHALLENGE CHAMBER; NASAL INSPIRATORY FLOW; IMMUNOTHERAPY TRIALS; RHINITIS; SEVERITY; EFFICACY; PATENCY; DESIGN	Background: Field clinical trials of pollen allergy are affected by the impossibility of predicting and determining individual allergen exposure because of many factors (eg, pollen season, atmospheric variations, pollutants, and lifestyles). Environmental exposure chambers, delivering a fixed amount of allergen in a controlled environmental setting, can overcome these limitations. Environmental exposure chambers are currently already used in phase 2, 3, and even 4 trials. Unfortunately, few chambers exist in the world, and this makes it difficult to perform large, multicenter clinical trials. The new Global Allergy and Asthma European Network (GA(2)LEN) mobile exposure chamber is a step forward because the mobility of the chamber makes it convenient for patients to participate in clinical testing. Objective: This study was made to validate the reproducibility, sensitivity, and specificity of the results obtained in the new GA(2)LEN chamber. Methods: Seventy-two adult patients (19-61 years old) with allergic rhinitis with or without asthma caused by grass pollen were included in different clinical validation tests. Total symptom scores and total nasal symptom scores were recorded at time zero (0) and every 10 minutes during exposures, along with nasal and respiratory parameters. Results: Exposure tests confirmed the reproducibility between subsequent runs and the sensitivity (P < .00001 vs patients exposed to placebo) and specificity (very low score in nonallergic subjects) in the GA(2)LEN chamber. No adverse reactions were recorded during the tests. Conclusions: The mobility of the GA(2)LEN chamber provides a new, potentially effective, and safe way of generating reliable data in allergy multicenter clinical trials.	[Zuberbier, Torsten; Boelke, Georg; Bergmann, Karl-Christian] Charite Univ Med Berlin, Dept Dermatol & Allergy, Comprehens Allergy Ctr Charite, Berlin, Germany; [Zuberbier, Torsten; Boelke, Georg; Bergmann, Karl-Christian] Global Allergy & Asthma European Network GA2LEN, Berlin, Germany; [Abelson, Mark B.] Harvard Univ, Dept Ophthalmol, Andover, MA USA; [Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Bachert, Claus] Univ Ghent, Upper Airway Res Lab, Ghent, Belgium; [Bachert, Claus] Karolinska Inst, Clintec, Div ENT Dis, Stockholm, Sweden; [Berger, Uwe] Med Univ Vienna, Dept Otorhinolaryngol, Aerobiol & Pollen Informat Res Unit, Vienna, Austria; [Bindslev-Jensen, Carsten] Odense Univ Hosp, Odense Res Ctr Anaphylaxis, Dept Dermatol, Odense, Denmark; [Bindslev-Jensen, Carsten] Odense Univ Hosp, Odense Res Ctr Anaphylaxis, Allergy Ctr, Odense, Denmark; [Bousquet, Jean] Univ Hosp, Montpellier, France; [Canonica, Giorgio Walter] DIMI Univ Genoa, IRCCS AOU San Martino, Allergy & Resp Dis Clin, Genoa, Italy; [Casale, Thomas B.] Univ S Florida, Div Allergy & Immunol, Tampa, FL USA; [Jutel, Marek] Wroclaw Med Univ, ALL MED Med Res Inst, Dept Clin Immunol, Wroclaw 2, Poland; [Kowalski, Marek L.] Med Univ Lodz, Dept Immunol Rheumatol & Allergy, Lodz, Poland; [Madonini, Enzo] Allergopharma SpA, Rome, Italy; [Papadopoulos, Nikolaos G.] Univ Athens, Dept Allergy, Athens, Greece; [Papadopoulos, Nikolaos G.] Univ Manchester, Div Infect Immun & Resp Med, Manchester M13 9PL, Lancs, England; [Pfaar, Oliver] Ctr Rhinol & Allergol, Wiesbaden, Germany; [Pfaar, Oliver] Heidelberg Univ, Med Fac Mannheim, Univ Med Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Mannheim, Germany; [Sehlinger, Torsten] Bluestone Technol GmbH, Woerrstadt, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Harvard University; Swiss Institute of Allergy & Asthma Research; University of Zurich; Ghent University; Karolinska Institutet; Medical University of Vienna; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; Universite de Montpellier; CHU de Montpellier; University of Genoa; IRCCS AOU San Martino IST; State University System of Florida; University of South Florida; Wroclaw Medical University; Medical University Lodz; National & Kapodistrian University of Athens; University of Manchester; Ruprecht Karls University Heidelberg	Zuberbier, T (corresponding author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Charitepl 1, D-10117 Berlin, Germany.	torsten.zuberbier@charite.de	Akdis, Cezmi/AAV-4844-2020; Bergmann, Karl-Christian/AAA-4104-2019; Bindslev-Jensen, Carsten/H-1877-2011; Bousquet, Jean/O-4221-2019; N.G., Papadopoulos/L-8670-2013; canonica, giorgio walter/ABF-2037-2020; Bachert, Claus/J-8825-2012	Akdis, Cezmi/0000-0001-8020-019X; Bindslev-Jensen, Carsten/0000-0002-8940-038X; N.G., Papadopoulos/0000-0002-4448-3468; canonica, giorgio walter/0000-0001-8467-2557; Zuberbier, Torsten/0000-0002-1466-8875; Bergmann, Karl-Christian/0000-0002-0306-9922; JUTEL, MAREK/0000-0003-1555-9379; Bousquet, Jean/0000-0002-4061-4766	GA2LEN; Mobile Chamber Experts	GA2LEN; Mobile Chamber Experts	Supported by GA<SUP>2</SUP>LEN and Mobile Chamber Experts.	Badorrek P, 2011, ANN ALLERG ASTHMA IM, V106, P336, DOI 10.1016/j.anai.2010.12.018; Bernstein JA, 2012, J ALLERGY CLIN IMMUN, V130, P128, DOI 10.1016/j.jaci.2012.05.032; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2011, ALLERGY, V66, P765, DOI 10.1111/j.1398-9995.2011.02590.x; Bousquet PJ, 2007, ALLERGY, V62, P367, DOI 10.1111/j.1398-9995.2006.01276.x; Couroux P, 2009, ANN ALLERG ASTHMA IM, V102, P62, DOI 10.1016/S1081-1206(10)60110-X; Day J. H., 2006, Clinical and Experimental Allergy Reviews, V6, P31, DOI 10.1111/j.1365-2222.2005.00099.x; del Cuvillo A, 2011, J INVEST ALLERG CLIN, V21, P40; Demoly P, 2013, CLIN EXP ALLERGY, V43, P881, DOI 10.1111/cea.12121; Devillier P, 2011, ALLERGY, V66, P163, DOI 10.1111/j.1398-9995.2010.02473.x; Donovan JP, 1996, ANN ALLERG ASTHMA IM, V77, P74, DOI 10.1016/S1081-1206(10)63483-7; European Medicines Agency, 2008, CHMPEWP185042006 EUR; Hohlfeld JM, 2010, CLIN EXP ALLERGY, V40, P998, DOI 10.1111/j.1365-2222.2010.03498.x; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; Horak F, 2010, INFLAMM RES, V59, P391, DOI 10.1007/s00011-009-0117-4; Horak F, 2009, J ALLERGY CLIN IMMUN, V124, P471, DOI 10.1016/j.jaci.2009.06.006; Howarth P, 2012, ALLERGY, V67, P321, DOI 10.1111/j.1398-9995.2011.02759.x; Jacobs RL, 2014, J ALLERGY CLIN IMMUN, V133, P1340, DOI 10.1016/j.jaci.2013.09.051; Jacobs RL, 2012, J ALLERGY CLIN IMMUN, V130, P122, DOI 10.1016/j.jaci.2012.03.031; Krug N, 2003, CLIN EXP ALLERGY, V33, P1667, DOI 10.1111/j.1365-2222.2003.01810.x; Narkus A, 2013, CLIN TRANSL ALLERGY, V3, P42, DOI DOI 10.1186/2045-7022-3-42; Ottaviano G, 2016, ALLERGY, V71, P162, DOI 10.1111/all.12778; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Pfaar O, 2014, ALLERGY, V69, P854, DOI 10.1111/all.12383; Rosner-Friese K, 2015, J ALLERGY CLIN IMMUN, V135, P636, DOI 10.1016/j.jaci.2014.10.045; Salapatek AM, 2010, AM J RHINOL ALLERGY, V24, P433, DOI 10.2500/ajra.2010.24.3548; Spector SL, 2003, ANN ALLERG ASTHMA IM, V91, P105, DOI 10.1016/S1081-1206(10)62160-6; Starling-Schwanz R, 2005, ALLERGY, V60, P795, DOI 10.1111/j.1398-9995.2005.00779.x; Yuki Ayumi, 2011, Allergology International, V60, P533, DOI 10.2332/allergolint.10-OA-0264; Zieglmayer PU, 2013, CURR OPIN ALLERGY CL, V13, P244, DOI 10.1097/ACI.0b013e328360c7b6	30	18	18	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1158	1166		10.1016/j.jaci.2016.08.025	http://dx.doi.org/10.1016/j.jaci.2016.08.025			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27697498	Green Published, hybrid, Green Accepted, Green Submitted			2022-12-18	WOS:000398771800011
J	den Dekker, HT; Ros, KPI; de Jongste, JC; Reiss, IK; Jaddoe, VW; Duijts, L				den Dekker, Herman T.; Ros, Karen P. I.; de Jongste, Johan C.; Reiss, Irwin K.; Jaddoe, Vincent W.; Duijts, Liesbeth			Body fat mass distribution and interrupter resistance, fractional exhaled nitric oxide, and asthma at school-age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Obesity; body composition; body fat mass distribution; Rint; fractional exhaled nitric oxide (FENO); wheezing; asthma	VISCERAL ADIPOSE-TISSUE; TO-HIP RATIO; SUBCUTANEOUS FAT; CHILDHOOD ASTHMA; AIRWAY INFLAMMATION; WAIST CIRCUMFERENCE; PULMONARY-FUNCTION; SERUM ADIPONECTIN; LUNG-FUNCTION; L-ARGININE	Background: Obesity and asthma often coexist. We hypothesized that detailed body fat distribution measures might be more strongly associated than body mass index (BMI) with childhood asthma. Objective: We examined the associations of total body and abdominal fat measures with respiratory resistance (Rint), fractional exhaled nitric oxide (FENO), and risks of wheezing and asthma in school-aged children. Methods: In a population-based prospective cohort study among 6178 children aged 6 years, we measured BMI, fat mass index, android/gynoid ratio, and preperitoneal and subcutaneous fat mass by physical examinations, dual-energy x-ray absorptiometry, and ultrasound, respectively. We performed Rint and FENO measurements, and assessed physician-diagnosed wheezing and asthma by questionnaires. Results: A higher BMI was associated with a higher Rint (Z score [95% CI], 0.06 [0.01-0.12]) and increased risk of wheezing (odds ratio [95% CI], 1.07 [1.00-1.14], per Z score BMI increase), but not with FENO or asthma. A high fat mass index was associated with a higher Rint (Z score [95% CI], 0.40 [0.13-0.68]). A high android/gynoid fat mass ratio was associated with a lower FENO(Sym% [95% CI], -9.8 [-16.3 to -3.4]), whereas a high preperitoneal fat mass was associated with a higher FENO (Sym% [95% CI], 6.5 [0.1-12.9]). Subcutaneous fat mass was not associated with any respiratory outcome. Conclusions: Studying detailed body fat distribution measures might provide better insight into the obesity-asthma paradigm.	[den Dekker, Herman T.; Ros, Karen P. I.; Jaddoe, Vincent W.] Erasmus Univ, Med Ctr, Generat Study Grp R, NL-3000 DR Rotterdam, Netherlands; [den Dekker, Herman T.; Ros, Karen P. I.; de Jongste, Johan C.; Duijts, Liesbeth] Erasmus Univ, Med Ctr, Div Resp Med, Dept Pediat, NL-3000 DR Rotterdam, Netherlands; [den Dekker, Herman T.; Ros, Karen P. I.; Jaddoe, Vincent W.; Duijts, Liesbeth] Erasmus Univ, Med Ctr, Dept Epidemiol, NL-3000 DR Rotterdam, Netherlands; [Reiss, Irwin K.; Duijts, Liesbeth] Erasmus Univ, Med Ctr, Div Neonatol, Dept Pediat, NL-3000 DR Rotterdam, Netherlands; [Jaddoe, Vincent W.] Erasmus Univ, Med Ctr, Dept Pediat, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Duijts, L (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC Sophia, Sp-3435,POB 2060, NL-3000 CB Rotterdam, Netherlands.	l.duijts@erasmusmc.nl			Erasmus University Medical Center, Rotterdam; Erasmus University Rotterdam; Netherlands Organization for Health Research and Development; Netherlands Organization for Health Research and Development (ZonMw-VIDI); European Research Council Consolidator Grant [ERC-2014-CoG-648916]; Lung Foundation Netherlands [3.2.12.089]	Erasmus University Medical Center, Rotterdam; Erasmus University Rotterdam; Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); Netherlands Organization for Health Research and Development (ZonMw-VIDI)(Netherlands Organization for Health Research and Development); European Research Council Consolidator Grant(European Research Council (ERC)); Lung Foundation Netherlands	The Generation R Study is made possible by financial support from the Erasmus University Medical Center, Rotterdam, the Erasmus University Rotterdam, and The Netherlands Organization for Health Research and Development. V.J. received an additional grant from The Netherlands Organization for Health Research and Development (ZonMw-VIDI) and a European Research Council Consolidator Grant (grant no. ERC-2014-CoG-648916). L.D. received an additional grant from the Lung Foundation Netherlands (grant no. 3.2.12.089; 2012). The researchers are independent from the funders. The study sponsors had no role in the study design, data analysis, interpretation of data, or writing of this report.	Altomonte J, 2003, METABOLISM, V52, P958, DOI 10.1016/S0026-0495(03)00092-1; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Arteaga-Solis E, 2013, CELL METAB, V17, P35, DOI 10.1016/j.cmet.2012.12.004; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Ashwell M, 2005, INT J FOOD SCI NUTR, V56, P303, DOI 10.1080/09637480500195066; Bekkers MBM, 2012, EUR RESPIR J, V39, P1468, DOI 10.1183/09031936.00094511; Benson Renee C, 2011, J Allergy (Cairo), V2011, P736319, DOI 10.1155/2011/736319; Berg CM, 2011, CHEST, V139, P1109, DOI 10.1378/chest.10-1299; Beydon N, 2007, RESP MED, V101, P2482, DOI 10.1016/j.rmed.2007.07.005; Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST; Calixto MC, 2010, BRIT J PHARMACOL, V159, P617, DOI 10.1111/j.1476-5381.2009.00560.x; Chan DC, 2003, QJM-INT J MED, V96, P441, DOI 10.1093/qjmed/hcg069; Chen YC, 2014, AM J RESP CRIT CARE, V189, P1194, DOI 10.1164/rccm.201401-0097OC; Cole TJ, 2000, STAT MED, V19, P3109, DOI 10.1002/1097-0258(20001130)19:22<3109::AID-SIM558>3.0.CO;2-F; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Consilvio NP, 2010, PEDIATR PULM, V45, P1103, DOI 10.1002/ppul.21295; de Beurs E., 2009, BRIEF SYMPTOM INVENT; Delacourt C, 2001, AM J RESP CRIT CARE, V164, P965, DOI 10.1164/ajrccm.164.6.2010153; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Egan KB, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-121; Einstein FH, 2005, DIABETES, V54, P672, DOI 10.2337/diabetes.54.3.672; Eising JB, 2014, EUR RESPIR J, V43, P1189, DOI 10.1183/09031936.00149613; Farb MG, 2012, ARTERIOSCL THROM VAS, V32, P467, DOI 10.1161/ATVBAHA.111.235846; Fenger RV, 2012, CLIN EXP ALLERGY, V42, P1237, DOI 10.1111/j.1365-2222.2012.03972.x; Forno E, 2014, J ALLERGY CLIN IMMUN, V133, P1308, DOI 10.1016/j.jaci.2013.09.041; Gaggini M, 2015, HORM MOL BIOL CLIN I, V22, P7, DOI 10.1515/hmbci-2015-0006; Guibas GV, 2013, ALLERGY, V68, P1298, DOI 10.1111/all.12245; Han YY, 2014, AM J RESP CRIT CARE, V190, P32, DOI 10.1164/rccm.201403-0565OC; Helba M, 2009, PEDIATR RADIOL, V39, P647, DOI 10.1007/s00247-009-1247-0; Holzhauer S, 2009, EUR J EPIDEMIOL, V24, P521, DOI 10.1007/s10654-009-9368-1; Kaul S, 2012, OBESITY, V20, P1313, DOI 10.1038/oby.2011.393; Kipping RR, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1848; Klug B, 1998, PEDIATR PULM, V25, P322, DOI 10.1002/(SICI)1099-0496(199805)25:5<322::AID-PPUL6>3.0.CO;2-K; Komakula S, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-32; Kouda K, 2015, J CLIN DENSITOM; Kruithof CJ, 2014, EUR J EPIDEMIOL, V29, P911, DOI 10.1007/s10654-014-9980-6; Kujawska-Luczak M, 2015, ENDOKRYNOL POL, V66, P526, DOI 10.5603/EP.2015.0065; Lai CKW, 2009, THORAX, V64, P476, DOI 10.1136/thx.2008.106609; Lara A, 2008, AM J RESP CRIT CARE, V178, P673, DOI 10.1164/rccm.200710-1542OC; Lu FL, 2006, AM J PHYSIOL-LUNG C, V290, pL856, DOI 10.1152/ajplung.00386.2005; Makki Kassem, 2013, ISRN Inflamm, V2013, P139239, DOI 10.1155/2013/139239; Merkus PJFM, 2010, EUR RESPIR J, V36, P157, DOI 10.1183/09031936.00125009; Merkus PJFM, 2001, AM J RESP CRIT CARE, V163, P1350, DOI 10.1164/ajrccm.163.6.2005076; Miczke A, 2015, INT J CLIN EXP MED, V8, P10358; Mook-Kanamori DO, 2009, ULTRASOUND MED BIOL, V35, P1938, DOI 10.1016/j.ultrasmedbio.2009.07.002; Permaul P, 2014, ANN ALLERG ASTHMA IM, V113, P244, DOI 10.1016/j.anai.2014.07.001; POULIOT MC, 1994, AM J CARDIOL, V73, P460, DOI 10.1016/0002-9149(94)90676-9; Salvi S, 1999, AM J RESP CELL MOL, V20, P984, DOI 10.1165/ajrcmb.20.5.3463; Savgan-Gurol E, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-86; Shore SA, 2006, J ALLERGY CLIN IMMUN, V118, P389, DOI 10.1016/j.jaci.2006.04.021; Sideleva O, 2012, AM J RESP CRIT CARE, V186, P598, DOI 10.1164/rccm.201203-0573OC; Singleton MD, 2014, J ASTHMA, V51, P756, DOI 10.3109/02770903.2014.912302; Staiger H, 2003, OBES RES, V11, P368, DOI 10.1038/oby.2003.48; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; SUZUKI R, 1993, AM J MED, V95, P309, DOI 10.1016/0002-9343(93)90284-V; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; Turner Elizabeth L, 2010, Epidemiol Perspect Innov, V7, P9, DOI 10.1186/1742-5573-7-9; Weinmayr G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113996; World Health Organization [ WHO], 2013, NUTR PHYS ACT OBS; YOKOYAMA A, 1995, AM J RESP CRIT CARE, V151, P1354, DOI 10.1164/ajrccm.151.5.7735584	60	18	18	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					810	+		10.1016/j.jaci.2016.06.022	http://dx.doi.org/10.1016/j.jaci.2016.06.022			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27592177				2022-12-18	WOS:000397295800013
J	Gies, V; Guffroy, A; Danion, F; Billaud, P; Keime, C; Fauny, JD; Susini, S; Soley, A; Martin, T; Pasquali, JL; Gros, F; Andre-Schmutz, I; Soulas-Sprauel, P; Korganow, AS				Gies, Vincent; Guffroy, Aurelien; Danion, Francois; Billaud, Philippe; Keime, Celine; Fauny, Jean-Daniel; Susini, Sandrine; Soley, Anne; Martin, Thierry; Pasquali, Jean-Louis; Gros, Frederic; Andre-Schmutz, Isabelle; Soulas-Sprauel, Pauline; Korganow, Anne-Sophie			B cells differentiate in human thymus and express AIRE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NEGATIVE SELECTION; SELF-ANTIGENS; PATHWAYS		[Gies, Vincent; Guffroy, Aurelien; Danion, Francois; Fauny, Jean-Daniel; Soley, Anne; Martin, Thierry; Pasquali, Jean-Louis; Gros, Frederic; Soulas-Sprauel, Pauline; Korganow, Anne-Sophie] IBMC, CNRS, UPR Immunopathol & Therapeut Chem 3572, Lab Excellence Medalis, Strasbourg, France; [Gies, Vincent; Guffroy, Aurelien; Danion, Francois; Martin, Thierry; Pasquali, Jean-Louis; Soulas-Sprauel, Pauline; Korganow, Anne-Sophie] Hop Univ Strasbourg, Dept Clin Immunol & Internal Med, Natl Reference Ctr Autoimmune Dis, Strasbourg, France; [Billaud, Philippe] Hop Univ Strasbourg, Dept Cardiovasc Surg, Strasbourg, France; [Keime, Celine] Univ Strasbourg, IGBMC, INSERM, Illkirch Graffenstaden, France; [Susini, Sandrine; Andre-Schmutz, Isabelle] Univ Paris 05, INSERM, Sorbonne Paris Cite, Inst Imagine, Paris, France; [Martin, Thierry; Pasquali, Jean-Louis; Korganow, Anne-Sophie] Univ Strasbourg, UFR Med, Strasbourg, France; [Gros, Frederic] Univ Strasbourg, Fac Sci Vie, Strasbourg, France; [Soulas-Sprauel, Pauline] Univ Strasbourg, UFR Sci Pharmaceut, Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Korganow, AS (corresponding author), IBMC, CNRS, UPR Immunopathol & Therapeut Chem 3572, Lab Excellence Medalis, Strasbourg, France.; Korganow, AS (corresponding author), Hop Univ Strasbourg, Dept Clin Immunol & Internal Med, Natl Reference Ctr Autoimmune Dis, Strasbourg, France.	korganow@unistra.fr	Andre, Isabelle/F-6263-2013; GROS, Frédéric/G-6332-2013; Andre-Schmutz, Isabelle/M-1279-2016; Danion, François FD/Q-2764-2017	Andre, Isabelle/0000-0002-3905-9910; GROS, Frédéric/0000-0002-6252-4323; Danion, François FD/0000-0003-3907-0658; Gies, Vincent/0000-0002-8658-8604; Guffroy, Aurelien/0000-0003-0615-5305; Fauny, Jean-Daniel/0000-0002-1651-8555; Martin, Thierry/0000-0002-2776-2641; KEIME, Celine/0000-0001-7604-3814; Korganow, Anne-Sophie/0000-0002-1664-6311; Soulas-Sprauel, Pauline/0000-0002-2058-4811				Berkowska MA, 2015, J IMMUNOL, V195, P1417, DOI 10.4049/jimmunol.1402708; Berkowska MA, 2011, BLOOD, V118, P2150, DOI 10.1182/blood-2011-04-345579; Fujihara C, 2014, J IMMUNOL, V193, P5534, DOI 10.4049/jimmunol.1401655; ISAACSON PG, 1987, LANCET, V2, P1488; Klein L, 2014, NAT REV IMMUNOL, V14, P377, DOI 10.1038/nri3667; Perera J, 2013, P NATL ACAD SCI USA, V110, P17011, DOI 10.1073/pnas.1313001110; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; WORTIS HH, 1995, P NATL ACAD SCI USA, V92, P3348, DOI 10.1073/pnas.92.8.3348; Yamano T, 2015, IMMUNITY, V42, P1048, DOI 10.1016/j.immuni.2015.05.013	9	18	18	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					1049	1052		10.1016/j.jaci.2016.09.044	http://dx.doi.org/10.1016/j.jaci.2016.09.044			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27864026	Bronze			2022-12-18	WOS:000397295800043
J	Blankestijn, MA; Blom, WM; Otten, HG; Baumert, JL; Taylor, SL; Bruijnzeel-Koomen, CAFM; Houben, GF; Knulst, AC; Klemans, RJB				Blankestijn, Mark A.; Blom, W. Marty; Otten, Henny G.; Baumert, Joe L.; Taylor, Steve L.; Bruijnzeel-Koomen, Carla A. F. M.; Houben, Geert F.; Knulst, Andre C.; Klemans, Rob J. B.			Specific IgE to Jug r 1 has no additional value compared with extract-based testing in diagnosing walnut allergy in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ARA H 2; PEANUT ALLERGY; CHILDREN; SENSITIZATION; ACCURACY		[Blankestijn, Mark A.; Bruijnzeel-Koomen, Carla A. F. M.; Houben, Geert F.; Knulst, Andre C.; Klemans, Rob J. B.] Univ Med Ctr Utrecht, Dept Dermatol Allergol, Utrecht, Netherlands; [Blom, W. Marty; Houben, Geert F.] Netherlands Org Appl Sci Res, Zeist, Netherlands; [Otten, Henny G.] Univ Med Ctr Utrecht, Dept Immunol, Utrecht, Netherlands; [Baumert, Joe L.; Taylor, Steve L.] Univ Nebraska, Food Allergy Res & Resource Program, Lincoln, NE USA	Utrecht University; Utrecht University Medical Center; Netherlands Organization Applied Science Research; Utrecht University; Utrecht University Medical Center; University of Nebraska System; University of Nebraska Lincoln	Blankestijn, MA (corresponding author), Univ Med Ctr Utrecht, Dept Dermatol Allergol, Utrecht, Netherlands.	m.a.blankestijn@umcutrecht.nl	Taylor, Steve L./V-1341-2019	Blom, W.M./0000-0002-6853-0900; Houben, Geert/0000-0001-7261-3912; Blankestijn, Mark/0000-0003-4163-0685; Knulst, Andre/0000-0002-1056-3179	Food Allergy Research & Resource Program of the University of Nebraska, Lincoln, Nebraska; Netherlands Organization for Applied Scientific Research (TNO) Governmental Research Cooperation Funds, The Netherlands	Food Allergy Research & Resource Program of the University of Nebraska, Lincoln, Nebraska; Netherlands Organization for Applied Scientific Research (TNO) Governmental Research Cooperation Funds, The Netherlands	This research was funded by the Food Allergy Research & Resource Program of the University of Nebraska, Lincoln, Nebraska, and The Netherlands Organization for Applied Scientific Research (TNO) Governmental Research Cooperation Funds, The Netherlands.	Asero R, 1998, ALLERGY, V53, P908, DOI 10.1111/j.1398-9995.1998.tb04004.x; Klemans RJB, 2015, CLIN EXP ALLERGY, V45, P720, DOI 10.1111/cea.12412; Klemans RJB, 2014, ALLERGY, V69, P1112, DOI 10.1111/all.12424; Klemans RJB, 2013, J ALLER CL IMM-PRACT, V1, P632, DOI 10.1016/j.jaip.2013.07.014; Klemans RJB, 2013, J ALLERGY CLIN IMMUN, V131, P157, DOI 10.1016/j.jaci.2012.08.010; Masthoff LJN, 2013, J ALLERGY CLIN IMMUN, V132, P393, DOI 10.1016/j.jaci.2013.02.024; Rayes H, 2016, CLIN EXP ALLERGY, V46, P654, DOI 10.1111/cea.12693; Savvatianos S, 2015, J ALLERGY CLIN IMMUN, V136, P192, DOI 10.1016/j.jaci.2015.03.037; Wallowitz M, 2006, J AGR FOOD CHEM, V54, P8369, DOI 10.1021/jf061329s	9	18	20	2	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					688	690		10.1016/j.jaci.2016.07.026	http://dx.doi.org/10.1016/j.jaci.2016.07.026			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27597723	Bronze			2022-12-18	WOS:000397002400036
J	Rao, K; Adams, S; Qasim, W; Allwood, Z; Worth, A; Silva, J; Lucchini, G; Chiesa, R; Veys, P; Amrolia, P				Rao, Kanchan; Adams, Stuart; Qasim, Waseem; Allwood, Zoe; Worth, Austen; Silva, Juliana; Lucchini, Giovanna; Chiesa, Robert; Veys, Paul; Amrolia, Persis			Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency disorder; hematopoietic stem cell transplantation; chimerism; lineage specific; reduced intensity	VERSUS-HOST-DISEASE; PERIPHERAL-BLOOD; BONE-MARROW; UNRELATED DONORS; GRAFT SOURCE; TRANSPLANTATION; HISTOCOMPATIBILITY	Background: Reduced-intensity conditioning (RIC) regimens are increasingly being used in the transplantation of patients with primary immunodeficiency disorders (PIDs), but there are no large studies looking at long-term lineage-specific chimerism. Objectives: We sought to analyze long-term chimerism and event-free survival in children undergoing transplantation for PIDs using RIC with fludarabine and melphalan (Flu/Melph) and to study the effect of donor type and stem cell source. Methods: One hundred forty-two children underwent transplantation with RIC by using Flu/Melph and for PIDs by using bone marrow (n = 93) or peripheral blood stem cells (PBSCs; n = 49). Donors were matched unrelated donors (n = 72), mismatched unrelated donors (n = 37), matched sibling donors (n = 14), matched family donors (n = 12), and mismatched family donors (n = 7). Results: Overall survival at a median follow-up of 7.5 years was 78%, irrespective of stem cell source or donor type. When bone marrow was used as the stem cell source, 26% of patients ended up with very low levels of donor chimerism (<10% donor), especially in the myeloid lineage. Event-free survival in this group was significantly lower compared with that in the rest of the group (25% vs 70%, P <.001). With the use of PBSCs, more than 90% of patients achieved complete donor chimerism or high-level mixed chimerism (>50% donor chimerism) in all lineages. Conclusions: On the basis of our experience, we would suggest that PBSCs should be the stem cell source of choice in children with PIDs undergoing transplantation with Flu/Melph RIC from a matched donor source. This is most likely to ensure sustained high-level donor chimerism.	[Rao, Kanchan; Adams, Stuart; Qasim, Waseem; Allwood, Zoe; Worth, Austen; Silva, Juliana; Lucchini, Giovanna; Chiesa, Robert; Veys, Paul; Amrolia, Persis] Great Ormond St Hosp Sick Children, Dept Blood & Marrow Transplantat, London, England; [Qasim, Waseem; Worth, Austen; Amrolia, Persis] UCL, Inst Child Hlth, Mol Immunol Unit, London WC1E 6BT, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Rao, K (corresponding author), Great Ormond St Hosp Sick Children, Dept Blood & Marrow Transplantat, London WC1N 3JH, England.	kanchan.rao@gosh.nhs.uk		QASIM, WASEEM/0000-0001-8353-4494	National Institute for Health Research (NIHR) through the Great Ormond Street Hospital Biomedical Research Centre; NIHR Research Professorship; National Institute for Health Research [RP-2014-05-007] Funding Source: researchfish	National Institute for Health Research (NIHR) through the Great Ormond Street Hospital Biomedical Research Centre; NIHR Research Professorship; National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by the National Institute for Health Research (NIHR) through the Great Ormond Street Hospital Biomedical Research Centre. P.A. is a recipient of an NIHR Research Professorship.	Blache C, 2010, BIOL BLOOD MARROW TR, V16, P430, DOI 10.1016/j.bbmt.2009.10.027; Breuer S, 2012, LEUKEMIA, V26, P509, DOI 10.1038/leu.2011.244; Cavazzana-Calvo M, 2007, BLOOD, V109, P4575, DOI 10.1182/blood-2006-07-029090; Dey BR, 2007, BONE MARROW TRANSPL, V40, P19, DOI 10.1038/sj.bmt.1705688; Eapen M, 2004, J CLIN ONCOL, V22, P4872, DOI 10.1200/JCO.2004.02.189; Eapen M, 2014, BEST PRACT RES CL HA, V27, P278, DOI 10.1016/j.beha.2014.10.010; Gungor T, 2014, LANCET, V383, P436, DOI [10.1016/s0140-6736(13)62069-3, 10.1016/S0140-6736(13)62069-3]; Gyurkocza B, 2014, BLOOD, V124, P344, DOI 10.1182/blood-2014-02-514778; Ho VT, 2006, BONE MARROW TRANSPL, V37, P845, DOI 10.1038/sj.bmt.1705315; Malard F, 2013, LEUKEMIA, V27, P2113, DOI 10.1038/leu.2013.170; Mattsson J, 2008, BIOL BLOOD MARROW TR, V14, P165, DOI 10.1016/j.bbmt.2007.10.025; Mead AJ, 2010, BLOOD, V115, P5147, DOI 10.1182/blood-2010-01-265413; Morishima Y, 2002, BLOOD, V99, P4200, DOI 10.1182/blood.V99.11.4200; Morton J, 2001, BLOOD, V98, P3186, DOI 10.1182/blood.V98.12.3186; Neven B, 2009, BLOOD, V113, P4114, DOI 10.1182/blood-2008-09-177923; Petersdorf EW, 2001, NEW ENGL J MED, V345, P1794, DOI 10.1056/NEJMoa011826; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Pulsipher MA, 2005, BONE MARROW TRANSPL, V35, P361, DOI 10.1038/sj.bmt.1704743; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; Teshima T, 2002, NAT MED, V8, P575, DOI 10.1038/nm0602-575; Worth AJJ, 2013, CURR OPIN HEMATOL, V20, P501, DOI 10.1097/MOH.0b013e328365a13b; Yu C, 1998, BLOOD, V91, P2581, DOI 10.1182/blood.V91.7.2581.2581_2581_2587	22	18	19	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1152	1160		10.1016/j.jaci.2016.01.053	http://dx.doi.org/10.1016/j.jaci.2016.01.053			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27241891	Bronze, Green Submitted			2022-12-18	WOS:000385499400021
J	Sarnowski, C; Sugier, PE; Granell, R; Jarvis, D; Dizier, MH; Ege, M; Imboden, M; Laprise, C; Khusnutdinova, EK; Freidin, MB; Cookson, WOC; Moffatt, M; Lathrop, M; Siroux, V; Ogorodova, LM; Karunas, AS; James, A; Probst-Hensch, NM; von Mutius, E; Pin, I; Kogevinas, M; Henderson, AJ; Demenais, F; Bouzigon, E				Sarnowski, Chloe; Sugier, Pierre-Emmanuel; Granell, Raquel; Jarvis, Debbie; Dizier, Marie-Helene; Ege, Markus; Imboden, Medea; Laprise, Catherine; Khusnutdinova, Elza K.; Freidin, Maxim B.; Cookson, William O. C.; Moffatt, Miriam; Lathrop, Mark; Siroux, Valerie; Ogorodova, Ludmila M.; Karunas, Alexandra S.; James, Alan; Probst-Hensch, Nicole M.; von Mutius, Erika; Pin, Isabelle; Kogevinas, Manolis; Henderson, A. John; Demenais, Florence; Bouzigon, Emmanuelle			Identification of a new locus at 16q12 associated with time to asthma onset	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; age of onset; genetics; genome-wide association study; survival analysis; conditional analysis; CYLD; NOD2	GENOME-WIDE ASSOCIATION; CHILDHOOD; PHENOTYPES; VARIANTS; GENETICS; SUSCEPTIBILITY; INFLAMMATION; DISEASE; 17Q21; AGE	Background: Asthma is a heterogeneous disease in which age of onset plays an important role. Objective: We sought to identify the genetic variants associated with time to asthma onset (TAO). Methods: We conducted a large-scale meta-analysis of 9 genome-wide association studies of TAO (total of 5462 asthmatic patients with a broad range of age of asthma onset and 8424 control subjects of European ancestry) performed by using survival analysis techniques. Results: We detected 5 regions associated with TAO at the genome-wide significant level (P < 5 x 10(-8)). We evidenced a new locus in the 16q12 region (near cylindromatosis turban tumor syndrome gene [CYLD]) and confirmed 4 asthma risk regions: 2q12 (IL-1 receptor-like 1 [IL1RL1]), 6p21 (HLA-DQA1), 9p24 (IL33), and 17q12-q21 (zona pellucida binding protein 2 [ZPBP2]-gasdermin A [GSDMA]). Conditional analyses identified 2 distinct signals at 9p24 (both upstream of IL33) and 17q12-q21 (near ZPBP2 and within GSDMA). Together, these 7 distinct loci explained 6.0% of the variance in TAO. In addition, we showed that genetic variants at 9p24 and 17q12-q21 were strongly associated with an earlier onset of childhood asthma (P <= .002), whereas the 16q12 single nucleotide polymorphism was associated with later asthma onset (P = .04). A high burden of disease risk alleles at these loci was associated with earlier age of asthma onset (4 vs 9-12 years, P = 10(-4)). Conclusion: The new susceptibility region for TAO at 16q12 harbors variants that correlate with the expression of CYLD and nucleotide-binding oligomerization domain 2 (NOD2), 2 strong candidates for asthma. This study demonstrates that incorporating the variability of age of asthma onset in asthma modeling is a helpful approach in the search for disease susceptibility genes.	[Sarnowski, Chloe; Sugier, Pierre-Emmanuel; Demenais, Florence; Bouzigon, Emmanuelle] INSERM, UMR 946, Paris, France; [Sarnowski, Chloe; Sugier, Pierre-Emmanuel; Demenais, Florence; Bouzigon, Emmanuelle] Univ Paris Diderot, Sorbonne Paris Cite, Inst Univ Hematol, Paris, France; [Granell, Raquel; Henderson, A. John] Univ Bristol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England; [Jarvis, Debbie] Imperial Coll, Natl Heart & Lung Inst, Resp Epidemiol Occupat Med & Publ Hlth, London, England; [Jarvis, Debbie] MRC PHE Ctr Environm & Hlth, London, England; [Ege, Markus; von Mutius, Erika] Univ Munich, Dr Von Hauner Childrens Hosp, Munich, Germany; [Ege, Markus; von Mutius, Erika] German Ctr Lung Res, CPC M, Munich, Germany; [Imboden, Medea; Probst-Hensch, Nicole M.] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Imboden, Medea; Probst-Hensch, Nicole M.] Univ Basel, CH-4003 Basel, Switzerland; [Laprise, Catherine] Univ Quebec Chicoutimi, Dept Sci Fondamentales, Saguenay, PQ, Canada; [Khusnutdinova, Elza K.; Karunas, Alexandra S.] Russian Acad Sci, Ufa Sci Ctr, Inst Biochem & Genet, Ufa, Russia; [Khusnutdinova, Elza K.; Karunas, Alexandra S.] Bashkir State Univ, Dept Genet & Fundamental Med, Ufa, Russia; [Freidin, Maxim B.] Res Inst Med Genet, Tomsk, Russia; [Cookson, William O. C.; Moffatt, Miriam] Imperial Coll London, Natl Heart Lung Inst, London, England; [Lathrop, Mark] McGill Univ, Montreal, PQ, Canada; [Lathrop, Mark] Genome Quebec Innovat Ctr, Montreal, PQ, Canada; [Siroux, Valerie; Pin, Isabelle] Univ Grenoble Alpes, IAB, Team Environm Epidemiol Appl Reprod & Resp Hlth, Grenoble, France; [Siroux, Valerie; Pin, Isabelle] INSERM, Grenoble, France; [Siroux, Valerie] CHU Grenoble, IAB, Team Environm Epidemiol Appl Reprod & Resp Hlth, Grenoble, France; [Ogorodova, Ludmila M.] Siberian State Med Univ, Tomsk, Russia; [James, Alan] Sir Charles Gairdner Hosp, Dept Pulm Physiol & Sleep Med, Busselton Populat Med Res Inst, Nedlands, WA, Australia; [Pin, Isabelle] Univ Western Australia, Sch Populat Hlth, Crawley, WA, Australia; [Kogevinas, Manolis] CHU Grenoble, Pediat, Grenoble, France; [Kogevinas, Manolis] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain; [Kogevinas, Manolis] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain; [Kogevinas, Manolis] IMIM Hosp Mar Med Res Inst, Barcelona, Spain; [Kogevinas, Manolis] Univ Pompeu Fabra, Barcelona, Spain	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Bristol; Imperial College London; University of Munich; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; University of Quebec; University of Quebec Chicoutimi; Institute of Biochemistry & Genetics of Ufa Science Centre of the RAS; Russian Academy of Sciences; Bashkir State University; Russian Academy of Sciences; Tomsk National Research Medical Center; Research Institute of Medical Genetics - Tomsk; Imperial College London; McGill University; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Grenoble Alpes; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Siberian State Medical University; University of Western Australia; University of Western Australia; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Pompeu Fabra University	Bouzigon, E (corresponding author), Univ Paris Diderot, Inst Genet Mol, INSERM, UMR 946, 27 Rue Juliette Dodu, F-75010 Paris, France.	emmanuelle.bouzigon@inserm.fr	siroux, valerie/N-1865-2013; Freidin, Maxim B/A-8222-2014; Freydin, Maxim/A-5603-2011; Demenais, Florence/G-3298-2013; Ege, Markus/C-1962-2012; Khusnutdinova, Elza Kamilevna/A-4810-2013; Granell, Raquel/AAB-5256-2022; Ogorodova, Ludmila M/S-5058-2016; PIN, Isabelle/N-3020-2013; Cookson, William/HHC-1790-2022; Karunas, Alexandra S/E-6421-2014; Kogevinas, Manolis/C-3918-2017; Bouzigon, Emmanuelle/L-2766-2017; Dizier, Marie-Hélène/K-8463-2018; Granell, Raquel/AAY-4846-2020	siroux, valerie/0000-0001-7329-7237; Freidin, Maxim B/0000-0002-1439-6259; Freydin, Maxim/0000-0002-1439-6259; Demenais, Florence/0000-0001-8361-0936; Ege, Markus/0000-0001-6643-3923; Khusnutdinova, Elza Kamilevna/0000-0003-2987-3334; Granell, Raquel/0000-0002-4890-4012; Ogorodova, Ludmila M/0000-0002-2962-1076; Karunas, Alexandra S/0000-0002-2570-0789; Kogevinas, Manolis/0000-0002-9605-0461; Bouzigon, Emmanuelle/0000-0001-5756-4286; Dizier, Marie-Hélène/0000-0001-8460-7667; Jarvis, Deborah/0000-0002-1753-3896; Laprise, Catherine/0000-0001-5526-9945; von Mutius, Erika/0000-0002-8893-4515; Sarnowski, Chloe/0000-0002-6090-7099; Sugier, Pierre-Emmanuel/0000-0002-5846-1104	French National Agency for Research [ANR-CES-2009, ANR-11-BSV1-027-GWIS-AM]; Region Ile-de-France (DIM-SEnT grant); Fonds de dotation Recherche en Sante Respiratoire; Russian Foundation for Basic Research [13-04-01397, 01-04-48213a]; Healthway; UK Medical Research Council; Wellcome Trust [102215/2/13/2, WT084703MA]; University of Bristol; Swiss National Science Foundation [33CS30-148470/1]; Canadian Institutes of Health Research (CIHR); European Commission [LSHB-CT-2006-018996-GABRIEL]; Departments of Science and Health of the Government of Western Australia; MRC [G0401540] Funding Source: UKRI; Medical Research Council [G9815508, MC_PC_15018, G0401540] Funding Source: researchfish	French National Agency for Research(French National Research Agency (ANR)); Region Ile-de-France (DIM-SEnT grant)(Region Ile-de-France); Fonds de dotation Recherche en Sante Respiratoire; Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); Healthway; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); University of Bristol; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); European Commission(European CommissionEuropean Commission Joint Research Centre); Departments of Science and Health of the Government of Western Australia; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by the French National Agency for Research (ANR-CES-2009, ANR-11-BSV1-027-GWIS-AM), Region Ile-de-France (DIM-SEnT grant), "Fonds de dotation Recherche en Sante Respiratoire,'' the Russian Foundation for Basic Research (grants 13-04-01397 and 01-04-48213a), Healthway and the Departments of Science and Health of the Government of Western Australia, the UK Medical Research Council, the Wellcome Trust (grant 102215/2/13/2), the University of Bristol, and the Swiss National Science Foundation (current grants no 33CS30-148470/1). The Canada Research Chair held by C.L. and the funding supports from Canadian Institutes of Health Research (CIHR) enabled the maintenance and continuation of the SLSJ asthma study. Genotyping was supported by grants from the European Commission (no. LSHB-CT-2006-018996-GABRIEL) and the Wellcome Trust (WT084703MA).	Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Bouzigon E, 2007, HUM GENET, V121, P711, DOI 10.1007/s00439-007-0363-x; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Cleynen I, 2014, GUT, V63, P1265, DOI 10.1136/gutjnl-2012-303205; Dijk FN, 2013, CURR OPIN ALLERGY CL, V13, P193, DOI 10.1097/ACI.0b013e32835eb707; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Elding H, 2011, AM J HUM GENET, V89, P798, DOI 10.1016/j.ajhg.2011.11.006; Ferreira MAR, 2014, J ALLERGY CLIN IMMUN, V133, P1564, DOI 10.1016/j.jaci.2013.10.030; Forno E, 2012, J ALLERGY CLIN IMMUN, V130, P83, DOI 10.1016/j.jaci.2012.03.020; Fuertes E, 2015, J ALLERGY CLIN IMMUN, V135, P573, DOI 10.1016/j.jaci.2014.08.016; Granell R, 2013, J ALLERGY CLIN IMMUN, V131, P685, DOI 10.1016/j.jaci.2012.09.021; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hao K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003029; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Hinds DA, 2013, NAT GENET, V45, P907, DOI 10.1038/ng.2686; Ioannidis JPA, 2009, NAT REV GENET, V10, P318, DOI 10.1038/nrg2544; Kenny EE, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002559; Kugathasan S, 2008, NAT GENET, V40, P1211, DOI 10.1038/ng.203; Kurakula K, 2015, J IMMUNOL, V195, P1388, DOI 10.4049/jimmunol.1401714; Li CS, 2006, J HUM GENET, V51, P292, DOI 10.1007/s10038-006-0359-8; Li XN, 2012, J ALLERGY CLIN IMMUN, V130, P861, DOI 10.1016/j.jaci.2012.04.041; Li Y, 2009, ANNU REV GENOM HUM G, V10, P387, DOI 10.1146/annurev.genom.9.081307.164242; Liang LM, 2013, GENOME RES, V23, P716, DOI 10.1101/gr.142521.112; Lim JH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1776; Lin L, 2004, SCIENCE, V303, P1017, DOI 10.1126/science.1093889; Liu H, 2015, NAT GENET, V47, P267, DOI 10.1038/ng.3212; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Martinez FD, 2013, LANCET, V382, P1360, DOI 10.1016/S0140-6736(13)61536-6; McGeachie MJ, 2015, J ALLERGY CLIN IMMUN, V136, P1503, DOI 10.1016/j.jaci.2015.04.039; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Montgomery SB, 2010, NATURE, V464, P773, DOI 10.1038/nature08903; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Pattaro C, 2007, J CLIN EPIDEMIOL, V60, P704, DOI 10.1016/j.jclinepi.2006.10.010; Poynter ME, 2004, J IMMUNOL, V173, P7003, DOI 10.4049/jimmunol.173.11.7003; Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419; Radhakrishnan DK, 2014, J ALLERGY CLIN IMMUN, V134, P1057, DOI 10.1016/j.jaci.2014.05.012; Savenije OE, 2014, J ALLERGY CLIN IMMUN, V134, P170, DOI 10.1016/j.jaci.2013.12.1080; Siroux V, 2011, EUR RESPIR J, V38, P310, DOI 10.1183/09031936.00120810; Siroux V, 2014, EUR RESPIR J, V43, P439, DOI 10.1183/09031936.00032713; Stranger BE, 2007, NAT GENET, V39, P1217, DOI 10.1038/ng2142; Sun SC, 2010, CELL DEATH DIFFER, V17, P25, DOI 10.1038/cdd.2009.43; Szefler SJ, 2014, J ALLERGY CLIN IMMUN, V133, P3, DOI 10.1016/j.jaci.2013.10.018; Toren K, 2006, J CLIN EPIDEMIOL, V59, P90, DOI 10.1016/j.jclinepi.2005.03.019; van der Valk RJP, 2014, J ALLERGY CLIN IMMUN, V134, P46, DOI 10.1016/j.jaci.2013.08.053; Veyrieras JB, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000214; Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917; Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Westra HJ, 2013, NAT GENET, V45, P1238, DOI 10.1038/ng.2756; Williams RL, 2000, BIOMETRICS, V56, P645, DOI 10.1111/j.0006-341X.2000.00645.x; Zhang FR, 2011, NAT GENET, V43, P1247, DOI 10.1038/ng.973	57	18	20	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1071	1080		10.1016/j.jaci.2016.03.018	http://dx.doi.org/10.1016/j.jaci.2016.03.018			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27130862	Green Submitted, Bronze			2022-12-18	WOS:000385499400012
J	Kirstein, F; Nieuwenhuizen, NE; Jayakumar, J; Horsnell, WGC; Brombacher, F				Kirstein, Frank; Nieuwenhuizen, Natalie E.; Jayakumar, Jaisubash; Horsnell, William G. C.; Brombacher, Frank			Role of IL-4 receptor alpha-positive CD4(+) T cells in chronic airway hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)2 cell; acute allergic airway disease; chronic asthma; cytokine receptors; IL-4; IL-13; gene-deficient mice	INNATE LYMPHOID-CELLS; ALTERNATIVELY ACTIVATED MACROPHAGES; LEISHMANIA-MAJOR INFECTION; ALLERGIC-ASTHMA; IN-VIVO; MAST-CELLS; LUNG INFLAMMATION; IMMUNE-RESPONSES; BALB/C MICE; MOUSE MODEL	Background: T(H)2 cells and their cytokines are associated with allergic asthma in human subjects and with mouse models of allergic airway disease. IL-4 signaling through the IL-4 receptor a (IL-4R alpha) chain on CD4(+) T cells leads to T(H)2 cell differentiation in vitro, implying that IL-4R alpha-responsive CD4(+) T cells are critical for the induction of allergic asthma. However, mechanisms regulating acute and chronic allergen-specific T(H)2 responses in vivo remain incompletely understood. Objective: This study defines the requirements for IL-4R alpha-responsive CD4(+) T cells and the IL-4R alpha ligands IL-4 and IL-13 in the development of allergen-specific T(H)2 responses during the onset and chronic phase of experimental allergic airway disease. Methods: Development of acute and chronic ovalbumin (OVA)-induced allergic asthma was assessed weekly in CD4(+) T cell-specific IL-4R alpha-deficient BALB/c mice (Lck cre IL-4R alpha 2/lox) and respective control mice in the presence or absence of IL-4 or IL-13. Results: During acute allergic airway disease, IL-4 deficiency did not prevent the onset of T(H)2 immune responses and OVA-induced airway hyperresponsiveness or goblet cell hyperplasia, irrespective of the presence or absence of IL-4R alpha-responsive CD4(+) T cells. In contrast, deficiency of IL-13 prevented allergic asthma, irrespective of the presence or absence of IL-4R alpha-responsive CD4(+) T cells. Importantly, chronic allergic inflammation and airway hyperresponsiveness were dependent on IL-4R alpha-responsive CD4(+) T cells. Deficiency in IL-4R alpha-responsive CD4(+) T cells resulted in increased numbers of IL-17-producing T cells and, consequently, increased airway neutrophilia. Conclusion: IL-4-responsive T helper cells are dispensable for acute OVA-induced airway disease but crucial in maintaining chronic asthmatic pathology.	Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, ICGEB, ZA-7925 Cape Town, South Africa; Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, Div Immunol, ZA-7925 Cape Town, South Africa; [Nieuwenhuizen, Natalie E.] Max Planck Inst Infekt Biol, Dept Immunol, D-10117 Berlin, Germany	International Center for Genetic Engineering & Biotechnology (ICGEB); ICGEB Cape Town; University of Cape Town; University of Cape Town; Max Planck Society	Brombacher, F (corresponding author), Univ Cape Town Campus, Fac Hlth Sci, ICGEB, Level 1 Werner & Beit South,Anzio Rd, ZA-7925 Cape Town, South Africa.	frank.brombacher@icgeb.org	Jayakumar, Jaisubash/AAC-6614-2019; Nieuwenhuizen, Natalie/AAP-2400-2021; Horsnell, William GC/A-9512-2013	Jayakumar, Jaisubash/0000-0001-9359-516X; Nieuwenhuizen, Natalie/0000-0001-5749-2462	National Research Foundation (NRF; South Africa) [80747]; South African Research Chairs Initiative (SARChI) [64761]; South African Medical Research Council (SAMRC; Immunology of Infectious Disease); International Centre for Genetic Engineering and Biotechnology (ICGEB; Cytokines and Diseases)	National Research Foundation (NRF; South Africa)(National Research Foundation - South Africa); South African Research Chairs Initiative (SARChI); South African Medical Research Council (SAMRC; Immunology of Infectious Disease); International Centre for Genetic Engineering and Biotechnology (ICGEB; Cytokines and Diseases)	Supported by grants from the National Research Foundation (NRF; South Africa; grant no. 80747), the South African Research Chairs Initiative (SARChI; grant no. 64761), the South African Medical Research Council (SAMRC; Immunology of Infectious Disease), and the International Centre for Genetic Engineering and Biotechnology (ICGEB; Cytokines and Diseases).	Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; Cunningham AF, 2004, EUR J IMMUNOL, V34, P686, DOI 10.1002/eji.200324510; Doherty TA, 2009, AM J PHYSIOL-LUNG C, V296, pL229, DOI 10.1152/ajplung.90543.2008; Foster PS, 2002, LAB INVEST, V82, P455, DOI 10.1038/labinvest.3780438; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; Gold MJ, 2014, J ALLERGY CLIN IMMUN, V133, P1142, DOI 10.1016/j.jaci.2014.02.033; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Hoving JC, 2012, GASTROENTEROLOGY, V142, P96, DOI 10.1053/j.gastro.2011.09.044; Jankovic D, 2000, J IMMUNOL, V164, P3047, DOI 10.4049/jimmunol.164.6.3047; Kirstein F, 2010, J ALLERGY CLIN IMMUN, V126, P347, DOI 10.1016/j.jaci.2010.04.028; Kirstein F, 2010, INFECT IMMUN, V78, P4077, DOI 10.1128/IAI.01131-09; Kobayashi T, 2000, J IMMUNOL, V164, P3855, DOI 10.4049/jimmunol.164.7.3855; Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248; Kuperman DA, 2005, J IMMUNOL, V175, P3746, DOI 10.4049/jimmunol.175.6.3746; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780, DOI 10.4049/jimmunol.181.7.4780; Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Leigh R, 2004, J APPL PHYSIOL, V97, P2258, DOI 10.1152/japplphysiol.00597.2004; Leigh R, 2004, AM J RESP CRIT CARE, V170, P851, DOI 10.1164/rccm.200311-1488OC; Leigh R, 2004, AM J RESP CRIT CARE, V169, P860, DOI 10.1164/rccm.200305-706OC; Leigh R, 2002, AM J RESP CELL MOL, V27, P526, DOI 10.1165/rcmb.2002-0048OC; McKenzie GJ, 1998, CURR BIOL, V8, P339, DOI 10.1016/S0960-9822(98)70134-4; Mearns H, 2008, INFECT IMMUN, V76, P5535, DOI 10.1128/IAI.00210-08; Mohrs M, 2001, IMMUNITY, V15, P303, DOI 10.1016/S1074-7613(01)00186-8; Muller U, 2012, MUCOSAL IMMUNOL, V5, P299, DOI 10.1038/mi.2012.9; Nieuwenhuizen N, 2009, ALLERGY, V64, P1309, DOI 10.1111/j.1398-9995.2009.02002.x; Nieuwenhuizen N, 2007, J IMMUNOL, V179, P2758, DOI 10.4049/jimmunol.179.5.2758; Nieuwenhuizen NE, 2012, J ALLERGY CLIN IMMUN, V130, P743, DOI 10.1016/j.jaci.2012.03.011; NobenTrauth N, 1997, P NATL ACAD SCI USA, V94, P10838, DOI 10.1073/pnas.94.20.10838; NobenTrauth N, 1996, SCIENCE, V271, P987, DOI 10.1126/science.271.5251.987; Okano M, 2000, ALLERGY, V55, P723, DOI 10.1034/j.1398-9995.2000.00429.x; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Perkins C, 2011, J EXP MED, V208, P853, DOI 10.1084/jem.20100023; Radwanska M, 2007, PLOS PATHOG, V3, P619, DOI 10.1371/journal.ppat.0030068; Robinson DS, 2010, J ALLERGY CLIN IMMUN, V126, P1081, DOI 10.1016/j.jaci.2010.06.025; Roediger B, 2013, NAT IMMUNOL, V14, P564, DOI 10.1038/ni.2584; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Song DJ, 2009, J IMMUNOL, V183, P5333, DOI 10.4049/jimmunol.0801421; Taube C, 2004, J IMMUNOL, V172, P6398, DOI 10.4049/jimmunol.172.10.6398; Uyttenhove C, 2006, EUR J IMMUNOL, V36, P2868, DOI 10.1002/eji.200636662; van Panhuys N, 2008, P NATL ACAD SCI USA, V105, P12423, DOI 10.1073/pnas.0806372105; Voehringer D, 2007, J LEUKOCYTE BIOL, V81, P1434, DOI 10.1189/jlb.1106686; Webb DC, 2003, EUR J IMMUNOL, V33, P3377, DOI 10.1002/eji.200324178; You DH, 2013, J LEUKOCYTE BIOL, V93, P933, DOI 10.1189/jlb.1012498; Yu M, 2006, J CLIN INVEST, V116, P1633, DOI 10.1172/JCI25702; Zhang M, 2007, BLOOD, V109, P4280, DOI 10.1182/blood-2006-08-039255	50	18	21	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1852	+		10.1016/j.jaci.2015.10.036	http://dx.doi.org/10.1016/j.jaci.2015.10.036			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26688514	Bronze, Green Published			2022-12-18	WOS:000377527200027
J	Trian, T; Allard, B; Ozier, A; Maurat, E; Dupin, I; Thumerel, M; Ousova, O; Gillibert-Duplantier, J; Le Morvan, V; Begueret, H; Girodet, PO; Marthan, R; Berger, P				Trian, Thomas; Allard, Benoit; Ozier, Annaig; Maurat, Elise; Dupin, Isabelle; Thumerel, Matthieu; Ousova, Olga; Gillibert-Duplantier, Jennifer; Le Morvan, Valerie; Begueret, Hugues; Girodet, Pierre-Olivier; Marthan, Roger; Berger, Patrick			Selective dysfunction of p53 for mitochondrial biogenesis induces cellular proliferation in bronchial smooth muscle from asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; remodeling; lentivirus; peroxisome proliferator-activated receptor gamma coactivator 1 alpha; mitochondrial transcription factor A	SUPPRESSOR PROTEIN P53; SKELETAL-MUSCLE; CELLS; APOPTOSIS; EXPRESSION; PATHWAY; CANCER; MDM2; CYCLE; PHOSPHORYLATION	Background: Increase of bronchial smooth muscle (BSM) mass is a crucial feature of asthma remodeling. The mechanisms of such an increased BSM mass are complex but involve enhanced mitochondrial biogenesis, leading to increased proliferation of BSM cells in asthmatic patients. The major tumor suppressor protein p53 is a key cell regulator involved in cell proliferation and has also been implicated in mitochondrial biogenesis. However, the role of p53 in BSM cell proliferation and mitochondrial biogenesis has not been investigated thus far. Objective: We sought to evaluate the role of p53 in proliferation of BSM cells in asthmatic patients and mitochondrial biogenesis. Methods: The expression of p53 was assessed both in vitro by using flow cytometry and Western blotting and ex vivo by using RT-PCR after laser microdissection. The role of p53 was assessed with small hairpin RNA lentivirus in both asthmatic patients and control subjects with BSM cell proliferation by using 5-bromo-2'-deoxyuridine and cell counting and in the expression of p21, BCL2-associated X protein, mitochondrial transcription factor A (TFAM), and peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha). Results: Twenty-nine patients with moderate-to-severe asthma and 26 control subjects were enrolled in the study. p53 expression was increased in BSM from asthmatic patients both ex vivo and in vitro, with a decreased interaction with mouse double minute 2 homolog (Mdm2) and an increased phosphorylation of serine 20. p53 did not inhibit the transcription of both TFAM and PGC-1 alpha in BSM cells from asthmatic patients. As a consequence, p53 is unable to slow the increased mitochondrial biogenesis and hence the subsequent increased proliferation of BSM cells in asthmatic patients. Conclusion: This study suggests that p53 might act as a new potential therapeutic target against BSM remodeling in asthmatic patients.	[Trian, Thomas; Allard, Benoit; Ozier, Annaig; Maurat, Elise; Dupin, Isabelle; Thumerel, Matthieu; Ousova, Olga; Gillibert-Duplantier, Jennifer; Girodet, Pierre-Olivier; Marthan, Roger; Berger, Patrick] Univ Bordeaux, Ctr Rech Cardiothorac Bordeaux, U1045, Dept Pharmacol, F-33076 Bordeaux, France; [Trian, Thomas; Allard, Benoit; Ozier, Annaig; Maurat, Elise; Dupin, Isabelle; Thumerel, Matthieu; Ousova, Olga; Gillibert-Duplantier, Jennifer; Girodet, Pierre-Olivier; Marthan, Roger; Berger, Patrick] INSERM, Ctr Rech Cardiothorac Bordeaux, U1045, Bordeaux, France; [Ozier, Annaig; Thumerel, Matthieu; Begueret, Hugues; Girodet, Pierre-Olivier; Marthan, Roger; Berger, Patrick] CHU Bordeaux, Serv Explorat Fonct Resp, Serv Chirurg Thorac, Serv Anatomopathol, Pessac, France; [Le Morvan, Valerie] Inst Bergonie Bordeaux, Unite Inserm VINCO, Bordeaux, France	UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UNICANCER; Institut Bergonie	Trian, T (corresponding author), Univ Bordeaux, Ctr Rech Cardiothorac Bordeaux, INSERM, U1045, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	thomas.trian@u-bordeaux.fr	Dupin, Isabelle/ABE-7780-2020; Berger, Patrick/D-8779-2012	Dupin, Isabelle/0000-0002-4992-9625; Berger, Patrick/0000-0003-4702-0343; trian, thomas/0000-0002-2567-4867; Girodet, Pierre-Olivier/0000-0002-9298-9711; thumerel, matthieu/0000-0003-4673-8433; Allard, Benoit/0000-0002-7093-5851; Marthan, Roger/0000-0001-5412-5712	Agence Nationale de la Recherche [2010 CESA 001 01 [2010-0145], ANR-12-BSV1-0023-03]	Agence Nationale de la Recherche(French National Research Agency (ANR))	Supported by grants from the Agence Nationale de la Recherche (no. 2010 CESA 001 01 [2010-0145] and ANR-12-BSV1-0023-03). T.T. was funded by the Agence Nationale de la Recherche (no. 2010 CESA 001 01 [2010-0145]).	Abriss B, 2003, J HEPATOL, V38, P169, DOI 10.1016/S0168-8278(02)00361-6; Allard B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086945; Aquilano K, 2013, ANTIOXID REDOX SIGN, V18, P386, DOI 10.1089/ars.2012.4615; Avery-Kiejda KA, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-203; Bara I, 2010, EUR RESPIR J, V36, P1174, DOI 10.1183/09031936.00019810; Bara I, 2012, AM J RESP CRIT CARE, V185, P715, DOI 10.1164/rccm.201105-0915OC; Battersby BJ, 2013, J CELL SCI, V126, P4331, DOI 10.1242/jcs.131888; Begueret H, 2007, THORAX, V62, P8, DOI 10.1136/thx.2006.062141; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Boesten LSM, 2006, CELL DEATH DIFFER, V13, P2089, DOI 10.1038/sj.cdd.4401973; Brosh R, 2010, MOL BIOSYST, V6, P17, DOI 10.1039/b911416e; Chan KC, 2008, PHARMACOL RES, V58, P247, DOI 10.1016/j.phrs.2008.08.005; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Fister S, 2009, CANCER RES, V69, P6473, DOI 10.1158/0008-5472.CAN-08-4657; Girodet PO, 2010, ALLERGY, V65, P1004, DOI 10.1111/j.1398-9995.2009.02308.x; Girodet PO, 2015, AM J RESP CRIT CARE, V191, P876, DOI 10.1164/rccm.201410-1874OC; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Hsieh JK, 2000, ARTERIOSCL THROM VAS, V20, P973, DOI 10.1161/01.ATV.20.4.973; Jiang WD, 2010, INT J CANCER, V127, P1011, DOI 10.1002/ijc.25118; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; Kaminska M, 2009, J ALLERGY CLIN IMMUN, V124, P45, DOI 10.1016/j.jaci.2009.03.049; Lee CH, 2011, AM J PATHOL, V178, P2066, DOI 10.1016/j.ajpath.2011.01.056; Liang YY, 2014, CELL CYCLE, V13, P1440, DOI 10.4161/cc.28416; Maitre M, 2011, J NEUROSCI METH, V198, P204, DOI 10.1016/j.jneumeth.2011.04.001; Masuo T, 2009, CANCER LETT, V285, P66, DOI 10.1016/j.canlet.2009.05.001; Montano X, 2009, ONCOGENE, V28, P3787, DOI 10.1038/onc.2009.143; Peng X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097283; Petersson F, 2002, DIGEST DIS SCI, V47, P1558, DOI 10.1023/A:1015938303993; Ramos-Barbon D, 2010, AM J RESP CRIT CARE, V182, P317, DOI 10.1164/rccm.200905-0745OC; Rao JJ, 2012, MOL CELL BIOCHEM, V367, P9, DOI 10.1007/s11010-012-1313-z; Rundle CH, 2008, BONE, V43, P880, DOI 10.1016/j.bone.2008.07.239; Sahin E, 2011, NATURE, V470, P359, DOI 10.1038/nature09787; Saleem A, 2013, J PHYSIOL-LONDON, V591, P3625, DOI 10.1113/jphysiol.2013.252791; Saleem A, 2009, PHYSIOL GENOMICS, V37, P58, DOI 10.1152/physiolgenomics.90346.2008; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Trian T, 2006, AM J RESP CELL MOL, V34, P49, DOI 10.1165/rcmb.2005-0187OC; Trian T, 2007, J EXP MED, V204, P3173, DOI 10.1084/jem.20070956; Trian T, 2015, AM J RESP CRIT CARE, V191, P538, DOI 10.1164/rccm.201409-1582OC; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Villeneuve C, 2013, ANTIOXID REDOX SIGN, V18, P5, DOI 10.1089/ars.2011.4373; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Yazici AC, 2007, J DERMATOL, V34, P367, DOI 10.1111/j.1346-8138.2007.00290.x; Zhang EB, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.201	45	18	19	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1717	+		10.1016/j.jaci.2015.10.031	http://dx.doi.org/10.1016/j.jaci.2015.10.031			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26688517	Bronze			2022-12-18	WOS:000377527200011
J	Howrylak, JA; Moll, M; Weiss, ST; Raby, BA; Wu, W; Xing, EP				Howrylak, Judie A.; Moll, Matthew; Weiss, Scott T.; Raby, Benjamin A.; Wu, Wei; Xing, Eric P.			Gene expression profiling of asthma phenotypes demonstrates molecular signatures of atopy and asthma control	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood asthma; asthma phenotypes; gene expression profiling; microarray analysis; longitudinal study	CHILDHOOD ASTHMA; RESISTANCE; IDENTIFICATION; RECEPTOR	Background: Recent studies have used cluster analysis to identify phenotypic clusters of asthma with differences in clinical traits, as well as differences in response to therapy with anti-inflammatory medications. However, the correspondence between different phenotypic clusters and differences in the underlying molecular mechanisms of asthma pathogenesis remains unclear. Objective: We sought to determine whether clinical differences among children with asthma in different phenotypic clusters corresponded to differences in levels of gene expression. Methods: We explored differences in gene expression profiles of CD4(+) lymphocytes isolated from the peripheral blood of 299 young adult participants in the Childhood Asthma Management Program study. We obtained gene expression profiles from study subjects between 9 and 14 years of age after they participated in a randomized, controlled longitudinal study examining the effects of inhaled anti-inflammatory medications over a 48-month study period, and we evaluated the correspondence between our earlier phenotypic cluster analysis and subsequent follow-up clinical and molecular profiles. Results: We found that differences in clinical characteristics observed between subjects assigned to different phenotypic clusters persisted into young adulthood and that these clinical differences were associated with differences in gene expression patterns between subjects in different clusters. We identified a subset of genes associated with atopic status, validated the presence of an atopic signature among these genes in an independent cohort of asthmatic subjects, and identified the presence of common transcription factor binding sites corresponding to glucocorticoid receptor binding. Conclusion: These findings suggest that phenotypic clusters are associated with differences in the underlying pathobiology of asthma. Further experiments are necessary to confirm these findings.	[Howrylak, Judie A.] Penn State Milton S Hershey Med Ctr, Dept Med, Div Pulm Allergy & Crit Care Med, Hershey, PA USA; [Moll, Matthew] Boston Univ, Dept Med, Boston, MA 02215 USA; [Weiss, Scott T.; Raby, Benjamin A.] Harvard Univ, Sch Med, Boston, MA USA; [Weiss, Scott T.; Raby, Benjamin A.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Weiss, Scott T.; Raby, Benjamin A.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Wu, Wei] Carnegie Mellon Univ, Sch Comp Sci, Computat Biol Dept, Pittsburgh, PA 15213 USA; [Xing, Eric P.] Carnegie Mellon Univ, Sch Comp Sci, Dept Machine Learning, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Boston University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Carnegie Mellon University; Carnegie Mellon University	Howrylak, JA (corresponding author), Penn State Hershey Med Ctr, Dept Med, 500 Univ Dr, Hershey, PA 17033 USA.	jhowrylak@hmc.psu.edu	Moll, Matthew/AAB-4542-2020; Raby, Benjamin/AAK-3866-2021	Moll, Matthew/0000-0002-0683-0975	National Heart, Lung, and Blood Institute/National Institutes of Health (NIH/NHLBI) [R01 HL086601]; NIH/and NHLBI [U01 HL075419, U01 HL65899, P01 HL083069, T32 HL07427]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002014, KL2TR002015] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007427, R01HL086601, U01HL065899, P01HL083069, U01HL075419] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM093156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P30DA035778] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute/National Institutes of Health (NIH/NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/and NHLBI; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Supported by grant R01 HL086601 from the National Heart, Lung, and Blood Institute/National Institutes of Health (NIH/NHLBI). The Childhood Asthma Management Program Genetics Ancillary Study is supported by U01 HL075419, U01 HL65899, P01 HL083069, and T32 HL07427 from the NIH/and NHLBI.	Adcock IM, 2008, CURR ALLERGY ASTHM R, V8, P171, DOI 10.1007/s11882-008-0028-4; [Anonymous], 1999, MATH STAT; Auerbach RK, 2013, BIOINFORMATICS, V29, P1922, DOI 10.1093/bioinformatics/btt316; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Barnes PJ, 2013, J ALLERGY CLIN IMMUN, V131, P636, DOI 10.1016/j.jaci.2012.12.1564; Barnes PJ, 2010, J STEROID BIOCHEM, V120, P76, DOI 10.1016/j.jsbmb.2010.02.018; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boudier A, 2013, AM J RESP CRIT CARE, V188, P550, DOI 10.1164/rccm.201301-0156OC; Chambers J, 1999, J VIROL, V73, P5757, DOI 10.1128/JVI.73.7.5757-5766.1999; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Covar RA, 2012, CURR PULMONOL REP, V1, P243, DOI 10.1007/s13665-012-0026-9; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Gonzalez P, 1999, BIOTECHNIQUES, V26, P884, DOI 10.2144/99265st01; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Howrylak JA, 2014, J ALLERGY CLIN IMMUN, V133, P1289, DOI 10.1016/j.jaci.2014.02.006; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Kendziorski CM, 2006, BIOMETRICS, V62, P19, DOI 10.1111/j.1541-0420.2005.00437.x; Kendziorski CM, 2003, STAT MED, V22, P3899, DOI 10.1002/sim.1548; Li LB, 2010, AM J RESP CRIT CARE, V182, P877, DOI 10.1164/rccm.201001-0015OC; Mobini R, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-19; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Murphy A, 2010, HUM MOL GENET, V19, P4745, DOI 10.1093/hmg/ddq392; Newton MA, 2004, BIOSTATISTICS, V5, P155, DOI 10.1093/biostatistics/5.2.155; Newton MA, 2001, J COMPUT BIOL, V8, P37, DOI 10.1089/106652701300099074; NEWTON MA, 2003, ANAL GENE EXPRESSION; Olshen R., 1984, CLASSIFICATION REGRE; Ripley BD., 1996; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yuan M, 2006, BIOMETRICS, V62, P1089, DOI 10.1111/j.1541-0420.2006.00611.x; Zorn E, 2004, J EXP MED, V199, P1133, DOI 10.1084/jem.20031560	36	18	19	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1390	+		10.1016/j.jaci.2015.09.058	http://dx.doi.org/10.1016/j.jaci.2015.09.058			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26792209	Bronze, Green Accepted			2022-12-18	WOS:000376180200013
J	MacGlashan, D; Hamilton, RG				MacGlashan, Donald, Jr.; Hamilton, Robert G.			Parameters determining the efficacy of CD32 to inhibit activation of Fc epsilon RI in human basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GAMMA; RECEPTORS		[MacGlashan, Donald, Jr.; Hamilton, Robert G.] Johns Hopkins Asthma & Allergy Ctr, Dept Med, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine	MacGlashan, D (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Dept Med, Baltimore, MD USA.	dmacglas@jhmi.edu			NIAID NIH HHS [AI100952, R56 AI100952, U01 AI100952] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI100952, U01AI100952] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cady CT, 2010, IMMUNOL LETT, V130, P57, DOI 10.1016/j.imlet.2009.12.001; Cassard L, 2012, J IMMUNOL, V189, P2995, DOI 10.4049/jimmunol.1200968; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Li XL, 2003, ARTHRITIS RHEUM, V48, P3242, DOI 10.1002/art.11313; MacGlashan D, 2014, CLIN EXP ALLERGY, V44, P713, DOI 10.1111/cea.12155; Stenius F, 2011, ALLERGY, V66, P1330, DOI 10.1111/j.1398-9995.2011.02662.x; Stenius F, 2010, PSYCHONEUROENDOCRINO, V35, P1431, DOI 10.1016/j.psyneuen.2010.05.010; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; WARMERDAM PAM, 1991, J IMMUNOL, V147, P1338	10	18	18	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1256	+		10.1016/j.jaci.2015.10.043	http://dx.doi.org/10.1016/j.jaci.2015.10.043			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26774660	Green Accepted, Bronze			2022-12-18	WOS:000373351200037
J	Esnault, S; Kelly, EA; Sorkness, RL; Evans, MD; Busse, WW; Jarjour, NN				Esnault, Stephane; Kelly, Elizabeth A.; Sorkness, Ronald L.; Evans, Michael D.; Busse, William W.; Jarjour, Nizar N.			Airway factor XIII associates with type 2 inflammation and airway obstruction in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Factor XIII; asthma; severe asthma; allergy; pulmonary function; airway obstruction; air trapping; inflammation; eosinophils; IL-13	BRONCHOALVEOLAR LAVAGE FLUID; DENDRITIC CELL SUBSETS; HUMAN EOSINOPHILS; ALLERGEN CHALLENGE; BLOOD-COAGULATION; HUMAN-MONOCYTES; CROSS-LINKING; EXPRESSION; ACTIVATION; CYTOKINES	Background: Coagulation Factor XIII (FXIII) plays an important role in wound healing by stabilizing fibrin clots and cross-linking extracellular matrix proteins. FXIII is expressed in cells of the monocyte/macrophage and dendritic cell lineages in response to type 2 cytokines. Objective: We sought to determine the association between FXIII and asthma pathobiology. Methods: We analyzed the expression of FXIII mRNA and protein levels in bronchoalveolar lavage samples obtained before and after segmental allergen challenge from patients with mild asthma and in induced sputum samples collected from patients with mild-to-moderate and severe asthma. Results: FXIII mRNA and protein levels were highly upregulated in bronchoalveolar cells and fluid after allergen challenge and mRNA levels correlated with protein levels. In sputum of asthmatic patients, FXIII expression was positively correlated with type 2 immune response and dendritic cell markers (CD209 and CD207). FXIII expression was also associated with increased airflow limitation (FEV1/forced vital capacity and residual volume/total lung capacity ratios) and greater reversibility to beta-agonists. Conclusions: FXIII expression was upregulated in the airways of asthmatic patients after allergen exposure. Expression in the sputum of asthmatic patients correlated with the type 2 immune response and airflow limitation. Excessive activity of FXIII could contribute to the pathophysiology of airway obstruction in asthmatic patients.	[Esnault, Stephane; Kelly, Elizabeth A.; Busse, William W.; Jarjour, Nizar N.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Allergy Pulm & Crit Care Med, 600 Highland Ave,CSC K4-928, Madison, WI 53792 USA; [Sorkness, Ronald L.] Univ Wisconsin, Sch Med & Publ Hlth, Sch Pharm, Madison, WI 53792 USA; [Evans, Michael D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jarjour, NN (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Allergy Pulm & Crit Care Med, 600 Highland Ave,CSC K4-928, Madison, WI 53792 USA.	nnj@medicine.wisc.edu	Esnault, Stephane/AAJ-4511-2020; Esnault, Stephane/AAO-4712-2020	Esnault, Stephane/0000-0001-7238-8671; Busse, William/0000-0003-2591-4696; Kelly, Elizabeth/0000-0001-7335-6698; Evans, Michael/0000-0001-7449-3993	Asthma Research Program Grants from the National Institutes of Health [R01 HL069116, U10 HL109168]; Program Project Grant from the National Institutes of Health [P01 HL088594]; Clinical and Translational Research Center Grants from the National Institutes of Health [UL1 RR025011, UL1 TR000427]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL088594, U10HL109168, R01HL069116] Funding Source: NIH RePORTER	Asthma Research Program Grants from the National Institutes of Health; Program Project Grant from the National Institutes of Health; Clinical and Translational Research Center Grants from the National Institutes of Health; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by Severe Asthma Research Program Grants R01 HL069116 and U10 HL109168, Program Project Grant P01 HL088594, and Clinical and Translational Research Center Grants UL1 RR025011 and UL1 TR000427 from the National Institutes of Health.	Adany R, 1996, THROMB HAEMOSTASIS, V76, P74; Al-Muhsen S, 2011, J ALLERGY CLIN IMMUN, V128, P451, DOI 10.1016/j.jaci.2011.04.047; BARRY ELR, 1990, J BIOL CHEM, V265, P9302; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Bratke K, 2007, THORAX, V62, P168, DOI 10.1136/thx.2006.067793; Brims FJH, 2009, THORAX, V64, P1037, DOI 10.1136/thx.2009.114439; Brogan TV, 2002, PEDIATR PULM, V34, P482, DOI 10.1002/ppul.10179; Buechler C, 2000, J LEUKOCYTE BIOL, V67, P97, DOI 10.1002/jlb.67.1.97; Cagnoni EF, 2015, J ALLERGY CLIN IMMUN, V135, P1352, DOI 10.1016/j.jaci.2014.08.021; Chaitidis P, 2005, CYTOKINE, V30, P366, DOI 10.1016/j.cyto.2005.02.004; Chambers RC, 2008, BRIT J PHARMACOL, V153, pS367, DOI 10.1038/sj.bjp.0707603; Dardik R, 2007, CELL PHYSIOL BIOCHEM, V19, P113, DOI 10.1159/000099199; de Boer JD, 2012, BLOOD, V119, P3236, DOI 10.1182/blood-2011-11-391532; Denlinger LC, 2011, AM J RESP CRIT CARE, V184, P1007, DOI 10.1164/rccm.201103-0585OC; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Esnault S, 2012, CLIN EXP ALLERGY, V42, P1756, DOI 10.1111/j.1365-2222.2012.04060.x; Esnault S, 2014, CLIN IMMUNOL, V150, P90, DOI 10.1016/j.clim.2013.11.009; Esnault S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067560; Fukuda T, 1995, J ALLERGY CLIN IMMUN, V96, P1076, DOI 10.1016/S0091-6749(95)70193-1; Gabazza EC, 1999, LUNG, V177, P253, DOI 10.1007/PL00007645; Gern JE, 2000, AM J RESP CRIT CARE, V162, P2226, DOI 10.1164/ajrccm.162.6.2003019; Gill MA, 2012, J ALLERGY CLIN IMMUN, V129, P889, DOI 10.1016/j.jaci.2012.02.028; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Jayo A, 2009, EUR J CELL BIOL, V88, P423, DOI 10.1016/j.ejcb.2009.04.002; Katona L, 2005, J THROMB HAEMOST, V3, P1407, DOI 10.1111/j.1538-7836.2005.01353.x; Kelly EAB, 2012, CYTOKINE, V58, P199, DOI 10.1016/j.cyto.2012.01.009; Kelly HW, 2009, ANN PHARMACOTHER, V43, P519, DOI 10.1345/aph.1L546; Liu LY, 2007, J IMMUNOL, V179, P4840, DOI 10.4049/jimmunol.179.7.4840; Liu LY, 2006, ALLERGY, V61, P589, DOI 10.1111/j.1398-9995.2006.01060.x; Liu LY, 2002, J IMMUNOL, V169, P6452, DOI 10.4049/jimmunol.169.11.6452; Meerschaert J, 1999, AM J RESP CRIT CARE, V159, P619, DOI 10.1164/ajrccm.159.2.9806053; MUSZBEK L, 1985, THROMB RES, V37, P401, DOI 10.1016/0049-3848(85)90069-6; Muszbek L, 2011, PHYSIOL REV, V91, P931, DOI 10.1152/physrev.00016.2010; Muszbek L, 2010, SEMIN THROMB HEMOST, V36, P18, DOI 10.1055/s-0030-1248721; NEMETH AJ, 1988, J AM ACAD DERMATOL, V19, P1102, DOI 10.1016/S0190-9622(88)70279-0; NESTLE FO, 1994, J CLIN INVEST, V94, P202, DOI 10.1172/JCI117308; PAYE M, 1991, BIOCHIM BIOPHYS ACTA, V1073, P437, DOI 10.1016/0304-4165(91)90212-Y; POLGAR J, 1990, BIOCHEM J, V267, P557, DOI 10.1042/bj2670557; Richardson VR, 2013, CLIN SCI, V124, P123, DOI 10.1042/CS20120233; Sarvary A, 2004, CELL IMMUNOL, V228, P81, DOI 10.1016/j.cellimm.2004.04.007; Seear M, 1997, AM J RESP CRIT CARE, V155, P364, DOI 10.1164/ajrccm.155.1.9001337; Sharma S, 2014, J ALLERGY CLIN IMMUN, V134, P1153, DOI 10.1016/j.jaci.2014.04.011; Shifren Adrian, 2012, J Allergy (Cairo), V2012, P316049, DOI 10.1155/2012/316049; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Sotto MN, 2010, AM J DERMATOPATH, V32, P15, DOI 10.1097/DAD.0b013e3181ab4695; Takabayashi T, 2013, J ALLERGY CLIN IMMUN, V132, P584, DOI 10.1016/j.jaci.2013.02.003; Terada M, 2004, AM J RESP CRIT CARE, V169, P373, DOI 10.1164/rccm.200308-1156OC; Torocsik D, 2005, CELL MOL LIFE SCI, V62, P2132, DOI 10.1007/s00018-005-5242-9; Ueno H, 2007, IMMUNOL REV, V219, P118, DOI 10.1111/j.1600-065X.2007.00551.x; Van den Heuvel MM, 1999, J LEUKOCYTE BIOL, V66, P858, DOI 10.1002/jlb.66.5.858; Wagers SS, 2004, J CLIN INVEST, V114, P104, DOI 10.1172/JCI200419569	52	18	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					767	+		10.1016/j.jaci.2015.05.053	http://dx.doi.org/10.1016/j.jaci.2015.05.053			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26525229	Green Accepted, Bronze			2022-12-18	WOS:000371897500019
J	Francuzik, W; Nassiri, M; Babina, M; Worm, M				Francuzik, Wojciech; Nassiri, Maria; Babina, Magda; Worm, Margitta			Impact of sex on anaphylaxis severity-data from the Anaphylaxis Registry	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Francuzik, Wojciech; Nassiri, Maria; Babina, Magda; Worm, Margitta] Charite, Dept Dermatol & Allergy, Allergy Ctr Charite, CCM, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Francuzik, W (corresponding author), Charite, Dept Dermatol & Allergy, Allergy Ctr Charite, CCM, D-13353 Berlin, Germany.	Margitta.Worm@charite.de	Francuzik, Wojciech/H-6773-2019	Francuzik, Wojciech/0000-0001-5361-9876; Worm, Margitta/0000-0002-3449-1245; Babina, Magda/0000-0002-4500-7615				Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Hox V, 2015, J ALLERGY CLIN IMMUN, V135, P729, DOI 10.1016/j.jaci.2014.11.003; Nassiri M, 2015, J ALLERGY CLIN IMMUN, V135, P491, DOI 10.1016/j.jaci.2014.09.004; RING J, 1977, LANCET, V1, P466; Webb LM, 2006, ANN ALLERG ASTHMA IM, V97, P39, DOI 10.1016/S1081-1206(10)61367-1; Worm M, 2012, ALLERGY, V67, P691, DOI 10.1111/j.1398-9995.2012.02795.x	6	18	18	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1425	1426		10.1016/j.jaci.2015.06.052	http://dx.doi.org/10.1016/j.jaci.2015.06.052			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26392054	Bronze			2022-12-18	WOS:000364787200042
J	Erbas, B; Dharmage, SC; Tang, MLK; Akram, M; Allen, KJ; Vicendese, D; Davies, JM; Hyndman, RJ; Newbigin, EJ; Taylor, PE; Bardin, PG; Abramson, MJ				Erbas, Bircan; Dharmage, Shyamali C.; Tang, Mimi L. K.; Akram, Muhammad; Allen, Katrina J.; Vicendese, Don; Davies, Janet M.; Hyndman, Rob J.; Newbigin, Ed J.; Taylor, Philip E.; Bardin, Philip G.; Abramson, Michael J.			Do human rhinovirus infections and food allergy modify grass pollen-induced asthma hospital admissions in children?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GENOME-WIDE ASSOCIATION; RISK-FACTORS; CHILDHOOD; EXACERBATIONS; SENSITIZATION; IMPUTATION; ADMIXTURE; SELECTION; ANCESTRY		[Erbas, Bircan; Vicendese, Don] La Trobe Univ, Sch Publ Hlth & Human Biosci, Bundoora, Vic 3086, Australia; [Dharmage, Shyamali C.] Univ Melbourne, Sch Populat Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic 3010, Australia; [Tang, Mimi L. K.] Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia; [Tang, Mimi L. K.] Univ Melbourne, Murdoch Childrens Res Inst, Dept Allergy & Immune Dis, Melbourne, Vic 3010, Australia; [Tang, Mimi L. K.] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia; [Akram, Muhammad; Abramson, Michael J.] Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, Clayton, Vic 3800, Australia; [Allen, Katrina J.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Gastro & Food Allergy, Melbourne, Vic, Australia; [Davies, Janet M.] Univ Queensland, Sch Med, Brisbane, Qld, Australia; [Davies, Janet M.] Univ Queensland, Translat Res Inst, Brisbane, Qld, Australia; [Hyndman, Rob J.] Monash Univ, Dept Econometr & Business Stat, Clayton, Vic 3800, Australia; [Newbigin, Ed J.] Univ Melbourne, Sch Bot, Melbourne, Vic 3010, Australia; [Taylor, Philip E.] Deakin Univ, Sch Life & Environm Sci, Geelong, Vic 3217, Australia; [Bardin, Philip G.] Monash Med Ctr, Dept Resp & Sleep Med, Melbourne, Vic, Australia	La Trobe University; University of Melbourne; Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; Monash University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Queensland; University of Queensland; Monash University; University of Melbourne; Deakin University; Monash University	Erbas, B (corresponding author), La Trobe Univ, Sch Publ Hlth & Human Biosci, Bundoora, Vic 3086, Australia.	b.erbas@latrobe.edu.au	Allen, Katrina/I-4361-2018; Tang, Mimi/ABD-8350-2020; Abramson, Michael/AAQ-2671-2020; Hyndman, Rob/A-2268-2008	Allen, Katrina/0000-0002-1921-4493; Tang, Mimi/0000-0002-3839-5293; Abramson, Michael/0000-0002-9954-0538; Newbigin, Ed/0000-0002-9644-302X; Vicendese, Don/0000-0002-0176-0314; Akram, Muhammad/0000-0003-1073-3614; Hyndman, Rob/0000-0002-2140-5352; Davies, Janet/0000-0002-6378-4119				Albertine JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111712; Alexander DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/gr.094052.109; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; de Jong AB, 2011, PEDIAT ALLERG IMM-UK, V22, P166, DOI 10.1111/j.1399-3038.2010.00993.x; Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]; Delaneau O, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-540; Erbas B, 2012, CLIN EXP ALLERGY, V42, P799, DOI 10.1111/j.1365-2222.2012.03995.x; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Galanter JM, 2014, J ALLERGY CLIN IMMUN, V134, P295, DOI 10.1016/j.jaci.2013.08.055; Ghunaim N, 2006, CLIN EXP ALLERGY, V36, P722, DOI 10.1111/j.1365-2222.2006.02489.x; Gonzalez JR, 2007, BIOINFORMATICS, V23, P644, DOI 10.1093/bioinformatics/btm025; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; Han B, 2011, AM J HUM GENET, V88, P586, DOI 10.1016/j.ajhg.2011.04.014; Hoffmann TJ, 2011, GENOMICS, V98, P422, DOI 10.1016/j.ygeno.2011.08.007; Howie B, 2012, NAT GENET, V44, P955, DOI 10.1038/ng.2354; Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529; Huang L, 2009, AM J HUM GENET, V85, P692, DOI 10.1016/j.ajhg.2009.09.017; Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Nishimura KK, 2013, AM J RESP CRIT CARE, V188, P309, DOI 10.1164/rccm.201302-0264OC; Pino-Yanes MI, 2014, J ALLERGY CLIN IMMUN, V134, P1201, DOI 10.1016/j.jaci.2014.05.031; Pino-Yanes M, 2012, J ALLERGY CLIN IMMUN, V129, P573, DOI 10.1016/j.jaci.2011.10.001; Pino-Yanes M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018389; Price AL, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0030236; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419; Rawlinson WD, 2003, J INFECT DIS, V187, P1314, DOI 10.1086/368411; Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172; Sears MR, 2008, J ALLERGY CLIN IMMUN, V122, P662, DOI 10.1016/j.jaci.2008.08.003; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Sun X, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Sun XG, 2010, J ALLERGY CLIN IMMUN, V126, P241, DOI 10.1016/j.jaci.2010.04.036; Torgerson DG, 2012, J ALLERGY CLIN IMMUN, V130, P76, DOI 10.1016/j.jaci.2012.02.040; TURNER DJ, 1995, AM J RESP CRIT CARE, V151, P1441, DOI 10.1164/ajrccm.151.5.7735598; Vicendese D., 2013, OPEN J EPIDEMIOL, V3, P125, DOI [10.4236/ojepi.2013.33019, DOI 10.4236/OJEPI.2013.33019]; Weale ME, 2003, AM J HUM GENET, V73, P551, DOI 10.1086/378098	39	18	18	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1118	1120		10.1016/j.jaci.2015.04.030	http://dx.doi.org/10.1016/j.jaci.2015.04.030			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	26048665				2022-12-18	WOS:000362976300040
J	Thysen, AH; Larsen, JM; Rasmussen, MA; Stokholm, J; Bonnelykke, K; Bisgaard, H; Brix, S				Thysen, Anna Hammerich; Larsen, Jeppe Madura; Rasmussen, Morten Arendt; Stokholm, Jakob; Bonnelykke, Klaus; Bisgaard, Hans; Brix, Susanne			Prelabor cesarean section bypasses natural immune cell maturation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGIC DISEASES; DISORDERS; DELIVERY; LIFE		[Thysen, Anna Hammerich; Rasmussen, Morten Arendt; Stokholm, Jakob; Bonnelykke, Klaus; Bisgaard, Hans] Univ Copenhagen, Copenhagen Prospect Studies Asthma Childhood, Fac Hlth & Med Sci, Copenhagen, Denmark; [Thysen, Anna Hammerich; Rasmussen, Morten Arendt; Stokholm, Jakob; Bonnelykke, Klaus; Bisgaard, Hans] Univ Copenhagen, Gentofte Hosp, Copenhagen, Denmark; [Thysen, Anna Hammerich; Larsen, Jeppe Madura; Brix, Susanne] Tech Univ Denmark, Dept Syst Biol, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark; [Rasmussen, Morten Arendt] Univ Copenhagen, Spect & Chemometr, Dept Food Sci, Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; Technical University of Denmark; University of Copenhagen	Thysen, AH (corresponding author), Univ Copenhagen, Copenhagen Prospect Studies Asthma Childhood, Fac Hlth & Med Sci, Copenhagen, Denmark.	bisgaard@copsac.com	Arendt, Morten/S-8843-2017; Rasmussen, Morten/AAE-9517-2020; Pedersen, Susanne Brix/B-3484-2009; Larsen, Jeppe Madura/K-6518-2019; Bisgaard, Hans/N-4761-2016	Arendt, Morten/0000-0001-7431-5206; Rasmussen, Morten/0000-0001-7431-5206; Pedersen, Susanne Brix/0000-0001-8951-6705; Larsen, Jeppe Madura/0000-0003-1492-0708; Bisgaard, Hans/0000-0003-4131-7592; Thysen, Anna Hammerich/0000-0002-2914-1099; Stokholm, Jakob/0000-0003-4989-9769; Bonnelykke, Klaus/0000-0003-2003-1018				Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Betran AP, 2007, PAEDIATR PERINAT EP, V21, P98, DOI 10.1111/j.1365-3016.2007.00786.x; Bisgaard H, 2013, CLIN EXP ALLERGY, V43, P1384, DOI 10.1111/cea.12213; Cho CE, 2013, AM J OBSTET GYNECOL, V208, P249, DOI 10.1016/j.ajog.2012.08.009; Ferreira-Valente MA, 2011, PAIN, V152, P2399, DOI 10.1016/j.pain.2011.07.005; Prescott SL, 2013, J ALLERGY CLIN IMMUN, V131, P23, DOI 10.1016/j.jaci.2012.11.019; Robinson DP, 2012, HORM BEHAV, V62, P263, DOI 10.1016/j.yhbeh.2012.02.023; Romero R, 2013, AM J OBSTET GYNECOL, V208, P243, DOI 10.1016/j.ajog.2012.12.026; Sevelsted A, 2015, PEDIATRICS, V135, pE92, DOI 10.1542/peds.2014-0596; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027	10	18	18	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1123	1125		10.1016/j.jaci.2015.04.044	http://dx.doi.org/10.1016/j.jaci.2015.04.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	26094084	Bronze			2022-12-18	WOS:000362976300042
J	Maggadottir, SM; Li, J; Glessner, JT; Li, YR; Wei, Z; Chang, X; Mentch, FD; Thomas, KA; Kim, CE; Zhao, Y; Hou, CP; Wang, FX; Jorgensen, SF; Perez, EE; Sullivan, KE; Orange, JS; Karlsen, TH; Chapel, H; Cunningham-Rundles, C; Hakonarson, H				Maggadottir, S. Melkorka; Li, Jin; Glessner, Joseph T.; Li, Yun Rose; Wei, Zhi; Chang, Xiao; Mentch, Frank D.; Thomas, Kelly A.; Kim, Cecilia E.; Zhao, Yan; Hou, Cuiping; Wang, Fengxiang; Jorgensen, Silje F.; Perez, Elena E.; Sullivan, Kathleen E.; Orange, Jordan S.; Karlsen, Tom H.; Chapel, Helen; Cunningham-Rundles, Charlotte; Hakonarson, Hakon			Rare variants at 16p11.2 are associated with common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunodeficiency; immunogenetics; genome-wide association study; ITGAM; rare variants	SYSTEMIC-LUPUS-ERYTHEMATOSUS; AMYOTROPHIC-LATERAL-SCLEROSIS; ANTIBODY-DEFICIENCY SYNDROME; GENOME-WIDE ASSOCIATION; NF-KAPPA-B; COMPLEMENT RECEPTOR-3; T-CELLS; FUNCTIONAL VARIANT; CRITICAL REGULATOR; DENDRITIC CELLS	Background: Common variable immunodeficiency (CVID) is characterized clinically by inadequate quantity and quality of serum immunoglobulins with increased susceptibility to infections, resulting in significant morbidity and mortality. Only a few genes have been uncovered, and the genetic background of CVID remains elusive to date for the majority of patients. Objective: We sought to seek novel associations of genes and genetic variants with CVID. Methods: We performed association analyses in a discovery cohort of 164 patients with CVID and 19,542 healthy control subjects genotyped on the Immuno Bead Chip from Il lumina platform; replication of findings was examined in an independent cohort of 135 patients with CVID and 2,066 healthy control subjects, followed by meta-analysis. Results: We identified 11 single nucleotide polymorphisms (SNPs) at the 16p11.2 locus associated with CVID at a genome- wide significant level in the discovery cohort. The most significant SNP, rs929867 (P = 6.21 x 10(-9)), is in the gene fused-in-sarcoma (FUS), with 4 other SNPs mapping to integrin CD11b (ITGAM). Results were confirmed in our replication cohort. Conditional association analysis suggests a single association signal at the 16p11.2 locus. A strong trend of association was also seen for 38 SNPs (P < 5 x 10(-5)) in the MHC region, supporting that this is a genuine CVID locus. Interestingly, we found that 80% of patients with the rare ITGAM variants have reduced switched memory B-cell counts. Conclusion: We report a novel association of CVID with rare variants at the FUSIITGAM (CD11b) locus on 16p11.2. The association signal is enriched for promoter/enhancer markers in the ITGAM gene. ITGAM encodes the integrin CD11b, a part of complement receptor 3, a novel candidate gene implicated here for the first time in the pathogenesis of CVID.	[Maggadottir, S. Melkorka; Sullivan, Kathleen E.] Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA USA; [Maggadottir, S. Melkorka; Li, Jin; Glessner, Joseph T.; Li, Yun Rose; Chang, Xiao; Mentch, Frank D.; Thomas, Kelly A.; Kim, Cecilia E.; Zhao, Yan; Hou, Cuiping; Wang, Fengxiang; Hakonarson, Hakon] Childrens Hosp Philadelphia, Ctr Appl Genom, Abramson Res Ctr, Philadelphia, PA USA; [Hakonarson, Hakon] Childrens Hosp Philadelphia, Div Human Genet, Philadelphia, PA USA; [Wei, Zhi] New Jersey Inst Technol, Dept Comp Sci, Newark, NJ 07102 USA; [Jorgensen, Silje F.; Karlsen, Tom H.] Oslo Univ Hosp, Rikshosp, Div Canc Med Surg & Transplantat, Internal Med Res Inst,KG Jebsen Inflammat Res Ctr, N-0450 Oslo, Norway; [Perez, Elena E.] Univ S Florida, Dept Pediat, Div Rheumatol Allergy & Immunol, St Petersburg, FL USA; [Orange, Jordan S.] Texas Childrens Hosp, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA; [Chapel, Helen] Univ Oxford, Nuffield Dept Med, Oxford OX1 2JD, England; [Chapel, Helen] Oxford Radcliffe Hosp, Oxford, England; [Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, Inst Immunol, New York, NY USA; [Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, Dept Med, New York, NY USA; [Hakonarson, Hakon] Univ Penn, Perelman Sch Med Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; [Hakonarson, Hakon] Univ Penn, Perelman Sch Med Philadelphia, Med Scientist Training Program, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; New Jersey Institute of Technology; University of Oslo; National Hospital Norway; State University System of Florida; University of South Florida; Baylor College of Medicine; University of Oxford; University of Oxford; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Pennsylvania; University of Pennsylvania	Hakonarson, H (corresponding author), Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.	Hakonarson@email.chop.edu	Xiao, Chang/AAO-9713-2020; , AndyWei/H-4415-2012	Wei, Zhi/0000-0001-6059-4267; Li, Yun Rose/0000-0002-8077-4975; Maggadottir, Solrun Melkorka/0000-0001-5704-1995; Glessner, Joseph/0000-0001-5131-2811; orange, jordan/0000-0001-7117-7725	Institute Development Fund from CHOP [U01HG006830]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG006830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U24AI086037, P01AI061093, R18AI048693] Funding Source: NIH RePORTER	Institute Development Fund from CHOP; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by an Institute Development Fund from CHOP, U01HG006830, and a donation from the Kubert Estate Foundation.	Alexeyenko A, 2009, GENOME RES, V19, P1107, DOI 10.1101/gr.087528.108; Anaya JM, 2012, AUTOIMMUN REV, V11, P276, DOI 10.1016/j.autrev.2011.07.007; Araujo PR, 2012, COMP FUNCT GENOM, DOI 10.1155/2012/475731; Bacchelli C, 2007, CLIN EXP IMMUNOL, V149, P401, DOI 10.1111/j.1365-2249.2007.03461.x; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bai Y, 2012, J IMMUNOL, V188, P5293, DOI 10.4049/jimmunol.1102371; Baron DM, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-30; Bernstein BE, 2010, NAT BIOTECHNOL, V28, P1045, DOI 10.1038/nbt1010-1045; Cao CZ, 2010, J CLIN INVEST, V120, P1971, DOI 10.1172/JCI40380; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Chamary JV, 2006, NAT REV GENET, V7, P98, DOI 10.1038/nrg1770; Chapel H, 2009, BRIT J HAEMATOL, V145, P709, DOI 10.1111/j.1365-2141.2009.07669.x; Chen K, 2013, AM J HUM GENET, V93, P812, DOI 10.1016/j.ajhg.2013.09.009; Cortes A, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3204; Coustet B, 2011, J RHEUMATOL, V38, P1033, DOI 10.3899/jrheum.101053; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Dai ZP, 2009, J EXP MED, V206, P793, DOI 10.1084/jem.20081648; Delaneau O, 2013, NAT METHODS, V10, P5, DOI 10.1038/nmeth.2307; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Escobar D, 2010, CELL IMMUNOL, V262, P105, DOI 10.1016/j.cellimm.2010.01.002; Fossati-Jimack L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057082; Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094; Gao K, 2014, PARKINSONISM RELAT D, V20, P119, DOI 10.1016/j.parkreldis.2013.09.010; Garber M, 2009, BIOINFORMATICS, V25, pI54, DOI 10.1093/bioinformatics/btp190; Green MRJ, 2007, ARTHRITIS RHEUM-US, V56, P303, DOI 10.1002/art.22326; Griffin DO, 2011, J EXP MED, V208, P2591, DOI 10.1084/jem.20110978; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Hajishengallis G, 2007, FRONT BIOSCI-LANDMRK, V12, P4547, DOI 10.2741/2409; Han CF, 2010, NAT IMMUNOL, V11, P734, DOI 10.1038/ni.1908; Han SZ, 2009, HUM MOL GENET, V18, P1171, DOI 10.1093/hmg/ddp007; Harley JB, 2008, NAT GENET, V40, P204, DOI 10.1038/ng.81; Hom G, 2008, NEW ENGL J MED, V358, P900, DOI 10.1056/NEJMoa0707865; Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529; Huynh L, 2012, J IMMUNOL, V188, P3447, DOI 10.4049/jimmunol.1102211; Iguchi Y, 2013, J NEUROL, V260, P2917, DOI 10.1007/s00415-013-7112-y; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Kanegane H, 2007, GENES IMMUN, V8, P663, DOI 10.1038/sj.gene.6364431; Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308; Kuijpers TW, 2010, J CLIN INVEST, V120, P214, DOI 10.1172/JCI40231; Liu HF, 2007, GENE DEV, V21, P1179, DOI 10.1101/gad.1529307; MacPherson M, 2011, J BIOL CHEM, V286, P17303, DOI 10.1074/jbc.M110.182998; Maller JB, 2012, NAT GENET, V44, P1294, DOI 10.1038/ng.2435; Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088; Marth T, 1997, J EXP MED, V185, P1987, DOI 10.1084/jem.185.11.1987; McCarthy SE, 2009, NAT GENET, V41, P1223, DOI 10.1038/ng.474; Mignone F, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews0004; Nal JE., 2009, J ALLERGY CLIN IMMUN, V124, P340; Nal JE.KnightAK, 2009, J ALLERGY CLIN IMMUN, V124, pe1; Nath SK, 2008, NAT GENET, V40, P152, DOI 10.1038/ng.71; OLERUP O, 1992, P NATL ACAD SCI USA, V89, P10653, DOI 10.1073/pnas.89.22.10653; Ombrello MJ, 2012, NEW ENGL J MED, V366, P330, DOI 10.1056/NEJMoa1102140; Orange JS, 2011, J ALLERGY CLIN IMMUN, V127, P1360, DOI 10.1016/j.jaci.2011.02.039; Palmer ND, 2011, DIABETES, V60, P662, DOI 10.2337/db10-0134; Pan-Hammarstrom Q, 2007, NAT GENET, V39, P429, DOI 10.1038/ng0407-429; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Qi CF, 2003, P NATL ACAD SCI USA, V100, P633, DOI 10.1073/pnas.0237127100; Reed JH, 2013, J BIOL CHEM, V288, P9077, DOI 10.1074/jbc.M112.403303; Rhodes B, 2012, ANN RHEUM DIS, V71, P2028, DOI 10.1136/annrheumdis-2012-201390; Rosetti F, 2012, J IMMUNOL, V189, P3714, DOI 10.4049/jimmunol.1201594; Sachs UJH, 2004, BLOOD, V104, P727, DOI 10.1182/blood-2003-11-3809; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Salzer U, 2004, CLIN IMMUNOL, V113, P234, DOI 10.1016/j.clim.2004.07.002; Schmitt T, 2014, NUCLEIC ACIDS RES, V42, pD380, DOI 10.1093/nar/gkt984; Sekine H, 2007, P NATL ACAD SCI USA, V104, P7193, DOI 10.1073/pnas.0700815104; Shelkovnikova TA, 2013, CELL CYCLE, V12, P3194, DOI 10.4161/cc.26241; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Skoberne M, 2006, BLOOD, V108, P947, DOI 10.1182/blood-2005-12-4812; Snel B, 2000, NUCLEIC ACIDS RES, V28, P3442, DOI 10.1093/nar/28.18.3442; Trynka G, 2011, NAT GENET, V43, P1193, DOI 10.1038/ng.998; van Gisbergen KPJM, 2005, FEBS LETT, V579, P6159, DOI 10.1016/j.febslet.2005.09.089; van Gisbergen KPJM, 2005, J EXP MED, V201, P1281, DOI 10.1084/jem.20041276; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; van Zelm MC, 2010, J CLIN INVEST, V120, P1265, DOI 10.1172/JCI39748; VOLANAKIS JE, 1992, J CLIN INVEST, V89, P1914, DOI 10.1172/JCI115797; Wagner C, 2001, EUR J IMMUNOL, V31, P1173, DOI 10.1002/1521-4141(200104)31:4<1173::AID-IMMU1173>3.0.CO;2-9; Walters RG, 2010, NATURE, V463, P671, DOI 10.1038/nature08727; Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Weiss LA, 2008, NEW ENGL J MED, V358, P667, DOI 10.1056/NEJMoa075974; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Yang WL, 2009, HUM MOL GENET, V18, P2063, DOI 10.1093/hmg/ddp118; Yoshida Y, 1998, J IMMUNOL, V161, P5873; Zhou YB, 2013, ARTHRITIS RHEUM-US, V65, P2907, DOI 10.1002/art.38117	86	18	18	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1569	1577		10.1016/j.jaci.2014.12.1939	http://dx.doi.org/10.1016/j.jaci.2014.12.1939			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25678086	Green Accepted			2022-12-18	WOS:000355933400020
J	Patel, MR; Leo, HL; Baptist, AP; Cao, YY; Brown, RW				Patel, Minal R.; Leo, Harvey L.; Baptist, Alan P.; Cao, Yanyun; Brown, Randall W.			Asthma outcomes in children and adolescents with multiple morbidities: Findings from the National Health Interview Survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Outcomes; comorbidity; epidemiology; asthma; pediatrics	ADULTS; PREVALENCE; OBESITY	Background: More Americans are managing multiple chronic conditions (MCCs), and trends are particularly alarming in youth. Objective: The purpose of this study was to examine the prevalence and distribution of 9 chronic conditions in children and adolescents with and without asthma, and adverse asthma outcomes associated with having MCCs. Methods: Cross-sectional interview data from the National Health Interview Survey were analyzed (N = 66,790) between 2007 and 2012 in youth 0 to 17 years of age. Bivariate analysis methods and multivariate generalized linear regression were used to examine associations. Results: Five percent of children with asthma had 1 or more coexisting health conditions. The prevalence of 1 or more comorbidities was greater among those with asthma than those without (5.07% [95% CI: 4.5-5.6] vs 2.73% [95% CI: 2.6-2.9]). Those with asthma were twice as likely to have co-occurring hypertension (prevalence ratio [PR] 52.2 [95% CI: 1.5-3.2]) and arthritis (PR 5 2.7 [95% CI: 1.8-4.0]) compared with those without asthma. Every additional chronic condition with asthma was associated with a greater likelihood of an asthma attack (PR 5 1.1 [95% CI: 1.0-1.2]), all-cause emergency department visits (PR 5 1.3 [95% CI: 1.1-1.5]), and missed school days (PR 5 2.3 [95% CI: 1.7-3.2]). Conclusions: Children and adolescents with asthma in the US who suffer from MCCs have increased asthma symptoms, missed school days, and all-cause emergency department visits. Further research on optimal management strategies for this group is needed.	[Patel, Minal R.] Univ Michigan, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA; [Leo, Harvey L.; Baptist, Alan P.; Brown, Randall W.] Univ Michigan, Ctr Managing Chron Dis, Ann Arbor, MI 48109 USA; [Baptist, Alan P.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Cao, Yanyun] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; [Leo, Harvey L.] St Joseph Mercy Hosp, Ann Arbor, MI 48104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Saint Joseph Mercy Health System (SJMHS)	Patel, MR (corresponding author), Univ Michigan, Dept Hlth Behav & Hlth Educ, 1415 Washington Hts, Ann Arbor, MI 48109 USA.	minalrp@umich.edu		Patel, Minal/0000-0002-3400-5155	American Partnership for Eosinophilic Disorders; Teva	American Partnership for Eosinophilic Disorders; Teva(Teva Pharmaceutical Industries)	H. Leo has consultant arrangements with Sanofi and has received research support from the American Partnership for Eosinophilic Disorders. R. Brown has received payment for lectures from Teva. The rest of the authors declare that they have no relevant conflicts of interest.	Ali Z, 2013, RESP MED, V107, P1287, DOI 10.1016/j.rmed.2013.03.019; Aung T, 2010, CARDIOL J, V17, P443; Baptist AP, 2010, QUAL HEALTH RES, V20, P117, DOI 10.1177/1049732309355288; Bayliss EA, 2014, ANN FAM MED, V12, P260, DOI 10.1370/afm.1643; Berry JG, 2013, JAMA-J AM MED ASSOC, V309, P372, DOI 10.1001/jama.2012.188351; Bloom Barbara, 2011, Vital Health Stat 10, P1; Centers for Disease Control and Prevention, 2011, MMWR-MORBID MORTAL W, V60, P547; Centers for Disease Control and Prevention, 2014, BEST PRACT COMPR TOB; Centers for Disease Control and Prevention. National Center for Health Statistics, 2012, NAT HLTH INT SURV DA; Clark NM, 2010, J ASTHMA ALLERGY, V3, P187, DOI 10.2147/JAA.S14772; Evans GW, 2009, CHAOS CHILDRENS DEV; Goodman RA, 2013, PREV CHRONIC DIS, V10, DOI 10.5888/pcd10.120239; Kurowski EM, 2014, ACAD EMERG MED, V21, P778, DOI 10.1111/acem.12412; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; National Heart Blood and Lung Institute, 2007, 3 NIH NAT HEART BLOO; Neuman MI, 2014, PEDIATRICS, V134, P100, DOI 10.1542/peds.2014-0331; NEWACHECK PW, 1994, J PEDIATR-US, V124, P40, DOI 10.1016/S0022-3476(94)70252-7; Papoutsakis C, 2013, J ACAD NUTR DIET, V113, P77, DOI 10.1016/j.jand.2012.08.025; Patel Minal R, 2013, Ann Am Thorac Soc, V10, P426, DOI 10.1513/AnnalsATS.201302-032OC; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; US Department of Health and Human Services, 2010, MULT CHRON COND STRA; Van Cleave J, 2010, JAMA-J AM MED ASSOC, V303, P623, DOI 10.1001/jama.2010.104; Zenk SN, 2013, APPETITE, V65, P170, DOI 10.1016/j.appet.2013.02.008; Zhong W, 2014, J PRIM CARE COMMUNIT	24	18	18	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1444	1449		10.1016/j.jaci.2014.11.008	http://dx.doi.org/10.1016/j.jaci.2014.11.008			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25533524				2022-12-18	WOS:000355933400005
J	Arvinen, KMJ; Suarez-Farinas, M; Savilahti, E; Sampson, HA; Berin, MC				Arvinen, Kirsi M. J.; Suarez-Farinas, Mayte; Savilahti, Erkki; Sampson, Hugh A.; Berin, M. Cecilia			Immune factors in breast milk related to infant milk allergy are independent of maternal atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA; IL-6		[Arvinen, Kirsi M. J.] Albany Med Coll, Div Allergy & Immunol, Albany, NY 12208 USA; [Arvinen, Kirsi M. J.] Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA; [Arvinen, Kirsi M. J.; Sampson, Hugh A.; Berin, M. Cecilia] Icahn Sch Med Mt Sinai, Div Allergy & Immunol, New York, NY 10029 USA; [Arvinen, Kirsi M. J.; Sampson, Hugh A.; Berin, M. Cecilia] Icahn Sch Med Mt Sinai, Jaffe Inst Food Allergy, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Rockefeller Univ, Lab Investigat Dermatol, New York, NY 10021 USA; [Savilahti, Erkki] Univ Helsinki, Childrens Hosp, Div Paediat Gastroenterol & Clin Immunol, Helsinki, Finland	Albany Medical College; Albany Medical College; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rockefeller University; University of Helsinki	Arvinen, KMJ (corresponding author), Albany Med Coll, Div Allergy & Immunol, Albany, NY 12208 USA.	kirsi_jarvinen-seppo@URMC.Rochester.edu		berin, cecilia/0000-0002-9051-9249	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI066738, K08AI091655, R01AI093577, P01AI044236] Funding Source: NIH RePORTER; NCRR NIH HHS [RR026134] Funding Source: Medline; NIAID NIH HHS [P01 AI044236, AI093577, AI066738, R01 AI093577, AI44236, U19 AI066738, K08 AI091655] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ganeshan K, 2012, J IMMUNOL, V188, P594, DOI 10.4049/jimmunol.1102389; Jarvinen KM, 2014, CLIN EXP ALLERGY, V44, P69, DOI 10.1111/cea.12228; Jarvinen KM, 2002, PEDIAT ALLERG IMM-UK, V13, P243, DOI 10.1034/j.1399-3038.2002.00087.x; Moon MR, 2000, SHOCK, V13, P374; Ochiai S, 2013, INT ARCH ALLERGY IMM, V160, P401, DOI 10.1159/000342995; Osterlund P, 2004, PEDIATR RES, V55, P296, DOI 10.1203/01.PDR.0000106315.00474.6F; Rogier EW, 2014, P NATL ACAD SCI USA, V111, P3074, DOI 10.1073/pnas.1315792111; Soto-Ramirez N, 2012, ALLERGY ASTHMA CL IM, V8, DOI 10.1186/1710-1492-8-11; Verhasselt V, 2008, NAT MED, V14, P170, DOI 10.1038/nm1718; Wittkowski KM, 2004, STAT MED, V23, P1579, DOI 10.1002/sim.1778	10	18	18	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1390	+		10.1016/j.jaci.2014.10.051	http://dx.doi.org/10.1016/j.jaci.2014.10.051			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25533649	Green Accepted			2022-12-18	WOS:000353980700036
J	Robbins, KA; Guerrerio, AL; Hauck, SA; Henry, BJ; Keet, CA; Brereton, NH; Oh, S; Stasinopoulos, DM; Wood, RA				Robbins, Karen A.; Guerrerio, Anthony L.; Hauck, Sara A.; Henry, Bobbie J.; Keet, Corinne A.; Brereton, Nga Hong; Oh, Susan; Stasinopoulos, D. Mikis; Wood, Robert A.			Growth and nutrition in children with food allergy requiring amino acid-based nutritional formulas	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EOSINOPHILIC ESOPHAGITIS; ENVIRONMENTAL-FACTORS; CHILDHOOD; PREVALENCE; DISORDERS; ASTHMA; ATOPY; DIET		[Robbins, Karen A.; Keet, Corinne A.; Wood, Robert A.] Johns Hopkins Univ, Sch Med, Div Pediat Allergy & Immunol, Baltimore, MD 21218 USA; [Hauck, Sara A.; Henry, Bobbie J.; Brereton, Nga Hong] Johns Hopkins Univ, Sch Med, Inst Clin & Translat Res, Baltimore, MD USA; [Oh, Susan] Johns Hopkins Univ, Sch Med, Res Nutr Program, Baltimore, MD USA; [Oh, Susan] Inst Clin & Translat Res, Baltimore, MD USA; [Stasinopoulos, D. Mikis] London Metropolitan Univ, Storm Res Ctr, London, England	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; London Metropolitan University	Robbins, KA (corresponding author), Johns Hopkins Univ, Sch Med, Div Pediat Allergy & Immunol, Baltimore, MD 21218 USA.	krobbins1@lifespan.org	Guerrerio, Anthony/T-2632-2019	Guerrerio, Anthony/0000-0003-2458-7160; Robbins, Karen/0000-0002-9906-9088; Keet, Corinne/0000-0002-6585-239X	NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007007, K23AI103187] Funding Source: NIH RePORTER; NCRR NIH HHS [UL1 RR 025005] Funding Source: Medline; NIAID NIH HHS [K23 AI103187, K23AI103187, 5T32AI007007-34] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Christie L, 2002, J AM DIET ASSOC, V102, P1648, DOI 10.1016/S0002-8223(02)90351-2; Flammarion S, 2011, PEDIAT ALLERG IMM-UK, V22, P161, DOI 10.1111/j.1399-3038.2010.01028.x; Guerrerio AL, 2011, J PEDIATR GASTR NUTR, V53, P115, DOI 10.1097/MPG.0b013e31821404d4; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hill DJ, 2007, CLIN EXP ALLERGY, V37, P808, DOI 10.1111/j.1365-2222.2007.02724.x; Institute of Medicine, 1998, DIET REF INT THIAM R, P390, DOI [DOI 10.17226/6015, 10.17226/6015]; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Kurukulaaratchy RJ, 2008, J ASTHMA, V45, P944, DOI 10.1080/02770900802404090; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; Markowitz JE, 2003, AM J GASTROENTEROL, V98, P777, DOI 10.1111/j.1572-0241.2003.07390.x; Mehta H, 2013, CURR OPIN ALLERGY CL, V13, P275, DOI 10.1097/ACI.0b013e328360949d; Niggemann B, 2010, ALLERGY, V65, P2, DOI 10.1111/j.1398-9995.2009.02170.x; Scott M, 2010, THORAX, V65, P258, DOI 10.1136/thx.2009.125443; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2	18	18	19	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1463	1466		10.1016/j.jaci.2014.08.053	http://dx.doi.org/10.1016/j.jaci.2014.08.053			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25445831				2022-12-18	WOS:000346075400036
J	Hunter, D; Klancnik, M; Grayson, MH				Hunter, Desire; Klancnik, Meribeth; Grayson, Mitchell H.			CD49d-expressing neutrophils differentiate atopic from nonatopic individuals	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LUNG DENDRITIC CELLS; VIRAL-INFECTION; EOSINOPHILS; CRTH2; ASTHMA; ANTAGONIST; EXPRESSION; BASOPHILS; RECEPTOR		[Hunter, Desire; Klancnik, Meribeth; Grayson, Mitchell H.] Med Coll Wisconsin, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Hunter, D (corresponding author), Med Coll Wisconsin, Milwaukee, WI 53226 USA.	wheeze@allergist.com	Grayson, Mitchell/AAX-3674-2020; Grayson, Mitchell H/A-3693-2008	Grayson, Mitchell/0000-0002-4673-2122; Grayson, Mitchell H/0000-0002-4673-2122				Cheung DS, 2010, J IMMUNOL, V185, P4983, DOI 10.4049/jimmunol.1002456; Elghetany MT, 2002, BLOOD CELL MOL DIS, V28, P260, DOI 10.1006/bcmd.2002.0513; Gervais FG, 2001, J ALLERGY CLIN IMMUN, V108, P982, DOI 10.1067/mai.2001.119919; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Khan SH, 2010, J ALLERGY CLIN IMMUN, V125, P265, DOI 10.1016/j.jaci.2009.09.038; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Royer JF, 2008, EUR J CLIN INVEST, V38, P663, DOI 10.1111/j.1365-2362.2008.01989.x; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Simoes EAF, 2010, J ALLERGY CLIN IMMUN, V126, P256, DOI 10.1016/j.jaci.2010.05.026; Stein LH, 2009, J INNATE IMMUN, V1, P618, DOI 10.1159/000233235; Subrata LS, 2009, J IMMUNOL, V183, P2793, DOI 10.4049/jimmunol.0900695; Sugimoto H, 2003, J PHARMACOL EXP THER, V305, P347, DOI 10.1124/jpet.102.046748; Vasudev M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032556; Yahara H, 2010, J EUR ACAD DERMATOL, V24, P75, DOI 10.1111/j.1468-3083.2009.03267.x	15	18	18	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					901	+		10.1016/j.jaci.2013.09.035	http://dx.doi.org/10.1016/j.jaci.2013.09.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24360325				2022-12-18	WOS:000332397600041
J	Baar, A; Pahr, S; Constantin, C; Giavi, S; Manoussaki, A; Papadopoulos, NG; Ebner, C; Mari, A; Vrtala, S; Valenta, R				Baar, Alexandra; Pahr, Sandra; Constantin, Claudia; Giavi, Stavroula; Manoussaki, Alkisti; Papadopoulos, Nikolaos G.; Ebner, Christof; Mari, Adriano; Vrtala, Susanne; Valenta, Rudolf			Specific IgE reactivity to Tri a 36 in children with wheat food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GRASS-POLLEN ALLERGENS; OMEGA-5 GLIADIN; INDUCED ANAPHYLAXIS; HEALTH OUTCOMES; MAJOR ALLERGEN; LOW-INCOME; ASTHMA; HOSPITALIZATIONS; INSECURITY; ANTIBODIES		[Baar, Alexandra; Pahr, Sandra; Constantin, Claudia; Vrtala, Susanne; Valenta, Rudolf] Med Univ Vienna, Vienna Gen Hosp, Ctr Pathophysiol Infectiol & Immunol, Div Immunopathol,Dept Pathophysiol & Allergy Res, Vienna, Austria; [Baar, Alexandra; Pahr, Sandra; Vrtala, Susanne; Valenta, Rudolf] Med Univ Vienna, Christian Doppler Lab Dev Allergen Chips, Vienna, Austria; [Manoussaki, Alkisti] Univ Athens, Allergy & Immunol Res Ctr, Athens, Greece; [Ebner, Christof] Ambulatory Allergy & Clin Immunol, Vienna, Austria; [Mari, Adriano] Associated Ctr Mol Allergol, Rome, Italy	Medical University of Vienna; Medical University of Vienna; National & Kapodistrian University of Athens	Baar, A (corresponding author), Med Univ Vienna, Vienna Gen Hosp, Ctr Pathophysiol Infectiol & Immunol, Div Immunopathol,Dept Pathophysiol & Allergy Res, Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Papadopoulos, Nikolaos/ABE-1774-2021; N.G., Papadopoulos/L-8670-2013	Papadopoulos, Nikolaos/0000-0002-4448-3468; N.G., Papadopoulos/0000-0002-4448-3468; Valenta, Rudolf/0000-0001-5944-3365; Vrtala, Susanne/0000-0003-4250-8243				Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; Baar A, 2012, J IMMUNOL, V189, P3018, DOI 10.4049/jimmunol.1200438; Beyer K, 2008, J ALLERGY CLIN IMMUN, V122, P419, DOI 10.1016/j.jaci.2008.06.006; Coleman-Jensen A, 2013, ERR155 USDA EC RES S; Constantin C, 2009, ALLERGY, V64, P1030, DOI 10.1111/j.1398-9995.2009.01955.x; Cook JT, 2004, J NUTR, V134, P1432; Ebisawa M, 2012, INT ARCH ALLERGY IMM, V158, P71, DOI 10.1159/000330661; Fox P, 2007, PEDIATRICS, V120, pE902, DOI 10.1542/peds.2006-1805; Jones R, 2008, J ASTHMA, V45, P916, DOI 10.1080/02770900802395488; Kowaleski-Jones L, 2002, AM J PUBLIC HEALTH, V92, P799, DOI 10.2105/AJPH.92.5.799; Kushel MB, 2006, J GEN INTERN MED, V21, P71, DOI 10.1111/j.1525-1497.2005.00278.x; Levy M, 2006, J SCHOOL HEALTH, V76, P320, DOI 10.1111/j.1746-1561.2006.00120.x; Mansour ME, 2000, PEDIATRICS, V106, P512, DOI 10.1542/peds.106.3.512; Matsuo H, 2005, FEBS J, V272, P4431, DOI 10.1111/j.1742-4658.2005.04858.x; Mehta H, 2013, CURR OPIN ALLERGY CL, V13, P275, DOI 10.1097/ACI.0b013e328360949d; National Center for Health Statistics, 2013, NAT HLTH INT SURV QU; Pahr S, 2012, CLIN EXP ALLERGY, V42, P597, DOI 10.1111/j.1365-2222.2012.03961.x; Palosuo K, 2001, J ALLERGY CLIN IMMUN, V108, P634, DOI 10.1067/mai.2001.118602; Price JH, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/787616; Tanaka M, 2011, INT ARCH ALLERGY IMM, V156, P434, DOI 10.1159/000324469; Westritschnig K, 2008, EUR J CLIN INVEST, V38, P260, DOI 10.1111/j.1365-2362.2008.01938.x; Zuidmeer L, 2008, J ALLERGY CLIN IMMUN, V121, P1210, DOI 10.1016/j.jaci.2008.02.019	22	18	19	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					585	587		10.1016/j.jaci.2013.10.044	http://dx.doi.org/10.1016/j.jaci.2013.10.044			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24332265				2022-12-18	WOS:000332397100039
J	Toelle, BG; Garden, FL; Ng, KKW; Belousova, EG; Almqvist, C; Cowell, CT; Tovey, ER; Webb, KL; Leeder, SR; Marks, GB				Toelle, Brett G.; Garden, Frances L.; Ng, Kitty K. W.; Belousova, Elena G.; Almqvist, Catarina; Cowell, Chris T.; Tovey, Euan R.; Webb, Karen L.; Leeder, Stephen R.; Marks, Guy B.		Childhood Asthma Prevention Study	Outcomes of the Childhood Asthma Prevention Study at 11.5 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FATTY-ACID MODIFICATION; AVOIDANCE; TRIAL; CAPS; AGE		[Toelle, Brett G.; Garden, Frances L.; Ng, Kitty K. W.; Belousova, Elena G.; Almqvist, Catarina; Tovey, Euan R.; Marks, Guy B.] Woolcock Inst Med Res, Sydney, NSW, Australia; [Toelle, Brett G.; Garden, Frances L.; Cowell, Chris T.; Tovey, Euan R.; Leeder, Stephen R.; Marks, Guy B.] Univ Sydney, Sydney, NSW 2006, Australia; [Almqvist, Catarina] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Cowell, Chris T.] Childrens Hosp Westmead, Westmead, NSW, Australia; [Webb, Karen L.] Univ Calif Berkeley, Atkins Ctr Weight & Hlth, Berkeley, CA 94720 USA	University of Sydney; Woolcock Institute of Medical Research; University of Sydney; Karolinska Institutet; University of Sydney; University of California System; University of California Berkeley	Toelle, BG (corresponding author), Woolcock Inst Med Res, Sydney, NSW, Australia.	brett.toelle@woolcock.org.au	Marks, Guy B./F-5058-2013; Toelle, Brett G/B-1531-2008	Marks, Guy B./0000-0002-8976-8053; Toelle, Brett G/0000-0002-7375-0019; Garden, Frances/0000-0003-1653-3031				Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Gehring U, 2012, ALLERGY, V67, P248, DOI 10.1111/j.1398-9995.2011.02739.x; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Mihrshahi S, 2001, CONTROL CLIN TRIALS, V22, P333, DOI 10.1016/S0197-2456(01)00112-X; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Scott M, 2012, THORAX, V67, P1046, DOI 10.1136/thoraxjnl-2012-202150; Toelle BG, 2010, J ALLERGY CLIN IMMUN, V126, P388, DOI 10.1016/j.jaci.2010.04.031	8	18	18	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1220	1222		10.1016/j.jaci.2013.06.005	http://dx.doi.org/10.1016/j.jaci.2013.06.005			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	23900055				2022-12-18	WOS:000326235600027
J	Justicia, JL; Cardona, V; Guardia, P; Ojeda, P; Olaguibel, JM; Vega, JM; Vidal, C; Baro, E; Garcia, MA				Luis Justicia, Jose; Cardona, Victoria; Guardia, Pedro; Ojeda, Pedro; Maria Olaguibel, Jose; Maria Vega, Jose; Vidal, Carmen; Baro, Eva; Alberto Garcia, Mario			Validation of the first treatment-specific questionnaire for the assessment of patient satisfaction with allergen-specific immunotherapy in allergic patients: The ESPIA questionnaire	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; allergen-specific immunotherapy; satisfaction; questionnaire; validation; reliability	QUALITY-OF-LIFE; PSYCHOMETRIC EVALUATION; RHINITIS; ADHERENCE; CARE	Background: Satisfaction with treatment is a patient-reported outcome shown to be associated with the patient's health-related decisions and treatment-related behavior, thereby influencing the chances of successful treatment, and is especially relevant in long-term treatment, such as allergen-specific immunotherapy (AIT). Objective: We sought to assess the psychometric properties of the Satisfaction Scale for Patients Receiving Allergen Immunotherapy (ESPIA) questionnaire so as to determine the satisfaction of patients receiving AIT treatment. Methods: An observational, longitudinal, multicenter study was performed on patients with allergic rhinitis (AR) undergoing AIT treatment. Sociodemographic, clinical, and patient-centered health outcomes data were gathered at the study visits. Feasibility, reliability, validity, and sensitivity to change of the prevalidated version of the ESPIA questionnaire were assessed. Results: Four hundred twenty-nine patients were included (52.2% women, 33.6 years of age, 54.5% of the cases with intermittent AR and 62.5% with moderate AR). Low levels of missing items and ceiling/floor effects were found for the overall score of the ESPIA questionnaire. The overall Cronbach alpha value and intraclass correlation coefficient were 0.90 and 0.92, respectively. The overall score for the ESPIA questionnaire was strongly associated with months receiving AIT, AR type and intensity, presence of conjunctivitis, self-perceived health status, effect of AR on daily life, and expectations about the AIT treatment. The pattern of correlations obtained with other patient-centered health outcomes was consistent with expectations. The ESPIA questionnaire also showed good sensitivity to change for improved health status. Conclusion: The ESPIA questionnaire to assess patient satisfaction with respect to AIT treatment presented satisfactory psychometric properties for its use in clinical practice.	[Luis Justicia, Jose; Alberto Garcia, Mario] Stallergenes Iber, Dept Med, Barcelona, Spain; [Cardona, Victoria] Hosp Univ Vall dHebron, Barcelona, Spain; [Guardia, Pedro] Hosp Univ Virgen Macarena, Seville, Spain; [Ojeda, Pedro] Ojeda, Clin Asma & Alergia Dres, Madrid, Spain; [Maria Olaguibel, Jose] Complejo Hosp Navarra, Pamplona, Spain; [Maria Vega, Jose] Hosp Reg Univ Carlos Haya, Malaga, Spain; [Vidal, Carmen] Complejo Hosp Univ Santiago, Santiago De Compostela, Spain; [Baro, Eva] 3D Hlth Res, Hlth Outcomes Res Dept, Barcelona, Spain	Stallergenes Greer; Hospital Universitari Vall d'Hebron; Hospital Universitario Virgen Macarena; Servicio Navarro de Salud - Osasunbidea; Hospital Carlos Haya; Complexo Hospitalario Universitario de Santiago de Compostela	Garcia, MA (corresponding author), Stallergenes Iber SA, C Ramon Turro 91, Barcelona 08005, Spain.	mgarciag@stallergenes.es	RIVERA, JOSE MARIA OLAGUIBEL/AAK-3845-2020; Cardona, Victoria/GRX-4196-2022	RIVERA, JOSE MARIA OLAGUIBEL/0000-0002-9126-4559; Cardona, Victoria/0000-0003-2197-9767	Stallergenes Iberica, S.A.; Stallergenes; Diater Laboratories; Allergopharma; 3D Health Research	Stallergenes Iberica, S.A.; Stallergenes; Diater Laboratories; Allergopharma; 3D Health Research	Supported by Stallergenes Iberica, S.A.; Disclosure of potential conflict of interest: J. L. Justicia and M. A. Garcia are employed by Stallergenes Iberica. V. Cardona and C. Vidal have consultant arrangements with and have received travel support from Stallergenes. P. Guardia has received grants and consulting fees from Stallergenes. P. Ojeda is on the advisory board for Stallergenes, has consultant arrangements with ALK-Abello and Reig Jofre, and has received grants from Diater Laboratories and Allergopharma. J. M. Olaguibel has received travel support and fees for participation in review activities from Stallergenes. J. M. Vega has consultant arrangements with and has received travel support from Stallergenes Iberica. E. Baro has received fees for participation in review activities and payment for writing or reviewing this manuscript from 3D Health Research.	Abramson MJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001186.pub2; Albrecht G, 1998, COMMUNITY DENT ORAL, V26, P139, DOI 10.1111/j.1600-0528.1998.tb01940.x; Atkinson Mark J, 2004, Health Qual Life Outcomes, V2, P12, DOI 10.1186/1477-7525-2-12; Baro E, 2004, CLIN THER, V26, P1124, DOI 10.1016/S0149-2918(04)90185-3; Beyer AP, 2010, SLEEP MED, V11, P766, DOI 10.1016/j.sleep.2009.12.010; Caballero Martinez F., 2006, ALERGOLOGICA 2005 FA, P69; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Chow A, 2009, SURGERY, V146, P435, DOI 10.1016/j.surg.2009.03.019; Clotet B, 2004, HIV CLIN TRIALS, V5, P33; Cohen J., 1988, STAT POWER ANAL BEHA; Compalati E, 2009, ANN ALLERG ASTHMA IM, V102, P22, DOI 10.1016/S1081-1206(10)60103-2; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Deal LS, 2010, QUAL LIFE RES, V19, P899, DOI 10.1007/s11136-010-9640-6; Donatti C, 2008, DIABETES RES CLIN PR, V80, P108, DOI 10.1016/j.diabres.2007.11.005; Guadano EM, 2004, ALLERGY, V59, P766, DOI 10.1111/j.1398-9995.2004.00576.x; Gutteling JJ, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-25; Hill CD, 2007, MENOPAUSE, V14, P1047, DOI 10.1097/gme.0b013e31803816b8; Incorvaia Cristoforo, 2008, Patient Prefer Adherence, V2, P247; Juniper Elizabeth F, 2005, J Allergy Clin Immunol, V115, pS390, DOI 10.1016/j.jaci.2004.12.014; Justicia JL, 2011, PATIENT PREFER ADHER, V5, P239, DOI 10.2147/PPA.S19219; MCHORNEY CA, 1995, QUAL LIFE RES, V4, P293, DOI 10.1007/BF01593882; Nunnally J., 1994, PSYCHOMETRIC THEORY, DOI DOI 10.1037/018882; Radulovic Suzana, 2010, Cochrane Database Syst Rev, pCD002893, DOI 10.1002/14651858.CD002893.pub2; Reay Naomi, 2010, Nurs Times, V106, P12; Ruiz MA, 2008, VALUE HEALTH, V11, P913, DOI 10.1111/j.1524-4733.2008.00323.x; Ruiz MA, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-127; Senna G, 2009, CURR OPIN ALLERGY CL, V9, P544, DOI 10.1097/ACI.0b013e328332b8df; Streiner DL, 1995, HLTH MEASUREMENT SCA, V2nd; Valero A, 2007, VALUE HEALTH, V10, P466, DOI 10.1111/j.1524-4733.2007.00202.x; Valero A, 2007, J ALLERGY CLIN IMMUN, V120, P359, DOI 10.1016/j.jaci.2007.04.006	30	18	19	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1539	+		10.1016/j.jaci.2012.11.049	http://dx.doi.org/10.1016/j.jaci.2012.11.049			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23352631				2022-12-18	WOS:000320532800012
J	Cattaneo, F; Recher, M; Masneri, S; Baxi, SN; Fiorini, C; Antonelli, F; Wysocki, CA; Calderon, JG; Eibel, H; Smith, AR; Bonilla, FA; Tsitsikov, E; Giliani, S; Notarangelo, LD; Pai, SY				Cattaneo, Federica; Recher, Mike; Masneri, Stefania; Baxi, Sachin N.; Fiorini, Claudia; Antonelli, Francesca; Wysocki, Christian A.; Calderon, Jose G.; Eibel, Hermann; Smith, Angela R.; Bonilla, Francisco A.; Tsitsikov, Erdyni; Giliani, Silvia; Notarangelo, Luigi D.; Pai, Sung-Yun			Hypomorphic Janus kinase 3 mutations result in a spectrum of immune defects, including partial maternal T-cell engraftment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe combined immunodeficiency; cytokine signaling; maternal engraftment	SEVERE COMBINED-IMMUNODEFICIENCY; BONE-MARROW-TRANSPLANTATION; RECEPTOR-GAMMA-CHAIN; IMMUNOLOGICAL MANIFESTATIONS; LYMPHOCYTES; DEFICIENCY; DISEASE; JAK3; IDENTIFICATION; PHENOTYPE	Background: Mutations in Janus kinase 3 (JAK3) are a cause of severe combined immunodeficiency, but hypomorphic JAK3 defects can result in a milder clinical phenotype, with residual development and function of autologous T cells. Maternal T-cell engraftment is a common finding in infants with severe combined immunodeficiency but is not typically observed in patients with residual T-cell development. Objective: We sought to study in detail the molecular, cellular, and humoral immune phenotype and function of 3 patients with hypomorphic JAK3 mutations. Methods: We analyzed the distribution and function of T and B lymphocytes in 3 patients and studied the in vitro and in vivo responses of maternal T lymphocytes in 1 patient with maternal T-cell engraftment and residual production of autologous T lymphocytes. Results: B cells were present in normal numbers but with abnormal distribution of marginal zone-like and memory B cells. B-cell differentiation to plasmablasts in vitro in response to CD40 ligand and IL-21 was abolished. In 2 patients the T-cell repertoire was moderately restricted. Surprisingly, 1 patient showed coexistence of maternal and autologous T lymphocytes. By using an mAb recognizing the maternal noninherited HLA-A2 antigen, we found that autologous cells progressively accumulated in vivo but did not compete with maternal cells in vitro. Conclusion: The study of 3 patients with hypomorphic JAK3 mutations suggests that terminal B-cell maturation/differentiation requires intact JAK3 function, even if partially functioning T lymphocytes are present. Maternal T-cell engraftment can occur in patients with JAK3 mutations despite the presence of autologous T cells. (J Allergy Clin Immunol 2013; 131:1136-45.)	[Cattaneo, Federica; Fiorini, Claudia; Pai, Sung-Yun] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA; [Recher, Mike; Notarangelo, Luigi D.] Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA USA; [Recher, Mike; Baxi, Sachin N.; Bonilla, Francisco A.; Notarangelo, Luigi D.] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Tsitsikov, Erdyni] Boston Childrens Hosp, Dept Lab Med, Boston, MA USA; [Masneri, Stefania; Antonelli, Francesca; Giliani, Silvia] Univ Brescia, A Nocivelli Inst Mol Med, Brescia, Italy; [Masneri, Stefania; Antonelli, Francesca; Giliani, Silvia] Spedali Civil Brescia, Lab Genet Disorders Childhood, I-25125 Brescia, Italy; [Wysocki, Christian A.; Calderon, Jose G.] Yale Univ, Sch Med, Yale New Haven Hosp, Sect Allergy & Clin Immunol, New Haven, CT USA; [Eibel, Hermann] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiencies, Freiburg, Germany; [Smith, Angela R.] Univ Minnesota, Div Pediat Blood & Marrow Transplantat, Minneapolis, MN USA; [Notarangelo, Luigi D.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Pai, Sung-Yun] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; University of Brescia; Hospital Spedali Civili Brescia; Yale University; University of Freiburg; University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Pai, SY (corresponding author), Boston Childrens Hosp, Karp Family Res Labs, 1 Blackfan Circle,Rm 08214, Boston, MA 02115 USA.	sung-yun.pai@childrens.harvard.edu	Notarangelo, Luigi D/F-9718-2016; Giliani, Silvia/AAX-8843-2020; Pai, Sung-Yun/AAH-7762-2019	Notarangelo, Luigi D/0000-0002-8335-0262; Giliani, Silvia/0000-0001-8137-4642; Pai, Sung-Yun/0000-0002-0158-8147; Recher, Mike/0000-0002-9121-6936; Fiorini, Claudia/0000-0003-4878-2438	Translational Investigator Service at Boston Children's Hospital; Manton Foundation; National Institutes of Health [U54AI082973]; FondazioneNocivelli; Swiss National Science Foundation (SNSF/SSMBS) [PASMP3-127678]; National Institute of Allergy and Infectious Diseases and from Translational Research Program at Boston Children's Hospital	Translational Investigator Service at Boston Children's Hospital; Manton Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FondazioneNocivelli; Swiss National Science Foundation (SNSF/SSMBS); National Institute of Allergy and Infectious Diseases and from Translational Research Program at Boston Children's Hospital	Supported by the Translational Investigator Service at Boston Children's Hospital (to S.-Y.P.), the Manton Foundation (to L.D.N.), the National Institutes of Health (U54AI082973 to S.-Y.P. and L.D.N.), and FondazioneNocivelli (to S. G). M. R. was supported by the Swiss National Science Foundation (SNSF/SSMBS) grant PASMP3-127678.; Disclosure of potential conflict of interest: M. Recher has been supported by one or more grants from the Swiss National Science Foundation (SNSF/SSMBS; Nrz PASMP3127678). C. A. Wysocki has been supported by one or more grants from the National Institutes of Health. L. D. Notarangelo has received one or more grants from the National Institutes of Health and from the Manton Foundation, is a Board member for the Immune Disease Institute, is employed by Boston Children's Hospital, has received one or more grants from or has one or more grants pending with the Wiskott-Aldrich Foundation and with the March of Dimes, and has received royalties from UpToDate. S.-Y. Pai has been supported by one or more grants from the National Institute of Allergy and Infectious Diseases and from Translational Research Program at Boston Children's Hospital. The rest of the authors declare that they have no relevant conflicts of interest.	Al-Muhsen SZ, 2010, ANN SAUDI MED, V30, P239, DOI 10.4103/0256-4947.62834; Brugnoni D, 1998, BLOOD, V91, P949, DOI 10.1182/blood.V91.3.949.949_949_955; Buckley RH, 2010, J ALLERGY CLIN IMMUN, V125, P790, DOI 10.1016/j.jaci.2010.02.012; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Candotti F, 1997, BLOOD, V90, P3996, DOI 10.1182/blood.V90.10.3996; Casanova JL, 2012, IMMUNITY, V36, P515, DOI 10.1016/j.immuni.2012.03.016; COWAN MJ, 1985, J CLIN IMMUNOL, V5, P370, DOI 10.1007/BF00915333; DISANTO JP, 1994, P NATL ACAD SCI USA, V91, P9466, DOI 10.1073/pnas.91.20.9466; Felgentreff K, 2011, CLIN IMMUNOL, V141, P73, DOI 10.1016/j.clim.2011.05.007; Fischer A, 2005, IMMUNOL REV, V203, P98, DOI 10.1111/j.0105-2896.2005.00223.x; Frucht DM, 2001, GENES IMMUN, V2, P422, DOI 10.1038/sj.gene.6363802; Gerstel-Thompson JL, 2010, CLIN CHEM, V56, P1466, DOI 10.1373/clinchem.2010.144915; Haddad E, 1998, BLOOD, V91, P3646; Hale JE, 2010, J ALLERGY CLIN IMMUN, V126, P1073, DOI 10.1016/j.jaci.2010.08.043; KNOBLOCH C, 1991, J IMMUNOL, V146, P4157; Li J, 2010, CYTOKINE, V49, P221, DOI 10.1016/j.cyto.2009.09.009; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Mayo Medical Laboratories, T CELL REC EXC CIRCL; Mella P, 2000, CLIN IMMUNOL, V95, P39, DOI 10.1006/clim.2000.4842; Muller SM, 2001, BLOOD, V98, P1847, DOI 10.1182/blood.V98.6.1847; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Notorangelo LD, 2001, HUM MUTAT, V18, P255; Ocejo-Vinyals JG, 2000, ARCH DIS CHILD, V83, P165, DOI 10.1136/adc.83.2.165; Palmer K, 2007, J ALLERGY CLIN IMMUN, V120, P423, DOI 10.1016/j.jaci.2007.02.047; POLLACK MS, 1982, NEW ENGL J MED, V307, P662, DOI 10.1056/NEJM198209093071106; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Railey MD, 2009, J PEDIATR-US, V155, P834, DOI 10.1016/j.jpeds.2009.07.049; Recher M, 2011, BLOOD, V118, P6824, DOI 10.1182/blood-2011-06-362533; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; STEPHAN JL, 1993, J PEDIATR-US, V123, P564, DOI 10.1016/S0022-3476(05)80951-5; Tezcan I, 2005, J PEDIATR-US, V146, P137, DOI 10.1016/j.jpeds.2004.09.010; THOMPSON LF, 1984, J IMMUNOL, V133, P2513; Ursini MV, 2002, CLIN EXP IMMUNOL, V129, P502, DOI 10.1046/j.1365-2249.2002.01823.x; van Gent R, 2009, CLIN IMMUNOL, V133, P95, DOI 10.1016/j.clim.2009.05.020; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Wada T, 2008, BLOOD, V112, P1872, DOI 10.1182/blood-2008-04-149708; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106	40	18	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1136	1145		10.1016/j.jaci.2012.12.667	http://dx.doi.org/10.1016/j.jaci.2012.12.667			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23384681	Green Accepted			2022-12-18	WOS:000317187200024
J	Ilarraza, R; Wu, YQ; Skappak, CD; Ajamian, F; Proud, D; Adamko, DJ				Ilarraza, Ramses; Wu, Yingqi; Skappak, Christopher D.; Ajamian, Farnam; Proud, David; Adamko, Darryl J.			Rhinovirus has the unique ability to directly activate human T cells in vitro	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma exacerbation; T cells; viral infection; rhinovirus; respiratory syncytial virus	NF-KAPPA-B; RESPIRATORY VIRAL-INFECTIONS; LOWER AIRWAYS; TRANSCRIPTIONAL REGULATION; TRANSPLANT RECIPIENTS; ASTHMA EXACERBATIONS; ANTIGEN PRESENTATION; ADHESION MOLECULE-1; CYTOKINE PRODUCTION; VIRUS	Background: Rhinovirus infection is a leading cause of exacerbation of airway diseases. We hypothesize that airway viruses activate inflammatory cells, inducing airway dysfunction. We have previously shown that airway viruses can induce eosinophil degranulation when cocultured with T cells and monocyte-derived dendritic cells (moDCs). These findings suggested that antigen presentation was important for T-cell activation. Objective: Given the clinical importance of rhinovirus, we sought to determine whether it had any unique abilities to activate inflammatory cells compared with another common virus, such as respiratory syncytial virus (RSV). Methods: We cocultured combinations of human leukocytes (T cells, moDCs, and eosinophils) with each virus. Using assays of BrdU incorporation, flow cytometry, and ELISA, we measured T-cell activation, rhinovirus expression, T-cell death, and eosinophil cysteinyl leukotriene release. Results: In contrast to RSV, rhinovirus induced T-cell activation without the involvement of moDCs. Without moDCs, rhinovirus induced T-cell proliferation of both CD4 and CD8(+) cells, cytokine production, and ultimately, eosinophil stimulation. Although chloroquine inhibited RSV-induced activation of T cells through moDCs, rhinovirus was not inhibited; UV inactivation did block the rhinovirus effect. We also found that T cells could be infected by rhinovirus in vitro and within human nasal explant tissue. Although Toll-like receptors did not appear to be involved in T-cell activation, antagonists of Jun N-terminal kinase and nuclear factor kappa B did inhibit T-cell responses to rhinovirus. Conclusion: Rhinovirus has the unique ability to bypass antigen presentation and directly infect and activate human T cells. This could explain the strong association of rhinovirus with exacerbation of airway diseases. (J Allergy Clin Immunol 2013;131:395-404.)	[Ilarraza, Ramses; Wu, Yingqi; Skappak, Christopher D.; Adamko, Darryl J.] Univ Alberta, Dept Pediat, Edmonton, AB, Canada; [Ajamian, Farnam; Adamko, Darryl J.] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Adamko, Darryl J.] Univ Saskatchewan, Coll Med, Dept Pediat, Saskatoon, SK S7N 0W8, Canada; [Proud, David] Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB T2N 1N4, Canada	University of Alberta; University of Alberta; University of Saskatchewan; University of Calgary	Adamko, DJ (corresponding author), Univ Saskatchewan, Coll Med, Dept Pediat, 270 Ellis Hall, Saskatoon, SK S7N 0W8, Canada.	darryl.adamko@usask.ca			Canadian Institutes of Health Research; CONACyT-Mexico	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); CONACyT-Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	Supported by the Canadian Institutes of Health Research. D.J.A. was an Alberta Heritage Clinical Investigator. R. I. received funding from CONACyT-Mexico. D. P. holds a Canada Research Chair in Inflammatory Airway Diseases.	Anz D, 2010, J IMMUNOL, V184, P939, DOI 10.4049/jimmunol.0901245; Barnes PJ, 2006, LAB INVEST, V86, P867, DOI 10.1038/labinvest.3700456; Bella J, 1999, VIRUS RES, V62, P107, DOI 10.1016/S0168-1702(99)00038-6; Blonska M, 2009, IMMUNOL REV, V228, P199, DOI 10.1111/j.1600-065X.2008.00749.x; Bubici C, 2004, CELL CYCLE, V3, P1524, DOI 10.4161/cc.3.12.1321; Burns JL, 2012, INFLUENZA OTHER RESP, V6, P218, DOI 10.1111/j.1750-2659.2011.00292.x; Caron G, 2005, J IMMUNOL, V175, P1551, DOI 10.4049/jimmunol.175.3.1551; Croft M, 1997, CRIT REV IMMUNOL, V17, P89, DOI 10.1615/CritRevImmunol.v17.i1.40; Davoine F, 2008, J ALLERGY CLIN IMMUN, V122, P69, DOI 10.1016/j.jaci.2008.03.028; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Donadini R, 2004, STRUCTURE, V12, P145, DOI 10.1016/j.str.2003.12.002; Dubey C, 1996, J IMMUNOL, V157, P3280; DUBEY C, 1995, J IMMUNOL, V155, P45; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Gern JE, 2004, PEDIATR INFECT DIS J, V23, pS78, DOI 10.1097/01.inf.0000108196.46134.a6; Gern JE, 1996, J INFECT DIS, V174, P1143, DOI 10.1093/infdis/174.6.1143; Gern JE, 1996, J IMMUNOL, V157, P1605; Gern JE, 1997, J INFECT DIS, V175, P1108, DOI 10.1086/516449; Gern JE, 1996, J IMMUNOL, V156, P621; Goldstein JS, 2000, EUR J IMMUNOL, V30, P3266, DOI 10.1002/1521-4141(200011)30:11<3266::AID-IMMU3266>3.0.CO;2-F; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; Hamid Qutayba, 2003, Journal of Allergy and Clinical Immunology, V111, pS5, DOI 10.1067/mai.2003.22; Hayden FG, 2004, REV MED VIROL, V14, P17, DOI 10.1002/rmv.406; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; Huang SC, 2011, J IMMUNOL, V186, P931, DOI 10.4049/jimmunol.1001092; HUGHES JH, 1979, ARCH VIROL, V61, P313, DOI 10.1007/BF01315018; Ison MG, 2007, ANTIVIR THER, V12, P627; Jacoby DB, 2004, J AEROSOL MED, V17, P169, DOI 10.1089/0894268041457156; JAIN J, 1992, J IMMUNOL, V148, P1240; Johnston Sebastian L, 2007, Proc Am Thorac Soc, V4, P267, DOI 10.1513/pats.200701-030AW; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kaiser L, 2006, AM J RESP CRIT CARE, V174, P1392, DOI 10.1164/rccm.200604-489OC; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kato H, 2008, J EXP MED, V205, P1601, DOI 10.1084/jem.20080091; Kim CH, 2010, BIOCHEM BIOPH RES CO, V391, P1182, DOI 10.1016/j.bbrc.2009.12.012; Kingeter LM, 2010, J IMMUNOL, V185, P4520, DOI 10.4049/jimmunol.1001051; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Kuznik A, 2011, J IMMUNOL, V186, P4794, DOI 10.4049/jimmunol.1000702; Lee KK, 2007, PEDIATR PULM, V42, P290, DOI 10.1002/ppul.20578; Leigh R, 2008, J ALLERGY CLIN IMMUN, V121, P1238, DOI 10.1016/j.jaci.2008.01.067; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Llewelyn M, 2002, LANCET INFECT DIS, V2, P156, DOI 10.1016/S1473-3099(02)00222-0; Mallia P, 2011, AM J RESP CRIT CARE, V183, P734, DOI 10.1164/rccm.201006-0833OC; Melino M, 2008, J IMMUNOL, V181, P7300, DOI 10.4049/jimmunol.181.10.7300; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; Mosser AG, 2002, J INFECT DIS, V185, P734, DOI 10.1086/339339; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; OHKUMA S, 1981, J CELL BIOL, V90, P656, DOI 10.1083/jcb.90.3.656; Olszewska-Pazdrak B, 1998, J IMMUNOL, V160, P4889; Palmenberg AC, 2010, J ALLERGY CLIN IMMUN, V125, P1190, DOI 10.1016/j.jaci.2010.04.010; Palmenberg AC, 2009, SCIENCE, V324, P55, DOI 10.1126/science.1165557; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Sanders SP, 1998, J VIROL, V72, P934, DOI 10.1128/JVI.72.2.934-942.1998; Schwarze J, 2000, AM J RESP CRIT CARE, V162, P380, DOI 10.1164/ajrccm.162.2.9903057; Singh M, 2010, J ALLERGY CLIN IMMUN, V125, P1369, DOI 10.1016/j.jaci.2010.02.035; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Sutcliffe AM, 2009, BRIT J PHARMACOL, V157, P436, DOI 10.1111/j.1476-5381.2009.00143.x; Tregoning JS, 2010, CLIN MICROBIOL REV, V23, P74, DOI 10.1128/CMR.00032-09; VANSEVENTER GA, 1992, J IMMUNOL, V149, P3872; Wang ZQ, 2008, J BIOL CHEM, V283, P21011, DOI 10.1074/jbc.M802229200; Wos M, 2008, AM J RESP CRIT CARE, V177, P1082, DOI 10.1164/rccm.200607-973OC; Yasuda H, 2005, TOHOKU J EXP MED, V207, P109, DOI 10.1620/tjem.207.109; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175; Zwart W, 2005, IMMUNITY, V22, P221, DOI 10.1016/j.immuni.2005.01.006	68	18	18	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					395	404		10.1016/j.jaci.2012.11.041	http://dx.doi.org/10.1016/j.jaci.2012.11.041			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23374267	Bronze			2022-12-18	WOS:000314661500017
J	Saito, N; Yoshioka, N; Abe, R; Qiao, HJ; Fujita, Y; Hoshina, D; Suto, A; Kase, S; Kitaichi, N; Ozaki, M; Shimizu, H				Saito, Nao; Yoshioka, Naoya; Abe, Riichiro; Qiao, Hongjiang; Fujita, Yasuyuki; Hoshina, Daichi; Suto, Asuka; Kase, Satoru; Kitaichi, Nobuyoshi; Ozaki, Michitaka; Shimizu, Hiroshi			Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Stevens-Johnson syndrome; toxic epidermal necrolysis; animal	T-CELLS; EXPRESSION; DISEASE; GRANULYSIN; MARKER; FASL	Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening cutaneous reactions caused by drugs or infections and exhibiting widespread epidermal necrosis. Currently, there is no animal model that reproduces SJS/TEN symptoms. Objective: We sought to develop a novel mouse model of SJS/TEN by using PBMCs and skin from patients who had recovered from SJS/TEN. Methods: For our mouse model, patients' PBMCs were injected intravenously into immunocompromised NOD/Shi-scid, IL-2R gamma(null) (NOG) mice, followed by oral administration of a causative drug. Subsequently, to replace human skin, unaffected skin specimens obtained from patients who had recovered from SJS/TEN were grafted onto NOG mice, after which patient-derived PBMCs and the causative drug were applied. Results: Mice injected with PBMCs from patients with SJS/TEN and given the causative drug showed marked conjunctival congestion and numerous cell death of conjunctival epithelium, whereas there were no symptoms in mice injected with PBMCs from patients with ordinary drug skin reactions. CD8(+) T lymphocyte-depleted PBMCs from patients with SJS/TEN did not elicit these symptoms. In addition, skin-grafted mice showed darkening of the skin-grafted areas. Cleaved caspase-3 staining showed that dead keratinocytes were more numerous in the skin-grafted mice than in the healthy control animals. Conclusion: We have established a novel human-oriented SJS/TEN mouse model and proved the importance of CD8(+) T lymphocytes in SJS/TEN pathogenesis. The mouse model promises to promote diagnostic and therapeutic approaches. (J Allergy Clin Immunol 2013;131:434-41.)	[Saito, Nao; Yoshioka, Naoya; Abe, Riichiro; Qiao, Hongjiang; Fujita, Yasuyuki; Hoshina, Daichi; Suto, Asuka; Shimizu, Hiroshi] Hokkaido Univ, Grad Sch Med, Dept Dermatol, Sapporo, Hokkaido 0608638, Japan; [Kase, Satoru; Kitaichi, Nobuyoshi] Hokkaido Univ, Grad Sch Med, Dept Ophthalmol, Sapporo, Hokkaido 0608638, Japan; [Ozaki, Michitaka] Hokkaido Univ, Grad Sch Med, Dept Mol Surg, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University; Hokkaido University	Abe, R (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Dermatol, Kita Ku, N15 W7, Sapporo, Hokkaido 0608638, Japan.	aberi@med.hokudai.ac.jp; shimizu@med.hokudai.ac.jp	Kim, Seongman/N-6910-2014; Fujita, Yasuyuki/A-5464-2012	Fujita, Yasuyuki/0000-0001-7934-9261	Ministry of Health, Labor, and Welfare of Japan (Research on Allergic Diseases and Immunology) [H21-Meneki-Wakate-009]; Akiyama Life Science Foundation	Ministry of Health, Labor, and Welfare of Japan (Research on Allergic Diseases and Immunology); Akiyama Life Science Foundation	Supported in part by Health and Labor Sciences Research Grants from the Ministry of Health, Labor, and Welfare of Japan (Research on Allergic Diseases and Immunology; H21-Meneki-Wakate-009 to R. A.) and by the Akiyama Life Science Foundation (to R.A.).	Abe R, 2003, AM J PATHOL, V162, P1515, DOI 10.1016/S0002-9440(10)64284-8; Abe R, 2009, ANN INTERN MED, V151, P514, DOI 10.7326/0003-4819-151-7-200910060-00016; Azukizawa H, 2005, EUR J IMMUNOL, V35, P1722, DOI 10.1002/eji.200425773; Azukizawa H, 2003, EUR J IMMUNOL, V33, P1879, DOI 10.1002/eji.200323630; BASTUJIGARIN S, 1993, ARCH DERMATOL, V129, P92, DOI 10.1001/archderm.129.1.92; Beeler A, 2006, J ALLERGY CLIN IMMUN, V117, P455, DOI 10.1016/j.jaci.2005.10.030; Chung WH, 2012, J DERMATOL SCI, V66, P190, DOI 10.1016/j.jdermsci.2012.04.002; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Das H, 1999, BRIT J HAEMATOL, V104, P795, DOI 10.1046/j.1365-2141.1999.01246.x; Di Pascuale MA, 2005, OPHTHALMOLOGY, V112, P904, DOI 10.1016/j.ophtha.2004.11.035; Hanafusa T, 2012, J DERMATOL SCI, V65, P213, DOI 10.1016/j.jdermsci.2011.12.002; Hari Y, 2001, CLIN EXP ALLERGY, V31, P1398, DOI 10.1046/j.1365-2222.2001.01164.x; Ito M, 2008, CURR TOP MICROBIOL, V324, P53; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Ito R, 2009, TRANSPLANTATION, V87, P1654, DOI 10.1097/TP.0b013e3181a5cb07; Lee JY, 2004, J VIRAL HEPATITIS, V11, P130, DOI 10.1046/j.1365-2893.2003.00486.x; Morel E, 2011, ALLERGY, V66, P360, DOI 10.1111/j.1398-9995.2010.02484.x; Morel E, 2010, J ALLERGY CLIN IMMUN, V125, P703, DOI 10.1016/j.jaci.2009.10.030; Murata J, 2008, J ALLERGY CLIN IMMUN, V122, P992, DOI 10.1016/j.jaci.2008.06.013; Nakata H, 2005, J VIROL, V79, P2087, DOI 10.1128/JVI.79.4.2087-2096.2005; Pereira FA, 2007, J AM ACAD DERMATOL, V56, P181, DOI 10.1016/j.jaad.2006.04.048; Posadas SJ, 2002, J ALLERGY CLIN IMMUN, V109, P155, DOI 10.1067/mai.2002.120563; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Rozieres A, 2009, ALLERGY, V64, P534, DOI 10.1111/j.1398-9995.2008.01674.x; Schneck J, 2008, J AM ACAD DERMATOL, V58, P33, DOI 10.1016/j.jaad.2007.08.039; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490	27	18	20	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					434	+		10.1016/j.jaci.2012.09.014	http://dx.doi.org/10.1016/j.jaci.2012.09.014			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23111236	Bronze			2022-12-18	WOS:000314661500022
J	Khan, DA				Khan, David A.			Cutaneous drug reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							EPIDERMAL NECROLYSIS; SYSTEMIC SYMPTOMS; ERUPTIONS; EUROSCAR; DRESS		Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Allergy & Immunol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Khan, DA (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Allergy & Immunol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	dave.khan@utsouthwestern.edu						Bachot N, 2003, AM J CLIN DERMATOL, V4, P561, DOI 10.2165/00128071-200304080-00006; Fortuna G, 2012, J AM ACAD DERMATOL, V66, P988, DOI 10.1016/j.jaad.2011.09.018; Joint Task Force on Practice Parameters; American Academy of Allergy Asthma and Immunology; American College of Allergy Asthma and Immunology; Joint Council of Allergy Asthma and Immunology, 2010, ANN ALLERGY ASTHMA I, V105, P259; Kardaun SH, 2007, BRIT J DERMATOL, V156, P609, DOI 10.1111/j.1365-2133.2006.07704.x; Knowles S, 2009, DERMATOL THER, V22, P441, DOI 10.1111/j.1529-8019.2009.01260.x; McKenna JK, 2004, IMMUNOL ALLERGY CLIN, V24, P399, DOI 10.1016/j.iac.2004.03.007; Mockenhaupt M, 2008, J INVEST DERMATOL, V128, P35, DOI 10.1038/sj.jid.5701033; Shiohara T, 2009, CURR OPIN ALLERGY CL, V9, P316, DOI 10.1097/ACI.0b013e32832cda4c; Sidoroff A, 2007, BRIT J DERMATOL, V157, P989, DOI 10.1111/j.1365-2133.2007.08156.x; Stern RS, 2012, NEW ENGL J MED, V366, P2492, DOI 10.1056/NEJMcp1104080; Walsh SA, 2011, CLIN EXP DERMATOL, V36, P6, DOI 10.1111/j.1365-2230.2010.03967.x	11	18	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1225	+		10.1016/j.jaci.2012.08.007	http://dx.doi.org/10.1016/j.jaci.2012.08.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	23116633				2022-12-18	WOS:000310571400036
J	Pino-Yanes, M; Sanchez-Machin, I; Cumplido, J; Figueroa, J; Torres-Galvan, MJ; Gonzalez, R; Corrales, A; Acosta-Fernandez, O; Garcia-Robaina, JC; Carrillo, T; Sanchez-Palacios, A; Villar, J; Hernandez, M; Flores, C				Pino-Yanes, Maria; Sanchez-Machin, Inmaculada; Cumplido, Jose; Figueroa, Javier; Jose Torres-Galvan, Maria; Gonzalez, Ruperto; Corrales, Almudena; Acosta-Fernandez, Orlando; Carlos Garcia-Robaina, Jose; Carrillo, Teresa; Sanchez-Palacios, Anselmo; Villar, Jesus; Hernandez, Mariano; Flores, Carlos			IL-1 receptor-associated kinase 3 gene (IRAK3) variants associate with asthma in a replication study in the Spanish population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Pino-Yanes, Maria; Corrales, Almudena; Villar, Jesus; Flores, Carlos] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain; [Pino-Yanes, Maria; Corrales, Almudena; Flores, Carlos] Hosp Univ NS Candelaria, Res Unit, Tenerife, Spain; [Sanchez-Machin, Inmaculada; Gonzalez, Ruperto; Carlos Garcia-Robaina, Jose] Hosp Univ NS Candelaria, Allergy Unit, Tenerife, Spain; [Cumplido, Jose; Carrillo, Teresa] Hosp Univ Dr Negrin, Allergy Unit, Las Palmas Gran Canaria, Spain; [Figueroa, Javier; Sanchez-Palacios, Anselmo] Hosp Univ Insular Gran Canaria, Allergy Unit, Las Palmas Gran Canaria, Spain; [Villar, Jesus] Hosp Univ Dr Negrin, Res Unit, MODERN, Las Palmas Gran Canaria, Spain; [Acosta-Fernandez, Orlando] Hosp Univ Canarias, Neumol Unit, Tenerife, Spain; [Villar, Jesus] St Michaels Hosp, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada; [Hernandez, Mariano] Univ La Laguna, Genet Lab, Inst Univ Enfermedades Trop & Salud Publ Canarias, Tenerife, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; Universidad de la Laguna; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Universidad de la Laguna	Pino-Yanes, M (corresponding author), Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain.	cflores@ull.es	Pino-Yanes, Maria/C-8498-2017; Hernandez, Mariano/K-6679-2015; Machín, María Inmaculada Sánchez/ABF-6003-2020; Hernandez, Mariano/AAK-3143-2020; Corrales, Almudena/G-5391-2017; Flores, Carlos/R-1159-2019; Villar, Jesús/R-4526-2019; Ruperto, González-Pérez/AAE-6200-2022	Pino-Yanes, Maria/0000-0003-0332-437X; Hernandez, Mariano/0000-0003-1219-0246; Hernandez, Mariano/0000-0003-1219-0246; Corrales, Almudena/0000-0002-2207-5463; Villar, Jesús/0000-0001-5687-3562; Sanchez-Machin, Inmaculada/0000-0003-0109-8735; Flores, Carlos/0000-0001-5352-069X				Balaci L, 2007, AM J HUM GENET, V80, P1103, DOI 10.1086/518259; Dickson SP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000294; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Nakashima K, 2006, J HUM GENET, V51, P284, DOI 10.1007/s10038-005-0358-1; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Pino-Yanes M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018389; Pino-Yanes M, 2011, AM J RESP CELL MOL, V45, P740, DOI 10.1165/rcmb.2010-0292OC; Rogers AJ, 2009, AM J RESP CRIT CARE, V179, P1084, DOI 10.1164/rccm.200812-1860OC; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; WU H, 2010, J ALLERGY CLIN IMMUN, V125, pE13; Wu H, 2010, J ALLERGY CLIN IMMUN, V125, P321, DOI 10.1016/j.jaci.2009.09.007	11	18	18	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					573	575		10.1016/j.jaci.2011.10.001	http://dx.doi.org/10.1016/j.jaci.2011.10.001			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22070913				2022-12-18	WOS:000299951700046
J	Prescott, SL; Tulic, M; Kumah, AO; Richman, T; Crook, M; Martino, D; Dunstan, JA; Novakovic, B; Saffery, R; Clifton, VL				Prescott, Susan L.; Tulic, Meri; Kumah, Annette Osei; Richman, Tara; Crook, Maxine; Martino, David; Dunstan, Janet A.; Novakovic, Boris; Saffery, Richard; Clifton, Vicki L.			Reduced placental FOXP3 associated with subsequent infant allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							REGULATORY T-CELLS; METHYLATION; BLOOD		[Prescott, Susan L.; Tulic, Meri; Richman, Tara; Martino, David; Dunstan, Janet A.] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia; [Kumah, Annette Osei; Clifton, Vicki L.] Univ Adelaide, Robinson Inst, Dept Paediat & Reprod Hlth, Adelaide, SA, Australia; [Crook, Maxine] Princess Margaret Hosp, PathW Lab Med, Div Paediat Pathol, Perth, WA, Australia; [Novakovic, Boris; Saffery, Richard] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Novakovic, Boris; Saffery, Richard] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia	University of Western Australia; Robinson Research Institute; University of Adelaide; University of Western Australia; Murdoch Children's Research Institute; University of Melbourne	Prescott, SL (corresponding author), Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia.	sprescott@meddent.uwa.edu.au	Tulic, Meri/P-6613-2016; Tulic, Meri K/ABB-5138-2020; Clifton, Vicki/A-1445-2012; Prescott, Susan/H-5665-2014; Novakovic, Boris/D-8018-2013; Clifton, Vicki/AAV-2749-2021; Martino, DJ/X-1753-2019; Saffery, Richard/GLS-1976-2022	Tulic, Meri/0000-0002-2661-2369; Tulic, Meri K/0000-0002-2661-2369; Clifton, Vicki/0000-0002-4892-6748; Novakovic, Boris/0000-0002-5623-9008; Clifton, Vicki/0000-0002-4892-6748; Martino, DJ/0000-0001-6823-4696; Saffery, Richard/0000-0002-9510-4181				Aluvihare VR, 2004, NAT IMMUNOL, V5, P266, DOI 10.1038/ni1037; Amsalem H, 2008, INT IMMUNOL, V20, P1147, DOI 10.1093/intimm/dxn072; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Murphy VE, 2011, J CLIN ENDOCR METAB, V87, P1660; Novakovic B, 2010, J BIOL CHEM, V285, P9583, DOI 10.1074/jbc.M109.064956; Prescott SL, 2008, J ALLERGY CLIN IMMUN, V122, P391, DOI 10.1016/j.jaci.2008.04.042; Schaub B, 2008, J ALLERGY CLIN IMMUN, V121, P1491, DOI 10.1016/j.jaci.2008.04.010; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Schumacher A, 2009, J IMMUNOL, V182, P5488, DOI 10.4049/jimmunol.0803177; Scott NM, 2009, J IMMUNOL, V182, P1411, DOI 10.4049/jimmunol.182.3.1411; Tilburgs T, 2008, J IMMUNOL, V180, P5737, DOI 10.4049/jimmunol.180.8.5737; Wong NC, 2008, CANCER LETT, V268, P56, DOI 10.1016/j.canlet.2008.03.033; Wong NC, 2008, BIOTECHNIQUES, V45, P423, DOI 10.2144/000112945	14	18	20	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					886	U315		10.1016/j.jaci.2011.05.017	http://dx.doi.org/10.1016/j.jaci.2011.05.017			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21719077	Bronze			2022-12-18	WOS:000296538100028
J	Deffert, C; Olleros, ML; Yuan, HP; Herrmann, FR; Zekry, D; Garcia, I; Krause, KH; Schappi, MG				Deffert, Christine; Olleros, Maria L.; Yuan Huiping; Herrmann, Francois R.; Zekry, Dina; Garcia, Irene; Krause, Karl-Heinz; Schaeppi, Michela G.			TNF-alpha blockade in chronic granulomatous disease-induced hyperinflammation: Patient analysis and murine model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PHAGOCYTE NADPH OXIDASE		[Deffert, Christine; Schaeppi, Michela G.] Univ Hosp Geneva, Dept Pediat, Pediat Gastroenterol & Transplantat Div, Geneva, Switzerland; [Deffert, Christine; Olleros, Maria L.; Yuan Huiping; Garcia, Irene; Krause, Karl-Heinz; Schaeppi, Michela G.] Fac Med, Dept Pathol & Immunol, Geneva, Switzerland; [Krause, Karl-Heinz] Fac Med, Dept Genet & Lab Med, Geneva, Switzerland; [Herrmann, Francois R.; Zekry, Dina] Univ Hosp Geneva, Dept Rehabil & Geriatr, Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva	Deffert, C (corresponding author), Univ Hosp Geneva, Dept Pediat, Pediat Gastroenterol & Transplantat Div, Geneva, Switzerland.	michela.tempia-caliera@hcuge.ch	Schäppi, Michela/D-5363-2012; Krause, Karl-Heinz/E-8030-2011; HERRMANN, Francois R/B-6710-2011; Schäppi Tempia-Caliera, Michela/A-7619-2012; HERRMANN, Francois/M-7390-2019	Krause, Karl-Heinz/0000-0002-9033-6768; HERRMANN, Francois R/0000-0003-1312-1517; Schäppi Tempia-Caliera, Michela/0000-0002-9860-7294; HERRMANN, Francois/0000-0003-1312-1517				Hatanaka E, 2004, IMMUNOL LETT, V94, P43, DOI 10.1016/j.imlet.2004.04.016; Marciano BE, 2004, PEDIATRICS, V114, P462, DOI 10.1542/peds.114.2.462; Olleros ML, 2010, J HEPATOL, V53, P1059, DOI 10.1016/j.jhep.2010.05.029; Petersen JE, 2002, J INVEST DERMATOL, V118, P424, DOI 10.1046/j.0022-202x.2001.01691.x; Schappi MG, 2008, J PATHOL, V214, P434, DOI 10.1002/path.2298; Schappi MG, 2008, SEMIN IMMUNOPATHOL, V30, P255, DOI 10.1007/s00281-008-0119-2; Seger RA, 2010, NETH J MED, V68, P334; van de Loo FAJ, 2003, AM J PATHOL, V163, P1525, DOI 10.1016/S0002-9440(10)63509-2; Warris A, 2003, SCAND J INFECT DIS, V35, P482, DOI 10.1080/00365540310013009	9	18	18	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					675	677		10.1016/j.jaci.2011.04.028	http://dx.doi.org/10.1016/j.jaci.2011.04.028			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21596423				2022-12-18	WOS:000294283400033
J	Begin, P; Roches, AD; Nguyen, M; Masse, MS; Paradis, J; Paradis, L				Begin, Philippe; Roches, Anne Des; Melanie Nguyen; Masse, Marie-Soleil; Paradis, Jean; Paradis, Louis			Freezing does not alter antigenic properties of freshfruits for skin testing in patients with birch tree pollen-induced oral allergy syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHALLENGE; CARROT		[Begin, Philippe; Melanie Nguyen; Masse, Marie-Soleil; Paradis, Jean; Paradis, Louis] Ctr Hosp Univ Montreal, Dept Med, Montreal, PQ, Canada; [Roches, Anne Des; Paradis, Louis] Ctr Hosp Univ St Justine, Dept Pediat, Serv Allergy & Clin Immunol, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine	Begin, P (corresponding author), Ctr Hosp Univ Montreal, Dept Med, Montreal, PQ, Canada.	lparadis@aei.ca	Bégin, Philippe/AAU-9126-2021					Ballmer-Weber BK, 2001, J ALLERGY CLIN IMMUN, V108, P301, DOI 10.1067/mai.2001.116430; Cao EH, 2003, BIOTECHNOL BIOENG, V82, P684, DOI 10.1002/bit.10612; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Lidholm J, 2006, CURR OPIN ALLERGY CL, V6, P234, DOI 10.1097/01.all.0000225166.90768.d6; Metcalfe D., 2003, FOOD ALLERGY ADVERSE; Nash S, 2007, CURR ALLERGY ASTHM R, V7, P1, DOI 10.1007/s11882-007-0022-2; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; ORTOLANI C, 1993, ANN ALLERGY, V71, P470; Webber CM, 2010, ANN ALLERG ASTHMA IM, V104, P101, DOI 10.1016/j.anai.2009.11.007	10	18	18	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1624	1626		10.1016/j.jaci.2011.01.028	http://dx.doi.org/10.1016/j.jaci.2011.01.028			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21411128				2022-12-18	WOS:000291048500046
J	Rachid, R; Leslie, D; Schneider, L; Twarog, F				Rachid, Rima; Leslie, David; Schneider, Lynda; Twarog, Frank			Hypersensitivity to systemic corticosteroids: An infrequent but potentially life-threatening condition	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANAPHYLACTOID REACTION; METHYLPREDNISOLONE; SUCCINATE		[Rachid, Rima; Schneider, Lynda; Twarog, Frank] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Allergy & Immunol, Boston, MA 02115 USA; [Leslie, David] Franciscan Hosp Children, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard Medical School	Rachid, R (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, Div Allergy & Immunol, Boston, MA 02115 USA.	rachid@childrens.harvard.edu						Burgdorff T, 2002, ANN ALLERG ASTHMA IM, V89, P425, DOI 10.1016/S1081-1206(10)62046-7; Butani L, 2002, ANN ALLERG ASTHMA IM, V89, P439, DOI 10.1016/S1081-1206(10)62077-7; Calogiuri GF, 2004, BRIT J DERMATOL, V151, P707, DOI 10.1111/j.1365-2133.2004.06102.x; FULCHER DA, 1991, MED J AUSTRALIA, V154, P210, DOI 10.5694/j.1326-5377.1991.tb121038.x; Kamm GL, 1999, ANN PHARMACOTHER, V33, P451, DOI 10.1345/aph.18276; Klein-Gitelman MS, 1998, J RHEUMATOL, V25, P1995; PRYSEPHILLIPS WEM, 1984, NEUROLOGY, V34, P1119, DOI 10.1212/WNL.34.8.1119; Ventura MT, 2007, INT J IMMUNOPATH PH, V20, P387, DOI 10.1177/039463200702000220; Ventura MT, 2003, BRIT J DERMATOL, V148, P139, DOI 10.1046/j.1365-2133.2003.05061.x	9	18	18	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					524	+		10.1016/j.jaci.2010.09.030	http://dx.doi.org/10.1016/j.jaci.2010.09.030			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21093900				2022-12-18	WOS:000286808000031
J	Lockey, RF; Hankin, CS				Lockey, Richard F.; Hankin, Cheryl S.			Health economics of allergen-specific immunotherapy in the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Cost-benefit analysis; allergen immunotherapy	POLLEN INDUCED RHINOCONJUNCTIVITIS; COST-EFFECTIVENESS; SYMPTOMATIC TREATMENT; DRUG-TREATMENT; RHINITIS; ASTHMA; PREVENTION; GRAZAX(R); EUROPE		[Lockey, Richard F.] Univ S Florida, Coll Med, Div Allergy & Immunol, Tampa, FL 33612 USA; [Hankin, Cheryl S.] BioMedEcon, Moss Beach, CA USA	State University System of Florida; University of South Florida	Lockey, RF (corresponding author), Univ S Florida, Coll Med, Div Allergy & Immunol, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	rlockey@health.usf.edu						Ariano R, 2006, ALLERGY ASTHMA PROC, V27, P159; Ariano R, 2009, ANN ALLERG ASTHMA IM, V103, P254, DOI 10.1016/S1081-1206(10)60190-1; Bachert C, 2007, CLIN EXP ALLERGY, V37, P772, DOI 10.1111/j.1365-2222.2007.02706.x; Bernstein Jonathan A, 2004, Clin Allergy Immunol, V18, P151; BERTO P, 2005, ALLERG IMMUNOL PARIS, V37, P303; Berto P, 2008, CURR MED RES OPIN, V24, P261, DOI 10.1185/030079908X253726; Bruggenjurgen B, 2008, ANN ALLERG ASTHMA IM, V101, P316, DOI 10.1016/S1081-1206(10)60498-X; Buchner K, 1995, ALLERGO J, V4, P156; Canonica GW, 2007, RESP MED, V101, P1885, DOI 10.1016/j.rmed.2007.05.003; Donahue JG, 1999, ANN ALLERG ASTHMA IM, V82, P339, DOI 10.1016/S1081-1206(10)63282-6; Hankin CS, 2008, J ALLERGY CLIN IMMUN, V121, P227, DOI 10.1016/j.jaci.2007.10.026; Hankin CS, 2010, ANN ALLERG ASTHMA IM, V104, P79, DOI 10.1016/j.anai.2009.11.010; Keiding H, 2007, CURR MED RES OPIN, V23, P1113, DOI 10.1185/030079907X187865; Law AW, 2003, J ALLERGY CLIN IMMUN, V111, P296, DOI 10.1067/mai.2003.68; LEPEN C, 1997, REV FRANC ALLERGOL I, V37, P11; Nasser S, 2008, ALLERGY, V63, P1624, DOI 10.1111/j.1398-9995.2008.01743.x; OMNES LF, 2007, ALLERG IMMUNOL PARIS, V39, P148; Petersen K D, 2005, Allergol Immunopathol (Madr), V33, P296, DOI 10.1016/S0301-0546(05)73246-8; Pokladnikova J, 2008, ANN ALLERG ASTHMA IM, V100, P482, DOI 10.1016/S1081-1206(10)60475-9; Schadlich PK, 2000, PHARMACOECONOMICS, V17, P37, DOI 10.2165/00019053-200017010-00003; SULLIVAN TJ, 1996, AM COLL ALLERGY ASTH, P1	21	18	18	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					39	43		10.1016/j.jaci.2010.09.033	http://dx.doi.org/10.1016/j.jaci.2010.09.033			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211640	Bronze			2022-12-18	WOS:000285917300005
J	Garcia-Marcos, L; Martinez, FD				Garcia-Marcos, Luis; Martinez, Fernando D.			Multitrigger versus episodic wheeze in toddlers: New phenotypes or severity markers?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							PRESCHOOL-CHILDREN; INHALED CORTICOSTEROIDS; ASTHMA; RISK; LIFE		[Martinez, Fernando D.] Univ Arizona, Coll Med, Arizona Resp Ctr, Tucson, AZ 85724 USA; [Garcia-Marcos, Luis; Martinez, Fernando D.] Univ Arizona, Inst BIO5, Tucson, AZ 85724 USA; [Martinez, Fernando D.] Univ Arizona, Dept Pediat, Tucson, AZ 85724 USA; [Garcia-Marcos, Luis] Univ Murcia, Arrixaca Univ, Childrens Hosp, Pediat Pulmonol & Allergy Unit, Murcia, Spain	University of Arizona; University of Arizona; University of Arizona; Hospital Clinico Universitario Virgen de la Arrixaca; University of Murcia	Martinez, FD (corresponding author), Univ Arizona, Coll Med, Arizona Resp Ctr, 1501 N Campbell Ave,POB 245030, Tucson, AZ 85724 USA.	Fernando@arc.arizona.edu		Garcia-Marcos, Luis/0000-0002-0925-3851	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064307, R01HL056177, U10HL098112] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL056177, U10HL064307, U10HL098112] Funding Source: Medline; NICHD NIH HHS [N01HD80034] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Castro-Rodriguez JA, 2009, PEDIATRICS, V123, pe519, DOI 10.1542/peds.2008-2867; Ermers MJJ, 2007, J ALLERGY CLIN IMMUN, V119, P1086, DOI 10.1016/j.jaci.2006.12.655; Fitzgerald Dominic A, 2006, Treat Respir Med, V5, P407, DOI 10.2165/00151829-200605060-00006; Garcia-Marcos L, 2010, PEDIAT ALLERG IMM-UK, V21, P878, DOI 10.1111/j.1399-3038.2010.01035.x; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; MARTINEZ F, 2003, WHEEZING DISORDERS P, P55; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Schultz A, 2010, ACTA PAEDIATR, V99, P56, DOI 10.1111/j.1651-2227.2009.01508.x; Sonnappa S, 2010, J ALLERGY CLIN IMMUN, V126, P519, DOI 10.1016/j.jaci.2010.04.018; Stein RT, 1997, THORAX, V52, P946, DOI 10.1136/thx.52.11.946	15	18	18	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					489	490		10.1016/j.jaci.2010.06.037	http://dx.doi.org/10.1016/j.jaci.2010.06.037			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20816185				2022-12-18	WOS:000281512500012
J	Conway, DH; Dara, J; Bagashev, A; Sullivan, KE				Conway, Daniel H.; Dara, Jasmeen; Bagashev, Asen; Sullivan, Kathleen E.			Myeloid differentiation primary response gene 88 (MyD88) deficiency in a large kindred	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PYOGENIC BACTERIAL-INFECTIONS; IRAK-4 DEFICIENCY; IMMUNITY; HUMANS		[Conway, Daniel H.; Dara, Jasmeen] Drexel Univ, Coll Med, St Christophers Hosp Children, Immunol Sect, Philadelphia, PA 19104 USA; [Bagashev, Asen; Sullivan, Kathleen E.] Childrens Hosp Philadelphia, Div Allergy Immunol, Philadelphia, PA 19104 USA	Drexel University; University of Pennsylvania; Childrens Hospital of Philadelphia	Conway, DH (corresponding author), Drexel Univ, Coll Med, St Christophers Hosp Children, Immunol Sect, Philadelphia, PA 19104 USA.	sullivak@mail.med.upenn.edu	Bagashev, Asen/D-2913-2011	Bagashev, Asen/0000-0001-9900-8106; Sullivan, Kathleen/0000-0003-4018-1646				Day N, 2004, J PEDIATR-US, V144, P524, DOI 10.1016/j.jpeds.2003.11.025; Guay HM, 2007, J IMMUNOL, V178, P5124, DOI 10.4049/jimmunol.178.8.5124; Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004; Ku CL, 2007, J EXP MED, V204, P2407, DOI 10.1084/jem.20070628; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Puel A, 2005, J ENDOTOXIN RES, V11, P220, DOI 10.1179/096805105X37367; von Bernuth H, 2005, CLIN INFECT DIS, V41, pS436, DOI 10.1086/431994; von Bernuth H, 2008, SCIENCE, V321, P691, DOI 10.1126/science.1158298	8	18	18	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					172	175		10.1016/j.jaci.2010.04.014	http://dx.doi.org/10.1016/j.jaci.2010.04.014			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20538326				2022-12-18	WOS:000280061800034
J	Hepworth, MR; Hamelmann, E; Lucius, R; Hartmann, S				Hepworth, Matthew R.; Hamelmann, Eckard; Lucius, Richard; Hartmann, Susanne			Looking into the future of Trichuris suis therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SKIN-TEST REACTIVITY		[Hepworth, Matthew R.; Lucius, Richard; Hartmann, Susanne] Humboldt Univ, Dept Mol Parasitol, Berlin, Germany; [Hamelmann, Eckard] Charite Hosp, Dept Paediat, Allergy Ctr, Berlin, Germany; [Hamelmann, Eckard] Ruhr Univ Bochum, Univ Childrens Hosp, Bochum, Germany	Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruhr University Bochum; University of Hamburg; University Medical Center Hamburg-Eppendorf	Hepworth, MR (corresponding author), Humboldt Univ, Dept Mol Parasitol, Berlin, Germany.	Susanne.Hartmann@hu-berlin.de	Hartmann, Susanne/M-9154-2016; Hamelmann, Eckard/AAJ-9124-2021	Hepworth, Matthew/0000-0002-9613-7858; Hartmann, Susanne/0000-0001-6846-0650				Bager P, 2010, J ALLERGY CLIN IMMUN, V125, P123, DOI 10.1016/j.jaci.2009.08.006; Flohr C., 2009, CLIN EXP ALLERGY; Hartmann S, 2009, CLIN EXP ALLERGY, V39, P1585, DOI 10.1111/j.1365-2222.2009.03290.x; Rodrigues LC, 2008, CLIN EXP ALLERGY, V38, P1769, DOI 10.1111/j.1365-2222.2008.03027.x; Schnoeller C, 2008, J IMMUNOL, V180, P4265, DOI 10.4049/jimmunol.180.6.4265; Summers RW, 2005, GUT, V54, P87, DOI 10.1136/gut.2004.041749; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767	7	18	20	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					767	768		10.1016/j.jaci.2009.11.041	http://dx.doi.org/10.1016/j.jaci.2009.11.041			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20153034				2022-12-18	WOS:000275883200048
J	Wang, H; Barrenas, F; Bruhn, S; Mobini, R; Benson, M				Wang, Hui; Barrenas, Fredrik; Bruhn, Soren; Mobini, Reza; Benson, Mikael			Increased IFN-gamma activity in seasonal allergic rhinitis is decreased by corticosteroid treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INTERFERON-GAMMA; T-CELLS; CD4(+)		[Wang, Hui; Barrenas, Fredrik; Bruhn, Soren; Mobini, Reza; Benson, Mikael] Univ Gothenburg, Queen Silvia Childrens Hosp, Unit Clin Syst Biol, Gothenburg, Sweden; [Benson, Mikael] Queen Silvia Childrens Hosp, Pediat Allergy Unit, Gothenburg, Sweden	Queen Silvia Children's Hospital; University of Gothenburg; Queen Silvia Children's Hospital	Wang, H (corresponding author), Univ Gothenburg, Queen Silvia Childrens Hosp, Unit Clin Syst Biol, Gothenburg, Sweden.	hui.wang@gu.se		Mobini, Reza/0000-0002-3690-5739				Benson M, 2004, J ALLERGY CLIN IMMUN, V113, P1137, DOI 10.1016/j.jaci.2004.02.028; Benson M, 2000, J ALLERGY CLIN IMMUN, V106, P307, DOI 10.1067/mai.2000.108111; Benson M, 2006, J ALLERGY CLIN IMMUN, V118, P220, DOI 10.1016/j.jaci.2006.03.006; Bocek P, 2004, J EXP MED, V199, P1619, DOI 10.1084/jem.20032014; Cho SH, 2005, AM J RESP CRIT CARE, V171, P224, DOI 10.1164/rccm.200310-1416OC; Devadas S, 2006, IMMUNITY, V25, P237, DOI 10.1016/j.immuni.2006.06.011; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; Sugimoto T, 2004, J EXP MED, V199, P535, DOI 10.1084/jem.20031368; Woodfolk JA, 2007, J ALLERGY CLIN IMMUN, V119, P280, DOI 10.1016/j.jaci.2006.11.008	9	18	18	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1360	1362		10.1016/j.jaci.2009.09.037	http://dx.doi.org/10.1016/j.jaci.2009.09.037			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	19910031	Bronze			2022-12-18	WOS:000273071500035
J	Somech, R; Lai, YH; Grunebaum, E; Le Saux, N; Cutz, E; Roifman, CM				Somech, Raz; Lai, Yew Hon; Grunebaum, Eyal; Le Saux, Nicole; Cutz, Ernest; Roifman, Chaim M.			Polyethylene glycol-modified adenosine deaminase improved lung disease but not liver disease in partial adenosine deaminase deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PULMONARY INFLAMMATION; MUTATIONS; MICE		[Somech, Raz; Lai, Yew Hon; Grunebaum, Eyal; Roifman, Chaim M.] Univ Toronto, Div Immunol & Allergy, Toronto, ON, Canada; [Somech, Raz; Lai, Yew Hon; Grunebaum, Eyal; Roifman, Chaim M.] Univ Toronto, Canadian Ctr Primary Immunodeficiency, Toronto, ON, Canada; [Somech, Raz; Lai, Yew Hon; Grunebaum, Eyal; Cutz, Ernest; Roifman, Chaim M.] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; [Le Saux, Nicole] Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Paediat, Ottawa, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Ottawa; Children's Hospital of Eastern Ontario	Somech, R (corresponding author), Univ Toronto, Div Immunol & Allergy, Toronto, ON, Canada.	chaim.roifman@sickkids.ca						Blackburn MR, 2000, J EXP MED, V192, P159, DOI 10.1084/jem.192.2.159; Blackburn MR, 2005, ADV IMMUNOL, V86, P1, DOI 10.1016/S0065-2776(04)86001-2; Bollinger ME, 1996, NEW ENGL J MED, V334, P1367, DOI 10.1056/NEJM199605233342104; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; HERSHFIELD MS, 1995, METABOLIC MOL BASIS, V1, P1725; HIRSCHHORN R, 1990, Immunodeficiency Reviews, V2, P175; SANTISTEBAN I, 1995, HUM MOL GENET, V4, P2081, DOI 10.1093/hmg/4.11.2081; SANTISTEBAN I, 1993, J CLIN INVEST, V92, P2291, DOI 10.1172/JCI116833; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673	9	18	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					848	850		10.1016/j.jaci.2009.07.003	http://dx.doi.org/10.1016/j.jaci.2009.07.003			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19665771				2022-12-18	WOS:000270802800035
J	Haitchi, HM; Bassett, DJP; Bucchieri, F; Gao, XF; Powell, RM; Hanley, NA; Wilson, DI; Holgate, ST; Davies, DE				Haitchi, Hans Michael; Bassett, David J. P.; Bucchieri, Fabio; Gao, Xiufeng; Powell, Robert M.; Hanley, Neil A.; Wilson, David I.; Holgate, Stephen T.; Davies, Donna E.			Induction of a disintegrin and metalloprotease 33 during embryonic lung development and the influence of IL-13 or maternal allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ADAM33; embryonic/fetal; lung development; maternal allergy; environment gene interaction; geNorm analysis	HUMAN ADAM33; BRONCHIAL HYPERRESPONSIVENESS; AIRWAY HYPERRESPONSIVENESS; FUNCTION DECLINE; RISK-FACTORS; ASTHMA; EXPRESSION; LIFE; POLYMORPHISMS; MORPHOGENESIS	Background: Asthma pathogenesis involves gene and environmental interactions. A disintegrin and metalloprotease 33 (ADAM33)/Adam33 is a susceptibility gene for asthma and bronchial hyperresponsiveness in human beings and mice. ADAM33 is almost exclusively expressed in mesenchymal cells, including mesenchymal progenitors in developing lungs. Objective: Because maternal allergy is a risk factor for asthma, we hypothesized that an allergic environment affects ADAM33/Adam33 expression during human and mouse lung development. Methods: Human embryonic/fetal lung (HEL) tissues were collected from first-trimester terminations of pregnancy. These were processed immediately or used for explant culture +/- IL-13. MF1 mice or ovalbumin-sensitized A/J mice (Bronchial hyperresponsivness (Bhr)1/Adam33 locus-positive) were time-mated and challenged with ovalbumin (A/J mice only) during pregnancy. Lungs were harvested at different times during gestation and post partum. ADAM33/Adam33 expression was analyzed by using reverse transcriptase quantitative polymerase chain reaction and Western blotting. Results: ADAM33 mRNA was detectable in HELs in the pseudoglandular stage of development and showed a significant increase from 7 to 9 weeks postconception. IL-13 significantly suppressed ADAM33 mRNA in HEL explants. In developing murine lungs, Adam33 mRNA and protein expression increased significantly in the early pseudoglandular stage and showed another large increase post partum. In A/J mice, maternal allergy significantly suppressed Adam33 mRNA in lungs of newborn pups, whereas processed Adam33 protein increased and several smaller isoforms were detected. Conclusion: Adam33/Adam33 shows 2 significant increments in expression during lung morphogenesis, suggesting important developmental regulation. The ability of maternal allergy or exogenous IL-13 to suppress Adam33/ADAM33 mRNA but enhance Adam33 processing suggests a gene-environment interaction that may be relevant for asthma pathogenesis. (J Allergy Clin Immunol 2009; 124: 590-7.)	[Haitchi, Hans Michael; Bucchieri, Fabio; Powell, Robert M.; Holgate, Stephen T.; Davies, Donna E.] Univ Southampton, Roger Brooke Lab, Div Infect Inflammat & Immun, Southampton SO16 6YD, Hants, England; [Hanley, Neil A.; Wilson, David I.] Univ Southampton, Ctr Human Dev Stem Cells & Regenerat, Div Human Genet, Sch Med, Southampton SO16 6YD, Hants, England; [Bassett, David J. P.; Gao, Xiufeng] Wayne State Univ, Sch Med, Dept Family Med & Publ Hlth Sci, Detroit, MI USA	University of Southampton; University of Southampton; Wayne State University	Haitchi, HM (corresponding author), Univ Southampton, Southampton Gen Hosp, Div Infect Inflammat & Immun, Sch Med, MP 810,Level F,S Acad Block,Tremona Rd, Southampton SO16 6YD, Hants, England.	hmha@soton.ac.uk	Davies, Donna E/H-2993-2012; Bucchieri, Fabio/F-8877-2012; Wilson, David/A-6264-2010	Wilson, David/0000-0001-8779-2060; Davies, Donna/0000-0002-5117-2991; Hanley, Neil/0000-0003-3234-4038; BUCCHIERI, Fabio/0000-0002-0209-8668; Haitchi, Hans Michael/0000-0001-8603-302X	Michigan University Challenge Initiative; Synairgen Research Ltd; Wayne State University Research Enhancement; Engineering and Physical Sciences Research Council UK; Asthma, Allergy and Inflammation Research (AAIR) Charity; British Lung Foundation; Medical Research Council; Roger Brooke Charitable Trust, United Kingdom; Research Enhancement Funds, Wayne State University, Detroit, Mich; Medical Research Council [G0400473, G19/34] Funding Source: researchfish; MRC [G0400473, G19/34] Funding Source: UKRI	Michigan University Challenge Initiative; Synairgen Research Ltd; Wayne State University Research Enhancement; Engineering and Physical Sciences Research Council UK(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Asthma, Allergy and Inflammation Research (AAIR) Charity; British Lung Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Roger Brooke Charitable Trust, United Kingdom; Research Enhancement Funds, Wayne State University, Detroit, Mich; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Disclosure of potential conflict of interest: D. J. P. Bassett and X. Gao have received research support from the Michigan University Challenge Initiative, Synairgen Research Ltd, and Wayne State University Research Enhancement. D. I. Wilson has received research support from the Engineering and Physical Sciences Research Council UK. The rest of the authors have declared that they have no conflict of interest.; Supported by the Asthma, Allergy and Inflammation Research (AAIR) Charity, the British Lung Foundation, the Medical Research Council, and the Roger Brooke Charitable Trust, United Kingdom; and Research Enhancement Funds, Wayne State University, Detroit, Mich.	Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Bridges LC, 2005, BIOCHEM J, V387, P101, DOI 10.1042/BJ20041444; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Chen C, 2006, MOL CELL BIOL, V26, P6950, DOI 10.1128/MCB.00646-06; Dealtry GB, 1998, AM J REPROD IMMUNOL, V40, P283; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; Foster H. L., 1983, MOUSE BIOMEDICAL RES; Garlisi CG, 2003, BIOCHEM BIOPH RES CO, V301, P35, DOI 10.1016/S0006-291X(02)02976-5; Gunn TM, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-2; Haitchi HM, 2009, EUR RESPIR J, V33, P1095, DOI 10.1183/09031936.00157108; Haitchi HM, 2005, AM J RESP CRIT CARE, V171, P958, DOI 10.1164/rccm.200409-1251OC; HAITCHI HM, 2008, EUR RESP J IN PRESS; Hanley NA, 2000, MECH DEVELOP, V91, P403, DOI 10.1016/S0925-4773(99)00307-X; Hegde PS, 2003, CURR OPIN BIOTECH, V14, P647, DOI 10.1016/j.copbio.2003.10.006; Ito I, 2007, J ALLERGY CLIN IMMUN, V119, P89, DOI 10.1016/j.jaci.2006.08.038; Jesudason EC, 2005, AM J RESP CELL MOL, V32, P118, DOI 10.1165/rcmb.2004-0304OC; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x; Lannero E, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-3; Lee JY, 2006, AM J RESP CRIT CARE, V173, P729, DOI 10.1164/rccm.200409-1175OC; Meng JF, 2007, GENES IMMUN, V8, P215, DOI 10.1038/sj.gene.6364376; Perl AKT, 1999, CLIN GENET, V56, P14, DOI 10.1034/j.1399-0004.1999.560103.x; Powell RM, 2004, AM J RESP CELL MOL, V31, P13, DOI 10.1165/rcmb.2003-0330OC; Puxeddu I, 2008, J ALLERGY CLIN IMMUN, V121, P1400, DOI 10.1016/j.jaci.2008.03.003; Richter A, 2001, AM J RESP CELL MOL, V25, P385, DOI 10.1165/ajrcmb.25.3.4437; Schittny JC, 2000, AM J RESP CELL MOL, V23, P11, DOI 10.1165/ajrcmb.23.1.3926; Sears MR, 1996, ARCH DIS CHILD, V75, P392, DOI 10.1136/adc.75.5.392; Simpson A, 2005, AM J RESP CRIT CARE, V172, P55, DOI 10.1164/rccm.200412-1708OC; Spinozzi F, 2001, INT ARCH ALLERGY IMM, V124, P497, DOI 10.1159/000053785; Temelkovski J, 1998, THORAX, V53, P849, DOI 10.1136/thx.53.10.849; TENHAVEOPBROEK AAW, 1991, EXP LUNG RES, V17, P111, DOI 10.3109/01902149109064406; Umland SP, 2003, AM J RESP CELL MOL, V29, P571, DOI 10.1165/rcmb.2003-0028OC; van Diemen CC, 2005, AM J RESP CRIT CARE, V172, P329, DOI 10.1164/rccm.200411-1486OC; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; von Mutius E, 2002, J ALLERGY CLIN IMMUN, V109, pS525, DOI 10.1067/mai.2002.124565; Wan HJ, 2005, J BIOL CHEM, V280, P13809, DOI 10.1074/jbc.M414122200; Williams TJ, 2000, J ALLERGY CLIN IMMUN, V105, P951, DOI 10.1067/mai.2000.106211; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Yang YW, 2008, J ALLERGY CLIN IMMUN, V121, P1393, DOI 10.1016/j.jaci.2008.02.031; Yoshinaka T, 2002, GENE, V282, P227, DOI 10.1016/S0378-1119(01)00818-6; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zou J, 2004, J BIOL CHEM, V279, P9818, DOI 10.1074/jbc.M309696200	43	18	18	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					590	U301		10.1016/j.jaci.2009.06.026	http://dx.doi.org/10.1016/j.jaci.2009.06.026			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19665773				2022-12-18	WOS:000274315900027
J	Smith, AM; Bernstein, DI				Smith, Andrew M.; Bernstein, David I.			Management of work-related asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Work-related asthma; occupational asthma; work-exacerbated asthma; irritant-induced asthma	STANDARDIZED LATEX EXTRACT; IRRITANT-INDUCED ASTHMA; NATURAL-RUBBER LATEX; OCCUPATIONAL ASTHMA; DOUBLE-BLIND; DIPHENYLMETHANE DIISOCYANATE; RESPIRATORY SYMPTOMS; IMMUNOGLOBULIN G4; FATAL ASTHMA; IMMUNOTHERAPY	The physician managing work-related asthma (WRA) assumes many roles. The first is to confirm an accurate diagnosis, recognizing that WRA has multiple phenotypes, including sensitizer-induced occupational asthma (OA) caused by high-molecular-weight (HMW) proteins or low-molecular-weight (LMW) chemicals; irritant-induced asthma; and work-exacerbated asthma. Pharmacotherapy for WRA is identical to nonwork-related asthma and should be guided by current asthma guidelines emphasizing control of both asthma impairment and risk domains. It is well established that the majority of workers diagnosed with OA caused by sensitizers experience persistent asthma after leaving the workplace. However, the long-term risk of persistent unremitting asthma can be prevented in a minority of cases, particularly with OA caused by LMW sensitizers, by establishing an early diagnosis of OA and reducing or eliminating exposure. The physician consultant may advise employers on workplace interventions needed to minimize effectively an affected employee's exposure to a causative agent or condition, and what measures are required to prevent new cases of WRA (ie, primary prevention). Although allergen immunotherapy has a putative role in treating and preventing WRA caused by HMW sensitizers, further study is needed. Q Allergy Clin Immunol 2009;123:551-7.)	[Smith, Andrew M.; Bernstein, David I.] Univ Cincinnati, Dept Internal Med, Div Immunol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Bernstein, DI (corresponding author), Univ Cincinnati, Dept Internal Med, Div Immunol, 231 Albert Sabin Way,ML 0563, Cincinnati, OH 45267 USA.	bernstdd@ucmail.uc.edu			National Institute for Occupational Safety; Health/Centers for Disease Control and Prevention; Association of Specialty Professors/American Academy of Allergy, Asthma Immunology	National Institute for Occupational Safety(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); Health/Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Association of Specialty Professors/American Academy of Allergy, Asthma Immunology	Disclosure of potential conflict of interest: D. I. Bernstein has received research support from the National Institute for Occupational Safety and Health/Centers for Disease Control and Prevention. A. M. Smith has received research support from the Association of Specialty Professors/American Academy of Allergy, Asthma & Immunology.	Anees W, 2006, THORAX, V61, P751, DOI 10.1136/thx.2005.054080; ARMENTIA A, 1990, ANN ALLERGY, V65, P265; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; BANKS DE, 1990, CHEST, V97, P121, DOI 10.1378/chest.97.1.121; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Baur X, 2003, ANN ALLERG ASTHMA IM, V90, P11, DOI 10.1016/S1081-1206(10)61642-0; Bernstein DI, 2002, AM J RESP CRIT CARE, V166, P445, DOI 10.1164/rccm.2109018; BERNSTEIN DI, 1993, J ALLERGY CLIN IMMUN, V92, P387, DOI 10.1016/0091-6749(93)90117-X; Bernstein DI, 2002, J ALLERGY CLIN IMMUN, V110, pS111, DOI 10.1067/mai.2002.125330; Bernstein I. L., 2006, ASTHMA WORKPLACE, V3, P1; Blanc PD, 1999, AM J MED, V107, P580, DOI 10.1016/S0002-9343(99)00307-1; Breton CV, 2006, OCCUP ENVIRON MED, V63, P411, DOI 10.1136/oem.2005.025064; Brooks SM, 1998, CHEST, V113, P42, DOI 10.1378/chest.113.1.42; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; Carino M, 1997, RESPIRATION, V64, P111, DOI 10.1159/000196653; CHANYEUNG M, 1993, AM REV RESPIR DIS, V147, P1056; EHRLICH RI, 1994, AM J IND MED, V26, P799, DOI 10.1002/ajim.4700260608; FABBRI LM, 1988, AM REV RESPIR DIS, V137, P1494, DOI 10.1164/ajrccm/137.6.1494; Gautrin D, 2008, AM J RESP CRIT CARE, V177, P871, DOI 10.1164/rccm.200707-991OC; Global Strategy for Asthma Management and Prevention, 2006, GLOB STRAT ASTHM MAN; Goe SK, 2004, OCCUP ENVIRON MED, V61, P512, DOI 10.1136/oem.2003.008177; Grammer LC, 2002, CHEST, V121, P1317, DOI 10.1378/chest.121.4.1317; Henneberger PK, 2006, OCCUP ENVIRON MED, V63, P551, DOI 10.1136/oem.2005.024786; Jaakkola MS, 2006, EUR RESPIR J, V28, P397, DOI 10.1183/09031936.06.00001306; Jeal H, 2006, AM J RESP CRIT CARE, V174, P21, DOI 10.1164/rccm.200506-964OC; Klusackova P, 2006, IND HEALTH, V44, P629, DOI 10.2486/indhealth.44.629; Kogevinas M, 2007, LANCET, V370, P336, DOI 10.1016/S0140-6736(07)61164-7; LaMontagne AD, 2006, OCCUP ENVIRON MED, V63, P359, DOI 10.1136/oem.2005.025221; Lemiere C, 2007, J ALLERGY CLIN IMMUN, V120, P1354, DOI 10.1016/j.jaci.2007.07.043; Leynadier F, 2000, J ALLERGY CLIN IMMUN, V106, P585, DOI 10.1067/mai.2000.109173; Liu YC, 2006, J OCCUP ENVIRON HYG, V3, P234, DOI 10.1080/15459620600628704; Maestrelli P, 2004, J ALLERGY CLIN IMMUN, V113, P643, DOI 10.1016/j.jaci.2003.12.586; MAESTRELLI P, 1993, AM REV RESPIR DIS, V148, P407, DOI 10.1164/ajrccm/148.2.407; Malo JL, 1996, AM J RESP CRIT CARE, V153, P953, DOI 10.1164/ajrccm.153.3.8630579; MALO JL, 1991, AM REV RESPIR DIS, V143, P528, DOI 10.1164/ajrccm/143.3.528; Mapp CE, 2005, AM J RESP CRIT CARE, V172, P280, DOI 10.1164/rccm.200311-1575SO; Matsui EC, 2006, CLIN EXP ALLERGY, V36, P1097, DOI 10.1111/j.1365-2222.2006.02534.x; Matsui EC, 2005, CLIN EXP ALLERGY, V35, P1347, DOI 10.1111/j.1365-2222.2005.02331.x; Medina-Ramon M, 2006, EUR RESPIR J, V27, P1196, DOI 10.1183/09031936.06.00085405; Menzies D, 2006, JAMA-J AM MED ASSOC, V296, P1742, DOI 10.1001/jama.296.14.1742; Muller-Wening D, 1998, EUR RESPIR J, V12, P569, DOI 10.1183/09031936.98.12030569; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Nicholson PJ, 2005, OCCUP ENVIRON MED, V62, P290, DOI 10.1136/oem.2004.016287; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; Park HS, 2002, CLIN EXP ALLERGY, V32, P551, DOI 10.1046/j.0954-7894.2002.01349.x; Perkner JJ, 1998, J OCCUP ENVIRON MED, V40, P136, DOI 10.1097/00043764-199802000-00009; Pichler CE, 2001, ALLERGY, V56, P301, DOI 10.1034/j.1398-9995.2001.00834.x; Pifferi M, 2002, ALLERGY, V57, P785, DOI 10.1034/j.1398-9995.2002.23498.x; Pronk A, 2007, AM J RESP CRIT CARE, V176, P1090, DOI 10.1164/rccm.200702-215OC; Quirce S, 2000, J ASTHMA, V37, P267, DOI 10.3109/02770900009055449; Rachiotis G, 2007, THORAX, V62, P147, DOI 10.1136/thx.2006.061952; Rosenman KD, 1997, J OCCUP ENVIRON MED, V39, P415, DOI 10.1097/00043764-199705000-00007; Sastre J, 2003, J ALLERGY CLIN IMMUN, V111, P985, DOI 10.1067/mai.2003.1390; Schweigert MK, 2000, CLIN EXP ALLERGY, V30, P1511, DOI 10.1046/j.1365-2222.2000.00893.x; Susitaival P, 2003, AM J IND MED, V44, P166, DOI 10.1002/ajim.10253; Sussman GL, 2002, METHODS, V27, P3, DOI 10.1016/S1046-2023(02)00045-2; Tarlo SM, 2008, CHEST, V134, p1S, DOI 10.1378/chest.08-0201; Taylor AJN, 2005, THORAX, V60, P364, DOI 10.1136/thx.2004.032367; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709, DOI 10.1016/S0091-6749(98)70181-2; Vandenplas O, 2003, EUR RESPIR J, V22, P689, DOI 10.1183/09031936.03.00053203; Vandenplas O, 2002, J ALLERGY CLIN IMMUN, V109, P125, DOI 10.1067/mai.2002.120760; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Wisnewski AV, 2007, CURR OPIN ALLERGY CL, V7, P138, DOI 10.1097/ACI.0b013e3280895d22; Yacoub MR, 2007, EUR RESPIR J, V29, P889, DOI 10.1183/09031936.00127206	64	18	18	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					551	557		10.1016/j.jaci.2008.12.1129	http://dx.doi.org/10.1016/j.jaci.2008.12.1129			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19281902				2022-12-18	WOS:000264731200010
J	Wu, AC; Tantisira, K; Li, LL; Schuemann, B; Weiss, S				Wu, Ann Chen; Tantisira, Kelan; Li, Lingling; Schuemann, Brooke; Weiss, Scott		Childhood Asthma Management Progra	Repeatability of response to asthma medications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; drug response; heritability; bronchodilator; pharmacogenetics	CHILDHOOD ASTHMA; PULMONARY-FUNCTION; HERITABILITY; MONTELUKAST; CHILDREN; TWINS	Background: Pharmacogenetic studies of drug response in asthma assume that patients respond consistently to a treatment but that treatment response varies across patients; however, no formal studies have demonstrated this. Objective: To determine the repeatability of commonly used outcomes for treatment response to asthma medications: bronchodilator response, FEV1, and PC20. Methods: The Childhood Asthma Management Program was a multicenter clinical trial of children randomized to receiving budesonide, nedocromil, or placebo. We determined the intraclass correlation coefficient (ICC) for each outcome over repeated visits over a period of 4 years in the Childhood Asthma Management Program by using mixed-effects regression models. We adjusted for the covariates age, race/ethnicity, height, family income, parental education, and symptom score. We incorporated each outcome for each child as repeated outcome measurements and stratified by treatment group. Results: The ICC for bronchodilator response was 0.31 in the budesonide group, 0.35 in the nedocromil group, and 0.40 in the placebo group, after adjusting for covariates. The ICC for FEV1 was 0.71 in the budesonide group, 0.60 in the nedocromil group, and 0.69 in the placebo group, after adjusting for covariates. The ICC for PC20 was 0.67 in the budesonide and placebo groups and 0.73 in the nedocromil group, after adjusting for covariates. Conclusion: The within-treatment group repeatability of FEV1 and PC20 is high; thus, these phenotypes are heritable. FEV1 and PC20 may he better phenotypes than bronchodilator response for studies of treatment response in asthma. (J Allergy Clin Immunol 2009;123:385-90.)	[Wu, Ann Chen; Li, Lingling] Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; [Wu, Ann Chen; Tantisira, Kelan; Li, Lingling; Weiss, Scott] Harvard Univ, Sch Med, Cambridge, MA 02138 USA; [Wu, Ann Chen] Childrens Hosp, Dept Pediat, Boston, MA USA; [Tantisira, Kelan; Schuemann, Brooke; Weiss, Scott] Brigham & Womens Hosp, Ctr Genom Med, Dept Med, Channing Lab, Boston, MA 02115 USA	Harvard Pilgrim Health Care; Harvard University; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital	Wu, AC (corresponding author), Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA.	ann.wu@childrens.harvard.cdu	Wu, Ann/AAY-4293-2020	Wu, Ann/0000-0003-0599-9063	The Childhood Asthma Management Program [NO1-HR-16044, 16045, 16046, 16047, 160411, 16049, 161150, 16051, 16052]; National Heart, lung. and Blood Institute and General Clinical Research Center [M01 RR00051, M01 RR0099718-24, M01 RR02719-14, RR00036]; National Center for Research Resources;  [U01 HL65899]; DIVISION OF LUNG DISEASES [N01HR016050, N01HR016044, N01HR016047, N01HR016051, N01HR016052, N01HR016049, N01HR016048, N01HR016046, N01HR016045] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051, M01RR000036, M01RR002719] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL065899] Funding Source: NIH RePORTER	The Childhood Asthma Management Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Heart, lung. and Blood Institute and General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)NIH National Center for Research Resources (NCRR)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); ; DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The Childhood Asthma Management Program is supported by contracts NO1-HR-16044, 16045, 16046, 16047, 160411, 16049, 161150, 16051, and 16052 with the National Heart, lung. and Blood Institute and General Clinical Research Center grant, M01 RR00051 M01 RR0099718-24, M01 RR02719-14, and RR00036 from the National Center for Research Resources. This work was also supported by U01 HL65899.	Brown GP, 2007, J EVOLUTION BIOL, V20, P588, DOI 10.1111/j.1420-9101.2006.01256.x; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Choy YH, 2002, J ANIM SCI, V80, P2071; CHRISTIAN HA, 1942, OSLERS PRINCIPLES PR; Drazen JM, 2000, BRIT MED BULL, V56, P1054, DOI 10.1258/0007142001903535; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; Fuhlbrigge AL, 2006, PEDIATRICS, V118, pE347, DOI 10.1542/peds.2005-2962; GHIO AJ, 1989, CHEST, V96, P743, DOI 10.1378/chest.96.4.743; Hartl DL, 1997, PRINCIPLES POPULATIO; HUBERT HB, 1982, AM REV RESPIR DIS, V125, P409; Kitch BT, 2004, CHEST, V126, P1875, DOI 10.1378/chest.126.6.1875; Lemanske RF, 1997, AM J RESP CRIT CARE, V156, P685, DOI 10.1164/ajrccm.156.3.ed-13; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; NIEMINEN MM, 1991, CHEST, V100, P70, DOI 10.1378/chest.100.1.70; ROSNER B, 1977, AM J EPIDEMIOL, V106, P306, DOI 10.1093/oxfordjournals.aje.a112466; Rosner B., 2000, FUNDAMENTALS BIOSTAT; Senn S, 2004, BMJ-BRIT MED J, V329, P966, DOI 10.1136/bmj.329.7472.966; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Tantisira KG, 2006, J ALLERGY CLIN IMMUN, V117, P1264, DOI 10.1016/j.jaci.2006.01.050	22	18	18	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					385	390		10.1016/j.jaci.2008.10.015	http://dx.doi.org/10.1016/j.jaci.2008.10.015			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19064281	Green Accepted, Bronze			2022-12-18	WOS:000263495000014
J	Vercelli, D				Vercelli, Donata			Gene-environment interactions: The road less traveled by in asthma genetics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Genetics; environment; gene-environment; interactions; asthma	SERUM IGE LEVELS; EXPOSURE; POLYMORPHISM; CD14/-260; VARIANTS; CHILDREN		[Vercelli, Donata] Univ Arizona, Dept Cell Biol, Tucson, AZ 85724 USA; [Vercelli, Donata] Univ Arizona, Arizona Initiat Biol Complex Dis, Arizona Resp Ctr, Tucson, AZ 85724 USA	University of Arizona; University of Arizona	Vercelli, D (corresponding author), Univ Arizona, Arizona Initiat Biol Complex Dis, Arizona Resp Ctr, Tucson, AZ 85724 USA.	donata@arc.arizona.edu						Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; HIRSCHHORN JN, 2005, NATURE REV GENETICS, V6, P108; Idaghdour Y, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000052; Leynaert B, 2006, J ALLERGY CLIN IMMUN, V118, P658, DOI 10.1016/j.jaci.2006.06.015; Meyers DA, 2005, J ALLERGY CLIN IMMUN, V115, P1169, DOI 10.1016/j.jaci.2005.01.070; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; von Mutius E, 2008, J ALLERGY CLIN IMMUN, V122, P99, DOI 10.1016/j.jaci.2008.05.017; Weiss LA, 2006, NAT GENET, V38, P218, DOI 10.1038/ng1726; Williams LK, 2006, J ALLERGY CLIN IMMUN, V118, P851, DOI 10.1016/j.jaci.2006.07.007; Willis-Owen SAG, 2009, J ALLERGY CLIN IMMUN, V123, P14, DOI 10.1016/j.jaci.2008.09.016; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001	16	18	18	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					26	27		10.1016/j.jaci.2008.11.031	http://dx.doi.org/10.1016/j.jaci.2008.11.031			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19130923				2022-12-18	WOS:000262793900004
J	Pemberton, AD; Rose-Zerilli, MJ; Holloway, JW; Gray, RD; Holgate, ST				Pemberton, Alan D.; Rose-Zerilli, Matthew J.; Holloway, John W.; Gray, Robert D.; Holgate, Stephen T.			A single-nucleotide polymorphism in intelectin 1 is associated with increased asthma risk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SUSCEPTIBILITY; DISEASES; GENES		[Pemberton, Alan D.] Univ Edinburgh, Easter Bush Vet Ctr, Royal Dick Sch Vet Studies, Div Vet Clin Studies, Roslin, Midlothian, Scotland; [Rose-Zerilli, Matthew J.; Holloway, John W.; Holgate, Stephen T.] Univ Southampton, Sch Med, Div Infect Inflammat & Repair, Edinburgh, Midlothian, Scotland; [Rose-Zerilli, Matthew J.; Holloway, John W.] Univ Southampton, Sch Med, Div Human Genet, Edinburgh, Midlothian, Scotland; [Gray, Robert D.] Univ Edinburgh, Western Gen Hosp, Sch Mol & Clin Med, Edinburgh, Midlothian, Scotland	University of Edinburgh; University of Southampton; University of Southampton; University of Edinburgh	Pemberton, AD (corresponding author), Univ Edinburgh, Easter Bush Vet Ctr, Royal Dick Sch Vet Studies, Div Vet Clin Studies, Roslin, Midlothian, Scotland.	alan.pemberton@ed.ac.uk	Holloway, John W/B-5424-2009	Holloway, John W/0000-0001-9998-0464; Gray, Robert/0000-0002-2203-2703	MRC [G0800766] Funding Source: UKRI; Medical Research Council [G0800766] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Barrett R, 2008, J MOTOR BEHAV, V40, P62, DOI 10.3200/JMBR.40.1.62-70; Beghe B, 2003, CLIN EXP ALLERGY, V33, P1111, DOI 10.1046/j.1365-2222.2003.01731.x; FRENCH AT, 2007, VET IMMUNOL IMMUNOP, V26, P2237; Gray RD, 2008, AM J RESP CRIT CARE, V178, P444, DOI 10.1164/rccm.200703-409OC; Knight PA, 2008, PARASITOLOGY, V135, P655, DOI 10.1017/S0031182008004319; Kuperman DA, 2005, J ALLERGY CLIN IMMUN, V116, P305, DOI 10.1016/j.jaci.2005.03.024; Schafler A, 2007, CARDIOVASC DIABETOL, V6, DOI 10.1186/1475-2840-6-3; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257	9	18	19	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					1033	1034		10.1016/j.jaci.2008.08.037	http://dx.doi.org/10.1016/j.jaci.2008.08.037			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	19000584				2022-12-18	WOS:000260940100027
J	Canfield, SM; Jacobson, JS; Perzanowski, MS; Mellins, RB; Zemble, RM; Chew, GL; Goldstein, IF				Canfield, Stephen M.; Jacobson, Judith S.; Perzanowski, Matthew S.; Mellins, Robert B.; Zemble, Robert M.; Chew, Ginger L.; Goldstein, Inge F.			Total and specific IgE associations between New York City Head Start children and their parents	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; familial; total IgE; specific IgE; Hispanic; Head Start; children	SKIN-TEST REACTIVITY; INDOOR ALLERGENS; SERUM IGE; PRESCHOOL-CHILDREN; COCKROACH ALLERGEN; RISK-FACTORS; ASTHMA; EXPOSURE; SENSITIZATION; SENSITIVITY	Background: Allergy and asthma risk share strong inherited components; however, the relative importance of maternal and paternal atopy in predicting child atopy remain unclear. Objective: We sought to identify relationships between parents' and children's total and specific IgE levels within family units as predictors of allergic risk in children. Methods: Total and allergen-specific IgE (to dust mite, cockroach, mouse, and cat) were determined by means of ImmunoCap (Phadia, Inc, Portage, Mich) in a sample of families participating in New York City Head Start programs. Regression models were developed to determine the associations of parents' and children's total IgE levels and sensitization patterns. Results: Blood specimens were collected from 161 family triads of mother, father, and child (83 boys and 78 girls). At a mean age of 4 years, boys had significantly higher total IgE levels than girls. Boys' total IgE levels were highly correlated with both mothers' (P<.002) and fathers' (P=.002) total IgE levels; girls' total IgE levels were not. Unlike total IgE levels, specific IgE levels among both boys and girls were associated with their mothers' specific IgE levels. Dust mite sensitization among mothers was predictive of children's sensitization to each of the 4 aeroallergens. Conclusion: The strong associations between parents' and children's IgE levels suggest that assessment of parents' total and locally relevant allergen-specific IgE levels might have value in predicting atopy in children of preschool age.	[Canfield, Stephen M.; Zemble, Robert M.] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; [Mellins, Robert B.] Columbia Univ, Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; [Jacobson, Judith S.; Goldstein, Inge F.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA; [Perzanowski, Matthew S.; Chew, Ginger L.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10027 USA	Columbia University; Columbia University; Columbia University; Columbia University	Canfield, SM (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, PH8 E,Suite 101,622 W 168th St, New York, NY 10032 USA.	smc12@columbia.edu		Perzanowski, Matthew/0000-0003-1300-0985	NHLBI NIH HHS [HL068236] Funding Source: Medline; NIEHS NIH HHS [P30 ES009089] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahmadi KR, 2003, GENES IMMUN, V4, P289, DOI 10.1038/sj.gene.6363968; Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1497, DOI 10.1164/ajrccm.152.5.7582283; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BURROWS B, 1995, J ALLERGY CLIN IMMUN, V95, P548, DOI 10.1016/S0091-6749(95)70317-9; Chang W. T., 2005, Acta Paediatrica Taiwanica, V46, P272; Chew GL, 2008, J ALLERGY CLIN IMMUN, V121, P240, DOI 10.1016/j.jaci.2007.08.024; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; Crestani E, 2004, J ALLERGY CLIN IMMUN, V113, P284, DOI 10.1016/j.jaci.2003.11.009; Elizur A, 2007, ANN ALLERG ASTHMA IM, V98, P540, DOI 10.1016/S1081-1206(10)60732-6; Flores G, 2002, JAMA-J AM MED ASSOC, V288, P82, DOI 10.1001/jama.288.1.82; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Hagendorens MM, 2005, CLIN EXP ALLERGY, V35, P733, DOI 10.1111/j.1365-2222.2005.02254.x; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Jacobson JS, 2008, ALLERGY, V63, P87, DOI 10.1111/j.1398-9995.2007.01529.x; Johnson CC, 1998, AM J EPIDEMIOL, V147, P1145; Karihaloo C, 2002, CLIN EXP ALLERGY, V32, P1316, DOI 10.1046/j.1365-2745.2002.01447.x; Kim YK, 2002, ANN ALLERG ASTHMA IM, V88, P170, DOI 10.1016/S1081-1206(10)61992-8; Liu CA, 2003, J ALLERGY CLIN IMMUN, V112, P899, DOI 10.1016/j.jaci.2003.08.030; Lopez N, 1999, J INVEST ALLERG CLIN, V9, P392; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995, DOI 10.1164/ajrccm.164.6.2011107; Nickel R, 2005, CLIN EXP ALLERGY, V35, P619, DOI 10.1111/j.1365-2222.2005.02237.x; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sears MR, 1996, ARCH DIS CHILD, V75, P392, DOI 10.1136/adc.75.5.392; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Simpson A, 2005, J ALLERGY CLIN IMMUN, V116, P744, DOI 10.1016/j.jaci.2005.06.032; Stevenson LA, 2001, J ALLERGY CLIN IMMUN, V108, P747, DOI 10.1067/mai.2001.119410; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Torio A, 2003, HUM IMMUNOL, V64, P811, DOI 10.1016/S0198-8859(03)00109-5; Tunnicliffe WS, 1999, EUR RESPIR J, V13, P654, DOI 10.1183/09031936.99.13365499; *US BUR CENS, POP CHAR HISP POP US; Williams PB, 2000, J ALLERGY CLIN IMMUN, V105, P1221, DOI 10.1067/mai.2000.105219	32	18	18	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1422	1427		10.1016/j.jaci.2008.03.011	http://dx.doi.org/10.1016/j.jaci.2008.03.011			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18472147	Bronze			2022-12-18	WOS:000256771700018
J	Calabria, CW; Coop, CA; Tankersley, MS				Calabria, Christopher W.; Coop, Christopher A.; Tankersley, Michael S.			The GILL study: Glycerin-induced local reactions in immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						glycerin; local reactions; large local reactions; immunotherapy	ALLERGEN IMMUNOTHERAPY; SYSTEMIC REACTIONS; INJECTIONS	Background: The mechanism of local reactions is not well defined. Glycerin, an excellent preservative used commonly in immunotherapy extracts, is a recognized irritant. Objective: This study was undertaken to examine whether higher glycerin concentration in immunotherapy extracts is associated with an increase in local reaction rates during immunotherapy. Methods: A retrospective analysis of electronic immunotherapy records over a 12-month period was performed from a single site. A small local reaction was defined as induration and/or erythema at the injection site smaller than or equal to the size of the patient's palm. A large local reaction was defined as a reaction larger than the patient's palm. Results: Over the 12-month period, 360 patients received a total of 9678 immunotherapy injections. For all injections, the total local reaction rate was 16.3% (1574/9678), the small local reaction rate was 15.9% (1536/9678), and the large local reaction rate was 0.4% (38/9678). For aeroallergens, small local reaction rates increased significantly with increasing allergen concentrations, from 7.3% (1:1000 vol/vol) to 23.0% (1:1 vol/ vol; P < .001). The small local reaction rate was higher with increasing allergen content but not higher glycerin concentration. Large local reactions were infrequent and did not significantly increase with allergen or glycerin concentration. Conclusions: Small local, but not large local, reaction rates increase with higher allergen concentration, number, and volume. Higher glycerin concentrations (even 50%) are not associated with significantly higher small or large local reaction rates.	[Calabria, Christopher W.; Coop, Christopher A.; Tankersley, Michael S.] Wilford Hall USAF Med Ctr, Dept Allergy & Immunol, Lackland AFB, TX 78236 USA	United States Department of Defense; United States Air Force	Calabria, CW (corresponding author), Wilford Hall USAF Med Ctr, Dept Allergy & Immunol, 2200 Bergquist Dr,Suite 1, Lackland AFB, TX 78236 USA.	christopher.calabria@lackland.af.mil						ANDERSON MC, 1982, J ALLERGY CLIN IMMUN, V69, P3, DOI 10.1016/0091-6749(82)90080-X; Coop CA, 2007, ANN ALLERG ASTHMA IM, V99, P77, DOI 10.1016/S1081-1206(10)60625-4; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; Hurst DS, 2002, OTOLARYNG HEAD NECK, V127, P177, DOI 10.1067/mhn.2002.127890; Joint Task Force on Practice Parameters, 2003, Ann Allergy Asthma Immunol, V90, P1; Kain ZN, 2007, PEDIATRICS, V119, P608, DOI 10.1542/peds.2006-3030; Kelso JM, 2004, ANN ALLERG ASTHMA IM, V92, P225, DOI 10.1016/S1081-1206(10)61551-7; KORDASH TR, 1993, ANN ALLERGY, V71, P240; More DR, 2002, ANN ALLERG ASTHMA IM, V88, P391, DOI 10.1016/S1081-1206(10)62370-8; NELSON BL, 1986, ANN ALLERGY, V56, P331; NELSON H, 1978, J ALLERGY CLIN IMMUN, V63, P417; NELSON HS, 1981, J ALLERGY CLIN IMMUN, V67, P64, DOI 10.1016/0091-6749(81)90047-6; PRIGAL SJ, 1972, ANN ALLERGY, V30, P529; RAMIREZ DA, 1981, ANN ALLERGY, V47, P435; Tankersley MS, 2000, J ALLERGY CLIN IMMUN, V106, P840, DOI 10.1067/mai.2000.110468; TINKELMAN DG, 1995, J ALLERGY CLIN IMMUN, V95, P8, DOI 10.1016/S0091-6749(95)70146-X; VanMetre TE, 1996, J ALLERGY CLIN IMMUN, V97, P1033, DOI 10.1016/S0091-6749(96)70254-3	17	18	18	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					222	226		10.1016/j.jaci.2007.08.016	http://dx.doi.org/10.1016/j.jaci.2007.08.016			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17919703				2022-12-18	WOS:000252372000034
J	Yamazaki, K; Murray, JA; Kita, H				Yamazaki, Kiyoshi; Murray, Joseph A.; Kita, Hirohito			Innate immunomodulatory effects of cereal grains through induction of IL-10	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rice; wheat; cereal grains; food; IL-10; immunomodulation; lipopolysaccharide	INFLAMMATORY BOWEL-DISEASE; TOLL-LIKE RECEPTORS; LIPOPOLYSACCHARIDE LPS; ACTIVATED MACROPHAGE; MURINE MODEL; WHEAT-FLOUR; INTERLEUKIN-10; CYTOKINE; HOMEOSTASIS; COLITIS	Background: Interactions between the gastrointestinal immune system and the luminal environment play critical roles in maintaining immune homeostasis and in diseases such as inflammatory bowel disease. Although immunomodulation by microbial factors has been studied extensively, little attention has been given to the potential immunomodulatory effects of ingested foods. Objective: We characterized the effects of cereal grains on the immune response in human subjects and investigated the mechanism. Methods: PBMCs from healthy individuals were incubated with cereal grain extracts, and cytokine levels in cell-free supernatants were measured. The cellular source of IL-10 and the role of monocytes were investigated by means of flow cytometry and cell-depletion/reconstitution experiments. Results: Extracts of cereal grains, including rice and wheat, induced marked IL-10 production from PBMCs. Intracellular cytokine staining and cell-depletion experiments showed that CD14(+) monocytes produced IL-10. Importantly, when PBMCs were stimulated with concanavalin A, cereal grains concentration-dependently inhibited their production of IL-5, IL-13, and IFN-gamma; neutralizing IL-10 or removing the monocytes abrogated this inhibitory effect. This cereal grain-induced IL-10 response was polymyxin B sensitive, heat resistant, and inhibited by blocking the Toll-like receptor 4. Conclusion: Cereal grains have strong innate immunomodulatory effects by inducing marked production of IL-10 from CD14(+) monocytes in vitro. LPS or LPS-mimicking activity in cereal grains might be responsible. The potential immunomodulatory effects of cereal grains need further study in vivo.	[Yamazaki, Kiyoshi; Kita, Hirohito] Mayo Clin & Mayo Fdn, Allerg Dis Res Lab, Rochester, MN 55905 USA; [Murray, Joseph A.] Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Kita, H (corresponding author), Mayo Clin & Mayo Fdn, Allerg Dis Res Lab, Guggenheim 402,200 1st St SW, Rochester, MN 55905 USA.	kita.hirohito@mayo.edu		murray, joseph/0000-0003-1941-9090	NIAID NIH HHS [T32 AI07047, P01 AI50494, R01 AI49235] Funding Source: Medline; NIDDK NIH HHS [R01 DK57982, R01 DK071003] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049235, T32AI007047, P01AI050494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071003] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andrews JH, 2000, ANNU REV PHYTOPATHOL, V38, P145, DOI 10.1146/annurev.phyto.38.1.145; Araki A, 2005, J GASTROENTEROL, V40, P16, DOI 10.1007/s00535-004-1492-9; Asadullah K, 2003, PHARMACOL REV, V55, P241, DOI 10.1124/pr.55.2.4; Bashir MEH, 2004, J IMMUNOL, V172, P6978, DOI 10.4049/jimmunol.172.11.6978; Bellinghausen I, 2001, INT ARCH ALLERGY IMM, V126, P97, DOI 10.1159/000049499; Bettelli E, 2003, J AUTOIMMUN, V20, P265, DOI 10.1016/S0896-8411(03)00048-9; Byrne A, 2002, J IMMUNOL, V168, P1968, DOI 10.4049/jimmunol.168.4.1968; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Cominelli F, 2004, NEW ENGL J MED, V351, P2045, DOI 10.1056/NEJMp048253; Foey AD, 1998, J IMMUNOL, V160, P920; *FOOD AGR ORG UN, 2004, FOOD OUTL, V3, P1; Fukata M, 2005, AM J PHYSIOL-GASTR L, V288, pG1055, DOI 10.1152/ajpgi.00328.2004; GRIMM MC, 1995, J GASTROEN HEPATOL, V10, P387, DOI 10.1111/j.1440-1746.1995.tb01589.x; Hedden P, 2003, TRENDS GENET, V19, P5, DOI 10.1016/S0168-9525(02)00009-4; INAGAWA H, 1992, CHEM PHARM BULL, V40, P998, DOI 10.1248/cpb.40.998; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lang R, 2003, P NUTR SOC, V62, P123, DOI 10.1079/PNS2002219; Lindow SE, 2003, APPL ENVIRON MICROB, V69, P1875, DOI 10.1128/AEM.69.4.1875-1883.2003; Lindsay JO, 2001, ALIMENT PHARM THER, V15, P1709, DOI 10.1046/j.1365-2036.2001.01093.x; MIZUNO D, 1992, MOL BIOTHER, V4, P166; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; NISHIZAWA T, 1992, CHEM PHARM BULL, V40, P479, DOI 10.1248/cpb.40.479; Palosuo K, 2003, CURR OPIN ALLERGY CL, V3, P205, DOI [10.1097/00130832-200306000-00009, 10.1097/01.all.0000072717.82112.cc]; POMMERVILLE JC, 2004, ALCAMOS FUNDAMENTALS, P659; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rogler G, 1998, CLIN EXP IMMUNOL, V112, P205; RUGTVEIT J, 1994, GUT, V35, P669, DOI 10.1136/gut.35.5.669; Rugtveit J, 1997, GASTROENTEROLOGY, V112, P1493, DOI 10.1016/S0016-5085(97)70030-1; Sansonetti PJ, 2004, NAT REV IMMUNOL, V4, P953, DOI 10.1038/nri1499; Smythies LE, 2005, J CLIN INVEST, V115, P66, DOI 10.1172/JCI200519229; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tomoyose M, 1998, SCAND J GASTROENTERO, V33, P435; YAMAZAKI K, 2005, J ALLERGY CLIN IMMUN, V115, pS70; Yamazaki K, 2006, DIGEST DIS SCI, V51, P1934, DOI 10.1007/s10620-005-9048-2	37	18	18	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					172	178		10.1016/j.jaci.2007.08.031	http://dx.doi.org/10.1016/j.jaci.2007.08.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17919702	Bronze			2022-12-18	WOS:000252372000025
J	Rothers, J; Stern, DA; Spangenberg, A; Lohman, IC; Halonen, M; Wright, AL				Rothers, Janet; Stern, Debra A.; Spangenberg, Amber; Lohman, I. Carla; Halonen, Marilyn; Wright, Anne L.			Influence of early day-care exposure on total IgE levels through age 3 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; day care; atopy; asthma; infancy; microbial exposure; hygiene hypothesis	HAY-FEVER; EARLY-LIFE; ENDOTOXIN EXPOSURE; EARLY-CHILDHOOD; BIRTH COHORT; FAMILY-SIZE; FOLLOW-UP; ASTHMA; CHILDREN; ATTENDANCE	Background: Early day care is inversely associated with asthma and atopy in later childhood, but its association with early immunologic markers of asthma risk is not known. Objective: We sought to assess the relation of day care by 3 months to total IgE levels through age 3 years. Methods: Day care was assessed prospectively among 362 nonselected infants enrolled in the Infant Immune Study. Children were categorized based on day-care status by 3 months of age as follows: no day care, day care inside the home with other children, day care outside the home with no other children, or day care outside the home with other children. Total IgE levels were measured in blood obtained at 3, 42, 24, and 36 months. Relations between day care and IgE levels were assessed at each age and longitudinally, with stratification by maternal asthma and atopy. Results: Day care by 3 months was associated with decreased IgE levels through age 3 years (coefficient: -0.19 log IU/mL, P =.001). The greatest effect was evident for children cared for outside the home. Stratified analyses indicated that the relation existed primarily among children who had atopic or asthmatic mothers. Day-care entry after 3 months showed no relation with IgE levels. Conclusion: Day-care attendance by 3 months is associated with decreased total IgE levels in the first 3 years of life in children of mothers who are atopic, asthmatic, or both. Clinical implications: Early day-care exposure can reduce g levels, which in turn might reflect a reduced risk of allergic disease in predisposed children.	Univ Arizona, Hlth Sci Ctr, Arizona Resp Ctr, Tucson, AZ 85724 USA; Univ Arizona, Dept Pharmacol, Tucson, AZ 85721 USA; Univ Arizona, Dept Pediat, Tucson, AZ 85721 USA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona	Wright, AL (corresponding author), Univ Arizona, Hlth Sci Ctr, Arizona Resp Ctr, 1501 N Campbell Ave,POB 245030, Tucson, AZ 85724 USA.	awright@arc.arizona.edu		Halonen, Marilyn/0000-0001-9606-935X	NIAID NIH HHS [AI61811, AI 42268] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042268, R01AI061811] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Butland BK, 1997, BRIT MED J, V315, P717, DOI 10.1136/bmj.315.7110.717; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Celedon JC, 2002, ARCH PEDIAT ADOL MED, V156, P241, DOI 10.1001/archpedi.156.3.241; de Meer G, 2005, ALLERGY, V60, P619, DOI 10.1111/j.1398-9995.2005.00746.x; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Haby MM, 2000, PEDIATR PULM, V30, P377, DOI 10.1002/1099-0496(200011)30:5<377::AID-PPUL3>3.0.CO;2-3; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Hoffjan S, 2005, AM J HUM GENET, V76, P696, DOI 10.1086/429418; Infante-Rivard C, 2001, AM J EPIDEMIOL, V153, P653, DOI 10.1093/aje/153.7.653; Koppelman GH, 2003, CLIN EXP ALLERGY, V33, P170, DOI 10.1046/j.1365-2222.2003.01591.x; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Kulig M, 1999, J PEDIATR-US, V134, P453, DOI 10.1016/S0022-3476(99)70203-9; McKeever TM, 2001, THORAX, V56, P758, DOI 10.1136/thorax.56.10.758; Nafstad P, 2005, PEDIATRICS, V116, pE255, DOI 10.1542/peds.2004-2785; Ponsonby AL, 1999, THORAX, V54, P664, DOI 10.1136/thx.54.8.664; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rizzo MC, 1997, PEDIAT ALLERG IMM-UK, V8, P121; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Svanes C, 2002, THORAX, V57, P945, DOI 10.1136/thorax.57.11.945; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x	22	18	18	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1201	1207		10.1016/j.jaci.2007.07.036	http://dx.doi.org/10.1016/j.jaci.2007.07.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17854882				2022-12-18	WOS:000250973400033
J	Falt, A; Bengtsson, T; Kennedy, BM; Gyllenberg, A; Lindberg, B; Thorsson, L; Strandgarden, K				Falt, Anette; Bengtsson, Thomas; Kennedy, Britt-Marie; Gyllenberg, Ann; Lindberg, Bengt; Thorsson, Lars; Strandgarden, Kerstin			Exposure of infants to budesonide through breast milk of asthmatic mothers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pulmicort; budesonide; asthma; breast milk	PHARMACOKINETICS; PREGNANCY; PREDNISOLONE	Background: Maintenance treatment with inhaled corticosteroids is often required for asthmatic nursing women. Data on the transfer of inhaled corticosteroids from plasma to breast milk and the subsequent exposure of the breast-feeding infant has been unavailable. Objective: We sought to assess budesonide concentrations in milk and plasma of asthmatic nursing women receiving maintenance treatment with the Pulmicort Turbuhaler and estimate the exposure of their breast-fed infants. Methods: Milk and plasma samples were collected up to 8 hours after dosing from 8 mothers receiving budesonide maintenance treatment (200 or 400 mu g twice daily). Pharmacokinetic parameters were calculated from budesonide milk and plasma concentrations. Infant exposure was estimated based on average milk budesonide concentrations. A single blood sample was obtained from 5 infants close to expected infant maximum concentration. Results: Budesonide concentrations in milk reflected those in maternal plasma, supporting passive diffusion of budesonide between plasma and milk, and was always lower than that in plasma. The mean milk/plasma ratio was 0.46. The estimated daily infant dose was 0.3% of the daily maternal dose for both dose levels, and the average plasma concentration in infants was estimated to be 1/600th of the concentrations observed in maternal plasma, assuming complete infant oral bioavailability. Budesonide concentrations in infant plasma samples were all less than the limit of quantification. Conclusion: Maintenance treatment with inhaled budesonide (200 or 400 mu g twice daily) in asthmatic nursing women results in negligible systemic exposure to budesonide in breast-fed infants. Clinical implications: These data support continued use of inhaled budesonide during breast-feeding.	AstraZeneca R&D, Clin Dev, S-22187 Lund, Sweden; AstraZeneca R&D, Dev DMPK & Bioanal, Lund, Sweden; Malmo Univ Hosp, Dept Paediat, Malmo, Sweden	AstraZeneca; AstraZeneca; Lund University; Skane University Hospital	Falt, A (corresponding author), AstraZeneca R&D, Clin Dev, S-22187 Lund, Sweden.	anette.falt@astrazeneca.com						Agertoft L, 1999, ARCH DIS CHILD, V80, P241, DOI 10.1136/adc.80.3.241; Begg Evan J, 2002, J Hum Lact, V18, P323, DOI 10.1177/089033402237904; BENNETT PN, 1996, DRUGS HUMAN LACTATIO, P309; Bennett PN., 1996, DRUGS HUMAN LACTATIO, VSecond ed.; BRIGGS G, 2005, REFERENCE GUIDE FETA; Kaiser H, 1999, BRIT J CLIN PHARMACO, V48, P309; Kallen B, 1999, OBSTET GYNECOL, V93, P392, DOI 10.1016/S0029-7844(98)00454-2; KATZ FH, 1975, NEW ENGL J MED, V293, P1154; MCKENZIE SA, 1975, ARCH DIS CHILD, V50, P894, DOI 10.1136/adc.50.11.894; *NAT ASTHM ED PREV, 2005, PUBL NAT ASTHM ED PR; Norjavaara E, 2003, J ALLERGY CLIN IMMUN, V111, P736, DOI 10.1067/mai.2003.1340; OST L, 1985, J PEDIATR-US, V106, P1008, DOI 10.1016/S0022-3476(85)80259-6; Silverman M, 2005, ANN ALLERG ASTHMA IM, V95, P566, DOI 10.1016/S1081-1206(10)61020-4; Thorsson L, 2001, BRIT J CLIN PHARMACO, V52, P529, DOI 10.1046/j.0306-5251.2001.01493.x; *TNO, 2000, V5056 TNO; *TNO, 2000, V3130 TNO	16	18	21	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					798	802		10.1016/j.jaci.2007.07.023	http://dx.doi.org/10.1016/j.jaci.2007.07.023			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17825891				2022-12-18	WOS:000250157700012
J	Koehm, S; Slavin, RG; Hutcheson, PS; Trejo, T; David, CS; Bellone, CJ				Koehm, Sherri; Slavin, Raymond G.; Hutcheson, Patricia S.; Trejo, Theodore; David, Chella S.; Bellone, Clifford J.			HLA-DRB1 alleles control allergic bronchopulmonary aspergillosis-like pulmonary responses in humanized transgenic mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic bronchopulmonary aspergillosis; Aspergillus fumigatus; T(H)2; HLA-DR; pulmonary immuinity; MHC; asthma; cystic fibrosis; eosinophilia; transgenic	CLASS-II MOLECULES; CELL SUBSET ACTIVATION; IMMUNE-RESPONSE; ATOPIC ASTHMA; MHC GENOTYPE; T-CELLS; ASSOCIATION; IGE; RESTRICTION; DISEASE	Background: Allergic bronchopulmonary aspergillosis (ABPA) is a lung hypersensitivity disease mediated in part by CD4(+) T(H)2 cells. There is a significant association between ABPA and the HLA-DR2 genotypes DRB1*1501 and DRB1*1503, whereas resistance might be associated with HLA-DRB1*1502. Objective: We sought to elucidate the role of HLA-DR alleles in allergic inflammation in lungs. Methods: HLA-DR humanized transgenic mice expressing either the susceptible or resistant alleles were analyzed for the nature and extent of pulmonary inflammation after exposure to Aspergillus species antigens. Results: Exposed DRB1*1501 and DRB1*1503 transgenic mice displayed infiltrates made up prominently of eosinophils, which is consistent with the inflammation found in ABPA. The resistant DRB1*1502 mice, on the other hand, displayed minimal to moderate inflammation, consisting mainly of T-cell infiltrates. Significantly more mucin was produced in the DRB1*1503 and DRB1*1501 mice, and their ability to limit the number of Aspergillus species conidia within the lung parenchyma was impaired. Despite their differences, both the DRB1*1503 and DRB1*1502 strains mounted comparable T cell-proliferative responses to Aspergillus species antigens. Conclusion: The HLA-DR2 alleles DRB1*1501 and DRB1*1503 play a major role in the development of allergic pulmonary inflammation. In contrast, the HLA-DR2 allele DRB1*1502 mediates a nonallergic T(H)1-like response to the organism, possibly explaining an ABPA resistance factor. These results are in support of our published human studies in patients with cystic fibrosis and asthma. Clinical implications: HLA-DR typing in patients with cystic fibrosis and asthma will aid in the identification of individuals at risk for ABPA.	St Louis Univ, Sch Med, Dept Mol Biol & Immunol, St Louis, MO 63104 USA; St Louis Univ, Dept Mol Microbiol & Immunol, St Louis, MO USA; St Louis Univ, Dept Internal Med, St Louis, MO USA; Mayo Clin, Rochester, MN 55905 USA	Saint Louis University; Saint Louis University; Saint Louis University; Mayo Clinic	Bellone, CJ (corresponding author), St Louis Univ, Sch Med, Dept Mol Biol & Immunol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	Bellonec@slu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043626, R21AI043626] Funding Source: NIH RePORTER; NIAID NIH HHS [AI043626] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELLONE CJ, 2005, J ALLERGY CLIN IMM S, V115, pS2234; Brogdon JL, 2002, J IMMUNOL, V168, P3825, DOI 10.4049/jimmunol.168.8.3825; Chauhan B, 1997, J IMMUNOL, V159, P4072; Chauhan B, 2000, J ALLERGY CLIN IMMUN, V106, P723, DOI 10.1067/mai.2000.109913; Chauhan B, 2003, FRONT BIOSCI, V8, pS140, DOI 10.2741/971; Chauhan B, 1996, J CLIN INVEST, V97, P2324, DOI 10.1172/JCI118675; Cohn L, 2001, J IMMUNOL, V166, P2760, DOI 10.4049/jimmunol.166.4.2760; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; Curik I, 2003, GENET SEL EVOL, V35, pS177, DOI 10.1051/gse:2003026; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; GAJEWSKI TF, 1991, J IMMUNOL, V146, P1750; Gebe JA, 2001, J IMMUNOL, V167, P3250, DOI 10.4049/jimmunol.167.6.3250; GonzalezGay MA, 1996, HUM IMMUNOL, V50, P54, DOI 10.1016/0198-8859(96)00123-1; Hogaboam CM, 2000, AM J PATHOL, V156, P723, DOI 10.1016/S0002-9440(10)64775-X; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; HUANG SK, 1991, EUR J IMMUNOL, V21, P1469, DOI 10.1002/eji.1830210621; KNUTSEN AP, 1994, J ALLERGY CLIN IMMUN, V94, P215, DOI 10.1016/0091-6749(94)90043-4; KURUP VP, 1992, J IMMUNOL, V148, P3783; Lara-Marquez ML, 1999, CLIN EXP ALLERGY, V29, P60, DOI 10.1046/j.1365-2222.1999.00461.x; Marsh D G, 1991, Clin Exp Allergy, V21 Suppl 1, P168, DOI 10.1111/j.1365-2222.1991.tb01722.x; MURRAY JS, 1989, J EXP MED, V170, P2135, DOI 10.1084/jem.170.6.2135; MURRAY JS, 1992, EUR J IMMUNOL, V22, P559, DOI 10.1002/eji.1830220239; MURRAY JS, 1993, J IMMUNOL, V150, P4270; Mycko MP, 2004, J IMMUNOL, V173, P1689, DOI 10.4049/jimmunol.173.3.1689; Nabozny GH, 1996, J EXP MED, V183, P27, DOI 10.1084/jem.183.1.27; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; PFEIFFER C, 1991, IMMUNOL REV, V123, P65, DOI 10.1111/j.1600-065X.1991.tb00606.x; Rogers PR, 1999, J IMMUNOL, V163, P1205; Schountz T, 1996, J IMMUNOL, V157, P3893; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Senechal H, 1999, J ALLERGY CLIN IMMUN, V104, P395, DOI 10.1016/S0091-6749(99)70384-2; SLAVIN RG, 1992, J ALLERGY CLIN IMMUN, V90, P1006, DOI 10.1016/0091-6749(92)90479-L; SOLOWAY P, 1991, J EXP MED, V174, P847, DOI 10.1084/jem.174.4.847; Stephan V, 1999, CLIN EXP ALLERGY, V29, P1049, DOI 10.1046/j.1365-2222.1999.00610.x; Svensson AC, 1996, IMMUNOGENETICS, V43, P304, DOI 10.1007/BF02440998; THOMSON G, 1995, CRIT REV CL LAB SCI, V32, P183, DOI 10.3109/10408369509084684; Torio A, 2003, HUM IMMUNOL, V64, P811, DOI 10.1016/S0198-8859(03)00109-5; TRINCHIERI G, 1993, IMMUNOL TODAY, V14, P335, DOI 10.1016/0167-5699(93)90230-I; Yoshitake S, 1999, TISSUE ANTIGENS, V53, P350, DOI 10.1034/j.1399-0039.1999.530405.x	40	18	21	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					570	577		10.1016/j.jaci.2007.04.037	http://dx.doi.org/10.1016/j.jaci.2007.04.037			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17561243				2022-12-18	WOS:000249505400015
J	Haverkamp, HC; Dempsey, JA; Pegelow, DF; Miller, JD; Romer, LM; Santana, M; Eldridge, MW				Haverkamp, Hans C.; Dempsey, Jerome A.; Pegelow, David F.; Miller, Jordan D.; Romer, Lee M.; Santana, Marcus; Eldridge, Marlowe W.			Treatment of airway inflammation improves exercise pulmonary gas exchange and performance in asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway inflammation; arterial blood gases; asthma; exercise; exercise-induced bronchospasm; flow-volume loop; inhaled corticosteroids; pulmonary gas exchange; pulmonary function; pulmonary mechanics	INDUCED BRONCHOCONSTRICTION; INDUCED SPUTUM; MILD ASTHMA; METHACHOLINE; RESPONSES; OBSTRUCTION; HISTAMINE; PERFUSION; DURATION; DEFECTS	Background: Asthma is an inflammatory disease of the airways that can lead to impaired arterial blood oxygenation during exercise. Objective: We asked whether treatment of airway inflammation in asthmatic subjects would improve arterial blood gases during whole-body exercise. Methods: By using a double-blind parallel-group design, 19 asthmatic subjects completed treadmill exercise to exhaustion on 2 occasions: (1) before and (2) after 6 weeks' treatment with an inhaled corticosteroid (ICS; n = 9) or placebo (n = 10). Results: The ICS group had improved resting pulmonary function, decreased exercise-induced bronchospasm, and decreased postexercise sputum histamine during the posttreatment study compared with that during the pretreatment study. In the ICS group exercise PaO2 was significantly increased after treatment (84.8 to 93.8 mm Hg). Increased alveolar ventilation (arterial PCO2 decreased from 36.9 to 34.1 mm Hg) accounted for 37% of the increased PaO2 and improved gas exchange efficiency (alveolar-to-arterial PO2 difference decreased from 22.5 to 16.3 mm Hg) accounted for the remaining 63 % of the increased PaO2] after treatment. In the ICS group exercise time to exhaustion was increased from 9.9 minutes during the pretreatment study to 14.8 minutes during the posttreatment study. Conclusion: Treatment of airway inflammation in asthmatic subjects can improve arterial blood oxygenation during exercise by (1) improving airway function, thereby allowing increased alveolar ventilation during exercise, and (2) improving the efficiency of alveolar-to-arterial blood O-2 exchange. Clinical implications: In asthmatic patients ICSs not only attenuate exercise-induced bronchospasm but also improve arterial blood oxygenation during exercise.	Univ Vermont, Dept Med, Burlington, VT 05405 USA; Univ Wisconsin, Dept Populat Hlth Serv, Rankin Lab Pulm Med, Madison, WI 53706 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52240 USA; Brunel Univ, Sch Sport & Educ, Ctr Sports Med & Human Performance, Uxbridge UB8 3PH, Middx, England; Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomed Engn, Madison, WI 53706 USA	University of Vermont; University of Wisconsin System; University of Wisconsin Madison; University of Iowa; Brunel University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Haverkamp, HC (corresponding author), Univ Vermont, Dept Med, 149 Beaumont Ave,HSRF 226, Burlington, VT 05405 USA.	hans.haverkamp@uvm.edu		Miller, Jordan/0000-0002-9868-4097; Romer, Lee/0000-0002-4261-2879	NHLBI NIH HHS [R01 HL015469, T32 HL07654] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007654, R01HL015469] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acuna AA, 2002, EUR RESPIR J, V19, P872, DOI 10.1183/09031936.02.00268802; ALBAZZAZ MK, 1992, EUR RESPIR J, V5, P967; ALTON EW, 1996, J ALLERGY CLIN IMMUN, V98, P102; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453, DOI 10.1067/mai.2000.109822; BAMES NC, 2000, RESP MED SF, V94, pS16; BARNES PJ, 1997, LUNG SCI FDN, P1297; Birring SS, 2004, AM J RESP CRIT CARE, V169, P15, DOI 10.1164/rccm.200308-1092OC; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; CRAPO RO, 1995, AM J RESP CRIT CARE, V152, P1107, DOI DOI 10.1164/AJRCCM.152.3.7663792; Crimi E, 2002, J APPL PHYSIOL, V92, P2353, DOI 10.1152/japplphysiol.01248.2001; Echazarreta AL, 2001, AM J RESP CRIT CARE, V164, P202, DOI 10.1164/ajrccm.164.2.2101105; Echazarreta AL, 2001, EUR RESPIR J, V17, P609, DOI 10.1183/09031936.01.17406090; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P586, DOI 10.1016/j.jaci.2005.04.035; Hallstrand TS, 2005, AM J RESP CRIT CARE, V172, P679, DOI 10.1164/rccm.200412-1667OC; HAMIS CA, 2000, MED SCI SPORTS EXERC, V32, P1101; Harris RS, 2006, AM J RESP CRIT CARE, V174, P245, DOI 10.1164/rccm.200510-1634OC; Haverkamp HC, 2005, J APPL PHYSIOL, V99, P1843, DOI 10.1152/japplphysiol.01399.2004; Haverkamp HC, 2005, J APPL PHYSIOL, V99, P1938, DOI 10.1152/japplphysiol.00041.2005; Hofstra WB, 2000, PEDIATR PULM, V29, P415, DOI 10.1002/(SICI)1099-0496(200006)29:6<415::AID-PPUL1>3.0.CO;2-7; JOHNSON BD, 1995, J APPL PHYSIOL, V79, P892, DOI 10.1152/jappl.1995.79.3.892; McClaran SR, 1998, J APPL PHYSIOL, V84, P1872, DOI 10.1152/jappl.1998.84.6.1872; MORGAN DJR, 1983, THORAX, V38, P771, DOI 10.1136/thx.38.10.771; *NIH NHLBI, 2005, 023659 NIH; O'Donnell DE, 2002, AM J RESP CRIT CARE, V166, P663, DOI 10.1164/rccm.2201003; Pizzichini E, 1996, EUR RESPIR J, V9, P1174, DOI 10.1183/09031936.96.09061174; Samee S, 2003, J ALLERGY CLIN IMMUN, V111, P1205, DOI 10.1067/mai.2003.1544; St Croix CM, 1999, AM J RESP CRIT CARE, V159, P1125, DOI 10.1164/ajrccm.159.4.9806144; Subbarao P, 2006, J ALLERGY CLIN IMMUN, V117, P1008, DOI 10.1016/j.jaci.2005.11.048; SUMAN OE, 1995, AM J RESP CRIT CARE, V152, P24, DOI 10.1164/ajrccm.152.1.7599830; Wagner PD, 1996, EUR RESPIR J, V9, P1278, DOI 10.1183/09031936.96.09061278; Wetter TJ, 2002, J APPL PHYSIOL, V93, P116, DOI 10.1152/japplphysiol.01095.2001; Wetter TJ, 2001, J APPL PHYSIOL, V91, P847, DOI 10.1152/jappl.2001.91.2.847; YOUNG IH, 1982, AM REV RESPIR DIS, V125, P304	33	18	19	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					39	47		10.1016/j.jaci.2007.03.013	http://dx.doi.org/10.1016/j.jaci.2007.03.013			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17451800				2022-12-18	WOS:000248066400005
J	Marshall, GD				Marshall, Gailen D.		AM ACAD Allergy Asthma	The status of US allergy/immunology physicians in the 21st century: A report from the American Academy of Allergy, Asthma & Immunology Workforce Committee	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						workforce; allergist; immunologist; sex; demographics		The American Academy of Allergy, Asthma & Immunology has tracked the US allergy/immunology physician workforce (AIPW) over the past 3 decades by funding 2 workforce surveys (1999, 2004). Results have demonstrated both accomplishments of and challenges for the US AIPW. Accomplishments include increases in diversity (25% women in 2004,20% in 1999, 10% in 1989; 6% underrepresented minorities in 2004,5% in 1999),95% of AIPW has completed an allergy/immunology (A/I) training program, and 91% are American Board of Allergy and Immunology (a conjoint board of the American Board of Internal Medicine and the American Board of Pediatrics)-certified (90% in 1999). Training positions and program numbers are slowly increasing, and numbers of new graduates from accredited A/I programs have also increased. We are seeing patients with more complex allergic and immune diseases and giving less allergen immunotherapy. Personal, professional, and economic satisfaction is increasing. Challenges relate primarily to diminishing practitioner supply (4245 in 2004 vs 4356 in 1999) amid growing US population demand. The AIPW is gradually aging (the average age is 53 years in 2004, compared with 51 years in 1999) and working longer before retiring. The combination of job satisfaction, the high demand for A/I services, and the large number of fellowship applicants all support expanding the supply of trained allergists/immunologists.	Univ Mississippi, Med Ctr, Dept Med, Div Clin Immunol & Allergy, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center	Marshall, GD (corresponding author), Univ Mississippi, Med Ctr, Dept Med, Div Clin Immunol & Allergy, Jackson, MS 39216 USA.	gmarshall@medicine.umsmed.edu	Marshall, Gailen D./R-7459-2019					Cooper RA, 2003, HEALTH SERV RES, V38, P675, DOI 10.1111/1475-6773.00139; *COUNC GRAD MED ED, 2005, 16 COUNC GRAD MED ED; Meltzer Eli O, 2004, J Manag Care Pharm, V10, P310	3	18	18	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					802	807		10.1016/j.jaci.2007.01.040	http://dx.doi.org/10.1016/j.jaci.2007.01.040			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17418660				2022-12-18	WOS:000245729500005
J	Chang, Y; Senechal, S; de Nadai, P; Chenivesse, C; Gilet, J; Vorng, H; Legendre, B; Tonnel, AB; Wallaert, B; Lassalle, P; Tsicopoulos, A				Chang, Ying; Senechal, Stephanie; de Nadai, Patricia; Chenivesse, Cecile; Gilet, Jules; Vorng, Han; Legendre, Benjamin; Tonnel, Andre-Bernard; Wallaert, Benoit; Lassalle, Philippe; Tsicopoulos, Anne			Diesel exhaust exposure favors T(H)2 cell recruitment in nonatopic subjects by differentially regulating chemokine production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						diesel; chemokines; allergy; asthma; air pollution	MACROPHAGE-DERIVED CHEMOKINE; C-C CHEMOKINE; IN-VIVO; PERIPHERAL-BLOOD; EPITHELIAL-CELLS; INFLAMMATORY RESPONSES; AIRWAY INFLAMMATION; CYTOKINE PRODUCTION; MONONUCLEAR-CELLS; ORGANIC EXTRACTS	Background: The prevalence of allergic diseases has increased in the last 20 years, and a number of studies have shown that diesel exhaust particle-associated polyaromatic hydrocarbons can exacerbate the allergic reaction. Much less is known about their potential capacity to generate a T(H)2-type allergic reaction in nonatopic subjects. Objective: The aim of this study was to test the hypothesis that diesel exhaust exposure might favor, in nonatopic donors, T(H)2-type cell recruitment, either through increased production of T(H)2-attracting chemokines or decreased production of T(H)1-attracting chemokines. Methods: PBMCs from nonatopic donors were incubated with diesel exhaust particle-polyaromatic hydrocarbons, and the supernatants were evaluated for the presence of pro-T(H)1 chemokines (IFN-gamma-induced protein 10 and monokine Induced by IFN-gamma) and pro-T(H)2 chemokines (macrophage-derived chemokine, I-309, and pulmonary and activation-regulated chemokine) by means of ELISA. The functional effect was evaluated by using chemotaxis assays with polarized T(H)1 and T(H)2 cells. Results: Diesel exhaust exposure of PBMCs from nonatopic donors induced a late increase after 48 hours in pulmonary and activation-regulated chemokine mediated by IL-13 and a decrease in IFN-gamma-induced protein 10 levels selectively at both the protein and mRNA levels. The functional effect of these chemokine variations resulted in an enhanced chermotaxis of T(H)2, but not T(H)1, Cells. Conclusion: These findings show that diesel exhaust exposure might be involved in the genesis of allergic diseases by differentially regulating chemokines favoring the recruitment of T(H)2 cells in nonatopic subjects. Clinical implications: Environmental factors, especially air pollution, might favor the genesis of allergic diseases.	Inst Pasteur, INSERM, U 774, F-59019 Lille, France; Clin Malad Resp, Lille, France; Ctr Hosp Reg, Lille, France; Univ Lille, Lille, France; Jilin Univ, Clin Coll 3, Dept Cent Res, Jilin, Peoples R China	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre Hospitalier Annecy Genevois; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; Universite de Lille; Jilin University	Tsicopoulos, A (corresponding author), Inst Pasteur, INSERM, U 774, BP 245, F-59019 Lille, France.	anne.tsicopoulos@pasteur-lille.fr	Tsicopoulos, Anne/C-2260-2019; Lassalle, Philippe/L-6705-2018; Chang, Ying/I-1362-2012	Tsicopoulos, Anne/0000-0002-1579-2763; de NADAI, Patricia/0000-0001-6084-7447; GILET, Jules/0000-0002-1132-9608				Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; Andrew DP, 1998, J IMMUNOL, V161, P5027; Asselin S, 1998, EUR J IMMUNOL, V28, P532, DOI 10.1002/(SICI)1521-4141(199802)28:02<532::AID-IMMU532>3.0.CO;2-U; BASCOM R, 1991, AM REV RESPIR DIS, V143, P1304, DOI 10.1164/ajrccm/143.6.1304; Bayram H, 1998, AM J RESP CELL MOL, V18, P441, DOI 10.1165/ajrcmb.18.3.2882; Behndig AF, 2006, EUR RESPIR J, V27, P359, DOI 10.1183/09031936.06.00136904; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Bochner BS, 2003, J ALLERGY CLIN IMMUN, V112, P930, DOI 10.1016/j.jaci.2003.08.012; Boorsma DM, 1998, ARCH DERMATOL RES, V290, P335, DOI 10.1007/s004030050314; Chvatchko Y, 2000, J EXP MED, V191, P1755, DOI 10.1084/jem.191.10.1755; De Nadai P, 2006, J IMMUNOL, V176, P6286, DOI 10.4049/jimmunol.176.10.6286; Devouassoux G, 2002, J ALLERGY CLIN IMMUN, V109, P847, DOI 10.1067/mai.2002.122843; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; DiazSanchez D, 1997, ALLERGY, V52, P52; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Fahy O, 1999, J ALLERGY CLIN IMMUN, V103, P1115, DOI 10.1016/S0091-6749(99)70187-9; Fahy O, 2002, J IMMUNOL, V168, P5912, DOI 10.4049/jimmunol.168.11.5912; Fahy O, 2000, AM J RESP CELL MOL, V23, P247, DOI 10.1165/ajrcmb.23.2.4116; Farber JM, 1997, J LEUKOCYTE BIOL, V61, P246, DOI 10.1002/jlb.61.3.246; Flier J, 2001, J PATHOL, V194, P398, DOI 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507, DOI 10.1165/ajrcmb.19.3.3143; Gangur V, 1999, INT ARCH ALLERGY IMM, V118, P387, DOI 10.1159/000024144; Gasperini S, 1999, J IMMUNOL, V162, P4928; Goebeler M, 2001, AM J PATHOL, V158, P431, DOI 10.1016/S0002-9440(10)63986-7; Gunther C, 2005, J IMMUNOL, V174, P1723, DOI 10.4049/jimmunol.174.3.1723; Haque NS, 2001, BLOOD, V97, P39, DOI 10.1182/blood.V97.1.39; Hieshima K, 1997, J IMMUNOL, V159, P1140; Holgate ST, 2003, RES REP HLTH EFF I, V112, P1; Iellem A, 2000, EUR J IMMUNOL, V30, P1030, DOI 10.1002/(SICI)1521-4141(200004)30:4<1030::AID-IMMU1030>3.0.CO;2-8; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Inngjerdingen M, 2000, J IMMUNOL, V164, P4048, DOI 10.4049/jimmunol.164.8.4048; Jimenez LA, 2002, AM J PHYSIOL-LUNG C, V282, pL237, DOI 10.1152/ajplung.00024.2001; Kaplan AP, 2001, INT ARCH ALLERGY IMM, V124, P423, DOI 10.1159/000053777; Kim Chang H., 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P343, DOI 10.2174/1568008043339712; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161, DOI 10.1164/ajrccm.162.1.9908092; Nilsen AM, 2003, INT ARCH ALLERGY IMM, V131, P201, DOI 10.1159/000071487; Ohtani T, 2005, J IMMUNOL, V174, P2412, DOI 10.4049/jimmunol.174.4.2412; Ohtoshi T, 1998, J ALLERGY CLIN IMMUN, V101, P778, DOI 10.1016/S0091-6749(98)70307-0; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Pardo A, 2001, J LEUKOCYTE BIOL, V70, P610; Peden DB, 2005, J ALLERGY CLIN IMMUN, V115, P213, DOI 10.1016/j.jaci.2004.12.003; Piali L, 1998, EUR J IMMUNOL, V28, P961, DOI 10.1002/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4; Politz O, 2000, CYTOKINE, V12, P120, DOI 10.1006/cyto.1999.0538; Pourazar J, 2004, RESP MED, V98, P821, DOI 10.1016/j.rmed.2004.02.025; Reape TJ, 1999, AM J PATHOL, V154, P365, DOI 10.1016/S0002-9440(10)65283-2; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702, DOI 10.1164/ajrccm.159.3.9709083; Salvi SS, 2000, AM J RESP CRIT CARE, V161, P550, DOI 10.1164/ajrccm.161.2.9905052; Sauty A, 1999, J IMMUNOL, V162, P3549; Senechal S, 2003, AM J RESP CRIT CARE, V168, P215, DOI 10.1164/rccm.200211-1289OC; Steerenberg PA, 1998, EXP LUNG RES, V24, P85, DOI 10.3109/01902149809046056; Stenfors N, 2004, EUR RESPIR J, V23, P82, DOI 10.1183/09031936.03.00004603; Sydbom A, 2001, EUR RESPIR J, V17, P733, DOI 10.1183/09031936.01.17407330; Tan JQ, 2000, J IMMUNOL, V165, P1548, DOI 10.4049/jimmunol.165.3.1548; Wang M, 1999, CLIN IMMUNOL, V90, P47, DOI 10.1006/clim.1998.4628; Zingoni A, 1998, J IMMUNOL, V161, P547	59	18	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					354	360		10.1016/j.jaci.2006.04.050	http://dx.doi.org/10.1016/j.jaci.2006.04.050			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890758				2022-12-18	WOS:000239877700009
J	Kuehni, CE; Strippoli, MPF; Silverman, M				Kuehni, Claudia E.; Strippoli, Marie-Pierre F.; Silverman, Michael			Food intolerance and wheezing in young South Asian and white children: Prevalence and clinical significance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA; ALLERGY; LIFE		Univ Bern, Swiss Paediat Resp Res Grp, Dept Social & Prevent Med, Bern, Switzerland; Univ Leicester, Leicester Childrens Asthma Ctr, Div Child Hlth, Dept Infect Immun & Inflammat, Leicester, Leics, England	University of Bern; University of Leicester	Kuehni, CE (corresponding author), Univ Bern, Swiss Paediat Resp Res Grp, Dept Social & Prevent Med, Bern, Switzerland.		Strippoli, Marie-Pierre F/K-8164-2013	Strippoli, Marie-Pierre F/0000-0003-3053-484X; Kuehni, Claudia E./0000-0001-8957-2002				Csonka P, 2000, PEDIAT ALLERG IMM-UK, V11, P225, DOI 10.1034/j.1399-3038.2000.00088.x; Gibson PG, 2003, PEDIATR PULM, V36, P209, DOI 10.1002/ppul.10323; Kuehni CE, 2001, LANCET, V357, P1821, DOI 10.1016/S0140-6736(00)04958-8; Netuveli G, 2005, LANCET, V365, P312, DOI 10.1016/S0140-6736(05)17785-X; Roberts G, 2003, J ALLERGY CLIN IMMUN, V112, P168, DOI 10.1067/mai.2003.1569; Roberts Graham, 2003, Paediatr Respir Rev, V4, P205, DOI 10.1016/S1526-0542(03)00058-7; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Wang JL, 2005, J ALLERGY CLIN IMMUN, V115, P1076, DOI 10.1016/j.jaci.2005.02.014; WILSON N, 2002, CHILDHOOD ASTHMA OTH, P229; WILSON NM, 1985, ARCH DIS CHILD, V60, P861, DOI 10.1136/adc.60.9.861	10	18	19	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					528	530		10.1016/j.jaci.2006.04.019	http://dx.doi.org/10.1016/j.jaci.2006.04.019			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890786				2022-12-18	WOS:000239877700037
J	Nageotte, C; Park, M; Havstad, S; Zoratti, E; Ownby, D				Nageotte, Christian; Park, Michael; Havstad, Suzanne; Zoratti, Edward; Ownby, Dennis			Duration of airborne Fel d 1 reduction after cat washing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FEL-D-I; ALLERGEN		Henry Ford Hlth Syst, Detroit, MI 48202 USA; Adv Allergy & Asthma Care, Portage, MI USA; Med Coll Georgia, Augusta, GA 30912 USA	Henry Ford Health System; Henry Ford Hospital; University System of Georgia; Augusta University	Nageotte, C (corresponding author), Henry Ford Hlth Syst, 1 Ford Pl, Detroit, MI 48202 USA.							Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; ARBES SJ, 2003, J ALLERGY CLIN IMMUN, V112, P265; Avner DB, 1997, J ALLERGY CLIN IMMUN, V100, P307, DOI 10.1016/S0091-6749(97)70242-2; DEGROOT H, 1988, J ALLERGY CLIN IMMUN, V82, P778, DOI 10.1016/0091-6749(88)90079-6; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; KLUCKA CV, 1995, J ALLERGY CLIN IMMUN, V95, P1164, DOI 10.1016/S0091-6749(95)70072-2; WENTZ PE, 1990, J ALLERGY CLIN IMMUN, V85, P94, DOI 10.1016/0091-6749(90)90228-V; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7; Wood RA, 1998, AM J RESP CRIT CARE, V158, P115, DOI 10.1164/ajrccm.158.1.9712110	9	18	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					521	522		10.1016/j.jaci.2006.04.049	http://dx.doi.org/10.1016/j.jaci.2006.04.049			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890781	Bronze			2022-12-18	WOS:000239877700032
J	Abraham, JH; Finn, PW; Milton, DK; Ryan, LM; Perkins, DL; Gold, DR				Abraham, JH; Finn, PW; Milton, DK; Ryan, LM; Perkins, DL; Gold, DR			Infant home endotoxin is associated with reduced allergen-stimulated lymphocyte proliferation and IL-13 production in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; lymphocyte proliferation; cytokine; childhood; allergy	HOUSE-DUST ENDOTOXIN; TOLL-LIKE RECEPTOR-4; AIRBORNE ENDOTOXIN; LIMULUS ASSAY; EARLY-LIFE; HAY-FEVER; EXPOSURE; ASTHMA; SENSITIZATION; RISK	Background: Infant endotoxin exposure has been proposed as a factor that might protect against allergy and the early childhood immune responses that increase the risk of IgE production to allergens. Objective: Using a prospective study design, we tested the hypothesis that early-life endotoxin exposure is associated with allergen- and mitogen-induced cytokine production and proliferative responses of PBMCs isolated from infants with a parental history of physician-diagnosed asthma or allergy. Methods: We assessed household dust endotoxin at age 2 to 3 months and PBMC proliferative and cytokine responses to cockroach allergen (Bla g 2), dust mite allergen (Der f 1), cat allergen (Fel d 1), and the nonspecific mitogen PHA at age 2 to 3 years. Results: We found that increased endotoxin levels were associated with decreased IL-13 levels in response to cockroach, dust mite, and cat allergens, but not mitogen stimulation. Endotoxin levels were not correlated with allergen- or mitogen-induced IFN-gamma, TNF-alpha, or IL-10. Increased endotoxin levels were associated with decreased lymphocyte proliferation after cockroach allergen stimulation. An inverse, although nonsignificant, association was also found between endotoxin and proliferation to the other tested stimuli. Conclusion: Increased early-life exposure to household endotoxin was associated with reduced allergen-induced production of the T(H)2 cytokine IL-13 and reduced lymphoproliferative responses at age 2 to 3 years in children at risk for allergy and asthma. Early-life endotoxin-related reduction of IL-13 production might represent one pathway through which increased endotoxin decreases the risk of allergic disease and allergy in later childhood.	Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Gold, DR (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	diane.gold@channing.harvard.edu	Milton, Donald K/G-3286-2010; Ryan, Louise M/A-4562-2009	Milton, Donald K/0000-0002-0550-7834; Ryan, Louise M/0000-0001-5957-2490	NHLBI NIH HHS [HL07427-23] Funding Source: Medline; NIAID NIH HHS [AI/EHS35786] Funding Source: Medline; NIEHS NIH HHS [R01 ES-07036, 2P30ES00002] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007036, P30ES000002] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bellou A, 2003, CURR OPIN ALLERGY CL, V3, P487, DOI 10.1097/01.all.0000104445.09202.e7; Beutler B, 2000, EUR CYTOKINE NETW, V11, P143; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536, DOI 10.1164/ajrccm.157.5.9708011; Contreras JP, 2003, J ALLERGY CLIN IMMUN, V112, P1072, DOI 10.1016/j.jaci.2003.08.036; Cook DN, 2004, GENOMICS, V83, P961, DOI 10.1016/j.ygeno.2003.12.008; CRONER S, 1992, ALLERGY, V47, P150, DOI 10.1111/j.1398-9995.1992.tb00956.x; Dabbagh K, 2003, CURR OPIN INFECT DIS, V16, P199, DOI 10.1097/00001432-200306000-00003; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Delayre-Orthez C, 2004, CLIN EXP ALLERGY, V34, P1789, DOI 10.1111/j.1365-2222.2004.02082.x; Donovan CE, 1999, THORAX, V54, P938, DOI 10.1136/thx.54.10.938; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Finn PW, 2000, J ALLERGY CLIN IMMUN, V105, P933, DOI 10.1067/mai.2000.106546; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gerhold K, 2002, J ALLERGY CLIN IMMUN, V110, P110, DOI 10.1067/mai.2002.125831; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Imrich A, 1999, TOXICOL APPL PHARM, V159, P117, DOI 10.1006/taap.1999.8731; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Lara-Marquez ML, 1998, J ALLERGY CLIN IMMUN, V101, P699, DOI 10.1016/S0091-6749(98)70180-0; LE JM, 1986, J IMMUNOL, V136, P4525; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; MILTON DK, 1992, ENVIRON RES, V57, P212, DOI 10.1016/S0013-9351(05)80081-7; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Park JH, 2001, ENVIRON HEALTH PERSP, V109, P859, DOI 10.2307/3454831; Phipatanakul W, 2004, PEDIATRICS, V114, P13, DOI 10.1542/peds.114.1.13; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; Rodriguez D, 2003, J IMMUNOL, V171, P1001, DOI 10.4049/jimmunol.171.2.1001; Schaub B, 2004, J INTERF CYTOK RES, V24, P543, DOI 10.1089/jir.2004.24.543; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Velasco G, 2005, AM J RESP CELL MOL, V32, P218, DOI 10.1165/rcmb.2003-0435OC; Vollmer WM, 1998, AM J RESP CRIT CARE, V157, P1079, DOI 10.1164/ajrccm.157.4.9704140; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943; Wan GH, 2000, CLIN EXP ALLERGY, V30, P426; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139	46	18	19	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					431	437		10.1016/j.jaci.2005.05.015	http://dx.doi.org/10.1016/j.jaci.2005.05.015			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083802				2022-12-18	WOS:000235686400030
J	Luskin, AT				Luskin, AT			What the asthma end points we know and love do and do not tell us	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; control; severity; outcomes; phenotypes; variability; asthma-related quality of life	QUALITY-OF-LIFE; RANDOMIZED CONTROLLED TRIAL; INHALED CORTICOSTEROIDS; PERSISTENT ASTHMA; VARIABILITY; MONTELUKAST; SEVERITY; ADULTS	Asthma is a disorder characterized by common features of reversible airflow obstruction and bronchial hyperreactivity in the setting of airway mucosal and submucosal inflammation. However, the clinical manifestations are syndromic and not unimodal. There is marked variability in severity of symptoms, natural history, risks of adverse outcomes, pathologic characteristics, and response to therapy. Understanding the relationship between these factors has been complicated by the variability of outcomes and the lack of correlation between them. There is a striking absence of correlation among the pathologic, physiologic, and clinical manifestations of the asthmatic disorders. Lung function tends to correlate poorly with clinical outcomes, and there is only modest correlation between clinical outcomes. Response to therapy is variable both externally (between patients) and internally, depending on which outcome is evaluated. A more complete understanding of the variability of disease and the genetic and environmental causes of the variability likely will change how we approach asthma and its therapy.	Univ Wisconsin, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison	Luskin, AT (corresponding author), Amer Acad Allergy Asthma & Immunol, 611 E Wells St, Milwaukee, WI 53202 USA.							Bjermer L, 2003, BMJ-BRIT MED J, V327, P891, DOI 10.1136/bmj.327.7420.891; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Chipps B., 2004, Journal of Allergy and Clinical Immunology, V113, pS277, DOI 10.1016/j.jaci.2004.01.470; Eisner MD, 2002, ANN ALLERG ASTHMA IM, V89, P46, DOI 10.1016/S1081-1206(10)61910-2; Ford ES, 2003, CHEST, V123, P119, DOI 10.1378/chest.123.1.119; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Langley SJ, 2003, ANN ALLERG ASTHMA IM, V91, P398, DOI 10.1016/S1081-1206(10)61688-2; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lee S, 2003, ANN ALLERG ASTHMA IM, V91, P449, DOI 10.1016/S1081-1206(10)61512-8; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Moy ML, 2001, AM J RESP CRIT CARE, V163, P924, DOI 10.1164/ajrccm.163.4.2008014; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Shingo S, 2001, EUR RESPIR J, V17, P220, DOI 10.1183/09031936.01.17202200; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Strine TW, 2004, CHEST, V126, P1849, DOI 10.1378/chest.126.6.1849; SULLIVAN SD, 2005, IN PRESS J MANAGED C; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Zhang J, 2002, EUR RESPIR J, V20, P1102, DOI 10.1183/09031936.02.02402001	19	18	18	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4		S			S539	S545		10.1016/j.jaci.2005.01.027	http://dx.doi.org/10.1016/j.jaci.2005.01.027			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	918FS	15806037				2022-12-18	WOS:000228528300004
J	Zhang, J; Noguchi, E; Migita, O; Yokouchi, Y; Nakayama, J; Shibasaki, M; Arinami, T				Zhang, J; Noguchi, E; Migita, O; Yokouchi, Y; Nakayama, J; Shibasaki, M; Arinami, T			Association of a haplotype block spanning SDAD1 gene and CXC chemokine genes with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						seasonal allergic rhinitis; linkage; HHRR; CXC chemokine; SDAD1	GENOME-WIDE SEARCH; ASTHMA-SUSCEPTIBILITY LOCI; ATOPIC-DERMATITIS; AIRWAY HYPERREACTIVITY; IFN-GAMMA; DIFFERENTIAL EXPRESSION; INDUCIBLE PROTEIN-10; FOUNDER POPULATION; JAPANESE FAMILIES; INTERFERON-GAMMA	Background: Seasonal allergic rhinitis (SAR) is a common allergic disorder characterized by episodes of sneezing, rhinorrhea, and swelling of the nasal mucosa. Although the pathogenesis of SAR remains unclear, there does appear to be a genetic predisposition to development of SAR. We previously identified regions of chromosomes 1p, 4q, and 9q linked to SAR in 48 families (188 members) identified through children with SAR against orchard grass pollens. Objective: The aim of the current study was to identify susceptibility genes for SAR on 4q. Methods: We screened for markers associated with SAR on 4q with 17 microsatellite markers and then for mutations in 11 genes. We genotyped 44 single nucleotide polymorphisms (SNPs) in 48 SAR families and performed haplotype-based haplotype relative risk statistics implemented in the UNPHASED program. We also examined expression of genes with human multiple tissue and immune system cDNA panels. Results: We found that 1 microsatellite marker, D4S3042, was associated with SAR (P = .034). The haplotype-based haplotype relative risk approach revealed that SNPs in SDAI domain containing 1; chemokine, CXC motif, ligand (CXCL)-9; CXCL10; and CXCL11 were associated with SAR (P = .001-.04). These SNPs made up a haplotype block, and the most common haplotype of this block was transmitted preferentially to affected offspring (P = .002). Conclusion: Our results suggests that genetic variations in a haplotype block spanning the SDA1 domain containing 1 and CXC chemokine genes on 4q21 may contribute to development of SAR in the Japanese population.	Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Med Genet, Majors Med Sci,Lab Adv Res D, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Pediat, Majors Med Sci, Tsukuba, Ibaraki 3058577, Japan; Tsukuba Coll Technol, Dept Pediat, Tsukuba, Ibaraki, Japan	University of Tsukuba; University of Tsukuba; Tsukuba University of Technology	Noguchi, E (corresponding author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Med Genet, Majors Med Sci,Lab Adv Res D, 1-1-1 Tennondai, Tsukuba, Ibaraki 3058577, Japan.	enoguchi@md.tsukuba.ac.jp		Yokouchi, Yukako/0000-0003-2108-7515				Amichay D, 1996, J IMMUNOL, V157, P4511; BARRETT JC, 2004, HAPLOVIEW ANAL VISUA; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Bradley M, 2002, HUM MOL GENET, V11, P1539, DOI 10.1093/hmg/11.13.1539; Burney P, 1997, AM J RESP CRIT CARE, V156, P1773; Campbell JD, 2002, INT IMMUNOL, V14, P1255, DOI 10.1093/intimm/dxf098; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252; El-Asrar AMA, 2003, AM J OPHTHALMOL, V136, P853, DOI 10.1016/S0002-9394(03)00446-X; Flier J, 1999, J INVEST DERMATOL, V113, P574, DOI 10.1046/j.1523-1747.1999.00730.x; Flier J, 2001, J PATHOL, V194, P398, DOI 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; GERGEN PJ, 1992, AM REV RESPIR DIS, V146, P823, DOI 10.1164/ajrccm/146.4.823; Giustizieri ML, 2001, J ALLERGY CLIN IMMUN, V107, P871, DOI 10.1067/mai.2001.114707; Goebeler M, 2001, AM J PATHOL, V158, P431, DOI 10.1016/S0002-9440(10)63986-7; Haagerup A, 2002, ALLERGY, V57, P680, DOI 10.1034/j.1398-9995.2002.23523.x; Haagerup A, 2001, EUR J HUM GENET, V9, P945, DOI 10.1038/sj.ejhg.5200753; Hakonarson H, 2002, AM J HUM GENET, V71, P483, DOI 10.1086/342205; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; HOPPER JL, 1990, GENET EPIDEMIOL, V7, P277, DOI 10.1002/gepi.1370070406; *IASSC, 1998, LANCET, V361, P1225; Khan IA, 2000, IMMUNITY, V12, P483, DOI 10.1016/S1074-7613(00)80200-9; Lack G, 1996, J IMMUNOL, V157, P1432; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/88319; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Li L, 1998, J IMMUNOL, V161, P3128; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Marsh DG, 1997, NAT GENET, V15, P389; Medoff BD, 2002, J IMMUNOL, V168, P5278, DOI 10.4049/jimmunol.168.10.5278; Moed H, 2004, J PATHOL, V204, P39, DOI 10.1002/path.1619; Nakamura Akihiko, 2002, Nihon Jibiinkoka Gakkai Kaiho, V105, P215; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Siveke JT, 1998, J IMMUNOL, V160, P550; Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, pS2, DOI 10.1067/mai.2001.115569; Sorensen TL, 2002, J NEUROIMMUNOL, V127, P59, DOI 10.1016/S0165-5728(02)00097-8; Thomas MS, 2004, J IMMUNOL, V173, P615, DOI 10.4049/jimmunol.173.1.615; Villagomez MT, 2004, BRIT J DERMATOL, V150, P910, DOI 10.1111/j.1365-2133.2004.05937.x; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Wosinska-Becler K, 2004, CLIN EXP ALLERGY, V34, P123, DOI 10.1111/j.1365-2222.2004.01850.x; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201; Yokouchi Y, 2002, GENES IMMUN, V3, P9, DOI 10.1038/sj.gene.6363815; Yu YT, 2001, GENOME RES, V11, P1392, DOI 10.1101/gr.175501	48	18	21	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					548	554		10.1016/j.jaci.2004.11.034	http://dx.doi.org/10.1016/j.jaci.2004.11.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753903				2022-12-18	WOS:000227687000018
J	Sicherer, SH				Sicherer, SH		Adverse Reactions Food Comm; Adverse Reactions Drugs Biolog	Risk of severe allergic reactions from the use of potassium iodide for radiation emergencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						potassium iodide allergy; radiocontrast; shellfish allergy	CONTRAST-MEDIA; INTRAVENOUS-INJECTION; ADVERSE REACTIONS; POVIDONE-IODINE; IODODERMA; VASCULITIS	Potassium iodide (KI) may be prescribed for widespread use in the event of a radiation emergency to prevent the uptake of radioactive iodide by the thyroid gland. The available literature was reviewed and expert opinion sought among members of the Adverse Reactions to Foods and the Adverse Reactions to Drugs and Biologicals Committees of the Academy to assemble evidenced-based conclusions regarding the risks of an allergic reaction to this therapy. This article describes the information leading to the following conclusions: (1) anaphylactoid reactions to radiocontrast media should not be considered evidence of KI allergy, (2) allergic contact dermatitis from iodine-containing antibacterial preparations should not be considered evidence of IgE antibody-mediated KI allergy or sensitivity, (3) IgE antibody-mediated allergy to seafood should not be considered evidence of KI allergy or sensitivity, and (4) physicians should ensure that persons are not allergic to inactive ingredients or components of the KI formulation prescribed.	Mt Sinai Hosp, Div Allergy Immunol, Elliot & Roslyn Jaffe Food Allergy Inst, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Elliot & Roslyn Jaffe Food Allergy Inst, Dept Pediat, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu						Alpay K, 1996, PEDIATR DERMATOL, V13, P51, DOI 10.1111/j.1525-1470.1996.tb01189.x; *AM AC ALL ASTHM I, 1999, ANN ALLERG ASTHMA IM, V83, P665; Balk SJ, 2003, PEDIATRICS, V111, P1455; Coakley FV, 1997, AM J ROENTGENOL, V169, P951, DOI 10.2214/ajr.169.4.9308442; CURD JG, 1979, ANN INTERN MED, V91, P853, DOI 10.7326/0003-4819-91-6-853; HUANG TY, 1981, ANN ALLERGY, V46, P264; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; KHAN F, 1973, NEW ENGL J MED, V289, P1018, DOI 10.1056/NEJM197311082891907; Konen E, 2002, CLIN RADIOL, V57, P132, DOI 10.1053/crad.2001.0849; Li XM, 2003, J ALLERGY CLIN IMMUN, V111, P1140, DOI 10.1067/mai.2003.1494; NAUMAN J, 1993, AM J MED, V94, P524, DOI 10.1016/0002-9343(93)90089-8; PATTERSON R, 1975, ANN INTERN MED, V83, P277, DOI 10.7326/0003-4819-83-2-277; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; SORIA C, 1990, J AM ACAD DERMATOL, V22, P418, DOI 10.1016/0190-9622(90)70057-O; STONE OJ, 1985, INT J DERMATOL, V24, P565, DOI 10.1111/j.1365-4362.1985.tb05851.x; *US FOOD DRUG ADM, 2001, CTR DRUG EV RES; VAILLANT L, 1990, CLIN EXP DERMATOL, V15, P232, DOI 10.1111/j.1365-2230.1990.tb02079.x; VANKETEL WG, 1990, DERMATOL CLIN, V8, P107, DOI 10.1016/S0733-8635(18)30531-X; WARAN KD, 1995, LANCET, V345, P1506, DOI 10.1016/S0140-6736(95)91063-8	19	18	19	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1395	1397		10.1016/j.jaci.2004.09.026	http://dx.doi.org/10.1016/j.jaci.2004.09.026			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577843				2022-12-18	WOS:000225577400022
J	Rabinovitch, N; Zhang, LN; Murphy, JR; Vedal, S; Dutton, SJ; Gelfand, EW				Rabinovitch, N; Zhang, LN; Murphy, JR; Vedal, S; Dutton, SJ; Gelfand, EW			Effects of wintertime ambient air pollutants on asthma exacerbations in urban minority children with moderate to severe disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						air pollution; asthma; minority; urban; children	RESPIRATORY HEALTH; CHANGING PATTERNS; CHILDHOOD ASTHMA; PM10 POLLUTION; MEDICATION USE; RISK-FACTORS; TIME-SERIES; MORTALITY; PARTICLES; HOSPITALIZATION	Urban minority children with asthma are at higher risk for severe exacerbations leading to hospitalizations and deaths. Because multiple studies have reported associations between air pollution and asthma worsening, elevated levels of air pollution are cited as a possible trigger for increased asthma morbidity in urban areas. Few studies have prospectively followed panels of urban children with asthma to determine whether air pollution levels are associated with clinically relevant outcomes such as asthma exacerbations. Objective: To determine the association between levels of ambient air pollutants and asthma exacerbations in urban poor children with moderate to severe asthma. Methods: A school-based panel of children with difficult-to-control disease was followed over a period of 3 consecutive winters in Denver, Colo. The panel consisted of predominantly urban African American children with moderate to severe asthma. Levels of Environmental Protection Agency criteria air pollutants were measured on a daily basis with concurrent monitoring of lung function, bronchodilator use, symptoms, and asthma exacerbations. Results: After controlling for time-varying factors such as upper respiratory infections and meteorologic factors, a weak association was found between ambient carbon monoxide levels and bronchodilator use. Ozone levels were associated with daytime symptoms only. No association was observed between daily air pollution concentrations and daily levels of FEV1, peak flow, nighttime symptom scores, or asthma exacerbations over the 3-year period. Conclusion: Ambient levels of Environmental Protection Agency criteria air pollutants in Denver do not lead to clinically significant asthma worsening in urban children with moderate to severe asthma during winter months when children are primarily indoors.	Natl Jewish Med & Res Ctr, Div Allergy Immunol, Dept Pediat, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Biostat, Dept Med, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Environm & Occupat Med, Dept Med, Denver, CO 80206 USA	National Jewish Health; National Jewish Health; National Jewish Health	Rabinovitch, N (corresponding author), Natl Jewish Med & Res Ctr, Div Allergy Immunol, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	rabinovitchn@njc.org	Dutton, Steven J/C-5912-2011					Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Aligne CA, 2000, AM J RESP CRIT CARE, V162, P873; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860, DOI 10.1164/ajrccm.164.10.2010138; BURKEY P, 1999, LANCET, V353, P859; Castro M, 2001, J ASTHMA, V38, P625, DOI 10.1081/JAS-100107540; Cloutier MM, 2002, CHEST, V122, P1571, DOI 10.1378/chest.122.5.1571; Colice GL, 1999, AM J RESP CRIT CARE, V160, P1962, DOI 10.1164/ajrccm.160.6.9902112; Crater DD, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.6.e97; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.2307/3434265; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; *EPA, 2000, AIR QUAL STAT CIT AP; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; OSTRO BD, 1991, AM J PUBLIC HEALTH, V81, P694, DOI 10.2105/AJPH.81.6.694; PERRY GB, 1983, AM J PUBLIC HEALTH, V73, P50, DOI 10.2105/AJPH.73.1.50; Peters A, 1997, ENVIRON HEALTH PERSP, V105, P430, DOI 10.2307/3433341; Peters A, 1997, EUR RESPIR J, V10, P872; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376, DOI 10.1164/ajrccm.155.4.9105082; POPE CA, 1991, AM REV RESPIR DIS, V144, P668, DOI 10.1164/ajrccm/144.3_Pt_1.668; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123, DOI 10.1164/ajrccm/145.5.1123; ROEMER W, 1993, AM REV RESPIR DIS, V147, P118, DOI 10.1164/ajrccm/147.1.118; Roemer W, 1998, EUR RESPIR J, V12, P1354, DOI 10.1183/09031936.98.12061354; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; Segala C, 1998, EUR RESPIR J, V11, P677; Sly RM, 1997, ANN ALLERG ASTHMA IM, V78, P347, DOI 10.1016/S1081-1206(10)63195-X; Vedal S, 1998, AM J RESP CRIT CARE, V157, P1034, DOI 10.1164/ajrccm.157.4.9609008; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; Zeger SL, 2000, ENVIRON HEALTH PERSP, V108, P419, DOI 10.2307/3454382	30	18	18	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1131	1137		10.1016/j.jaci.2004.08.026	http://dx.doi.org/10.1016/j.jaci.2004.08.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536421				2022-12-18	WOS:000225047800021
J	Ludwig-Portugall, I; Montermann, E; Kremer, A; Reske-Kunz, AB; Sudowe, S				Ludwig-Portugall, I; Montermann, E; Kremer, A; Reske-Kunz, AB; Sudowe, S			Prevention of long-term IgE antibody production by gene gun-mediated DNA vaccination	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; type I allergy; allergen gene tranfer; gene gun-mediated DNA immunization; genetic vaccination; mouse; beta-galactosidase	IMMUNE-RESPONSE; DENDRITIC CELLS; IN-VIVO; IMMUNIZATION; INHIBITION; INDUCTION; INOCULATION; SUPPRESSION; DELIVERY; VACCINES	Background: Vaccination with allergen-encoding DNA represents a promising approach for the treatment of allergic diseases. Objective: In a mouse model of type I allergy, we analyzed the ability of biolistic transfection to inhibit antigen-specific IgE production and to modulate T(H)2 responses. Methods: BALB/c mice were vaccinated by means of gene gun-mediated DNA immunization with plasmid vector pCMV-betaGal, encoding beta-galactosidase as a model allergen. Subsequently, mice were immunized by means of repeated intraperitoneal injection of beta-galactosidase adsorbed to the adjuvant aluminum hydroxide. Development of IgE, IgG1, and IgG2a antibody titers during the course of immunization was followed, and anaphylactic potential of sera was determined by using RBL-2H3 degranulation assay. Spleen cells of vaccinated mice and unvaccinated control animals were stimulated in vitro to analyze cytokine production and induction of CD8(+) effector T cells. Results: Gene gun-mediated DNA immunization with pCMV-betaGal very efficiently prevented IgE antibody production on a long-term basis. Concomitantly, IgG1 antibody levels in vaccinated mice were strongly reduced, whereas IgG2a antibody production was increased. Analysis of cytokine profiles indicated immune deviation from a T(H)2-biased response in control mice toward a mixed T(H)1/T(H)2 response in vaccinated mice. In addition, substantial numbers of IFN-gamma-producing CD8(+) effector T cells were found in vaccinated mice. Conclusion: Gene gun-mediated DNA vaccination prevents the induction of long-lasting IgE antibody production.	Johannes Gutenberg Univ Mainz, Dept Dermatol, Clin Res Unit Allergol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Sudowe, S (corresponding author), Johannes Gutenberg Univ Mainz, Dept Dermatol, Clin Res Unit Allergol, Obere Zahlbacher Str 63, D-55131 Mainz, Germany.	sudowe@mail.uni-mainz.de						Adel-Patient K, 2001, INT ARCH ALLERGY IMM, V126, P59, DOI 10.1159/000049495; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; Feltquate DM, 1997, J IMMUNOL, V158, P2278; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; Hochreiter R, 2003, EUR J IMMUNOL, V33, P1667, DOI 10.1002/eji.200323377; Hochreiter R, 2001, INT ARCH ALLERGY IMM, V124, P406, DOI 10.1159/000053772; Hsu CH, 1996, INT IMMUNOL, V8, P1405, DOI 10.1093/intimm/8.9.1405; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Jilek S, 2001, J IMMUNOL, V166, P3612, DOI 10.4049/jimmunol.166.5.3612; Jonuleit H, 2003, J IMMUNOL, V171, P6323, DOI 10.4049/jimmunol.171.12.6323; Kemeny DM, 1998, CURR OPIN IMMUNOL, V10, P628, DOI 10.1016/S0952-7915(98)80080-0; Kwon SS, 2001, ALLERGY, V56, P741, DOI 10.1034/j.1398-9995.2001.056008741.x; Lee DJ, 1997, INT ARCH ALLERGY IMM, V113, P227, DOI 10.1159/000237554; Lee SW, 1998, IMMUNOLOGY, V94, P285, DOI 10.1046/j.1365-2567.1998.00557.x; Leitner WW, 2003, EXPERT OPIN BIOL TH, V3, P627, DOI 10.1517/eobt.3.4.627.21200; Maecker HT, 2001, J IMMUNOL, V166, P959, DOI 10.4049/jimmunol.166.2.959; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; Peng HJ, 2002, VACCINE, V20, P1761, DOI 10.1016/S0264-410X(02)00029-4; PERTMER TM, 1995, VACCINE, V13, P1427, DOI 10.1016/0264-410X(95)00069-D; Pertmer TM, 1996, J VIROL, V70, P6119, DOI 10.1128/JVI.70.9.6119-6125.1996; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; Ross R, 2003, GENE THER, V10, P1035, DOI 10.1038/sj.gt.3301968; Sudowe S, 2003, MOL THER, V8, P567, DOI 10.1016/S1525-0016(03)00242-9; Sudowe S, 2002, GENE THER, V9, P147, DOI 10.1038/sj.gt.3301625; Toda M, 2002, EUR J IMMUNOL, V32, P1631, DOI 10.1002/1521-4141(200206)32:6<1631::AID-IMMU1631>3.0.CO;2-O; Toda M, 2000, IMMUNOLOGY, V99, P179, DOI 10.1046/j.1365-2567.2000.00935.x; Yoshida A, 2000, VACCINE, V18, P1725, DOI 10.1016/S0264-410X(99)00432-6	27	18	20	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					951	957		10.1016/j.jaci.2004.06.013	http://dx.doi.org/10.1016/j.jaci.2004.06.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480341	Bronze			2022-12-18	WOS:000224439100035
J	Escribano, L; Garcia-Montero, A; Nunez-Lopez, R; Lopez-Jimenez, J; Almeida, J; Prados, A; Orfao, A				Escribano, L; Garcia-Montero, A; Nunez-Lopez, R; Lopez-Jimenez, J; Almeida, J; Prados, A; Orfao, A		Spanish Network Mastocytosis	Systemic mastocytosis associated with acute myeloid leukemia: Case report and implications for disease pathogenesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cell; mastocytosis; acute myeloid leukemia	MAST-CELL DISEASE; CHRONIC MYELOMONOCYTIC LEUKEMIA; WORLD-HEALTH-ORGANIZATION; NON-HODGKINS-LYMPHOMAS; BONE-MARROW SAMPLES; C-KIT; IMMUNOPHENOTYPIC CHARACTERIZATION; MYELOPROLIFERATIVE DISORDERS; MYELODYSPLASTIC SYNDROMES; HEMATOLOGIC MALIGNANCIES	Mastocytosis may be associated with clonal nonmast cell lineage hematologic diseases, including myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia. Here we present a patient with the simultaneous diagnosis of mastocytosis and an acute myeloid leukemia, M2 subtype in the French-American-British classification, with t(8;21) carrying a population of immature mast cell precursors, and discuss this presentation in the context of a potential pathogenetic cellular link between this leukemia and mastocytosis.	Hosp Ramon y Cajal, Hematol Serv, Unidad Mastocitosis, Lab K Frank Austen, E-28034 Madrid, Spain; Univ Salamanca, Serv Gen Citometria, Ctr Invest Canc, E-37008 Salamanca, Spain; Univ Salamanca, Dept Med, E-37008 Salamanca, Spain	Hospital Universitario Ramon y Cajal; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca	Escribano, L (corresponding author), Hosp Ramon y Cajal, Hematol Serv, Unidad Mastocitosis, Lab K Frank Austen, Carretera Colmenar Km 9-1, E-28034 Madrid, Spain.	lescribano.hrc@salud.madrid.org	Montero, Andres/HGA-9093-2022; Garcia-Montero, Andres C/B-6558-2017; Orfao, Alberto/B-5801-2017	Garcia-Montero, Andres C/0000-0003-4360-1386; 				Akin C, 2000, EXP HEMATOL, V28, P140, DOI 10.1016/S0301-472X(99)00145-9; BENNETT JM, 1994, BRIT J HAEMATOL, V87, P746, DOI 10.1111/j.1365-2141.1994.tb06734.x; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; BENNETT JM, 1991, BRIT J HAEMATOL, V78, P325, DOI 10.1111/j.1365-2141.1991.tb04444.x; COOPER AJ, 1982, J AM ACAD DERMATOL, V7, P215, DOI 10.1016/S0190-9622(82)70110-0; Escribano L, 2002, ANN HEMATOL, V81, P677, DOI 10.1007/s00277-002-0575-z; Escribano L, 1998, BLOOD, V91, P2731, DOI 10.1182/blood.V91.8.2731.2731_2731_2736; Escribano L, 1998, ANAL CELL PATHOL, V16, P151, DOI 10.1155/1998/341340; Escribano L, 2002, LEUKEMIA RES, V26, P1043, DOI 10.1016/S0145-2126(02)00073-5; ESCRIBANO L, 2004, CYTOM PART B-CLIN CY, V55, P1; ESCRIBANO L, 2000, CURRENT PROTOCOLS CY; GARCIALARANA J, 2002, HAEMATOLOGICA S1, V87, P385; Harris NL, 1999, J CLIN ONCOL, V17, P3835, DOI 10.1200/JCO.1999.17.12.3835; HORNY HP, 1985, HUM PATHOL, V16, P808, DOI 10.1016/S0046-8177(85)80252-5; Horny HP, 2001, LEUKEMIA RES, V25, P543, DOI 10.1016/S0145-2126(01)00021-2; HORNY HP, 1990, BRIT J HAEMATOL, V76, P186, DOI 10.1111/j.1365-2141.1990.tb07870.x; HUTCHINSON RM, 1992, LEUKEMIA LYMPHOMA, V7, P29, DOI 10.3109/10428199209053599; LAWRENCE JB, 1991, AM J MED, V91, P612, DOI 10.1016/0002-9343(91)90214-I; LENNERT K, 1979, HISTOPATHOLOGY, V3, P349, DOI 10.1111/j.1365-2559.1979.tb03017.x; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS1, DOI 10.1111/1523-1747.ep12468869; Molin D, 2002, BRIT J HAEMATOL, V119, P122, DOI 10.1046/j.1365-2141.2002.03768.x; NUNEZ R, 2002, BRIT J HAEMATOL, V120, P257; Orfao A, 1996, AM J PATHOL, V149, P1493; Pardanani A, 2003, LEUKEMIA RES, V27, P883, DOI 10.1016/S0145-2126(03)00065-1; PARMLEY RT, 1975, LAB INVEST, V32, P469; PARWARESCH MR, 1985, PATHOL RES PRACT, V179, P439, DOI 10.1016/S0344-0338(85)80184-9; Ribatti D, 2000, INT J CANCER, V85, P171, DOI 10.1002/(SICI)1097-0215(20000115)85:2<171::AID-IJC4>3.0.CO;2-W; Ribatti D, 1998, BRIT J CANCER, V77, P1900, DOI 10.1038/bjc.1998.316; San Miguel JF, 2003, SEMIN ONCOL, V30, P187, DOI 10.1053/sonc.2003.50074; Sotlar K, 2002, LEUKEMIA RES, V26, P979, DOI 10.1016/S0145-2126(02)00041-3; SOTLAR K, 2002, AM J PATHOL, V81, P677; Sperr WR, 2001, LEUKEMIA RES, V25, P529, DOI 10.1016/S0145-2126(01)00041-8; Sperr WR, 2002, LEUKEMIA LYMPHOMA, V43, P1097, DOI 10.1080/10428190290021470; Sperr WR, 2002, LEUKEMIA LYMPHOMA, V43, P2257, DOI 10.1080/1042819021000039965; Sperr WR, 2002, INT ARCH ALLERGY IMM, V127, P140, DOI 10.1159/000048186; Sperr WR, 2001, BLOOD, V98, P2200, DOI 10.1182/blood.V98.7.2200; Sperr WR, 2000, LEUKEMIA LYMPHOMA, V37, P473, DOI 10.3109/10428190009058500; TRAVIS WD, 1989, ARCH PATHOL LAB MED, V113, P365; TRAVIS WD, 1988, CANCER, V62, P965, DOI 10.1002/1097-0142(19880901)62:5<965::AID-CNCR2820620520>3.0.CO;2-M; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Valent P, 2003, HEMATOL ONCOL CLIN N, V17, P1227, DOI 10.1016/S0889-8588(03)00089-3; Valent P, 2003, LEUKEMIA RES, V27, P635, DOI 10.1016/S0145-2126(02)00168-6; Valent P, 2001, LEUKEMIA RES, V25, P595, DOI 10.1016/S0145-2126(01)00040-6; Wimazal F, 1999, AM J HEMATOL, V61, P66, DOI 10.1002/(SICI)1096-8652(199905)61:1<66::AID-AJH12>3.0.CO;2-3; Worobec AS, 2002, INT ARCH ALLERGY IMM, V127, P153, DOI 10.1159/000048189; Worobec AS, 2000, HEMATOL ONCOL CLIN N, V14, P659, DOI 10.1016/S0889-8588(05)70301-4; Yavuz AS, 2002, BLOOD, V100, P661, DOI 10.1182/blood-2002-01-0203; YOO D, 1982, AM J MED, V73, P539, DOI 10.1016/0002-9343(82)90333-3; YOO D, 1978, ANN INTERN MED, V88, P753, DOI 10.7326/0003-4819-88-6-753; [No title captured]	50	18	18	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					28	33		10.1016/j.jaci.2004.02.042	http://dx.doi.org/10.1016/j.jaci.2004.02.042			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15241340	Bronze			2022-12-18	WOS:000222534300004
J	Casale, TB				Casale, TB			Status of immunotherapy: Current and future	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						allergen vaccines; allergen immunotherapy	INJECTIONS; IGE; AMB		Creighton Univ, Dept Med, Div Allergy & Immunol, Omaha, NE 68131 USA	Creighton University	Casale, TB (corresponding author), Creighton Univ, Dept Med, Div Allergy & Immunol, 601 N 30Th St,Suite 5850, Omaha, NE 68131 USA.	tbcasale@creighton.edu	Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377				Aaronson DW, 2004, J ALLERGY CLIN IMMUN, V113, P1117, DOI 10.1016/j.jaci.2004.01.756; Bellinghausen I, 2001, INT ARCH ALLERGY IMM, V126, P97, DOI 10.1159/000049499; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; COHEN S, 2004, IN PRESS J ALLERGY C; Dworetzky M, 2004, J ALLERGY CLIN IMMUN, V113, P1231, DOI 10.1016/j.jaci.2004.03.041; Hsu CH, 2004, J ALLERGY CLIN IMMUN, V113, P1079, DOI 10.1016/j.jaci.2004.02.047; Joint Task Force on Practice Parameters, 2003, Ann Allergy Asthma Immunol, V90, P1; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Lombardi C, 2004, J ALLERGY CLIN IMMUN, V113, P1219, DOI 10.1016/j.jaci.2004.03.013; Norman PS, 1998, J ALLERGY CLIN IMMUN, V102, P1, DOI 10.1016/S0091-6749(98)70046-6; Norman PS, 2004, J ALLERGY CLIN IMMUN, V113, P1013, DOI 10.1016/j.jaci.2004.03.020; Pierson-Mullany LK, 2000, ANN ALLERG ASTHMA IM, V84, P241, DOI 10.1016/S1081-1206(10)62761-5; Shirota H, 2000, J IMMUNOL, V164, P5575, DOI 10.4049/jimmunol.164.11.5575; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Vissers JLM, 2004, J ALLERGY CLIN IMMUN, V113, P1204, DOI 10.1016/j.jaci.2004.02.041	18	18	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1036	1039		10.1016/j.jaci.2004.04.017	http://dx.doi.org/10.1016/j.jaci.2004.04.017			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208579				2022-12-18	WOS:000222091000003
J	Frew, AJ				Frew, AJ			Advances in environmental and occupational diseases 2003	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						occupational risk factors; allergy; environment	DUST MITE ALLERGEN; AIRWAY INFLAMMATION; PET OWNERSHIP; RISK-FACTORS; SENSITIZATION; ASTHMA; HOUSE; EXPOSURE; EXPRESSION; CHILDREN	The past year has seen a welcome increase in the number of articles published in the Journal on environmental and occupational disorders. Some of the major themes have been risk factors for allergic sensitization, the measurement and containment of domestic allergens (especially cockroach but also house dust mite), and risk factors for occupational allergy and asthma. Some important articles were also presented on mechanisms of occupational and environmental asthma.	Univ Southampton, Sch Med, Med Special Clin Grp, Southampton SO9 5NH, Hants, England	University of Southampton	Frew, AJ (corresponding author), Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.	A.J.Frew@soton.ac.uk	Kelly, Frank J/C-6125-2009	Kelly, Frank J/0000-0003-2558-8392				Alexis NE, 2003, J ALLERGY CLIN IMMUN, V112, P353, DOI 10.1067/mai.2003.1651; Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V111, P408, DOI 10.1067/mai.2003.16; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V112, P339, DOI 10.1067/mai.2003.1597; Arlian LG, 2003, J ALLERGY CLIN IMMUN, V111, P1269, DOI 10.1067/mai.2003.1547; Barker RD, 1998, OCCUP ENVIRON MED, V55, P684, DOI 10.1136/oem.55.10.684; Baur X, 2003, J ALLERGY CLIN IMMUN, V111, P177, DOI 10.1067/mai.2003.14; Bernstein DI, 2003, J ALLERGY CLIN IMMUN, V111, P610, DOI 10.1067/mai.2003.164; Bodtger U, 2003, J ALLERGY CLIN IMMUN, V111, P149, DOI 10.1067/mai.2003.37; Caplan EL, 2003, J ALLERGY CLIN IMMUN, V111, P1274, DOI 10.1067/mai.2003.1453; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; Custovic A, 2003, J ALLERGY CLIN IMMUN, V111, P402, DOI 10.1067/mai.2003.55; Frew AJ, 2003, ANN ALLERG ASTHMA IM, V90, P7, DOI 10.1016/S1081-1206(10)61641-9; Gijzen M, 2003, J ALLERGY CLIN IMMUN, V112, P803, DOI 10.1016/S0091-6749(03)01884-0; Gore RB, 2003, J ALLERGY CLIN IMMUN, V111, P784, DOI 10.1067/mai.2003.1378; Halken S, 2003, J ALLERGY CLIN IMMUN, V111, P169, DOI 10.1067/mai.2003.5; Hao MQ, 2003, J ALLERGY CLIN IMMUN, V112, P905, DOI 10.1016/j.jaci.2003.07.005; Homer AA, 2001, J ALLERGY CLIN IMMUN, V108, P417, DOI 10.1067/mai.2001.117795; Jeal H, 2003, J ALLERGY CLIN IMMUN, V111, P795, DOI 10.1067/mai.2003.176; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; Kuo IC, 2003, J ALLERGY CLIN IMMUN, V111, P603, DOI 10.1067/mai.2003.167; Langley SJ, 2003, J ALLERGY CLIN IMMUN, V112, P362, DOI 10.1067/mai.2003.1654; Lee KS, 2003, J ALLERGY CLIN IMMUN, V111, P1278, DOI 10.1067/mai.2003.1501; Lemiere C, 2002, J ALLERGY CLIN IMMUN, V110, P641, DOI 10.1067/mai.2002.128806; Linneberg A, 2003, J ALLERGY CLIN IMMUN, V111, P980, DOI 10.1067/mai.2003.1394; Lluch M, 2003, J ALLERGY CLIN IMMUN, V112, P802, DOI 10.1016/S0091-6749(03)01867-0; Mahakittikun V, 2003, J ALLERGY CLIN IMMUN, V112, P1239, DOI 10.1016/j.jaci.2003.08.045; Matsui E, 2003, J ALLERGY CLIN IMMUN, V111, P396, DOI 10.1067/mai.2003.11; Matsui EC, 2003, J ALLERGY CLIN IMMUN, V112, P87, DOI 10.1067/mai.2003.1588; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Nam HS, 2003, J ALLERGY CLIN IMMUN, V112, P624, DOI 10.1067/mai.2003.1644; Nguyen B, 2003, J ALLERGY CLIN IMMUN, V111, P807, DOI 10.1067/mai.2003.1341; Page K, 2003, J ALLERGY CLIN IMMUN, V112, P1112, DOI 10.1016/j.jaci.2003.08.050; Peake HL, 2003, J ALLERGY CLIN IMMUN, V112, P531, DOI 10.1067/mai.2003.1655; Perry T, 2003, J ALLERGY CLIN IMMUN, V112, P346, DOI 10.1067/mai.2003.1640; Pouladi MA, 2004, AM J RESP CELL MOL, V30, P84, DOI 10.1165/rcmb.2003-0051OC; Quirce S, 2003, J ALLERGY CLIN IMMUN, V111, P788, DOI 10.1067/mai.2003.166; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rodier F, 2003, J ALLERGY CLIN IMMUN, V112, P1105, DOI 10.1016/j.jaci.2003.08.011; Ronmark E, 2003, J ALLERGY CLIN IMMUN, V112, P747, DOI 10.1016/S0091-6749(03)01866-9; Roy SR, 2003, J ALLERGY CLIN IMMUN, V112, P571, DOI 10.1067/mai.2003.1711; Sastre J, 2003, J ALLERGY CLIN IMMUN, V111, P985, DOI 10.1067/mai.2003.1390; Tabar-Purroy AI, 2003, J ALLERGY CLIN IMMUN, V111, P415, DOI 10.1067/mai.2003.51; Weber E, 2003, J ALLERGY CLIN IMMUN, V112, P79, DOI 10.1067/mai.2003.1602; Wisnewski AV, 2003, J ALLERGY CLIN IMMUN, V112, P538, DOI 10.1067/mai.2003.1713	45	18	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1161	1166		10.1016/j.jaci.2004.03.039	http://dx.doi.org/10.1016/j.jaci.2004.03.039			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208599				2022-12-18	WOS:000222091000023
J	Makinen-Kiljunen, S; Plosila, M				Makinen-Kiljunen, S; Plosila, M			A father's IgE-mediated contact urticaria from mother's milk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BETA-LACTOGLOBULIN; ALLERGY		Univ Helsinki, Cent Hosp, Skin & Allergy Hosp, Helsinki, Finland; Finnish Student Hlth Serv, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital	Makinen-Kiljunen, S (corresponding author), Univ Helsinki, Cent Hosp, Skin & Allergy Hosp, POB 160, Helsinki, Finland.							Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P688, DOI 10.1067/mai.2002.123235; Makinen-Kiljunen S, 2002, ALLERGY, V57, P1084, DOI 10.1034/j.1398-9995.2002.23836_6.x; MAKINENKILJUNEN S, 1992, ALLERGY, V47, P347, DOI 10.1111/j.1398-9995.1992.tb02070.x; MAKINENKILJUNEN S, 1994, J ALLERGY CLIN IMMUN, V93, P990, DOI 10.1016/S0091-6749(94)70046-X; SORVA R, 1994, J ALLERGY CLIN IMMUN, V93, P787, DOI 10.1016/0091-6749(94)90259-3; Tan BM, 2001, ANN ALLERG ASTHMA IM, V86, P583, DOI 10.1016/S1081-1206(10)62908-0; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x	7	18	18	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					353	354		10.1016/j.jaci.2003.10.060	http://dx.doi.org/10.1016/j.jaci.2003.10.060			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767454	Bronze			2022-12-18	WOS:000188885700027
J	Crimi, N; Pagano, C; Palermo, F; Mastruzzo, C; Prosperini, G; Pistorio, MP; Vancheri, C				Crimi, N; Pagano, C; Palermo, F; Mastruzzo, C; Prosperini, G; Pistorio, MP; Vancheri, C			Inhibitory effect of a leukotriene receptor antagonist (montelukast) on neurokinin A-induced bronchoconstriction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						neurokinin A; cysLT receptor antagonist; bronchial asthma; leukotrienes	NEUTRAL ENDOPEPTIDASE INHIBITOR; SUBSTANCE-P; ASTHMATIC SUBJECTS; AIRWAY RESPONSES; MAST-CELLS; ALLERGEN; HISTAMINE; RELEASE; EOSINOPHILS; RECRUITMENT	Background: Tachykinins are potent contractors of human airways producing a dose-related bronchoconstriction when administered by means of inhalation to asthmatic subjects. Objective: The aim of this study was to examine the effective role played by leukotrienes (LTs) in neurokinin A (NKA)-induced bronchoconstriction in asthmatic patients. Methods: To address this question, we investigated the protective effect of a selective cysteinyl LT receptor antagonist, montelukast, against inhaled NKA and determined LTE4 excretion in the urine. Results: Inhaled NKA in the absence of any drug treatment produced a concentration-related bronchospasm with a geometric mean provocative concentration required to produce a 15% decrease in FEV1 from the postsaline baseline value (PC15) value of 290.9 mug/mL (+SE, 407.1 mug/mL; -SE, 207.84 mug/mL). Montelukast pretreatment significantly increased (P < .01) the PC15 NKA value (708.8 &mu;g/mL; +SE, 890.47 &mu;g/ml,; -SE, 564.15 &mu;g/mL,) in comparison with placebo (394.4 &mu;g/mL,; +SE, 491.88 &mu;g/mL; -SE, 248.16 &mu;g/mL) and produced a shift of the NKA concentration-response curve to the right in all the subjects studied. When compared with placebo, montelukast did not have a significant protective effect against methacholine challenge; the geometric mean PC15 values obtained were 0.87 and 0.96 &mu;g/mL with placebo and montelukast, respectively. Although we have not observed any increase in urinary LTE4 excretion after NKA inhalation, we have shown that pretreatment of asthmatic subjects with montelukast elicits a significant protection against NKA-induced bronchoconstriction. Conclusion: In asthmatic subjects NKA-induced bronchoconstriction is indirectly caused by the release of LTs, and this mechanism could explain some of the antiasthmatic and anti-inflammatory effects of LT antagonists.			Crimi, N (corresponding author), Univ Catania, Dept Internal & Specialist Med, Sect Resp Dis & Infect Dis, Via Passo Gravina 187, I-95125 Catania, Italy.		Crimi, Nunzio/AAL-2994-2020; VANCHERI, Carlo/K-9417-2016	Crimi, Nunzio/0000-0002-8591-4535; VANCHERI, Carlo/0000-0002-5120-9926				ALI H, 1986, INT ARCH ALLER A IMM, V79, P413, DOI 10.1159/000234011; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187, DOI 10.1164/ajrccm/144.5.1187; BLOOMQUIST EI, 1986, J PHARMACOL EXP THER, V240, P523; CHEUNG D, 1992, AM REV RESPIR DIS, V145, P1275, DOI 10.1164/ajrccm/145.6.1275; CHEUNG D, 1993, AM REV RESPIR DIS, V148, P1467, DOI 10.1164/ajrccm/148.6_Pt_1.1467; Cocchiara R, 1999, NEUROREPORT, V10, P575, DOI 10.1097/00001756-199902250-00024; Cocchiara R, 1999, J NEUROIMMUNOL, V101, P128, DOI 10.1016/S0165-5728(99)00138-1; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; CRIMI N, 1993, J ALLERGY CLIN IMMUN, V91, P1096, DOI 10.1016/0091-6749(93)90225-5; CRIMI N, 1990, ANN ALLERGY, V65, P115; CRIMI N, 1988, CLIN ALLERGY, V18, P375, DOI 10.1111/j.1365-2222.1988.tb02885.x; CRIMI N, 1992, CLIN EXP ALLERGY, V22, P75, DOI 10.1111/j.1365-2222.1992.tb00117.x; DIAMANT Z, 1994, EUR RESPIR J, V7, P459, DOI 10.1183/09031936.94.07030459; DRAZEN JM, 1992, AM REV RESPIR DIS, V146, P104, DOI 10.1164/ajrccm/146.1.104; Dunzendorfer S, 2000, ANN MED, V32, P429, DOI 10.3109/07853890009002017; ELLIS JL, 1991, J PHYSIOL-LONDON, V436, P469, DOI 10.1113/jphysiol.1991.sp018561; Fajac I, 1995, ALLERGY, V50, P970, DOI 10.1111/j.1398-9995.1995.tb02509.x; FULLER R W, 1992, American Review of Respiratory Disease, V145, pA290; HEANEY LG, 1994, AGENTS ACTIONS, V41, P19; HENDERSON WR, 1982, J IMMUNOL, V128, P2609; Ishikawa J, 1996, EUR RESPIR J, V9, P486, DOI 10.1183/09031936.96.09030486; Jacoby DB, 2001, J ALLERGY CLIN IMMUN, V107, P211, DOI 10.1067/mai.2001.112940; JOOS G, 1987, THORAX, V42, P779, DOI 10.1136/thx.42.10.779; Joos GF, 2000, ALLERGY, V55, P321, DOI 10.1034/j.1398-9995.2000.00112.x; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; Markham A, 1998, DRUGS, V56, P251, DOI 10.2165/00003495-199856020-00010; MARTINS MA, 1991, AM J PHYSIOL, V261, P449; NIEBER K, 1992, J ALLERGY CLIN IMMUN, V90, P646, DOI 10.1016/0091-6749(92)90138-R; OLLERENSHAW SL, 1991, EUR RESPIR J, V4, P673; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1472, DOI 10.1164/ajrccm/147.6_Pt_1.1472; SCHIERHORN K, 1995, INT ARCH ALLERGY IMM, V107, P109, DOI 10.1159/000236946; SLADEK K, 1990, AM REV RESPIR DIS, V141, P1441, DOI 10.1164/ajrccm/141.6.1441; SMITH CM, 1992, EUR RESPIR J, V5, P693; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; TOMAKI M, 1995, AM J RESP CRIT CARE, V151, P613; Turner DJ, 2000, PULM PHARMACOL THER, V13, P181, DOI 10.1006/pupt.2000.0247; Yang XX, 1997, J APPL PHYSIOL, V82, P538, DOI 10.1152/jappl.1997.82.2.538	37	18	18	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					833	839		10.1067/mai.2003.161	http://dx.doi.org/10.1067/mai.2003.161			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704366				2022-12-18	WOS:000182258500026
J	Maccario, J; Oryszczyn, MP; Charpin, D; Kauffmann, F				Maccario, J; Oryszczyn, MP; Charpin, D; Kauffmann, F			Methodologic aspects of the quantification of skin prick test responses: The EGEA study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; epidemiology; methods	GENERAL-POPULATION SAMPLE; TEST REACTIVITY; BRONCHIAL HYPERRESPONSIVENESS; COMMON AEROALLERGENS; RESPIRATORY SYMPTOMS; CROSS-REACTIVITY; LUNG-FUNCTION; ENVIRONMENTAL ALLERGENS; TOTAL IGE; ASTHMA	Background: The expression of responses of allergy skin prick tests is not standardized. Usual definitions of atopy are not Is quantitative. Objective: We sought to perform a biometric analysis of responses to various allergens to propose synthetic, quantitative indices independent of the heterogeneity of responses to various allergens. Methods: Adults (N = 1286) from the. Epidemiological Study on the Genetics and Environment of Asthma, Bronchial Hyperresponsiveness, and Atopy (EGEA) were included in the analysis. The first step, conducted for 678 subjects with at least 1 wheal >0, was to perform a standardization of wheal diameters to obtain comparable figures for 10 allergens through use of the means of the squares of wheal size as a scaling factor. The second step was a factor analysis of the standardized responses conducted not only for all subjects but also separately for asthmatic case and nonasthmatic control subjects. Finally, the strength of the link between various dichotomous and quantitative scores was assessed with multiRAST, total IgE, and asthma. Analyzed quantitative scores were based on the number of positive responses and on the nonstandardized and standardized sizes of the wheals. Results: The standardization was efficient. Among asthmatic subjects but not other subjects, factor analysis evidenced a pattern with 3 factors, corresponding to outdoor, indoor, and mold allergens. The link study showed that all scores performed very similarly. Conclusion: The number of positive tests is a quantitative score with valid biometric properties. It should be used more widely in clinical settings and in epidemiology to assess the severity of atopy.	INSERM, U472, F-94807 Villejuif, France; UPRES 3287, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Maccario, J (corresponding author), INSERM, U472, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.							Ariano R, 2000, Allerg Immunol (Paris), V32, P135; Baldacci S, 1996, ALLERGY, V51, P149, DOI 10.1111/j.1398-9995.1996.tb00055.x; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; Beasley R, 2001, PEDIATR PULM, P149; BIRNBAUM J, 1995, J ALLERGY CLIN IMMUN, V96, P561, DOI 10.1016/S0091-6749(95)70303-9; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1111/j.1365-2222.1997.tb00672.x; BOUTIN Y, 1988, CLIN ALLERGY, V18, P287, DOI 10.1111/j.1365-2222.1988.tb02871.x; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; BURROWS B, 1995, J ALLERGY CLIN IMMUN, V95, P548, DOI 10.1016/S0091-6749(95)70317-9; Cabanas R, 2000, J INVEST ALLERG CLIN, V10, P71; CHANYEUNG M, 1985, ARCH ENVIRON HEALTH, V40, P53, DOI 10.1080/00039896.1985.10545889; Chinn S, 1996, EUR J EPIDEMIOL, V12, P155, DOI 10.1007/BF00145501; FREIDHOFF LR, 1983, J ALLERGY CLIN IMMUN, V72, P274, DOI 10.1016/0091-6749(83)90032-5; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Gottlieb DJ, 1996, AM J RESP CRIT CARE, V153, P561, DOI 10.1164/ajrccm.153.2.8564098; GRIGOREAS C, 1993, ALLERGY, V48, P142, DOI 10.1111/j.1398-9995.1993.tb00703.x; Hirschwehr R, 1998, J ALLERGY CLIN IMMUN, V101, P196, DOI 10.1016/S0091-6749(98)70384-7; JENSEN EJ, 1992, J ALLERGY CLIN IMMUN, V90, P224, DOI 10.1016/0091-6749(92)90075-D; Kauffmann F, 1997, AM J RESP CRIT CARE, V156, pS123, DOI 10.1164/ajrccm.156.4.12tac9; Kauffmann F, 2001, REV EPIDEMIOL SANTE, V49, P343; KIM JO, 1979, INTRO FACTOR ANAL; KUEHR J, 1992, J ALLERGY CLIN IMMUN, V90, P358, DOI 10.1016/S0091-6749(05)80015-6; LEUNG R, 1994, CLIN EXP ALLERGY, V24, P353, DOI 10.1111/j.1365-2222.1994.tb00246.x; Pandjaitan B, 2000, J ALLERGY CLIN IMMUN, V105, P279, DOI 10.1016/S0091-6749(00)90077-0; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; PEAT JK, 1994, EUR RESPIR J, V7, P1805, DOI 10.1183/09031936.94.07101805; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; ROORDA RJ, 1992, CLIN EXP ALLERGY, V22, P627, DOI 10.1111/j.1365-2222.1992.tb00179.x; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; Spitzauer S, 1997, J ALLERGY CLIN IMMUN, V99, P100, DOI 10.1016/S0091-6749(97)70306-3; Suphioglu C, 2000, CLIN EXP ALLERGY, V30, P1335, DOI 10.1046/j.1365-2222.2000.00955.x; TAYLOR RG, 1985, THORAX, V40, P17, DOI 10.1136/thx.40.1.17; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; WARREN CPW, 1982, J ALLERGY CLIN IMMUN, V69, P370, DOI 10.1016/0091-6749(82)90148-8; WELTY C, 1984, AM REV RESPIR DIS, V130, P198	35	18	19	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					750	756		10.1067/mai.2003.1386	http://dx.doi.org/10.1067/mai.2003.1386			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704353				2022-12-18	WOS:000182258500013
J	Domae, M; Sagara, H; Sakaue, M; Fukuda, T; Kamikawa, Y				Domae, M; Sagara, H; Sakaue, M; Fukuda, T; Kamikawa, Y			The antiallergic drug oxatomide promotes human eosinophil apoptosis and suppresses IL-5-induced eosinophil survival	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; apoptosis; oxatomide; allergic inflammation	COLONY-STIMULATING FACTOR; LATE ASTHMATIC RESPONSES; AIRWAY HYPERRESPONSIVENESS; INHALED CORTICOSTEROIDS; PROLONGED SURVIVAL; RESISTANT ASTHMA; MAST-CELLS; INTERLEUKIN-5; THEOPHYLLINE; GLUCOCORTICOIDS	Eosinophils accumulated in sites of allergic inflammation are thought to play a crucial role in the pathogenesis of allergic disorders including asthma, allergic rhinitis, and atopic dermatitis, and tissue eosinophilia is attributable to increased eosinophil survival or decreased eosinophil apoptosis. Objective: Effects of the antiallergic, histamine H-1 blocker oxatomide on viability and apoptosis of eosinophils isolated from the peripheral blood of atopic subjects were studied. Methods: Eosinophil viability and apoptosis were evaluated by using a colorimetric assay and annexin V-labeling, caspase-3 activity, and DNA fragmentation assay. Results: The viability of eosinophils increased in the presence of IL-5 (10 ng/mL), confirming that IL-5 prolongs eosinophil survival in vitro. Application of oxatomide at concentrations over 20 mumol/L for 24 hours decreased the IL-5-induced enhancement of eosinophil viability. Double staining of the cells with annexin V and propidium iodide showed that deprivation of IL-5 promoted spontaneous eosinophil apoptosis and that oxatomide facilitated apoptosis and suppressed the prolongation of eosinophil survival stimulated by IL-5. In the absence of IL-5, approximately 71% and 96% of eosinophils after 24 and 48 hours, respectively, underwent spontaneous apoptosis. IL-5 decreased the rate of eosinophil apoptosis to 38% and 52% after 24 and 48 hours, respectively. Oxatomide increased eosinophil apoptosis in a concentration-dependent manner in the presence of IL-5. Furthermore, oxatomide increased caspase-3 activity and DNA fragmentation. Conclusion: We demonstrated that oxatomide possesses a novel therapeutic effect of apoptosis promotion on eosinophils and prevents the antiapoptotic effects of IL-5, suggesting that oxatomide may contribute to resolution of tissue eosinophilia in allergic inflammation.	Dokkyo Univ, Sch Med, Dept Pharmacol, Mibu, Tochigi 3210293, Japan; Dokkyo Univ, Sch Med, Dept Pulm Med & Clin Immunol, Mibu, Tochigi 3210293, Japan	Dokkyo Medical University; Dokkyo Medical University	Domae, M (corresponding author), Dokkyo Univ, Sch Med, Dept Pharmacol, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan.							ADACHI T, 1995, AM J RESP CRIT CARE, V151, P618; Adachi T, 1996, J ALLERGY CLIN IMMUN, V98, pS207, DOI 10.1016/S0091-6749(96)70068-4; Barnes PJ, 2000, J ALLERGY CLIN IMMUN, V106, P5, DOI 10.1067/mai.2000.107930; BOCHNER BS, 1994, ANNU REV IMMUNOL, V12, P295; COCKCROFT DW, 1988, CHEST, V94, P178, DOI 10.1378/chest.94.1.178; Fukuda T, 1996, AM J RESP CELL MOL, V14, P84, DOI 10.1165/ajrcmb.14.1.8534490; Giembycz MA, 1999, PHARMACOL REV, V51, P213; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Gommerman JL, 1998, BLOOD, V91, P1891, DOI 10.1182/blood.V91.6.1891.1891_1891_1900; GUNDEL RH, 1989, AM REV RESPIR DIS, V140, P629, DOI 10.1164/ajrccm/140.3.629; GUYRE PM, 1988, J STEROID BIOCHEM, V30, P89, DOI 10.1016/0022-4731(88)90080-5; Hamid QA, 2000, J ALLERGY CLIN IMMUN, V105, P20, DOI 10.1016/S0091-6749(00)90172-6; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HOJO M, 1994, ANN ALLERGY, V73, P21; IDE M, 1994, J IMMUNOL METHODS, V168, P187, DOI 10.1016/0022-1759(94)90054-X; LAMAS AM, 1991, J IMMUNOL, V147, P254; Lee NA, 2001, J ALLERGY CLIN IMMUN, V107, P945, DOI 10.1067/mai.2001.116002; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; LUKACS NW, 1995, AM J RESP CELL MOL, V13, P1; Marone G, 1999, J INVEST ALLERG CLIN, V9, P207; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; NICOLAIZIK WH, 1994, AM J RESP CRIT CARE, V150, P624, DOI 10.1164/ajrccm.150.3.8087329; Nutku E, 2001, J IMMUNOL, V167, P1039, DOI 10.4049/jimmunol.167.2.1039; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; OHASHI Y, 1992, AM REV RESPIR DIS, V145, P1469, DOI 10.1164/ajrccm/145.6.1469; Ohmori K, 1998, ARZNEIMITTEL-FORSCH, V48, P43; Ohta K, 1996, CLIN EXP ALLERGY, V26, P10, DOI 10.1111/j.1365-2222.1996.tb01137.x; Patella V, 1996, INT ARCH ALLERGY IMM, V111, P23, DOI 10.1159/000237340; Paulussen JJC, 1996, EUR J PHARMACOL, V312, P121, DOI 10.1016/0014-2999(96)00453-0; PHILLIP M, 1992, PEDIATR PULM, V12, P84, DOI 10.1002/ppul.1950120205; POZNANSKY MC, 1985, CLIN EXP IMMUNOL, V61, P135; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; Sagara H, 1997, INT ARCH ALLERGY IMM, V112, P287, DOI 10.1159/000237468; Sagara H, 2001, INT ARCH ALLERGY IMM, V124, P371, DOI 10.1159/000053761; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCHLEIMER RP, 1994, J ALLERGY CLIN IMMUN, V94, P1202, DOI 10.1016/0091-6749(94)90333-6; Simon HU, 2001, IMMUNOL REV, V179, P156, DOI 10.1034/j.1600-065X.2001.790115.x; SIMONS FER, 1991, ANN ALLERGY, V66, P5; Spahn JD, 2002, J ALLERGY CLIN IMMUN, V109, P3, DOI 10.1067/mai.2002.120756; Tenor H, 1996, BRIT J PHARMACOL, V118, P1727, DOI 10.1111/j.1476-5381.1996.tb15598.x; TOOGOOD JH, 1991, J ALLERGY CLIN IMMUN, V88, P572, DOI 10.1016/0091-6749(91)90150-M; WALLEN N, 1991, J IMMUNOL, V147, P3940; Walsh GM, 1998, J IMMUNOL METHODS, V217, P153, DOI 10.1016/S0022-1759(98)00103-3; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; YAMAGUCHI Y, 1991, BLOOD, V78, P2542	47	18	20	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					567	572		10.1067/mai.2003.136	http://dx.doi.org/10.1067/mai.2003.136			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642838				2022-12-18	WOS:000181639500019
J	Donfack, J; Kogut, P; Forsythe, S; Solway, J; Ober, C				Donfack, J; Kogut, P; Forsythe, S; Solway, J; Ober, C			Sequence variation in the promoter region of the cholinergic receptor muscarinic 3 gene and asthma and atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; muscarinic receptors	GENOME-WIDE SEARCH; ACETYLCHOLINE-RECEPTORS; LINKAGE DISEQUILIBRIUM; FOUNDER POPULATION; AIRWAYS; POLYMORPHISMS; ASSOCIATION; SUBTYPES; FAMILY	Background: Muscarinic acetylcholine receptors are members of the superfamily of G protein-coupled, 7 transmembrane-spanning proteins. They are important in the development of airway hyperresponsiveness. In the lung the M-3 receptor, encoded by the cholinergic receptor muscarinic 3 gene, is present in airway smooth muscle and mediates smooth muscle contraction. Objective: We considered the cholinergic, receptor muscarinic 3 gene as a possible candidate gene for bronchial asthma and initiated studies to identify polymorphisms in the promoter region. Method: We identified 4 single-nucleotide polymorphisms; (-708A/G, -627G/C, -513C/A, and -492C/T) and 2 short tandem repeat polymorphisms, a tetranucleotide (CTTT)(12-20) and a dinucleotide (GT)(6-19) repeat. Results: None of the identified single nucleotide polymorphisms were significantly more frequent in asthmatic patients (n = 76) compared with in healthy control subjects (n = 81). Furthermore, there was no evidence for nonrandom transmission of short tandem repeat polymorphism haplotypes to individuals with asthma or bronchial hyperresponsiveness (P > .50) in a large Hutterite pedigree. However, there was significant nonrandom transmission of haplotypes to individuals with skin test reactivity to cockroach allergens (global transmission disequilibrium test: chi(2) = 38.55, P =.013). Conclusions: These results suggest a possible role for this gene in atopic disorders. (J Allergy Clin Immunol 2003;111:527-32.).	Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Ober, C (corresponding author), Univ Chicago, Dept Human Genet, 920 E 58th St,Rm 507 C, Chicago, IL 60637 USA.		Solway, Julian/B-1116-2008	Solway, Julian/0000-0002-0898-8530	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066533, U01HL049596, R01HL064095, P50HL056399, R01HL072414] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00055] Funding Source: Medline; NHLBI NIH HHS [HL56399, R01 HL072414, HL49596, HL64095, R01 HL066533, P50 HL056399] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES PJ, 1992, PHYSIOL REV, V72, P699, DOI 10.1152/physrev.1992.72.3.699; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1991, CYTOGENET CELL GENET, V58, P1850; CABEZAS GA, 1971, J APPL PHYSIOL, V31, P651, DOI 10.1152/jappl.1971.31.5.651; COLEBATCH HJH, 1963, J APPL PHYSIOL, V18, P881, DOI 10.1152/jappl.1963.18.5.881; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Dewar JC, 1997, J ALLERGY CLIN IMMUN, V100, P261, DOI 10.1016/S0091-6749(97)70234-3; DOUGLAS NJ, 1979, J APPL PHYSIOL, V46, P256, DOI 10.1152/jappl.1979.46.2.256; Fenech AG, 2001, BRIT J PHARMACOL, V133, P43, DOI 10.1038/sj.bjp.0704039; Forsythe SM, 2002, AM J RESP CELL MOL, V26, P298, DOI 10.1165/ajrcmb.26.3.4564; GREEN JM, 1972, J PHYSL, V32, P160; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; Hall D, 1997, AM J HUM GENET, V61, pA200; Hall IP, 2000, METH MOL B, V136, P117; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; KANEDA T, 1993, MOL PHARMACOL, V43, P356; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; MAEDA A, 1988, FEBS LETT, V239, P339, DOI 10.1016/0014-5793(88)80947-5; Marsh DG, 1997, NAT GENET, V15, P389; MOLFINO NA, 1993, AM REV RESPIR DIS, V148, P1238, DOI 10.1164/ajrccm/148.5.1238; NADEL JA, 1984, ANNU REV MED, V35, P451, DOI 10.1146/annurev.med.35.1.451; *NIH, 1997, GUID DIAGN MAN ASTHM; O'Donovan MC, 1998, GENOMICS, V52, P44, DOI 10.1006/geno.1998.5411; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 1997, AM J HUM GENET, V61, P497, DOI 10.1086/515511; Ober C, 2001, AM J HUM GENET, V69, P1068, DOI 10.1086/324025; Ramsay CE, 1999, HUM GENET, V104, P269, DOI 10.1007/s004390050947; ROEFFEL A, 1990, PULM PHARMACOL, V3, P47; Spielman RS, 1996, AM J HUM GENET, V59, P983; Tayebati SK, 1999, J NEUROIMMUNOL, V99, P224, DOI 10.1016/S0165-5728(99)00119-8; WEEKS DE, 1995, AM J HUM GENET, V56, P1506; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Zheng CX, 1999, GENET EPIDEMIOL, V17, P79, DOI 10.1002/(SICI)1098-2272(1999)17:2<79::AID-GEPI1>3.0.CO;2-N	34	18	20	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					527	532		10.1067/mai.2003.71	http://dx.doi.org/10.1067/mai.2003.71			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642833				2022-12-18	WOS:000181639500014
J	Strunk, RC; Bender, B; Young, DA; Sagel, S; Glynn, E; Caesar, M; Lawhon, C				Strunk, RC; Bender, B; Young, DA; Sagel, S; Glynn, E; Caesar, M; Lawhon, C			Predictors of protocol adherence in a pediatric asthma clinical trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adherences; pediatric asthma clinical trial; retention	BUDESONIDE INHALATION SUSPENSION; YOUNG-CHILDREN; CHILDHOOD; PROGRAM	Background: Declining protocol adherence can threaten the validity of a clinical trial. Objective: We sought to explore patient and family factors important for protocol adherence in the 133 patients followed at one of the 8 Childhood Asthma Management Program (CAMP) clinical centers. Difficulties with timely return of diary cards (diary card problem), with keeping or frequently rescheduling appointments (appointment problem), and with commitment to all aspects of the trial (commitment problem) were tracked prospectively during the treatment phase of CAMP, which ranged from 20 to 40 months at the time of the analysis. Methods: We performed a cross-sectional analysis. Results: During the course of this investigation, no St Louis CAMP patients dropped out of the study, although signs of eroding participation were observed in 44% of patients. For this cross-sectional analysis, the percentage of patients exhibiting protocol-adherence problems was greater the longer patients had been in the trial: 33.3% at 20 to 25 months, 39.5% at 26 to 30 months, 51.4% at 31 to 35 months, and 69.2% at 36 to 40 months (P < .01). The diary card problem was present in 22.2% of the patients enrolled in the trial for 20 to 25 months compared with 66.7% for patients enrolled for 36 to 40 months (P < .005). Appointment and commitment problems were present in smaller percentages of patients and did not change by time in the trial (P = .41 and .22, respectively). A logistic regression analysis of demographic characteristics indicated that age at randomization and time in the trial were significant factors: for every 2-year increase in age, a child was twice as likely to have a commitment problem (odds ratio [OR], 1.96; 95% CI, 1.50-2.57), and for each additional 5 months of participation in the study, a child was twice as likely to have a diary card problem (OR, 1.91; 95% CI, 1.76-2.07). There was no influence of family income, patient race, or patient sex on the occurrence of any of the 3 protocol-adherence problems. A similar analysis of psychologic characteristics of the child and family indicated (1) a 2-fold increase in the risk of a diary card problem with a 10% increase in the percentage of total commissions on the attention scale of the Gordon Diagnostic Study (OR, 2.18; 95% CI, 2.02-2.35), (2) a 2-fold decrease in the risk of an appointment problem with a 10-unit increase in the Child Manifest Anxiety Scale (OR, 0.46; 95% CI, 0.44-0.49), (3) a 2-fold decrease in risk of an appointment problem with a 10-unit increase in the cohesion subscale of the Family Environment Scale (OR, 0.58; 95% CI, 0.55-0.60), and (4) a 5-fold decrease in the risk of a commitment problem with a 10-unit increase in the Child Depression Index score (OR, 0.21; 95% CI, 0.18-0.24). Conclusions: Adherence and retention problems commonly occur in longer clinical trials. CAMP patients and families were selected in part on the basis of likelihood of being able to participate in the trial to enhance the conclusions of the trial. Despite this selection process, adherence problems were noted. Problems increased with duration of participation, increasing child age, and the presence of less family cohesion or attention problems in the child. In contrast, the presence of mild emotional distress (anxiety and depression) in the child was associated with fewer protocol-adherence problems. Incorporating procedures that help anticipate and identify adherence problems early might improve continued participation in all aspects of a trial and even retention in long-term clinical trials.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA; Natl Jewish Med & Res Ctr, Dept Psychol, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80202 USA; Univ Colorado, Hlth Sci Ctr, Dept Psychol, Denver, CO 80202 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med, Denver, CO 80202 USA; Univ Colorado, Hlth Sci Ctr, Dept Biometr, Denver, CO 80202 USA	Washington University (WUSTL); National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Strunk, RC (corresponding author), Washington Univ, St Louis Childrens Hosp,Sch Med, Dept Pediat, Div Allergy & Pulm Med, 1 Childrens Pl, St Louis, MO 63110 USA.							Achenbach T. M., 1999, MANUAL CHILD BEHAV C; Bender B, 1998, J ASTHMA, V35, P347, DOI 10.3109/02770909809075667; Bender BG, 2000, ARCH PEDIAT ADOL MED, V154, P706, DOI 10.1001/archpedi.154.7.706; Bender BG, 1997, J ALLERGY CLIN IMMUN, V99, P197, DOI 10.1016/S0091-6749(97)70096-4; Bender T, 1998, AM LIT HIST, V10, P1; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Childhood Asthma Management Program Res Grp, 1999, J ASTHMA, V36, P217; Gordon M., 1987, TECHNICAL GUIDE GORD; Jonasson G, 2000, ARCH DIS CHILD, V83, P330, DOI 10.1136/adc.83.4.330; KOVACS M, 1981, ACTA PAEDOPSYCHIATR, V46, P305; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; Moos RH., 1994, FAMILY ENV SCALE MAN, V3; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; PROBSTFIELD JL, 1986, AM J MED, V80, P777, DOI 10.1016/0002-9343(86)90615-7; Reynolds C.R., 1985, REVISED CHILDRENS MA; SATTLER JH, 1991, ASSESSMENT CHILDREN; Shapiro G, 1998, J ALLERGY CLIN IMMUN, V102, P789, DOI 10.1016/S0091-6749(98)70019-3; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; Skoner DP, 2000, J ALLERGY CLIN IMMUN, V105, P259, DOI 10.1016/S0091-6749(00)90074-5; STEIN REK, 1980, MED CARE, V18, P465, DOI 10.1097/00005650-198004000-00010; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; Szefler SJ, 1998, ANN ALLERG ASTHMA IM, V81, P571; TINKELMAN DG, 1993, PEDIATRICS, V92, P64	23	18	19	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2002	110	4					596	602		10.1067/mai.2002.128803	http://dx.doi.org/10.1067/mai.2002.128803			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	602JJ	12373267				2022-12-18	WOS:000178501900009
J	Zhang, K; Zhang, L; Zhu, DC; Bae, D; Nel, A; Saxon, A				Zhang, K; Zhang, L; Zhu, DC; Bae, D; Nel, A; Saxon, A			CD40-mediated p38 mitogen-activated protein kinase activation is required for immunoglobulin class switch recombination to IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B lymphocyte; antibody; gene rearrangement; signal transduction	HUMAN B-CELLS; NF-KAPPA-B; CROSS-LINKING CD40; T-CELLS; MAP KINASE; RECEPTOR; EXPRESSION; PATHWAY; TRANSCRIPTS; INHIBITOR	Background: Signaling through CD40 activates multiple kinases and signal pathways that drive diverse CD40-mediated biologic functions. The specific pathways activated by CD40 signaling involving CD40-dependent Ig class switch recombination (CSR) have not been defined. Objective: We sought to dissect CD40-activated signaling required for CD40-mediated Ig CSR by using the specific signal pathway inhibitors, with the emphasis on CD40-activated p38 mitogen-activated protein kinase (p38 MAPK) signaling in CB40-mediated CSR to IgE. Methods: Human B cells were costimulated with IL-4 plus anti-CD40 in the presence or absence of specific signal pathway inhibitors. Ig production, kinase phosphorylation, IgH epsilon germline transcripts and Smu-Sepsilon recombination were examined, and their relationships were analyzed. Results: CD40-dependent IgE induction was inhibited by the specific p38 MAPK inhibitor SB203580 but not by the extracellular signal-regulated protein kinase-specific inhibitor PD98059 or the phosphatidylinositol 3-kinase-specific inhibitor LV294002. CD40 activation of p38 MAPK correlated with CD40-dependent IgE production, and IgE suppression by SB203580 correlated with the inhibition of CD40-activated p38 MAPK phosphorylation. Suppression of IgE production by SB203580 was not due to inhibition of cell proliferation because SB203580 did not suppress IL-4 plus alpha-CD40-induced cell proliferation. SB203580, but neither PD98059 nor LY294002, inhibited CD40-dependent Smu-Sepsilon recombination, as determined by using a digestion circularization PCR assay. The inhibitory effects of SB203580 on IgE production and Smu-Sepsilon recombination were directly related to its ability to suppress production of Ig e germline transcripts. Conclusion: These results demonstrate that p38 MAPK is required for CD40-mediated class switching to IgE.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol,Hart & Louis Lab, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Zhang, K (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol,Hart & Louis Lab, 52-175 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Nel, Andre E/J-2808-2012		NIAID NIH HHS [AI 40551, AI 15251] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040551, R01AI015251, R21AI015251] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arimura Y, 2001, J BIOL CHEM, V276, P8550, DOI 10.1074/jbc.M009242200; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Brady K, 2001, BIOCHEM BIOPH RES CO, V289, P276, DOI 10.1006/bbrc.2001.5968; Chin AID, 1999, MOL CELL BIOL, V19, P6665; CHU CC, 1992, P NATL ACAD SCI USA, V89, P6978, DOI 10.1073/pnas.89.15.6978; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; Craxton A, 1998, J IMMUNOL, V161, P3225; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Faris M, 1996, J BIOL CHEM, V271, P27366, DOI 10.1074/jbc.271.44.27366; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; Grant PA, 1996, EMBO J, V15, P6691, DOI 10.1002/j.1460-2075.1996.tb01059.x; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Gulbins E, 1996, J IMMUNOL, V157, P2844; HU HM, 1994, J BIOL CHEM, V269, P30069; Iciek LA, 1997, J IMMUNOL, V158, P4769; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Kanda K, 2000, J BIOL CHEM, V275, P32338, DOI 10.1074/jbc.M004148200; Karras JG, 1997, J IMMUNOL, V159, P4350; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Kinoshita K, 1998, IMMUNITY, V9, P849, DOI 10.1016/S1074-7613(00)80650-0; Lee HH, 1999, P NATL ACAD SCI USA, V96, P1421, DOI 10.1073/pnas.96.4.1421; LORENZ M, 1995, SCIENCE, V267, P1825, DOI 10.1126/science.7892607; Muto T, 2000, GENOMICS, V68, P85, DOI 10.1006/geno.2000.6268; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Snapper CM, 1997, IMMUNITY, V6, P217, DOI 10.1016/S1074-7613(00)80324-6; Suttles J, 1999, J BIOL CHEM, V274, P5835, DOI 10.1074/jbc.274.9.5835; TARYLEHMANN M, 1992, J EXP MED, V175, P503, DOI 10.1084/jem.175.2.503; VanKooten C, 1996, ADV IMMUNOL, V61, P1; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WORM M, 1995, EUR J IMMUNOL, V25, P2438, DOI 10.1002/eji.1830250905; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; ZHANG K, 1991, J IMMUNOL, V146, P1836	37	18	19	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					421	428		10.1067/mai.2002.126382	http://dx.doi.org/10.1067/mai.2002.126382			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209089				2022-12-18	WOS:000177936900012
J	Takizawa, T; Kato, M; Kimura, H; Suzuki, M; Tachibana, A; Obinata, H; Izumi, T; Tokuyama, K; Morikawa, A				Takizawa, T; Kato, M; Kimura, H; Suzuki, M; Tachibana, A; Obinata, H; Izumi, T; Tokuyama, K; Morikawa, A			Inhibition of protein kinases A and C demonstrates dual modes of response in human eosinophils stimulated with platelet-activating factor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; protein kinase C; protein kinase A; CD11b; adhesion	SUPEROXIDE ANION GENERATION; PURIFIED HUMAN EOSINOPHILS; OPSONIZED PARTICLES; SIGNAL-TRANSDUCTION; DE-GRANULATION; DEGRANULATION; INTEGRIN; NEUTROPHILS; EXPRESSION; RECEPTORS	Background: Platelet-activating factor (PAF) is a potent stimulator of human eosinophils involved in the pathogenesis of allergic diseases. However, intracellular signaling mechanisms in eosinophils involving the PAF receptor are incompletely understood. Objective: We sought to determine the roles of protein kinase C (PKC) and cyclic AMP-dependent protein kinase (protein kinase A [PKA]) in signaling pathways of human eosinophils stimulated with PAR Methods: After pretreatment with a PKC inhibitor, bisindolylmaleimide I, or a PKA inhibitor, H89, we investigated PAF-evoked functions, such as CD11b expression, cellular adhesion, superoxide anion generation, and degranulation in human eosinophils. Results: Preincubation of eosinophils with bisindolylmaleimide I resulted in enhancement of upregulated CD11b expression and adhesion induced by PAR H89 pretreatment also enhanced PAF-induced cellular adhesion. Superoxide anion generation and degranulation were suppressed by means of inhibition of either PKC or PKA. Conclusion: PKC and PKA negatively regulate PAF-induced CD11b upregulation and cellular adhesion but promote eosinophil effector functions, such as superoxide anion generation and degranulation. PKC and PKA modulate PAF-evoked intracellular signaling of the eosinophil function in distinct ways.	Gunma Univ, Sch Med, Dept Pediat, Maebashi, Gumma 3718511, Japan; Gunma Univ, Sch Med, Dept Biochem, Maebashi, Gumma 371, Japan; Gunma Prefectural Inst Publ Hlth & Environm Sci, Maebashi, Gumma, Japan	Gunma University; Gunma University	Kato, M (corresponding author), Gunma Univ, Sch Med, Dept Pediat, 3-39-22 Showa Machi, Maebashi, Gumma 3718511, Japan.		Takizawa, Takumi/AAH-4996-2020	Takizawa, Takumi/0000-0003-2169-0787				ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; BARNES PJ, 1991, ANN NY ACAD SCI, V629, P193; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; BLOM M, 1992, J IMMUNOL, V149, P3672; BRUIJNZEEL PLB, 1987, PROSTAGLANDINS, V34, P205, DOI 10.1016/0090-6980(87)90244-9; BUTTERFIELD JH, 1995, SAMTERS IMMUNOLOGIC, P501; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; Dent G, 1998, AM J RESP CELL MOL, V18, P136, DOI 10.1165/ajrcmb.18.1.2817; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; Evans DJ, 1999, AM J PHYSIOL-LUNG C, V277, pL233, DOI 10.1152/ajplung.1999.277.2.L233; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HORIE S, 1994, J IMMUNOL, V152, P5457; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IDE M, 1994, J IMMUNOL METHODS, V168, P187, DOI 10.1016/0022-1759(94)90054-X; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; KANEKO M, 1995, J IMMUNOL, V155, P2631; KATO M, 1995, J IMMUNOL, V155, P357; Kato M, 1998, AM J RESP CELL MOL, V18, P675, DOI 10.1165/ajrcmb.18.5.2885; KATO M, 1993, EUR J PHARMACOL, V232, P7, DOI 10.1016/0014-2999(93)90721-S; Kita H, 1998, ALLERGY PRINCIPLES P, P242; KROEGEL C, 1994, AM J RESP CELL MOL, V11, P593, DOI 10.1165/ajrcmb.11.5.7946388; KROEGEL C, 1989, J IMMUNOL, V142, P3518; KROEGEL C, 1988, IMMUNOLOGY, V64, P559; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; Lynch OT, 1999, BRIT J PHARMACOL, V128, P1149, DOI 10.1038/sj.bjp.0702892; Milligan G, 1995, Adv Pharmacol, V32, P1, DOI 10.1016/S1054-3589(08)61010-8; Momose T, 1998, INT ARCH ALLERGY IMM, V117, P138, DOI 10.1159/000024001; NAKANO M, 1990, METHOD ENZYMOL, V186, P585; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oshiro T, 2000, CLIN EXP ALLERGY, V30, P699; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEDGWICK JB, 1988, J ALLERGY CLIN IMMUN, V81, P876, DOI 10.1016/0091-6749(88)90945-1; Teixeira MM, 1997, BLOOD, V89, P4566, DOI 10.1182/blood.V89.12.4566; TOOL ATJ, 1992, BLOOD, V79, P2729; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANDERBRUGGEN T, 1993, J LEUKOCYTE BIOL, V54, P552, DOI 10.1002/jlb.54.6.552; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; ZORATTI EM, 1991, J ALLERGY CLIN IMMUN, V88, P749, DOI 10.1016/0091-6749(91)90182-N	41	18	18	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					241	248	UNSP 1/83/126303	10.1067/mai.2002.126303	http://dx.doi.org/10.1067/mai.2002.126303			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170264				2022-12-18	WOS:000177509800008
J	Weissman, DN; Lewis, DM				Weissman, DN; Lewis, DM			Allergic and latex-specific sensitization: Route, frequency, and amount of exposure that are required to initiate IgE production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on Natural Rubber Latex Sensitivity	FEB 09-10, 2001	SAN FRANCISCO, CALIFORNIA	Malaysian Rubber Res Inst		latex; IgE; sensitization; exposure-response	NATURAL-RUBBER LATEX; HEALTH-CARE WORKERS; OCCUPATIONAL ASTHMA; HOSPITAL PERSONNEL; SPINA-BIFIDA; RESPONSE RELATIONSHIPS; RESPIRATORY ALLERGY; GENERAL-POPULATION; LABORATORY-ANIMALS; BAKING INDUSTRY	Quantitative data that documents human exposure-response relationships for IgE sensitization to allergens are limited. Although seemingly straightforward, documentation of exposure-response relationships can be difficult. Issues that are related to study design, allergen standardization, exposure assessment, and evaluation for sensitization can impact greatly on study results. Despite these issues, exposure-response relationships for sensitization to protein allergens have been documented in several occupational groups, which include enzyme-detergent workers, bakers, and laboratory animal workers. In general, atopy acts as an effect modifier in these settings, steepening the exposure-response relationship. Several studies suggest that the greatest risk for sensitization is within the first several years of exposure. For 1 allergen, the protease subtilisin, a short-term exposure limit of 60 ng/m(3) has been recommended by the American Council of Governmental Industrial Hygienists. With regard to natural rubber latex, exposure-related factors such as number of operations have been shown to be risk factors for sensitization of children with spina bifida. By contrast, fewer studies show exposure-response relationships for IgE sensitization of health care workers to natural rubber latex, and the area remains controversial. However, a recent cohort study that evaluated incident sensitization in dental hygiene students suggests strongly that, with sufficient exposure, employment in health care can lead to an increased risk of IgE sensitization to natural rubber latex.	NIOSH, HELD, ASB, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Weissman, DN (corresponding author), NIOSH, HELD, ASB, Mailstop L-4218,1095 Willowdale Rd, Morgantown, WV 26505 USA.							Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; Archambault S, 2001, J ALLERGY CLIN IMMUN, V107, P921; Baur X, 1998, ALLERGY, V53, P562, DOI 10.1111/j.1398-9995.1998.tb03931.x; Baur X, 1998, J ALLERGY CLIN IMMUN, V101, P24, DOI 10.1016/S0091-6749(98)70188-5; Baur X, 1998, CLIN EXP ALLERGY, V28, P537; BAUR X, 1995, ALLERGOL INT, V20, P105; Beck Lisa A., 2000, Journal of Allergy and Clinical Immunology, V106, pS258; BUBAK ME, 1992, MAYO CLIN PROC, V67, P1075, DOI 10.1016/S0025-6196(12)61122-7; Cullinan P, 1999, EUR RESPIR J, V13, P1139, DOI 10.1034/j.1399-3003.1999.13e33.x; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; Garabrant DH, 2001, AM J RESP CRIT CARE, V163, P1501, DOI 10.1164/ajrccm.163.6.16362c; Garabrant DH, 2001, AM J EPIDEMIOL, V153, P515, DOI 10.1093/aje/153.6.515; Gautrin D, 2000, AM J RESP CRIT CARE, V162, P1222, DOI 10.1164/ajrccm.162.4.2001023; Gautrin D, 2001, EUR RESPIR J, V17, P904, DOI 10.1183/09031936.01.17509040; Gautrin D, 2001, AM J RESP CRIT CARE, V163, P899, DOI 10.1164/ajrccm.163.4.2008011; Grzybowski M, 1996, J ALLERGY CLIN IMMUN, V98, P535, DOI 10.1016/S0091-6749(96)70087-8; Hamilton RG, 2000, J ALLERGY CLIN IMMUN, V105, P839, DOI 10.1067/mai.2000.105224; Hamilton RG, 1999, J ALLERGY CLIN IMMUN, V103, P925, DOI 10.1016/S0091-6749(99)70440-9; Hayes BB, 2000, TOXICOL SCI, V56, P262, DOI 10.1093/toxsci/56.2.262; Hollander A, 1997, AM J RESP CRIT CARE, V155, P562, DOI 10.1164/ajrccm.155.2.9032195; Houba R, 1998, AM J IND MED, V34, P529, DOI 10.1002/(SICI)1097-0274(199812)34:6&lt;529::AID-AJIM1&gt;3.0.CO;2-I; Houba R, 1998, AM J RESP CRIT CARE, V158, P1499, DOI 10.1164/ajrccm.158.5.9803055; Houba R, 1996, AM J RESP CRIT CARE, V154, P130, DOI 10.1164/ajrccm.154.1.8680668; JUNIPER CP, 1984, J SOC OCCUP MED, V34, P127; JUNIPER CP, 1977, J SOC OCCUP MED, V27, P3; Kaczmarek RG, 1996, ANN ALLERG ASTHMA IM, V76, P51, DOI 10.1016/S1081-1206(10)63406-0; Kelly KJ, 1998, ANN EMERG MED, V32, P723, DOI 10.1016/S0196-0644(98)70073-3; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V94, P53, DOI 10.1016/0091-6749(94)90071-X; Kibby T, 1997, ANN ALLERG ASTHMA IM, V78, P41, DOI 10.1016/S1081-1206(10)63370-4; Kurup VP, 1996, INT ARCH ALLERGY IMM, V109, P58, DOI 10.1159/000237232; Kurup VP, 2000, CLIN EXP ALLERGY, V30, P359; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; Levy DA, 1999, JAMA-J AM MED ASSOC, V281, P988, DOI 10.1001/jama.281.11.988; Liss GM, 1999, AM J IND MED, V35, P196, DOI 10.1002/(SICI)1097-0274(199902)35:2<196::AID-AJIM12>3.0.CO;2-Y; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; Mace SR, 1998, ANN ALLERG ASTHMA IM, V80, P252, DOI 10.1016/S1081-1206(10)62966-3; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P505, DOI 10.1016/S0091-6749(97)70143-X; Nel A, 1998, ANN ALLERG ASTHMA IM, V81, P388, DOI 10.1016/S1081-1206(10)63135-3; Nieto A, 1996, J ALLERGY CLIN IMMUN, V98, P501, DOI 10.1016/S0091-6749(96)70082-9; Niggemann B, 1998, J ALLERGY CLIN IMMUN, V102, P665, DOI 10.1016/S0091-6749(98)70285-4; Novembre E, 1997, ALLERGY, V52, P101, DOI 10.1111/j.1398-9995.1997.tb02553.x; Ownby DR, 2000, ANN ALLERG ASTHMA IM, V84, P193, DOI 10.1016/S1081-1206(10)62755-X; Ownby DR, 1996, J ALLERGY CLIN IMMUN, V97, P1188, DOI 10.1016/S0091-6749(96)70183-5; Page EH, 2000, J OCCUP ENVIRON MED, V42, P613, DOI 10.1097/00043764-200006000-00010; Saxon A, 2000, ANN ALLERG ASTHMA IM, V84, P199, DOI 10.1016/S1081-1206(10)62756-1; Schweigert MK, 2000, CLIN EXP ALLERGY, V30, P1511, DOI 10.1046/j.1365-2222.2000.00893.x; SLATER JE, 1991, J UROLOGY, V146, P578, DOI 10.1016/S0022-5347(17)37860-6; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V101, P171, DOI 10.1016/S0091-6749(98)70381-1; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; van Kampen V, 2000, AM J IND MED, V38, P164, DOI 10.1002/1097-0274(200008)38:2<164::AID-AJIM7>3.3.CO;2-U; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; YASSIN MS, 1992, ANN ALLERGY, V69, P207; Yeang HY, 2000, ANN ALLERG ASTHMA IM, V84, P628, DOI 10.1016/S1081-1206(10)62415-5; Yip L, 2000, INT ARCH ALLERGY IMM, V121, P292, DOI 10.1159/000024342; Ylitalo L, 1997, J ALLERGY CLIN IMMUN, V100, P606, DOI 10.1016/S0091-6749(97)70163-5	58	18	19	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2		S			S57	S63		10.1067/mai.2002.125333	http://dx.doi.org/10.1067/mai.2002.125333			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	586ET	12170244				2022-12-18	WOS:000177572200009
J	Watanabe, M; Kaneko, H; Shikano, H; Aoki, M; Sakaguchi, H; Matsui, E; Inoue, R; Kato, Z; Kasahara, K; Fukutomi, O; Kondo, T; Kondo, N				Watanabe, M; Kaneko, H; Shikano, H; Aoki, M; Sakaguchi, H; Matsui, E; Inoue, R; Kato, Z; Kasahara, K; Fukutomi, O; Kondo, T; Kondo, N			Predominant expression of 950delCAG of IL-18R alpha chain cDNA is associated with reduced IFN-gamma production and high serum IgE levels in atopic Japanese children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; IL-18; INF-gamma; IgE; IL-18 receptor	T-CELLS; INTERLEUKIN-18 RECEPTOR; MESSENGER-RNA; TH2 CELLS; B-CELLS; EOSINOPHILIA; INDUCTION; CYTOKINE; IL-4; SYNERGISM	Background: We previously reported that serum IgE levels were negatively correlated with the amount of IFN-gamma produced by phytohemagglutinin-stimulated or IL-12-stimulated PBMCs and that one of the mechanisms of the pathogenesis of atopy was the reduced IFN-gamma production, which led to upregulated IgE production. Objective: IL-18 is also known to be a strong inducer of IFN-gamma production. However, it has not yet been determined whether IL-18 is associated with atopic disease. Methods: We investigated the response to IL-18 or IL-12 stimulation and the sequence of IL-18 receptor (IL-18R) alpha chain cDNA in 41 nonatopic controls and 39 atopic patients. Results: Serum IgE level was negatively correlated with IFN-gamma production by PBMCs stimulated with IL-18. The IL-18R alpha chain cDNA of atopic patients was sequenced. We identified a 3-base deletion of the IL-18R alpha chain cDNA (950delCAG), which was generated by alternative splicing, as determined on the basis of genomic sequence data for the IL-18R alpha chain gene. PBMCs with the predominant expression of 950delCAG significantly showed the reduced IFN-gamma production after IL-18 stimulation. There was a significant difference in the expression pattern of the IL-18R alpha chain transcript between the atopic patients and the nonatopic controls. Conclusion: According to these results, the dominant expression of the 950delCAG transcript of IL-18R alpha chain cDNA, which was associated with reduced IFN-gamma production by IL-18 stimulation and high serum IgE levels, is predisposition to some atopic diseases.	Gifu Univ, Sch Med, Dept Pediat, Gifu 5008705, Japan	Gifu University	Watanabe, M (corresponding author), Gifu Univ, Sch Med, Dept Pediat, 40 Tsukasa Machi, Gifu 5008705, Japan.		Kato, Zenichiro/E-8900-2010					Dinarello CA, 1999, METHODS, V19, P121, DOI 10.1006/meth.1999.0837; Glare EM, 1999, J ALLERGY CLIN IMMUN, V104, P978, DOI 10.1016/S0091-6749(99)70078-3; Hakonarson H, 1999, J ALLERGY CLIN IMMUN, V104, P575, DOI 10.1016/S0091-6749(99)70326-X; Hofstra CL, 1998, J IMMUNOL, V161, P5054; Hoshino T, 1999, J IMMUNOL, V162, P5070; Hoshino T, 2000, EUR J IMMUNOL, V30, P1998, DOI 10.1002/1521-4141(200007)30:7<1998::AID-IMMU1998>3.0.CO;2-U; Karras JG, 2000, MOL PHARMACOL, V58, P380, DOI 10.1124/mol.58.2.380; Kodama T, 2000, J ALLERGY CLIN IMMUN, V105, P45, DOI 10.1016/S0091-6749(00)90176-3; Kohno K, 1997, J IMMUNOL, V158, P1541; Kumano K, 1999, AM J RESP CRIT CARE, V160, P873, DOI 10.1164/ajrccm.160.3.9805026; Matsui E, 2000, CLIN EXP ALLERGY, V30, P1250, DOI 10.1046/j.1365-2222.2000.00931.x; Matsui E, 1999, BIOCHEM BIOPH RES CO, V266, P551, DOI 10.1006/bbrc.1999.1859; Micallef MJ, 1996, EUR J IMMUNOL, V26, P1647, DOI 10.1002/eji.1830260736; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Parnet P, 1996, J BIOL CHEM, V271, P3967; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; Shirakawa T, 2000, IMMUNOL TODAY, V21, P60, DOI 10.1016/S0167-5699(99)01492-9; Teramoto T, 1998, CLIN EXP ALLERGY, V28, P74; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; Tsutsui H, 1997, J IMMUNOL, V159, P3961; Ushio S, 1996, J IMMUNOL, V156, P4274; Wild JS, 2000, J IMMUNOL, V164, P2701, DOI 10.4049/jimmunol.164.5.2701; Xu DM, 1998, J EXP MED, V188, P1485, DOI 10.1084/jem.188.8.1485; Yoshimoto T, 1999, P NATL ACAD SCI USA, V96, P13962, DOI 10.1073/pnas.96.24.13962; Yoshimoto T, 2000, NAT IMMUNOL, V1, P132, DOI 10.1038/77811; Yoshimoto T, 1998, J IMMUNOL, V161, P3400; Yoshimoto T, 1997, P NATL ACAD SCI USA, V94, P3948, DOI 10.1073/pnas.94.8.3948	28	18	20	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					669	675		10.1067/mai.2002.122158	http://dx.doi.org/10.1067/mai.2002.122158			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941317				2022-12-18	WOS:000175132600016
J	Miller, JLC; Petteway, SR; Lee, DC				Miller, JLC; Petteway, SR; Lee, DC			Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	IVIG Advisory Meeting	OCT 26-29, 2000	SANTA BARBARA, CA	Bayer Biol		pathogen safety; immunoglobulin; plasma protein; virus; transmissible spongiform encephalopathy	TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY; LIPID-ENVELOPED VIRUSES; PRION PROTEIN; BLOOD COMPONENTS; PRODUCTS; INFECTIVITY; INACTIVATION; DERIVATIVES	Countless patients and clinicians rely on therapeutic proteins, such as intravenous immunoglobulins (IVIGs), isolated from human blood plasma. Since plasma is predisposed to contamination by a variety of blood-borne pathogens, ascertaining and ensuring the pathogen safety of plasma-derived therapeutics is a priority among manufacturers. Even though the pathogen safety records for IVIG and other plasma proteins are excellent, the industry remains active in research programs aimed at improving the margin of safety. Industry Initiatives designed to increase the safety of plasma-derived products range from donor screening and testing to Implementing methods into the manufacturing processes that can inactivate or remove pathogens from product streams. In general, the industry's comprehensive strategy is designed to provide patients and caregivers with the safest plasma products possible.	Bayer Corp, Dept Pathogen Safety Res Biol Prod, Res Triangle Pk, NC 27709 USA	Bayer AG	Miller, JLC (corresponding author), Bayer Corp, Dept Pathogen Safety Res Biol Prod, 85 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.							Bos OJM, 1998, BIOLOGICALS, V26, P267, DOI 10.1006/biol.1998.0148; Brown P, 1999, TRANSFUSION, V39, P1169, DOI 10.1046/j.1537-2995.1999.39111169.x; Brown P, 1998, TRANSFUSION, V38, P810, DOI 10.1046/j.1537-2995.1998.38998408999.x; Chin S, 1997, PHOTOCHEM PHOTOBIOL, V65, P432, DOI 10.1111/j.1751-1097.1997.tb08584.x; COHN EJ, 1950, J AM CHEM SOC, V72, P465, DOI 10.1021/ja01157a122; Foster PR, 2000, VOX SANG, V78, P86, DOI 10.1159/000031156; HART HF, 1994, VOX SANG, V67, P345, DOI 10.1111/j.1423-0410.1994.tb01271.x; HOROWITZ B, 1985, TRANSFUSION, V25, P516, DOI 10.1046/j.1537-2995.1985.25686071422.x; LAMBRECHT B, 1991, VOX SANG, V60, P207, DOI 10.1111/j.1423-0410.1991.tb00907.x; Lee DC, 2001, TRANSFUSION, V41, P449, DOI 10.1046/j.1537-2995.2001.41040449.x; Lee DC, 2000, J VIROL METHODS, V84, P77, DOI 10.1016/S0166-0934(99)00135-4; LUNDBLAD JL, 1991, VOX SANG, V60, P75, DOI 10.1111/j.1423-0410.1991.tb00878.x; MORGENTHALER JJ, 1993, DEV BIOL STAND, V81, P185; NOWAK T, 1993, DEV BIOL STAND, V81, P169; REID KG, 1988, VOX SANG, V55, P75, DOI 10.1111/j.1423-0410.1988.tb05140.x	15	18	20	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4		S			S91	S94		10.1067/mai.2001.117823	http://dx.doi.org/10.1067/mai.2001.117823			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	487KL	11586272				2022-12-18	WOS:000171874200002
J	Yunginger, JW; Jones, RT; Kita, H; Saito, K; Hefle, SL; Taylor, SL				Yunginger, JW; Jones, RT; Kita, H; Saito, K; Hefle, SL; Taylor, SL			Allergic reactions after ingestion of erythritol-containing foods and beverages	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pediat, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Adolescent Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Allerg Dis Res Lab, Rochester, MN 55905 USA; Towa Hosp, Hanamaki, Japan; Univ Nebraska, Food Allergy Res & Resource Program, Lincoln, NE USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Nebraska System; University of Nebraska Lincoln	Yunginger, JW (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, 200 1St St SW, Rochester, MN 55905 USA.		Taylor, Steve L./V-1341-2019					Hino H, 2000, J Dermatol, V27, P163; Munro IC, 1998, FOOD CHEM TOXICOL, V36, P1139, DOI 10.1016/S0278-6915(98)00091-X; 1997, Patent No. 0767159	3	18	18	2	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					650	650						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590396				2022-12-18	WOS:000171760300029
J	Tang, CB; Ward, C; Reid, D; Bish, R; O'Byrne, PM; Walters, EH				Tang, CB; Ward, C; Reid, D; Bish, R; O'Byrne, PM; Walters, EH			Normally suppressing CD40 coregulatory signals delivered by airway macrophages to T(H)2 lymphocytes are defective in patients with atopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD40; B; IL-12; IL-5; asthma	DENDRITIC CELLS; ALVEOLAR MACROPHAGES; IMMUNE-RESPONSE; BRONCHOALVEOLAR LAVAGE; AUTOIMMUNE-DISEASE; IL-12 PRODUCTION; B7-2 CD86; T-CELLS; INTERLEUKIN-12; ANTIGEN	Background: We have previously shown that airway macrophages (AMs) from atopic nonasthmatic subjects, but not atopic asthmatic subjects, inhibit T-cell IL-5 production during an allergen-dependent interaction. However, the mechanisms responsible for the IL-5-modulating effect of the AMs are less clear. Objectives: The aim of the present study was to define the roles of B7 and CD40 costimulatory signals delivered by AMs in regulating T-cell IL-5 responses in an allergen-stimulated coculture system. Methods: Peripheral blood CD4(+) T cells and AMs were cocultured under different conditions. Results: Compared with those from well-matched atopic nonasthmatic subjects, AMs from atopic asthmatic subjects demonstrated a significantly lower expression of B7-1 and CD40, but not B7-2 and HLA-DR, after either fresh isolation or coculture with allergen-reactive CD4+ T cells. Lon:er IL-12 production by the AMs from asthmatic subjects was also observed under the same conditions. Allergen-related T-cell IFN-I and IL-5 production was inhibited by the addition of either neutralizing B7-1 or B7-2 antibody to the cocultures in both atopic groups. In contrast, IL-5 production was significantly increased by the addition of blocking CD40 antibody, whereas IL-12 production by the AMs was inhibited. Anti-IL 12 mAb enhanced IL-5 production in the cocultures from atopic nonasthmatic subjects, whereas a dose-dependent suppressive effect of recombinant human IL-12 on IL-5 production was seen in atopic asthmatic subjects. Conclusion: In this coculture model system, lower IL-12 production by AMs and higher IL-5 production by CD4(+) T cells in atopic asthmatic subjects compared with that found in atopic nonasthmatic subjects: are related to the loner expression of CD40 rather than B7-1 signals on the AMs from these patients.	Alfred Hosp, Dept Resp Med, Prahran, Vic 3181, Australia; Monash Univ, Melbourne, Vic 3004, Australia; McMaster Univ, Asthma Res Grp, Hamilton, ON, Canada	Florey Institute of Neuroscience & Mental Health; Monash University; McMaster University	Walters, EH (corresponding author), Alfred Hosp, Dept Resp Med, Prahran, Vic 3181, Australia.		Reid, David W/Y-2343-2018; Reid, David W/B-3263-2011; WALTERS, Eugene/AAL-2264-2021; Ward, Christopher/B-8175-2013	Reid, David W/0000-0001-9517-8212; Ward, Christopher/0000-0002-6954-9611; Walters, Eugene/0000-0002-0993-4374; O'Byrne, Paul/0000-0003-0979-281X				Borriello F, 1997, IMMUNITY, V6, P303, DOI 10.1016/S1074-7613(00)80333-7; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254, DOI 10.1165/ajrcmb.12.3.7873190; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; DeKruyff RH, 1997, J IMMUNOL, V158, P359; Desmedt M, 1998, J IMMUNOL, V160, P5300; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; DUDDRIDGE M, 1990, EUR RESPIR J, V3, P1166; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; Gao JX, 1999, IMMUNOLOGY, V98, P159; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; GOLDSTEIN RA, 1985, AM REV RESPIR DIS, V132, P180; Greenwald RJ, 1997, J IMMUNOL, V158, P4088; HILKENS CMU, 1996, J IMMUNOL, V156, P1772; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Iwamoto I, 1996, AM J RESP CRIT CARE, V154, P1257, DOI 10.1164/ajrccm.154.5.8912732; Iwasaki A, 1999, J EXP MED, V190, P229, DOI 10.1084/jem.190.2.229; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; OSWALD IP, 1994, J IMMUNOL, V153, P1707; Schweitzer AN, 1998, J IMMUNOL, V161, P2762; Segal BM, 1998, J EXP MED, V187, P537, DOI 10.1084/jem.187.4.537; SHU U, 1995, EUR J IMMUNOL, V25, P1125, DOI 10.1002/eji.1830250442; Stuber E, 1996, J EXP MED, V183, P693, DOI 10.1084/jem.183.2.693; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Tang C, 1997, EUR RESPIR J, V10, P624; Tang C, 1999, EUR RESPIR J, V14, P106, DOI 10.1034/j.1399-3003.1999.14a18.x; Tang CB, 1998, AM J RESP CRIT CARE, V157, P1120, DOI 10.1164/ajrccm.157.4.9706118; Tang CB, 1998, J ALLERGY CLIN IMMUN, V102, P368, DOI 10.1016/S0091-6749(98)70122-8; Tsuyuki S, 1997, J EXP MED, V185, P1671, DOI 10.1084/jem.185.9.1671; Ward RJ, 1999, EUR RESPIR J, V14, P430, DOI 10.1034/j.1399-3003.1999.14b31.x; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862	36	18	19	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					863	870		10.1067/mai.2001.114987	http://dx.doi.org/10.1067/mai.2001.114987			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344354				2022-12-18	WOS:000168812300015
J	Tarlo, SM; Liss, GM				Tarlo, SM; Liss, GM			Can medical surveillance measures improve the outcome of occupational asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							ISOCYANATE EXPOSURE; REFINERY WORKERS; PLATINUM SALTS; SENSITIZATION; ANTIBODY; SMOKING; PLANT		Univ Toronto, Gage Occupat & Environm Hlth Unit, Toronto, ON, Canada; Univ Toronto, Dept Med & Publ Hlth Sci, Toronto, ON, Canada	University of Toronto; University of Toronto	Tarlo, SM (corresponding author), Toronto Western Hosp, EC4-009,399 bathurst St, Toronto, ON M5T 2S8, Canada.			Tarlo, Susan/0000-0002-4746-5310				BAKER DB, 1990, AM J IND MED, V18, P653, DOI 10.1002/ajim.4700180604; BECKLAKE MR, 1999, ASTHMA WORKPLACE, P27; BERNSTEIN DI, 1993, J ALLERGY CLIN IMMUN, V92, P387, DOI 10.1016/0091-6749(93)90117-X; Blanc PD, 1999, AM J MED, V107, P580, DOI 10.1016/S0002-9343(99)00307-1; CALVERLEY AE, 1995, OCCUP ENVIRON MED, V52, P661, DOI 10.1136/oem.52.10.661; CHANYEUNG M, 1987, J ALLERGY CLIN IMMUN, V79, P792, DOI 10.1016/0091-6749(87)90212-0; Gordon SB, 1997, OCCUP MED-OXFORD, V47, P361, DOI 10.1093/occmed/47.6.361; Grammer L, 1998, CHEST, V114, P1199, DOI 10.1378/chest.114.4.1199; Kraw M, 1999, AM J IND MED, V35, P87, DOI 10.1002/(SICI)1097-0274(199901)35:1<87::AID-AJIM12>3.3.CO;2-O; Liss GM, 1999, AM J IND MED, V35, P465, DOI 10.1002/(SICI)1097-0274(199905)35:5<465::AID-AJIM3>3.0.CO;2-V; Liss GM, 2000, AM J RESP CRIT CARE, V162, P112, DOI 10.1164/ajrccm.162.1.9906108; LISS GM, 1984, J ALLERGY CLIN IMMUN, V73, P348, DOI 10.1016/0091-6749(84)90407-X; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; Meredith SK, 2000, OCCUP ENVIRON MED, V57, P830, DOI 10.1136/oem.57.12.830; Merget R, 1999, INT ARCH OCC ENV HEA, V72, P33, DOI 10.1007/s004200050331; Tarlo SM, 1997, AM J IND MED, V32, P517, DOI 10.1002/(SICI)1097-0274(199711)32:5<517::AID-AJIM12>3.0.CO;2-5; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; Tarlo SM, 1997, OCCUP ENVIRON MED, V54, P756, DOI 10.1136/oem.54.10.756; VENABLES KM, 1989, BMJ-BRIT MED J, V299, P939, DOI 10.1136/bmj.299.6705.939	19	18	18	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					583	585						3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295642				2022-12-18	WOS:000168190100003
J	Li, SD; Li, XM; Burks, AW; Bannon, GA; Sampson, HA				Li, SD; Li, XM; Burks, AW; Bannon, GA; Sampson, HA			Modulation of peanut allergy by peptide-based immunotherapy.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Univ Arkansas, Little Rock, AR 72204 USA; Mt Sinai Sch Med, New York, NY USA	University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Icahn School of Medicine at Mount Sinai									0	18	18	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2		S		764	S233	S233						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	405RE					2022-12-18	WOS:000167172300760
J	Nagai, H; Abe, T; Yamaguchi, I; Mito, K; Tsunematsu, M; Kimata, M; Inagaki, N				Nagai, H; Abe, T; Yamaguchi, I; Mito, K; Tsunematsu, M; Kimata, M; Inagaki, N			Role of mast cells in the onset of IgE-mediated late-phase cutaneous response in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on New Trends in Immunopharmacology 1998	JUL   25, 1998	TOKYO, JAPAN			mast cells; degranulation	ULTRASTRUCTURAL ANALYSIS; ALLERGIC INFLAMMATION; HUMAN BASOPHILS; CYCLOSPORINE-A; MESSENGER-RNA; SKIN REACTION; TNF-ALPHA; INTERLEUKIN-6; EXPRESSION; INHIBITION	Background: In mice that are passively sensitized to IgE, cutaneous antigen challenge produces a biphasic response with peaks at 1 and 24 hours after challenge. Objective: We investigated the role of mast cells in the IgE-mediated late-phase reaction in mice. Methods: We histologically and ultrastructurally investigated the morphologic changes of mast cells during the biphasic responses. Results: Degranulation of mast cells, which was observed between 4 and 24 hours after challenge, reached a peak at 8 hours. Piecemeal degranulation was seen during the immediate phase reaction. The number of IL-6-positive mast cells was increased after 4 hours in both IgE-sensitized and unsensitized mice, but positive cells showed a greater increase in sensitized mice and reached a peak after 8 hours. With in situ hybridization experiments, mast cells were positive for IL-6 messenger RNA at 6 hours after challenge. Conclusion: These findings indicate that anaphylactic degranulation of mast cells and the expression of IL-6 mRNA within 4 hours after antigen challenge are important for the onset of the late-phase allergic cutaneous reaction in mice.	Gifu Pharmaceut Univ, Dept Pharmacol, Gifu 5028585, Japan	Gifu Pharmaceutical University	Nagai, H (corresponding author), Gifu Pharmaceut Univ, Dept Pharmacol, 5-6-1 Mitahora Higashi, Gifu 5028585, Japan.							CHARLESWORTH EN, 1995, CHEM IMMUNOL, V62, P84; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CHURCH MK, 1994, ANN NY ACAD SCI, V725, P13, DOI 10.1111/j.1749-6632.1994.tb39785.x; COLEMAN JW, 1995, INT ARCH ALLERGY IMM, V107, P154, DOI 10.1159/000236961; Dvorak A M, 1992, Immunol Ser, V57, P169; DVORAK AM, 1995, INT J CLIN LAB RES, V25, P7, DOI 10.1007/BF02592571; DVORAK AM, 1992, AM J PATHOL, V141, P1309; DVORAK AM, 1993, HDB IMMUNOPHARMACOLO, P89; GALLI SJ, 1990, LAB INVEST, V62, P5; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GELICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160; GRENETT HE, 1990, NUCLEIC ACIDS RES, V18, P6455, DOI 10.1093/nar/18.21.6455; HAUT M, 1989, NATURE, V339, P64; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; KATAYAMA I, 1990, INT ARCH ALLER A IMM, V93, P148, DOI 10.1159/000235294; Kay AB, 1997, INT ARCH ALLERGY IMM, V113, P196, DOI 10.1159/000237545; LEALBERUMEN I, 1994, J IMMUNOL, V152, P5468; LEALBERUMEN I, 1995, J IMMUNOL, V154, P4759; LEWIS RA, 1985, INT ARCH ALLER A IMM, V77, P131; MATSUDA H, 1989, J IMMUNOL, V142, P927; MICAN JAM, 1992, J ALLERGY CLIN IMMUN, V90, P815, DOI 10.1016/0091-6749(92)90107-D; NAGAI H, 1995, BIOL PHARM BULL, V18, P239; Nagai H, 1996, INFLAMM RES, V45, P136, DOI 10.1007/BF02265167; OXHOLM A, 1992, APMIS S, V24, P5; PRADALIER A, 1993, INT ARCH ALLERGY IMM, V101, P322, DOI 10.1159/000236471; RAY A, 1989, ANN NY ACAD SCI, V557, P353; Sawada K, 1997, CLIN EXP ALLERGY, V27, P225; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WERSHIL BK, 1995, J IMMUNOL, V154, P1391; WILLIAMS CMM, 1995, IMMUNOLOGY, V86, P244	30	18	18	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	2	S			S91	S98		10.1067/mai.2000.106778	http://dx.doi.org/10.1067/mai.2000.106778			8	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	339NF	10887340				2022-12-18	WOS:000088482600013
J	Upham, JW; Hayes, LM; Lundahl, J; Sehmi, R; Denburg, JA				Upham, JW; Hayes, LM; Lundahl, J; Sehmi, R; Denburg, JA			Reduced expression of hemopoietic cytokine receptors on cord blood progenitor cells in neonates at risk for atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokine receptors; atopy; hemopoiesis; neonate; CD34	COLONY-STIMULATING FACTOR; CD34(+) CELLS; GENETIC RISK; T-CELLS; SENSITIZATION; RESPONSES; INFANTS	Background: Recent findings point to an association between allergic asthma in adults and increased responsiveness of myeloid progenitor cells to certain hemopoietic growth factors. However, it is not clear at what age these changes in progenitor cells first become manifest, although increasing evidence suggests that the allergic phenotype may begin to emerge in very early life. Objective: We sought to compare expression of hemopoietic cytokine receptors on CD34(+) progenitor cells in cord blood from normal infants ("low risk" for subsequent atopy) and infants with at least one atopic first degree relative ("at risk" for subsequent atopy). Methods: Cord blood was obtained from 21 neonates. Nonadherent mononuclear cells were stained with mAbs directed against CD45, CD34, and the alpha-chains of the GM-CSF, IL-3, and IL-5 receptors and analyzed by flow cytometry. Results: No differences in absolute CD34(+) numbers were observed between the 2 groups. However, expression of GMCSF receptor on CD34(+) cells was reduced in the "at-risk" compared with the 'low- risk" group (P = .021), although no significant differences were noted between the 2 groups with respect to IL-3 and IL-5 receptor expression. Conclusion: The functional sequelae of reduced GM-CSF receptor expression on CD34(+) cells remain to be determined. Nonetheless, these findings show an association between genetic risk for atopy and changes in the expression of hemopoietic cytokine receptors on cord blood progenitor cells and support the notion that the allergic phenotype may begin to evolve in the perinatal period.	McMaster Univ, Hlth Sci Ctr, Dept Med, Div Clin Immunol & Allergy, Hamilton, ON L8N 3Z5, Canada	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba	Denburg, JA (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Med, Div Clin Immunol & Allergy, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.		Upham, John/F-4420-2010	Upham, John/0000-0002-0017-3433				Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; Calbi M, 1993, Pediatr Allergy Immunol, V4, P86, DOI 10.1111/j.1399-3038.1993.tb00072.x; DENBURG JA, 1985, J ALLERGY CLIN IMMUN, V76, P466, DOI 10.1016/0091-6749(85)90728-6; ENGLISH BK, 1992, PEDIATR RES, V31, P211, DOI 10.1203/00006450-199203000-00004; GIBSON PG, 1990, CLIN EXP ALLERGY, V20, P661, DOI 10.1111/j.1365-2222.1990.tb02705.x; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P85, DOI 10.1111/j.1399-3038.1995.tb00264.x; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P80, DOI 10.1111/j.1399-3038.1995.tb00263.x; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; Kurata H, 1995, J ALLERGY CLIN IMMUN, V96, P1083, DOI 10.1016/S0091-6749(95)70194-X; MAGNUSSON CGM, 1989, ALLERGY, V44, P143, DOI 10.1111/j.1398-9995.1989.tb02237.x; Miles E A, 1994, Pediatr Allergy Immunol, V5, P202, DOI 10.1111/j.1399-3038.1994.tb00240.x; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301, DOI 10.1159/000236541; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645, DOI 10.1165/ajrcmb.15.5.8918371; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Sutherland D R, 1996, J Hematother, V5, P213, DOI 10.1089/scd.1.1996.5.213; SUTHERLAND DR, 1994, EXP HEMATOL, V22, P1003; TESTA U, 1993, BLOOD, V81, P1442; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; WILIMAS JA, 1995, J PEDIAT HEMATOL ONC, V17, P176, DOI 10.1097/00043426-199505000-00014	21	18	19	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				370	375		10.1016/S0091-6749(99)70381-7	http://dx.doi.org/10.1016/S0091-6749(99)70381-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452759				2022-12-18	WOS:000082364800030
J	Bheekha-Escura, R; Chance, SR; Langdon, JM; MacGlashan, DW; MacDonald, SM				Bheekha-Escura, R; Chance, SR; Langdon, JM; MacGlashan, DW; MacDonald, SM			Pharmacologic regulation of histamine release by the human recombinant histamine-releasing factor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						histamine-releasing factor; human basophils; IgE heterogeneity; pharmacologic regulation	PROTEIN-KINASE-C; HUMAN BASOPHILS; IGE; INHIBITOR; POTENT; CELLS; IDENTIFICATION; HETEROGENEITY; CHEMOKINES; ROTTLERIN	Background: The recently cloned human recombinant IgE-dependent histamine releasing factor (HrHRF) was initially thought to stimulate histamine release from human basophils from a subpopulation of allergic donors by interacting with the IgE molecules on the surface of these cells. Additional data suggest that HrHRF exerts its biologic effects by binding to a distinct cell surface structure and not to IgE, Objective: To address the hypothesis that the HrHRF signaling pathway is distinct from the classical high-affinity IgE receptor (Fc epsilon RI) pathway, we used pharmacologic agents known to affect basophil histamine release. Methods: In this report we compared the effect of staurosporine, Bis II, Go 6976, rottlerin, and pertussis toxin on histamine release from human basophils mediated by the following stimuli: HrHRF, polyclonal human anti-IgE antibody, and antigen, as well as the IgE-independent stimulus, FMLP. Results: None of these modulators, except rottlerin, could differentiate histamine release induced by anti-IgE or antigen from that induced by HrHRF. Rottlerin enhanced HrHRF-mediated histamine release and dose dependently blocked FMLP-mediated release without affecting basophil activation by either anti-IgE or antigen. Conclusion: These data suggest a unique signaling pathway for HrHRF and thus strengthen the hypothesis that HrHRF binds to a specific receptor other than IgE.	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	MacDonald, SM (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NIAID NIH HHS [R0-1 AI 32651, AI 20253] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032651, R01AI020253] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEZA ML, 1989, J CLIN INVEST, V83, P1204, DOI 10.1172/JCI114002; BERGSTRAND H, 1992, J PHARMACOL EXP THER, V260, P1028; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; BIT RA, 1993, J MED CHEM, V36, P21, DOI 10.1021/jm00053a003; GILBERT HS, 1975, BLOOD, V46, P279; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; GSCHWENDT M, 1994, FEBS LETT, V338, P85, DOI 10.1016/0014-5793(94)80121-5; Kinet J P, 1996, Eur Respir J Suppl, V22, p116s; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; KUNA P, 1993, J IMMUNOL, V150, P1932; MACDONALD SM, 1989, J IMMUNOL, V142, P3527; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MACDONALD SM, 1995, SCIENCE, V269, P688, DOI 10.1126/science.7542803; MACDONALD SM, 1991, CLIN EXP ALLERGY, V21, P133, DOI 10.1111/j.1365-2222.1991.tb00815.x; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; Schroeder JT, 1997, J IMMUNOL, V159, P447; Schroeder JT, 1996, J EXP MED, V183, P1265, DOI 10.1084/jem.183.3.1265; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; THUESON DO, 1979, J IMMUNOL, V123, P626; VERCELLI D, 1995, J BIOL REG HOMEOS AG, V9, P1; WARNER JA, 1986, J IMMUNOL, V136, P2583; WARNER JA, 1987, J IMMUNOL, V139, P161; WARNER JA, 1990, J IMMUNOL, V145, P1897; WEBER M, 1995, INT ARCH ALLERGY IMM, V107, P148, DOI 10.1159/000236959	28	18	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				937	943		10.1016/S0091-6749(99)70442-2	http://dx.doi.org/10.1016/S0091-6749(99)70442-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329832				2022-12-18	WOS:000080470200033
J	Chihara, J; Yamamoto, T; Kayaba, H; Kakazu, T; Kurachi, D; Yamamoto, J; Iwasa, S; Iida, K; Urayama, O; Kobayashi, Y				Chihara, J; Yamamoto, T; Kayaba, H; Kakazu, T; Kurachi, D; Yamamoto, J; Iwasa, S; Iida, K; Urayama, O; Kobayashi, Y			Degranulation of eosinophils mediated by intercellular adhesion molecule-1 and its ligands is involved in adhesion molecule expression on endothelial cells-selective induction of VCAM-1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on New Trends in Immunopharmacology 1997	JUL   12, 1997	TOKYO, JAPAN	Novartis Pharma K K Tokyo		adhesion molecules; integrins; eosinophils; degranulation	COLONY-STIMULATING FACTOR; ASTHMATIC-PATIENTS; ADHERENCE; RECEPTOR; ICAM-1; NEUTROPHILS; MECHANISMS; INFLAMMATION; LYMPHOCYTES; ACTIVATION	Background: Adhesion molecules and eosinophils may play an important role in the pathogenesis of allergic inflammatory reactions. Objective: We attempted to clarify eosinophil activation, such as degranulation, by signaling through adhesion molecule and to determine whether degranulation is involved in adhesion molecule expression on endothelial cells. Methods: Eosinophils were cultured with or without recombinant soluble intercellular adhesion molecule-1 (ICAM-1), and the levels of eosinophil cationic protein and eosinophil-derived neurotoxin were determined. The influence of these eosinophil granule proteins or supernatant from eosinophil cultured with ICAM-1 on the expression of ICAM-1 or vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells was also examined by flow-cytometric analysis. Results: Supernatant levels of eosinophil granule protein mere significantly increased by culture for 4 hourss or 16 hours with recombinant soluble ICAM-1, suggesting degranulation by adherence to ICAM-1. Both granule proteins and the supernatants of eosinophils cultured with recombinant soluble ICAM-1 induced expression of ICAM-1 and VCAM-1 on endothelial cells, with the latter showing a more prominant increase. Conclusion: Degranulation mediated through adherence to endothelial cells by ICAM-1 and its ligands may be involved in the expression of adhesion molecules, such as ICAM-1 or VCAM-1, on these cells. Our finding of the selective induction of VCAM-1 expression suggests that eosinophil adherence to endothelial cells, even if it is because of ICAM-1, may be involved in selective eosinophil recruitment and accumulation at sites of allergic inflammation.	Akita Univ, Sch Med, Dept Clin & Lab Med, Akita 0108543, Japan; Kinki Univ, Sch Med, Dept Internal Med 4, Sayama, Osaka, Japan; Inst Takeda Pharmaceut Co, Osaka, Japan	Akita University; Kindai University (Kinki University); Takeda Pharmaceutical Company Ltd	Chihara, J (corresponding author), Akita Univ, Sch Med, Dept Clin & Lab Med, Akita 0108543, Japan.							ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; ACKERMAN SJ, 1983, J IMMUNOL, V131, P2977; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; Blease K, 1998, AM J RESP CELL MOL, V18, P620, DOI 10.1165/ajrcmb.18.5.3052; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CANONICA GW, 1994, ALLERGY, V49, P135, DOI 10.1111/j.1398-9995.1994.tb00815.x; CHIHARA J, 1995, ALLERGY, V50, P11, DOI 10.1111/j.1398-9995.1995.tb02477.x; CHIHARA J, 1990, J EXP MED, V172, P1347, DOI 10.1084/jem.172.5.1347; CHIHARA J, 1995, INT ARCH ALLERGY IMM, V108, P45, DOI 10.1159/000237201; CHIHARA J, 1994, IMMUNOL LETT, V42, P25, DOI 10.1016/0165-2478(94)90030-2; Chihara J, 1992, Eur Cytokine Netw, V3, P53; CHIHARA J, 1995, IMMUNOL LETT, V46, P241, DOI 10.1016/0165-2478(95)00053-8; CHIHARA J, 1992, J LIPID MEDIATORS, V5, P152; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; Kita H, 1996, J ALLERGY CLIN IMMUN, V97, P889, DOI 10.1016/S0091-6749(96)80061-3; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; Motojima S, 1996, J ALLERGY CLIN IMMUN, V98, pS216, DOI 10.1016/S0091-6749(96)70069-6; ODONNEL MC, 1991, J EXP MED, V157, P1981; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PETERS MS, 1988, BLOOD, V71, P780; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SPRY CJF, 1988, EOSINOPHILS COMPRHEN; THORNHILL MH, 1990, J IMMUNOL, V144, P3060; TOMASSINI M, 1991, J ALLERGY CLIN IMMUN, V88, P365, DOI 10.1016/0091-6749(91)90099-A; TREVOR T, 1992, CLIN EXP ALLERGY, V22, P345; WALSH GM, 1991, J IMMUNOL, V146, P3419; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430; Weller PF, 1997, J ALLERGY CLIN IMMUN, V100, P283, DOI 10.1016/S0091-6749(97)70237-9; Wolyniec WW, 1998, AM J RESP CELL MOL, V18, P777, DOI 10.1165/ajrcmb.18.6.3056	38	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	2	S			S452	S456		10.1016/S0091-6749(99)70161-2	http://dx.doi.org/10.1016/S0091-6749(99)70161-2			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199TV	10329848				2022-12-18	WOS:000080500200007
J	Zargari, A; Schmidt, M; Lundberg, M; Scheynius, A; Whitley, P				Zargari, A; Schmidt, M; Lundberg, M; Scheynius, A; Whitley, P			Immunologic characterization of natural and recombinant Mal f 1 yeast allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						malassezia furfur; pityrosporum orbiculare; fungi; recombinant allergen; expression system; atopic dermatitis; IgE; CAP RAST; in vitro translation	PITYROSPORUM-ORBICULARE; ATOPIC-DERMATITIS; IGE ANTIBODIES; CANDIDA-ALBICANS; OVALE; CHILDREN; COMPONENTS; EXPRESSION; MEMBRANE; PROTEIN	Background: Individuals with atopic dermatitis (AD) often have IgE antibodies against protein components of Malassezia furfur. The cDNA encoding one of these proteins (Mal f 1) has recently been cloned and sequenced. Objective: We sought to express recombinant Mal fl (rMal f I) allergen in large quantities by using different expression systems. The primary aim was to characterize the IgE-binding properties of rMal f 1 in comparison with its natural counterpart in M furfur extract. Methods: We have expressed and purified Mal fl from prokaryotic (Escherichia coli) and eukaryotic cells (baculovirus-infected insect cells). The rMal f 1 produced in both systems has been tested for the ability to be recognized by IgE from patients with specific serum IgE to M furfur by using immunoblotting and the Pharmacia CAP System PAST FEIA. Results: Sixty-one percent of sera from 95 patients showed positive RAST responses to the rMal fl produced in the baculovirus expression system and 43% to the E coli-produced rMal f 1, Both the E coli- and baculovirus-produced proteins can specifically inhibit IgE binding to a 36-kd protein band (Mal f 1) in immunoblotting, indicating that the recombinant proteins contain the majority, if not all, the IgE-binding epitopes of Mal f 1, Recombinant Mal f 1 is able to release histamine from basophils of an atopic individual. Conclusion: We have expressed and purified rMal f 1, which can bind IgE in a way resembling natural Mal f 1, The ability to produce recombinant allergens with similar properties to their native counterparts has many potential uses, such as accurately diagnosing causes of IgE-mediated allergy.	Karolinska Hosp & Inst, Div Clin Immunol, Dept Lab Med, Stockholm, Sweden; E Carolina Univ, Dept Biol, Greenville, NC USA; E Carolina Univ, Dept Phys, Greenville, NC USA	Karolinska Institutet; Karolinska University Hospital; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	Zargari, A (corresponding author), Karolinska Hosp, Dept Lab Med, Div Clin Immunol, S-17176 Stockholm, Sweden.							BACK O, 1995, ARCH DERMATOL RES, V287, P448, DOI 10.1007/BF00373427; BROBERG A, 1992, ACTA DERM-VENEREOL, V72, P187; FAERGEMANN J, 1983, ACTA DERM-VENEREOL, V63, P346; GORDON MA, 1951, J INVEST DERMATOL, V17, P267, DOI 10.1038/jid.1951.93; HUANG X, 1995, ALLERGY, V50, P648, DOI 10.1111/j.1398-9995.1995.tb02581.x; JENSENJAROLIM E, 1992, J ALLERGY CLIN IMMUN, V89, P44, DOI 10.1016/S0091-6749(05)80039-9; JOHANSSON S, 1991, ACTA DERM-VENEREOL, V71, P11; KIEFFER M, 1990, J AM ACAD DERMATOL, V22, P739, DOI 10.1016/0190-9622(90)70100-V; LILJESTROM P, 1991, J VIROL, V65, P147; Lintu P, 1997, CLIN EXP ALLERGY, V27, P87, DOI 10.1111/j.1365-2222.1997.tb00677.x; NILSSON I, 1993, J BIOL CHEM, V268, P5798; NORDVALL SL, 1990, ACTA PAEDIATR SCAND, V79, P343, DOI 10.1111/j.1651-2227.1990.tb11467.x; POTTER BS, 1973, ARCH DERMATOL, V107, P388, DOI 10.1001/archderm.107.3.388; ROBERTS SOB, 1969, BRIT J DERMATOL, V81, P264, DOI 10.1111/j.1365-2133.1969.tb13978.x; Sambrook J, 1989, MOL CLONING LAB MANU, V1, P1; SAVOLAINEN J, 1992, CLIN EXP ALLERGY, V22, P469, DOI 10.1111/j.1365-2222.1992.tb00149.x; Schmidt M, 1997, EUR J BIOCHEM, V246, P181, DOI 10.1111/j.1432-1033.1997.00181.x; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; WAERSTED A, 1985, ACTA DERM-VENEREOL, P146; Zargari A, 1997, CLIN EXP ALLERGY, V27, P584, DOI 10.1111/j.1365-2222.1997.tb00749.x; ZARGARI A, 1994, ALLERGY, V49, P50, DOI 10.1111/j.1398-9995.1994.tb00773.x; Zargari A, 1995, CLIN EXP ALLERGY, V25, P1235, DOI 10.1111/j.1365-2222.1995.tb03048.x	23	18	18	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				877	884		10.1016/S0091-6749(99)70433-1	http://dx.doi.org/10.1016/S0091-6749(99)70433-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329823				2022-12-18	WOS:000080470200024
J	Michils, A; Mairesse, M; Ledent, C; Gossart, B; Baldassarre, S; Duchateau, J				Michils, A; Mairesse, M; Ledent, C; Gossart, B; Baldassarre, S; Duchateau, J			Modified antigenic reactivity of antiphospholipase A(2) IgG antibodies in patients allergic to bee venom: Conversion with immunotherapy and relation to subclass expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bee venom allergy; rush immunotherapy; IgG antibody; IgG subclasses; epitopes; immunodominance	PHOSPHOLIPASE A(2); HONEYBEE VENOM; INTERLEUKIN-4 PRODUCTION; PREDICTIVE VALUE; IN-VITRO; T-CELLS; PROTECTION; STINGS; IMMUNIZATION; INDIVIDUALS	Background: We have previously reported that, in addition to modifying IgG levels and subclass distributions, wasp venom immunotherapy (VIT) rapidly changes IgG antibody specificity. Objectives: We investigated whether such a change can be documented in the IgG response to the major bee venom allergen, phospholipase A(2) (PLA(2)), from patients allergic to bees treated with VIT; whether it is coupled to the shift in IgG subclass distribution (IgG(4) predominance) usually observed during VIT; and whether it restores the specificity displayed by IgG antibodies from nonallergic individuals. Methods: Antibody specificity was evaluated in 17 patients allergic to bee venom in competitive ELISAs by using streptavidin biotin technology. Patients were tested before and during specific immunotherapy (at 15 days and 6 months) and compared with another group of 17 patients treated with venom injections for at least 2 years (VIT patients) and 30 healthy individuals. Results: The capacity of individual sera to prevent PLA(2) binding of pooled IgG from allergic patients changed rapidly with mean percentage inhibitions falling from 84% +/- 14% before starting VIT to 27% +/- 13% and 28% +/- 7% after 15 days and 6 months of treatment, respectively (p < 0.001 by one-way analysis of variance [ANOVA]). IgG titers were only slightly increased. The capacity of individual sera to prevent the binding of pooled IgG from patients receiving VIT changed rapidly with mean percentage inhibition increasing from 60% +/- 12% before starting VIT to 85% +/- 6% and 82% +/- 6% after 15 days and 6 months of treatment, respectively (p < 0.001 by one-way ANOVA). Similar results were found regardless of whether pooled IgG(1) or pooled IgG(4) were used. Conclusion: VIT results in a rapid change in the antigenic reactivity of anti-PLA(2) Ige antibody of human allergic sera, restoring, although not completely, the specificity peculiar to Ige from healthy individuals. This suggests that allergic status and immunoprotection correlate with the preferential expression of distinct IgG specificities, which appear equally distributed over the IgG(1) and IgG(4) antibody subclasses. It is, however. not known whether the shift in IgG specificity is one of the operative mechanisms of VIT.	CUB Erasme, Chest Dept, Brussels, Belgium; Clin St Luc, Chest Dept, Bouge, Belgium; Free Univ Brussels, Hop Univ Brugmann, Dept Immunol, B-1020 Brussels, Belgium	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Michils, A (corresponding author), Erasme Univ Hosp, Chest Dept, 808 Route Lennik, B-1070 Brussels, Belgium.							AALBERSE RC, 1983, J IMMUNOL, V130, P722; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akoum H, 1996, IMMUNOLOGY, V87, P593, DOI 10.1046/j.1365-2567.1996.506585.x; AMON R, 1992, FASEB J, V6, P3265; BJORCK L, 1984, J IMMUNOL, V133, P969; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V79, P947, DOI 10.1016/0091-6749(87)90245-4; BOUSQUET J, 1988, ANN ALLERGY, V61, P63; BOUTIN Y, 1994, J ALLERGY CLIN IMMUN, V93, P1039, DOI 10.1016/S0091-6749(94)70053-2; CARBALLIDO JM, 1994, J ALLERGY CLIN IMMUN, V93, P758, DOI 10.1016/0091-6749(94)90256-9; DEVEY ME, 1989, J ALLERGY CLIN IMMUN, V84, P326, DOI 10.1016/0091-6749(89)90416-8; DJURUP R, 1985, J ALLERGY CLIN IMMUN, V76, P46, DOI 10.1016/0091-6749(85)90803-6; Duchateau J, 1997, CLIN EXP ALLERGY, V27, P296, DOI 10.1111/j.1365-2222.1997.tb00708.x; DUDLER T, 1994, J IMMUNOL, V152, P5514; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; EWAN PW, 1993, CLIN EXP ALLERGY, V23, P647, DOI 10.1111/j.1365-2222.1993.tb01791.x; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; HUGH SM, 1995, CLIN EXP ALLERGY, V25, P828; JUTEL M, 1995, J IMMUNOL, V154, P4187; KEMENY DM, 1988, CLIN ALLERGY, V18, P79, DOI 10.1111/j.1365-2222.1988.tb02846.x; KEMENY DM, 1983, J ALLERGY CLIN IMMUN, V72, P376, DOI 10.1016/0091-6749(83)90503-1; KHAN RH, 1991, J ALLERGY CLIN IMMUN, V88, P199, DOI 10.1016/0091-6749(91)90329-M; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; KOLBE L, 1995, IMMUNOLOGY, V84, P285; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; LAWRENCE ID, 1986, J ALLERGY CLIN IMMUN, V77, P178; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; Michils A, 1997, CLIN EXP ALLERGY, V27, P1036, DOI 10.1111/j.1365-2222.1997.tb01255.x; MOLKOU P, 1996, ALLERGOLOGIE, P793; MUELLER U, 1979, Allergy (Copenhagen), V34, P369; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; MULLER UR, 1995, J ALLERGY CLIN IMMUN, V96, P395, DOI 10.1016/S0091-6749(95)70059-5; OBrien RM, 1997, CLIN EXP ALLERGY, V27, P46, DOI 10.1046/j.1365-2222.1997.d01-424.x; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P282, DOI 10.1016/S0091-6749(05)80004-1; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V89, P1189, DOI 10.1016/0091-6749(92)90304-K; RIHET P, 1992, EUR J IMMUNOL, V22, P2063, DOI 10.1002/eji.1830220816; RZANY B, 1991, ALLERGY, V46, P251, DOI 10.1111/j.1398-9995.1991.tb00582.x; SCHNEIDER T, 1994, J ALLERGY CLIN IMMUN, V94, P61, DOI 10.1016/0091-6749(94)90072-8; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; SOBOTKA AK, 1976, J ALLERGY CLIN IMMUN, V57, P29, DOI 10.1016/0091-6749(76)90076-2; URBANEK R, 1986, CLIN ALLERGY, V16, P317, DOI 10.1111/j.1365-2222.1986.tb01963.x; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X; VANDERZWAN JC, 1983, BRIT MED J, V287, P1329, DOI 10.1136/bmj.287.6402.1329; VanRee R, 1997, CLIN EXP ALLERGY, V27, P68, DOI 10.1046/j.1365-2222.1997.d01-416.x; VANREGENMOORTEL MH, 1987, IMMUNOGENICITY PROTE, P21; WETTERWALD A, 1985, INT ARCH ALLER A IMM, V77, P195, DOI 10.1159/000233784	48	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1998	102	1					118	126		10.1016/S0091-6749(98)70062-4	http://dx.doi.org/10.1016/S0091-6749(98)70062-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	102DX	9679855				2022-12-18	WOS:000074909500017
J	Barker, RD; Harris, JM; Welch, JA; Venables, KM; Taylor, AJN				Barker, RD; Harris, JM; Welch, JA; Venables, KM; Taylor, AJN			Occupational asthma caused by tetrachlorophthalic anhydride: A 12-year follow-up	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HISTAMINE		Univ London, Natl Heart & Lung Inst, Imperial Coll, Sch Med,Occupat & Environm Med Grp, London SW3 6LR, England; Royal Brompton Hosp, London, England	Imperial College London; University of London; Royal Brompton Hospital	Venables, KM (corresponding author), Univ London, Natl Heart & Lung Inst, Imperial Coll, Sch Med,Occupat & Environm Med Grp, 1B Manresa Rd, London SW3 6LR, England.							BICE DE, 1993, AM J RESP CELL MOL, V8, P662, DOI 10.1165/ajrcmb/8.6.662; BRITTON J, 1986, THORAX, V41, P128, DOI 10.1136/thx.41.2.128; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COURSAGET P, 1991, LANCET, V337, P1180, DOI 10.1016/0140-6736(91)92857-X; LASSALLE P, 1993, EUR J IMMUNOL, V23, P796, DOI 10.1002/eji.1830230404; MALO JL, 1988, AM REV RESPIR DIS, V138, P807, DOI 10.1164/ajrccm/138.4.807; VENABLES KM, 1987, J ALLERGY CLIN IMMUN, V80, P212, DOI 10.1016/0091-6749(87)90131-X; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	8	18	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				717	719		10.1016/S0091-6749(98)70401-4	http://dx.doi.org/10.1016/S0091-6749(98)70401-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648696	Bronze			2022-12-18	WOS:000074414200001
J	Bonno, M; Kawasaki, H; Hori, H; Umemoto, M; Komada, Y; Sakurai, M				Bonno, M; Kawasaki, H; Hori, H; Umemoto, M; Komada, Y; Sakurai, M			Rapid desensitization for L-asparaginase hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Mie Univ, Sch Med, Dept Pediat, Tsu, Mie 514, Japan	Mie University	Bonno, M (corresponding author), Mie Univ, Sch Med, Dept Pediat, 2-174 Edobashi, Tsu, Mie 514, Japan.							Essayan DM, 1996, J ALLERGY CLIN IMMUN, V97, P42, DOI 10.1016/S0091-6749(96)70281-6; Goldberg A, 1996, J ALLERGY CLIN IMMUN, V98, P841, DOI 10.1016/S0091-6749(96)70134-3; NESBIT M, 1979, American Journal of Pediatric Hematology Oncology, V1, P9	3	18	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				571	572						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564820				2022-12-18	WOS:000073113500032
J	Rautiainen, J; Rytkonen, M; Syrjanen, K; Pentikainen, J; Zeiler, T; Virtanen, T; Mantyjarvi, R				Rautiainen, J; Rytkonen, M; Syrjanen, K; Pentikainen, J; Zeiler, T; Virtanen, T; Mantyjarvi, R			Tissue localization of bovine dander allergen Bos d 2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; Bos d 2; bovine; calycin; cow; immunohistochemistry; lipocalin; RT-PCR	IGE ANTIBODY-RESPONSES; DOG ALLERGENS; PROTEINS; CLONING; BINDING; SKIN; RNA	Background: Domestic mammals are important sources of indoor allergens. However, the origin at the tissue level and the biologic function of mammalian allergens are largely unknowm. Objective: The aim of this study was to localize the source of the major bovine dander allergen, Bos d 2, in bovine tissues. Methods: Samples from several organs were tested for the presence of mRNA encoding Bos d 2 and Bos d 2 protein by using the reverse transcriptase polymerase chain reaction and immunohistochemical staining, respectively. Results: Skin proved to be the only tissue where mRNA encoding Bos d 2 was detected. This observation was confirmed by immunohistochemistry with a monoclonal anti-Bos d 2 antibody as the primary antibody. In the skin sections, Bos d 2 was found in the secretory cells of apocrine sweat glands and the basement membranes of the epithelium and hair follicles. Bos d 2 belongs to the family of lipocalins comprising a number of pheromone carrier proteins that are present, for example, in the secretions of the apocrine sweat glands. Conclusion: Together with earlier data, our findings suggest that Bos d 2 is produced in sweat glands and transported to the skin surface as a carrier of the pheromone ligand. Because dander allergens of a number of mammalian species are lipocalins, the common biologic function of being pheromone carriers seems to be a common feature of an important group of aeroallergens.	Univ Kuopio, Dept Clin Microbiol, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Pathol, Kuopio, Finland; Univ Kuopio, Cent Hosp, Lab Clin Microbiol, Kuopio, Finland	University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland	Rautiainen, J (corresponding author), Univ Kuopio, Dept Clin Microbiol, POB 1627, FIN-70211 Kuopio, Finland.			Syrjanen, Kari/0000-0001-7180-7491; Rytkonen-Nissinen, Marja/0000-0002-2014-8315				Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; BARTHOLOME K, 1985, J ALLERGY CLIN IMMUN, V76, P503, DOI 10.1016/0091-6749(85)90734-1; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; CHARPIN C, 1991, J ALLERGY CLIN IMMUN, V88, P77, DOI 10.1016/0091-6749(91)90303-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHN BA, 1994, ARCH DERMATOL, V130, P1048, DOI 10.1001/archderm.130.8.1048; Gregoire C, 1996, J BIOL CHEM, V271, P32951, DOI 10.1074/jbc.271.51.32951; JalilColome J, 1996, J ALLERGY CLIN IMMUN, V98, P165, DOI 10.1016/S0091-6749(96)70238-5; KONIECZNY A, 1995, J ALLERGY CLIN IMMUN, V95, P161; MANCINI MA, 1989, J HISTOCHEM CYTOCHEM, V37, P149, DOI 10.1177/37.2.2463299; Mantyjarvi R, 1996, J ALLERGY CLIN IMMUN, V97, P1297, DOI 10.1016/S0091-6749(96)70198-7; PRICE JA, 1990, CLIN EXP ALLERGY, V20, P71, DOI 10.1111/j.1365-2222.1990.tb02778.x; Rautiainen J, 1997, J ALLERGY CLIN IMMUN, V100, P251, DOI 10.1016/S0091-6749(97)70232-X; SCHUMMER A, 1981, ANATOMY DOMESTIC ANI, P458; SPITZAUER S, 1993, INT ARCH ALLERGY IMM, V100, P60, DOI 10.1159/000236389; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1111/j.1365-2222.1996.tb00641.x; YLONEN J, 1992, CLIN EXP ALLERGY, V22, P83, DOI 10.1111/j.1365-2222.1992.tb00118.x; YLONEN J, 1994, ALLERGY, V49, P707, DOI 10.1111/j.1398-9995.1994.tb02091.x; YLONEN J, 1994, J ALLERGY CLIN IMMUN, V93, P851, DOI 10.1016/0091-6749(94)90377-8; Zeng CH, 1996, P NATL ACAD SCI USA, V93, P6626, DOI 10.1073/pnas.93.13.6626	20	18	20	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					349	353		10.1016/S0091-6749(98)70247-7	http://dx.doi.org/10.1016/S0091-6749(98)70247-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525451				2022-12-18	WOS:000072593900012
J	Borish, LC; Nelson, HS; Lanz, M; Claussen, LR; Martin, DW; Garrison, L				Borish, LC; Nelson, HS; Lanz, M; Claussen, LR; Martin, DW; Garrison, L			Phase I/II study of interleukin-4 receptor (IL-4R) in moderate asthma.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Immunex Corp, Seattle, WA USA; Natl Jewish Med & Res Ctr, Denver, CO USA	Immunex Corporation; National Jewish Health									0	18	18	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	2			35	S8	S9						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YW339					2022-12-18	WOS:000071924800036
J	Peng, Z; Lam, H; Xu, W; Cheng, L; Chen, YL; Simons, FER				Peng, Z; Lam, H; Xu, W; Cheng, L; Chen, YL; Simons, FER			Characterization and clinical relevance of two recombinant mosquito Aedes aegypti salivary allergens rAed a 1 and rAed a 2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Univ Manitoba, Winnipeg, MB R3T 2N2, Canada	University of Manitoba									0	18	18	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	2			139	S32	S32						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YW339					2022-12-18	WOS:000071924800140
J	Niggemann, B; Bauer, A; Jendroska, K; Wahn, U				Niggemann, B; Bauer, A; Jendroska, K; Wahn, U			Latex allergy as a cause of eosinophilia in cerebrospinal fluid in a child with a ventricular shunt	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Humboldt Univ, Childrens Hosp, Virchow Clin, Dept Pediat,Div Pediat Pneumol & Immunol, D-13353 Berlin, Germany; Humboldt Univ, Virchow Clin, Dept Neurol, D-13353 Berlin, Germany	Humboldt University of Berlin; Humboldt University of Berlin	Niggemann, B (corresponding author), Humboldt Univ, Childrens Hosp, Virchow Clin, Dept Pediat,Div Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.							NERENBERG ST, 1975, J LAB CLIN MED, V86, P887; PRASAD R, 1985, AM J CLIN PATHOL, V83, P190, DOI 10.1093/ajcp/83.2.190; SINDIC CJM, 1984, J NEUROIMMUNOL, V6, P319, DOI 10.1016/0165-5728(84)90021-3	3	18	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				849	850		10.1016/S0091-6749(97)70284-7	http://dx.doi.org/10.1016/S0091-6749(97)70284-7			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438497				2022-12-18	WOS:000071353600021
J	Brueckner, JW; Marshik, P; Sherman, J; Hendeles, L				Brueckner, JW; Marshik, P; Sherman, J; Hendeles, L			Reliability of the Medtrac MDI Chronolog	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MDI; chronolog; adherence	CLINICAL-TRIAL; NEBULIZER CHRONOLOG; INHALER ADHERENCE	Background: The Medtrac MDI Chronolog is an electronic device for monitoring adherence to metered-dose inhalers. It replaces previous models of the Nebulizer Chronolog and uses a different mechanism of recording actuations. Objective: This study was carried out to determine whether the new model can accurately record and report the date, time, and number of metered-dose inhaler actuations. Methods: Four canisters of beclomethasone (Beclovent) were discharged through four Chronologs with fresh batteries at a rate of 1, 2, 4, or 8 times twice daily for 7 days. Four additional canisters were used as controls and discharged simultaneously through the standard actuator. The weight of ail canisters and Chronolog battery voltage were measured before and at the end of the 7-day experiment. The data retrieved from the Chronologs were compared with the information recorded manually during each discharge. Results: The loss in canister weight was consistent for the number of puffs discharged from all four Chronolog units and controls. However, the accuracy of the Chronologs in recording the number of actuations varied between 50% and 100%. The largest amount of data loss occurred with the unit used to discharge 8 puffs and was associated with a dead battery at the end of the 7-day trial, For actuations that were retrievable, the Chronologs accurately recorded the date and time. Conclusions: Unexpected battery voltage drain and other mechanical problems that were encountered may cause data loss and the false appearance of missed doses, Thus the units that we tested were not sufficiently reliable to monitor patient adherence.	UNIV FLORIDA,HLTH SCI CTR,COLL PHARM,ASTHMA RES LAB,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT PEDIAT,DIV PULM,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida								BENDER B, 1997, AM J RESP CRIT CARE, V155, pA259; GONG H, 1988, J ALLERGY CLIN IMMUN, V82, P5, DOI 10.1016/0091-6749(88)90043-7; NIDES MA, 1993, CHEST, V104, P501, DOI 10.1378/chest.104.2.501; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; Simmons MS, 1996, CHEST, V109, P963, DOI 10.1378/chest.109.4.963; TASHKIN DP, 1991, AM J MED, V91, pS33; WAMBOLDT F, 1997, AM J RESP CRIT CARE, V155, pA259; WEEKS K, 1997, AM J RESP CRIT CARE, V155, pA259	8	18	18	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					488	491		10.1016/S0091-6749(97)70140-4	http://dx.doi.org/10.1016/S0091-6749(97)70140-4			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338542				2022-12-18	WOS:A1997YA52900010
J	Siebers, R				Siebers, R			The effects of temperature and buffer on the extraction of Der p 1 from dust	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter											Siebers, R (corresponding author), WELLINGTON SCH MED, WELLINGTON ASTHMA RES GRP, POB 7343, WELLINGTON, NEW ZEALAND.		Siebers, Robert/A-4102-2009	Siebers, Robert/0000-0002-6359-3144				LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Siebers R, 1997, J ALLERGY CLIN IMMUN, V99, P1596; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x	3	18	20	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					580	580						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338557				2022-12-18	WOS:A1997YA52900026
J	Majori, M; Piccoli, ML; Bertacco, S; Cuomo, A; Cantini, L; Pesci, A				Majori, M; Piccoli, ML; Bertacco, S; Cuomo, A; Cantini, L; Pesci, A			Inhaled beclomethasone dipropionate downregulates CD4 and CD8 T-lymphocyte activation in peripheral blood of patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; beclomethasone dipropionate; inhaled corticosteroids; peripheral blood lymphocytes	BRONCHOALVEOLAR LAVAGE; CELL CLONES; INTERLEUKIN-5; EOSINOPHILIA; PROFILES; SUBSETS; SWITCH	Background: Previous studies demonstrated a downregulation of T-lymphocyte (CD3(+) cells) activation in peripheral blood after treatment with inhaled corticosteroids in patients with asthma. Objective: This study was carried out to evaluate the effect of inhaled corticosteroids on CD4 and CD8 T-lymphocyte activation, respectively. Methods: We examined the expression of three surface activation markers (CD25, HLA-DR, and very late activation antigen 1) on circulating CD4(+) and CD8(+) T-cell subsets in subjects with asthma (n = 23) before and 8 weeks after treatment with inhaled beclomethasone dipropionate dry powder (daily dose, 800 mu g). Results: Beclomethasone dipropionate treatment had a marked effect in reducing the expression of the activation marker CD25 (p < 0.01) in both CD4(+) and CD8(+) T-cell subsets in peripheral blood of patients with asthma. However, no correlation was found between the downregulation of CD4 and CD8 T-lymphocyte activation and the improvement in physiologic indices of disease activity. Conclusions: These data add to the view that CD4(+) and CD8(+) T lymphocytes in peripheral blood of patients with asthma are in an activated state that is downregulated by inhaled corticosteroids.	UNIV PARMA,IST CLIN MALATTIE APPARATO RESP,I-43100 PARMA,ITALY; DIREZ MED CHIESI FARMACEUT,PARMA,ITALY	University of Parma; Chiesi Pharmaceuticals Inc				Majori, Maria/0000-0001-7453-7247				BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1, DOI 10.1164/ajrccm/148.4_Pt_2.S1; *BRIT THOR SOC, 1990, BRIT MED J, V142, P434; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; CORRIGAN CJ, 1988, LANCET, V1, P1129; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; CROFT M, 1994, J EXP MED, V180, P1715, DOI 10.1084/jem.180.5.1715; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DJUKANOVIC R, 1995, INT ARCH ALLERGY IMM, V107, P389, DOI 10.1159/000237047; GERBLICH AA, 1991, AM REV RESPIR DIS, V143, P533, DOI 10.1164/ajrccm/143.3.533; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; [National Heart Lung and Blood Institute National Asthma Education Program Department of Health and Human Services], 1991, EXP PAN REP GUID DIA; ODDERA S, 1995, ALLERGY, V50, P397, DOI 10.1111/j.1398-9995.1995.tb01169.x; ROMAGNANI S, 1994, AIDS RES HUM RETROV, V10, pR3, DOI 10.1089/aid.1994.10.iii; SAD S, 1995, IMMUNITY, V2, P271, DOI 10.1016/1074-7613(95)90051-9; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; WALKER C, 1991, J IMMUNOL, V146, P1829; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WILSON JW, 1994, AM J RESP CRIT CARE, V149, P86, DOI 10.1164/ajrccm.149.1.8111605; WILSON JW, 1992, AM REV RESPIR DIS, V145, P958, DOI 10.1164/ajrccm/145.4_Pt_1.958	20	18	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					379	382		10.1016/S0091-6749(97)70252-5	http://dx.doi.org/10.1016/S0091-6749(97)70252-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314351				2022-12-18	WOS:A1997XX47900016
J	Melo, RE; Sole, D; Naspitz, CK				Melo, RE; Sole, D; Naspitz, CK			Comparative efficacy of inhaled furosemide and disodium cromoglycate in the treatment of exercise-induced asthma in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exercise-induced asthma; inhaled furosemide; disodium cromoglycate; children	METHACHOLINE-INDUCED BRONCHOCONSTRICTION; CHRONIC BRONCHOPULMONARY DYSPLASIA; ADENOSINE 5'-MONOPHOSPHATE; SODIUM METABISULFITE; BRONCHIAL RESPONSE; DISTILLED WATER; FRUSEMIDE; INHIBITION; INFANTS; PROSTAGLANDIN-E2	Background: Inhaled furosemide has been shown, in patients with asthma, to have prophylactic properties similar to those of disodium cromoglycate. Objective: The aim of this study was to evaluate the protective effect of these drugs in the treatment of exercise-induced asthma. Methods: Fifteen children with exercise-induced asthma (mean age, 10.8 years) underwent exercise challenge after a single dose of nebulized placebo, furosemide (20 mg/m(2) body area), or disodium cromoglycate (20 mg), 2 days apart, in a single-blind crossover trial. Results: Both furosemide and disodium cromoglycate exerted significant protection against the bronchial response to exercise challenge, with a mean maximum percentage falls in FEV(1) of 4.66% and 7.22%, respectively (p < 0.05). On the placebo day, the mean maximum percentage fall in FEV(1) was 34.50% (p < 0.05). Conclusion: The results of this study suggest that furosemide and disodium cromoglycate provide comparable efficacy in preventing exercise-induce asthma in children, with no side effects.			Melo, RE (corresponding author), UNIV FED SAO PAULO, ESCOLA PAULISTA MED, DEPT PEDIAT, DISCIPLINA ALERGIA IMUNOL CLIN & REUMATOL, BR-04025002 SAO PAULO, BRAZIL.		Solé, Dirceu/D-7789-2013					*AM AC ALL, 1979, J ALLERGY CLIN IMMUN, V64, P642; ANDERSON SD, 1991, NEW ENGL J MED, V324, P131; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BIANCO S, 1988, LANCET, V2, P252; BIANCO S, 1989, NEW ENGL J MED, V321, P1069, DOI 10.1056/NEJM198910193211602; CHIN T, 1994, PEDIATR PULM, V18, P93, DOI 10.1002/ppul.1950180207; CROCE M, 1992, J INVEST ALLERG CLIN, V2, P205; ENGELHARDT B, 1989, J PEDIATR-US, V114, P619, DOI 10.1016/S0022-3476(89)80708-5; FEATHER IR, 1991, AUST NZ J MED, V21, P7, DOI 10.1111/j.1445-5994.1991.tb02993.x; FORESI A, 1992, AM REV RESPIR DIS, V146, P364, DOI 10.1164/ajrccm/146.2.364; GEHAN EA, 1970, CANCER CHEMOTH REP 1, V54, P225; GODFREY S, 1976, THORAX, V31, P137, DOI 10.1136/thx.31.2.137; HUFNAGLE KG, 1982, PEDIATRICS, V70, P360; KARPEL JP, 1994, CHEST, V106, P1396, DOI 10.1378/chest.106.5.1396; MATHE AA, 1975, AM REV RESPIR DIS, V111, P313; MELILLO E, 1994, AM J RESP CRIT CARE, V149, P1138, DOI 10.1164/ajrccm.149.5.8173753; MIYANOSHITA A, 1989, J PHARMACOL EXP THER, V251, P1155; MOCHIZUKI H, 1995, CHEST, V107, P413, DOI 10.1378/chest.107.2.413; MOSCATO G, 1991, AM REV RESPIR DIS, V143, P561, DOI 10.1164/ajrccm/143.3.561; MULLOL J, 1993, THORAX, V48, P260, DOI 10.1136/thx.48.3.260; NICHOL GM, 1990, AM REV RESPIR DIS, V142, P576, DOI 10.1164/ajrccm/142.3.576; NOVEMBRE E, 1994, J ALLERGY CLIN IMMUN, V94, P201, DOI 10.1016/0091-6749(94)90041-8; OCONNOR BJ, 1991, AM REV RESPIR DIS, V143, P1329, DOI 10.1164/ajrccm/143.6.1329; ODONNELL WJ, 1992, AM REV RESPIR DIS, V146, P1518, DOI 10.1164/ajrccm/146.6.1518; PAVORD I, 1995, AM J RESP CRIT CARE, V152, P1164, DOI 10.1164/ajrccm.152.4.7551365; PAVORD ID, 1991, THORAX, V46, P633, DOI 10.1136/thx.46.9.633; PAVORD ID, 1992, THORAX, V47, P797, DOI 10.1136/thx.47.10.797; POLOSA R, 1990, EUR RESPIR J, V3, P665; POLOSA R, 1993, J ALLERGY CLIN IMMUN, V92, P288, DOI 10.1016/0091-6749(93)90172-C; PRAT J, 1993, J ALLERGY CLIN IMMUN, V92, P248, DOI 10.1016/0091-6749(93)90168-F; RAJAKULASINGAM K, 1994, THORAX, V49, P485, DOI 10.1136/thx.49.5.485; RODWELL LT, 1993, THORAX, V48, P208, DOI 10.1136/thx.48.3.208; RUSH MG, 1990, J PEDIATR-US, V117, P112, DOI 10.1016/S0022-3476(05)82458-8; SEIDENBERG J, 1992, ARCH DIS CHILD, V67, P214, DOI 10.1136/adc.67.2.214; SHIMIZU T, 1993, CHEST, V104, P1723, DOI 10.1378/chest.104.6.1723; TULLETT WM, 1985, THORAX, V40, P41, DOI 10.1136/thx.40.1.41; VARGAS FS, 1992, CHEST, V102, P408, DOI 10.1378/chest.102.2.408	37	18	18	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					204	209		10.1016/S0091-6749(97)70097-6	http://dx.doi.org/10.1016/S0091-6749(97)70097-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042046	Bronze			2022-12-18	WOS:A1997WH83100009
J	Motojima, S; Adachi, T; Manaka, KI; Arima, M; Fukuda, T; Makino, S				Motojima, S; Adachi, T; Manaka, KI; Arima, M; Fukuda, T; Makino, S			Eosinophil peroxidase stimulates the release of granulocyte-macrophage colony-stimulating factor from bronchial epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; BEAS-2B cell; bronchial epithelium; eosinophil peroxidase; granulocyte-macrophage colony-stimulating factor	INFLAMMATORY CYTOKINES; SCHISTOSOMA-MANSONI; ASTHMA; EXPRESSION; PROTEINS; INTERLEUKIN-8; TOXICITY; SPUTUM	Background: Asthma is characterized by an accumulation of activated eosinophils in the airway. Eosinophil viability-enhancing activity is present in the sputum of patients with asthma, largely because of granulocyte-macrophage colony-stimulating factor (GM-CSF). Bronchial epithelial cells have been shown to release cytokines including GM-CSF when stimulated with IL-1 beta or tumor necrosis factor-alpha. Objective: the study was designed to determine whether eosinophil peroxidase (EPO) stimulates the release of GM-CSF from bronchial epithelial cells. Methods: Epithelial cells (BEAS-2B) were cultured in serum free HD-F12 medium in a 24-well tissue culture plated until they became confluent. the cells were then exposed to EPO (5.9 x 10(-8) to 5.9 x 10(-7) mol/L) for 15 minutes, washed twice, and cultured in 1 ml of HD-F12. The supernatants were harvested at 3, 6 or 24 hours, and GM-CSF concentration was measured by ELISA. BEAS-2B cells were also treated with a system comprising EPO (1.9 x 10(-9) to 5.9 x 10(-8) mol/L) + 10(-5) mol/L H2O2 + 10(-4) mol/L Br for 24 hours. Results: The GM-CSF concentration in the supernatant pretreated with EPO increased in a time- and concentration-dependent manner compared with control The release of GM-CSF was not inhibited by catalase but was inhibited by cyclohexamide and by mixing of EPO with heparin, suggesting that the action is due to the cationic property of EPO. When EPO was combined with H2O2 and Br, 5.9 x 10(-9) mol/L EPO + 10(-5) mol/L H2O2 released two times more GM-CSF into the supernatants compared with control. Conclusion: These results suggest that EPO stimulates epithelial cells to release GM-CSF and forms a self-stimulatory cycle.	DOKKYO UNIV,SCH MED,LAB TISSUE CULTURE,MIBU,TOCHIGI,JAPAN	Dokkyo Medical University	Motojima, S (corresponding author), DOKKYO UNIV,SCH MED,DEPT MED & CLIN IMMUNOL,MIBU,TOCHIGI 32102,JAPAN.		Manaka, Ken-ichi/C-3081-2008; Arima, Masafumi/L-1951-2018	Arima, Masafumi/0000-0002-5169-7536				ABE MK, 1994, AM J RESP CELL MOL, V11, P577, DOI 10.1165/ajrcmb.11.5.7946386; ABUGHAZALEH RI, 1992, J MEMBRANE BIOL, V121, P153; ADACHI T, 1995, AM J RESP CRIT CARE, V151, P618; Adachi T, 1996, J ALLERGY CLIN IMMUN, V97, P506; BUSSE WW, 1993, ALLERGY PRINCIPLES P, P1173; BUTTERWORTH AE, 1979, J IMMUNOL, V122, P221; CROMWELL O, 1992, IMMUNOLOGY, V77, P330; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271, DOI 10.1165/ajrcmb/9.3.271; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; HAMANN KJ, 1990, J IMMUNOL, V144, P3166; HENDERSON WR, 1980, J EXP MED, V152, P265, DOI 10.1084/jem.152.2.265; JONG EC, 1981, J IMMUNOL, V126, P468; KLEBANOFF SJ, 1975, SEMIN HEMATOL, V12, P117; LINNALA A, 1995, AM J RESP CELL MOL, V13, P578, DOI 10.1165/ajrcmb.13.5.7576694; Makino Sohei, 1993, P329; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; MOTOJIMA S, 1987, J ALLERGY CLIN IMMUN, V79, P128; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; MOTOJIMA S, 1993, ALLERGY, V48, P98, DOI 10.1111/j.1398-9995.1993.tb04709.x; NOAH TL, 1993, AM J PHYSIOL, V265, pL472, DOI 10.1152/ajplung.1993.265.5.L472; OHTOSHI T, 1991, INT ARCH ALLER A IMM, V95, P376, DOI 10.1159/000235476; ROHRBACH MS, 1990, J EXP MED, V172, P1271, DOI 10.1084/jem.172.4.1271; SAUSA A, 1993, AM REV RESPIR DIS, V147, P1557; SMITH H, 1992, CLIN EXP ALLERGY, V22, P189; SUR S, 1993, ALLERGY PRINCIPLES P, P169; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; WANG JH, 1994, J ALLERGY CLIN IMMUN, V94, P1025, DOI 10.1016/0091-6749(94)90121-X; WARDLAW AJ, 1993, BRONCHIAL ASTHMA MEC, P258	28	18	18	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	2	S			S216	S223		10.1016/S0091-6749(96)70069-6	http://dx.doi.org/10.1016/S0091-6749(96)70069-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WC447	8977530	Bronze			2022-12-18	WOS:A1996WC44700007
J	Laberge, S; Wu, L; Olivenstein, R; Xu, LJ; Renzi, PM; Martin, JG				Laberge, S; Wu, L; Olivenstein, R; Xu, LJ; Renzi, PM; Martin, JG			Depletion of CD8(+) T cells enhances pulmonary inflammation but not airway responsiveness after antigen challenge in rats	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sprague-Dawley rats; methacholine challenge; eosinophils; T lymphocytes	ALLERGEN-INDUCED INCREASE; NATURAL-KILLER CELLS; CD4+ LYMPHOCYTES-T; MONOCLONAL-ANTIBODIES; BRONCHOALVEOLAR LAVAGE; PERIPHERAL-BLOOD; IMMUNE REGULATION; BRONCHIAL-ASTHMA; ATOPIC ASTHMA; IFN-GAMMA	Background: CD8(+) (OX-8(+)) T cells may suppress airway inflammation and airway responsiveness after allergen challenge. Objective: We studied the effects of depletion of OX-8(+) T cells on allergen-induced lung eosinophilia and airway responsiveness in the Sprague-Dawley rat. Methods: Sprague-Dawley rats were sensitized to ovalbumin and challenged by aerosol 14 days later. Test animals received either low-dose (2 mg, n = 9) or high-dose (3 mg, n = 7) OX-8 monoclonal antibody (mAB), whereas controls (n = 8) received BALB/c ascites fluid. A fourth group of animals (n = 10) was not sensitized to ovalbumin and also received ascites fluid. Twenty-four hours after ovalbumin challenge, responsiveness to methacholine was measured, and lung inflammation was assessed in the large airways and small airways and parenchyma. Results: Circulating and airway CD8(+) T cells were decreased by OX-8 mAB administration with greatest changes in animals treated with high-dose OX-8 mAB compared with controls (blood: 1.0% +/- 3.6% vs 18.7% +/- 3.9%, p < 0.05); (large airways: 2.5% +/- 1.2% vs 13.8% +/- 1.2%, p < 0.05). Ovalbumin challenge resulted in increases in macrophages and neutrophils in the small airways and parenchyma of sensitized compared with unsensitized rats (p < 0.05). High-dose OX-8 mAB further increased total leukocytes, attributable to increases in neutrophils and eosinophils, retrieved from the large airways and small airways and parenchyma compared with other groups (p < 0.05). Airway responsiveness to methacholine was not significantly different between control and ovalbumin-challenged animals and was not augmented by OX-8 pretreatment. Conclusion: CD8(+) T cells modulate the extent of allergen-induced airway inflammation. However, the enhancement of inflammation was not sufficient to affect airway responsiveness.	MCGILL UNIV,MEAKINS CHRISTIE LABS,ROYAL VICTORIA HOSP,MONTREAL,PQ H2X 2P2,CANADA; RESP HLTH NETWORK CTR EXCELLENCE,MONTREAL,PQ,CANADA	McGill University; Royal Victoria Hospital				Martin, James/0000-0001-7574-5363				ASSAWI M, 1990, AM REV RESPIR DIS, V142, P1407; BRIDEAU RJ, 1980, EUR J IMMUNOL, V10, P609, DOI 10.1002/eji.1830100807; CANTRELL DA, 1982, IMMUNOLOGY, V45, P97; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; EIDELMAN DH, 1988, AM REV RESPIR DIS, V137, P1033, DOI 10.1164/ajrccm/137.5.1033; ELWOOD W, 1992, INT ARCH ALLERGY IMM, V99, P91, DOI 10.1159/000236340; ENGEL P, 1984, ANN ALLERGY, V53, P337; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; GAJEWSKI TF, 1989, J IMMUNOL, V143, P15; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; GERBLICH AA, 1991, AM REV RESPIR DIS, V143, P533, DOI 10.1164/ajrccm/143.3.533; GERSHON RK, 1972, J IMMUNOL, V108, P586; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GONZALEZ MC, 1987, AM REV RESPIR DIS, V136, P600, DOI 10.1164/ajrccm/136.3.600; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; HARPER TB, 1980, CLIN ALLERGY, V10, P555, DOI 10.1111/j.1365-2222.1980.tb02137.x; HWANG KC, 1985, CLIN ALLERGY, V15, P67, DOI 10.1111/j.1365-2222.1985.tb02257.x; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; KEMENY DM, 1994, IMMUNOL TODAY, V15, P107, DOI 10.1016/0167-5699(94)90152-X; KUS J, 1985, CLIN ALLERGY, V15, P523, DOI 10.1111/j.1365-2222.1985.tb02305.x; LABERGE S, 1995, AM J RESP CRIT CARE, V151, P822; LIKE AA, 1986, J EXP MED, V164, P1145, DOI 10.1084/jem.164.4.1145; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; MURPHY DB, 1993, CURR OPIN IMMUNOL, V5, P411, DOI 10.1016/0952-7915(93)90061-V; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; NOBLE A, 1993, IMMUNOLOGY, V80, P326; NOBLE A, 1993, IMMUNOLOGYY, V78, P513; OLIVENSTEIN R, 1993, J CLIN INVEST, V92, P1477, DOI 10.1172/JCI116725; RENZ H, 1994, J IMMUNOL, V152, P351; RENZI PM, 1993, AM REV RESPIR DIS, V148, P932, DOI 10.1164/ajrccm/148.4_Pt_1.932; RENZI PM, 1993, AM REV RESPIR DIS, V147, P967, DOI 10.1164/ajrccm/147.4.967; RENZI PM, 1995, J ALLERGY CLIN IMMUN, V95, P275; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROLAPLESZCZYNSKI M, 1981, INT ARCH ALLER A IMM, V64, P361, DOI 10.1159/000232717; SEDGWICK JD, 1988, EUR J IMMUNOL, V18, P495, DOI 10.1002/eji.1830180402; SHARDONOFSKY FR, 1990, J APPL PHYSIOL, V68, P2230, DOI 10.1152/jappl.1990.68.5.2230; STITZ L, 1992, J VIROL, V66, P3316, DOI 10.1128/JVI.66.6.3316-3323.1992; UNDERWOOD SL, 1995, IMMUNOLOGY, V85, P156; VANOOSTERHOUT AJM, 1993, AM REV RESPIR DIS, V147, P548, DOI 10.1164/ajrccm/147.3.548; WALKER C, 1991, J IMMUNOL, V146, P1829; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WILSON JW, 1992, AM REV RESPIR DIS, V145, P958, DOI 10.1164/ajrccm/145.4_Pt_1.958	48	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					617	627		10.1016/S0091-6749(96)70096-9	http://dx.doi.org/10.1016/S0091-6749(96)70096-9			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828540				2022-12-18	WOS:A1996VJ42800019
J	Rose, G; Arlian, L; Bernstein, D; Grant, A; Lopez, M; Metzger, J; Wasserman, S; PlattsMills, TAE				Rose, G; Arlian, L; Bernstein, D; Grant, A; Lopez, M; Metzger, J; Wasserman, S; PlattsMills, TAE			Evaluation of household dust mite exposure and levels of specific IgE and IgG antibodies in asthmatic patients enrolled in a trial of immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; asthma; exposure; sensitization; skin testing; dust mites	BRONCHIAL HYPERREACTIVITY; DERMATOPHAGOIDES-PTERONYSSINUS; RISK-FACTORS; P-I; ALLERGEN; CHILDREN; SENSITIZATION	Background: Monitoring the response to immunotherapy entails understanding exposure to relevant allergens. For the major indoor allergens, this requires sampling of dust from the patient's house. The objectives of this study were to measure indoor allergen levels during a controlled trial of dust mite immunotherapy for asthma and to relate these results to serum antibody levels. Methods: Eighty-eight asthmatic patients with mite allergy from seven geographic areas in the United States were enrolled in and completed a course of immunotherapy with Dermatophagoides extract or placebo control. Sensitization was evaluated by quantitative measurements of IgG and IgE antibodies. Dust samples were assayed for group I mite (Der p I and Der f 1), cat (Fel d 1), and cockroach (Bin g 1) allergens by monoclonal antibody-based ELISA. Results: Over the 4 years of the study, each of the houses had at least one sample that contained more than 2 mu g of group I mite allergen pet gram of dust. Mean mite allergen levels, however varied over a wide range, from 0.2 mu g/gm or less to more than 50 mu g/gm. IgE antibodies to mite were present in sera from 78% of the patients whereas IgE antibodies to cat and cockroach allergens were found in sera from 34% and 11% of patients, respectively. Sixty-four percent of the patients had exposure and sensitization to mite, whereas the comparable figure for each of the other allergens was 5%. Conclusions: Examination of the results suggested that allergen exposure, relative to a trial of immunotherapy, could be expressed as (1) the maximum level found in the house, (2) the percentage of sites having greater than 2 mu g/gm, or (3) the mean value at the site with the maximum level. This report provides a background for evaluating the clinical results of immunotherapy in these patients and a model for the way in which sensitization and exposure should be monitored in studies of this kind.	UNIV VIRGINIA, MED CTR, ASTHMA & ALLERG DIS CTR, CHARLOTTESVILLE, VA 22908 USA; WRIGHT STATE UNIV, DEPT BIOL SCI, DAYTON, OH 45435 USA; UNIV TEXAS, MED BRANCH, GALVESTON, TX 77550 USA; UNIV CALIF SAN DIEGO, MED CTR, SAN DIEGO, CA 92103 USA; E CAROLINA UNIV, SCH MED, GREENVILLE, NC USA; TULANE UNIV, SCH MED, NEW ORLEANS, LA 70112 USA; UNIV CINCINNATI, MED CTR, CINCINNATI, OH 45267 USA	University of Virginia; University System of Ohio; Wright State University Dayton; University of Texas System; University of Texas Medical Branch Galveston; University of California System; University of California San Diego; University of North Carolina; East Carolina University; Tulane University; University System of Ohio; University of Cincinnati				Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI021987, R01AI020565, U01AI021984, R37AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20565, AI-21987, AI-21984] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; BONER AL, 1985, ANN ALLERGY, V54, P42; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P1, DOI 10.1016/0091-6749(94)90064-7; BUSSE WW, 1993, ALLERGY PRINCIPLES P, P1173; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, 1980, INT ARCH ALLER A IMM, V61, P431, DOI 10.1159/000232471; Ciba Guest Symposium, 1959, THORAX, V14, P286, DOI 10.1136/thx.14.4.286; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; Freeman J, 1911, LANCET, V2, P814; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; HASSNER A, 1983, J IMMUNOL, V130, P1567; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MURRAY AB, 1983, PEDIATRICS, V71, P418; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1988, J ALLERGY CLIN IMMUN, V81, P992, DOI 10.1016/0091-6749(88)90167-4; OHMAN JL, 1989, J ALLERGY CLIN IMMUN, V84, P133, DOI 10.1016/0091-6749(89)90313-8; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Spain WC, 1924, J IMMUNOL, V9, P521; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P199; 1987, AM REV RESPIR DIS, V136, P224	32	18	21	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1996	97	5					1071	1078		10.1016/S0091-6749(96)70260-9	http://dx.doi.org/10.1016/S0091-6749(96)70260-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UL261	8626984				2022-12-18	WOS:A1996UL26100007
J	Li, CS; Hsu, CW; Chua, KY; Hsieh, KH; Lin, RH				Li, CS; Hsu, CW; Chua, KY; Hsieh, KH; Lin, RH			Environmental distribution of house dust mite allergen (Der p 5)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL TAIWAN UNIV,COLL MED,GRAD INST IMMUNOL,SECT 1,TAIPEI 10764,TAIWAN; NATL TAIWAN UNIV,COLL PUBL HLTH,GRAD INST ENVIRONM HLTH,TAIPEI 10764,TAIWAN; NATL TAIWAN UNIV,COLL MED,DEPT PEDIAT,TAIPEI 10764,TAIWAN	National Taiwan University; National Taiwan University; National Taiwan University								CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; LI CS, 1994, J ALLERGY CLIN IMMUN, V94, P131, DOI 10.1016/0091-6749(94)90080-9; LIN KL, 1994, J ALLERGY CLIN IMMUN, V94, P989, DOI 10.1016/0091-6749(94)90117-1; LIN KL, 1991, ANN ALLERGY, V67, P63	5	18	19	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1996	97	3					857	859		10.1016/S0091-6749(96)80166-7	http://dx.doi.org/10.1016/S0091-6749(96)80166-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UA975	8613645				2022-12-18	WOS:A1996UA97500019
J	Bonno, M; Fujisawa, T; Iguchi, K; Uchida, Y; Kamiya, H; Komada, Y; Sakurai, M				Bonno, M; Fujisawa, T; Iguchi, K; Uchida, Y; Kamiya, H; Komada, Y; Sakurai, M			Mite-specific induction of interleukin-2 receptor on T lymphocytes from children with mite-sensitive asthma: Modified immune response with immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-2 receptor; CD25; Mik-beta 1; asthma; immunotherapy; children; Dermatophagoides farinae; CD8(+) T lymphocyte; IgG(4)	MESSENGER-RNA EXPRESSION; HOUSE DUST; DERMATOPHAGOIDES-PTERONYSSINUS; BRONCHIAL BIOPSIES; GRASS-POLLEN; ALLERGEN; CELLS; RESPONSIVENESS; HYPOSENSITIZATION; EOSINOPHILS	Background: The efficacy of immunotherapy is still controversial. To elucidate the mechanisms of immunotherapy, we studied mite-specific induction of IL-2 receptor (IL-2R) expression on T lymphocytes from children with mite-sensitive asthma. Methods: Peripheral blood mononuclear cells were obtained from 28 children with mite-sensitive asthma: 13 had never received house dust immunotherapy (nonimmunotherapy group), 15 had been receiving house dust immunotherapy at the time of the study (immunotherapy group). After a 6-day culture with or without Dermatophagoides farinae (Df) antigen, the expression of IL-2Rp55 (CD25) and p75 on CD4(+) or CD8(+) T lymphocytes was measured by flow cytometry. Results: The nonimmunotherapy group showed significant Df-specific CD25 induction on CD4(+) T lymphocytes (Delta CD4(+) CD25(+)) but little induction on CD8(+) T lymphocytes (Delta CD8(+) CD25(+)). Delta CD4(+) CD25(+) was correlated with the severity of the disease. In the immunotherapy group Delta CD8(+) CD25(+) was significantly higher than in the nonimmunotherapy group or in normal subjects and correlated with Df-specific IgG(4) and cumulative doses of house dust extract, whereas Delta CD4(+) CD25(+) was similar in the nonimmunotherapy and the immunotherapy groups. IL-2Rp75 was not induced either on CD4(+) or CD8(+) T lymphocytes. Conclusions: Our data suggest that house dust immunotherapy may have induced Df-specific CD8(+) T lymphocytes in patients with mite-sensitive asthma and that the efficacy of immunotherapy may be attributed to the generation of Df-specific CD8(+) T lymphocytes.	MIE NATL HOSP, DEPT PEDIAT, TSU, MIE 51401, JAPAN; MIE UNIV, SCH MED, DEPT PEDIAT, TSU, MIE 51401, JAPAN	Mie University								AALBERSE RC, 1983, J IMMUNOL, V130, P722; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; GAJEWSKI TF, 1989, IMMUNOL REV, V111, P79, DOI 10.1111/j.1600-065X.1989.tb00543.x; GIRARD JP, 1967, J ALLERGY, V39, P65, DOI 10.1016/0021-8707(67)90113-X; GONZALEZ MC, 1987, AM REV RESPIR DIS, V136, P600, DOI 10.1164/ajrccm/136.3.600; HING JA, 1989, J ALLERGY CLIN IMMUN, V83, P101; HIRATANI M, 1981, J ALLERGY CLIN IMMUN, V68, P205, DOI 10.1016/0091-6749(81)90185-8; HSIEH KH, 1985, J ALLERGY CLIN IMMUN, V76, P188, DOI 10.1016/0091-6749(85)90700-6; KAWAGUCHI R, 1992, JPN J CLIN PATHOL, V40, P435; KAWANO Y, 1992, CLIN IMMUNOL IMMUNOP, V62, P327, DOI 10.1016/0090-1229(92)90111-Z; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; OHASHI Y, 1989, J IMMUNOL, V143, P3548; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PIENKOWSKI MM, 1985, J ALLERGY CLIN IMMUN, V76, P729, DOI 10.1016/0091-6749(85)90679-7; RAWLE FC, 1984, J IMMUNOL, V133, P195; RENZ H, 1994, J IMMUNOL, V152, P351; RIVLIN J, 1981, CLIN ALLERGY, V11, P353, DOI 10.1111/j.1365-2222.1981.tb01605.x; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; SHEFFER AL, 1991, J ALLERGY CLIN IMMUN, V87, P468, DOI 10.1016/0091-6749(91)90002-6; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; VANBEVER HP, 1990, J ALLERGY CLIN IMMUN, V86, P141, DOI 10.1016/S0091-6749(05)80058-2; VANBEVER HP, 1988, ALLERGY, V43, P378, DOI 10.1111/j.1398-9995.1988.tb00432.x; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; WELTMAN JK, 1976, J ALLERGY CLIN IMMUN, V58, P426, DOI 10.1016/0091-6749(76)90123-8; WIDE L, 1967, LANCET, V2, P1105; YASUEDA H, 1991, Japanese Journal of Allergology, V40, P1218; YOSHIZAWA I, 1989, J ALLERGY CLIN IMMUN, V84, P246, DOI 10.1016/0091-6749(89)90332-1	30	18	18	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1996	97	2					680	688		10.1016/S0091-6749(96)70314-7	http://dx.doi.org/10.1016/S0091-6749(96)70314-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW087	8621854				2022-12-18	WOS:A1996TW08700014
J	Sallusto, F; Corinti, S; Pini, C; Biocca, MM; Bruno, G; DiFelice, G				Sallusto, F; Corinti, S; Pini, C; Biocca, MM; Bruno, G; DiFelice, G			Parietaria judaica-specific T-cell clones from atopic patients: Heterogeneity in restriction, V beta usage, and cytokine profile	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						parietaria judaica; allergens; T-cell clones; T-H1; T-H2; HLA restriction; V beta usage; cytokines; IL-4; IFN-gamma	HOUSE-DUST MITE; X-LINKED IMMUNODEFICIENCY; HUMAN LYMPHOCYTES-T; FUNCTIONAL SUBSETS; POLLEN ALLERGEN; MAJOR ALLERGEN; HYPER-IGM; RESPONSES; DERMATOPHAGOIDES; PATTERNS	The pollen of Parietaria spp. is one of the most clinically relevant sources of allergens in the Mediterranean area. CD4(+) T-lymphocyte clones specific for Parietaria allergens were isolated from peripheral blood of atopic donors, and their phenotype, HLA restriction, V beta usage, and cytokine profile were determined. All the T-cell clones expressed the alpha/beta T-cell receptor and were induced to express CD40 ligand after activation with phorbol-myristate-acetate plus ionomycin. When the proliferative response to three chromatographic fractions of the extract was analyzed, distinct reactivity patterns were found. Interestingly, most of the clones responded to the fraction that was the most enriched for the major allergen Par j 1. The clones were either HLA-DR- or HLA-DQ-restricted and did not show any preferential usage of T-cell receptor V beta segments. Five of the 17 clones tested produced only IL-4 and no interferon-gamma, thus displaying a T-H2 phenotype. The other clones displayed a T-H0 phenotype in that they produced both IL-4 and interferon-gamma. These results show that in atopic patients T-cell response against Parietaria judaica allergen involves different T-cell subsets in terms of restriction, V beta usage, and cytokine profile.	IST SUPER SANITA, DEPT IMMUNOL, I-00161 ROME, ITALY; UNIV ROMA LA SAPIENZA, MED CLIN 1, ROME, ITALY	Istituto Superiore di Sanita (ISS); Sapienza University Rome			Di Felice, Gabriella/B-9985-2016; CORINTI, SILVIA/B-9984-2016	Di Felice, Gabriella/0000-0001-7387-9683; CORINTI, SILVIA/0000-0003-4096-4931				ANSARI AA, 1991, IMMUNOGENETICS, V33, P24; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BASKAR S, 1992, J IMMUNOL, V148, P2378; BISCHOFF SC, 1990, J EXP MED, V172, P1577, DOI 10.1084/jem.172.6.1577; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; CARBALLIDO JM, 1992, EUR J IMMUNOL, V22, P1357, DOI 10.1002/eji.1830220605; COSTA MA, 1994, FEBS LETT, V341, P182, DOI 10.1016/0014-5793(94)80453-2; DAMATO G, 1989, J ALLERGY CLIN IMMUN, V83, P116, DOI 10.1016/0091-6749(89)90485-5; DAMATO G, 1992, ALLERGY, V47, P443, DOI 10.1111/j.1398-9995.1992.tb00661.x; DELPRETE G, 1992, ALLERGY, V47, P450; DIFELICE G, 1989, ALLERGY, V44, P322; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; EBNER C, 1993, J IMMUNOL, V150, P1047; FITCH FW, 1993, ANNU REV IMMUNOL, V11, P29, DOI 10.1146/annurev.immunol.11.1.29; GIULIANI A, 1987, ALLERGY, V42, P434, DOI 10.1111/j.1398-9995.1987.tb00359.x; HUANG SK, 1991, EUR J IMMUNOL, V21, P1469, DOI 10.1002/eji.1830210621; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZAVECCHIA A, 1983, CLIN EXP IMMUNOL, V52, P21; LIFE P, 1994, J EXP MED, V180, P1775, DOI 10.1084/jem.180.5.1775; MAGGI E, 1992, J IMMUNOL, V148, P2142; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MATSUSHITA S, 1987, J IMMUNOL, V138, P109; MOHAPATRA SS, 1994, CLIN REV ALLERG, V12, P3; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OHEHIR RE, 1990, P NATL ACAD SCI USA, V87, P8884, DOI 10.1073/pnas.87.22.8884; OHEHIR RE, 1988, IMMUNOLOGY, V64, P627; OHEHIR RE, 1991, CLIN EXP ALLERGY, V21, P209, DOI 10.1111/j.1365-2222.1991.tb00832.x; OKANO M, 1993, INT ARCH ALLERGY IMM, V101, P82, DOI 10.1159/000236502; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PENE J, 1994, IMMUNOLOGY, V81, P58; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; SALLUSTO F, 1993, ALLERGY, V48, P37, DOI 10.1111/j.1398-9995.1993.tb02172.x; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SPIEGELBERG HL, 1994, J IMMUNOL, V152, P4706; VANNEERVEN RJJ, 1994, J IMMUNOL, V152, P4203; VANNEERVEN RJJ, 1993, J IMMUNOL, V151, P2326; WEDDERBURN LR, 1993, P NATL ACAD SCI USA, V90, P8214, DOI 10.1073/pnas.90.17.8214; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; YSSEL H, 1992, J IMMUNOL, V148, P738; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	45	18	19	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1996	97	2					627	637		10.1016/S0091-6749(96)70308-1	http://dx.doi.org/10.1016/S0091-6749(96)70308-1			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW087	8621848				2022-12-18	WOS:A1996TW08700008
J	Weinstein, RE; Lobocki, CA; Gravett, S; Hum, H; Negrich, R; Herbst, J; Greenberg, D; Pieper, DR				Weinstein, RE; Lobocki, CA; Gravett, S; Hum, H; Negrich, R; Herbst, J; Greenberg, D; Pieper, DR			Decreased adrenal sex steroid levels in the absence of glucocorticoid suppression in postmenopausal asthmatic women	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; DHEAS; estrogen; sex steroids; adrenergic blockade	DEHYDROEPIANDROSTERONE SULFATE CONCENTRATIONS; TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS; CELLS; ANDROGEN; INHIBITION; MICE; CYTOKINES	Background and aim: Reduction of serum sex steroid levels has been reported to occur after the administration of beta-adrenergic medication. In that beta-adrenergic blockade is a central pathophysiologic feature of asthma, this study was done to explore the possibility of hormonal alteration in asthma. Methods: Sex steroids obtained from 22 postmenopausal asthmatic and 22 age-matched postmenopausal, nonasthmatic women were assayed. No subject had received estrogens, progestins, or oral corticosteroids for 120 days before the study. Results: Mean dehydroepiandrosterone sulfate (DHEAS; p < 0.002), dehydroepiandrosterone (DHEA; p < 0.03), estradiol (p < 0.02), and estrone (p < 0.02) levels were lower in asthmatic patients compared with nonasthmatic subjects. Results could not be accounted for by current medication. Patients with asthma demonstrated no decrease in 17-hydroxyprogesterone or cortisol compared with nonasthmatic subjects, limiting findings to the Delta(5), and not the Delta(4), steroidogenic pathway. In a second phase of the study, DHEAS was measured before and after 3 days of oral beta-agonist stimulation in eight postmenopausal asthmatic women. Serum DHEAS concentration increased in eight of eight subjects, from a mean of 28.6 +/- 19.9, mu g/dl (mean +/- SD) to 40.7 +/- 24.8 mu g/dl (p = 0.002). Serum cortisol concentration was unchanged. Conclusion: The results indicate that postmenopausal asthmatic women have lower serum levels of adrenally derived sex steroids than their nonasthmatic peels and that this anomaly may be ameliorated by adrenergic stimulation.	PROVIDENCE HOSP,DEPT INTERNAL MED,SOUTHFIELD,MI 48037; PROVIDENCE HOSP,DEPT PHYSIOL RES,SOUTHFIELD,MI 48037					Pieper, David/0000-0001-6383-4377				ANAKWE OO, 1984, LIFE SCI, V35, P2041, DOI 10.1016/0024-3205(84)90561-7; BARRETTCONNOR E, 1986, NEW ENGL J MED, V315, P1519, DOI 10.1056/NEJM198612113152405; BEST CL, 1994, OBSTET GYNECOL, V84, P121; BJORKSTEN B, 1987, CLIN REV ALLERG, V5, P339; DANENBERG HD, 1992, ANTIMICROB AGENTS CH, V36, P2275, DOI 10.1128/AAC.36.10.2275; DAYNES RA, 1993, J IMMUNOL, V150, P5219; DAYNES RA, 1990, EUR J IMMUNOL, V20, P793, DOI 10.1002/eji.1830200413; DEIGHTON CM, 1992, J RHEUMATOL, V19, P1663; DELREY A, 1992, EUR J CLIN INVEST, V22, P10; DUNN PJ, 1984, NEW ZEAL MED J, V97, P805; FEHER KG, 1983, ACTA MED HUNG, V40, P125; HALL GM, 1993, ANN RHEUM DIS, V52, P211, DOI 10.1136/ard.52.3.211; HARLIN CA, 1993, ACTA ENDOCRINOL-COP, V128, P136, DOI 10.1530/acta.0.1280136; HERMUS ARMM, 1990, J STEROID BIOCHEM, V37, P867, DOI 10.1016/0960-0760(90)90434-M; HERNANDEZ ER, 1988, ENDOCRINOLOGY, V122, P1592, DOI 10.1210/endo-122-4-1592; JAATTELA M, 1991, ENDOCRINOLOGY, V128, P623; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KARALUS NC, 1985, NEW ZEAL MED J, V98, P843; KOSTIS JB, 1986, CIRCULATION, V74, P191; LEPHART ED, 1987, J CLIN ENDOCR METAB, V64, P842, DOI 10.1210/jcem-64-4-842; LEWIS MJ, 1980, CLIN SCI, V58, P22; LONGCOPE C, 1986, CLIN ENDOCRINOL META, V15, P213, DOI 10.1016/S0300-595X(86)80021-4; LUCAS JA, 1985, J CLIN INVEST, V75, P2091, DOI 10.1172/JCI111929; MOORE C, 1991, J ENDOCRINOL, V129, P381, DOI 10.1677/joe.0.1290381; Mulay S, 1992, ADRENAL GLAND, P105; O'Malley BW, 1991, REPROD ENDOCRINOLOGY, P156; ORENTREICH N, 1984, J CLIN ENDOCR METAB, V59, P551, DOI 10.1210/jcem-59-3-551; PARKER CR, 1993, AM J OBSTET GYNECOL, V169, P1407, DOI 10.1016/0002-9378(93)90409-C; PARKER CR, 1992, J CLIN ENDOCR METAB, V75, P1519, DOI 10.1210/jc.75.6.1519; PARKER CR, 1991, P SOC EXP BIOL MED, V197, P165, DOI 10.3181/00379727-197-43239; RISDON G, 1991, BLOOD, V78, P2387; ROSEN RC, 1988, ARCH SEX BEHAV, V17, P241, DOI 10.1007/BF01541742; ROSENFIELD RS, 1972, J ENDOCRINOL METAB, V35, P178; SCHWARTZ AG, 1979, CANCER RES, V39, P1129; SEMPLE CG, 1987, ACTA ENDOCRINOL-COP, V116, P155, DOI 10.1530/acta.0.1160155; SPECTOR TD, 1991, CLIN RHEUMATOL, V10, P316, DOI 10.1007/BF02208698; STANKOVIC AK, 1994, MOL CELL ENDOCRINOL, V99, P145, DOI 10.1016/0303-7207(94)90002-7; SUZUKI H, 1988, J HYPERTENS, V6, pS649, DOI 10.1097/00004872-198812040-00204; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TANNEN RH, 1982, FED PROC, V41, P463; WEKSLER ME, 1993, EUR J CLIN PHARMACOL, V45, pS21, DOI 10.1007/BF01844199; YOUNG JB, 1983, ADRENOCEPTORS CATECH, P157	42	18	18	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	1				1	8		10.1016/S0091-6749(96)70276-2	http://dx.doi.org/10.1016/S0091-6749(96)70276-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TR947	8568121				2022-12-18	WOS:A1996TR94700001
J	Muto, A; Watanabe, S; Itoh, T; Miyajima, A; Yokota, T; Arai, K				Muto, A; Watanabe, S; Itoh, T; Miyajima, A; Yokota, T; Arai, K			Roles of the cytoplasmic domains of the alpha and beta subunits of human granulocyte-macrophage colony-stimulating factor receptor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	New Trends in Immunopharmacology 1994 Conference	JUL 23, 1994	TOKYO, JAPAN	Sandoz Pharm Ltd		CM-CSF receptor; alpha subunit; beta subunit; cytoplasmic domain; receptor oligomerization; signal transduction	GM-CSF RECEPTOR; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; INTERLEUKIN-5 RECEPTOR; MOUSE INTERLEUKIN-3; EXPRESSION CLONING; MOLECULAR-CLONING; GENE FAMILY; GROWTH; IL-3	The high-affinity and functional granulocyte-macrophage colony-stimulating factor receptor (GMR) is composed of two distinct subunits, alpha and beta; and the cytoplasmic domain of the beta subunit is essential to transduce growth-promoting signals. In contrast to the beta subunit, the role of the alpha subunit is not well characterized. We examined the requirement of the cytoplasmic domain of the alpha subunit and its functional region by deletion analyses. We demonstrated that the cytoplasmic domain of the alpha subunit, especially 29 amino acids residues near the transmembrane domain, was absolutely required for val ions signaling events including activation of immediate early genes, induction of tyrosine phosphorylation of cellular proteins, and cell growth. We further analyzed the role of the cytoplasmic domain of each subunit by constructing chimeric subunits, designated alpha/beta and beta,alpha, by exchanging cytoplasmic domains of the alpha and beta subunits of human (h) GMR. Reconstituted high-affinity chimeric hGMRs, hGMR(alpha/beta,beta alpha) and hGMR(alpha/beta,beta), transduced signals at levels similar to the wild type hGMR(alpha,beta) in Ba/F3 cells and in NIH3T3 cells. These observations indicate that the original configuration between the extracellular and the cytoplasmic domains of the hGMR(alpha,beta) subunits is not required and that hGMR(alpha/beta,beta) transduced signals through the cytoplasmic domain of the beta subunit in an oligomeric form, without involvement of the cytoplasmic domain of the alpha subunit. Therefore human granulocyte-macrophage colony-stimulating factor signals are mainly transduced through the beta subunit, and the cytoplasmic domain of the alpha subunit is likely to activate the beta subunit in the normal hGMR.	UNIV TOKYO, INST MED SCI, DEPT MOLEC & DEV BIOL, MINATO KU, TOKYO, JAPAN; DNAX RES INST MOLEC & CELLULAR BIOL INC, DEPT MOLEC BIOL, PALO ALTO, CA 94304 USA	University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Muto, Akihiko/O-1199-2016; Yokota, Takashi/J-8483-2015; Itoh, Tohru/GYQ-8698-2022	Itoh, Tohru/0000-0002-6579-1638				BALDWIN GC, 1992, DEV BIOL, V151, P352, DOI 10.1016/0012-1606(92)90175-G; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HARELBELLAN A, 1987, BIOCHEM BIOPH RES CO, V148, P1001, DOI 10.1016/S0006-291X(87)80231-0; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERCUS TR, 1994, BLOOD, V83, P3500; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KANAKURA Y, 1990, BLOOD, V76, P706; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SASAKI K, 1993, J BIOL CHEM, V268, P13697; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WANG HM, 1989, EMBO J, V8, P3677, DOI 10.1002/j.1460-2075.1989.tb08542.x; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WATANABE S, 1993, MOL BIOL CELL, V4, P983, DOI 10.1091/mbc.4.10.983; WATANABE Y, 1992, BLOOD, V80, P2215; WEISS M, 1993, BLOOD, V82, P3298	38	18	18	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	2	S			1100	1114		10.1016/S0091-6749(95)70195-8	http://dx.doi.org/10.1016/S0091-6749(95)70195-8			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	TQ509	8543767				2022-12-18	WOS:A1995TQ50900006
J	SUZUKI, S; OKUBO, M; KAISE, S; OHARA, M; KASUKAWA, R				SUZUKI, S; OKUBO, M; KAISE, S; OHARA, M; KASUKAWA, R			GOLD SODIUM THIOMALATE SELECTIVITY INHIBITS INTERLEUKIN-5-MEDIATED EOSINOPHIL SURVIVAL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BRONCHIAL ASTHMA; EOSINOPHILS; INTERLEUKIN-5; GOLD SODIUM THIOMALATE; APOPTOSIS	PROGRAMMED CELL-DEATH; COLONY-STIMULATING FACTOR; APOPTOSIS; ASTHMA; MACROPHAGES; ACTIVATION; INFLAMMATION; PHAGOCYTOSIS; RESPONSES; CYTOKINE	Gold sodium thiomalate (GST) has been used for treatment of patients with bronchial asthma. In this study we investigated the effects of GST on interleukin (IL)-5-mediated eosinophil survival in vitro. Blood cells were obtained from patients with bronchial asthma (n = 18). Eosinophils were purified from the blood samples by a Percoll discontinuous method and negative selection of neutrophils. Eosinophils (10(6) cells/ml) were incubated for 96 hours in 10% fetal bovine serum-RPMI 1640 (Nissui Pharmaceutical Co. Ltd., Tokyo, Japan) with various concentrations of recombinant human IL-5 (2 x 10(-9) to 2 X 10(-5) mmol/L) and with GST (0.01 to 100 mu mol/L) in 96-well, flat-bottomed microtiter plates at 37 degrees C in a humidified 5% carbon dioxide atmosphere. Eosinophil viability was determined by trypan blue exclusion. IL-5 enhanced eosinophil survival in a dose-dependent manner Higher concentrations of GST inhibited IL-5-mediated eosinophil survival. Moreover, GST induced apoptosis of eosinophils by antagonizing the effects of lL-5. However CST did not inhibit IL-3- or granulocyte-macophage colony stimulating factor-mediated eosinophil survival, suggesting that GST selectivity inhibits IL-5-mediated eosinophil survival. These results suggest that IL-5-mediated eosinophil survival is inhibited by GST and that GST blocks eosinophil apoptosis by IL-5. It is possible that GST may be capable of controlling eosinophil functions regulated by IL-5 in patients with bronchial asthma.	FUKUSHIMA MED COLL,DEPT INTERNAL MED 2,FUKUSHIMA,JAPAN	Fukushima Medical University				Okubo, Mitsuo/0000-0001-9098-4477				American Rheumatism Association, 1973, ARTHRITIS RHEUM, V16, P353; [Anonymous], 1960, ANN RHEUM DIS, V19, P95; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GARTNER I, 1983, IMMUNOLOGY, V40, P133; GLEICH GJ, 1984, ANNU REV IMMUNOL, V2, P429, DOI 10.1146/annurev.immunol.2.1.429; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; HILL HR, 1991, J EXP MED, V173, P767, DOI 10.1084/jem.173.3.767; JESSOP JD, 1973, ANN RHEUM DIS, V32, P294, DOI 10.1136/ard.32.4.294; LAMAS AM, 1991, J IMMUNOL, V147, P254; LIPSKY PE, 1977, J CLIN INVEST, V59, P455, DOI 10.1172/JCI108660; LOPEZ AF, 1986, J EXP MED, V167, P219; METZGER WJ, 1985, CLIN REV ALLERG, V3, P145, DOI 10.1007/BF02992980; MURANAKA M, 1974, J ALLERGY CLIN IMMUN, V54, P32, DOI 10.1016/S0091-6749(74)80006-0; MURANAKA M, 1978, ANN ALLERGY, V40, P132; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PERSELLIN RH, 1966, ARTHRITIS RHEUM-US, V9, P57, DOI 10.1002/art.1780090107; ROBERTS BV, 1973, ANN RHEUM DIS, V32, P301; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SFIKAKIS PP, 1993, ARTHRITIS RHEUM, V36, P208, DOI 10.1002/art.1780360211; SILBERSTEIN DS, 1987, IMMUNOL TODAY, V8, P380, DOI 10.1016/0167-5699(87)90214-3; STERN M, 1992, J IMMUNOL, V148, P3543; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; UGAI K, 1979, ARTHRITIS RHEUM, V22, P1352, DOI 10.1002/art.1780221206; VENGE P, 1987, INT ARCH ALLER A IMM, V82, P333, DOI 10.1159/000234219; WALKER C, 1991, J IMMUNOL, V146, P1829; WALLEN N, 1991, J IMMUNOL, V147, P3490; WOLF RE, 1988, ARTHRITIS RHEUM, V31, P176, DOI 10.1002/art.1780310204; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; YAMAGUCHI Y, 1991, BLOOD, V78, P2542; 1961, ANNR HEUM DIS, V20, P315	35	18	19	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					251	256		10.1016/S0091-6749(95)70015-3	http://dx.doi.org/10.1016/S0091-6749(95)70015-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636062				2022-12-18	WOS:A1995RQ00100015
J	TIBERG, E; DREBORG, S; BJORKSTEN, B				TIBERG, E; DREBORG, S; BJORKSTEN, B			ALLERGY TO GREEN-ALGAE (CHLORELLA) AMONG CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									UNIV UPPSALA, DEPT PHYSIOL BOT, S-75105 UPPSALA, SWEDEN; FAC HLTH SCI LINKOPING, DEPT PEDIAT, LINKOPING, SWEDEN	Uppsala University; Linkoping University								[Anonymous], 1989, ALLERGY S10, V10, P1; DREBORG S, 1992, ALLERGY, V47, P418, DOI 10.1111/j.1398-9995.1992.tb02082.x; Dreborg S, 1985, ALLERGY S4, V40, P66; MCELHENNEY TR, 1962, ANN ALLERGY, V20, P739; SCHLICHTING H E JR, 1969, Journal of the Air Pollution Control Association, V19, P946; TIBERG E, 1990, INT ARCH ALLER A IMM, V92, P23, DOI 10.1159/000235219	6	18	18	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					257	259		10.1016/S0091-6749(95)70016-1	http://dx.doi.org/10.1016/S0091-6749(95)70016-1			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636063	Bronze			2022-12-18	WOS:A1995RQ00100016
J	CANONICA, GW; PASSALACQUA, G; PRONZATO, C; CORBETTA, L; BAGNASCO, M				CANONICA, GW; PASSALACQUA, G; PRONZATO, C; CORBETTA, L; BAGNASCO, M			EFFECTIVE LONG-TERM ALPHA-INTERFERON TREATMENT FOR HYPEREOSINOPHILIC SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									OSPED CIVILE SAN GIOVANNI & PAOLO, DIV PNEUMOL, VENICE, ITALY	ULSS 3 Serenissima; Ospedale SS Giovanni Paolo Venezia	CANONICA, GW (corresponding author), UNIV GENOA, DEPT INTERNAL MED, ALLERGY & CLIN IMMUNOL SERV, VLE BENEDETTO XV 6, I-16132 GENOA, ITALY.		canonica, giorgio walter/ABF-2037-2020	canonica, giorgio walter/0000-0001-8467-2557				BUSCH FW, 1991, ANN INTERN MED, V114, P338, DOI 10.7326/0003-4819-114-4-338_2; DELPRETE G, 1992, ALLERGY, V47, P450; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; MURPHY PT, 1990, BRIT J HAEMATOL, V75, P619, DOI 10.1111/j.1365-2141.1990.tb07811.x; ZIELINSKI RM, 1990, ANN INTERN MED, V113, P716, DOI 10.7326/0003-4819-113-9-716	5	18	19	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1995	96	1					131	133		10.1016/S0091-6749(95)70043-9	http://dx.doi.org/10.1016/S0091-6749(95)70043-9			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RK383	7622756				2022-12-18	WOS:A1995RK38300018
J	PROEBSTLE, TM; GALL, H; JUGERT, FK; MERK, HF; STERRY, W				PROEBSTLE, TM; GALL, H; JUGERT, FK; MERK, HF; STERRY, W			SPECIFIC IGE AND IGG SERUM ANTIBODIES TO THIAMINE ASSOCIATED WITH ANAPHYLACTIC REACTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									UNIV ULM,DEPT DERMATOL & VENEROL,W-7900 ULM,GERMANY; UNIV COLOGNE,DEPT DERMATOL & VENEROL,W-5000 COLOGNE,GERMANY	Ulm University; University of Cologne								ASSEM ESK, 1973, PRACTITIONER, V211, P565; FERRARI G, 1982, PFLUG ARCH EUR J PHY, V393, P37, DOI 10.1007/BF00582388; REINGOLD IM, 1946, JAMA-J AM MED ASSOC, V130, P491; WEIGAND C G, 1950, Geriatrics, V5, P274; WRENN KD, 1989, ANN EMERG MED, V18, P867, DOI 10.1016/S0196-0644(89)80215-X	5	18	18	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	1				1059	1060		10.1016/S0091-6749(95)70111-7	http://dx.doi.org/10.1016/S0091-6749(95)70111-7			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY917	7751506				2022-12-18	WOS:A1995QY91700022
J	BABE, KS; ARLIAN, LG; CONFER, PD; KIM, R				BABE, KS; ARLIAN, LG; CONFER, PD; KIM, R			HOUSE-DUST MITE (DERMATOPHAGOIDES-FARINAE AND DERMATOPHAGOIDES-PTERONYSSINUS) PREVALENCE IN THE ROOMS AND HALLWAYS OF A TERTIARY CARE HOSPITAL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGENICITY; ALLERGIC DISEASE; ASTHMA; CARPET; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; HOUSE DUST MITE; RELATIVE HUMIDITY; TERTIARY CARE HOSPITAL	SOUTHERN-CALIFORNIA; ACARINA-PYROGLYPHIDAE; ASTHMA; ALLERGENS; REDUCTION; EXPOSURE; HOMES; ABUNDANCE; ACARICIDE; CHILDHOOD	Background: House dust mites, Dermatophagoides farinae and Dermatophagoides pteronyssinus, are important components in the development of asthma. Objective: We measured the prevalence of house dust mites in a tertiary care hospital located in a temperate geographic region where dust mites were prevalent in homes. Methods: The density of Dermatophagoides spp, was measured in hospital hallways, carpeted patients' rooms, and noncarpeted patients' rooms by vacuuming the floor in the summer and winter seasons. Bedrooms in the homes of employees were sampled as a summer control group. A total of 141 dust samples was obtained. Results: No D. farinae or D. pteronyssinus was found in 60 hospital dust samples that were obtained during the winter season. Although mites were found in some locations in the hospital during the summer dust collection, mite density in these locations and the average mite density for all samples were insignificant During the summer dust samples from the bedroom carpets of all employees' homes sampled were positive for mites, with many homes having moderate or high populations (range, 22 to 8340 mites per gram of dust). Conclusions: The dust mite prevalence in a hospital could be kept very low even though mite levels in employees' homes were moderate to high. The factors responsible for the low mite density in the hospital were maintenance of low relative humidity use of low-pile carpets, and good housekeeping and laundering practices.	WRIGHT STATE UNIV,DEPT BIOL SCI,DAYTON,OH 45435; WRIGHT STATE UNIV,DEPT MICROBIOL & IMMUNOL,DAYTON,OH 45435; MED CTR DELAWARE,DEPT INTERNAL MED,NEWARK,DE; MED CTR DELAWARE,ALLERGY & IMMUNOL SECT,NEWARK,DE	Wright State University Dayton; Wright State University Dayton								ANDERSEN A, 1989, ALLERGY, V44, P396, DOI 10.1111/j.1398-9995.1989.tb04170.x; ARLIAN L G, 1977, Journal of Medical Entomology, V14, P484, DOI 10.1093/jmedent/14.4.484; ARLIAN LG, 1992, EXP APPL ACAROL, V16, P15, DOI 10.1007/BF01201490; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; ARLIAN LG, 1975, J MED ENTOMOL, V12, P437, DOI 10.1093/jmedent/12.4.437; ARLIAN LG, 1974, J INSECT PHYSIOL, V20, P1063, DOI 10.1016/0022-1910(74)90148-6; ARLIAN LG, 1983, J MED ENTOMOL, V20, P99, DOI 10.1093/jmedent/20.1.99; ARLIAN LG, 1978, J MED ENTOMOL, V15, P35, DOI 10.1093/jmedent/15.1.35; BATES JM, 1993, 6TH P INT C IND AIR, V6, P297; BRANDT RL, 1976, J MED ENTOMOL, V13, P327, DOI 10.1093/jmedent/13.3.327; BROWN HM, 1991, ANN ALLERGY, V67, P25; FULWOOD R, 1990, MMWR-MORBID MORTAL W, V39, P493; HAYDEN ML, 1992, J ALLERGY CLIN IMMUN, V89, P536, DOI 10.1016/0091-6749(92)90320-2; KERSTEN W, 1988, ALLERGOLOGIE, V11, P371; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; KORSGAARD J, 1982, AM REV RESPIR DIS, V125, P80; LANG JD, 1977, ENVIRON ENTOMOL, V6, P213, DOI 10.1093/ee/6.2.213; LANG JD, 1978, ENVIRON ENTOMOL, V7, P281, DOI 10.1093/ee/7.2.281; LINTNER TJ, 1993, J ALLERGY CLIN IMMUN, V91, P862, DOI 10.1016/0091-6749(93)90343-E; MCDONALD LG, 1992, J ALLERGY CLIN IMMUN, V90, P599, DOI 10.1016/0091-6749(92)90132-L; MITCHELL EB, 1985, CLIN ALLERGY, V15, P235, DOI 10.1111/j.1365-2222.1985.tb02280.x; MULLA MS, 1975, J MED ENTOMOL, V12, P5, DOI 10.1093/jmedent/12.1.5; MURRAY AB, 1983, PEDIATRICS, V71, P418; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; PERNAUD A, 1977, CLIN ALLERGY, V7, P49; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1982, LANCET, V2, P675; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P711, DOI 10.1136/adc.49.9.711; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; WALSHAW MJ, 1986, Q J MED, V59, P199	32	18	19	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1995	95	4					801	805		10.1016/S0091-6749(95)70121-4	http://dx.doi.org/10.1016/S0091-6749(95)70121-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QT468	7722158				2022-12-18	WOS:A1995QT46800003
J	QUINN, JM; WICKERN, GM; WHISMAN, BA; GOETZ, DW				QUINN, JM; WICKERN, GM; WHISMAN, BA; GOETZ, DW			IMMUNOTHERAPY (ITX) IN ALLERGIC BIPOLARIS SINUSITIS (ABS) - A CASE-REPORT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	18	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	2				201	201						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QE854					2022-12-18	WOS:A1995QE85400242
J	BOCHNER, BS; STERBINSKY, SA; KNOL, EF; KATZ, BJ; LICHTENSTEIN, LM; MACGLASHAN, DW; SCHLEIMER, RP				BOCHNER, BS; STERBINSKY, SA; KNOL, EF; KATZ, BJ; LICHTENSTEIN, LM; MACGLASHAN, DW; SCHLEIMER, RP			FUNCTION AND EXPRESSION OF ADHESION MOLECULES ON HUMAN BASOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ENDOTHELIAL-CELLS; MAST-CELLS; NEUTROPHILS; ADHERENCE; FIBRONECTIN; ACTIVATION; RECEPTORS; EOSINOPHILS; CHEMOTAXIS; INTEGRINS				BOCHNER, BS (corresponding author), JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21224, USA.			Knol, Edward/0000-0001-7368-9820				Askenase P W, 1977, Prog Allergy, V23, P199, DOI 10.1159/000314242; BAROODY FM, 1994, IN PRESS ARCH OTORHI; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; BOCHNER BS, 1989, J IMMUNOL METHODS, V125, P265, DOI 10.1016/0022-1759(89)90102-6; BOCHNER BS, 1990, J IMMUNOL, V145, P1832; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BOCHNER BS, 1989, J IMMUNOL, V142, P3180; BOCHNER BS, 1988, J CLIN INVEST, V81, P1355, DOI 10.1172/JCI113463; BOCHNER BS, 1991, J IMMUNOL, V146, P2367; BOCHNER BS, 1994, IN PRESS J ALLERGY C; BOCHNER BS, UNPUB COUNTERRECEPTO; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; EBISAWA M, 1993, J ALLERGY CLIN IMMUN, V91, P691; GEORAS SN, 1992, AM J RESP CELL MOL, V7, P261, DOI 10.1165/ajrcmb/7.3.261; GUO CB, 1994, AM J RESP CELL MOL, V10, P384, DOI 10.1165/ajrcmb.10.4.7510984; HARLAN JM, 1992, ADHESION ITS ROLE IN; HILDRETH JEK, 1985, J IMMUNOL, V134, P3272; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; LETTBROWN MA, 1976, J IMMUNOL, V117, P246; LETTBROWN MA, 1981, J CLIN INVEST, V67, P547, DOI 10.1172/JCI110065; LICHTENSTEIN LM, 1991, ANN NY ACAD SCI, V629, P48; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; MITCHELL EB, 1983, CLIN REV ALLERG, V1, P427; MONTEFORT S, 1993, EUR RESPIR J, V6, P1044; POSTIGO AA, 1993, J IMMUNOL, V151, P2471; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SHAW S, 1994, IN PRESS LEUKOCYTE T, V5; SMYTH SS, 1993, BLOOD, V81, P2827; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAIN C, 1987, BLOOD, V70, P1872; TANIMOTO Y, 1992, CLIN EXP ALLERGY, V22, P1020, DOI 10.1111/j.1365-2222.1992.tb03031.x; VALENT P, 1992, ADV IMMUNOL, V52, P333, DOI 10.1016/S0065-2776(08)60879-2; VALENT P, 1990, CRIT REV ONCOL HEMAT, V10, P327, DOI 10.1016/1040-8428(90)90009-H; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; YAMADA T, 1993, J ALLERGY CLIN IMMUN, V91, P692	44	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1157	1162		10.1016/0091-6749(94)90326-3	http://dx.doi.org/10.1016/0091-6749(94)90326-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798554				2022-12-18	WOS:A1994QA02000006
J	CHARLESWORTH, EN				CHARLESWORTH, EN			THE SKIN AS A MODEL TO STUDY THE PATHOGENESIS OF IGE-MEDIATED ACUTE AND LATE-PHASE RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PLATELET-ACTIVATING FACTOR; CUTANEOUS ALLERGIC RESPONSES; HISTAMINE-RELEASE; MAST-CELL; ANTIGEN CHALLENGE; HUMAN BASOPHILS; INVIVO; INTERLEUKIN-1; EOSINOPHILS; INHIBITION				CHARLESWORTH, EN (corresponding author), WILFORD HALL USAF MED CTR, DEPT ALLERGY & CLIN IMMUNOL, LACKLAND AFB, TX 78236 USA.							ALAM R, 1993, AM REV RESPIR DIS, V148, P1066, DOI 10.1164/ajrccm/148.4_Pt_1.1066; ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BASRAN GS, 1984, CLIN ALLERGY, V14, P75, DOI 10.1111/j.1365-2222.1984.tb02193.x; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; Blackley C. H., 1873, EXPT RES CAUSES NATU, P77; BLANK IH, 1950, J INVEST DERMATOL, V15, P9, DOI 10.1038/jid.1950.64; BOCHNER BS, 1990, J ALLERGY CLIN IMMUN, V86, P830, DOI 10.1016/S0091-6749(05)80143-5; BRADDING P, 1993, J IMMUNOL, V151, P3853; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHARLESWORTH EN, 1992, J PHARMACOL EXP THER, V262, P964; CHARLESWORTH EN, 1991, J IMMUNOL, V146, P671; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; Cooke RA, 1922, J IMMUNOL, V7, P219; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; FREW AJ, 1991, SKIN PHARMACOL, V4, P71; HAAKFRENDSCHO M, 1988, J ALLERGY CLIN IMMUN, V82, P218, DOI 10.1016/0091-6749(88)91002-0; HENOCQ E, 1988, J ALLERGY CLIN IMMUN, V81, P691, DOI 10.1016/0091-6749(88)91040-8; HEXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323; KIISTALA U, 1967, J INVEST DERMATOL, V48, P466, DOI 10.1038/jid.1967.72; LEE CE, 1992, J ALLERGY CLIN IMMUN, V89, P1010, DOI 10.1016/0091-6749(92)90224-P; LEIFERMAN KM, 1990, LAB INVEST, V62, P579; MASSEY W, 1993, J IMMUNOL, V150, P1084; MICHEL L, 1987, J INVEST DERMATOL, V88, P675, DOI 10.1111/1523-1747.ep12470331; MOLLER A, 1993, J IMMUNOL, V151, P3261; MORRIS FM, 1994, J ALLERGY CLIN IMMUN, V93, P261; PEPYS J, 1969, MONOGR ALLERGY, V4, P22; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SCHLEIMER RP, 1981, NATURE, V292, P454, DOI 10.1038/292454a0; SCHLEIMER RP, 1986, J IMMUNOL, V136, P649; SHALIT M, 1989, J ALLERGY CLIN IMMUN, V83, P691, DOI 10.1016/0091-6749(89)90084-5; SHALIT M, 1988, J IMMUNOL, V141, P821; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; SUBRAMANIAN N, 1987, J IMMUNOL, V138, P271; TALBOT SF, 1985, J CLIN INVEST, V76, P650, DOI 10.1172/JCI112018; TALBOT SF, 1984, J ALLERGY CLIN IMMUN, V74, P819, DOI 10.1016/0091-6749(84)90185-4; TAMURA N, 1987, BIOCHEM BIOPH RES CO, V142, P638, DOI 10.1016/0006-291X(87)91462-8; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P417, DOI 10.1016/0091-6749(80)90122-0; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; WARNER JO, 1978, LANCET, V2, P912; WEISS M, 1988, J ALLERGY CLIN IMMUN, V81, P224, DOI 10.1016/0091-6749(88)90459-9; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; ZWEIMAN B, 1987, J ALLERGY CLIN IMMUN, V79, P169	48	18	18	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1240	1250		10.1016/0091-6749(94)90338-7	http://dx.doi.org/10.1016/0091-6749(94)90338-7			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798566				2022-12-18	WOS:A1994QA02000018
J	JARMAN, ER; HAWRYLOWICZ, CM; PANAGIOTOPOLOU, E; OHEHIR, RE; LAMB, JR				JARMAN, ER; HAWRYLOWICZ, CM; PANAGIOTOPOLOU, E; OHEHIR, RE; LAMB, JR			INHIBITION OF HUMAN T-CELL RESPONSES TO HOUSE-DUST MITE ALLERGENS BY A T-CELL RECEPTOR PEPTIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HOUSE DUST MITE; T CELLS; TCR-CDR2 PEPTIDE	RHEUMATOID-ARTHRITIS; BASIC-PROTEIN; AUTOIMMUNE ENCEPHALOMYELITIS; ANTIGEN RECOGNITION; MULTIPLE-SCLEROSIS; RESPONSIVENESS; HETEROGENEITY; SUPERANTIGEN; SPECIFICITY; EXPRESSION	Recent analysis of the usage of T-cell receptor (TcR) beta chain variable region (V beta) geme elements by house dust mite (HDM)-reactive T cells from an atopic donor suggested that TcR-V beta 3 gene products may form a major component of the human T-cell repertoire, reactive to this common allergen. In this study a peptide analog of the TcR-V beta 3 complementarity determining region 2 (CDR2) is shown to inhibit the polyclonal human T-cell response to HDM; this effect is specific because inhibition is dependent on the presence of V beta 3 + T cells. This experimental approach has been used to determine whether the pattern seen in T-cell clones derived from one atopic donor reflects TcR-V beta usage in the polyclonal response to allergen in the general population. Inhibition of more than 50% of the polyclonal response to allergen by V beta 3-CDR2 peptide,vas observed ill 16 of 21 donors tested, suggesting that TcR-V beta 3 gene usage may form a major component of the human HDM repertoire and as such offer a suitable target for T cell-directed specific immunotherapy in HDM-allergic individuals. Depletion of CD8+ T cells abolishes peptide-mediated inhibition of CD4+ T-cell proliferation to HDM, suggesting that induction of a CD8+ regulatory T-cell subset by the CDR2 peptide may modulate HDM-specific allergic T-cell responses.	ST MARYS HOSP,IMPERIAL COLL SCI TECHNOL & MED,SCH MED,DEPT IMMUNOL,LONDON W2 1PG,ENGLAND	Imperial College London			O'Hehir, Robyn E/H-3627-2011; Hawrylowicz, Catherine/Q-8483-2017	O'Hehir, Robyn E/0000-0002-3489-7595; Hawrylowicz, Catherine/0000-0002-2337-7463	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; BUSH R, 1991, J IMMUNOL, V147, P1292; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; GAUR A, 1993, SCIENCE, V259, P91, DOI 10.1126/science.8418501; GOLD DP, 1992, J IMMUNOL, V148, P1712; GRUNEWALD J, 1991, SCAND J IMMUNOL, V34, P161, DOI 10.1111/j.1365-3083.1991.tb01533.x; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; HOWELL MD, 1991, P NATL ACAD SCI USA, V88, P10921, DOI 10.1073/pnas.88.23.10921; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; KOTZIN BL, 1991, P NATL ACAD SCI USA, V88, P9161, DOI 10.1073/pnas.88.20.9161; MILLER A, 1991, J EXP MED, V174, P791, DOI 10.1084/jem.174.4.791; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OFFNER H, 1991, SCIENCE, V251, P430, DOI 10.1126/science.1989076; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; OHEHIR RE, 1987, IMMUNOLOGY, V62, P635; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; Pepys J., 1975, BR J HOSP MED, V14, P412; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; SOTTINI A, 1991, EUR J IMMUNOL, V21, P461, DOI 10.1002/eji.1830210231; UEMATSU Y, 1991, P NATL ACAD SCI USA, V88, P8534, DOI 10.1073/pnas.88.19.8534; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; VERCELLI D, 1989, J CLIN IMMUNOL, V9, P75, DOI 10.1007/BF00916934; VINEY JL, 1992, HYBRIDOMA, V11, P701, DOI 10.1089/hyb.1992.11.701; WEDDERBURN LR, 1993, P NATL ACAD SCI USA, V90, P8214, DOI 10.1073/pnas.90.17.8214; WHITE J, 1993, J EXP MED, V177, P119, DOI 10.1084/jem.177.1.119; WITT C, 1986, J ALLERGY CLIN IMMUN, V77, P698, DOI 10.1016/0091-6749(86)90413-6	28	18	21	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1994	94	5					844	852		10.1016/0091-6749(94)90152-X	http://dx.doi.org/10.1016/0091-6749(94)90152-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PR240	7963153	Bronze			2022-12-18	WOS:A1994PR24000009
J	REIJULA, KE; KELLY, KJ; CHOI, H; BONGARD, RD; DAWSON, CA; FINK, JN; KURUP, VP				REIJULA, KE; KELLY, KJ; CHOI, H; BONGARD, RD; DAWSON, CA; FINK, JN; KURUP, VP			LATEX-INDUCED DERMAL AND PULMONARY HYPERSENSITIVITY IN RABBITS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NATURAL RUBBER LATEX; EOSINOPHILS; SKIN TESTS; LUNG LAVAGE; PULMONARY HISTOLOGY	CONTACT URTICARIA; SURGICAL GLOVES; ALLERGY; ASTHMA; ANAPHYLAXIS	Background: Natural rubber latex (NRL) causes immediate, IgE-mast cell-mediated reactions in sensitized individuals, especially among health care workers and children with spina bifida. The immunopathogenesis of the reaction is obscure. Methods: To study the immunologic mechanisms of NRL allergy, rabbits were sensitized with two nonammoniated and one ammoniated NRL antigens. Subcutaneous and intratracheal injections were used to immunize rabbits. Intradermal skin tests, IgG antibodies against NRL in serum and lung lavage fluid and pulmonary histologic features were evaluated. Results: One of nine sensitized rabbits died of anaphylaxis immediately after the third intratracheal injection with nonammoniated NRL. All sensitized rabbits but not the controls, showed an immediate wheal and flare reaction in intradermal skin testing with NRL antigens. A positive skin reaction was detected 6 and 48 hours after the intradermal injections in four of five sensitized rabbits. A significant increase in NRL-specific IgG antibodies was detected in serum and lung lavage fluid of immunized rabbits. Lung histologic evaluation of NRL-sensitized rabbits showed a granulomatous interstitial and bronchial inflammation with a predominance of eosinophils and histiocytes in bath intratracheally and subcutaneously sensitized rabbits. Vasculitis, hypertrophia, and contraction of pulmonary arteries could be detected in sensitized animals. Conclusion: The results of the first NRL rabbit model study indicate that eosinophils and IgE antibodies play a major role in the immunopathogenesis of NRL-induced allergy and anaphylaxis. A wide range of inflammatory responses detected in rabbits injected by subcutaneous route without intratracheal exposure suggests that NRL exposure may pose a risk for a subsequent systemic reaction.	MED COLL WISCONSIN,DEPT MED,DIV ALLERGY IMMUNOL,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT PATHOL,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT PHYSIOL,MILWAUKEE,WI 53226; VET ADM MED CTR,RES SERV,MILWAUKEE,WI 53295; VET ADM MED CTR,LAB SERV,MILWAUKEE,WI 53295	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)	REIJULA, KE (corresponding author), INST OCCUPAT HLTH,ARINATIE 3 A,SF-00370 HELSINKI,FINLAND.			Kelly, Kevin/0000-0002-2954-6117				CARRILLO T, 1986, CONTACT DERMATITIS, V15, P69, DOI 10.1111/j.1600-0536.1986.tb01279.x; FORSTROM L, 1980, CONTACT DERMATITIS, V6, P33, DOI 10.1111/j.1600-0536.1980.tb03887.x; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; KUJALA V, 1994, IN PRESS AM J IND ME; KURUP VP, 1994, INT ARCH ALLERGY IMM, V103, P370, DOI 10.1159/000236656; KURUP VP, 1992, ALLERGY PROC, V13, P329, DOI 10.2500/108854192778816915; KURUP VP, 1990, INT ARCH ALLER A IMM, V91, P145, DOI 10.1159/000235106; KURUP VP, 1986, ZENTRALBL BAKTERIO A, V216, P509; LAGIER F, 1990, LANCET, V336, P516, DOI 10.1016/0140-6736(90)92076-T; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LOHMAN IC, 1993, AM REV RESPIR DIS, V147, P1223, DOI 10.1164/ajrccm/147.5.1223; REIJULA K, 1985, PATHOL RES PRACT, V181, P418; REIJULA K, 1985, PATHOL RES PRACT, V181, P718; SEATON A, 1988, BRIT MED J, V296, P531, DOI 10.1136/bmj.296.6621.531-a; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V90, P279, DOI 10.1016/S0091-6749(05)80003-X; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x	19	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1994	94	5					891	902		10.1016/0091-6749(94)90157-0	http://dx.doi.org/10.1016/0091-6749(94)90157-0			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PR240	7963158				2022-12-18	WOS:A1994PR24000014
J	FOX, RW				FOX, RW			AIR CLEANERS - A REVIEW	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Symposium on Building-Related and Home-Related Complaints and Illnesses: Sick Building Syndrome	DEC 03-05, 1992	LAKE BUENA VISTA, FL				ENVIRONMENTAL-CONTROL; INDOOR AIR	Air cleaners are manufactured by many companies in the United States. Air cleaning devices vary widely in design, methods of operation, cost, and level of efficiency. No universally accepted performance standards are available to compare the capabilities of the available air cleaners. These units are classified as household appliances, not as medical devices. Clinical studies have failed to substantiate a significant impact of air cleaners on patients' symptoms. Air cleaners should be used when it is desirable to further reduce airborne contaminant concentrations that are not eliminated by other environmental control measures. Air cleaners should not be the primary means of improving indoor air quality.			FOX, RW (corresponding author), UNIV S FLORIDA,DIV ALLERGY & IMMUNOL,TAMPA,FL 33620, USA.							[Anonymous], 1991, BUILDING AIR QUALITY; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; FERNANDEZCALDAS E, 1992, MED CLIN N AM, V76, P935, DOI 10.1016/S0025-7125(16)30333-9; NELSON HS, 1988, J ALLERGY CLIN IMMUN, V82, P661, DOI 10.1016/0091-6749(88)90980-3; OFFERMANN FJ, 1985, ATMOS ENVIRON, V19, P1761, DOI 10.1016/0004-6981(85)90003-4; PLATTSMILLS TAE, 1989, IMMUNOL ALLERGY CLIN, V9, P269; REISMAN RE, 1990, J ALLERGY CLIN IMMUN, V85, P1050, DOI 10.1016/0091-6749(90)90050-E; SAMET J, 1990, AM REV RESPIR DIS, V142, P915, DOI 10.1164/ajrccm/142.4.915; 1990, RESIDENTIAL AIR CLEA; 1992, CONSUM REP, V57, P657; 1988, INDOOR AIR FACTS VEN	11	18	20	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2	2				413	416		10.1053/ai.1994.v94.a56025	http://dx.doi.org/10.1053/ai.1994.v94.a56025			4	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG770	8077600				2022-12-18	WOS:A1994PG77000022
J	LICHTENSTEIN, LM				LICHTENSTEIN, LM			A REAPPRAISAL OF STING CHALLENGES - TO WHOM SHOULD WE OFFER VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							SENSITIVITY; ALLERGY				LICHTENSTEIN, LM (corresponding author), JOHNS HOPKINS ASTHMA & ALLERGY CTR,DIV CLIN IMMUNOL,5501 HOPKINS BAYVIEW CIRCLE,BALTIMORE,MD 21224, USA.							GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; GOLDEN DBK, 1992, J ALLERGY CLIN IMMUN, V90, P386, DOI 10.1016/S0091-6749(05)80019-3; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Lichtenstein L. M., 1975, Hospital Practice, V10, P67; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; MUELLER HL, 1971, IMMUNOLOGIC DISEASES, P893; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305	9	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2					137	138		10.1016/0091-6749(94)90030-2	http://dx.doi.org/10.1016/0091-6749(94)90030-2			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC926	8064065				2022-12-18	WOS:A1994PC92600001
J	DEBLAY, F; PAULI, G; VELTEN, M; BESSOT, JC				DEBLAY, F; PAULI, G; VELTEN, M; BESSOT, JC			INFLUENCE OF MITE EXPOSURE ON SYMPTOMS OF MITE-SENSITIVE PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							DER-P-I; DUST MITE		HOP UNIV STRASOURG,HOP CIVIL,SERV PNEUMOL,F-67091 STRASBOURG,FRANCE; FAC MED STRASBOURG,EPIDEMIOL & SANTE PUBL LAB,STRASBOURG,FRANCE	CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								HOYET C, 1991, J ALLERGY CLIN IMMUN, V88, P678, DOI 10.1016/0091-6749(91)90162-H; KOPFERSCHMITTKUBLER MC, 1987, J ALLERGY CLIN IMMUN, V80, P730, DOI 10.1016/0091-6749(87)90295-8; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; VERVLOET D, 1991, ALLERGY, V46, P554, DOI 10.1111/j.1398-9995.1991.tb00620.x	5	18	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	1				136	138		10.1016/0091-6749(94)90242-9	http://dx.doi.org/10.1016/0091-6749(94)90242-9			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MT781	8308180	Bronze			2022-12-18	WOS:A1994MT78100016
J	DEMOLY, P; VACHIER, I; PENE, J; MICHEL, FB; GODARD, P; DAMO, M				DEMOLY, P; VACHIER, I; PENE, J; MICHEL, FB; GODARD, P; DAMO, M			IGE PRODUCES MONOCYTE SUPEROXIDE ANION RELEASE - CORRELATION WITH CD23 EXPRESSION - COMPARISON OF PATIENTS WITH ASTHMA, PATIENTS WITH RHINITIS, AND NORMAL SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC ASTHMA; ALLERGIC RHINITIS; SUPEROXIDE ANION; BLOOD MONOCYTES; IGE; CD23	LOW AFFINITY RECEPTOR; ALVEOLAR MACROPHAGES; CHEMI-LUMINESCENCE; BLOOD MONOCYTES; FC-RECEPTORS	Allergic inflammation involves many different cell types among which mononuclear cells, such as macrophages and monocytes, play an important role. These cells release numerous chemical mediators, including superoxide anion (O-2(.-)). We evaluated the capacity of atopic serum to stimulate peripheral blood monocyte O-2(.-) release. Thirteen untreated allergic patients (seven with asthma and six with rhinitis), and five nonallergic control subjects were studied. O-2(.-) was measured in a photon-counting camera with Lucigenin-enhanced (Sigma Chemical Co., St. Louis, Mo.) chemiluminescence. Results were expressed (mean +/- SEM) in relation to basal values (peak/basal chemiluminescence values). Spontaneous production of O-2(.-) was greater in allergic patients. Moreover; atopic serum stimulated O-2(.-) production of blood monocytes in all subjects, but this was greater in subjects with allergic asthma than in subjects with allergic rhinitis and normal subjects. Anti-IgE immunoadsorption of atopic serum completely abrogated this effect, which was restored by the IgE-rich eluted fraction. IgE-induced O-2(.-) release decreased as adherence duration increased and was correlated with surface CD23 expression. These results indicate that monocytes from allergic patients are in an activated state and that binding of IgE to their receptors generates O-2(.-) possibly by direct activation of blood monocyte reduced nicotinamide adenine dinucleotide phosphate oxidase.	HOP ARNAUD VILLENEUVE,MALAD RESP CLIN,F-34059 MONTPELLIER 1,FRANCE; INSERM,U58,F-34100 MONTPELLIER,FRANCE	Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			Demoly, Pascal/Y-9938-2019; Vachier, Isabelle/AAV-5731-2020	Demoly, Pascal/0000-0001-7827-7964; Vachier, Isabelle/0000-0003-2730-5165				AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; ALLEN RC, 1986, METHOD ENZYMOL, V133, P449; BERTON G, 1983, IMMUNOLOGY, V49, P693; BONNEFOY JY, 1987, J IMMUNOL, V138, P2970; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CHANEZ P, 1992, J ALLERGY CLIN IMMUN, V89, P284; CLUZEL M, 1987, J ALLERGY CLIN IMMUN, V80, P195, DOI 10.1016/0091-6749(87)90129-1; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DAMON M, 1989, J BIOLUM CHEMILUM, V4, P279, DOI 10.1002/bio.1170040140; DAMON M, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P345; GOSSET P, 1991, J ALLERGY CLIN IMMUN, V88, P561, DOI 10.1016/0091-6749(91)90149-I; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; MELEWICZ FM, 1981, J IMMUNOL, V126, P1592; METZGER H, 1988, FASEB J, V2, P3, DOI 10.1096/fasebj.2.1.3275562; PAWLOWSKI NA, 1983, J EXP MED, V158, P393, DOI 10.1084/jem.158.2.393; POLLA BS, 1992, J ALLERGY CLIN IMMUN, V89, P545, DOI 10.1016/0091-6749(92)90321-R; RANKIN JA, 1982, NATURE, V297, P329, DOI 10.1038/297329a0; THOMAS ED, 1976, SCIENCE, V192, P1016, DOI 10.1126/science.775638; TONNEL AB, 1983, LANCET, V1, P406; VACHIER I, 1992, AM REV RESPIR DIS, V146, P1161, DOI 10.1164/ajrccm/146.5_Pt_1.1161; 1987, AM REV RESPIR DIS, V136, P225; 1985, 340UV SIGM TECHN B; 1986, CLIN ALLERGY S1, V16, P19	27	18	20	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	1				108	116		10.1016/0091-6749(94)90239-9	http://dx.doi.org/10.1016/0091-6749(94)90239-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MT781	8308176				2022-12-18	WOS:A1994MT78100013
J	GLASS, M; SNADER, LA; ISRAEL, E				GLASS, M; SNADER, LA; ISRAEL, E			EFFECT OF THE INHALED LTD(4)-RECEPTOR ANTAGONIST, ICI 204,219, ON COLD-AIR-INDUCED BRONCHOCONSTRICTION IN PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									ZENECA PHARMACEUT GRP,WILMINGTON,DE; BETH ISRAEL HOSP,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center									0	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	2				295	295						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MV317					2022-12-18	WOS:A1994MV31700793
J	HASSNER, A; LAU, MS; GOETZL, EJ; ADELMAN, DC				HASSNER, A; LAU, MS; GOETZL, EJ; ADELMAN, DC			ISOTYPE-SPECIFIC REGULATION OF HUMAN LYMPHOCYTE-PRODUCTION OF IMMUNOGLOBULINS BY SUSTAINED EXPOSURE TO VASOACTIVE-INTESTINAL-PEPTIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						VASOACTIVE INTESTINAL PEPTIDE; IMMUNOGLOBULIN ISOTYPE REGULATION; NEUROPEPTIDES	HIGH-AFFINITY RECEPTORS; T-CELLS; SUBSTANCE-P; MONONUCLEAR-CELLS; INVITRO; NEUROPEPTIDES; POLYPEPTIDE; BINDING; MITOGEN; INVIVO	Exposure of lymphocytes to nanomolar to micromolar concentrations of vasoactive intestinal peptide (VIP) for 1 to 3 days only modestly suppressed or enhanced the production of IgA and IgM, bw not IgG. The effects of twice daily additions of 10(-12) to 10(-7) mol/L VIP for up to 18 days on pokeweed mitogen- stimulated peripheral blood mononuclear cells (PBMCs) from normal human subjects was examined by quantifying the production of IgG, IgM, and IgA. The maximum suppression of IgG by 10(-9) mol/L VIP was 79% +/- 33% (mean +/- SD) (range, 41% to 970%; p < 0.015) on day 9 and 84% +/- 1% (range, 74% to 96%; p < 0.0001) on day 14 and was significant at 6 x 10(-10) to 4 x 10(-9) mol/L VIP. Suppression of IgM production by 10(-9) mol/L VIP was significant and was observed first on day 5 and persisted through day 14. VIP did not alter IgA production or affect the proliferation or viability of PBMCs. The production of IgE by interleukin-4 stimulated PBMCs was enhanced consistently in two subjects but not in two other subjects. The duration of exposure to nanomolar concentrations VIP is thus a critical determinant of its immunoregulatory effect, as manifested by late suppression of production of IgG and IgM and concurrent enhancement of production of IgE in some subjects.	UNIV CALIF SAN FRANCISCO,MED CTR,DEPT MED,DIV ALLERGY & IMMUNOL,533 PARNASSUS AVE 4426,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,MED CTR,DEPT MICROBIOL,DIV ALLERGY & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIAID NIH HHS [AI 29912] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029912, R37AI029912] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CALVO CF, 1992, J IMMUNOL, V148, P3498; CALVO JR, 1986, PEPTIDES, V7, P177, DOI 10.1016/0196-9781(86)90209-3; CHENG P P J, 1991, Journal of Allergy and Clinical Immunology, V87, P260, DOI 10.1016/0091-6749(91)91764-K; CLAASSEN JL, 1990, J IMMUNOL, V144, P2123; DANEK A, 1983, J IMMUNOL, V131, P1173; DREW PA, 1985, AUST J EXP BIOL MED, V63, P313, DOI 10.1038/icb.1985.35; FINCH RJ, 1989, J IMMUNOL, V142, P1977; GOETZL EJ, 1988, J BIOL CHEM, V263, P9083; GOETZL EJ, 1989, IMMUNOLOGY, V66, P554; KRCO CJ, 1986, CLIN IMMUNOL IMMUNOP, V39, P308, DOI 10.1016/0090-1229(86)90094-2; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; LYCKE N, 1992, FASEB J, V6, pA1708; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; MATHEW RC, 1992, J IMMUNOL, V148, P3572; ODORISIO MS, 1989, J IMMUNOL, V142, P3533; OTTAWAY CA, 1984, J IMMUNOL, V132, P417; OTTAWAY CA, 1987, IMMUNOLOGY, V62, P291; OTTAWAY CA, 1984, J EXP MED, V160, P1054, DOI 10.1084/jem.160.4.1054; OTTAWAY CA, 1988, ANN NY ACAD SCI, V527, P486; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROPER RL, 1992, J IMMUNOL, V149, P2984; SODER O, 1987, INT ARCH ALLER A IMM, V84, P205, DOI 10.1159/000234424; STANISZ AM, 1986, J IMMUNOL, V136, P152; STANISZ AM, 1988, ANN NY ACAD SCI, V527, P478; WAGNER F, 1987, REGUL PEPTIDES, V19, P355, DOI 10.1016/0167-0115(87)90177-7; WOOD CL, 1985, J BIOL CHEM, V260, P1243	27	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1993	92	6					891	901		10.1016/0091-6749(93)90067-P	http://dx.doi.org/10.1016/0091-6749(93)90067-P			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML893	8258623				2022-12-18	WOS:A1993ML89300015
J	OWNBY, DR				OWNBY, DR			IS RUBBER ELONGATION-FACTOR THE MAJOR ALLERGEN OF LATEX	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							SURGICAL GLOVES; ANAPHYLAXIS				OWNBY, DR (corresponding author), HENRY FORD HOSP,DEPT INTERNAL MED,DIV ALLERGY & CLIN IMMUNOL,2799 W GRAND BLVD,DETROIT,MI 48202, USA.							ATTANYAKA DPSTG, 1991, PLANT MOL BIOL, V16, P1079, DOI 10.1007/BF00016080; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; DENNIS MS, 1989, J BIOL CHEM, V264, P18618; GERBER AC, 1989, ANESTHESIOLOGY, V71, P800, DOI 10.1097/00000542-198911000-00031; Hamann CP, 1993, AM J CONTACT DERMATI, V4, P4, DOI DOI 10.1097/01634989-199303000-00003; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; KURUP VP, 1993, J ALLERGY CLIN IMMUN, V92, P638, DOI 10.1016/0091-6749(93)90005-Z; LEYNADIER F, 1989, ANAESTHESIA, V44, P547, DOI 10.1111/j.1365-2044.1989.tb11438.x; LIGHT DR, 1989, J BIOL CHEM, V264, P18608; MAKINENKILJUNEN S, 1992, J ALLERGY CLIN IMMUN, V90, P230, DOI 10.1016/0091-6749(92)90076-E; MARSH DG, 1987, J ALLERGY CLIN IMMUN, V80, P639, DOI 10.1016/0091-6749(87)90282-X; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; SLATER J, 1989, NEW ENGL J MED, V17, P1126; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844	14	18	18	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					633	635		10.1016/0091-6749(93)90003-X	http://dx.doi.org/10.1016/0091-6749(93)90003-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	8227852	Bronze			2022-12-18	WOS:A1993MG98200001
J	YANG, JP; RENZI, PM				YANG, JP; RENZI, PM			INTERLEUKIN-2 AND LYMPHOCYTE-INDUCED EOSINOPHIL PROLIFERATION AND SURVIVAL IN ASTHMATIC-PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-2; LYMPHOCYTE CONDITIONED MEDIUM; EOSINOPHIL; ASTHMA	COLONY-STIMULATING FACTOR; HUMAN PERIPHERAL-BLOOD; FACTOR GM-CSF; BRONCHOALVEOLAR LAVAGE; MILD ASTHMA; CELLS; LUNG; HYPERRESPONSIVENESS; PROGENITORS; VIABILITY	Background: Eosinophils are increased in the airways and blood of asthmatic patients. However, the mechanism of regulation of eosinophilia is incompletely understood. Methods: To study the potential effect of asthmatic lymphocytes on eosinophils, lymphocytes from the blood of asthmatic patients in exacerbation, or from healthy subjects, were isolated and cultured in medium alone (LC-CM) or with interleukin-2 (IL-2-CM) (125 U/ml), and the effect of supernatant obtained from these cultures on eosinophil proliferation from progenitors and survival was studied. Results: IL-2-CM from asthmatic patients significantly increased eosinophil colony formation from asthmatic blood but had no effect on colony formation from the blood of healthy subjects. IL-2-CM from asthmatic patients also significantly prolonged the survival of eosinophils. IL-2 alone and IL-2-CM from healthy subjects had no effect on eosinophil proliferation and survival. Asthmatic lymphocytes had more IL-2 receptors (CD25) than normal lymphocytes, and this difference persisted even after culture in IL-2. However, upregulation of the CD25 receptor on normal lymphocytes by incubation with concanavalin A led to the production of IL-2-CM, which did not increase eosinophil proliferation from progenitors. Conclusions: Lymphocytes from asthmatic patients but not from normal blood can significantly increase eosinophil proliferation and survival. The effects on eosinophil proliferation do not seem to be directly related to the presence of increased CD25 expression on lymphocytes.	UNIV MONTREAL, ST LUC HOSP, PULM UNIT, 1058 ST DENIS ST, MONTREAL H2X 3J4, PQ, CANADA; UNIV MONTREAL, ST LUC HOSP, ANDRE VIALLET RES INST, MONTREAL H3C 3J7, QUEBEC, CANADA; MCGILL UNIV, CTR EXCELLENCE CANADA, RESP HLTH NETWORK, MONTREAL H3A 2T5, QUEBEC, CANADA; MCGILL UNIV, MEAKINS CHRISTIE LABS, MONTREAL H3A 2T5, QUEBEC, CANADA	Universite de Montreal; Universite de Montreal; McGill University; McGill University								BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BURKE LA, 1991, J ALLERGY CLIN IMMUN, V88, P226, DOI 10.1016/0091-6749(91)90333-J; BUSSE WW, 1989, AM REV RESPIR DIS, V10, P72; CANTRELL DA, 1983, J EXP MED, V158, P1895, DOI 10.1084/jem.158.6.1895; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DENBURG JA, 1985, BLOOD, V66, P312; DENBURG JA, 1983, BLOOD, V61, P775; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; ENOKIHARA H, 1989, BLOOD, V73, P1809; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FUKUDA T, 1991, Journal of Allergy and Clinical Immunology, V87, P302, DOI 10.1016/0091-6749(91)91932-J; FUKUDA T, 1985, AM REV RESPIR DIS, V42, P321; GIBSON P G, 1989, American Review of Respiratory Disease, V139, pA482; GIBSON PG, 1991, AM REV RESPIR DIS, V143, P331, DOI 10.1164/ajrccm/143.2.331; GRIFFIN E, 1991, J ALLERGY CLIN IMMUN, V87, P548, DOI 10.1016/0091-6749(91)90014-F; HOLGATE ST, 1987, CLIN SCI, V73, P561, DOI 10.1042/cs0730561; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; JACOBSON MR, 1991, J ALLERGY CLIN IMMUN, V87, P213; KAMEI T, 1990, American Review of Respiratory Disease, V141, pA821; KERN P, 1986, BLUT, V52, P249, DOI 10.1007/BF00321085; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; LOTZE MT, 1985, CELLULAR MOL BIOL LY, P711; MIALE JB, 1967, LABORATORY MED HEMAT, P1126; NAKAMURA Y, 1990, AM J RESP CELL MOL, V3, P291, DOI 10.1165/ajrcmb/3.4.291; OTSUKA H, 1986, AM REV RESPIR DIS, V133, P757; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; RENZI PM, 1991, AM REV RESPIR DIS, V143, P375, DOI 10.1164/ajrccm/143.2.375; RENZI PM, 1992, AM REV RESPIR DIS, V146, P163, DOI 10.1164/ajrccm/146.1.163; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SCHATZ M, 1982, ARCH INTERN MED, V142, P1515, DOI 10.1001/archinte.142.8.1515; SPRY CJF, 1971, CELL TISSUE KINET, V4, P365, DOI 10.1111/j.1365-2184.1971.tb01546.x; TSAI J J, 1991, Journal of Allergy and Clinical Immunology, V87, P348, DOI 10.1016/0091-6749(91)92117-J; VANCHERI C, 1989, AM J RESP CELL MOL, V1, P289, DOI 10.1165/ajrcmb/1.4.289; WALKER C, 1991, J IMMUNOL, V146, P1829; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WARREN DJ, 1988, J IMMUNOL, V140, P94	37	18	19	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1993	91	3					792	801		10.1016/0091-6749(93)90199-P	http://dx.doi.org/10.1016/0091-6749(93)90199-P			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KU203	8454801				2022-12-18	WOS:A1993KU20300012
J	APTER, AJ; MOTT, AE; CAIN, WS; SPIRO, JD; BARWICK, MC				APTER, AJ; MOTT, AE; CAIN, WS; SPIRO, JD; BARWICK, MC			OLFACTORY LOSS AND ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							NASAL POLYPOSIS; DOUBLE-BLIND; SMELL; TASTE; DYSFUNCTION; EPITHELIUM; RECEPTION; POSITION; EFFICACY; EVENTS		UNIV CONNECTICUT, CTR HLTH, CONNECTICUT CHEMOSENSORY CLIN RES CTR, FARMINGTON, CT 06032 USA	University of Connecticut	APTER, AJ (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT MED, LG-006, FARMINGTON, CT 06030 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P50DC000168, P01DC000168] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC00168] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Amoore J. E., 1986, TOXICOLOGY NASAL PAS; ANHOLT RRH, 1987, TRENDS BIOCHEM SCI, V12, P58, DOI 10.1016/0968-0004(87)90031-4; BARWICK MC, 1989, EAR NOSE THROAT J, V68, P356; CAIN WS, 1988, LARYNGOSCOPE, V98, P83; CANCIANI M, 1988, ACTA PAEDIATR SCAND, V77, P612, DOI 10.1111/j.1651-2227.1988.tb10715.x; CHALTON R, 1985, BRIT MED J, V291, P788, DOI 10.1136/bmj.291.6498.788; Costanzo RM., 1986, CLIN MEASUREMENTS TA, P565; Doty R, 1987, PRINCIPLES PRACTICE, P761; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; DOTY RL, 1986, CLIN NEUROBIOLOGY, V1, P466; DOUEK E, 1975, P ROY SOC MED, V68, P467, DOI 10.1177/003591577506800801; FEIN BT, 1966, ANN ALLERGY, V24, P278; Frank M E, 1989, Ear Nose Throat J, V68, P291; FRYE RE, 1990, JAMA-J AM MED ASSOC, V263, P1233, DOI 10.1001/jama.263.9.1233; GETCHELL TV, 1986, PHYSIOL REV, V66, P772, DOI 10.1152/physrev.1986.66.3.772; GETCHELL TV, 1984, PROG NEUROBIOL, V23, P317, DOI 10.1016/0301-0082(84)90008-X; HENKIN RI, 1976, AM J MED SCI, V272, P285, DOI 10.1097/00000441-197611000-00006; HENKIN RI, 1975, ANN OTO RHINOL LARYN, V84, P672, DOI 10.1177/000348947508400519; Jafek BW., 1990, AM J RHINOL, V4, P91, DOI [10.2500/105065890782009497, DOI 10.2500/105065890782009497]; LAFFORT P, 1974, ANN NY ACAD SCI, V237, P193, DOI 10.1111/j.1749-6632.1974.tb49854.x; LANCET D, 1987, TRENDS BIOCHEM SCI, V12, P63, DOI 10.1016/0968-0004(87)90032-6; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; LANCET D, 1987, ANNU REV NEUROSCI, V12, P63; MABRY RL, 1980, SOUTHERN MED J, V73, P1176, DOI 10.1097/00007611-198009000-00004; MABRY RL, 1986, SO MED J, V79, P465; MORRISON EE, 1990, J COMP NEUROL, V297, P1, DOI 10.1002/cne.902970102; MOTT AE, 1991, MED CLIN N AM, V75, P1321, DOI 10.1016/S0025-7125(16)30391-1; MOTT AE, 1991, SMELL TASTE HLTH DIS, P553; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NAKASHIMA T, 1984, ARCH OTOLARYNGOL, V110, P641; NAKASHIMA T, 1985, LARYNGOSCOPE, V95, P391; SCHATZ M, 1988, NEW ENGL REG ALLERGY, V9, P545, DOI 10.2500/108854188778965627; SCHATZ M, 1988, ALLERGY PRINCIPLES P, P1135; SCHIFFMAN SS, 1983, NEW ENGL J MED, V308, P1275; SCOTT A, 1988, CHEM SENSES, V13, P735; SCOTT A E, 1989, Chemical Senses, V14, P745; SLAVIN RG, 1988, ALLERGY PRINCIPLES P, P1291; WILSON R, 1987, THORAX, V42, P631, DOI 10.1136/thx.42.8.631; [No title captured]	39	18	18	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	1				670	680		10.1016/0091-6749(92)90141-N	http://dx.doi.org/10.1016/0091-6749(92)90141-N			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT995	1401646				2022-12-18	WOS:A1992JT99500014
J	LINDNER, PS; PARDANANI, B; ANGADI, C; FRIERI, M				LINDNER, PS; PARDANANI, B; ANGADI, C; FRIERI, M			ACUTE NONLYMPHOCYTIC LEUKEMIA IN SYSTEMIC MASTOCYTOSIS WITH BICLONAL GAMMOPATHY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									NASSAU CTY MED CTR,DIV ANAT & CLIN IMMUNOPATHOL,2201 HEMPSTEAD TURNPIKE,E MEADOW,NY 11554; NASSAU CTY MED CTR,DEPT MED,E MEADOW,NY 11554; NASSAU CTY MED CTR,DEPT PATHOL & LABS,E MEADOW,NY 11554; SUNY STONY BROOK,MED & PATHOL,STONY BROOK,NY 11794; NASSAU CTY MED CTR,ALLERGY IMMUNOL FELLOWSHIP PROGRAM,E MEADOW,NY 11554	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								FRIERI M, 1982, ANN INTERN MED, V97, P220, DOI 10.7326/0003-4819-97-2-220; FRIERI M, 1985, AM J MED, V78, P9, DOI 10.1016/0002-9343(85)90454-1; FRIERI M, 1991, J ALLERGY CLIN IMMUN, V86, P126; KYLE RA, 1981, AM J MED, V71, P999, DOI 10.1016/0002-9343(81)90326-0; MEGGS WJ, 1985, ANN INTERN MED, V103, P894, DOI 10.7326/0003-4819-103-6-894; TRAVIS WD, 1988, CANCER, V62, P965, DOI 10.1002/1097-0142(19880901)62:5<965::AID-CNCR2820620520>3.0.CO;2-M	6	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	1				410	412		10.1016/S0091-6749(05)80024-7	http://dx.doi.org/10.1016/S0091-6749(05)80024-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP520	1527326				2022-12-18	WOS:A1992JP52000022
J	VANOOSTERHOUT, AJM; STAM, WB; VANDERSCHUEREN, RGJRA; NIJKAMP, FP				VANOOSTERHOUT, AJM; STAM, WB; VANDERSCHUEREN, RGJRA; NIJKAMP, FP			EFFECTS OF CYTOKINES ON BETA-ADRENOCEPTOR FUNCTION OF HUMAN PERIPHERAL-BLOOD MONONUCLEAR-CELLS AND GUINEA-PIG TRACHEA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BETA-ADRENOCEPTOR; CAMP; CYTOKINES; MONONUCLEAR CELLS; TRACHEA	COLONY-STIMULATING FACTOR; RECOMBINANT INTERFERON-GAMMA; ADRENERGIC-RECEPTORS; BRONCHOALVEOLAR LAVAGE; PULMONARY MACROPHAGES; NEUTRAL ENDOPEPTIDASE; ALVEOLAR MACROPHAGES; RESPIRATORY AIRWAY; BRONCHIAL BIOPSIES; ASTHMATIC-PATIENTS	In asthma, a beta-adrenoceptor dysfunction may be the consequence of an active disease state rather than a fundamental abnormality. In the present study the possible involvement of T lymphocytes in beta-adrenergic impairment was investigated by studying the effects of lymphocyte-derived mediators on beta-adrenoceptor function of human peripheral blood mononuclear cells (PBMCs) and guinea pig trachea. Supernatants of phytohemagglutinin- or concanavalin A-activated PBMCs from either persons with asthma or healthy persons inhibited isoprenaline stimulated cyclic adenosine 3',5'-monophosphate (cAMP) production of PBMCs after 20 hours of preincubation. These supernatants also inhibited beta-adrenoceptor function of PBMCs from patients with asthma to the same extent. The isoprenaline stimulated cAMP production of PBMCs was not altered after a 2-hour preincubation period with human interleukin-1 (IL-1), IL-2, IL-3, IL-4, granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon (IFN-gamma). In contrast, after 20 hours of preincubation, stimulated cAMP praduction of PBMCs was significantly diminished, with 63% by IL-1 (40 U/ml, p < 0.01), with 36% by IL-2 (100 U/ml, p < 0.05), with 37% by IFN-gamma (1000 U/ml, p < 0.05), and with 21% by GM-CSF (100 U/ml, p < 0.05). Preincubation of guinea pig tracheal segments with IL-1, IL-2, IL-4, or GM-CSF during 1 or 3 days did not affect the EC50 values or the maximal relaxation of isoprenaline dose response curves.	ST ANTONIUS HOSP,NIEUWEGEIN,NETHERLANDS	St. Antonius Hospital Utrecht	VANOOSTERHOUT, AJM (corresponding author), UNIV UTRECHT,FAC PHARM,DEPT PHARMACOL,POB 80082,3508 TB UTRECHT,NETHERLANDS.							ADAMS DO, 1989, IMMUNOL TODAY, V10, P33, DOI 10.1016/0167-5699(89)90298-3; AGRAWAL DK, 1987, BIOCHEM BIOPH RES CO, V143, P1, DOI 10.1016/0006-291X(87)90620-6; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BAI TR, 1990, AM REV RESPIR DIS, V141, P552, DOI 10.1164/ajrccm/141.3.552; BECKNER SK, 1986, J BIOL CHEM, V261, P3043; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROOKS SM, 1979, J ALLERGY CLIN IMMUN, V63, P401, DOI 10.1016/0091-6749(79)90213-6; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; CERRINA J, 1986, AM REV RESPIR DIS, V134, P57; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; DUSSER DJ, 1989, J APPL PHYSIOL, V67, P1504, DOI 10.1152/jappl.1989.67.4.1504; ENGELS F, 1987, J PHARMACOL EXP THER, V241, P994; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; FOLKERTS G, 1989, BRIT J PHARMACOL, V96, P388, DOI 10.1111/j.1476-5381.1989.tb11829.x; FOLKERTS G, 1990, AGENTS ACTIONS, V30, P261, DOI 10.1007/BF01969055; GERBLICH AA, 1984, NEW ENGL J MED, V310, P1349, DOI 10.1056/NEJM198405243102103; GERBLICH AA, 1991, AM REV RESPIR DIS, V143, P533, DOI 10.1164/ajrccm/143.3.533; GOLDIE RG, 1990, AM REV RESPIR DIS, V141, pS151, DOI 10.1164/ajrccm/141.3_Pt_2.S151; GONZALEZ MC, 1987, AM REV RESPIR DIS, V136, P600, DOI 10.1164/ajrccm/136.3.600; GULICK T, 1989, P NATL ACAD SCI USA, V86, P6753, DOI 10.1073/pnas.86.17.6753; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HEROLD KC, 1986, EUR J IMMUNOL, V16, P1533, DOI 10.1002/eji.1830161211; IKUTA N, 1992, AM REV RESPIR DIS, V145, P561, DOI 10.1164/ajrccm/145.3.561; INSEL PA, 1990, FASEB J, V4, P2732, DOI 10.1096/fasebj.4.10.2197153; JENSEN WA, 1988, CELL IMMUNOL, V117, P369, DOI 10.1016/0008-8749(88)90126-8; KAUSHANSKY K, 1989, CELL IMMUNOL, V122, P62, DOI 10.1016/0008-8749(89)90148-2; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; MEURS H, 1982, J ALLERGY CLIN IMMUN, V70, P272, DOI 10.1016/0091-6749(82)90063-X; MORRISSEY PJ, 1989, INT ARCH ALLER A IMM, V88, P40, DOI 10.1159/000234745; NAGASAWA H, 1987, AM REV RESPIR DIS, V136, P916, DOI 10.1164/ajrccm/136.4.916; NAKANE T, 1990, J IMMUNOL, V145, P260; NIJKAMP FP, 1992, PHYSIOL REV, V72, P323, DOI 10.1152/physrev.1992.72.2.323; NIJKAMP FP, 1990, AM REV RESPIR DIS, V141, pS145, DOI 10.1164/ajrccm/141.3_Pt_2.S145; NOVOGRODSKY A, 1982, BIOCHEM BIOPH RES CO, V104, P389, DOI 10.1016/0006-291X(82)90649-0; PALIARD X, 1988, J IMMUNOL, V141, P849; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; REED SG, 1987, J EXP MED, V166, P1734, DOI 10.1084/jem.166.6.1734; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SANO Y, 1983, J ALLERGY CLIN IMMUN, V72, P495, DOI 10.1016/0091-6749(83)90587-0; SEKIZAWA K, 1987, J PHARMACOL EXP THER, V243, P1211; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STERN L, 1988, J BIOL CHEM, V263, P15876; SVEDMYR NLV, 1976, CHEST, V69, P479, DOI 10.1378/chest.69.4.479; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; THOMASSEN MJ, 1989, CANCER RES, V49, P4086; VANOOSTERHOUT AJM, 1988, EUR J PHARMACOL, V149, P191, DOI 10.1016/0014-2999(88)90063-5; VANOOSTERHOUT AJM, 1988, EUR J PHARMACOL, V147, P421, DOI 10.1016/0014-2999(88)90177-X; WILLSKARP M, 1990, EUR J PHARMACOL, V183, P1185, DOI 10.1016/0014-2999(90)94275-3; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0	49	18	18	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	1				340	348		10.1016/S0091-6749(05)80013-2	http://dx.doi.org/10.1016/S0091-6749(05)80013-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP520	1326572	Bronze			2022-12-18	WOS:A1992JP52000011
J	OHRUI, T; SEKIZAWA, K; AIKAWA, T; YAMAUCHI, K; SASAKI, H; TAKISHIMA, T				OHRUI, T; SEKIZAWA, K; AIKAWA, T; YAMAUCHI, K; SASAKI, H; TAKISHIMA, T			VASCULAR-PERMEABILITY AND AIRWAY NARROWING DURING LATE ASTHMATIC RESPONSE IN DOGS TREATED WITH METOPIRONE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; BRONCHIAL PROVOCATION TESTS; AIRWAY OBSTRUCTION; BRONCHI; EDEMA; ADRENALECTOMY; STEROID	BRONCHOALVEOLAR LAVAGE; ANTIGEN CHALLENGE; MAST-CELLS; BRONCHIAL MICROCIRCULATION; GUINEA-PIGS; ALLERGEN; INFLAMMATION; LEAKAGE; EOSINOPHILS; TISSUES	Recently, we have developed an animal model of late asthmatic response (LAR) by treating naturally sensitized dogs to Ascaris suum antigen with the cortisol-synthesizing inhibitor, Metopirone. By using this animal model, we examined the contribution of edema in the airway wall to the development of LAR. To study whether airway microvascular leakage is increased in association with LAR, we performed antigen challenge in dogs treated with Metopirone. We measured the amount of extravasated Evans blue (EB) dye from the esophagus, trachea, and large and small bronchi 8 hours after the antigen challenge in dogs demonstrating immediate asthmatic response alone (IAR) and in dogs demonstrating both IAR and LAR. Airway responses to A. suum antigen were assessed by changes in respiratory resistance measured with the force oscillation technique at 3 Hz. EB dye extravasation did not increase significantly from that of control in any tissues in IAR (p > 0.10), but in LAR, it increased significantly from that of control (p < 0.01) and IAR (p < 0.05) in large and small bronchi. Histologic assessment of vascular permeability revealed that Monastral blue-labeled leaking vessels were only in sections from LAR, and leaking vessels were limited to small vessels (10 to 25-mu-m) in the trachea, large (diameter, > 5 mm) and small bronchi (2 to 4 mm in diameter), and bronchiole. The permeability index defined as the ratio of area of small vessels labeled with Monastral blue to that of the total small vessels in the walls was highest in the small bronchi. LAR significantly increased submucosal thickness of the small bronchi (p < 0.05) compared with that in IAR. Both EB dye extravasation and permeability index in large and small bronchi also significantly increased during IAR within 3 minutes after the antigen challenge (p < 0.05), but IAR did not alter the submucosal thickness of the small bronchi. These results imply that the increase in vascular permeability and submucosal thickness, especially in small bronchi, may be an important factor in the pathogenesis of LAR.			OHRUI, T (corresponding author), TOHOKU UNIV,SCH MED,DEPT INTERNAL MED 1,SENDAI,MIYAGI 980,JAPAN.		Yamauchi, Kohei/N-2749-2016					ABRAHAM WM, 1983, AM REV RESPIR DIS, V128, P839; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BEHRENS BL, 1987, LAB INVEST, V56, P101; BOSCHETTO P, 1990, AM REV RESPIR DIS, V141, P183; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1984, J ALLERGY CLIN IMMUN, V74, P41, DOI 10.1016/0091-6749(84)90085-X; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; EVANS TW, 1988, AM REV RESPIR DIS, V138, P395, DOI 10.1164/ajrccm/138.2.395; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; FICK RB, 1987, J APPL PHYSIOL, V63, P1147, DOI 10.1152/jappl.1987.63.3.1147; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; HOUSTON JC, 1953, THORAX, V8, P207, DOI 10.1136/thx.8.3.207; HYATT RE, 1970, J APPL PHYSIOL, V28, P675, DOI 10.1152/jappl.1970.28.5.675; IIJIMA H, 1987, AM REV RESPIR DIS, V136, P922, DOI 10.1164/ajrccm/136.4.922; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; JORIS I, 1982, STAIN TECHNOL, V57, P177, DOI 10.3109/10520298209066611; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PERSSON CGA, 1986, ACTA PHYSIOL SCAND, V127, P95, DOI 10.1111/j.1748-1716.1986.tb07880.x; PERSSON CGA, 1991, ASTHMA ITS PATHOLOGY, P209; PIETRA GG, 1978, FED PROC, V37, P2466; SARIA A, 1983, J NEUROSCI METH, V8, P41, DOI 10.1016/0165-0270(83)90050-X; SARIA A, 1983, N-S ARCH PHARMACOL, V324, P212, DOI 10.1007/BF00503897; SASAKI H, 1987, AM REV RESPIR DIS, V136, P1459, DOI 10.1164/ajrccm/136.6.1459; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; UDAKA K, 1970, P SOC EXP BIOL MED, V133, P1384; WANNER A, 1989, J APPL PHYSIOL, V67, P917, DOI 10.1152/jappl.1989.67.3.917; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WOODWARD DF, 1983, EUR J PHARMACOL, V93, P9, DOI 10.1016/0014-2999(83)90025-0	35	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1992	89	5					933	943		10.1016/0091-6749(92)90215-N	http://dx.doi.org/10.1016/0091-6749(92)90215-N			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HU542	1583251				2022-12-18	WOS:A1992HU54200003
J	YANG, M; OLSEN, E; DOLOVICH, J; SEHON, AH; MOHAPATRA, SS				YANG, M; OLSEN, E; DOLOVICH, J; SEHON, AH; MOHAPATRA, SS			IMMUNOLOGICAL CHARACTERIZATION OF A RECOMBINANT KENTUCKY BLUEGRASS (POA-PRATENSIS) ALLERGENIC PEPTIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DUST MITE ALLERGEN; ESCHERICHIA-COLI; POLLEN; CLONING; EXPRESSION; DER-P-1; PROTEIN; GENE; IGE	A recombinant peptide of Kentucky bluegrass (KBG) pollen was synthesized as a fusion protein (FP) in Escherichia coli by recombinant DNA procedures and was compared with its natural counterparts with respect to its allergenic properties. The FP was demonstrated to bind to the IgE antibodies (Abs) of greater-than-or-equal-to 95% of 55 individual sera examined. A positive correlation (r = 0.90) was observed between the levels of IgE Abs corresponding to the FP and the grass-pollen extract(s). With sera of five allergic patients, the IgE binding of three different protein preparations were compared, namely, KBG pollen proteins, 27 to 35 kd gel-purified pollen proteins, and the FP. Results indicated that about 50% of the total IgE binding of KBG pollen proteins was due to the IgE Abs specific to FP. Comparison of the above protein preparations with respect to their abilities to specifically stimulate murine popliteal lymph node cells in vitro indicated that the total pollen proteins stimulated the highest proliferation of lymph node cells. Interestingly, the FP supported higher proliferation of lymph node cells than the gel-purified proteins. Collectively, these results suggest that the recombinant peptide constitutes a major allergenic constituent of grass pollens and may be of diagnostic and therapeutic value.	UNIV MANITOBA,DEPT IMMUNOL,WINNIPEG R3E 0W3,MANITOBA,CANADA; UNIV MANITOBA,MRC,ALLERGY RES GRP,WINNIPEG R3E 0W3,MANITOBA,CANADA; MCMASTER UNIV,DEPT PEDIAT,HAMILTON L8S 4L8,ONTARIO,CANADA	University of Manitoba; University of Manitoba; McMaster University			Mohapatra, Shyam/C-2500-2012					ATASSI MZ, 1990, EPITOPES ATOPIC ALLE, P33; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; CRETICOS BS, 1987, ALLERGY INT TXB, P617; EKRAMODDOULLAH AKM, 1986, INT ARCH ALLER A IMM, V79, P397, DOI 10.1159/000234009; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; FORD SA, 1986, INT ARCH ALLER A IMM, V81, P193, DOI 10.1159/000234134; GUO LH, 1984, GENE, V29, P251, DOI 10.1016/0378-1119(84)90186-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marston F. A. O., 1987, DNA CLONING, P59; MOHAPATRA SS, 1990, INT ARCH ALLER A IMM, V91, P362, DOI 10.1159/000235142; MOHAPATRA SS, IN PRESS AEROBIOLOGI; MOHAPATRA SS, 1990, EPITOPES ATOPIC ALLE, P61; NORMAN PS, 1988, J ALLERGY CLIN IMMUN, V81, P992, DOI 10.1016/0091-6749(88)90167-4; SEHON AH, 1982, PROG ALLERGY, V32, P161; SILVANOVICH A, 1991, J BIOL CHEM, V266, P1204; THOMAS WR, 1988, INT ARCH ALLER A IMM, V85, P127, DOI 10.1159/000234488; TOVEY ER, 1989, J EXP MED, V170, P1457, DOI 10.1084/jem.170.4.1457; WALSH DJ, 1989, INT ARCH ALLER A IMM, V90, P78, DOI 10.1159/000235004	19	18	20	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1991	87	6					1096	1104		10.1016/0091-6749(91)92155-T	http://dx.doi.org/10.1016/0091-6749(91)92155-T			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR066	2045614	Bronze			2022-12-18	WOS:A1991FR06600009
J	SATO, T; BEWTRA, AK; HOPP, RJ; NAIR, N; TOWNLEY, RG				SATO, T; BEWTRA, AK; HOPP, RJ; NAIR, N; TOWNLEY, RG			ALPHA-ADRENERGIC-RECEPTOR AND BETA-ADRENERGIC-RECEPTOR SYSTEMS IN BRONCHIAL-ASTHMA AND IN SUBJECTS WITHOUT ASTHMA - REDUCED MONONUCLEAR CELL BETA-RECEPTORS IN BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CYCLIC ADENOSINE-MONOPHOSPHATE; PLATELET-ACTIVATING FACTOR; ADENYLATE-CYCLASE; POSSIBLE MECHANISM; ATOPIC DISEASE; DESENSITIZATION; BINDING; LYMPHOCYTES; ADRENOCEPTORS; METABOLISM	We assessed the adrenergic-receptor system in individuals with bronchial hyperreactivity. beta-Adrenergic receptors on mononuclear cell membranes, alpha-adrenergic receptors on platelet membranes, and the cAMP response in these cell types to different stimuli, including platelet-activating factor (PAF), were determined. Studies were assessed in 10 subjects with mild asthma, six methacholine-sensitive subjects without asthma, and 10 normal subjects. The density and affinity of beta-receptors and alpha-receptors were determined by Scatchard analysis. Our findings were that (1) subjects with asthma had a significantly lower density of beta-receptors compared to normal subjects, (2) subjects with asthma had a significantly lower cAMP response to isoproterenol stimulation compared to the two other groups, (3) in subjects without asthma, PAF decreased the basal cAMP level and significantly inhibited the response to isoproterenol stimulation, (4) there was no difference in density and affinity of platelet alpha-receptors or in platelet cAMP responses to stimulation by alpha-agonists among these three groups, and (5) neither cAMP response or beta-receptor density on mononuclear cells were significantly correlated with pulmonary-function tests (FEV1/FVC times 100), sensitivity to methacholine, or cold-air inhalation. These results suggest that patients with asthma may have a lower isoproterenol cAMP response and decreased density of beta-adrenergic receptors on mononuclear cells in the absence of beta-agonist therapy. It is speculated that release of PAF and other mediators secondary to allergen exposure, even in the absence of overt attacks of asthma, may inhibit the response to endogenous or exogenous beta-adrenergic agonists.	CREIGHTON UNIV,SCH MED,DEPT MED,CTR ALLERG DIS,2500 CALIF ST,OMAHA,NE 68178	Creighton University			Hopp, Russell/K-4578-2019					AGRAWAL DK, 1987, BIOCHEM BIOPH RES CO, V143, P1, DOI 10.1016/0006-291X(87)90620-6; AGRAWAL DK, UNPUB J PHARM EXP TH; AGRAWAL DK, 1988, GINKGOLIDES CHEM BIO, V1, P217; ALSTON WC, 1974, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.5898.90; BARNES PJ, 1980, NATURE, V285, P569, DOI 10.1038/285569a0; BISHOPRIC NH, 1980, J ALLERGY CLIN IMMUN, V65, P29, DOI 10.1016/0091-6749(80)90173-6; BRESLIN FJ, 1980, J APPL PHYSIOL, V48, P619, DOI 10.1152/jappl.1980.48.4.619; BROOKS SM, 1979, J ALLERGY CLIN IMMUN, V63, P401, DOI 10.1016/0091-6749(79)90213-6; BRUYNZEEL PLB, 1979, ANN ALLERGY, V43, P105; BRYAN LJ, 1981, J PHARMACOL EXP THER, V216, P395; BUSSE WW, 1977, J CLIN INVEST, V59, P1080, DOI 10.1172/JCI108731; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; CONOLLY ME, 1982, J ALLERGY CLIN IMMUN, V70, P423, DOI 10.1016/0091-6749(82)90004-5; DAIGUJI M, 1981, LIFE SCI, V28, P2705, DOI 10.1016/0024-3205(81)90171-5; DAVIES AO, 1983, J CLIN INVEST, V71, P565, DOI 10.1172/JCI110801; DAVIS PB, 1982, J ALLERGY CLIN IMMUN, V69, P35, DOI 10.1016/0091-6749(82)90084-7; FELDMAN RD, 1983, J CLIN INVEST, V72, P164, DOI 10.1172/JCI110954; FRAZER J, 1981, J CLIN INVEST, V67, P1777; GILLESPIE E, 1974, J ALLERGY CLIN IMMUN, V53, P27, DOI 10.1016/0091-6749(74)90096-7; GREWE SR, 1982, J ALLERGY CLIN IMMUN, V70, P452, DOI 10.1016/0091-6749(82)90008-2; HOFFMAN BB, 1979, J CYCLIC NUCL PROT, V5, P355; HOFFMAN BB, 1979, LIFE SCI, V24, P1739, DOI 10.1016/0024-3205(79)90061-4; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V74, P154, DOI 10.1016/0091-6749(84)90279-3; JOHNSON GL, 1978, J BIOL CHEM, V253, P1472; JONES SB, 1983, CLIN PHARMACOL THER, V34, P90, DOI 10.1038/clpt.1983.135; KARIMAN K, 1980, LUNG, V158, P41, DOI 10.1007/BF02713701; KOETER GH, 1982, EUR J RESPIR DI S121, V62, P72; LOCKEY SD, 1967, J ALLERGY, V40, P349, DOI 10.1016/0021-8707(67)90024-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEURS H, 1982, J ALLERGY CLIN IMMUN, V70, P272, DOI 10.1016/0091-6749(82)90063-X; MORRIS HG, 1977, CLIN PHARMACOL THER, V22, P352; MOTULSKY HJ, 1982, BIOCHEM PHARMACOL, V31, P2591, DOI 10.1016/0006-2952(82)90705-5; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; RAAIJMAKERS JAM, 1987, THESIS U UTRECHT UTR, P67; ROSS GD, 1980, MANUAL CLIN IMMUNOLO, P213; RYO UY, 1976, J ALLERGY CLIN IMMUN, V57, P12, DOI 10.1016/0091-6749(76)90074-9; SAFKO MJ, 1981, J ALLERGY CLIN IMMUN, V68, P218, DOI 10.1016/0091-6749(81)90187-1; SANO Y, 1983, J ALLERGY CLIN IMMUN, V72, P495, DOI 10.1016/0091-6749(83)90587-0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHOCKEN DD, 1977, NATURE, V267, P856, DOI 10.1038/267856a0; SHELHAMER JH, 1976, J ALLERGY CLIN IMMUN, V57, P12; Szentivanyi A, 1979, Ann N Y Acad Sci, V332, P295, DOI 10.1111/j.1749-6632.1979.tb47123.x; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TACHKIN DP, 1982, AM REV RESPIR DIS, V125, P185; TOWNLEY RG, 1989, J ALLERGY CLIN IMMUN, V83, P997, DOI 10.1016/0091-6749(89)90437-5; TOWNLEY RG, 1990, AIRWAY SMOOTH MUSCLE; WESSELS MR, 1979, MOL PHARMACOL, V16, P10	47	18	18	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	1				839	850		10.1016/S0091-6749(05)80144-7	http://dx.doi.org/10.1016/S0091-6749(05)80144-7			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EQ045	2175758	Bronze			2022-12-18	WOS:A1990EQ04500003
J	FINNERTY, JP; POLOSA, R; HOLGATE, ST				FINNERTY, JP; POLOSA, R; HOLGATE, ST			REPEATED EXPOSURE OF ASTHMATIC AIRWAYS TO INHALED ADENOSINE 5'-MONOPHOSPHATE ATTENUATES BRONCHOCONSTRICTION PROVOKED BY EXERCISE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FINNERTY, JP (corresponding author), SOUTHAMPTON GEN HOSP,IMMUNOPHARMACOL GRP,MED 1,LEVEL D,CTR BLOCK,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							Arch J R, 1978, Essays Biochem, V14, P82; BELCHER NG, 1987, AM REV RESPIR DIS, V135, P822, DOI 10.1164/arrd.1987.135.4.822; BOULET LP, 1987, RESPIRATION, V52, P237, DOI 10.1159/000195332; Burnstock G, 1980, Prog Biochem Pharmacol, V16, P141; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHRISTIE J, 1980, BRIT J PHARMACOL, V70, P512, DOI 10.1111/j.1476-5381.1980.tb09768.x; CHURCH MK, 1986, BRIT J PHARMACOL, V87, P233, DOI 10.1111/j.1476-5381.1986.tb10176.x; CRIMI N, 1988, CLIN ALLERGY, V18, P367, DOI 10.1111/j.1365-2222.1988.tb02884.x; CRIMI N, 1989, J ALLERGY CLIN IMMUN, V83, P921, DOI 10.1016/0091-6749(89)90106-1; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; DAS DK, 1988, J APPL PHYSIOL, V62, P297; DAXUN Z, 1989, J ALLERGY CLIN IMMUN, V83, P152, DOI 10.1016/0091-6749(89)90490-9; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; EGGLESTON PA, 1985, J ALLERGY CLIN IMMUN, V75, P125, DOI 10.1016/0091-6749(85)90218-0; FINNERTY JP, 1989, AM REV RESPIR DIS, V140, P593, DOI 10.1164/ajrccm/140.3.593; FINNERTY JP, 1989, THORAX, V44, pP867; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; FULLER RW, 1987, BRIT J CLIN PHARMACO, V24, P309; HAHN AG, 1984, THORAX, V39, P919, DOI 10.1136/thx.39.12.919; HAMIELEC CM, 1988, AM REV RESPIR DIS, V138, P794, DOI 10.1164/ajrccm/138.4.794; HUGHES PJ, 1984, BIOCHEM PHARMACOL, V33, P3847, DOI 10.1016/0006-2952(84)90050-9; KLABUNDE RE, 1983, EUR J PHARMACOL, V93, P21, DOI 10.1016/0014-2999(83)90026-2; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; MANN JS, 1986, J APPL PHYSIOL, V61, P1667, DOI 10.1152/jappl.1986.61.5.1667; MARQUARDT DL, 1987, BIOCHEM PHARMACOL, V36, P4297, DOI 10.1016/0006-2952(87)90674-5; MARQUARDT DL, 1984, J IMMUNOL, V133, P932; MENTZER RM, 1975, AM J PHYSIOL, V229, P1625; OBYRNE PM, 1986, AM REV RESPIR DIS, V134, P69; PHILLIPS GD, 1987, THORAX, V42, P939, DOI 10.1136/thx.42.12.939; PHILLIPS GD, 1989, AM REV RESPIR DIS, V139, P463, DOI 10.1164/ajrccm/139.2.463; PHILLIPS GD, 1990, AM REV RESPIR DIS, V141, P9, DOI 10.1164/ajrccm/141.1.9; PHILLIPS GD, 1989, AM REV RESPIR DIS, V140, P321, DOI 10.1164/ajrccm/140.2.321; PHILLIPS GD, 1989, EUR RESPIR J, V2, P210; WATT AH, 1986, BRIT MED J, V293, P1455, DOI 10.1136/bmj.293.6560.1455; ZAWADSKI DK, 1988, J APPL PHYSIOL, V64, P812, DOI 10.1152/jappl.1988.64.2.812	36	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1990	86	3	1				353	359		10.1016/S0091-6749(05)80098-3	http://dx.doi.org/10.1016/S0091-6749(05)80098-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA859	2212408				2022-12-18	WOS:A1990EA85900009
J	KASLOW, JE; NOVEY, HS; ZUCH, RH; SPEAR, GS				KASLOW, JE; NOVEY, HS; ZUCH, RH; SPEAR, GS			DISSEMINATED STRONGYLOIDIASIS - AN UNHERALDED RISK OF CORTICOSTEROID-THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									UNIV CALIF IRVINE,DEPT PATHOL,ORANGE,CA 92613	University of California System; University of California Irvine	KASLOW, JE (corresponding author), UNIV CALIF IRVINE,DEPT MED,POB 14091,ORANGE,CA 92613, USA.							CIVANTOS F, 1969, AM J DIG DIS, V14, P643, DOI 10.1007/BF02239276; GILL GV, 1979, BRIT MED J, V2, P572, DOI 10.1136/bmj.2.6190.572; IGRASIEGMAN Y, 1981, REV INFECT DIS, V3, P397; JONES CA, 1950, GASTROENTEROLOGY, V16, P743, DOI 10.1016/S0016-5085(19)36487-X; MANSONBAR PEL, 1982, MANSONS TROPICAL DIS, P194; NEVA FA, 1986, J INFECT DIS, V153, P397, DOI 10.1093/infdis/153.3.397; SCOWDEN EB, 1978, MEDICINE, V57, P527, DOI 10.1097/00005792-197811000-00004	7	18	18	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					138	138		10.1016/S0091-6749(05)80135-6	http://dx.doi.org/10.1016/S0091-6749(05)80135-6			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	2370384				2022-12-18	WOS:A1990DQ68800021
J	BURKE, LA; CREA, AEG; WILKINSON, JRW; ARM, JP; SPUR, BW; LEE, TH				BURKE, LA; CREA, AEG; WILKINSON, JRW; ARM, JP; SPUR, BW; LEE, TH			COMPARISON OF THE GENERATION OF PLATELET-ACTIVATING FACTOR AND LEUKOTRIENE-C4 IN HUMAN EOSINOPHILS STIMULATED BY UNOPSONIZED ZYMOSAN AND BY THE CALCIUM IONOPHORE A23187 - THE EFFECTS OF NEDOCROMIL SODIUM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT ALLERGY & ALLIED RESP DISORDERS,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London				Spur, Bernd/0000-0002-7581-4741; Lee, Tak/0000-0002-7554-4059				ARNOUX B, 1981, AGENTS ACTIONS, V11, P555, DOI 10.1007/BF01978737; ARNOUX B, 1980, EUR J CLIN INVEST, V10, P437, DOI 10.1111/j.1365-2362.1980.tb02082.x; BENVENISTE J, 1977, NATURE, V269, P170, DOI 10.1038/269170a0; BRUIJNZEEL PLB, 1989, BRIT J PHARMACOL, V96, P631, DOI 10.1111/j.1476-5381.1989.tb11862.x; COHEN SG, 1978, ALLERGY PRINCIPLES P, P584; DAHL R, 1986, EUR J RESPIR DIS, V69, P263; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; GRESELE P, 1985, LANCET, V1, P347; HOFFMAN SL, 1982, ARCH BIOCHEM BIOPHYS, V215, P237; LEE TC, 1984, J BIOL CHEM, V259, P5526; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; MAHAUTHAMAN R, 1988, J ALLERGY CLIN IMMUN, V81, P696, DOI 10.1016/0091-6749(88)91041-X; MARKUS HB, 1969, BIOCHIM BIOPHYS ACTA, V187, P486, DOI 10.1016/0005-2760(69)90045-9; MENCIAHUERTA JM, 1983, J IMMUNOL, V131, P2958; MOQBEL R, 1988, ALLERGY, V43, P268, DOI 10.1111/j.1398-9995.1988.tb00899.x; ORR TSC, 1986, ASTHMA CLIN PHARM TH, P265; ROCCHICCIOLI K, 1986, EUR J RESPIR DIS, V69, P292; ROUBIN R, 1983, LYMPHOKINES, V8, P248; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SHAW RJ, 1985, BRIT J DIS CHEST, V79, P385, DOI 10.1016/0007-0971(85)90073-7; TAMURA N, 1987, BIOCHEM BIOPH RES CO, V142, P638, DOI 10.1016/0006-291X(87)91462-8; VADAS MA, 1979, J IMMUNOL, V122, P1228; VARGAFTIG BB, 1980, EUR J PHARMACOL, V65, P185, DOI 10.1016/0014-2999(80)90391-X; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WYKLE RL, 1980, J BIOL CHEM, V255, P256	25	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				26	35		10.1016/0091-6749(90)90217-R	http://dx.doi.org/10.1016/0091-6749(90)90217-R			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2153720				2022-12-18	WOS:A1990CM37800005
J	NORMAN, PS				NORMAN, PS			SAFETY OF ALLERGEN IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											NORMAN, PS (corresponding author), GOOD SAMARITAN HOSP,5601 LOCH RAVEN BLVD,BALTIMORE,MD 21239, USA.							LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; THOMPSON RA, 1989, LANCET, V1, P259; 1986, BRIT MED J, V293, P148	3	18	18	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	1				438	439		10.1016/0091-6749(89)90355-2	http://dx.doi.org/10.1016/0091-6749(89)90355-2			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW760	2794289				2022-12-18	WOS:A1989AW76000003
J	KOSSOY, AF; HILL, M; LIN, FL; SZEFLER, SJ				KOSSOY, AF; HILL, M; LIN, FL; SZEFLER, SJ			ARE THEOPHYLLINE LEVELS A RELIABLE INDICATOR OF COMPLIANCE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PED,1400 JACKSON ST,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,IRA J & JACQUELINE NEIMARK LAB CLIN PHARMACOL PEDIAT,DENVER,CO; FITZSIMONS ARMY MED CTR,ALLERGY IMMUNOL SERV,AURORA,CO; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT & PHARMACOL,DENVER,CO 80262	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								AVIRAM M, 1987, PEDIATRICS, V80, P894; HALTOM JR, 1985, J PEDIATR-US, V107, P805, DOI 10.1016/S0022-3476(85)80425-X; LAGAS M, 1983, EUR J CLIN PHARMACOL, V24, P761, DOI 10.1007/BF00607084; MENENDEZ R, 1983, AM J DIS CHILD, V137, P469, DOI 10.1001/archpedi.1983.02140310051015; PEDERSEN S, 1985, CLIN ALLERGY, V15, P253, DOI 10.1111/j.1365-2222.1985.tb02282.x; PEDERSEN S, 1984, PEDIATRICS, V74, P534; ROGERS RJ, 1985, J PEDIATR-US, V106, P496, DOI 10.1016/S0022-3476(85)80690-9; SCOTT PH, 1981, J PEDIATR-US, V99, P476, DOI 10.1016/S0022-3476(81)80354-X; SZEFLER SJ, 1987, DRUG THERAPY ASTHMA, P363; VAUGHAN LM, 1986, LANCET, V1, P184; WAGNER JG, 1983, J PHARM SCI, V72, P578, DOI 10.1002/jps.2600720531; WARREN JB, 1985, BRIT J CLIN PHARMACO, V19, P707, DOI 10.1111/j.1365-2125.1985.tb02701.x; WEINBERGER M, 1981, J PEDIATR-US, V99, P145, DOI 10.1016/S0022-3476(81)80982-1; WILLIAMS RL, 1983, J ASTHMA, V20, P27, DOI 10.3109/02770908309070908	14	18	18	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1989	84	1					60	65		10.1016/0091-6749(89)90179-6	http://dx.doi.org/10.1016/0091-6749(89)90179-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG120	2754145	Bronze			2022-12-18	WOS:A1989AG12000010
J	MATTHIESEN, F; SCHUMACHER, MJ; LOWENSTEIN, H				MATTHIESEN, F; SCHUMACHER, MJ; LOWENSTEIN, H			AN IMMUNOELECTROPHORETIC ANALYSIS OF THE ALLERGENS OF CYNODON-DACTYLON (BERMUDA GRASS) POLLEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV ARIZONA,DEPT PEDIAT,TUCSON,AZ 85721	University of Arizona	MATTHIESEN, F (corresponding author), ALK RES,POB 408,BOGE ALLE 10-12,DK-2970 HORSHOLM,DENMARK.							AXELSEN NH, 1983, SCAND J IMMUNOL S10, V17; BAER H, 1986, J ALLERGY CLIN IMMUN, V78, P624, DOI 10.1016/0091-6749(86)90080-1; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; BJERRUM OJ, 1975, SCAND J IMMUNOL   S2, V4, P81; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHAKRABARTY S, 1981, INT ARCH ALLER A IMM, V66, P142, DOI 10.1159/000232813; COTTAM GP, 1986, BIOCHEM J, V234, P305, DOI 10.1042/bj2340305; EKRAMODDOULLAH AKM, 1986, INT ARCH ALLER A IMM, V80, P100, DOI 10.1159/000234033; EKRAMODDOULLAH AKM, 1983, MOL IMMUNOL, V20, P465, DOI 10.1016/0161-5890(83)90027-5; EKRAMODDOULLAH AKM, 1980, INT ARCH ALLER A IMM, V63, P220, DOI 10.1159/000232630; ESCH RE, 1987, J ALLERGY CLIN IMMUN, V79, P489, DOI 10.1016/0091-6749(87)90367-8; FORD SA, 1987, J ALLERGY CLIN IMMUN, V79, P711, DOI 10.1016/0091-6749(87)90201-6; FORD SA, 1985, INT ARCH ALLER A IMM, V78, P15, DOI 10.1159/000233855; FORD SA, 1986, INT ARCH ALLER A IMM, V81, P193, DOI 10.1159/000234134; HAAVIK S, 1985, INT ARCH ALLER A IMM, V78, P260, DOI 10.1159/000233896; HARBOE N, 1973, Scandinavian Journal of Immunology, V2, P161; HOWLETT BJ, 1981, BIOCHEM J, V197, P695, DOI 10.1042/bj1970695; JOHNSON P, 1966, IMMUNOCHEMISTRY, V3, P101, DOI 10.1016/0019-2791(66)90291-6; JOHNSON P, 1966, IMMUNOCHEMISTRY, V3, P91, DOI 10.1016/0019-2791(66)90290-4; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P129, DOI 10.1016/0091-6749(76)90148-2; LIN ZW, 1988, INT ARCH ALLER A IMM, V87, P294, DOI 10.1159/000234688; LOWENSTEIN H, 1984, ALLERGY, V39, P421, DOI 10.1111/j.1398-9995.1984.tb01964.x; LOWENSTEIN H, 1978, INT ARCH ALLER A IMM, V57, P379, DOI 10.1159/000232128; LOWENSTEIN H, 1978, ALLERGY, V33, P30, DOI 10.1111/j.1398-9995.1978.tb01504.x; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSH DG, 1970, J ALLERGY, V46, P107, DOI 10.1016/0021-8707(70)90078-X; MARSH DG, 1975, ANTIGENS, V3, P271; MARTIN BG, 1985, ANN ALLERGY, V54, P99; MECHERI S, 1985, INT ARCH ALLER A IMM, V78, P283, DOI 10.1159/000233899; RENCK B, 1984, INT ARCH ALLER A IMM, V73, P193, DOI 10.1159/000233466; SCHUMACHER M J, 1984, Journal of Allergy and Clinical Immunology, V73, P191; SCHUMACHER MJ, 1985, ANN ALLERGY, V55, P584; SHEN HD, 1988, CLIN ALLERGY, V18, P401, DOI 10.1111/j.1365-2222.1988.tb02888.x; VANREE R, 1989, J ALLERGY CLIN IMMUN, V83, P144, DOI 10.1016/0091-6749(89)90489-2; WEEKE B, 1983, SCAND J IMMUNOL S10, V17, P265	36	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1989	83	6					1124	1134		10.1016/0091-6749(89)90456-9	http://dx.doi.org/10.1016/0091-6749(89)90456-9			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC235	2732412				2022-12-18	WOS:A1989AC23500018
J	LESOURD, B; PAUPE, J; THIOLLET, M; MOULIAS, R; SAINTELAUDY, J; SCHEINMANN, P				LESOURD, B; PAUPE, J; THIOLLET, M; MOULIAS, R; SAINTELAUDY, J; SCHEINMANN, P			HYMENOPTERA VENOM IMMUNOTHERAPY .1. INDUCTION OF T-CELL-MEDIATED IMMUNITY BY HONEYBEE VENOM IMMUNOTHERAPY - RELATIONSHIPS WITH SPECIFIC ANTIBODY-RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LAB IMMUNOALLERGOL,PARIS,FRANCE; HOP NECKER ENFANTS MALAD,SERV ALLERGOL & PNEUMOL INFATILES,F-75730 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	LESOURD, B (corresponding author), FAC MED PITIE SALPETRIERE,IMMUNOL LAB,105 BD HOP,F-75013 PARIS,FRANCE.							ANFOSSO F, 1982, ALLERGY, V37, P613, DOI 10.1111/j.1398-9995.1982.tb02349.x; BARSELA S, 1981, ANN ALLERGY, V47, P460; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V79, P947, DOI 10.1016/0091-6749(87)90245-4; BRAUN L. I. B., 1925, SOUTH AFRICAN MEDICAL RECORD, V23, P408; CANONICA CW, 1979, J IMMUNOL, V123, P3669; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CHEUNG NKV, 1983, ANN ALLERGY, V50, P155; DJURUP R, 1985, ALLERGY, V40, P469, DOI 10.1111/j.1398-9995.1985.tb00253.x; EINARSSON R, 1987, INT ARCH ALLER A IMM, V83, P217, DOI 10.1159/000234360; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1984, ANN ALLERGY, V53, P444; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P435, DOI 10.1016/0091-6749(86)90177-6; GOTO A, 1983, Radioisotopes, V32, P404, DOI 10.3769/radioisotopes.32.9_404; GRAFT DF, 1984, J ALLERGY CLIN IMMUN, V73, P61, DOI 10.1016/0091-6749(84)90485-8; GRANT JA, 1981, J ALLERGY CLIN IMMUN, V68, P112, DOI 10.1016/0091-6749(81)90168-8; HOFFMAN DR, 1981, ANN ALLERGY, V46, P17; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KEMENY DM, 1983, J ALLERGY CLIN IMMUN, V72, P376, DOI 10.1016/0091-6749(83)90503-1; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; LESOURD B, 1984, 7TH P INT C TET COP, P101; LESOURD B, 1987, REV FR ALLERGOL, V27, P224; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LOMNITZER R, 1986, J ALLERGY CLIN IMMUN, V76, P25; MAHMOOD T, 1982, J ALLERGY CLIN IMMUN, V70, P445, DOI 10.1016/0091-6749(82)90007-0; MORETTA L, 1977, J EXP MED, V146, P184, DOI 10.1084/jem.146.1.184; MULLER UR, 1986, J ALLERGY CLIN IMMUN, V78, P115, DOI 10.1016/0091-6749(86)90123-5; NAGAYA H, 1985, J ALLERGY CLIN IMMUN, V75, P388, DOI 10.1016/0091-6749(85)90077-6; NAKAGAWA T, 1981, INT ARCH ALLER A IMM, V64, P201, DOI 10.1159/000232693; NORDVALL SL, 1986, ALLERGY, V41, P89, DOI 10.1111/j.1398-9995.1986.tb00283.x; OHMAN S, 1986, ALLERGY, V41, P81, DOI 10.1111/j.1398-9995.1986.tb00282.x; PATTERSON R, 1985, J ALLERGY CLIN IMMUN, V76, P394, DOI 10.1016/0091-6749(85)90660-8; PERELMUTTER L, 1986, ANN ALLERGY, V57, P78; RANDOLPH CC, 1986, J ALLERGY CLIN IMMUN, V77, P823, DOI 10.1016/0091-6749(86)90379-9; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P553, DOI 10.1016/0091-6749(85)90028-4; REISMAN RE, 1979, CLIN ALLERGY, V9, P303, DOI 10.1111/j.1365-2222.1979.tb01557.x; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P735; ROCKLIN RE, 1983, J ALLERGY CLIN IMMUN, V72, P323, DOI 10.1016/0091-6749(83)90492-X; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; SANSONI P, 1985, J CLIN INVEST, V75, P650, DOI 10.1172/JCI111743; SCHNEIDER H, 1984, CLIN EXP IMMUNOL, V57, P449; SETTIPANE GA, 1972, J ALLERGY CLIN IMMUN, V50, P146, DOI 10.1016/0091-6749(72)90045-0; TAMIR R, 1987, J ALLERGY CLIN IMMUN, V79, P591, DOI 10.1016/S0091-6749(87)80154-9; THOMPSON LF, 1983, J IMMUNOL, V131, P2772; UHLIN T, 1987, ALLERGY, V42, P222, DOI 10.1111/j.1398-9995.1987.tb02203.x; URBANEK R, 1985, J PEDIATR-US, V107, P367, DOI 10.1016/S0022-3476(85)80508-4; URBANEK R, 1986, CLIN ALLERGY, V16, P317, DOI 10.1111/j.1365-2222.1986.tb01963.x; WIDE L, 1967, LANCET, V2, P1105; WIDE L, 1974, 9TH P EUR C ALL CLIN, P176; WUTHRICH B, 1981, SCHWEIZ MED WSCHR, V111, P1756	50	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1989	83	3					563	571		10.1016/0091-6749(89)90067-5	http://dx.doi.org/10.1016/0091-6749(89)90067-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T8596	2522473				2022-12-18	WOS:A1989T859600001
J	MAGNUSSEN, H; REUSS, G; JORRES, R; AURICH, R				MAGNUSSEN, H; REUSS, G; JORRES, R; AURICH, R			DURATION OF THE EFFECT OF A SINGLE DOSE OF AZELASTINE ON HISTAMINE-INDUCED BRONCHOCONSTRICTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHEM WERK HOMBURG,FRANKFURT,FED REP GER		MAGNUSSEN, H (corresponding author), KRANKENHAUS GROSSHANSDORF,ZENTRUM PNEUMOL & THORAXCHIRURG,LVA HAMBURG,WOHRENDAMM 80,D-2070 GROSSHANSDORF,FED REP GER.							ATKINS P, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90385-9; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHAI H, 1969, BIOMETRIKA, V56, P229; Diamantis W., 1981, PHARMACOLOGIST, V23, P149; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; HOLGATE ST, 1985, J ALLERGY CLIN IMMUN, V76, P375, DOI 10.1016/0091-6749(85)90657-8; KEMP JP, 1987, J ALLERGY CLIN IMMUN, V79, P893, DOI 10.1016/0091-6749(87)90238-7; MAGNUSSEN H, 1987, CHEST, V91, P855, DOI 10.1378/chest.91.6.855; MAGNUSSEN H, 1988, CHEST, V93, P937, DOI 10.1378/chest.93.5.937; MAGNUSSEN H, 1985, ATEMWEG LUNGENKRANK, V11, P312; NORMAN PS, 1985, J ALLERGY CLIN IMMUN, V76, P366, DOI 10.1016/0091-6749(85)90655-4; OLLIER S, 1986, J ALLERGY CLIN IMMUN, V78, P358, DOI 10.1016/S0091-6749(86)80090-2; OREHEK J, 1981, AM REV RESPIR DIS, V123, P269; PERHACH J, 1984, Journal of Allergy and Clinical Immunology, V73, P144; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; SCHEFFE H, 1953, BIOMETRIKA, V40, P87, DOI 10.1093/biomet/40.1-2.87; STORMS W, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90386-0	18	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	1				467	471		10.1016/0091-6749(89)90135-8	http://dx.doi.org/10.1016/0091-6749(89)90135-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4489	2563744				2022-12-18	WOS:A1989T448900016
J	GOLDEN, DBK; KWITEROVICH, KA; KAGEYSOBOTKA, A; VALENTINE, MD; LICHTENSTEIN, LM				GOLDEN, DBK; KWITEROVICH, KA; KAGEYSOBOTKA, A; VALENTINE, MD; LICHTENSTEIN, LM			DISCONTINUING VENOM IMMUNOTHERAPY (VIT) - DETERMINANTS OF CLINICAL REACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					273	273						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419					2022-12-18	WOS:A1989T041900426
J	ANNESI, I; KAUFFMANN, F; ORYSZCZYN, MP; NEUKIRCH, F; ORVOENFRIJA, E; LELLOUCH, J				ANNESI, I; KAUFFMANN, F; ORYSZCZYN, MP; NEUKIRCH, F; ORVOENFRIJA, E; LELLOUCH, J			LEUKOCYTE COUNT AND BRONCHIAL HYPERRESPONSIVENESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOTEL DIEU,F-75181 PARIS 04,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP	ANNESI, I (corresponding author), INSERM,UNITE METHODES STAT & EPIDEMIOL & APPLICAT ETUDE MALAD CHRON 169,F-94807 VILLEJUIF,FRANCE.							ABBOUD RT, 1985, CLIN INVEST MED, V4, pA204; ANNESI I, 1987, B EUR PHYSIOPATH RES, V23, P397; CHANYEUNG M, 1984, AM J MED, V76, P31; CORRE F, 1971, LANCET, V2, P632; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; FABBRI LM, 1984, AM REV RESPIR DIS, V129, P288; HARGREAVE FE, 1986, J ALLERGY CLIN IMMUN, V78, P825, DOI 10.1016/0091-6749(86)90226-5; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; HUNNINGHAKE GW, 1983, AM REV RESPIR DIS, V128, P833; KAUFFMANN F, 1988, THORAX, V43, P456, DOI 10.1136/thx.43.6.456; KELLY C, 1987, THORAX, V42, P224; LEE ET, 1980, STATISTICAL METHODS, V18, P355; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; MULLEN JBM, 1986, AM REV RESPIR DIS, V133, P120, DOI 10.1164/arrd.1986.133.1.120; NADEL JA, 1984, ASTHMA PHYSL IMMUNOP, P129; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P220; OBYRNE PM, 1986, CHEST, V90, P575, DOI 10.1378/chest.90.4.575; OREHEK J, 1975, BMJ-BRIT MED J, V1, P123, DOI 10.1136/bmj.1.5950.123; PRIDE N, 1986, CLIN ALLERGY, V16, P3, DOI 10.1111/j.1365-2222.1986.tb01946.x; PRIDE NB, 1987, B EUR PHYSIOPATH RES, V23, P369; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321, DOI 10.1152/jappl.1986.60.4.1321; Snedecor G.W., 1980, STAT METHODS, V7; SPARROW D, 1984, CHEST, V86, P383, DOI 10.1378/chest.86.3.383; TAYLOR RG, 1985, THORAX, V40, P17, DOI 10.1136/thx.40.1.17; TAYLOR RG, 1985, THORAX, V40, P718; TAYLOR RG, 1987, EUR J RESPIR, V71, P35	26	18	18	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					1006	1011		10.1016/0091-6749(88)90137-6	http://dx.doi.org/10.1016/0091-6749(88)90137-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	3060510				2022-12-18	WOS:A1988R631100008
J	FRIEDMAN, MM; KALINER, M				FRIEDMAN, MM; KALINER, M			ULTRASTRUCTURAL-CHANGES IN HUMAN-SKIN MAST-CELLS DURING ANTIGEN-INDUCED DE-GRANULATION INVIVO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BLDG 10,RM 11C105,BETHESDA,MD 20892; GEORGETOWN UNIV,MED CTR,DIV MOLEC VIROL & IMMUNOL,ROCKVILLE,MD	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Georgetown University					NIAID NIH HHS [N01-AI-72623, N01-AI-22665] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI072623, N01AI022665] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEHRENDT H, 1978, INT ARCH ALLER A IMM, V56, P188, DOI 10.1159/000232022; BRINKMAN GL, 1968, J ULTRA MOL STRUCT R, V23, P115, DOI 10.1016/S0022-5320(68)80035-8; CAULFIELD JP, 1980, J CELL BIOL, V85, P299, DOI 10.1083/jcb.85.2.299; DVORAK AM, 1976, J IMMUNOL, V116, P687; DVORAK AM, 1983, FED PROC, V42, P2510; DVORAK AM, 1985, LAB INVEST, V53, P45; DVORAK AM, 1976, LAB INVEST, V34, P179; DVORAK AM, 1976, CLIN IMMUNOL IMMUNOP, V5, P235, DOI 10.1016/0090-1229(76)90028-3; Enerback L., 1981, MONOGR ALLERGY, V17, P222; FOX B, 1981, J CLIN PATHOL, V34, P1333, DOI 10.1136/jcp.34.12.1333; FRIEDMAN MM, 1985, J ALLERGY CLIN IMMUN, V76, P70, DOI 10.1016/0091-6749(85)90807-3; FRIEDMAN MM, 1987, AM REV RESPIR DIS, V135, P1157; FRIEDMAN MM, 1986, MAST CELL DIFFERENTI, P367; HASHIMOT.K, 1966, J INVEST DERMATOL, V46, P139, DOI 10.1038/jid.1966.23; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; KARNOVSKY MJ, 1971, J CELL BIOL, V284, P146; KAWANAMI O, 1979, LAB INVEST, V40, P717; KOBAYASI T, 1969, ACTA DERM-VENEREOL, V49, P369; MURPHY GF, 1987, J ALLERGY CLIN IMMUN, V80, P603, DOI 10.1016/0091-6749(87)90015-7; SAAVEDRADELGADO AMP, 1984, AGENTS ACTIONS, V14, P1, DOI 10.1007/BF01966825; TROTTER C M, 1974, Clinical Allergy, V4, P421, DOI 10.1111/j.1365-2222.1974.tb01403.x; TROTTER CM, 1973, CLIN ALLERGY, V3, P411, DOI 10.1111/j.1365-2222.1973.tb01349.x; WILLINGHAM MC, 1984, J HISTOCHEM CYTOCHEM, V32, P455, DOI 10.1177/32.4.6323574	24	18	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					998	1005		10.1016/0091-6749(88)90136-4	http://dx.doi.org/10.1016/0091-6749(88)90136-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	3204257				2022-12-18	WOS:A1988R631100007
J	MALANIN, G; KALIMO, K				MALANIN, G; KALIMO, K			ANGIOEDEMA AND URTICARIA CAUSED BY COTTONSEED PROTEIN IN WHOLE-GRAIN BREAD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TURKU,DEPT DERMATOL,SF-20520 TURKU 52,FINLAND	University of Turku								ATKINS FM, 1987, J ALLERGY CLIN IMMUN, V79, P137; BERNTON HARRY S., 1940, JOUR ALLERGY, V11, P138, DOI 10.1016/S0021-8707(40)90828-0; BOUHUYS A, 1976, LUNG, V154, P3, DOI 10.1007/BF02713514; BROWN GRAFTON TYLER, 1929, JOUR AMER MED ASSOC, V93, P370; Coca AF, 1925, J IMMUNOL, V10, P445; FIGLEY KD, 1949, J ALLERGY, V20, P198, DOI 10.1016/0021-8707(49)90095-7; HANNUKSELA M, 1977, CONTACT DERMATITIS, V3, P79, DOI 10.1111/j.1600-0536.1977.tb03603.x; HARRIS MC, 1950, J ALLERGY, V21, P208, DOI 10.1016/0021-8707(50)90128-6; JUHLIN-DANNFELT CARL, 1953, ACTA ALLERGOL, V6, P1, DOI 10.1111/j.1398-9995.1953.tb03465.x; KAUPPINEN K, 1980, CONTACT DERMATITIS, V6, P251, DOI 10.1111/j.1600-0536.1980.tb04924.x; KUSHIMOTO H, 1985, ARCH DERMATOL, V121, P355, DOI 10.1001/archderm.121.3.355; PLYMER RE, 1959, U MICH MED B, V25, P220; PRENNER BM, 1976, ANN ALLERGY, V37, P180; SCHACHTER EN, 1985, J ALLERGY CLIN IMMUN, V76, P481, DOI 10.1016/0091-6749(85)90731-6; Spies Joseph R., 1942, JOUR ALLERGY, V14, P7, DOI 10.1016/S0021-8707(42)90259-4; SPIES JOSEPH R., 1939, JOUR ALLERGY, V10, P113, DOI 10.1016/S0021-8707(39)90044-4; SPIES JR, 1953, J ALLERGY, V24, P483, DOI 10.1016/0021-8707(53)90022-7; Taub SJ, 1934, J AMER MED ASSOC, V103, P0334, DOI 10.1001/jama.1934.02750310028009; WARIN RP, 1974, URTICARIA, P51; WARING NP, 1985, J ALLERGY CLIN IMMUN, V76, P440, DOI 10.1016/0091-6749(85)90724-9	20	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1988	82	2					261	264		10.1016/0091-6749(88)91009-3	http://dx.doi.org/10.1016/0091-6749(88)91009-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8741	3403866				2022-12-18	WOS:A1988P874100019
J	SKEDINGER, MC; AUGUSTINE, NH; MORRIS, EZ; NIELSON, DW; ZIMMERMAN, GA; HILL, HR				SKEDINGER, MC; AUGUSTINE, NH; MORRIS, EZ; NIELSON, DW; ZIMMERMAN, GA; HILL, HR			EFFECT OF DISODIUM-CROMOGLYCATE ON NEUTROPHIL MOVEMENT AND INTRACELLULAR CALCIUM MOBILIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV UTAH,SCH MED,DEPT PATHOL,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DEPT MED,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DEPT PEDIAT,SALT LAKE CITY,UT 84112; KAROLINSKA HOSP,DEPT THORAC MED,S-10401 STOCKHOLM 60,SWEDEN	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Karolinska Institutet; Karolinska University Hospital					NIAID NIH HHS [AI 13150, AI 19094] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI013150, R01AI019094] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNSTEIN IL, 1985, CHEST, V87, pS68, DOI 10.1378/chest.87.1_Supplement.68S; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BRESLIN FJ, 1980, AM REV RESPIR DIS, V122, P11; BRIGHAM KL, 1984, CIRC RES, V54, P623, DOI 10.1161/01.RES.54.6.623; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; DAVIES SE, 1968, BRIT MED J, V3, P593, DOI 10.1136/bmj.3.5618.593; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; FABBRI LM, 1984, AM REV RESPIR DIS, V129, P288; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FILLEY WV, 1982, LANCET, V2, P11; GLOVSKY MM, 1985, CHEST, V87, pS169, DOI 10.1378/chest.87.5_Supplement.169S; HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9; HINSON JM, 1984, J APPL PHYSIOL, V56, P411, DOI 10.1152/jappl.1984.56.2.411; HOGG JC, 1985, CHEST, V87, pS152, DOI 10.1378/chest.87.5_Supplement.152S; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; HOWELL JBL, 1967, LANCET, V2, P539; KAY A B, 1984, Journal of Allergy and Clinical Immunology, V73, P170; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; LEWIS RA, 1985, CHEST, V87, pS5, DOI 10.1378/chest.87.1.5S; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; METZGER WJ, 1985, CHEST, V87, pS16, DOI 10.1378/chest.87.1_Supplement.16S; MOQBEL R, 1986, CLIN ALLERGY, V16, P73, DOI 10.1111/j.1365-2222.1986.tb01956.x; NADEL JA, 1985, CHEST, V87, pS171, DOI 10.1378/chest.87.5_Supplement.171S; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; OFLAHERTY JT, 1981, AM J PATHOL, V105, P264; SACCHI F, 1984, J EXP MED, V160, P1247, DOI 10.1084/jem.160.4.1247; WHITE JR, 1983, BIOCHEM BIOPH RES CO, V113, P44, DOI 10.1016/0006-291X(83)90429-1	27	18	18	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1987	80	4					573	577		10.1016/0091-6749(87)90009-1	http://dx.doi.org/10.1016/0091-6749(87)90009-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K5224	3117863				2022-12-18	WOS:A1987K522400009
J	SIEGEL, SC				SIEGEL, SC			HISTORY OF ASTHMA DEATHS FROM ANTIQUITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ADAMS F, 1856, ARETAEUS CAPPODOCIA; ALEXANDER HL, 1963, J ALLERGY, V34, P305, DOI 10.1016/0021-8707(63)90039-X; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; BURANAKUL B, 1974, AM J DIS CHILD, V128, P343, DOI 10.1001/archpedi.1974.02110280073009; DOLL R, 1968, BR MED J, V3, P245; FAULKNER WB, 1937, J ALLERGY, V8, P267; FISCHER T J, 1975, Journal of Asthma Research, V13, P27, DOI 10.3109/02770907509104156; FITCH SS, 1856, 6 LECTURES FUNCTIONS; FRAZIER PM, 1971, BR J DIS CHEST, V65, P71; GANDEVIA B, 1973, MED J AUSTRALIA, V1, P273, DOI 10.5694/j.1326-5377.1973.tb119742.x; GREENBERG MJ, 1967, BMJ-BRIT MED J, V1, P563, DOI 10.1136/bmj.1.5539.563; GREGG I, 1969, BRIT MED J, V2, P29, DOI 10.1136/bmj.2.5648.29; HERBERDEN W, 1802, COMMENTARIES HIST CU; Huber HL, 1922, ARCH INTERN MED, V30, P689, DOI 10.1001/archinte.1922.00110120002001; KRAVIS LP, 1978, ADV ASTHMA ALLERGY P, V4, P26; LAENNEC RTH, 1834, TREATISE DISEASES CH; Laslett T, 1867, LECT TIMBER; LEBOE F, 1717, PRACTICE PHYSICH; MAIMONIDES M, 1963, TREATISE ASTHMA; MELLIS CM, 1977, THORAX, V32, P29, DOI 10.1136/thx.32.1.29; MILLAR J, 1769, OBSERVATIONS ASTHMA; MOH J, 1985, PHARMACOTHERAPY, V5, P331; ORMEROD LP, 1980, BRIT MED J, V280, P687, DOI 10.1136/bmj.280.6215.687; Osler WB, 1892, PRINCIPLES PRACTICE, P498; PALM CR, 1970, J ALLERGY, V46, P257, DOI 10.1016/0021-8707(70)90067-5; PESHKIN M M, 1970, Journal of Asthma Research, V8, P9, DOI 10.3109/02770907009105027; RACHEMANN FM, 1944, J ALLERGY, V15, P249; RICHARDS W, 1965, AM J DIS CHILD, V110, P4, DOI 10.1001/archpedi.1965.02090030010003; ROUNDS VJ, 1954, PEDIATRICS, V14, P528; RUBENSTEIN S, 1984, ANN ALLERGY, V53, P311; Salter HH, 1860, ASTHMA ITS PATHOLOGY; SEARS MR, 1986, ARCH DIS CHILD, V61, P6, DOI 10.1136/adc.61.1.6; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; STEWART CJ, 1985, BRIT J DIS CHEST, V79, P229, DOI 10.1016/S0007-0971(85)80023-1; STOLLEY PD, 1972, AM REV RESPIR DIS, V105, P883; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; UNGER L, 1945, SOUTH MED J, V38, P513, DOI DOI 10.1097/00007611-194508000-00004; Vance BM, 1942, ARCH PATHOL, V34, P849; VEITH I, 1856, LONG STORY ASTHMA; Waldbott GL, 1935, AM J DIS CHILD, V49, P1531; WATSON W, 1963, ANN ALLERGY, V21, P51; WILLIS T, 1678, PRACTICE PHYSIC PHAR; WILSON JD, 1981, LANCET, V1, P1235; 1983, THORAX, V38, P801; 1968, BR MED J, V1, P329	45	18	18	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			458	462		10.1016/0091-6749(87)90075-3	http://dx.doi.org/10.1016/0091-6749(87)90075-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037	3305669				2022-12-18	WOS:A1987K103700023
J	ATKINS, PC; ZWEIMAN, B				ATKINS, PC; ZWEIMAN, B			THE IGE-MEDIATED LATE-PHASE SKIN-RESPONSE - UNRAVELING THE ENIGMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,PHILADELPHIA,PA 19104	University of Pennsylvania								ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; ATKINS P, 1985, J ALLERGY CLIN IMMUN, V75, P148, DOI 10.1016/0091-6749(85)90309-4; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BASRAN GS, 1982, AM REV RESPIR DIS, V125, P52; BEDARD PM, 1983, J ALLERGY CLIN IMMUN, V71, P394, DOI 10.1016/0091-6749(83)90068-4; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DOR PJ, 1983, J ALLERGY CLIN IMMUN, V71, P363, DOI 10.1016/0091-6749(83)90063-5; DORSCH W, 1981, J ALLERGY CLIN IMMUN, V67, P117, DOI 10.1016/0091-6749(81)90006-3; EADY RAJ, 1979, BRIT J DERMATOL, V100, P623, DOI 10.1111/j.1365-2133.1979.tb08065.x; FLEEKOP P, 1986, J ALLERGY CLIN IMMUN, V77, P243; LEMANSKE RF, 1983, J IMMUNOL, V130, P2837; METZGER WJ, 1986, J ALLERGY CLIN IMMUN, V78, P282; OERTEL H, 1981, J ALLERGY CLIN IMMUN, V68, P238, DOI 10.1016/0091-6749(81)90190-1; OERTEL HL, 1981, J IMMUNOL, V127, P1398; SCHENKEL E, 1982, J ALLERGY CLIN IMMUN, V70, P321, DOI 10.1016/0091-6749(82)90020-3; SHAIKH W, 1977, J ALLERGY CLIN IMMUN, V60, P242, DOI 10.1016/0091-6749(77)90138-5; SHALIT M, 1986, J ALLERGY CLIN IMMUN, V77, P183; SHALIT M, 1986, CLIN RES, V34, P279; SLOTT RI, 1975, J ALLERGY CLIN IMMUN, V55, P232, DOI 10.1016/0091-6749(75)90142-6; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; TALBOT S, 1984, Journal of Allergy and Clinical Immunology, V73, P147; TALBOT SF, 1985, J CLIN INVEST, V76, P650, DOI 10.1172/JCI112018; TANNENBAUM S, 1980, J IMMUNOL, V125, P325; TING S, 1981, J IMMUNOL, V127, P557; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P478; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756	30	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					12	15		10.1016/S0091-6749(87)80008-8	http://dx.doi.org/10.1016/S0091-6749(87)80008-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810	3543094				2022-12-18	WOS:A1987F881000004
J	MACDONALD, SM; KAGEYSOBOTKA, A; PROUD, D; NACLERIO, RM; LICHTENSTEIN, LM				MACDONALD, SM; KAGEYSOBOTKA, A; PROUD, D; NACLERIO, RM; LICHTENSTEIN, LM			HISTAMINE RELEASING-FACTOR - RELEASE MECHANISM AND RESPONDING POPULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					248	248						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810					2022-12-18	WOS:A1987F881000518
J	ZEISS, CR; LEVITZ, D; LEACH, CL; HATOUM, NS; RATAJCZAK, HV; CHANDLER, MJ; ROGER, JC; GARVIN, PJ				ZEISS, CR; LEVITZ, D; LEACH, CL; HATOUM, NS; RATAJCZAK, HV; CHANDLER, MJ; ROGER, JC; GARVIN, PJ			A MODEL OF IMMUNOLOGICAL LUNG INJURY INDUCED BY TRIMELLITIC ANHYDRIDE INHALATION - ANTIBODY-RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; IIT,RES INST,CHICAGO,IL 60616; AMOCO CORP,DEPT ENVIRONM AFFAIRS & SAFETY,CHICAGO,IL	Northwestern University; Illinois Institute of Technology	ZEISS, CR (corresponding author), VET ADM LAKESIDE MED CTR,ACOS RES & DEV,400 E ONTARIO,CHICAGO,IL 60611, USA.							LEACH CL, TOXICOL APPL PHARM; LEDBETTER AD, UNPUB AM IND HYG ASS; LIU FT, 1980, J ALLERGY CLIN IMMUN, V66, P322, DOI 10.1016/0091-6749(80)90028-7; PATTERSON R, 1979, AM REV RESPIR DIS, V120, P1259; PATTERSON R, 1980, CLIN IMMUNOL IMMUNOP, V15, P357, DOI 10.1016/0090-1229(80)90047-1; RATAJCZAK H, 1985, FED PROC, V44, P921; WEI BY, 1984, IMMUNOLOGY, V51, P687; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZEISS CR, 1983, ANN INTERN MED, V98, P8, DOI 10.7326/0003-4819-98-1-8; ZEISS CR, 1980, INT ARCH ALLER A IMM, V61, P380; ZEISS CR, 1985, J ALLERGY CLIN IMMUN, V75, P135, DOI 10.1016/0091-6749(85)90259-3; ZEISS CR, 1982, J ALLERGY CLIN IMMUN, V70, P15, DOI 10.1016/0091-6749(82)90195-6	12	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					59	63		10.1016/S0091-6749(87)80017-9	http://dx.doi.org/10.1016/S0091-6749(87)80017-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810	3805548				2022-12-18	WOS:A1987F881000013
J	KARIM, A				KARIM, A			EFFECTS OF FOOD ON THE BIOAVAILABILITY OF THEOPHYLLINE FROM CONTROLLED-RELEASE PRODUCTS IN ADULTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KARIM, A (corresponding author), GD SEARLE & CO,DIV RES & DEV,CLIN BIOAVAILABIL & PHARMACOKINET,4901 SEARLE PKWY,SKOKIE,IL 60077, USA.							COULTHARD KP, 1983, EUR J CLIN PHARMACOL, V25, P667, DOI 10.1007/BF00542356; KARIM A, 1985, CLIN PHARMACOL THER, V38, P77, DOI 10.1038/clpt.1985.138; KARIM A, 1985, CLIN PHARMACOL THER, V38, P642, DOI 10.1038/clpt.1985.238; KARIM A, 1984, PHARMACOTHERAPY, V4, P192; KARIM A, 1985, AM PHARM NS, V25, P132; LAGAS M, 1983, EUR J CLIN PHARMACOL, V24, P761, DOI 10.1007/BF00607084; LEEDS NH, 1982, J CLIN PHARMACOL, V22, P196, DOI 10.1002/j.1552-4604.1982.tb02162.x; MATURU PK, 1985, 39TH APHA AC PHARM S, V15, P137; PEDERSEN S, 1984, PEDIATRICS, V74, P534; PEDERSEN S, 1981, BRIT J CLIN PHARMACO, V12, P904, DOI 10.1111/j.1365-2125.1981.tb01329.x; SCOTT PH, 1981, J PEDIATR-US, V99, P476, DOI 10.1016/S0022-3476(81)80354-X; SIPS AP, 1984, EUR J CLIN PHARMACOL, V26, P405, DOI 10.1007/BF00548776; TAYLOR DR, 1984, BRIT J CLIN PHARMACO, V18, P27, DOI 10.1111/j.1365-2125.1984.tb05017.x; TAYLOR DR, 1983, BR J CLIN PHARM, V16, P416; VAUGHAN L, 1984, DRUG INTEL CLIN PHAR, V18, P510; WARREN JB, 1985, BRIT J CLIN PHARMACO, V19, P707, DOI 10.1111/j.1365-2125.1985.tb02701.x; WEARLEY L, 1985, 12TH INT S CONTR REL	17	18	18	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	2				695	703		10.1016/0091-6749(86)90048-5	http://dx.doi.org/10.1016/0091-6749(86)90048-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5684	3771959	Bronze			2022-12-18	WOS:A1986E568400006
J	WEINBERGER, M; HENDELES, L				WEINBERGER, M; HENDELES, L			THERAPEUTIC EFFECT AND DOSING STRATEGIES FOR THEOPHYLLINE IN THE TREATMENT OF CHRONIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV FLORIDA,GAINESVILLE,FL 32611	State University System of Florida; University of Florida	WEINBERGER, M (corresponding author), UNIV IOWA,JCP,DEPT PEDIAT,DIV PEDIAT ALLERGY & PULM,IOWA CITY,IA 52242, USA.				NCRR NIH HHS [RR 59] Funding Source: Medline; NIAID NIH HHS [AI 16151-01] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DUSDIEKER L, 1982, J PEDIATR-US, V101, P281; EKWO E, 1978, J ALLERGY CLIN IMMUN, V61, P240, DOI 10.1016/0091-6749(78)90198-7; HAMBLETON G, 1977, LANCET, V1, P381; HENDELES L, 1978, AM J DIS CHILD, V132, P876; HENDELES L, 1985, CHEST, V87, P758, DOI 10.1378/chest.87.6.758; HENDELES L, 1984, CLIN PHARMACOKINET, V9, P95, DOI 10.2165/00003088-198409020-00001; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; HENDELES L, 1978, AM REV RESPIR DIS, V118, P97; HENDELES L, 1983, ALLERGY PRINCIPLES P, P535; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P349; JOAD J, J ALLERGY CLIN IMMUN; KARIM A, 1985, CLIN PHARMACOL THER, V38, P77, DOI 10.1038/clpt.1985.138; KATZ RM, 1978, J PEDIATR-US, V92, P663, DOI 10.1016/S0022-3476(78)80318-7; KATZ RM, 1977, OCT AM AC FAM PHYS M; MILAVETZ G, 1986, J PEDIATR-US, V109, P351, DOI 10.1016/S0022-3476(86)80403-6; NASSIF EG, 1981, J PEDIATR-US, V98, P158; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; PEDERSEN S, 1984, PEDIATRICS, V74, P534; RACHELEFSKY GS, 1978, ANN ALLERGY, V40, P252; RAPOPORT JL, 1981, DEV PHARMACOL THERAP, V3, P74, DOI 10.1159/000457425; RICHER C, 1982, CLIN PHARMACOL THER, V31, P579, DOI 10.1038/clpt.1982.81; SCHULTZEWERNINGHAUS G, 1982, CLIN ALLERGY, V12, P211, DOI 10.1111/j.1365-2222.1982.tb01641.x; SIMONS FER, 1982, AM J DIS CHILD, V136, P790, DOI 10.1001/archpedi.1982.03970450032008; SPECTOR SL, 1985, J ALLERGY CLIN IMMUN, V76, P302, DOI 10.1016/0091-6749(85)90646-3; TOOGOOD JH, 1981, J ALLERGY CLIN IMMUN, V67, P317, DOI 10.1016/0091-6749(81)90028-2; TURNERWARWICK M, 1957, BRIT MED J, V2, P67, DOI 10.1136/bmj.2.5036.67; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WEINBERGER M, 1975, CLIN PHARMACOL THER, V17, P585; WEINBERGER M, 1984, J ALLERGY CLIN IMMUN, V73, P525, DOI 10.1016/0091-6749(84)90505-0; WEINBERGER MM, 1984, PHARMACOTHERAPY, V4, P181; WYATT R, 1978, J PEDIATR-US, V92, P125, DOI 10.1016/S0022-3476(78)80093-6	31	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	2				762	768		10.1016/0091-6749(86)90058-8	http://dx.doi.org/10.1016/0091-6749(86)90058-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5684	3534057				2022-12-18	WOS:A1986E568400016
J	STEWART, GA; FISHER, WF				STEWART, GA; FISHER, WF			CROSS-REACTIVITY BETWEEN THE HOUSE DUST MITE DERMATOPHAGOIDES-PTERONYSSINUS AND THE MANGE MITES PSOROPTES-CUNICULI AND PSOROPTES-OVIS .1. DEMONSTRATION OF ANTIBODIES TO THE HOUSE DUST MITE ALLERGEN DPT-12 INSERA FROM PSOROPTES-CUNICULI-INFESTED RABBITS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									USDA ARS,LIVESTOCK INSECTS LAB,BITING FLY & CATTLE RES UNIT,KERRVILLE,TX	United States Department of Agriculture (USDA)	STEWART, GA (corresponding author), PRINCESS MARGARET CHILDRENS HOSP,CLIN IMMUNOL RES UNIT,THOMAS ST,SUBIACO,WA 6008,AUSTRALIA.							ACKLAND J, 1984, J ALLERGY CLIN IMMUN, V74, P848, DOI 10.1016/0091-6749(84)90189-1; ARLIAN LG, 1984, J ALLERGY CLIN IMMUN, V74, P172, DOI 10.1016/0091-6749(84)90282-3; CHAPMAN MD, 1985, INT ARCH ALLER A IMM, V77, P166, DOI 10.1159/000233774; Culbertson JT, 1935, P SOC EXP BIOL MED, V32, P1239; FALK ES, 1981, ALLERGY, V36, P233, DOI 10.1111/j.1398-9995.1981.tb01568.x; FALK ES, 1980, BRIT J DERMATOL, V102, P283; FISHER W F, 1979, Southwestern Entomologist, V4, P249; FISHER WF, 1977, J MED ENTOMOL, V14, P146, DOI 10.1093/jmedent/14.2.146; FISHER WF, 1972, J PARASITOL, V58, P1218, DOI 10.2307/3278176; FISHER WF, 1983, J MED ENTOMOL, V20, P257, DOI 10.1093/jmedent/20.3.257; HEARN MTW, 1981, J CHROMATOGR, V218, P483, DOI 10.1016/S0021-9673(00)82074-9; KRAUS AL, 1984, BIOL LABORATORY RABB, P287; LEMAO J, 1983, J ALLERGY CLIN IMMUN, V71, P588, DOI 10.1016/0091-6749(83)90441-4; PLATTSMILLS TAE, 1985, INT ARCH ALLER A IMM, V77, P163; REED SM, 1981, ANAL BIOCHEM, V116, P53; RINER J C, 1981, Southwestern Entomologist, V6, P62; Romagnani S, 1972, Clin Allergy, V2, P115, DOI 10.1111/j.1365-2222.1972.tb01276.x; SARSFIELD JK, 1973, CLIN EXP IMMUNOL, V13, P619; STEWART GA, 1985, COMP BIOCHEM PHYS B, V81, P915, DOI 10.1016/0305-0491(85)90089-6; STEWART GA, 1980, AUST J EXP BIOL MED, V58, P259, DOI 10.1038/icb.1980.26; STEWART GA, 1982, INT ARCH ALLER A IMM, V69, P224, DOI 10.1159/000233175; STEWART GA, 1983, J IMMUNOL METHODS, V61, P157, DOI 10.1016/0022-1759(83)90158-8; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; URIEL J, 1971, METHODS IMMUNOLOGY I, V3, P294; VENOV D, 1984, 15 P NORD C ALL TURK; VOLLER A, 1980, MANUAL CLIN IMMUNOLO, P506; WEISBROTH SH, 1972, P FED AM SOC EXP BIO, V31, P614	27	18	18	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1986	78	2					293	299		10.1016/S0091-6749(86)80079-3	http://dx.doi.org/10.1016/S0091-6749(86)80079-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D7261	2426321	Bronze			2022-12-18	WOS:A1986D726100009
J	MACDONALD, AJ; MOQBEL, R; WARDLAW, AJ; KAY, AB				MACDONALD, AJ; MOQBEL, R; WARDLAW, AJ; KAY, AB			PLATELET-ACTIVATING-FACTOR (PAF-ACETHER) ENHANCES EOSINOPHIL CYTOTOXICITY INVITRO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									BROMPTON HOSP,INST CARDIOTHORAC,LONDON SW3 6HP,ENGLAND	Royal Brompton Hospital									0	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	2	S			227	227						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD38					2022-12-18	WOS:A1986AZD3800423
J	GRAMMER, LC; SHAUGHNESSY, MA; PATERSON, BF; PATTERSON, R				GRAMMER, LC; SHAUGHNESSY, MA; PATERSON, BF; PATTERSON, R			CHARACTERIZATION OF AN ANTIGEN IN ACUTE ANAPHYLACTIC DIALYSIS REACTIONS - ETHYLENE-OXIDE ALTERED HUMAN-SERUM ALBUMIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GRAMMER, LC (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.			Grammer, Leslie/0000-0001-6860-2014	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRUCH CW, 1972, IND STERILIZATION, P49; DOLOVICH J, 1978, J ALLERGY CLIN IMMUN, V62, P30, DOI 10.1016/0091-6749(78)90069-6; GRAMMER LC, 1984, J ALLERGY CLIN IMMUN, V74, P544, DOI 10.1016/0091-6749(84)90392-0; GREENWOOD FC, 1963, BIOCHEM J, V89, P14; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; MARSHALL C, 1984, Journal of Allergy and Clinical Immunology, V73, P164; PATTERSON R, 1982, J ALLERGY CLIN IMMUN, V70, P19, DOI 10.1016/0091-6749(82)90196-8; PATTERSON R, 1978, J CLIN INVEST, V62, P971, DOI 10.1172/JCI109226; PATTERSON R, 1981, J CLIN IMMUNOL, V1, P181, DOI 10.1007/BF00922761; POPLI S, 1982, ARTIF ORGANS, V6, P312; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0	12	18	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	5					670	675		10.1016/0091-6749(85)90669-4	http://dx.doi.org/10.1016/0091-6749(85)90669-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AUU34	3932500				2022-12-18	WOS:A1985AUU3400003
J	OBYRNE, PM; THOMSON, NC; LATIMER, KM; ROBERTS, RS; MORRIS, MM; DANIEL, EE; HARGREAVE, FE				OBYRNE, PM; THOMSON, NC; LATIMER, KM; ROBERTS, RS; MORRIS, MM; DANIEL, EE; HARGREAVE, FE			THE EFFECT OF INHALED HEXAMETHONIUM BROMIDE AND ATROPINE SULFATE ON AIRWAY RESPONSIVENESS TO HISTAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST JOSEPHS HOSP,DEPT MED,FIRESTONE REG CHEST & ALLERGY UNIT,50 CHARLTON AVE E,HAMILTON L8N 4A6,ONTARIO,CANADA; MCMASTER UNIV,DEPT MED,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,DEPT NEUROSCI,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,DEPT EPIDEMIOL & BIOSTAT,HAMILTON L8S 4L8,ONTARIO,CANADA	McGill University; McMaster University; McMaster University; McMaster University; McMaster University				O'Byrne, Paul/0000-0003-0979-281X; Thomson, Neil/0000-0003-1632-6630				BOULET LP, 1984, AM REV RESPIR DIS, V130, P368; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DEAL EC, 1978, J APPL PHYSIOL, V45, P238, DOI 10.1152/jappl.1978.45.2.238; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FLACKE W, 1976, ARCH PHARM EXP PATHO, V259, P265; FLEISS JL, 1973, STATISTICAL METHODS, P20; GAYAL RK, 1975, J CLIN INVEST, V55, P1119; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HERXHEIMER A, 1958, BRIT J PHARM CHEMOTH, V13, P184, DOI 10.1111/j.1476-5381.1958.tb00215.x; HOLTZMAN MJ, 1980, AM REV RESPIR DIS, V122, P17; KLEINBAUM DG, 1978, APPLIED REGRESSION A, P289; NADEL J A, 1973, P29; OBYRNE PM, 1983, AM REV RESPIR DIS, V128, P611; ROSENTHAL RR, 1977, J APPL PHYSIOL, V42, P600, DOI 10.1152/jappl.1977.42.4.600; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; TAYLOR P, 1980, PHARMACOL BASIS THER, P211	17	18	18	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	1					97	103		10.1016/0091-6749(85)90810-3	http://dx.doi.org/10.1016/0091-6749(85)90810-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AMV84	2861223				2022-12-18	WOS:A1985AMV8400013
J	PECK, CC; NICHOLS, AI; BAKER, J; LENERT, LL; EZRA, D				PECK, CC; NICHOLS, AI; BAKER, J; LENERT, LL; EZRA, D			CLINICAL PHARMACODYNAMICS OF THEOPHYLLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WALTER REED ARMY MED CTR,ALLERGY & CLIN IMMUNOL SERV,WASHINGTON,DC 20012	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	PECK, CC (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DIV CLIN PHARMACOL,4301 JONES BRIDGE RD,BETHESDA,MD 20814, USA.							Gibaldi M, 1982, PHARMACOKINETICS; HENDELES L, 1984, CLIN PHARMACOKINET, V9, P95, DOI 10.2165/00003088-198409020-00001; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; HOLFORD NHG, 1981, CRC CR REV BIOM ENG, V5, P273; HOLFORD NHG, 1981, CLIN PHARMACOKINET, V6, P429, DOI 10.2165/00003088-198106060-00002; JACKSON RH, 1964, DIS CHEST, V45, P75, DOI 10.1378/chest.45.1.75; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P349; JUSKO WJ, 1979, J PHARM SCI, V68, P1358, DOI 10.1002/jps.2600681106; LEVY G, 1975, J PEDIATR-US, V86, P789, DOI 10.1016/S0022-3476(75)80374-X; MASELLI R, 1970, J PEDIATR, V76, P777, DOI 10.1016/S0022-3476(70)80305-5; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; MUNGALL D, 1983, THER DRUG MONIT, V5, P95, DOI 10.1097/00007691-198303000-00009; PECK C, 1983, CLIN PHARMACOL THER, V33, P201; PECK C, 1983, CLIN PHARMACOL THER, V33, P259; PECK C, 1985, BEDSIDE CLIN PHARMAC; PECK CC, 1983, 2ND P WORLD C CLIN P; PECK CC, 1984, PHARMACOKINETIC BASI, P349; SEIDENFELD JJ, 1984, ANN EMERG MED, V13, P248, DOI 10.1016/S0196-0644(84)80472-2; TURNERWARWICK M, 1957, BRIT MED J, V2, P67, DOI 10.1136/bmj.2.5036.67; VOZEH S, 1982, AM REV RESPIR DIS, V125, P181; WHITING B, 1984, BRIT J CLIN PHARMACO, V17, P1; WHITING B, 1981, BRIT J CLIN PHARMACO, V12, P481, DOI 10.1111/j.1365-2125.1981.tb01254.x	22	18	18	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					292	297		10.1016/0091-6749(85)90644-X	http://dx.doi.org/10.1016/0091-6749(85)90644-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	4019957				2022-12-18	WOS:A1985APE8900008
J	PETRY, RW; VOSS, MJ; KROUTIL, LA; CROWLEY, W; BUSH, RK; BUSSE, WW				PETRY, RW; VOSS, MJ; KROUTIL, LA; CROWLEY, W; BUSH, RK; BUSSE, WW			MONKEY DANDER ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WILLIAM S MIDDLETON MEM VET ADM HOSP,ALLERGY RES LAB,2500 OVERLOOK TERRACE,MADISON,WI 53705; UNIV WISCONSIN,CTR CLIN SCI,DEPT MED,ALLERGY CLIN IMMUNOL SECT,MADISON,WI 53706	US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison								ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P794; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GUERIN B, 1981, ANN ALLERGY, V46, P127; HOFFMAN DR, 1980, ANN ALLERGY, V45, P205; LOWENSTEIN H, 1976, INT ARCH ALLER A IMM, V51, P38, DOI 10.1159/000231577; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSKY II, 1975, ANN ALLERGY, V35, P201; LYNCH RV, 1982, LESSER BUSH BABY GAL, P312; MCLEAN AC, 1980, ANN ALLERGY, V45, P199; MOORE BS, 1977, ANN ALLERGY, V39, P240; MOORE BS, 1980, J ALLERGY CLIN IMMUN, V66, P198, DOI 10.1016/0091-6749(80)90039-1; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; PRAHL P, 1982, ALLERGY, V37, P49, DOI 10.1111/j.1398-9995.1982.tb04116.x; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V63, P435, DOI 10.1016/0091-6749(79)90219-7; 1979, AFFINITY CHROMATOGRA, P15	16	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	2					268	271		10.1016/0091-6749(85)90056-9	http://dx.doi.org/10.1016/0091-6749(85)90056-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABZ05	3968337	Bronze			2022-12-18	WOS:A1985ABZ0500006
J	FERGUSON, AC; SALINAS, FA				FERGUSON, AC; SALINAS, FA			ELEVATED IGG IMMUNE-COMPLEXES IN CHILDREN WITH ATOPIC ECZEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CANC CONTROL AGCY BRITISH COLUMBIA,VANCOUVER,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT PAEDIAT,VANCOUVER V6T 1W5,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT PATHOL,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia; University of British Columbia				Ferguson, Alexander C./0000-0002-3143-5619				ALY R, 1980, ACTA DERM VENERE S92, V69, P16; BEARD LJ, 1981, ACTA PAEDIATR SCAND, V70, P551, DOI 10.1111/j.1651-2227.1981.tb05739.x; BROSTOFF J, 1977, LANCET, V2, P741; BROSTOFF J, 1979, LANCET, V1, P1268; BUTLER JM, 1983, J ALLERGY CLIN IMMUN, V71, P490, DOI 10.1016/0091-6749(83)90467-0; BYROM NA, 1979, BRIT J DERMATOL, V100, P491, DOI 10.1111/j.1365-2133.1979.tb05574.x; COOPER KD, 1980, CLIN RES, V28, pA20; DESHAZO RD, 1982, J ALLERGY CLIN IMMUN, V69, P429, DOI 10.1016/0091-6749(82)90117-8; ELLIOTT ST, 1979, ARCH DERMATOL, V115, P36, DOI 10.1001/archderm.115.1.36; FEARON DT, 1983, J ALLERGY CLIN IMMUN, V71, P520, DOI 10.1016/0091-6749(83)90431-1; FISER PM, 1979, J IMMUNOL, V123, P1788; HANIFIN JM, 1977, ARCH DERMATOL, V113, P663, DOI 10.1001/archderm.113.5.663; HODGKINSON GI, 1977, BRIT J DERMATOL, V96, P357, DOI 10.1111/j.1365-2133.1977.tb07129.x; JACKSON PG, 1981, LANCET, V1, P1285; JENSEN JR, 1981, CLIN EXP IMMUNOL, V45, P118; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; KAHN G, 1975, PEDIATR CLIN N AM, V22, P203; KANTOR FS, 1975, NEW ENGL J MED, V292, P629; KOHLER PF, 1978, ALLERGY PRINCIPLES P, P155; KRAGBALLE K, 1979, ALLERGY, V34, P35, DOI 10.1111/j.1398-9995.1979.tb01998.x; LEUNG DYM, 1982, J IMMUNOL, V128, P1736; LEUNG DYM, 1981, J ALLERGY CLIN IMMUN, V67, P450, DOI 10.1016/0091-6749(81)90098-1; MCGEADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393, DOI 10.1016/0091-6749(75)90133-5; MITCHELL EB, 1982, LANCET, V1, P127; PAGANELLI R, 1979, LANCET, V1, P1270; PAGANELLI R, 1981, CLIN EXP IMMUNOL, V46, P44; PAGANELLI R, 1983, ARCH DIS CHILD, V58, P201, DOI 10.1136/adc.58.3.201; Pirquet Clemens von, 1906, MUNCHEN MED WOCHEN, V30, P1457; RACHELEFSKY GS, 1976, J ALLERGY CLIN IMMUN, V57, P569, DOI 10.1016/0091-6749(76)90008-7; RASMUSSEN JE, 1978, ATOPIC DERMATITIS AL, P1039; RING J, 1978, BRIT J DERMATOL, V99, P495, DOI 10.1111/j.1365-2133.1978.tb02016.x; RING J, 1981, INT ARCH ALLER A IMM, V66, P156, DOI 10.1159/000232892; SALINAS AF, 1981, IMMUNE COMPLEXES PLA, P253; SALINAS FA, 1981, CANCER IMMUNOL IMMUN, V12, P11; SHOHAT B, 1980, CLIN IMMUNOL IMMUNOP, V15, P646, DOI 10.1016/0090-1229(80)90009-4; SOTER NA, 1973, NEW ENGL J MED, V289, P189, DOI 10.1056/NEJM197307262890406; THEOFILOPOULOS AN, 1982, NEW ENGL J MED, V307, P1208, DOI 10.1056/NEJM198211043071910; WILLIAMS RC, 1980, IMMUNE COMPLEXES CLI, P39; ZURAW BL, 1982, CLIN RES, V30, P97	39	18	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	5					678	682		10.1016/0091-6749(84)90229-X	http://dx.doi.org/10.1016/0091-6749(84)90229-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TT169	6501740				2022-12-18	WOS:A1984TT16900004
J	FIELD, M; MUSCH, MW; MILLER, RL; GOETZL, EJ				FIELD, M; MUSCH, MW; MILLER, RL; GOETZL, EJ			REGULATION OF EPITHELIAL ELECTROLYTE TRANSPORT BY METABOLITES OF ARACHIDONIC-ACID	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CHICAGO,DEPT PHARMACOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHYSIOL SCI,CHICAGO,IL 60637; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	FIELD, M (corresponding author), UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637, USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002121] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-21345, AM-26155] Funding Source: Medline; NIDA NIH HHS [DA-02121] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALBAZZAZ FJ, 1979, J APPL PHYSIOL, V46, P111, DOI 10.1152/jappl.1979.46.1.111; BOLTON JE, 1977, J MEMBRANE BIOL, V35, P159, DOI 10.1007/BF01869947; FIELD M, 1981, PHYSL GASTROINTESTIN, V2, P963; FRIZZELL RA, 1976, J MEMBRANE BIOL, V27, P297, DOI 10.1007/BF01869142; GUANDALINI S, 1982, AM J PHYSIOL, V243, P636; KIMBERG DV, 1971, J CLIN INVEST, V50, P1218, DOI 10.1172/JCI106599; LANGRIDGESMITH J, PFLUGERS ARCH; LEWIS RA, 1981, NATURE, V293, P103, DOI 10.1038/293103a0; MUSCH MW, 1982, SCIENCE, V217, P1255, DOI 10.1126/science.6810465; MUSCH MW, 1983, J CLIN INVEST, V71, P1073, DOI 10.1172/JCI110857; SCHULTZ SG, 1981, PHYSL GASTROINTESTIN, V2, P991; SCHULTZ SG, 1981, PHYSL GASTROINTESTIN, V2, P983; SELLIN J, 1983, GASTROENTEROLOGY, V84, P1304; SHOROFSKY SR, 1982, PHILOS T ROY SOC B, V299, P597, DOI 10.1098/rstb.1982.0155; STENSON WF, 1979, J CLIN INVEST, V64, P1457, DOI 10.1172/JCI109604; STIRLING CE, 1972, J CELL BIOL, V53, P704, DOI 10.1083/jcb.53.3.704	16	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					382	385		10.1016/0091-6749(84)90135-0	http://dx.doi.org/10.1016/0091-6749(84)90135-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ633	6432879				2022-12-18	WOS:A1984TQ63300015
J	HALWIG, JM; GREENBERGER, PA; LEVINE, M; PATTERSON, R				HALWIG, JM; GREENBERGER, PA; LEVINE, M; PATTERSON, R			RECURRENCE OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS AFTER 7 YEARS OF REMISSION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GREENBERGER PA, 1980, J ALLERGY CLIN IMMUN, V66, P327, DOI 10.1016/0091-6749(80)90029-9; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P91, DOI 10.1016/0091-6749(78)90084-2; MENDELSON EB, CHEST; PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286; PATTERSON R, 1983, ANN INTERN MED, V99, P18, DOI 10.7326/0003-4819-99-1-18; PATTERSON R, 1973, AM J MED, V54, P16, DOI 10.1016/0002-9343(73)90078-8; RADIN RC, 1983, CLIN ALLERGY, V13, P271, DOI 10.1111/j.1365-2222.1983.tb02598.x; RICKETTI AJ, 1984, J ALLERGY CLIN IMMUN, V74, P68, DOI 10.1016/0091-6749(84)90089-7; RICKETTI AJ, 1984, INT ARCH ALLER A IMM, V73, P283, DOI 10.1159/000233483; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; ROSENBERG M, 1977, J PEDIATR, V11, P914; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; TURNER ES, 1980, ANN INTERN MED, V6, P905	14	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	5					738	740		10.1016/0091-6749(84)90238-0	http://dx.doi.org/10.1016/0091-6749(84)90238-0			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TT169	6501745				2022-12-18	WOS:A1984TT16900013
J	KAUFFMAN, HF; BEAUMONT, F; SLUITER, HJ; DEVRIES, K				KAUFFMAN, HF; BEAUMONT, F; SLUITER, HJ; DEVRIES, K			IMMUNOLOGICAL OBSERVATIONS IN SERA OF A PATIENT WITH ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS BY MEANS OF THE ENZYME-LINKED IMMUNOSORBENT-ASSAY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV GRONINGEN HOSP,INTERNAL MED CLIN,DEPT PULMONOL,9713 EZ GRONINGEN,NETHERLANDS	University of Groningen	KAUFFMAN, HF (corresponding author), STATE UNIV GRONINGEN HOSP,INTERNAL MED CLIN,DEPT ALLERGOL,9713 EZ GRONINGEN,NETHERLANDS.							BEAUMONT F, 1984, ALLERGY, V39, P183, DOI 10.1111/j.1398-9995.1984.tb02623.x; GRAMMER L, 1981, INT ARCH ALLER A IMM, V66, P179, DOI 10.1159/000232817; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P91, DOI 10.1016/0091-6749(78)90084-2; JARRETT EEE, 1981, EUR J IMMUNOL, V11, P520, DOI 10.1002/eji.1830110615; KAUFFMAN HF, 1983, J ALLERGY CLIN IMMUN, V72, P255, DOI 10.1016/0091-6749(83)90029-5; KAUFFMAN HF, J ALLERGY CLIN IMMUN; KAUFFMANN HF, 1980, INT ARCH ALLER A IMM, V62, P265, DOI 10.1159/000232522; OUCHTERLONY O, 1953, ACTA PATHOL MIC SC, V32, P231; PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286; POSEY WC, 1978, J ALLERGY CLIN IMMUN, V62, P340, DOI 10.1016/0091-6749(78)90134-3; ROSENBERG M, 1978, AM J MED, V64, P599, DOI 10.1016/0002-9343(78)90579-X; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; TURNER KJ, 1974, CLIN ALLERGY, V4, P149, DOI 10.1111/j.1365-2222.1974.tb01372.x	14	18	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	5					741	746		10.1016/0091-6749(84)90239-2	http://dx.doi.org/10.1016/0091-6749(84)90239-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TT169	6389649				2022-12-18	WOS:A1984TT16900014
J	RONCHETTI, R; LUCARINI, N; LUCARELLI, P; MARTINEZ, F; MACRI, F; CARAPELLA, E; BOTTINI, E				RONCHETTI, R; LUCARINI, N; LUCARELLI, P; MARTINEZ, F; MACRI, F; CARAPELLA, E; BOTTINI, E			A GENETIC-BASIS FOR HETEROGENEITY OF ASTHMA SYNDROME IN PEDIATRIC AGES - ADENOSINE-DEAMINASE PHENOTYPES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV LA SAPIENZA,SEZVIZIO FISOPATOL RESP INFANTILE,ROME,ITALY; ACCAD NAZL LINCEI,CTR LINCEO INTERDISCIPLINARE SCI MATEMAT & APPLICAZ,ROME,ITALY; UNIV CAMERINO,GENET LAB,I-62032 CAMERINO,ITALY; UNIV LA SAPIENZA,IST DIPUERICULTURA,ROME,ITALY	Sapienza University Rome; University of Camerino; Sapienza University Rome								BATTISTUZZI G, 1974, NATURE, V251, P711, DOI 10.1038/251711a0; BEKER JW, 1974, J PEDIATR, V85, P473; BOTTINI E, 1981, J MED GENET, V18, P333; COLE P, 1971, BRIT J PREV SOC MED, V25, P242; EISEN AH, 1963, PEDIATRICS, V31, P859; HENDERSON FW, 1979, J PEDIATR-US, V95, P183; HIRRSCHHORN R, 1977, CELL IMMUNOL, V32, P350; KUTTESCH JF, 1978, J LIQ CHROMATOGR, V1, P97, DOI 10.1080/01483917808068381; LUCARELLI P, 1976, AM J PHYS ANTHROPOL, V45, P211, DOI 10.1002/ajpa.1330450208; Marone G, 1979, Ric Clin Lab, V9, P131; MARONE G, 1979, J IMMUNOL, V123, P1473; PAGLIA DE, 1978, 4TH P RED CELL INT C, P319; RAPAPORT E, 1976, P NATL ACAD SCI USA, V73, P3122, DOI 10.1073/pnas.73.9.3122; ROONEY JC, 1971, J PEDIATR, V79, P144; SCOZZARI R, 1970, HUMANGENETIK, V8, P364, DOI 10.1007/BF00280340; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671; SPENCER N, 1968, ANN HUM GENET, V32, P9, DOI 10.1111/j.1469-1809.1968.tb00044.x; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; WITTIG HJ, 1969, PEDIATR CLIN N AM, V16, P55	19	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	1					81	84		10.1016/0091-6749(84)90092-7	http://dx.doi.org/10.1016/0091-6749(84)90092-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SZ648	6736486				2022-12-18	WOS:A1984SZ64800013
J	DOLL, NJ; DIEM, JE; JONES, RN; RODRIGUEZ, M; BOZELKA, BE; STANKUS, RP; WEILL, H; SALVAGGIO, JE				DOLL, NJ; DIEM, JE; JONES, RN; RODRIGUEZ, M; BOZELKA, BE; STANKUS, RP; WEILL, H; SALVAGGIO, JE			HUMORAL IMMUNOLOGICAL ABNORMALITIES IN WORKERS EXPOSED TO ASBESTOS CEMENT DUST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,SCH MED,PULM SECT,NEW ORLEANS,LA 70112	Tulane University	DOLL, NJ (corresponding author), TULANE UNIV,SCH MED,DEPT MED,CLIN IMMUNOL SECT,NEW ORLEANS,LA 70112, USA.				NHLBI NIH HHS [HL-15092] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL015092] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALL J, 1961, ANN RHEUM DIS, V20, P235, DOI 10.1136/ard.20.3.235; CAMMARATA RJ, 1967, J AMER MED ASSOC, V199, P455, DOI 10.1001/jama.199.7.455; COCCHIARA R, 1981, IMMUNOLOGY, V44, P817; DOLL NJ, 1981, J ALLERGY CLIN IMMUN, V68, P281; DOLL NJ, 1980, J CLIN INVEST, V66, P464; DREISIN RB, 1978, NEW ENGL J MED, V298, P353, DOI 10.1056/NEJM197802162980701; GAUMER HR, 1981, CLIN EXP IMMUNOL, V44, P108; HASLAM PL, 1979, CLIN EXP IMMUNOL, V37, P381; KAGAN E, 1977, CLIN EXP IMMUNOL, V28, P268; LANGE A, 1980, ENVIRON RES, V22, P162, DOI 10.1016/0013-9351(80)90128-0; LANGE A, 1980, ENVIRON RES, V22, P176, DOI 10.1016/0013-9351(80)90129-2; OUCHTERLONY O, 1953, ACTA PATHOL MIC SC, V32, P231; PERNIS B, 1965, ANN NY ACAD SCI, V132, P112, DOI 10.1111/j.1749-6632.1965.tb41094.x; ROTHFIELD NF, 1975, J CLIN INVEST, V55, P1067; SONTHEIMER RD, 1978, J LAB CLIN MED, V91, P551; STANSFIELD D, 1974, BRIT J DIS CHEST, V68, P166, DOI 10.1016/0007-0971(74)90034-5; TURNERWARWICK M, 1970, BMJ-BRIT MED J, V3, P492, DOI 10.1136/bmj.3.5721.492; 1972, OCCUPATIONAL SAFETY, V22	18	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	5					509	512		10.1016/0091-6749(83)90589-4	http://dx.doi.org/10.1016/0091-6749(83)90589-4			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RR916	6630800				2022-12-18	WOS:A1983RR91600013
J	GRANT, JA; RAHR, R; THUESON, DO; LETTBROWN, MA; HOKANSON, JA; YUNGINGER, JW				GRANT, JA; RAHR, R; THUESON, DO; LETTBROWN, MA; HOKANSON, JA; YUNGINGER, JW			DIAGNOSIS OF POLISTES WASP HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901	Mayo Clinic	GRANT, JA (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,ALLERGY SECT,GALVESTON,TX 77550, USA.				NCRR NIH HHS [RR-73] Funding Source: Medline; NIAID NIH HHS [AI-12621, AI-11483] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CONROY MC, 1977, FED PROC, V36, P1216; FINDLAY SR, 1977, J ALLERGY CLIN IMMUN, V60, P230, DOI 10.1016/0091-6749(77)90135-X; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HOFFMAN DR, 1981, ANN ALLERGY, V46, P304; HOFFMAN DR, 1980, ANN ALLERGY, V45, P276; HOFFMAN DR, 1982, ANN ALLERGY, V48, P83; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, N ENGL J MED, V299, P620; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; Krombein KV, 1979, CATALOG HYMENOPTERA, V2, P1253; MICKS D W, 1960, Tex Rep Biol Med, V18, P624; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P789; RAMIREZ DA, 1981, ANN ALLERGY, V47, P303; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V70, P281, DOI 10.1016/0091-6749(82)90064-1; REISMAN RE, 1975, J ALLERGY CLIN IMMUN, V56, P443, DOI 10.1016/0091-6749(75)90062-7; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V69, P268, DOI 10.1016/S0091-6749(82)80003-1; RICHARDS O W, 1973, Revista Brasileira de Entomologia, V17, P85; SANTRACH PJ, 1980, ANN ALLERGY, V45, P130; SCHWARTZ HJ, 1981, J ALLERGY CLIN IMMUN, V67, P81, DOI 10.1016/0091-6749(81)90051-8; SIRAGANIAN RP, 1980, MANUAL CLIN IMMUNOLO, P808; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; THUESON DO, 1979, J IMMUNOL, V123, P626	24	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	4					399	406		10.1016/0091-6749(83)90506-7	http://dx.doi.org/10.1016/0091-6749(83)90506-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RN330	6194197	Bronze			2022-12-18	WOS:A1983RN33000011
J	WANNER, A				WANNER, A			ALLERGIC MUCOCILIARY DYSFUNCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											WANNER, A (corresponding author), MT SINAI MED CTR,DEPT MED,DIV PULM DIS,MIAMI BEACH,FL 33140, USA.							AHMED T, 1981, AM REV RESPIR DIS, V124, P110; ALLEGRA L, J APPL PHYSL; BATEMAN JRM, 1979, THORAX, V34, P418; BATTISTA SP, 1972, TOXICOL APPL PHARM, V22, P56; CALLERAME ML, 1971, J ALLERGY, V47, P187, DOI 10.1016/S0091-6749(71)80464-5; CHEVANCE L G, 1957, Acta Otolaryngol, V47, P480, DOI 10.3109/00016485709130372; CHEVANCE LG, 1971, ACTA OTO-LARYNGOL, V72, P121, DOI 10.3109/00016487109122464; CUTZ E, 1978, HISTOPATHOLOGY, V2, P407, DOI 10.1111/j.1365-2559.1978.tb01735.x; DULFANO MJ, 1982, THORAX, V37, P646, DOI 10.1136/thx.37.9.646; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; FOSTER WM, 1978, AM REV RESPIR DIS, V117, P337; GUERCIO JP, 1980, J ALLERGY CLIN IMMUN, V66, P61, DOI 10.1016/0091-6749(80)90139-6; MARIN MG, 1977, J APPL PHYSIOL, V42, P735, DOI 10.1152/jappl.1977.42.5.735; MAROM Z, 1981, J CLIN INVEST, V67, P1695, DOI 10.1172/JCI110207; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MAURER DR, 1982, J APPL PHYSIOL, V52, P1018, DOI 10.1152/jappl.1982.52.4.1018; MAURER DR, 1982, CELL MOTIL S, V1, P67; MEZEY RJ, 1978, AM REV RESPIR DIS, V118, P677, DOI 10.1164/arrd.1978.118.4.677; OLVER RE, 1975, AM REV RESPIR DIS, V112, P811; PHIPPS R, 1982, FED PROC, V41, P1509; RUSSI E, 1983, FED PROC, V42, P908; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; SIELCZAK M, 1983, FED PROC, V42, P797; WANNER A, 1975, J APPL PHYSIOL, V39, P950, DOI 10.1152/jappl.1975.39.6.950; WANNER A, 1979, AM J MED, V67, P477, DOI 10.1016/0002-9343(79)90797-6; WATANABE K, 1981, ANN OTO RHINOL LARYN, V90, P204, DOI 10.1177/000348948109000302; WIHL JA, 1977, ACTA OTO-LARYNGOL, V84, P281, DOI 10.3109/00016487709123968; YAMATAKE Y, 1977, JPN J PHARMACOL, V27, P285, DOI 10.1254/jjp.27.285	28	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	4					347	350		10.1016/0091-6749(83)90498-0	http://dx.doi.org/10.1016/0091-6749(83)90498-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RN330	6352779				2022-12-18	WOS:A1983RN33000003
J	MORELL, F; JEANNERET, A; AIACHE, JM; MOLINA, C				MORELL, F; JEANNERET, A; AIACHE, JM; MOLINA, C			LEUKOCYTE MIGRATION-INHIBITION IN FARMERS LUNG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CLERMONT FERRAND 2,F-63006 CLERMONT FERRAND,FRANCE	Universite Clermont Auvergne (UCA)	MORELL, F (corresponding author), UNIV AUTONOMA BARCELONA,CIUDAD SANIT FF,PNEUMOL SERV,BARCELONA 16,SPAIN.							ALLEN DH, 1976, CHEST, V69, P283, DOI 10.1378/chest.69.2.283; BACH C, 1971, PRESSE MED, V79, P383; BENDIXEN G, 1970, J IMMUNOL, V104, P1551; CALDWELL JR, 1973, J ALLERGY CLIN IMMUN, V52, P225, DOI 10.1016/0091-6749(73)90060-2; CROWLE AJ, 1978, IMMUNOLOGICAL DISEAS, P139; EDWARDS JH, 1981, J ALLERGY CLIN IMMUN, V68, P58, DOI 10.1016/0091-6749(81)90124-X; Fink J. N., 1976, IMMUNOLOGIC INFECTIO, P229; FINK JN, 1975, INT ARCH ALLER A IMM, V49, P831, DOI 10.1159/000231466; GIRARD JP, 1978, CLIN ALLERGY, V8, P455, DOI 10.1111/j.1365-2222.1978.tb01496.x; GRANT IWB, 1972, BRIT MED J, V1, P530, DOI 10.1136/bmj.1.5799.530; HANSEN PJ, 1974, INT ARCH ALLER A IMM, V47, P498, DOI 10.1159/000231244; MADSEN D, 1976, AM REV RESPIR DIS, V113, P171; MARX JJ, 1978, J ALLERGY CLIN IMMUN, V62, P185, DOI 10.1016/0091-6749(78)90105-7; MOORE V, 1978, J ALLERGY CLIN IMMUN, V61, P210, DOI 10.1016/0091-6749(78)90182-3; MOORE VL, 1980, J ALLERGY CLIN IMMUN, V65, P365, DOI 10.1016/0091-6749(80)90214-6; MOORE VL, 1974, J ALLERGY CLIN IMMUN, V53, P319, DOI 10.1016/0091-6749(74)90115-8; PEPYS J, 1963, LANCET, V2, P607; ROBERTS RC, 1977, AM REV RESPIR DIS, V116, P1075; SCHATZ M, 1979, NEW ENGL J MED, V300, P1310, DOI 10.1056/NEJM197906073002305; SCHLUETER DP, 1974, AM J MED, V57, P476, DOI 10.1016/0002-9343(74)90141-7; SOBORG M, 1967, ACTA MED SCAND, V181, P247; TURNERWARWICK M, 1978, IMMUNOLOGY LUNG, P176; WENZEL FJ, 1971, J ALLERGY CLIN IMMUN, V48, P224, DOI 10.1016/0091-6749(71)90069-8; WILLIAMS J. V., 1963, THORAX, V18, P182, DOI 10.1136/thx.18.2.182	24	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	5					405	409		10.1016/0091-6749(82)90114-2	http://dx.doi.org/10.1016/0091-6749(82)90114-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NP934	7076981	Bronze			2022-12-18	WOS:A1982NP93400001
J	PLATTSMILLS, TAE; CHAPMAN, MD; MARSH, DG				PLATTSMILLS, TAE; CHAPMAN, MD; MARSH, DG			HUMAN IMMUNOGLOBULIN-E AND IMMUNOGLOBULIN-G ANTIBODY-RESPONSES TO THE MINOR RAGWEED ALLERGEN RA3 - CORRELATION WITH SKIN-TESTS AND COMPARISON WITH OTHER ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GOOD SAMARITAN HOSP,JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239	Johns Hopkins University	PLATTSMILLS, TAE (corresponding author), CLIN RES CTR,DIV IMMUNOL,WATFORD RD,HARROW HA1 3UJ,MIDDLESEX,ENGLAND.			Chapman, Martin/0000-0002-0845-3632				ADOLPHSON C, 1978, J ALLERGY CLIN IMMUN, V62, P197, DOI 10.1016/0091-6749(78)90208-7; BIAS WB, 1978, LUNG BIOL HLTH DISEA, V2; BLACK PL, 1976, IMMUNOGENETICS, V3, P349, DOI 10.1007/BF01576967; BOLTON AE, 1972, J ENDOCRINOL, V55, pR30; CHAPMAN MD, 1978, CLIN EXP IMMUNOL, V34, P126; CHAPMAN MD, 1980, INT ARCH ALLER A IMM, V61, P431, DOI 10.1159/000232471; DEUSCHL H, 1977, CLIN ALLERGY, V7, P315, DOI 10.1111/j.1365-2222.1977.tb01459.x; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; HAMBURGER RN, 1973, MECHANISMS ALLERGY R, P131; ISHIZAKA K, 1967, J IMMUNOL, V98, P490; KING TP, 1976, ADV IMMUNOL, V23, P77, DOI 10.1016/S0065-2776(08)60319-3; LEVINE BB, 1972, SCIENCE, V178, P1201, DOI 10.1126/science.178.4066.1201; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MARSH DG, 1979, P NATL ACAD SCI USA, V76, P2903, DOI 10.1073/pnas.76.6.2903; MARSH DG, 1972, IMMUNOLOGY, V22, P1013; MARSH DG, 1977, IMMUNOGENETICS, V5, P217, DOI 10.1007/BF01570478; MARSH DG, 1975, ANTIGENS, V3, P271; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; PAULL BR, 1978, J IMMUNOL, V120, P1917; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; PLATTSMILLS TAE, 1978, J IMMUNOL, V120, P1201; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; ROEBBER M, 1976, THESIS MCGILL U MONT; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; SCHELLENBERG RR, 1979, J ALLERGY CLIN IMMUN, V63, P15, DOI 10.1016/0091-6749(79)90156-8; UNDERDOWN BJ, 1969, BIOCHEMISTRY-US, V8, P980, DOI 10.1021/bi00831a031; WIDE L, 1967, LANCET, V2, P1105; YAGI Y, 1963, J IMMUNOL, V91, P83; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	30	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	2					129	134		10.1016/0091-6749(81)90008-7	http://dx.doi.org/10.1016/0091-6749(81)90008-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LB947	7451780				2022-12-18	WOS:A1981LB94700008
J	POPA, VT				POPA, VT			RESPIRATORY ALLERGY TO RAGWEED - CORRELATION OF BRONCHIAL RESPONSES TO ALLERGEN WITH BRONCHIAL RESPONSES TO HISTAMINE AND CIRCULATING IMMUNOGLOBULIN-E	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											POPA, VT (corresponding author), MED COLL OHIO,PULM SECT,TOLEDO,OH 43699, USA.							AAS K, 1976, MOL BIOL ASPECTS ACU, P3; APOLD J, 1974, Clinical Allergy, V4, P401, DOI 10.1111/j.1365-2222.1974.tb01401.x; BAUR X, 1978, KLIN WOCHENSCHR, V56, P1205, DOI 10.1007/BF01477076; BENNICH H, 1976, BRONCHIAL ASTHMA, P171; BERT TLO, 1974, J ALLERGY CLIN IMMUN, V54, P209; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; BRUCE CA, 1975, J ALLERGY CLIN IMMUN, V56, P331, DOI 10.1016/0091-6749(75)90126-8; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; BRYANT DH, 1976, CLIN ALLERGY, V6, P373, DOI 10.1111/j.1365-2222.1976.tb01919.x; BRYANT DH, 1976, CLIN ALLERGY, V6, P523, DOI 10.1111/j.1365-2222.1976.tb01937.x; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; DOMIZI DB, 1970, FAL DECUS P, P19; ERIKSSON NE, 1977, INT ARCH ALLER A IMM, V54, P88, DOI 10.1159/000231811; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V59, P377, DOI 10.1016/0091-6749(77)90022-7; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GLEICH GJ, 1975, J ALLERG CLIN IMMUNO, V55, P336; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HITCHCOCK M, 1973, Comparative and General Pharmacology, V4, P81, DOI 10.1016/0010-4035(73)90025-6; ITKIN IH, 1967, J ALLERGY, V40, P245, DOI 10.1016/0021-8707(67)90087-1; KILIAN D, 1976, CLIN ALLERGY, V6, P219; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; KREUKNIET J, 1973, RESPIRATION, V30, P345, DOI 10.1159/000193049; KURIMOTO Y, 1978, CLIN ALLERGY, V8, P175, DOI 10.1111/j.1365-2222.1978.tb00462.x; LAUGIER CJ, 1976, BIOCHIM BIOPHYS ACTA, V453, P185, DOI 10.1016/0005-2795(76)90262-2; MERRETT TG, 1978, CLIN ALLERGY, V8, P543, DOI 10.1111/j.1365-2222.1978.tb01508.x; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; MORR H, 1975, PNEUMONOLOGIE, V152, P57, DOI 10.1007/BF02101574; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; PAULI G, 1977, CLIN ALLERGY, V7, P337, DOI 10.1111/j.1365-2222.1977.tb01461.x; PERMUTT S, 1977, ASTHMA PHYSL IMMUNOP, P265; POPA V, 1970, ACTA ALLERGOL, V25, P159, DOI 10.1111/j.1398-9995.1970.tb01389.x; POPA V, 1973, J ALLERGY CLIN IMMUN, V51, P344, DOI 10.1016/0091-6749(73)90073-0; POPA V, 1976, J LAB CLIN MED, V4, P225; POPA V, CHEST; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; SNEDCOR GW, 1976, STATISTICAL METHODS; Tiffeneau R, 1958, Acta Allergol Suppl (Copenh), V5, P187; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429; WOOLCOCK AJ, 1978, CLIN ALLERGY, V8, P155, DOI 10.1111/j.1365-2222.1978.tb00460.x; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P109, DOI 10.1016/0091-6749(72)90006-1	43	18	18	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	5					389	397		10.1016/0091-6749(80)90218-3	http://dx.doi.org/10.1016/0091-6749(80)90218-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV955	7372957				2022-12-18	WOS:A1980JV95500012
J	SPECTOR, SL				SPECTOR, SL			EFFECT OF A SELECTIVE BETA-2 ADRENERGIC AGONIST AND THEOPHYLLINE ON SKIN-TEST REACTIVITY AND CARDIOVASCULAR PARAMETERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,MED CTR,DENVER,CO 80220	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	SPECTOR, SL (corresponding author), NATL JEWISH HOSP & RES CTR,ALLERGY & CLIN IMMUNOL SECT,DENVER,CO 80206, USA.							ASSEM ESK, 1971, IMMUNOLOGY, V21, P729; CHIPPS BE, 1978, J ALLERGY CLIN IMMUN, V61, P171, DOI 10.1016/0091-6749(78)90382-2; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P245, DOI 10.1016/0091-6749(73)90144-9; GOTTLIEB PHILIP M., 1960, ANN ALLERGY, V18, P949; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P193, DOI 10.1016/0091-6749(78)90207-5; KRAM JA, 1975, J ALLERGY CLIN IMMUN, V56, P387, DOI 10.1016/0091-6749(75)90132-3; LICHTENSTEIN L M, 1973, P91; MOSKO MM, 1950, J ALLERGY, V21, P242, DOI 10.1016/0021-8707(50)90132-8; PERPER RJ, 1972, INT ARCH ALLER A IMM, V43, P837, DOI 10.1159/000230901; SHEREFF RH, 1973, J ALLERGY CLIN IMMUN, V52, P328, DOI 10.1016/0091-6749(73)90091-2; SPECTOR SL, 1974, MED CLIN N AM, V58, P71, DOI 10.1016/S0025-7125(16)32178-2	12	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	1					23	28		10.1016/0091-6749(79)90078-2	http://dx.doi.org/10.1016/0091-6749(79)90078-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HC424	36422				2022-12-18	WOS:A1979HC42400006
J	WYPYCH, JI; REISMAN, RE; ELLIOTT, WB; STEGER, RJ; ARBESMAN, CE				WYPYCH, JI; REISMAN, RE; ELLIOTT, WB; STEGER, RJ; ARBESMAN, CE			IMMUNOLOGICAL AND BIOCHEMICAL EVALUATION OF THE POTENCY OF WHOLE INSECT BODY EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14203; SUNY BUFFALO,DEPT MED,DIV ALLERGY,BUFFALO,NY 14214; SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14214; SUNY BUFFALO,DEPT MICROBIOL,BUFFALO,NY 14214	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								ARBESMAN CE, 1976, CLIN ALLERGY, V6, P587, DOI 10.1111/j.1365-2222.1976.tb01945.x; BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LIGHT WC, 1976, J ALLERGY CLIN IMMUN, V58, P322, DOI 10.1016/0091-6749(76)90138-X; NAIR BC, 1976, J ALLERGY CLIN IMMUN, V58, P101, DOI 10.1016/0091-6749(76)90111-1; RAPP D, 1962, J ALLERGY, V33, P97, DOI 10.1016/0021-8707(62)90001-1; REISMAN RE, 1975, J ALLERGY CLIN IMMUN, V56, P443, DOI 10.1016/0091-6749(75)90062-7; REISMAN RE, 1978, J ALLERGY CLIN IMMUN, V61, P135, DOI 10.1016/0091-6749(78)90260-9; REISMAN RE, 1976, J ALLERGY CLIN IMMUN, V57, P547, DOI 10.1016/0091-6749(76)90005-1; SCHWARTZ HJ, 1965, JAMA-J AM MED ASSOC, V194, P113; SOBOTKA A, 1974, J ALLERGY CLIN IMMUN, V53, P103; YOCUM MW, 1973, J ALLERGY CLIN IMMUN, V52, P265, DOI 10.1016/0091-6749(73)90045-6	13	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	4					267	272		10.1016/0091-6749(79)90111-8	http://dx.doi.org/10.1016/0091-6749(79)90111-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GR842	107209				2022-12-18	WOS:A1979GR84200007
J	GALLAGHER, JS; BERNSTEIN, IL; MACCIA, CA; SPLANSKY, GL; GLUECK, HI				GALLAGHER, JS; BERNSTEIN, IL; MACCIA, CA; SPLANSKY, GL; GLUECK, HI			CYCLIC PLATELET DYSFUNCTION IN IGE-MEDIATED ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,COLL MED,DEPT INTERNAL MED,DIV IMMUNOL ALLERGY,CINCINNATI,OH 45221; UNIV CINCINNATI,COLL MED,DEPT INTERNAL MED,DIV HEMATOL,CINCINNATI,OH 45221; UNIV CINCINNATI,COLL MED,DEPT PATHOL,CINCINNATI,OH 45221	University of Cincinnati; University of Cincinnati; University of Cincinnati								BENVENISTE J, 1974, NATURE, V249, P481; BERNSTEIN IL, 1973, FED PROC, V32, P813; COFFEY RG, 1975, INT ARCH ALLER A IMM, V48, P171, DOI 10.1159/000231303; FISHEL C W, 1970, Federation Proceedings, V29, P640; GROTTUM KA, 1969, BRIT J HAEMATOL, V17, P373, DOI 10.1111/j.1365-2141.1969.tb01383.x; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HARDISTY RM, 1972, BRIT J HAEMATOL, V23, P679, DOI 10.1111/j.1365-2141.1972.tb03483.x; HASTIE R, 1975, FED PROC, V34, P1000; HENSON PM, 1976, J EXP MED, V143, P937, DOI 10.1084/jem.143.4.937; HUBSCHER T, 1975, J IMMUNOL, V114, P1379; Ivy AC, 1941, J LAB CLIN MED, V26, P1812; MACCIA CA, 1977, J ALLERGY CLIN IMMUN, V59, P101, DOI 10.1016/0091-6749(77)90210-X; MILLS DCB, 1967, J PHYSIOL-LONDON, V193, P443, DOI 10.1113/jphysiol.1967.sp008369; MONCADA S, 1977, LANCET, V1, P18; OBRIEN JR, 1966, NATURE, V212, P1057, DOI 10.1038/2121057a0; ROSSI EC, 1975, J LAB CLIN MED, V85, P300; SCHWARTZ HJ, 1973, INT ARCH ALLER A IMM, V45, P899, DOI 10.1159/000231088; SOLINGER A, 1973, J ALLERGY CLIN IMMUN, V51, P29; SULLIVAN AL, 1971, J EXP MED, V134, P1403, DOI 10.1084/jem.134.6.1403; WEISS HJ, 1976, BRIT J HAEMATOL, V32, P257, DOI 10.1111/j.1365-2141.1976.tb00929.x; WEISS HJ, 1972, ANN NY ACAD SCI, V201, P161, DOI 10.1111/j.1749-6632.1972.tb16297.x	21	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	4					229	235		10.1016/0091-6749(78)90212-9	http://dx.doi.org/10.1016/0091-6749(78)90212-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FS392	701657				2022-12-18	WOS:A1978FS39200006
J	ONG, KS; GRIECO, MH; ROSNER, W				ONG, KS; GRIECO, MH; ROSNER, W			ENHANCEMENT BY OLEANDOMYCIN OF INHIBITORY EFFECT OF METHYLPREDNISOLONE ON PHYTOHEMAGGLUTININ-STIMULATED LYMPHOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROOSEVELT HOSP,RA COOKE INST ALLERGY,NEW YORK,NY 10019; ROOSEVELT HOSP,MED SERV,DIV ENDOCRINOL,NEW YORK,NY 10019; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Mount Sinai West; Mount Sinai West; Columbia University								BLOMGREN H, 1974, SCAND J IMMUNOL, V3, P655, DOI 10.1111/j.1365-3083.1974.tb01299.x; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; FOX JL, 1961, PENN MED J, V64, P634; GOODMAN LS, 1965, PHARMACOLOGICAL BASI, P1272; HEILMAN DH, 1973, CLIN EXP IMMUNOL, V15, P203; ITKIN IH, 1970, J ALLERGY, V45, P146, DOI 10.1016/0021-8707(70)90124-3; ITKIN IH, 1967, EXCERPTA MEDICA  144, P90; KAPLAN M, 1959 MEDICAL ENCYCLO, P273; SELENKE W, 1969, J ALLERGY, V43, P156; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; TOWNLEY RG, 1967, 9 INT C ALL, V144, P90; WEINBERGER M, 1977, J ALLERGY CLIN IMMUN, V59, P228, DOI 10.1016/0091-6749(77)90154-3	12	18	18	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	2					115	118		10.1016/0091-6749(78)90088-X	http://dx.doi.org/10.1016/0091-6749(78)90088-X			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL835	307564				2022-12-18	WOS:A1978FL83500008
J	STEIN, MR; WEBER, RW; TOWNER, TG				STEIN, MR; WEBER, RW; TOWNER, TG			EFFECT OF THEOPHYLLINE ON LOWER ESOPHAGEAL SPHINCTER PRESSURE (LESP)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	18	19	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	3					137	137		10.1016/0091-6749(78)90268-3	http://dx.doi.org/10.1016/0091-6749(78)90268-3			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ES173					2022-12-18	WOS:A1978ES17300029
J	KARPAS, AB; BAER, H; HOOTON, ML; EVANS, R				KARPAS, AB; BAER, H; HOOTON, ML; EVANS, R			HIGH MOLECULAR-WEIGHT ALLERGENIC FRACTION OF HONEYBEE VENOM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BUR BIOL, FOOD & DRUG ADM, BETHESDA, MD 20014 USA; WALTER REED ARMY MED CTR, WASHINGTON, DC 20012 USA	US Food & Drug Administration (FDA); United States Department of Defense; United States Army; Walter Reed National Military Medical Center								BENTON A W, 1967, Journal of Apicultural Research, V6, P91; BURNETT GW, 1957, MANUAL MICROBIOLOGIC, P55; DAVIS BJ, 1968, METHODS IMMUNOLOGY I, V2, P38; EVANS RS, TO BE PUBLISHED; FRANKLIN R, 1975, J ALLERGY CLIN IMMUN, V55, P285, DOI 10.1016/0091-6749(75)90001-9; FRUCHTER RG, 1965, J BIOL CHEM, V240, P3868; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HABERMANN E, 1972, ANAL BIOCHEM, V50, P163, DOI 10.1016/0003-2697(72)90495-2; HOFFMAN DR, 1976, J ALLERGY CLIN IMMUN, V58, P551, DOI 10.1016/0091-6749(76)90201-3; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P147, DOI 10.1016/0091-6749(77)90217-2; KERN F, 1976, J ALLERGY CLIN IMMUN, V57, P554, DOI 10.1016/0091-6749(76)90006-3; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MARSH DG, 1975, ANTIGENS, V3, P294; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MUNJAL D, 1972, TOXICON, V10, P367, DOI 10.1016/0041-0101(72)90060-8; NAIR BC, 1976, J ALLERGY CLIN IMMUN, V58, P101, DOI 10.1016/0091-6749(76)90111-1; OWEN MD, 1976, TOXICON, V14, P1, DOI 10.1016/0041-0101(76)90113-6; ROTH M, 1971, ANAL CHEM, V43, P880, DOI 10.1021/ac60302a020; SAELINGER CB, 1974, INT ARCH ALLER A IMM, V46, P28, DOI 10.1159/000231110; SALLE AJ, 1961, LABORATORY MANUAL FU, P66; SHEPHERD GW, 1974, PREP BIOCHEM, V4, P71, DOI 10.1080/00327487408068187; SHIPOLIN.RA, 1971, EUR J BIOCHEM, V20, P459, DOI 10.1111/j.1432-1033.1971.tb01414.x; SHULMAN S, 1966, J ALLERGY, V37, P350, DOI 10.1016/0021-8707(66)90134-1; SOBOTKA AK, 1976, J ALLERGY CLIN IMMUN, V57, P29, DOI 10.1016/0091-6749(76)90076-2; WEBER K, 1969, J BIOL CHEM, V244, P4406; WIDE L, 1967, LANCET, V2, P1105	27	18	18	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	3					155	162		10.1016/0091-6749(77)90118-X	http://dx.doi.org/10.1016/0091-6749(77)90118-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DU852	70436				2022-12-18	WOS:A1977DU85200002
J	BOOTH, BH; LEFOLDT, RH; MOFFITT, EM				BOOTH, BH; LEFOLDT, RH; MOFFITT, EM			WOOD DUST HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MISSISSIPPI,SCH MED,DEPT MED,UNIVERSITY,MS	University of Mississippi								BOOTH BH, 1972, ALLERGIC DISEASES DI, P63; EATON K K, 1973, Clinical Allergy, V3, P307, DOI 10.1111/j.1365-2222.1973.tb01338.x; ITKIN IH, 1963, J ALLERGY, V34, P97, DOI 10.1016/0021-8707(63)90062-5; ORDMAN D, 1949, Ann Allergy, V7, P492; OUCHTERLONY O, 1962, PROG ALLERGY, V6, P30, DOI 10.1159/000313795; PHILLIPS GL, 1967, MANUAL CLIN ALLERGY, P507; SOSMAN AJ, 1969, NEW ENGL J MED, V281, P977, DOI 10.1056/NEJM196910302811802	7	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	4					352	357		10.1016/0091-6749(76)90092-0	http://dx.doi.org/10.1016/0091-6749(76)90092-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BM689	1262610				2022-12-18	WOS:A1976BM68900009
J	CLARK, RAF; GALLIN, JI; KAPLAN, AP				CLARK, RAF; GALLIN, JI; KAPLAN, AP			MEDIATOR RELEASE FROM BASOPHIL GRANULOCYTES IN CHRONIC MYELOGENOUS LEUKEMIA - DEMONSTRATION OF EOSINOPHIL CHEMOTACTIC ACTIVITY OF HISTAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID, CLIN INVEST LAB, ALLERGIC DIS SECT, BETHESDA, MD 20014 USA; NIAID, CLIN INVEST LAB, CLIN PHYSIOL SECT, BETHESDA, MD 20014 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ARCHER RK, 1956, J PATHOL BACTERIOL, V72, P87, DOI 10.1002/path.1700720112; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BROCKLEHURST WE, 1960, J PHYSIOL-LONDON, V151, P416, DOI 10.1113/jphysiol.1960.sp006449; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; CLARK RA, 1975, J ALLERGY CLIN IMMUN, V55, P85; CLARK RAF, 1975, J EXP MED, V142, P1462, DOI 10.1084/jem.142.6.1462; Czarnetzki B M, 1976, Inflammation, V1, P201, DOI 10.1007/BF00917530; Dale HH, 1913, J PHARMACOL EXP THER, V4, P167; EIDINGER D, 1964, J ALLERGY, V35, P77, DOI 10.1016/0021-8707(64)90052-8; GOETZL EJ, 1975, P NATL ACAD SCI USA, V72, P4123, DOI 10.1073/pnas.72.10.4123; GRANT JA, 1974, J IMMUNOL, V112, P897; ISHIZAKA K, 1974, JOHNS HOPKINS MED J, V135, P67; ISHIZAKA T, 1970, J IMMUNOL, V104, P854; IZHIZAKA T, 1972, J IMMUNOL, V108, P1000; KALINER M, 1973, J EXP MED, V138, P1077, DOI 10.1084/jem.138.5.1077; KAY AB, 1971, J IMMUNOL, V107, P899; KAY AB, 1971, J EXP MED, V133, P602, DOI 10.1084/jem.133.3.602; KLINE B. S., 1932, JOUR ALLERGY, V3, P531, DOI 10.1016/S0021-8707(32)90148-8; LEWIS RA, 1975, J IMMUNOL, V114, P87; LEWIS RA, 1974, J EXP MED, V140, P1133, DOI 10.1084/jem.140.5.1133; Parish W E, 1972, Clin Allergy, V2, P381, DOI 10.1111/j.1365-2222.1972.tb01302.x; Parish W E, 1974, Antibiot Chemother (1971), V19, P233; PARISH WE, 1970, BRIT J DERMATOL, V82, P42, DOI 10.1111/j.1365-2133.1970.tb02193.x; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; SNYDERMAN R, 1972, J IMMUNOL, V108, P857; SPEIRS RS, 1955, ANN NY ACAD SCI, V59, P706, DOI 10.1111/j.1749-6632.1955.tb45980.x; STECHSCHULTE DJ, 1967, J EXP MED, V125, P127, DOI 10.1084/jem.125.1.127; VAUGHN J, 1953, BLOOD, V8, P1; VEGAD JL, 1972, INDIAN J EXP BIOL, V10, P147; WASSERMAN SI, 1974, J IMMUNOL, V112, P351; WASSERMAN SI, 1974, NEW ENGL J MED, V290, P420, DOI 10.1056/NEJM197402212900802; WASSERMAN SI, 1974, IMMUNOLOGY, V26, P677	32	18	18	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	6					623	634		10.1016/0091-6749(76)90174-3	http://dx.doi.org/10.1016/0091-6749(76)90174-3			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP077	62774				2022-12-18	WOS:A1976CP07700001
J	KURUP, VP; BARBORIAK, JJ; FINK, JN; SCRIBNER, G				KURUP, VP; BARBORIAK, JJ; FINK, JN; SCRIBNER, G			IMMUNOLOGICAL CROSS-REACTIONS AMONG THERMOPHILIC ACTINOMYCETES ASSOCIATED WITH HYPERSENSITIVITY PNEUMONITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN,DEPT PATHOL,MILWAUKEE,WI 53233; MED COLL WISCONSIN,DEPT PHARMACOL,MILWAUKEE,WI 53233; MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53233	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin								BARBORIAK JJ, 1965, J LAB CLIN MED, V65, P600; BARBORIAK JJ, 1972, J ALLERGY CLIN IMMUN, V49, P81, DOI 10.1016/0091-6749(72)90059-0; EDWARDS JH, 1972, J LAB CLIN MED, V79, P683; KURUP VP, 1975, INT J SYST BACTERIOL, V25, P150, DOI 10.1099/00207713-25-2-150; LACEY J, 1971, J GEN MICROBIOL, V66, P327, DOI 10.1099/00221287-66-3-327; WENZEL FJ, 1974, AM REV RESPIR DIS, V109, P464	6	18	18	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	5					417	421		10.1016/0091-6749(76)90056-7	http://dx.doi.org/10.1016/0091-6749(76)90056-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BR201	816841				2022-12-18	WOS:A1976BR20100004
J	MATHE, AA; LEVINE, BI; ANTONUCCI, MJ				MATHE, AA; LEVINE, BI; ANTONUCCI, MJ			UPTAKE OF CATECHOLAMINES IN GUINEA-PIG LUNG - INFLUENCE OF CORTISOL AND ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BOSTON UNIV,SCH MED,DEPT PHARMACOL,BOSTON,MA; BOSTON UNIV,SCH MED,DEPT PSYCHIAT,LAB BIOGENIC AMINES & ALLERGY,80 E CONCORD ST,BOSTON,MA 02118	Boston University; Boston University								ALABASTER VA, 1973, BRIT J PHARMACOL, V47, P325, DOI 10.1111/j.1476-5381.1973.tb08330.x; ALMGREN O, 1973, J PHARM PHARMACOL, V25, P537, DOI 10.1111/j.2042-7158.1973.tb09153.x; ASSEM ESK, 1971, INT ARCH ALLERGY, V40, P567; AVIADO DM, 1970, BRIT J PHARMACOL, V38, P374, DOI 10.1111/j.1476-5381.1970.tb08525.x; BERNSTEIN IL, 1973, FED PROC, V32, P813; BURNSTOCK G, 1972, BRIT J PHARMACOL, V46, P243, DOI 10.1111/j.1476-5381.1972.tb06869.x; BURNSTOCK G, 1971, BRIT J PHARMACOL, V43, P295; EULER USV, 1964, NEUROENDOCRINOLOGY, V2, pCH25; GILLESPIE JS, 1973, BRIT MED BULL, V29, P136, DOI 10.1093/oxfordjournals.bmb.a070983; GILLESPIE JS, 1970, J PHYSIOL-LONDON, V206, P591, DOI 10.1113/jphysiol.1970.sp009032; GILLIS CN, 1972, J APPL PHYSIOL, V33, P404, DOI 10.1152/jappl.1972.33.3.404; GILLIS CN, 1972, CIRC RES, V30, P666, DOI 10.1161/01.RES.30.6.666; GINN R, 1968, NATURE, V219, P740, DOI 10.1038/219740a0; HEDQVIST P, 1971, ACTA PHYSIOL SCAND, V82, pA29, DOI 10.1111/j.1748-1716.1971.tb05033.x; HEINEMANN HO, 1969, PHYSIOL REV, V49, P1; HEISLER S, 1972, ACTA PHYSIOL SCAND, V86, P145, DOI 10.1111/j.1748-1716.1972.tb05321.x; HUGHES J, 1969, J PHARMACOL EXP THER, V169, P237; HUGHES J, 1972, BRIT J PHARMACOL, V44, P472, DOI 10.1111/j.1476-5381.1972.tb07285.x; Iversen L., 1967, UPTAKE STORAGE NORAD; IVERSEN LL, 1970, BRIT J PHARMACOL, V40, P528, DOI 10.1111/j.1476-5381.1970.tb10637.x; IVERSEN LL, 1973, BRIT MED BULL, V29, P130, DOI 10.1093/oxfordjournals.bmb.a070982; IVERSEN LL, 1974, FRONTIERS CATECHOLAM, P403; JARROTT B, 1970, BRIT J PHARMACOL, V38, P810, DOI 10.1111/j.1476-5381.1970.tb09890.x; KALSNER S, 1969, CIRC RES, V24, P383, DOI 10.1161/01.RES.24.3.383; KALSNER S, 1969, BRIT J PHARMACOL, V36, P582, DOI 10.1111/j.1476-5381.1969.tb08013.x; KAUMANN AJ, 1972, N-S ARCH PHARMAKOL, V273, P134, DOI 10.1007/BF00508086; MATHE AA, 1969, NEW ENGL J MED, V281, P234, DOI 10.1056/NEJM196907312810503; MATHE AA, 1973, BRIT MED J, V1, P193, DOI 10.1136/bmj.1.5847.193; MATHE AA, 1971, J PSYCHOSOM RES, V15, P349, DOI 10.1016/0022-3999(71)90048-1; MATHE AA, IN PRESS; MATHE AA, 1973, PROSTAGLANDINS, V4, P863; MORRIS HG, 1972, J ALLERGY CLIN IMMUN, V50, P138, DOI 10.1016/0091-6749(72)90044-9; NICOL CJM, 1972, BRIT J PHARMACOL, V44, pP361; PUN LQ, 1973, EUR J PHARMACOL, V22, P162, DOI 10.1016/0014-2999(73)90007-1; SALT PJ, 1972, EUR J PHARMACOL, V20, P329, DOI 10.1016/0014-2999(72)90194-X; SALT PJ, 1972, NATURE-NEW BIOL, V238, P91, DOI 10.1038/newbio238091a0; SCHILD H., 1936, QUART JOUR EXP PHYSIOL, V26, P165; SMITH AP, 1973, PROSTAGLANDINS, V1, pCH7; STJARNE L, IN PRESS; TRENDELENBURG U, 1974, FRONTIERS CATECHOLAM, P527; VANE JR, 1969, BRIT J PHARMACOL, V35, P209, DOI 10.1111/j.1476-5381.1969.tb07982.x; ZWEIFACH BW, 1953, ANN NY ACAD SCI, V56, P626, DOI 10.1111/j.1749-6632.1953.tb27383.x	42	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	3					170	179		10.1016/0091-6749(75)90013-5	http://dx.doi.org/10.1016/0091-6749(75)90013-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V8448	1112950				2022-12-18	WOS:A1975V844800004
J	ELLIS, EF; YAFFEE, SJ; LEVY, G				ELLIS, EF; YAFFEE, SJ; LEVY, G			PHARMACOKINETICS OF THEOPHYLLINE IN ASTHMATIC CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	18	18	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	2					79	79						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S0380					2022-12-18	WOS:A1974S038000037
J	SINGER, AD; HOBEL, CJ; HEINER, DC				SINGER, AD; HOBEL, CJ; HEINER, DC			EVIDENCE FOR SECRETORY IGA AND IGE IN-UTERO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	18	18	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	2					94	94						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S0380					2022-12-18	WOS:A1974S038000074
